diff --git "a/test_predictions.txt" "b/test_predictions.txt"
new file mode 100644--- /dev/null
+++ "b/test_predictions.txt"
@@ -0,0 +1,148530 @@
+Physical O
+mapping O
+220 O
+kb O
+centromeric O
+of O
+the O
+human B
+MHC I
+and O
+DNA O
+sequence O
+analysis O
+of O
+the O
+43 O
+- O
+kb O
+segment O
+including O
+the O
+RING1 B
+, O
+HKE6 B
+, O
+and O
+HKE4 B
+genes I
+. O
+
+The O
+synthesis O
+of O
+endo O
+- O
+adduct O
+[ O
+4aS O
+, O
+5S O
+, O
+8R O
+, O
+8aR O
+, O
+SS O
+] O
+- O
+9d O
+resulting O
+from O
+cycloaddition O
+on O
+the O
+substituted O
+C O
+( O
+2 O
+) O
+- O
+C O
+( O
+3 O
+) O
+double O
+bond O
+was O
+achieved O
+in O
+a O
+chemo O
+- O
+and O
+diastereoselective O
+way O
+from O
+quinone O
+1d O
+in O
+the O
+presence O
+of O
+ZnBr O
+( O
+2 O
+) O
+. O
+
+DNA O
+elements O
+recognizing O
+NF B
+- I
+Y I
+and O
+Sp1 B
+regulate O
+the O
+human B
+multidrug I
+- I
+resistance I
+gene I
+promoter I
+. O
+
+Radioimmunoassay O
+of O
+plasma O
+gonadotropins B
+; O
+problems O
+of O
+specificity O
+
+Patients O
+randomized O
+into O
+the O
+active O
+treatment O
+groups O
+A30 O
+( O
+n O
+= O
+49 O
+) O
+and O
+A60 O
+( O
+n O
+= O
+48 O
+) O
+received O
+topical O
+treatment O
+with O
+3 O
+. O
+0 O
+% O
+diclofenac O
+in O
+2 O
+. O
+5 O
+% O
+hyaluronan O
+gel O
+0 O
+. O
+5 O
+g O
+twice O
+daily O
+for O
+30 O
+or O
+60 O
+days O
+, O
+respectively O
+. O
+
+As O
+tat B
+itself O
+dramatically O
+increases O
+HIV O
+- O
+1 O
+gene O
+expression O
+, O
+it O
+too O
+is O
+presumably O
+regulated O
+in O
+the O
+latent O
+state O
+, O
+and O
+may O
+also O
+be O
+activated O
+by O
+mitogenic O
+stimulation O
+. O
+
+To O
+clarify O
+the O
+difference O
+, O
+both O
+the O
+Crk B
+II I
+and O
+Crk B
+II I
+- I
+23 I
+, O
+proteins O
+were O
+expressed O
+in O
+E O
+. O
+coli O
+and O
+examined O
+their O
+binding O
+capacity O
+in O
+vitro O
+. O
+
+CONCLUSIONS O
+: O
+Systemic O
+factors O
+that O
+increase O
+bone O
+mineral O
+density O
+appear O
+to O
+be O
+involved O
+in O
+the O
+pathogenesis O
+of O
+ossification O
+of O
+the O
+posterior O
+longitudinal O
+ligament O
+, O
+and O
+these O
+factors O
+may O
+be O
+activated O
+after O
+middle O
+age O
+. O
+
+Thus O
+, O
+in O
+V O
+. O
+furnissii O
+, O
+the O
+E B
+. I
+coli I
+manX I
+equivalent I
+comprises O
+two O
+genes O
+, O
+which O
+are O
+separated O
+in O
+the O
+genome O
+by O
+two O
+other O
+genes O
+of O
+the O
+ptsM B
+complex I
+. O
+
+Id B
+- I
+1H I
+and O
+Id B
+- I
+2H I
+seem O
+to O
+be O
+human B
+homologues I
+of I
+mouse I
+Id I
+- I
+1 I
+and O
+Id B
+- I
+2 I
+, O
+respectively O
+, O
+and O
+have O
+potential O
+to O
+encode O
+154 O
+and O
+135 O
+amino O
+acid O
+proteins O
+. O
+
+Characterization O
+of O
+insertion O
+mutations O
+in O
+the O
+Saccharomyces B
+cerevisiae I
+MSH1 I
+and O
+MSH2 B
+genes I
+: O
+evidence O
+for O
+separate O
+mitochondrial O
+and O
+nuclear O
+functions O
+. O
+
+Transcription O
+of O
+FN B
+promoter I
+- O
+chloramphenicol B
+acetyltransferase I
+fusion O
+genes O
+carrying O
+the O
+base O
+substitution O
+in O
+one O
+or O
+more O
+of O
+these O
+G O
+- O
+rich O
+sequences O
+both O
+in O
+vivo O
+and O
+in O
+vitro O
+revealed O
+that O
+the O
+base O
+substitution O
+in O
+any O
+G O
+- O
+rich O
+sequence O
+results O
+in O
+reduction O
+of O
+promoter O
+activity O
+, O
+although O
+the O
+downstream O
+GC O
+box O
+( O
+GCd O
+) O
+plays O
+a O
+primary O
+role O
+. O
+
+Morphologically O
+, O
+corrugation O
+of O
+the O
+internal O
+elastic O
+lamina O
+of O
+vessels O
+was O
+often O
+observed O
+in O
+the O
+vehicle O
+- O
+treated O
+group O
+, O
+but O
+was O
+not O
+prominent O
+in O
+the O
+GLNVA O
+- O
+treated O
+groups O
+or O
+healthy O
+controls O
+. O
+
+A O
+GT O
+- O
+rich O
+sequence O
+binding O
+the O
+transcription O
+factor O
+Sp1 B
+is O
+crucial O
+for O
+high O
+expression O
+of O
+the O
+human B
+type I
+VII I
+collagen I
+gene I
+( O
+COL7A1 B
+) O
+in O
+fibroblasts O
+and O
+keratinocytes O
+. O
+
+Each O
+received O
+20 O
+mL O
+of O
+one O
+of O
+three O
+test O
+solutions O
+: O
+levobupivacaine O
+control O
+, O
+levobupivacaine O
+and O
+fentanyl O
+2 O
+microg O
+/ O
+mL O
+, O
+or O
+levobupivacaine O
+and O
+fentanyl O
+3 O
+microg O
+/ O
+mL O
+. O
+
+The O
+XPR2 B
+gene I
+from O
+Yarrowia O
+lipolytica O
+encodes O
+an O
+inducible O
+alkaline O
+extracellular O
+protease O
+. O
+
+CONCLUSIONS O
+: O
+This O
+study O
+shows O
+that O
+the O
+annual O
+rate O
+of O
+de O
+novo O
+aneurysm O
+formation O
+is O
+relatively O
+high O
+( O
+0 O
+. O
+89 O
+% O
+) O
+and O
+that O
+the O
+cumulative O
+risk O
+becomes O
+significant O
+after O
+9 O
+years O
+. O
+
+It O
+was O
+found O
+that O
+Nopp140 B
+binds O
+primarily O
+to O
+the O
+CK2 B
+regulatory I
+subunit I
+, I
+beta I
+. O
+
+Juvenile O
+idiopathic O
+inflammatory O
+myopathies O
+: O
+the O
+value O
+of O
+magnetic O
+resonance O
+imaging O
+in O
+the O
+detection O
+of O
+muscle O
+involvement O
+. O
+
+Previous O
+analysis O
+of O
+this O
+motif O
+in O
+the O
+lactose B
+permease I
+( O
+A O
+. O
+
+Combined O
+chemotherapy O
+with O
+VM O
+26 O
+and O
+BCNU O
+for O
+recurrent O
+malignant O
+gliomas O
+after O
+operation O
+and O
+irradiation O
+. O
+
+Like O
+other O
+IAPs B
+, O
+ch B
+- I
+IAP1 I
+contains O
+the O
+N B
+- I
+terminal I
+baculovirus I
+IAP I
+repeats I
+and O
+C O
+- O
+terminal O
+RING O
+finger O
+motifs O
+. O
+
+Effects O
+of O
+long O
+- O
+term O
+use O
+of O
+raloxifene O
+, O
+a O
+selective O
+estrogen B
+receptor I
+modulator O
+, O
+on O
+thyroid O
+function O
+test O
+profiles O
+. O
+
+The O
+donors O
+of O
+10 O
+patients O
+were O
+ABO O
+- O
+incompatible O
+, O
+and O
+for O
+five O
+pairs O
+the O
+ABO O
+incompatibility O
+was O
+major O
+. O
+
+Alternative O
+splicing O
+of O
+the O
+human B
+serotonin I
+transporter I
+gene I
+. O
+
+Interestingly O
+, O
+basal O
+MAPK B
+, O
+but O
+not O
+Raf B
+- I
+1 I
+, O
+activity O
+was O
+constitutively O
+enhanced O
+in O
+Jak1 B
+- O
+deficient O
+HeLa O
+cells O
+. O
+
+This O
+case O
+report O
+describes O
+the O
+treatment O
+of O
+a O
+patient O
+with O
+periodontosis O
+. O
+
+The O
+aim O
+of O
+this O
+work O
+was O
+to O
+organize O
+chemical O
+data O
+in O
+a O
+client O
+- O
+server O
+environment O
+using O
+Database O
+Management O
+System O
+and O
+Web O
+fashion O
+for O
+the O
+client O
+interface O
+. O
+
+Cerumen O
+management O
+in O
+hearing O
+conservation O
+: O
+the O
+Dallas O
+( O
+Texas O
+) O
+Independent O
+School O
+District O
+program O
+. O
+
+Lactate O
+, O
+pyruvate O
+and O
+actual O
+pH O
+values O
+in O
+the O
+venous O
+blood O
+of O
+newborn O
+calves O
+
+This O
+article O
+focuses O
+on O
+a O
+general O
+approach O
+to O
+the O
+use O
+of O
+ARV O
+agents O
+. O
+
+Platelets O
+and O
+RBCs O
+from O
+each O
+animal O
+were O
+labeled O
+with O
+51Cr O
+and O
+99mTc O
+, O
+respectively O
+, O
+and O
+were O
+rapidly O
+injected O
+into O
+the O
+right O
+atrium O
+while O
+blood O
+was O
+sampled O
+from O
+the O
+ascending O
+aorta O
+. O
+
+The O
+comparisons O
+of O
+swimming O
+performance O
+before O
+and O
+after O
+treatments O
+with O
+deltamethrin O
+have O
+shown O
+a O
+significant O
+effect O
+on O
+locomotory O
+ability O
+of O
+rainbow O
+trout O
+which O
+at O
+the O
+end O
+of O
+strong O
+exposure O
+( O
+e O
+. O
+g O
+. O
+
+Protection O
+levels O
+of O
+33 O
+. O
+3 O
+% O
+, O
+36 O
+. O
+6 O
+% O
+and O
+37 O
+. O
+0 O
+% O
+were O
+achieved O
+in O
+groups O
+which O
+had O
+received O
+, O
+respectively O
+, O
+1000 O
+20 O
+- O
+krad O
+cercariae O
+, O
+1000 O
+10 O
+- O
+krad O
+cercariae O
+, O
+2000 O
+40 O
+- O
+krad O
+cercariae O
+and O
+2000 O
+60 O
+- O
+krad O
+cercariae O
+. O
+
+In O
+Types O
+I O
+and O
+II O
+, O
+capillary O
+walls O
+became O
+thinner O
+and O
+more O
+capillary O
+lumens O
+were O
+visiable O
+. O
+
+Thus O
+, O
+primate O
+vs O
+. O
+rodent O
+promoter O
+selectivity O
+mediated O
+by O
+the O
+TBP B
+- O
+TAFI B
+complex O
+is O
+likely O
+to O
+be O
+the O
+result O
+of O
+cumulative O
+subtle O
+differences O
+between O
+individual O
+subunits O
+that O
+lead O
+to O
+species O
+- O
+specific O
+properties O
+of O
+RNA B
+polymerase I
+I I
+transcription O
+. O
+
+The O
+effects O
+of O
+pretreatment O
+with O
+the O
+non O
+- O
+competitive O
+NMDA O
+antagonist O
+( O
++ O
+) O
+MK O
+- O
+801 O
+on O
+the O
+behavioral O
+alterations O
+induced O
+by O
+repeated O
+restraint O
+stress O
+were O
+investigated O
+. O
+
+When O
+gene O
+conversion O
+is O
+initiated O
+by O
+a O
+double O
+- O
+strand O
+break O
+( O
+DSB O
+) O
+, O
+any O
+nonhomologous O
+DNA O
+that O
+may O
+be O
+present O
+at O
+the O
+ends O
+must O
+be O
+removed O
+before O
+new O
+DNA O
+synthesis O
+can O
+be O
+initiated O
+. O
+
+In O
+this O
+reconstituted O
+system O
+, O
+RNAP B
+IIA I
+, O
+but O
+not O
+RNAP B
+IIB I
+, O
+can O
+transcribe O
+from O
+the O
+DHFR B
+promoter I
+. O
+
+The O
+cDNA O
+clones O
+encode O
+a O
+polypeptide O
+of O
+657 O
+amino O
+acids O
+with O
+a O
+bHLH O
+( O
+basic O
+- O
+helix O
+- O
+loop O
+- O
+helix O
+) O
+domain O
+, O
+characteristic O
+of O
+a O
+large O
+family O
+of O
+transcription O
+factors O
+, O
+and O
+a O
+PAS B
+( O
+Per B
+- I
+Arnt I
+- I
+Sim I
+) O
+domain O
+in O
+the O
+amino O
+- O
+terminal O
+half O
+region O
+. O
+
+FTF O
+( O
+Joint O
+Council O
+of O
+Civil O
+Servants O
+and O
+Functionaries O
+) O
+: O
+clarification O
+about O
+membership O
+in O
+the O
+main O
+organizations O
+
+Lumbar O
+spine O
+bone O
+mineral O
+density O
+( O
+BMD O
+) O
+by O
+dual O
+- O
+energy O
+X O
+- O
+ray O
+absorptiometry O
+( O
+DXA O
+) O
+increased O
+by O
+0 O
+. O
+6 O
+% O
+, O
+3 O
+. O
+6 O
+% O
+and O
+8 O
+. O
+1 O
+% O
+after O
+48 O
+weeks O
+in O
+groups O
+L O
+, O
+M O
+and O
+H O
+respectively O
+, O
+responses O
+in O
+groups O
+M O
+and O
+H O
+being O
+significantly O
+higher O
+than O
+in O
+L O
+( O
+p O
+< O
+0 O
+. O
+05 O
+, O
+Mann O
+- O
+Whitney O
+U O
+- O
+test O
+) O
+. O
+
+Synergy O
+between O
+interferon B
+- I
+gamma I
+and O
+tumor B
+necrosis I
+factor I
+- I
+alpha I
+in O
+transcriptional O
+activation O
+is O
+mediated O
+by O
+cooperation O
+between O
+signal B
+transducer I
+and I
+activator I
+of I
+transcription I
+1 I
+and O
+nuclear B
+factor I
+kappaB I
+. O
+
+1H O
+and O
+15N O
+magnetic O
+resonance O
+assignments O
+, O
+secondary O
+structure O
+, O
+and O
+tertiary O
+fold O
+of O
+Escherichia B
+coli I
+DnaJ I
+( I
+1 I
+- I
+78 I
+) I
+. O
+
+A O
+cDNA O
+for O
+human B
+microfibril I
+- I
+associated I
+glycoprotein I
+- I
+2 I
+( O
+MAGP B
+- I
+2 I
+) O
+was O
+used O
+to O
+screen O
+a O
+human O
+leukocyte O
+genomic O
+DNA O
+library O
+in O
+EMBL O
+- O
+3 O
+vector O
+. O
+
+Furthermore O
+, O
+ERK B
+phosphorylation O
+was O
+substantially O
+prolonged O
+in O
+LC B
+/ O
+BRY B
+- O
+treated O
+cells O
+compared O
+to O
+those O
+exposed O
+to O
+BRY B
+alone O
+, O
+and O
+pretreatment O
+with O
+the O
+highly O
+specific O
+MEK B
+inhibitors O
+, O
+PD98059 O
+, O
+U0126 O
+, O
+and O
+SL327 O
+, O
+opposed O
+ERK B
+activation O
+while O
+protecting O
+cells O
+from O
+LC B
+/ O
+BRY B
+- O
+induced O
+lethality O
+. O
+
+The O
+cholesterol B
+7alpha I
+- I
+hydroxylase I
+gene I
+( O
+CYP7A B
+) O
+is O
+transcriptionally O
+regulated O
+by O
+a O
+number O
+of O
+factors O
+, O
+including O
+hormones O
+, O
+bile O
+acids O
+, O
+and O
+diurnal O
+rhythm O
+. O
+
+CNS O
+preventive O
+treatment O
+without O
+cranial O
+irradiation O
+was O
+effective O
+in O
+all O
+the O
+groups O
+of O
+ALL O
+patients O
+. O
+
+Additionally O
+, O
+the O
+members O
+of O
+this O
+family O
+display O
+strong O
+sequence O
+homologies O
+between O
+their O
+larger O
+C O
+- O
+terminal O
+effector O
+binding O
+/ O
+oligomerization O
+domains O
+. O
+
+Aspartame O
+is O
+a O
+synthetic O
+sweetener O
+commonly O
+used O
+in O
+soft O
+drinks O
+and O
+many O
+foods O
+. O
+
+The O
+rat O
+anococcygeus O
+muscle O
+was O
+used O
+in O
+postsynaptic O
+studies O
+. O
+
+The O
+purpose O
+of O
+this O
+presentation O
+is O
+to O
+review O
+the O
+current O
+state O
+of O
+knowledge O
+regarding O
+5 O
+, O
+8 O
+, O
+11 O
+, O
+14 O
+- O
+eicosatetraynoic O
+acid O
+( O
+ETYA O
+, O
+Ro O
+3 O
+- O
+1428 O
+) O
+and O
+its O
+effects O
+on O
+lipid O
+metabolism O
+. O
+
+A O
+Meis1 B
+cDNA I
+clone I
+that O
+encoded O
+a O
+novel O
+member O
+of O
+the O
+homeobox B
+gene I
+family I
+was O
+identified O
+. O
+
+The O
+S B
+. I
+typhimurium I
+aspartyl I
+/ I
+asparaginyl I
+beta I
+- I
+hydroxylase I
+homologue I
+( O
+designated O
+lpxO B
+) O
+was O
+cloned O
+into O
+pBluescriptSK O
+and O
+expressed O
+in O
+Escherichia O
+coli O
+K O
+- O
+12 O
+, O
+which O
+does O
+not O
+contain O
+lpxO B
+. O
+
+The O
+levels O
+of O
+soluble O
+L B
+- I
+selectin I
+and O
+ICAM B
+- I
+1 I
+in O
+the O
+serum O
+were O
+determined O
+by O
+the O
+ELISA O
+method O
+. O
+
+The O
+highest O
+TTX O
+content O
+is O
+10 O
+. O
+0 O
+microg O
+/ O
+g O
+in O
+N O
+. O
+livescens O
+. O
+
+On O
+the O
+other O
+hand O
+hypokalemia O
+, O
+induced O
+by O
+diuretics O
+, O
+may O
+also O
+be O
+accompanied O
+by O
+a O
+significant O
+depletion O
+of O
+total O
+body O
+K O
+, O
+bringing O
+about O
+more O
+general O
+consequences O
+. O
+
+Glutathione B
+reductase I
+activities O
+in O
+liver O
+, O
+kidney O
+, O
+lung O
+, O
+and O
+brain O
+were O
+not O
+affected O
+by O
+diet O
+. O
+
+Here O
+, O
+we O
+describe O
+the O
+nucleotide O
+( O
+nt O
+) O
+sequence O
+and O
+genomic O
+organization O
+of O
+ipiB B
+and O
+ipiO B
+. O
+
+Vancomycin O
+and O
+tetracycline O
+eliminated O
+toxin O
+in O
+stools O
+and O
+delayed O
+death O
+. O
+
+Soluble O
+fibrin B
+monomer I
+complexes I
+in O
+thromboembolism O
+
+Comparison O
+to O
+the O
+murine O
+homologues O
+of O
+these O
+molecules O
+reveals O
+a O
+high O
+degree O
+of O
+conservation O
+between O
+the O
+products O
+of O
+one O
+of O
+these O
+genes O
+, O
+Fc B
+gamma I
+RIIb I
+, O
+and O
+the O
+murine O
+beta O
+gene O
+in O
+primary O
+sequence O
+, O
+splicing O
+pattern O
+, O
+and O
+tissue O
+distribution O
+. O
+
+Acidosis O
+provoked O
+by O
+30 O
+% O
+CO2 O
+irreversibly O
+increased O
+the O
+BDRT O
+, O
+however O
+the O
+TRT O
+were O
+not O
+changed O
+. O
+
+Others O
+as O
+for O
+example O
+C O
+- O
+11 O
+labeled O
+short O
+chain O
+fatty O
+acids O
+are O
+on O
+the O
+horizon O
+. O
+
+The O
+average O
+progression O
+was O
+11 O
+. O
+6 O
+( O
+SD O
+9 O
+. O
+0 O
+) O
+. O
+
+80 O
+bp O
+) O
+surrounding O
+the O
+site O
+of O
+transcription O
+initiation O
+. O
+
+Ultrastructure O
+and O
+toxin O
+formation O
+of O
+Cor O
+. O
+diphtheriae O
+PW O
+- O
+8 O
+cultured O
+in O
+the O
+presence O
+of O
+penicillin O
+
+EMT B
+was O
+localized O
+to O
+chromosome O
+5q31 O
+- O
+32 O
+, O
+a O
+region O
+that O
+contains O
+the O
+genes O
+for O
+several O
+growth O
+factors O
+and O
+receptors O
+as O
+well O
+as O
+early O
+activation O
+genes O
+, O
+particularly O
+those O
+involved O
+in O
+the O
+hematopoietic O
+system O
+. O
+
+Tbx6 B
+maps O
+to O
+chromosome O
+7 O
+and O
+does O
+not O
+appear O
+to O
+be O
+linked O
+to O
+any O
+known O
+mutation O
+. O
+
+Kaposi O
+' O
+s O
+eruptive O
+disease O
+. O
+
+It O
+is O
+not O
+tested O
+yet O
+, O
+whether O
+the O
+extent O
+of O
+glaucoma O
+damage O
+should O
+be O
+better O
+quantified O
+using O
+reference O
+plane O
+1 O
+or O
+2 O
+. O
+
+Importin B
+beta I
+mediates O
+nuclear O
+translocation O
+of O
+Smad B
+3 I
+. O
+
+The O
+encoded O
+protein O
+contains O
+an O
+amino O
+terminal O
+PDZ B
+domain I
+, O
+followed O
+by O
+a O
+predicted O
+coiled O
+- O
+coil O
+region O
+, O
+a O
+PEST O
+domain O
+, O
+and O
+a O
+carboxy O
+- O
+terminal O
+SAM O
+domain O
+. O
+
+Using O
+lasers O
+, O
+PRK O
+involves O
+reshaping O
+the O
+cornea O
+so O
+that O
+its O
+refractive O
+power O
+is O
+increased O
+. O
+
+However O
+, O
+sphincter O
+length O
+decreased O
+with O
+age O
+from O
+24 O
+. O
+3 O
+to O
+14 O
+. O
+8 O
+mm O
+. O
+, O
+maximal O
+urethral O
+pressure O
+from O
+88 O
+. O
+7 O
+to O
+55 O
+cm O
+. O
+water O
+and O
+maximal O
+urethral O
+pressure O
+during O
+voluntary O
+contraction O
+from O
+221 O
+. O
+4 O
+to O
+166 O
+. O
+3 O
+cm O
+. O
+water O
+. O
+
+Several O
+studies O
+have O
+demonstrated O
+that O
+the O
+corticotropin B
+- I
+releasing I
+factor I
+test O
+( O
+CRF B
+) O
+is O
+useful O
+for O
+the O
+aetiological O
+diagnosis O
+of O
+Cushing O
+' O
+s O
+syndrome O
+: O
+in O
+Cushing O
+' O
+s O
+disease O
+, O
+as O
+opposed O
+to O
+ectopic O
+ACTH B
+secretion O
+syndrome O
+, O
+the O
+hypothalamus O
+- O
+pituitary O
+- O
+adrenal O
+( O
+HPA O
+) O
+axis O
+can O
+still O
+be O
+stimulated O
+by O
+CRF B
+. O
+
+Transcription O
+initiation O
+from O
+this O
+region O
+was O
+also O
+detected O
+in O
+vivo O
+, O
+when O
+the O
+cloned O
+rRNA O
+gene O
+cluster O
+was O
+present O
+on O
+a O
+multi O
+- O
+copy O
+plasmid O
+. O
+
+The O
+results O
+of O
+the O
+transient O
+- O
+transfection O
+assay O
+showed O
+that O
+the O
+Sp1 B
+binding I
+element I
+located O
+in O
+the O
+core O
+region O
+( O
+positions O
+- O
+- O
+64 O
+to O
++ O
+1 O
+) O
+of O
+the O
+alpha2 B
+- I
+integrin I
+promoter I
+plays O
+an O
+essential O
+role O
+in O
+the O
+alpha2 B
+- I
+integrin I
+promoter I
+activity O
+and O
+its O
+downregulation O
+by O
+Erb B
+- I
+B2 I
+. O
+
+Principal O
+component O
+analysis O
+using O
+psychosocial O
+factors O
+in O
+women O
+showed O
+two O
+psychosocial O
+structures O
+, O
+i O
+. O
+e O
+. O
+the O
+second O
+principal O
+( O
+high O
+SOC O
+, O
+high O
+lifestyle O
+, O
+and O
+low O
+stress O
+) O
+and O
+the O
+4th O
+principal O
+components O
+( O
+high O
+supernatural O
+HLC O
+, O
+and O
+high O
+PHLC O
+) O
+. O
+
+Expression O
+of O
+FNCAT B
+increased O
+on O
+serum O
+treatment O
+indicating O
+that O
+the O
+region O
+of O
+the O
+FN B
+gene I
+between O
+positions O
++ O
+69 O
+and O
+- O
+510 O
+bp O
+mediated O
+serum O
+responsiveness O
+. O
+
+Interaction O
+of O
+the O
+v B
+- I
+rel I
+protein I
+with O
+an O
+NF B
+- I
+kappa I
+B I
+DNA I
+binding I
+site I
+. O
+
+This O
+increase O
+is O
+not O
+the O
+result O
+of O
+alterations O
+in O
+the O
+deposition O
+of O
+inhaled O
+particles O
+of O
+capsaicin O
+brought O
+about O
+by O
+volume O
+restriction O
+. O
+
+Providing O
+appropriate O
+care O
+to O
+both O
+sexes O
+. O
+
+To O
+test O
+this O
+hypothesis O
+, O
+we O
+developed O
+a O
+system O
+of O
+transient O
+transfection O
+of O
+rat O
+adipocytes O
+with O
+constructs O
+containing O
+glyceraldehyde B
+- I
+3 I
+- I
+phosphate I
+dehydrogenase I
+( O
+GAPDH B
+) O
+and O
+fatty B
+acid I
+synthetase I
+( O
+FAS B
+) O
+promoters O
+fused O
+to O
+gene O
+reporter O
+CAT B
+. O
+
+In O
+the O
+green O
+unicellular O
+alga O
+Chlamydomonas O
+eugametos O
+, O
+cellular O
+division O
+is O
+readily O
+synchronized O
+by O
+light O
+/ O
+dark O
+cycles O
+. O
+
+SHBG B
+concentrations O
+in O
+women O
+were O
+also O
+significantly O
+higher O
+at O
+T O
+- O
+2 O
+and O
+T O
+- O
+3 O
+when O
+compared O
+to O
+T O
+- O
+1 O
+values O
+. O
+
+Simvastatin O
+decreased O
+levels O
+of O
+total O
+cholesterol O
+by O
+20 O
+. O
+8 O
+% O
+, O
+LDL B
+cholesterol I
+by O
+29 O
+. O
+7 O
+% O
+, O
+triglycerides O
+by O
+13 O
+. O
+6 O
+% O
+, O
+apolipoprotein B
+B I
+by O
+22 O
+. O
+4 O
+% O
+, O
+alpha O
+- O
+tocopherol O
+by O
+16 O
+. O
+2 O
+% O
+, O
+beta O
+- O
+carotene O
+by O
+19 O
+. O
+5 O
+% O
+, O
+and O
+ubiquinol O
+- O
+10 O
+by O
+22 O
+. O
+0 O
+% O
+( O
+P O
+< O
+. O
+001 O
+for O
+all O
+) O
+and O
+increased O
+levels O
+of O
+HDL B
+cholesterol I
+by O
+7 O
+. O
+0 O
+% O
+( O
+P O
+< O
+. O
+001 O
+) O
+and O
+serum B
+insulin I
+by O
+13 O
+
+. O
+2 O
+% O
+( O
+P O
+= O
+. O
+005 O
+) O
+. O
+
+The O
+more O
+severe O
+the O
+CRF O
+, O
+the O
+more O
+likely O
+that O
+total O
+HDL B
+and O
+HDL2 B
+cholesterol I
+will O
+be O
+low O
+. O
+
+They O
+are O
+growth O
+- O
+inhibited O
+by O
+TGF B
+- I
+beta1 I
+. O
+
+To O
+investigate O
+the O
+in O
+vivo O
+role O
+of O
+this O
+chimeric B
+bZIP I
+protein I
+in O
+oncogenic O
+transformation O
+, O
+its O
+expression O
+was O
+directed O
+to O
+the O
+lymphoid O
+compartments O
+of O
+transgenic O
+mice O
+. O
+
+This O
+is O
+consistent O
+with O
+the O
+need O
+for O
+a O
+nuclear B
+retinoid I
+receptor I
+function O
+in O
+RA O
+- O
+induced O
+ERK2 B
+activation O
+. O
+
+In O
+the O
+virus O
+- O
+infected O
+cells O
+, O
+translation O
+of O
+the O
+M1 B
+protein I
+was O
+reduced O
+to O
+10 O
+to O
+20 O
+% O
+of O
+that O
+of O
+the O
+wild O
+- O
+type O
+virus O
+; O
+however O
+, O
+the O
+translation O
+of O
+neither O
+the O
+nucleoprotein O
+nor O
+NS1 B
+was O
+significantly O
+interfered O
+with O
+, O
+indicating O
+the O
+important O
+role O
+of O
+NS1 B
+in O
+translational O
+stimulation O
+of O
+the O
+M1 B
+protein I
+. O
+
+Some O
+cells O
+were O
+excited O
+, O
+others O
+inhibited O
+by O
+, O
+and O
+only O
+some O
+were O
+directionally O
+sensitive O
+to O
+the O
+optomotor O
+stimulus O
+. O
+
+LT B
+- I
+beta I
+transcription O
+is O
+maximal O
+in O
+the O
+thymic O
+medulla O
+and O
+in O
+splenic O
+white O
+pulp O
+. O
+
+A O
+novel O
+Cdc42Hs B
+mutant I
+induces O
+cellular O
+transformation O
+. O
+
+Interactions O
+were O
+also O
+detected O
+between O
+full B
+- I
+length I
+HSF1 I
+and O
+the O
+small O
+subunit O
+( O
+gamma O
+) O
+of O
+TFIIA B
+. O
+
+We O
+report O
+that O
+Nim1 B
+possesses O
+intrinsic O
+serine B
+- I
+kinase I
+, O
+threonine B
+- I
+kinase I
+and O
+tyrosine B
+- I
+kinase I
+activities O
+. O
+
+A O
+short O
+conserved O
+motif O
+is O
+required O
+for O
+repressor O
+domain O
+function O
+in O
+the O
+myeloid O
+- O
+specific O
+transcription O
+factor O
+CCAAT B
+/ I
+enhancer I
+- I
+binding I
+protein I
+epsilon I
+. O
+
+Androgen O
+ablation O
+- O
+- O
+50 O
+years O
+later O
+. O
+
+In O
+conclusion O
+, O
+ORCA3 B
+regulates O
+jasmonate O
+- O
+responsive O
+expression O
+of O
+the O
+Str B
+gene I
+via O
+direct O
+interaction O
+with O
+the O
+JERE B
+. O
+
+Also O
+, O
+the O
+absence O
+of O
+PdNi B
+between O
+the O
+segments O
+reduces O
+the O
+heat O
+production O
+of O
+the O
+seed O
+. O
+
+Theoretical O
+mechanisms O
+of O
+hyperuricemia O
+. O
+
+ORF3 O
+encodes O
+a O
+putative O
+periplasmic B
+c I
+- I
+type I
+cytochrome I
+with O
+a O
+molecular O
+mass O
+of O
+94 O
+, O
+000 O
+Da O
+and O
+contains O
+seven O
+c O
+- O
+heme O
+- O
+binding O
+motifs O
+but O
+shows O
+no O
+sequence O
+homology O
+to O
+occ B
+or O
+ORF1 O
+. O
+
+Doxazosin O
+produced O
+increases O
+in O
+both O
+mean O
+and O
+maximum O
+urinary O
+flow O
+rates O
+of O
+1 O
+. O
+01 O
+ml O
+/ O
+s O
+and O
+3 O
+. O
+2 O
+ml O
+/ O
+s O
+respectively O
+, O
+compared O
+with O
+0 O
+. O
+21 O
+ml O
+/ O
+s O
+and O
+2 O
+. O
+2 O
+ml O
+/ O
+s O
+on O
+placebo O
+. O
+
+Hypoxia O
+decreased O
+the O
+rate O
+of O
+spontaneous O
+impulse O
+initiation O
+in O
+SA O
+nodal O
+fibers O
+by O
+decreasing O
+the O
+slope O
+of O
+diastolic O
+depolarization O
+. O
+
+BACKGROUND O
+- O
+- O
+Platelet B
+activating I
+factor I
+( O
+PAF B
+) O
+has O
+been O
+implicated O
+in O
+the O
+pathogenesis O
+of O
+airway O
+hyperresponsiveness O
+in O
+asthma O
+. O
+
+TFEC B
+RNA I
+is O
+found O
+in O
+many O
+tissues O
+of O
+adult O
+rats O
+, O
+but O
+the O
+relative O
+concentrations O
+of O
+TFEC B
+and O
+TFE3 B
+RNAs I
+vary O
+considerably O
+in O
+these O
+different O
+tissues O
+. O
+
+Our O
+results O
+show O
+that O
+unlike O
+the O
+case O
+for O
+sos1 B
+, O
+sos2 B
+gene I
+function O
+is O
+dispensable O
+for O
+normal O
+mouse O
+development O
+, O
+growth O
+, O
+and O
+fertility O
+. O
+
+Studies O
+of O
+HS2 B
+- I
+gamma I
+gene I
+reporter I
+constructs I
+carrying O
+CACCC O
+box O
+deletions O
+revealed O
+that O
+the O
+CACCC O
+box O
+sequence O
+of O
+the O
+gamma O
+gene O
+promoter O
+mediates O
+the O
+activation O
+of O
+the O
+gamma O
+gene O
+by O
+FKLF B
+. O
+
+Advisory O
+Committee O
+report O
+recommends O
+that O
+US O
+make O
+amends O
+for O
+human O
+radiation O
+experiments O
+. O
+
+Animals O
+were O
+divided O
+into O
+six O
+equal O
+groups O
+as O
+follows O
+: O
+( O
+1 O
+) O
+no O
+oral O
+drug O
+( O
+water O
+) O
+, O
+no O
+hemodilution O
+, O
+no O
+IV O
+drug O
+( O
+saline O
+) O
+; O
+( O
+2 O
+) O
+oral O
+water O
+, O
+hemodilution O
+, O
+IV O
+saline O
+; O
+( O
+3 O
+) O
+oral O
+water O
+, O
+no O
+hemodilution O
+, O
+IV O
+propranolol O
+; O
+( O
+4 O
+) O
+oral O
+water O
+, O
+hemodilution O
+, O
+IV O
+propranolol O
+; O
+( O
+5 O
+) O
+oral O
+propranolol O
+, O
+no O
+hemodilution O
+, O
+IV O
+saline O
+; O
+and O
+( O
+6 O
+) O
+oral O
+propranolol O
+, O
+hemodilution O
+, O
+IV O
+saline O
+. O
+
+First O
+, O
+a O
+GATA B
+- I
+1 I
+motif I
+was O
+found O
+to O
+bind O
+nuclear O
+factor O
+( O
+s O
+) O
+, O
+presumably O
+the O
+GATA B
+- I
+1 I
+factor I
+, O
+present O
+in O
+K O
+- O
+562 O
+cell O
+extracts O
+and O
+in O
+living O
+K O
+- O
+562 O
+cells O
+. O
+
+BPN O
+can O
+be O
+experimentally O
+produced O
+by O
+intratracheal O
+inoculation O
+of O
+microorganisms O
+in O
+high O
+concentrations O
+and O
+ventilator O
+- O
+associated O
+BPN O
+by O
+ventilating O
+baboons O
+with O
+oleic O
+- O
+acid O
+lung O
+injury O
+. O
+
+A O
+mouth O
+asymmetry O
+study O
+. O
+
+Additionally O
+, O
+these O
+findings O
+have O
+important O
+implications O
+for O
+the O
+understanding O
+of O
+the O
+mechanisms O
+of O
+HIV O
+- O
+1 O
+latency O
+and O
+reactivation O
+. O
+
+This O
+inhibition O
+was O
+due O
+to O
+competition O
+from O
+the O
+EMC B
+virus I
+IRES I
+present O
+in O
+pEP B
+- I
+2A I
+transcripts I
+, O
+as O
+well O
+as O
+the O
+expression O
+of O
+proteolytically O
+active O
+2Apro B
+. O
+
+Some O
+may O
+affect O
+the O
+folding O
+pathway O
+or O
+the O
+affinity O
+for O
+chaperonins B
+. O
+
+Diet O
+imbalances O
+and O
+aflatoxicosis O
+
+48 O
+. O
+35 O
++ O
+/ O
+- O
+5 O
+. O
+07 O
+mg O
+/ O
+l O
+in O
+R3 O
+; O
+p O
+< O
+0 O
+. O
+05 O
+) O
+and O
+in O
+the O
+AUC O
+( O
+0 O
+. O
+50 O
+h O
+) O
+( O
+1429 O
+. O
+92 O
++ O
+/ O
+- O
+284 O
+. O
+23 O
+in O
+PR O
+vs O
+. O
+
+The O
+effect O
+on O
+FIV B
+LTR I
+promoter I
+activity O
+of O
+progressively O
+deleting O
+these O
+nuclear O
+factor O
+binding O
+sites O
+was O
+examined O
+by O
+linking O
+LTR O
+deletion O
+mutants O
+to O
+the O
+chloramphenicol B
+acetyltransferase I
+( O
+CAT B
+) O
+gene O
+. O
+
+A O
+series O
+of O
+sequence O
+fragments O
+were O
+placed O
+5 O
+' O
+to O
+the O
+chloramphenicol B
+acetyltransferase I
+( O
+CAT B
+) O
+reporter O
+gene O
+and O
+ability O
+to O
+mediate O
+transcription O
+of O
+CAT B
+in O
+response O
+to O
+IFN B
+gamma I
+or O
+LPS O
+treatment O
+was O
+studied O
+following O
+transient O
+transfection O
+in O
+the O
+macrophage O
+- O
+like O
+cell O
+line O
+RAW O
+264 O
+. O
+7 O
+. O
+
+As O
+part O
+of O
+a O
+large O
+Dutch O
+prospective O
+multicenter O
+study O
+( O
+Netherlands O
+Cooperative O
+Study O
+on O
+the O
+Adequacy O
+of O
+Dialysis O
+- O
+2 O
+) O
+, O
+we O
+consecutively O
+included O
+all O
+new O
+patients O
+with O
+end O
+- O
+stage O
+renal O
+disease O
+for O
+whom O
+residual O
+renal O
+function O
+could O
+be O
+obtained O
+0 O
+to O
+4 O
+weeks O
+before O
+the O
+start O
+of O
+dialysis O
+therapy O
+. O
+
+Module O
+2 O
+of O
+RifA B
+lacks O
+a O
+beta B
+- I
+ketoacyl I
+: I
+acyl I
+carrier I
+protein I
+reductase I
+( O
+KR B
+) O
+domain O
+and O
+the O
+one O
+in O
+module O
+3 O
+has O
+an O
+apparently O
+inactive O
+NADPH O
+binding O
+motif O
+, O
+similar O
+to O
+one O
+found O
+in O
+the O
+Er B
+PKS I
+, O
+while O
+the O
+other O
+eight O
+KR B
+domains O
+of O
+the O
+Rf B
+PKS I
+should O
+be O
+functional O
+. O
+
+In O
+murine O
+cells O
+, O
+FPGS B
+expression O
+is O
+controlled O
+by O
+two O
+promoters O
+that O
+, O
+as O
+we O
+show O
+here O
+, O
+vary O
+substantially O
+in O
+their O
+efficiency O
+, O
+at O
+least O
+in O
+the O
+context O
+of O
+a O
+reporter O
+gene O
+assay O
+. O
+
+Should O
+we O
+use O
+thiazide O
+diuretics O
+in O
+hypertensive O
+patients O
+with O
+non O
+- O
+insulin B
+- O
+dependent O
+diabetes O
+mellitus O
+? O
+
+Reduced O
+glutathione O
+in O
+whole O
+blood O
+decreases O
+within O
+a O
+blood O
+Se O
+range O
+of O
+1 O
+. O
+01 O
+to O
+2 O
+. O
+28 O
+micrograms O
+in O
+the O
+high O
+Se O
+area O
+. O
+
+Sucrose O
+produced O
+in O
+source O
+leaves O
+is O
+the O
+predominant O
+carbon O
+source O
+for O
+developing O
+sink O
+tissues O
+in O
+most O
+higher O
+plants O
+. O
+
+A O
+personal O
+view O
+of O
+future O
+trends O
+in O
+the O
+field O
+of O
+immunoassay O
+concludes O
+this O
+review O
+. O
+
+In O
+accordance O
+with O
+Ann O
+Arbor O
+classification O
+, O
+we O
+observed O
+12 O
+CS O
+IA O
+( O
+21 O
+. O
+3 O
+% O
+) O
+, O
+2 O
+CS O
+IB O
+( O
+3 O
+. O
+5 O
+% O
+) O
+, O
+14 O
+CS O
+IIA O
+( O
+25 O
+. O
+4 O
+% O
+) O
+and O
+27 O
+CS O
+IIB O
+( O
+49 O
+. O
+7 O
+% O
+) O
+. O
+
+Numerous O
+genes O
+of O
+this O
+family O
+have O
+been O
+identified O
+in O
+animals O
+, O
+with O
+the O
+largest O
+number O
+found O
+in O
+vertebrates O
+. O
+
+The O
+GST B
+- O
+CBL B
+- O
+LZIP B
+fusion O
+protein O
+contains O
+a O
+binding O
+site O
+for O
+the O
+SH2 B
+domain I
+of O
+the O
+p85 B
+subunit I
+of O
+phosphatidylinositol B
+3 I
+- I
+kinase I
+, O
+which O
+mapped O
+to O
+Tyr731 O
+, O
+which O
+is O
+present O
+in O
+the O
+sequence O
+YEAM O
+. O
+
+We O
+have O
+previously O
+shown O
+that O
+UNC B
+- I
+4 I
+expression O
+in O
+the O
+VA O
+motor O
+neurons O
+specifies O
+the O
+wild O
+- O
+type O
+pattern O
+of O
+presynaptic O
+input O
+. O
+
+Significant O
+differences O
+were O
+observed O
+in O
+the O
+composition O
+of O
+nuclear O
+transcription O
+factors O
+bound O
+to O
+cis O
+- O
+elements O
+within O
+the O
+LDH B
+/ I
+C I
+proximal I
+promoter I
+region O
+in O
+somatic O
+versus O
+germ O
+cells O
+. O
+
+Above O
+this O
+transition O
+temperature O
+the O
+calcium O
+antagonist O
+lowers O
+fm O
+more O
+pronouncedly O
+than O
+below O
+. O
+
+( O
+1986 O
+) O
+described O
+optic O
+nerve O
+degenerations O
+in O
+patients O
+with O
+Alzheimer O
+' O
+s O
+disease O
+and O
+Sadun O
+published O
+a O
+dropout O
+of O
+retinal O
+ganglion O
+cells O
+that O
+range O
+from O
+30 O
+% O
+to O
+60 O
+% O
+. O
+
+It O
+has O
+become O
+clear O
+that O
+there O
+is O
+not O
+one O
+mediator O
+responsible O
+for O
+ALI O
+, O
+but O
+rather O
+a O
+complex O
+interplay O
+exists O
+between O
+diverse O
+proinflammatory O
+( O
+e O
+. O
+g O
+. O
+, O
+lipopolysaccharide O
+, O
+complement O
+products O
+, O
+cytocains O
+, O
+chemocains O
+, O
+reactive O
+oxygen O
+species O
+and O
+arachidonic O
+acid O
+products O
+) O
+and O
+anti O
+- O
+inflammatory O
+( O
+IL B
+- I
+10 I
+, O
+IL B
+- I
+1 I
+- I
+RA I
+, O
+PGI2 O
+) O
+mediators O
+. O
+
+We O
+then O
+supplemented O
+these O
+spliceosomes O
+with O
+purified O
+proteins O
+or O
+yeast O
+extract O
+fractions O
+as O
+a O
+functional O
+assay O
+for O
+second O
+- O
+step O
+splicing O
+factors O
+. O
+
+Contrast O
+radiography O
+appears O
+to O
+be O
+an O
+especially O
+inaccurate O
+method O
+to O
+document O
+PUD O
+in O
+CF O
+because O
+the O
+duodenal O
+mucosa O
+typically O
+appears O
+nodular O
+and O
+distorted O
+with O
+poor O
+definition O
+of O
+the O
+mucosal O
+folds O
+. O
+
+We O
+now O
+show O
+that O
+the O
+FRAP B
+Ser2035 I
+- O
+- O
+> O
+Ala I
+mutant I
+displays O
+similar O
+binding O
+affinity O
+when O
+compared O
+with O
+the O
+wild O
+- O
+type O
+protein O
+, O
+whereas O
+all O
+other O
+mutations O
+at O
+this O
+site O
+, O
+including O
+mimics O
+of O
+phosphoserine O
+, O
+abolish O
+binding O
+, O
+presumably O
+due O
+to O
+either O
+unfavorable O
+steric O
+interactions O
+or O
+induced O
+conformational O
+changes O
+. O
+
+A O
+Brassica O
+cDNA O
+clone O
+encoding O
+a O
+bifunctional O
+hydroxymethylpyrimidine B
+kinase I
+/ O
+thiamin B
+- I
+phosphate I
+pyrophosphorylase I
+involved O
+in O
+thiamin O
+biosynthesis O
+. O
+
+Titres O
+of O
+antistreptolysin B
+O I
+in O
+mothers O
+of O
+children O
+affected O
+with O
+Down O
+' O
+s O
+syndrome O
+. O
+
+Differential O
+decay O
+of O
+a O
+polycistronic O
+Escherichia O
+coli O
+transcript O
+is O
+initiated O
+by O
+RNaseE B
+- O
+dependent O
+endonucleolytic O
+processing O
+. O
+
+Defects O
+in O
+RT6 B
+expression O
+coincide O
+with O
+increased O
+susceptibility O
+in O
+animal O
+models O
+for O
+insulin B
+- O
+dependent O
+diabetes O
+mellitus O
+and O
+other O
+autoimmune O
+diseases O
+. O
+
+By O
+means O
+of O
+early O
+detection O
+and O
+correction O
+of O
+the O
+possible O
+causes O
+, O
+the O
+goal O
+of O
+increasing O
+therapeutic O
+efficacy O
+can O
+be O
+achieved O
+. O
+
+We O
+have O
+previously O
+described O
+the O
+partial O
+purification O
+of O
+Ap4A B
+hydrolase I
+from O
+S O
+. O
+pombe O
+[ O
+Robinson O
+, O
+de O
+la O
+Pena O
+and O
+Barnes O
+( O
+1993 O
+) O
+Biochim O
+. O
+
+Effect O
+of O
+a O
+new O
+positive O
+inotropic O
+agent O
+( O
+OPC O
+- O
+8212 O
+) O
+on O
+intracellular O
+potential O
+of O
+isolated O
+canine O
+ventricular O
+papillary O
+muscle O
+
+The O
+unc B
+- I
+101 I
+, O
+sli B
+- I
+1 I
+, O
+and O
+rok B
+- I
+1 I
+genes I
+encode O
+a O
+distinct O
+set O
+of O
+negative O
+regulators O
+of O
+vulval O
+differentiation O
+. O
+
+Thirty O
+- O
+seven O
+patients O
+with O
+severe O
+temporal O
+lobe O
+epilepsy O
+were O
+studied O
+interictally O
+with O
+[ O
+18F O
+] O
+fluorodeoxyglucose O
+- O
+PET O
+in O
+each O
+of O
+three O
+conditions O
+: O
+resting O
+, O
+during O
+emotional O
+speech O
+, O
+and O
+while O
+performing O
+a O
+visual O
+recognition O
+task O
+. O
+
+SYC1 B
+( O
+suppressor B
+of I
+yeast I
+cbf5 I
+- I
+1 I
+) O
+was O
+identified O
+as O
+a O
+multicopy O
+suppressor O
+of O
+cbf5 B
+- I
+1 I
+and O
+subsequently O
+was O
+found O
+to O
+be O
+identical O
+to O
+RRN3 B
+, O
+an O
+RNA B
+polymerase I
+I I
+transcription I
+factor I
+. O
+
+Newly O
+hatched O
+F1 O
+nymphs O
+of O
+Aiolopus O
+thalassinus O
+( O
+Fabr O
+. O
+) O
+were O
+fed O
+on O
+food O
+treated O
+with O
+various O
+concentrations O
+of O
+HgCl2 O
+, O
+CdCl2 O
+, O
+and O
+PbCl2 O
+until O
+the O
+end O
+of O
+adult O
+life O
+. O
+
+Neuronal O
+activity O
+of O
+58 O
+dopaminergic O
+( O
+DA O
+) O
+and O
+200 O
+non O
+- O
+dopaminergic O
+( O
+non O
+- O
+DA O
+) O
+neurons O
+in O
+the O
+ventral O
+tegmental O
+area O
+( O
+VTA O
+) O
+of O
+female O
+monkeys O
+was O
+recorded O
+, O
+and O
+correlation O
+to O
+bar O
+press O
+feeding O
+, O
+sensory O
+stimulation O
+and O
+change O
+in O
+motivation O
+was O
+investigated O
+. O
+
+Both O
+sequence O
+analysis O
+and O
+restriction O
+fragment O
+length O
+polymorphism O
+analysis O
+revealed O
+a O
+high O
+degree O
+of O
+sequence O
+( O
+97 O
+% O
+homology O
+) O
+and O
+structural O
+similarity O
+among O
+members O
+of O
+the O
+ART B
+- O
+CH B
+family O
+, O
+indicating O
+their O
+common O
+origin O
+and O
+recent O
+penetration O
+into O
+chicken O
+DNA O
+. O
+
+Three O
+of O
+these O
+positions O
+are O
+novel O
+in O
+that O
+they O
+had O
+not O
+been O
+identified O
+to O
+be O
+important O
+for O
+binding O
+PC B
+by O
+previous O
+crystallographic O
+analysis O
+. O
+
+We O
+demonstrate O
+inhibition O
+of O
+2 O
+- O
+deoxyglucose O
+uptake O
+in O
+isolated O
+primary O
+rat O
+adipocytes O
+and O
+3T3 O
+- O
+L1 O
+adipocytes O
+pretreated O
+with O
+U73122 O
+. O
+
+The O
+elevated O
+levels O
+of O
+inositol O
+phosphates O
+resulting O
+from O
+N O
+( O
+epi O
+) O
+alpha I
+qQ209L I
+expression O
+were O
+similar O
+to O
+those O
+obtained O
+with O
+carbachol O
+activation O
+of O
+the O
+M1 B
+muscarinic I
+acetylcholine I
+receptor I
+. O
+
+In O
+addition O
+, O
+wild O
+- O
+type O
+and O
+mutated O
+DNA O
+templates O
+were O
+used O
+as O
+probes O
+in O
+DNase B
+I I
+protection O
+experiments O
+to O
+determine O
+sites O
+of O
+protein O
+- O
+DNA O
+interaction O
+. O
+
+We O
+tested O
+the O
+hypothesis O
+that O
+PEH O
+is O
+associated O
+with O
+reductions O
+in O
+TPR O
+and O
+sympathetic O
+nerve O
+activity O
+( O
+SNA O
+) O
+. O
+
+Salt O
+wars O
+. O
+
+RESULTS O
+: O
+BMK O
+- O
+1 O
+and O
+other O
+19 O
+contents O
+significantly O
+decreased O
+depolarization O
+parameters O
+Vmax O
+, O
+APA O
+, O
+OS O
+, O
+and O
+MDP O
+, O
+which O
+was O
+similar O
+to O
+that O
+of O
+TTX O
+and O
+different O
+from O
+that O
+of O
+Nim O
+and O
+BaCl2 O
+. O
+
+In O
+the O
+latter O
+, O
+the O
+cells O
+and O
+adjacent O
+matrix O
+had O
+several O
+characteristics O
+of O
+fibrocartilage O
+, O
+including O
+chondrocytes O
+. O
+
+Mannich O
+bases O
+of O
+vanillin O
+oxime O
+. O
+
+All O
+exon O
+/ O
+intron O
+splice O
+junctions O
+follow O
+the O
+GT O
+/ O
+AG O
+rule O
+. O
+
+Previous O
+work O
+has O
+shown O
+that O
+glucose O
+repression O
+of O
+PRB1 B
+transcription O
+is O
+not O
+mediated O
+by O
+HXK2 B
+or O
+by O
+the O
+SNF1 B
+, O
+SNF4 B
+, O
+and O
+SNF6 B
+genes I
+( O
+C O
+. O
+
+Comparison O
+of O
+the O
+encoded O
+ERCC3Dm B
+protein I
+with O
+the O
+homologous O
+proteins O
+of O
+mouse O
+and O
+man O
+shows O
+a O
+strong O
+amino O
+acid O
+conservation O
+( O
+71 O
+% O
+identity O
+) O
+, O
+especially O
+in O
+the O
+postulated O
+DNA O
+binding O
+region O
+and O
+seven O
+' B
+helicase I
+' I
+domains I
+. O
+
+The O
+pyridostigmine O
+inhibited O
+AChE B
+recovered O
+only O
+in O
+the O
+100 O
+mumol O
+kg O
+- O
+1 O
+kg O
+oxime O
+groups O
+at O
+the O
+end O
+of O
+the O
+experiment O
+. O
+
+In O
+the O
+case O
+of O
+a O
+moderate O
+buccal O
+Class O
+II O
+tendency O
+, O
+55 O
+% O
+of O
+the O
+molars O
+were O
+in O
+a O
+Class O
+I O
+relationship O
+when O
+evaluated O
+from O
+the O
+lingual O
+side O
+, O
+whereas O
+45 O
+% O
+belonged O
+to O
+mild O
+( O
+1st O
+degrees O
+) O
+Class O
+II O
+with O
+molar O
+rotations O
+present O
+in O
+81 O
+% O
+of O
+the O
+cases O
+. O
+
+Mutation O
+of O
+this O
+threonine O
+to O
+isoleucine O
+had O
+no O
+observable O
+effect O
+on O
+either O
+nuclear O
+localization O
+of O
+E1 B
+or O
+DNA O
+replication O
+of O
+the O
+intact O
+viral O
+genome O
+. O
+
+Serum B
+prolactin I
+and O
+oestradiol O
+levels O
+at O
+different O
+stages O
+of O
+puberty O
+. O
+
+This O
+suggests O
+that O
+the O
+duration O
+of O
+varicocele O
+per O
+se O
+could O
+affect O
+DHT O
+seminal O
+plasma O
+levels O
+. O
+
+Left O
+ventricular O
+responses O
+to O
+dopamine O
+in O
+dilated O
+cardiomyopathy O
+as O
+assessed O
+by O
+two O
+- O
+dimensional O
+echocardiography O
+and O
+compared O
+with O
+findings O
+of O
+thallium O
+- O
+201 O
+scintigraphy O
+. O
+
+Detailed O
+comparison O
+of O
+the O
+urinary O
+excretion O
+of O
+purines O
+in O
+a O
+patient O
+with O
+the O
+Lesch O
+- O
+Nyhan O
+syndrome O
+and O
+a O
+control O
+subject O
+. O
+
+This O
+enzyme O
+is O
+distinct O
+from O
+other O
+known O
+E3s B
+, O
+including O
+E3 B
+alpha I
+/ O
+UBR1 B
+, O
+E3 B
+beta I
+, O
+and O
+E6 B
+- I
+AP I
+. O
+
+This O
+evidence O
+, O
+together O
+with O
+the O
+ability O
+of O
+a O
+carboxyl O
+- O
+terminal O
+coding O
+sequence O
+starting O
+from O
+the O
+BamHI B
+site I
+to O
+complement O
+a O
+shy1 B
+mutant I
+, O
+suggests O
+that O
+the O
+Shy1p B
+contains O
+two O
+domains O
+that O
+can O
+be O
+separately O
+expressed O
+to O
+form O
+a O
+functional O
+protein O
+. O
+
+The O
+zinc B
+finger I
+protein I
+A20 I
+is O
+a O
+tumor B
+necrosis I
+factor I
+( O
+TNF B
+) O
+- O
+and O
+interleukin B
+1 I
+( O
+IL B
+- I
+1 I
+) O
+- O
+inducible O
+protein O
+that O
+negatively O
+regulates O
+nuclear B
+factor I
+- I
+kappa I
+B I
+( O
+NF B
+- I
+kappaB I
+) O
+- O
+dependent O
+gene O
+expression O
+. O
+
+A O
+visibly O
+distinct O
+muscular O
+hypertrophy O
+( O
+mh O
+) O
+, O
+commonly O
+known O
+as O
+double O
+muscling O
+, O
+occurs O
+with O
+high O
+frequency O
+in O
+the O
+Belgian O
+Blue O
+and O
+Piedmontese O
+cattle O
+breeds O
+. O
+
+For O
+the O
+population O
+of O
+patients O
+with O
+melanoma O
+levels O
+III O
+and O
+IV O
+significant O
+differences O
+in O
+survival O
+rate O
+were O
+associated O
+with O
+thickness O
+( O
+less O
+than O
+2 O
+mm O
+or O
+greater O
+than O
+or O
+equal O
+to O
+2 O
+mm O
+; O
+p O
+less O
+than O
+0 O
+, O
+001 O
+) O
+, O
+though O
+not O
+with O
+level O
+. O
+
+At O
+least O
+one O
+such O
+complex O
+is O
+eliminated O
+by O
+preincubating O
+the O
+nuclear O
+extract O
+with O
+an O
+antibody O
+with O
+broad O
+cross O
+- O
+reactivity O
+with O
+Ets B
+- I
+1 I
+and O
+Ets B
+- I
+2 I
+proteins I
+, O
+thus O
+confirming O
+that O
+an O
+ETS B
+transcription I
+factor I
+( I
+s I
+) I
+recognizes O
+the O
+- O
+12 O
+motif O
+. O
+
+Mutant B
+beta2 I
+- I
+adrenergic I
+receptors I
+with O
+a O
+Tyr O
+- O
+to O
+- O
+Phe O
+substitution O
+at O
+Tyr O
+- O
+350 O
+do O
+not O
+display O
+agonist O
+- O
+induced O
+desensitization O
+, O
+Src B
+recruitment O
+, O
+or O
+Src B
+activation O
+. O
+
+Role O
+of O
+distinct O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+pathways O
+and O
+cooperation O
+between O
+Ets B
+- I
+2 I
+, O
+ATF B
+- I
+2 I
+, O
+and O
+Jun B
+family I
+members O
+in O
+human B
+urokinase I
+- I
+type I
+plasminogen I
+activator I
+gene I
+induction O
+by O
+interleukin B
+- I
+1 I
+and O
+tetradecanoyl O
+phorbol O
+acetate O
+. O
+
+Immunoblot O
+analysis O
+of O
+purified O
+and O
+protease O
+- O
+digested O
+intracellular O
+mature O
+virus O
+( O
+IMV O
+) O
+and O
+extracellular O
+enveloped O
+virus O
+( O
+EEV O
+) O
+showed O
+that O
+the O
+A36R B
+proteins I
+were O
+present O
+on O
+the O
+surface O
+of O
+EEV O
+with O
+type O
+II O
+membrane O
+topology O
+, O
+but O
+were O
+absent O
+from O
+IMV O
+. O
+
+Here O
+we O
+demonstrate O
+that O
+several O
+genes O
+associated O
+with O
+NHEJ O
+perform O
+essential O
+functions O
+in O
+the O
+repair O
+of O
+endonuclease O
+- O
+induced O
+DSBs O
+in O
+vivo O
+. O
+
+The O
+failure O
+suggests O
+that O
+these O
+assembly O
+competent O
+but O
+complementation O
+- O
+negative O
+alpha B
+mutants I
+lack O
+an O
+as O
+yet O
+unidentified O
+function O
+( O
+s O
+) O
+. O
+
+Psychopathological O
+, O
+vegetative O
+, O
+and O
+vital O
+parameters O
+were O
+assessed O
+every O
+hour O
+. O
+
+RESULTS O
+: O
+Considering O
+an O
+inulin O
+clearance O
+of O
+less O
+than O
+80 O
+ml O
+/ O
+min O
+/ O
+1 O
+. O
+73 O
+m2 O
+, O
+the O
+cut O
+- O
+off O
+value O
+for O
+serum O
+creatinine O
+was O
+11 O
+. O
+5 O
+mumol O
+/ O
+liter O
+for O
+men O
+and O
+90 O
+mumol O
+/ O
+liter O
+for O
+women O
+. O
+
+These O
+data O
+may O
+indicate O
+redundancy O
+between O
+members O
+of O
+the O
+NGFI B
+- I
+B I
+/ O
+Nurr1 B
+/ O
+Nor1 B
+subfamily O
+and O
+could O
+explain O
+why O
+no O
+phenotypic O
+disturbances O
+have O
+yet O
+been O
+found O
+in O
+mice O
+in O
+which O
+the O
+NGFI B
+- I
+B I
+gene I
+has O
+been O
+inactivated O
+. O
+
+Manual O
+sample O
+clean O
+- O
+up O
+procedures O
+as O
+well O
+as O
+the O
+addition O
+of O
+an O
+internal O
+standard O
+are O
+not O
+needed O
+. O
+
+To O
+directly O
+address O
+this O
+issue O
+, O
+we O
+used O
+a O
+tetracycline O
+- O
+regulated O
+system O
+in O
+human O
+U2OS O
+osteosarcoma O
+cells O
+and O
+thus O
+found O
+that O
+BCL6 B
+mediates O
+growth O
+suppression O
+associated O
+with O
+impaired O
+S O
+phase O
+progression O
+and O
+apoptosis O
+. O
+
+TAAG O
+sites O
+that O
+serve O
+as O
+functional O
+late O
+promoters O
+in O
+OpMNPV O
+were O
+found O
+to O
+mediate O
+transcription O
+initiation O
+at O
+only O
+basal O
+levels O
+in O
+the O
+context O
+of O
+the O
+AcMNPV O
+genome O
+, O
+suggesting O
+that O
+late O
+promoter O
+activation O
+may O
+be O
+virus O
+specific O
+within O
+the O
+family O
+Baculoviridae O
+. O
+
+Stability O
+of O
+125 O
+I O
+- O
+labeled O
+insulin B
+used O
+in O
+radioimmunoassay O
+of O
+insulin B
+. O
+
+In O
+absence O
+of O
+i O
+. O
+m O
+. O
+medication O
+, O
+levels O
+over O
+1 O
+, O
+000 O
+U O
+must O
+be O
+carefully O
+screened O
+in O
+order O
+to O
+rule O
+out O
+SNM O
+or O
+organic O
+pathology O
+associated O
+. O
+
+Paclitaxel O
+caused O
+a O
+rapid O
+and O
+transient O
+increase O
+in O
+c B
+- I
+Jun I
+NH2 I
+- I
+terminal I
+kinase I
+( O
+JNK B
+) O
+activity O
+, O
+a O
+proposed O
+mediator O
+of O
+stress O
+activation O
+pathways O
+. O
+
+These O
+results O
+indicate O
+that O
+H B
+- I
+2RIIBP I
+( I
+i I
+) I
+is O
+a O
+member O
+of O
+the O
+superfamily O
+of O
+nuclear B
+hormone I
+receptors I
+and O
+( O
+ii O
+) O
+may O
+regulate O
+not O
+only O
+MHC B
+class I
+I I
+genes I
+but O
+also O
+genes O
+containing O
+the O
+ERE O
+and O
+related O
+sequences O
+. O
+
+Two O
+courses O
+of O
+chemotherapy O
+( O
+CBCDA O
++ O
+VDS O
+) O
+failed O
+to O
+gain O
+any O
+improvement O
+, O
+and O
+the O
+pain O
+resulting O
+from O
+recurrent O
+bone O
+metastases O
+was O
+managed O
+mainly O
+by O
+the O
+administration O
+of O
+the O
+best O
+supportive O
+care O
+. O
+
+We O
+show O
+here O
+that O
+Spb1p B
+is O
+able O
+to O
+bind O
+[ O
+( O
+3 O
+) O
+H O
+] O
+AdoMet O
+in O
+vitro O
+, O
+suggesting O
+that O
+it O
+is O
+a O
+novel O
+methylase B
+, O
+whose O
+possible O
+substrates O
+will O
+be O
+discussed O
+. O
+
+RESULTS O
+: O
+Lateral O
+PF O
+OA O
+was O
+more O
+common O
+than O
+medial O
+PF O
+OA O
+( O
+P O
+< O
+0 O
+. O
+0001 O
+) O
+. O
+
+CONCLUSION O
+: O
+Urbanisation O
+is O
+associated O
+with O
+an O
+increase O
+in O
+the O
+prevalence O
+rates O
+of O
+some O
+risk O
+behaviours O
+. O
+
+However O
+, O
+additional O
+studies O
+on O
+cell O
+lines O
+and O
+whole O
+animals O
+are O
+required O
+to O
+understand O
+GnRH B
+signaling O
+in O
+the O
+context O
+of O
+other O
+hormones O
+during O
+the O
+reproductive O
+cycle O
+of O
+mouse O
+and O
+human O
+. O
+
+Serum B
+angiogenin I
+concentrations O
+in O
+young O
+patients O
+with O
+diabetes O
+mellitus O
+. O
+
+This O
+duplicated O
+genomic O
+region O
+is O
+also O
+linked O
+tightly O
+to O
+D1Z2 B
+, O
+a O
+genetic O
+marker O
+containing O
+a O
+highly O
+polymorphic O
+VNTR O
+( O
+variable O
+number O
+tandem O
+repeat O
+) O
+consisting O
+of O
+an O
+unusual O
+40 O
+- O
+bp O
+reiterated O
+sequence O
+. O
+
+ATF6 B
+, O
+a O
+basic B
+- I
+leucine I
+zipper I
+protein I
+, O
+was O
+isolated O
+by O
+binding O
+to O
+SRF B
+and O
+in O
+particular O
+to O
+its O
+transcriptional O
+activation O
+domain O
+. O
+
+Cetn1 B
+possesses O
+the O
+sequence O
+features O
+of O
+an O
+expressed O
+retroposon O
+: O
+the O
+gene O
+lacks O
+introns O
+, O
+the O
+open O
+reading O
+frame O
+is O
+not O
+interrupted O
+by O
+stop O
+codons O
+, O
+and O
+the O
+coding O
+region O
+is O
+flanked O
+by O
+a O
+pair O
+of O
+direct O
+repeats O
+. O
+
+The O
+largest O
+one O
+probably O
+corresponds O
+to O
+the O
+precursor O
+form O
+of O
+PS2 B
+in O
+E O
+. O
+coli O
+. O
+
+The O
+Aspergillus B
+uvsH I
+gene I
+encodes O
+a O
+product O
+homologous O
+to O
+yeast B
+RAD18 I
+and O
+Neurospora B
+UVS I
+- I
+2 I
+. O
+
+On O
+average O
+these O
+maximum O
+potency O
+estimates O
+were O
+within O
+one O
+order O
+of O
+magnitude O
+of O
+the O
+inverse O
+maximum O
+dose O
+tested O
+. O
+
+VAV B
+and O
+SOCS1 B
+form O
+a O
+protein O
+complex O
+through O
+interactions O
+between O
+the O
+VAV B
+NH I
+( I
+2 I
+) I
+- I
+terminal I
+regulatory I
+region I
+and O
+the O
+SH2 B
+domain I
+of O
+SOCS1 B
+in O
+a O
+phosphotyrosine O
+- O
+independent O
+manner O
+. O
+
+The O
+originally O
+embryonic B
+gamma I
+- I
+globin I
+locus I
+duplicated O
+and O
+acquired O
+a O
+novel O
+( O
+fetal O
+) O
+pattern O
+of O
+expression O
+in O
+a O
+defined O
+time O
+period O
+( O
+55 O
+- O
+40 O
+million O
+years O
+ago O
+) O
+during O
+primate O
+phylogeny O
+. O
+
+Clostridium O
+botulinum O
+in O
+marine O
+sediment O
+
+Northern O
+blot O
+analysis O
+with O
+GPR37 B
+probes O
+revealed O
+a O
+main O
+3 O
+. O
+8 O
+- O
+kb O
+mRNA O
+and O
+a O
+less O
+abundant O
+8 O
+- O
+kb O
+mRNA O
+, O
+both O
+expressed O
+in O
+human O
+brain O
+tissues O
+, O
+particularly O
+in O
+corpus O
+callosum O
+, O
+medulla O
+, O
+putamen O
+, O
+and O
+caudate O
+nucleus O
+. O
+
+Our O
+studies O
+indicate O
+no O
+single O
+trans O
+- O
+acting O
+factor O
+is O
+absolutely O
+essential O
+for O
+enhancer O
+activity O
+, O
+and O
+that O
+the O
+enhancer O
+activity O
+of O
+MerI B
+is O
+mediated O
+via O
+a O
+combinatorial O
+and O
+additive O
+mechanism O
+. O
+
+In O
+human O
+WI38 O
+cells O
+, O
+the O
+E1B B
+19K I
+gene I
+mutant I
+viruses O
+had O
+a O
+substantial O
+growth O
+advantage O
+over O
+the O
+wild O
+- O
+type O
+virus O
+, O
+yielding O
+500 O
+- O
+fold O
+- O
+higher O
+titers O
+. O
+
+To O
+elucidate O
+the O
+mechanism O
+of O
+these O
+hormonal O
+effects O
+, O
+we O
+have O
+studied O
+the O
+regulatory O
+regions O
+of O
+the O
+PFK B
+- I
+2 I
+gene I
+in O
+transfection O
+experiments O
+. O
+
+Consequently O
+, O
+during O
+the O
+evolution O
+of O
+mammals O
+, O
+it O
+is O
+the O
+CKbeta4GT B
+- I
+I I
+gene I
+lineage I
+that O
+has O
+been O
+recruited O
+for O
+the O
+biosynthesis O
+of O
+lactose O
+. O
+
+Furthermore O
+, O
+disruption O
+of O
+pcr1 B
+reduced O
+expression O
+of O
+fbp1 B
+, O
+a O
+glucose O
+- O
+repressible O
+gene O
+negatively O
+regulated O
+by O
+PKA B
+. O
+
+In O
+solution O
+, O
+[ O
+( O
+125 O
+) O
+I O
+] O
+- O
+labeled O
+ankyrin B
+was O
+found O
+by O
+ND O
+- O
+PAGE3 O
+to O
+enhance O
+the O
+affinity O
+of O
+spectrin B
+self O
+- O
+association O
+by O
+10 O
+- O
+fold O
+. O
+
+Transcription O
+analysis O
+of O
+the O
+EcoRI B
+D I
+region I
+of I
+the I
+baculovirus I
+Autographa I
+californica I
+nuclear I
+polyhedrosis I
+virus I
+identifies O
+an O
+early O
+4 O
+- O
+kilobase O
+RNA O
+encoding O
+the O
+essential O
+p143 B
+gene I
+. O
+
+Anesthesia O
+in O
+the O
+radical O
+surgery O
+of O
+arteriosclerotic O
+coronary O
+disease O
+
+5 O
+Intravenous O
+prizidilol O
+hydrochloride O
+decreases O
+resting O
+blood O
+pressure O
+and O
+left O
+ventricular O
+area O
+, O
+increases O
+pulse O
+rate O
+and O
+has O
+virtually O
+no O
+effect O
+on O
+left O
+ventricular O
+ejection O
+fraction O
+. O
+
+In O
+this O
+study O
+, O
+the O
+subcellular O
+location O
+, O
+domain O
+structure O
+, O
+and O
+biochemical O
+function O
+of O
+metaxin B
+were O
+investigated O
+. O
+
+The O
+human O
+cDNA O
+was O
+cloned O
+and O
+sequenced O
+; O
+it O
+was O
+shown O
+to O
+have O
+an O
+open O
+reading O
+frame O
+encoding O
+a O
+296 O
+- O
+amino O
+- O
+acid O
+protein O
+in O
+which O
+could O
+be O
+identified O
+four O
+peptides O
+previously O
+identified O
+by O
+micro O
+- O
+sequencing O
+purified O
+protein O
+. O
+
+Our O
+aim O
+was O
+to O
+evaluate O
+this O
+technique O
+by O
+cross O
+- O
+calibrating O
+the O
+DXA O
+method O
+with O
+the O
+carcass O
+chemical O
+analysis O
+in O
+a O
+heterogeneous O
+population O
+of O
+nondiabetic O
+Wistar O
+and O
+diabetic O
+GK O
+rats O
+( O
+21 O
+animals O
+were O
+used O
+for O
+precision O
+error O
+and O
+reproducibility O
+determinations O
+and O
+26 O
+were O
+used O
+for O
+accuracy O
+studies O
+) O
+. O
+
+Flux O
+of O
+the O
+paramyxovirus O
+hemagglutinin B
+- O
+neuraminidase I
+glycoprotein O
+through O
+the O
+endoplasmic O
+reticulum O
+activates O
+transcription O
+of O
+the O
+GRP78 B
+- O
+BiP B
+gene O
+. O
+
+The O
+preference O
+for O
+third O
+base O
+codon O
+in O
+Y O
+position O
+prolines O
+is O
+U O
+for O
+the O
+alpha B
+2 I
+( I
+VI I
+) I
+collagen I
+as O
+it O
+is O
+for O
+the O
+human B
+fibrillar I
+collagen I
+genes I
+. O
+
+Small O
+cell O
+tumors O
+in O
+children O
+: O
+contribution O
+to O
+the O
+solution O
+of O
+the O
+problem O
+of O
+differential O
+diagnosis O
+with O
+immunohistochemistry O
+and O
+electron O
+microscopy O
+
+Detonation O
+- O
+traumatic O
+load O
+during O
+military O
+service O
+
+In O
+static O
+conditions O
+, O
+body O
+sway O
+was O
+assessed O
+using O
+a O
+conventional O
+force O
+platform O
+with O
+eyes O
+open O
+and O
+with O
+eyes O
+closed O
+. O
+
+Soggy B
+, O
+a O
+spermatocyte O
+- O
+specific O
+gene O
+, O
+lies O
+3 O
+. O
+8 O
+kb O
+upstream O
+of O
+and O
+antipodal O
+to O
+TEAD B
+- I
+2 I
+, O
+a O
+transcription O
+factor O
+expressed O
+at O
+the O
+beginning O
+of O
+mouse O
+development O
+. O
+
+Teratospermia O
+is O
+therefore O
+an O
+important O
+factor O
+in O
+evaluating O
+fertilization O
+capacity O
+. O
+
+Results O
+of O
+the O
+study O
+suggest O
+that O
+Chinese O
+medicine O
+use O
+among O
+this O
+population O
+depends O
+on O
+health O
+conditions O
+, O
+and O
+that O
+having O
+a O
+regular O
+source O
+of O
+care O
+for O
+Chinese O
+medicine O
+as O
+well O
+as O
+a O
+preference O
+for O
+Chinese O
+medicine O
+are O
+two O
+predictors O
+for O
+its O
+use O
+. O
+
+The O
+greatest O
+risk O
+of O
+preterm O
+prelabour O
+rupture O
+of O
+membranes O
+( O
+PPROM O
+) O
+is O
+preterm O
+delivery O
+. O
+
+DISCUSSION O
+: O
+The O
+higher O
+absolute O
+knee O
+extension O
+strength O
+measures O
+of O
+leg O
+and O
+the O
+similar O
+extension O
+strength O
+of O
+the O
+trunk O
+in O
+the O
+obese O
+sample O
+compared O
+to O
+the O
+lean O
+might O
+be O
+explained O
+by O
+the O
+training O
+effect O
+of O
+weight O
+bearing O
+and O
+support O
+of O
+a O
+larger O
+body O
+mass O
+. O
+
+Residues O
+of O
+Stauffer O
+R O
+- O
+3828 O
+and O
+its O
+oxygen O
+analogue O
+in O
+the O
+body O
+tissues O
+of O
+cattle O
+fed O
+R O
+- O
+3828 O
+in O
+the O
+diet O
+. O
+
+The O
+goals O
+of O
+these O
+experiments O
+were O
+to O
+determine O
+whether O
+lactational O
+anestrus O
+would O
+be O
+prolonged O
+by O
+a O
+48 O
+- O
+h O
+fast O
+at O
+days O
+13 O
+and O
+14 O
+postpartum O
+( O
+pp O
+) O
+and O
+, O
+if O
+so O
+, O
+to O
+determine O
+whether O
+this O
+effect O
+could O
+be O
+reversed O
+by O
+treatment O
+with O
+the O
+Ob B
+protein I
+leptin B
+. O
+
+In O
+pituitary O
+GH3 O
+cells O
+, O
+vitamin O
+D O
+increases O
+the O
+levels O
+of O
+PRL B
+transcripts I
+and O
+stimulates O
+the O
+PRL B
+promoter I
+. O
+
+However O
+, O
+electron O
+microscopy O
+revealed O
+that O
+while O
+sec4 B
+mutant I
+cells O
+accumulate O
+secretory O
+vesicles O
+, O
+ypt31 B
+/ I
+32 I
+mutant I
+cells O
+accumulate O
+aberrant O
+Golgi O
+structures O
+. O
+
+METHODS O
+: O
+We O
+retrospectively O
+analyzed O
+the O
+data O
+of O
+20 O
+patients O
+who O
+underwent O
+both O
+gated O
+fluorine O
+18 O
+deoxyglucose O
+( O
+FDG O
+) O
+- O
+PET O
+and O
+equilibrium O
+radionuclide O
+angiography O
+( O
+ERNA O
+) O
+. O
+
+However O
+, O
+it O
+is O
+now O
+suggested O
+that O
+the O
+use O
+of O
+more O
+slowly O
+digested O
+starchy O
+foods O
+may O
+have O
+positive O
+health O
+benefits O
+. O
+
+Northern O
+blot O
+analysis O
+demonstrated O
+that O
+the O
+genes O
+are O
+transcribed O
+separately O
+. O
+
+Complete O
+activation O
+of O
+signal B
+transducer I
+and I
+activator I
+of I
+transcription I
+1 I
+( O
+STAT1 B
+) O
+requires O
+phosphorylation O
+at O
+both O
+Y701 O
+and O
+a O
+conserved O
+PMS O
+( O
+727 O
+) O
+P O
+sequence O
+. O
+
+Over O
+half O
+of O
+the O
+children O
+initially O
+unresponsive O
+to O
+H O
+. O
+influenzae O
+type O
+b O
+meningitis O
+subsequently O
+developed O
+specific O
+antibodies O
+. O
+
+It O
+is O
+important O
+to O
+understand O
+the O
+etiology O
+of O
+HITT O
+because O
+of O
+its O
+devastating O
+clinical O
+consequences O
+. O
+
+Five O
+sequence O
+variants O
+were O
+identified O
+. O
+
+The O
+Ras B
+GTPase I
+- I
+activating I
+- I
+protein I
+- I
+related I
+human I
+protein I
+IQGAP2 I
+harbors O
+a O
+potential O
+actin B
+binding I
+domain I
+and O
+interacts O
+with O
+calmodulin B
+and O
+Rho B
+family I
+GTPases I
+. O
+
+We O
+anticipated O
+SNS O
+function O
+after O
+CVA O
+to O
+be O
+asymmetric O
+and O
+selected O
+null O
+hypotheses O
+of O
+bilaterally O
+symmetric O
+SSR O
+latencies O
+and O
+amplitudes O
+irrespective O
+of O
+side O
+of O
+stimulation O
+and O
+/ O
+or O
+recording O
+. O
+
+Partial O
+hepatectomy O
+in O
+metastatic O
+Wilms O
+' O
+tumor O
+. O
+
+The O
+adoption O
+of O
+a O
+twisted O
+structure O
+of O
+importin B
+- I
+beta I
+is O
+essential O
+for O
+the O
+protein O
+- O
+protein O
+interaction O
+required O
+for O
+nuclear O
+transport O
+. O
+
+The O
+presence O
+of O
+a O
+short O
+( O
+70 O
+bp O
+) O
+intron O
+near O
+the O
+N O
+- O
+terminus O
+of O
+the O
+atX B
+gene I
+was O
+predicted O
+that O
+contains O
+the O
+canonical O
+GT O
+and O
+AG O
+dinucleotides O
+at O
+its O
+5 O
+' O
+- O
+and O
+3 O
+' O
+- O
+splicing O
+junctions O
+. O
+
+Moreover O
+, O
+a O
+hybrid O
+protein O
+composed O
+of O
+a O
+PvALF B
+activation I
+domain I
+and O
+the O
+DNA O
+binding O
+and O
+dimerization O
+domain O
+of O
+ROM2 B
+activated O
+gene O
+expression O
+, O
+indicating O
+that O
+ROM2 B
+recognizes O
+the O
+DLEC2 B
+enhancer I
+in O
+vivo O
+; O
+consequently O
+, O
+ROM2 B
+functions O
+as O
+a O
+DNA O
+binding O
+site O
+- O
+dependent O
+repressor O
+. O
+
+Tc O
+- O
+99m O
+HMPAO O
+brain O
+SPECT O
+compared O
+to O
+CT O
+and O
+EEG O
+after O
+seizures O
+in O
+childhood O
+. O
+
+We O
+found O
+that O
+the O
+central O
+nonconserved O
+region O
+of O
+the O
+large O
+subunit O
+is O
+not O
+essential O
+for O
+function O
+and O
+likely O
+acts O
+as O
+a O
+spacer O
+between O
+the O
+conserved O
+N O
+- O
+and O
+C O
+- O
+terminal O
+regions O
+. O
+
+On O
+the O
+other O
+hand O
+, O
+NE O
+transport O
+and O
+antagonist O
+( O
+[ O
+125I O
+] O
+RTI O
+- O
+55 O
+) O
+binding O
+assays O
+on O
+whole O
+LLC O
+- O
+NET O
+cells O
+treated O
+with O
+tunicamycin O
+reveal O
+a O
+pronounced O
+reduction O
+in O
+NE O
+transport O
+activity O
+and O
+hNET B
+membrane O
+density O
+paralleled O
+by O
+an O
+inability O
+of O
+NET O
+proteins O
+to O
+replenish O
+the O
+higher O
+M O
+( O
+r O
+) O
+hNET B
+pool O
+. O
+
+We O
+show O
+that O
+the O
+upstream O
+region O
+of O
+the O
+beta B
+- I
+MyHC I
+gene I
+( O
+- O
+5518 O
+to O
+- O
+2490 O
+relative O
+to O
+the O
+transcriptional O
+start O
+site O
+) O
+directed O
+high O
+levels O
+of O
+transcriptional O
+activity O
+only O
+when O
+stably O
+integrated O
+, O
+but O
+not O
+when O
+expressed O
+extrachromosomally O
+in O
+transient O
+assays O
+. O
+
+DNase B
+I I
+protection O
+analysis O
+as O
+well O
+as O
+oligonucleotide O
+competition O
+experiments O
+indicate O
+that O
+this O
+binding O
+is O
+sequence O
+specific O
+. O
+
+Plasmid O
+pSP64E6E7 O
+which O
+contains O
+the O
+reading O
+frames O
+of O
+both O
+E6 B
+and O
+E7 B
+was O
+constructed O
+in O
+order O
+to O
+study O
+the O
+expression O
+of O
+both O
+proteins O
+in O
+a O
+coupled O
+transcription O
+/ O
+rabbit O
+reticulocyte O
+translation O
+system O
+. O
+
+In O
+transient O
+transfections O
+using O
+luciferase B
+reporter I
+genes I
+driven O
+by O
+1 O
+kb O
+of O
+the O
+5 O
+' O
+flanking O
+DNA O
+of O
+the O
+three O
+CALM B
+genes I
+, O
+the O
+promoter O
+activity O
+correlated O
+with O
+the O
+endogenous O
+CALM B
+transcriptional O
+activity O
+, O
+but O
+only O
+when O
+the O
+5 O
+' O
+untranslated O
+regions O
+were O
+included O
+in O
+the O
+constructs O
+. O
+
+These O
+findings O
+suggest O
+that O
+PGE1 O
+is O
+effective O
+in O
+increasing O
+PVF O
+in O
+the O
+liver O
+transplanted O
+condition O
+; O
+however O
+, O
+the O
+hepatic O
+circulatory O
+improvement O
+attributed O
+to O
+this O
+agent O
+would O
+be O
+limited O
+to O
+the O
+first O
+few O
+days O
+following O
+transplantation O
+. O
+
+The O
+derepressed O
+expression O
+of O
+fixN B
+was O
+not O
+observed O
+in O
+a O
+purH B
+mutant I
+. O
+
+Nearly O
+1 O
+. O
+5 O
+million O
+American O
+men O
+age O
+65 O
+and O
+older O
+have O
+osteoporosis O
+, O
+and O
+another O
+3 O
+. O
+5 O
+million O
+are O
+at O
+risk O
+. O
+
+Both O
+viruses O
+express O
+the O
+mil B
+/ O
+raf B
+oncogene O
+product O
+as O
+a O
+gag B
+- I
+fusion I
+polyprotein I
+, O
+while O
+the O
+myc B
+oncogene I
+of O
+MH2 O
+is O
+expressed O
+via O
+a O
+subgenomic O
+mRNA O
+. O
+
+CONCLUSION O
+: O
+DaunoXome O
+has O
+an O
+improved O
+pharmacokinetic O
+profile O
+compared O
+with O
+free O
+daunorubicin O
+, O
+and O
+is O
+well O
+tolerated O
+. O
+
+This O
+regimen O
+may O
+be O
+considered O
+front O
+- O
+line O
+therapy O
+when O
+autologous O
+stem O
+cell O
+transplantation O
+is O
+not O
+feasible O
+and O
+when O
+a O
+rapid O
+response O
+is O
+particularly O
+important O
+. O
+
+Recombinant O
+protein O
+encoded O
+by O
+ESX B
+( O
+for O
+epithelial B
+- I
+restricted I
+with I
+serine I
+box I
+) O
+exhibits O
+Ets B
+- O
+like O
+DNA O
+binding O
+specificity O
+in O
+electrophoretic O
+mobility O
+shift O
+assays O
+and O
+, O
+in O
+transient O
+transfection O
+assays O
+, O
+transactivates O
+Ets B
+- I
+responsive I
+promoter I
+elements I
+including O
+that O
+found O
+in O
+the O
+HER2 B
+/ O
+neu B
+oncogene O
+. O
+
+In O
+area O
+CA1 O
+of O
+the O
+hippocampus O
+, O
+numbers O
+of O
+normal O
+neurons O
+were O
+increased O
+11 O
+- O
+to O
+14 O
+- O
+fold O
+by O
+MK O
+- O
+801 O
+treatment O
+( O
+p O
+< O
+0 O
+. O
+01 O
+) O
+. O
+
+The O
+temporal O
+changes O
+in O
+the O
+plasma O
+concentration O
+of O
+immunoreactive B
+atrial I
+natriuretic I
+factor I
+( O
+iANF B
+) O
+were O
+studied O
+in O
+six O
+conscious O
+dogs O
+with O
+an O
+arteriovenous O
+( O
+AV O
+) O
+fistula O
+, O
+a O
+model O
+of O
+chronic O
+high O
+- O
+output O
+heart O
+failure O
+. O
+
+The O
+revaluation O
+at O
+the O
+end O
+of O
+the O
+study O
+showed O
+a O
+good O
+compliance O
+for O
+the O
+proposed O
+diet O
+scheme O
+by O
+children O
+, O
+but O
+a O
+poor O
+compliance O
+by O
+their O
+families O
+. O
+
+The O
+delta O
+G O
+values O
+of O
+these O
+regions O
+were O
+higher O
+, O
+i O
+. O
+e O
+. O
+potential O
+secondary O
+structural O
+elements O
+were O
+fewer O
+, O
+than O
+in O
+TIR O
+of O
+genes O
+from O
+E O
+. O
+coli O
+. O
+
+Two O
+closely O
+related O
+groups O
+of O
+transcripts O
+, O
+Sagrp1 B
+and O
+Sagrp2 B
+, O
+controlled O
+by O
+a O
+circadian O
+rhythm O
+have O
+been O
+isolated O
+. O
+
+Of O
+921 O
+specimens O
+, O
+95 O
+yielded O
+non O
+- O
+albicans O
+species O
+, O
+mainly O
+from O
+patients O
+with O
+low O
+CD4 B
+lymphocyte O
+counts O
+and O
+extensive O
+previous O
+azole O
+exposure O
+. O
+
+These O
+findings O
+suggest O
+that O
+eIF5 B
+- O
+eIF2beta B
+interaction O
+plays O
+an O
+essential O
+role O
+in O
+eIF5 B
+function O
+in O
+eukaryotic O
+cells O
+. O
+
+Three O
+simple O
+methods O
+of O
+detecting O
+malnutrition O
+on O
+medical O
+wards O
+. O
+
+Compared O
+with O
+controls O
+, O
+patients O
+in O
+the O
+unmedicated O
+state O
+had O
+low O
+smooth O
+pursuit O
+gain O
+, O
+had O
+a O
+higher O
+rate O
+of O
+corrective O
+catch O
+- O
+up O
+saccades O
+, O
+and O
+tended O
+to O
+spend O
+less O
+time O
+engaged O
+in O
+the O
+tracking O
+task O
+. O
+
+Cytokine O
+- O
+mediated O
+I B
+kappa I
+B I
+alpha I
+reappearance O
+was O
+completely O
+blocked O
+by O
+the O
+protein O
+synthesis O
+inhibitor O
+cycloheximide O
+. O
+
+Development O
+of O
+P O
+carinii O
+pneumonia O
+was O
+associated O
+with O
+the O
+stage O
+of O
+Kaposi O
+' O
+s O
+sarcoma O
+, O
+B O
+subtype O
+disease O
+, O
+and O
+the O
+presence O
+of O
+0 O
+. O
+20 O
+X O
+10 O
+( O
+9 O
+) O
+/ O
+L O
+( O
+200 O
+/ O
+mm3 O
+) O
+or O
+fewer O
+CD4 B
+cells O
+at O
+study O
+entry O
+. O
+
+The O
+effects O
+of O
+tilmicosin O
+administration O
+in O
+the O
+feed O
+at O
+400 O
+mg O
+/ O
+kg O
+and O
+an O
+injection O
+therapy O
+of O
+clinically O
+diseased O
+pigs O
+with O
+long O
+- O
+acting O
+oxytetracycline O
+( O
+Terramycine O
+LA O
+) O
+at O
+20 O
+mg O
+/ O
+kg O
+bodyweight O
+were O
+compared O
+. O
+
+Those O
+participating O
+in O
+this O
+investigation O
+( O
+65 O
+centers O
+= O
+79 O
+% O
+) O
+received O
+a O
+series O
+of O
+computer O
+disks O
+containing O
+50 O
+99mTc O
+- O
+DMSA O
+studies O
+. O
+
+Pathogenesis O
+of O
+fever O
+. O
+
+Two O
+full O
+- O
+length O
+clones O
+( O
+pBCH1 B
+and O
+pBCH2 B
+) O
+were O
+isolated O
+. O
+
+Childbirth O
+and O
+authoritative O
+knowledge O
+. O
+
+The O
+ends O
+of O
+the O
+barrel O
+are O
+capped O
+by O
+short O
+helices O
+. O
+
+Non O
+- O
+finger O
+- O
+coding O
+modules O
+conserved O
+among O
+members O
+of O
+subfamilies O
+of O
+zinc B
+finger I
+genes I
+have O
+been O
+described O
+in O
+the O
+murine O
+genome O
+( O
+finger O
+- O
+associated O
+boxes O
+, O
+or O
+FAX B
+domain I
+) O
+and O
+the O
+human O
+genome O
+( O
+Kruppel B
+- I
+associated I
+boxes I
+, O
+or O
+KRAB B
+domain I
+) O
+. O
+
+This O
+combination O
+is O
+considered O
+pathognomonic O
+for O
+factitious O
+hyperinsulinism O
+. O
+
+Comparison O
+of O
+the O
+5 O
+' O
+flanking O
+regions O
+of O
+the O
+mouse O
+J B
+kappa I
+elements O
+, O
+including O
+the O
+conserved O
+putative O
+recombination O
+target O
+sequences O
+, O
+shows O
+no O
+obvious O
+differences O
+consistent O
+with O
+the O
+variation O
+in O
+recombinational O
+efficiency O
+, O
+so O
+we O
+conclude O
+that O
+, O
+although O
+the O
+consensus O
+heptamer O
+and O
+nonamer O
+signals O
+may O
+be O
+sufficient O
+to O
+identify O
+a O
+recombination O
+site O
+, O
+the O
+probability O
+that O
+that O
+site O
+will O
+be O
+used O
+depends O
+also O
+on O
+other O
+determinants O
+. O
+
+The O
+melanoma O
+growth O
+stimulatory O
+activity I
+/ O
+growth O
+- O
+regulated O
+protein O
+, O
+CXCL1 B
+, O
+is O
+constitutively O
+expressed O
+at O
+high O
+levels O
+during O
+inflammation O
+and O
+progression O
+of O
+melanocytes O
+into O
+malignant O
+melanoma O
+. O
+
+Genetic O
+analysis O
+places O
+CWH43 B
+upstream O
+of O
+the O
+BCK2 B
+branch O
+of O
+the O
+PKC1 B
+signalling O
+pathway O
+, O
+since O
+cwh43 B
+mutations O
+were O
+synthetic O
+lethal O
+with O
+pkc1 B
+deletion O
+, O
+whereas O
+the O
+cwh43 B
+defects O
+could O
+be O
+rescued O
+by O
+overexpression O
+of O
+BCK2 B
+and O
+not O
+by O
+high O
+- O
+copy O
+- O
+number O
+expression O
+of O
+genes O
+encoding O
+downstream O
+proteins O
+of O
+the O
+PKC1 B
+pathway O
+However O
+, O
+unlike O
+BCK2 B
+, O
+whose O
+disruption O
+in O
+a O
+cln3 B
+mutant I
+resulted O
+in O
+growth O
+arrest O
+in O
+G O
+( O
+1 O
+) O
+, O
+no O
+growth O
+defect O
+was O
+observed O
+in O
+a O
+double O
+cwh43 B
+cln3 B
+mutants O
+. O
+
+Twelve O
+( O
+92 O
+% O
+) O
+showed O
+cognitive O
+dysfunction O
+including O
+impairments O
+in O
+memory O
+, O
+attention O
+, O
+and O
+affective O
+disturbances O
+( O
+anxiety O
+, O
+depression O
+, O
+irritability O
+, O
+and O
+poor O
+frustration O
+tolerance O
+) O
+. O
+
+To O
+clarify O
+the O
+mechanisms O
+that O
+regulate O
+transcription O
+of O
+the O
+GTP B
+cyclohydrolase I
+I I
+gene I
+and O
+to O
+generate O
+multiple O
+species O
+of O
+mRNA O
+, O
+we O
+isolated O
+genomic O
+DNA O
+clones O
+for O
+the O
+human O
+and I
+mouse B
+GTP I
+cyclohydrolase I
+I I
+genes I
+. O
+
+Therefore O
+, O
+a O
+structural O
+interaction O
+between O
+PsaL B
+and O
+PsaI B
+may O
+stabilize O
+the O
+association O
+of O
+PsaL B
+with O
+the O
+photosystem O
+I O
+core O
+. O
+
+Reversal O
+of O
+' O
+refractory O
+septic O
+shock O
+' O
+by O
+infusion O
+of O
+amrinone O
+and O
+angiotensin B
+II I
+in O
+an O
+anthracycline O
+- O
+treated O
+patient O
+. O
+
+The O
+present O
+study O
+deals O
+with O
+the O
+screening O
+of O
+11 O
+of O
+these O
+plants O
+against O
+the O
+opportunistic O
+pathogen O
+fungus O
+Candida O
+albicans O
+. O
+
+Negative O
+modulation O
+of O
+alpha1 B
+( I
+I I
+) I
+procollagen I
+gene I
+expression O
+in O
+human O
+skin O
+fibroblasts O
+: O
+transcriptional O
+inhibition O
+by O
+interferon B
+- I
+gamma I
+. O
+
+On O
+the O
+basis O
+of O
+this O
+homology O
+, O
+we O
+examined O
+the O
+potential O
+role O
+of O
+c B
+- I
+Rel I
+in O
+controlling O
+IL B
+- I
+2R I
+alpha I
+transcription O
+. O
+
+Expression O
+of O
+CBP B
+/ O
+p300 B
+potentiated O
+HS2 B
+- O
+mediated O
+transactivation O
+. O
+
+We O
+next O
+developed O
+a O
+rapid O
+purification O
+method O
+for O
+bacterial O
+recombinant O
+MyoD B
+- O
+bHLH I
+domain O
+by O
+affinity O
+chromatography O
+using O
+a O
+calmodulin B
+- O
+Sepharose O
+column O
+and O
+investigated O
+the O
+phosphorylation O
+of O
+that O
+peptide O
+by O
+PKC B
+and O
+its O
+interactions O
+with O
+calmodulin B
+and O
+S100a B
+. O
+
+According O
+to O
+the O
+penetration O
+of O
+Ca O
+- O
+45 O
+, O
+the O
+microleakage O
+level O
+was O
+scored O
+for O
+each O
+section O
+. O
+
+HL B
+is O
+hypothesized O
+to O
+directly O
+couple O
+HDL B
+lipid O
+metabolism O
+to O
+tissue O
+/ O
+cellular O
+lipid O
+metabolism O
+. O
+
+Epstein B
+- I
+Barr I
+virus I
+nuclear I
+antigen I
+2 I
+exerts O
+its O
+transactivating O
+function O
+through O
+interaction O
+with O
+recombination B
+signal I
+binding I
+protein I
+RBP I
+- I
+J I
+kappa I
+, O
+the O
+homologue O
+of O
+Drosophila B
+Suppressor I
+of I
+Hairless I
+. O
+
+Maduromycosis O
+in O
+Italy O
+
+Two O
+patient O
+groups O
+were O
+studied O
+: O
+Type O
+I O
+- O
+- O
+with O
+a O
+new O
+ePTFE O
+graft O
+; O
+and O
+Type O
+II O
+- O
+- O
+with O
+thrombectomy O
+and O
+/ O
+or O
+revision O
+of O
+a O
+previously O
+placed O
+ePTFE O
+graft O
+. O
+
+The O
+author O
+describes O
+the O
+technique O
+in O
+detail O
+and O
+presents O
+the O
+findings O
+for O
+25 O
+patients O
+( O
+10 O
+men O
+and O
+15 O
+women O
+) O
+examined O
+for O
+suspected O
+ileostomy O
+dysfunction O
+, O
+recurrent O
+Crohn O
+' O
+s O
+disease O
+or O
+ileal O
+obstruction O
+remote O
+from O
+the O
+stoma O
+. O
+
+Increased O
+susceptibility O
+of O
+aphasics O
+to O
+a O
+distractor O
+task O
+in O
+the O
+recall O
+of O
+verbal O
+commands O
+. O
+
+Lasting O
+paraplegia O
+caused O
+by O
+loss O
+of O
+lumbar O
+spinal O
+cord O
+interneurons O
+in O
+rats O
+: O
+no O
+direct O
+correlation O
+with O
+motor O
+neuron O
+loss O
+. O
+
+The O
+existence O
+of O
+universal O
+non O
+- O
+specific O
+mechanism O
+of O
+action O
+of O
+external O
+factors O
+upon O
+the O
+living O
+tissue O
+based O
+on O
+the O
+DEL O
+- O
+reaction O
+is O
+suggested O
+. O
+
+Rv O
+was O
+7 O
+. O
+7 O
++ O
+/ O
+- O
+1 O
+. O
+4 O
+mmHg O
+. O
+ml O
+- O
+1 O
+. O
+min O
+. O
+100 O
+g O
+- O
+1 O
+and O
+Cv O
+was O
+0 O
+. O
+59 O
++ O
+/ O
+- O
+0 O
+. O
+25 O
+ml O
+/ O
+mmHg O
+, O
+tau O
+v O
+calculated O
+from O
+the O
+product O
+of O
+Rv O
+and O
+Cv O
+was O
+4 O
+. O
+20 O
++ O
+/ O
+- O
+1 O
+. O
+58 O
+s O
+and O
+from O
+the O
+ratio O
+of O
+delta O
+V O
+to O
+delta O
+Q O
+was O
+4 O
+. O
+95 O
++ O
+/ O
+- O
+1 O
+. O
+53 O
+s O
+( O
+P O
+= O
+NS O
+) O
+at O
+a O
+mean O
+Pel O
+of O
+17 O
+. O
+6 O
++ O
+/ O
+- O
+3 O
+. O
+7 O
+mmHg O
+. O
+delta O
+V O
+was O
+also O
+produced O
+by O
+changing O
+Pv O
+
+; O
+the O
+average O
+tau O
+v O
+( O
+1 O
+. O
+95 O
++ O
+/ O
+- O
+0 O
+. O
+37 O
+s O
+) O
+, O
+was O
+shorter O
+than O
+that O
+with O
+changes O
+in O
+flow O
+. O
+
+We O
+constructed O
+a O
+stable O
+, O
+doubly O
+transfected O
+cell O
+line O
+( O
+TIS O
+- O
+10 O
+) O
+carrying O
+a O
+chromosomally O
+integrated O
+ptetO7 B
+- I
+CMV I
+- I
+L I
+reporter O
+construct O
+and O
+expressing O
+the O
+TetR B
+- O
+KRAB B
+protein O
+. O
+
+We O
+suggest O
+that O
+electrical O
+stimulation O
+of O
+the O
+NTS O
+in O
+rats O
+undergoing O
+such O
+surgical O
+preparation O
+to O
+observe O
+the O
+pressor O
+response O
+and O
+/ O
+or O
+increase O
+in O
+pVP O
+, O
+represents O
+a O
+rapid O
+approach O
+for O
+screening O
+the O
+neurosecretory O
+function O
+of O
+the O
+central O
+neural O
+integration O
+to O
+release O
+vasopressin B
+. O
+
+To O
+study O
+adaptive O
+processes O
+following O
+spinal O
+cord O
+injury O
+, O
+unstructured O
+audiotaped O
+interviews O
+were O
+conducted O
+on O
+an O
+almost O
+daily O
+basis O
+with O
+a O
+30 O
+- O
+year O
+- O
+old O
+divorced O
+male O
+during O
+the O
+first O
+3 O
+months O
+of O
+his O
+initial O
+comprehensive O
+inpatient O
+rehabilitation O
+. O
+
+Melioidosis O
+in O
+Sika O
+deer O
+( O
+Cervus O
+nippon O
+nippon O
+) O
+. O
+
+Enterobius O
+vermicularis O
+eggs O
+were O
+demonstrated O
+during O
+microscopic O
+examination O
+of O
+a O
+smear O
+taken O
+from O
+the O
+posterior O
+fornix O
+of O
+the O
+vagina O
+. O
+
+Together O
+with O
+previous O
+work O
+our O
+results O
+suggest O
+that O
+C B
+/ I
+EBP I
+may O
+be O
+a O
+general O
+cooperation O
+partner O
+for O
+v B
+- I
+Myb I
+in O
+myelomonocytic O
+cells O
+. O
+
+When O
+medical O
+aid O
+was O
+sought O
+a O
+false O
+history O
+was O
+given O
+and O
+the O
+true O
+nature O
+of O
+the O
+child O
+' O
+s O
+illness O
+, O
+heat O
+stroke O
+, O
+was O
+not O
+determined O
+until O
+after O
+death O
+. O
+
+Both O
+DMP2 B
+and O
+DMP3 B
+are O
+closely O
+localized O
+on O
+mouse O
+chromosome O
+5q21 O
+, O
+corresponding O
+to O
+human O
+chromosome O
+4q21 O
+. O
+
+This O
+article O
+expands O
+the O
+analysis O
+of O
+a O
+numeric O
+example O
+included O
+in O
+the O
+SAS O
+GLM O
+procedure O
+to O
+cover O
+several O
+crucial O
+statistical O
+aspects O
+relevant O
+to O
+ANCOVA O
+, O
+and O
+to O
+highlight O
+the O
+meaning O
+of O
+the O
+statistical O
+results O
+obtained O
+. O
+
+A O
+novel O
+alternative O
+spliced O
+variant O
+of O
+the O
+transcription B
+factor I
+AP2alpha I
+is O
+expressed O
+in O
+the O
+murine O
+ocular O
+lens O
+. O
+
+Fig1p B
+and O
+Fig2p B
+are O
+likely O
+to O
+act O
+at O
+the O
+cell O
+surface O
+as O
+Fig1 B
+: O
+: O
+beta B
+- I
+gal I
+and O
+Fig2 B
+: O
+: O
+beta B
+- I
+gal I
+fusion I
+proteins I
+localize O
+to O
+the O
+periphery O
+of O
+mating O
+cells O
+. O
+
+Crystals O
+of O
+the O
+triple O
+mutant O
+A42D O
+/ O
+D47P O
+/ O
+A63L O
+, O
+which O
+are O
+stable O
+for O
+days O
+in O
+its O
+oxidized O
+form O
+, O
+were O
+grown O
+from O
+ammonium O
+sulfate O
+, O
+with O
+the O
+cell O
+constants O
+a O
+= O
+b O
+= O
+34 O
+. O
+3 O
+A O
+and O
+c O
+= O
+111 O
+. O
+8 O
+A O
+belonging O
+to O
+space O
+group O
+P3 O
+( O
+2 O
+) O
+21 O
+. O
+
+Nevertheless O
+, O
+PEG O
+influenced O
+in O
+vitro O
+drug O
+availability O
+considerably O
+, O
+by O
+increasing O
+both O
+drug O
+solubility O
+and O
+dissolution O
+rate O
+. O
+
+Normal O
+replication O
+of O
+DNA O
+A O
+still O
+carrying O
+the O
+AC3 B
+ORF I
+mutation I
+was O
+found O
+in O
+extracts O
+from O
+these O
+plants O
+. O
+
+Such O
+saturation O
+often O
+occurs O
+for O
+several O
+recording O
+sweeps O
+after O
+large O
+amplitude O
+signals O
+such O
+as O
+eye O
+blinks O
+are O
+rejected O
+. O
+
+Muscle O
+and O
+liver O
+biopsies O
+demonstrated O
+the O
+same O
+anomalies O
+, O
+again O
+without O
+branching O
+enzyme O
+deficiency O
+in O
+the O
+liver O
+. O
+
+Possibility O
+of O
+using O
+gynecologic O
+nurses O
+in O
+the O
+independently O
+administered O
+health O
+centers O
+
+Airborne O
+rabies O
+encephalitis O
+: O
+demonstration O
+of O
+rabies O
+virus O
+in O
+the O
+human O
+central O
+nervous O
+system O
+. O
+
+T1 O
+and O
+T2 O
+values O
+were O
+calculated O
+from O
+guinea O
+pig O
+brain O
+in O
+vivo O
+at O
+0 O
+. O
+5 O
+T O
+. O
+
+Autophosphorylation O
+on O
+the O
+major O
+phosphorylation O
+site O
+Y1235 O
+upregulates O
+the O
+kinase O
+activity O
+of O
+the O
+receptor O
+, O
+increasing O
+the O
+Vmax O
+of O
+the O
+phosphotransfer O
+reaction O
+. O
+
+Clinical O
+development O
+of O
+interleukin B
+- I
+10 I
+. O
+
+By O
+cloning O
+genes O
+encoding O
+benzene O
+- O
+degradative O
+enzymes O
+, O
+we O
+found O
+that O
+strain O
+JS150 O
+also O
+carries O
+genes O
+for O
+a O
+toluene B
+/ I
+benzene I
+- I
+2 I
+- I
+monooxygenase I
+. O
+
+Our O
+data O
+suggest O
+that O
+association O
+of O
+TBP B
+with O
+the O
+TATA O
+box O
+may O
+be O
+regulated O
+, O
+directly O
+or O
+indirectly O
+, O
+by O
+a O
+substrate O
+of O
+Snf1 B
+. O
+
+Fusion O
+proteins O
+were O
+isolated O
+by O
+affinity O
+chromatography O
+on O
+APTG B
+- O
+Sepharose O
+. O
+
+It O
+differed O
+from O
+cued O
+recall O
+only O
+in O
+the O
+instructions O
+, O
+which O
+directed O
+subjects O
+away O
+from O
+the O
+memory O
+aspects O
+of O
+the O
+test O
+and O
+asked O
+them O
+to O
+complete O
+each O
+three O
+- O
+letter O
+cue O
+with O
+the O
+first O
+word O
+that O
+came O
+to O
+mind O
+. O
+
+Real O
+- O
+time O
+two O
+- O
+dimensional O
+echocardiographic O
+studies O
+of O
+the O
+mitral O
+valve O
+in O
+short O
+- O
+axis O
+view O
+were O
+obtained O
+from O
+10 O
+normal O
+subjects O
+. O
+
+RESULTS O
+: O
+Sixty O
+- O
+one O
+percent O
+of O
+the O
+patients O
+had O
+damage O
+within O
+7 O
+years O
+of O
+onset O
+( O
+mean O
+3 O
+. O
+8 O
+yrs O
+) O
+. O
+
+It O
+was O
+previously O
+shown O
+that O
+Vi B
+antigen I
+expression O
+was O
+regulated O
+by O
+a O
+system O
+similar O
+to O
+the O
+rcs B
+regulatory I
+system I
+involved O
+in O
+colanic O
+acid O
+synthesis O
+in O
+Escherichia O
+coli O
+. O
+
+The O
+map O
+is O
+based O
+on O
+the O
+CEPH O
+reference O
+pedigrees O
+and O
+includes O
+over O
+4000 O
+new O
+genotypes O
+, O
+our O
+previously O
+reported O
+data O
+plus O
+29 O
+allele O
+systems O
+from O
+the O
+published O
+CEPH O
+version O
+5 O
+database O
+, O
+and O
+was O
+constructed O
+using O
+the O
+program O
+package O
+CRI O
+- O
+MAP O
+. O
+
+To O
+identify O
+the O
+GRK6 B
+homologue I
+on O
+chromsome O
+13 O
+, O
+several O
+sets O
+of O
+closely O
+- O
+spaced O
+primers O
+were O
+designed O
+based O
+on O
+the O
+GRK6 B
+cDNA I
+sequence I
+and O
+then O
+used O
+to O
+amplify O
+human O
+genomic O
+DNA O
+by O
+PCR O
+. O
+
+In O
+the O
+absence O
+of O
+Mg2 O
++ O
+, O
+the O
+extent O
+of O
+destabilization O
+of O
+tRNAPhe B
+is O
+greater O
+but O
+appears O
+to O
+be O
+confined O
+to O
+internal O
+regions O
+of O
+the O
+acceptor O
+and O
+T O
+psi O
+C O
+helices O
+, O
+as O
+evidenced O
+by O
+the O
+selectively O
+enhanced O
+exchange O
+rates O
+for O
+imino O
+protons O
+associated O
+with O
+these O
+base O
+pairs O
+. O
+
+Studies O
+in O
+26 O
+patients O
+. O
+
+Serum B
+alpha I
+- I
+amylase I
+, O
+trypsin B
+, O
+trypsin B
+inhibitor O
+, O
+lipase B
+and O
+total O
+protease O
+activity O
+in O
+the O
+pancreatic O
+tissue O
+was O
+studied O
+as O
+indicator O
+of O
+the O
+treatment O
+efficacy O
+with O
+5 O
+- O
+fluorouracil O
+electro O
+- O
+cumulation O
+. O
+
+1 O
+The O
+effects O
+of O
+high O
+doses O
+of O
+piretanide O
+, O
+a O
+new O
+diuretic O
+agent O
+chemically O
+related O
+to O
+frusemide O
+and O
+bumetanide O
+were O
+evaluated O
+in O
+twelve O
+patients O
+with O
+severe O
+chronic O
+renal O
+insufficiency O
+( O
+creatinine O
+clearance O
+below O
+25 O
+ml O
+/ O
+min O
+) O
+. O
+
+Synthesis O
+of O
+22 O
+- O
+oxavitamin O
+D3 O
+analogues O
+. O
+
+This O
+effect O
+is O
+independent O
+of O
+the O
+Gal4 B
+protein I
+, O
+as O
+it O
+operates O
+in O
+a O
+gal4 B
+mutant I
+background O
+as O
+well O
+. O
+
+Consistent O
+with O
+the O
+large O
+pocket O
+of O
+Rb B
+binding O
+to O
+TAF B
+( I
+II I
+) I
+250 I
+, O
+the O
+large O
+pocket O
+domains O
+of O
+both O
+p107 B
+and O
+p130 B
+are O
+able O
+to O
+bind O
+to O
+TAF B
+( I
+II I
+) I
+250 I
+in O
+vivo O
+. O
+
+50 O
+- O
+nucleotide O
+) O
+intron O
+to O
+AA O
+. O
+
+The O
+educational O
+program O
+was O
+the O
+significant O
+factor O
+that O
+influenced O
+the O
+change O
+of O
+concern O
+trajectories O
+, O
+and O
+the O
+recurrent O
+/ O
+non O
+- O
+recurrent O
+factor O
+influenced O
+the O
+change O
+of O
+concern O
+only O
+in O
+pamphlet O
+group O
+. O
+
+Amplification O
+of O
+4q21 O
+- O
+q22 O
+and O
+the O
+MXR B
+gene I
+in O
+independently O
+derived O
+mitoxantrone O
+- O
+resistant O
+cell O
+lines O
+. O
+
+Activation O
+of O
+the O
+receptor O
+induces O
+Ret B
+phosphorylation O
+that O
+leads O
+the O
+survival O
+- O
+promoting O
+effects O
+. O
+
+In O
+patients O
+in O
+which O
+these O
+criteria O
+were O
+not O
+met O
+only O
+the O
+reproducibility O
+of O
+the O
+VO2 O
+obtained O
+in O
+both O
+the O
+P O
+- O
+MET O
+and O
+the O
+C O
+- O
+MET O
+indicated O
+that O
+the O
+maximal O
+VO2 O
+for O
+these O
+4 O
+patients O
+had O
+been O
+reached O
+. O
+
+This O
+paper O
+describes O
+a O
+course O
+of O
+therapy O
+with O
+an O
+agoraphobic O
+female O
+patient O
+. O
+
+A O
+previously O
+developed O
+kinetic O
+model O
+was O
+used O
+to O
+identify O
+major O
+chemical O
+reaction O
+pathways O
+involving O
+PAH O
+in O
+the O
+afterburner O
+. O
+
+Henry O
+Quastler O
+brought O
+experience O
+from O
+an O
+actual O
+x O
+- O
+ray O
+treatment O
+, O
+and O
+Dr O
+. O
+
+Critical O
+review O
+of O
+tests O
+for O
+the O
+HBs B
+antigen I
+in O
+the O
+detection O
+of O
+infectious O
+blood O
+
+A O
+direct O
+statistically O
+reliable O
+correction O
+of O
+decrease O
+of O
+the O
+enzymes O
+with O
+the O
+initial O
+state O
+of O
+the O
+patients O
+has O
+been O
+established O
+in O
+an O
+analysis O
+of O
+25 O
+patients O
+aged O
+from O
+18 O
+to O
+60 O
+years O
+in O
+prosthesis O
+of O
++ O
+the O
+mitral O
+valve O
+( O
+n O
+- O
+9 O
+) O
+and O
+closed O
+mitral O
+commissurotomy O
+( O
+n O
+- O
+16 O
+) O
+. O
+
+DSS4 B
+- I
+1 I
+is O
+a O
+dominant O
+suppressor O
+of O
+sec4 B
+- I
+8 I
+that O
+encodes O
+a O
+nucleotide O
+exchange O
+protein I
+that O
+aids O
+Sec4p B
+function O
+. O
+
+These O
+findings O
+indicate O
+that O
+KCTG O
+can O
+contribute O
+to O
+improved O
+monitoring O
+in O
+high O
+- O
+risk O
+pregnancies O
+. O
+
+The O
+MI O
+site O
+is O
+predictive O
+of O
+hemodynamic O
+left O
+ventricular O
+dysfunction O
+both O
+at O
+rest O
+and O
+during O
+exercise O
+: O
+anterior O
+MIs O
+are O
+more O
+impaired O
+than O
+inferior O
+MIs O
+. O
+
+The O
+vaccine O
+was O
+highly O
+immunogenic O
+, O
+since O
+111 O
+of O
+113 O
+patients O
+( O
+98 O
+% O
+) O
+produced O
+anti B
+- I
+HBs I
+( O
+10 O
+mIU O
+/ O
+ml O
+or O
+more O
+) O
+. O
+
+The O
+interleukin B
+- I
+2 I
+receptor I
+alpha I
+( O
+IL B
+- I
+2R I
+alpha I
+) O
+chain O
+gene O
+contains O
+a O
+sequence O
+similar O
+to O
+the O
+immunoglobulin B
+( I
+Ig I
+) I
+kappa I
+( O
+kappa B
+) O
+enhancer O
+NF B
+- I
+kappa I
+B I
+binding O
+site O
+. O
+
+Comparison O
+of O
+the O
+derived O
+amino O
+acid O
+sequence O
+with O
+that O
+of O
+the O
+HCMV B
+UL99 I
+gene I
+product I
+reveals O
+34 O
+. O
+8 O
+% O
+identity O
+in O
+an O
+overlap O
+of O
+66 O
+amino O
+acids O
+. O
+
+Although O
+mutant B
+pex5delta I
+cells O
+expressing O
+a O
+yeast B
+/ I
+tobacco I
+Pex5p I
+chimaera I
+failed O
+to O
+import O
+a O
+GFP B
+- O
+Eci1p B
+reporter O
+protein O
+, O
+they O
+were O
+able O
+to O
+grow O
+on O
+oleic O
+acid O
+. O
+
+Consistent O
+with O
+this O
+observation O
+, O
+introduction O
+of O
+Smad B
+sites I
+into O
+a O
+TGFbeta B
+- O
+insensitive O
+LEF1 B
+/ O
+TCF B
+target O
+gene O
+confers O
+cooperative O
+TGFbeta B
+and O
+Wnt B
+responsiveness O
+to O
+the O
+promoter O
+. O
+
+In O
+analogy O
+to O
+human B
+CD70 I
+, O
+mCD70 B
+transcript I
+levels O
+are O
+strongly O
+but O
+transiently O
+up O
+- O
+regulated O
+during O
+lymphocyte O
+activation O
+, O
+which O
+is O
+in O
+line O
+with O
+a O
+role O
+for O
+the O
+CD27 B
+- O
+CD70 B
+receptor O
+pair O
+early O
+in O
+the O
+immune O
+response O
+. O
+
+Serum B
+IgM I
+levels O
+showed O
+a O
+highly O
+significant O
+increase O
+in O
+all O
+types O
+of O
+brain O
+tumour O
+when O
+compared O
+to O
+controls O
+. O
+
+Beyond O
+the O
+first O
+year O
+post O
+- O
+renal O
+transplantation O
+there O
+was O
+no O
+difference O
+in O
+C O
+( O
+IO O
+) O
+between O
+LRD O
+and O
+CAD O
+allografts O
+. O
+
+Vk8 B
+/ O
+Jk2 B
+and O
+Vk1 B
+/ O
+Jk5 B
+rearrangements O
+encoded O
+the O
+respective O
+L B
+chain O
+V O
+- O
+regions O
+. O
+
+The O
+phenomena O
+of O
+nursing O
+are O
+deeply O
+rooted O
+in O
+the O
+human O
+condition O
+. O
+
+Clinical O
+findings O
+plaque O
+index O
+, O
+PI O
+; O
+gingival O
+index O
+, O
+GI O
+; O
+bleeding O
+on O
+probing O
+, O
+BOP O
+; O
+pus O
+discharge O
+, O
+pus O
+; O
+and O
+probing O
+depth O
+, O
+PD O
+at O
+both O
+PT O
+- O
+01 O
+and O
+control O
+sites O
+were O
+measured O
+at O
+every O
+visit O
+for O
+4 O
+weeks O
+. O
+
+One O
+of O
+these O
+elements O
+resembles O
+the O
+binding O
+site O
+of O
+a O
+previously O
+identified O
+cellular O
+" O
+transcription O
+" O
+factor O
+. O
+
+NER O
+was O
+also O
+measured O
+by O
+a O
+plasmid O
+host O
+cell O
+re O
+- O
+activation O
+assay O
+using O
+a O
+vector O
+containing O
+a O
+luciferase B
+reporter I
+gene I
+. O
+
+Plasma O
+Pi O
+, O
+tibia O
+breaking O
+strength O
+, O
+and O
+percentage O
+of O
+tibia O
+ash O
+were O
+increased O
+by O
+raising O
+dietary O
+Pav O
+in O
+the O
+presence O
+of O
+. O
+392 O
+% O
+A1 O
+with O
+either O
+level O
+of O
+Ca O
+. O
+
+A O
+total O
+of O
+114 O
+animals O
+were O
+infected O
+by O
+E O
+. O
+coli O
+O2 O
+: O
+K1 O
+: O
+H4 O
+by O
+the O
+hematogenic O
+route O
+. O
+
+In O
+the O
+fungus O
+Neurospora O
+crassa O
+, O
+nit B
+- I
+2 I
+, O
+the O
+major O
+nitrogen O
+regulatory O
+gene O
+, O
+activates O
+the O
+expression O
+of O
+unlinked O
+structural O
+genes O
+that O
+specify O
+nitrogen O
+- O
+catabolic O
+enzymes O
+during O
+conditions O
+of O
+nitrogen O
+limitation O
+. O
+
+The O
+matrix O
+of O
+the O
+CBs O
+contains O
+the O
+diagnostic O
+protein O
+p80 B
+- O
+coilin B
+, O
+which O
+is O
+colocalized O
+with O
+the O
+U7 B
+small I
+nuclear I
+ribonucleoprotein I
+( O
+snRNP O
+) O
+, O
+whereas O
+the O
+attached O
+and O
+embedded O
+B B
+- I
+snurposomes I
+contain O
+splicing O
+snRNPs O
+. O
+
+During O
+an O
+observation O
+period O
+of O
+12 O
+weeks O
+after O
+halving O
+atenolol O
+from O
+a O
+mean O
+dose O
+of O
+82 O
+mg O
+to O
+41 O
+mg O
+, O
+no O
+significant O
+changes O
+in O
+systolic O
+and O
+diastolic O
+blood O
+pressure O
+or O
+in O
+response O
+rate O
+( O
+defined O
+as O
+a O
+diastolic O
+blood O
+pressure O
+of O
+95 O
+mm O
+Hg O
+or O
+less O
+) O
+were O
+observed O
+. O
+
+Comparative O
+volumetric O
+analysis O
+is O
+defined O
+as O
+the O
+difference O
+between O
+mean O
+corpuscular O
+erythrocyte O
+volume O
+in O
+peripheral O
+blood O
+( O
+MCVB O
+) O
+diluted O
+in O
+urine O
+supernatant O
+after O
+centrifugation O
+and O
+mean O
+corpuscular O
+volume O
+of O
+urinary O
+erythrocytes O
+( O
+MCVU O
+) O
+. O
+
+PATIENTS O
+: O
+33 O
+HIV O
+- O
+infected O
+, O
+zidovudine O
+- O
+experienced O
+patients O
+with O
+serum O
+HIV O
+RNA O
+levels O
+of O
+at O
+least O
+20 O
+, O
+000 O
+copies O
+/ O
+mL O
+and O
+CD4 B
+counts O
+ranging O
+from O
+50 O
+to O
+400 O
+cells O
+/ O
+mm3 O
+. O
+
+Within O
+the O
+last O
+few O
+years O
+, O
+the O
+WWW O
+has O
+grown O
+enormously O
+. O
+
+These O
+data O
+, O
+taken O
+together O
+, O
+suggest O
+that O
+CRF B
+produces O
+its O
+behavioral O
+activating O
+and O
+anxiogenic O
+effects O
+, O
+at O
+least O
+in O
+part O
+, O
+by O
+increasing O
+the O
+activity O
+of O
+LC O
+noradrenergic O
+neurons O
+. O
+
+On O
+the O
+basis O
+of O
+8 O
+cases O
+, O
+the O
+authors O
+report O
+different O
+clinical O
+pictures O
+all O
+caused O
+by O
+cardiac O
+toxicity O
+of O
+5FU O
+. O
+
+The O
+sequence O
+of O
+Vac1p B
+contains O
+two O
+putative O
+zinc O
+- O
+binding O
+RING O
+motifs O
+, O
+a O
+zinc O
+finger O
+motif O
+, O
+and O
+a O
+coiled O
+- O
+coil O
+motif O
+. O
+
+Although O
+cardiac O
+output O
+decreased O
+slightly O
+with O
+PCF O
+, O
+hemodynamic O
+changes O
+due O
+to O
+PCF O
+were O
+unlikely O
+to O
+account O
+for O
+the O
+observed O
+fall O
+in O
+PaO2 O
+. O
+
+Anti B
+- I
+Jo I
+- I
+1 I
+antibody I
+was O
+not O
+present O
+. O
+
+The O
+first O
+operon O
+, O
+orf1 B
+- O
+tolQRA B
+, O
+is O
+iron O
+regulated O
+throughout O
+growth O
+, O
+but O
+iron O
+- O
+regulated O
+expression O
+of O
+tolB B
+and O
+oprL B
+fusions I
+occurs O
+only O
+in O
+late O
+log O
+phase O
+. O
+
+S O
+. O
+aureus O
+leakage O
+into O
+the O
+totally O
+submerged O
+test O
+specimens O
+was O
+detected O
+in O
+1 O
+of O
+5 O
+samples O
+incubated O
+for O
+4 O
+weeks O
+, O
+while O
+no O
+leakage O
+was O
+detected O
+in O
+specimens O
+incubated O
+for O
+3 O
+, O
+5 O
+, O
+6 O
+, O
+7 O
+, O
+and O
+8 O
+weeks O
+. O
+
+We O
+examined O
+the O
+contribution O
+of O
+a O
+cryptic O
+plasmid O
+, O
+pRmeGR4b O
+, O
+to O
+the O
+nodulation O
+of O
+Medicago O
+sativa O
+by O
+strain O
+GR4 O
+of O
+Rhizobium O
+meliloti O
+. O
+
+It O
+also O
+appears O
+that O
+in O
+patients O
+with O
+laboratory O
+diagnosis O
+of O
+prerenal O
+acute O
+renal O
+failure O
+( O
+i O
+. O
+e O
+. O
+, O
+a O
+RFT O
+less O
+than O
+1 O
+. O
+0 O
+) O
+, O
+the O
+response O
+to O
+treatment O
+is O
+unpredictable O
+and O
+in O
+fact O
+may O
+have O
+a O
+worse O
+prognosis O
+than O
+in O
+those O
+with O
+a O
+RFI O
+greater O
+than O
+1 O
+. O
+0 O
+( O
+5 O
+/ O
+7 O
+deaths O
+vs O
+10 O
+/ O
+48 O
+deaths O
+) O
+. O
+
+Paraplegia O
+associated O
+with O
+intraaortic O
+balloon O
+pump O
+counterpulsation O
+. O
+
+CTP O
+, O
+GDP O
+, O
+GTP O
+, O
+ITP O
+) O
+did O
+not O
+affect O
+the O
+response O
+. O
+
+Using O
+green B
+fluorescent I
+protein I
+fusions O
+we O
+demonstrate O
+that O
+the O
+SYT B
+, O
+SSX B
+and O
+the O
+SYT B
+- O
+SSX B
+proteins O
+are O
+nuclear O
+proteins O
+. O
+
+The O
+anaesthetic O
+management O
+of O
+41 O
+patients O
+who O
+underwent O
+cardiac O
+transplantation O
+during O
+a O
+40 O
+month O
+period O
+at O
+Clinica O
+Puerta O
+de O
+Hierro O
+is O
+reviewed O
+. O
+
+Acute O
+respiratory O
+distress O
+syndrome O
+. O
+
+These O
+data O
+suggested O
+that O
+mutant B
+PS1 I
+may O
+cause O
+disease O
+as O
+a O
+result O
+of O
+reduction O
+in O
+PS1 B
+function O
+. O
+
+The O
+analysis O
+of O
+the O
+organization O
+of O
+the O
+sequence O
+of O
+the O
+human O
+ABP B
+/ O
+DAO B
+gene O
+reveals O
+that O
+the O
+2 O
+. O
+4 O
+- O
+kilobase O
+messenger O
+RNA O
+is O
+transcribed O
+from O
+two O
+close O
+origins O
+identifying O
+the O
+proximal O
+promoter O
+. O
+
+Most O
+important O
+, O
+after O
+all O
+, O
+is O
+not O
+the O
+ionization O
+technique O
+but O
+the O
+stage O
+with O
+a O
+47 O
+. O
+1 O
+% O
+five O
+- O
+year O
+survival O
+rate O
+in O
+T1N0 O
+as O
+compared O
+to O
+T2N0 O
+with O
+28 O
+. O
+6 O
+% O
+and O
+T1N1 O
+with O
+19 O
+. O
+4 O
+% O
+. O
+
+To O
+investigate O
+the O
+step O
+of O
+spliceosome O
+assembly O
+at O
+which O
+Snu17p B
+acts O
+, O
+we O
+have O
+used O
+nondenaturing O
+gel O
+electrophoresis O
+. O
+
+We O
+also O
+show O
+that O
+an O
+internal O
+fragment O
+of O
+U24 B
+methylation I
+guide I
+snoRNA I
+, O
+encompassing O
+the O
+upstream O
+antisense O
+element O
+and O
+the O
+D O
+' O
+and O
+C O
+' O
+box O
+motifs O
+, O
+can O
+support O
+the O
+site O
+- O
+specific O
+methylation O
+of O
+rRNA O
+. O
+
+Mammalian B
+ribonucleotide I
+reductase I
+shows O
+S O
+- O
+phase O
+specific O
+expression O
+and O
+consists O
+of O
+two O
+non O
+- O
+identical O
+subunits O
+, O
+proteins O
+R1 O
+( O
+large O
+subunit O
+) O
+and O
+R2 O
+( O
+small O
+subunit O
+) O
+. O
+
+Effects O
+of O
+dexamethasone O
+on O
+the O
+development O
+of O
+radiation O
+nephropathy O
+in O
+the O
+rat O
+. O
+
+Recombinant B
+MsERK1 I
+( O
+rMsERK1 B
+) O
+, O
+when O
+overexpressed O
+in O
+Escherichia O
+coli O
+, O
+is O
+recognized O
+by O
+antibodies O
+raised O
+against O
+MAP B
+kinases I
+from I
+rat I
+, I
+Xenopus I
+, I
+and I
+sea I
+star I
+and O
+by O
+anti B
+- I
+phosphotyrosine I
+antibodies I
+. O
+
+The O
+identification O
+of O
+SRP54sc B
+and O
+SRP54sp B
+provides O
+the O
+first O
+evidence O
+for O
+SRP B
+related I
+proteins I
+in O
+yeast O
+. O
+
+We O
+previously O
+demonstrated O
+that O
+AKT2 B
+, O
+a O
+member O
+of O
+protein B
+kinase I
+B I
+family I
+, O
+is O
+activated O
+by O
+a O
+number O
+of O
+growth O
+factors O
+via O
+Ras B
+and O
+PI B
+3 I
+- I
+kinase I
+signaling O
+pathways O
+. O
+
+So O
+it O
+is O
+sometimes O
+more O
+convenient O
+to O
+use O
+the O
+back O
+Radon O
+transform O
+R O
+- O
+1 O
+and O
+then O
+to O
+correct O
+the O
+result O
+, O
+taking O
+into O
+account O
+attenuation O
+. O
+
+Before O
+flecainide O
+, O
+all O
+patients O
+had O
+easily O
+inducible O
+VT O
+that O
+was O
+morphologically O
+identical O
+to O
+their O
+spontaneously O
+occurring O
+arrhythmia O
+. O
+
+An O
+additional O
+dose O
+of O
+20 O
+- O
+25 O
+Gy O
+was O
+delivered O
+to O
+the O
+site O
+of O
+original O
+involvement O
+using O
+an O
+implant O
+when O
+feasible O
+. O
+
+The O
+prominent O
+fracture O
+of O
+women O
+older O
+than O
+75 O
+years O
+is O
+the O
+hip O
+fracture O
+( O
+type O
+II O
+osteoporosis O
+) O
+. O
+
+The O
+expected O
+products O
+of O
+the O
+cloned O
+bph B
+genes I
+, O
+except O
+bphA3 B
+, O
+were O
+observed O
+in O
+E O
+. O
+coli O
+in O
+an O
+in O
+vitro O
+transcription O
+- O
+translation O
+system O
+. O
+
+It O
+is O
+our O
+conclusion O
+that O
+Sonoclot O
+coagulation O
+analysis O
+is O
+unlikely O
+to O
+identify O
+patients O
+with O
+prolonged O
+bleeding O
+time O
+in O
+whom O
+platelet O
+count O
+and O
+other O
+coagulation O
+factors O
+are O
+normal O
+. O
+
+RESULTS O
+: O
+Analysis O
+by O
+Pearson O
+' O
+s O
+correlation O
+showed O
+that O
+the O
+subjects O
+who O
+had O
+higher O
+scores O
+of O
+SSMS O
+during O
+the O
+drum O
+rotation O
+generated O
+the O
+following O
+: O
+a O
+) O
+a O
+higher O
+rating O
+of O
+over O
+- O
+all O
+sickness O
+( O
+r O
+= O
+0 O
+. O
+76 O
+) O
+; O
+b O
+) O
+a O
+higher O
+ratio O
+of O
+spectral O
+power O
+of O
+EGG O
+at O
+4 O
+- O
+9 O
+cycles O
+per O
+minute O
+( O
+cpm O
+) O
+between O
+drum O
+rotation O
+and O
+baseline O
+periods O
+( O
+r O
+= O
+0 O
+. O
+63 O
+) O
+; O
+c O
+) O
+a O
+higher O
+net O
+percent O
+increase O
+of O
+spectral O
+power O
+in O
+the O
+EEG O
+frequency O
+band O
+0 O
+. O
+5 O
+- O
+4 O
+Hz O
+between O
+drum O
+rotation O
+and O
+baseline O
+periods O
+on O
+C3 O
+( O
+r O
+= O
+0 O
+. O
+29 O
+) O
+
+and O
+C4 O
+( O
+r O
+= O
+0 O
+. O
+31 O
+) O
+; O
+d O
+) O
+a O
+higher O
+ratio O
+of O
+spectral O
+power O
+of O
+EEG O
+frequency O
+band O
+0 O
+. O
+5 O
+- O
+4 O
+Hz O
+between O
+drum O
+rotation O
+and O
+baseline O
+periods O
+on O
+C3 O
+( O
+r O
+= O
+0 O
+. O
+31 O
+) O
+; O
+and O
+e O
+) O
+a O
+higher O
+level O
+of O
+net O
+increase O
+in O
+skin O
+conductance O
+from O
+baseline O
+to O
+drum O
+rotation O
+( O
+r O
+= O
+0 O
+. O
+30 O
+) O
+. O
+
+Salts O
+of O
+these O
+four O
+metal O
+ions O
+may O
+be O
+added O
+to O
+the O
+growth O
+medium O
+to O
+facilitate O
+selective O
+isolation O
+of O
+Acinetobacter O
+. O
+
+The O
+consensus O
+mammalian O
+ER O
+stress O
+response O
+element O
+( O
+ERSE O
+) O
+conserved O
+among O
+grp B
+promoters I
+consists O
+of O
+a O
+tripartite O
+structure O
+CCAAT O
+( O
+N9 O
+) O
+CCACG O
+, O
+with O
+N O
+being O
+a O
+strikingly O
+GC O
+- O
+rich O
+region O
+of O
+9 O
+bp O
+. O
+
+Acute O
+toxicity O
+tests O
+were O
+conducted O
+to O
+measure O
+the O
+response O
+of O
+first O
+instar O
+Toxorhynchites O
+splendens O
+to O
+commonly O
+used O
+mosquito O
+adulticides O
+: O
+malathion O
+, O
+naled O
+and O
+resmethrin O
+. O
+
+A O
+positive O
+correlation O
+was O
+also O
+established O
+between O
+the O
+level O
+of O
+FP9C B
+binding O
+and O
+the O
+degree O
+of O
+cell O
+differentiation O
+in O
+vitro O
+. O
+
+Effects O
+of O
+acute O
+exposure O
+to O
+cold O
+on O
+pulmonary O
+arterial O
+blood O
+pressure O
+in O
+awake O
+rats O
+. O
+
+When O
+labeled O
+by O
+the O
+described O
+method O
+, O
+99mTc O
+on O
+DTPA O
+coupled O
+antibodies O
+shows O
+instability O
+in O
+serum O
+but O
+superior O
+stability O
+than O
+99mTc O
+on O
+antibodies O
+without O
+the O
+attached O
+DTPA O
+. O
+
+Unlike O
+CSK B
+, O
+the O
+SH3 B
+domain I
+of O
+HYL B
+was O
+unique O
+since O
+the O
+ALYDY B
+motif I
+was O
+absent O
+. O
+
+As O
+the O
+mechanism O
+of O
+the O
+intractability O
+, O
+cell O
+function O
+involved O
+in O
+the O
+defense O
+against O
+infection O
+was O
+evaluated O
+. O
+
+88 O
+, O
+3739 O
+- O
+3743 O
+) O
+) O
+. O
+
+OBJECTIVE O
+: O
+To O
+report O
+a O
+case O
+of O
+fulminant O
+neuropathy O
+with O
+severe O
+quadriparesis O
+associated O
+with O
+vincristine O
+chemotherapy O
+. O
+
+The O
+median O
+survival O
+time O
+was O
+18 O
+months O
+. O
+
+Hemorrheological O
+evaluation O
+and O
+proposed O
+pharmacological O
+uses O
+. O
+
+Its O
+phosphorylation O
+strongly O
+potentiates O
+its O
+ability O
+to O
+activate O
+transcription O
+of O
+the O
+c B
+- I
+fos I
+promoter I
+through O
+a O
+ternary O
+complex O
+assembled O
+on O
+the O
+c B
+- I
+fos I
+serum I
+response I
+element I
+. O
+
+Fus3p B
+and O
+Kss1p B
+together O
+increase O
+the O
+expression O
+of O
+CLN3 B
+and O
+PCL2 B
+genes I
+that O
+promote O
+budding O
+, O
+and O
+Kss1p B
+inhibits O
+the O
+MAP B
+kinase I
+cascade O
+. O
+
+Consistent O
+with O
+our O
+observation O
+that O
+AP B
+- I
+1 I
+binding O
+does O
+not O
+contribute O
+to O
+c B
+- I
+Jun I
+coactivation O
+is O
+the O
+observation O
+that O
+the O
+activation O
+of O
+PU B
+. I
+1 I
+by O
+c B
+- I
+Jun I
+is O
+blocked O
+by O
+overexpression O
+of O
+c B
+- I
+Fos I
+. O
+
+A O
+possible O
+correlation O
+between O
+mandibular O
+growth O
+retardation O
+and O
+palatal O
+clefting O
+is O
+discussed O
+. O
+
+Time O
+dependence O
+of O
+frequency O
+potentiation O
+in O
+the O
+isolated O
+guinea O
+- O
+pig O
+' O
+s O
+atrium O
+. O
+
+We O
+found O
+4 O
+highly O
+conserved O
+regions O
+to O
+vertebrate B
+Hsp90 I
+exclusively O
+and O
+27 O
+amino O
+acids O
+conserved O
+among O
+but O
+differing O
+between O
+Hsp90 B
+alpha I
+and O
+Hsp90 B
+beta I
+sequences I
+. O
+
+Characterization O
+of O
+trinucleotide O
+- O
+and O
+tandem O
+repeat O
+- O
+containing O
+transcripts O
+obtained O
+from O
+human O
+spinal O
+cord O
+cDNA O
+library O
+by O
+high O
+- O
+density O
+filter O
+hybridization O
+. O
+
+We O
+present O
+here O
+the O
+complete O
+primary O
+structure O
+of O
+human B
+gp330 I
+, O
+the O
+human O
+variant O
+of O
+the O
+principal O
+kidney O
+autoantigen O
+causing O
+Heymann O
+membranous O
+glomerulonephritis O
+in O
+rats O
+. O
+
+The O
+platelet B
+membrane I
+glycoprotein I
+IIb I
+/ I
+IIIa I
+receptor I
+inhibitor O
+abciximab O
+is O
+used O
+for O
+the O
+treatment O
+of O
+patients O
+undergoing O
+high O
+- O
+risk O
+percutaneous O
+coronary O
+interventions O
+and O
+is O
+used O
+in O
+approximately O
+one O
+third O
+of O
+coronary O
+interventions O
+in O
+the O
+United O
+States O
+and O
+a O
+growing O
+number O
+of O
+procedures O
+in O
+Europe O
+. O
+
+In O
+the O
+conscious O
+animals O
+the O
+increase O
+reached O
+statistical O
+significance O
+when O
+the O
+animals O
+were O
+exposed O
+to O
+12 O
+% O
+oxygen O
+in O
+nitrogen O
+, O
+which O
+produced O
+a O
+fall O
+in O
+arterial O
+PaO2 O
+of O
+44 O
+. O
+7 O
++ O
+/ O
+- O
+5 O
+. O
+0 O
+% O
+. O
+
+Prenatal O
+diagnosis O
+of O
+genetic O
+diseases O
+. O
+
+Human B
+epidermal I
+growth I
+factor I
+( O
+EGF B
+) O
+, O
+a O
+naturally O
+occurring O
+protein O
+, O
+has O
+been O
+implicated O
+in O
+the O
+protection O
+of O
+gastrointestinal O
+mucosal O
+integrity O
+. O
+
+A O
+ready O
+- O
+made O
+prosthesis O
+is O
+placed O
+on O
+the O
+external O
+side O
+of O
+the O
+ribs O
+vertically O
+bridging O
+the O
+flailed O
+chest O
+segment O
+, O
+and O
+fixed O
+to O
+the O
+first O
+upper O
+and O
+first O
+lower O
+intact O
+rib O
+as O
+well O
+as O
+to O
+the O
+mobile O
+segments O
+of O
+the O
+affected O
+ribs O
+. O
+
+DESIGN O
+: O
+Prospective O
+case O
+study O
+( O
+Canadian O
+Task O
+Force O
+classification O
+II O
+- O
+2 O
+) O
+. O
+
+Site O
+- O
+directed O
+mutagenesis O
+of O
+the O
+T4 B
+endonuclease I
+V I
+gene I
+: O
+role O
+of O
+lysine O
+- O
+130 O
+. O
+
+A O
+minimal O
+pheromone O
+induction O
+domain O
+, O
+delineated O
+as O
+residues O
+301 O
+to O
+335 O
+of O
+Ste12p B
+, O
+is O
+dependent O
+on O
+the O
+pheromone O
+mitogen B
+- I
+activated I
+protein I
+( I
+MAP I
+) I
+kinase I
+pathway O
+for O
+induction O
+activity O
+. O
+
+The O
+library O
+will O
+thus O
+be O
+useful O
+for O
+the O
+selection O
+of O
+cosmid O
+clones O
+which O
+carry O
+CDC B
+genes I
+from O
+yeast O
+by O
+complementing O
+first O
+, O
+with O
+the O
+vectorial O
+yeast B
+gene I
+URA1 I
+, O
+the O
+pyrimidine O
+auxotrophy O
+of O
+most O
+cdc B
+- O
+strains O
+and O
+then O
+, O
+with O
+the O
+respective O
+CDC B
+wild I
+- I
+type I
+genes I
+, O
+of O
+the O
+temperature O
+- O
+sensitive O
+mutant O
+alleles O
+. O
+
+These O
+mutant B
+rps7 I
+leaders I
+were O
+ligated O
+into O
+an O
+aadA B
+expression I
+cassette I
+and O
+transformed O
+into O
+the O
+chloroplast O
+of O
+C O
+. O
+reinhardtii O
+and O
+into O
+E O
+. O
+coli O
+. O
+
+In O
+addition O
+, O
+both O
+activated O
+Ral B
+- I
+GDS I
+- I
+like I
+factor I
+and O
+Raf B
+stimulate O
+cyclin B
+D I
+( I
+1 I
+) I
+transcription O
+and O
+E2F B
+activity O
+and O
+act O
+in O
+synergy O
+with O
+PI B
+3 I
+- I
+kinase I
+. O
+
+From O
+the O
+present O
+results O
+a O
+concept O
+of O
+hormone O
+- O
+dependent O
+AR B
+activation O
+is O
+proposed O
+, O
+which O
+requires O
+a O
+functional O
+, O
+direct O
+or O
+indirect O
+intramolecular O
+interaction O
+between O
+the O
+TAD O
+and O
+the O
+LBD O
+. O
+
+Like O
+the O
+DMA B
+, O
+but O
+unlike O
+all O
+other O
+mammalian B
+class I
+II I
+A I
+genes I
+, O
+the O
+zebrafish O
+gene O
+codes O
+for O
+two O
+cysteine O
+residues O
+which O
+might O
+potentially O
+be O
+involved O
+in O
+the O
+formation O
+of O
+a O
+disulfide O
+bond O
+in O
+the O
+alpha O
+1 O
+domain O
+. O
+
+Down O
+- O
+regulation O
+of O
+Id1 B
+mRNA I
+correlated O
+with O
+mitogenesis O
+and O
+occurred O
+when O
+quiescent O
+cells O
+were O
+treated O
+with O
+growth O
+factors O
+that O
+activate O
+G B
+protein I
+- I
+coupled I
+receptors I
+and O
+receptor B
+protein I
+tyrosine I
+kinases I
+but O
+not O
+with O
+a O
+non O
+- O
+mitogenic O
+cAMP O
+analog O
+. O
+
+Secretogranin B
+II I
+( O
+SgII B
+) O
+is O
+a O
+secretory O
+polypeptide O
+stored O
+in O
+large O
+dense O
+core O
+vesicles O
+of O
+neuroendocrine O
+and O
+neuronal O
+cells O
+. O
+
+CONCLUSIONS O
+: O
+In O
+the O
+results O
+of O
+this O
+study O
+, O
+SDB O
+, O
+even O
+snoring O
+, O
+was O
+independently O
+associated O
+with O
+hypertension O
+in O
+both O
+men O
+and O
+women O
+. O
+
+The O
+electron O
+spin O
+resonance O
+study O
+also O
+demonstrated O
+that O
+the O
+formation O
+of O
+superoxide O
+- O
+DMPO O
+spin O
+adduct O
+was O
+strongly O
+inhibited O
+by O
+a O
+selective O
+cyclooxygenase B
+- I
+2 I
+inhibitor O
+, O
+etodolac O
+, O
+in O
+a O
+concentration O
+- O
+dependent O
+manner O
+. O
+
+BK O
+- O
+induced O
+translocation O
+and O
+overexpression O
+of O
+PKC B
+isoforms I
+as O
+well O
+as O
+coexpression O
+of O
+inactive O
+or O
+constitutively O
+active O
+mutants O
+of O
+different O
+PKC B
+isozymes I
+provided O
+evidence O
+for O
+a O
+role O
+of O
+the O
+diacylglycerol O
+- O
+sensitive O
+PKCs B
+alpha I
+and I
+epsilon I
+in O
+BK O
+signaling O
+toward O
+MAPK B
+. O
+
+Embryonal O
+mortality O
+
+A O
+lead O
+phthalocyanin O
+method O
+for O
+the O
+demonstration O
+of O
+acid B
+hydrolases I
+in O
+plant O
+and O
+animal O
+tissues O
+. O
+
+Here O
+we O
+describe O
+the O
+characterization O
+of O
+cDNAs O
+encoding O
+two O
+unusual O
+E2Fs B
+, O
+E2F B
+- I
+4 I
+and O
+E2F B
+- I
+5 I
+, O
+each O
+identified O
+by O
+the O
+ability O
+of O
+their O
+gene O
+product O
+to O
+interact O
+with O
+p130 B
+in O
+a O
+yeast O
+two O
+- O
+hybrid O
+system O
+. O
+
+Interestingly O
+, O
+unlike O
+PAK65 B
+, O
+HPK1 B
+does O
+not O
+contain O
+the O
+small B
+GTPase I
+Rac1 B
+/ O
+Cdc42 B
+- O
+binding O
+domain O
+and O
+does O
+not O
+bind O
+to O
+either O
+Rac1 B
+or O
+Cdc42 B
+, O
+suggesting O
+that O
+HPK1 B
+. O
+activation O
+is O
+Rac1 B
+/ O
+Cdc42 B
+- O
+independent O
+. O
+
+The O
+results O
+were O
+compared O
+with O
+the O
+findings O
+in O
+pair O
+- O
+fed O
+non O
+- O
+treated O
+animals O
+( O
+Control O
+Group O
+) O
+. O
+
+Tumor B
+necrosis I
+factor I
+levels O
+were O
+measured O
+by O
+enzyme O
+- O
+linked O
+immunoabsorbent O
+assay O
+in O
+plasma O
+samples O
+obtained O
+from O
+the O
+hyperthermic O
+isolated O
+limb O
+perfusion O
+circuit O
+and O
+systemic O
+circulation O
+. O
+
+However O
+, O
+only O
+plasma O
+fibrinogen B
+concentrations O
+showed O
+statistically O
+significant O
+positive O
+associations O
+with O
+IMT O
+in O
+both O
+groups O
+. O
+
+Without O
+a O
+team O
+, O
+there O
+is O
+little O
+hope O
+for O
+fetal O
+survival O
+; O
+mortality O
+will O
+be O
+80 O
+- O
+100 O
+% O
+. O
+
+Analysis O
+of O
+deletion O
+and O
+substitution O
+mutations O
+in O
+the O
+MER2 B
+5 O
+' O
+exon O
+demonstrates O
+that O
+the O
+unusually O
+large O
+size O
+of O
+this O
+exon O
+plays O
+an O
+important O
+role O
+in O
+splicing O
+regulation O
+. O
+
+To O
+study O
+the O
+signaling O
+pathways O
+that O
+regulate O
+cytoskeletal O
+rearrangements O
+in O
+T O
+lymphocytes O
+, O
+we O
+set O
+up O
+a O
+conjugate O
+formation O
+assay O
+using O
+Jurkat O
+T O
+cells O
+as O
+effectors O
+and O
+cell O
+- O
+sized O
+latex O
+beads O
+coated O
+with O
+various O
+antibodies O
+as O
+artificial O
+APCs O
+. O
+
+Reexamination O
+of O
+the O
+cdc4 B
+- I
+1 I
+mutant I
+revealed O
+that O
+, O
+in O
+addition O
+to O
+being O
+defective O
+in O
+the O
+onset O
+of O
+S O
+phase O
+, O
+it O
+is O
+also O
+defective O
+in O
+G O
+( O
+2 O
+) O
+/ O
+M O
+transition O
+when O
+released O
+from O
+hydroxyurea O
+- O
+induced O
+S O
+- O
+phase O
+arrest O
+. O
+
+All O
+such O
+polypeptides O
+containing O
+263 O
+or O
+more O
+residues O
+derived O
+from O
+the O
+C O
+- O
+terminus O
+of O
+P130gag B
+- O
+fps B
+( O
+i O
+. O
+e O
+. O
+residues O
+920 O
+- O
+1182 O
+) O
+were O
+enzymatically O
+active O
+as O
+tyrosine B
+kinases I
+. O
+
+A O
+structural O
+model O
+for O
+Vpu B
+is O
+proposed O
+in O
+which O
+the O
+membrane O
+anchor O
+precedes O
+a O
+region O
+comprising O
+two O
+amphipathic O
+alpha O
+- O
+helices O
+of O
+opposed O
+polarity O
+, O
+joined O
+by O
+a O
+strongly O
+acidic O
+turn O
+that O
+protrudes O
+into O
+the O
+cytoplasm O
+and O
+contains O
+the O
+CK B
+- I
+2 I
+phosphorylation I
+sites I
+. O
+
+The O
+recombinant O
+containing O
+the O
+full B
+- I
+length I
+polyhedrin I
+leader I
+sequence I
+gave O
+levels O
+of O
+N B
+mRNA I
+comparable O
+to O
+those O
+of O
+AcNPV B
+polyhedrin I
+mRNA I
+. O
+
+Immune O
+and O
+clinical O
+impact O
+of O
+Lactobacillus O
+acidophilus O
+on O
+asthma O
+. O
+
+Thus O
+, O
+CARP B
+is O
+a O
+YB B
+- I
+1 I
+associated I
+factor I
+and O
+represents O
+the O
+first O
+identified O
+cardiac O
+- O
+restricted O
+downstream O
+regulatory O
+gene O
+in O
+the O
+homeobox B
+gene I
+Nkx2 B
+- I
+5 I
+pathway O
+and O
+may O
+serve O
+as O
+a O
+negative O
+regulator O
+of O
+HF B
+- I
+1 I
+- O
+dependent O
+pathways O
+for O
+ventricular O
+muscle O
+gene O
+expression O
+. O
+
+Each O
+receptor O
+must O
+therefore O
+engage O
+a O
+unique O
+subset O
+of O
+the O
+available O
+signaling O
+elements O
+- O
+- O
+at O
+least O
+partly O
+through O
+the O
+selection O
+of O
+proteins O
+with O
+src B
+- I
+homology I
+2 I
+domains I
+( O
+SH2 B
+proteins I
+) O
+. O
+
+A O
+proposed O
+method O
+. O
+
+A O
+model O
+for O
+the O
+SMase B
+- O
+sphingomyelin I
+complex O
+structure O
+was O
+built O
+to O
+investigate O
+how O
+the O
+SMase B
+specifically O
+recognizes O
+its O
+substrate O
+. O
+
+Two O
+estimates O
+of O
+the O
+fractal O
+exponent O
+are O
+considered O
+which O
+do O
+not O
+suffer O
+from O
+this O
+limit O
+: O
+one O
+derived O
+from O
+the O
+Allan O
+variance O
+, O
+which O
+was O
+developed O
+by O
+the O
+authors O
+, O
+and O
+one O
+based O
+on O
+the O
+periodogram O
+. O
+
+Births O
+, O
+marriages O
+, O
+divorces O
+, O
+and O
+deaths O
+for O
+July O
+1997 O
+. O
+
+In O
+conclusion O
+, O
+in O
+coronary O
+artery O
+disease O
+patients O
+, O
+exercise O
+- O
+redistribution O
+201Thallium O
+cardiac O
+imaging O
+with O
+reinjection O
+at O
+rest O
+can O
+identify O
+severely O
+ischemic O
+but O
+still O
+viable O
+myocardium O
+and O
+may O
+be O
+particularly O
+useful O
+in O
+the O
+prognosis O
+of O
+such O
+patients O
+. O
+
+However O
+, O
+the O
+recovery O
+curve O
+of O
+the O
+R2 O
+component O
+of O
+the O
+blink O
+reflex O
+diminished O
+in O
+patients O
+with O
+tension O
+- O
+type O
+headache O
+compared O
+with O
+the O
+other O
+groups O
+. O
+
+When O
+recombinant B
+gE I
+produced O
+in O
+HeLa O
+cells O
+was O
+probed O
+with O
+the O
+same O
+antiphosphotyrosine B
+antibody I
+, O
+a O
+dimeric O
+gE B
+form O
+at O
+130 O
+kDa O
+was O
+detected O
+on O
+the O
+cell O
+surface O
+. O
+
+Transforming B
+growth I
+factor I
+- I
+beta I
+( O
+TGF B
+- I
+beta I
+) O
+inhibits O
+cell O
+cycle O
+progression O
+, O
+in O
+part O
+through O
+up O
+- O
+regulation O
+of O
+gene O
+expression O
+of O
+the O
+p21 B
+( O
+WAF1 B
+/ O
+Cip1 B
+) O
+( O
+p21 B
+) O
+cell O
+cycle O
+inhibitor O
+. O
+
+The O
+results O
+suggest O
+that O
+both O
+superficial O
+and O
+deep O
+cortical O
+venous O
+drainage O
+of O
+the O
+cat O
+kidney O
+should O
+be O
+considered O
+when O
+measuring O
+renal B
+renin I
+release O
+. O
+
+CONCLUSION O
+: O
+Detection O
+of O
+recurrent O
+head O
+and O
+neck O
+cancer O
+is O
+feasible O
+with O
+FDG O
+PET O
+. O
+
+There O
+were O
+no O
+differences O
+in O
+the O
+incidence O
+of O
+fractured O
+zonas O
+. O
+
+DSIP O
+was O
+found O
+to O
+significantly O
+increase O
+slow O
+- O
+waves O
+( O
+delta O
+sleep O
+) O
+in O
+the O
+sleep O
+EEG O
+. O
+
+Accuracy O
+and O
+predictive O
+value O
+of O
+ultrasound O
+in O
+acute O
+rejection O
+. O
+
+7 O
+- O
+Nitroindazole O
+( O
+7NI O
+) O
+, O
+a O
+relatively O
+selective O
+neuronal B
+nitric I
+oxide I
+synthase I
+( O
+nNOS B
+) O
+inhibitor O
+. O
+was O
+intraperitoneally O
+administered O
+to O
+the O
+guinea O
+pigs O
+30 O
+minutes O
+before O
+the O
+onset O
+of O
+local O
+anoxia O
+. O
+
+Mutations O
+that O
+extend O
+the O
+specificity O
+of O
+the O
+endonuclease O
+activity O
+of O
+lambda B
+terminase I
+. O
+
+The O
+gene O
+set O
+in O
+this O
+mitochondrial O
+genome O
+is O
+a O
+subset O
+of O
+that O
+of O
+Reclinomonas O
+americana O
+, O
+an O
+amoeboid O
+protozoan O
+. O
+
+An O
+evaluation O
+of O
+a O
+positive O
+control O
+for O
+platelet O
+neutralization O
+procedure O
+testing O
+with O
+seven O
+commercial O
+activated O
+partial O
+thromboplastin B
+time O
+reagents O
+. O
+
+The O
+prosomal B
+RNA I
+- I
+binding I
+protein I
+p27K I
+is O
+a O
+member O
+of O
+the O
+alpha B
+- I
+type I
+human I
+prosomal I
+gene I
+family I
+. O
+
+A O
+single O
+clone O
+, O
+which O
+was O
+conserved O
+and O
+had O
+near O
+- O
+perfect O
+homology O
+to O
+eight O
+human O
+/ O
+rodent O
+expressed O
+sequence O
+tags O
+, O
+was O
+used O
+as O
+template O
+for O
+5 O
+' O
+and O
+3 O
+' O
+rapid O
+amplification O
+of O
+cDNA O
+ends O
+and O
+SPICE O
+( O
+system O
+for O
+polymerase O
+chain O
+reaction O
+amplification O
+of O
+cDNA O
+ends O
+) O
+reactions O
+to O
+obtain O
+the O
+3 O
+. O
+6 O
+- O
+kb O
+cDNA O
+, O
+LGL2 B
+( O
+Genbank O
+, O
+AF O
+110195 O
+) O
+encoding O
+a O
+deduced O
+polypeptide O
+( O
+lgl2 B
+) O
+of O
+963 O
+amino O
+acids O
+. O
+
+These O
+tiny O
+premature O
+infants O
+also O
+received O
+PN O
+for O
+significantly O
+longer O
+periods O
+of O
+time O
+, O
+and O
+the O
+longer O
+the O
+infusions O
+were O
+administered O
+the O
+greater O
+was O
+the O
+risk O
+of O
+cholestasis O
+developing O
+. O
+
+The O
+SM O
+- O
+specific O
+selection O
+of O
+exon O
+2 O
+results O
+from O
+the O
+inhibition O
+of O
+exon O
+3 O
+. O
+
+It O
+is O
+always O
+present O
+and O
+has O
+a O
+discrete O
+origin O
+and O
+insertion O
+. O
+
+Medical O
+management O
+of O
+early O
+- O
+stage O
+breast O
+cancer O
+. O
+
+Five O
+girls O
+with O
+Turner O
+' O
+s O
+syndrome O
+aged O
+12 O
+to O
+17 O
+years O
+showed O
+LH B
+values O
+( O
+5 O
+. O
+0 O
+- O
+14 O
+. O
+5 O
+IU O
+/ O
+12 O
+h O
+) O
+at O
+the O
+upper O
+end O
+of O
+or O
+slightly O
+above O
+the O
+normal O
+range O
+and O
+pathologically O
+high O
+values O
+( O
+22 O
+. O
+2 O
+- O
+43 O
+. O
+5 O
+IU O
+/ O
+12 O
+h O
+) O
+for O
+FSH B
+. O
+
+In O
+vitro O
+death O
+assays O
+with O
+transient O
+overexpression O
+of O
+deletion O
+constructs O
+of O
+both O
+isoforms O
+using O
+beta B
+- I
+galactosidase I
+as O
+a O
+reporter O
+gene O
+in O
+MCF7 O
+cells O
+suggest O
+the O
+following O
+: O
+1 O
+) O
+the O
+nucleotide O
+binding O
+domain O
+may O
+act O
+as O
+a O
+negative O
+regulator O
+of O
+the O
+killing O
+activity O
+of O
+DEFCAP B
+; O
+2 O
+) O
+the O
+LRR B
+/ O
+CARD B
+represents O
+a O
+putative O
+constitutively O
+active O
+inducer O
+of O
+apoptosis O
+; O
+3 O
+) O
+the O
+killing O
+activity O
+of O
+LRR B
+/ O
+CARD B
+is O
+inhibitable O
+by O
+benzyloxycarbonyl O
+- O
+Val O
+- O
+Ala O
+- O
+
+Asp O
+( O
+OMe O
+) O
+- O
+fluoromethyl O
+ketone O
+and O
+to O
+a O
+lesser O
+extent O
+by O
+Asp O
+- O
+Glu O
+- O
+Val O
+- O
+Asp O
+( O
+OMe O
+) O
+- O
+fluoromethyl O
+ketone O
+; O
+and O
+4 O
+) O
+the O
+CARD O
+is O
+critical O
+for O
+killing O
+activity O
+of O
+DEFCAP O
+. O
+
+In O
+6 O
+patients O
+( O
+9 O
+kidneys O
+) O
+irrigation O
+with O
+Solution O
+G O
+in O
+the O
+renal O
+pelvis O
+was O
+performed O
+for O
+the O
+dissolution O
+of O
+their O
+infectious O
+stones O
+. O
+
+The O
+use O
+of O
+sigma B
+54 I
+promoters I
+, O
+known O
+to O
+require O
+cognate O
+binding O
+proteins O
+, O
+could O
+allow O
+the O
+fine O
+- O
+tuning O
+that O
+provides O
+the O
+temporal O
+ordering O
+of O
+flagellar O
+gene O
+transcription O
+. O
+
+The O
+association O
+of O
+I B
+- I
+92 I
+with O
+p92 B
+, O
+p84 B
+, O
+p75 B
+, O
+p73 B
+, O
+p69 B
+, O
+and O
+p57 B
+was O
+completely O
+reversible O
+after O
+treatment O
+with O
+the O
+detergent O
+deoxycholate O
+( O
+DOC O
+) O
+. O
+
+To O
+our O
+knowledge O
+no O
+transcription O
+factors O
+have O
+previously O
+been O
+identified O
+that O
+exhibit O
+androgen O
+- O
+dependent O
+expression O
+in O
+the O
+epididymis O
+. O
+
+Focal O
+or O
+regional O
+8 O
+- O
+to O
+20 O
+- O
+Hz O
+low O
+- O
+voltage O
+epileptiform O
+paroxysms O
+in O
+either O
+hippocampus O
+( O
+10 O
+patients O
+) O
+, O
+amygdala O
+( O
+1 O
+patient O
+) O
+, O
+or O
+both O
+( O
+1 O
+patient O
+) O
+preceded O
+initial O
+motionless O
+staring O
+. O
+
+The O
+lack O
+of O
+heterozygous O
+positions O
+essentially O
+facilitates O
+on O
+the O
+one O
+hand O
+the O
+data O
+analysis O
+and O
+on O
+the O
+other O
+hand O
+the O
+detection O
+of O
+new O
+alleles O
+. O
+
+Epithelial O
+cell O
+- O
+specific O
+activation O
+is O
+achieved O
+by O
+the O
+cooperative O
+interaction O
+of O
+apparently O
+ubiquitous O
+transcriptional O
+factors O
+. O
+
+Human O
+parvovirus O
+B19 I
+gene O
+expression O
+from O
+the O
+viral B
+p6 I
+promoter I
+( O
+B19p6 B
+) O
+is O
+restricted O
+to O
+primary O
+human O
+hematopoietic O
+cells O
+undergoing O
+erythroid O
+differentiation O
+. O
+
+The O
+effectiveness O
+and O
+pathogenetic O
+expediency O
+of O
+correcting O
+disorders O
+of O
+lipid O
+metabolism O
+in O
+atherosclerosis O
+with O
+enterosorbents O
+is O
+substantiated O
+. O
+
+To O
+prevent O
+section O
+wrinkles O
+usually O
+encountered O
+with O
+the O
+use O
+of O
+coated O
+single O
+- O
+hole O
+grids O
+, O
+a O
+simple O
+method O
+was O
+developed O
+. O
+
+The O
+Cryotherapy O
+for O
+Retinopathy O
+of O
+Prematurity O
+Study O
+has O
+shown O
+that O
+this O
+number O
+can O
+be O
+halved O
+with O
+treatment O
+. O
+
+Ultrasound O
+- O
+guided O
+fine O
+- O
+needle O
+aspiration O
+biopsy O
+( O
+US O
+- O
+FNAB O
+) O
+revealed O
+normal O
+- O
+looking O
+squamous O
+cells O
+. O
+
+Bleeding O
+was O
+successfully O
+prevented O
+in O
+28 O
+patients O
+with O
+the O
+use O
+of O
+a O
+combined O
+treatment O
+incorporating O
+IV O
+desmopressin O
+, O
+an O
+antifibrinolytic O
+agent O
+( O
+tranexamic O
+acid O
+) O
+, O
+and O
+local O
+methods O
+( O
+surgical O
+glue O
+and O
+compression O
+techniques O
+) O
+. O
+
+Hetero O
+- O
+oligomerization O
+of O
+Smad4 B
+with O
+the O
+pathway O
+- O
+restricted O
+SMAD B
+proteins I
+is O
+essential O
+for O
+Smad4 B
+- O
+mediated O
+transcription O
+. O
+
+This O
+fragment O
+contains O
+two O
+complete O
+endo B
+- I
+beta I
+- I
+1 I
+, I
+4 I
+- I
+glucanase I
+- I
+encoding I
+genes I
+, O
+designated O
+celCCC B
+and O
+celCCG B
+. O
+
+One O
+of O
+them O
+is O
+its O
+limited O
+sensitivity O
+to O
+weak O
+interactions O
+, O
+which O
+are O
+common O
+in O
+the O
+mammalian O
+cerebral O
+cortex O
+. O
+
+Analysis O
+of O
+the O
+5 O
+' O
+and O
+3 O
+' O
+termini O
+of O
+the O
+transcripts O
+produced O
+in O
+vivo O
+from O
+the O
+puf B
+operon I
+of I
+R I
+. I
+sphaeroides I
+PUF I
+delta I
+348 I
+- I
+420 I
+( O
+three O
+transcripts O
+; O
+0 O
+. O
+59 O
+, O
+0 O
+. O
+64 O
+, O
+and O
+2 O
+. O
+63 O
+kilobases O
+) O
+lacking O
+the O
+puf B
+- O
+intercistronic O
+terminator O
+structure O
+were O
+identical O
+to O
+those O
+of O
+the O
+corresponding O
+puf B
+transcripts I
+derived O
+from O
+wild O
+- O
+type O
+R O
+. O
+sphaeroides O
+2 I
+. I
+4 I
+. I
+1 I
+( O
+four O
+transcripts O
+; O
+0 O
+. O
+50 O
+, O
+0 O
+. O
+66 O
+, O
+0 O
+. O
+71 O
+, O
+and O
+2 O
+. O
+7 O
+kilobases O
+) O
+showing O
+
+that O
+the O
+transcripts O
+begin O
+and O
+end O
+at O
+the O
+same O
+sites O
+. O
+
+The O
+optimum O
+cooling O
+rate O
+from O
+RT O
+to O
+5 O
+degrees O
+C O
+resulting O
+in O
+maximum O
+survival O
+of O
+human O
+spermatozoa O
+was O
+found O
+to O
+be O
+0 O
+. O
+5 O
+to O
+1 O
+degree O
+per O
+minute O
+when O
+cooled O
+from O
+RT O
+to O
+5 O
+degrees O
+C O
+and O
+subsequently O
+frozen O
+- O
+thawed O
+in O
+liquid O
+nitrogen O
+( O
+LN2 O
+) O
+. O
+
+The O
+cerebellar O
+cortical O
+vessels O
+: O
+they O
+are O
+compared O
+to O
+the O
+cerebral O
+vessels O
+. O
+
+Transesophageal O
+echocardiography O
+risk O
+factors O
+for O
+stroke O
+in O
+nonvalvular O
+atrial O
+fibrillation O
+. O
+
+22 O
+- O
+Veneto O
+Region O
+) O
+
+Preventive O
+health O
+counseling O
+tailored O
+to O
+the O
+needs O
+of O
+this O
+group O
+may O
+be O
+most O
+beneficial O
+. O
+
+Strains O
+lacking O
+a O
+functional O
+RPL16A B
+gene I
+grow O
+as O
+rapidly O
+as O
+wild O
+type O
+, O
+whereas O
+those O
+containing O
+a O
+null O
+allele O
+of O
+RPL16B B
+grow O
+more O
+slowly O
+than O
+wild O
+type O
+. O
+
+Neonatal O
+hyperthyroidism O
+
+After O
+Northern O
+blot O
+hybridization O
+, O
+two O
+Cx31 B
+transcripts I
+of O
+2 O
+. O
+2 O
+and O
+1 O
+. O
+8 O
+kb O
+were O
+detected O
+in O
+total O
+RNA O
+of O
+the O
+human O
+keratinocyte O
+cell O
+line O
+HaCaT O
+and O
+two O
+transcripts O
+of O
+2 O
+. O
+2 O
+and O
+1 O
+. O
+9 O
+kb O
+in O
+total O
+RNA O
+of O
+E6 B
+/ O
+E7 B
+transfected O
+human O
+keratinocytes O
+( O
+HEK O
+cells O
+) O
+. O
+
+In O
+summary O
+, O
+FGFR3 B
+signaling O
+pathway O
+utilizes O
+two O
+GRB2 B
+- I
+containing I
+complexes I
+; O
+Shc B
+. O
+GRB2 B
+. O
+Sos B
+and O
+80K O
+- O
+H O
+. O
+pp66 B
+. O
+GRB2 B
+. O
+Sos B
+; O
+these O
+two O
+complexes O
+may O
+alternatively O
+link O
+FGFG3 B
+to O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+. O
+
+In O
+an O
+effort O
+to O
+identify O
+factors O
+involved O
+in O
+the O
+expression O
+of O
+this O
+important O
+erythroid O
+- O
+specific O
+regulatory O
+protein O
+, O
+we O
+have O
+isolated O
+the O
+mouse O
+EKLF B
+gene I
+and O
+systematically O
+analyzed O
+the O
+promoter O
+region O
+. O
+
+Their O
+main O
+representatives O
+are O
+the O
+American O
+diagnostic O
+and O
+statistical O
+manual O
+of O
+mental O
+disorders O
+, O
+DSM O
+- O
+III O
+, O
+its O
+revised O
+version O
+DSM O
+- O
+III O
+- O
+R O
+and O
+the O
+new O
+international O
+classification O
+of O
+mental O
+disorders O
+iCD O
+- O
+10 O
+. O
+
+Any O
+opacity O
+on O
+a O
+chest O
+radiograph O
+has O
+a O
+wide O
+differential O
+diagnosis O
+. O
+
+At O
+the O
+same O
+acoustic O
+power O
+, O
+the O
+rate O
+of O
+chloride O
+formation O
+with O
+20 O
+kHz O
+ultrasound O
+was O
+greater O
+when O
+a O
+probe O
+with O
+a O
+larger O
+tip O
+area O
+was O
+used O
+, O
+but O
+significantly O
+less O
+than O
+the O
+rate O
+with O
+900 O
+kHz O
+. O
+
+In O
+contrast O
+to O
+Torpedo O
+, O
+where O
+only O
+a O
+single O
+transcript O
+is O
+seen O
+, O
+the O
+mouse O
+expresses O
+several O
+mRNAs O
+encoding O
+different O
+isoforms O
+. O
+
+Four O
+families O
+of O
+homing B
+endonucleases I
+have O
+been O
+identified O
+, O
+including O
+the O
+LAGLIDADG O
+, O
+the O
+His O
+- O
+Cys O
+box O
+, O
+the O
+GIY O
+- O
+YIG B
+and O
+the O
+H B
+- I
+N I
+- I
+H I
+endonucleases I
+. O
+
+Convergence O
+of O
+trigeminal O
+input O
+with O
+visceral O
+and O
+phrenic O
+inputs O
+on O
+primate O
+C1 O
+- O
+C2 O
+spinothalamic O
+tract O
+neurons O
+. O
+
+The O
+GvpE B
+protein I
+involved O
+in O
+the O
+regulation O
+of O
+gas O
+vesicles O
+synthesis O
+in O
+halophilic O
+archaea O
+has O
+been O
+identified O
+as O
+the O
+transcriptional O
+activator O
+for O
+the O
+promoter O
+located O
+upstream O
+of O
+the O
+gvpA B
+gene I
+encoding O
+the O
+major O
+gas B
+vesicle I
+structural I
+protein I
+GvpA B
+. O
+
+Nosographic O
+problems O
+
+In O
+early O
+midgestation O
+embryos O
+it O
+is O
+expressed O
+in O
+telencephalic O
+, O
+diencephalic O
+and O
+mesencephalic O
+regions O
+but O
+from O
+day O
+11 O
+. O
+75 O
+of O
+gestation O
+its O
+expression O
+disappears O
+from O
+dorsal O
+telencephalon O
+and O
+is O
+confined O
+to O
+diencephalic O
+and O
+mesencephalic O
+regions O
+. O
+
+The O
+training O
+programs O
+had O
+a O
+duration O
+of O
+30 O
+days O
+, O
+5 O
+days O
+/ O
+week O
+, O
+and O
+was O
+performed O
+on O
+a O
+motor O
+- O
+driven O
+treadmill O
+. O
+
+Phylogenetic O
+analysis O
+using O
+a O
+neighbor O
+- O
+joining O
+algorithm O
+showed O
+closest O
+similarity O
+of O
+the O
+horse B
+mu I
+chain I
+- I
+encoding I
+constant I
+region I
+gene I
+to O
+human O
+and O
+dog O
+sequences O
+. O
+
+Using O
+probes O
+from O
+these O
+regions O
+, O
+rearrangements O
+have O
+been O
+identified O
+in O
+each O
+of O
+nine O
+cases O
+of O
+t O
+( O
+8 O
+; O
+21 O
+) O
+AML O
+examined O
+. O
+
+Cloning O
+and O
+nucleotide O
+sequence O
+analysis O
+reveals O
+that O
+BUR6 B
+encodes O
+a O
+homolog B
+of O
+DRAP1 B
+( O
+also O
+called O
+NC2alpha B
+) O
+, O
+a O
+mammalian O
+repressor O
+of O
+basal O
+transcription O
+. O
+
+BRAP2 B
+also O
+shares O
+significant O
+homology O
+with O
+a O
+hypothetical O
+protein O
+from O
+yeast O
+Saccharomyces O
+cerevisiae O
+, O
+especially O
+in O
+the O
+zinc O
+finger O
+region O
+. O
+
+Earlier O
+published O
+data O
+, O
+indicating O
+Sp1 B
+binding O
+to O
+the O
+R1 O
+alpha O
+/ O
+beta O
+regions O
+, O
+could O
+not O
+be O
+confirmed O
+, O
+suggesting O
+that O
+the O
+R1 O
+initiator O
+element O
+may O
+function O
+independent O
+of O
+Sp1 B
+. O
+
+In O
+addition O
+, O
+reduced O
+metabolism O
+to O
+cotinine O
+from O
+the O
+proliposomes O
+and O
+MP O
+was O
+apparently O
+responsible O
+for O
+the O
+sustained O
+plasma O
+nicotine O
+levels O
+. O
+
+Activation O
+of O
+HIV O
+- O
+1 O
+requires O
+the O
+binding O
+of O
+host O
+cell O
+transcription O
+factors O
+to O
+cis O
+elements O
+in O
+the O
+proviral B
+long O
+terminal O
+repeat O
+( O
+LTR O
+) O
+. O
+
+The O
+yeast B
+mitochondrial I
+Hsp70 I
+, O
+Ssc1p B
+, O
+functions O
+as O
+a O
+molecular O
+chaperone O
+with O
+its O
+partner O
+proteins O
+, O
+Mdj1p B
+( O
+DnaJ B
+homologue I
+) O
+and O
+Yge1p B
+( O
+GrpE B
+homologue I
+) O
+. O
+
+Increased O
+TRE O
+DNA O
+binding O
+failed O
+to O
+lead O
+to O
+increased O
+transactivation O
+correlating O
+with O
+the O
+inability O
+of O
+SB O
+203580 O
+to O
+increase O
+phosphorylation O
+of O
+these O
+AP B
+- I
+1 I
+proteins I
+. O
+
+The O
+rice O
+gene O
+consists O
+of O
+four O
+exons O
+. O
+
+However O
+, O
+and O
+in O
+contrast O
+to O
+other O
+MMP B
+genes I
+, O
+no O
+significative O
+synergistic O
+effect O
+on O
+CAT B
+activity O
+between O
+the O
+AP B
+- I
+1 I
+and O
+PEA B
+- I
+3 I
+elements I
+found O
+in O
+the O
+collagenase B
+- I
+3 I
+gene I
+promoter I
+was O
+found O
+. O
+
+The O
+equation O
+for O
+mean O
+trabecular O
+number O
+passed O
+the O
+test O
+, O
+whereas O
+the O
+validity O
+of O
+the O
+equations O
+for O
+mean O
+trabecular O
+separation O
+and O
+Tb O
+. O
+Wi O
+appeared O
+limited O
+. O
+
+Methodological O
+considerations O
+limiting O
+causal O
+assertions O
+permissible O
+with O
+nonexperimental O
+data O
+are O
+discussed O
+. O
+
+In O
+contrast O
+, O
+postmitotic O
+neurons O
+possessed O
+extremely O
+low O
+levels O
+of O
+E2F1 B
+protein I
+as O
+assessed O
+by O
+the O
+electrophoretic O
+mobility O
+shift O
+assay O
+and O
+Western O
+blotting O
+. O
+
+Recurrence O
+of O
+the O
+hepatic O
+cyst O
+after O
+partial O
+excision O
+and O
+drainage O
+was O
+complicated O
+by O
+fistula O
+formation O
+between O
+the O
+cyst O
+and O
+the O
+duodenum O
+. O
+
+Reversal O
+of O
+mefloquine O
+resistance O
+in O
+rodent O
+Plasmodium O
+. O
+
+Possible O
+consequences O
+of O
+such O
+binder O
+distribution O
+through O
+powder O
+aggregates O
+are O
+discussed O
+. O
+
+The O
+human B
+parvalbumin I
+mRNA I
+contains O
+the O
+putative O
+polyadenylation O
+signal O
+AATAAA O
+13 O
+nucleotides O
+upstream O
+from O
+the O
+polyadenylation O
+site O
+. O
+
+The O
+delta O
+Mo O
++ O
+SV O
+tumor O
+DNAs O
+from O
+B O
+- O
+lineage O
+tumors O
+were O
+typically O
+rearranged O
+at O
+the O
+immunoglobulin B
+gene I
+loci I
+and O
+contained O
+germ O
+line O
+configurations O
+of O
+the O
+T B
+- I
+cell I
+receptor I
+beta I
+gene I
+. O
+
+The O
+experimental O
+results O
+suggest O
+equilibrium O
+complex O
+formation O
+between O
+OTC B
+and O
+PVP B
+, O
+it O
+being O
+mainly O
+the O
+complex O
+which O
+is O
+i O
+. O
+v O
+. O
+injected O
+when O
+both O
+products O
+are O
+combined O
+in O
+an O
+injection O
+formulation O
+. O
+
+We O
+conclude O
+that O
+the O
+MMF O
+lesion O
+is O
+secondary O
+to O
+intramuscular O
+injection O
+of O
+aluminium O
+hydroxide O
+- O
+containing O
+vaccines O
+, O
+shows O
+both O
+long O
+- O
+term O
+persistence O
+of O
+aluminium O
+hydroxide O
+and O
+an O
+ongoing O
+local O
+immune O
+reaction O
+, O
+and O
+is O
+detected O
+in O
+patients O
+with O
+systemic O
+symptoms O
+which O
+appeared O
+subsequently O
+to O
+vaccination O
+. O
+
+To O
+examine O
+the O
+effect O
+of O
+the O
+cAMP O
+signal O
+transduction O
+pathway O
+on O
+transcription O
+of O
+the O
+gene O
+encoding O
+the O
+catalytic O
+subunit O
+of O
+glucose B
+- I
+6 I
+- I
+phosphatase I
+( O
+G6Pase B
+) O
+, O
+G6Pase B
+- O
+chloramphenicol B
+acetyltransferase I
+( O
+CAT B
+) O
+fusion O
+genes O
+were O
+transiently O
+transfected O
+into O
+either O
+the O
+liver O
+- O
+derived O
+HepG2 O
+or O
+kidney O
+- O
+derived O
+LLC O
+- O
+PK O
+cell O
+line O
+. O
+
+Whereas O
+the O
+sequence O
+of O
+alpha B
+- I
+actinin I
+( O
+Noegel O
+, O
+A O
+. O
+, O
+W O
+. O
+
+By O
+contrast O
+, O
+clonidine O
+( O
+1 O
+micrograms O
+/ O
+kg O
+) O
+elicited O
+an O
+immediate O
+and O
+prolonged O
+fall O
+in O
+blood O
+pressure O
+and O
+heart O
+rate O
+when O
+given O
+into O
+the O
+vertebral O
+artery O
+, O
+but O
+not O
+intravenously O
+. O
+
+The O
+shift O
+from O
+complex O
+I O
+to O
+complex O
+II O
+seen O
+only O
+in O
+SCM O
+- O
+1 O
+- O
+producer O
+T O
+cell O
+lines O
+upon O
+activation O
+was O
+completely O
+suppressed O
+by O
+cyclosporin O
+A O
+. O
+
+( O
+We O
+observed O
+a O
+ferritin B
+value O
+as O
+high O
+as O
+47 O
+mg O
+/ O
+L O
+in O
+one O
+patient O
+. O
+) O
+Results O
+with O
+all O
+these O
+kits O
+did O
+not O
+inter O
+- O
+compare O
+well O
+for O
+ferritin B
+concentrations O
+greater O
+than O
+300 O
+micrograms O
+/ O
+L O
+, O
+a O
+finding O
+that O
+casts O
+further O
+doubt O
+on O
+the O
+controversial O
+use O
+of O
+serum O
+ferritin B
+measurement O
+in O
+cases O
+of O
+iron O
+overload O
+. O
+
+Post O
+- O
+CPB O
+cardiac O
+index O
+was O
+superior O
+in O
+group O
+B O
+( O
+3 O
+. O
+9 O
++ O
+/ O
+- O
+0 O
+. O
+3 O
+vs O
+. O
+
+ER B
+beta I
+was O
+less O
+potent O
+than O
+ER B
+alpha I
+in O
+activating O
+E2 O
+- O
+stimulated O
+ERELuc B
+activity O
+( O
+4 O
+- O
+vs O
+. O
+
+The O
+expression O
+pattern O
+of O
+LjEmx B
+changed O
+dramatically O
+during O
+embryogenesis O
+; O
+expression O
+was O
+seen O
+initially O
+in O
+the O
+entire O
+neural O
+tube O
+and O
+mesoderm O
+, O
+which O
+were O
+secondarily O
+downregulated O
+, O
+and O
+secondarily O
+in O
+cranial O
+nerve O
+ganglia O
+and O
+in O
+the O
+craniofacial O
+mesenchyme O
+. O
+
+Disruption O
+of O
+PML B
+subnuclear O
+domains O
+by O
+the O
+acidic O
+IE1 B
+protein I
+of O
+human O
+cytomegalovirus O
+is O
+mediated O
+through O
+interaction O
+with O
+PML B
+and O
+may O
+modulate O
+a O
+RING O
+finger O
+- O
+dependent O
+cryptic O
+transactivator O
+function O
+of O
+PML B
+. O
+
+Furthermore O
+, O
+the O
+GC O
+- O
+rich O
+sequences O
+could O
+confer O
+Sp1 B
+- O
+dependent O
+transactivation O
+to O
+a O
+heterologous O
+prolactin B
+minimal I
+promoter I
+. O
+
+Twelve O
+patients O
+of O
+leprosy O
+with O
+arthritis O
+and O
+161 O
+patients O
+without O
+arthritis O
+were O
+studied O
+for O
+immunological O
+parameters O
+like O
+immunoglobulins B
+( O
+IgG B
+, O
+IgM B
+, O
+IgA B
+) O
+, O
+C B
+- I
+reactive I
+proteins I
+and O
+rheumatoid B
+factor I
+. O
+
+Several O
+reports O
+assert O
+that O
+prolactin B
+affects O
+the O
+delta O
+5 O
+and O
+delta O
+4 O
+pathways O
+through O
+its O
+effect O
+on O
+the O
+activity O
+of O
+3beta B
+- I
+hydroxysteroid I
+dehydrogenase I
+( O
+3beta B
+- I
+OHSD I
+) O
+. O
+
+The O
+NrfC B
+polypeptide I
+, O
+M O
+( O
+r O
+) O
+24 O
+, O
+567 O
+, O
+contains O
+16 O
+cysteine O
+residues O
+arranged O
+in O
+four O
+clusters O
+typical O
+of O
+the O
+CooF B
+super I
+- I
+family I
+of O
+non B
+- I
+haem I
+iron I
+- I
+sulphur I
+proteins I
+. O
+
+Zonography O
+in O
+urology O
+( O
+author O
+' O
+s O
+transl O
+) O
+
+( O
+i O
+) O
+p60 B
+bound O
+fast O
+- O
+migrating O
+, O
+underprocessed O
+wild B
+- I
+type I
+ICP22 I
+and O
+ICP22 B
+lacking O
+the O
+carboxyl O
+- O
+terminal O
+24 O
+amino O
+acids O
+but O
+not O
+ICP22 B
+lacking O
+the O
+carboxyl O
+- O
+terminal O
+40 O
+amino O
+acids O
+, O
+whereas O
+the O
+previously O
+identified O
+cellular O
+protein O
+p78 B
+( O
+R O
+. O
+
+Stress O
+thallium O
+- O
+201 O
+myocardial O
+imaging O
+was O
+used O
+in O
+two O
+angina O
+- O
+free O
+patients O
+with O
+severe O
+congestive O
+heart O
+failure O
+to O
+identify O
+clinically O
+silent O
+areas O
+of O
+ischemic O
+myocardium O
+and O
+to O
+distinguish O
+between O
+scar O
+and O
+reversibly O
+ischemic O
+myocardium O
+as O
+a O
+cause O
+for O
+akinesia O
+of O
+left O
+ventricular O
+wall O
+segments O
+. O
+
+The O
+community O
+- O
+acquired O
+bacteremia O
+was O
+mainly O
+due O
+to O
+E O
+. O
+coli O
+. O
+
+Y1 B
+, O
+Y2 B
+, O
+and O
+Y4 B
+/ O
+PP1 B
+. O
+
+Low O
+plasma O
+glucose O
+concentrations O
+that O
+may O
+or O
+may O
+not O
+be O
+sufficiently O
+low O
+to O
+result O
+in O
+symptoms O
+can O
+be O
+observed O
+as O
+a O
+concomitant O
+of O
+several O
+diverse O
+diseases O
+. O
+
+Developmentally O
+- O
+regulated O
+interaction O
+of O
+a O
+transcription O
+factor O
+complex O
+containing O
+CDP B
+/ O
+cut B
+with O
+the O
+early O
+histone B
+H3 I
+gene I
+promoter I
+of O
+the O
+sea O
+urchin O
+Tetrapygus O
+niger O
+is O
+associated O
+with O
+changes O
+in O
+chromatin O
+structure O
+and O
+gene O
+expression O
+. O
+
+Procedures O
+with O
+perfected O
+method O
+
+After O
+a O
+shift O
+to O
+37 O
+degrees O
+C O
+, O
+the O
+mutant O
+Rat7 B
+- I
+1p I
+/ O
+Nup159 B
+- I
+1p I
+is O
+lost O
+from O
+the O
+nuclear O
+rim O
+of O
+rat7 O
+- O
+1 O
+cells O
+and O
+NPCs O
+, O
+which O
+are O
+clustered O
+together O
+in O
+these O
+cells O
+grown O
+under O
+permissive O
+conditions O
+become O
+substantially O
+less O
+clustered O
+. O
+
+The O
+mRNA O
+for O
+this O
+protein O
+is O
+expressed O
+in O
+the O
+T O
+- O
+ALL O
+cell O
+line O
+Jurkat O
+and O
+has O
+been O
+designated O
+HUG1 B
+, O
+for O
+HOX11 B
+Upstream I
+Gene I
+. O
+
+The O
+STS O
+sequence O
+WI O
+- O
+14920 O
+is O
+in O
+fact O
+derived O
+from O
+the O
+3 O
+' O
+- O
+untranslated O
+region O
+of O
+the O
+human B
+PUNC I
+gene I
+. O
+
+Its O
+activity O
+was O
+twice O
+that O
+of O
+a O
+construct O
+where O
+the O
+CAT B
+gene I
+was O
+driven O
+by O
+the O
+H B
+- I
+2Kb I
+5 I
+' I
+enhancer I
+region I
+( O
+H2TF1 B
+/ O
+KBF1 B
+site O
+) O
+and O
+comparable O
+to O
+that O
+of O
+pRSVCAT O
+construct O
+carrying O
+the O
+strong O
+Rous B
+sarcoma I
+virus I
+LTR I
+enhancer I
+. O
+
+ORF3 O
+appears O
+to O
+encode O
+the O
+homologue O
+of O
+the O
+well O
+- O
+conserved O
+proteasomal B
+26S I
+regulatory I
+subunit I
+. O
+
+The O
+tam B
+A I
+gene I
+of I
+Aspergillus O
+nidulans O
+encodes O
+a O
+739 O
+- O
+amino O
+acid O
+protein O
+with O
+similarity O
+to O
+Uga35p B
+/ O
+Dal81p B
+/ O
+DurLp B
+of O
+Saccharomyces O
+cerevisiae O
+. O
+
+Little O
+honoured O
+in O
+his O
+own O
+country O
+: O
+statues O
+in O
+recognition O
+of O
+Edward O
+Jenner O
+MD O
+FRS O
+. O
+
+A O
+pharmacokinetic O
+interaction O
+between O
+LY354740 O
+and O
+diazepam O
+, O
+leading O
+to O
+the O
+lowering O
+of O
+the O
+plasma O
+level O
+of O
+free O
+diazepam O
+, O
+was O
+also O
+demonstrated O
+. O
+
+The O
+promoter O
+of O
+this O
+methyltransferase B
+gene O
+lacks O
+an O
+identifiable O
+TATA O
+box O
+but O
+is O
+characterized O
+by O
+a O
+CpG O
+island O
+which O
+begins O
+approximately O
+723 O
+nucleotides O
+upstream O
+of O
+the O
+major O
+transcriptional O
+start O
+site O
+and O
+extends O
+through O
+exon O
+1 O
+and O
+into O
+the O
+first O
+intron O
+. O
+
+No O
+promoter O
+activity O
+could O
+be O
+detected O
+with O
+various O
+mouse O
+Fli B
+- I
+1 I
+promoter O
+- O
+CAT B
+constructs O
+containing O
+600 O
+bp O
+of O
+the O
+5 O
+' O
+flanking O
+region O
+, O
+the O
+complete O
+exon O
+1 O
+, O
+the O
+5 O
+' O
+end O
+of O
+intron O
+1 O
+and O
+/ O
+or O
+retroviral B
+LTR I
+sequence O
+. O
+
+The O
+D O
+. O
+discoideum O
+proteins O
+were O
+entirely O
+conserved O
+over O
+the O
+four O
+regions O
+known O
+to O
+be O
+important O
+for O
+GTP O
+binding O
+and O
+all O
+contained O
+the O
+C O
+- O
+terminal O
+CAAX O
+aa O
+motifs O
+shared O
+by O
+other O
+Rho B
+proteins I
+. O
+
+An O
+81 O
+- O
+nt O
+tandem O
+duplication O
+of O
+the O
+C O
+- O
+terminal O
+coding O
+region O
+is O
+located O
+adjacent O
+to O
+the O
+termination O
+codon O
+of O
+the O
+CyIIIb B
+gene I
+, O
+a O
+potential O
+relic O
+of O
+a O
+slipped O
+mispairing O
+and O
+replication O
+event O
+. O
+
+Only O
+53 O
+% O
+of O
+all O
+injuries O
+and O
+12 O
+. O
+5 O
+% O
+of O
+serious O
+injuries O
+involved O
+children O
+, O
+and O
+in O
+contrast O
+to O
+the O
+1950s O
+and O
+early O
+1960s O
+, O
+young O
+adults O
+appear O
+at O
+greatest O
+risk O
+in O
+the O
+1980s O
+. O
+
+The O
+method O
+was O
+tested O
+on O
+7 O
+rats O
+with O
+48 O
+- O
+hr O
+- O
+old O
+myocardial O
+infarction O
+and O
+4 O
+sham O
+- O
+operated O
+controls O
+. O
+
+Here O
+we O
+examine O
+the O
+population O
+of O
+gammaS B
+transcripts I
+in O
+adult O
+human O
+lens O
+and O
+the O
+structure O
+of O
+the O
+human B
+CRYGS I
+genes I
+. O
+
+The O
+slope O
+of O
+QD O
+versus O
+QEMF O
+for O
+the O
+four O
+tubes O
+was O
+near O
+unity O
+. O
+
+The O
+extent O
+of O
+the O
+odontoblast O
+process O
+in O
+human O
+dentin O
+. O
+
+Mouse B
+macrophage I
+beta I
+subunit I
+( O
+CD11b B
+) O
+cDNA O
+for O
+the O
+CR3 B
+complement I
+receptor I
+/ O
+Mac B
+- I
+1 I
+antigen I
+. O
+
+Enoxacin O
+has O
+been O
+shown O
+to O
+be O
+an O
+effective O
+well O
+tolerated O
+and O
+convenient O
+treatment O
+for O
+gonorrhoea O
+. O
+
+We O
+assessed O
+cardiovascular O
+variables O
+and O
+blood O
+O2 O
+contents O
+in O
+order O
+to O
+characterize O
+O2 O
+transport O
+in O
+ponies O
+during O
+treadmill O
+exercise O
+. O
+
+The O
+findings O
+are O
+discussed O
+with O
+reference O
+to O
+possible O
+mechanisms O
+by O
+which O
+parasite O
+development O
+might O
+be O
+controlled O
+. O
+
+The O
+80 O
+kb O
+preceding O
+the O
+expression O
+site O
+has O
+few O
+, O
+if O
+any O
+, O
+functional O
+ORFs O
+, O
+but O
+contains O
+50 O
+bp O
+repeats O
+, O
+INGI B
+retrotransposon I
+- I
+like I
+elements I
+, O
+and O
+novel O
+4 O
+- O
+12 O
+kb O
+repeats O
+found O
+near O
+other O
+telomeres O
+. O
+
+The O
+predicted O
+proteins O
+show O
+strong O
+homology O
+to O
+an O
+ABA O
+- O
+inducible O
+glycine O
+- O
+rich O
+protein O
+from O
+maize O
+embryos O
+and O
+to O
+the O
+mammalian B
+RNA B
+- I
+binding I
+protein I
+A1 I
+of O
+the O
+heterogeneous O
+nuclear O
+ribonucleoprotein O
+complex O
+involved O
+in O
+pre O
+- O
+mRNA O
+splicing O
+. O
+
+Increase O
+in O
+[ O
+Ca O
++ O
++ O
+] O
+counteracted O
+the O
+effects O
+of O
+verapamil O
+on O
+RAD O
+. O
+
+We O
+compared O
+the O
+quantities O
+collected O
+with O
+both O
+pollen O
+traps O
+during O
+February O
+, O
+March O
+and O
+April O
+1988 O
+and O
+1989 O
+. O
+
+Cbl B
+is O
+a O
+signaling O
+molecule O
+with O
+multiple O
+functional O
+domains O
+: O
+an O
+SH2 B
+domain I
+which O
+binds O
+phosphotyrosine O
+residues O
+, O
+a O
+RING O
+finger O
+domain O
+which O
+acts O
+as O
+a O
+ubiquitin B
+ligase I
+, O
+a O
+proline O
+- O
+rich O
+region O
+which O
+serves O
+as O
+a O
+docking O
+site O
+for O
+SH3 B
+- I
+containing I
+proteins O
+, O
+phosphotyrosine O
+residues O
+which O
+serve O
+as O
+docking O
+sites O
+for O
+SH2 B
+- O
+containing O
+proteins O
+such O
+a O
+CrkL B
+and O
+the O
+p85 B
+subunit I
+of O
+PI B
+3 I
+- I
+kinase I
+, O
+and O
+a O
+nuclear O
+localization O
+signal O
+. O
+
+Surprisingly O
+, O
+apo B
+- I
+iso I
+- I
+1 I
+- I
+cytochrome I
+c I
+is O
+absent O
+in O
+cyc3 B
+- O
+strains O
+, O
+although O
+apo B
+- I
+iso I
+- I
+2 I
+- I
+cytochrome I
+c I
+is O
+present O
+at O
+approximately O
+the O
+same O
+level O
+at O
+which O
+holo B
+- I
+iso I
+- I
+2 I
+- I
+cytochrome I
+c I
+is O
+found O
+in O
+CYC3 B
++ I
+strains O
+. O
+
+Here O
+, O
+we O
+identify O
+the O
+analytical O
+form O
+of O
+the O
+PDF O
+of O
+one O
+such O
+measure O
+, O
+the O
+order O
+parameter O
+in O
+the O
+low O
+temperature O
+phase O
+of O
+the O
+2D O
+XY B
+model O
+. O
+
+The O
+ventricular O
+demand O
+pacemaker O
+( O
+VVI O
+) O
+was O
+implanted O
+three O
+years O
+ago O
+and O
+because O
+of O
+further O
+impairment O
+of O
+cardiac O
+performance O
+an O
+av O
+- O
+sequential O
+pacemaker O
+( O
+DDD O
+) O
+was O
+used O
+to O
+restore O
+atrio O
+- O
+ventricular O
+synchronisation O
+. O
+
+It O
+was O
+predicted O
+that O
+the O
+Stroop O
+task O
+would O
+trigger O
+greater O
+consumption O
+of O
+ice O
+cream O
+than O
+a O
+fearful O
+film O
+, O
+and O
+that O
+this O
+effect O
+would O
+be O
+more O
+pronounced O
+for O
+binge O
+- O
+eaters O
+than O
+non O
+- O
+binge O
+- O
+eaters O
+. O
+
+Our O
+data O
+are O
+in O
+line O
+with O
+the O
+hypothesis O
+that O
+E2F B
+functions O
+as O
+a O
+growth O
+- O
+and O
+cell O
+cycle O
+regulated O
+tethering O
+factor O
+between O
+Sp1 B
+and O
+the O
+basic O
+transcription O
+machinery O
+. O
+
+There O
+was O
+a O
+positive O
+correlation O
+between O
+change O
+from O
+baseline O
+in O
+parietal O
+lobe O
+gray O
+- O
+matter O
+cytosolic O
+choline O
+, O
+expressed O
+in O
+terms O
+of O
+choline O
+/ O
+creatine O
+resonance O
+ratios O
+, O
+and O
+cognitive O
+performance O
+as O
+measured O
+with O
+the O
+Alzheimer O
+' O
+s O
+Disease O
+Assessment O
+Scale O
+Cognitive O
+Subscale O
+. O
+
+Colonization O
+increased O
+with O
+level O
+of O
+care O
+: O
+from O
+9 O
+per O
+cent O
+in O
+independent O
+residents O
+of O
+apartments O
+to O
+60 O
+per O
+cent O
+in O
+patients O
+on O
+an O
+acute O
+hospital O
+ward O
+( O
+P O
+less O
+than O
+0 O
+. O
+0001 O
+) O
+. O
+
+IRA2 B
+, O
+a O
+second O
+gene O
+of O
+Saccharomyces O
+cerevisiae O
+that O
+encodes O
+a O
+protein O
+with O
+a O
+domain O
+homologous O
+to O
+mammalian B
+ras I
+GTPase I
+- I
+activating I
+protein I
+. O
+
+Exon O
+A1a O
+encodes O
+most O
+of O
+the O
+5 O
+' O
+- O
+untranslated O
+region O
+. O
+
+Co O
+- O
+operativity O
+of O
+functional O
+domains O
+in O
+the O
+muscle B
+- I
+specific I
+transcription I
+factor I
+Myf I
+- I
+5 I
+. O
+
+Creatinine O
+and O
+creatine B
+phosphokinase I
+( O
+CPK B
+) O
+. O
+
+In O
+our O
+initial O
+studies O
+, O
+we O
+treated O
+MCF O
+- O
+7 O
+cells O
+with O
+paclitaxel O
+, O
+which O
+results O
+in O
+the O
+arrest O
+of O
+cells O
+in O
+G1 O
+with O
+4n O
+DNA O
+content O
+( O
+pseudo O
+G1 O
+) O
+. O
+
+These O
+alterations O
+occurred O
+at O
+both O
+the O
+mRNA O
+and O
+protein O
+levels O
+but O
+did O
+not O
+significantly O
+affect O
+the O
+subcellular O
+distribution O
+of O
+any O
+of O
+the O
+four O
+isoforms O
+. O
+
+The O
+glyoxysomal O
+and O
+plastid O
+molecular O
+chaperones O
+( O
+70 B
+- I
+kDa I
+heat I
+shock I
+protein I
+) O
+of O
+watermelon O
+cotyledons O
+are O
+encoded O
+by O
+a O
+single O
+gene O
+. O
+
+Suspected O
+pelvic O
+endometriosis O
+was O
+prospectively O
+evaluated O
+in O
+31 O
+women O
+with O
+T1 O
+- O
+and O
+T2 O
+- O
+weighted O
+conventional O
+spin O
+- O
+echo O
+( O
+CSE O
+) O
+magnetic O
+resonance O
+imaging O
+alone O
+and O
+in O
+combination O
+with O
+T1 O
+- O
+weighted O
+fat O
+- O
+suppressed O
+( O
+T1FS O
+) O
+and O
+gadolinium O
+- O
+enhanced O
+T1FS O
+( O
+Gd O
+- O
+T1FS O
+) O
+spin O
+- O
+echo O
+techniques O
+. O
+
+Seroconversion O
+after O
+hepatitis O
+B O
+vaccination O
+. O
+
+A O
+case O
+of O
+bilateral O
+testicular O
+germ O
+cell O
+tumors O
+in O
+a O
+23 O
+- O
+year O
+- O
+old O
+male O
+is O
+reported O
+. O
+
+Total O
+body O
+BMD O
+( O
+r O
+= O
+0 O
+. O
+30 O
+; O
+P O
+= O
+0 O
+. O
+02 O
+) O
+and O
+femoral O
+neck O
+BMD O
+( O
+r O
+= O
+0 O
+. O
+39 O
+; O
+P O
+= O
+0 O
+. O
+002 O
+) O
+were O
+positively O
+correlated O
+with O
+weight O
+- O
+bearing O
+activity O
+but O
+not O
+with O
+non O
+- O
+weight O
+- O
+bearing O
+activity O
+. O
+
+The O
+effects O
+of O
+castor O
+oil O
+, O
+alone O
+, O
+as O
+well O
+as O
+in O
+combination O
+with O
+PGI2 O
+and O
+indomethacin O
+on O
+gastrointestinal O
+functions O
+have O
+been O
+examined O
+in O
+rats O
+. O
+
+Checking O
+for O
+patient O
+compliance O
+, O
+samples O
+( O
+n O
+= O
+10 O
+) O
+with O
+a O
+FK O
+I O
+concentration O
+of O
+0 O
+ng O
+/ O
+mL O
+were O
+re O
+- O
+analyzed O
+. O
+
+K O
+. O
+
+The O
+hematopoietic O
+form O
+of O
+PTPN6 B
+transcript I
+is O
+initiated O
+at O
+a O
+downstream O
+promoter O
+separated O
+by O
+7 O
+kb O
+from O
+the O
+first O
+. O
+
+The O
+residual O
+small O
+rRNAs O
+in O
+[ B
+poky I
+] I
+appear O
+to O
+be O
+synthesized O
+via O
+the O
+upstream O
+promoter O
+( O
+s O
+) O
+, O
+but O
+are O
+missing O
+37 O
+- O
+44 O
+nucleotides O
+from O
+their O
+5 O
+' O
+ends O
+, O
+indicating O
+either O
+that O
+pre O
+- O
+rRNAs O
+are O
+processed O
+abnormally O
+or O
+that O
+abnormal O
+5 O
+' O
+RNA O
+ends O
+are O
+unstable O
+. O
+
+Extra O
+dose O
+due O
+to O
+extravehicular O
+activity O
+during O
+the O
+NASA4 O
+mission O
+measured O
+by O
+an O
+on O
+- O
+board O
+TLD O
+system O
+. O
+
+Unconventional O
+mRNA O
+processing O
+in O
+the O
+expression O
+of O
+two O
+calcineurin B
+B I
+isoforms I
+in O
+Dictyostelium O
+. O
+
+The O
+deduced O
+amino O
+acid O
+sequence O
+of O
+this O
+open O
+reading O
+frame O
+is O
+significantly O
+homologous O
+to O
+the O
+HSV B
+1 I
+UL49 I
+. I
+5 I
+gene I
+product I
+, O
+and O
+as O
+with O
+UL49 B
+. I
+5 I
+, O
+it O
+contains O
+a O
+potential O
+signal O
+sequence O
+and O
+transmembrane O
+domain O
+characteristic O
+of O
+membrane O
+- O
+associated O
+proteins O
+. O
+
+It O
+has O
+been O
+demonstrated O
+that O
+stimulation O
+of O
+the O
+pontomesencephalic O
+parabrachial O
+region O
+( O
+PBR O
+) O
+by O
+microinjection O
+of O
+cholinergic O
+drugs O
+or O
+electricity O
+in O
+the O
+cat O
+produces O
+potent O
+pain O
+suppression O
+which O
+is O
+not O
+antagonized O
+by O
+the O
+opiate O
+antagonist O
+, O
+naloxone O
+. O
+
+GAGA B
+factor I
+is O
+known O
+to O
+remodel O
+the O
+chromatin O
+structure O
+in O
+concert O
+with O
+nucleosome B
+- I
+remodeling I
+factor I
+NURF I
+in O
+a O
+Drosophila O
+embryonic O
+S150 O
+extract O
+. O
+
+Also O
+, O
+like O
+TUB B
+, O
+it O
+has O
+a O
+wider O
+pattern O
+of O
+tissue O
+expression O
+than O
+either O
+TULP1 B
+or O
+TULP2 B
+. O
+
+After O
+nine O
+months O
+GFR O
+improved O
+spontaneously O
+to O
+32 O
+ml O
+/ O
+min O
+/ O
+1 O
+. O
+73 O
+m2 O
+despite O
+no O
+improvement O
+in O
+his O
+hypertension O
+. O
+
+First O
+, O
+ste12Delta B
+cells O
+differ O
+from O
+cells O
+with O
+disruptions O
+of O
+the O
+upstream O
+signaling O
+elements O
+( O
+e O
+. O
+g O
+. O
+, O
+ste4Delta B
+, O
+ste20Delta B
+, O
+ste5Delta B
+, O
+ste11Delta B
+, O
+ste7Delta B
+, O
+or O
+fus3Delta B
+kss1Delta B
+cells O
+) O
+in O
+that O
+they O
+clearly O
+retain O
+some O
+capacity O
+for O
+inducing O
+Ste3p B
+phosphorylation O
+. O
+
+Herein O
+, O
+we O
+report O
+that O
+CRE O
+- O
+decoy O
+oligonucleotide O
+treatment O
+results O
+in O
+an O
+increase O
+in O
+the O
+p53 B
+protein I
+level O
+in O
+MCF O
+- O
+7 O
+human O
+breast O
+cancer O
+cells O
+that O
+express O
+wild B
+- I
+type I
+p53 I
+. O
+
+The O
+selective O
+5 B
+- I
+HT2 I
+receptor I
+blocker O
+ketanserin O
+was O
+found O
+to O
+reduce O
+maximal O
+urethral O
+pressures O
+in O
+healthy O
+females O
+by O
+about O
+40 O
+% O
+without O
+reducing O
+blood O
+pressure O
+. O
+
+It O
+thus O
+seems O
+likely O
+that O
+genistein O
+affects O
+a O
+common O
+pathway O
+downstream O
+of O
+these O
+signals O
+. O
+
+Studies O
+in O
+B O
+. O
+glabrata O
+, O
+B O
+. O
+straminea O
+and O
+B O
+. O
+tenagophila O
+under O
+outdoor O
+conditions O
+. O
+
+The O
+electrocardiogram O
+in O
+tachycardia O
+. O
+
+Identification O
+of O
+a O
+putative O
+chromosomal O
+replication O
+origin O
+from O
+Helicobacter O
+pylori O
+and O
+its O
+interaction O
+with O
+the O
+initiator B
+protein I
+DnaA I
+. O
+
+The O
+primary O
+structure O
+of O
+cholesterol B
+esterase I
+displayed O
+no O
+significant O
+homology O
+with O
+other O
+lipases B
+, O
+although O
+the O
+putative O
+lipid O
+interfacial O
+recognition O
+site O
+of O
+G O
+- O
+X O
+- O
+S O
+- O
+X O
+- O
+G O
+is O
+present O
+in O
+the O
+cholesterol B
+esterase I
+sequence I
+. O
+
+The O
+essential O
+questions O
+about O
+hepatitis O
+C O
+
+The O
+transcriptional O
+initiation O
+site O
+of O
+RAG1 B
+was O
+localized O
+at O
+A O
+, O
+26 O
+bp O
+upstream O
+of O
+the O
+putative O
+translational O
+initiation O
+codon O
+, O
+ATG O
+, O
+by O
+the O
+primer O
+extension O
+assay O
+. O
+
+Coronary O
+arteriographies O
+and O
+ventriculographies O
+corresponding O
+to O
+274 O
+consecutive O
+patients O
+( O
+January O
+, O
+1975 O
+- O
+October O
+, O
+1978 O
+) O
+with O
+significant O
+coronary O
+lesions O
+are O
+reviewed O
+. O
+
+Visualization O
+of O
+the O
+cells O
+by O
+phase O
+contrast O
+microscopy O
+indicated O
+that O
+murine B
+PKCepsilon I
+expression O
+in O
+the O
+presence O
+of O
+glycerol O
+resulted O
+in O
+a O
+significant O
+increase O
+in O
+the O
+number O
+of O
+yeast O
+cells O
+exhibiting O
+very O
+small O
+buds O
+. O
+
+Sonography O
+depicted O
+the O
+true O
+morphology O
+of O
+these O
+cystic O
+lesions O
+more O
+clearly O
+than O
+CT O
+, O
+and O
+the O
+sonographic O
+findings O
+virtually O
+excluded O
+uncomplicated O
+hepatic O
+cyst O
+as O
+a O
+diagnosis O
+. O
+
+Protein B
+kinase I
+C I
+transiently O
+activated O
+heteromeric B
+N I
+- I
+methyl I
+- I
+D I
+- I
+aspartate I
+receptor I
+channels O
+independent O
+of O
+the O
+phosphorylatable O
+C O
+- O
+terminal O
+splice O
+domain O
+and O
+of O
+consensus O
+phosphorylation O
+sites O
+. O
+
+A O
+24 O
+- O
+year O
+- O
+old O
+pregnant O
+woman O
+started O
+to O
+have O
+hyperemesis O
+gravidarum O
+6 O
+weeks O
+before O
+admission O
+. O
+
+Highly O
+significant O
+similarities O
+were O
+detected O
+between O
+the O
+N O
+- O
+terminal O
+region O
+of O
+P30 B
+and O
+those O
+of O
+GENA B
+[ O
+the O
+product O
+of O
+another O
+unidentified O
+gene O
+( O
+geneA B
+) O
+located O
+upstream O
+of O
+the O
+aceEF B
+- O
+lpd B
+operon O
+] O
+, O
+and O
+GNTR B
+( O
+a O
+putative O
+transcriptional O
+repressor O
+of O
+the O
+gluconate B
+operon I
+of I
+Bacillus I
+subtilis I
+) O
+. O
+
+In O
+vitro O
+DNA O
+binding O
+assays O
+indicate O
+that O
+the O
+elements O
+identified O
+can O
+specifically O
+interact O
+with O
+c B
+- I
+Ets I
+- I
+1 I
+protein I
+. O
+
+They O
+are O
+found O
+to O
+have O
+several O
+advantages O
+over O
+the O
+conventional O
+indices O
+of O
+skewness O
+and O
+kurtosis O
+( O
+square O
+root O
+of O
+b1 O
+and O
+b2 O
+) O
+and O
+no O
+serious O
+drawbacks O
+. O
+
+They O
+elicit O
+similar O
+regional O
+cerebral O
+blood O
+flow O
+( O
+rCBF O
+) O
+patterns O
+, O
+even O
+though O
+sign O
+language O
+is O
+dependent O
+on O
+spatial O
+information O
+. O
+
+Siglec B
+- I
+9 I
+is O
+predicted O
+to O
+contain O
+three O
+extracellular O
+immunoglobulin B
+- I
+like I
+domains I
+that O
+comprise O
+an O
+N O
+- O
+terminal O
+V B
+- O
+set O
+domain O
+and O
+two O
+C2 B
+- O
+set O
+domains O
+, O
+a O
+transmembrane O
+region O
+and O
+a O
+cytoplasmic O
+tail O
+containing O
+two O
+putative O
+tyrosine O
+- O
+based O
+signaling O
+motifs O
+. O
+
+Determination O
+of O
+the O
+LD O
+50 O
+( O
+30 O
+) O
+during O
+infant O
+period O
+and O
+growth O
+period O
+
+The O
+availability O
+of O
+a O
+commercial O
+program O
+( O
+PCNONLIN O
+) O
+is O
+needed O
+to O
+carry O
+out O
+matrix O
+handling O
+calculations O
+. O
+
+The O
+introduction O
+gives O
+also O
+the O
+history O
+of O
+Research O
+Programme O
+MZ O
+- O
+XVII O
+and O
+its O
+implementation O
+in O
+several O
+regions O
+of O
+Poland O
+. O
+
+The O
+fecal O
+excretion O
+is O
+found O
+to O
+be O
+only O
+one O
+third O
+of O
+that O
+measured O
+in O
+urine O
+. O
+
+The O
+COR B
+biosynthetic I
+gene I
+cluster I
+in O
+P O
+. O
+syringae O
+pv O
+. O
+glycinea O
+PG4180 O
+is O
+encoded O
+by O
+a O
+32 O
+- O
+kb O
+region O
+which O
+contains O
+both O
+the O
+structural O
+and O
+regulatory O
+genes O
+needed O
+for O
+COR B
+synthesis O
+. O
+
+Model O
+experiments O
+on O
+pheasants O
+using O
+single O
+doses O
+of O
+the O
+insecticide O
+( O
+Lindane O
+) O
+the O
+herbicide O
+( O
+Terbutryn O
+) O
+a O
+mineral O
+fertilizer O
+( O
+calcium O
+ammonium O
+nitrate O
+) O
+and O
+the O
+fungicide O
+( O
+HCB O
+) O
+. O
+
+In O
+this O
+technique O
+, O
+the O
+posterior O
+wall O
+of O
+the O
+neopharynx O
+consists O
+only O
+of O
+the O
+prevertebral O
+tissue O
+, O
+while O
+the O
+flap O
+forms O
+the O
+anterior O
+and O
+lateral O
+walls O
+. O
+
+The O
+most O
+common O
+hosts O
+were O
+equines O
+( O
+31 O
+% O
+) O
+, O
+bovines O
+( O
+25 O
+% O
+) O
+and O
+raccoons O
+( O
+19 O
+% O
+) O
+. O
+
+A O
+single O
+HD O
+session O
+using O
+cellulose O
+triacetate O
+or O
+polysulfone O
+membrane O
+significantly O
+increased O
+water O
+content O
+both O
+at O
+forearm O
+and O
+lower O
+leg O
+( O
+p O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+Both O
+claR B
+and O
+car B
+are O
+expressed O
+as O
+monocistronic O
+transcripts O
+; O
+the O
+level O
+of O
+transcript O
+declined O
+rapidly O
+after O
+48h O
+in O
+complex O
+media O
+, O
+but O
+low O
+sustained O
+levels O
+of O
+both O
+transcripts O
+were O
+observed O
+in O
+defined O
+GSPG O
+medium O
+until O
+96h O
+. O
+
+claR B
+and O
+car B
+were O
+not O
+significantly O
+expressed O
+in O
+mutants O
+disrupted O
+in O
+the O
+ccaR B
+gene I
+, O
+a O
+regulatory O
+gene O
+that O
+controls O
+positively O
+clavulanic O
+acid O
+and O
+cephamycin O
+biosynthesis O
+. O
+
+Whereas O
+mutant O
+6C4 O
+specified O
+a O
+wild B
+- I
+type I
+- I
+size I
+Pol I
+protein I
+, O
+we O
+detected O
+no O
+full B
+- I
+length I
+Pol I
+protein I
+in O
+7E4 O
+- O
+infected O
+cell O
+extracts O
+. O
+
+The O
+hepatic O
+isoform O
+of O
+6 B
+- I
+phosphofructo I
+- I
+2 I
+- I
+kinase I
+/ O
+fructose B
+- I
+2 I
+, I
+6 I
+- I
+bisphosphatase I
+( O
+PF2K B
+/ O
+Fru B
+- I
+2 I
+, I
+6 I
+- I
+BPase I
+) O
+is O
+transcriptionally O
+stimulated O
+by O
+glucocorticoids O
+, O
+whereas O
+insulin B
+blocks O
+this O
+stimulatory O
+effect O
+. O
+
+Being O
+implicated O
+in O
+insulin B
+and O
+GK B
+gene I
+regulations O
+as O
+a O
+common O
+transcription O
+factor O
+, O
+IPF1 B
+/ O
+STF B
+- I
+1 I
+/ O
+PDX B
+- I
+1 I
+is O
+likely O
+to O
+play O
+an O
+essential O
+role O
+in O
+maintaining O
+normal O
+beta O
+- O
+cell O
+functions O
+. O
+
+The O
+Caenorhabditis B
+elegans I
+NK I
+- I
+2 I
+class I
+homeoprotein I
+CEH B
+- I
+22 I
+is O
+involved O
+in O
+combinatorial O
+activation O
+of O
+gene O
+expression O
+in O
+pharyngeal O
+muscle O
+. O
+
+Mouse O
+embryo O
+cells O
+( O
+C57BL O
+/ O
+6 O
+, O
+H O
+- O
+2b O
+) O
+transformed O
+by O
+the O
+E1A B
+and O
+E1B B
+genes I
+of O
+adenovirus O
+type O
+5 O
+( O
+Ad5E1 O
+MEC O
+) O
+are O
+highly O
+immunogenic O
+. O
+
+The O
+largest O
+age O
+adjusted O
+differences O
+between O
+men O
+with O
+low O
+and O
+normal O
+mood O
+were O
+for O
+the O
+AH4 O
+( O
+3 O
+points O
+, O
+t O
+= O
+5 O
+. O
+6 O
+, O
+p O
+< O
+0 O
+. O
+0001 O
+) O
+and O
+the O
+CAMCOG O
+( O
+2 O
+points O
+, O
+t O
+= O
+5 O
+. O
+8 O
+, O
+p O
+< O
+0 O
+. O
+0001 O
+) O
+. O
+
+Our O
+findings O
+suggest O
+that O
+resting O
+Tl O
+- O
+201 O
+scintigraphy O
+has O
+limited O
+value O
+in O
+the O
+detection O
+of O
+coronary O
+artery O
+disease O
+in O
+patients O
+with O
+Hurler O
+syndrome O
+. O
+
+We O
+demonstrate O
+that O
+the O
+WRM B
+- I
+1 I
+protein I
+binds O
+to O
+LIT B
+- I
+1 I
+in O
+vivo O
+and O
+that O
+WRM B
+- I
+1 I
+can O
+activate O
+the O
+LIT B
+- I
+1 I
+protein I
+kinase I
+when O
+coexpressed O
+in O
+vertebrate O
+tissue O
+culture O
+cells O
+. O
+
+RESULTS O
+: O
+All O
+primary O
+tumors O
+were O
+positive O
+for O
+CAM5 B
+. I
+2 I
+. O
+
+Nuclear O
+extracts O
+from O
+Sertoli O
+cells O
+were O
+found O
+to O
+cause O
+an O
+E O
+- O
+box O
+gel O
+shift O
+when O
+the O
+cells O
+were O
+stimulated O
+to O
+differentiate O
+in O
+culture O
+, O
+but O
+not O
+under O
+basal O
+conditions O
+. O
+
+On O
+the O
+sixth O
+postirradiation O
+day O
+the O
+absorption O
+of O
+phenobarbitone O
+, O
+sulphafurazole O
+and O
+mecamylamine O
+had O
+returned O
+to O
+the O
+control O
+level O
+, O
+but O
+the O
+absorption O
+of O
+quinidine O
+and O
+isoniazid O
+was O
+still O
+retarded O
+. O
+
+To O
+determine O
+the O
+transactivation O
+potential O
+of O
+each O
+of O
+the O
+four O
+Ahr B
+Sp1 B
+sites O
+, O
+we O
+fused O
+the O
+Ahr B
+promoter I
+to O
+a O
+luciferase B
+( O
+LUC B
+) O
+reporter O
+gene O
+and O
+transfected O
+the O
+construct O
+into O
+the O
+Drosophila O
+cell O
+line O
+Schneider O
+- O
+2 O
+, O
+which O
+contains O
+no O
+Sp1 B
+or O
+Sp1 B
+- I
+like I
+factors I
+. O
+
+We O
+determined O
+that O
+Hop B
+( I
+T42 I
+) I
+contains O
+a O
+glutamic O
+acid O
+- O
+to O
+- O
+lysine O
+substitution O
+at O
+amino O
+acid O
+residue O
+695 O
+( O
+E695K O
+) O
+. O
+
+The O
+organotins O
+. O
+
+Results O
+of O
+these O
+studies O
+indicate O
+that O
+binding O
+of O
+biotin O
+to O
+the O
+protein O
+results O
+in O
+protection O
+of O
+regions O
+of O
+the O
+central O
+domain O
+in O
+the O
+vicinity O
+of O
+the O
+active O
+site O
+and O
+the O
+C O
+- O
+terminal O
+domain O
+from O
+chemical O
+cleavage O
+. O
+
+The O
+psh3 B
+( I
++ I
+) I
+gene I
+encodes O
+a O
+protein O
+of O
+215 O
+amino O
+acids O
+, O
+which O
+shares O
+a O
+high O
+degree O
+of O
+structural O
+and O
+functional O
+similarity O
+with O
+Shr3p B
+. O
+
+The O
+impairment O
+of O
+the O
+nocturnal O
+secretion O
+was O
+related O
+to O
+the O
+subjects O
+' O
+age O
+and O
+, O
+for O
+the O
+GH B
+secretory O
+pattern O
+only O
+, O
+also O
+to O
+the O
+MMSE O
+score O
+. O
+
+Thus O
+, O
+the O
+antibody O
+class O
+switch O
+appears O
+to O
+be O
+directed O
+by O
+induction O
+of O
+accessibility O
+, O
+as O
+assayed O
+by O
+transcription O
+of O
+germ B
+line I
+CH I
+genes I
+. O
+
+This O
+growth O
+- O
+inhibitory O
+effect O
+was O
+suppressed O
+by O
+the O
+mpk1 B
+delta I
+mutation I
+, O
+suggesting O
+that O
+hyperactivation O
+of O
+the O
+Mpk1 B
+pathway O
+is O
+toxic O
+to O
+cells O
+. O
+
+The O
+chicken O
+genome O
+contains O
+two O
+functional O
+nonallelic B
+beta1 I
+, I
+4 I
+- I
+galactosyltransferase I
+genes I
+. O
+
+Recombinant B
+Human I
+Erythropoietin I
+and O
+Platinum O
+- O
+Based O
+Chemotherapy O
+In O
+Advanced O
+Ovarian O
+Cancer O
+
+Homodimers O
+of O
+RIP60 B
+( O
+replication B
+initiation I
+- I
+region I
+protein I
+60 I
+kDA I
+) O
+purified O
+from O
+nuclear O
+extract O
+bind O
+two O
+ATT O
+- O
+rich O
+sites O
+in O
+oribeta B
+and O
+foster O
+the O
+formation O
+of O
+a O
+twisted O
+720 O
+bp O
+DNA O
+loop O
+in O
+vitro O
+. O
+
+Endodontic O
+treatment O
+of O
+deciduous O
+teeth O
+using O
+the O
+formocresol O
+amputation O
+method O
+
+Some O
+of O
+these O
+physiological O
+responses O
+are O
+regulated O
+via O
+activation O
+of O
+transcription O
+factors O
+such O
+as O
+activator B
+protein I
+1 I
+( O
+AP B
+- I
+1 I
+) O
+. O
+
+To O
+test O
+the O
+role O
+of O
+myb B
+family I
+members I
+in O
+progression O
+through O
+the O
+cell O
+cycle O
+, O
+we O
+comicroinjected O
+c B
+- I
+myc I
+and O
+myb B
+expression O
+vectors O
+into O
+serum O
+- O
+deprived O
+quiescent O
+SMCs O
+. O
+
+Overall O
+graft O
+and O
+patient O
+survival O
+after O
+HAT O
+were O
+33 O
+. O
+3 O
+% O
+and O
+75 O
+% O
+, O
+respectively O
+. O
+
+LAC9 B
+is O
+a O
+DNA O
+- O
+binding O
+protein O
+that O
+regulates O
+transcription O
+of O
+the O
+lactose B
+- I
+galactose I
+regulon I
+in O
+Kluyveromyces O
+lactis O
+. O
+
+We O
+determined O
+the O
+complete O
+nucleotide O
+sequence O
+of O
+the O
+gypsy B
+element I
+present O
+at O
+the O
+forked B
+locus I
+of I
+Drosophila I
+melanogaster I
+in O
+the O
+f1 B
+allele I
+. O
+
+The O
+same O
+high O
+degree O
+of O
+sequence O
+homology O
+between O
+the O
+two O
+F O
+. O
+diplosiphon O
+PC B
+alpha I
+and O
+PC B
+beta I
+sequences I
+( O
+85 O
+and O
+77 O
+% O
+, O
+respectively O
+) O
+was O
+found O
+at O
+both O
+the O
+nucleotide O
+and O
+amino O
+acid O
+levels O
+, O
+and O
+similar O
+results O
+were O
+obtained O
+for O
+interspecies O
+comparisons O
+. O
+
+A O
+wound O
+model O
+for O
+decubitus O
+and O
+leg O
+ulcers O
+consisting O
+of O
+human O
+dermal O
+fibroblasts O
+in O
+type B
+I I
+collagen I
+dermal O
+" I
+equivalent O
+" O
+matrix O
+( O
+DEM O
+) O
+was O
+exposed O
+in O
+vitro O
+to O
+electric O
+fields O
+similar O
+to O
+postulated O
+endogenous O
+fields O
+in O
+wounds O
+. O
+
+A O
+group O
+of O
+factors O
+known O
+as O
+activating B
+transcription I
+factors I
+( O
+ATF B
+) O
+have O
+been O
+found O
+to O
+bind O
+to O
+the O
+latter O
+and O
+related O
+sequences O
+found O
+upstream O
+of O
+early O
+adenovirus O
+promoters O
+induced O
+by O
+E1A B
+, O
+and O
+these O
+factors O
+are O
+highly O
+homologous O
+to O
+the O
+CREB B
+protein I
+. O
+
+In O
+addition O
+to O
+these O
+cases O
+, O
+patients O
+w O
+with O
+high O
+Loa O
+microfilaremia O
+also O
+developed O
+milder O
+neurologic O
+manifestations O
+causing O
+functional O
+impairment O
+lasting O
+for O
+at O
+least O
+one O
+week O
+after O
+treatment O
+. O
+
+The O
+vertebrate O
+transcription O
+factors O
+TCF B
+( O
+T B
+cell I
+factor I
+) O
+and O
+LEF B
+( O
+lymphocyte B
+enhancer I
+binding I
+factor I
+) O
+interact O
+with O
+beta B
+- I
+catenin I
+and O
+are O
+hypothesized O
+to O
+mediate O
+Wingless B
+/ O
+Wnt B
+signaling O
+. O
+
+Some O
+of O
+these O
+DNA O
+: O
+protein O
+complexes O
+were O
+also O
+present O
+, O
+but O
+at O
+lower O
+levels O
+, O
+in O
+nuclear O
+extracts O
+from O
+untransformed O
+rat O
+cells O
+suggesting O
+the O
+possible O
+involvement O
+of O
+cellular O
+factors O
+in O
+the O
+mechanism O
+of O
+down O
+- O
+regulation O
+mediated O
+by O
+Ad12 B
+E1A I
+. O
+
+Hypocalcemia O
+is O
+usually O
+due O
+to O
+either O
+a O
+disturbance O
+in O
+the O
+parathyroid B
+hormone I
+- O
+adenylate B
+cyclase I
+system O
+or O
+a O
+disturbance O
+in O
+vitamin O
+D O
+metabolism O
+. O
+
+Activity O
+was O
+reconstituted O
+, O
+however O
+, O
+by O
+combining O
+fractions O
+that O
+were O
+enriched O
+in O
+the O
+two O
+components O
+. O
+
+If O
+failure O
+to O
+solve O
+invisible O
+displacements O
+was O
+due O
+to O
+increased O
+memory O
+requirements O
+, O
+then O
+the O
+primates O
+should O
+perform O
+at O
+chance O
+level O
+on O
+all O
+3 O
+problems O
+. O
+
+In O
+seven O
+patients O
+( O
+7 O
+. O
+8 O
+% O
+) O
+with O
+new O
+Q O
+- O
+waves O
+and O
+a O
+pathologic O
+CK B
+- I
+MB I
+profile O
+( O
+group O
+II O
+) O
+troponin B
+T I
+reached O
+median O
+levels O
+of O
+10 O
+. O
+47 O
+micrograms O
+/ O
+l O
+( O
+quartile O
+6 O
+. O
+34 O
+- O
+12 O
+. O
+50 O
+micrograms O
+/ O
+l O
+) O
+( O
+P O
+< O
+0 O
+. O
+001 O
+I O
+vs O
+II O
+) O
+. O
+
+Mineralized O
+bone O
+nodule O
+formation O
+in O
+vitro O
+by O
+cell O
+populations O
+from O
+young O
+adult O
+rabbit O
+alveolar O
+bone O
+. O
+
+Mouse B
+GRK6 I
+- I
+C I
+displays O
+none O
+of O
+these O
+motifs O
+. O
+
+Comparisons O
+of O
+the O
+efficacy O
+of O
+benazepril O
+and O
+hydrochlorothiazide O
+alone O
+and O
+in O
+combination O
+have O
+shown O
+that O
+benazepril O
+20 O
+mg O
+once O
+daily O
+is O
+as O
+effective O
+as O
+or O
+more O
+effective O
+in O
+lowering O
+diastolic O
+blood O
+pressure O
+than O
+hydrochlorothiazide O
+25 O
+mg O
+once O
+daily O
+and O
+that O
+the O
+combination O
+of O
+benazepril O
+20 O
+mg O
+and O
+hydrochlorothiazide O
+25 O
+mg O
+has O
+a O
+possibly O
+synergistic O
+effect O
+on O
+diastolic O
+blood O
+pressure O
+. O
+
+The O
+132 B
+- I
+bp I
+PHO8p I
+fragment I
+, O
+connected O
+at O
+position O
+- O
+281 O
+of O
+the O
+5 O
+' O
+upstream O
+region O
+of O
+a O
+HIS5 B
+' I
+- I
+' B
+lacZ I
+fused O
+gene O
+, O
+could O
+sense O
+Pi O
+signals O
+in O
+vivo O
+, O
+but O
+a O
+20 O
+- O
+bp O
+synthetic O
+oligonucleotide O
+having O
+the O
+same O
+sequence O
+from O
+- O
+544 O
+to O
+- O
+525 O
+of O
+the O
+PHO8p B
+DNA O
+could O
+not O
+. O
+
+1988 O
+) O
+. O
+
+Sequences O
+within O
+the O
+UAS2 O
+element O
+of O
+the O
+ENO2 B
+gene I
+bound O
+a O
+second O
+protein O
+which O
+corresponded O
+to O
+the O
+ABFI B
+( O
+autonomously B
+replicating I
+sequence I
+- I
+binding I
+factor I
+) O
+protein O
+. O
+
+Plasmid O
+subclones O
+of O
+recombinant O
+phage O
+lambda O
+Asm152 O
+were O
+able O
+to O
+complement O
+both O
+Escherichia B
+coli I
+gltB I
+and O
+A B
+. I
+sesbaniae I
+Asm B
+- I
+Vi I
+mutants I
+; O
+NADPH B
+- I
+glutamate I
+synthase I
+activity O
+was O
+detected O
+in O
+all O
+such O
+strains O
+complemented O
+to O
+Asm B
++ I
+. O
+
+The O
+sequence O
+of O
+LZ321 B
+matched O
+that O
+of O
+RREB1 B
+, O
+a O
+transcription O
+factor O
+that O
+bound O
+to O
+a O
+Ras B
+responsive I
+element I
+( O
+RRE B
+) O
+very O
+different O
+from O
+the O
+sequence O
+with O
+which O
+we O
+isolated O
+LZ321 B
+. O
+
+Steady O
+- O
+state O
+levels O
+of O
+murine B
+MMR I
+mRNA I
+were O
+measured O
+in O
+the O
+macrophage O
+cell O
+line O
+J774E O
+, O
+which O
+is O
+known O
+to O
+express O
+the O
+protein O
+at O
+the O
+cell O
+surface O
+. O
+
+Basal O
+level O
+expression O
+was O
+reduced O
+to O
+20 O
+and O
+50 O
+% O
+when O
+the O
+UGA O
+stop O
+codon O
+was O
+replaced O
+by O
+UAG O
+or O
+UAA O
+, O
+respectively O
+, O
+consistent O
+with O
+the O
+finding O
+that O
+in O
+E O
+. O
+coli O
+translation O
+terminates O
+more O
+efficiently O
+at O
+UAG O
+and O
+UAA O
+than O
+at O
+UGA O
+. O
+
+Discriminant O
+function O
+analysis O
+suggests O
+that O
+AUDIT O
+scores O
+can O
+successfully O
+identify O
+SAT O
+- O
+positive O
+and O
+SAT O
+- O
+negative O
+patients O
+; O
+the O
+analysis O
+accounted O
+for O
+42 O
+. O
+5 O
+% O
+of O
+the O
+variance O
+and O
+correctly O
+classified O
+84 O
+. O
+6 O
+% O
+of O
+the O
+sample O
+. O
+
+Coronatine B
+( O
+COR B
+) O
+is O
+a O
+plasmid O
+- O
+encoded O
+phytotoxin O
+synthesized O
+by O
+several O
+pathovars O
+of O
+phytopathogenic O
+Pseudomonas O
+syringae O
+. O
+
+Both O
+the O
+5 O
+' O
+and O
+3 O
+' O
+untranslated O
+regions O
+also O
+show O
+significant O
+similarity O
+to O
+the O
+murine O
+gene O
+, O
+with O
+79 O
+and O
+70 O
+% O
+sequence O
+identity O
+, O
+respectively O
+. O
+
+One O
+patient O
+exhibited O
+a O
+non O
+- O
+sense O
+mutation O
+( O
+codon O
+388 O
+) O
+, O
+which O
+changed O
+a O
+glutamine O
+codon O
+( O
+CAG O
+) O
+to O
+a O
+stop O
+codon O
+( O
+TAG O
+) O
+. O
+
+The O
+transcriptional O
+activity O
+of O
+P B
+- I
+450 I
+( I
+11 I
+beta I
+) I
+gene I
+was O
+studied O
+with O
+an O
+in O
+vitro O
+transcription O
+system O
+using O
+nuclear O
+extracts O
+prepared O
+from O
+bovine O
+adrenal O
+cortex O
+. O
+
+Renal O
+dysplasia O
+with O
+multisystem O
+malformation O
+- O
+- O
+a O
+study O
+of O
+9 O
+cases O
+. O
+
+This O
+bud O
+morphology O
+results O
+at O
+least O
+in O
+part O
+from O
+a O
+cell O
+cycle O
+delay O
+imposed O
+by O
+the O
+Cdc28p B
+- I
+inhibitory I
+kinase I
+Swe1p B
+. O
+
+Eleven O
+of O
+the O
+12 O
+exons O
+have O
+complete O
+sequence O
+homology O
+with O
+the O
+RBM B
+- I
+1 I
+sequence I
+. O
+
+Copyright O
+1998 O
+Academic O
+Press O
+. O
+
+Laparoscopic O
+examination O
+1 O
+year O
+after O
+surgery O
+revealed O
+an O
+enlarged O
+, O
+thin O
+- O
+walled O
+, O
+and O
+fluid O
+- O
+filled O
+uterine O
+segment O
+cranial O
+to O
+the O
+midcornus O
+occlusion O
+sites O
+in O
+all O
+animals O
+. O
+
+The O
+three O
+proteins O
+copurified O
+through O
+several O
+biochemical O
+fractionation O
+steps O
+and O
+could O
+be O
+coimmunoprecipitated O
+by O
+using O
+antibodies O
+against O
+GCD1 B
+or O
+GCD2 B
+. O
+
+Cellular O
+fractionation O
+and O
+Percoll O
+gradient O
+centrifugation O
+combined O
+with O
+immunoblotting O
+show O
+that O
+p67 B
+cofractionates O
+with O
+nuclei O
+and O
+is O
+enriched O
+in O
+resistant O
+structure O
+that O
+is O
+insoluble O
+in O
+2 O
+M O
+NaCl O
+, O
+25 O
+mM O
+lithium O
+3 O
+, O
+5 O
+' O
+- O
+diiodosalicylate O
+, O
+and O
+1 O
+% O
+Triton O
+but O
+is O
+soluble O
+in O
+8 O
+M O
+urea O
+. O
+
+For O
+the O
+first O
+time O
+also O
+a O
+genomic O
+sequence O
+for O
+a O
+red B
+algal I
+lhc I
+gene I
+is O
+presented O
+. O
+
+Elimination O
+of O
+brush O
+border O
+as O
+well O
+as O
+of O
+glomerular O
+marker O
+proteins O
+was O
+significantly O
+lower O
+after O
+intravenous O
+injection O
+of O
+low O
+- O
+osmolar O
+CM O
+iopamidol O
+370 O
+( O
+832 O
+mOsm O
+/ O
+kg O
+) O
+than O
+after O
+meglumine O
+diatrizoate O
+76 O
+( O
+2100 O
+mOsm O
+/ O
+kg O
+) O
+. O
+
+Raman O
+scattering O
+from O
+VO2 O
+single O
+crystals O
+: O
+A O
+study O
+of O
+the O
+effects O
+of O
+surface O
+oxidation O
+. O
+
+Combination O
+chemotherapy O
+in O
+advanced O
+ovarian O
+cancer O
+. O
+
+Making O
+sense O
+out O
+of O
+oxygen O
+sensor O
+. O
+
+In O
+comparison O
+to O
+a O
+silent O
+baseline O
+, O
+CBF O
+increases O
+were O
+observed O
+in O
+auditory O
+cortex O
+bilaterally O
+and O
+in O
+the O
+right O
+superior O
+parietal O
+, O
+right O
+dorsolateral O
+frontal O
+, O
+and O
+right O
+premotor O
+regions O
+, O
+with O
+no O
+modulation O
+as O
+a O
+function O
+of O
+attentional O
+condition O
+. O
+
+In O
+vitro O
+, O
+c B
+- I
+Src I
+phosphorylated O
+FAK B
+Tyr O
+- O
+925 O
+in O
+a O
+glutathione B
+S I
+- I
+transferase I
+- O
+FAK B
+C O
+- O
+terminal O
+domain O
+fusion O
+protein O
+, O
+whereas O
+FAK B
+did O
+not O
+. O
+
+METHODS O
+AND O
+RESULTS O
+: O
+The O
+effect O
+of O
+prolonged O
+nitrate O
+therapy O
+between O
+2 O
+days O
+and O
+6 O
+weeks O
+during O
+healing O
+after O
+infarction O
+on O
+serial O
+parameters O
+of O
+ventricular O
+remodeling O
+( O
+scar O
+expansion O
+, O
+scar O
+thinning O
+, O
+ventricular O
+dilation O
+, O
+and O
+hypertrophy O
+) O
+and O
+function O
+( O
+asynergy O
+or O
+akinesis O
+plus O
+dyskinesis O
+and O
+ejection O
+fraction O
+) O
+by O
+serial O
+two O
+- O
+dimensional O
+echocardiography O
+, O
+hemodynamics O
+, O
+postmortem O
+topography O
+( O
+computerized O
+planimetry O
+, O
+geometric O
+maps O
+, O
+and O
+radiographs O
+) O
+, O
+and O
+collagen B
+content O
+( O
+hydroxyproline O
+
+) O
+was O
+studied O
+in O
+64 O
+instrumented O
+dogs O
+randomized O
+2 O
+days O
+after O
+left O
+anterior O
+descending O
+coronary O
+artery O
+ligation O
+to O
+various O
+nitrate O
+regimens O
+( O
+n O
+= O
+32 O
+) O
+over O
+the O
+first O
+2 O
+weeks O
+( O
+subgroup O
+1 O
+: O
+2 O
+% O
+transdermal O
+nitroglycerin O
+at O
+8 O
+AM O
+and O
+4 O
+PM O
+, O
+n O
+= O
+6 O
+; O
+subgroup O
+2 O
+: O
+2 O
+% O
+transdermal O
+nitroglycerin O
+plus O
+2 O
+. O
+6 O
+mg O
+of O
+sustained O
+- O
+release O
+oral O
+nitroglycerin O
+at O
+8 O
+AM O
+, O
+3 O
+PM O
+, O
+and O
+10 O
+PM O
+, O
+n O
+= O
+5 O
+; O
+subgroup O
+3 O
+: O
+oral O
+isosorbide O
+dinitrate O
+, O
+30 O
+mg O
+at O
+8 O
+AM O
+and O
+4 O
+
+PM O
+, O
+n O
+= O
+11 O
+) O
+or O
+6 O
+weeks O
+( O
+subgroup O
+4 O
+: O
+isosorbide O
+dinitrate O
+, O
+n O
+= O
+10 O
+) O
+and O
+in O
+matching O
+controls O
+( O
+n O
+= O
+32 O
+) O
+. O
+
+The O
+essential O
+oil O
+composition O
+of O
+three O
+Zingiberaceae O
+widely O
+used O
+as O
+medicinal O
+aromatic O
+plants O
+from O
+S O
+. O
+
+Gel O
+shift O
+analysis O
+of O
+protein O
+binding O
+from O
+nuclear O
+extracts O
+to O
+these O
+caveolin B
+promoter I
+DNA I
+sequences I
+, O
+together O
+with O
+DNase B
+I I
+footprinting O
+, O
+confirmed O
+nucleoprotein O
+binding O
+to O
+the O
+SRE O
+- O
+like O
+elements O
+as O
+part O
+of O
+the O
+transcriptional O
+response O
+to O
+LDL B
+- I
+FC I
+. O
+
+A O
+new O
+model O
+for O
+objective O
+assessment O
+of O
+cervical O
+ripening O
+: O
+the O
+effect O
+of O
+prostaglandin O
+E2 O
+and O
+prelabor O
+contractility O
+. O
+
+CONCLUSIONS O
+: O
+The O
+MC O
+/ O
+UA O
+ratio O
+improves O
+the O
+sensitivity O
+for O
+the O
+prediction O
+of O
+poor O
+perinatal O
+outcome O
+when O
+it O
+is O
+combined O
+with O
+the O
+NST O
+. O
+
+Evaluation O
+of O
+materials O
+and O
+technics O
+in O
+vascular O
+surgery O
+using O
+111 O
+- O
+Indium O
+
+The O
+claustrocortical O
+connection O
+was O
+investigated O
+in O
+13 O
+cats O
+with O
+selective O
+injections O
+of O
+30 O
+% O
+HRP O
+in O
+the O
+three O
+subdivisions O
+of O
+the O
+auditory O
+cortex O
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+400 O
+WORDS O
+) O
+
+Applying O
+the O
+experience O
+mentioned O
+above O
+, O
+4 O
+- O
+META O
+was O
+used O
+to O
+bond O
+a O
+proprietary O
+photocuring O
+microfilled O
+composite O
+material O
+to O
+Class O
+V O
+cavities O
+in O
+freshly O
+extracted O
+human O
+teeth O
+. O
+
+The O
+phP1 B
+mutation I
+was O
+induced O
+by O
+insertion O
+of O
+a O
+1 O
+. O
+2 O
+- O
+kb O
+P O
+element O
+into O
+the O
+5 O
+' O
+transcribed O
+nontranslated O
+region O
+of O
+the O
+proximal O
+polyhomeotic O
+gene O
+. O
+
+METHOD O
+: O
+Six O
+instruments O
+were O
+reviewed O
+: O
+the O
+Berg O
+Balance O
+Scale O
+( O
+Berg O
+) O
+, O
+the O
+Clinical O
+Test O
+of O
+Sensory O
+Interaction O
+and O
+Balance O
+( O
+CTSIB O
+) O
+, O
+the O
+Functional O
+Reach O
+Test O
+, O
+the O
+Tinetti O
+Balance O
+Test O
+of O
+the O
+Performance O
+- O
+Oriented O
+Assessment O
+of O
+Mobility O
+Problems O
+( O
+Tinetti O
+) O
+, O
+the O
+Timed O
+" O
+Up O
+and O
+Go O
+" O
+Test O
+( O
+TU O
+& O
+GT O
+) O
+, O
+and O
+the O
+Physical O
+Performance O
+Test O
+( O
+PPT O
+) O
+. O
+
+Genome O
+timeline O
+. O
+
+Initial O
+computer O
+based O
+similarity O
+searches O
+identified O
+human B
+retinoblastoma I
+binding I
+protein I
+1 I
+( O
+RBP B
+- I
+1 I
+) O
+, O
+Drosophila B
+melanogaster I
+male I
+specific I
+lethal I
+- I
+3 I
+( O
+Msl B
+- I
+3 I
+) O
+, O
+S O
+. O
+pombe O
+altered B
+polarity I
+- I
+13 I
+( O
+Alp13 B
+) O
+and O
+S B
+. I
+cerevisiae I
+Eaf3p I
+, O
+a O
+component O
+of O
+the O
+yeast B
+NuA4 B
+HAT B
+complex I
+( O
+Galarneau O
+et O
+al O
+. O
+, O
+2000 O
+. O
+
+The O
+pressure O
+measurements O
+under O
+steady O
+flow O
+conditions O
+showed O
+that O
+the O
+hemodynamic O
+performance O
+( O
+including O
+pressure O
+gradient O
+and O
+effective O
+orifice O
+area O
+) O
+of O
+SPAB O
+is O
+superior O
+to O
+that O
+of O
+its O
+stented O
+counterpart O
+, O
+especially O
+in O
+the O
+smaller O
+sizes O
+. O
+
+Serum B
+prolactin I
+rapidly O
+decreased O
+after O
+institution O
+of O
+treatment O
+, O
+with O
+actual O
+normalization O
+( O
+less O
+than O
+20 O
+ng O
+/ O
+ml O
+) O
+by O
+the O
+3rd O
+month O
+. O
+
+We O
+report O
+five O
+of O
+13 O
+evaluable O
+patients O
+undergoing O
+allogeneic O
+sibling O
+BM O
+or O
+PBSC O
+transplantation O
+for O
+MM O
+between O
+1990 O
+and O
+1997 O
+who O
+met O
+the O
+criteria O
+for O
+adjuvant O
+alpha B
+- I
+IFN I
+therapy O
+. O
+
+Moist O
+healing O
+versus O
+wet O
+- O
+to O
+- O
+dry O
+. O
+
+In O
+this O
+report O
+, O
+we O
+identify O
+Tyr319 O
+as O
+a O
+functionally O
+important O
+phosphorylation O
+site O
+in O
+the O
+ZAP B
+- I
+70 I
+interdomain I
+B I
+region I
+. O
+
+These O
+findings O
+suggest O
+that O
+low O
+- O
+power O
+laser O
+irradiation O
+can O
+be O
+used O
+for O
+promotion O
+of O
+vascularization O
+and O
+take O
+of O
+tissue O
+transplants O
+. O
+
+RESEARCH O
+DESIGN O
+AND O
+METHODS O
+: O
+A O
+total O
+of O
+26 O
+IDDM O
+patients O
+with O
+normoalbuminuria O
+were O
+randomized O
+into O
+two O
+groups O
+, O
+with O
+one O
+group O
+receiving O
+placebo O
+( O
+n O
+= O
+13 O
+, O
+age O
+36 O
++ O
+/ O
+- O
+3 O
+years O
+, O
+BMI O
+24 O
+. O
+5 O
++ O
+/ O
+- O
+1 O
+. O
+1 O
+kg O
+/ O
+m2 O
+) O
+and O
+the O
+other O
+group O
+receiving O
+an O
+average O
+of O
+15 O
+mg O
+lisinopril O
+daily O
+( O
+n O
+= O
+13 O
+, O
+age O
+34 O
++ O
+/ O
+- O
+2 O
+years O
+, O
+BMI O
+24 O
+. O
+4 O
++ O
+/ O
+- O
+0 O
+. O
+9 O
+kg O
+/ O
+m2 O
+) O
+. O
+
+Previously O
+, O
+a O
+cDNA O
+( O
+GT2 B
+) O
+encoding O
+this O
+protein O
+was O
+isolated O
+from O
+a O
+mouse O
+3T3 O
+- O
+L1 O
+adipocyte O
+library O
+and O
+was O
+sequenced O
+. O
+
+Expression O
+of O
+human B
+complement I
+receptor I
+type I
+2 I
+( O
+CR2 B
+/ O
+CD21 B
+) O
+is O
+primarily O
+restricted O
+to O
+mature O
+B O
+cells O
+and O
+follicular O
+dendritic O
+cells O
+. O
+
+The O
+6 O
+. O
+5 O
+- O
+kb O
+genomic O
+fragment O
+contains O
+the O
+complete O
+coding O
+region O
+of O
+MyoD B
+, O
+distributed O
+over O
+three O
+exons O
+, O
+plus O
+2 O
+. O
+3 O
+kb O
+of O
+5 O
+' O
+- O
+noncoding O
+sequence O
+and O
+1 O
+. O
+4 O
+kb O
+of O
+3 O
+' O
+- O
+noncoding O
+sequence O
+. O
+
+Synthetic O
+studies O
+on O
+furan O
+derivatives O
+by O
+the O
+wittig O
+reaction O
+
+The O
+apparent O
+binding O
+constant O
+of O
+6 O
+to O
+calf O
+thymus O
+DNA O
+is O
+1 O
+. O
+68 O
+X O
+10 O
+( O
+5 O
+) O
+M O
+- O
+1 O
+whereas O
+netropsin O
+under O
+similar O
+conditions O
+gives O
+a O
+value O
+of O
+1 O
+. O
+85 O
+X O
+10 O
+( O
+7 O
+) O
+M O
+- O
+1 O
+. O
+
+Phenotypic O
+screening O
+of O
+mutations O
+in O
+Pmr1 B
+, O
+the O
+yeast O
+secretory O
+pathway O
+Ca2 B
++ I
+/ I
+Mn2 I
++ I
+- I
+ATPase I
+, O
+reveals O
+residues O
+critical O
+for O
+ion O
+selectivity O
+and O
+transport O
+. O
+
+Molecular O
+cloning O
+of O
+cDNAs O
+encoding O
+alpha O
+- O
+subunits O
+of O
+guanine B
+nucleotide I
+- I
+binding I
+regulatory I
+proteins I
+( O
+G B
+- I
+proteins I
+) O
+has O
+revealed O
+the O
+existence O
+of O
+nine O
+species O
+of O
+alpha O
+- O
+subunits O
+. O
+
+No O
+transactivation O
+of O
+the O
+ovalbumin B
+promoter I
+( O
+pLovTATA B
+) O
+template O
+control O
+was O
+observed O
+. O
+
+Pros O
+and O
+cons O
+of O
+selective O
+inhibition O
+of O
+cyclooxygenase B
+- I
+2 I
+versus O
+dual O
+lipoxygenase B
+/ O
+cyclooxygenase B
+inhibition O
+: O
+is O
+two O
+better O
+than O
+one O
+? O
+
+At O
+11 O
+. O
+5 O
+years O
+of O
+follow O
+- O
+up O
+, O
+521 O
+major O
+coronary O
+disease O
+events O
+had O
+occurred O
+, O
+261 O
+fatal O
+and O
+260 O
+non O
+- O
+fatal O
+. O
+
+The O
+etiology O
+was O
+established O
+in O
+73 O
+( O
+76 O
+. O
+8 O
+% O
+) O
+out O
+of O
+95 O
+cases O
+. O
+
+Morphometry O
+of O
+the O
+intestine O
+of O
+the O
+pig O
+. O
+
+Serum O
+zinc O
+and O
+copper O
+levels O
+and O
+urine O
+copper O
+concentrations O
+in O
+men O
+were O
+significantly O
+lower O
+than O
+in O
+women O
+, O
+while O
+there O
+were O
+no O
+differences O
+in O
+serum O
+or O
+urinary O
+zinc O
+and O
+copper O
+levels O
+with O
+age O
+. O
+
+HDE B
+was O
+found O
+to O
+be O
+exclusively O
+targeted O
+to O
+and O
+imported O
+into O
+peroxisomes O
+in O
+both O
+heterologous O
+expression O
+systems O
+. O
+
+GeneCalling O
+analysis O
+was O
+successful O
+in O
+detecting O
+members O
+of O
+complex O
+metabolic O
+pathways O
+and O
+uncovering O
+novel O
+genes O
+that O
+were O
+either O
+coincidentally O
+regulated O
+or O
+directly O
+involved O
+in O
+such O
+pathways O
+. O
+
+Transformations O
+with O
+circular O
+plasmids O
+yielded O
+slowly O
+and O
+irregularly O
+growing O
+geneticin B
+- O
+resistant O
+mycelia O
+in O
+which O
+1 O
+% O
+of O
+nuclei O
+contained O
+plasmid O
+sequences O
+. O
+
+CONCLUSION O
+: O
+In O
+these O
+patients O
+control O
+of O
+ventricular O
+response O
+rate O
+with O
+either O
+HBA O
++ O
+VVIR O
+pacemaker O
+or O
+atrioventricular O
+modifying O
+drugs O
++ O
+VVI O
+pacemaker O
+will O
+lead O
+to O
+a O
+significant O
+improvement O
+in O
+exercise O
+duration O
+and O
+quality O
+of O
+life O
+. O
+
+The O
+other O
+regions O
+include O
+potential O
+binding O
+sites O
+for O
+transcription B
+factors I
+ATF I
+, O
+NF1 B
+, O
+and O
+a O
+CCAAT B
+- I
+binding I
+protein I
+. O
+
+Both O
+purH B
+and O
+purD B
+genes I
+constitute O
+a O
+single O
+operon O
+and O
+are O
+coregulated O
+in O
+expression O
+by O
+purines O
+as O
+other O
+purine O
+genes O
+are O
+. O
+
+The O
+patient O
+demographics O
+( O
+means O
++ O
+/ O
+- O
+standard O
+deviations O
+) O
+were O
+as O
+follows O
+: O
+age O
+, O
+57 O
++ O
+/ O
+- O
+12 O
+years O
+; O
+sex O
+, O
+nine O
+males O
+and O
+three O
+females O
+; O
+APACHE O
+II O
+score O
+, O
+15 O
++ O
+/ O
+- O
+3 O
+; O
+diagnosis O
+, O
+9 O
+of O
+12 O
+patients O
+with O
+pneumonia O
+. O
+
+In O
+situ O
+hybridization O
+reveals O
+strong O
+signals O
+for O
+Zep B
+mRNA I
+in O
+the O
+cerebellum O
+and O
+olfactory O
+bulb O
+with O
+moderate O
+signals O
+detected O
+in O
+the O
+hippocampus O
+and O
+cortex O
+. O
+
+TNF B
+- I
+alpha I
+effect O
+was O
+eliminated O
+by O
+a O
+2 O
+- O
+bp O
+substitution O
+mutation O
+in O
+the O
+NF B
+- I
+kappa I
+B1 I
+binding I
+half I
+site I
+of O
+the O
+NF B
+- I
+kappa I
+B I
+cis O
+element I
+. O
+
+UV O
+- O
+cross O
+- O
+linking O
+studies O
+suggested O
+that O
+these O
+two O
+complexes O
+represent O
+one O
+and O
+two O
+molecules O
+of O
+ADR1 B
+bound O
+to O
+DNA O
+. O
+
+As O
+already O
+available O
+for O
+the O
+other O
+known O
+mammalian O
+members O
+of O
+this O
+enzyme O
+family O
+, O
+we O
+here O
+define O
+structural O
+and O
+functional O
+features O
+of O
+human B
+lymphoma I
+proprotein I
+convertase I
+( O
+LPC B
+) O
+. O
+
+The O
+M O
+- O
+phase O
+induction O
+activity O
+of O
+Cdc2 B
+- O
+Cdc13 B
+is O
+inhibited O
+by O
+Wee1 B
+tyrosine B
+kinase I
+, O
+which O
+phosphorylates O
+Cdc2 B
+on O
+tyrosine O
+- O
+15 O
+. O
+
+Nucleotide O
+sequencing O
+revealed O
+a O
+2076 O
+- O
+base O
+pair O
+open O
+reading O
+frame O
+encoding O
+a O
+692 O
+- O
+amino O
+acid O
+protein O
+. O
+
+But O
+it O
+is O
+possible O
+that O
+the O
+two O
+hemispheres O
+differ O
+in O
+the O
+manner O
+in O
+which O
+they O
+make O
+use O
+of O
+semantic O
+structures O
+: O
+the O
+left O
+hemisphere O
+in O
+a O
+selective O
+manner O
+, O
+appropriate O
+for O
+the O
+solution O
+of O
+a O
+specific O
+task O
+, O
+and O
+the O
+right O
+hemisphere O
+in O
+a O
+more O
+diffuse O
+and O
+global O
+manner O
+. O
+
+Supportive O
+therapy O
+with O
+xenogenous O
+peptides O
+in O
+patients O
+with O
+metastatic O
+breast O
+cancer O
+undergoing O
+aggressive O
+chemotherapy O
+( O
+modified O
+AC O
+- O
+protocol O
+) O
+: O
+a O
+prospective O
+, O
+randomized O
+double O
+- O
+blind O
+study O
+
+The O
+pregnancies O
+were O
+terminated O
+at O
+19 O
+and O
+12 O
+weeks O
+of O
+gestation O
+, O
+respectively O
+. O
+
+Single O
+substitutions O
+of O
+three O
+highly O
+conserved O
+phenylalanine O
+residues O
+( O
+Phe O
+- O
+15 O
+, O
+Phe O
+- O
+17 O
+, O
+Phe O
+- O
+27 O
+) O
+by O
+alanine O
+and O
+substitution O
+of O
+one O
+histidine O
+( O
+His O
+- O
+29 O
+) O
+by O
+glutamine O
+, O
+all O
+located O
+within O
+the O
+putative O
+RNA O
+- O
+binding O
+sites O
+RNP B
+- I
+1 I
+and O
+RNP B
+- I
+2 I
+, O
+abolished O
+the O
+nucleic O
+acid O
+- O
+binding O
+activity O
+of O
+CspB B
+. O
+
+The O
+cases O
+with O
+terminal O
+forces O
+of O
+left O
+ventricular O
+activation O
+in O
+the O
+same O
+direction O
+as O
+the O
+delta O
+wave O
+, O
+superiorly O
+and O
+to O
+the O
+left O
+at O
+- O
+60 O
+degrees O
+or O
+inferiorly O
+and O
+to O
+the O
+right O
+at O
++ O
+120 O
+degrees O
+, O
+forming O
+a O
+single O
+deflection O
+of O
+over O
+0 O
+, O
+12 O
+seconds O
+' O
+duration O
+, O
+are O
+the O
+result O
+of O
+delayed O
+activation O
+of O
+the O
+anterior O
+or O
+posterior O
+fascicle O
+of O
+the O
+left O
+bundle O
+after O
+a O
+long O
+delay O
+. O
+
+The O
+genes O
+encoding O
+these O
+carotenoids O
+in O
+E O
+. O
+herbicola O
+Eho13 B
+are O
+clustered O
+in O
+a O
+7 O
+kb O
+DNA O
+fragment O
+. O
+
+The O
+results O
+show O
+that O
+while O
+a O
+larger O
+polypeptide O
+substrate O
+carrying O
+the O
+HD1 B
+/ O
+3C B
+site O
+was O
+processed O
+more O
+efficiently O
+than O
+a O
+polypeptide O
+substrate O
+carrying O
+the O
+POL B
+/ I
+Zn I
+site O
+, O
+cleavage O
+of O
+the O
+synthetic O
+peptide O
+substrates O
+containing O
+these O
+two O
+cleavage O
+sites O
+occurred O
+at O
+similar O
+efficiencies O
+. O
+
+Using O
+transgenic O
+lines O
+a O
+detailed O
+analysis O
+of O
+the O
+Hoxa B
+- I
+7 I
+enhancer O
+- O
+directed O
+expression O
+during O
+embryogenesis O
+was O
+performed O
+. O
+
+lacZ B
+expression O
+was O
+first O
+detected O
+in O
+the O
+allantois O
+at O
+day O
+7 O
+. O
+5 O
+p O
+. O
+c O
+. O
+and O
+in O
+mesoderm O
+and O
+ectoderm O
+at O
+day O
+8 O
+. O
+5 O
+of O
+gestation O
+. O
+
+An O
+ERp60 B
+- I
+like I
+protein I
+from O
+the O
+filarial O
+parasite O
+Dirofilaria O
+immitis O
+has O
+both O
+transglutaminase B
+and O
+protein B
+disulfide I
+isomerase I
+activity O
+. O
+
+At O
+promoters O
+that O
+initiate O
+with O
++ O
+1 O
+GGG O
+, O
+T7 B
+RNAP I
+synthesizes O
+a O
+ladder O
+of O
+poly O
+( O
+G O
+) O
+products O
+as O
+a O
+result O
+of O
+slippage O
+of O
+the O
+transcript O
+on O
+the O
+three O
+C O
+residues O
+in O
+the O
+template O
+strand O
+from O
++ O
+1 O
+to O
++ O
+3 O
+. O
+
+Serum O
+levels O
+of O
+angiotensin B
+converting I
+enzyme I
+were O
+well O
+maintained O
+. O
+
+The O
+UL3 B
+ORF I
+of O
+204 O
+amino O
+acids O
+shows O
+significant O
+homology O
+to O
+UL3 B
+( O
+nuclear B
+phosphoprotein I
+) O
+of O
+HSV O
+- O
+1 O
+( O
+62 O
+% O
+) O
+and O
+PRV O
+( O
+53 O
+% O
+) O
+. O
+
+On O
+Western O
+blots O
+, O
+the O
+same O
+antibodies O
+recognized O
+the O
+recombinant O
+protein O
+migrating O
+slightly O
+slower O
+on O
+SDS O
+/ O
+PAGE O
+than O
+chicken B
+axonin I
+- I
+1 I
+. O
+
+For O
+routine O
+medical O
+applications O
+, O
+no O
+sophisticated O
+adjustment O
+of O
+the O
+CHESS O
+pulse O
+is O
+needed O
+, O
+as O
+reported O
+in O
+previous O
+methods O
+. O
+
+The O
+10 O
+eyes O
+injected O
+with O
+human O
+RPE O
+cells O
+showed O
+STAGE O
+2 O
+or O
+less O
+in O
+4 O
+weeks O
+. O
+
+This O
+report O
+establishes O
+that O
+the O
+effect O
+of O
+homozygous O
+sickle O
+cell O
+disease O
+on O
+growth O
+patterns O
+in O
+childhood O
+is O
+apparent O
+before O
+the O
+age O
+of O
+6 O
+years O
+. O
+
+The O
+remaining O
+77 O
+nucleotides O
+at O
+the O
+3 O
+' O
+end O
+of O
+domain O
+II O
+and O
+all O
+of O
+domains O
+III O
+( O
+655 O
+nucleotides O
+) O
+and O
+IV O
+( O
+770 O
+nucleotides O
+) O
+are O
+not O
+present O
+in O
+DIssE O
+RNA O
+. O
+
+The O
+biological O
+actions O
+of O
+VHR B
+in O
+oocytes O
+clearly O
+distinguish O
+it O
+from O
+other O
+dual O
+specificity O
+phosphatases O
+, O
+which O
+have O
+shown O
+inhibitory O
+effects O
+when O
+tested O
+in O
+oocytes O
+. O
+
+The O
+presence O
+of O
+chloroquine O
+in O
+saliva O
+from O
+seven O
+healthy O
+volunteers O
+for O
+21 O
+days O
+after O
+a O
+single O
+600 O
+mg O
+oral O
+dose O
+of O
+the O
+drug O
+was O
+established O
+by O
+chromatographic O
+and O
+spectroscopic O
+methods O
+. O
+
+The O
+gp41 B
+peptide I
+( O
+Glu O
+- O
+Leu O
+- O
+Asp O
+- O
+Lys O
+- O
+Trp O
+- O
+Ala O
+) O
+fused O
+to O
+the O
+C O
+- O
+terminus O
+of O
+Sj B
+GST I
+forms O
+a O
+loop O
+stabilized O
+by O
+symmetry O
+- O
+related O
+GSTs B
+. O
+
+Comparison O
+of O
+bioreactive O
+and O
+immunoreactive O
+gastrin B
+. O
+
+Also O
+, O
+PTx O
+had O
+no O
+effect O
+on O
+shear O
+- O
+dependent O
+activation O
+of O
+JNK B
+. O
+
+A O
+score O
+( O
+APACHE O
+II O
+) O
+was O
+calculated O
+to O
+assess O
+the O
+severity O
+of O
+disease O
+. O
+
+We O
+tested O
+several O
+growth O
+regulatory O
+genes O
+that O
+are O
+repressed O
+in O
+senescent O
+cells O
+for O
+ability O
+to O
+restore O
+activity O
+to O
+T B
+[ I
+K1 I
+] I
+. O
+
+We O
+analyzed O
+the O
+contribution O
+of O
+the O
+three O
+different O
+types O
+of O
+UV O
+- O
+inducible O
+mitogen B
+- I
+activated I
+protein I
+( I
+MAP I
+) I
+kinases I
+( O
+ERK B
+, O
+JNK B
+/ O
+SAPK B
+, O
+and O
+p38 B
+) O
+to O
+the O
+activation O
+of O
+the O
+murine B
+uPA I
+promoter I
+by O
+UV O
+. O
+
+The O
+high O
+degree O
+of O
+sequence O
+conservation O
+together O
+with O
+the O
+ability O
+to O
+direct O
+nucleolar O
+protein O
+transport O
+supports O
+the O
+hypothesis O
+that O
+MAK16 B
+proteins I
+play O
+a O
+key O
+role O
+in O
+the O
+biogenesis O
+of O
+60S B
+subunits I
+. O
+
+Characterization O
+of O
+a O
+nuclear B
+deformed I
+epidermal I
+autoregulatory I
+factor I
+- I
+1 I
+( O
+DEAF B
+- I
+1 I
+) O
+- O
+related O
+( O
+NUDR B
+) O
+transcriptional O
+regulator O
+protein O
+. O
+
+Here O
+we O
+show O
+that O
+the O
+sck1 B
+gene I
+, O
+cloned O
+as O
+a O
+high O
+copy O
+number O
+suppressor O
+of O
+a O
+mutation O
+in O
+git3 B
+, O
+is O
+able O
+to O
+suppress O
+the O
+defects O
+conferred O
+by O
+a O
+mutation O
+in O
+any O
+of O
+these O
+git B
+genes I
+. O
+
+Hamdija O
+Karamehmedovic O
+; O
+Ibn O
+al O
+- O
+Nefis O
+, O
+" O
+Mudzez O
+al O
+- O
+Kanum O
+" O
+, O
+Republicki O
+zavod O
+za O
+zdravstvenu O
+zastitu O
+Sarajevo O
+, O
+1961 O
+, O
+1 O
+- O
+219 O
+; O
+Mr O
+ph O
+Samuel O
+Elazar O
+, O
+Ajnija O
+Omanic O
+: O
+" O
+Bibliografija O
+medicinskih O
+djela O
+u O
+SR O
+BiH O
+do O
+1895 O
+. O
+" O
+Medicinska O
+knjiga O
+Beograd O
+- O
+Zagreb O
+1984 O
+; O
+Besides O
+, O
+the O
+great O
+contribution O
+in O
+bibliography O
+was O
+given O
+by O
+dr O
+Lujo O
+Taler O
+, O
+prof O
+. O
+
+dr O
+. O
+
+The O
+longest O
+cDNA O
+insert O
+identified O
+was O
+2 O
+. O
+2 O
+kb O
+and O
+encoded O
+the O
+entire O
+462 O
+- O
+amino O
+acid O
+open O
+reading O
+frame O
+of O
+rat B
+CgA I
+including O
+an O
+18 O
+- O
+amino O
+acid O
+hydrophobic O
+signal O
+peptide O
+. O
+
+We O
+have O
+used O
+systemic O
+application O
+of O
+the O
+ototoxic O
+drug O
+amikacin O
+, O
+to O
+induce O
+total O
+cochlear O
+haircell O
+loss O
+in O
+the O
+chinchilla O
+, O
+in O
+order O
+to O
+create O
+an O
+animal O
+model O
+of O
+profound O
+deafness O
+. O
+
+Cotransfection O
+with O
+C B
+/ I
+EBPbeta I
+and O
+GATA B
+- I
+1 I
+expression O
+vectors O
+produced O
+a O
+5 O
+- O
+fold O
+increase O
+compared O
+with O
+cotransfection O
+with O
+the O
+C B
+/ I
+EBPbeta I
+or O
+GATA B
+- I
+1 I
+expression O
+vectors O
+individually O
+. O
+
+Among O
+the O
+different O
+epithelial O
+cell O
+lines O
+tested O
+, O
+only O
+RTS3b O
+cells O
+allowed O
+an O
+expression O
+pattern O
+similar O
+to O
+that O
+observed O
+in O
+naturally O
+infected O
+benign O
+condylomas O
+. O
+
+In O
+contrast O
+to O
+the O
+p16 B
+- O
+mediated O
+G1 O
+block O
+, O
+G1 O
+arrest O
+mediated O
+by O
+the O
+cdk B
+inhibitors O
+p21Cip1 B
+or O
+p27Kip1 B
+cannot O
+be O
+bypassed O
+either O
+by O
+inactivation O
+of O
+pRb B
+or O
+overexpression O
+of O
+E2F B
+family I
+members I
+. O
+
+In O
+addition O
+, O
+the O
+authors O
+found O
+one O
+an3 B
+allele I
+( O
+an3 B
+- I
+W138A I
+) O
+in O
+which O
+a O
+dTph1 B
+element I
+had O
+inserted O
+30 O
+bp O
+upstream O
+the O
+translation O
+start O
+, O
+without O
+inactivating O
+the O
+gene O
+. O
+
+Case O
+of O
+nephrotic O
+syndrome O
+caused O
+by O
+gold O
+preparations O
+
+To O
+investigate O
+the O
+role O
+of O
+bHLH B
+proteins I
+in O
+MC3T3 O
+- O
+E1 O
+osteoblasts O
+, O
+which O
+undergo O
+a O
+developmental O
+sequence O
+in O
+vitro O
+, O
+we O
+analyzed O
+the O
+transcriptional O
+control O
+of O
+osteocalcin B
+gene I
+expression O
+by O
+stable O
+transfection O
+of O
+an O
+osteocalcin B
+promoter I
+- O
+luciferase B
+chimeric O
+gene O
+( O
+p637OC B
+- O
+luc B
+) O
+and O
+assessed O
+the O
+role O
+of O
+E O
+- O
+box O
+cis O
+- O
+acting O
+elements O
+in O
+osteocalcin B
+promoter I
+by O
+DNA O
+binding O
+assays O
+. O
+
+In O
+summary O
+, O
+the O
+only O
+treatment O
+- O
+related O
+effect O
+noted O
+in O
+this O
+study O
+was O
+hydrocarbon O
+nephropathy O
+in O
+male O
+rats O
+, O
+which O
+is O
+not O
+considered O
+relevant O
+for O
+human O
+health O
+. O
+
+In O
+this O
+study O
+, O
+we O
+show O
+that O
+HNF B
+- I
+4 I
+, O
+a O
+member O
+of O
+the O
+steroid B
+hormone I
+receptor I
+superfamily I
+, O
+binds O
+the O
+AF O
+- O
+1 O
+site O
+on O
+the O
+apoB B
+promoter I
+and O
+through O
+it O
+activates O
+transcription O
+in O
+transient O
+transfection O
+assays O
+in O
+both O
+liver O
+and O
+non O
+- O
+liver O
+cell O
+lines O
+, O
+HepG2 O
+and O
+HeLa O
+, O
+respectively O
+. O
+
+Gastrointestinal O
+accumulation O
+of O
+indium O
+- O
+111 O
+labelled O
+granulocytes O
+in O
+reactive O
+arthritis O
+. O
+
+Acute O
+intoxication O
+with O
+cypermethrin O
+( O
+NRDC O
+149 O
+) O
+. O
+
+We O
+have O
+previously O
+shown O
+that O
+the O
+transcriptional O
+activator O
+CREM B
+is O
+highly O
+expressed O
+in O
+postmeiotic O
+cells O
+. O
+
+No O
+interaction O
+with O
+epidural O
+anesthesia O
+was O
+observed O
+. O
+
+In O
+late O
+October O
+, O
+1974 O
+, O
+Staphylococcus O
+aureus O
+postoperative O
+wound O
+infection O
+was O
+recorded O
+in O
+a O
+nonhuman O
+primate O
+( O
+Macaca O
+mulatta O
+) O
+which O
+had O
+recently O
+undergone O
+surgical O
+operation O
+. O
+
+Twenty O
+- O
+six O
+calves O
+were O
+subjected O
+to O
+a O
+technique O
+of O
+cryoablation O
+in O
+order O
+to O
+establish O
+an O
+animal O
+model O
+of O
+complete O
+cardiac O
+denervation O
+. O
+
+Our O
+current O
+study O
+aims O
+at O
+clarifying O
+the O
+role O
+of O
+myristoylation O
+in O
+caveolar O
+targeting O
+using O
+well O
+- O
+characterized O
+acylation O
+mutants O
+of O
+two O
+model O
+proteins O
+, O
+namely O
+Gi1 B
+alpha I
+and O
+c B
+- I
+Src I
+. O
+
+The O
+effect O
+of O
+deferoxamine O
+B O
+on O
+the O
+blood O
+sugar O
+behavior O
+in O
+intravenous O
+glucose O
+loading O
+in O
+healthy O
+persons O
+
+We O
+infer O
+that O
+RecA B
+- O
+mediated O
+cleavage O
+of O
+UmuD B
+is O
+another O
+role O
+for O
+RecA B
+in O
+SOS O
+mutagenesis O
+, O
+probably O
+activating O
+UmuD B
+for O
+its O
+mutagenic O
+function O
+. O
+
+SETTING O
+: O
+Participants O
+in O
+the O
+Physicians O
+' O
+Health O
+Study O
+, O
+a O
+randomized O
+trial O
+of O
+aspirin O
+and O
+beta O
+- O
+carotene O
+among O
+U O
+. O
+S O
+. O
+male O
+physicians O
+. O
+
+The O
+prevalence O
+of O
+microalbuminuria O
+, O
+defined O
+as O
+an O
+UAER O
+in O
+the O
+range O
+of O
+15 O
+- O
+150 O
+micrograms O
+min O
+- O
+1 O
+in O
+an O
+overnight O
+urine O
+sample O
+, O
+was O
+3 O
+% O
+( O
+95 O
+% O
+C O
+. O
+I O
+. O
+interval O
+: O
+1 O
+. O
+9 O
+- O
+4 O
+. O
+0 O
+) O
+. O
+
+The O
+Rep B
+proteins I
+of O
+adeno O
+- O
+associated O
+virus O
+type O
+2 O
+( O
+AAV O
+) O
+are O
+known O
+to O
+bind O
+to O
+Rep B
+recognition I
+sequences I
+( O
+RRSs O
+) O
+in O
+the O
+AAV O
+inverted O
+terminal O
+repeats O
+( O
+ITRs O
+) O
+, O
+the O
+AAV B
+p5 I
+promoter I
+, O
+and O
+the O
+preferred O
+AAV O
+integration O
+site O
+in O
+human O
+chromosome O
+19 O
+, O
+called O
+AAVS1 B
+. O
+
+LIP O
+and O
+DIP O
+are O
+less O
+common O
+IIPs O
+, O
+both O
+characterized O
+by O
+ground O
+- O
+glass O
+attenuation O
+. O
+
+The O
+levels O
+of O
+TPAR1 B
+mRNAs I
+were O
+dramatically O
+down O
+- O
+regulated O
+in O
+regenerating O
+rat O
+liver O
+when O
+compared O
+to O
+normal O
+adult O
+liver O
+. O
+
+Copyright O
+1999 O
+Academic O
+Press O
+. O
+
+The O
+authors O
+suggest O
+that O
+alprazolam O
+may O
+have O
+enhanced O
+specificity O
+for O
+a O
+subpopulation O
+of O
+benzodiazepine B
+receptors I
+. O
+
+Southern O
+hybridization O
+analysis O
+of O
+BenR O
+and O
+BenS B
+transformants O
+suggested O
+that O
+plasmid O
+integration O
+occurred O
+most O
+frequently O
+at O
+the O
+chromosomal B
+bens I
+locus I
+, O
+however O
+evidence O
+for O
+gene O
+conversion O
+and O
+heterologous O
+recombination O
+was O
+also O
+observed O
+. O
+
+The O
+analysis O
+of O
+the O
+effects O
+of O
+eight O
+signaling O
+molecules O
+in O
+the O
+TGFbeta B
+, O
+FGF B
+, O
+Hh B
+, O
+Wnt B
+, O
+and O
+EGF B
+families I
+in O
+tooth O
+explant O
+cultures O
+revealed O
+that O
+the O
+expression O
+of O
+edar B
+was O
+induced O
+by O
+activinbetaA B
+, O
+whereas O
+Wnt6 B
+induced O
+ectodysplasin B
+expression O
+. O
+
+In O
+mouse O
+, O
+two O
+high O
+- O
+affinity O
+binding O
+sites O
+with O
+an O
+apparent O
+dissociation O
+constant O
+( O
+Kd O
+) O
+of O
+50 O
+to O
+100 O
+nM O
+have O
+been O
+mapped O
+in O
+the O
+5 O
+' O
+ETS O
+upstream O
+from O
+the O
+early O
+pre O
+- O
+rRNA O
+processing O
+site O
+. O
+
+Single O
+oblique O
+- O
+view O
+mammography O
+for O
+periodic O
+screening O
+for O
+breast O
+cancer O
+in O
+women O
+. O
+
+Radiative O
+corrections O
+to O
+pi O
+l2 O
+decays O
+. O
+
+This O
+deletion O
+disrupts O
+the O
+PU B
+. I
+1 I
+Ets B
+domain O
+. O
+
+In O
+turn O
+, O
+production O
+of O
+sufficient O
+amounts O
+of O
+TraR B
+apparently O
+is O
+sensitive O
+to O
+a O
+cellular O
+function O
+requiring O
+RNase B
+D I
+. O
+
+The O
+predicted O
+product O
+exhibits O
+91 O
+% O
+amino O
+acid O
+identity O
+to O
+the O
+murine B
+voltage I
+- I
+gated I
+potassium I
+channel I
+protein I
+Kv1 I
+. I
+7 I
+( O
+Kcna7 B
+) O
+, O
+which O
+plays O
+an O
+important O
+role O
+in O
+the O
+repolarization O
+of O
+cell O
+membranes O
+. O
+
+Phytohemagglutinin B
+( O
+PHA B
+) O
+, O
+the O
+seed B
+lectin I
+of I
+the I
+common O
+bean O
+, O
+accumulates O
+in O
+protein O
+storage O
+vacuoles O
+of O
+storage O
+parenchyma O
+cells O
+in O
+cotyledons O
+. O
+
+This O
+dynamic O
+nature O
+may O
+be O
+relevant O
+to O
+the O
+ability O
+of O
+E47 B
+both O
+to O
+homodimerize O
+and O
+to O
+heterodimerize O
+with O
+MyoD B
+, O
+Id B
+, O
+and O
+Tal1 B
+. O
+
+Blood O
+samples O
+( O
+30 O
+ml O
+) O
+were O
+collected O
+via O
+an O
+indwelling O
+arm O
+catheter O
+at O
+rest O
+, O
+and O
+at O
+minutes O
+13 O
+and O
+28 O
+of O
+exercise O
+for O
+determinations O
+of O
+plasma O
+EPI O
+, O
+serum O
+free O
+fatty O
+acid O
+( O
+FFA O
+) O
+, O
+serum O
+glycerol O
+( O
+GLY O
+) O
+, O
+blood O
+glucose O
+( O
+GLU O
+) O
+, O
+and O
+blood O
+lactate O
+( O
+LA O
+) O
+concentrations O
+. O
+
+Among O
+these O
+, O
+four O
+patients O
+had O
+the O
+AIDS O
+syndrome O
+, O
+while O
+42 O
+individuals O
+were O
+HIV O
+carriers O
+. O
+
+Subjects O
+were O
+73 O
+male O
+and O
+female O
+employees O
+of O
+the O
+Xerox O
+Corporation O
+joining O
+a O
+newly O
+developed O
+health O
+fitness O
+program O
+. O
+
+Overexpression O
+of O
+p50 B
+in O
+transient O
+cotransfection O
+studies O
+using O
+the O
+proximal O
+CRP B
+promoter I
+( O
+- O
+125 O
+/ O
++ O
+9 O
+) O
+linked O
+to O
+a O
+luciferase B
+reporter I
+caused O
+a O
+3 O
+- O
+fold O
+increase O
+of O
+luciferase B
+activity O
+, O
+while O
+C B
+/ I
+EBPbeta I
+overexpression O
+caused O
+an O
+18 O
+- O
+fold O
+increase O
+; O
+simultaneous O
+overexpression O
+of O
+both O
+transcription O
+factors O
+increased O
+luciferase B
+activity O
+approximately O
+600 O
+- O
+fold O
+. O
+
+Our O
+results O
+suggest O
+that O
+it O
+might O
+be O
+possible O
+to O
+augment O
+IN O
+function O
+in O
+vivo O
+through O
+a O
+heterologous O
+domain O
+. O
+
+While O
+differential O
+expression O
+of O
+the O
+two O
+transcripts O
+was O
+not O
+found O
+, O
+the O
+promoter O
+controlling O
+LT1 B
+/ O
+LT2 B
+transcription O
+is O
+regulated O
+in O
+a O
+cell O
+cycle O
+- O
+dependent O
+manner O
+. O
+
+Schottky O
+- O
+barrier O
+heights O
+of O
+Ti O
+and O
+TiSi2 O
+on O
+n O
+- O
+type O
+and O
+p O
+- O
+type O
+Si O
+( O
+100 O
+) O
+. O
+
+A O
+survey O
+of O
+children O
+with O
+HBsAg B
+markers O
+related O
+to O
+their O
+parents O
+HBV O
+markers O
+. O
+
+Immunological O
+studies O
+also O
+failed O
+to O
+demonstrate O
+any O
+significant O
+change O
+except O
+for O
+a O
+significant O
+increase O
+of O
+natural O
+killer O
+( O
+NK O
+) O
+cell O
+activity O
+after O
+IFN B
+- I
+gamma I
+infusion O
+. O
+
+Fetal O
+PaO2 O
+fell O
+somewhat O
+during O
+the O
+recovery O
+stages O
+in O
+both O
+NIT O
+and O
+control O
+groups O
+. O
+
+Genetic O
+analyses O
+indicate O
+that O
+most O
+of O
+the O
+dominant O
+mutants O
+are O
+cis O
+- O
+acting O
+and O
+that O
+the O
+recessive O
+mutants O
+define O
+a O
+minimum O
+of O
+three O
+complementation O
+groups O
+, O
+indicating O
+that O
+defects O
+in O
+several O
+different O
+genes O
+can O
+restore O
+higher O
+levels O
+of O
+HIS4C B
+expression O
+. O
+
+Rat B
+cholesterol I
+side I
+- I
+chain I
+cleavage I
+cytochrome I
+P I
+- I
+450 I
+( O
+P B
+- I
+450scc I
+) O
+gene O
+. O
+
+Histopathologic O
+studies O
+displaying O
+spongiform O
+changes O
+in O
+the O
+gray O
+matter O
+, O
+neuronal O
+loss O
+, O
+and O
+atrogliosis O
+confirmed O
+the O
+clinical O
+diagnosis O
+of O
+Creutzfeldt O
+- O
+Jakob O
+disease O
+. O
+
+Pig O
+uPA B
+promoter O
+- O
+CAT B
+constructs O
+were O
+more O
+active O
+than O
+mouse O
+constructs O
+in O
+this O
+assay O
+. O
+
+Cloning O
+the O
+cDNA O
+for O
+a O
+new O
+human B
+zinc I
+finger I
+protein I
+defines O
+a O
+group O
+of O
+closely O
+related O
+Kruppel B
+- I
+like I
+transcription I
+factors I
+. O
+
+By O
+computed O
+homology O
+search O
+, O
+we O
+noticed O
+significant O
+similarities O
+between O
+US3 B
+PK I
+and O
+p21 B
+- I
+activated I
+kinase I
+( O
+PAK B
+) O
+, O
+which O
+is O
+activated O
+by O
+the O
+Cdc42 B
+or O
+Rac B
+. O
+
+The O
+mean O
+amount O
+of O
+blood O
+loss O
+prior O
+to O
+time O
+of O
+injection O
+was O
+4 O
+. O
+5 O
+units O
+( O
+a O
+range O
+of O
+3 O
+to O
+10 O
+units O
+) O
+. O
+
+In O
+response O
+to O
+acoustical O
+stimulation O
+the O
+properties O
+of O
+response O
+latency O
+, O
+discharge O
+pattern O
+, O
+frequency O
+tuning O
+, O
+binaural O
+interaction O
+, O
+and O
+habituation O
+were O
+examined O
+to O
+allow O
+an O
+appraisal O
+of O
+the O
+differentiation O
+of O
+the O
+MGB O
+by O
+electrophysiological O
+means O
+. O
+
+These O
+8 B
+- I
+oxoguanine I
+DNA I
+glycosylases I
+, O
+hOgg1 B
+( O
+human O
+) O
+and O
+mOgg1 B
+( O
+murine O
+) O
+, O
+are O
+homologous O
+to O
+each O
+other O
+and O
+to O
+yeast B
+Ogg1 I
+. O
+
+The O
+CHED B
+protein I
+includes O
+the O
+consensus O
+ATP O
+binding O
+and O
+phosphorylation O
+domains O
+characteristic O
+of O
+kinases O
+, O
+displays O
+34 O
+- O
+42 O
+% O
+identically O
+aligned O
+amino O
+acid O
+residues O
+with O
+other O
+cdc2 B
+- I
+related I
+kinases I
+, O
+and O
+is O
+considerably O
+longer O
+at O
+its O
+amino O
+and O
+carboxyl O
+termini O
+. O
+
+CONCLUSIONS O
+: O
+These O
+results O
+suggest O
+that O
+, O
+by O
+interacting O
+with O
+cellular O
+transcription O
+factors O
+and O
+cofactors O
+, O
+vIRF B
+- I
+2 I
+may O
+modulate O
+the O
+expression O
+of O
+the O
+early O
+inflammatory O
+genes O
+and O
+potentially O
+deregulate O
+the O
+immune O
+system O
+. O
+
+However O
+, O
+in O
+7 O
+patients O
+with O
+normal O
+CT O
+results O
+the O
+latter O
+method O
+showed O
+areas O
+of O
+cerebral O
+activity O
+anatomically O
+correlated O
+with O
+neurological O
+signs O
+or O
+vascular O
+lesions O
+. O
+
+We O
+report O
+that O
+Gcn5 B
+, O
+a O
+histone B
+H3 I
+acetylase I
+, O
+plays O
+a O
+central O
+role O
+in O
+initiation O
+of O
+meiosis O
+via O
+effects O
+on O
+IME2 B
+expression O
+. O
+
+The O
+carboxy O
+- O
+proximal O
+regions O
+of O
+the O
+VP1 B
+, O
+which O
+contain O
+very O
+low O
+amino O
+acid O
+homology O
+, O
+displayed O
+evidence O
+of O
+conservation O
+in O
+structural O
+features O
+such O
+as O
+a O
+hydrophilic O
+, O
+highly O
+basic O
+domain O
+. O
+
+Interferon B
+- I
+alpha I
+inducibility O
+of O
+IFI16 B
+may O
+be O
+regulated O
+by O
+an O
+interferon B
+- I
+alpha I
+/ I
+beta I
+- I
+stimulated I
+response I
+consensus I
+element I
+in O
+the O
+5 O
+' O
+UT O
+exon O
+, O
+as O
+a O
+similar O
+motif O
+is O
+conserved O
+in O
+the O
+corresponding O
+position O
+in O
+the O
+related O
+myeloid B
+cell I
+nuclear I
+differentiation I
+antigen I
+gene I
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+400 O
+WORDS O
+) O
+
+DESIGN O
+- O
+- O
+A O
+randomised O
+double O
+blind O
+placebo O
+controlled O
+parallel O
+arm O
+trial O
+. O
+
+Genealogical O
+analysis O
+suggested O
+mainly O
+a O
+mother O
+- O
+to O
+- O
+offspring O
+transmission O
+of O
+this O
+STLV B
+- I
+1 I
+. O
+
+These O
+back O
+mutations O
+led O
+to O
+a O
+modest O
+decrease O
+in O
+kinase O
+activity O
+, O
+decreased O
+tumorigenic O
+potential O
+in O
+chickens O
+, O
+and O
+an O
+unexpected O
+increase O
+in O
+transforming O
+activity O
+in O
+rat O
+cells O
+. O
+
+The O
+quantification O
+limit O
+was O
+50 O
+ng O
+/ O
+ml O
+for O
+each O
+of O
+PHT O
+, O
+m O
+- O
+HPPH O
+and O
+p O
+- O
+HPPH O
+. O
+
+Individual O
+intolerance O
+to O
+betaxolol O
+will O
+continue O
+to O
+occur O
+and O
+care O
+is O
+always O
+required O
+when O
+patients O
+with O
+cardiac O
+or O
+respiratory O
+dysfunction O
+are O
+exposed O
+to O
+any O
+beta O
+- O
+antagonist O
+. O
+
+Pretoria O
+Pasteurisation O
+is O
+feasible O
+and O
+reliable O
+under O
+a O
+range O
+of O
+conditions O
+. O
+
+In O
+the O
+present O
+study O
+we O
+use O
+a O
+tnaC B
+- O
+UGA O
+- O
+' B
+lacZ I
+construct O
+lacking O
+the O
+tnaC B
+- O
+tnaA B
+spacer O
+region O
+to O
+analyze O
+the O
+effect O
+of O
+TnaC B
+synthesis O
+on O
+the O
+behavior O
+of O
+the O
+ribosome O
+that O
+translates O
+tnaC B
+. O
+
+The O
+in O
+vitro O
+activity O
+of O
+KP O
+- O
+103 O
+, O
+a O
+novel O
+triazole O
+derivative O
+, O
+against O
+pathogenic O
+fungi O
+that O
+cause O
+dermatomycoses O
+and O
+its O
+therapeutic O
+efficacy O
+against O
+plantar O
+tinea O
+pedis O
+and O
+cutaneous O
+candidiasis O
+in O
+guinea O
+pigs O
+were O
+investigated O
+. O
+
+Restriction O
+analysis O
+of O
+the O
+isolated O
+genomic O
+clones O
+indicated O
+that O
+the O
+endogenous O
+sequences O
+abutting O
+the O
+3 O
+' O
+ends O
+of O
+the O
+94 O
+- O
+A O
+and O
+94 O
+- O
+K O
+transgenes O
+are O
+separated O
+by O
+less O
+than O
+20 O
+kb O
+, O
+providing O
+strong O
+support O
+for O
+the O
+single O
+integration O
+model O
+. O
+
+Serum O
+triglycerides O
+also O
+showed O
+an O
+increase O
+from O
+birth O
+to O
+6 O
+months O
+of O
+age O
+, O
+but O
+a O
+decrease O
+from O
+6 O
+months O
+to O
+1 O
+years O
+of O
+age O
+. O
+
+Female O
+Wistar O
+rats O
+receiving O
+alcohol O
+( O
+5 O
+% O
+) O
+in O
+drinking O
+water O
+during O
+lactation O
+( O
+N O
+= O
+7 O
+) O
+were O
+compared O
+to O
+normal O
+controls O
+fed O
+ad O
+libitum O
+( O
+N O
+= O
+6 O
+) O
+. O
+
+Antisense O
+oligonucleotides O
+complementary O
+to O
+the O
+5 O
+' O
+end O
+of O
+PKC B
+- I
+zeta I
+mRNA I
+sequences I
+significantly O
+reduced O
+the O
+collagen B
+lattice O
+- O
+stimulated O
+alpha2 B
+and O
+MMP B
+- I
+1 I
+mRNA I
+levels O
+. O
+
+Overexpression O
+of O
+a O
+HIF B
+- I
+1alpha I
+construct I
+with O
+deletions O
+of O
+the O
+basic O
+domain O
+and O
+carboxy O
+terminus O
+blocked O
+reporter O
+gene O
+activation O
+by O
+endogenous B
+HIF I
+- I
+1 I
+in O
+hypoxic O
+cells O
+. O
+
+We O
+hypothesized O
+that O
+conjugated O
+estrogens O
+, O
+which O
+contain O
+several O
+vasoactive O
+estrogenic O
+compounds O
+, O
+may O
+favorably O
+influence O
+the O
+vasomotor O
+response O
+to O
+acetylcholine O
+in O
+men O
+. O
+
+In O
+Experiment O
+2 O
+, O
+levels O
+were O
+: O
+amprolium O
+and O
+ethopabate O
+, O
+. O
+02 O
+% O
+; O
+salinomycin O
+, O
+55 O
+mg O
+/ O
+kg O
+; O
+monensin O
+, O
+99 O
+mg O
+/ O
+kg O
+; O
+and O
+lasalocid O
+, O
+110 O
+mg O
+/ O
+kg O
+. O
+
+Residues O
+crucial O
+for O
+Ras B
+interaction O
+with O
+GDP B
+- I
+GTP I
+exchangers I
+. O
+
+4 O
+. O
+
+In O
+serum O
+- O
+starved O
+NIH O
+3T3 O
+cells O
+, O
+v B
+- I
+raf I
+increased O
+mdr1 B
+promoter I
+activity O
+approximately O
+10 O
+- O
+fold O
+compared O
+to O
+a O
+v B
+- I
+raf I
+frame O
+- O
+shift O
+control O
+. O
+
+Searching O
+the O
+human O
+DNA O
+data O
+base O
+of O
+expressed O
+sequence O
+tags O
+( O
+EST O
+) O
+revealed O
+novel O
+partial O
+sequences O
+similar O
+to O
+, O
+but O
+distinct O
+from O
+, O
+the O
+sequences O
+of O
+the O
+previously O
+known O
+PEF B
+proteins I
+. O
+
+Under O
+control O
+conditions O
+and O
+in O
+the O
+presence O
+of O
+3 O
+micromol O
+/ O
+kg O
+MIB O
+and O
+VER O
+the O
+maximal O
+effect O
+of O
+noradrenaline O
+was O
+reached O
+at O
+0 O
+. O
+1 O
+micromol O
+/ O
+kg O
+whereas O
+in O
+the O
+presence O
+of O
+10 O
+micromol O
+/ O
+kg O
+MIB O
+and O
+VER O
+it O
+was O
+reached O
+at O
+a O
+dose O
+of O
+1 O
+micromol O
+/ O
+kg O
+. O
+
+It O
+is O
+also O
+affected O
+by O
+the O
+HAP2 B
+/ I
+3 I
+/ I
+4 I
+transcription I
+factor I
+complex I
+and O
+by O
+SNF1 B
+and O
+SSN6 B
+. O
+
+The O
+effective O
+use O
+of O
+superoxide B
+dismutase I
+from O
+human O
+erythrocytes O
+in O
+the O
+late O
+stages O
+of O
+experimental O
+influenza O
+infection O
+
+Two O
+different O
+genes O
+( O
+polA B
+and O
+polB B
+) O
+encoding O
+family B
+B I
+DNA I
+polymerases I
+were O
+cloned O
+from O
+the O
+organism O
+by O
+PCR O
+using O
+degenerated O
+primers O
+based O
+on O
+the O
+two O
+conserved O
+motifs O
+( O
+motif O
+A O
+and O
+B O
+) O
+. O
+
+The O
+effects O
+on O
+survival O
+of O
+adjuvant O
+treatments O
+, O
+including O
+pre O
+- O
+or O
+postoperative O
+systemic O
+or O
+postoperative O
+intra O
+- O
+arterial O
+chemotherapy O
+, O
+are O
+currently O
+under O
+evaluation O
+. O
+
+Structure O
+and O
+regulation O
+of O
+the O
+luteinizing B
+hormone I
+receptor I
+gene I
+. O
+
+The O
+disease O
+processes O
+that O
+affect O
+transplant O
+patients O
+both O
+before O
+and O
+after O
+transplantation O
+are O
+not O
+seen O
+frequently O
+in O
+the O
+general O
+practice O
+of O
+gastroenterology O
+. O
+
+METHODS O
+: O
+Single O
+white O
+flash O
+ERG O
+, O
+photopic O
+ERG O
+, O
+scotopic O
+ERG O
+and O
+flicker O
+ERG O
+were O
+recorded O
+in O
+30 O
+cases O
+of O
+unilateral O
+CRVO O
+. O
+
+However O
+, O
+to O
+encourage O
+good O
+contact O
+between O
+the O
+farmers O
+and O
+the O
+inseminating O
+personnel O
+, O
+it O
+is O
+beneficial O
+that O
+herdsmen O
+are O
+present O
+when O
+cows O
+are O
+inseminated O
+. O
+
+Soft O
+independent O
+modelling O
+of O
+class O
+analogy O
+( O
+SIMCA O
+) O
+is O
+applied O
+to O
+identify O
+near O
+- O
+infrared O
+( O
+NIR O
+) O
+spectra O
+of O
+ten O
+excipients O
+used O
+in O
+the O
+pharmaceutical O
+industry O
+. O
+
+Multiple O
+organ O
+failure O
+( O
+MOF O
+) O
+following O
+major O
+trauma O
+occurs O
+in O
+response O
+to O
+perfusion O
+deficits O
+, O
+a O
+persistent O
+inflammatory O
+focus O
+, O
+or O
+a O
+persistent O
+focus O
+of O
+dead O
+and O
+/ O
+or O
+injured O
+tissue O
+. O
+
+Western O
+immunoblot O
+analysis O
+detected O
+p55gag B
+and O
+its O
+cleavage O
+products O
+p39 B
+and O
+p27 B
+in O
+purified O
+particles O
+derived O
+by O
+expression O
+of O
+gag B
+and O
+gag B
+- O
+pol B
+, O
+respectively O
+. O
+
+Cefminox O
+shows O
+greater O
+in O
+vivo O
+activity O
+than O
+that O
+expected O
+for O
+the O
+MICs O
+, O
+excellent O
+efficacy O
+and O
+safety O
+. O
+
+CONCLUSION O
+: O
+high O
+resolution O
+MF O
+- O
+ERG O
+seems O
+more O
+sensitive O
+than O
+low O
+resolution O
+MF O
+- O
+ERG O
+. O
+
+3 O
+- O
+5 O
+- O
+fold O
+increases O
+in O
+EGF B
+receptor I
+but O
+not O
+p185 B
+( O
+neu B
+) O
+tyrosine O
+phosphorylation O
+occur O
+following O
+Gi B
+- I
+coupled I
+receptor I
+stimulation O
+. O
+
+Next O
+, O
+to O
+examine O
+the O
+regulation O
+mechanism O
+of O
+CD44 B
+/ O
+ERM B
+interaction O
+in O
+vivo O
+, O
+we O
+reexamined O
+the O
+immunoprecipitated O
+CD44 B
+/ O
+ERM B
+complex O
+from O
+BHK O
+cells O
+and O
+found O
+that O
+it O
+contains O
+Rho B
+- I
+GDP I
+dissociation I
+inhibitor I
+( O
+GDI B
+) O
+, O
+a O
+regulator O
+of O
+Rho B
+GTPase I
+. O
+
+The O
+results O
+showed O
+a O
+significant O
+group O
+effect O
+only O
+on O
+the O
+active O
+task O
+. O
+
+On O
+days O
+7 O
+, O
+21 O
+, O
+and O
+35 O
+postinoculation O
+( O
+PI O
+) O
+, O
+all O
+birds O
+received O
+sheep O
+erythrocytes O
+intravenously O
+. O
+
+To O
+determine O
+cis O
+- O
+acting O
+elements O
+controlling O
+the O
+rat O
+B B
+- I
+50 I
+/ O
+GAP B
+- I
+43 I
+gene O
+expression O
+, O
+the O
+genomic O
+DNA O
+encoding O
+exon O
+1 O
+and O
+the O
+5 O
+' O
+flanking O
+sequence O
+was O
+isolated O
+. O
+
+In O
+this O
+paper O
+, O
+the O
+authors O
+used O
+measured O
+weight O
+for O
+1 O
+, O
+259 O
+white O
+women O
+aged O
+65 O
+- O
+74 O
+years O
+from O
+the O
+Epidemiologic O
+Follow O
+- O
+up O
+Study O
+of O
+the O
+First O
+National O
+Health O
+and O
+Nutrition O
+Examination O
+Survey O
+to O
+examine O
+the O
+effect O
+of O
+overweight O
+on O
+coronary O
+heart O
+disease O
+incidence O
+( O
+mean O
+length O
+of O
+follow O
+- O
+up O
+, O
+14 O
+years O
+) O
+. O
+
+Through O
+genomic O
+library O
+screening O
+and O
+PCR O
+- O
+based O
+genomic O
+walking O
+we O
+have O
+now O
+cloned O
+the O
+mouse B
+E I
+- I
+Tmod I
+gene I
+, O
+whose O
+coding O
+region O
+spans O
+approximately O
+60kb O
+containing O
+nine O
+exons O
+and O
+eight O
+introns O
+. O
+
+TNF B
+- I
+alpha I
+stimulated O
+these O
+changes O
+in O
+part O
+by O
+increasing O
+transcription O
+and O
+stabilization O
+of O
+RNA O
+for O
+amphiregulin B
+, O
+an O
+EGF B
+receptor I
+ligand I
+, O
+and O
+amphiregulin B
+directly O
+increased O
+HPV O
+- O
+16 O
+E6 I
+/ O
+E7 B
+and O
+cyclin B
+A I
+RNAs O
+. O
+
+The O
+data O
+obtained O
+included O
+1 O
+) O
+the O
+mean O
+frequency O
+of O
+abnormal O
+teased O
+myelinated O
+fibers O
+and O
+its O
+upper O
+limit O
+value O
+of O
+95 O
+% O
+confidence O
+interval O
+, O
+and O
+2 O
+) O
+the O
+mean O
+densities O
+of O
+total O
+, O
+large O
+and O
+small O
+myelinated O
+fibers O
+and O
+of O
+unmyelinated O
+fibers O
+and O
+their O
+lower O
+limit O
+value O
+of O
+95 O
+% O
+confidence O
+interval O
+for O
+each O
+decade O
+. O
+
+Fusions O
+between O
+the O
+GAL B
+DNA I
+binding I
+domain I
+and O
+full B
+- I
+length I
+mSin3 I
+were O
+also O
+capable O
+of O
+repression O
+. O
+
+None O
+of O
+the O
+19 O
+women O
+with O
+probable O
+RA O
+and O
+100 O
+of O
+the O
+116 O
+women O
+with O
+definite O
+RA O
+met O
+the O
+1987 O
+criteria O
+. O
+
+The O
+initial O
+oral O
+administration O
+of O
+the O
+1 O
+and O
+2 O
+mg O
+/ O
+kg O
+doses O
+of O
+enoximone O
+improved O
+central O
+hemodynamic O
+parameters O
+with O
+apparent O
+preferential O
+reduction O
+of O
+limb O
+vascular O
+resistance O
+and O
+augmentation O
+of O
+blood O
+flow O
+to O
+the O
+limb O
+region O
+( O
+peripheral O
+musculoskeletal O
+system O
+) O
+. O
+
+Antibodies O
+against O
+REAP B
+- I
+1 I
+inhibit O
+in O
+vitro O
+RNA O
+editing O
+reactions O
+confirming O
+its O
+role O
+in O
+RNA O
+editing O
+. O
+
+The O
+full O
+- O
+length O
+cDNA O
+was O
+cloned O
+and O
+sequenced O
+, O
+and O
+the O
+inferred O
+amino O
+acid O
+sequence O
+was O
+found O
+to O
+encode O
+a O
+novel O
+protein O
+, O
+which O
+we O
+named O
+cystatin B
+M I
+, O
+with O
+40 O
+% O
+homology O
+to O
+human B
+family I
+2 I
+cystatins I
+and O
+similar O
+overall O
+structure O
+. O
+
+42nd O
+annual O
+meeting O
+of O
+the O
+American O
+Academy O
+of O
+Oral O
+Pathology O
+. O
+
+BAG B
+- I
+1 I
+also O
+prevented O
+growth O
+arrest O
+following O
+UV O
+- O
+irradiation O
+- O
+induced O
+genotoxic O
+injury O
+without O
+interfering O
+with O
+accumulation O
+of O
+p53 B
+protein I
+or O
+p21 B
+( O
+waf B
+- I
+1 I
+) O
+expression O
+. O
+
+The O
+side O
+effect O
+of O
+pulmonary O
+fibrosis O
+occurs O
+in O
+20 O
+to O
+30 O
+percent O
+of O
+patients O
+receiving O
+this O
+drug O
+. O
+
+These O
+larger O
+sizes O
+, O
+however O
+, O
+are O
+consistent O
+with O
+predictions O
+from O
+the O
+DNA O
+sequence O
+of O
+the O
+pol B
+gene I
+. O
+
+Primary O
+care O
+programs O
+for O
+the O
+indigent O
+. O
+
+N0 O
+disease O
+is O
+more O
+favorable O
+than O
+N1 O
+or O
+N2 O
+disease O
+. O
+
+In O
+serial O
+recall O
+from O
+short O
+- O
+term O
+memory O
+, O
+repeated O
+items O
+are O
+recalled O
+well O
+when O
+close O
+together O
+( O
+repetition O
+facilitation O
+) O
+, O
+but O
+not O
+when O
+far O
+apart O
+( O
+repetition O
+inhibition O
+; O
+the O
+Ranschburg O
+effect O
+) O
+. O
+
+In O
+addition O
+, O
+two O
+cis O
+- O
+acting O
+elements O
+direct O
+the O
+first O
+zygotic O
+expression O
+of O
+Kr B
+in O
+a O
+striped O
+subpattern O
+within O
+the O
+central O
+region O
+of O
+the O
+blastoderm O
+embryo O
+. O
+
+Two O
+hundred O
+and O
+eighty O
+- O
+three O
+patients O
+, O
+217 O
+females O
+( O
+median O
+age O
+24 O
+years O
+, O
+range O
+0 O
+. O
+5 O
+- O
+73 O
+) O
+and O
+66 O
+males O
+( O
+median O
+age O
+20 O
+years O
+, O
+range O
+0 O
+. O
+75 O
+- O
+72 O
+) O
+, O
+were O
+examined O
+. O
+
+The O
+Robert O
+Wood O
+Johnson O
+Foundation O
+: O
+billion O
+dollar O
+force O
+for O
+health O
+- O
+care O
+change O
+. O
+
+We O
+have O
+isolated O
+a O
+unique O
+murine B
+FLT3 I
+cDNA I
+that O
+codes O
+for O
+a O
+variant O
+isoform O
+of O
+FLT3 B
+, O
+devoid O
+of O
+the O
+fifth O
+Ig B
+- I
+like I
+domain I
+, O
+by O
+comparison O
+with O
+the O
+prototypic O
+form O
+. O
+
+P53 B
+mutations O
+also O
+offer O
+new O
+approaches O
+to O
+the O
+study O
+of O
+the O
+origins O
+of O
+mutations O
+in O
+human O
+cancer O
+. O
+
+( O
+1993 O
+) O
+8 O
+, O
+94 O
+- O
+99 O
+) O
+. O
+
+Desarrollo O
+de O
+un O
+modelo O
+matematico O
+general O
+para O
+los O
+procesos O
+fermentativos O
+, O
+Cinetica O
+de O
+la O
+degradacion O
+anaerobia O
+, O
+Ph O
+. O
+D O
+. O
+
+Particle O
+bombardment O
+of O
+barley O
+aleurone O
+with O
+a O
+B22EL8 B
+promoter I
+- O
+GUS B
+( O
+beta B
+- I
+glucuronidase I
+) O
+construct O
+demonstrates O
+that O
+the O
+promoter O
+( O
+3 O
+kb O
+) O
+is O
+active O
+in O
+developing O
+barley O
+grains O
+. O
+
+Changes O
+in O
+BHR O
+were O
+found O
+to O
+correlate O
+significantly O
+with O
+changes O
+in O
+the O
+levels O
+of O
+24 O
+h O
+mean O
+SO2 O
+, O
+NO2 O
+and O
+smoke O
+; O
+48 O
+h O
+mean O
+NO2 O
+and O
+smoke O
+; O
+24 O
+h O
+lag O
+NO2 O
+; O
+although O
+the O
+effect O
+was O
+only O
+small O
+, O
+accounting O
+for O
+approximately O
+10 O
+% O
+of O
+the O
+variability O
+in O
+within O
+- O
+subject O
+BHR O
+between O
+visits O
+. O
+
+The O
+N O
+- O
+terminal O
+sequences O
+of O
+isoforms O
+beta O
+to O
+epsilon O
+contain O
+a O
+PEST O
+region O
+which O
+could O
+induce O
+rapid O
+intracellular O
+degradation O
+of O
+isoforms O
+beta O
+and O
+delta O
+. O
+
+Characterization O
+of O
+regions O
+of O
+fibronectin B
+besides O
+the O
+arginine O
+- O
+glycine O
+- O
+aspartic O
+acid O
+sequence O
+required O
+for O
+adhesive O
+function O
+of O
+the O
+cell O
+- O
+binding O
+domain O
+using O
+site O
+- O
+directed O
+mutagenesis O
+. O
+
+The O
+clinical O
+effects O
+of O
+valproate O
+and O
+ethosuximide O
+can O
+be O
+related O
+to O
+this O
+differential O
+modulation O
+of O
+thalamocortical O
+excitability O
+. O
+
+Elements O
+regulating O
+cell O
+- O
+and O
+stage O
+- O
+specific O
+expression O
+of O
+the O
+C B
+. I
+elegans I
+MyoD I
+family I
+homolog I
+hlh B
+- I
+1 I
+. O
+
+An O
+analysis O
+of O
+the O
+c B
+- I
+kit I
+5 I
+' I
+flanking I
+region I
+using O
+the O
+bacterial B
+chloramphenicol I
+acetyltransferase I
+gene I
+( O
+CAT B
+assay O
+) O
+in O
+human O
+erythroleukemia O
+HEL O
+cells O
+, O
+which O
+express O
+the O
+endogenous O
+c B
+- I
+kit I
+mRNA I
+at O
+high O
+levels O
+, O
+showed O
+that O
+a O
+region O
+from O
+- O
+180 O
+to O
+- O
+22 O
+is O
+important O
+for O
+the O
+expression O
+of O
+the O
+c B
+- I
+kit I
+gene I
+. O
+
+After O
+5 O
+days O
+stimulation O
+with O
+G B
+- I
+CSF I
+( O
+10 O
+micrograms O
+/ O
+kg O
+) O
+1l O
+of O
+blood O
+was O
+drawn O
+, O
+kept O
+unprocessed O
+for O
+3 O
+days O
+and O
+reinfused O
+24 O
+h O
+after O
+completion O
+of O
+chemotherapy O
+. O
+
+OAT O
+has O
+become O
+safer O
+in O
+recent O
+years O
+, O
+particularly O
+if O
+monitored O
+in O
+special O
+anticoagulation O
+clinics O
+. O
+
+However O
+, O
+the O
+relative O
+substrate O
+specificity O
+of O
+RSK3 B
+differed O
+from O
+that O
+reported O
+for O
+other O
+isoforms O
+. O
+
+Our O
+data O
+indicate O
+that O
+the O
+various O
+subunits O
+of O
+the O
+human B
+P I
+- I
+TEFb I
+complex I
+may O
+play O
+distinct O
+roles O
+at O
+multiple O
+stages O
+to O
+mediate O
+Tat B
+activation O
+of O
+HIV O
+- O
+1 O
+transcription O
+elongation O
+. O
+
+Corresponding O
+oligonucleotides O
+were O
+used O
+to O
+screen O
+a O
+rat O
+liver O
+cDNA O
+library O
+constructed O
+in O
+the O
+plasmid O
+cloning O
+vector O
+, O
+pcDV O
+. O
+
+In O
+fifty O
+non O
+selected O
+ductal O
+carcinomas O
+of O
+the O
+breast O
+we O
+found O
+that O
+a O
+marked O
+tumoral O
+inflammatory O
+infiltrate O
+( O
+P O
+less O
+than O
+0 O
+. O
+025 O
+) O
+, O
+perinodal O
+tumoral O
+infiltrate O
+( O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+, O
+sinus O
+catarrh O
+( O
+P O
+less O
+than O
+0 O
+. O
+05 O
+) O
+, O
+follicular O
+hyperplasia O
+( O
+P O
+less O
+than O
+0 O
+. O
+025 O
+) O
+, O
+mixed O
+pattern O
+in O
+lymph O
+nodes O
+( O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+and O
+with O
+54 O
+years O
+of O
+age O
+or O
+younger O
+( O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+correlated O
+significantly O
+with O
+lymph O
+node O
+metastases O
+and O
+/ O
+
+or O
+high O
+histologic O
+grade O
+. O
+
+Capillary O
+tortuosity O
+was O
+a O
+function O
+of O
+sarcomere O
+length O
+in O
+all O
+animals O
+and O
+this O
+relationship O
+was O
+not O
+changed O
+by O
+hypoxia O
+. O
+
+Sox8 B
+maps O
+to O
+the O
+t B
+complex I
+on O
+mouse O
+chromosome O
+17 O
+and O
+to O
+human O
+chromosome O
+16p13 O
+. O
+3 O
+, O
+a O
+region O
+associated O
+with O
+the O
+microphthalmia O
+- O
+cataract O
+syndrome O
+CATM O
+and O
+the O
+alpha B
+- I
+thalassemia O
+/ O
+mental O
+retardation O
+syndrome O
+ATR O
+- O
+16 O
+. O
+
+Directional O
+growth O
+of O
+a O
+smectic O
+- O
+A O
+- O
+smectic O
+- O
+B O
+interface O
+lying O
+along O
+a O
+forbidden O
+orientation O
+. O
+
+The O
+TCR B
+beta I
+enhancer I
+was O
+active O
+on O
+both O
+the O
+minimal O
+simian B
+virus I
+40 I
+promoter I
+and O
+a O
+TCR B
+beta I
+variable I
+gene I
+promoter I
+in O
+both O
+TCR B
+alpha I
+/ I
+beta I
++ I
+and O
+TCR B
+gamma I
+/ I
+delta I
++ I
+T O
+cells O
+. O
+
+U O
+. O
+
+Recently O
+, O
+we O
+demonstrated O
+that O
+platelet B
+- I
+derived I
+growth I
+factor I
+( I
+PDGF I
+) I
+- I
+beta I
+receptor I
+stimulation O
+, O
+but O
+not O
+various O
+other O
+growth O
+factors O
+, O
+inhibits O
+transcription O
+of O
+alpha1D B
+- I
+, O
+but O
+not O
+alpha1A B
+- I
+or O
+alpha1B I
+- I
+ARs I
+, O
+resulting O
+in O
+reduced O
+norepinephrine O
+- O
+mediated O
+SMC O
+growth O
+. O
+
+Southern O
+blot O
+analysis O
+following O
+reverse O
+transcription O
+and O
+PCR O
+showed O
+that O
+B2R B
+is O
+expressed O
+in O
+most O
+mouse O
+tissues O
+, O
+except O
+the O
+liver O
+and O
+spleen O
+, O
+which O
+is O
+consistent O
+with O
+the O
+wide O
+distribution O
+of O
+B2R B
+activity O
+as O
+deduced O
+from O
+pharmacological O
+studies O
+. O
+
+Long O
+- O
+term O
+renal O
+function O
+in O
+on O
+- O
+heart O
+- O
+beating O
+donor O
+kidney O
+transplantation O
+: O
+a O
+single O
+- O
+center O
+experience O
+. O
+
+The O
+study O
+of O
+the O
+intensity O
+of O
+pain O
+evoked O
+by O
+heat O
+is O
+relatively O
+exhaustive O
+: O
+the O
+influence O
+of O
+various O
+local O
+, O
+stimulus O
+- O
+dependent O
+or O
+general O
+factors O
+upon O
+threshold O
+values O
+has O
+been O
+well O
+studied O
+, O
+as O
+has O
+the O
+relation O
+between O
+pain O
+and O
+stimulus O
+intensities O
+. O
+
+The O
+vaccine O
+was O
+at O
+least O
+80 O
+% O
+efficacious O
+against O
+Chlamydia O
+and O
+Campylobacter O
+spp O
+and O
+appeared O
+to O
+be O
+protective O
+. O
+
+The O
+centromeric O
+dodeca O
+- O
+satellite O
+of O
+Drosophila O
+forms O
+altered O
+DNA O
+structures O
+in O
+vitro O
+in O
+which O
+its O
+purine O
+- O
+rich O
+strand O
+( O
+G O
+- O
+strand O
+) O
+forms O
+stable O
+fold O
+- O
+back O
+structures O
+, O
+while O
+the O
+complementary O
+C O
+- O
+strand O
+remains O
+unstructured O
+. O
+
+Pneumatic O
+dilation O
+of O
+the O
+lower O
+esophageal O
+sphincter O
+was O
+accomplished O
+by O
+endoscopic O
+visualization O
+and O
+positioning O
+of O
+a O
+modified O
+polyurethane O
+dilator O
+( O
+90 O
+F O
+diameter O
+) O
+without O
+fluoroscopy O
+in O
+17 O
+consecutive O
+patients O
+with O
+advanced O
+symptomatic O
+achalasia O
+. O
+
+Mean O
+CD4 B
+percentages O
+were O
+lower O
+postpartum O
+( O
+21 O
+. O
+9 O
++ O
+/ O
+- O
+3 O
+. O
+4 O
+) O
+than O
+prepartum O
+( O
+45 O
+. O
+1 O
++ O
+/ O
+- O
+6 O
+. O
+7 O
+) O
+in O
+all O
+five O
+patients O
+studied O
+, O
+although O
+proliferative O
+responses O
+to O
+the O
+mitogens O
+phytohemagglutinin B
+and O
+pokeweed O
+were O
+unchanged O
+during O
+the O
+study O
+period O
+. O
+
+The O
+second O
+system O
+( O
+VacFix O
+) O
+uses O
+a O
+0 O
+. O
+15 O
+mm O
+thick O
+plastic O
+bag O
+loosely O
+filled O
+with O
+1 O
+mm O
+polysterol O
+spheres O
+. O
+
+Mean O
+24 O
+h O
+urinary O
+excretion O
+values O
+confirmed O
+this O
+observation O
+. O
+
+However O
+, O
+the O
+safety O
+of O
+design O
+4 O
+was O
+assured O
+as O
+long O
+as O
+all O
+patients O
+received O
+three O
+courses O
+of O
+chemotherapy O
+, O
+which O
+is O
+unusual O
+in O
+phase O
+I O
+studies O
+in O
+Japan O
+. O
+
+The O
+results O
+indicate O
+that O
+the O
+RNA O
+in O
+T7 B
+RNA I
+polymerase I
+is O
+not O
+free O
+of O
+steric O
+interactions O
+in O
+the O
+ternary O
+complex O
+and O
+not O
+available O
+for O
+structure O
+formation O
+until O
+it O
+is O
+at O
+least O
+10 O
+bases O
+away O
+from O
+the O
+site O
+of O
+polymerization O
+. O
+
+The O
+STP1 B
+locus I
+is O
+located O
+on O
+chromosome O
+IV O
+close O
+to O
+at O
+least O
+two O
+other O
+genes O
+involved O
+in O
+RNA O
+splicing O
+: O
+PRP3 B
+and O
+SPP41 B
+. O
+
+An O
+ICU O
+length O
+of O
+stay O
+shorter O
+than O
+24 O
+h O
+was O
+not O
+related O
+to O
+the O
+frequency O
+of O
+group O
+C O
+errors O
+. O
+
+In O
+vitro O
+, O
+SHIP B
+catalyzes O
+the O
+conversion O
+of O
+the O
+phosphoinositide B
+3 I
+- I
+kinase I
+( O
+PI3K B
+) O
+product O
+phosphatidylinositol O
+3 O
+, O
+4 O
+, O
+5 O
+- O
+trisphosphate O
+( O
+PIP3 O
+) O
+into O
+phosphatidylinositol O
+3 O
+, O
+4 O
+- O
+bisphosphate O
+. O
+
+Like O
+pimethixene O
+and O
+cyproheptadine O
+, O
+WA O
+335 O
+has O
+no O
+distinct O
+antagonistic O
+qualities O
+against O
+bradykinin B
+. O
+
+To O
+confirm O
+the O
+data O
+obtained O
+using O
+the O
+HPLC O
+- O
+ESI O
+- O
+MS O
+procedure O
+, O
+fractions O
+of O
+the O
+glycosides O
+from O
+four O
+berries O
+were O
+separated O
+, O
+hydrolyzed O
+, O
+silylated O
+and O
+the O
+sugars O
+were O
+analyzed O
+using O
+gas O
+chromatography O
+- O
+mass O
+spectrometry O
+. O
+
+This O
+clone O
+will O
+be O
+useful O
+for O
+identifying O
+the O
+genetic O
+determinants O
+of O
+FIV O
+- O
+Oma B
+' O
+s O
+biological O
+activities O
+. O
+
+The O
+WEB2 B
+gene I
+encodes O
+a O
+1 O
+, O
+522 O
+- O
+amino O
+- O
+acid O
+protein O
+with O
+homology O
+to O
+nucleic B
+acid I
+- I
+dependent I
+ATPases I
+. O
+
+Evidence O
+that O
+the O
+AT1A B
+receptor I
+activates O
+transcription O
+factor O
+- O
+Stat91 B
+and O
+/ O
+or O
+a O
+related O
+protein O
+. O
+
+There O
+was O
+91 O
+% O
+concordance O
+between O
+ST O
+- O
+RD O
+/ O
+RI O
+/ O
+LRD O
+201Tl O
+and O
+R O
+- O
+ST O
+/ O
+N O
++ O
+Inf O
+99Tcm O
+- O
+tetrofosmin O
+imaging O
+regarding O
+reversibility O
+. O
+
+The O
+two O
+complexes O
+were O
+detected O
+with O
+a O
+similar O
+activation O
+kinetics O
+upon O
+IL B
+- I
+4 I
+stimulation O
+. O
+
+These O
+results O
+suggest O
+that O
+dauricine O
+and O
+verapamil O
+have O
+a O
+salutary O
+effect O
+in O
+extracorporeal O
+circulation O
+. O
+
+These O
+results O
+demonstrate O
+the O
+preferential O
+endometrial O
+cell O
+- O
+type O
+expression O
+of O
+BTEB B
+and O
+suggest O
+its O
+regulatory O
+role O
+in O
+pregnancy O
+- O
+associated O
+endometrial O
+epithelial O
+gene O
+expression O
+. O
+
+Spen B
+is O
+the O
+only O
+known O
+homeotic B
+protein I
+with O
+RNP O
+binding O
+motifs O
+, O
+which O
+indicates O
+that O
+splicing O
+, O
+transport O
+, O
+or O
+other O
+RNA O
+regulatory O
+steps O
+are O
+involved O
+in O
+the O
+diversification O
+of O
+segmental O
+morphology O
+. O
+
+Long O
+- O
+term O
+follow O
+- O
+up O
+of O
+kidney O
+donors O
+: O
+a O
+longitudinal O
+study O
+. O
+
+Recent O
+research O
+on O
+lipolysis O
+. O
+
+CONCLUSIONS O
+: O
+The O
+present O
+study O
+showed O
+it O
+is O
+possible O
+to O
+use O
+a O
+modified O
+Stroop O
+task O
+as O
+a O
+measure O
+of O
+implicit O
+processing O
+of O
+alcohol O
+stimuli O
+. O
+
+Six O
+patients O
+( O
+24 O
+% O
+) O
+developed O
+sepsis O
+and O
+only O
+one O
+survived O
+. O
+
+None O
+of O
+the O
+10 O
+sequences O
+has O
+hitherto O
+been O
+recognized O
+as O
+part O
+of O
+the O
+p53 B
+signaling O
+pathway O
+. O
+
+The O
+Prompt O
+and O
+Praise O
+condition O
+was O
+superior O
+to O
+the O
+other O
+two O
+conditions O
+in O
+encouraging O
+participation O
+in O
+low O
+- O
+interest O
+recreational O
+activities O
+. O
+
+The O
+majority O
+of O
+the O
+human B
+Ig I
+heavy I
+chain I
+( I
+IgH I
+) O
+constant B
+( I
+C I
+) I
+region I
+locus O
+has O
+been O
+cloned O
+and O
+mapped O
+. O
+
+A O
+. O
+
+We O
+analyzed O
+right O
+ventricular O
+size O
+and O
+function O
+and O
+201Tl O
+uptake O
+to O
+determine O
+if O
+there O
+was O
+a O
+relationship O
+between O
+201Tl O
+uptake O
+and O
+systolic O
+function O
+in O
+19 O
+patients O
+with O
+pulmonary O
+artery O
+hypertension O
+who O
+were O
+being O
+evaluated O
+for O
+heart O
+- O
+lung O
+transplantation O
+. O
+
+The O
+transcriptional O
+start O
+site O
+( O
+s O
+) O
+of O
+the O
+IA B
+- I
+2 I
+gene I
+was O
+mapped O
+by O
+5 O
+' O
+rapid O
+amplification O
+of O
+cDNA O
+ends O
+to O
+97 O
+bp O
+upstream O
+of O
+the O
+translational O
+start O
+site O
+. O
+
+The O
+RAG B
+- I
+2 I
+gene I
+encodes O
+a O
+component O
+of O
+the O
+V B
+( I
+D I
+) I
+J I
+recombinase I
+which O
+is O
+essential O
+for O
+the O
+assembly O
+of O
+antigen O
+receptor O
+genes O
+in O
+B O
+and O
+T O
+lymphocytes O
+. O
+
+The O
+lamina O
+densa O
+was O
+always O
+interrupted O
+by O
+numerous O
+small O
+gaps O
+and O
+in O
+some O
+areas O
+the O
+basement O
+membrane O
+could O
+not O
+be O
+identified O
+over O
+a O
+long O
+distance O
+. O
+
+We O
+have O
+characterized O
+21 O
+mutations O
+in O
+the O
+type B
+VII I
+collagen I
+gene I
+( O
+COL7A1 B
+) O
+encoding O
+the O
+anchoring O
+fibrils O
+, O
+18 O
+of O
+which O
+were O
+not O
+previously O
+reported O
+, O
+in O
+patients O
+from O
+15 O
+unrelated O
+families O
+with O
+recessive O
+dystrophic O
+epidermolysis O
+bullosa O
+( O
+RDEB O
+) O
+. O
+
+The O
+data O
+when O
+used O
+to O
+stimulate O
+the O
+collection O
+of O
+the O
+information O
+at O
+antenatal O
+or O
+postnatal O
+visits O
+, O
+nonetheless O
+provide O
+an O
+accurate O
+description O
+of O
+under O
+- O
+3 O
+mortality O
+trends O
+and O
+differences O
+for O
+the O
+two O
+periods O
+examined O
+- O
+- O
+before O
+1984 O
+and O
+before O
+1989 O
+. O
+
+Both O
+residues O
+are O
+conserved O
+in O
+the O
+three O
+phosphorylated O
+paralogs O
+but O
+are O
+absent O
+in O
+the O
+ones O
+that O
+were O
+not O
+substrates O
+of O
+RsbT B
+: O
+YetI B
+and O
+YezB B
+, O
+each O
+of O
+which O
+bears O
+only O
+one O
+of O
+the O
+conserved O
+residues O
+; O
+and O
+YtvA B
+, O
+which O
+lacks O
+both O
+residues O
+and O
+instead O
+possesses O
+an O
+N O
+- O
+terminal O
+PAS B
+domain O
+. O
+
+There O
+is O
+a O
+good O
+correlation O
+between O
+the O
+occurrence O
+in O
+any O
+particular O
+vascular O
+segment O
+of O
+the O
+transient O
+contractile O
+response O
+and O
+intrinsic O
+tone O
+as O
+assessed O
+by O
+relaxation O
+to O
+papaverine O
+( O
+10 O
+( O
+- O
+6 O
+) O
+M O
+) O
+. O
+
+Both O
+atracurium O
+1 O
+- O
+100 O
+mumol O
+litre O
+- O
+1 O
+and O
+laudanosine O
+1 O
+- O
+50 O
+mumol O
+litre O
+- O
+1 O
+enhanced O
+the O
+release O
+of O
+3H O
+- O
+NA O
+evoked O
+by O
+field O
+stimulation O
+( O
+2 O
+Hz O
+, O
+24 O
+stimuli O
+) O
+, O
+but O
+did O
+not O
+affect O
+resting O
+release O
+. O
+
+S16 O
+, O
+16 O
+. O
+8 O
+% O
+, O
+P O
+= O
+0 O
+. O
+001 O
+) O
+. O
+
+The O
+Zn B
+- I
+15 I
+DNA I
+- I
+binding I
+domain I
+comprises O
+three O
+zinc O
+fingers O
+separated O
+by O
+unusually O
+long O
+linker O
+sequences O
+that O
+would O
+be O
+expected O
+to O
+interrupt O
+specific O
+DNA O
+site O
+recognition O
+. O
+
+Replication O
+regions O
+from O
+plant O
+- O
+pathogenic O
+Pseudomonas O
+syringae O
+plasmids O
+are O
+similar O
+to O
+ColE2 O
+- O
+related O
+replicons O
+. O
+
+There O
+has O
+been O
+no O
+significant O
+toxicity O
+associated O
+with O
+repeated O
+5 O
+- O
+FU O
+instillation O
+into O
+the O
+airway O
+. O
+
+Twenty O
+male O
+volunteers O
+were O
+studied O
+during O
+almokalant O
+infusion O
+aiming O
+at O
+plasma O
+concentrations O
+( O
+Cpl O
+) O
+of O
+20 O
+, O
+50 O
+, O
+100 O
+, O
+and O
+150 O
+nmol O
+/ O
+l O
+. O
+
+Consistently O
+, O
+we O
+show O
+that O
+phosphorylation O
+by O
+protein B
+kinase I
+A I
+inhibits O
+Sfl1 B
+DNA O
+binding O
+in O
+vitro O
+, O
+and O
+that O
+a O
+tpk2Delta B
+mutation I
+increases O
+the O
+levels O
+of O
+Sfl1 B
+protein I
+associated O
+with O
+specific O
+promoter O
+elements O
+in O
+vivo O
+. O
+
+The O
+response O
+sequences O
+were O
+localized O
+between O
+- O
+67 O
+and O
++ O
+30 O
+in O
+the O
+simian B
+cytomegalovirus I
+IE94 I
+promoter I
+and O
+upstream O
+of O
+position O
++ O
+9 O
+in O
+the O
+HCMV B
+IE68 I
+promoter I
+. O
+
+Some O
+CHOP B
+- O
+C B
+/ I
+EBP I
+heterodimers O
+apparently O
+bind O
+to O
+alternative O
+DNA O
+sequence O
+and O
+thereby O
+regulate O
+the O
+transcription O
+of O
+other O
+genes O
+. O
+
+To O
+identify O
+and O
+determine O
+the O
+function O
+of O
+Ino2p B
+in O
+yeast O
+cells O
+, O
+we O
+raised O
+antibodies O
+to O
+a O
+beta B
+- I
+galactosidase I
+/ O
+Ino2 B
+fusion O
+protein O
+. O
+
+Northern O
+blot O
+analyses O
+were O
+used O
+to O
+examine O
+the O
+regulated O
+expression O
+of O
+the O
+cys B
+- I
+14 I
++ I
+gene I
+. O
+
+Typicality O
+is O
+probably O
+a O
+better O
+representation O
+of O
+Alexander O
+, O
+Dunbar O
+and O
+others O
+' O
+conclusions O
+than O
+specificity O
+, O
+which O
+was O
+always O
+too O
+absolute O
+a O
+term O
+. O
+
+Additions O
+of O
+NH4 O
++ O
+up O
+to O
+200 O
+micrograms O
+1 O
+( O
+- O
+1 O
+) O
+were O
+not O
+stimulatory O
+, O
+whereas O
+at O
+1 O
+. O
+0 O
+mg O
+1 O
+( O
+- O
+1 O
+) O
+levels O
+, O
+Ke O
+was O
+50 O
+% O
+greater O
+than O
+for O
+NO3 O
+- O
+enriched O
+medium O
+. O
+
+Cardiovascular O
+drug O
+use O
+and O
+hospitalizations O
+attributable O
+to O
+type O
+2 O
+diabetes O
+. O
+
+The O
+arrangement O
+of O
+amino O
+acids O
+in O
+the O
+helix O
+1 O
+and O
+helix O
+2 O
+regions O
+is O
+quite O
+similar O
+to O
+those O
+of O
+Mxi B
+and O
+Mad B
+, O
+but O
+different O
+from O
+those O
+of O
+E2F B
+- I
+1 I
+and O
+DP B
+- I
+1 I
+. O
+
+They O
+contain O
+a O
+large O
+( O
+0 O
+. O
+9 O
+X O
+10 O
+( O
+3 O
+) O
+to O
+1 O
+. O
+88 O
+X O
+10 O
+( O
+3 O
+) O
+base O
+- O
+pairs O
+) O
+intron O
+in O
+the O
+middle O
+of O
+the O
+gene O
+and O
+are O
+further O
+interrupted O
+close O
+to O
+the O
+5 O
+' O
+end O
+of O
+the O
+gene O
+. O
+
+The O
+present O
+study O
+also O
+emphasizes O
+the O
+need O
+of O
+establishing O
+dose O
+- O
+response O
+curves O
+to O
+correctly O
+assess O
+the O
+relative O
+contribution O
+of O
+the O
+different O
+regions O
+of O
+steroid B
+hormone I
+receptors I
+in O
+activation O
+of O
+transcription O
+. O
+
+Routine O
+and O
+default O
+retrieval O
+home O
+visits O
+were O
+given O
+to O
+ensure O
+maximal O
+drug O
+compliance O
+. O
+
+D O
+. O
+, O
+and O
+Long O
+, O
+C O
+. O
+
+By O
+contrast O
+with O
+ama B
+- I
+1 I
+, O
+rpc B
+- I
+1 I
+was O
+not O
+deleted O
+by O
+mDf4 B
+or O
+larger O
+deficiencies O
+examined O
+, O
+indicating O
+that O
+these O
+genes O
+are O
+no O
+closer O
+than O
+150 O
+kb O
+. O
+
+Accordingly O
+, O
+constitutive O
+downregulation O
+of O
+expression O
+of O
+accessory O
+molecules O
+of O
+the O
+MHC B
+class I
+I I
+pathway O
+can O
+reveal O
+differences O
+between O
+H2 B
+class I
+I I
+alleles I
+in O
+antigen O
+presentation O
+not O
+encountered O
+when O
+the O
+expression O
+levels O
+are O
+augmented O
+. O
+
+Anovulatory O
+cycles O
+with O
+an O
+apparently O
+normal O
+level O
+of O
+blood B
+prolactin I
+. O
+
+Legionella O
+antibodies O
+in O
+domestic O
+animals O
+
+By O
+differential O
+screening O
+of O
+a O
+Xenopus O
+laevis O
+egg O
+cDNA O
+library O
+, O
+we O
+have O
+isolated O
+a O
+2 O
+, O
+111 O
+bp O
+cDNA O
+which O
+corresponds O
+to O
+a O
+maternal O
+mRNA O
+specifically O
+deadenylated O
+after O
+fertilisation O
+. O
+
+Similar O
+immunological O
+disturbances O
+were O
+observed O
+in O
+SCI O
+but O
+not O
+in O
+the O
+PC2 O
+subgroup O
+, O
+i O
+. O
+e O
+. O
+patients O
+examined O
+later O
+than O
+6 O
+months O
+after O
+injury O
+. O
+
+This O
+study O
+demonstrates O
+that O
+Fluosol O
+significantly O
+attenuates O
+neutrophil O
+adherence O
+, O
+cytotoxicity O
+, O
+and O
+enzyme O
+release O
+in O
+an O
+in O
+vitro O
+model O
+of O
+microvascular O
+injury O
+. O
+
+Using O
+the O
+same O
+electrical O
+analog O
+, O
+we O
+present O
+an O
+analysis O
+that O
+allows O
+calculation O
+of O
+these O
+parameters O
+, O
+as O
+well O
+as O
+the O
+corner O
+frequency O
+of O
+the O
+network O
+( O
+f1 O
+) O
+, O
+without O
+need O
+for O
+similar O
+assumptions O
+. O
+
+We O
+further O
+examined O
+the O
+interaction O
+of O
+JAK2 B
+with O
+the O
+GHR B
+cytoplasmic I
+domain I
+by O
+two O
+lines O
+of O
+investigation O
+. O
+
+These O
+p21 B
+- O
+E2F B
+complexes O
+, O
+while O
+present O
+in O
+young O
+G1 O
+cells O
+at O
+very O
+low O
+levels O
+, O
+were O
+elevated O
+in O
+senescent O
+cells O
+. O
+
+There O
+is O
+little O
+similarity O
+among O
+the O
+sequences O
+upstream O
+from O
+the O
+CAP O
+site O
+of O
+the O
+Spec2 B
+genes I
+except O
+the O
+TATA O
+consensus O
+sequence O
+and O
+a O
+repeating O
+trinucleotide O
+, O
+AAC O
+. O
+
+Thus O
+, O
+d O
+- O
+delta3 O
+- O
+carene O
+was O
+about O
+four O
+times O
+more O
+potent O
+as O
+a O
+sensory O
+irritant O
+than O
+I O
+- O
+beta O
+- O
+pinene O
+, O
+whereas O
+the O
+difference O
+with O
+I O
+- O
+alpha O
+- O
+pinene O
+was O
+more O
+marked O
+; O
+as O
+a O
+sensory O
+irritant O
+, O
+I O
+- O
+alpha O
+- O
+pinene O
+is O
+almost O
+inactive O
+. O
+
+The O
+reconstituted O
+RNA B
+polymerases I
+containing O
+the O
+mutant O
+alpha O
+subunits O
+were O
+examined O
+for O
+their O
+response O
+to O
+transcription O
+activation O
+by O
+cAMP B
+- I
+CRP I
+and O
+the O
+rrnBP1 B
+UP I
+element I
+. O
+
+The O
+study O
+drugs O
+( O
+combination O
+vinblastine O
+- O
+CCNU O
+and O
+single O
+- O
+agent O
+triazinate O
+or O
+dactinomycin O
+) O
+failed O
+to O
+provide O
+any O
+meaningful O
+antitumor O
+activity O
+for O
+these O
+patients O
+with O
+advanced O
+renal O
+cell O
+cancer O
+. O
+
+Our O
+results O
+indicate O
+that O
+GCN4 B
+contains O
+two O
+activation O
+domains O
+of O
+similar O
+potency O
+that O
+can O
+function O
+independently O
+to O
+promote O
+high O
+- O
+level O
+transcription O
+of O
+the O
+target O
+genes O
+HIS3 B
+and O
+HIS4 B
+. O
+
+Those O
+diagnosed O
+as O
+having O
+affective O
+disorder O
+( O
+n O
+= O
+96 O
+) O
+, O
+according O
+to O
+DSM O
+- O
+IIIR O
+criteria O
+, O
+were O
+compared O
+with O
+the O
+other O
+non O
+- O
+affective O
+suicide O
+attempters O
+( O
+n O
+= O
+161 O
+) O
+. O
+
+Tax B
+was O
+demonstrated O
+to O
+interact O
+directly O
+with O
+CREB1 B
+but O
+not O
+with O
+other O
+bZIP B
+proteins I
+, O
+including O
+CREB2 B
+and O
+Jun B
+. O
+
+Anxiogenic O
+effects O
+of O
+pentagastrin O
+in O
+patients O
+with O
+social O
+phobia O
+and O
+healthy O
+controls O
+. O
+
+Ischaemia O
+and O
+reperfusion O
+injury O
+in O
+the O
+kidney O
+: O
+current O
+status O
+and O
+future O
+direction O
+. O
+
+Non O
+- O
+dialyzable O
+transfer B
+factor I
+
+We O
+also O
+demonstrate O
+that O
+a O
+p110RB1 B
+mutant I
+, O
+which O
+is O
+refractory O
+to O
+cell O
+cycle O
+phosphorylation O
+but O
+intact O
+in O
+E1a B
+/ O
+large B
+T I
+antigen I
+- O
+binding O
+properties O
+, O
+represses O
+EIIaE B
+with O
+50 O
+- O
+to O
+80 O
+- O
+fold O
+greater O
+efficiency O
+than O
+wild B
+- I
+type I
+p110RB1 I
+. O
+
+Subgroup O
+analysis O
+failed O
+to O
+show O
+any O
+benefit O
+for O
+etoposide O
+in O
+patients O
+with O
+monocytic O
+or O
+myelomonocytic O
+disease O
+, O
+or O
+in O
+any O
+other O
+diagnostic O
+subgroup O
+. O
+
+The O
+IGFBP B
+- I
+1 I
+IRS B
+and O
+PEPCK B
+IRS I
+both O
+bind O
+the O
+alpha O
+and O
+beta O
+forms O
+of O
+hepatic B
+nuclear I
+factor I
+3 I
+( O
+HNF B
+- I
+3 I
+) O
+, O
+although O
+the O
+latter O
+does O
+so O
+with O
+a O
+sixfold O
+- O
+lower O
+relative O
+affinity O
+. O
+
+Polyglutamine O
+- O
+containing O
+protein O
+fragments O
+have O
+been O
+shown O
+to O
+accumulate O
+as O
+aggregates O
+in O
+the O
+nucleus O
+and O
+in O
+the O
+cytoplasm O
+, O
+and O
+to O
+induce O
+cell O
+death O
+when O
+expressed O
+in O
+cultured O
+cells O
+, O
+leading O
+to O
+the O
+proposal O
+that O
+polyglutamine O
+aggregation O
+is O
+an O
+important O
+step O
+in O
+the O
+pathogenesis O
+. O
+
+It O
+is O
+suggested O
+that O
+on O
+presentation O
+of O
+tail O
+tip O
+necrosis O
+in O
+kittens O
+a O
+diagnosis O
+of O
+neonatal O
+isoerythrolysis O
+or O
+isoagglutination O
+should O
+be O
+considered O
+. O
+
+Microscopically O
+, O
+cartilage O
+showed O
+markedly O
+stunted O
+and O
+disorganized O
+endochondral O
+ossification O
+. O
+
+Our O
+data O
+provide O
+the O
+first O
+evidence O
+that O
+differential O
+splicing O
+in O
+the O
+extracellular O
+region O
+of O
+a O
+receptor O
+gene O
+generates O
+receptor O
+variants O
+with O
+different O
+ligand O
+- O
+binding O
+specificities O
+. O
+
+Sucrose O
+- O
+specific O
+signalling O
+represses O
+translation O
+of O
+the O
+Arabidopsis B
+ATB2 I
+bZIP I
+transcription I
+factor I
+gene I
+. O
+
+Wolf O
+- O
+Hirschhorn O
+syndrome O
+( O
+WHS O
+) O
+is O
+a O
+malformation O
+syndrome O
+associated O
+with O
+a O
+hemizygous O
+deletion O
+of O
+the O
+distal O
+short O
+arm O
+of O
+chromosome O
+4 O
+( O
+4p16 O
+. O
+3 O
+) O
+. O
+
+Our O
+aim O
+was O
+to O
+check O
+whether O
+, O
+during O
+PG O
+- O
+DS O
+administration O
+, O
+serum B
+lipase I
+activity O
+changes O
+simultaneously O
+with O
+serum B
+amylase I
+activity O
+, O
+and O
+, O
+if O
+so O
+, O
+what O
+the O
+reason O
+is O
+for O
+the O
+detected O
+change O
+. O
+
+A O
+long O
+- O
+term O
+follow O
+- O
+up O
+study O
+of O
+a O
+children O
+' O
+s O
+psychiatric O
+day O
+treatment O
+center O
+. O
+
+Sequencing O
+and O
+restriction O
+enzyme O
+analysis O
+demonstrated O
+that O
+this O
+single O
+- O
+copy O
+gene O
+contains O
+11 O
+exons O
+and O
+spans O
+9596 O
+base O
+pairs O
+. O
+
+In O
+phase O
+II O
+studies O
+, O
+MDL O
+72 O
+, O
+974A O
+is O
+proving O
+to O
+be O
+a O
+useful O
+adjunct O
+to O
+conventional O
+therapy O
+. O
+
+However O
+, O
+no O
+consensus O
+on O
+indications O
+exists O
+and O
+, O
+according O
+to O
+the O
+literature O
+, O
+results O
+are O
+contradictory O
+. O
+
+The O
+effect O
+of O
+the O
+NMDA B
+- I
+receptor I
+antagonist O
+( O
++ O
+/ O
+- O
+) O
+- O
+CPP O
+on O
+the O
+conditioned O
+- O
+reflex O
+activation O
+of O
+an O
+operant O
+reaction O
+in O
+the O
+brain O
+electrical O
+self O
+- O
+stimulation O
+test O
+in O
+rats O
+
+Within O
+any O
+cell O
+line O
+, O
+several O
+Tcfs B
+and O
+TLEs B
+are O
+co O
+- O
+expressed O
+. O
+
+Constructs O
+containing O
+fragments O
+of O
+the O
+upstream O
+region O
+of O
+the O
+cytotactin B
+gene I
+fused O
+to O
+a O
+promoterless O
+gene O
+for O
+chloramphenicol B
+acetyltransferase I
+were O
+transiently O
+transfected O
+into O
+chicken O
+embryo O
+fibroblasts O
+to O
+define O
+functional O
+promoter O
+sequences O
+. O
+
+We O
+investigated O
+the O
+pattern O
+of O
+evolution O
+of O
+bronchial B
+albumin I
+, O
+IgA B
+, O
+and O
+IgG B
+levels O
+in O
+ventilated O
+ICU O
+patients O
+in O
+relation O
+to O
+nosocomial O
+pneumonia O
+. O
+
+Mortality O
+among O
+patients O
+with O
+CAVB O
+is O
+still O
+high O
+and O
+has O
+not O
+declined O
+within O
+the O
+last O
+decade O
+. O
+
+Mutations O
+away O
+from O
+splice O
+site O
+recognition O
+sequences O
+might O
+cis O
+- O
+modulate O
+alternative O
+splicing O
+of O
+goat B
+alpha I
+s1 I
+- I
+casein I
+transcripts I
+. O
+
+SETTING O
+: O
+A O
+private O
+office O
+- O
+based O
+fertility O
+program O
+. O
+
+Promoter O
+, O
+spliced O
+leader O
+, O
+and O
+coding O
+sequence O
+for O
+BICP4 B
+, O
+the O
+largest O
+of O
+the O
+immediate B
+- I
+early I
+proteins I
+of I
+bovine I
+herpesvirus I
+1 O
+. O
+
+The O
+limb O
+defects O
+, O
+oligodactyly O
+and O
+syndactyly O
+, O
+have O
+been O
+traced O
+to O
+improper O
+differentiation O
+of O
+the O
+apical O
+ectodermal O
+ridge O
+( O
+AER O
+) O
+and O
+shortening O
+of O
+the O
+anteroposterior O
+limb O
+axis O
+. O
+
+Our O
+data O
+suggest O
+that O
+the O
+ZF B
+- O
+HD B
+class O
+of O
+homeodomain B
+proteins I
+may O
+be O
+involved O
+in O
+the O
+establishment O
+of O
+the O
+characteristic O
+expression O
+pattern O
+of O
+the O
+C4 B
+PEPCase I
+gene I
+. O
+
+There O
+was O
+no O
+correlation O
+between O
+starting O
+platelet B
+- I
+associated I
+IgG I
+levels O
+or O
+changes O
+in O
+platelet B
+- I
+associated I
+IgG I
+levels O
+with O
+therapy O
+and O
+the O
+increment O
+in O
+the O
+patient O
+' O
+s O
+platelet O
+count O
+. O
+
+We O
+investigated O
+whether O
+two O
+WT1 B
+splice I
+variants I
+lacking O
+or O
+including O
+a O
+three O
+- O
+amino O
+- O
+acid O
+( O
+KTS O
+) O
+insertion O
+between O
+the O
+third O
+and O
+fourth O
+zinc O
+finger O
+in O
+the O
+DNA O
+- O
+binding O
+domain O
+could O
+repress O
+the O
+IR B
+promoter I
+in O
+vitro O
+. O
+
+An O
+oligomer O
+synthesized O
+to O
+this O
+region O
+of O
+homology O
+produced O
+two O
+DNA O
+- O
+protein O
+complexes O
+with O
+oviduct O
+nuclear O
+proteins O
+. O
+
+The O
+deduced O
+amino O
+acid O
+sequence O
+exhibits O
+95 O
+. O
+3 O
+and O
+76 O
+. O
+1 O
+% O
+identity O
+with O
+the O
+CAD B
+sequences I
+of I
+hamster I
+and I
+Squalus I
+acanthias I
+. O
+
+In O
+contrast O
+translocation O
+of O
+G1 B
+to O
+the O
+Golgi O
+was O
+not O
+observed O
+when O
+G1 B
+was O
+coexpressed O
+with O
+NSm B
+, O
+although O
+NSm B
+itself O
+was O
+still O
+detected O
+in O
+the O
+Golgi O
+. O
+
+Since O
+simian B
+virus I
+40 I
+( I
+SV40 I
+) I
+large I
+T I
+antigen I
+and O
+human B
+papillomavirus I
+type I
+16 I
+( I
+HPV16 I
+) I
+E7 I
+protein I
+also O
+bind O
+host O
+regulatory O
+factors O
+, O
+we O
+investigated O
+whether O
+these O
+viral O
+proteins O
+can O
+complement O
+E1A B
+mutants I
+which O
+are O
+defective O
+in O
+early B
+gene I
+activation O
+. O
+
+We O
+further O
+showed O
+a O
+significant O
+repression O
+of O
+promoter O
+activity O
+( O
+> O
+40 O
+fold O
+) O
+by O
+E2 B
+- I
+2 I
+( O
+lacking O
+the O
+amino O
+acid O
+sequence O
+RSRS O
+) O
+when O
+the O
+E47 B
+reporter I
+construct I
+, O
+containing O
+a O
+hexameric O
+E O
+- O
+box O
+site O
+, O
+was O
+used O
+. O
+
+Similar O
+observations O
+were O
+obtained O
+when O
+these O
+mutated O
+versions O
+of O
+site O
+A O
+were O
+evaluated O
+by O
+transient O
+cotransfection O
+assays O
+in O
+CV1 O
+cells O
+. O
+
+The O
+shear O
+bond O
+strength O
+recorded O
+for O
+the O
+Novabond O
+system O
+was O
+significantly O
+lower O
+( O
+17 O
+MPa O
+) O
+. O
+
+A O
+400 O
+- O
+bp O
+fragment O
+( O
+bp O
+- O
+339 O
+through O
++ O
+71 O
+) O
+of O
+the O
+CD22 B
+promoter I
+region I
+was O
+subcloned O
+into O
+a O
+pGEM O
+- O
+chloramphenicol B
+acetyltransferase I
+vector O
+and O
+after O
+transfection O
+into O
+B O
+and O
+T O
+cells O
+was O
+found O
+to O
+be O
+active O
+in O
+both O
+B O
+and O
+T O
+cells O
+. O
+
+RESULTS O
+: O
+There O
+were O
+no O
+significant O
+differences O
+in O
+the O
+mean O
+serum O
+vitamin O
+A O
+, O
+E O
+concentrations O
+and O
+vitamin O
+E O
+/ O
+cholesterol O
+ratio O
+between O
+pregnant O
+women O
+with O
+normal O
+hemoglobin B
+and O
+hemoglobinopathies B
+, O
+while O
+confounding O
+variables O
+that O
+might O
+affect O
+serum O
+vitamin O
+levels O
+i O
+. O
+e O
+. O
+maternal O
+age O
+, O
+gravida O
+, O
+BMI O
+, O
+gestational O
+age O
+, O
+hematocrit O
+, O
+hemoglobin B
+, O
+mean O
+corpuscular B
+hemoglobin I
+concentration O
+and O
+blood O
+group O
+were O
+not O
+different O
+. O
+
+Fourteen O
+samples O
+, O
+seven O
+each O
+of O
+IR64 O
+and O
+IR66 O
+were O
+studied O
+with O
+regard O
+to O
+moisture O
+content O
+, O
+germination O
+test O
+, O
+abnormal O
+seedlings O
+, O
+speed O
+of O
+germination O
+, O
+conductance O
+of O
+leachates O
+, O
+total O
+dehydrogenase O
+activity O
+, O
+total O
+free O
+amino O
+acids O
+, O
+total O
+soluble O
+sugar O
+, O
+fat O
+acidity O
+, O
+gelatinization O
+temperature O
+, O
+gel O
+consistency O
+, O
+amylose O
+content O
+, O
+translucency O
+, O
+and O
+per O
+cent O
+whiteness O
+. O
+
+Electrophoretic O
+mobility O
+- O
+shift O
+assays O
+between O
+viral O
+RNA O
+and O
+BMV B
+CP I
+peptides I
+with O
+either O
+proline O
+or O
+alanine O
+substitutions O
+revealed O
+that O
+the O
+interaction O
+is O
+nonspecific O
+. O
+
+Thus O
+, O
+over O
+a O
+wide O
+range O
+of O
+arterial O
+dimensions O
+, O
+results O
+obtained O
+with O
+caliper O
+estimates O
+of O
+luminal O
+area O
+and O
+diameter O
+are O
+comparable O
+to O
+those O
+obtained O
+with O
+videodensitometry O
+using O
+the O
+XR O
+- O
+70 O
+system O
+. O
+
+CONCLUSIONS O
+: O
+Neurodevelopmental O
+assessment O
+at O
+1 O
+year O
+is O
+predictive O
+of O
+school O
+performance O
+and O
+outcome O
+in O
+the O
+adolescent O
+period O
+. O
+
+We O
+reviewed O
+the O
+different O
+published O
+cases O
+of O
+acute O
+high O
+dose O
+methotrexate O
+neurotoxicity O
+and O
+the O
+different O
+underlying O
+mechanisms O
+. O
+
+Drug O
+therapy O
+of O
+AAPMC O
+is O
+directed O
+at O
+reducing O
+the O
+amount O
+of O
+Cl O
+. O
+difficile O
+in O
+the O
+colon O
+and O
+promoting O
+normalization O
+of O
+intestinal O
+flora O
+. O
+
+The O
+yield O
+of O
+endocervical O
+cells O
+and O
+the O
+incidence O
+of O
+dysplasia O
+was O
+determined O
+for O
+both O
+the O
+prenatal O
+and O
+the O
+postpartum O
+Pap O
+smears O
+performed O
+for O
+this O
+group O
+of O
+patients O
+. O
+
+No O
+significant O
+difference O
+in O
+plasma O
+ET B
+levels O
+was O
+found O
+between O
+cardiac O
+and O
+peripheral O
+sampling O
+sites O
+( O
+pulmonary O
+artery O
+; O
+1 O
+. O
+07 O
++ O
+/ O
+- O
+0 O
+. O
+28 O
+, O
+right O
+atrium O
+; O
+1 O
+. O
+02 O
++ O
+/ O
+- O
+0 O
+. O
+28 O
+, O
+peripheral O
+artery O
+; O
+1 O
+. O
+12 O
++ O
+/ O
+- O
+0 O
+. O
+23 O
+, O
+peripheral O
+vein O
+; O
+1 O
+. O
+14 O
++ O
+/ O
+- O
+0 O
+. O
+38 O
+fmol O
+/ O
+ml O
+: O
+N O
+. O
+S O
+. O
+) O
+, O
+or O
+among O
+patients O
+with O
+uncomplicated O
+MI O
+, O
+unstable O
+angina O
+( O
+1 O
+. O
+00 O
++ O
+/ O
+- O
+0 O
+. O
+32 O
+fmol O
+/ O
+ml O
+) O
+, O
+and O
+healthy O
+subjects O
+( O
+1 O
+. O
+01 O
++ O
+/ O
+- O
+0 O
+. O
+29 O
+
+fmol O
+/ O
+ml O
+) O
+. O
+
+Dose O
+- O
+dependent O
+pharmacokinetics O
+: O
+emphasis O
+on O
+phase O
+I O
+metabolism O
+. O
+
+Inhibition O
+of O
+DNA B
+topoisomerase I
+II I
+alpha I
+gene I
+expression O
+by O
+the O
+p53 B
+tumor O
+suppressor O
+. O
+
+Activation O
+of O
+HIV O
+gene O
+expression O
+by O
+UV O
+must O
+therefore O
+involve O
+additional O
+cellular O
+processes O
+, O
+such O
+as O
+those O
+triggered O
+by O
+DNA O
+damage O
+, O
+for O
+generation O
+of O
+a O
+full O
+gene O
+expression O
+response O
+. O
+
+4 O
+. O
+
+Microsporum O
+persicolor O
+, O
+an O
+easily O
+misinterpreted O
+dermatophyt O
+
+We O
+propose O
+that O
+, O
+while O
+Y O
+. O
+lipolytica O
+CEN O
+DNA O
+is O
+essential O
+for O
+plasmid O
+maintenance O
+, O
+this O
+function O
+can O
+be O
+supplied O
+by O
+several O
+sub O
+- O
+fragments O
+which O
+, O
+together O
+, O
+form O
+the O
+active O
+chromosomal O
+centromere O
+. O
+
+In O
+this O
+second O
+clinical O
+paper O
+, O
+the O
+genetic O
+features O
+of O
+the O
+case O
+of O
+microphthalmia O
+in O
+sheep O
+reported O
+by O
+Wagenaar O
+is O
+discussed O
+in O
+greater O
+detail O
+. O
+
+Our O
+study O
+reveals O
+a O
+consequence O
+of O
+adhesion O
+receptor O
+- O
+mediated O
+signaling O
+in O
+T O
+cells O
+, O
+which O
+is O
+potentially O
+important O
+in O
+the O
+regulation O
+of O
+T O
+cell O
+activation O
+, O
+including O
+production O
+of O
+cytokines O
+and O
+expression O
+of O
+proto O
+- O
+oncogenes O
+, O
+many O
+of O
+which O
+are O
+controlled O
+through O
+3 O
+' O
+AU O
+- O
+rich O
+elements O
+. O
+
+The O
+gap B
+protein I
+knirps B
+mediates O
+both O
+quenching O
+and O
+direct O
+repression O
+in O
+the O
+Drosophila O
+embryo O
+. O
+
+The O
+family O
+histories O
+were O
+obtained O
+from O
+the O
+parents O
+. O
+
+The O
+DW O
+directions O
+uniformly O
+sampled O
+the O
+diffusion O
+ellipsoid O
+surface O
+. O
+
+Here O
+we O
+demonstrate O
+that O
+CD40 B
+or O
+IgM B
+receptor I
+stimulation O
+of O
+primary O
+B O
+cells O
+results O
+in O
+transactivation O
+of O
+this O
+enhancer O
+. O
+
+This O
+cell O
+line O
+expresses O
+productively O
+rearranged O
+immunoglobulin B
+genes I
+as O
+well O
+as O
+the O
+Oct B
+- I
+2 I
+gene I
+at O
+high O
+levels O
+which O
+are O
+comparable O
+to O
+those O
+observed O
+in O
+activated O
+murine O
+splenic O
+B O
+cells O
+. O
+
+The O
+relationship O
+between O
+CSF B
+somatostatin I
+and O
+peripheral O
+thyroid O
+hormones O
+was O
+assessed O
+in O
+11 O
+affectively O
+ill O
+patients O
+before O
+and O
+during O
+carbamazepine O
+treatment O
+. O
+
+Both O
+RNA14 B
+and O
+RNA15 B
+wild I
+- I
+type I
+genes I
+, O
+when O
+cloned O
+on O
+a O
+multicopy O
+plasmid O
+, O
+are O
+able O
+to O
+suppress O
+the O
+temperature O
+- O
+sensitive O
+phenotype O
+of O
+strains O
+bearing O
+either O
+the O
+rna14 B
+or O
+the O
+rna15 B
+mutation I
+, O
+suggesting O
+that O
+the O
+encoded O
+proteins O
+could O
+interact O
+with O
+each O
+other O
+. O
+
+Treatments O
+were O
+two O
+adrenocorticotrophin B
+( O
+ACTH B
+) O
+preparations O
+given O
+intramuscularly O
+at O
+2 O
+. O
+2 O
+U O
+/ O
+kg O
+, O
+one O
+of O
+the O
+ACTH B
+preparations O
+given O
+intramuscularly O
+at O
+1 O
+U O
+/ O
+kg O
+and O
+a O
+synthetic O
+polypeptide O
+with O
+ACTH B
+- O
+like O
+activity O
+( O
+tetracosactrin O
+, O
+cosyntropin B
+) O
+given O
+intravenously O
+at O
+5 O
+micrograms O
+/ O
+kg O
+. O
+
+It O
+is O
+very O
+probable O
+that O
+this O
+change O
+was O
+due O
+to O
+mechanical O
+effects O
+induced O
+by O
+injecting O
+a O
+hypertonic O
+solution O
+of O
+MT O
+- O
+141 O
+at O
+a O
+rate O
+of O
+70 O
+- O
+- O
+130 O
+ml O
+/ O
+dog O
+. O
+
+It O
+is O
+not O
+well O
+known O
+that O
+giant O
+cell O
+arteritis O
+can O
+cause O
+fatal O
+complications O
+due O
+to O
+rupture O
+of O
+aortic O
+aneurysms O
+or O
+cerebral O
+and O
+myocardial O
+infarctions O
+. O
+
+PRIP B
+contains O
+two O
+LXXLL O
+signature O
+motifs O
+. O
+
+Basal O
+urinary O
+17 O
+- O
+hydroxycorticoid O
+( O
+17 O
+- O
+OHCS O
+) O
+values O
+were O
+elevated O
+in O
+9 O
+/ O
+12 O
+patients O
+and O
+low O
+dose O
+dexamethasone O
+suppression O
+test O
+favoured O
+Cushing O
+' O
+s O
+syndrome O
+in O
+8 O
+/ O
+9 O
+patients O
+. O
+
+Like O
+the O
+human O
+gene O
+, O
+the O
+Drosophila O
+gene O
+encodes O
+at O
+least O
+three O
+isoforms O
+of O
+full B
+length I
+dystrophin I
+- I
+like I
+proteins I
+( O
+dmDLP1 B
+, O
+dmDLP2 B
+and O
+dmDLP3 B
+, O
+) O
+, O
+regulated O
+by O
+different O
+promoters O
+located O
+at O
+the O
+5 O
+' O
+end O
+of O
+the O
+gene O
+, O
+and O
+a O
+smaller O
+product O
+regulated O
+by O
+an O
+internal O
+promoter O
+( O
+dmDp186 B
+) O
+. O
+
+Accordingly O
+, O
+infection O
+of O
+IFN B
+- O
+pretreated O
+HeLa O
+S3 O
+cells O
+with O
+an O
+E3L B
+- O
+deficient O
+VV O
+( O
+VVDeltaE3L O
+) O
+resulted O
+in O
+increased O
+phosphorylation O
+levels O
+of O
+both O
+PKR B
+and O
+eIF2alpha B
+. O
+
+The O
+goal O
+of O
+our O
+work O
+was O
+to O
+determine O
+hearing O
+thresholds O
+in O
+patients O
+with O
+hearing O
+impairment O
+due O
+to O
+hereditary O
+motor O
+and O
+sensory O
+neuropathy O
+( O
+HMSN O
+I O
+) O
+. O
+
+Influence O
+of O
+dietary O
+supplementation O
+with O
+Streptococcus O
+faecium O
+M O
+- O
+74 O
+on O
+broiler O
+body O
+weight O
+, O
+feed O
+conversion O
+, O
+carcass O
+characteristics O
+, O
+and O
+intestinal O
+microbial O
+colonization O
+. O
+
+The O
+results O
+reveal O
+preferences O
+for O
+particular O
+initiating O
+nucleotides O
+( O
+ATP O
+> O
+or O
+= O
+GTP O
+> O
+UTP O
+> O
+> O
+CTP O
+) O
+and O
+for O
+starting O
+positions O
+downstream O
+of O
+the O
+Pribnow B
+box O
+( O
+7 O
+> O
+> O
+6 O
+and O
+8 O
+> O
+9 O
+> O
+10 O
+) O
+. O
+
+Trimethylcolchicinic O
+acid O
+methyl O
+ether O
+d O
+- O
+tartrate O
+( O
+TMCA O
+; O
+NSC O
+- O
+36351 O
+) O
+was O
+administered O
+daily O
+by O
+mouth O
+to O
+71 O
+patients O
+with O
+malignant O
+lymphomas O
+. O
+
+Gene O
+transcripts O
+are O
+detected O
+on O
+tissues O
+such O
+as O
+bovine O
+liver O
+, O
+kidney O
+, O
+lung O
+, O
+and O
+brain O
+. O
+
+Assessment O
+of O
+ammonia O
+and O
+urea O
+blood O
+content O
+in O
+metabolic O
+acid O
+- O
+base O
+disorders O
+in O
+white O
+rats O
+. O
+
+The O
+immediate O
+and O
+remote O
+results O
+of O
+surgical O
+treatment O
+of O
+renal O
+adenocarcinomas O
+. O
+
+Vibrio O
+cholerae O
+iron B
+transport O
+: O
+haem O
+transport O
+genes O
+are O
+linked O
+to O
+one O
+of O
+two O
+sets O
+of O
+tonB B
+, O
+exbB B
+, O
+exbD B
+genes I
+. O
+
+The O
+predicted O
+amino O
+- O
+acid O
+sequence O
+includes O
+an O
+N O
+- O
+terminal O
+signal O
+sequence O
+of O
+27 O
+amino O
+acids O
+, O
+a O
+27 O
+amino O
+- O
+acid O
+pro O
+- O
+region O
+, O
+a O
+251 O
+amino O
+- O
+acid O
+catalytic O
+domain O
+typical O
+of O
+a O
+serine B
+protease I
+with O
+trypsin B
+- O
+like O
+specificity O
+, O
+and O
+a O
+C O
+- O
+terminal O
+hydrophobic O
+extension O
+which O
+is O
+predicted O
+to O
+function O
+as O
+a O
+membrane O
+anchor O
+. O
+
+To O
+examine O
+the O
+biochemical O
+mechanism O
+of O
+Tax1 B
+transactivation O
+, O
+we O
+have O
+developed O
+an O
+in O
+vitro O
+transactivation O
+assay O
+in O
+which O
+wild B
+- I
+type I
+Tax1 I
+is O
+able O
+to O
+specifically O
+transactivate O
+a O
+polymerase B
+II I
+promoter I
+through O
+upstream O
+Tax1 B
+- I
+responsive I
+elements I
+. O
+
+Interestingly O
+, O
+PMA O
+- O
+, O
+PDGF B
+- O
+, O
+and O
+serum O
+- O
+induced O
+GHR B
+proteolysis O
+was O
+associated O
+with O
+substantial O
+decreases O
+in O
+GH B
+- O
+induced O
+activation O
+of O
+Janus B
+kinase I
+- I
+2 I
+, O
+which O
+were O
+also O
+prevented O
+by O
+IC3 O
+. O
+
+Thus O
+, O
+IF O
+- O
+laser O
+therapy O
+has O
+a O
+certain O
+antioxidative O
+effect O
+by O
+increasing O
+SOD B
+activity O
+in O
+RA O
+patients O
+' O
+blood O
+cells O
+and O
+reducing O
+the O
+production O
+of O
+highly O
+reactive O
+oxygen O
+and O
+nitrogen O
+forms O
+. O
+
+Reactive O
+mesothelial O
+cells O
+, O
+usually O
+seen O
+as O
+exfoliated O
+cells O
+, O
+were O
+consistently O
+strongly O
+positive O
+for O
+alpha B
+1 I
+- I
+antichymotrypsin I
+and O
+more O
+variably O
+for O
+alpha B
+1 I
+- I
+antitrypsin I
+and O
+lysozyme B
+. O
+
+Recombinant O
+propeptides O
+containing O
+mutations O
+of O
+one O
+of O
+the O
+three O
+tryptophan O
+residues O
+were O
+three O
+orders O
+of O
+magnitude O
+less O
+effective O
+as O
+inhibitors O
+of O
+mature B
+cathepsin I
+S I
+than O
+the O
+wild O
+- O
+type O
+propeptide O
+. O
+
+The O
+highest O
+incidence O
+was O
+observed O
+for O
+V O
+. O
+alginolyticus O
+( O
+92 O
+- O
+100 O
+% O
+) O
+, O
+followed O
+by O
+V O
+. O
+parahaemolyticus O
+( O
+67 O
+- O
+92 O
+% O
+) O
+, O
+V O
+. O
+fluvialis O
+( O
+34 O
+- O
+67 O
+% O
+) O
+, O
+V O
+. O
+vulnificus O
+( O
+8 O
+- O
+17 O
+% O
+) O
+, O
+V O
+. O
+furnissii O
+( O
+0 O
+- O
+17 O
+% O
+) O
+, O
+V O
+. O
+mimicus O
+( O
+0 O
+- O
+17 O
+% O
+) O
+and O
+V O
+. O
+cholerae O
+non O
+- O
+O1 O
+( O
+0 O
+- O
+8 O
+% O
+) O
+. O
+
+Acute O
+morphine O
+treatment O
+did O
+not O
+increase O
+the O
+locomotor O
+activity O
+of O
+mice O
+withdrawn O
+for O
+1 O
+day O
+, O
+after O
+withdrawal O
+for O
+3 O
+days O
+the O
+increase O
+was O
+similar O
+to O
+that O
+in O
+controls O
+, O
+and O
+after O
+5 O
+days O
+the O
+increase O
+was O
+clearly O
+larger O
+than O
+in O
+controls O
+. O
+
+In O
+patients O
+with O
+active O
+TB O
+, O
+cytokines O
+that O
+were O
+elevated O
+in O
+serum O
+were O
+IFN B
+- I
+gamma I
+, O
+IL B
+- I
+6 I
+and O
+IL B
+- I
+10 I
+. O
+
+Isolation O
+and O
+properties O
+of O
+Drosophila B
+melanogaster I
+ferritin B
+- O
+- O
+molecular O
+cloning O
+of O
+a O
+cDNA O
+that O
+encodes O
+one O
+subunit O
+, O
+and O
+localization O
+of O
+the O
+gene O
+on O
+the O
+third O
+chromosome O
+. O
+
+We O
+show O
+that O
+Fos B
+down O
+regulates O
+several O
+immediate B
+- I
+early I
+genes I
+( O
+c B
+- I
+fos I
+, O
+Egr B
+- I
+1 I
+, O
+and O
+Egr B
+- I
+2 I
+) O
+after O
+mitogenic O
+stimulation O
+. O
+
+This O
+study O
+demonstrates O
+a O
+novel O
+link O
+between O
+alterations O
+in O
+platelet B
+- I
+derived I
+growth I
+factor I
+( O
+PDGF B
+) O
+regulation O
+of O
+ornithine B
+decarboxylase I
+( O
+ODC B
+) O
+expression O
+during O
+malignant O
+conversion O
+. O
+
+Circulating O
+immune O
+complexes O
+were O
+determined O
+by O
+the O
+method O
+of O
+phagocytosis O
+and O
+immunofluorescence O
+. O
+
+The O
+human B
+IFI16 I
+gene I
+is O
+a O
+member O
+of O
+an O
+interferon B
+- O
+inducible O
+family O
+of O
+mouse O
+and O
+human O
+genes O
+closely O
+linked O
+on O
+syntenic O
+regions O
+of O
+chromosome O
+1 O
+. O
+
+In O
+agreement O
+with O
+this O
+model O
+, O
+elimination O
+of O
+the O
+ADAM13 B
+cytoplasmic I
+domain I
+increased O
+developmental O
+alterations O
+attributable O
+to O
+ADAM13 B
+proteolytic O
+activity O
+. O
+
+Diabetic O
+osteopathy O
+. O
+
+A O
+third O
+GEF B
+, O
+GRP3 B
+( O
+KIAA0846 B
+) O
+, O
+activated O
+both O
+Ras B
+and O
+Rap1 B
+and O
+shared O
+significant O
+sequence O
+homology O
+with O
+the O
+calcium B
+- I
+and I
+diacylglycerol I
+- I
+activated I
+GEFs I
+, O
+GRP1 B
+and O
+GRP2 B
+. O
+
+A O
+new O
+simple O
+identification O
+of O
+rheumatoid B
+factor I
+on O
+nitrocellulose O
+was O
+developed O
+that O
+allows O
+quantitative O
+detection O
+. O
+
+Comparisons O
+of O
+defective O
+HTLV O
+- O
+I O
+proviruses O
+predict O
+the O
+mode O
+of O
+origin O
+and O
+coding O
+potential O
+of O
+internally O
+deleted O
+genomes O
+. O
+
+Reversal O
+of O
+biliary O
+sphincter O
+spasm O
+with O
+low O
+dose O
+glucagon B
+during O
+operative O
+cholangiography O
+. O
+
+Previous O
+studies O
+have O
+shown O
+that O
+the O
+IME1 B
+gene I
+is O
+required O
+for O
+sporulation O
+and O
+the O
+expression O
+of O
+meiosis O
+specific O
+genes O
+in O
+Saccharomyces O
+cerevisiae O
+. O
+
+A O
+case O
+comparison O
+of O
+acquired O
+immune O
+deficiency O
+syndrome O
+( O
+AIDS O
+) O
+in O
+homosexual O
+males O
+with O
+spindle O
+- O
+endothelial O
+cell O
+abnormalities O
+and O
+with O
+recrudescent O
+melioidosis O
+. O
+
+Intrathecal O
+injections O
+of O
+small O
+volumes O
+of O
+the O
+alpha B
+2 I
+- I
+adrenoceptor I
+agonists O
+, O
+xylazine O
+and O
+clonidine O
+, O
+into O
+the O
+cervical O
+region O
+of O
+the O
+spinal O
+cord O
+of O
+conscious O
+unrestrained O
+sheep O
+produced O
+a O
+dose O
+- O
+dependent O
+analgesia O
+of O
+the O
+forelimbs O
+as O
+measured O
+using O
+a O
+mechanical O
+pressure O
+device O
+. O
+
+Second O
+, O
+CGGA O
+- O
+containing O
+sequences O
+placed O
+at O
+- O
+88 O
+in O
+the O
+delta O
+MTV B
+- O
+CAT B
+reporter O
+plasmid O
+conferred O
+insulin B
+responsiveness O
+to O
+the O
+mammary B
+tumor I
+virus I
+promoter O
+. O
+
+In O
+the O
+absence O
+of O
+c B
+- I
+fos I
+gene I
+expression O
+, O
+c B
+- I
+Fos I
+protein I
+appears O
+to O
+be O
+replaced O
+by O
+proteins O
+of O
+Fos B
+family I
+( O
+Fra B
+- I
+1 I
+) O
+and O
+ATF B
+family I
+( O
+ATF B
+- I
+2 I
+and O
+ATFa B
+) O
+. O
+
+The O
+dopamine B
+D1 I
+dopamine I
+receptor I
+antagonist O
+SCH O
+23390 O
+dose O
+dependently O
+( O
+7 O
+. O
+5 O
+- O
+30 O
+micrograms O
+/ O
+kg O
+s O
+. O
+c O
+. O
+) O
+antagonized O
+the O
+stimulant O
+locomotor O
+effect O
+on O
+both O
+drugs O
+but O
+did O
+not O
+prevent O
+their O
+antiimmobility O
+effect O
+on O
+the O
+behavioral O
+despair O
+test O
+. O
+
+The O
+results O
+obtained O
+show O
+that O
+expression O
+of O
+the O
+gene O
+is O
+low O
+at O
+23 O
+degrees O
+C O
+and O
+is O
+induced O
+rapidly O
+at O
+37 O
+degrees O
+C O
+. O
+
+Characterization O
+of O
+Chlamydomonas O
+reinhardtii O
+zygote O
+- O
+specific O
+cDNAs O
+that O
+encode O
+novel O
+proteins O
+containing O
+ankyrin B
+repeats I
+and O
+WW O
+domains O
+. O
+
+Adenomas O
+in O
+the O
+upper O
+gastrointestinal O
+tract O
+were O
+found O
+in O
+all O
+of O
+the O
+patients O
+: O
+Vater O
+' O
+s O
+papilla O
+- O
+- O
+12 O
+, O
+duodenum O
+- O
+- O
+nine O
+, O
+and O
+gastric O
+antrum O
+- O
+- O
+seven O
+. O
+
+Microenvironments O
+dominated O
+by O
+cyanobacteria O
+( O
+BPC O
+) O
+had O
+a O
+higher O
+pH O
+( O
+pH O
+7 O
+- O
+8 O
+) O
+than O
+those O
+dominated O
+by O
+lichen O
+( O
+LTL O
+) O
+( O
+pH O
+4 O
+. O
+5 O
+- O
+5 O
+. O
+5 O
+) O
+. O
+
+A O
+total O
+of O
+64 O
+uncomplicated O
+Type O
+- O
+2 O
+diabetic O
+individuals O
+of O
+higher O
+middle O
+class O
+to O
+rich O
+socio O
+- O
+economic O
+status O
+were O
+studied O
+. O
+
+A O
+drop O
+of O
+methylprednisolone O
+acetate O
+or O
+vehicle O
+constituent O
+was O
+placed O
+on O
+the O
+dissected O
+plantar O
+nerve O
+proximal O
+to O
+the O
+stimulating O
+electrodes O
+after O
+recording O
+control O
+responses O
+( O
+A O
+- O
+fibre O
+volley O
+in O
+the O
+sciatic O
+nerve O
+and O
+C O
+- O
+fibre O
+evoked O
+reflex O
+discharge O
+in O
+flexor O
+motoneurons O
+) O
+. O
+
+Basic B
+helix I
+- I
+loop I
+- I
+helix I
+proteins I
+can O
+act O
+at O
+the O
+E O
+- O
+box O
+within O
+the O
+serum O
+response O
+element O
+of O
+the O
+c B
+- I
+fos I
+promoter I
+to O
+influence O
+hormone O
+- O
+induced O
+promoter O
+activation O
+in O
+Sertoli O
+cells O
+. O
+
+Using O
+yeast O
+two O
+- O
+hybrid O
+screening O
+, O
+we O
+isolated O
+histone B
+H3 I
+as O
+an O
+interacting O
+factor O
+of O
+CIA B
+. O
+
+Concentrations O
+of O
+Co O
+, O
+Cu O
+, O
+Fe O
+, O
+Hg O
+, O
+Mn O
+, O
+Sb O
+, O
+Se O
+and O
+Zn O
+in O
+IAEA O
+milk O
+( O
+dry O
+) O
+standard O
+A O
+- O
+11 O
+were O
+re O
+- O
+evaluated O
+with O
+the O
+help O
+of O
+instrumental O
+and O
+radiochemical O
+neutron O
+activation O
+analysis O
+( O
+NAA O
+) O
+. O
+
+Gallstone O
+- O
+formation O
+has O
+traditionally O
+been O
+attributed O
+to O
+supersaturation O
+of O
+bile O
+with O
+cholesterol O
+. O
+
+Sixteen O
+patients O
+on O
+maintenance O
+hemodialysis O
+underwent O
+dialysis O
+with O
+either O
+cuprophane O
+( O
+n O
+= O
+8 O
+) O
+or O
+polymethylmethacrylate O
+( O
+PMMA O
+; O
+n O
+= O
+8 O
+) O
+membranes O
+for O
+1 O
+week O
+and O
+then O
+switched O
+to O
+the O
+opposite O
+membrane O
+during O
+the O
+second O
+week O
+. O
+
+Gene O
+expression O
+is O
+in O
+part O
+controlled O
+by O
+chromatin O
+remodeling O
+factors O
+and O
+the O
+acetylation O
+state O
+of O
+nucleosomal B
+histones I
+. O
+
+Each O
+patient O
+was O
+seen O
+for O
+5 O
+to O
+13 O
+postsurgical O
+maintenance O
+visits O
+. O
+
+Furthermore O
+, O
+Grap B
+is O
+associated O
+with O
+a O
+Ras B
+guanine I
+nucleotide I
+exchange I
+factor I
+mSos1 B
+, O
+primarily O
+through O
+its O
+N O
+- O
+terminal O
+SH3 B
+domain I
+. O
+
+Recurrent O
+infections O
+, O
+episodic O
+lymphopenia O
+and O
+impaired O
+cellular O
+immunity O
+. O
+
+After O
+3 O
+months O
+of O
+intervention O
+, O
+sustained O
+physical O
+training O
+was O
+associated O
+with O
+the O
+decrease O
+of O
+FVII B
+and O
+PAI B
+- I
+1 I
+levels O
+. O
+
+Thirty O
+- O
+three O
+percent O
+had O
+elevated O
+titers O
+( O
+above O
+1 O
+: O
+20 O
+dilution O
+) O
+. O
+
+Xa4 B
+is O
+a O
+dominantly O
+inherited O
+rice O
+gene O
+that O
+confers O
+resistance O
+to O
+Philippine O
+race O
+1 O
+of O
+the O
+bacterial O
+blight O
+pathogen O
+Xanthomonas O
+oryzae O
+pv O
+. O
+oryzae O
+in O
+rice O
+. O
+
+In O
+uraemic O
+patients O
+, O
+similar O
+maximum O
+serum O
+concentrations O
+were O
+found O
+after O
+a O
+single O
+7 O
+. O
+5 O
+mg O
+/ O
+kg O
+iv O
+dose O
+. O
+
+The O
+effect O
+of O
+buthionine O
+sulfoximine O
+( O
+BSO O
+) O
+and O
+disulfiram O
+( O
+DSF O
+) O
+on O
+the O
+urotoxicity O
+induced O
+by O
+cyclophosphamide O
+( O
+CPA O
+) O
+was O
+examined O
+in O
+mice O
+. O
+
+All O
+the O
+previously O
+mapped O
+structural O
+protein O
+- O
+encoding O
+genes O
+of O
+phage O
+LL O
+- O
+H O
+were O
+included O
+in O
+the O
+sequence O
+. O
+
+When O
+a O
+longer O
+- O
+714 O
+to O
++ O
+78 O
+fragment O
+of O
+the O
+PBGD B
+promoter I
+is O
+used O
+, O
+the O
+- O
+70 O
+GATA B
+mutant I
+still O
+displays O
+erythroid O
+- O
+specific O
+activity O
+and O
+is O
+cis O
+- O
+activated O
+by O
+the O
+5 B
+' O
+HS I
+- I
+2 I
+enhancer I
+, O
+while O
+the O
+- O
+100 O
+CCACC O
+mutant O
+is O
+completely O
+inactive O
+in O
+the O
+absence O
+or O
+in O
+the O
+presence O
+of O
+the O
+5 O
+' O
+HS O
+- O
+2 O
+enhancer O
+. O
+
+Surprisingly O
+, O
+in O
+adult O
+animals O
+, O
+the O
+suprabasal O
+expression O
+of O
+dnRXR B
+alpha I
+significantly O
+reduced O
+the O
+ability O
+of O
+topically O
+applied O
+tRA O
+to O
+stimulate O
+proliferation O
+of O
+undifferentiated O
+keratinocytes O
+in O
+the O
+basal O
+layer O
+of O
+epidermis O
+. O
+
+In O
+many O
+other O
+contractile B
+protein I
+gene I
+families I
+, O
+genes O
+encoding O
+cardiac O
+isoforms O
+are O
+expressed O
+early O
+in O
+skeletal O
+muscle O
+development O
+and O
+are O
+later O
+repressed O
+. O
+
+1995 O
+. O
+
+For O
+il8ra B
+, O
+it O
+is O
+formed O
+from O
+two O
+exons O
+, O
+whereas O
+for O
+il8rb B
+, O
+seven O
+distinct O
+neutrophil O
+mRNAs O
+are O
+formed O
+by O
+alternative O
+splicing O
+of O
+11 O
+exons O
+. O
+
+Endocarditis O
+remains O
+a O
+life O
+- O
+threatening O
+disease O
+with O
+substantial O
+morbidity O
+and O
+mortality O
+. O
+
+The O
+gene O
+encoding O
+the O
+cellulase B
+( O
+Avicelase B
+) O
+Cel1 B
+from I
+Streptomyces I
+reticuli I
+and O
+analysis O
+of O
+protein O
+domains O
+. O
+
+From O
+this O
+comparison O
+of O
+aa O
+sequences O
+, O
+the O
+ATPK7 B
+protein I
+is O
+considered O
+to O
+be O
+a O
+member O
+of O
+a O
+novel O
+subfamily O
+of O
+Ser B
+/ I
+Thr I
+PKs I
+in O
+plants O
+. O
+
+Of O
+these O
+, O
+23 O
+( O
+13 O
+. O
+6 O
+% O
+) O
+were O
+due O
+to O
+GIB O
+( O
+Upper O
+GIB O
+= O
+19 O
+, O
+Lower O
+GIB O
+= O
+4 O
+) O
+. O
+
+The O
+E O
+. O
+multilocularis O
+/ O
+Mongolian O
+gerbil O
+system O
+can O
+replace O
+the O
+natural O
+canid O
+hosts O
+as O
+a O
+new O
+way O
+to O
+obtain O
+infective O
+eggs O
+and O
+to O
+analyze O
+host O
+- O
+parasite O
+interactions O
+. O
+
+E1 B
+recognition I
+sequences I
+in O
+the O
+bovine O
+papillomavirus O
+type O
+1 O
+origin O
+of O
+DNA O
+replication O
+: O
+interaction O
+between O
+half O
+sites O
+of O
+the O
+inverted O
+repeats O
+. O
+
+We O
+found O
+that O
+secretion O
+of O
+chitinolytic O
+enzymes O
+by O
+cultured O
+L O
+. O
+major O
+parasites O
+is O
+inhibited O
+by O
+blood O
+or O
+hemoglobin B
+, O
+and O
+hence O
+these O
+enzymes O
+are O
+apparently O
+absent O
+from O
+the O
+blood O
+- O
+fed O
+infected O
+flies O
+, O
+where O
+the O
+cardiac O
+valve O
+appears O
+undamaged O
+. O
+
+Patients O
+in O
+the O
+mucinous O
+cyst O
+group O
+had O
+significantly O
+lower O
+CA B
+125 I
+cystic O
+fluid O
+levels O
+compared O
+with O
+women O
+with O
+endometriomas O
+and O
+dermoids O
+( O
+P O
+& O
+lt O
+; O
+0 O
+. O
+05 O
+) O
+. O
+
+SATB1 B
+interacted O
+with O
+CDP B
+through O
+its O
+DNA O
+- O
+binding O
+domain O
+, O
+as O
+demonstrated O
+by O
+glutathione B
+S I
+- I
+transferase I
+( O
+GST B
+) O
+pull O
+- O
+down O
+assays O
+. O
+
+Plasma B
+prolactin I
+concentrations O
+in O
+pinealectomized O
+ewes O
+receiving O
+melatonin O
+treatment O
+and O
+in O
+pineal O
+intact O
+ewes O
+maintained O
+under O
+a O
+non O
+- O
+24 O
+- O
+hour O
+photoperiod O
+. O
+
+It O
+is O
+targeted O
+to O
+peroxisomes O
+when O
+expressed O
+in O
+mammalian O
+cells O
+and O
+yeast O
+. O
+
+The O
+transcriptional O
+start O
+site O
+, O
+identified O
+by O
+primer O
+extension O
+and O
+S1 B
+nuclease I
+assay O
+, O
+is O
+34 O
+nt O
+upstream O
+of O
+the O
+translation O
+initiation O
+codon O
+. O
+
+Nonlinearities O
+in O
+cochlear O
+hydrodynamics O
+. O
+
+Electronic O
+structure O
+and O
+optical O
+properties O
+of O
+the O
+B12O2 O
+crystal O
+. O
+
+Spongiosa O
+regeneration O
+in O
+the O
+millipore O
+chamber O
+
+The O
+predicted O
+5 O
+' O
+and O
+3 O
+' O
+ends O
+of O
+the O
+transcript O
+are O
+in O
+very O
+good O
+agreement O
+with O
+the O
+previously O
+determined O
+size O
+of O
+the O
+LEU3 B
+message I
+. O
+
+This O
+cDNA O
+corresponded O
+to O
+FGF B
+- I
+binding I
+protein I
+( O
+FGF B
+- I
+BP I
+) O
+, O
+a O
+secreted O
+protein O
+previously O
+shown O
+to O
+bind O
+acidic B
+and I
+basic I
+FGF I
+and O
+to O
+modulate O
+their O
+activities O
+. O
+
+Analysis O
+of O
+replicative O
+intermediates O
+shows O
+that O
+plasmid O
+YRp7 O
+, O
+which O
+contains O
+the O
+chromosomal B
+replicator I
+ARS1 I
+, O
+initiates O
+bidirectional O
+replication O
+in O
+a O
+100 O
+bp O
+region O
+within O
+the O
+sequence O
+required O
+for O
+autonomous O
+replication O
+in O
+vivo O
+. O
+
+Such O
+results O
+suggest O
+that O
+there O
+are O
+no O
+differences O
+in O
+the O
+BMR O
+of O
+age O
+- O
+and O
+weight O
+- O
+matched O
+Asian O
+Indian O
+males O
+, O
+other O
+tropical O
+populations O
+and O
+Americans O
+. O
+
+Rewarding O
+properties O
+of O
+methylphenidate O
+: O
+sensitization O
+by O
+prior O
+exposure O
+to O
+the O
+drug O
+and O
+effects O
+of O
+dopamine B
+D1 I
+- I
+and I
+D2 I
+- I
+receptor I
+antagonists O
+. O
+
+Similar O
+to O
+what O
+was O
+observed O
+for O
+P O
+. O
+putida O
+, O
+a O
+psrA B
+null I
+mutant I
+of O
+P O
+. O
+aeruginosa O
+also O
+showed O
+a O
+90 O
+% O
+reduction O
+in O
+rpoS B
+promoter I
+activity O
+; O
+both O
+mutants O
+could O
+be O
+complemented O
+for O
+rpoS B
+promoter I
+activity O
+when O
+the O
+psrA B
+gene I
+was O
+provided O
+in O
+trans O
+. O
+
+psrA B
+mutants I
+of O
+both O
+Pseudomonas O
+species O
+lost O
+the O
+ability O
+to O
+induce O
+rpoS B
+expression O
+at O
+stationary O
+phase O
+, O
+but O
+they O
+retained O
+the O
+ability O
+to O
+produce O
+quorum O
+- O
+sensing O
+autoinducer O
+molecules O
+. O
+
+The O
+role O
+of O
+the O
+putative O
+C2 B
+domain O
+of O
+Nedd4 B
+has O
+not O
+been O
+elucidated O
+. O
+
+ZF87 B
+specifically O
+binds O
+the O
+ME1a1 B
+element I
+with O
+higher O
+affinity O
+than O
+the O
+ME1a2 B
+element I
+. O
+
+We O
+found O
+a O
+significant O
+increase O
+of O
+thromboxane O
+as O
+evidenced O
+by O
+the O
+major O
+urinary O
+metabolite O
+2 O
+, O
+3 O
+- O
+dinorthromboxane O
+B2 O
+in O
+the O
+oestrogen O
+group O
+as O
+compared O
+to O
+the O
+orchidectomy O
+group O
+. O
+
+Multivariable O
+logistic O
+regression O
+showed O
+that O
+mean O
+blood O
+glucose O
+level O
+for O
+the O
+first O
+2 O
+days O
+( O
+p O
+= O
+0 O
+. O
+002 O
+) O
+, O
+obesity O
+( O
+p O
+< O
+0 O
+. O
+002 O
+) O
+, O
+and O
+use O
+of O
+the O
+internal O
+mammary O
+artery O
+( O
+p O
+< O
+0 O
+. O
+02 O
+) O
+were O
+all O
+independent O
+predictors O
+of O
+deep O
+wound O
+infection O
+. O
+
+However O
+the O
+precise O
+function O
+of O
+DNA B
+- I
+PK I
+in O
+DNA O
+double O
+- O
+strand O
+break O
+repair O
+is O
+not O
+known O
+. O
+
+This O
+new O
+receptor O
+, O
+TOR B
+( O
+thymus B
+orphan I
+receptor I
+) O
+, O
+is O
+most O
+closely O
+related O
+in O
+both O
+its O
+DNA O
+- O
+binding O
+domain O
+and O
+ligand O
+- O
+binding O
+domain O
+, O
+90 O
+% O
+and O
+53 O
+% O
+, O
+respectively O
+, O
+to O
+ROR B
+alpha I
+/ O
+RZR B
+alpha I
+and O
+clusters O
+with O
+these O
+two O
+receptors O
+and O
+RZR B
+beta I
+in O
+a O
+phylogenetic O
+tree O
+, O
+when O
+both O
+the O
+DNA O
+- O
+binding O
+domain O
+and O
+the O
+ligand O
+- O
+binding O
+domain O
+sequences O
+of O
+nuclear O
+receptors O
+are O
+compared O
+. O
+
+In O
+this O
+report O
+, O
+we O
+have O
+examined O
+whether O
+PTP1B B
+effects O
+transformation O
+induced O
+by O
+p210 B
+bcr B
+- O
+abl B
+. O
+
+S1 B
+nuclease I
+analysis O
+of O
+the O
+RNA O
+from O
+a O
+number O
+of O
+QT6 O
+- O
+LD O
+clones O
+gave O
+similar O
+results O
+, O
+indicating O
+that O
+the O
+LD O
+population O
+was O
+composed O
+of O
+viruses O
+with O
+similar O
+but O
+not O
+identical O
+deletion O
+endpoints O
+. O
+
+Association O
+of O
+Smads B
+with O
+lymphoid B
+enhancer I
+binding I
+factor I
+1 I
+/ O
+T B
+cell I
+- I
+specific I
+factor I
+mediates O
+cooperative O
+signaling O
+by O
+the O
+transforming B
+growth I
+factor I
+- I
+beta I
+and O
+wnt B
+pathways O
+. O
+
+The O
+three O
+OAS B
+genes I
+are O
+flanked O
+by O
+markers O
+WI O
+- O
+10614 O
+( O
+cen O
+) O
+and O
+D12S2293 B
+( O
+tel B
+) O
+and O
+are O
+contained O
+within O
+three O
+sets O
+of O
+overlapping O
+cosmid O
+clones O
+. O
+
+22 O
+. O
+6 O
+% O
+of O
+patients O
+were O
+found O
+to O
+be O
+positive O
+at O
+histology O
+in O
+the O
+corpus O
+mucosa O
+; O
+all O
+but O
+one O
+of O
+these O
+patients O
+had O
+elevated O
+circulating O
+IgG B
+to O
+H O
+. O
+pylori O
+( O
+Group O
+C O
+) O
+. O
+
+Rottlerin O
+also O
+inhibited O
+the O
+activation O
+of O
+MAP B
+kinase I
+kinase I
+( O
+MEK B
+) O
+in O
+response O
+to O
+activated O
+Raf B
+, O
+but O
+had O
+no O
+effect O
+upon O
+c B
+- I
+Raf I
+activity O
+or O
+ERK B
+activation O
+by O
+activated O
+MEK B
+. O
+
+Quasidiatomic O
+study O
+of O
+Ly O
+- O
+alpha O
+- O
+producing O
+H2 O
++ O
+- O
+Ne O
+collisions O
+at O
+keV O
+energies O
+. O
+
+The O
+NH O
+( O
+2 O
+) O
+- O
+terminus O
+of O
+all O
+three O
+proteins O
+contains O
+a O
+POZ O
+domain O
+, O
+a O
+conserved O
+120 O
+amino O
+acid O
+motif O
+involved O
+in O
+transcriptional O
+repression O
+and O
+protein O
+dimerization O
+. O
+
+The O
+isolation O
+of O
+crt5 B
+- I
+262 I
+, O
+an O
+additional O
+cdc B
+allele I
+of O
+POL1 B
+/ O
+CDC17 B
+, O
+suggests O
+for O
+the O
+first O
+time O
+that O
+directly O
+blocking O
+DNA O
+replication O
+can O
+provide O
+a O
+signal O
+to O
+induce O
+the O
+DNA O
+damage O
+response O
+. O
+
+crt2 B
+mutants I
+show O
+a O
+defect O
+in O
+basal O
+level O
+expression O
+of O
+RNR1 B
+- O
+lacZ B
+reporter O
+constructs O
+. O
+
+Greer O
+, O
+and O
+L O
+. O
+A O
+. O
+
+We O
+prospectively O
+studied O
+serum O
+prolactin B
+( O
+PRL B
+) O
+elevation O
+after O
+different O
+types O
+of O
+documented O
+seizures O
+in O
+17 O
+patients O
+. O
+
+However O
+, O
+both O
+peptides O
+1 O
+- O
+49 O
+and O
+63 O
+- O
+87 O
+bound O
+to O
+PDE B
+alpha I
+/ I
+beta I
+in O
+a O
+solid O
+- O
+phase O
+binding O
+assay O
+. O
+
+Values O
+of O
+K1 O
+and O
+Vd O
+were O
+significantly O
+increased O
+in O
+the O
+tumour O
+tissue O
+. O
+
+The O
+mutation O
+also O
+preferentially O
+limits O
+( O
+compared O
+with O
+total O
+protein O
+synthesis O
+) O
+translation O
+of O
+an O
+induced O
+gene O
+that O
+depends O
+on O
+five O
+AGA O
+codons O
+, O
+i O
+. O
+e O
+. O
+, O
+the O
+lambda B
+cI I
+repressor I
+gene I
+. O
+
+Five O
+RNA O
+transcripts O
+of O
+about O
+1 O
+. O
+2 O
+to O
+1 O
+. O
+7 O
+kilobases O
+were O
+mapped O
+to O
+a O
+part O
+of O
+the O
+genome O
+of O
+insect O
+iridescent O
+virus O
+type O
+6 O
+( O
+Chilo O
+iridescent O
+virus O
+; O
+CIV O
+) O
+between O
+genome O
+coordinates O
+0 O
+. O
+832 O
+and O
+0 O
+. O
+856 O
+within O
+the O
+EcoRI B
+DNA I
+fragment I
+F I
+. O
+
+Other O
+similar O
+patients O
+must O
+be O
+found O
+before O
+it O
+is O
+established O
+that O
+the O
+colloid O
+cyst O
+is O
+part O
+of O
+the O
+nevoid O
+basal O
+cell O
+carcinoma O
+syndrome O
+. O
+
+Portions O
+of O
+the O
+3 O
+' O
+- O
+coding O
+and O
+3 O
+' O
+- O
+untranslated O
+regions O
+were O
+found O
+to O
+be O
+missing O
+from O
+the O
+7 O
+. O
+2 O
+- O
+and O
+4 B
+. I
+8 I
+- I
+kb I
+topo I
+II I
+alpha I
+mRNAs I
+by O
+Northern O
+blot O
+analysis O
+. O
+
+In O
+addition O
+, O
+a O
+double O
+mutant O
+( O
+E482A O
+, O
+D489A O
+) O
+which O
+removed O
+negative O
+charges O
+along O
+one O
+side O
+of O
+the O
+helix O
+had O
+negligible O
+effects O
+on O
+fusion O
+activity O
+. O
+
+A O
+GTP O
+/ O
+GDP O
+exchange O
+assay O
+was O
+used O
+to O
+assess O
+the O
+potential O
+role O
+of O
+Ras B
+in O
+the O
+pathway O
+leading O
+to O
+ERK B
+phosphorylation O
+; O
+DADLE O
+failed O
+to O
+stimulate O
+GTP O
+/ O
+GDP O
+exchange O
+in O
+comparison O
+to O
+PMA O
+. O
+
+Phenotypic O
+analysis O
+demonstrates O
+that O
+trio B
+and O
+Abl B
+cooperate O
+in O
+regulating O
+axon O
+outgrowth O
+in O
+the O
+embryonic O
+central O
+nervous O
+system O
+( O
+CNS O
+) O
+. O
+
+Recombinant B
+caspases I
+are O
+typically O
+produced O
+in O
+Escherichia O
+coli O
+expression O
+systems O
+with O
+the O
+attendant O
+problems O
+of O
+solubilization O
+, O
+re O
+- O
+folding O
+and O
+activation O
+of O
+the O
+protease O
+. O
+
+The O
+gene B
+encoding I
+rat I
+peptidylglycine I
+alpha I
+- I
+amidating I
+monooxygenase I
+( O
+PAM B
+) O
+contains O
+26 O
+protein O
+- O
+coding O
+exons O
+. O
+
+This O
+bound O
+[ O
+3H O
+] O
+iloprost O
+with O
+high O
+affinity O
+and O
+stimulated O
+cAMP O
+production O
+when O
+exposed O
+to O
+agonist O
+. O
+
+Structure O
+of O
+the O
+connective O
+stroma O
+of O
+the O
+epididymis O
+in O
+the O
+zebu O
+
+Free O
+protein B
+S I
+deficiency O
+in O
+acute O
+ischemic O
+stroke O
+. O
+
+In O
+a O
+series O
+of O
+papers O
+, O
+the O
+staging O
+system O
+for O
+melanoma O
+was O
+critically O
+analyzed O
+, O
+and O
+many O
+shortcomings O
+were O
+identified O
+. O
+
+Reproduction O
+and O
+maternal O
+response O
+of O
+the O
+rat O
+when O
+thiamine O
+intake O
+is O
+limited O
+. O
+
+Total O
+meso O
+- O
+pore O
+volume O
+and O
+surface O
+area O
+ranged O
+from O
+0 O
+. O
+004 O
+- O
+0 O
+. O
+08 O
+cm3 O
+g O
+( O
+- O
+1 O
+) O
+and O
+from O
+0 O
+. O
+33 O
+- O
+6 O
+. O
+9 O
+m2 O
+g O
+( O
+- O
+1 O
+) O
+respectively O
+, O
+accounting O
+for O
+up O
+33 O
+% O
+of O
+the O
+BET O
+surface O
+area O
+. O
+
+The O
+NF B
+- I
+kappa I
+B I
+precursor I
+p100 B
+( O
+lyt B
+- I
+10 I
+, O
+p97 B
+, O
+p98 B
+) O
+generates O
+after O
+proteolytic O
+processing O
+a O
+52 O
+kDa O
+subunit O
+, O
+which O
+can O
+bind O
+to O
+kappa B
+B I
+- I
+motifs I
+. O
+
+CONCLUSION O
+: O
+The O
+biodistribution O
+of O
+111In O
+IgG B
+is O
+similar O
+to O
+that O
+of O
+99mTc O
+- O
+HMPAO O
+- O
+labeled O
+leukocytes O
+. O
+
+Based O
+on O
+29 O
+determinations O
+of O
+the O
+glucose O
+from O
+sinigrin O
+, O
+analyzed O
+under O
+different O
+conditions O
+, O
+accuracy O
+of O
+the O
+total O
+glucosinolate O
+determination O
+was O
+94 O
+. O
+8 O
++ O
+/ O
+- O
+7 O
+. O
+3 O
+% O
+. O
+
+Receptor B
+- I
+type I
+serine I
+/ I
+threonine I
+kinases I
+( O
+RSKs B
+) O
+have O
+been O
+organized O
+into O
+two O
+distinct O
+classes O
+known O
+as O
+types O
+I O
+and O
+II O
+on O
+the O
+basis O
+of O
+sequence O
+similarity O
+. O
+
+In O
+a O
+previous O
+study O
+of O
+transforming B
+growth I
+factor I
+- I
+beta1 I
+- O
+mediated O
+inhibition O
+of O
+the O
+cyclin B
+A I
+promoter I
+, O
+we O
+mapped O
+the O
+inhibitory O
+effect O
+to O
+the O
+ATF B
+site I
+; O
+in O
+the O
+present O
+study O
+of O
+IFN B
+- I
+gamma I
+treatment O
+, O
+functional O
+analysis O
+by O
+transient O
+transfection O
+showed O
+that O
+inhibition O
+of O
+the O
+cyclin B
+A I
+promoter I
+persisted O
+despite O
+mutation O
+of O
+the O
+ATF B
+, O
+NF B
+- I
+Y I
+, O
+or O
+CDE O
+elements O
+. O
+
+The O
+RsmA B
+- I
+mutant I
+, O
+like O
+its O
+parent O
+, O
+produces O
+N O
+- O
+( O
+3 O
+- O
+oxohexanoyl O
+) O
+- O
+L O
+- O
+homoserine O
+lactone O
+( O
+HSL O
+) O
+, O
+a O
+starvation O
+/ O
+cell O
+density O
+- O
+sensing O
+signal O
+required O
+for O
+extracellular O
+enzyme O
+production O
+. O
+
+The O
+inactive O
+X O
+allele O
+, O
+however O
+, O
+is O
+hypermethylated O
+in O
+leukocytes O
+, O
+presumably O
+reflecting O
+early O
+X O
+inactivation O
+events O
+that O
+become O
+important O
+for O
+gene O
+dosage O
+in O
+expressing O
+lineages O
+. O
+
+Intensive O
+therapy O
+of O
+viral O
+hepatitis O
+
+Also O
+, O
+the O
+RVW O
+hypertrophy O
+, O
+the O
+IVS O
+hypertrophy O
+, O
+and O
+the O
+RV O
+high O
+pressure O
+load O
+to O
+the O
+LV O
+through O
+the O
+IVS O
+may O
+be O
+related O
+to O
+the O
+small O
+LV O
+, O
+high O
+EF O
+, O
+and O
+abnormal O
+two O
+chamber O
+inflow O
+in O
+the O
+PS O
+group O
+before O
+BV O
+. O
+
+Analysis O
+of O
+the O
+DNA O
+- O
+binding O
+and O
+transcriptional O
+activation O
+functions O
+of O
+human B
+Fli B
+- I
+1 I
+protein I
+. O
+
+This O
+pattern O
+of O
+expression O
+and O
+differential O
+processing O
+suggests O
+a O
+role O
+for O
+inrpk1 B
+in O
+some O
+aspect O
+of O
+SD O
+photoperiodic O
+- O
+induced O
+flowering O
+in O
+morning O
+glory O
+. O
+
+Progressive O
+immunodeficiency O
+in O
+a O
+patient O
+with O
+IgA B
+deficiency O
+
+RMR O
+was O
+positively O
+correlated O
+with O
+TEF O
+( O
+r O
+= O
+0 O
+. O
+613 O
+, O
+p O
+< O
+0 O
+. O
+01 O
+) O
+and O
+net O
+TEF O
+( O
+r O
+= O
+0 O
+. O
+648 O
+, O
+p O
+< O
+0 O
+. O
+005 O
+) O
+in O
+the O
+luteal O
+but O
+not O
+the O
+follicular O
+phase O
+. O
+
+ESR O
+spectra O
+of O
+Er3 O
++ O
+in O
+SmB6 O
+single O
+crystals O
+: O
+Dynamic O
+Jahn O
+- O
+Teller O
+effect O
+in O
+a O
+mixed O
+- O
+valence O
+compound O
+. O
+
+The O
+N O
+- O
+terminal O
+exon1 O
+had O
+no O
+homology O
+at O
+the O
+amino O
+acid O
+level O
+with O
+NGFI B
+- I
+B I
+, O
+the O
+mammalian O
+homologue O
+. O
+
+This O
+paper O
+describes O
+a O
+longitudinal O
+study O
+in O
+which O
+clinical O
+parameters O
+and O
+aspartate B
+aminotransferase I
+( O
+AST B
+) O
+in O
+gingival O
+crevicular O
+fluid O
+( O
+GCF O
+) O
+were O
+monitored O
+bimonthly O
+over O
+a O
+6 O
+- O
+12 O
+months O
+period O
+in O
+970 O
+sites O
+from O
+7 O
+treated O
+periodontitis O
+patients O
+. O
+
+We O
+conclude O
+from O
+these O
+observations O
+that O
+the O
+cTnC O
+3 O
+' O
+Ile O
+element O
+is O
+a O
+composite O
+enhancer O
+that O
+functions O
+through O
+the O
+combined O
+interactions O
+of O
+at O
+least O
+five O
+regulatory O
+elements O
+and O
+their O
+cognate O
+binding O
+factors O
+: O
+three O
+or O
+four O
+E O
+- O
+boxes O
+, O
+a O
+MEF B
+- I
+2 I
+site I
+, O
+and O
+a O
+MEF B
+- I
+3 I
+site I
+. O
+
+The O
+analysis O
+consisted O
+of O
+1 O
+) O
+fitting O
+first O
+- O
+and O
+second O
+- O
+order O
+autoregressive O
+models O
+( O
+AR1 O
+and O
+AR2 O
+) O
+and O
+2 O
+) O
+obtaining O
+the O
+power O
+spectra O
+of O
+the O
+data O
+by O
+fast O
+- O
+Fourier O
+transform O
+. O
+
+We O
+identified O
+Tyr O
+( O
+112 O
+) O
+and O
+Leu O
+( O
+175 O
+) O
+within O
+the O
+RNA O
+- O
+binding O
+domain O
+of O
+the O
+U1 B
+70K I
+protein I
+to O
+be O
+cross O
+- O
+linked O
+to O
+G O
+( O
+28 O
+) O
+and O
+U O
+( O
+30 O
+) O
+in O
+stem O
+- O
+loop O
+I O
+, O
+respectively O
+. O
+
+Kudzu O
+extract O
+shows O
+potential O
+for O
+moderating O
+alcohol O
+abuse O
+. O
+
+Furthermore O
+, O
+the O
+data O
+suggest O
+an O
+immunological O
+non O
+- O
+responsiveness O
+to O
+enterotoxin B
+A I
+in O
+a O
+considerable O
+portion O
+of O
+the O
+patients O
+. O
+
+BCV O
+mRNAs O
+5 I
+and I
+5 I
+- I
+1 I
+appear O
+to O
+be O
+used O
+for O
+the O
+synthesis O
+of O
+the O
+12 O
+. O
+7 O
+- O
+and O
+9 O
+. O
+5 O
+- O
+kDa O
+proteins O
+, O
+respectively O
+, O
+which O
+demonstrates O
+a O
+pattern O
+of O
+expression O
+strikingly O
+different O
+from O
+that O
+utilized O
+by O
+MHV O
+. O
+
+Disaster O
+medicine O
+
+The O
+longest O
+S1 O
+- O
+S2 O
+interval O
+at O
+which O
+S2 O
+failed O
+to O
+capture O
+( O
+effective O
+refractory O
+period O
+) O
+was O
+longer O
+by O
+5 O
+. O
+5 O
++ O
+/ O
+- O
+8 O
+. O
+2 O
+msec O
+at O
+twice O
+threshold O
+( O
+0 O
+. O
+05 O
+less O
+than O
+p O
+less O
+than O
+0 O
+. O
+10 O
+) O
+and O
+5 O
+. O
+5 O
++ O
+/ O
+- O
+3 O
+. O
+5 O
+msec O
+at O
+5 O
+times O
+threshold O
+stimulation O
+( O
+p O
+less O
+than O
+0 O
+. O
+01 O
+) O
+when O
+the O
+basic O
+drive O
+and O
+extrastimuli O
+were O
+delivered O
+to O
+separate O
+sites O
+. O
+
+The O
+use O
+of O
+specific O
+somatic O
+cell O
+hybrids O
+have O
+allowed O
+us O
+to O
+locate O
+the O
+YAC O
+contig O
+telomeric O
+to O
+the O
+D3F15S2 B
+locus I
+, O
+in O
+a O
+region O
+which O
+is O
+frequently O
+deleted O
+in O
+lung O
+carcinomas O
+. O
+
+Experiments O
+were O
+performed O
+without O
+polarization O
+or O
+with O
+cathodic O
+and O
+anodic O
+polarization O
+of O
+the O
+adsorbent O
+. O
+
+Chronic O
+active O
+hepatitis O
+and O
+cirrhosis O
+of O
+the O
+liver O
+. O
+
+This O
+regulation O
+is O
+mediated O
+by O
+several O
+kinases O
+that O
+phosphorylate O
+specific O
+residues O
+in O
+the O
+different O
+functional O
+domains O
+of O
+the O
+p53 B
+molecule I
+. O
+
+These O
+data O
+show O
+that O
+the O
+processing O
+of O
+specific O
+target O
+transcripts O
+, O
+such O
+as O
+the O
+P B
+- I
+element I
+mRNA I
+, O
+is O
+regulated O
+by O
+a O
+functional O
+PSI B
+- O
+U1 B
+snRNP O
+interaction O
+in O
+Drosophila O
+. O
+
+Effect O
+of O
+dimethyl O
+sulfoxide O
+on O
+cooling O
+rates O
+of O
+unrestrained O
+rats O
+. O
+
+In O
+four O
+calves O
+given O
+Haemonchus O
+contortus O
+larvae O
+, O
+the O
+serum B
+pepsinogen I
+concentration O
+rose O
+quickly O
+to O
+reach O
+a O
+mean O
+of O
+3 O
+. O
+5 O
+iu O
+tyrosine O
+on O
+day O
+14 O
+after O
+infection O
+. O
+
+These O
+results O
+strongly O
+suggest O
+that O
+HSV O
+- O
+1 O
+infection O
+inhibits O
+host O
+cell O
+splicing O
+through O
+the O
+action O
+of O
+ICP27 B
+. O
+
+The O
+T O
+( O
+CCO2 O
+) O
+was O
+related O
+to O
+the O
+PCO2 O
+by O
+a O
+Pearson O
+product O
+coefficient O
+of O
+0 O
+. O
+79 O
+( O
+p O
+< O
+. O
+0005 O
+) O
+, O
+with O
+a O
+mean O
+difference O
+of O
+1 O
+. O
+94 O
+( O
+T O
+( O
+CCO2 O
+) O
+> O
+P O
+( O
+CO2 O
+) O
+and O
+95 O
+% O
+confidence O
+interval O
+of O
+- O
+0 O
+. O
+12 O
+to O
+4 O
+. O
+07 O
+. O
+
+Transformation O
+of O
+chicken O
+embryo O
+fibroblasts O
+( O
+CEF O
+) O
+with O
+the O
+Gag B
+- O
+Crk B
+fusion O
+protein O
+results O
+in O
+the O
+elevation O
+of O
+tyrosine O
+phosphorylation O
+on O
+specific O
+cellular O
+proteins O
+with O
+molecular O
+weights O
+of O
+130 O
+, O
+000 O
+, O
+110 O
+, O
+000 O
+, O
+and O
+70 O
+, O
+000 O
+( O
+p130 B
+, O
+p110 B
+, O
+and O
+p70 B
+, O
+respectively O
+) O
+, O
+an O
+event O
+which O
+has O
+been O
+correlated O
+with O
+cell O
+transformation O
+. O
+
+Urease B
+activity O
+, O
+judged O
+as O
+the O
+amount O
+of O
+ammonia O
+production O
+from O
+urea O
+, O
+could O
+be O
+measured O
+at O
+25 O
+ng O
+per O
+tube O
+( O
+S O
+/ O
+N O
+= O
+1 O
+. O
+5 O
+) O
+with O
+Jack B
+bean I
+meal I
+urease I
+. O
+
+Here O
+, O
+we O
+provide O
+direct O
+evidence O
+that O
+the O
+meiotic O
+defect O
+caused O
+by O
+either O
+unregulated O
+cAPK B
+activity O
+or O
+unregulated O
+ran1 B
++ I
+kinase I
+activity O
+is O
+due O
+to O
+inability O
+to O
+induce O
+transcription O
+of O
+the O
+mei2 B
++ I
+gene I
+, O
+which O
+is O
+required O
+for O
+meiotic O
+initiation O
+. O
+
+Optical O
+rotation O
+of O
+the O
+second O
+harmonic O
+radiation O
+from O
+retinal O
+in O
+bacteriorhodopsin B
+monomers I
+in O
+Langmuir O
+- O
+Blodgett O
+film O
+: O
+evidence O
+for O
+nonplanar O
+retinal O
+structure O
+. O
+
+Ultrasonography O
+is O
+a O
+diagnostic O
+alternative O
+which O
+may O
+replace O
+arthrography O
+. O
+
+In O
+K562 O
+cells O
+, O
+using O
+the O
+bicistronic O
+vector O
+, O
+selection O
+with O
+colchicine O
+led O
+to O
+at O
+least O
+20 O
+- O
+fold O
+higher O
+expression O
+of O
+the O
+MDR1 B
+gene I
+product I
+than O
+did O
+selection O
+with O
+G418 O
+, O
+suggesting O
+that O
+the O
+stringent O
+MDR1 B
+selection O
+system O
+is O
+very O
+efficient O
+for O
+obtaining O
+overexpression O
+of O
+foreign O
+genes O
+. O
+
+In O
+this O
+report O
+, O
+several O
+health O
+behaviors O
+were O
+investigated O
+in O
+relation O
+to O
+maintaining O
+mobility O
+during O
+4 O
+years O
+of O
+follow O
+- O
+up O
+among O
+6 O
+, O
+981 O
+men O
+and O
+women O
+aged O
+65 O
+years O
+and O
+older O
+with O
+intact O
+mobility O
+at O
+baseline O
+between O
+1981 O
+and O
+1983 O
+who O
+lived O
+in O
+one O
+of O
+three O
+communities O
+: O
+East O
+Boston O
+, O
+Massachusetts O
+; O
+Iowa O
+and O
+Washington O
+counties O
+, O
+Iowa O
+; O
+and O
+New O
+Haven O
+, O
+Connecticut O
+. O
+
+Our O
+analysis O
+indicates O
+that O
+a O
+gene O
+correction O
+mechanism O
+has O
+been O
+operating O
+on O
+the O
+Hbbs B
+chromosome O
+to O
+keep O
+beta B
+s I
+and O
+beta B
+t I
+evolving O
+in O
+concert O
+, O
+whereas O
+on O
+the O
+Hbbd B
+chromosome O
+, O
+beta B
+dmin I
+has O
+diverged O
+considerably O
+from O
+beta B
+dmaj I
+. O
+
+Structure O
+and O
+regulation O
+of O
+KGD2 B
+, O
+the O
+structural O
+gene O
+for O
+yeast B
+dihydrolipoyl I
+transsuccinylase I
+. O
+
+In O
+dehydrated O
+animals O
+at O
+Ta O
+38 O
+degrees O
+C O
+, O
+Tb O
+and O
+EWL O
+were O
+both O
+significantly O
+altered O
+( O
+P O
+less O
+than O
+0 O
+. O
+001 O
+) O
+from O
+the O
+normally O
+hydrated O
+state O
+and O
+were O
+measured O
+at O
+39 O
+. O
+9 O
++ O
+/ O
+- O
+0 O
+. O
+2 O
+degree O
+C O
+and O
+0 O
+. O
+84 O
++ O
+/ O
+- O
+0 O
+. O
+09 O
+W O
+. O
+
+kg O
+- O
+1 O
+respectively O
+. O
+
+We O
+identify O
+YY1 B
+recognition I
+sequences I
+within O
+the O
+vitamin O
+D O
+response O
+element O
+( O
+VDRE O
+) O
+of O
+the O
+osteocalcin B
+gene I
+that O
+are O
+critical O
+for O
+YY1 B
+- O
+dependent O
+repression O
+of O
+vitamin O
+D O
+- O
+enhanced O
+promoter O
+activity O
+. O
+
+Back O
+- O
+ground O
+factors O
+which O
+affect O
+the O
+outcome O
+of O
+steroid O
+withdrawal O
+therapy O
+in O
+patients O
+with O
+chronic O
+type O
+B O
+hepatitis O
+- O
+- O
+statistical O
+evaluation O
+of O
+the O
+importance O
+of O
+the O
+mode O
+of O
+HBV O
+transmission O
+
+Point O
+mutations O
+of O
+Stat3 B
+within O
+the O
+interacting O
+domains O
+blocked O
+both O
+physical O
+interaction O
+of O
+Stat3 B
+with O
+c B
+- I
+Jun I
+and O
+their O
+cooperation O
+in O
+IL B
+- I
+6 I
+- O
+induced O
+transcription O
+directed O
+by O
+the O
+alpha B
+( I
+2 I
+) I
+- I
+macroglobulin I
+enhancer I
+. O
+
+Three O
+patients O
+with O
+Mirizzi O
+type O
+II O
+syndrome O
+and O
+two O
+patients O
+with O
+Mirizzi O
+type O
+I O
+syndrome O
+were O
+treated O
+laparoscopically O
+. O
+
+Synchronous O
+multicentric O
+giant O
+cell O
+tumour O
+: O
+a O
+case O
+report O
+with O
+review O
+of O
+literature O
+. O
+
+From O
+the O
+comparison O
+of O
+the O
+nod B
+box I
+sequences O
+of O
+( O
+brady O
+) O
+rhizobia O
+with O
+a O
+more O
+divergent O
+nod B
+box O
+from O
+Azorhizobium O
+caulinodans O
+, O
+we O
+now O
+propose O
+a O
+modular O
+build O
+- O
+up O
+of O
+the O
+nod B
+box O
+with O
+the O
+sequence O
+A O
+- O
+T O
+- O
+C O
+- O
+N9 O
+- O
+G O
+- O
+A O
+- O
+T O
+as O
+the O
+binding O
+target O
+of O
+the O
+NodD B
+protein I
+( O
+the O
+NodD B
+box I
+) O
+. O
+
+The O
+prgX B
+gene I
+is O
+adjacent O
+to O
+prgQ B
+which O
+provides O
+the O
+promoter O
+for O
+prgB B
+expression O
+. O
+
+METHODS O
+: O
+A O
+discriminant O
+function O
+predicting O
+surgery O
+outcome O
+( O
+seizure O
+- O
+free O
+vs O
+. O
+non O
+- O
+seizure O
+- O
+free O
+) O
+was O
+computed O
+separately O
+for O
+samples O
+of O
+patients O
+with O
+left O
+( O
+n O
+= O
+79 O
+) O
+and O
+right O
+( O
+n O
+= O
+62 O
+) O
+temporal O
+lobectomy O
+( O
+LATL O
+, O
+RATL O
+) O
+. O
+
+It O
+is O
+likely O
+that O
+these O
+recordings O
+are O
+incomplete O
+; O
+the O
+actual O
+number O
+of O
+activated O
+neurons O
+is O
+estimated O
+to O
+be O
+about O
+300 O
+in O
+the O
+acutely O
+sensitized O
+preparation O
+. O
+
+The O
+possibility O
+to O
+use O
+this O
+method O
+for O
+common O
+diagnostic O
+problems O
+is O
+indicated O
+. O
+
+Genetic O
+analysis O
+of O
+the O
+role O
+of O
+herpes B
+simplex I
+virus I
+type I
+1 I
+glycoprotein I
+K I
+in O
+infectious O
+virus O
+production O
+and O
+egress O
+. O
+
+A O
+conventional O
+N O
+- O
+terminal O
+signal O
+sequence O
+was O
+not O
+detected O
+in O
+the O
+NodO B
+protein I
+. O
+
+Dynamic O
+expression O
+of O
+broad B
+- I
+complex I
+isoforms I
+mediates O
+temporal O
+control O
+of O
+an O
+ecdysteroid O
+target O
+gene O
+at O
+the O
+onset O
+of O
+Drosophila O
+metamorphosis O
+. O
+
+The O
+study O
+was O
+carried O
+out O
+according O
+to O
+the O
+BSI O
+( O
+1980 O
+) O
+recommendations O
+for O
+testing O
+restorative O
+materials O
+in O
+vivo O
+. O
+
+Cellular O
+lysates O
+were O
+analyzed O
+for O
+luciferase B
+and O
+beta B
+- I
+galactosidase I
+activities O
+. O
+
+Cytokines O
+and O
+steroid O
+hormones O
+use O
+different O
+sets O
+of O
+signal O
+transduction O
+pathways O
+, O
+which O
+seem O
+to O
+be O
+unrelated O
+. O
+
+These O
+findings O
+suggest O
+that O
+the O
+proteolipids O
+of O
+the O
+vacuolar B
+H I
++ I
+- I
+ATPases I
+were O
+evolved O
+in O
+parallel O
+with O
+the O
+eubacterial O
+proteolipid O
+, O
+from O
+a O
+common O
+ancestral O
+gene O
+that O
+underwent O
+gene O
+duplication O
+. O
+
+This O
+mutant O
+also O
+functions O
+in O
+vivo O
+as O
+a O
+trans O
+- O
+acting O
+dominant O
+negative O
+regulator O
+: O
+the O
+transcriptional O
+inducibility O
+of O
+the O
+HIV B
+long I
+terminal I
+repeat I
+( O
+which O
+contains O
+two O
+potential O
+NF B
+- I
+kappa I
+B I
+binding I
+sites I
+) O
+by O
+phorbol O
+ester O
+( O
+PMA O
+) O
+is O
+inhibited O
+when O
+it O
+is O
+co O
+- O
+transfected O
+into O
+CD4 B
++ I
+T O
+cells O
+with O
+the O
+delta B
+SP I
+mutant I
+. O
+
+In O
+addition O
+, O
+measurements O
+of O
+shielded O
+and O
+unshielded O
+syringes O
+containing O
+99mTc O
+- O
+labelled O
+radiopharmaceuticals O
+were O
+carried O
+out O
+. O
+
+This O
+study O
+tests O
+the O
+hypothesis O
+that O
+O2 O
+is O
+a O
+critical O
+component O
+in O
+myocardial O
+protection O
+afforded O
+by O
+BCP O
+. O
+
+Biomass O
+growth O
+monitoring O
+using O
+pressure O
+drop O
+in O
+a O
+cocurrent O
+biofilter O
+
+This O
+alternative O
+splice O
+acceptor O
+site O
+is O
+also O
+used O
+by O
+a O
+biologically O
+active O
+provirus O
+with O
+an O
+efficiency O
+of O
+approximately O
+5 O
+% O
+compared O
+with O
+the O
+upstream O
+site O
+. O
+
+Homology O
+is O
+much O
+higher O
+( O
+64 O
+% O
+) O
+between O
+the O
+28 O
+- O
+kDa O
+protein O
+and O
+regions O
+that O
+are O
+strongly O
+conserved O
+among O
+the O
+members O
+of O
+the O
+serine B
+protease I
+family I
+. O
+
+We O
+have O
+isolated O
+and O
+structurally O
+characterized O
+genomic O
+DNA O
+and O
+cDNA O
+sequences O
+encoding O
+ribulose B
+- I
+1 I
+, I
+5 I
+- I
+bisphosphate I
+carboxylase I
+/ I
+oxygenase I
+( I
+Rbu I
+- I
+P2 I
+carboxylase I
+) I
+activase O
+from O
+barley O
+( O
+Hordeum I
+vulgare O
+L O
+. O
+) O
+. O
+
+Expression O
+of O
+putative O
+constitutively O
+active O
+forms O
+of O
+DdMEK1 B
+in O
+a O
+ddmek1 B
+null O
+background O
+is O
+capable O
+, O
+at O
+least O
+partially O
+, O
+of O
+complementing O
+the O
+small O
+aggregate O
+size O
+defect O
+and O
+the O
+ability O
+to O
+activate O
+guanylyl B
+cyclase I
+. O
+
+Constant O
+slowing O
+of O
+median O
+MNCV O
+and O
+SNCV O
+and O
+ulnar O
+SNCV O
+without O
+changes O
+in O
+morphology O
+, O
+amplitude O
+and O
+duration O
+of O
+MAP O
+and O
+SAP O
+have O
+been O
+observed O
+in O
+92 O
+patients O
+, O
+with O
+persistent O
+abnormalities O
+in O
+64 O
+cases O
+after O
+six O
+months O
+. O
+
+Moreover O
+, O
+such O
+mutations O
+lead O
+to O
+a O
+dramatic O
+transition O
+in O
+chromatin O
+structure O
+: O
+the O
+DNase B
+I I
+hypersensitive O
+region O
+is O
+replaced O
+by O
+two O
+stable O
+, O
+sequence O
+- O
+positioned O
+nucleosomes O
+. O
+
+During O
+chronic O
+treatment O
+with O
+salmon B
+calcitonin I
+, O
+alkaline B
+phosphatase I
+activity O
+and O
+urinary O
+hydroxyproline O
+excretion O
+decrease O
+on O
+an O
+average O
+of O
+50 O
+% O
+in O
+patients O
+with O
+Paget O
+' O
+s O
+disease O
+. O
+
+187 O
+- O
+200 O
+. O
+
+Because O
+of O
+the O
+structural O
+similarities O
+the O
+new O
+gene O
+will O
+be O
+termed O
+scERV2 B
+from O
+now O
+on O
+. O
+
+Experience O
+in O
+a O
+Kenya O
+district O
+hospital O
+
+The O
+2 O
+. O
+3 O
+x O
+10 O
+( O
+3 O
+) O
+base O
+SUF12 B
++ I
+transcript I
+contains O
+an O
+open O
+reading O
+frame O
+sufficient O
+to O
+encode O
+a O
+88 O
+x O
+10 O
+( O
+3 O
+) O
+Mr O
+protein O
+. O
+
+Cortical O
+somatosensory O
+evoked O
+potentials O
+to O
+median O
+nerve O
+stimulation O
+revealed O
+significantly O
+delayed O
+peak O
+latencies O
+of O
+N20 O
+, O
+P20 O
+, O
+P25 O
+, O
+and O
+N26 O
+, O
+although O
+N16 O
+latency O
+was O
+normal O
+. O
+
+A O
+new O
+family O
+of O
+rate O
+- O
+adaptive O
+pacemakers O
+accomplishes O
+this O
+circadian O
+rate O
+variation O
+by O
+modeling O
+the O
+patient O
+' O
+s O
+sleep O
+- O
+wake O
+cycle O
+using O
+a O
+time O
+- O
+of O
+- O
+day O
+clock O
+inside O
+the O
+device O
+. O
+
+Progestins O
+: O
+present O
+and O
+future O
+. O
+
+Bilirubin O
+and O
+red O
+cell O
+metabolism O
+in O
+relation O
+to O
+neonatal O
+jaundice O
+. O
+
+Each O
+of O
+these O
+materials O
+were O
+placed O
+by O
+means O
+of O
+three O
+different O
+placement O
+techniques O
+( O
+Bulk O
+pack O
+, O
+Horizontal O
+layering O
+and O
+Vertical O
+layering O
+) O
+into O
+class O
+II O
+cavities O
+in O
+extracted O
+human O
+molars O
+. O
+
+This O
+ligand O
+- O
+independent O
+pathway O
+can O
+function O
+through O
+another O
+androgen O
+- O
+regulated O
+promoter O
+as O
+shown O
+by O
+the O
+use O
+of O
+the O
+mouse O
+mammary O
+tumor O
+virus O
+MMTV O
+- O
+CAT B
+reporter O
+. O
+
+Stress O
+- O
+induced O
+suppression O
+of O
+the O
+prolactin B
+afternoon O
+surge O
+in O
+ovariectomized O
+, O
+estrogen O
+- O
+treated O
+rats O
+and O
+the O
+nocturnal O
+surge O
+in O
+pseudopregnant O
+rats O
+are O
+accompanied O
+by O
+an O
+increase O
+in O
+median O
+eminence O
+dihydroxyphenylacetic O
+acid O
+concentrations O
+. O
+
+The O
+sensitivity O
+for O
+ergometry O
+and O
+treadmill O
+testing O
+was O
+75 O
+and O
+62 O
+% O
+respectively O
+. O
+
+Morphologic O
+evidence O
+that O
+rhe O
+renal O
+calyx O
+and O
+pelvis O
+control O
+ureteric O
+activity O
+in O
+the O
+rabbit O
+. O
+
+Children O
+with O
+repeated O
+proteinuria O
+during O
+follow O
+- O
+up O
+tend O
+to O
+have O
+a O
+higher O
+incidence O
+of O
+pathologic O
+findings O
+on O
+the O
+i O
+. O
+v O
+. O
+- O
+pyelogram O
+. O
+
+Parelaphostrongylus O
+odocoilei O
+is O
+redescribed O
+from O
+worms O
+collected O
+from O
+the O
+type O
+host O
+( O
+Odocoileus O
+hemionus O
+columbianus O
+) O
+in O
+California O
+, O
+as O
+well O
+as O
+material O
+from O
+experimentally O
+infected O
+mule O
+deer O
+( O
+O O
+. O
+h O
+. O
+heminus O
+) O
+in O
+Alberta O
+. O
+
+The O
+carboxyl O
+globular O
+domain O
+was O
+found O
+to O
+be O
+encoded O
+by O
+six O
+exons O
+which O
+appear O
+to O
+delineate O
+its O
+structural O
+subdomains O
+. O
+
+Expression O
+of O
+the O
+Asp B
+but O
+not O
+the O
+Ala B
+gB I
+mutation O
+resulted O
+in O
+an O
+increase O
+in O
+the O
+steady O
+- O
+state O
+expression O
+of O
+gB B
+at O
+the O
+plasma O
+membrane O
+( O
+PM O
+) O
+in O
+U373 O
+cells O
+. O
+
+Thus O
+integration B
+host I
+factor I
+is O
+required O
+for O
+normal O
+type B
+1 I
+fimbriae I
+phase O
+variation O
+in O
+E O
+. O
+coli O
+. O
+
+Insulin B
+therapy O
+has O
+been O
+expanded O
+by O
+development O
+of O
+human B
+insulin I
+and O
+new O
+modes O
+of O
+injection O
+, O
+including O
+insulin B
+pumps O
+. O
+
+Because O
+levels O
+of O
+Vo2DIR O
+and O
+Vo2INDIR O
+were O
+similar O
+in O
+both O
+groups O
+, O
+we O
+pooled O
+data O
+from O
+septic O
+and O
+control O
+animals O
+. O
+
+Further O
+interventions O
+were O
+: O
+nephrectomy O
+( O
+2x O
+) O
+, O
+resection O
+and O
+ligation O
+of O
+the O
+inferior O
+vena O
+cava O
+( O
+1x O
+) O
+, O
+resection O
+and O
+replacement O
+of O
+the O
+left O
+renal O
+vein O
+( O
+1x O
+) O
+. O
+
+OBJECTIVES O
+: O
+The O
+present O
+study O
+tested O
+the O
+hypothesis O
+that O
+stimulating O
+the O
+central O
+noradrenergic O
+system O
+using O
+the O
+new O
+noradrenaline O
+re O
+- O
+uptake O
+inhibitor O
+reboxetine O
+would O
+result O
+in O
+a O
+dose O
+- O
+dependent O
+enhancement O
+of O
+memory O
+for O
+emotional O
+material O
+in O
+man O
+. O
+
+We O
+examined O
+the O
+mechanisms O
+by O
+which O
+two O
+different O
+types O
+of O
+photonic O
+radiation O
+, O
+short O
+wavelength O
+UV O
+( O
+UV O
+- O
+C O
+) O
+and O
+gamma O
+radiation O
+, O
+activate O
+transcription B
+factor O
+NF B
+- I
+kappaB I
+. O
+
+However O
+, O
+coligation O
+of O
+Fc B
+gamma I
+RIIB1 I
+with O
+B B
+cell I
+Ag I
+receptors I
+( O
+BCR B
+) O
+inhibits O
+BCR B
+- O
+mediated O
+signaling O
+by O
+a O
+mechanism O
+that O
+may O
+involve O
+recruitment O
+of O
+phosphatases O
+SHP B
+- I
+1 I
+, O
+SHP B
+- I
+2 I
+, O
+and O
+the O
+SH2 B
+containing I
+inositol I
+5 I
+' I
+phosphatase I
+( O
+SHIP B
+) O
+to O
+the O
+phosphorylated O
+Fc B
+gamma I
+RIIB1 I
+immunoreceptor I
+tyrosine I
+- I
+based I
+inhibitory I
+motif I
+. O
+
+Using O
+the O
+standard O
+scoring O
+, O
+children O
+with O
+full O
+scale O
+IQ O
+< O
+or O
+= O
+84 O
+on O
+the O
+Wechsler O
+Preschool O
+and O
+Primary O
+Scale O
+of O
+Intelligence O
+at O
+age O
+4 O
+- O
+5 O
+years O
+were O
+poorly O
+identified O
+( O
+sensitivity O
+54 O
+% O
+) O
+from O
+the O
+composite O
+S O
+- O
+B O
+IV O
+score O
+at O
+age O
+3 O
+. O
+
+11 O
+: O
+5801 O
+- O
+5812 O
+, O
+1991 O
+) O
+present O
+evidence O
+that O
+the O
+Vps18 B
+/ O
+Pep3 B
+protein O
+colocalizes O
+with O
+the O
+Vps11 B
+/ O
+Pep5 B
+protein O
+to O
+the O
+cytosolic O
+face O
+of O
+the O
+vacuolar O
+membrane O
+. O
+
+This O
+study O
+includes O
+200 O
+patients O
+treated O
+from O
+1964 O
+to O
+1978 O
+, O
+with O
+an O
+age O
+range O
+from O
+15 O
+to O
+102 O
+years O
+, O
+who O
+required O
+329 O
+generators O
+. O
+
+We O
+conclude O
+that O
+the O
+BR B
+- I
+C I
+early I
+gene I
+directly O
+activates O
+late O
+gene O
+transcription O
+by O
+interacting O
+with O
+late O
+gene O
+cis O
+- O
+acting O
+regulatory O
+elements O
+and O
+that O
+this O
+interaction O
+is O
+responsible O
+for O
+the O
+temporal O
+linkage O
+of O
+early O
+and O
+late O
+ecdysone O
+- O
+induced O
+gene O
+expression O
+. O
+
+The O
+specificity O
+and O
+sensitivity O
+of O
+this O
+method O
+( O
+limit O
+of O
+detection O
+in O
+plasma O
+0 O
+. O
+025 O
+micrograms O
+/ O
+mL O
+and O
+< O
+or O
+= O
+0 O
+. O
+0125 O
+micrograms O
+/ O
+mL O
+for O
+febantel O
+and O
+its O
+metabolites O
+, O
+respectively O
+) O
+were O
+sufficiently O
+high O
+to O
+enable O
+us O
+to O
+characterize O
+the O
+time O
+course O
+of O
+the O
+drug O
+in O
+the O
+plasma O
+after O
+oral O
+administration O
+of O
+therapeutic O
+doses O
+to O
+sheep O
+. O
+
+We O
+have O
+identified O
+the O
+gene O
+encoding O
+sigma B
+E I
+using O
+a O
+genetic O
+screen O
+designed O
+to O
+isolate O
+trans O
+- O
+acting O
+mutations O
+that O
+abolish O
+expression O
+from O
+either O
+htrA B
+or O
+rpoHP3 B
+, O
+two O
+promoters O
+recognized O
+uniquely O
+by O
+sigma B
+E I
+- I
+containing I
+RNA I
+polymerase I
+. O
+
+Cytokinetics O
+of O
+the O
+Krebs O
+2 O
+carcinoma O
+. O
+
+Through O
+effective O
+use O
+of O
+laboratory O
+testing O
+database O
+, O
+it O
+will O
+be O
+possible O
+to O
+shift O
+away O
+our O
+vague O
+management O
+of O
+pre O
+- O
+analytic O
+phase O
+of O
+quality O
+control O
+so O
+far O
+to O
+its O
+established O
+system O
+based O
+on O
+objective O
+evaluation O
+. O
+
+These O
+patients O
+developed O
+severe O
+diabetic O
+symptoms O
+including O
+glucose O
+intolerance O
+, O
+weight O
+loss O
+, O
+impaired O
+energy O
+utilization O
+, O
+and O
+nerve O
+and O
+brain O
+disorders O
+that O
+were O
+refractory O
+to O
+insulin B
+. O
+
+One O
+promoter O
+, O
+p53P1 B
+, O
+is O
+located O
+100 O
+- O
+250 O
+bp O
+upstream O
+of O
+the O
+218 O
+- O
+bp O
+noncoding O
+first O
+exon O
+; O
+a O
+second O
+, O
+stronger O
+promoter O
+, O
+p53P2 B
+, O
+maps O
+within O
+the O
+first O
+intron O
+. O
+
+Both O
+PMP20 B
+gene I
+products I
+contain O
+the O
+carboxyl O
+- O
+terminal O
+sequence O
+AKL B
+, O
+similar O
+to O
+the O
+putative O
+SKL B
+peroxisomal O
+sorting O
+sequence I
+( O
+Gould O
+, O
+S O
+. O
+
+The O
+likelihood O
+of O
+death O
+was O
+more O
+than O
+3 O
+times O
+higher O
+among O
+patients O
+in O
+the O
+ERA O
+- O
+II O
+group O
+( O
+mortality O
+risk O
+ratio O
+3 O
+. O
+82 O
+[ O
+95 O
+% O
+CI O
+1 O
+. O
+48 O
+% O
+to O
+9 O
+. O
+84 O
+] O
+, O
+p O
+= O
+0 O
+. O
+006 O
+) O
+. O
+
+Barium O
+mucosal O
+coating O
+was O
+judged O
+to O
+be O
+better O
+in O
+the O
+members O
+to O
+whom O
+magnesium O
+sulphate O
+was O
+administered O
+( O
+p O
+= O
+0 O
+. O
+0007 O
+) O
+. O
+
+In O
+both O
+immortalized O
+and O
+normal O
+diploid O
+human O
+cells O
+, O
+wt O
+AAV O
+targeted O
+integration O
+to O
+ch B
+- I
+19 I
+. O
+
+The O
+corresponding O
+tetrapeptide O
+sequences O
+SSPD B
+and O
+SATD B
+for O
+human B
+and I
+mouse I
+PKC I
+- I
+epsilon I
+, O
+respectively O
+, O
+are O
+unusual O
+for O
+caspase B
+- I
+3 I
+. O
+
+The O
+lipopolysaccharide B
+- I
+binding I
+protein I
+is O
+a O
+secretory O
+class O
+1 O
+acute O
+- O
+phase O
+protein O
+whose O
+gene O
+is O
+transcriptionally O
+activated O
+by O
+APRF B
+/ O
+STAT B
+/ I
+3 I
+and O
+other O
+cytokine O
+- O
+inducible O
+nuclear O
+proteins O
+. O
+
+Tritium O
+concentrations O
+in O
+environmental O
+water O
+samples O
+were O
+found O
+to O
+be O
+determined O
+within O
+an O
+accuracy O
+of O
+10 O
+% O
+by O
+this O
+method O
+when O
+Vi O
+/ O
+Vf O
+was O
+14 O
+- O
+25 O
+. O
+
+This O
+region O
+does O
+not O
+contain O
+a O
+consensus O
+estrogen O
+response O
+element O
+, O
+and O
+ER B
+binding O
+to O
+this O
+DNA O
+sequence O
+was O
+not O
+observed O
+. O
+
+These O
+proteins O
+, O
+called O
+variant B
+surface I
+glycoproteins I
+( O
+VSGs B
+) O
+, O
+are O
+expressed O
+from O
+a O
+specific O
+locus O
+, O
+the O
+VSG B
+gene I
+expression I
+site I
+( O
+ES O
+) O
+. O
+
+The O
+strangulated O
+intestinal O
+pathologies O
+of O
+horses O
+are O
+accompanied O
+by O
+a O
+local O
+activation O
+of O
+the O
+neutrophils O
+, O
+that O
+can O
+be O
+revealed O
+by O
+measuring O
+the O
+tissular O
+enzymatic O
+activity O
+of O
+the O
+granulocytic B
+enzyme I
+myeloperoxidase I
+( O
+MPO B
+) O
+. O
+
+A O
+deletion O
+analysis O
+of O
+the O
+FAS1 B
+promoter I
+lacking O
+the O
+previously O
+characterized O
+inositol O
+/ O
+choline O
+- O
+responsive O
+- O
+element O
+motif O
+defined O
+a O
+region O
+( O
+nucleotides O
+- O
+760 O
+to O
+- O
+850 O
+) O
+responsible O
+for O
+most O
+of O
+the O
+remaining O
+activation O
+potency O
+. O
+
+Here O
+we O
+report O
+the O
+fabrication O
+of O
+single O
+- O
+molecule O
+transistors O
+based O
+on O
+individual O
+C60 O
+molecules O
+connected O
+to O
+gold O
+electrodes O
+. O
+
+The O
+homeodomain B
+transcription I
+factor I
+CDP B
+/ O
+cut B
+interacts O
+with O
+the O
+cell O
+cycle O
+regulatory O
+element O
+of O
+histone B
+H4 I
+genes I
+packaged O
+into O
+nucleosomes O
+. O
+
+They O
+encode O
+proteins O
+whose O
+core O
+regions O
+display O
+great O
+similarity O
+to O
+Aspergillus B
+HAPB I
+, O
+HAPC B
+and O
+HAPE B
+and O
+to O
+known O
+HAP B
+homologs I
+from O
+other O
+organisms O
+. O
+
+Furthermore O
+, O
+the O
+cognate O
+binding O
+protein O
+is O
+present O
+in O
+both O
+rat O
+and O
+human O
+( O
+HeLa O
+) O
+cell O
+nuclear O
+extracts O
+. O
+
+Transient O
+cotransfection O
+analyses O
+indicate O
+that O
+the O
+cooperative O
+association O
+of O
+NF B
+- I
+IL I
+- I
+6 I
+and O
+RelA B
+with O
+the O
+IL B
+- I
+8 I
+promoter I
+results O
+in O
+synergistic O
+transcriptional O
+activation O
+. O
+
+Heart O
+rate O
+during O
+the O
+behavioral O
+avoidance O
+test O
+was O
+shown O
+to O
+be O
+as O
+susceptible O
+to O
+experimental O
+demand O
+as O
+other O
+studies O
+have O
+shown O
+approach O
+behaviors O
+to O
+be O
+influenced O
+. O
+
+Function O
+was O
+retained O
+when O
+one O
+copy O
+of O
+the O
+sequence O
+was O
+present O
+, O
+suggesting O
+that O
+this O
+sequence O
+represents O
+an O
+essential O
+element O
+. O
+
+Decreased O
+plasma O
+level O
+of O
+antithrombin B
+III I
+was O
+assumed O
+to O
+be O
+one O
+of O
+the O
+major O
+factors O
+underlying O
+hypercoagulable O
+state O
+in O
+nephrotic O
+syndrome O
+. O
+
+NO2 O
+pollution O
+on O
+major O
+trunk O
+roads O
+frequently O
+exceeded O
+British O
+and O
+European O
+Union O
+air O
+quality O
+standards O
+, O
+while O
+particle O
+pollution O
+was O
+lower O
+. O
+
+Cotransfection O
+of O
+pINV B
+- O
+2473 O
+, O
+a O
+construct O
+containing O
+2473 O
+base O
+pairs O
+of O
+hINV B
+upstream I
+sequence I
+linked O
+to O
+luciferase B
+, O
+with O
+POU B
+homeodomain I
+transcription I
+factors I
+Oct1 B
+, O
+Oct2 B
+, O
+Brn4 B
+, O
+SCIP B
+, O
+Skn1a B
+or O
+Skn1i B
+, O
+results O
+in O
+a O
+strong O
+suppression O
+of O
+basal O
+promoter O
+activity O
+. O
+
+87 O
+, O
+7270 O
+- O
+7274 O
+) O
+. O
+
+I O
+. O
+
+Transcripts O
+initiating O
+at O
+the O
+CAGT O
+motif O
+( O
+proximal O
+transcripts O
+) O
+were O
+abolished O
+by O
+deletion O
+of O
+the O
+proximal O
+TATA O
+box O
+located O
+at O
+- O
+29 O
+relative O
+to O
+CAGT O
+. O
+
+Genomic O
+DNA O
+blot O
+analysis O
+indicates O
+that O
+the O
+trout B
+L2 I
+locus I
+has O
+a O
+cluster O
+- O
+like O
+organization O
+similar O
+to O
+the O
+trout B
+L1 I
+locus I
+and O
+the O
+IgL B
+locus I
+of O
+several O
+teleost O
+fish O
+. O
+
+Although O
+the O
+energy O
+- O
+based O
+DFT O
+was O
+not O
+affected O
+by O
+isoproterenol O
+( O
+from O
+6 O
+. O
+1 O
++ O
+/ O
+- O
+1 O
+. O
+5 O
+to O
+6 O
+. O
+0 O
++ O
+/ O
+- O
+1 O
+. O
+7 O
+J O
+) O
+, O
+it O
+was O
+decreased O
+to O
+3 O
+. O
+7 O
++ O
+/ O
+- O
+1 O
+. O
+6 O
+J O
+in O
+the O
+third O
+stage O
+by O
+infusion O
+of O
+E4031 O
+and O
+isoproterenol O
+( O
+p O
+< O
+0 O
+. O
+01 O
+vs O
+. O
+baseline O
+and O
+vs O
+. O
+isoproterenol O
+) O
+. O
+
+Gore O
+& O
+Associates O
+, O
+Inc O
+. O
+) O
+standard O
+wall O
+graft O
+segments O
+varying O
+in O
+length O
+from O
+4 O
+to O
+12 O
+cm O
+. O
+
+The O
+dynamics O
+of O
+N O
+- O
+interaction O
+and O
+N O
+- O
+retention O
+during O
+3 O
+hr O
+CPB O
+was O
+quantified O
+with O
+autologous O
+In O
+- O
+111 O
+labeled O
+neutrophils O
+( O
+INN O
+) O
+in O
+4 O
+groups O
+of O
+20 O
+Yorkshire O
+pigs O
+( O
+28 O
+- O
+35 O
+kg O
+, O
+5 O
+sham O
+; O
+5 O
+CPB O
+, O
+1 O
+hr O
+; O
+5 O
+CPB O
+, O
+3 O
+hr O
+and O
+5 O
+CPB O
+with O
+heparinized O
+circuit O
+, O
+3 O
+hr O
+) O
+; O
+anesthetized O
+pigs O
+were O
+injected O
+with O
+INN O
+( O
+500 O
+- O
+650 O
+microCi O
+) O
+, O
+30 O
+min O
+before O
+CPB O
+and O
+heparinized O
+, O
+and O
+underwent O
+CPB O
+with O
+a O
+roller O
+pump O
+, O
+a O
+hollow O
+
+fiber O
+OX O
+( O
+Bentley O
+CM O
+50 O
+, O
+5 O
+. O
+0 O
+m2 O
+) O
+and O
+AF O
+( O
+Bentley O
+AF O
+025 O
+, O
+0 O
+. O
+25 O
+m2 O
+) O
+at O
+2 O
+. O
+5 O
+- O
+3 O
+. O
+6 O
+l O
+/ O
+min O
+for O
+3 O
+hr O
+. O
+
+The O
+region O
+immediately O
+following O
+the O
+promoter O
+and O
+5 O
+' O
+to O
+ORF1 O
+has O
+a O
+potential O
+transcription O
+terminator O
+sequence O
+. O
+
+Studies O
+on O
+recurrences O
+in O
+gingival O
+hyperplasia O
+
+Preface O
+and O
+acknowledgements O
+. O
+
+We O
+conclude O
+that O
+clonidine O
+3 O
+micrograms O
+/ O
+kg O
+produces O
+sedation O
+comparable O
+to O
+diazepam O
+0 O
+. O
+2 O
+mg O
+/ O
+kg O
+and O
+also O
+attenuates O
+the O
+intubation O
+response O
+without O
+increasing O
+the O
+incidence O
+of O
+complications O
+. O
+
+Pancreatic O
+expression O
+of O
+the O
+glucagon B
+gene I
+depends O
+on O
+multiple O
+transcription O
+factors O
+interacting O
+with O
+at O
+least O
+three O
+DNA O
+control O
+elements O
+: O
+G1 O
+, O
+the O
+upstream O
+promoter O
+element O
+, O
+and O
+G2 O
+and O
+G3 O
+, O
+two O
+enhancer O
+- O
+like O
+sequences O
+. O
+
+We O
+have O
+compared O
+the O
+ability O
+of O
+GST B
+- O
+Bem3 B
+to O
+serve O
+as O
+a O
+GAP B
+for O
+Cdc42Hs B
+relative O
+to O
+other O
+members O
+of O
+the O
+rho B
+- O
+GAP B
+subfamily O
+and O
+found O
+the O
+following O
+order O
+of O
+potency O
+: O
+human B
+platelet I
+Cdc42Hs I
+GAP B
+> O
+p190 B
+> O
+Bem3 B
+> O
+break B
+point I
+cluster I
+region I
+protein I
+, O
+whereas O
+p85 B
+, O
+like O
+Bem2 B
+, O
+shows O
+no O
+GAP B
+activity O
+or O
+any O
+ability O
+to O
+bind O
+to O
+the O
+GTP O
+- O
+bound O
+form O
+of O
+Cdc42Hs B
+. O
+
+CONCLUSION O
+: O
+Men O
+presenting O
+with O
+urethritis O
+and O
+women O
+presenting O
+with O
+PID O
+both O
+have O
+significantly O
+greater O
+peripheral O
+blood O
+mononuclear O
+cell O
+proliferative O
+responses O
+to O
+the O
+DK20 O
+strain O
+of O
+C O
+trachomatis O
+than O
+controls O
+. O
+
+The O
+PDSS O
+identified O
+17 O
+( O
+94 O
+% O
+) O
+of O
+the O
+women O
+diagnosed O
+with O
+major O
+postpartum O
+depression O
+, O
+the O
+EPDS O
+identified O
+14 O
+of O
+these O
+women O
+( O
+78 O
+% O
+) O
+, O
+and O
+the O
+BDI O
+- O
+II O
+identified O
+10 O
+of O
+the O
+18 O
+women O
+( O
+56 O
+% O
+) O
+. O
+
+Men O
+and O
+women O
+entering O
+psychotherapy O
+more O
+often O
+had O
+negative O
+Wish O
+elements O
+than O
+others O
+. O
+
+Single O
+amino O
+acid O
+substitutions O
+were O
+shown O
+to O
+result O
+from O
+the O
+mutations O
+pdr1 B
+- I
+2 I
+( O
+M308I O
+) O
+, O
+pdr1 B
+- I
+3 I
+( O
+F815S O
+) O
+, O
+pdr1 B
+- I
+6 I
+( I
+K302Q I
+) I
+, O
+pdr1 B
+- I
+7 I
+( O
+P298A O
+) O
+and O
+pdr1 B
+- I
+8 I
+( O
+L1036 O
+W O
+) O
+, O
+whereas O
+the O
+intragenic O
+suppressor O
+mutant O
+pdr1 B
+- I
+100 I
+is O
+deleted O
+for O
+the O
+two O
+amino O
+acids O
+L537 O
+and O
+A538 O
+. O
+
+Both O
+merR B
+genes I
+consist O
+of O
+a O
+408 O
+bp O
+ORF O
+coding O
+for O
+135 O
+amino O
+acids O
+. O
+
+Amniotic O
+fluid O
+ionic O
+concentration O
+in O
+response O
+to O
+chronic O
+fetal B
+vasopressin I
+infusion O
+. O
+
+The O
+same O
+slice O
+was O
+imaged O
+three O
+times O
+each O
+with O
+sequences O
+using O
+spatial O
+presaturation O
+or O
+not O
+. O
+
+Molecular O
+cloning O
+of O
+the O
+alpha B
+- I
+globin I
+transcription I
+factor I
+CP2 B
+. O
+
+The O
+most O
+distal O
+active O
+site O
+in O
+TIGA B
+is O
+created O
+by O
+excision O
+of O
+a O
+66 O
+- O
+bp O
+intron O
+. O
+
+Denaturing O
+gradient O
+gel O
+electrophoresis O
+( O
+DGGE O
+) O
+with O
+sequence O
+analysis O
+showed O
+that O
+PGCL4 B
+is O
+a O
+major O
+member O
+in O
+the O
+female O
+mammary O
+gland O
+, O
+and O
+in O
+the O
+submaxillary O
+and O
+lachrymal O
+glands O
+of O
+both O
+sexes O
+, O
+while O
+the O
+counterpart O
+in O
+male O
+liver O
+and O
+the O
+coagulate O
+glands O
+was O
+found O
+to O
+be O
+PGCL1 B
+. O
+
+All O
+possessed O
+cutaneous O
+receptive O
+fields O
+on O
+the O
+distal O
+segments O
+of O
+digits O
+2 O
+, O
+3 O
+, O
+or O
+4 O
+. O
+
+Sesame O
+seed O
+should O
+also O
+be O
+considered O
+a O
+cause O
+of O
+allergic O
+reactions O
+to O
+drug O
+products O
+and O
+cosmetics O
+. O
+
+Ligand O
+binding O
+of O
+multi B
+- I
+chain I
+antigen I
+receptors I
+and O
+hematopoietin B
+/ I
+cytokine I
+receptors I
+results O
+in O
+rapid O
+activation O
+of O
+protein B
+tyrosine I
+kinase I
+( O
+PTK B
+) O
+- O
+dependent O
+signalling O
+molecules O
+such O
+as O
+phosphatidylinositol B
+3 I
+- I
+kinase I
+( O
+PI B
+3 I
+- I
+kinase I
+) O
+. O
+
+The O
+UASB O
+reactors O
+treated O
+a O
+VFA O
+mixture O
+( O
+with O
+an O
+acetate O
+: O
+propionate O
+: O
+butyrate O
+ratio O
+of O
+5 O
+: O
+3 O
+: O
+2 O
+on O
+COD O
+basis O
+) O
+or O
+acetate O
+as O
+the O
+sole O
+substrate O
+at O
+different O
+COD O
+: O
+sulfate O
+ratios O
+. O
+
+The O
+authors O
+emphasize O
+absence O
+of O
+specific O
+signs O
+of O
+vagal O
+involvement O
+, O
+importance O
+for O
+diagnosis O
+of O
+surgical O
+extirpation O
+, O
+and O
+mildness O
+of O
+post O
+operative O
+course O
+. O
+
+Now O
+: O
+pleasure O
+in O
+work O
+
+This O
+article O
+reviews O
+current O
+concepts O
+of O
+pathophysiology O
+and O
+summarises O
+clinical O
+features O
+, O
+natural O
+history O
+and O
+available O
+treatments O
+. O
+
+Previous O
+data O
+suggested O
+a O
+subtle O
+increase O
+in O
+serum O
+P O
+at O
+the O
+time O
+of O
+hCG B
+injection O
+without O
+LH B
+surge O
+reduces O
+the O
+PR O
+of O
+women O
+having O
+oocyte O
+retrievals O
+for O
+IVF O
+; O
+this O
+study O
+compared O
+PRs O
+of O
+recipients O
+in O
+a O
+shared O
+oocyte O
+program O
+according O
+to O
+the O
+donors O
+' O
+pre O
+- O
+hCG B
+P O
+level O
+. O
+
+Adequacy O
+of O
+the O
+Haldane O
+transformation O
+in O
+the O
+computation O
+of O
+exercise O
+V O
+O2 O
+in O
+man O
+. O
+
+M O
+. O
+, O
+Adrich O
+, O
+Z O
+. O
+, O
+Fournet O
+, O
+B O
+. O
+, O
+Capon O
+, O
+C O
+. O
+, O
+Bonicel O
+, O
+J O
+. O
+
+Association O
+between O
+hyperhomocysteinemia O
+and O
+ischemic O
+heart O
+disease O
+in O
+Sri O
+Lankans O
+. O
+
+Radiological O
+imaging O
+such O
+as O
+UGI O
+series O
+and O
+CT O
+scan O
+was O
+useful O
+to O
+arrive O
+at O
+an O
+accurate O
+diagnosis O
+. O
+
+The O
+architecture O
+of O
+the O
+hRap1 B
+Myb B
+domain O
+is O
+very O
+close O
+to O
+that O
+of O
+each O
+of O
+the O
+Myb B
+domains I
+from O
+TRF1 B
+, O
+scRap1p B
+and O
+c B
+- I
+Myb I
+. O
+
+80 O
+v B
+- I
+ets I
+- O
+encoded I
+amino I
+- O
+acids O
+located O
+immediately O
+after O
+the O
+v B
+- I
+myb I
+/ O
+v B
+- I
+ets I
+junction O
+are O
+not O
+found O
+in O
+P54 B
+/ I
+56c I
+- I
+ets I
+, O
+the O
+translation O
+product O
+of O
+the O
+c B
+- I
+ets I
+proto I
+- I
+oncogene I
+, O
+nor O
+in O
+a O
+set O
+of O
+cellular O
+proteins O
+of O
+64 O
+, O
+62 O
+, O
+and O
+60 O
+kDa O
+related O
+to O
+but O
+distinct O
+from O
+P54 B
+/ I
+56c I
+- I
+ets I
+. O
+
+We O
+have O
+raised O
+antibodies O
+against O
+a O
+peptide O
+specific O
+to O
+the O
+predicted O
+protein O
+product O
+of O
+this O
+second O
+mRNA O
+. O
+
+Because O
+controlled O
+- O
+release O
+niacin O
+seems O
+to O
+be O
+more O
+potent O
+than O
+crystalline O
+niacin O
+, O
+product O
+substitution O
+without O
+dose O
+adjustment O
+should O
+be O
+avoided O
+. O
+
+Interobserver O
+agreement O
+of O
+the O
+Nottingham O
+histologic O
+grading O
+scheme O
+for O
+infiltrating O
+duct O
+carcinoma O
+breast O
+. O
+
+This O
+dose O
+of O
+Na3 O
+citrate O
+produced O
+no O
+clinical O
+symptoms O
+suggestive O
+of O
+hypocalcaemia O
+in O
+these O
+subjects O
+, O
+even O
+though O
+the O
+use O
+of O
+acid O
+- O
+citrate O
+- O
+dextrose O
+, O
+NIH O
+formula O
+A O
+( O
+ACD O
+- O
+A O
+) O
+under O
+identical O
+conditions O
+has O
+been O
+reported O
+to O
+reduce O
+significantly O
+the O
+level O
+of O
+total O
+calcium O
+in O
+serum O
+, O
+and O
+concomitantly O
+increase O
+the O
+number O
+or O
+reactions O
+occurring O
+in O
+donors O
+. O
+
+Latex O
+products O
+( O
+gloves O
+, O
+balloons O
+, O
+and O
+condoms O
+) O
+directly O
+bound O
+IgE B
+from O
+all O
+four O
+patients O
+. O
+
+The O
+phosphoprotein B
+pUL69 I
+of O
+human O
+cytomegalovirus O
+( O
+HCMV O
+) O
+, O
+which O
+is O
+a O
+herpesvirus O
+of O
+considerable O
+medical O
+importance O
+in O
+immunosuppressed O
+patients O
+and O
+newborns O
+, O
+has O
+previously O
+been O
+identified O
+as O
+an O
+early O
+- O
+late O
+viral O
+protein O
+that O
+can O
+stimulate O
+several O
+viral O
+and O
+cellular O
+promoters O
+and O
+thus O
+exerts O
+a O
+rather O
+broad O
+activation O
+pattern O
+. O
+
+Southern O
+blot O
+analysis O
+performed O
+on O
+genomic O
+DNA O
+demonstrated O
+altered O
+CpG O
+methylation O
+within O
+intron O
+1 O
+in O
+DNA O
+from O
+all O
+BCC O
+compared O
+to O
+normal O
+, O
+mortal O
+human O
+mammary O
+epithelial O
+cells O
+( O
+HMEC O
+) O
+. O
+
+Previous O
+studies O
+have O
+shown O
+that O
+TGFbeta1 B
+expression O
+is O
+upregulated O
+in O
+mouse O
+keratinocytes O
+infected O
+with O
+a O
+v O
+- O
+rasHa O
+retrovirus O
+, O
+although O
+the O
+functional O
+significance O
+of O
+this O
+has O
+not O
+been O
+clear O
+. O
+
+An O
+increased O
+incidence O
+of O
+ATN O
+has O
+been O
+reported O
+since O
+the O
+introduction O
+of O
+cyclosporin O
+A O
+. O
+
+Using O
+a O
+GTP O
+- O
+dependent O
+, O
+brefeldin O
+A O
+- O
+sensitive O
+in O
+vitro O
+AP B
+- I
+1 I
+binding O
+assay O
+, O
+we O
+have O
+determined O
+here O
+the O
+parameters O
+of O
+the O
+AP B
+- I
+1 I
+binding O
+reaction O
+. O
+
+The O
+overall O
+rate O
+of O
+biohydrogenation O
+of O
+C18 O
+: O
+2 O
+was O
+14 O
+. O
+3 O
+% O
+/ O
+h O
+, O
+but O
+declined O
+1 O
+. O
+2 O
+% O
+/ O
+h O
+for O
+each O
+percentage O
+unit O
+increase O
+in O
+C18 O
+: O
+2 O
+added O
+to O
+the O
+substrate O
+. O
+
+Plasma B
+enteroglucagon I
+was O
+measured O
+before O
+and O
+during O
+three O
+hours O
+after O
+a O
+standard O
+meal O
+in O
+21 O
+untreated O
+adult O
+patients O
+with O
+suspected O
+coeliac O
+disease O
+who O
+all O
+had O
+villous O
+atrophy O
+of O
+the O
+small O
+intestinal O
+mucosa O
+and O
+malabsorption O
+, O
+and O
+in O
+nine O
+control O
+subjects O
+. O
+
+After O
+control O
+for O
+body O
+mass O
+index O
+, O
+trait O
+anxiety O
+and O
+anger O
+- O
+in O
+remained O
+independent O
+predictors O
+of O
+diastolic O
+blood O
+pressure O
+among O
+the O
+women O
+. O
+
+Regulation O
+of O
+the O
+human B
+stress I
+response I
+gene I
+GADD153 I
+expression O
+: O
+role O
+of O
+ETS1 B
+and O
+FLI B
+- I
+1 I
+gene I
+products I
+. O
+
+The O
+PRP4 B
+protein I
+of O
+Saccharomyces I
+cerevisiae I
+is O
+an O
+essential O
+part O
+of O
+the O
+U4 B
+/ O
+U6 B
+snRNP O
+, O
+a O
+component O
+of O
+the O
+mRNA O
+splicing O
+apparatus O
+. O
+
+132 O
+varix O
+ligations O
+were O
+performed O
+during O
+44 O
+separate O
+EVL O
+sessions O
+. O
+
+Here O
+RFX B
+/ O
+X2BP B
+/ O
+DNA O
+complexes O
+were O
+formed O
+on O
+all O
+class O
+II O
+isotypes O
+regardless O
+of O
+the O
+ability O
+of O
+the O
+X O
+box O
+region O
+to O
+bind O
+either O
+factor O
+individually O
+. O
+
+The O
+psi B
+zeta I
+gene I
+has O
+a O
+nonsense O
+mutation O
+in O
+exon O
+1 O
+but O
+has O
+identical O
+promoter O
+sequence O
+and O
+RNA O
+processing O
+sites O
+to O
+the O
+zeta O
+gene O
+, O
+raising O
+the O
+possibility O
+that O
+both O
+psi B
+zeta I
+and I
+zeta I
+are O
+transcriptionally O
+active O
+. O
+
+Prospects O
+of O
+chemosterilant O
+and O
+genetic O
+control O
+of O
+rodents O
+. O
+
+Serum B
+PRL I
+concentrations O
+significantly O
+increased O
+after O
+MCP O
+administration O
+in O
+normal O
+women O
+, O
+hyperprolactinemic O
+patients O
+with O
+normal O
+sella O
+and O
+patients O
+with O
+microadenoma O
+, O
+but O
+not O
+in O
+macroadenoma O
+patients O
+with O
+and O
+without O
+suprasellar O
+expansion O
+( O
+SSE O
+) O
+. O
+
+The O
+Id4 B
+protein I
+contains O
+a O
+HLH B
+domain O
+highly O
+conserved O
+among O
+the O
+dnHLH B
+proteins I
+from I
+mouse I
+and I
+drosophila I
+. O
+
+The O
+coding O
+region O
+of O
+nifA B
+was O
+determined O
+using O
+a O
+translational O
+lacZ B
+fusion O
+and O
+by O
+site O
+- O
+directed O
+mutagenesis O
+to O
+identify O
+which O
+of O
+four O
+in O
+frame O
+AUG O
+codons O
+was O
+used O
+. O
+
+Peptide O
+competition O
+studies O
+have O
+localized O
+a O
+cyclin B
+A I
+interaction I
+site I
+to O
+a O
+Lys381Lys382Leu383Met384Phe385 O
+sequence O
+within O
+C O
+- O
+terminal O
+negative O
+regulatory O
+domain O
+of O
+human B
+p53 I
+. O
+
+Heterodimerization O
+mutant B
+RXR I
+failed O
+to O
+alter O
+GFP B
+- O
+VDR B
+and O
+nlsGFP O
+- O
+VDR B
+distribution O
+or O
+activity O
+. O
+
+Like O
+troponin B
+Cs I
+and O
+calmodulins B
+, O
+PfCPK B
+also O
+contains O
+four O
+EF O
+hand O
+calcium O
+- O
+binding O
+motifs O
+. O
+
+A O
+third O
+group O
+( O
+n O
+= O
+10 O
+) O
+was O
+assigned O
+to O
+receive O
+the O
+canalith O
+repositioning O
+maneuver O
+without O
+mastoid O
+vibration O
+. O
+
+Upstream O
+of O
+the O
+afa B
+- I
+3 I
+gene I
+cluster I
+, O
+a O
+1 O
+. O
+2 O
+- O
+kb O
+region O
+was O
+found O
+to O
+be O
+96 O
+% O
+identical O
+to O
+the O
+RepFIB B
+sequence I
+of O
+one O
+of O
+the O
+enterotoxigenic O
+E O
+. O
+coli O
+plasmids O
+( O
+P307 O
+) O
+, O
+suggesting O
+a O
+common O
+ancestor O
+plasmid O
+. O
+
+The O
+cats O
+with O
+stage O
+- O
+2 O
+lymphomas O
+that O
+were O
+FeLV O
+- O
+test O
+negative O
+had O
+the O
+best O
+response O
+to O
+treatment O
+. O
+
+We O
+hypothesize O
+that O
+the O
+ability O
+of O
+these O
+acidic O
+activators O
+to O
+specifically O
+interact O
+with O
+multiple O
+components O
+of O
+the O
+transcription O
+initiation O
+complex O
+likely O
+underlies O
+the O
+dramatic O
+functional O
+synergy O
+exhibited O
+by O
+this O
+class O
+of O
+activation O
+domains O
+in O
+vivo O
+. O
+
+Where O
+the O
+resonator O
+has O
+two O
+holes O
+, O
+these O
+terms O
+should O
+be O
+somewhat O
+modified O
+: O
+A O
+is O
+the O
+combined O
+area O
+of O
+the O
+two O
+holes O
+, O
+L O
+is O
+16 O
+/ O
+3pi O
+r O
+( O
+~ O
+1 O
+. O
+7r O
+) O
+for O
+a O
+simple O
+hole O
+in O
+a O
+thin O
+- O
+walled O
+vessel O
+and O
+r O
+is O
+the O
+radius O
+of O
+one O
+hole O
+( O
+Seto O
+, O
+1971 O
+) O
+. O
+
+Histological O
+and O
+immunophenotypic O
+studies O
+revealed O
+12 O
+large O
+cell O
+lymphomas O
+( O
+11 O
+B O
+cell O
+and O
+one O
+T O
+cell O
+) O
+, O
+two O
+small O
+noncleaved O
+cell O
+lymphomas O
+( O
+B O
+- O
+cell O
+phenotype O
+) O
+, O
+and O
+five O
+low O
+grade O
+B O
+- O
+cell O
+lymphomas O
+( O
+two O
+small O
+lymphocytic O
+and O
+three O
+follicular O
+mixed O
+lymphomas O
+) O
+. O
+
+The O
+deviation O
+site O
+is O
+equivalent O
+to O
+the O
+exon O
+1 O
+/ O
+exon O
+2 O
+splice O
+site O
+of O
+the O
+mouse B
+C I
+- I
+subunit I
+. O
+
+The O
+determination O
+of O
+diacetyl O
+, O
+2 O
+, O
+3 O
+- O
+pentanedione O
+and O
+acetoin O
+was O
+performed O
+in O
+two O
+steps O
+. O
+
+There O
+also O
+may O
+be O
+osmotic O
+challenges O
+to O
+mucosal O
+cell O
+function O
+as O
+evidenced O
+by O
+the O
+different O
+reaction O
+rates O
+with O
+hyper O
+- O
+and O
+hypotonic O
+saline O
+. O
+
+In O
+F9 O
+, O
+which O
+is O
+a O
+prototype O
+of O
+embryonal O
+carcinoma O
+cells O
+expressing O
+hst B
+, O
+the O
+expression O
+of O
+hst B
+gene I
+is O
+positively O
+regulated O
+by O
+a O
+downstream O
+octamer O
+motif O
+that O
+functions O
+as O
+an O
+enhancer O
+. O
+
+The O
+reading O
+achievement O
+of O
+students O
+with O
+learning O
+disabilities O
+who O
+received O
+reading O
+instruction O
+through O
+the O
+DISTAR O
+program O
+was O
+compared O
+to O
+that O
+of O
+similar O
+students O
+using O
+basal O
+reader O
+materials O
+. O
+
+Two O
+putative O
+ATP O
+- O
+binding O
+domains O
+were O
+identified O
+, O
+one O
+in O
+the O
+amino O
+- O
+terminal O
+half O
+of O
+the O
+argA B
+- I
+encoded I
+protein I
+and O
+the O
+other O
+in O
+the O
+carboxy O
+- O
+terminal O
+half O
+. O
+
+Chronic O
+granulocytic O
+leukemia O
+in O
+children O
+. O
+
+Purified O
+phosphorylated O
+PhoP B
+( O
+PhoPP B
+) O
+had O
+a O
+half O
+- O
+life O
+of O
+approximately O
+2 O
+. O
+5 O
+h O
+, O
+which O
+was O
+reduced O
+to O
+about O
+15 O
+min O
+by O
+addition O
+of O
+the O
+same O
+molar O
+amount O
+of O
+* B
+PhoR I
+( O
+the O
+cytoplasmic O
+region O
+of O
+PhoR B
+) O
+. O
+
+This O
+transformation O
+suppression O
+by O
+Rb B
+was O
+further O
+shown O
+to O
+be O
+due O
+to O
+transcriptional O
+repression O
+of O
+neu B
+using O
+Rb B
+expressing O
+effector O
+plasmid O
+and O
+neu B
+promoter I
+- O
+chloramphenicol B
+acetyltransferase I
+reporter O
+gene O
+. O
+
+Before O
+therapy O
+was O
+started O
+, O
+trabecular O
+bone O
+alterations O
+could O
+be O
+observed O
+which O
+were O
+typical O
+for O
+Paget O
+' O
+s O
+disease O
+of O
+bone O
+as O
+there O
+were O
+bulky O
+trabeculare O
+, O
+increased O
+remodelling O
+surfaces O
+and O
+giant O
+osteoclasts O
+. O
+
+T O
+. O
+infestans O
+, O
+T O
+. O
+delpontei O
+, O
+T O
+. O
+rubrovaria O
+, O
+T O
+. O
+sordida O
+, O
+T O
+. O
+guasayana O
+and O
+T O
+. O
+vitticeps O
+from O
+infestans O
+subgroup O
+and O
+T O
+. O
+pallidipennis O
+from O
+rubrofasciata O
+, O
+were O
+studied O
+. O
+
+Overexpression O
+of O
+N O
+- O
+terminal O
+mutations O
+disturbs O
+mitosis O
+and O
+produces O
+elongated O
+cells O
+, O
+Using O
+a O
+PCR O
+approach O
+, O
+we O
+isolated O
+a O
+putative O
+homologue O
+of O
+Prp4 B
+from O
+human O
+and O
+mouse O
+cells O
+. O
+
+1 O
+. O
+
+Biochemical O
+studies O
+and O
+studies O
+of O
+cells O
+expressing O
+mutant B
+IL I
+- I
+2 I
+receptors I
+indicate O
+that O
+IL B
+- I
+2 I
+- O
+induced O
+tyrosine B
+kinase I
+activation O
+initiates O
+a O
+complex O
+signaling O
+cascade O
+. O
+
+BACKGROUND O
+: O
+Peripheral O
+kappa B
+receptor I
+agonists O
+may O
+provide O
+a O
+new O
+therapeutic O
+approach O
+for O
+the O
+treatment O
+of O
+functional O
+dyspepsia O
+. O
+
+Fourteen O
+eyes O
+( O
+38 O
+. O
+9 O
+% O
+) O
+developed O
+DLK O
+after O
+an O
+epithelial O
+defect O
+, O
+representing O
+an O
+odds O
+ratio O
+of O
+13 O
+times O
+. O
+
+The O
+yeast O
+genome O
+contains O
+a O
+single O
+ORD1 B
+gene I
+that O
+resides O
+on O
+chromosome O
+XI O
+. O
+
+The O
+system O
+consists O
+of O
+a O
+TV O
+unit O
+compatible O
+to O
+IBM O
+PC O
+/ O
+AT O
+and O
+software O
+. O
+
+The O
+N O
+- O
+terminal O
+sequence O
+of O
+the O
+extracellular B
+MEP20 I
+, O
+TKVAS B
+, O
+was O
+found O
+at O
+aa O
+194 O
+- O
+198 O
+within O
+the O
+ORF O
+. O
+
+Isolates O
+of O
+B O
+. O
+burgdorferi O
+from O
+humans O
+, O
+rodents O
+, O
+and O
+I O
+. O
+dammini O
+are O
+usually O
+indistinguishable O
+, O
+but O
+strains O
+of O
+B O
+. O
+burgdorferi O
+with O
+different O
+major O
+proteins O
+have O
+been O
+identified O
+. O
+
+Cloning O
+of O
+the O
+GATA B
+- I
+binding I
+protein I
+that O
+regulates O
+endothelin B
+- I
+1 I
+gene I
+expression O
+in O
+endothelial O
+cells O
+. O
+
+The O
+Synechococcus B
+gene I
+rps1 I
+encoding O
+S1 B
+is O
+located O
+1 O
+. O
+1 O
+kb O
+downstream O
+from O
+psbB B
+, O
+which O
+encodes O
+the O
+photosystem B
+II I
+P680 I
+chlorophyll I
+a I
+apoprotein I
+. O
+
+Two O
+- O
+dimensional O
+echocardiographic O
+parasternal O
+long O
+- O
+and O
+short O
+- O
+axis O
+views O
+were O
+obtained O
+during O
+graded O
+bleeding O
+by O
+rapid O
+withdrawal O
+of O
+blood O
+from O
+an O
+arterial O
+cannula O
+, O
+with O
+increments O
+of O
+5 O
+% O
+each O
+up O
+to O
+30 O
+% O
+of O
+calculated O
+blood O
+volume O
+. O
+
+A O
+comparison O
+of O
+the O
+rate O
+of O
+recovery O
+and O
+time O
+for O
+detection O
+of O
+mycobacteria O
+from O
+clinical O
+specimens O
+of O
+the O
+newly O
+developed O
+Mycobacteria O
+Growth O
+Indicator O
+Tube O
+( O
+MGIT O
+) O
+, O
+the O
+biphasic O
+Septi O
+- O
+Chek O
+, O
+and O
+the O
+egg O
+- O
+based O
+Ogawa O
+medium O
+was O
+made O
+. O
+
+As O
+in O
+IncP O
+alpha O
+plasmids O
+, O
+these O
+operons O
+are O
+transcribed O
+from O
+a O
+bidirectional O
+promoter O
+region O
+consisting O
+of O
+trfAp B
+for O
+the O
+trfA B
+operon I
+and O
+trbAp B
+and O
+trbBp B
+for O
+the O
+trb B
+operon I
+. O
+
+CONCLUSIONS O
+: O
+These O
+principally O
+structural O
+studies O
+support O
+the O
+hypothesis O
+that O
+the O
+thrombus O
+is O
+a O
+self O
+- O
+sustaining O
+entity O
+that O
+may O
+have O
+significance O
+in O
+the O
+pathophysiologic O
+mechanism O
+of O
+abdominal O
+aortic O
+aneurysms O
+. O
+
+The O
+BHV B
+- I
+1 I
+UL24 I
+, O
+UL25 B
+, O
+UL26 B
+and O
+UL26 B
+. I
+5 I
+transcripts I
+all O
+terminated O
+at O
+a O
+common O
+3 O
+' O
+- O
+polyadenylation O
+site O
+and O
+varied O
+significantly O
+in O
+their O
+relative O
+abundance O
+. O
+
+Electrophoretic O
+mobility O
+shift O
+analysis O
+of O
+protein O
+- O
+DNA O
+complexes O
+formed O
+with O
+nuclear O
+proteins O
+isolated O
+from O
+I3C O
+- O
+treated O
+and O
+- O
+untreated O
+cells O
+, O
+in O
+combination O
+with O
+supershift O
+assays O
+using O
+Sp1 B
+antibodies I
+, O
+demonstrated O
+that O
+the O
+Sp1 B
+- I
+binding I
+site I
+in O
+the O
+CDK6 B
+promoter I
+forms O
+a O
+specific O
+I3C O
+- O
+responsive O
+DNA O
+- O
+protein O
+complex O
+that O
+contains O
+the O
+Sp1 B
+transcription I
+factor I
+. O
+
+These O
+results O
+suggest O
+that O
+both O
+the O
+distinct O
+DNA O
+binding O
+properties O
+of O
+PMLRAR B
+homodimers I
+and O
+the O
+sequestration O
+of O
+RXR B
+by O
+PMLRARs B
+may O
+contribute O
+to O
+the O
+molecular O
+mechanisms O
+which O
+underlie O
+the O
+pathogenesis O
+of O
+APL O
+. O
+
+The O
+analysis O
+showed O
+that O
+the O
+morning O
+active O
+( O
+MA O
+) O
+individuals O
+rose O
+earlier O
+and O
+went O
+to O
+bed O
+earlier O
+than O
+the O
+evening O
+active O
+( O
+EA O
+) O
+individuals O
+, O
+and O
+the O
+former O
+had O
+a O
+longer O
+sleep O
+length O
+than O
+the O
+latter O
+during O
+days O
+with O
+a O
+morning O
+shift O
+, O
+while O
+the O
+opposite O
+was O
+true O
+for O
+afternoon O
+and O
+night O
+shifts O
+. O
+
+This O
+ERD O
+is O
+recorded O
+over O
+the O
+contralateral O
+central O
+region O
+. O
+
+Deletion O
+mutations O
+were O
+constructed O
+, O
+removing O
+residues O
+2 O
+- O
+30 O
+, O
+31 O
+- O
+60 O
+, O
+61 O
+- O
+90 O
+, O
+and O
+49 O
+- O
+78 O
+of O
+the O
+N O
+- O
+terminal O
+cytoplasmic O
+domain O
+, O
+as O
+well O
+as O
+a O
+missense O
+mutation O
+of O
+a O
+dileucine O
+motif O
+. O
+
+Kluyveromyces O
+lactis O
+, O
+a O
+budding O
+yeast O
+related O
+to O
+Saccharomyces O
+cerevisiae O
+, O
+can O
+grow O
+on O
+a O
+wider O
+variety O
+of O
+substrates O
+and O
+shows O
+less O
+sensitivity O
+to O
+glucose O
+repression O
+than O
+does O
+Saccharomyces O
+cerevisiae O
+. O
+
+Low O
+- O
+affinity O
+E2 B
+- I
+binding I
+site I
+mediates O
+downmodulation O
+of O
+E2 B
+transactivation O
+of O
+the O
+human B
+papillomavirus I
+type I
+8 I
+late I
+promoter I
+. O
+
+Untransformed O
+3T3 O
+cells O
+carry O
+abundant O
+1 B
+. I
+9 I
+kb I
+Hox I
+1 I
+. I
+3 I
+RNA I
+, O
+whereas O
+the O
+methylcholanthrene O
+- O
+transformed O
+MB66 O
+and O
+LTK O
+- O
+cells O
+or O
+3T3 O
+cells O
+transformed O
+by O
+the O
+oncogenes O
+src B
+, O
+fos B
+or O
+SV40 B
+T I
+antigen I
+express O
+only O
+low O
+levels O
+. O
+
+Although O
+analysis O
+of O
+the O
+similarity O
+between O
+the O
+44 O
+- O
+kDa O
+protein O
+and O
+the O
+E B
+. I
+coli I
+RecA I
+protein I
+did O
+not O
+show O
+any O
+significant O
+homology O
+between O
+them O
+, O
+it O
+revealed O
+their O
+identity O
+by O
+five O
+amino O
+- O
+acid O
+residues O
+involved O
+in O
+the O
+formation O
+of O
+the O
+epitope O
+that O
+recognized O
+the O
+paratope O
+of O
+the O
+RecA B
+protein I
+antibody O
+for O
+subsequent O
+epitope O
+- O
+paratope O
+binding O
+of O
+these O
+proteins O
+. O
+
+Ureases B
+were O
+purified O
+from O
+the O
+recombinant O
+cells O
+and O
+shown O
+to O
+be O
+identical O
+to O
+control O
+enzyme O
+when O
+analyzed O
+by O
+gel O
+filtration O
+chromatography O
+and O
+sodium O
+dodecyl O
+sulfate O
+- O
+polyacrylamide O
+gel O
+electrophoresis O
+; O
+however O
+, O
+in O
+every O
+case O
+the O
+activity O
+levels O
+correlated O
+to O
+nickel O
+contents O
+as O
+analyzed O
+by O
+atomic O
+absorption O
+analysis O
+. O
+
+Deoxyuridine O
+- O
+suppression O
+test O
+and O
+bone O
+marrow O
+culture O
+for O
+the O
+diagnosis O
+of O
+macrocytic O
+refractory O
+anaemias O
+. O
+
+Finally O
+, O
+synthetic O
+peptides O
+corresponding O
+to O
+the O
+mutant O
+proteins O
+were O
+assessed O
+for O
+the O
+ability O
+to O
+act O
+as O
+substrates O
+for O
+PR B
+. O
+
+These O
+psoralens O
+are O
+being O
+used O
+in O
+research O
+projects O
+sponsored O
+by O
+the O
+National O
+Toxicology O
+Program O
+. O
+
+Root O
+surface O
+caries O
+incidence O
+in O
+the O
+groups O
+inoculated O
+with O
+A O
+. O
+viscosus O
+and O
+A O
+. O
+viscosus O
+plus O
+S O
+. O
+sobrinus O
+did O
+not O
+differ O
+. O
+
+These O
+results O
+demonstrate O
+that O
+the O
+entire O
+E3L B
+gene I
+is O
+required O
+for O
+pathogenesis O
+in O
+the O
+mouse O
+model O
+. O
+
+The O
+development O
+of O
+various O
+pathological O
+lesions O
+in O
+thymus O
+, O
+spleen O
+, O
+lymph O
+nodes O
+and O
+bone O
+- O
+marrow O
+is O
+frequently O
+observed O
+. O
+
+Recently O
+, O
+we O
+have O
+demonstrated O
+that O
+mouse O
+microglial O
+cells O
+, O
+the O
+brain O
+macrophages O
+, O
+express O
+both O
+IL B
+- I
+15 I
+and O
+IL B
+- I
+15 I
+/ O
+IL B
+- I
+2 I
+receptors I
+. O
+
+We O
+have O
+analyzed O
+the O
+role O
+of O
+the O
+HU B
+protein I
+in O
+invertasome O
+assembly O
+when O
+the O
+enhancer O
+is O
+located O
+at O
+variable O
+positions O
+close O
+to O
+one O
+of O
+the O
+recombination O
+sites O
+. O
+
+The O
+mode O
+of O
+action O
+is O
+often O
+suggested O
+as O
+an O
+explanation O
+for O
+the O
+different O
+slopes O
+of O
+concentration O
+- O
+effect O
+curves O
+. O
+
+This O
+may O
+be O
+another O
+example O
+of O
+the O
+principle O
+- O
+- O
+less O
+is O
+more O
+. O
+
+A O
+wide O
+conservation O
+of O
+iscSUA B
+genes I
+in O
+nature O
+and O
+evidence O
+that O
+NifU B
+and O
+NifS B
+participate O
+in O
+the O
+mobilization O
+of O
+iron O
+and O
+sulfur O
+for O
+nitrogenase B
+- O
+specific O
+iron O
+- O
+sulfur O
+cluster O
+formation O
+suggest O
+that O
+the O
+products O
+of O
+the O
+iscSUA B
+genes I
+could O
+play O
+a O
+general O
+role O
+in O
+the O
+formation O
+or O
+repair O
+of O
+iron O
+- O
+sulfur O
+clusters O
+. O
+
+On O
+transfer O
+from O
+glucose O
+, O
+succinate O
+, O
+malate O
+, O
+or O
+glycerol O
+medium O
+to O
+citrate O
+medium O
+, O
+the O
+Cit B
++ I
+Escherichia O
+coli O
+strains O
+showed O
+a O
+delay O
+of O
+36 O
+to O
+48 O
+h O
+before O
+growth O
+. O
+
+These O
+results O
+suggest O
+that O
+camptothecin O
+resistance O
+in O
+CEM O
+/ O
+DOX O
+cells O
+is O
+due O
+to O
+different O
+mechanism O
+( O
+s O
+) O
+than O
+topoisomerase B
+- O
+or O
+P B
+- I
+glycoprotein I
+- O
+associated O
+multidrug O
+resistance O
+. O
+
+Jornvall O
+, O
+B O
+. O
+
+The O
+pattern O
+of O
+expression O
+of O
+this O
+and O
+other O
+Chi26 B
+/ O
+Chi33 B
+chimeric O
+promoters O
+suggest O
+that O
+the O
+E O
+- O
+region O
+contains O
+cis O
+- O
+acting O
+sequences O
+which O
+activate O
+transcription O
+in O
+aleurone O
+and O
+silence O
+transcription O
+in O
+leaves O
+. O
+
+Spontaneous O
+coronary O
+artery O
+spasm O
+during O
+coronary O
+angiography O
+in O
+a O
+patient O
+with O
+exercise O
+- O
+induced O
+ST O
+segment O
+elevation O
+. O
+
+Four O
+newborns O
+in O
+this O
+group O
+became O
+HBsAg B
+carriers O
+. O
+
+Effectively O
+, O
+the O
+upstream O
+, O
+housekeeping O
+- O
+type O
+promoter O
+responds O
+to O
+FIXK B
+and O
+positively O
+regulates O
+the O
+downstream O
+, O
+sigma B
+54 I
+- I
+type I
+promoter I
+. O
+
+K O
+. O
+, O
+Weiss O
+, O
+M O
+. O
+
+New O
+TB O
+respirator O
+standards O
+mean O
+more O
+choices O
+at O
+less O
+cost O
+. O
+
+Electrophoretic O
+mobility O
+- O
+shift O
+assays O
+using O
+oligonucleotides O
+derived O
+from O
+these O
+sites O
+demonstrated O
+formation O
+of O
+specific O
+DNA O
+- O
+protein O
+complexes O
+. O
+
+A O
+5789 O
+- O
+nucleotide O
+- O
+long O
+EcoRI B
+fragment I
+from O
+the O
+genome O
+of O
+Thermotoga O
+maritima O
+, O
+identified O
+by O
+cross O
+- O
+hybridization O
+to O
+L11 B
+, O
+L1 B
+, O
+L10 B
+, O
+and O
+L12 B
+ribosomal I
+protein I
+gene I
+sequences I
+from O
+Escherichia O
+coli O
+, O
+was O
+cloned O
+and O
+sequenced O
+. O
+
+Background O
+reduction O
+with O
+various O
+agents O
+had O
+a O
+prominent O
+effect O
+on O
+DTIn1 B
+as O
+well O
+as O
+99mTc O
+- O
+DTPA O
+biodistribution O
+. O
+
+These O
+data O
+suggest O
+that O
+reduction O
+in O
+PRA O
+may O
+have O
+contributed O
+to O
+the O
+hemodynamic O
+effects O
+of O
+this O
+peak B
+III I
+PDE I
+inhibitor O
+. O
+
+The O
+following O
+parameters O
+were O
+measured O
+: O
+onset O
+time O
+( O
+time O
+interval O
+from O
+injection O
+to O
+maximal O
+or O
+total O
+block O
+) O
+, O
+T125 O
+/ O
+75 O
+( O
+time O
+for O
+T1 O
+to O
+reach O
+25 O
+% O
+or O
+75 O
+% O
+of O
+control O
+) O
+, O
+TOF70 O
+( O
+time O
+for O
+TOF O
+ratio O
+to O
+reach O
+70 O
+% O
+of O
+control O
+) O
+, O
+heart O
+rate O
+and O
+blood O
+pressure O
+. O
+
+A O
+. O
+
+Prematurely O
+inactivating O
+p42 B
+MAPK I
+in O
+egg O
+extracts O
+resulted O
+in O
+a O
+corresponding O
+hastening O
+of O
+the O
+first O
+mitosis O
+. O
+
+The O
+use O
+of O
+ALAD B
+activity O
+and O
+EP O
+as O
+cumulative O
+lead O
+exposure O
+indicators O
+is O
+suggested O
+. O
+
+Binding O
+of O
+C B
+/ I
+EBPs I
+to O
+all O
+three O
+spi B
+2 I
+. I
+3 I
+3 I
+' I
+UTR I
+repressor I
+sites I
+, O
+although O
+rather O
+weak O
+, O
+was O
+confirmed O
+by O
+electrophoretic O
+mobility O
+shift O
+assays O
+that O
+otherwise O
+failed O
+to O
+reveal O
+specific O
+interactions O
+with O
+other O
+liver O
+nuclear O
+proteins O
+in O
+vitro O
+. O
+
+Cell O
+cycle O
+regulatory O
+components O
+have O
+been O
+largely O
+conserved O
+in O
+eukaryotes O
+; O
+however O
+, O
+orthologs O
+of O
+neither O
+CAK1 B
+nor O
+csk1 B
+have O
+been O
+identified O
+in O
+other O
+species O
+to O
+date O
+. O
+
+In O
+this O
+study O
+, O
+we O
+cloned O
+the O
+full O
+- O
+length O
+cDNA O
+of O
+mouse B
+PAX4 I
+by O
+RACE O
+( O
+rapid O
+amplification O
+of O
+cDNA O
+ends O
+) O
+using O
+RNA O
+from O
+MIN6 O
+cells O
+, O
+a O
+mouse O
+insulinoma O
+cell O
+line O
+. O
+
+Kohtz O
+, O
+J O
+. O
+
+Hence O
+the O
+GAP1 B
+gene I
+encodes O
+a O
+protein O
+with O
+characteristics O
+typical O
+of O
+integral O
+membrane O
+proteins O
+translocating O
+ligants O
+across O
+cellular O
+membranes O
+. O
+
+The O
+results O
+suggest O
+that O
+proenzyme O
+processing O
+is O
+not O
+essential O
+for O
+secretion O
+of O
+PC2 B
+, O
+but O
+peptides O
+containing O
+mutations O
+that O
+affect O
+the O
+ability O
+of O
+the O
+propeptide O
+( O
+and O
+cleavage O
+sites O
+) O
+to O
+fold O
+within O
+the O
+catalytic O
+pocket O
+are O
+not O
+transferred O
+beyond O
+the O
+early O
+stages O
+of O
+the O
+secretory O
+pathway O
+. O
+
+These O
+results O
+suggest O
+that O
+transcription O
+influences O
+aspects O
+of O
+gene O
+conversion O
+after O
+initiation O
+, O
+such O
+as O
+strand O
+invasion O
+and O
+/ O
+or O
+mismatch O
+repair O
+( O
+MMR O
+) O
+. O
+
+Important O
+prognostic O
+factors O
+for O
+the O
+results O
+of O
+physiotherapeutic O
+exercises O
+in O
+intermittent O
+claudication O
+
+Finally O
+, O
+in O
+samples O
+obtained O
+from O
+two O
+patients O
+with O
+drug O
+refractory O
+ALL O
+, O
+BAC O
+- O
+derived O
+probes O
+applied O
+to O
+archived O
+marrow O
+cells O
+demonstrated O
+that O
+a O
+breakpoint O
+occurred O
+between O
+MDR1 B
+and O
+sequences O
+500 O
+- O
+1000 O
+KB O
+telomeric O
+to O
+MDR1 B
+, O
+consistent O
+with O
+a O
+random O
+chromosomal O
+rearrangement O
+. O
+
+Application O
+of O
+the O
+method O
+using O
+an O
+11 O
+- O
+year O
+microseismicity O
+record O
+revealed O
+systematic O
+spatial O
+and O
+temporal O
+changes O
+in O
+the O
+slip O
+rate O
+that O
+were O
+synchronous O
+with O
+earthquake O
+activity O
+and O
+other O
+independent O
+measures O
+of O
+fault O
+- O
+zone O
+slip O
+. O
+
+PC12 O
+cultures O
+that O
+had O
+been O
+" O
+primed O
+" O
+in O
+this O
+way O
+showed O
+an O
+accelerated O
+and O
+augmented O
+differentiation O
+response O
+to O
+nerve B
+growth I
+factor I
+. O
+
+One O
+of O
+these O
+clones O
+encodes O
+Xenopus B
+N I
+- I
+ras I
+. O
+
+The O
+Molteno O
+implant O
+is O
+an O
+effective O
+procedure O
+in O
+the O
+treatment O
+of O
+complicated O
+and O
+refractory O
+cases O
+of O
+glaucoma O
+in O
+high O
+- O
+risk O
+eyes O
+. O
+
+The O
+median O
+levels O
+of O
+t B
+- I
+PA I
+Ag I
+and O
+PAI B
+in O
+plasma O
+were O
+respectively O
+10 O
+. O
+7 O
+ng O
+/ O
+ml O
+( O
+interquartile O
+range O
+8 O
+. O
+6 O
+ng O
+/ O
+ml O
+) O
+and O
+15 O
+. O
+7 O
+IU O
+/ O
+ml O
+( O
+interquartile O
+range O
+12 O
+. O
+2 O
+IU O
+/ O
+ml O
+) O
+. O
+
+In O
+the O
+remaining O
+91 O
+patients O
+( O
+group O
+2 O
+) O
+, O
+Pseudomonas O
+( O
+18 O
+) O
+, O
+coagulase O
+- O
+negative O
+Staphylococci O
+( O
+15 O
+) O
+, O
+Staphylococcus O
+epidermidis O
+( O
+23 O
+) O
+, O
+Staphylococcus O
+aureus O
+( O
+16 O
+) O
+, O
+Corynebacterium O
+species O
+( O
+12 O
+) O
+, O
+and O
+others O
+( O
+seven O
+) O
+were O
+isolated O
+. O
+
+Stamps O
+in O
+cardiology O
+: O
+de O
+Musset O
+sign O
+. O
+
+A O
+factor O
+present O
+in O
+nuclear O
+extracts O
+of O
+wounded O
+potato O
+tubers O
+was O
+found O
+to O
+bind O
+specifically O
+to O
+nucleotides O
+located O
+between O
+- O
+135 O
+to O
+- O
+105 O
+, O
+suggesting O
+that O
+this O
+region O
+contains O
+important O
+cis O
+- O
+regulatory O
+elements O
+. O
+
+The O
+leucine O
+zipper O
+region O
+of O
+ATF B
+proteins I
+is O
+also O
+similar O
+to O
+that O
+of O
+the O
+AP B
+- I
+1 I
+/ O
+c B
+- I
+jun I
+family O
+of O
+transcription O
+factors O
+, O
+whose O
+DNA O
+- O
+binding O
+site O
+differs O
+from O
+the O
+ATF B
+- I
+binding I
+site I
+at O
+a O
+single O
+position O
+. O
+
+The O
+R260A O
+mutant O
+, O
+as O
+expected O
+, O
+was O
+unable O
+to O
+support O
+mRNA O
+synthesis O
+in O
+vitro O
+in O
+a O
+transcription O
+reconstitution O
+reaction O
+as O
+well O
+as O
+transcription O
+in O
+vivo O
+of O
+a O
+minigenome O
+using O
+a O
+reverse O
+genetic O
+approach O
+. O
+
+PEAP O
+was O
+significantly O
+higher O
+in O
+IDC O
+patients O
+compared O
+to O
+controls O
+( O
+48 O
+. O
+7 O
++ O
+/ O
+- O
+32 O
+. O
+6 O
+vs O
+. O
+
+Uterine O
+contractions O
+began O
+with O
+a O
+mean O
+latency O
+of O
+62 O
+min O
+in O
+the O
+PGF2 O
+alpha O
+infused O
+women O
+, O
+in O
+controls O
+uterine O
+activity O
+remained O
+unchanged O
+. O
+
+Were O
+this O
+hypothesis O
+correct O
+, O
+the O
+requirement O
+for O
+elF4A B
+should O
+correlate O
+with O
+the O
+degree O
+of O
+mRNA O
+secondary O
+structure O
+. O
+
+In O
+spite O
+of O
+the O
+presence O
+of O
+a O
+physician O
+, O
+the O
+real O
+pathology O
+of O
+an O
+indian O
+population O
+of O
+Colombie O
+is O
+not O
+very O
+well O
+known O
+. O
+
+Taken O
+together O
+, O
+these O
+results O
+demonstrate O
+that O
+the O
+BSMV B
+coat I
+protein I
+is O
+the O
+sole O
+translation O
+product O
+of O
+the O
+genomic O
+RNA O
+beta O
+, O
+whereas O
+sgRNA B
+beta I
+1 I
+serves O
+as O
+a O
+messenger O
+for O
+translation O
+of O
+the O
+beta B
+b I
+protein I
+, O
+and O
+sgRNA B
+beta I
+2 I
+functions O
+as O
+a O
+messenger O
+for O
+translation O
+of O
+beta B
+c I
+and O
+beta B
+d I
+and O
+the O
+newly O
+discovered O
+beta B
+d I
+' I
+protein I
+. O
+
+A O
+retrospective O
+study O
+of O
+clozapine O
+and O
+electroencephalographic O
+abnormalities O
+in O
+schizophrenic O
+patients O
+. O
+
+The O
+concepts O
+were O
+developed O
+by O
+Mines O
+and O
+Garrey O
+during O
+the O
+next O
+10 O
+years O
+. O
+
+When O
+the O
+measured O
+beta B
+- I
+galactosidase I
+activity O
+in O
+the O
+pWP B
+- O
+transfected O
+cells O
+was O
+normalized O
+to O
+the O
+pCH110 O
+- O
+transfected O
+cells O
+( O
+an O
+appropriate O
+control O
+if O
+the O
+SV40 B
+early I
+region I
+promoter I
+functions O
+constitutively O
+in O
+various O
+cell O
+lines O
+) O
+, O
+the O
+results O
+suggested O
+that O
+the O
+promoter O
+region O
+of O
+the O
+PLP B
+gene I
+contains O
+the O
+information O
+necessary O
+for O
+initiation O
+of O
+transcription O
+in O
+a O
+C6 O
+cell O
+- O
+specific O
+manner O
+. O
+
+PKK B
+exists O
+in O
+three O
+discernible O
+forms O
+at O
+steady O
+state O
+: O
+an O
+underphosphorylated O
+form O
+of O
+100 O
+kDa O
+; O
+a O
+soluble O
+, O
+cytosolic O
+, O
+phosphorylated O
+form O
+of O
+110 O
+kDa O
+; O
+and O
+a O
+phosphorylated O
+, O
+detergent O
+- O
+insoluble O
+form O
+of O
+112 O
+kDa O
+. O
+
+The O
+P B
+- I
+ITIM I
+- O
+compelled O
+multi O
+- O
+phosphoprotein O
+complex O
+binds O
+to O
+and O
+activates O
+SHP B
+- I
+2 I
+, O
+which O
+in O
+turn O
+dephosphorylates O
+SHIP B
+and O
+Shc B
+and O
+probably O
+other O
+substrates O
+. O
+
+When O
+PCR O
+was O
+used O
+to O
+amplify O
+agar O
+cultures O
+which O
+do O
+not O
+express O
+the O
+fimbriae O
+, O
+the O
+switch O
+region O
+was O
+OFF O
+only O
+. O
+
+Mechanisms O
+of O
+action O
+of O
+local O
+anaesthetics O
+. O
+
+Student O
+health O
+
+We O
+now O
+report O
+that O
+both O
+HSCR O
+mutations O
+impair O
+the O
+fixation O
+of O
+Shc B
+to O
+RET B
+and O
+consequently O
+prevent O
+its O
+phosphorylation O
+. O
+
+The O
+only O
+quantities O
+which O
+were O
+significantly O
+different O
+between O
+appendicitis O
+and O
+a O
+normal O
+appendix O
+were O
+sex O
+, O
+duration O
+of O
+symptoms O
+, O
+anorexia O
+and O
+vomiting O
+. O
+
+We O
+propose O
+that O
+U73 B
+is O
+involved O
+in O
+methylation O
+of O
+the O
+G1739 O
+residue O
+of O
+the O
+human B
+28S I
+rRNA I
+. O
+
+At O
+the O
+start O
+of O
+the O
+performance O
+ride O
+, O
+plasma O
+glucose O
+averaged O
+4 O
+. O
+2 O
++ O
+/ O
+- O
+0 O
+. O
+2 O
+, O
+5 O
+. O
+2 O
++ O
+/ O
+- O
+0 O
+. O
+1 O
+, O
+and O
+5 O
+. O
+7 O
++ O
+/ O
+- O
+0 O
+. O
+2 O
+mmol O
+. O
+l O
+- O
+1 O
+in O
+CON O
+, O
+CHO O
+- O
+7 O
+, O
+and O
+CHO O
+- O
+0 O
+/ O
+21 O
+, O
+respectively O
+( O
+all O
+different O
+, O
+P O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+Therefore O
+prostaglandin O
+E2 O
+is O
+characterized O
+in O
+relation O
+to O
+prostaglandin O
+F2 O
+- O
+alpha O
+not O
+only O
+by O
+a O
+stronger O
+uterine O
+effectiveness O
+, O
+but O
+also O
+at O
+the O
+same O
+time O
+a O
+pronounced O
+influence O
+on O
+the O
+cardiovascular O
+system O
+. O
+
+Copyright O
+1999 O
+Academic O
+Press O
+. O
+
+Ganglia O
+are O
+cysts O
+which O
+frequently O
+occur O
+in O
+the O
+proximity O
+of O
+joints O
+. O
+
+Lysates O
+of O
+COS O
+cells O
+transfected O
+with O
+modified O
+hGrzB B
+cDNA I
+were O
+able O
+to O
+hydrolyze O
+tert O
+- O
+butyloxycarbonyl O
+- O
+Ala O
+- O
+Ala O
+- O
+Asp O
+- O
+thiobenzyl O
+ester O
+( O
+Boc O
+- O
+Ala O
+- O
+Ala O
+- O
+Asp O
+- O
+SBzl O
+) O
+, O
+whereas O
+lysates O
+transfected O
+with O
+unmodified O
+hGrzB B
+cDNA I
+were O
+inactive O
+. O
+
+Proteins O
+PBP B
+- I
+1 I
+and O
+PBP B
+- I
+2 I
+bind O
+to O
+two O
+of O
+the O
+three O
+promoter O
+elements O
+in O
+the O
+trypanosomatid O
+Leptomonas O
+seymouri O
+. O
+
+Expression O
+of O
+medical O
+efficiency O
+by O
+integration O
+indicators O
+with O
+the O
+rational O
+utilization O
+of O
+budgeted O
+funds O
+
+The O
+present O
+study O
+tries O
+to O
+associate O
+some O
+of O
+the O
+causes O
+of O
+hot O
+ischaemia O
+during O
+the O
+agony O
+of O
+the O
+corpse O
+donor O
+and O
+to O
+evaluate O
+those O
+that O
+may O
+be O
+caused O
+by O
+sympathetic O
+efference O
+during O
+removal O
+. O
+
+The O
+enzyme O
+encoded O
+by O
+the O
+cloned O
+fragment O
+is O
+equally O
+active O
+on O
+pyruvate O
+and O
+hydroxypyruvate O
+, O
+indicating O
+that O
+the O
+enzyme O
+has O
+both O
+D B
+- I
+lactate I
+and O
+D B
+- I
+glycerate I
+dehydrogenase I
+activities O
+. O
+
+Noise O
+in O
+STM O
+due O
+to O
+atoms O
+moving O
+in O
+the O
+tunneling O
+space O
+. O
+
+The O
+human O
+sequence O
+contains O
+the O
+element O
+TGACTCT O
+that O
+also O
+is O
+found O
+in O
+a O
+murine B
+ras I
+- I
+responsive I
+enhancer I
+. O
+
+There O
+is O
+an O
+overall O
+functional O
+similarity O
+between O
+IL B
+- I
+6 I
+and O
+c B
+- I
+fos I
+promoters I
+, O
+since O
+transfection O
+of O
+excess O
+amounts O
+of O
+either O
+promoter O
+DNA O
+into O
+intact O
+HeLa O
+cells O
+modulates O
+the O
+function O
+of O
+the O
+heterologous O
+promoter O
+construct O
+. O
+
+Enhanced O
+phospholipid O
+hydrolysis O
+with O
+free O
+fatty O
+acid O
+and O
+thromboxane O
+accumulation O
+, O
+increased O
+release O
+of O
+excitatory O
+amino O
+acids O
+, O
+and O
+decreased O
+tissue O
+magnesium O
+levels O
+may O
+each O
+serve O
+to O
+worsen O
+secondary O
+tissue O
+damage O
+and O
+diminish O
+neurologic O
+recovery O
+after O
+spinal O
+cord O
+injury O
+associated O
+with O
+acute O
+alcohol O
+intoxication O
+. O
+
+To O
+determine O
+whether O
+the O
+transcript O
+encodes O
+an O
+active O
+enzyme O
+, O
+we O
+developed O
+a O
+novel O
+transient O
+embryonic O
+excision O
+assay O
+in O
+which O
+zebrafish O
+fertilized O
+eggs O
+were O
+co O
+- O
+injected O
+with O
+RNA O
+transcribed O
+in O
+vitro O
+using O
+the O
+Tol2 B
+cDNA I
+as O
+a O
+template O
+and O
+a O
+plasmid O
+DNA O
+harboring O
+a O
+nonautonomous O
+Tol2 B
+element I
+, O
+which O
+has O
+a O
+deletion O
+in O
+the O
+transposase B
+coding O
+region O
+. O
+
+The O
+overall O
+objective O
+response O
+rate O
+( O
+RR O
+) O
+was O
+50 O
+% O
+[ O
+95 O
+% O
+confidence O
+interval O
+( O
+CI O
+) O
+= O
+29 O
+- O
+71 O
+% O
+] O
+including O
+four O
+complete O
+responses O
+and O
+eight O
+partial O
+responses O
+. O
+
+We O
+suggest O
+that O
+this O
+relatively O
+small O
+deletion O
+affects O
+a O
+segment O
+containing O
+3 B
+' I
+VH I
+genes I
+with O
+important O
+regulatory O
+functions O
+, O
+the O
+loss O
+of O
+which O
+leads O
+to O
+the O
+ali O
+phenotype O
+. O
+
+Two O
+SH2 B
+domains I
+of O
+p120 B
+Ras B
+GTPase I
+- I
+activating I
+protein I
+bind O
+synergistically O
+to O
+tyrosine O
+phosphorylated O
+p190 B
+Rho I
+GTPase I
+- I
+activating I
+protein I
+. O
+
+p120 B
+GTPase B
+- I
+activating I
+protein I
+( O
+GAP B
+) O
+is O
+a O
+negative O
+regulator O
+of O
+Ras B
+that O
+functions O
+at O
+a O
+key O
+relay O
+point O
+in O
+signal O
+transduction O
+pathways O
+that O
+control O
+cell O
+proliferation O
+. O
+
+A O
+homologue O
+of O
+the O
+MAP B
+/ O
+ERK B
+family O
+of O
+protein O
+kinase O
+genes O
+is O
+expressed O
+in O
+vegetative O
+and O
+in O
+female O
+reproductive O
+organs O
+of O
+Petunia O
+hybrida O
+. O
+
+Its O
+prognostic O
+impact O
+is O
+superior O
+to O
+the O
+T1 O
+/ O
+2 O
+one O
+( O
+RR O
+= O
+2 O
+. O
+9 O
+; O
+p O
+= O
+0 O
+. O
+0010 O
+) O
+. O
+
+It O
+encodes O
+a O
+sequence O
+- O
+specific O
+transcription O
+factor O
+that O
+controls O
+, O
+in O
+concert O
+with O
+other O
+gene O
+products O
+, O
+differentiative O
+pathways O
+of O
+tissues O
+in O
+which O
+Scr B
+is O
+expressed O
+. O
+
+CONCLUSION O
+: O
+DMIPP O
+detects O
+regionally O
+hypoperfused O
+myocardium O
+, O
+in O
+which O
+agreement O
+between O
+MBF O
+and O
+fatty O
+acid O
+uptake O
+deteriorates O
+. O
+
+The O
+effect O
+of O
+guaiphenesin O
+on O
+absorption O
+and O
+bioavailability O
+of O
+paracetamol O
+from O
+composite O
+analgesic O
+preparations O
+. O
+
+Transcription O
+of O
+the O
+inserted O
+gene O
+into O
+the O
+predicted O
+subgenomic O
+polyadenylated O
+mRNA O
+was O
+demonstrated O
+by O
+Northern O
+( O
+RNA O
+) O
+blot O
+hybridization O
+analysis O
+, O
+and O
+the O
+encoded O
+protein O
+was O
+detected O
+by O
+enzyme O
+assay O
+and O
+by O
+radioimmunoprecipitation O
+. O
+
+These O
+results O
+suggest O
+that O
+panretinal O
+photocoagulation O
+offers O
+a O
+highly O
+effective O
+means O
+of O
+dealing O
+with O
+early O
+and O
+moderately O
+advanced O
+cases O
+of O
+angle O
+neovascularization O
+. O
+
+NBSII B
+is O
+essential O
+for O
+ribosome O
+- O
+stimulated O
+activity O
+. O
+
+Sixteen O
+patients O
+( O
+25 O
+. O
+4 O
+% O
+) O
+encountered O
+rejection O
+while O
+weaning O
+at O
+median O
+period O
+of O
+9 O
+. O
+5 O
+months O
+( O
+range O
+, O
+1 O
+- O
+63 O
+months O
+) O
+from O
+the O
+start O
+of O
+weaning O
+. O
+
+ALT B
+( O
+alanine B
+aminotransferase I
+) O
+and O
+Hb B
+( O
+hemoglobin B
+) O
+appeared O
+to O
+be O
+predictive O
+for O
+efficacy O
+. O
+
+Theophylline O
+QID O
+, O
+TID O
+, O
+BID O
+and O
+now O
+QD O
+? O
+
+A O
+report O
+on O
+24 O
+- O
+hour O
+dosing O
+with O
+slow O
+- O
+release O
+theophylline O
+formulations O
+with O
+emphasis O
+on O
+analyses O
+of O
+data O
+used O
+to O
+obtain O
+Food O
+and O
+Drug O
+Administration O
+approval O
+for O
+Theo O
+- O
+24 O
+. O
+
+Signal O
+transduction O
+in O
+fibroblasts O
+stably O
+transformed O
+by O
+[ B
+Val12 I
+] I
+Ras I
+- O
+- O
+the O
+activities O
+of O
+extracellular B
+- I
+signal I
+- I
+regulated I
+kinase I
+and O
+Jun B
+N I
+- I
+terminal I
+kinase I
+are O
+only O
+moderately O
+increased O
+, O
+and O
+the O
+activity O
+of O
+the O
+delta O
+- O
+inhibitor O
+of O
+c B
+- I
+Jun I
+is O
+not O
+alleviated O
+. O
+
+Time O
+for O
+action O
+on O
+hepatitis O
+B O
+immunisation O
+. O
+
+Escherichia O
+coli O
+cells O
+expressing O
+a O
+mutant B
+glyV I
+( O
+glycine B
+tRNA I
+) O
+gene O
+have O
+a O
+UVM O
+- O
+constitutive O
+phenotype O
+: O
+implications O
+for O
+mechanisms O
+underlying O
+the O
+mutA B
+or O
+mutC B
+mutator O
+effect O
+. O
+
+By O
+24 O
+h O
+, O
+there O
+was O
+no O
+significant O
+difference O
+in O
+FFA O
+levels O
+from O
+shams O
+. O
+
+This O
+result O
+suggests O
+that O
+the O
+target O
+protein O
+specificity O
+of O
+E2s B
+can O
+be O
+altered O
+by O
+the O
+addition O
+of O
+appropriate O
+C O
+- O
+terminal O
+extensions O
+, O
+thus O
+providing O
+a O
+way O
+to O
+modify O
+the O
+selectivity O
+of O
+the O
+ubiquitin B
+system O
+. O
+
+Here O
+we O
+report O
+the O
+cloning O
+of O
+the O
+hemF B
+gene I
+, O
+encoding O
+the O
+aerobic B
+coproporphyrinogen I
+III I
+oxidase I
+from O
+Escherichia O
+coli O
+, O
+by O
+functional O
+complementation O
+of O
+a O
+Saccharomyces B
+cerevisiae I
+HEM13 I
+mutant I
+. O
+
+This O
+study O
+was O
+undertaken O
+to O
+evaluate O
+the O
+physical O
+and O
+biological O
+characteristics O
+of O
+nebulized O
+interleukin B
+2 I
+liposomes O
+. O
+
+The O
+atopic O
+disposition O
+, O
+indicated O
+by O
+positive O
+skin O
+reactions O
+and O
+IgE B
+antibody I
+titers O
+etc O
+. O
+, O
+and O
+the O
+bronchial O
+reactivity O
+to O
+inhaled O
+acetylcholine O
+were O
+examined O
+on O
+the O
+following O
+three O
+groups O
+: O
+( O
+1 O
+) O
+20 O
+young O
+adults O
+with O
+a O
+history O
+of O
+childhood O
+asthma O
+who O
+have O
+been O
+symptom O
+- O
+free O
+for O
+more O
+than O
+4 O
+yr O
+; O
+( O
+2 O
+) O
+20 O
+current O
+asthmatics O
+, O
+and O
+( O
+3 O
+) O
+20 O
+healthy O
+young O
+adults O
+. O
+
+Previous O
+studies O
+showed O
+that O
+a O
+palindromic O
+sequence O
+located O
+at O
+- O
+159 O
+base O
+pairs O
+is O
+essential O
+for O
+induction O
+of O
+cutinase B
+gene I
+in O
+Fusarium O
+solani O
+f O
+. O
+
+sp O
+. O
+pisi O
+( O
+Nectria O
+haematococca O
+mating O
+type O
+VI O
+) O
+by O
+the O
+hydroxy O
+fatty O
+acids O
+from O
+plant O
+cutin B
+and O
+that O
+a O
+50 O
+- O
+kDa O
+nuclear O
+protein O
+binds O
+to O
+a O
+promoter O
+that O
+contains O
+this O
+element O
+. O
+
+This O
+preliminary O
+study O
+reports O
+an O
+initial O
+evaluation O
+of O
+HMPAO O
+- O
+SPECT O
+imaging O
+for O
+assessing O
+regional O
+alterations O
+in O
+brain O
+function O
+during O
+opiate O
+dependence O
+and O
+withdrawal O
+. O
+
+We O
+conclude O
+that O
+these O
+cDNAs O
+belong O
+to O
+a O
+novel O
+GST B
+class I
+hereby O
+designated O
+Kappa O
+, O
+with O
+the O
+rat B
+GST I
+subunit I
+13 I
+gene I
+designated O
+rGSTK1 B
+and O
+the O
+human O
+gene O
+being O
+called O
+hGSTK1 B
+. O
+
+Based O
+on O
+PCR O
+strategies O
+and O
+expression O
+studies O
+, O
+we O
+define O
+the O
+genomic O
+organization O
+of O
+the O
+FUT8b B
+gene I
+. O
+
+The O
+present O
+study O
+demonstrates O
+that O
+the O
+proto B
+- I
+oncogene I
+c I
+- I
+jun I
+represses O
+transcription O
+of O
+the O
+human B
+CG I
+alpha I
+and O
+CG B
+beta I
+promoters I
+. O
+
+c B
+- I
+Jun I
+repressed O
+the O
+CG B
+alpha I
+promoter I
+through O
+a O
+canonical O
+cAMP O
+response O
+element O
+( O
+CRE O
+) O
+that O
+is O
+known O
+to O
+bind O
+c B
+- I
+Jun I
+and O
+other O
+members O
+of O
+the O
+B B
+- I
+Zip I
+transcription I
+factor I
+family I
+. O
+
+Pulse O
+monitors O
+in O
+outpatient O
+dental O
+anaesthesia O
+. O
+
+Previous O
+studies O
+using O
+partial O
+sequences O
+have O
+suggested O
+the O
+potential O
+of O
+26S B
+or O
+large B
+- I
+subunit I
+( I
+LSU I
+) I
+rDNA I
+for O
+phylogeny O
+retrieval O
+at O
+taxonomic O
+levels O
+comparable O
+to O
+those O
+investigated O
+with O
+18S B
+rDNA I
+. O
+
+The O
+sensitivity O
+of O
+99mTc O
+- O
+IgG B
+scintigraphy O
+ranged O
+between O
+71 O
+% O
+and O
+100 O
+% O
+. O
+
+The O
+index O
+patient O
+, O
+a O
+10 O
+- O
+year O
+- O
+old O
+boy O
+, O
+presents O
+typical O
+symptoms O
+of O
+OPD O
+type O
+I O
+together O
+with O
+bowing O
+of O
+the O
+long O
+bones O
+and O
+abnormalities O
+of O
+the O
+thorax O
+and O
+spinal O
+column O
+. O
+
+The O
+cause O
+for O
+the O
+increase O
+in O
+plasma O
+ANP B
+levels O
+in O
+the O
+active O
+phase O
+remains O
+to O
+be O
+determined O
+. O
+
+A O
+genomic O
+clone O
+representing O
+the O
+5 O
+' O
+part O
+of O
+the O
+message O
+was O
+also O
+isolated O
+. O
+
+Antibiotics O
+and O
+CDCA O
+- O
+mediation O
+are O
+essential O
+for O
+symptomatic O
+therapy O
+. O
+
+The O
+main O
+side O
+- O
+effects O
+were O
+myelosuppression O
+, O
+mucositis O
+and O
+peripheral O
+neuropathy O
+, O
+which O
+were O
+all O
+common O
+and O
+often O
+severe O
+. O
+
+The O
+column O
+densities O
+of O
+frozen O
+molecular O
+hydrogen O
+and O
+methanol O
+are O
+inferred O
+to O
+be O
+about O
+2 O
+. O
+5 O
+x O
+10 O
+( O
+18 O
+) O
+and O
+3 O
+. O
+0 O
+x O
+10 O
+( O
+19 O
+) O
+, O
+respectively O
+. O
+
+Similarly O
+, O
+an O
+increase O
+in O
+CAT B
+expression O
+from O
+the O
+same O
+construct O
+( O
+pBLCAT B
+- O
+ENDOA B
+) O
+was O
+also O
+observed O
+in O
+7AQS2 O
+. O
+1 O
+cells O
+. O
+
+The O
+prevalence O
+of O
+antibodies O
+to O
+HRES B
+- I
+1 I
+peptides I
+pep14 B
+- I
+24 I
+and O
+pep117 B
+- I
+127 I
+was O
+determined O
+in O
+65 O
+normal O
+blood O
+donors O
+and O
+146 O
+patients O
+with O
+immunological O
+disorders O
+. O
+
+We O
+recently O
+reported O
+the O
+cloning O
+and O
+sequencing O
+of O
+the O
+alpha B
+7 I
+integrin I
+chain I
+and O
+its O
+regulated O
+expression O
+during O
+the O
+development O
+of O
+skeletal O
+muscle O
+( O
+Song O
+et O
+al O
+. O
+
+The O
+contractile O
+effects O
+of O
+oxytocin B
+, O
+prostaglandin O
+F2 O
+alpha O
+and O
+their O
+combined O
+use O
+on O
+human O
+pregnant O
+myometrium O
+were O
+studied O
+in O
+vitro O
+. O
+
+These O
+involve O
+( O
+1 O
+) O
+subcloning O
+a O
+promoterless O
+sucCD B
+fragment I
+downstream O
+of O
+the O
+lac B
+promoter I
+in O
+M13mp10 O
+, O
+and O
+( O
+2 O
+) O
+precise O
+splicing O
+of O
+the O
+suc B
+coding I
+regions I
+with O
+the O
+efficient O
+atpE B
+ribosome I
+- I
+binding I
+site I
+and O
+expression O
+from O
+the O
+thermoinducible O
+lambda O
+promoters O
+in O
+the O
+pJLA503 O
+vector O
+. O
+
+These O
+mutations O
+prevent O
+FKBP12 B
+- O
+rapamycin O
+binding O
+to O
+TOR2 B
+, O
+as O
+assayed O
+with O
+the O
+two O
+- O
+hybrid O
+system O
+. O
+
+Transcription O
+of O
+eukaryotic O
+tRNA O
+genes O
+is O
+dependent O
+on O
+the O
+A O
+- O
+and O
+B O
+- O
+Box O
+internal O
+control O
+regions O
+( O
+ICRs O
+) O
+and O
+the O
+upstream O
+transcription O
+modulatory O
+region O
+. O
+
+Failure O
+to O
+demonstrate O
+a O
+major O
+anti O
+- O
+inflammatory O
+effect O
+with O
+alpha O
+tocopherol O
+supplementation O
+( O
+400 O
+IU O
+/ O
+day O
+) O
+in O
+normal O
+subjects O
+. O
+
+Results O
+on O
+the O
+use O
+of O
+amiodarone O
+in O
+the O
+prevention O
+of O
+paroxysmal O
+AF O
+have O
+been O
+equivocal O
+; O
+this O
+may O
+be O
+attributed O
+to O
+differences O
+in O
+defining O
+paroxysmal O
+AF O
+. O
+
+High O
+- O
+level O
+expression O
+of O
+sccypB B
+as O
+well O
+as O
+of O
+sccypA B
+cloned O
+into O
+the O
+expression O
+vector O
+pIJ702 O
+did O
+not O
+produce O
+detectable O
+changes O
+in O
+growth O
+and O
+morphology O
+of O
+S O
+. O
+chrysomallus O
+and O
+S O
+. O
+lividans O
+. O
+
+Fas B
+( O
+APO B
+- I
+1 I
+/ O
+CD95 B
+) O
+, O
+which O
+is O
+a O
+member O
+of O
+the O
+tumor B
+necrosis I
+factor I
+receptor I
+superfamily I
+, O
+is O
+a O
+cell O
+surface O
+receptor O
+that O
+induces O
+apoptosis O
+. O
+
+In O
+the O
+future O
+, O
+transoesophageal O
+echocardiography O
+may O
+be O
+used O
+to O
+measure O
+variations O
+in O
+wall O
+thickness O
+which O
+change O
+the O
+global O
+loading O
+conditions O
+in O
+the O
+basal O
+midwall O
+compartments O
+of O
+the O
+left O
+ventricle O
+. O
+
+We O
+studied O
+18 O
+dogs O
+, O
+anaesthetised O
+and O
+spontaneously O
+breathing O
+both O
+room O
+air O
+and O
+after O
+the O
+inhalation O
+of O
+a O
+gas O
+mixture O
+containing O
+10 O
+% O
+CO2 O
+, O
+20 O
+. O
+9 O
+% O
+O2 O
+, O
+and O
+69 O
+. O
+1 O
+% O
+N2 O
+, O
+to O
+determine O
+the O
+role O
+of O
+histamine O
+, O
+serotonin O
+, O
+and O
+acidaemia O
+in O
+pulmonary O
+hypertension O
+produced O
+by O
+hypercapnia O
+. O
+
+Sequencing O
+of O
+this O
+fragment O
+showed O
+that O
+the O
+MRP13 B
+coding I
+region I
+specifies O
+a O
+324 O
+- O
+amino O
+- O
+acid O
+basic O
+protein O
+with O
+a O
+calculated O
+Mr O
+of O
+37 O
+, O
+366 O
+. O
+
+Viral B
+complementary I
+15 I
+S I
+mRNA I
+that O
+directs O
+the O
+synthesis O
+of O
+N B
+protein I
+and O
+hybridizes O
+to O
+the O
+predicted O
+N B
+gene I
+DNA I
+has O
+been O
+identified O
+in O
+infected O
+cell O
+extracts O
+. O
+
+Electrophoretic O
+mobility O
+shift O
+assays O
+and O
+DNase B
+I I
+protection O
+analyses O
+revealed O
+that O
+FP B
+I I
+was O
+bound O
+by O
+the O
+transcription O
+factor O
+PU B
+. I
+1 I
+/ O
+Spi B
+- I
+1 I
+. O
+
+Retroviral O
+vector O
+producer O
+cell O
+populations O
+and O
+cell O
+clones O
+were O
+established O
+for O
+each O
+chLTR B
+vector O
+, O
+and O
+all O
+were O
+capable O
+of O
+yielding O
+high O
+vector O
+titers O
+( O
+> O
+10 O
+( O
+5 O
+) O
+G418R O
+cfu O
+/ O
+ml O
+on O
+NIH O
+- O
+3T3 O
+) O
+. O
+
+However O
+, O
+a O
+few O
+sites O
+in O
+the O
+genomes O
+of O
+EC O
+cells O
+permit O
+M O
+- O
+MuLVneo O
+delta I
+Enh I
+proviral O
+expression O
+. O
+
+Increasing O
+insulin B
+sensitivity O
+in O
+type O
+I O
+diabetic O
+patients O
+should O
+alert O
+clinicians O
+to O
+the O
+possibility O
+of O
+glucocorticoid O
+deficiency O
+. O
+
+However O
+, O
+differential O
+utilization O
+of O
+these O
+determinants O
+mediate O
+RAR B
+- O
+RXR B
+heterodimer O
+binding O
+to O
+DR O
+- O
+2 O
+and O
+DR O
+- O
+5 O
+RAREs O
+. O
+
+Galactorrhoea O
+is O
+a O
+rare O
+presentation O
+of O
+an O
+empty O
+sella O
+syndrome O
+. O
+
+The O
+addition O
+of O
+novel O
+techniques O
+, O
+such O
+as O
+histopathologic O
+ultrastaging O
+, O
+immunohistochemistry O
+staining O
+, O
+and O
+reverse B
+transcriptase I
+polymerase O
+chain O
+reaction O
+assays O
+, O
+will O
+help O
+increase O
+the O
+accuracy O
+and O
+rate O
+of O
+detection O
+of O
+disease O
+. O
+
+Several O
+of O
+the O
+drugs O
+used O
+in O
+the O
+management O
+of O
+MAC O
+have O
+been O
+associated O
+with O
+significant O
+drug O
+interactions O
+involving O
+the O
+cytochrome B
+P450 I
+( O
+CYP B
+) O
+enzyme O
+system O
+. O
+
+Arterial O
+compliance O
+measurements O
+using O
+intraarterial O
+pulse O
+contour O
+analysis O
+and O
+a O
+modified O
+Windkessel O
+model O
+were O
+carried O
+out O
+in O
+19 O
+patients O
+with O
+isolated O
+systolic O
+hypertension O
+( O
+> O
+or O
+= O
+160 O
+/ O
+< O
+or O
+= O
+90 O
+mm O
+Hg O
+) O
+and O
+compared O
+to O
+measurements O
+in O
+29 O
+patients O
+with O
+essential O
+hypertension O
+( O
+diastolic O
+blood O
+pressure O
+[ O
+BP O
+] O
+> O
+or O
+= O
+95 O
+mm O
+Hg O
+) O
+and O
+47 O
+normotensive O
+control O
+subjects O
+. O
+
+Rather O
+than O
+seeking O
+a O
+blanket O
+characterization O
+of O
+an O
+essentially O
+heterogeneous O
+group O
+, O
+it O
+may O
+be O
+more O
+useful O
+to O
+consider O
+idiom O
+comprehension O
+a O
+secondary O
+manifestation O
+of O
+semantic O
+and O
+/ O
+or O
+pragmatic O
+difficulties O
+. O
+
+Methylprednisolone O
+and O
+U O
+- O
+74006F O
+were O
+equally O
+effective O
+at O
+preventing O
+neurological O
+dysfunction O
+compared O
+to O
+the O
+control O
+group O
+( O
+p O
+less O
+than O
+0 O
+. O
+01 O
+) O
+; O
+U O
+- O
+78517F O
+was O
+slightly O
+less O
+effective O
+than O
+U O
+- O
+74006F O
+and O
+methylprednisolone O
+but O
+was O
+significantly O
+better O
+than O
+vehicle O
+in O
+preventing O
+neurological O
+dysfunction O
+. O
+
+The O
+women O
+in O
+the O
+intermediate O
+calcium O
+group O
+had O
+approximately O
+the O
+same O
+mean O
+BMD O
+values O
+as O
+those O
+in O
+the O
+low O
+calcium O
+group O
+. O
+
+International O
+efforts O
+are O
+now O
+being O
+made O
+to O
+standardize O
+haemolytic O
+test O
+conditions O
+and O
+the O
+present O
+study O
+is O
+meant O
+as O
+a O
+contribution O
+to O
+this O
+. O
+
+The O
+transition O
+from O
+expression O
+of O
+early O
+meiotic O
+genes O
+to O
+expression O
+of O
+middle O
+sporulation O
+- O
+specific O
+genes O
+occurs O
+at O
+about O
+the O
+time O
+that O
+cells O
+exit O
+from O
+pachytene O
+and O
+form O
+the O
+meiosis O
+I O
+spindle O
+. O
+
+NF B
+- I
+kappaB I
+DNA I
+- I
+protein I
+binding O
+and O
+ICAM B
+- I
+1 I
+promoter I
+activity O
+were O
+enhanced O
+by O
+IL B
+- I
+1beta I
+and O
+these O
+effects O
+were O
+inhibited O
+by O
+tyrphostin O
+23 O
+, O
+but O
+not O
+by O
+PD O
+98059 O
+or O
+SB O
+203580 O
+. O
+
+Peripheral O
+neuropathy O
+in O
+the O
+cherry O
+- O
+red O
+spot O
+- O
+myoclonus O
+syndrome O
+( O
+sialidosis O
+type O
+I O
+) O
+. O
+
+Using O
+the O
+two O
+- O
+hybrid O
+screening O
+method O
+, O
+we O
+have O
+identified O
+an O
+additional O
+component O
+of O
+the O
+CCAAT B
+- I
+binding I
+factor I
+. O
+
+The O
+myb B
+proto I
+oncogene I
+product I
+( O
+c B
+- I
+Myb I
+) O
+is O
+a O
+transcriptional O
+regulator O
+and O
+its O
+expression O
+and O
+function O
+are O
+tightly O
+linked O
+to O
+the O
+cellular O
+entry O
+into O
+S O
+phase O
+and O
+DNA O
+synthesis O
+. O
+
+Both O
+the O
+p38 B
+kinase I
+inhibitor O
+SB205380 O
+( O
+SB O
+) O
+and O
+cotransfection O
+of O
+a O
+dominant O
+- O
+negative O
+mutant O
+of O
+p38 B
+kinase I
+reduced O
+IL B
+- I
+1beta I
+stimulation O
+of O
+the O
+hBNP B
+promoter I
+. O
+
+CLINICAL O
+FEATURES O
+: O
+This O
+30 O
+- O
+yr O
+- O
+old O
+gravida O
+V O
+para O
+0 O
+woman O
+presented O
+to O
+the O
+anaesthesia O
+consultation O
+clinic O
+at O
+37 O
+- O
+wk O
+gestation O
+to O
+discuss O
+pain O
+relief O
+options O
+for O
+labour O
+and O
+delivery O
+. O
+
+The O
+TaqI B
+and O
+HaeIII B
+RFLPs O
+will O
+provide O
+tools O
+for O
+the O
+genetic O
+analysis O
+of O
+CR2 B
+. O
+
+In O
+addition O
+, O
+because O
+SB203580 O
+had O
+no O
+effect O
+of O
+TNF B
+- O
+or O
+ceramide O
+- O
+induced O
+apoptosis O
+, O
+our O
+results O
+strongly O
+argue O
+against O
+a O
+role O
+for O
+p38 B
+MAPK O
+in O
+the O
+induction O
+of O
+TNF B
+- O
+- O
+or O
+ceramide O
+- O
+induced O
+apoptosis O
+. O
+
+Cognitive O
+measures O
+of O
+attention O
+included O
+the O
+Stroop O
+and O
+Controlled O
+Oral O
+Word O
+Association O
+Test O
+using O
+the O
+letters O
+" O
+C O
+, O
+" O
+" O
+F O
+, O
+" O
+and O
+" O
+L O
+" O
+( O
+COWAT O
+, O
+CFL O
+version O
+) O
+. O
+
+Ptx1 B
+belongs O
+to O
+an O
+expanding O
+family O
+of O
+bicoid B
+- I
+related I
+vertebrate I
+homeobox I
+genes I
+. O
+
+Effects O
+of O
+dietary O
+lipids O
+on O
+whole O
+- O
+body O
+retention O
+and O
+organ O
+distribution O
+of O
+organic O
+and O
+inorganic O
+mercury O
+in O
+mice O
+. O
+
+Differential O
+transcription O
+of O
+plastome O
+- O
+encoded O
+genes O
+in O
+the O
+mesophyll O
+and O
+bundle O
+- O
+sheath O
+chloroplasts O
+of O
+the O
+monocotyledonous O
+NADP B
+- I
+malic I
+enzyme I
+- O
+type O
+C4 O
+plants O
+maize O
+and O
+Sorghum O
+. O
+
+Sequential O
+immunoprecipitation O
+showed O
+all O
+detectable O
+p53 B
+to O
+be O
+of O
+the O
+PAb246 B
++ I
+class O
+in O
+each O
+LPV O
+- O
+transformed O
+cell O
+line O
+, O
+suggesting O
+that O
+the O
+stable O
+p53 B
+was O
+indeed O
+wild O
+type O
+. O
+
+Tissue O
+- O
+specific O
+gene O
+regulation O
+of O
+eukaryotic O
+organisms O
+is O
+to O
+a O
+large O
+extent O
+mediated O
+by O
+transcription O
+factors O
+that O
+interact O
+with O
+genomic O
+DNA O
+sequences O
+in O
+a O
+sequence O
+- O
+specific O
+manner O
+. O
+
+Enhanced O
+quantum O
+correlations O
+in O
+bound O
+higher O
+- O
+order O
+solitons O
+Quantum O
+effects O
+in O
+N O
+- O
+bound O
+solitons O
+can O
+be O
+drastically O
+enhanced O
+compared O
+to O
+the O
+fundamental O
+soliton O
+. O
+
+The O
+data O
+suggest O
+that O
+compromised O
+fibrinolytic O
+capacity O
+may O
+be O
+a O
+contributing O
+factor O
+in O
+the O
+development O
+of O
+thrombosis O
+in O
+patients O
+with O
+the O
+lupus O
+anticoagulant O
+. O
+
+The O
+MEE O
+was O
+significantly O
+greater O
+than O
+the O
+BEE O
+and O
+significantly O
+less O
+than O
+the O
+calculated O
+energy O
+expenditure O
+. O
+
+These O
+results O
+suggest O
+that O
+E6010 O
+may O
+be O
+of O
+clinical O
+value O
+in O
+the O
+treatment O
+of O
+coronary O
+occlusion O
+. O
+
+To O
+better O
+understand O
+the O
+relationship O
+between O
+expression O
+of O
+an O
+oncogene O
+and O
+genetic O
+instability O
+, O
+we O
+have O
+studied O
+a O
+cell O
+line O
+expressing O
+an O
+activated O
+human B
+Ha I
+- I
+ras I
+under O
+the O
+control O
+of O
+bacterial B
+lactose I
+operon I
+regulatory I
+elements I
+for O
+changes O
+in O
+methotrexate O
+resistance O
+and O
+dihydrofolate B
+reductase I
+( O
+dhfr B
+) O
+gene O
+amplification O
+following O
+mutant B
+Ha I
+- I
+ras I
+induction O
+. O
+
+On O
+a O
+variety O
+of O
+fronts O
+, O
+chronic O
+bacterial O
+infection O
+is O
+being O
+found O
+to O
+be O
+significantly O
+associated O
+with O
+the O
+development O
+of O
+atherosclerosis O
+and O
+the O
+clinical O
+complications O
+of O
+unstable O
+angina O
+, O
+myocardial O
+infarction O
+, O
+and O
+stroke O
+. O
+
+Long O
+- O
+term O
+results O
+and O
+curative O
+mechanisms O
+of O
+vesicoureteral O
+reflux O
+by O
+endoscopic O
+injection O
+of O
+blood O
+. O
+
+Inspection O
+of O
+X O
+. O
+tropicalis O
+, O
+mouse O
+and O
+human B
+U6 I
+DNA I
+upstream I
+sequences I
+revealed O
+the O
+presence O
+of O
+a O
+TATA O
+box O
+as O
+well O
+as O
+of O
+the O
+proximal O
+and O
+enhancer O
+( O
+octamer O
+motif O
+) O
+elements O
+contained O
+in O
+snRNA O
+genes O
+transcribed O
+by O
+RNA B
+polymerase I
+II I
+. O
+
+Characterization O
+of O
+an O
+unusual O
+tRNA O
+- O
+like O
+sequence O
+found O
+inserted O
+in O
+a O
+Neurospora O
+retroplasmid O
+. O
+
+Repeated O
+time O
+course O
+studies O
+in O
+the O
+same O
+patient O
+were O
+reproducible O
+although O
+the O
+absolute O
+concentrations O
+showed O
+some O
+variation O
+. O
+
+The O
+present O
+work O
+represents O
+an O
+attempt O
+to O
+develop O
+a O
+method O
+for O
+measuring O
+relative O
+blood O
+flow O
+in O
+intestinal O
+capillaries O
+, O
+by O
+the O
+use O
+of O
+sodium O
+fluorescein O
+( O
+Na O
+- O
+F O
+) O
+as O
+an O
+indicator O
+substance O
+. O
+
+The O
+human B
+PAX8 I
+gene I
+generates O
+at O
+least O
+five O
+different O
+alternatively O
+spliced O
+transcripts O
+encoding O
+different O
+PAX8 B
+isoforms I
+. O
+
+These O
+data O
+show O
+that O
+both O
+Sp1 B
+and O
+Sp3 B
+transcription I
+factors I
+upregulate O
+HGF B
+promoter I
+activity O
+by O
+binding O
+to O
+the O
+Sp1 B
+binding I
+site I
+at O
+position O
+- O
+318 O
+to O
+- O
+303 O
+bp O
+in O
+the O
+HGF B
+gene I
+promoter I
+. O
+
+After O
+a O
+1 O
+- O
+h O
+rest O
+( O
+for O
+T2 O
+return O
+to O
+baseline O
+) O
+, O
+subjects O
+repeated O
+the O
+5 O
+- O
+min O
+protocol O
+, O
+followed O
+by O
+a O
+final O
+MRI O
+/ O
+MRS O
+. O
+
+The O
+cells O
+arrest O
+in O
+the O
+G1 O
+phase O
+of O
+the O
+cell O
+cycle O
+and O
+grow O
+a O
+projection O
+towards O
+one O
+another O
+forming O
+a O
+shmoo O
+projection O
+. O
+
+Mammalian O
+homologues O
+of O
+the O
+Polycomb B
+- I
+group I
+gene I
+Enhancer O
+of O
+zeste B
+mediate O
+gene O
+silencing O
+in O
+Drosophila O
+heterochromatin O
+and O
+at O
+S O
+. O
+cerevisiae O
+telomeres O
+. O
+
+With O
+six O
+reports O
+in O
+the O
+literature O
+that O
+show O
+there O
+is O
+an O
+order O
+to O
+melanoma O
+nodal O
+metastases O
+and O
+that O
+the O
+SLN O
+histology O
+is O
+reflective O
+of O
+the O
+histology O
+of O
+the O
+remainder O
+of O
+the O
+nodal O
+basin O
+, O
+the O
+more O
+conservative O
+SLN O
+biopsy O
+can O
+be O
+performed O
+to O
+adequately O
+stage O
+nodally O
+the O
+patient O
+with O
+melanoma O
+. O
+
+The O
+results O
+obtained O
+with O
+[ B
+F304 B
+] I
+R2 I
+indicate O
+that O
+structural O
+changes O
+in O
+E B
+. I
+coli I
+R2 I
+in O
+the O
+vicinity O
+of O
+this O
+helix O
+distortion O
+can O
+influence O
+the O
+catalytic O
+activity O
+of O
+the O
+holoenzyme O
+. O
+
+Cloning O
+and O
+characterization O
+of O
+the O
+5 O
+' O
+flanking O
+region O
+of O
+human B
+ATP I
+- I
+citrate I
+lyase I
+gene I
+. O
+
+Cryoglobulinaemia O
+among O
+maintenance O
+haemodialysis O
+patients O
+and O
+its O
+relation O
+to O
+hepatitis O
+C O
+infection O
+. O
+
+The O
+S3 B
+protein I
+also O
+contains O
+a O
+DNA O
+repair O
+activity O
+, O
+efficiently O
+processing O
+8 O
+- O
+oxoguanine O
+residues O
+in O
+DNA O
+via O
+an O
+N B
+- I
+glycosylase I
+/ O
+apurinic B
+- I
+apyrimidinic I
+( I
+AP I
+) I
+lyase I
+activity O
+. O
+
+25 O
+patients O
+received O
+20 O
+mgs O
+of O
+hyoscine O
+N O
+- O
+butyl O
+bromide O
+and O
+the O
+rest O
+5 O
+mgs O
+propinoxate O
+, O
+i O
+. O
+v O
+. O
+plus O
+diazepam O
+. O
+
+We O
+present O
+here O
+a O
+statistical O
+technique O
+we O
+developed O
+to O
+identify O
+the O
+sequence O
+elements O
+that O
+may O
+be O
+responsible O
+for O
+this O
+cell O
+cycle O
+regulation O
+. O
+
+Computed O
+tomographic O
+( O
+CT O
+) O
+findings O
+of O
+pancreatic O
+ductal O
+adenocarcinoma O
+were O
+studied O
+with O
+the O
+combined O
+method O
+of O
+early O
+enhancement O
+CT O
+and O
+high O
+dose O
+enhancement O
+CT O
+in O
+72 O
+carcinomas O
+. O
+
+No O
+other O
+transcripts O
+of O
+different O
+length O
+could O
+be O
+detected O
+after O
+prolonged O
+exposure O
+. O
+
+We O
+conclude O
+, O
+therefore O
+, O
+that O
+in O
+the O
+absence O
+of O
+E1A B
+, O
+E4orf4 B
+is O
+sufficient O
+by O
+itself O
+to O
+trigger O
+a O
+p53 B
+- O
+independent O
+apoptosis O
+pathway O
+that O
+may O
+operate O
+independently O
+of O
+the O
+known O
+zVAD B
+- O
+inhibitable O
+caspases B
+, O
+and O
+that O
+may O
+involve O
+an O
+as O
+yet O
+uncharacterized O
+mechanism O
+. O
+
+The O
+antiserum O
+used O
+for O
+immunoblotting O
+specifically O
+supershifts O
+uteroglobin B
+promoter I
+- I
+protein I
+complexes I
+in O
+gel O
+shift O
+experiments O
+. O
+
+The O
+nucleotide O
+sequence O
+of O
+the O
+estrogen B
+receptor I
+gene I
+of I
+Oreochromis I
+aureus I
+( O
+OaER B
+) O
+indicates O
+that O
+the O
+hormone O
+- O
+binding O
+E O
+domain O
+is O
+composed O
+of O
+4 O
+exons O
+interspersed O
+by O
+short O
+introns O
+of O
+only O
+0 O
+. O
+18 O
+- O
+1 O
+. O
+3 O
+kb O
+each O
+. O
+
+The O
+expression O
+of O
+Scmh1 B
+and O
+rae28 B
+/ O
+mph1 B
+is O
+well O
+correlated O
+in O
+most O
+tissues O
+of O
+embryos O
+. O
+
+The O
+nucleoporin B
+98 I
+gene I
+( O
+NUP98 B
+) O
+, O
+which O
+is O
+rearranged O
+in O
+several O
+acute O
+myeloid O
+leukemia O
+translocations O
+, O
+is O
+located O
+within O
+this O
+region O
+. O
+
+We O
+have O
+isolated O
+and O
+sequenced O
+cDNA O
+sequences O
+corresponding O
+to O
+two O
+novel O
+genes O
+that O
+map O
+to O
+Xq28 O
+. O
+
+A O
+new O
+direct O
+hemagglutination O
+test O
+( O
+HI O
+- O
+GONAVIS O
+) O
+for O
+urinary O
+LH B
+was O
+compared O
+with O
+the O
+serum O
+radioimmuno O
+- O
+assay O
+of O
+LH B
+. O
+
+Diffusion O
+epidemic O
+models O
+with O
+incubation O
+and O
+crisscross O
+dynamics O
+. O
+
+CERIP B
+interaction O
+. O
+
+The O
+encoded O
+Arabidopsis B
+U3 I
+snRNAs I
+can O
+be O
+folded O
+into O
+a O
+secondary O
+structure O
+which O
+is O
+more O
+similar O
+to O
+that O
+of O
+U3 B
+RNAs I
+from O
+lower O
+eukaryotes O
+rather O
+than O
+from O
+metazoa O
+. O
+
+Therapy O
+and O
+prevention O
+of O
+irreversible O
+shock O
+with O
+pharmacological O
+doses O
+of O
+some O
+corticosteroids O
+
+Fentanyl O
+citrate O
+( O
+0 O
+. O
+1 O
+mL O
+) O
+and O
+2H5 O
+- O
+fentanyl O
+( O
+internal O
+standard O
+, O
+0 O
+. O
+05 O
+mL O
+, O
+100 O
+mg O
+/ O
+L O
+) O
+were O
+extracted O
+with O
+Toxi O
+- O
+A O
+tubes O
+( O
+Toxi O
+- O
+Lab O
+, O
+Irvine O
+, O
+CA O
+) O
+and O
+analyzed O
+by O
+gas O
+chromatography O
+- O
+mass O
+spectrometry O
+. O
+
+Positive O
+effects O
+of O
+radioactive O
+therapy O
+in O
+Guarapari O
+
+The O
+LT B
+- I
+beta I
+gene I
+is O
+expressed O
+in O
+lymphoid O
+cells O
+and O
+organs O
+, O
+but O
+little O
+is O
+known O
+about O
+its O
+inducible O
+regulation O
+. O
+
+Ciprofloxacin O
+attained O
+a O
+peak O
+serum O
+concentration O
+of O
+1 O
+. O
+2 O
+mg O
+/ O
+l O
+and O
+a O
+serum O
+half O
+- O
+life O
+of O
+34 O
+min O
+. O
+
+Dmyd B
+clone O
+encodes O
+a O
+polypeptide O
+of O
+332 O
+amino O
+acids O
+with O
+82 O
+% O
+identity O
+to O
+MyoD B
+in O
+the O
+41 O
+amino O
+acids O
+of O
+the O
+putative O
+helix O
+- O
+loop O
+- O
+helix O
+region O
+and O
+100 O
+% O
+identity O
+in O
+the O
+13 O
+amino O
+acids O
+of O
+the O
+basic O
+domain O
+proposed O
+to O
+contain O
+the O
+essential O
+recognition O
+code O
+for O
+muscle O
+- O
+specific O
+gene O
+activation O
+. O
+
+Identification O
+of O
+an O
+osteocalcin B
+gene I
+promoter I
+sequence I
+that O
+binds O
+AP1 B
+. O
+
+Treatment O
+is O
+based O
+on O
+antifungal O
+drugs O
+, O
+most O
+frequently O
+nystatin O
+, O
+amphotericin O
+B O
+and O
+ketoconazole O
+. O
+
+Mutations O
+abolishing O
+MalK B
+function O
+not O
+only O
+result O
+in O
+inability O
+to O
+transport O
+maltose O
+but O
+also O
+cause O
+constitutive O
+expression O
+of O
+the O
+maltose B
+regulon I
+. O
+
+Drosophila B
+melanogaster I
+casein I
+kinase I
+II I
+( O
+DmCKII B
+) O
+is O
+composed O
+of O
+catalytic O
+( O
+alpha O
+) O
+and O
+regulatory O
+( O
+beta O
+) O
+subunits O
+associated O
+as O
+an O
+alpha2beta2 B
+heterotetramer I
+. O
+
+The O
+aims O
+of O
+this O
+study O
+were O
+to O
+examine O
+whether O
+the O
+EORTC O
+( O
+European O
+Organisation O
+for O
+Research O
+and O
+Treatment O
+of O
+Cancer O
+) O
+QLQ O
+- O
+C30 O
+core O
+questionnaire O
+alone O
+could O
+distinguish O
+between O
+two O
+clinically O
+different O
+groups O
+of O
+patients O
+and O
+to O
+design O
+a O
+module O
+, O
+which O
+included O
+relevant O
+patient O
+- O
+defined O
+gastric O
+cancer O
+- O
+specific O
+variables O
+. O
+
+On O
+both O
+indocyanine O
+green O
+video O
+and O
+fluorescein O
+angiography O
+, O
+hypofluorescent O
+lesions O
+were O
+almost O
+the O
+same O
+size O
+as O
+the O
+light O
+yellow O
+area O
+and O
+the O
+dark O
+yellow O
+center O
+of O
+a O
+placoid O
+lesion O
+. O
+
+We O
+have O
+measured O
+percentage O
+O3 O
+uptake O
+in O
+30 O
+adult O
+Sprague O
+- O
+Dawley O
+rats O
+exposed O
+, O
+nose O
+only O
+, O
+for O
+1 O
+hr O
+to O
+0 O
+. O
+3 O
+, O
+0 O
+. O
+6 O
+, O
+or O
+1 O
+. O
+0 O
+ppm O
+O3 O
+. O
+
+The O
+signal O
+- O
+to O
+- O
+noise O
+ratio O
+( O
+SNR O
+) O
+was O
+calculated O
+in O
+the O
+T2 O
+- O
+weighted O
+sequence O
+. O
+
+Cell O
+rounding O
+was O
+abrogated O
+by O
+expression O
+of O
+either O
+kinase O
+- O
+dead O
+forms O
+of O
+US3 B
+PK I
+or O
+a O
+mutant O
+protein O
+lacking O
+the O
+acidic O
+cluster O
+in O
+the O
+kinase O
+regulatory O
+domain O
+. O
+
+Three O
+distinct O
+human B
+HDACs I
+are O
+homologous O
+to O
+RPD3 B
+, O
+a O
+yeast O
+transcriptional O
+regulator O
+. O
+
+The O
+4 O
+- O
+nt O
+sequence O
+of O
+the O
+rotavirus O
+3 O
+' O
+TE O
+represents O
+by O
+far O
+the O
+shortest O
+of O
+any O
+of O
+the O
+sequence O
+enhancers O
+known O
+to O
+stimulate O
+translation O
+. O
+
+OBJECTIVE O
+: O
+The O
+audiologic O
+presentation O
+of O
+vestibular O
+schwannoma O
+( O
+VS O
+) O
+associated O
+with O
+neurofibromatosis O
+type O
+2 O
+( O
+NF2 O
+) O
+has O
+not O
+been O
+well O
+characterized O
+. O
+
+Expression O
+of O
+these O
+chemokines O
+is O
+similar O
+in O
+that O
+both O
+require O
+the O
+NF B
+- I
+kappa I
+B I
+element I
+and O
+additional O
+regions O
+such O
+as O
+the O
+CAAT B
+/ I
+enhancer I
+binding I
+protein I
+( O
+C B
+/ I
+EBP I
+) O
+element O
+of O
+the O
+IL B
+- I
+8 I
+promoter I
+. O
+
+The O
+meaning O
+of O
+hope O
+in O
+health O
+and O
+illness O
+. O
+
+Assessment O
+of O
+two O
+anion O
+- O
+exchange O
+resins O
+for O
+direct O
+use O
+in O
+the O
+screening O
+method O
+for O
+urinary O
+porphobilinogen O
+. O
+
+Aggravation O
+of O
+peripheral O
+- O
+blood O
+cytopenia O
+during O
+the O
+first O
+weeks O
+and O
+hypocellularity O
+of O
+bone O
+- O
+marrow O
+aspirates O
+at O
+the O
+end O
+of O
+therapy O
+suggest O
+that O
+low O
+- O
+dose O
+Ara O
+C O
+exerts O
+its O
+main O
+activity O
+by O
+suppression O
+of O
+leukaemic O
+growth O
+, O
+rather O
+than O
+by O
+induction O
+of O
+differentiation O
+in O
+malignant O
+cells O
+. O
+
+All O
+depressive O
+groups O
+showed O
+improved O
+error O
+measures O
+post O
+- O
+treatment O
+. O
+
+Triaxiality O
+in O
+the O
+proton O
+- O
+neutron O
+interacting O
+boson O
+model O
+: O
+Perturbed O
+O O
+( O
+6 O
+) O
+symmetry O
+with O
+application O
+to O
+the O
+mass O
+A O
+
+The O
+best O
+sequences O
+for O
+pelvic O
+study O
+are O
+, O
+in O
+our O
+experience O
+, O
+IR O
+or O
+short O
+TR O
+spin O
+- O
+echo O
+for O
+T1 O
+- O
+weighted O
+images O
+, O
+and O
+spin O
+- O
+echo O
+with O
+1200 O
+TR O
+for O
+T2 O
+images O
+. O
+
+Cells O
+were O
+co O
+- O
+infected O
+simultaneously O
+with O
+IBV O
+, O
+the O
+recombinant O
+FPV O
+( O
+rFPV O
+) O
+containing O
+the O
+D B
+- O
+RNA O
+sequence O
+and O
+a O
+second O
+rFPV O
+expressing O
+T7 B
+RNA I
+polymerase I
+for O
+the O
+initial O
+expression O
+of O
+the O
+D B
+- I
+RNA I
+transcript I
+, O
+subsequently O
+rescued O
+by O
+helper O
+IBV O
+. O
+
+Seasonal O
+variation O
+of O
+the O
+cadmium O
+content O
+of O
+Murex O
+trunculus O
+in O
+a O
+non O
+- O
+cadmium O
+polluted O
+environment O
+. O
+
+These O
+results O
+are O
+discussed O
+in O
+relation O
+to O
+predicted O
+isoform B
+L I
+diversity O
+across O
+human O
+tissues O
+and O
+cells O
+. O
+
+Doctors O
+given O
+intrathecal O
+methotrexate O
+had O
+headache O
+when O
+20 O
+gauge O
+standard O
+needle O
+was O
+used O
+. O
+
+The O
+AP B
+- I
+1 I
+recruited O
+by O
+ARF1 B
+. I
+GTP I
+is O
+released O
+from O
+the O
+Golgi O
+membrane O
+by O
+treatment O
+with O
+1 O
+M O
+Tris O
+- O
+HCl O
+( O
+pH O
+7 O
+) O
+or O
+upon O
+reincubation O
+at O
+37 O
+degreesC O
+, O
+whereas O
+AP B
+- I
+1 I
+recruited O
+with O
+GTPgammaS B
+or O
+by O
+a O
+constitutively O
+active O
+point O
+mutant O
+, O
+ARF1 B
+( I
+Q71L I
+) I
+, O
+remains O
+membrane O
+bound O
+after O
+either O
+treatment O
+. O
+
+The O
+formation O
+of O
+tumorlike O
+lesions O
+in O
+the O
+cockroach O
+leucophaea O
+maderae O
+after O
+anal O
+blockage O
+. O
+
+Fine O
+tangled O
+pili O
+expressed O
+by O
+Haemophilus O
+ducreyi O
+are O
+a O
+novel O
+class O
+of O
+pili B
+. O
+
+We O
+found O
+remarkable O
+differences O
+in O
+the O
+expression O
+patterns O
+of O
+MTB B
+- I
+Zf I
+mRNA I
+and O
+two O
+other O
+hybridizable O
+mRNAs O
+of O
+5kb O
+and O
+8 O
+. O
+5 O
+kb O
+when O
+human O
+brain O
+and O
+primary O
+brain O
+tumors O
+were O
+compared O
+. O
+
+The O
+two O
+redox O
+centers O
+in O
+the O
+protein O
+, O
+FAD O
+and O
+a O
+[ O
+4Fe4S O
+] O
++ O
+2 O
+, O
++ O
+1 O
+cluster O
+, O
+are O
+present O
+in O
+a O
+64 O
+- O
+kDa O
+monomer O
+. O
+
+The O
+pra2 B
+gene I
+encodes O
+a O
+pea B
+( I
+Pisum I
+sativum I
+) I
+small I
+GTPase I
+belonging O
+to O
+the O
+YPT B
+/ O
+rab B
+family O
+, O
+and O
+its O
+expression O
+is O
+down O
+- O
+regulated O
+by O
+light O
+, O
+mediated O
+by O
+phytochrome B
+. O
+
+Carotid O
+body O
+chemoreceptor O
+activity O
+as O
+recorded O
+from O
+the O
+petrosal O
+ganglion O
+in O
+cats O
+. O
+
+Human B
+and I
+murine I
+cytotoxic I
+T I
+lymphocyte I
+serine I
+proteases I
+: O
+subsite O
+mapping O
+with O
+peptide O
+thioester O
+substrates O
+and O
+inhibition O
+of O
+enzyme O
+activity O
+and O
+cytolysis O
+by O
+isocoumarins O
+. O
+
+To O
+explore O
+further O
+the O
+role O
+of O
+the O
+carboxyl O
+- O
+terminal O
+domain O
+in O
+determining O
+the O
+cell O
+cycle O
+function O
+of O
+CDC34 B
+, O
+we O
+constructed O
+and O
+characterized O
+genes O
+encoding O
+chimeric B
+E2s I
+incorporating O
+sequences O
+from O
+CDC34 B
+and O
+the O
+related O
+but O
+functionally O
+distinct O
+E2 B
+RAD6 B
+( O
+UBC2 B
+) O
+. O
+
+MAPKK B
+kinase I
+/ O
+MEKK B
+phosphorylates O
+and O
+activates O
+its O
+downstream O
+protein O
+kinase O
+, O
+MAPK B
+kinase I
+/ O
+MEK B
+, O
+which O
+in O
+turn O
+activates O
+MAPK B
+. O
+
+Kondo O
+effect O
+in O
+Cu O
+( O
+Fe O
+) O
+films O
+. O
+
+However O
+, O
+ADAR1 B
+and O
+the O
+related O
+deaminase O
+ADAR2 B
+showed O
+significant O
+expression O
+in O
+all O
+regions O
+of O
+the O
+brain O
+examined O
+, O
+including O
+cortex O
+, O
+hippocampus O
+, O
+olfactory O
+bulb O
+, O
+and O
+striatum O
+, O
+where O
+the O
+5 B
+- I
+HT2CR I
+pre I
+- I
+mRNA I
+was O
+extensively O
+edited O
+. O
+
+To O
+investigate O
+its O
+transcription O
+, O
+1 O
+. O
+1 O
+kilobases O
+of O
+the O
+5 O
+' O
+- O
+flanking O
+sequence O
+were O
+fused O
+to O
+a O
+luciferase B
+reporter I
+gene I
+. O
+
+Influence O
+of O
+copper O
+addition O
+. O
+
+The O
+0 O
+. O
+018 O
+- O
+inch O
+FloWire O
+provides O
+a O
+high O
+- O
+fidelity O
+continuous O
+Doppler O
+signal O
+. O
+
+Monosulfates O
+of O
+16 O
+- O
+oxygenated O
+ketonic O
+C19 O
+steroids O
+in O
+adult O
+human O
+urine O
+. O
+
+Under O
+anaerobic O
+conditions O
+( O
+a O
+50 O
+- O
+day O
+experiment O
+) O
+these O
+organisms O
+degraded O
+15 O
+- O
+18 O
+% O
+of O
+the O
+TEM O
+, O
+20 O
+- O
+25 O
+% O
+of O
+some O
+alkanes O
+, O
+and O
+15 O
+- O
+18 O
+% O
+of O
+selected O
+polycyclic O
+aromatic O
+hydrocarbons O
+. O
+
+In O
+addition O
+, O
+WR O
+- O
+3689 O
+, O
+WR O
+- O
+109342 O
+, O
+and O
+WR O
+- O
+168643 O
+were O
+used O
+with O
+per O
+os O
+administration O
+to O
+determine O
+hematopoietic O
+lethality O
+. O
+
+Further O
+, O
+we O
+will O
+review O
+our O
+evaluation O
+of O
+the O
+survival O
+rate O
+and O
+prognostic O
+factors O
+for O
+9 O
+, O
+262 O
+patients O
+from O
+1981 O
+to O
+1996 O
+. O
+
+MEASURES O
+: O
+SF O
+- O
+36 O
+questionnaires O
+were O
+completed O
+by O
+patients O
+at O
+both O
+initial O
+and O
+discharge O
+examinations O
+. O
+
+In O
+contrast O
+, O
+corticotropin B
+releasing I
+factor I
+( O
+CRF B
+) O
+, O
+injected O
+centrally O
+produces O
+a O
+suppression O
+of O
+punished O
+and O
+non O
+- O
+punished O
+responding O
+in O
+the O
+conflict O
+test O
+consistent O
+with O
+its O
+hypothesized O
+role O
+in O
+mediating O
+behavioral O
+responses O
+to O
+stress O
+. O
+
+Temporal O
+recruitment O
+of O
+the O
+mSin3A B
+- O
+histone B
+deacetylase I
+corepressor O
+complex O
+to O
+the O
+ETS B
+domain I
+transcription I
+factor I
+Elk B
+- I
+1 I
+. O
+
+The O
+cluster O
+was O
+mapped O
+to O
+nucleotides O
+- O
+464 O
+to O
+- O
+434 O
+( O
+relative O
+to O
+nucleotide O
+A O
+in O
+the O
+initiation O
+codon O
+) O
+in O
+genomic O
+DNA O
+. O
+
+In O
+addition O
+, O
+FOP B
+- O
+FGFR1 B
+- O
+expressing O
+cells O
+show O
+constitutive O
+phosphorylation O
+of O
+the O
+positive O
+regulator O
+of O
+translation O
+p70S6 B
+kinase I
+; O
+this O
+phosphorylation O
+is O
+inhibited O
+by O
+PI3 B
+- I
+kinase I
+and O
+mTOR B
+( O
+mammalian B
+target I
+of I
+rapamycin I
+) O
+inhibitors O
+. O
+
+The O
+authors O
+report O
+two O
+cases O
+of O
+orbital O
+cavernous O
+hemangioma O
+diagnosed O
+by O
+Tc O
+- O
+99m O
+RBC O
+SPECT O
+. O
+
+Ciprofloxacin O
+levels O
+in O
+serum O
+and O
+blister O
+fluid O
+at O
+the O
+end O
+of O
+the O
+dosing O
+interval O
+( O
+8 O
+h O
+) O
+were O
+superior O
+or O
+almost O
+superior O
+to O
+MICs O
+for O
+sensitive O
+organisms O
+including O
+Pseudomonas O
+aeruginosa O
+. O
+
+Antibiotic O
+prophylaxis O
+in O
+a O
+surgical O
+setting O
+
+We O
+identified O
+clones O
+of O
+Chlamydomonas O
+genomic O
+DNA O
+that O
+rescued O
+the O
+Ca O
+( O
+2 O
++ O
+) O
+- O
+dependent O
+axonemal O
+microtubule O
+severing O
+defect O
+of O
+fa1 B
+mutants I
+. O
+
+These O
+changes O
+persisted O
+during O
+the O
+first O
+week O
+. O
+
+Hyperlipemia O
+has O
+been O
+recently O
+described O
+in O
+children O
+with O
+migraine O
+, O
+being O
+suggested O
+that O
+this O
+alteration O
+is O
+in O
+the O
+base O
+of O
+the O
+disease O
+. O
+
+Plasma B
+hemopexin I
+homeostasis O
+during O
+the O
+acute O
+phase O
+response O
+. O
+
+The O
+newly O
+identified O
+repressor O
+element O
+is O
+a O
+rare O
+example O
+of O
+a O
+naturally O
+occurring O
+perfect O
+palindromic O
+binding O
+motif O
+for O
+the O
+NF B
+- I
+kappa I
+B I
+/ O
+Rel B
+family O
+of O
+transcription O
+factors O
+. O
+
+Tryptophan O
+induction O
+prevents O
+Rho B
+- O
+dependent O
+transcription O
+termination O
+in O
+the O
+leader O
+region O
+of O
+the O
+operon O
+. O
+
+There O
+remains O
+the O
+physiological O
+problem O
+- O
+- O
+one O
+which O
+has O
+always O
+been O
+foremost O
+in O
+Moruzzi O
+' O
+s O
+thinking O
+about O
+the O
+intrinsic O
+regulation O
+of O
+brain O
+activity O
+- O
+- O
+of O
+how O
+the O
+separate O
+actions O
+of O
+the O
+different O
+arousal O
+systems O
+are O
+brought O
+together O
+into O
+a O
+functional O
+whole O
+. O
+
+The O
+nramp2 B
+gene I
+is O
+comprised O
+of O
+17 O
+exons O
+and O
+spans O
+more O
+than O
+36 O
+kb O
+. O
+
+The O
+immune O
+response O
+seems O
+to O
+be O
+partially O
+responsible O
+for O
+both O
+protection O
+and O
+the O
+destructive O
+consequences O
+of O
+chlamydial O
+infection O
+. O
+
+Results O
+: O
+hepatic O
+hydatidosis O
+: O
+177 O
+patients O
+. O
+
+This O
+is O
+similar O
+to O
+previous O
+reports O
+of O
+muscle B
+creatine I
+phosphokinase I
+release O
+in O
+psychiatric O
+patients O
+. O
+
+The O
+majority O
+of O
+putative O
+TSC2 B
+mutations O
+were O
+found O
+in O
+sporadic O
+rather O
+than O
+TSC2 B
+- O
+linked O
+families O
+. O
+
+Murine B
+ELAM I
+- I
+1 I
+is O
+encoded O
+by O
+a O
+single O
+- O
+copy O
+gene O
+, O
+spanning O
+about O
+13 O
+kb O
+, O
+which O
+is O
+structurally O
+organized O
+into O
+14 O
+exons O
+and O
+13 O
+introns O
+; O
+very O
+similar O
+to O
+that O
+of O
+its O
+human O
+counterpart O
+. O
+
+A O
+biopsy O
+specimen O
+taken O
+from O
+the O
+frontal O
+branch O
+of O
+the O
+right O
+superficial O
+artery O
+revealed O
+segmental O
+intimal O
+thickening O
+consistent O
+with O
+intimal O
+fibroplasia O
+type O
+FMD O
+upon O
+histological O
+examination O
+. O
+
+Thus O
+in O
+this O
+study O
+we O
+used O
+in O
+vitro O
+methods O
+to O
+directly O
+evaluate O
+whether O
+isolated O
+human O
+saphenous O
+vein O
+segments O
+respond O
+to O
+vasoconstrictor O
+agents O
+at O
+arterial O
+pressure O
+levels O
+. O
+
+We O
+found O
+that O
+the O
+PRP20 B
+gene I
+is O
+identical O
+to O
+the O
+yeast B
+SRM1 I
+gene I
+( O
+Clark O
+and O
+Sprague O
+1989 O
+) O
+. O
+
+Basal O
+JNK B
+MAPK I
+kinase O
+activity O
+was O
+also O
+specifically O
+induced O
+by O
+deltaEGFR B
+, O
+which O
+correlated O
+with O
+increased O
+phosphorylation O
+of O
+a O
+54 B
+- I
+kDa I
+JNK2 I
+protein I
+observed O
+in O
+deltaEGFR B
+- O
+containing O
+cells O
+. O
+
+Deletion O
+analysis O
+defines O
+distinct O
+functional O
+domains O
+for O
+protein O
+- O
+protein O
+and O
+nucleic O
+acid O
+interactions O
+in O
+the O
+ORF1 O
+protein O
+of O
+mouse O
+LINE O
+- O
+1 O
+. O
+
+PMA O
+produced O
+similar O
+results O
+, O
+but O
+the O
+induction O
+of O
+the O
+WT O
+AP1 B
+c B
+- I
+jun I
+promoter O
+- O
+CAT B
+plasmid O
+was O
+smaller O
+. O
+
+The O
+determination O
+of O
+antithrombin B
+III I
+( O
+AT B
+III I
+) O
+and O
+its O
+clinical O
+significance O
+
+One O
+ORF O
+extends O
+from O
+nucleotides O
+415 O
+to O
+1620 O
+, O
+encodes O
+402 O
+amino O
+acids O
+, O
+and O
+is O
+preceded O
+by O
+a O
+ribosome O
+- O
+binding O
+site O
+. O
+
+Glucose O
+consumption O
+of O
+the O
+human O
+brain O
+under O
+the O
+influence O
+of O
+intravenous O
+infusions O
+of O
+glucose O
+, O
+glucagon B
+and O
+glucose B
+- I
+insulin I
+
+D O
+. O
+, O
+Hughes O
+, O
+F O
+. O
+
+Deletion O
+of O
+CDC5 B
+was O
+lethal O
+and O
+resulted O
+in O
+a O
+dumbbell O
+- O
+shaped O
+terminal O
+morphology O
+, O
+with O
+the O
+nuclei O
+almost O
+divided O
+but O
+still O
+connected O
+. O
+
+These O
+cDNAs O
+were O
+found O
+to O
+be O
+derived O
+from O
+the O
+3 O
+" O
+- O
+untranslated O
+region O
+( O
+3 O
+" O
+- O
+UTR O
+) O
+of O
+the O
+methyl B
+- I
+CpG I
+- I
+binding I
+protein I
+2 I
+gene I
+( O
+MeCP2 B
+) O
+. O
+
+A O
+) O
+During O
+O2 O
+- O
+ischemia O
+both O
+extracellular O
+[ O
+K O
++ O
+] O
+and O
+change O
+of O
+pH O
+in O
+the O
+subepicardium O
+are O
+significantly O
+less O
+than O
+in O
+the O
+midmyocardium O
+. O
+
+The O
+generation O
+of O
+dorso O
+- O
+ventral O
+polarity O
+during O
+Drosophila O
+embryogenesis O
+is O
+regulated O
+by O
+the O
+action O
+of O
+12 O
+maternally O
+expressed O
+gene O
+products O
+, O
+the O
+dorsal O
+group O
+. O
+
+Ultimobranchial O
+body O
+and O
+parathyroid O
+glands O
+of O
+the O
+freshwater O
+snake O
+Natrix O
+piscator O
+in O
+response O
+to O
+vitamin O
+D3 O
+administration O
+. O
+
+These O
+observations O
+suggest O
+that O
+the O
+AF O
+- O
+1 O
+region O
+of O
+PPARalpha B
+is O
+partially O
+silenced O
+by O
+corepressor O
+proteins O
+, O
+which O
+might O
+interact O
+in O
+a O
+phosphorylation O
+- O
+dependent O
+manner O
+. O
+
+Two O
+authors O
+, O
+two O
+journal O
+titles O
+, O
+two O
+drug O
+names O
+, O
+and O
+two O
+topics O
+of O
+a O
+general O
+medical O
+nature O
+were O
+retrieved O
+under O
+identical O
+circumstances O
+and O
+conditions O
+on O
+the O
+hosts O
+DATA O
+- O
+STAR O
+, O
+DIALOG O
+, O
+DIMDI O
+, O
+and O
+STN O
+. O
+
+However O
+, O
+in O
+a O
+variation O
+of O
+this O
+assay O
+in O
+which O
+the O
+protease O
+is O
+omitted O
+, O
+the O
+mutant O
+enzymes O
+exhibited O
+substantial O
+levels O
+of O
+prolyl B
+isomerase I
+activity O
+( O
+5 O
+- O
+20 O
+% O
+of O
+wild O
+- O
+type O
+) O
+, O
+revealing O
+that O
+these O
+mutations O
+confer O
+sensitivity O
+to O
+protease O
+digestion O
+and O
+that O
+the O
+classic O
+in O
+vitro O
+assay O
+for O
+prolyl B
+isomerase I
+activity O
+may O
+be O
+misleading O
+. O
+
+As O
+a O
+test O
+of O
+this O
+hypothesis O
+, O
+we O
+predicted O
+that O
+mice O
+which O
+have O
+altered O
+expression O
+of O
+class O
+I O
+gene O
+products O
+, O
+the O
+beta2 B
+- I
+microglobulin I
+knockout O
+mice O
+, O
+[ O
+beta2m B
+( I
+- I
+/ I
+- I
+) I
+] I
+, O
+would O
+develop O
+Fe O
+overload O
+. O
+
+Nucleotide O
+sequence O
+of O
+the O
+gag B
+gene I
+and O
+gag B
+- O
+pol B
+junction O
+of O
+feline O
+leukemia O
+virus O
+. O
+
+Clinical O
+trial O
+endpoints O
+based O
+on O
+magnitude O
+of O
+reduction O
+in O
+HIV O
+- O
+1 O
+RNA O
+levels O
+provide O
+an O
+important O
+complement O
+to O
+endpoints O
+based O
+on O
+percentage O
+of O
+patients O
+achieving O
+complete O
+virologic O
+suppression O
+. O
+
+It O
+also O
+describes O
+the O
+preliminary O
+results O
+of O
+a O
+Phase O
+II O
+trial O
+going O
+on O
+at O
+the O
+Central O
+Institute O
+for O
+Tumors O
+in O
+Zagreb O
+, O
+using O
+a O
+combination O
+of O
+cis O
+- O
+DDP O
+, O
+5 O
+- O
+fluorouracil O
+and O
+vincristine O
+. O
+
+On O
+the O
+basis O
+of O
+the O
+physical O
+interactions O
+between O
+Sxl B
+and O
+Snf B
+, O
+we O
+present O
+a O
+model O
+for O
+Sxl B
+splicing O
+regulation O
+. O
+
+Though O
+it O
+has O
+been O
+established O
+that O
+skinfold O
+anthropometry O
+has O
+severe O
+limitations O
+as O
+a O
+method O
+of O
+deriving O
+total O
+body O
+fat O
+( O
+TBF O
+) O
+, O
+the O
+possibility O
+that O
+the O
+problem O
+might O
+be O
+related O
+more O
+to O
+the O
+assumptions O
+implicit O
+in O
+densitometry O
+has O
+to O
+be O
+addressed O
+. O
+
+The O
+average O
+mean O
+difference O
+compared O
+with O
+the O
+low O
+and O
+the O
+intermediate O
+calcium O
+group O
+was O
+11 O
+% O
+for O
+the O
+femoral O
+neck O
+, O
+8 O
+- O
+11 O
+% O
+for O
+the O
+lumbar O
+spine O
+and O
+5 O
+- O
+6 O
+% O
+for O
+total O
+body O
+BMDs O
+. O
+
+We O
+cloned O
+the O
+BamHI B
+- I
+F I
+fragment I
+from O
+the O
+left O
+end O
+of O
+Ad4 O
+in O
+pUC13 O
+- O
+1 O
+between O
+the O
+SalI B
+and O
+BamHI B
+sites I
+in O
+order O
+to O
+carry O
+out O
+the O
+structural O
+analysis O
+of O
+the O
+E1A B
+region I
+of I
+Ad4 O
+. O
+
+We O
+reviewed O
+81 O
+patients O
+with O
+dementia O
+and O
+autopsy O
+findings O
+of O
+Alzheimer O
+' O
+s O
+disease O
+( O
+AD O
+) O
+to O
+identify O
+patients O
+with O
+seizures O
+or O
+myoclonus O
+after O
+onset O
+of O
+dementia O
+. O
+
+BACKGROUND O
+: O
+In O
+lung O
+protective O
+strategy O
+, O
+positive O
+end O
+- O
+expiratory O
+pressure O
+( O
+PEEP O
+) O
+slightly O
+higher O
+than O
+the O
+Pflex O
+( O
+the O
+airway O
+pressure O
+corresponding O
+to O
+the O
+lower O
+inflection O
+point O
+( O
+LIP O
+) O
+on O
+the O
+inspiratory O
+pressure O
+- O
+volume O
+( O
+P O
+- O
+V O
+) O
+curve O
+measured O
+with O
+ZEEP O
+) O
+is O
+generally O
+recommended O
+. O
+
+3 O
+. O
+
+In O
+both O
+RAW O
+cells O
+and O
+the O
+microglia O
+cell O
+line O
+EOC20 O
+, O
+two O
+IFN B
+- I
+gamma I
+- I
+activated I
+transcription I
+factors I
+, O
+STAT B
+- I
+1alpha I
+and O
+IRF B
+- I
+1 I
+, O
+bind O
+the O
+GAS B
+and O
+IRF B
+elements I
+, O
+respectively O
+. O
+
+Thermal O
+changes O
+of O
+the O
+bovine O
+uterus O
+following O
+administration O
+of O
+estradiol O
+- O
+17beta O
+. O
+
+The O
+starting O
+dose O
+was O
+8 O
+mg O
+/ O
+m2 O
+administered O
+intravenously O
+( O
+IV O
+) O
+as O
+a O
+short O
+infusion O
+daily O
+for O
+5 O
+days O
+, O
+repeated O
+every O
+3 O
+weeks O
+with O
+dose O
+adjustments O
+depending O
+on O
+patient O
+tolerance O
+. O
+
+In O
+agreement O
+with O
+other O
+authors O
+, O
+we O
+recommend O
+the O
+procedure O
+as O
+a O
+safe O
+one O
+, O
+providing O
+satisfactory O
+results O
+. O
+
+After O
+inhibition O
+of O
+monoamine B
+oxidase I
+with O
+pargyline O
+( O
+10 O
+mg O
+/ O
+kg O
+. O
+i O
+. O
+v O
+. O
+) O
+, O
+the O
+effects O
+of O
+tyramine O
+( O
+1000 O
+micrograms O
+) O
+injected O
+into O
+the O
+hepatic O
+artery O
+were O
+potentiated O
+. O
+
+Helenalin B
+triggers O
+a O
+CD95 B
+death I
+receptor I
+- O
+independent O
+apoptosis O
+that O
+is O
+not O
+affected O
+by O
+overexpression O
+of O
+Bcl B
+- I
+x I
+( I
+L I
+) I
+or O
+Bcl B
+- I
+2 I
+. O
+
+Of O
+the O
+47 O
+women O
+with O
+AGCUS O
+, O
+16 O
+had O
+intraepithelial O
+or O
+invasive O
+neoplasms O
+( O
+34 O
+% O
+; O
+95 O
+% O
+confidence O
+interval O
+, O
+21 O
+- O
+49 O
+% O
+) O
+, O
+including O
+9 O
+low O
+or O
+high O
+grade O
+squamous O
+intraepithelial O
+lesions O
+, O
+1 O
+adenocarcinoma O
+in O
+situ O
+of O
+the O
+cervix O
+, O
+3 O
+adenocarcinomas O
+of O
+the O
+cervix O
+, O
+2 O
+adenocarcinomas O
+of O
+the O
+endometrium O
+and O
+1 O
+adenoid O
+basal O
+cell O
+carcinoma O
+of O
+the O
+cervix O
+. O
+
+The O
+DF3 B
+/ O
+MUC1 B
+gene O
+encodes O
+a O
+high O
+molecular O
+weight O
+mucin B
+- I
+like I
+glycoprotein I
+which O
+is O
+overexpressed O
+at O
+the O
+transcriptional O
+level O
+in O
+the O
+majority O
+of O
+human O
+breast O
+cancers O
+. O
+
+The O
+organization O
+of O
+the O
+MBP B
+- I
+A I
+gene I
+is O
+very O
+similar O
+to O
+the O
+arrangement O
+of O
+the O
+gene O
+encoding O
+the O
+highly O
+homologous O
+pulmonary B
+surfactant I
+apoprotein I
+, O
+although O
+one O
+of O
+the O
+intron O
+positions O
+is O
+shifted O
+by O
+a O
+single O
+amino O
+acid O
+. O
+
+Hip O
+fracture O
+mortality O
+and O
+prospective O
+payment O
+system O
+. O
+
+These O
+results O
+indicate O
+that O
+patients O
+with O
+SS O
+and O
+evidence O
+of O
+exercise O
+- O
+induced O
+ST O
+- O
+segment O
+depression O
+may O
+have O
+decreased O
+myocardial O
+oxygen O
+supply O
+due O
+to O
+low O
+hemoglobin B
+levels O
+and O
+increased O
+myocardial O
+oxygen O
+demand O
+( O
+elevated O
+double O
+products O
+) O
+when O
+compared O
+to O
+subjects O
+with O
+SS O
+who O
+do O
+not O
+have O
+exercise O
+- O
+induced O
+ST O
+- O
+segment O
+depression O
+. O
+
+Although O
+hSSTR5 B
+displays O
+approximately O
+75 O
+% O
+sequence O
+identity O
+with O
+rat B
+SSTR5 I
+, O
+the O
+two O
+receptors O
+display O
+significantly O
+different O
+pharmacological O
+profiles O
+, O
+especially O
+with O
+respect O
+to O
+their O
+binding O
+affinities O
+for O
+the O
+SST O
+analogue O
+SMS O
+201 O
+- O
+995 O
+. O
+
+A O
+significant O
+and O
+specific O
+reduction O
+in O
+binaural O
+peak O
+amplitude O
+and O
+area O
+of O
+the O
+echo O
+- O
+evoked O
+middle O
+- O
+latency O
+component O
+Pa O
+was O
+observed O
+. O
+
+EMBO O
+( O
+Eur O
+. O
+
+Using O
+this O
+oligonucleotide O
+as O
+a O
+probe O
+, O
+an O
+8 B
+- I
+kilobase I
+HindIII I
+fragment I
+of O
+genomic O
+DNA O
+was O
+isolated O
+and O
+subjected O
+to O
+Sanger O
+dideoxy O
+DNA O
+sequencing O
+. O
+
+Arg O
+- O
+130 O
+, O
+Gly O
+- O
+132 O
+and O
+Lys O
+- O
+167 O
+are O
+conserved O
+in O
+all O
+members O
+of O
+the O
+type B
+IB I
+topoisomerase I
+family I
+. O
+
+Four O
+cDNAs O
+( O
+Kox4 B
+, O
+Kox7 B
+, O
+Kox12 B
+, O
+and O
+Kox15 B
+) O
+were O
+identified O
+that O
+match O
+one O
+or O
+more O
+genomic O
+clones O
+; O
+these O
+matches O
+were O
+confirmed O
+by O
+nucleotide O
+sequence O
+analysis O
+. O
+
+2 O
+. O
+
+Prevalence O
+of O
+use O
+, O
+claims O
+volume O
+, O
+and O
+expenditures O
+were O
+compared O
+for O
+cisapride O
+, O
+proton O
+pump O
+inhibitors O
+, O
+histamine B
+- I
+2 I
+receptor I
+antagonists O
+, O
+and O
+the O
+prokinetic O
+agent O
+metoclopramide O
+during O
+these O
+periods O
+. O
+
+Relaxant O
+effect O
+of O
+prostaglandin O
+E1 O
+( O
+PGE1 O
+) O
+and O
+papaverine O
+( O
+PAP O
+) O
+were O
+measured O
+in O
+strips O
+of O
+corpus O
+cavernosum O
+smooth O
+muscle O
+taken O
+from O
+a O
+healthy O
+control O
+group O
+of O
+men O
+( O
+A O
+; O
+n O
+= O
+5 O
+) O
+, O
+from O
+arteriogenically O
+impotent O
+men O
+( O
+B O
+; O
+n O
+= O
+6 O
+) O
+and O
+from O
+additionally O
+diabetic O
+impotent O
+men O
+( O
+C O
+; O
+n O
+= O
+5 O
+) O
+with O
+venous O
+leakage O
+. O
+
+Primer O
+extension O
+experiments O
+using O
+dbcAMP O
+- O
+differentiated O
+U937 O
+RNA O
+indicated O
+a O
+single O
+transcriptional O
+initiation O
+site O
+. O
+
+In O
+contrast O
+, O
+group O
+II O
+showed O
+a O
+significant O
+improvement O
+in O
+peak O
+VO2 O
+with O
+rate O
+adaptive O
+AV O
+delay O
+compared O
+to O
+fixed O
+AV O
+delay O
+programming O
+( O
+P O
+less O
+than O
+0 O
+. O
+05 O
+) O
+. O
+
+Effect O
+of O
+family O
+visits O
+on O
+the O
+blood O
+pressure O
+and O
+heart O
+rate O
+of O
+patients O
+in O
+the O
+coronary O
+- O
+care O
+unit O
+. O
+
+Sequence O
+analysis O
+and O
+electrophoretic O
+mobility O
+shift O
+experiments O
+suggest O
+that O
+GnSE B
+response I
+elements I
+interact O
+, O
+in O
+these O
+two O
+regions O
+, O
+with O
+GATA B
+- O
+and O
+LIM B
+- I
+related I
+factors I
+, O
+respectively O
+. O
+
+The O
+transfer O
+by O
+conjugation O
+to O
+E O
+. O
+coli O
+K12 O
+of O
+ampicillin O
+and O
+carbenicillin O
+resistance O
+was O
+obtained O
+with O
+14 O
+strains O
+: O
+( O
+E O
+. O
+coli O
+: O
+9 O
+, O
+C O
+. O
+freundii O
+: O
+1 O
+, O
+K O
+. O
+pneumoniae O
+: O
+1 O
+, O
+E O
+. O
+cloacae O
+: O
+2 O
+, O
+P O
+. O
+stuartii O
+: O
+1 O
+) O
+. O
+
+Wild B
+type I
+MEKK1 I
+enhances O
+promoter O
+activity O
+and O
+the O
+activity O
+can O
+be O
+inhibited O
+by O
+dominant B
+negative I
+MEKK1 I
+, O
+MEK1 B
+, O
+MEK7 B
+, O
+MEK3 B
+, O
+p38 B
+/ O
+RK B
+, O
+and O
+c B
+- I
+Jun I
+. O
+
+250 O
+, O
+302 O
+- O
+311 O
+] O
+. O
+
+The O
+studies O
+permit O
+considering O
+the O
+detected O
+shifts O
+in O
+the O
+immunity O
+system O
+an O
+important O
+component O
+of O
+the O
+pathogenesis O
+of O
+chronic O
+nontumorous O
+diseases O
+of O
+the O
+parotid O
+glands O
+. O
+
+Coexistence O
+of O
+Turner O
+' O
+s O
+syndrome O
+and O
+schizophrenia O
+
+An O
+scrR B
+promoter I
+fragment I
+, O
+which O
+dose O
+not O
+contain O
+a O
+sequence O
+resembling O
+OB B
+, O
+was O
+not O
+shifted O
+by O
+the O
+fusion O
+protein O
+. O
+
+Using O
+the O
+conflict O
+drinking O
+test O
+as O
+a O
+model O
+, O
+we O
+studied O
+in O
+rats O
+the O
+effect O
+of O
+the O
+nonselective O
+beta B
+- I
+adrenoceptor I
+blockers O
+pindolol O
+and O
+cyanopindolol O
+which O
+bind O
+to O
+5 B
+- I
+HT1A I
+and O
+5 B
+- I
+HT1B I
+receptors I
+, O
+and O
+of O
+the O
+selective O
+beta B
+1 I
+- I
+and I
+beta I
+2 I
+- I
+adrenoceptor I
+antagonists O
+betaxolol O
+and O
+ICI O
+118 O
+, O
+551 O
+, O
+respectively O
+, O
+which O
+have O
+a O
+negligible O
+affinity O
+for O
+5 B
+- I
+HT I
+receptors I
+. O
+
+Although O
+several O
+other O
+signal O
+transduction O
+molecules O
+also O
+contain O
+tandemly O
+occurring O
+SH3 B
+and O
+SH2 B
+domains I
+, O
+the O
+function O
+of O
+these O
+closely O
+spaced O
+domains O
+is O
+not O
+well O
+understood O
+. O
+
+Glycoprotein O
+biosynthesis O
+in O
+Saccharomyces O
+cerevisiae O
+: O
+ngd29 B
+, O
+an O
+N O
+- O
+glycosylation O
+mutant O
+allelic O
+to O
+och1 B
+having O
+a O
+defect O
+in O
+the O
+initiation O
+of O
+outer O
+chain O
+formation O
+. O
+
+CONCLUSIONS O
+: O
+In O
+the O
+majority O
+of O
+patients O
+with O
+severe O
+ulcerative O
+colitis O
+, O
+circulating O
+concentrations O
+of O
+NOX O
+are O
+increased O
+at O
+presentation O
+and O
+fall O
+promptly O
+during O
+parenteral O
+steroid O
+therapy O
+, O
+irrespective O
+of O
+clinical O
+outcome O
+. O
+
+The O
+duration O
+of O
+naloxone O
+appears O
+to O
+be O
+dose O
+- O
+related O
+, O
+statistically O
+significant O
+up O
+to O
+approximately O
+1 O
+. O
+5 O
+hr O
+. O
+
+But O
+if O
+one O
+equalizes O
+the O
+upper O
+limits O
+of O
+normal O
+for O
+both O
+markers O
+to O
+a O
+common O
+95 O
+% O
+specificity O
+, O
+the O
+tumour O
+- O
+indicating O
+sensitivity O
+of O
+CA B
+19 I
+- I
+9 I
+clearly O
+surpasses O
+that O
+of O
+CA B
+50 I
+. O
+
+These O
+motions O
+were O
+found O
+in O
+the O
+N O
+- O
+and O
+C O
+- O
+terminal O
+tails O
+, O
+in O
+segment O
+33 O
+- O
+35 O
+which O
+forms O
+the O
+turn O
+between O
+beta O
+- O
+strands O
+S1 O
+and O
+S2 O
+, O
+and O
+residues O
+47 O
+- O
+52 O
+located O
+in O
+a O
+long O
+loop O
+preceding O
+strand O
+S3 O
+. O
+
+Genomic O
+Southern O
+analysis O
+reveals O
+10 O
+to O
+15 O
+hybridising O
+fragments O
+, O
+suggesting O
+that O
+maize O
+contains O
+a O
+small O
+gene O
+family O
+. O
+
+Custom O
+- O
+made O
+orthoses O
+play O
+an O
+invaluable O
+role O
+in O
+achieving O
+a O
+wide O
+range O
+of O
+therapeutic O
+goals O
+: O
+improving O
+function O
+and O
+pinch O
+, O
+stabilizing O
+individual O
+joints O
+, O
+preventing O
+positional O
+contractures O
+, O
+protecting O
+joints O
+from O
+trauma O
+, O
+stretching O
+the O
+intrinsic O
+muscles O
+, O
+correcting O
+joint O
+- O
+and O
+soft O
+- O
+tissue O
+contractures O
+, O
+and O
+controlling O
+inflammation O
+. O
+
+Is O
+exposure O
+to O
+a O
+patient O
+with O
+Crohn O
+' O
+s O
+disease O
+an O
+environmental O
+factor O
+for O
+developing O
+the O
+disease O
+. O
+
+The O
+ZAG1 B
+protein I
+from O
+in O
+vitro O
+translations O
+binds O
+to O
+a O
+consensus O
+target O
+site O
+that O
+is O
+recognized O
+by O
+the O
+AG B
+protein I
+. O
+
+The O
+uap100 B
+cis O
+- O
+acting O
+, O
+up O
+- O
+promoter O
+, O
+constitutive O
+mutation O
+is O
+a O
+duplication O
+that O
+comprises O
+two O
+GATA B
+sites O
+and O
+suppresses O
+weakly O
+the O
+AREA B
+zinc I
+finger I
+mutation I
+but O
+does O
+not O
+alleviate O
+the O
+need O
+for O
+functional O
+UAY B
+and O
+AREA B
+proteins I
+. O
+
+Pituitary O
+thyrotropic O
+adenoma O
+associated O
+with O
+congenital O
+hypothyroidism O
+. O
+
+This O
+region O
+was O
+unfavourable O
+, O
+due O
+to O
+malaria O
+in O
+the O
+past O
+. O
+
+Indeed O
+, O
+after O
+a O
+single O
+oral O
+dose O
+, O
+the O
+role O
+of O
+the O
+mu B
+- I
+receptor I
+agonist O
+component O
+of O
+the O
+antinociceptive O
+effect O
+of O
+tramadol O
+appears O
+to O
+be O
+minor O
+, O
+with O
+most O
+of O
+the O
+analgesic O
+effect O
+being O
+attributable O
+to O
+nonopioid O
+properties O
+of O
+the O
+parent O
+compound O
+. O
+
+CHIEF O
+OUTCOME O
+MEASURES O
+: O
+Endoluminal O
+release O
+of O
+prostacyclin O
+( O
+6 O
+- O
+Keto O
+- O
+PGF1 O
+alpha O
+) O
+and O
+thromboxane O
+B2 O
+( O
+TxB2 O
+) O
+, O
+patency O
+, O
+EC O
+coverage O
+and O
+cell O
+identity O
+. O
+
+Somatic O
+and O
+visceral O
+inputs O
+to O
+the O
+thoracic O
+spinal O
+cord O
+of O
+the O
+cat O
+: O
+effects O
+of O
+noxious O
+stimulation O
+of O
+the O
+biliary O
+system O
+. O
+
+We O
+have O
+produced O
+the O
+Ure2 B
+protein I
+to O
+high O
+yield O
+in O
+Escherichia O
+coli O
+from O
+a O
+synthetic O
+gene O
+. O
+
+Transfection O
+of O
+both O
+Calu O
+- O
+6 O
+and O
+JEG O
+- O
+3 O
+cells O
+with O
+a O
+PKA B
+expression O
+vector O
+resulted O
+in O
+a O
+10 O
+- O
+fold O
+induction O
+of O
+human B
+renin I
+transcriptional O
+activity O
+in O
+constructs O
+containing O
+the O
+native O
+or O
+consensus O
+CRE O
+and O
+5 O
+- O
+fold O
+activation O
+in O
+a O
+construct O
+containing O
+a O
+nonfunctional O
+CRE O
+. O
+
+We O
+undertook O
+this O
+study O
+to O
+examine O
+the O
+relationship O
+between O
+systemic O
+oxygen O
+delivery O
+( O
+DO2 O
+) O
+and O
+tissue O
+oxygen O
+tension O
+( O
+TPO2 O
+) O
+in O
+hypovolemic O
+shock O
+. O
+
+White O
+female O
+cases O
+were O
+more O
+likely O
+to O
+have O
+worked O
+as O
+registered O
+nurses O
+than O
+were O
+the O
+controls O
+( O
+OR O
+= O
+1 O
+. O
+9 O
+, O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+0 O
+- O
+3 O
+. O
+5 O
+) O
+. O
+
+METHODS O
+: O
+Children O
+with O
+attention O
+- O
+deficit O
+/ O
+hyperactivity O
+disorder O
+( O
+ADHD O
+; O
+n O
+= O
+282 O
+) O
+, O
+all O
+subtypes O
+, O
+ages O
+6 O
+to O
+12 O
+years O
+, O
+were O
+randomized O
+to O
+placebo O
+( O
+n O
+= O
+90 O
+) O
+, O
+immediate O
+- O
+release O
+methylphenidate O
+( O
+IR O
+MPH O
+) O
+3 O
+times O
+a O
+day O
+( O
+tid O
+; O
+dosed O
+every O
+4 O
+hours O
+; O
+n O
+= O
+97 O
+) O
+, O
+or O
+OROS O
+MPH O
+once O
+a O
+day O
+( O
+qd O
+; O
+n O
+= O
+95 O
+) O
+in O
+a O
+double O
+- O
+blind O
+, O
+28 O
+- O
+day O
+trial O
+. O
+
+Immunologic O
+tolerance O
+in O
+rats O
+during O
+13 O
+weeks O
+of O
+inhalation O
+exposure O
+to O
+trimellitic O
+anhydride O
+. O
+
+They O
+cause O
+temporary O
+disability O
+, O
+invalidity O
+and O
+mortality O
+of O
+a O
+great O
+part O
+of O
+the O
+productive O
+population O
+, O
+significantly O
+damaging O
+the O
+economic O
+status O
+of O
+the O
+country O
+. O
+
+Cloning O
+and O
+sequence O
+analysis O
+of O
+a O
+chymotrypsinlike B
+protease I
+from I
+Treponema I
+denticola O
+. O
+
+METHODS O
+AND O
+RESULTS O
+: O
+The O
+QTd O
+and O
+JTd O
+intervals O
+in O
+39 O
+children O
+with O
+long O
+QT O
+syndrome O
+were O
+compared O
+to O
+those O
+of O
+50 O
+normal O
+age O
+- O
+matched O
+children O
+. O
+
+V B
+- I
+ErbB I
+- O
+mediated O
+complex O
+formation O
+and O
+transformation O
+have O
+been O
+shown O
+to O
+occur O
+independently O
+of O
+Ras B
+activation O
+. O
+
+Both O
+parameters O
+were O
+determined O
+in O
+an O
+individual O
+eye O
+by O
+applying O
+the O
+dye O
+first O
+by O
+iontophoresis O
+and O
+then O
+by O
+intravitreal O
+injection O
+, O
+which O
+allows O
+the O
+influence O
+of O
+fluorescein O
+glucuronide O
+on O
+the O
+fluorophotometric O
+measurements O
+to O
+be O
+excluded O
+. O
+
+Organization O
+of O
+exons O
+suggests O
+that O
+, O
+similar O
+to O
+the O
+human B
+VEGF I
+gene I
+, O
+alternative O
+splicing O
+generates O
+the O
+120 O
+- O
+, O
+164 O
+- O
+, O
+and O
+188 O
+- O
+amino O
+acid O
+isoforms O
+, O
+but O
+does O
+not O
+predict O
+a O
+fourth O
+VEGF B
+isoform I
+corresponding O
+to O
+human B
+VEGF206 I
+. O
+
+Electron O
+microscopy O
+of O
+pH O
+7 O
+. O
+5 O
+- O
+treated O
+TMV O
+particles O
+incubated O
+in O
+SPN O
+- O
+treated O
+wheatgerm O
+extract O
+or O
+rabbit O
+reticulocyte O
+lysate O
+, O
+showed O
+that O
+approximately O
+10 O
+% O
+of O
+virions O
+complexed O
+with O
+one O
+ribosome O
+and O
+approximately O
+10 O
+% O
+with O
+two O
+bound O
+ribosomes O
+, O
+confirming O
+that O
+omega O
+at O
+least O
+had O
+been O
+uncoated O
+. O
+
+The O
+sequence O
+contained O
+five O
+repeats O
+of O
+the O
+hypothetical O
+leucine O
+zipper O
+motif O
+: O
+one O
+is O
+in O
+the O
+N O
+- O
+terminal O
+globular O
+domain O
+, O
+and O
+four O
+are O
+in O
+the O
+central O
+alpha O
+- O
+helical O
+stalk O
+. O
+
+Postheparin B
+lipoprotein I
+lipase I
+, O
+measured O
+using O
+fat O
+emulsion O
+as O
+substrate O
+, O
+also O
+was O
+significantly O
+greater O
+in O
+female O
+rats O
+compared O
+with O
+males O
+. O
+
+The O
+authors O
+report O
+a O
+case O
+of O
+a O
+painful O
+wrist O
+related O
+to O
+a O
+" O
+Manieux O
+muscle O
+" O
+of O
+the O
+dorsal O
+aspect O
+of O
+the O
+hand O
+. O
+
+Genomic O
+organization O
+of O
+the O
+human B
+multidrug I
+resistance I
+( O
+MDR1 B
+) O
+gene I
+and O
+origin O
+of O
+P B
+- I
+glycoproteins I
+. O
+
+The O
+response O
+to O
+nitroglycerin O
+, O
+however O
+, O
+remained O
+intact O
+regardless O
+of O
+initial O
+reperfusion O
+pressure O
+. O
+
+Deletion O
+analysis O
+revealed O
+that O
+only O
+the O
+TM O
+domain O
+of O
+E2 B
+was O
+required O
+for O
+Golgi O
+targeting O
+. O
+
+In O
+addition O
+, O
+putative O
+binding O
+sites O
+for O
+SH3 B
+and O
+SH2 B
+domains I
+are O
+present O
+in O
+the O
+amino O
+- O
+terminal O
+half O
+of O
+the O
+molecule O
+. O
+
+Since O
+nearly O
+all O
+transformants O
+involving O
+homeologous O
+DNAs O
+carried O
+a O
+single O
+recombinant O
+plasmid O
+in O
+both O
+Pms O
++ O
+and O
+Pms O
+- O
+strains O
+, O
+stable O
+heteroduplex O
+DNA O
+appears O
+less O
+likely O
+than O
+for O
+homologous O
+DNAs O
+. O
+
+All O
+rights O
+reserved O
+. O
+
+One O
+new O
+ORF O
+, O
+YBR0224 B
+, O
+was O
+detected O
+, O
+coding O
+for O
+a O
+protein O
+with O
+918 O
+amino O
+acids O
+. O
+
+A O
+sequence O
+- O
+ready O
+3 O
+- O
+Mb O
+PAC O
+contig O
+covering O
+16 O
+breakpoints O
+of O
+the O
+Wilms O
+tumor O
+/ O
+anirida O
+region O
+of O
+human O
+chromosome O
+11p13 O
+. O
+
+The O
+MAP B
+kinase I
+kinase I
+kinase I
+MLK2 B
+co O
+- O
+localizes O
+with O
+activated O
+JNK B
+along O
+microtubules O
+and O
+associates O
+with O
+kinesin B
+superfamily I
+motor O
+KIF3 B
+. O
+
+Bone O
+scintigraphy O
+is O
+an O
+excellent O
+screening O
+test O
+for O
+bone O
+lesions O
+and O
+Ga O
+- O
+67 O
+scintigraphy O
+is O
+a O
+useful O
+tool O
+for O
+detecting O
+inflammatory O
+lesions O
+. O
+
+Spontaneous O
+fracture O
+of O
+the O
+tarsal O
+bone O
+in O
+2 O
+cases O
+of O
+leprosy O
+
+They O
+are O
+transduced O
+through O
+TM B
+to O
+the O
+cytoplasmic O
+portion O
+( O
+cytoloops O
+and O
+the O
+C O
+- O
+terminal O
+tail O
+) O
+of O
+the O
+receptor O
+and O
+then O
+, O
+transferred O
+to O
+cytoplasmic O
+signaling O
+molecules O
+, O
+such O
+as O
+G B
+protein I
+. O
+
+Serum B
+alkaline I
+phosphatase I
+and O
+creatine B
+kinase I
+activities O
+were O
+significantly O
+increased O
+in O
+the O
+A O
+praelongus O
+- O
+fed O
+pigs O
+and O
+significantly O
+decreased O
+in O
+Na2SeO4 O
+- O
+fed O
+pigs O
+. O
+
+This O
+group O
+showed O
+the O
+presence O
+of O
+bacteria O
+infiltrated O
+at O
+the O
+dentinal O
+tubules O
+coronally O
+and O
+into O
+the O
+root O
+canals O
+. O
+
+Seven O
+Zebu O
+cattle O
+were O
+also O
+exposed O
+to O
+challenge O
+at O
+the O
+same O
+time O
+. O
+
+However O
+, O
+the O
+quasiparticle O
+scattering O
+rate O
+tau O
+( O
+- O
+1 O
+) O
+is O
+such O
+that O
+Planck O
+' O
+s O
+over O
+2pi O
+/ O
+tau O
+approximately O
+6t O
+( O
+perpendicular O
+) O
+, O
+implying O
+that O
+kappa O
+- O
+( O
+BEDT O
+- O
+TTF O
+) O
+2Cu O
+( O
+NCS O
+) O
+( O
+2 O
+) O
+meets O
+the O
+criterion O
+used O
+to O
+identify O
+interlayer O
+incoherence O
+. O
+
+The O
+effect O
+on O
+kidney O
+length O
+was O
+considerably O
+prolonged O
+compared O
+with O
+the O
+vascular O
+effect O
+. O
+
+Although O
+polyubiquitin B
+chains I
+linked O
+through O
+Lys O
+( O
+29 O
+) O
+of O
+ubiquitin B
+have O
+been O
+implicated O
+in O
+the O
+targeting O
+of O
+certain O
+substrates O
+to O
+proteasomes O
+, O
+the O
+signaling O
+properties O
+of O
+these O
+chains O
+are O
+poorly O
+understood O
+. O
+
+Diabetic O
+osteopenia O
+, O
+a O
+known O
+chronic O
+complication O
+of O
+diabetes O
+, O
+has O
+been O
+demonstrated O
+with O
+alterations O
+in O
+the O
+calcium O
+- O
+vitamin O
+D O
+endocrine O
+system O
+. O
+
+An O
+in O
+vitro O
+Raf B
+- I
+1 I
+kinase I
+assay O
+, O
+however O
+, O
+failed O
+to O
+detect O
+LPS O
+- O
+induced O
+Raf B
+- I
+1 I
+kinase I
+activity O
+in O
+RAW O
+264 O
+. O
+7 O
+cells O
+, O
+suggesting O
+that O
+in O
+RAW O
+264 O
+. O
+7 O
+cells O
+, O
+Raf B
+- I
+1 I
+kinase I
+is O
+not O
+an O
+activating O
+component O
+of O
+the O
+LPS O
+signaling O
+pathway O
+regulating O
+MAPK B
+activity O
+or O
+sIL B
+- I
+1Ra I
+promoter I
+activity O
+. O
+
+Phosphorylation O
+of O
+the O
+ras B
+GTPase I
+- I
+activating I
+protein I
+( O
+GAP B
+) O
+by O
+the O
+p93c B
+- I
+fes I
+protein I
+- I
+tyrosine I
+kinase I
+in O
+vitro O
+and O
+formation O
+of O
+GAP B
+- O
+fes B
+complexes O
+via O
+an O
+SH2 B
+domain O
+- O
+dependent O
+mechanism O
+. O
+
+Gingival O
+retraction O
+for O
+class O
+V O
+restorations O
+. O
+
+Two O
+methods O
+for O
+the O
+routine O
+determination O
+of O
+blood O
+hemoglobin B
+oxygen O
+affinity O
+are O
+described O
+. O
+
+Thirty O
+minutes O
+after O
+reperfusion O
+, O
+lung O
+lymph O
+flow O
+( O
+QL O
+) O
+increased O
+from O
+4 O
+. O
+3 O
+to O
+8 O
+. O
+3 O
+ml O
+/ O
+30 O
+minutes O
+( O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+, O
+lymph O
+/ O
+plasma O
+protein O
+ratio O
+was O
+unchanged O
+from O
+0 O
+. O
+6 O
+, O
+and O
+the O
+lymph O
+protein O
+clearance O
+increased O
+from O
+2 O
+. O
+6 O
+to O
+4 O
+. O
+6 O
+ml O
+/ O
+30 O
+minutes O
+( O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+, O
+data O
+consistent O
+with O
+increased O
+microvascular O
+permeability O
+. O
+
+U O
+. O
+S O
+. O
+A O
+. O
+
+RET B
+/ O
+PTC B
+oncogenes O
+, O
+generated O
+by O
+chromosomal O
+rearrangements O
+in O
+papillary O
+thyroid O
+carcinomas O
+, O
+are O
+constitutively O
+activated O
+versions O
+of O
+proto B
+- I
+RET I
+, O
+a O
+gene O
+coding O
+for O
+a O
+receptor B
+- I
+type I
+tyrosine I
+kinase I
+( O
+TK B
+) O
+whose O
+ligand O
+is O
+still O
+unknown O
+. O
+
+PCC I
+6803 I
+mutant I
+impaired O
+in O
+cytochrome B
+c I
+maturation O
+. O
+
+STUDY O
+OBJECTIVE O
+: O
+to O
+characterize O
+gas O
+exchange O
+and O
+cardiopulmonary O
+performance O
+during O
+maximal O
+progressive O
+arm O
+crank O
+exercise O
+. O
+
+In O
+this O
+study O
+, O
+we O
+show O
+that O
+the O
+activating O
+effect O
+of O
+this O
+mutation O
+is O
+not O
+the O
+result O
+of O
+creating O
+an O
+exonic O
+splicing O
+enhancer O
+( O
+ESE O
+) O
+or O
+disrupting O
+a O
+putative O
+secondary O
+structure O
+. O
+
+The O
+kinase O
+domains O
+encoded O
+in O
+the O
+COOH O
+- O
+terminal O
+moiety O
+are O
+94 O
+% O
+conserved O
+; O
+the O
+NH2 O
+- O
+terminal O
+moieties O
+are O
+approximately O
+65 O
+% O
+homologous O
+, O
+suggesting O
+this O
+region O
+may O
+encode O
+sequences O
+conferring O
+differential O
+regulation O
+of O
+the O
+two O
+kinases O
+. O
+
+In O
+rats O
+exposed O
+to O
+Cd O
+for O
+30 O
+d O
+, O
+the O
+levels O
+of O
+urinary O
+excretion O
+of O
+cAMP O
+after O
+treatment O
+with O
+parathyroid B
+hormone I
+( O
+PTH B
+) O
+, O
+parathyroidectomy O
+( O
+PTX O
+) O
+, O
+or O
+1 O
+alpha O
+- O
+hydroxycholecalciferol O
+( O
+1 O
+alpha O
+- O
+OH O
+- O
+D3 O
+) O
+showed O
+almost O
+the O
+same O
+patterns O
+as O
+those O
+of O
+control O
+rats O
+: O
+the O
+response O
+of O
+urinary O
+cAMP O
+to O
+treatment O
+with O
+PTH B
+was O
+not O
+influenced O
+by O
+continuous O
+oral O
+administration O
+of O
+Cd O
+. O
+
+The O
+goal O
+of O
+this O
+investigation O
+was O
+to O
+determine O
+whether O
+BMIPP O
+uptake O
+can O
+be O
+used O
+to O
+differentiate O
+viable O
+myocardium O
+from O
+scar O
+tissue O
+soon O
+after O
+coronary O
+thrombolysis O
+for O
+acute O
+myocardial O
+infarction O
+. O
+
+There O
+are O
+three O
+types O
+of O
+problems O
+: O
+problems O
+arising O
+before O
+the O
+drug O
+enters O
+the O
+body O
+( O
+solubilization O
+, O
+stabilization O
+and O
+improved O
+acceptability O
+) O
+; O
+problems O
+associated O
+with O
+the O
+penetration O
+and O
+fate O
+of O
+the O
+drug O
+in O
+the O
+body O
+( O
+absorption O
+, O
+barrier O
+crossing O
+, O
+duration O
+of O
+action O
+) O
+; O
+problems O
+relating O
+to O
+the O
+therapeutic O
+target O
+( O
+selective O
+local O
+delivery O
+) O
+. O
+
+In O
+the O
+absence O
+of O
+shock O
+, O
+sepsis O
+, O
+or O
+other O
+identifiable O
+causes O
+of O
+lactic O
+acidosis O
+, O
+the O
+severe O
+anemia O
+( O
+hemoglobin B
+1 O
+. O
+2 O
+g O
+/ O
+dl O
+) O
+appeared O
+to O
+be O
+the O
+primary O
+etiologic O
+factor O
+. O
+
+The O
+cumulative O
+experience O
+in O
+liver O
+transplantation O
+since O
+the O
+introduction O
+of O
+cyclosporine O
+A O
+has O
+confirmed O
+its O
+efficacy O
+in O
+the O
+treatment O
+of O
+diverse O
+liver O
+diseases O
+in O
+children O
+and O
+adults O
+. O
+
+Northern O
+blot O
+analysis O
+of O
+liver O
+, O
+muscle O
+, O
+fat O
+, O
+and O
+pituitary O
+RNA O
+from O
+normal O
+( O
+DwDw O
+) O
+chickens O
+shows O
+a O
+major O
+transcript O
+of O
+4 O
+. O
+3 O
+kilobases O
+( O
+kb O
+) O
+and O
+three O
+minor O
+transcripts O
+( O
+0 O
+. O
+8 O
+, O
+1 O
+. O
+7 O
+, O
+and O
+3 O
+. O
+2 O
+kb O
+) O
+, O
+which O
+correspond O
+to O
+the O
+cGHR O
+. O
+
+Copyright O
+1999 O
+Academic O
+Press O
+. O
+
+Despite O
+a O
+lowering O
+of O
+her O
+plasma O
+ACTH B
+concentration O
+during O
+therapy O
+with O
+valproic O
+acid O
+, O
+the O
+patient O
+' O
+s O
+tumour O
+showed O
+no O
+evidence O
+of O
+regression O
+while O
+she O
+was O
+taking O
+the O
+drug O
+. O
+
+The O
+Htf9 B
+- I
+a I
+gene I
+encodes O
+the O
+RanBP1 B
+protein I
+, O
+a O
+major O
+partner O
+of O
+the O
+Ran B
+GTPase I
+. O
+
+STUDY O
+DESIGN O
+: O
+Retrospective O
+review O
+. O
+
+Sequence O
+divergence O
+of O
+approximately O
+16 O
+% O
+reduced O
+transformation O
+frequencies O
+by O
+at O
+least O
+10 O
+- O
+fold O
+. O
+
+Our O
+studies O
+suggest O
+that O
+the O
+helicase B
+assembly I
+protein I
+is O
+responsible O
+for O
+loading O
+T4 B
+gene I
+41 I
+helicase I
+specifically O
+at O
+replication O
+forks O
+, O
+and O
+that O
+its O
+binding O
+sites O
+for O
+each O
+arm O
+must O
+hold O
+more O
+than O
+six O
+, O
+but O
+not O
+more O
+than O
+12 O
+nucleotides O
+. O
+
+During O
+the O
+1st O
+week O
+of O
+treatment O
+all O
+subjects O
+received O
+either O
+mianserin O
+30 O
+mg O
+or O
+clomipramine O
+75 O
+mg O
+once O
+daily O
+. O
+
+CBD O
+exploration O
+was O
+avoided O
+in O
+7 O
+patients O
+with O
+normal O
+POC O
+. O
+
+The O
+human B
+SHBG I
+proximal I
+promoter I
+was O
+analyzed O
+by O
+DNase B
+I I
+footprinting O
+, O
+and O
+the O
+functional O
+significance O
+of O
+6 O
+footprinted O
+regions O
+( O
+FP1 O
+- O
+FP6 O
+) O
+within O
+the O
+proximal O
+promoter O
+was O
+studied O
+in O
+human O
+HepG2 O
+hepatoblastoma O
+cells O
+. O
+
+We O
+exposed O
+Dorper O
+- O
+cross O
+ewes O
+at O
+approximately O
+120 O
+- O
+135 O
+days O
+of O
+gestation O
+to O
+a O
+hot O
+( O
+40 O
+degrees O
+C O
+, O
+60 O
+% O
+relative O
+humidity O
+) O
+and O
+a O
+cold O
+( O
+4 O
+degrees O
+C O
+, O
+90 O
+% O
+relative O
+humidity O
+) O
+environment O
+and O
+to O
+treadmill O
+exercise O
+( O
+2 O
+. O
+1 O
+km O
+/ O
+h O
+, O
+5 O
+degrees O
+gradient O
+) O
+and O
+measured O
+fetal O
+lamb O
+and O
+ewe O
+body O
+temperatures O
+using O
+previously O
+implanted O
+abdominal O
+radiotelemeters O
+. O
+
+Previously O
+identified O
+mutations O
+in O
+this O
+variant O
+have O
+been O
+within O
+or O
+close O
+to O
+the O
+coding O
+region O
+of O
+exon O
+1 O
+of O
+the O
+HMBS B
+gene I
+, O
+the O
+only O
+exon O
+that O
+is O
+expressed O
+solely O
+in O
+the O
+ubiquitous O
+isoform O
+. O
+
+As O
+an O
+approach O
+to O
+the O
+determination O
+of O
+structure O
+- O
+function O
+relationships O
+in O
+the O
+PRP4 B
+protein I
+, O
+we O
+have O
+isolated O
+more O
+than O
+fifty O
+new O
+alleles O
+of O
+the O
+PRP4 B
+gene I
+through O
+random O
+and O
+site O
+- O
+directed O
+mutagenesis O
+, O
+and O
+have O
+analyzed O
+the O
+phenotypes O
+of O
+many O
+of O
+them O
+. O
+
+Over O
+a O
+period O
+of O
+five O
+training O
+sessions O
+( O
+2 O
+. O
+5 O
+days O
+) O
+, O
+the O
+animals O
+learned O
+not O
+to O
+breathe O
+, O
+and O
+the O
+number O
+of O
+stimuli O
+received O
+in O
+the O
+fifth O
+session O
+was O
+significantly O
+lower O
+than O
+in O
+the O
+first O
+session O
+. O
+
+The O
+5 O
+' O
+- O
+flanking O
+region O
+of O
+the O
+gene O
+, O
+approximately O
+1 O
+. O
+1 O
+kbp O
+long O
+, O
+had O
+no O
+known O
+regulatory O
+elements O
+for O
+transcription O
+such O
+as O
+TATA O
+, O
+GC O
+, O
+and O
+CCAAT O
+boxes O
+. O
+
+We O
+find O
+that O
+Fus3p B
+and O
+Kss1p B
+both O
+control O
+G1 O
+arrest O
+through O
+multiple O
+functions O
+that O
+operate O
+in O
+parallel O
+with O
+Far1p B
+. O
+
+Tag B
+expression O
+induced O
+apoptosis O
+in O
+mammary O
+epithelial O
+cells O
+during O
+late O
+pregnancy O
+. O
+
+The O
+composition O
+of O
+renal O
+stones O
+analysed O
+by O
+infrared O
+spectroscopy O
+. O
+
+14 O
+. O
+9 O
+x O
+109 O
+L O
+- O
+1 O
+) O
+was O
+equal O
+for O
+both O
+groups O
+, O
+but O
+CCI O
+values O
+were O
+significantly O
+higher O
+for O
+the O
+bedside O
+filtered O
+PC O
+( O
+14 O
+. O
+1 O
++ O
+/ O
+- O
+9 O
+. O
+5 O
+vs O
+. O
+
+In O
+this O
+study O
+, O
+the O
+case O
+of O
+a O
+patient O
+presenting O
+a O
+second O
+hepatocellular O
+carcinoma O
+13 O
+years O
+after O
+resection O
+of O
+a O
+first O
+tumor O
+of O
+the O
+same O
+type O
+is O
+reported O
+. O
+
+The O
+time O
+- O
+dependent O
+changes O
+in O
+measured O
+facility O
+of O
+outflow O
+or O
+" O
+washout O
+phenomenon O
+" O
+appeared O
+to O
+result O
+from O
+the O
+gradual O
+dissolution O
+of O
+the O
+hyaluronidase B
+- O
+sensitive O
+component O
+of O
+the O
+barriers O
+to O
+aqueous O
+outflow O
+in O
+the O
+canine O
+eye O
+. O
+
+The O
+factors O
+defective O
+in O
+groups O
+A O
+( O
+CIITA B
+) O
+, O
+C O
+( O
+RFX5 B
+) O
+and O
+D O
+( O
+RFXAP B
+) O
+have O
+been O
+identified O
+. O
+
+It O
+differed O
+significantly O
+by O
+country O
+( O
+from O
+2 O
+. O
+4 O
+% O
+in O
+the O
+United O
+Kingdom O
+to O
+24 O
+. O
+7 O
+% O
+in O
+Portugal O
+) O
+and O
+by O
+transmission O
+category O
+( O
+2 O
+. O
+7 O
+% O
+among O
+homo O
+/ O
+bisexuals O
+, O
+5 O
+. O
+8 O
+% O
+among O
+injecting O
+drug O
+users O
+, O
+13 O
+. O
+6 O
+% O
+among O
+heterosexual O
+subgroup O
+1 O
+) O
+. O
+
+On O
+a O
+national O
+level O
+, O
+undiscounted O
+costs O
+are O
+expected O
+to O
+increase O
+up O
+to O
+approximately O
+DF1 O
+42 O
+million O
+annually O
+during O
+the O
+first O
+40 O
+years O
+after O
+introduction O
+of O
+the O
+preventative O
+strategy O
+. O
+
+By O
+deletion O
+analysis O
+, O
+we O
+identified O
+the O
+regions O
+of O
+c B
+- I
+Jun I
+encoding O
+transformation O
+and O
+transactivation O
+functions O
+. O
+
+A O
+survey O
+of O
+274 O
+late O
+detected O
+cases O
+of O
+CDH O
+born O
+in O
+the O
+years O
+1970 O
+- O
+- O
+74 O
+is O
+presented O
+. O
+
+To O
+test O
+for O
+progesterone B
+receptor I
+- O
+mediated O
+activation O
+of O
+transcription O
+in O
+yeast O
+, O
+reporter O
+plasmids O
+were O
+constructed O
+to O
+transform O
+yeast O
+cells O
+expressing O
+PRB B
+or O
+C1C2 B
+receptors I
+. O
+
+Fli B
+- I
+1 I
+is O
+a O
+proto O
+- O
+oncogene O
+which O
+is O
+rearranged O
+in O
+tumors O
+induced O
+by O
+three O
+different O
+retroviruses O
+, O
+Cas O
+- O
+Br O
+- O
+E O
+, O
+F O
+- O
+MuLV O
+, O
+and O
+10A1 O
+. O
+
+Ionic O
+composition O
+( O
+Na O
++ O
+, O
+K O
++ O
+, O
+Ca O
++ O
+2 O
+, O
+and O
+Mg2 O
++ O
+) O
+of O
+cerebrospinal O
+fluid O
+and O
+feeding O
+behavior O
+in O
+sheep O
+. O
+
+Materials O
+are O
+presented O
+of O
+a O
+comparative O
+study O
+of O
+morphological O
+and O
+cultural O
+properties O
+and O
+virulence O
+of O
+liophylized O
+cultures O
+of O
+Leishmania O
+tropica O
+major O
+after O
+their O
+rehydration O
+or O
+after O
+a O
+long O
+passage O
+on O
+the O
+NNN O
+medium O
+. O
+
+CONCLUSIONS O
+: O
+These O
+findings O
+imply O
+that O
+the O
+spinal O
+cord O
+is O
+not O
+a O
+simple O
+command O
+- O
+carrying O
+medium O
+from O
+the O
+brain O
+to O
+the O
+limbs O
+, O
+and O
+implies O
+that O
+some O
+computational O
+activities O
+take O
+place O
+at O
+the O
+spinal O
+cord O
+level O
+. O
+
+The O
+101st O
+annual O
+meeting O
+of O
+the O
+Japanese O
+Ophthalmological O
+Society O
+. O
+
+The O
+results O
+corroborate O
+the O
+proposed O
+physiological O
+function O
+of O
+CCoAOMT B
+in O
+elicited O
+plant O
+cells O
+and O
+may O
+shed O
+new O
+light O
+on O
+the O
+sequential O
+action O
+of O
+trans O
+- O
+active O
+factors O
+in O
+the O
+regulation O
+of O
+phenylpropanoid O
+genes O
+. O
+
+In O
+src B
+- O
+transformed O
+cells O
+GAP B
+forms O
+heteromeric O
+complexes O
+, O
+notably O
+with O
+a O
+highly O
+tyrosine O
+phosphorylated O
+62 O
+- O
+kDa O
+protein O
+( O
+p62 B
+) O
+. O
+
+A O
+study O
+of O
+characteristics O
+in O
+adult O
+asthmatics O
+who O
+are O
+sensitized O
+by O
+cats O
+and O
+dogs O
+allergens O
+
+PrRP B
+rapidly O
+and O
+transiently O
+activated O
+extracellular B
+signal I
+- I
+regulated I
+protein I
+kinase I
+( O
+ERK B
+) O
+in O
+both O
+types O
+of O
+cells O
+. O
+
+Cell O
+- O
+free O
+extracts O
+of O
+E O
+. O
+coli O
+( O
+fpg B
+mutY B
+) O
+harboring O
+pYSB10 B
+possess O
+an O
+enzymatic O
+activity O
+that O
+cleaves O
+a O
+34 O
+- O
+mer O
+oligonucleotide O
+containing O
+a O
+single O
+8 O
+- O
+oxoG O
+opposite O
+a O
+cytosine O
+( O
+8 O
+- O
+OxoG O
+/ O
+C O
+) O
+. O
+
+Estrogen O
+pretreated O
+castrated O
+males O
+also O
+showed O
+no O
+change O
+in O
+myocardial O
+blood O
+flow O
+after O
+17 O
+beta O
+- O
+estradiol O
+, O
+but O
+coronary O
+flow O
+velocity O
+decreased O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+compared O
+with O
+baseline O
+1 O
+h O
+after O
+the O
+200 O
+ng O
+/ O
+kg O
+dose O
+( O
+from O
+1 O
+. O
+69 O
++ O
+/ O
+- O
+0 O
+. O
+61 O
+to O
+1 O
+. O
+41 O
++ O
+/ O
+- O
+0 O
+. O
+42 O
+kHz O
+) O
+and O
+diastolic O
+coronary O
+resistance O
+increased O
+significantly O
+( O
+P O
+< O
+0 O
+. O
+01 O
+) O
+compared O
+with O
+control O
+at O
+this O
+time O
+( O
+51 O
++ O
+/ O
+- O
+15 O
+compared O
+with O
+39 O
++ O
+/ O
+- O
+14 O
+mmHg O
+/ O
+mkHz O
+) O
+. O
+
+Acute O
+renal O
+vein O
+thrombosis O
+in O
+renal O
+allografts O
+: O
+detection O
+with O
+duplex O
+Doppler O
+US O
+. O
+
+Several O
+DNA O
+clones O
+were O
+obtained O
+by O
+this O
+procedure O
+, O
+one O
+of O
+which O
+, O
+clone O
+18 O
+, O
+is O
+reported O
+and O
+characterized O
+here O
+. O
+
+Long O
+- O
+range O
+mapping O
+by O
+pulse O
+- O
+field O
+gel O
+electrophoresis O
+indicated O
+that O
+the O
+three O
+mdr B
+genes I
+are O
+closely O
+linked O
+on O
+a O
+genomic O
+DNA O
+segment O
+of O
+approximately O
+625 O
+kilobases O
+. O
+
+These O
+sequences O
+were O
+further O
+tested O
+for O
+the O
+presence O
+of O
+an O
+enhancer O
+element O
+, O
+by O
+their O
+ability O
+to O
+activate O
+a O
+fusion O
+reporter O
+gene O
+consisting O
+of O
+the O
+CAT B
+gene I
+linked O
+to O
+the O
+gamma B
+- I
+globin I
+gene I
+promoter I
+, O
+in O
+erythroid O
+( O
+K562 O
+) O
+and O
+non O
+- O
+erythroid O
+( O
+HeLa O
+) O
+cells O
+. O
+
+Two O
+sibs O
+with O
+identical O
+features O
+of O
+short O
+- O
+limbed O
+dwarfism O
+, O
+a O
+normal O
+skull O
+and O
+face O
+and O
+normal O
+intelligence O
+are O
+described O
+. O
+
+This O
+article O
+describes O
+a O
+program O
+that O
+resulted O
+in O
+a O
+75 O
+- O
+percent O
+reduction O
+of O
+inventory O
+over O
+a O
+five O
+- O
+year O
+interval O
+. O
+
+Further O
+comparative O
+analysis O
+identified O
+an O
+ADNP B
+paralog I
+( O
+33 O
+% O
+identity O
+and O
+46 O
+% O
+similarity O
+) O
+, O
+indicating O
+that O
+these O
+genes O
+belong O
+to O
+a O
+novel O
+protein O
+family O
+with O
+a O
+nine O
+- O
+zinc O
+finger O
+motif O
+followed O
+by O
+a O
+homeobox B
+domain O
+. O
+
+All O
+patients O
+received O
+marrow O
+from O
+HLA B
+- O
+identical O
+sibling O
+donors O
+, O
+underwent O
+similar O
+myeloablative O
+regimens O
+, O
+and O
+had O
+similar O
+pretreatment O
+characteristics O
+. O
+
+In O
+female O
+toads O
+, O
+Bufo O
+bufo O
+, O
+feeding O
+at O
+different O
+rates O
+, O
+the O
+uncorrected O
+value O
+of O
+n O
+was O
+0 O
+. O
+44 O
+, O
+when O
+metabolism O
+and O
+growth O
+were O
+expressed O
+as O
+kJ O
+kJ O
+- O
+1 O
+. O
+
+METHODS O
+: O
+Two O
+patients O
+developed O
+cervical O
+myelopathy O
+or O
+radiculopathy O
+after O
+spinal O
+manipulation O
+therapy O
+, O
+and O
+magnetic O
+resonance O
+imaging O
+showed O
+herniated O
+cervical O
+discs O
+at O
+C4 O
+- O
+C5 O
+and O
+C6 O
+- O
+C7 O
+, O
+respectively O
+. O
+
+Subclones O
+stably O
+expressing O
+alpha1A B
+- I
+, I
+alpha1B I
+- I
+, I
+and I
+alpha1D I
+- I
+ARs I
+under O
+control O
+of O
+an O
+inducible O
+promoter O
+, O
+or O
+at O
+high O
+and O
+low O
+receptor O
+density O
+, O
+were O
+isolated O
+and O
+characterized O
+. O
+
+Analysis O
+of O
+WT1 B
+target I
+gene I
+expression O
+in O
+stably O
+transfected O
+cell O
+lines O
+. O
+
+Soluble O
+recombinant B
+RI I
+and O
+soluble O
+recombinant B
+C I
+alpha I
+can O
+associate O
+in O
+vitro O
+and O
+be O
+activated O
+by O
+cyclic O
+AMP O
+. O
+
+IRIS B
+/ O
+GAS B
+DNA O
+also O
+formed O
+a O
+number O
+of O
+specific O
+complexes O
+with O
+constitutively O
+expressed O
+factors O
+, O
+none O
+of O
+which O
+were O
+affected O
+by O
+the O
+above O
+Abs O
+. O
+
+Simulation O
+results O
+based O
+on O
+the O
+presented O
+model O
+are O
+compared O
+with O
+the O
+experimental O
+data O
+for O
+two O
+types O
+of O
+cMUTs O
+reported O
+in O
+the O
+recent O
+literature O
+. O
+
+Tre O
+during O
+exercise O
+at O
+35 O
+W O
+at O
+23 O
+degrees O
+C O
+correlated O
+r O
+= O
+- O
+70 O
+with O
+Vo2max O
+and O
+r O
+= O
+0 O
+. O
+80 O
+with O
+Tre O
+during O
+exercise O
+in O
+heat O
+. O
+
+Electrophoretic O
+mobility O
+- O
+shift O
+assays O
+with O
+nuclear O
+extracts O
+from O
+COS O
+- O
+1 O
+cells O
+transfected O
+with O
+expression O
+vectors O
+for O
+SMADs B
+1 I
+- I
+5 I
+indicate O
+that O
+SMAD3 B
+forms O
+a O
+complex O
+with O
+a O
+migration O
+similar O
+to O
+that O
+of O
+the O
+endogenous B
+TGF I
+- I
+beta I
+- I
+specific I
+complex I
+observed O
+in O
+fibroblast O
+extracts O
+. O
+
+The O
+newly O
+identified O
+NF B
+kappa I
+B I
+enhancer I
+( O
+TGGAAATTCC O
+) O
+is O
+bound O
+by O
+a O
+TNF B
+alpha I
+- O
+induced O
+nuclear O
+protein O
+and O
+appears O
+to O
+be O
+the O
+key O
+element O
+in O
+rapid O
+transcription O
+induction O
+by O
+TNF B
+alpha I
+( O
+and O
+TPA O
+) O
+, O
+while O
+transactivation O
+of O
+this O
+element O
+is O
+repressed O
+by O
+the O
+ligand O
+- O
+bound O
+glucocorticoid B
+receptor I
+. O
+
+Our O
+results O
+showed O
+that O
+the O
+5 O
+- O
+hydroxytryptamine O
+( O
+5 O
+- O
+HT O
+) O
+content O
+in O
+platelets O
+was O
+: O
+( O
+1 O
+) O
+increased O
+in O
+the O
+subgroup O
+of O
+anti O
+- O
+social O
+alcoholics O
+; O
+( O
+2 O
+) O
+transiently O
+and O
+differently O
+altered O
+in O
+alcoholics O
+compared O
+to O
+opiate O
+addicts O
+; O
+and O
+( O
+3 O
+) O
+lowered O
+in O
+drinking O
+alcoholics O
+and O
+normal O
+in O
+alcoholics O
+who O
+were O
+drinking O
+as O
+well O
+as O
+smoking O
+( O
+that O
+may O
+occur O
+via O
+MAO B
+- I
+B I
+inhibition O
+by O
+smoke O
+) O
+. O
+
+In O
+the O
+second O
+group O
+, O
+which O
+consisted O
+of O
+babies O
+of O
+33 O
+to O
+36 O
+weeks O
+of O
+gestational O
+age O
+, O
+haptoglobin B
+was O
+detected O
+in O
+6 O
+infants O
+, O
+with O
+levels O
+less O
+than O
+25 O
+mg O
+/ O
+dl O
+in O
+3 O
+. O
+
+The O
+polypeptide O
+encoded O
+by O
+the O
+cDNA O
+contained O
+450 O
+amino O
+acids O
+with O
+a O
+calculated O
+M O
+( O
+r O
+) O
+of O
+52 O
+, O
+057 O
+, O
+and O
+showed O
+significant O
+homology O
+with O
+human B
+and I
+mouse I
+CAD I
+( O
+22 O
+% O
+identity O
+) O
+. O
+
+Correlation O
+of O
+alpha O
+activity O
+between O
+the O
+frontal O
+and O
+occipital O
+cortex O
+. O
+
+In O
+situ O
+localization O
+of O
+PCP B
+- I
+A1 I
+transcripts I
+revealed O
+that O
+they O
+accumulate O
+specifically O
+in O
+pollen O
+at O
+the O
+late O
+binucleate O
+/ O
+trinucleate O
+stage O
+of O
+development O
+rather O
+than O
+in O
+the O
+tapetum O
+, O
+which O
+previously O
+was O
+taken O
+to O
+be O
+the O
+principal O
+source O
+of O
+the O
+pollen O
+coat O
+. O
+
+Successful O
+resolution O
+of O
+progressive O
+multifocal O
+leukoencephalopathy O
+after O
+combination O
+therapy O
+with O
+cidofovir O
+and O
+cytosine O
+arabinoside O
+. O
+
+The O
+species O
+composition O
+and O
+abundance O
+upon O
+treatment O
+of O
+manure O
+with O
+polyethylene O
+, O
+polystyrene O
+and O
+glass O
+particles O
+was O
+similar O
+to O
+that O
+of O
+the O
+treatment O
+control O
+, O
+i O
+. O
+e O
+. O
+natural O
+and O
+inert O
+sand O
+. O
+
+However O
+, O
+H19 B
+and O
+IGF2 B
+lie O
+within O
+a O
+larger O
+imprinted O
+domain O
+, O
+and O
+the O
+gene O
+specificity O
+of O
+H19 B
+epimutation O
+has O
+been O
+a O
+persistent O
+question O
+. O
+
+Here O
+we O
+report O
+the O
+cloning O
+, O
+by O
+either O
+peptide O
+sequencing O
+or O
+by O
+sequence O
+similarity O
+to O
+the O
+human O
+cDNAs O
+, O
+of O
+the O
+S O
+. O
+cerevisiae O
+genes O
+RFC1 B
+, O
+RFC2 B
+, O
+RFC3 B
+, O
+RFC4 B
+, O
+and O
+RFC5 B
+. O
+
+It O
+is O
+of O
+interest O
+that O
+, O
+aside O
+from O
+starvation O
+, O
+the O
+nutrition O
+catastrophes O
+of O
+the O
+past O
+, O
+including O
+scurvy O
+( O
+vitamin O
+C O
+deficiency O
+) O
+resulting O
+from O
+lack O
+of O
+fresh O
+vegetables O
+and O
+fruit O
+and O
+beriberi O
+( O
+vitamin O
+B1 O
+deficiency O
+) O
+from O
+consumption O
+of O
+polished O
+rice O
+, O
+are O
+forgotten O
+and O
+only O
+of O
+interest O
+as O
+history O
+. O
+
+This O
+sequence O
+can O
+interact O
+with O
+at O
+least O
+two O
+proteins O
+in O
+a O
+fibroblast O
+nuclear O
+extract O
+that O
+have O
+binding O
+characteristics O
+of O
+an O
+Ets B
+family I
+protein I
+and O
+a O
+serum B
+response I
+factor I
+- I
+like I
+protein I
+. O
+
+As O
+much O
+thrombin B
+was O
+formed O
+during O
+cardiopulmonary O
+bypass O
+( O
+measured O
+by O
+the O
+prothrombin B
+activation I
+fragment I
+F1 I
++ I
+2 I
+and O
+thrombin B
+- O
+antithrombin B
+complexes O
+) O
+as O
+in O
+normal O
+patients O
+, O
+showing O
+that O
+factor B
+XII I
+was O
+not O
+necessary O
+for O
+thrombin B
+generation O
+. O
+
+The O
+molecular O
+event O
+( O
+s O
+) O
+underlying O
+the O
+functional O
+specificities O
+of O
+these O
+receptors O
+( O
+in O
+regulating O
+the O
+expression O
+of O
+their O
+native O
+target O
+genes O
+) O
+is O
+a O
+very O
+important O
+issue O
+that O
+remains O
+poorly O
+understood O
+. O
+
+MUS81 B
+encodes O
+a O
+novel O
+helix B
+- I
+hairpin I
+- I
+helix I
+protein I
+involved O
+in O
+the O
+response O
+to O
+UV O
+- O
+and O
+methylation O
+- O
+induced O
+DNA O
+damage O
+in O
+Saccharomyces O
+cerevisiae O
+. O
+
+Treatment O
+of O
+chronic O
+hepatitis O
+B O
+with O
+interferon B
+: O
+experience O
+in O
+western O
+countries O
+. O
+
+Several O
+positive O
+clones O
+were O
+isolated O
+, O
+one O
+of O
+which O
+encoded O
+the O
+C O
+- O
+terminal O
+253 O
+amino O
+acids O
+of O
+a O
+putative O
+RNA B
+helicase I
+, O
+a O
+DEAD B
+box I
+protein I
+designated O
+DDX3 B
+. O
+
+Kerstin O
+takes O
+the O
+abbreviated O
+medical O
+education O
+. O
+
+In O
+vitro O
+binding O
+studies O
+previously O
+showed O
+that O
+NF B
+- I
+kappa I
+B I
+p50 B
+homodimer O
+binds O
+the O
+switch B
+nuclear I
+B I
+- I
+site I
+protein I
+( O
+SNIP B
+) O
+of O
+the O
+S B
+gamma I
+3 I
+tandem I
+repeat O
+. O
+
+In O
+this O
+case O
+myogenic O
+factors O
+are O
+not O
+initially O
+expressed O
+and O
+these O
+migratory O
+cells O
+are O
+characterized O
+by O
+the O
+expression O
+of O
+the O
+paired B
+- I
+box I
+gene I
+Pax3 I
+. O
+
+It O
+is O
+concluded O
+that O
+the O
+atherogenic O
+process O
+includes O
+stimulation O
+of O
+collagen B
+and O
+elastin B
+synthesis O
+. O
+
+These O
+results O
+indicate O
+that O
+( O
+1 O
+) O
+RXR B
+- O
+TR B
+heterodimers O
+play O
+a O
+role O
+in O
+basal O
+transactivation O
+and O
+T3 O
+suppression O
+of O
+negatively O
+regulated O
+genes O
+, O
+and O
+( O
+2 O
+) O
+RXRs B
+increase O
+the O
+dominant O
+negative O
+effect O
+of O
+some O
+mutant B
+TRs I
+on O
+specific O
+negative O
+TREs O
+. O
+
+Phenotypic O
+responses O
+of O
+additional O
+mutants O
+, O
+including O
+exo1 B
+, O
+srs2 B
+, O
+rad5 B
+, O
+and O
+rdh54 B
+strains O
+, O
+suggest O
+roles O
+in O
+recombinational O
+repair O
+, O
+but O
+not O
+in O
+NHEJ O
+. O
+
+Furthermore O
+, O
+the O
+induction O
+of O
+cytochrome B
+P I
+- I
+450 I
+1A1 I
+observed O
+in O
+the O
+cormorant O
+indicates O
+that O
+the O
+Ah B
+receptor I
+- O
+mediated O
+process O
+, O
+by O
+which O
+TCDD O
+and O
+related O
+chemicals O
+exert O
+many O
+of O
+their O
+toxicities O
+, O
+has O
+been O
+activated O
+. O
+
+RESULT O
+( O
+S O
+) O
+: O
+A O
+prospective O
+study O
+was O
+conducted O
+with O
+44 O
+cycles O
+for O
+34 O
+couples O
+with O
+nafarelin O
+acetate O
+( O
+group O
+1 O
+) O
+and O
+47 O
+cycles O
+for O
+40 O
+couples O
+with O
+buserelin O
+acetate O
+( O
+group O
+2 O
+) O
+with O
+a O
+long O
+IVF O
+protocol O
+; O
+68 O
+cycles O
+for O
+46 O
+couples O
+with O
+nafarelin O
+acetate O
+( O
+group O
+3 O
+) O
+and O
+56 O
+cycles O
+for O
+39 O
+couples O
+with O
+buserelin O
+acetate O
+( O
+group O
+4 O
+) O
+with O
+a O
+short O
+IVF O
+protocol O
+; O
+39 O
+cycles O
+for O
+32 O
+couples O
+with O
+nafarelin O
+acetate O
+( O
+group O
+5 O
+) O
+and O
+50 O
+cycles O
+for O
+30 O
+couples O
+with O
+buserelin O
+acetate O
+( O
+group O
+6 O
+) O
+with O
+a O
+long O
+
+ICSI O
+protocol O
+; O
+and O
+87 O
+cycles O
+for O
+60 O
+couples O
+with O
+nafarelin O
+acetate O
+( O
+group O
+7 O
+) O
+and O
+81 O
+cycles O
+for O
+61 O
+couples O
+with O
+buserelin O
+acetate O
+( O
+group O
+8 O
+) O
+with O
+a O
+short O
+ICSI O
+protocol O
+. O
+
+This O
+study O
+demonstrates O
+the O
+feasibility O
+and O
+potential O
+usefulness O
+of O
+syngeneic O
+BM O
+Txp O
+in O
+myeloma O
+. O
+
+5 O
+. O
+3 O
++ O
+/ O
+- O
+6 O
+. O
+6 O
+for O
+risperidone O
+( O
+P O
+= O
+0 O
+. O
+09 O
+) O
+. O
+
+In O
+this O
+work O
+, O
+we O
+determined O
+the O
+sequences O
+of O
+eight O
+VirF B
+- I
+binding I
+sites I
+from O
+four O
+different O
+genes O
+, O
+by O
+DNase B
+I I
+or O
+hydroxyl O
+radical O
+footprinting O
+. O
+
+Although O
+they O
+are O
+similar O
+to O
+the O
+IL9R B
+gene I
+( O
+approximately O
+90 O
+% O
+identity O
+) O
+, O
+none O
+of O
+these O
+copies O
+encodes O
+a O
+functional O
+receptor O
+: O
+none O
+of O
+them O
+contains O
+sequences O
+homologous O
+to O
+the O
+5 O
+' O
+flanking O
+region O
+or O
+exon O
+1 O
+of O
+the O
+IL9R B
+gene I
+, O
+and O
+the O
+remaining O
+ORFs O
+have O
+been O
+inactivated O
+by O
+various O
+point O
+mutations O
+and O
+deletions O
+. O
+
+Type O
+II O
+neuroleptanalgesia O
+in O
+odonto O
+- O
+stomatology O
+
+273 O
+, O
+27420 O
+- O
+27429 O
+) O
+a O
+putative O
+peroxisome B
+proliferator I
+- I
+activated I
+receptor I
+response I
+element I
+( O
+PPRE O
+) O
+is O
+present O
+from O
+- O
+458 O
+to O
+- O
+474 O
+. O
+
+While O
+reviewing O
+gastric O
+specimens O
+from O
+215 O
+baboons O
+, O
+we O
+found O
+diffuse O
+giant O
+mucosal O
+folds O
+in O
+2 O
+specimens O
+and O
+multiple O
+giant O
+mucosal O
+nodules O
+in O
+another O
+3 O
+. O
+
+To O
+investigate O
+whether O
+the O
+two O
+RPG B
+- O
+boxes O
+mediate O
+transcription O
+activation O
+of O
+both O
+the O
+L46 B
+and O
+S24 B
+gene I
+, O
+two O
+experimental O
+strategies O
+were O
+followed O
+: O
+cloning O
+of O
+the O
+respective O
+genes O
+on O
+multicopy O
+vectors O
+and O
+construction O
+of O
+fusion O
+genes O
+. O
+
+When O
+the O
+opioid O
+antagonist O
+was O
+administered O
+to O
+animals O
+24 O
+hr O
+after O
+termination O
+of O
+single O
+or O
+multiple O
+exposures O
+to O
+restraint O
+, O
+NALT O
+- O
+induced O
+increases O
+in O
+basal O
+plasma O
+LH B
+were O
+significantly O
+attenuated O
+in O
+the O
+chronically O
+stressed O
+rats O
+compared O
+to O
+animals O
+subjected O
+to O
+stress O
+only O
+once O
+or O
+not O
+at O
+all O
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+250 O
+WORDS O
+) O
+
+The O
+psychosocial O
+features O
+of O
+people O
+using O
+self O
+- O
+ignition O
+as O
+a O
+method O
+of O
+suicide O
+are O
+consistent O
+with O
+those O
+of O
+suicide O
+in O
+general O
+. O
+
+This O
+was O
+further O
+suggested O
+by O
+transactivation O
+assays O
+in O
+which O
+mouse O
+fibroblasts O
+were O
+transiently O
+transfected O
+with O
+a O
+human B
+beta I
+- I
+globin I
+reporter I
+gene I
+in O
+the O
+absence O
+and O
+presence O
+of O
+an O
+LKLF B
+cDNA I
+construct I
+. O
+
+Plasma O
+colony B
+- I
+stimulating I
+factor I
+analysis O
+and O
+the O
+clinical O
+significance O
+
+Thus O
+, O
+in O
+addition O
+to O
+the O
+previously O
+characterized O
+FAS B
+- I
+binding I
+factor I
+1 I
+interacting O
+with O
+the O
+inositol O
+/ O
+choline O
+- O
+responsive O
+- O
+element O
+motif O
+, O
+a O
+second O
+motif O
+common O
+to O
+the O
+promoter O
+regions O
+of O
+both O
+FAS B
+genes I
+could O
+be O
+identified O
+. O
+
+Reconstruction O
+time O
+for O
+a O
+64 O
+x O
+64 O
+matrix O
+is O
+approximately O
+45 O
+s O
+/ O
+transaxial O
+slice O
+. O
+
+Sequence O
+analysis O
+identifies O
+a O
+ras B
+- O
+associating O
+( O
+RA O
+) O
+- O
+like O
+domain O
+in O
+the O
+N O
+- O
+termini O
+of O
+band B
+4 I
+. I
+1 I
+/ O
+JEF B
+domains O
+and O
+in O
+the O
+Grb7 B
+/ I
+10 I
+/ I
+14 I
+adapter I
+family I
+. O
+
+Patients O
+received O
+BPB O
+using O
+bupivacaine O
+2 O
+mg O
+kg O
+- O
+1 O
+with O
+adrenaline O
+1 O
+in O
+200 O
+, O
+000 O
+, O
+either O
+with O
+or O
+without O
+hyaluronidase B
+3000 O
+iu I
+, O
+in O
+a O
+volume O
+of O
+0 O
+. O
+5 O
+ml O
+per O
+2 O
+. O
+54 O
+cm O
+of O
+the O
+patient O
+' O
+s O
+height O
+. O
+
+Rhinovirus B
+2A I
+protease I
+and O
+foot B
+- I
+and I
+- I
+mouth I
+- I
+disease I
+virus I
+L I
+protease I
+were O
+used O
+to O
+analyze O
+the O
+association O
+of O
+eIF4G B
+with O
+eIF4A B
+, O
+eIF4E B
+, O
+and O
+eIF3 B
+. O
+
+One O
+hundred O
+cDNA O
+clones O
+were O
+sequenced O
+and O
+8 O
+RTKs B
+were O
+identified O
+, O
+as O
+well O
+as O
+12 O
+non B
+- I
+RTKs I
+and O
+2 O
+serine B
+/ I
+threonine I
+kinases I
+. O
+
+Roller O
+pumps O
+, O
+coronary O
+suction O
+and O
+an O
+open O
+cardiotomy O
+reservoir O
+were O
+used O
+. O
+
+Furthermore O
+, O
+it O
+was O
+found O
+that O
+the O
+Shb B
+- O
+overexpressing O
+cells O
+extended O
+neurites O
+in O
+response O
+to O
+epidermal B
+growth I
+factor I
+. O
+
+Levels O
+of O
+p53 B
+were O
+substantially O
+increased O
+by O
+E1A B
+expression O
+during O
+adenovirus O
+infection O
+. O
+
+In O
+cases O
+of O
+intracapsular O
+prostatic O
+cancer O
+the O
+level O
+of O
+prostatic B
+acid I
+phosphatase I
+( O
+PAP B
+) O
+measured O
+by O
+radioimmunoassay O
+was O
+1 O
+. O
+4 O
++ O
+/ O
+- O
+0 O
+. O
+8 O
+micrograms O
+/ O
+l O
+. O
+
+Healthy O
+subjects O
+received O
+the O
+following O
+regimens O
+, O
+dosed O
+to O
+steady O
+state O
+: O
+trovafloxacin O
+300 O
+mg O
+/ O
+24 O
+h O
+; O
+ciprofloxacin O
+400 O
+mg O
+/ O
+12 O
+h O
+; O
+trovafloxacin O
+300 O
+mg O
+/ O
+24 O
+h O
+plus O
+cefepime O
+2 O
+g O
+/ O
+12 O
+h O
+, O
+and O
+ciprofloxacin O
+400 O
+mg O
+/ O
+12 O
+h O
+plus O
+cefepime O
+2 O
+g O
+/ O
+12 O
+h O
+. O
+
+In O
+EGF B
+receptor I
+- O
+mediated O
+signaling O
+, O
+the O
+protein O
+kinase I
+PKB I
+/ O
+Akt B
+and O
+the O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+c B
+- I
+Jun I
+N I
+- I
+terminal I
+kinase I
+, O
+but O
+not O
+extracellular B
+signal I
+- I
+regulated I
+kinase I
+2 I
+, O
+function O
+downstream O
+of O
+phosphatidylinositol B
+3 I
+- I
+kinase I
+( O
+PI B
+3 I
+- I
+kinase I
+) O
+. O
+
+Immunoprecipitation O
+of O
+cell O
+lysates O
+with O
+anti B
+- I
+phosphotyrosine I
+and O
+immunoblotting O
+showed O
+phosphorylated O
+forms O
+of O
+the O
+mitogenic O
+pathway O
+proteins O
+Shc B
+and O
+MAPK B
+in O
+addition O
+to O
+p185 B
+( O
+neu B
+) O
+, O
+suggesting O
+that O
+the O
+Ras B
+to O
+MAPK B
+mitogenic O
+pathway O
+is O
+activated O
+. O
+
+Acad O
+. O
+
+We O
+suggest O
+that O
+this O
+effect O
+of O
+Myc B
+is O
+mediated O
+by O
+its O
+action O
+upstream O
+of O
+cyclin B
+E I
+- O
+CDK2 B
+, O
+and O
+occurs O
+via O
+the O
+neutralization O
+of O
+p27 B
+( O
+Kip1 B
+) O
+family O
+proteins O
+, O
+rather O
+than O
+induction O
+of O
+Cdc25A B
+. O
+
+Bile O
+reflux O
+demonstrated O
+by O
+99m O
+Tc O
+disofenin O
+. O
+
+These O
+data O
+suggest O
+that O
+certain O
+of O
+the O
+nuclear O
+protein O
+import O
+functions O
+of O
+NTF2 B
+and O
+Ran B
+/ O
+TC4 B
+are O
+closely O
+linked O
+and O
+that O
+NTF2 B
+may O
+serve O
+to O
+modulate O
+a O
+transport O
+step O
+involving O
+Ran B
+/ O
+TC4 B
+. O
+
+Almost O
+every O
+image O
+that O
+appears O
+during O
+a O
+therapy O
+session O
+reveals O
+a O
+symbolic O
+nature O
+, O
+but O
+the O
+very O
+concept O
+of O
+symbol O
+is O
+not O
+free O
+from O
+ambiguity O
+some O
+positions O
+originated O
+in O
+different O
+areas O
+of O
+investigation O
+are O
+mentioned O
+, O
+ending O
+with O
+a O
+description O
+of O
+the O
+traits O
+that O
+, O
+according O
+to O
+the O
+writer O
+, O
+bestow O
+a O
+symbolic O
+character O
+to O
+images O
+. O
+
+The O
+severity O
+of O
+the O
+psychomotor O
+retardation O
+varied O
+from O
+mild O
+to O
+severe O
+. O
+
+Both O
+oligonucleotide O
+cross O
+- O
+competition O
+and O
+antibody O
+supershift O
+experiments O
+established O
+that O
+the O
+double B
+- I
+strand I
+binding I
+protein I
+is O
+equivalent O
+to O
+Sp1 B
+. O
+
+The O
+wet O
+and O
+dry O
+methods O
+of O
+the O
+HA O
+synthesis O
+are O
+considered O
+. O
+
+All O
+these O
+abnormalities O
+returned O
+to O
+normal O
+after O
+removal O
+of O
+the O
+tumor O
+. O
+
+Although O
+FKH2 B
+is O
+redundant O
+with O
+FKH1 B
+in O
+controlling O
+pseudohyphal O
+growth O
+, O
+the O
+two O
+genes O
+have O
+different O
+functions O
+in O
+silencing O
+HMRa B
+. O
+
+Molecular O
+analysis O
+indicated O
+that O
+inactivation O
+of O
+H B
+- I
+2L I
+expression O
+in O
+nearly O
+every O
+null O
+clone O
+resulted O
+from O
+an O
+apparent O
+deletion O
+or O
+rearrangement O
+of O
+5 O
+' O
+- O
+flanking O
+and O
+5 O
+' O
+- O
+coding O
+H B
+- I
+2L I
+sequences I
+, O
+with O
+breakpoints O
+consistently O
+mapping O
+to O
+within O
+a O
+550 O
+bp O
+GC O
+- O
+rich O
+region O
+between O
+exon O
+1 O
+and O
+the O
+middle O
+of O
+intron O
+2 O
+. O
+
+However O
+, O
+C B
+/ I
+EBP I
+beta I
+stimulated O
+transcription O
+primarily O
+through O
+the O
+cAMP O
+- O
+responsive O
+element O
+( O
+CRE O
+) O
+, O
+which O
+maps O
+between O
+positions O
+- O
+77 O
+to O
+- O
+94 O
+, O
+but O
+not O
+at O
+the O
+more O
+5 O
+' O
+- O
+binding O
+sites O
+. O
+
+Heliox O
+improves O
+pulsus O
+paradoxus O
+and O
+peak O
+expiratory O
+flow O
+in O
+nonintubated O
+patients O
+with O
+severe O
+asthma O
+. O
+
+50 O
+- O
+fold O
+increase O
+in O
+foreign O
+protein O
+production O
+. O
+
+Ion O
+- O
+Bernstein O
+- O
+wave O
+heating O
+and O
+improved O
+confinement O
+in O
+the O
+Alcator O
+C O
+tokamak O
+. O
+
+However O
+, O
+the O
+molecular O
+mechanisms O
+by O
+which O
+specific O
+cis O
+- O
+and O
+trans O
+- O
+acting O
+factors O
+control O
+activity O
+of O
+the O
+prodynorphin B
+promoter I
+are O
+not O
+as O
+clearly O
+defined O
+. O
+
+Finally O
+, O
+antisense O
+mediated O
+reduction O
+of O
+Elk B
+- I
+1 I
+in O
+GH4 O
+cells O
+decreased O
+insulin B
+- O
+increased O
+prolactin B
+gene I
+expression O
+and O
+confirmed O
+the O
+requirement O
+for O
+Elk B
+- I
+1 I
+for O
+insulin B
+- O
+increased O
+prolactin B
+gene I
+expression O
+. O
+
+Substitutions O
+of O
+Asp11 B
+led O
+to O
+dominant O
+lethality O
+. O
+
+Three O
+modern O
+hematology O
+analyzers O
+( O
+Abbott O
+Cell O
+- O
+Dyn O
+3000 O
+, O
+Coulter O
+STKS O
+, O
+and O
+Sysmex O
+NE O
+- O
+8000 O
+) O
+with O
+high O
+throughput O
+and O
+5 O
+- O
+part O
+differential O
+capability O
+were O
+evaluated O
+using O
+a O
+protocol O
+designed O
+by O
+a O
+quality O
+team O
+. O
+
+Each O
+subject O
+was O
+injected O
+in O
+the O
+antecubital O
+vein O
+with O
+7 O
+mg O
+/ O
+kg O
+of O
+sodium O
+fluorescein O
+( O
+25 O
+% O
+solution O
+) O
+and O
+measurements O
+were O
+taken O
+1 O
+hr O
+postinjection O
+at O
+4 O
+. O
+5 O
+mm O
+and O
+7 O
+. O
+5 O
+mm O
+from O
+the O
+retina O
+. O
+
+The O
+cleft O
+walls O
+are O
+lined O
+with O
+highly O
+conserved O
+residues O
+and O
+NADP O
+is O
+bound O
+along O
+one O
+wall O
+. O
+
+cDNA O
+cloning O
+, O
+sequencing O
+and O
+chromosome O
+mapping O
+of O
+a O
+non B
+- I
+erythroid I
+spectrin I
+, O
+human B
+alpha I
+- I
+fodrin I
+. O
+
+The O
+aromatic B
+hydrocarbon I
+receptor I
+( O
+AHR B
+) O
+is O
+a O
+ligand O
+- O
+activated O
+transcription O
+factor O
+that O
+regulates O
+the O
+expression O
+of O
+several O
+drug O
+- O
+metabolizing O
+enzymes O
+and O
+has O
+been O
+implicated O
+in O
+immunosuppression O
+, O
+teratogenesis O
+, O
+cell O
+- O
+specific O
+hyperplasia O
+, O
+and O
+certain O
+types O
+of O
+malignancies O
+and O
+toxicities O
+. O
+
+( O
+1996 O
+) O
+J O
+. O
+
+To O
+define O
+the O
+molecular O
+mechanism O
+regulating O
+FGFR B
+- I
+1 I
+gene I
+expression O
+in O
+proliferating O
+myoblasts O
+and O
+post O
+- O
+mitotic O
+muscle O
+fibers O
+, O
+we O
+have O
+isolated O
+and O
+partially O
+characterized O
+the O
+avian B
+FGFR I
+- I
+1 I
+gene I
+promoter I
+. O
+
+Moreover O
+, O
+FACT B
+specifically O
+interacts O
+with O
+nucleosomes O
+and O
+histone B
+H2A I
+/ O
+H2B B
+dimers O
+, O
+indicating O
+that O
+it O
+may O
+work O
+by O
+promoting O
+nucleosome O
+disassembly O
+upon O
+transcription O
+. O
+
+Measures O
+of O
+sedation O
+, O
+BIS O
+, O
+deltaBIS O
+( O
+absolute O
+change O
+of O
+BIS O
+after O
+a O
+painful O
+stimulus O
+) O
+, O
+memory O
+, O
+and O
+drug O
+concentration O
+were O
+obtained O
+at O
+each O
+target O
+drug O
+concentration O
+. O
+
+ER O
+and O
+DR O
+were O
+significantly O
+correlated O
+with O
+MIB O
+- O
+1 O
+LI O
+( O
+P O
+< O
+0 O
+. O
+01 O
+and O
+P O
+< O
+0 O
+. O
+05 O
+, O
+respectively O
+) O
+, O
+but O
+RI O
+and O
+Td O
+/ O
+Te O
+were O
+not O
+. O
+
+Positive O
+linear O
+correlations O
+were O
+found O
+when O
+the O
+AUC O
+( O
+0 O
+- O
+12 O
+) O
+( O
+r O
+= O
+0 O
+. O
+68 O
+; O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+, O
+the O
+maximum O
+plasma O
+concentration O
+( O
+r O
+= O
+0 O
+. O
+34 O
+; O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+, O
+the O
+minimum O
+plasma O
+concentration O
+( O
+r O
+= O
+0 O
+. O
+55 O
+; O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+, O
+and O
+the O
+elimination O
+t1 O
+/ O
+2 O
+( O
+r O
+= O
+0 O
+. O
+46 O
+; O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+were O
+regressed O
+with O
+age O
+. O
+
+Psychophysical O
+evidence O
+is O
+given O
+for O
+the O
+existence O
+of O
+two O
+distinct O
+systems O
+in O
+human O
+vision O
+: O
+a O
+fast O
+, O
+sign O
+- O
+invariant O
+system O
+concerned O
+with O
+extracting O
+contours O
+and O
+a O
+slower O
+, O
+sign O
+- O
+sensitive O
+system O
+concerned O
+with O
+assigning O
+surface O
+color O
+. O
+
+Peripheral O
+visual O
+acuity O
+with O
+monovision O
+and O
+other O
+contact O
+lens O
+corrections O
+for O
+presbyopia O
+. O
+
+Fourteen O
+Centers O
+participated O
+in O
+this O
+trial O
+. O
+
+The O
+program O
+for O
+myogenic O
+differentiation O
+is O
+subject O
+to O
+negative O
+control O
+by O
+several O
+peptide O
+growth O
+factors O
+and O
+by O
+the O
+products O
+of O
+mutationally O
+activated O
+ras B
+oncogenes I
+, O
+which O
+persistently O
+activate O
+intracellular O
+cascades O
+normally O
+triggered O
+by O
+specific O
+growth O
+factors O
+. O
+
+Tetrazepam O
+: O
+a O
+benzodiazepine O
+which O
+dissociates O
+sedation O
+from O
+other O
+benzodiazepine O
+activities O
+. O
+
+The O
+difference O
+between O
+the O
+effects O
+of O
+the O
+two O
+dose O
+levels O
+of O
+Z O
+. O
+
+Mutation O
+of O
+the O
+distal O
+E2F B
+binding I
+site I
+in O
+the O
+cdc25A B
+promoter I
+abolished O
+E2 B
+- O
+induced O
+repression O
+, O
+whereas O
+mutation O
+of O
+the O
+proximal O
+E2F B
+site I
+or O
+the O
+E2 B
+site I
+had O
+no O
+effect O
+. O
+
+Plasmid O
+pNK21 O
+, O
+in O
+which O
+2 O
+. O
+05 O
+- O
+kb O
+sequence O
+covering O
+the O
+region O
+encoding O
+the O
+nitrilase B
+was O
+was O
+placed O
+under O
+the O
+control O
+of O
+the O
+lac B
+promoter I
+, O
+directed O
+overproduction O
+of O
+enzymatically O
+active O
+nitrilase B
+in O
+response O
+to O
+addition O
+of O
+isopropyl O
+beta O
+- O
+D O
+- O
+thiogalactopyranoside O
+in O
+Escherichia O
+coli O
+. O
+
+A O
+method O
+for O
+determining O
+the O
+toxicity O
+of O
+neutralizers O
+for O
+antimicrobial O
+agents O
+to O
+A O
+. O
+castellanii O
+was O
+also O
+evaluated O
+. O
+
+Expression O
+in O
+all O
+lines O
+was O
+decreased O
+by O
+the O
+inclusion O
+of O
+regions O
+further O
+upstream O
+, O
+and O
+extinguished O
+by O
+the O
+inclusion O
+of O
+the O
+first O
+intron O
+. O
+
+Static O
+and O
+dynamic O
+MRI O
+of O
+the O
+normal O
+and O
+pathological O
+female O
+pelvic O
+floor O
+
+IENF O
+density O
+at O
+the O
+calf O
+was O
+lower O
+than O
+that O
+obtained O
+from O
+skin O
+at O
+more O
+proximal O
+sites O
+, O
+indicating O
+the O
+length O
+dependency O
+of O
+small O
+- O
+fiber O
+loss O
+in O
+these O
+neuropathies O
+. O
+
+These O
+results O
+demonstrate O
+a O
+specific O
+association O
+of O
+SIV O
+and O
+HIV B
+- I
+2 I
+nef I
+, O
+but O
+not O
+HIV B
+- I
+1 I
+nef I
+, O
+with O
+TCRzeta B
+. O
+
+Insertion O
+of O
+alternatively O
+spliced O
+exon O
+W O
+into O
+CREB B
+mRNA I
+during O
+spermatogenesis O
+results O
+in O
+a O
+polycistronic O
+RNA O
+that O
+encodes O
+two O
+novel O
+internally O
+translated O
+CREB B
+repressor I
+isoforms I
+called O
+I B
+- I
+CREBs I
+, O
+consisting O
+of O
+the O
+carboxy O
+- O
+terminal O
+DNA O
+- O
+binding O
+domain O
+devoid O
+of O
+the O
+transactivation O
+domains O
+. O
+
+A O
+continuous O
+- O
+flow O
+BIPAP O
+system O
+consists O
+of O
+a O
+high O
+- O
+flow O
+CPAP O
+system O
+, O
+a O
+reservoir O
+bag O
+, O
+and O
+a O
+pneumatically O
+controlled O
+membrane O
+valve O
+in O
+the O
+expiratory O
+limb O
+. O
+
+Older O
+females O
+had O
+lumbar O
+( O
+0 O
+. O
+6 O
++ O
+/ O
+- O
+1 O
+. O
+3 O
+) O
+and O
+TB O
+( O
+1 O
+. O
+1 O
++ O
+/ O
+- O
+1 O
+. O
+1 O
+) O
+BMD O
+Z O
+scores O
+greater O
+than O
+0 O
+( O
+both O
+, O
+p O
+< O
+0 O
+. O
+001 O
+) O
+. O
+
+Smooth O
+pursuit O
+gain O
+and O
+the O
+percentage O
+of O
+total O
+eye O
+movement O
+due O
+to O
+various O
+saccadic O
+subtypes O
+were O
+computed O
+using O
+infrared O
+oculography O
+and O
+computerized O
+pattern O
+recognition O
+software O
+. O
+
+Upon O
+incubation O
+of O
+the O
+most O
+highly O
+purified O
+fractions O
+with O
+Mn O
+- O
+ATP O
+or O
+Mg O
+- O
+ATP O
+, O
+p40 B
+was O
+the O
+only O
+protein O
+phosphorylated O
+on O
+tyrosine O
+. O
+
+Consistent O
+with O
+this O
+hypothesis O
+, O
+alpha1 B
+- I
+PDX I
+prevents O
+cleavage O
+of O
+BMP B
+- I
+4 I
+in O
+an O
+oocyte O
+translation O
+assay O
+. O
+
+A O
+p53 B
+cDNA I
+deletion I
+mutant I
+( O
+delta B
+pro I
+AE I
+) O
+, O
+which O
+lacks O
+this O
+entire O
+proline O
+- O
+rich O
+domain O
+( O
+deleted O
+for O
+amino O
+acids O
+62 O
+- O
+91 O
+) O
+, O
+was O
+created O
+and O
+characterized O
+for O
+a O
+variety O
+of O
+p53 B
+functions O
+. O
+
+Multiple O
+aortic O
+thrombi O
+associated O
+with O
+protein B
+C I
+and I
+S I
+deficiency O
+. O
+
+Our O
+results O
+suggest O
+that O
+Bry1 B
+/ O
+Skn7 B
+can O
+influence O
+the O
+expression O
+of O
+MCB B
+- O
+and O
+SCB B
+- O
+driven O
+gene O
+expression O
+in O
+budding O
+yeast O
+, O
+perhaps O
+including O
+genes O
+involved O
+in O
+cell O
+wall O
+metabolism O
+, O
+via O
+a O
+two O
+- O
+component O
+signal O
+transduction O
+pathway O
+which O
+activates O
+Bry1 B
+/ O
+Skn7 B
+in O
+response O
+to O
+an O
+unidentified O
+signal O
+. O
+
+( O
+1992 O
+) O
+J O
+. O
+
+A O
+constructed O
+phylogenetic O
+tree O
+suggests O
+that O
+the O
+UbcP1 B
+protein I
+may O
+represent O
+a O
+member O
+of O
+a O
+distinct O
+subfamily O
+of O
+E2s B
+. O
+
+Platelet B
+factor I
+4 I
+levels O
+in O
+patients O
+with O
+coronary O
+artery O
+disease O
+. O
+
+We O
+functionally O
+characterised O
+AtXPO1 B
+by O
+its O
+interaction O
+with O
+NESs B
+of O
+animal O
+and O
+plant O
+proteins O
+, O
+which O
+is O
+inhibited O
+by O
+the O
+cytotoxin O
+leptomycin O
+B O
+( O
+LMB O
+) O
+, O
+and O
+also O
+by O
+its O
+interaction O
+with O
+the O
+small B
+GTPase I
+Ran1 I
+in O
+the O
+yeast O
+two O
+- O
+hybrid O
+system O
+. O
+
+A O
+backward O
+look O
+at O
+urinary O
+tract O
+infections O
+. O
+
+The O
+expression O
+of O
+cor14b B
+was O
+strongly O
+impaired O
+in O
+the O
+barley B
+albino I
+mutant I
+an I
+, O
+suggesting O
+the O
+involvement O
+of O
+a O
+plastidial O
+factor O
+in O
+the O
+control O
+of O
+gene O
+expression O
+. O
+
+MRS O
+allowed O
+the O
+differentiation O
+of O
+the O
+following O
+metabolites O
+in O
+5 O
+patients O
+: O
+N O
+- O
+acetyl O
+- O
+aspartate O
+( O
+NAA O
+) O
+, O
+creatine O
+and O
+phosphocreatine O
+, O
+phosphorylcholine O
+and O
+glycerophosphorylcholine O
+, O
+beta O
+- O
+and O
+gamma O
+- O
+glutamate O
+( O
+GLU O
+) O
+. O
+
+Overall O
+, O
+free O
+- O
+chlorine O
+treatments O
+( O
+0 O
+. O
+3 O
+or O
+1 O
+. O
+0 O
+mg O
+/ O
+L O
+) O
+showed O
+significantly O
+lower O
+heterotrophic O
+plate O
+numbers O
+than O
+those O
+without O
+free O
+chlorine O
+. O
+
+S1 B
+nuclease I
+protection O
+mapping O
+and O
+primer O
+extension O
+analysis O
+allowed O
+us O
+to O
+propose O
+that O
+the O
+A O
+residue O
+located O
+19 O
+bp O
+upstream O
+from O
+the O
+translation O
+initiation O
+codon O
+is O
+the O
+site O
+of O
+transcription O
+initiation O
+. O
+
+Various O
+stimuli O
+inactivate O
+IkappaB B
+alpha I
+by O
+triggering O
+phosphorylation O
+of O
+the O
+N O
+- O
+terminal O
+residues O
+Ser32 O
+and O
+Ser36 O
+. O
+
+There O
+was O
+no O
+difference O
+in O
+the O
+day O
+- O
+42 O
+cure O
+rates O
+between O
+the O
+QC7 O
+( O
+n O
+= O
+65 O
+) O
+and O
+A7 O
+( O
+n O
+= O
+64 O
+) O
+regimens O
+with O
+an O
+efficacy O
+of O
+100 O
+% O
+in O
+both O
+, O
+confirmed O
+by O
+parasite O
+genotyping O
+. O
+
+In O
+addition O
+, O
+the O
+results O
+suggest O
+that O
+N O
+region O
+diversity O
+at O
+V B
+( O
+D O
+) O
+J B
+junctions O
+within O
+rearranged B
+immunoglobulin B
+and O
+T B
+cell I
+receptor I
+gene I
+loci I
+can O
+only O
+be O
+introduced O
+after O
+the O
+generation O
+of O
+RAG B
+- O
+catalyzed O
+DNA O
+double O
+- O
+strand O
+breaks O
+, O
+i O
+. O
+e O
+. O
+during O
+the O
+DNA O
+end O
+joining O
+phase O
+of O
+the O
+V B
+( O
+D O
+) O
+J B
+recombination O
+reaction O
+. O
+
+We O
+conclude O
+that O
+99mTc O
+- O
+HL91 O
+is O
+a O
+potent O
+marker O
+of O
+myocardial O
+viability O
+when O
+used O
+during O
+the O
+early O
+acute O
+phase O
+after O
+reperfusion O
+. O
+
+Three O
+patients O
+treated O
+with O
+amphotericin O
+B O
+, O
+single O
+course O
+as O
+well O
+as O
+multiple O
+courses O
+, O
+and O
+other O
+antifungal O
+agents O
+( O
+hydroxystilbamidine O
+and O
+miconazole O
+) O
+have O
+all O
+relapsed O
+. O
+
+An O
+infant O
+of O
+8 O
+months O
+with O
+congenital O
+glaucoma O
+and O
+hemophilia O
+A O
+lost O
+one O
+eye O
+due O
+to O
+haemorrhages O
+after O
+trabeculotomy O
+in O
+an O
+eye O
+hospital O
+. O
+
+Anderson O
+Hospital O
+and O
+Tumor O
+Institute O
+at O
+Houston O
+during O
+a O
+30 O
+- O
+year O
+interval O
+( O
+1944 O
+to O
+1974 O
+) O
+, O
+with O
+a O
+minimum O
+of O
+ten O
+years O
+of O
+follow O
+- O
+up O
+, O
+we O
+determined O
+that O
+the O
+major O
+prognostic O
+factor O
+of O
+survival O
+was O
+the O
+number O
+of O
+positive O
+nodes O
+. O
+
+We O
+have O
+now O
+isolated O
+cDNA O
+for O
+an O
+invertebrate B
+Pax I
+- I
+6 I
+protein I
+from I
+sea I
+urchin I
+embryos I
+. O
+
+To O
+study O
+structural O
+diversity O
+of O
+the O
+three O
+homologous O
+loci O
+encoding O
+a O
+KN1 B
+- I
+like I
+homeobox I
+protein I
+in O
+the O
+hexaploid O
+wheat O
+genome O
+, O
+we O
+isolated O
+clones O
+from O
+a O
+cDNA O
+library O
+of O
+young O
+spikes O
+of O
+Japanese O
+common O
+wheat O
+cultivar O
+' O
+Norin O
+26 O
+' O
+. O
+
+Whether O
+or O
+not O
+these O
+novel O
+repeated O
+sequences O
+throughout O
+the O
+SMA O
+region O
+are O
+involved O
+in O
+the O
+disease O
+remains O
+to O
+be O
+determined O
+. O
+
+Thus O
+, O
+Shp2 B
+regulates O
+phosphotyrosine O
+- O
+signalling O
+events O
+during O
+the O
+complex O
+ectodermal O
+- O
+mesenchymal O
+interactions O
+that O
+regulate O
+mammalian O
+budding O
+morphogenesis O
+. O
+
+Moyamoya O
+is O
+an O
+intriguing O
+and O
+controversial O
+syndrome O
+. O
+
+However O
+, O
+elimination O
+of O
+the O
+kinase O
+activity O
+of O
+DCAMKL1 B
+has O
+no O
+detectable O
+effect O
+on O
+its O
+microtubule O
+polymerization O
+activity O
+. O
+
+We O
+have O
+thus O
+cloned O
+two O
+yeast B
+homologs I
+of I
+mammalian I
+p220 I
+. O
+
+The O
+glucose O
+effect O
+on O
+the O
+pyruvate B
+kinase I
+gene I
+is O
+reversibly O
+antagonized O
+by O
+agents O
+increasing O
+intracellular O
+cAMP O
+. O
+
+An O
+identical O
+polypeptide O
+was O
+detected O
+by O
+Western O
+blot O
+analysis O
+of O
+K1F O
+virions O
+. O
+
+Patients O
+with O
+PLM O
+show O
+excessive O
+daytime O
+sleepiness O
+or O
+insomnia O
+. O
+
+Coexpression O
+of O
+CREB B
+- I
+binding I
+protein I
+( O
+CBP B
+) O
+/ O
+p300 B
+with O
+TReP B
+- I
+132 I
+has O
+an O
+additive O
+effect O
+on O
+promoter O
+activity O
+, O
+and O
+the O
+proteins O
+were O
+demonstrated O
+to O
+interact O
+physically O
+. O
+
+It O
+is O
+believed O
+that O
+the O
+operation O
+is O
+effective O
+because O
+it O
+cuts O
+the O
+spinothalamic O
+tract O
+( O
+STT O
+) O
+, O
+a O
+primary O
+pathway O
+carrying O
+nociceptive O
+information O
+from O
+the O
+spinal O
+cord O
+to O
+the O
+brain O
+in O
+humans O
+. O
+
+Catalase B
+plays O
+a O
+key O
+role O
+as O
+an O
+antioxidant O
+, O
+protecting O
+aerobic O
+organisms O
+from O
+the O
+toxic O
+effects O
+of O
+hydrogen O
+peroxide O
+, O
+and O
+in O
+some O
+cases O
+has O
+been O
+postulated O
+to O
+be O
+a O
+virulence O
+factor O
+. O
+
+Recovery O
+rates O
+of O
+energy O
+level O
+and O
+intracellular O
+pH O
+during O
+stimulation O
+at O
+100Hz O
+were O
+greater O
+than O
+those O
+observed O
+during O
+stimulation O
+at O
+30Hz O
+. O
+
+Exhaled O
+NO O
+was O
+assessed O
+by O
+controlled O
+- O
+flow O
+chemoluminescence O
+after O
+adjusting O
+for O
+trapped O
+air O
+and O
+after O
+generating O
+pressure O
+in O
+the O
+oral O
+cavity O
+that O
+was O
+sufficient O
+to O
+close O
+the O
+soft O
+palate O
+( O
+Eco O
+Physics O
+CLD O
+77 O
+AM O
+analyzer O
+) O
+. O
+
+Recent O
+developments O
+in O
+the O
+study O
+of O
+growth O
+factors O
+: O
+GRF B
+and O
+somatomedins B
+. O
+
+New O
+concepts O
+of O
+condyloma O
+acuminata O
+in O
+children O
+. O
+
+This O
+is O
+the O
+first O
+clinical O
+case O
+report O
+of O
+NIHF O
+due O
+to O
+fetal O
+Kasabach O
+- O
+Merritt O
+syndrome O
+that O
+was O
+prenatally O
+diagnosed O
+by O
+sonography O
+, O
+computerized O
+tomography O
+, O
+and O
+percutaneous O
+umbilical O
+blood O
+sampling O
+. O
+
+Acetoacetate B
+decarboxylase I
+( O
+ADC B
+) O
+( O
+EC4 B
+. I
+1 I
+. I
+1 I
+. I
+4 I
+) O
+of O
+Clostridium O
+acetobutylicum O
+DSM O
+792 O
+was O
+purified O
+to O
+homogeneity O
+, O
+and O
+its O
+first O
+25 O
+N O
+- O
+terminal O
+amino O
+acids O
+were O
+determined O
+. O
+
+Transfer O
+of O
+health O
+care O
+to O
+natives O
+holds O
+much O
+promise O
+, O
+lecturers O
+say O
+. O
+
+The O
+sequence O
+of O
+the O
+127 B
+residue I
+NrfF I
+polypeptide I
+, O
+M O
+( O
+r O
+) O
+14 O
+, O
+522 O
+, O
+is O
+strikingly O
+similar O
+to O
+the O
+CcI2 B
+protein I
+of O
+R O
+. O
+capsulatus O
+, O
+especially O
+in O
+the O
+putative O
+haem O
+- O
+binding O
+motif O
+, O
+RCPQCQNQN O
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+400 O
+WORDS O
+) O
+
+CAT B
+assays O
+demonstrated O
+that O
+overexpression O
+of O
+RXRalpha B
+conferred O
+the O
+best O
+RA O
+response O
+, O
+consistent O
+with O
+our O
+previous O
+observation O
+that O
+9 O
+- O
+cis O
+- O
+RA O
+is O
+more O
+potent O
+than O
+all O
+- O
+trans O
+- O
+RA O
+for O
+inducing O
+the O
+expression O
+of O
+the O
+AFP B
+gene I
+. O
+
+For O
+rotating O
+stimuli O
+presented O
+to O
+the O
+dominant O
+eye O
+, O
+this O
+class O
+of O
+neurons O
+responded O
+best O
+to O
+rotation O
+of O
+the O
+visual O
+world O
+about O
+an O
+axis O
+oriented O
+near O
+the O
+horizontal O
+plane O
+and O
+approximately O
+45 O
+degrees O
+azimuth O
+. O
+
+None O
+of O
+these O
+patients O
+developed O
+clinical O
+events O
+before O
+disappearance O
+of O
+the O
+phospholipid O
+- O
+dependent O
+inhibitors O
+of O
+coagulation O
+. O
+
+In O
+spite O
+of O
+the O
+variability O
+of O
+DD95 O
+with O
+regard O
+to O
+body O
+weight O
+, O
+the O
+recovery O
+of O
+neuromuscular O
+transmission O
+in O
+the O
+patients O
+of O
+the O
+three O
+groups O
+is O
+comparable O
+. O
+
+We O
+have O
+studied O
+some O
+of O
+the O
+parameters O
+governing O
+the O
+expression O
+of O
+a O
+foreign O
+promoter O
+- O
+reporter O
+gene O
+construct O
+incorporated O
+into O
+herpes O
+simplex O
+virus O
+( O
+HSV O
+) O
+type O
+1 O
+. O
+
+Relation O
+between O
+clinical O
+and O
+roentgenological O
+scores O
+and O
+measures O
+of O
+lung O
+function O
+in O
+cystic O
+fibrosis O
+, O
+with O
+special O
+reference O
+to O
+pulmonary O
+Xenon133 O
+elimination O
+. O
+
+Each O
+fusion O
+leads O
+, O
+in O
+principle O
+, O
+to O
+the O
+same O
+effect O
+: O
+The O
+ret B
+tyrosine I
+kinase I
+is O
+uncoupled O
+from O
+its O
+stringent O
+physiological O
+regulation O
+by O
+replacement O
+of O
+its O
+5 O
+' O
+end O
+and O
+is O
+aberrantly O
+activated O
+by O
+the O
+5 O
+' O
+parts O
+of O
+fused O
+genes O
+in O
+thyrocytes O
+that O
+do O
+not O
+normally O
+express O
+ret B
+tyrosine I
+kinase I
+. O
+
+He O
+had O
+complained O
+of O
+fever O
+and O
+right O
+hypochondralgia O
+2 O
+months O
+after O
+being O
+operated O
+for O
+appendicitis O
+. O
+
+In O
+the O
+predicted O
+amino O
+acid O
+sequence O
+of O
+NPS1 B
+, O
+sequences O
+homologous O
+to O
+the O
+catalytic O
+domain O
+of O
+protein O
+kinases O
+were O
+found O
+. O
+
+Carcinoma O
+- O
+related O
+protein O
+production O
+may O
+have O
+played O
+a O
+role O
+in O
+the O
+development O
+of O
+the O
+observed O
+renal O
+lesions O
+. O
+
+These O
+results O
+provide O
+strong O
+evidence O
+that O
+conserved O
+interhelical O
+packing O
+interactions O
+in O
+the O
+gp41 B
+core I
+are O
+important O
+determinants O
+of O
+HIV O
+- O
+1 O
+entry O
+and O
+its O
+inhibition O
+. O
+
+Lag O
+phases O
+were O
+14 O
+. O
+89 O
+hours O
++ O
+/ O
+- O
+0 O
+. O
+77 O
+, O
+13 O
+. O
+33 O
+hours O
++ O
+/ O
+- O
+0 O
+. O
+50 O
+, O
+20 O
+. O
+22 O
+hours O
++ O
+/ O
+- O
+0 O
+. O
+76 O
+, O
+and O
+20 O
+. O
+00 O
+hours O
++ O
+/ O
+- O
+0 O
+. O
+79 O
+, O
+respectively O
+, O
+for O
+endothelial O
+cell O
+- O
+induced O
+LDL B
+oxidation O
+. O
+
+Forty O
+- O
+eight O
+pregnant O
+adult O
+and O
+122 O
+fetal O
+guinea O
+pigs O
+were O
+sacrificed O
+at O
+intervals O
+throughout O
+gestation O
+and O
+the O
+carcasses O
+analyzed O
+for O
+a O
+variety O
+of O
+growth O
+parameters O
+. O
+
+Here O
+we O
+demonstrate O
+the O
+ability O
+of O
+oligonucleotides O
+containing O
+the O
+C4T O
+sequence O
+to O
+confer O
+heat O
+shock O
+inducibility O
+on O
+the O
+reporter O
+gene O
+and O
+show O
+that O
+the O
+presence O
+of O
+two O
+such O
+elements O
+produces O
+more O
+than O
+additive O
+effects O
+on O
+induction O
+. O
+
+The O
+HPV B
+E1 I
+and O
+E2 B
+proteins I
+along O
+with O
+cellular O
+factors O
+, O
+are O
+required O
+for O
+replication O
+of O
+the O
+viral O
+genome O
+. O
+
+The O
+observed O
+alterations O
+in O
+lung O
+functions O
+in O
+these O
+subjects O
+indicate O
+that O
+individuals O
+performing O
+heavy O
+continuous O
+exercise O
+are O
+more O
+likely O
+to O
+be O
+affected O
+by O
+lower O
+O3 O
+levels O
+. O
+
+In O
+ten O
+other O
+endotoxin O
+- O
+albumin B
+- O
+treated O
+pigs O
+PGE1 O
+infusion O
+( O
+0 O
+. O
+25 O
+micrograms O
+X O
+kg O
+- O
+1 O
+X O
+min O
+- O
+1 O
+) O
+was O
+begun O
+after O
+established O
+pulmonary O
+and O
+cardiovascular O
+dysfunction O
+, O
+for O
+closer O
+mimicking O
+of O
+clinical O
+use O
+. O
+
+The O
+main O
+new O
+features O
+of O
+this O
+version O
+are O
+that O
+end O
+- O
+tidal O
+PO2 O
+instead O
+of O
+inspiratory O
+PO2 O
+can O
+be O
+kept O
+constant O
+, O
+and O
+that O
+the O
+correcting O
+activity O
+of O
+both O
+controllers O
+( O
+capnostat O
+and O
+oxystat O
+) O
+is O
+proportional O
+to O
+the O
+magnitude O
+of O
+the O
+difference O
+between O
+the O
+actual O
+and O
+the O
+adjusted O
+end O
+- O
+tidal O
+PCO2 O
+or O
+PO2 O
+. O
+
+Like O
+the O
+human B
+erythrocyte I
+P4 I
+. I
+2 I
+, O
+mouse B
+erythrocyte I
+P4 I
+. I
+2 I
+contains O
+regions O
+strikingly O
+homologous O
+with O
+the O
+transglutaminase B
+( O
+TGase B
+) O
+proteins O
+although O
+it O
+too O
+most O
+likely O
+lacks O
+TGase B
+crosslinking O
+activity O
+. O
+
+It O
+spans O
+20 O
+kilobases O
+, O
+consists O
+of O
+7 O
+exons O
+and O
+6 O
+introns O
+, O
+and O
+contains O
+a O
+TATA O
+motif O
+24 O
+nucleotides O
+upstream O
+of O
+the O
+transcriptional O
+start O
+site O
+. O
+
+Nine O
+months O
+after O
+the O
+end O
+of O
+the O
+vaccination O
+anti B
+- I
+HBsAg I
+levels O
+had O
+dropped O
+to O
+9 O
++ O
+/ O
+- O
+4 O
+IU O
+/ O
+1 O
+( O
+M O
++ O
+/ O
+- O
+SE O
+) O
+, O
+with O
+a O
+geometric O
+mean O
+of O
+5 O
+IU O
+/ O
+1 O
+, O
+in O
+the O
+nine O
+remaining O
+evaluable O
+patients O
+. O
+
+CONCLUSION O
+: O
+Ultrasound O
+biomicroscopy O
+is O
+a O
+useful O
+tool O
+for O
+the O
+evaluation O
+of O
+APVR O
+, O
+which O
+is O
+difficult O
+by O
+ordinary O
+methods O
+. O
+
+It O
+is O
+postulated O
+that O
+the O
+synthesis O
+of O
+the O
+peptidoglycan O
+layer O
+was O
+affected O
+by O
+the O
+antimetabolites O
+since O
+the O
+morphological O
+effects O
+were O
+strikingly O
+similar O
+to O
+those O
+caused O
+by O
+treatment O
+of O
+E O
+. O
+cloacae O
+with O
+disodium O
+edetate O
+plus O
+lysozyme B
+. O
+
+DRAP27 B
+is O
+recognized O
+by O
+CD9 B
+antibodies I
+. O
+
+Furthermore O
+we O
+elucidate O
+the O
+subtle O
+highly O
+anisotropic O
+interchain O
+correlations O
+and O
+reveal O
+the O
+detailed O
+atomic O
+structure O
+of O
+the O
+low O
+- O
+temperature O
+( O
+8x2 O
+) O
+phase O
+. O
+
+Control O
+oligomers O
+of O
+scrambled O
+sequence O
+but O
+identical O
+base O
+composition O
+were O
+ineffective O
+, O
+and O
+no O
+TFO O
+- O
+induced O
+recombination O
+was O
+seen O
+in O
+a O
+control O
+LTK O
+( I
+- I
+) I
+cell O
+line O
+carrying O
+an O
+otherwise O
+identical O
+dual O
+TK B
+gene I
+construct I
+lacking O
+the O
+30 O
+- O
+bp O
+polypurine O
+target O
+site O
+. O
+
+To O
+quantify O
+the O
+normal O
+coupling O
+patterns O
+, O
+fresh O
+cadaveric O
+human O
+lumbar O
+spine O
+specimens O
+( O
+L1 O
+- O
+S1 O
+) O
+were O
+used O
+. O
+
+One O
+cytoplasmic O
+target O
+which O
+reflects O
+the O
+functional O
+state O
+of O
+the O
+plastids O
+is O
+protein B
+kinase I
+C I
+. O
+
+These O
+three O
+chromosomes O
+share O
+the O
+transferrin B
+gene I
+( O
+TF B
+) O
+, O
+the O
+myosin B
+light I
+polypeptide I
+3 I
+gene I
+( O
+MYL3 B
+) O
+, O
+and O
+the O
+acylpeptide B
+hydrolase I
+gene I
+( O
+APEH B
+) O
+. O
+
+( O
+i O
+) O
+Several O
+ribosomal O
+proteins O
+were O
+synthesized O
+in O
+substantial O
+excess O
+. O
+
+This O
+experience O
+would O
+recommend O
+consideration O
+of O
+home O
+nutritional O
+support O
+in O
+patients O
+with O
+systemic O
+scleroderma O
+when O
+the O
+disease O
+is O
+relatively O
+stable O
+and O
+no O
+major O
+organ O
+failure O
+is O
+present O
+. O
+
+Based O
+on O
+our O
+sequence O
+data O
+, O
+ORF2 O
+from O
+most O
+isolates O
+excluding O
+G1 O
+encode O
+truncated O
+49 O
+aa O
+( O
+pORF2a B
+) O
+because O
+of O
+an O
+in O
+- O
+frame O
+stop O
+codon O
+, O
+although O
+ORF2s O
+from O
+most O
+G1 O
+isolates O
+encode O
+202 O
+aa O
+( O
+pORF2ab B
+) O
+. O
+
+In O
+the O
+present O
+study O
+we O
+prospectively O
+compared O
+side O
+effects O
+occurring O
+in O
+12 O
+patients O
+after O
+the O
+first O
+administration O
+of O
+low O
+- O
+dose O
+OKT3 B
+( O
+0 O
+. O
+5 O
+mg O
+twice O
+daily O
+) O
+induction O
+therapy O
+with O
+those O
+in O
+10 O
+patients O
+who O
+were O
+treated O
+with O
+a O
+conventional O
+dose O
+of O
+OKT3 B
+( O
+5 O
+mg O
+daily O
+) O
+for O
+acute O
+rejection O
+. O
+
+These O
+data O
+indicate O
+that O
+SB O
+203580 O
+sensitive O
+p38 B
+MAP I
+kinases I
+are O
+not O
+involved O
+in O
+okadaic O
+acid O
+mediated O
+increases O
+in O
+TRE O
+DNA O
+binding O
+and O
+transactivation O
+. O
+
+Together O
+, O
+these O
+results O
+indicate O
+that O
+YTS1 B
+is O
+a O
+bifunctional O
+protein O
+active O
+in O
+both O
+splicing O
+and O
+protein O
+synthesis O
+. O
+
+Oscillatory O
+flow O
+is O
+reestablished O
+in O
+the O
+model O
+at O
+the O
+capillary O
+- O
+cerebrospinal O
+fluid O
+and O
+capillary O
+- O
+venous O
+interfaces O
+. O
+
+Sgs B
+- I
+4 I
+is O
+one O
+of O
+the O
+eight O
+known O
+genes O
+coding O
+for O
+larval O
+secretion I
+proteins O
+in O
+Drosophila O
+melanogaster O
+. O
+
+We O
+conclude O
+that O
+although O
+the O
+G3 O
+sequence O
+contains O
+two O
+protein O
+- O
+binding O
+motifs O
+, O
+the O
+organization O
+of O
+the O
+G3 B
+enhancer I
+- I
+like I
+element I
+is O
+not O
+bipartite O
+. O
+
+Human B
+myotonic I
+dystrophy I
+protein I
+kinase I
+( O
+DMPK B
+) O
+is O
+a O
+member O
+of O
+a O
+novel O
+class O
+of O
+multidomain O
+protein O
+kinases O
+that O
+regulate O
+cell O
+size O
+and O
+shape O
+in O
+a O
+variety O
+of O
+organisms O
+. O
+
+The O
+human B
+BRCA1 I
+promoter I
+also O
+contains O
+a O
+conserved O
+E2F B
+site I
+and O
+is O
+similarly O
+regulated O
+by O
+E2F1 B
+and O
+Rb B
+. O
+
+The O
+translated O
+sequence O
+of O
+the O
+FLI B
+LRR I
+associated I
+protein I
+( O
+FLAP B
+) O
+encodes O
+a O
+novel O
+protein O
+not O
+represented O
+in O
+the O
+data O
+base O
+. O
+
+Corticosteroid O
+treatment O
+before O
+, O
+during O
+, O
+or O
+after O
+fludarabine O
+treatment O
+in O
+patients O
+with O
+alkylator O
+- O
+resistant O
+, O
+low O
+- O
+grade O
+lymphoid O
+malignancies O
+who O
+have O
+not O
+received O
+PCP O
+prophylaxis O
+is O
+associated O
+with O
+an O
+increased O
+risk O
+of O
+opportunistic O
+pulmonary O
+infections O
+. O
+
+In O
+this O
+respect O
+, O
+the O
+promoter O
+structure O
+of O
+COX B
+genes I
+resemble O
+those O
+of O
+many O
+house O
+- O
+keeping O
+genes O
+. O
+
+In O
+vitro O
+, O
+cytokine O
+- O
+or O
+hypoxia O
+- O
+induced O
+up O
+- O
+regulation O
+of O
+Fas B
+expression O
+is O
+associated O
+with O
+RTC O
+apoptosis O
+. O
+
+The O
+site O
+of O
+acetylation O
+of O
+Tat B
+was O
+mapped O
+to O
+the O
+double O
+- O
+lysine O
+motif O
+in O
+a O
+highly O
+conserved O
+region O
+, O
+( O
+49 O
+) O
+RKKRRQ O
+( O
+54 O
+) O
+, O
+of O
+the O
+basic O
+RNA O
+- O
+binding O
+motif O
+of O
+Tat B
+. O
+
+These O
+results O
+suggest O
+that O
+the O
+PVB O
+therapy O
+is O
+not O
+sufficient O
+to O
+cure O
+the O
+cases O
+with O
+choriocarcinoma O
+element O
+or O
+bulky O
+metastasis O
+. O
+
+The O
+KEMAR O
+measurements O
+show O
+that O
+the O
+two O
+models O
+give O
+an O
+improvement O
+of O
+the O
+signal O
+- O
+to O
+- O
+noise O
+ratio O
+of O
+approximately O
+7 O
+. O
+5 O
+dB O
+in O
+a O
+diffuse O
+sound O
+field O
+. O
+
+Indirect O
+determination O
+of O
+maximal O
+O2 O
+consumption O
+in O
+man O
+. O
+
+Using O
+unidirectional O
+PCR O
+we O
+isolated O
+a O
+361 O
+- O
+bp O
+5 O
+' O
+promoter O
+region O
+and O
+delineated O
+the O
+intronic O
+/ O
+exonic O
+boundaries O
+which O
+include O
+a O
+non O
+- O
+coding O
+exon O
+1 O
+, O
+a O
+single O
+intron O
+, O
+and O
+a O
+coding O
+exon O
+2 O
+, O
+a O
+structure O
+that O
+is O
+typical O
+of O
+genes O
+of O
+the O
+RNase B
+A I
+superfamily I
+. O
+
+When O
+severe O
+hypoxia O
+was O
+acutely O
+produced O
+by O
+ventilation O
+with O
+low O
+- O
+oxygen O
+mixtures O
+in O
+experimental O
+( O
+PaO2 O
+, O
+23 O
+. O
+7 O
++ O
+/ O
+- O
+1 O
+. O
+7 O
+torr O
+) O
+and O
+control O
+animals O
+( O
+PaO2 O
+, O
+26 O
+. O
+3 O
++ O
+/ O
+- O
+1 O
+. O
+0 O
+torr O
+) O
+, O
+plasma B
+insulin I
+responses O
+were O
+markedly O
+inhibited O
+in O
+both O
+. O
+
+Uptake O
+of O
+colicins O
+required O
+different O
+domains O
+in O
+TonB B
+, O
+for O
+colicin B
+B I
+and O
+M O
+around O
+residue O
+160 O
+and O
+for O
+colicin B
+Ia I
+, O
+a O
+domain O
+closer O
+to O
+the O
+C O
+- O
+terminal O
+end O
+. O
+
+D O
+. O
+
+When O
+lipid O
+X O
+was O
+combined O
+with O
+ticarcillin O
+, O
+survival O
+differences O
+were O
+both O
+significant O
+and O
+prolonged O
+. O
+
+Central O
+treatment O
+unit O
+saves O
+nurses O
+, O
+adds O
+income O
+, O
+improves O
+care O
+. O
+
+Gold O
+flaxseed O
+( O
+whole O
+or O
+ground O
+) O
+fed O
+at O
+levels O
+of O
+5 O
+or O
+15 O
+% O
+were O
+compared O
+to O
+a O
+1 O
+. O
+5 O
+% O
+menhaden O
+oil O
+or O
+a O
+typical O
+control O
+layer O
+ration O
+. O
+
+It O
+is O
+dangerous O
+to O
+label O
+such O
+conditions O
+as O
+' O
+inappropriate O
+' O
+secretion O
+of O
+ADH B
+since O
+the O
+maintenance O
+of O
+circulating O
+volume O
+is O
+at O
+least O
+as O
+important O
+a O
+physiological O
+requirement O
+as O
+the O
+defence O
+of O
+tonicity O
+. O
+
+The O
+complete O
+nucleotide O
+sequence O
+of O
+odontoglossum O
+ringspot O
+virus O
+( O
+Cy O
+- O
+1 O
+strain O
+) O
+genomic O
+RNA O
+. O
+
+An O
+enhancement O
+of O
+benign O
+liver O
+tumors O
+( O
+tumorigenic O
+effect O
+) O
+was O
+observed O
+only O
+in O
+CF1 O
+male O
+mice O
+( O
+17 O
+/ O
+56 O
+at O
+the O
+only O
+tested O
+dose O
+: O
+400 O
+ppm O
+vs O
+. O
+
+Cells O
+were O
+cotransfected O
+with O
+this O
+plasmid O
+, O
+and O
+the O
+appropriate O
+responder O
+plasmids O
+and O
+clonies O
+were O
+selected O
+on O
+the O
+basis O
+of O
+their O
+resistance O
+to O
+Geneticin B
+( O
+via O
+the O
+neomycin B
+aminoglycoside I
+phosphotransferase I
+gene I
+) O
+. O
+
+This O
+C O
+- O
+terminal O
+domain O
+contains O
+several O
+YxxI O
+/ O
+L O
+motifs O
+reminiscent O
+of O
+LMP2A B
+and O
+a O
+putative O
+TRAF B
+binding I
+site I
+as O
+in O
+LMP1 B
+. O
+
+Omitting O
+part O
+of O
+the O
+experimental O
+NOE O
+- O
+derived O
+distances O
+results O
+in O
+reduced O
+restraint O
+violations O
+and O
+lower O
+R O
+factors O
+but O
+impairs O
+structural O
+convergence O
+in O
+the O
+rMD O
+refinement O
+. O
+
+Cardiac O
+lesion O
+in O
+exotoxic O
+shock O
+
+Risk O
+factors O
+for O
+atherosclerosis O
+related O
+to O
+nutrition O
+are O
+hypercholesterolemia O
+, O
+hyperglycemia O
+- O
+diabetes O
+, O
+and O
+for O
+hypertension O
+, O
+obesity O
+, O
+high O
+salt O
+intake O
+, O
+and O
+excessive O
+use O
+of O
+alcohol O
+. O
+
+This O
+mutation O
+was O
+associated O
+with O
+reduced O
+or O
+absent O
+expression O
+of O
+TGF B
+- I
+beta I
+RI I
+protein I
+and O
+p53 B
+protein I
+in O
+tumor O
+tissues O
+. O
+
+SCAN O
+boxes O
+are O
+found O
+in O
+eight O
+other O
+genes O
+in O
+the O
+GenBank O
+database O
+, O
+five O
+of O
+which O
+are O
+also O
+in O
+the O
+Kruppel B
+family I
+of O
+zinc B
+finger I
+proteins I
+lacking O
+KRAB B
+A I
+and I
+B I
+domains I
+and O
+thereby O
+define O
+a O
+new O
+subclass O
+of O
+zinc B
+finger I
+proteins I
+. O
+
+However O
+, O
+they O
+had O
+no O
+cross O
+- O
+resistance O
+to O
+quinolone O
+, O
+josamycin O
+and O
+tylosin O
+. O
+
+Seventy O
+- O
+nine O
+percent O
+of O
+the O
+children O
+screened O
+and O
+91 O
+. O
+0 O
+% O
+of O
+the O
+children O
+with O
+PbB O
+at O
+least O
+10 O
+micrograms O
+/ O
+dL O
+were O
+Hispanic O
+. O
+
+Normal O
+dogs O
+were O
+exposed O
+to O
+either O
+10 O
+, O
+15 O
+, O
+or O
+30 O
+Gy O
+of O
+X O
+rays O
+to O
+a O
+single O
+hemisphere O
+and O
+the O
+gross O
+and O
+histopathologic O
+changes O
+were O
+evaluated O
+qualitatively O
+. O
+
+YACs O
+selected O
+from O
+our O
+contig O
+will O
+be O
+the O
+starting O
+point O
+for O
+the O
+cloning O
+of O
+the O
+LGMD2B B
+gene I
+and O
+thereby O
+establish O
+the O
+biological O
+basis O
+for O
+this O
+form O
+of O
+muscular O
+dystrophy O
+and O
+its O
+relationship O
+with O
+the O
+other O
+limb O
+- O
+girdle O
+muscular O
+dystrophies O
+. O
+
+The O
+amount O
+of O
+ERCC1 B
+detectable O
+by O
+immunoblotting O
+is O
+reduced O
+in O
+group O
+1 O
+, O
+group O
+4 O
+and O
+XP B
+- I
+F I
+extracts O
+. O
+
+In O
+the O
+plant O
+malate B
+synthases I
+, O
+the O
+extension O
+is O
+probably O
+involved O
+in O
+routing O
+to O
+the O
+microbodies O
+, O
+since O
+it O
+contains O
+the O
+potential O
+peroxisomal O
+targeting O
+signal O
+, O
+Ser O
+- O
+Arg O
+/ O
+Lys O
+- O
+Leu O
+, O
+at O
+the O
+carboxy O
+terminus O
+. O
+
+Optimized O
+USF B
+and O
+MYC B
+DNA I
+- I
+binding I
+sites I
+, O
+which O
+differ O
+in O
+the O
+nucleotides O
+bordering O
+the O
+hexanucleotide O
+box O
+displace O
+the O
+E B
+- I
+C4 I
+factor I
+in O
+competition O
+assays O
+but O
+with O
+lesser O
+efficiency O
+than O
+the O
+E B
+- I
+C4 I
+site I
+itself O
+. O
+
+Screening O
+of O
+human O
+cDNA O
+libraries O
+has O
+identified O
+two O
+different O
+5 O
+' O
+- O
+termini O
+and O
+alternatively O
+spliced O
+forms O
+of O
+the O
+human B
+Fli I
+- I
+1 I
+gene I
+( O
+Fli B
+- I
+1b I
+) O
+, O
+suggesting O
+the O
+possible O
+existence O
+of O
+two O
+independent O
+promoters O
+. O
+
+A O
+surge O
+in O
+the O
+rate O
+of O
+ascorbyl O
+radical O
+production O
+, O
+directly O
+correlated O
+with O
+oxyradical O
+stress O
+and O
+an O
+abrupt O
+fall O
+in O
+superoxide B
+dismutase I
+activity O
+in O
+the O
+granuloma O
+, O
+indicates O
+' O
+switching O
+on O
+' O
+of O
+a O
+free O
+radical O
+- O
+dependent O
+machinery O
+for O
+the O
+formation O
+of O
+granuloma O
+after O
+vasectomy O
+. O
+
+After O
+5 O
+- O
+h O
+thermal O
+induction O
+of O
+cells O
+carrying O
+the O
+runaway O
+recombinant O
+pBS1 B
+, O
+protein B
+B2 I
+constituted O
+40 O
+% O
+of O
+the O
+soluble O
+protein O
+fraction O
+of O
+the O
+cells O
+. O
+
+A O
+regulatory O
+element O
+of O
+the O
+empty B
+spiracles I
+homeobox I
+gene I
+is O
+composed O
+of O
+three O
+distinct O
+conserved O
+regions O
+that O
+bind O
+regulatory O
+proteins O
+. O
+
+Peak O
+reactive O
+hyperemia O
+( O
+mL O
+. O
+min O
+- O
+1 O
+. O
+100 O
+mL O
+- O
+1 O
+) O
+was O
+determined O
+in O
+the O
+calf O
+and O
+forearm O
+immediately O
+before O
+and O
+after O
+12 O
+weeks O
+of O
+training O
+. O
+
+These O
+characteristics O
+add O
+to O
+the O
+suitability O
+of O
+NM441 O
+as O
+an O
+effective O
+prodrug O
+of O
+NM394 O
+. O
+
+Vorozole O
+( O
+Rivizor O
+) O
+is O
+a O
+potent O
+and O
+stereospecific O
+inhibitor O
+of O
+aromatase B
+having O
+shown O
+promising O
+endocrine O
+effects O
+in O
+phase O
+I O
+studies O
+. O
+
+In O
+5 O
+cases O
+, O
+combined O
+sensitization O
+to O
+mercury O
+and O
+other O
+metal O
+salts O
+, O
+particularly O
+gold O
+sodium O
+thiosulfate O
+( O
+GST O
+) O
+and O
+palladium O
+chloride O
+( O
+PDC O
+) O
+, O
+was O
+observed O
+. O
+
+Gene O
+structure O
+and O
+precursor O
+processing O
+. O
+
+The O
+content O
+of O
+monoamine O
+metabolites O
+, O
+5 O
+- O
+hydroxyindoleacetic O
+acid O
+, O
+5 O
+- O
+HIAA O
+, O
+and O
+homovanillic O
+acid O
+( O
+HVA O
+) O
+, O
+and O
+- O
+- O
+for O
+17 O
+patients O
+- O
+- O
+tryptophan O
+, O
+in O
+the O
+cerebrospinal O
+fluid O
+was O
+determined O
+. O
+
+One O
+month O
+after O
+administration O
+of O
+131I O
+, O
+the O
+29 O
+cats O
+evaluated O
+were O
+clinically O
+improved O
+, O
+and O
+24 O
+( O
+83 O
+% O
+) O
+of O
+the O
+29 O
+cats O
+evaluated O
+had O
+normal O
+serum O
+T4 O
+concentrations O
+, O
+3 O
+cats O
+( O
+10 O
+% O
+) O
+remained O
+hyperthyroxinemic O
+, O
+and O
+2 O
+cats O
+( O
+7 O
+% O
+) O
+were O
+hypothyroxinemic O
+. O
+
+These O
+findings O
+suggest O
+that O
+T3R B
+can O
+repress O
+or O
+activate O
+transcription O
+while O
+tethered O
+to O
+the O
+LBD B
+of O
+GAL4 B
+- O
+RXR B
+and O
+that O
+heterodimerization O
+can O
+occur O
+in O
+vivo O
+without O
+stabilization O
+by O
+hormone O
+response O
+elements O
+. O
+
+Most O
+interestingly O
+, O
+although O
+the O
+effector O
+plasmid O
+containing O
+the O
+ICP27 B
+gene I
+had O
+little O
+effect O
+on O
+its O
+own O
+, O
+two O
+different O
+and O
+marked O
+effects O
+depending O
+on O
+the O
+target O
+were O
+observed O
+when O
+ICP27 B
+was O
+combined O
+with O
+ICP4 B
+or O
+ICP0 B
+or O
+both O
+. O
+
+In O
+renal O
+vein O
+thrombosis O
+, O
+similar O
+pattern O
+to O
+acute O
+tubular O
+necrosis O
+was O
+found O
+but O
+RI O
+venography O
+was O
+helpful O
+. O
+
+TOM1 B
+encodes O
+a O
+member O
+of O
+the O
+hect B
+- O
+domain O
+- O
+containing O
+E3 B
+ubiquitin B
+- O
+protein I
+ligase I
+family O
+that O
+is O
+required O
+for O
+growth O
+at O
+elevated O
+temperatures O
+. O
+
+Genomic O
+clones O
+containing O
+the O
+C O
+. O
+briggsae O
+gene O
+are O
+able O
+to O
+completely O
+rescue O
+the O
+unc B
+- I
+119 I
+phenotype O
+in O
+transgenic O
+C O
+. O
+elegans O
+mutants O
+. O
+
+The O
+rapid O
+decrease O
+of O
+plasma O
+potassium O
+during O
+the O
+first O
+two O
+hours O
+of O
+standard O
+HD O
+causes O
+a O
+membrane O
+hyperpolarization O
+. O
+
+Region O
+- O
+specific O
+enhancers O
+near O
+two O
+mammalian B
+homeo I
+box I
+genes I
+define O
+adjacent O
+rostrocaudal O
+domains O
+in O
+the O
+central O
+nervous O
+system O
+. O
+
+In O
+this O
+study O
+, O
+we O
+report O
+the O
+cloning O
+and O
+sequencing O
+of O
+several O
+overlapping O
+cDNAs O
+encoding O
+approximately O
+4 O
+. O
+1 O
+kb O
+of O
+the O
+human B
+homologue I
+of I
+Wnt I
+- I
+5A I
+. O
+
+Subtype O
+- O
+and O
+response O
+element O
+- O
+dependent O
+differences O
+in O
+transactivation O
+by O
+peroxisome B
+proliferator I
+- I
+activated I
+receptors I
+alpha I
+and I
+gamma I
+. O
+
+MRI O
+visualization O
+of O
+proteoglycan O
+depletion O
+in O
+articular O
+cartilage O
+via O
+intravenous O
+administration O
+of O
+Gd O
+- O
+DTPA O
+. O
+
+We O
+then O
+developed O
+a O
+yeast O
+artificial O
+chromosome O
+( O
+YAC O
+) O
+contig O
+for O
+this O
+region O
+. O
+
+We O
+suggest O
+that O
+the O
+induction O
+of O
+IFNA B
+promoter I
+region I
+requires O
+cooperation O
+between O
+alpha B
+F1 I
+binding I
+proteins I
+and O
+IRF B
+- I
+1 I
+. O
+
+Heterologous O
+hybridization O
+with O
+a O
+rps12 B
+gene I
+specific O
+probe O
+from O
+Euglena O
+has O
+revealed O
+the O
+presence O
+of O
+rps12 B
+homologous I
+sequences I
+within O
+the O
+inverted O
+repeat O
+of O
+Spirodela O
+chloroplast O
+DNA O
+on O
+the O
+fragment O
+BamHI B
+- I
+V I
+. O
+
+To O
+investigate O
+the O
+effect O
+of O
+hyperthyroidism O
+on O
+the O
+pattern O
+and O
+time O
+course O
+of O
+O2 O
+uptake O
+( O
+VO2 O
+) O
+following O
+the O
+transition O
+from O
+rest O
+to O
+exercise O
+, O
+six O
+patients O
+and O
+six O
+healthy O
+subjects O
+performed O
+cycle O
+exercise O
+at O
+an O
+average O
+work O
+rate O
+( O
+WR O
+) O
+of O
+18 O
+and O
+20 O
+W O
+respectively O
+. O
+
+However O
+, O
+to O
+date O
+, O
+no O
+viable O
+in O
+vitro O
+- O
+generated O
+deletion O
+mutant O
+of O
+PSTVd O
+has O
+been O
+reported O
+. O
+
+This O
+raises O
+the O
+possibility O
+that O
+recombination O
+occurred O
+between O
+corresponding O
+LTR B
+and O
+vif B
+loci I
+of O
+the O
+quasi O
+- O
+species O
+present O
+in O
+the O
+isolates O
+described O
+here O
+. O
+
+In O
+HMEC O
+stably O
+transfected O
+with O
+an O
+ER B
+mutant I
+containing O
+a O
+deletion O
+in O
+the O
+second O
+zinc O
+finger O
+of O
+the O
+DNA O
+- O
+binding O
+domain O
+, O
+E B
+and O
+HT B
+had O
+different O
+effects O
+on O
+EBBP B
+gene I
+expression O
+; O
+EBBP B
+regulation O
+by O
+E B
+was O
+dramatically O
+reduced O
+while O
+the O
+effects O
+of O
+HT B
+were O
+augmented O
+. O
+
+The O
+gene B
+atp6 I
+, O
+encoding O
+subunit O
+6 O
+of O
+the O
+mitochondrial B
+F0 I
+- I
+ATPase I
+complex I
+, O
+has O
+been O
+characterized O
+from O
+both O
+the O
+normal O
+( O
+fertile O
+) O
+and O
+Ogura O
+( O
+male O
+- O
+sterile O
+) O
+radish O
+cytoplasms O
+in O
+order O
+to O
+determine O
+if O
+previously O
+identified O
+atp6 B
+transcriptional O
+differences O
+could O
+play O
+a O
+role O
+in O
+cytoplasmic O
+male O
+sterility O
+. O
+
+When O
+the O
+same O
+single O
+- O
+amino O
+- O
+acid O
+mutations O
+were O
+directly O
+introduced O
+into O
+the O
+parental O
+PV O
+/ O
+CBV4 O
+- O
+2A O
+genome O
+, O
+chimeric O
+viruses O
+with O
+a O
+large O
+- O
+plaque O
+phenotype O
+and O
+a O
+wild O
+- O
+type O
+PV O
+- O
+like O
+growth O
+pattern O
+were O
+obtained O
+upon O
+transfection O
+, O
+an O
+observation O
+demonstrating O
+that O
+these O
+point O
+mutations O
+alone O
+had O
+a O
+drastic O
+effect O
+on O
+the O
+growth O
+of O
+the O
+PV O
+/ O
+CBV4 O
+chimeric O
+virus O
+. O
+
+The O
+gag B
+- O
+myc B
+proteins O
+encoded O
+by O
+these O
+variants O
+efficiently O
+localized O
+to O
+the O
+cell O
+nucleus O
+. O
+
+Hpr1 B
+forms O
+, O
+together O
+with O
+Tho2 B
+, O
+Mft1 B
+, O
+and O
+Thp2 B
+, O
+the O
+THO B
+complex I
+, O
+which O
+controls O
+transcription O
+elongation O
+and O
+genome O
+stability O
+in O
+Saccharomyces O
+cerevisiae O
+. O
+
+UPR O
+elements O
+present O
+in O
+other O
+ER B
+chaperone I
+genes I
+, O
+such O
+as O
+yeast B
+KAR2 I
+( O
+BiP B
+) O
+, O
+mammalian B
+GRP78 I
+( O
+BiP B
+) O
+, O
+and O
+GRP94 B
+, O
+function O
+in O
+an O
+analogous O
+manner O
+to O
+that O
+in O
+FKB2 B
+. O
+
+The O
+objective O
+of O
+this O
+research O
+was O
+to O
+determine O
+if O
+ergotamine O
+, O
+an O
+ergopeptine O
+alkaloid O
+isolated O
+from O
+Neotyphodium O
+- O
+infected O
+grasses O
+and O
+associated O
+with O
+toxicoses O
+in O
+livestock O
+, O
+altered O
+plasma O
+concentrations O
+of O
+reproductive O
+hormones O
+in O
+follicular O
+phase O
+heifers O
+and O
+in O
+cows O
+given O
+a O
+progestin O
+implant O
+. O
+
+Acute O
+spontaneous O
+subdural O
+haematoma O
+. O
+
+Strains O
+carrying O
+a O
+snf1 B
+mutation I
+are O
+unable O
+to O
+grow O
+on O
+sucrose O
+, O
+galactose O
+, O
+maltose O
+, O
+melibiose O
+, O
+or O
+nonfermentable O
+carbon O
+sources O
+; O
+utilization O
+of O
+these O
+carbon O
+sources O
+is O
+regulated O
+by O
+glucose O
+repression O
+. O
+
+2 O
+) O
+Depending O
+on O
+the O
+structure O
+, O
+certain O
+compounds O
+are O
+sequestered O
+in O
+the O
+cornea O
+( O
+presumably O
+the O
+stroma O
+) O
+and O
+form O
+a O
+release O
+system O
+into O
+the O
+anterior O
+aqueous O
+. O
+
+The O
+results O
+of O
+the O
+neural O
+network O
+were O
+compared O
+with O
+those O
+of O
+a O
+density O
+mask O
+( O
+thresholds O
+, O
+- O
+750 O
+/ O
+- O
+300 O
+H O
+) O
+, O
+with O
+a O
+radiologist O
+serving O
+as O
+the O
+gold O
+standard O
+. O
+
+These O
+data O
+also O
+suggest O
+the O
+existence O
+of O
+a O
+mechanism O
+by O
+which O
+regulatory O
+subunits O
+modulate O
+the O
+PI B
+3 I
+- I
+kinase I
+- O
+mediated O
+signals O
+, O
+independent O
+of O
+the O
+kinase O
+activity O
+, O
+possibly O
+through O
+subcellular O
+localization O
+of O
+the O
+catalytic O
+subunit O
+or O
+interaction O
+with O
+additional O
+signaling O
+molecules O
+. O
+
+These O
+results O
+suggest O
+that O
+the O
+PVB O
+therapy O
+is O
+not O
+sufficient O
+to O
+cure O
+the O
+cases O
+with O
+choriocarcinoma O
+element O
+or O
+bulky O
+metastasis O
+. O
+
+Right O
+- O
+sided O
+hemiplegia O
+of O
+5 O
+years O
+duration O
+occurred O
+in O
+the O
+remaining O
+case O
+. O
+
+Plasmid O
+subclones O
+of O
+the O
+hr1a B
+- O
+containing O
+AcMNPV B
+HindIII I
+- I
+N I
+fragment I
+were O
+examined O
+for O
+their O
+ability O
+to O
+replicate O
+in O
+virus O
+- O
+infected O
+( O
+Spodoptera O
+frugiperda O
+) O
+Sf9 O
+cells O
+, O
+and O
+to O
+stimulate O
+transcription O
+when O
+linked O
+in O
+cis O
+with O
+a O
+39K B
+gene I
+promoter I
+- O
+beta B
+- I
+glucuronidase I
+fusion O
+and O
+cotransfected O
+into O
+cells O
+along O
+with O
+a O
+plasmid O
+( O
+ple O
+- O
+1 O
+) O
+containing O
+the O
+gene O
+encoding O
+the O
+trans O
+- O
+acting O
+factor O
+IE B
+- I
+1 I
+. O
+
+Transfection O
+of O
+H B
+chain I
+loss O
+variant O
+myeloma O
+with O
+the O
+complete O
+12 O
+kb O
+construct O
+, O
+termed O
+238H B
+- I
+Cmicro I
+, O
+resulted O
+in O
+secretion O
+of O
+intact O
+Ig B
+pairing O
+238H B
+- I
+Cmicro I
+, O
+with O
+a B
+lambda B
+L I
+chain I
+; O
+however O
+, O
+transfectant O
+Ig B
+lacked O
+autoreactivity O
+and O
+pathogenicity O
+. O
+
+Divergent O
+regions O
+of O
+the O
+posterior O
+left O
+hemisphere O
+used O
+for O
+decoding O
+and O
+storage O
+of O
+information O
+emerged O
+in O
+each O
+working O
+memory O
+versus O
+control O
+task O
+comparison O
+. O
+
+In O
+normal O
+B O
+cells O
+stimulated O
+by O
+LPS O
+or O
+IL B
+- I
+4 I
+, O
+new O
+complexes O
+appear O
+that O
+bind O
+to O
+C B
+/ I
+EBP I
+and O
+NF B
+- I
+IL I
+- I
+4 I
+elements I
+, O
+respectively O
+, O
+located O
+within O
+the O
+- O
+125 O
+/ O
+- O
+101 O
+region O
+. O
+
+Here O
+, O
+we O
+describe O
+the O
+crystal O
+structure O
+at O
+2 O
+. O
+5 O
+A O
+resolution O
+of O
+a O
+fragment O
+of O
+the O
+integrase B
+of I
+Rous I
+sarcoma I
+virus I
+( O
+residues O
+49 O
+- O
+286 O
+) O
+containing O
+both O
+the O
+conserved O
+catalytic O
+domain O
+and O
+a O
+modulatory O
+DNA O
+- O
+binding O
+domain O
+( O
+C O
+domain O
+) O
+. O
+
+Vectorcardiography O
+in O
+coronary O
+patients O
+with O
+the O
+electrocardiographic O
+RS O
+segment O
+in O
+the O
+V1 O
+lead O
+
+The O
+B O
+. O
+aphidicola O
+argS B
+- O
+rrn B
+DNA O
+fragments O
+from O
+endosymbionts O
+from O
+seven O
+species O
+of O
+aphids O
+had O
+promoter O
+activities O
+in O
+E O
+. O
+coli O
+which O
+ranged O
+from O
+6 O
+to O
+135 O
+% O
+of O
+that O
+observed O
+with O
+a O
+comparable O
+DNA O
+fragment O
+of O
+E B
+. I
+coli I
+rrnB I
+. O
+
+The O
+adeno B
+- I
+associated I
+virus I
+type I
+2 I
+( I
+AAV I
+- I
+2 I
+) I
+Rep78 I
+/ O
+Rep68 B
+regulatory O
+proteins O
+are O
+pleiotropic O
+effectors O
+of O
+viral O
+and O
+cellular O
+DNA O
+replication O
+, O
+of O
+cellular O
+transformation O
+by O
+viral O
+and O
+cellular O
+oncogenes O
+, O
+and O
+of O
+homologous O
+and O
+heterologous O
+gene O
+expression O
+. O
+
+Role O
+of O
+the O
+CCAAT B
+/ I
+enhancer I
+binding I
+protein I
+- I
+alpha I
+transcription I
+factor I
+in O
+the O
+glucocorticoid O
+stimulation O
+of O
+p21waf1 B
+/ O
+cip1 B
+gene O
+promoter O
+activity O
+in O
+growth O
+- O
+arrested O
+rat O
+hepatoma O
+cells O
+. O
+
+Long O
+- O
+term O
+ambulatory O
+measurement O
+of O
+transcutaneous O
+arterial O
+CO2 O
+pressure O
+( O
+PCO2 O
+) O
+offers O
+an O
+opportunity O
+to O
+test O
+directly O
+the O
+co O
+- O
+occurrence O
+of O
+panic O
+and O
+hyperventilation O
+under O
+natural O
+conditions O
+. O
+
+The O
+highly O
+conserved O
+region O
+of O
+U6 B
+snRNA I
+has O
+a O
+structural O
+similarity O
+with O
+the O
+catalytic O
+domain O
+of O
+the O
+negative O
+strand O
+of O
+the O
+satellite O
+RNA O
+of O
+tobacco O
+ring O
+spot O
+virus O
+[ O
+( O
+- O
+) O
+sTRSV O
+] O
+, O
+suggesting O
+that O
+the O
+highly O
+conserved O
+region O
+of O
+U6 B
+snRNA I
+forms O
+the O
+catalytic O
+center O
+. O
+
+Here O
+we O
+show O
+that O
+one O
+nudF B
+suppressor I
+also O
+suppresses O
+hs O
+- O
+mutations O
+in O
+nudA B
+, O
+nudC B
+, O
+and O
+nudG B
+and O
+deletions O
+in O
+nudA B
+and O
+nudF B
+. O
+
+Treatment O
+of O
+cells O
+for O
+10 O
+min O
+with O
+TNF B
+- I
+alpha I
+resulted O
+in O
+activation O
+of O
+p44 B
+/ I
+42 I
+MAPK I
+, O
+p38 B
+, O
+and O
+JNK B
+. O
+
+This O
+report O
+describes O
+the O
+isolation O
+and O
+recombinant O
+expression O
+of O
+a O
+cDNA O
+clone O
+encoding O
+HER4 B
+, O
+the O
+fourth O
+member O
+of O
+the O
+human B
+epidermal I
+growth I
+factor I
+receptor I
+( O
+EGFR B
+) O
+family O
+. O
+
+In O
+conclusion O
+, O
+when O
+pulmonary O
+abnormalities O
+are O
+found O
+in O
+HTLV O
+- O
+1 O
+carriers O
+, O
+we O
+should O
+be O
+careful O
+in O
+determining O
+whether O
+such O
+pulmonary O
+involvements O
+are O
+etiologically O
+related O
+to O
+HTLV O
+- O
+1 O
+infection O
+. O
+
+A O
+clinical O
+trial O
+of O
+a O
+new O
+mitomycin O
+C O
+derivative O
+, O
+KW O
+- O
+2083 O
+( O
+7 O
+- O
+N O
+- O
+( O
+p O
+- O
+hydroxyphenyl O
+) O
+- O
+mitomycin O
+C O
+) O
+
+Excess O
+recombinant B
+PTB I
+squelches O
+the O
+splicing O
+switch O
+and O
+reestablishes O
+exon O
+skipping O
+as O
+the O
+predominant O
+splicing O
+pathway O
+. O
+
+A O
+child O
+presumed O
+to O
+have O
+the O
+21 B
+- I
+hydroxylase I
+deficiency O
+form O
+of O
+congenital O
+adrenal O
+hyperplasia O
+was O
+studied O
+extensively O
+as O
+an O
+infant O
+. O
+
+Sixtieth O
+anniversary O
+of O
+Angiotensin B
+. O
+
+Inability O
+of O
+niacin O
+to O
+protect O
+from O
+in O
+vivo O
+hyperoxia O
+or O
+in O
+vitro O
+microsomal O
+lipid O
+peroxidation O
+. O
+
+MDA O
+- O
+MB O
+- O
+468 O
+cells O
+were O
+stably O
+transfected O
+with O
+either O
+a O
+plasmid O
+having O
+a O
+CMV O
+promoter O
+- O
+driven O
+rabbit B
+beta I
+- I
+globin I
+gene I
+or O
+plasmids O
+having O
+a O
+CMV O
+promoter O
+- O
+driven O
+chimeric O
+gadd45 B
+5 I
+" I
+- I
+UTR I
+- O
+rabbit B
+beta I
+- I
+globin I
+gene O
+, O
+where O
+the O
+entire O
+gadd45 B
+5 I
+" I
+- I
+UTR I
+( O
+from O
++ O
+1 O
+to O
++ O
+298 O
+) O
+or O
+a O
+45 O
+bp O
+subfragment O
+of O
+the O
+gadd45 B
+5 I
+" I
+- I
+UTR I
+( O
+from O
++ O
+10 O
+to O
++ O
+55 O
+) O
+was O
+positioned O
+at O
+the O
+5 O
+" O
+- O
+end O
+of O
+
+the O
+rabbit B
+beta I
+- I
+globin I
+gene I
+. O
+
+The O
+University O
+of O
+North O
+Carolina O
+caries O
+risk O
+assessment O
+was O
+conducted O
+between O
+1986 O
+and O
+1989 O
+with O
+5000 O
+children O
+initially O
+in O
+grades O
+1 O
+and O
+5 O
+from O
+low O
+fluoride O
+sites O
+in O
+South O
+Carolina O
+and O
+Maine O
+. O
+
+Following O
+EGF B
+or O
+NGF B
+stimulation O
+of O
+the O
+v B
+- I
+CrkPC12 I
+cells O
+, O
+the O
+v B
+- I
+Crk I
+protein I
+itself O
+became O
+tyrosine O
+phosphorylated O
+within O
+1 O
+min O
+. O
+
+BCR B
+- O
+ABL B
+expression O
+confers O
+cross O
+- O
+resistance O
+to O
+multiple O
+genotoxic O
+anticancer O
+drugs O
+by O
+inhibition O
+of O
+the O
+apoptotic O
+response O
+to O
+DNA O
+damage O
+in O
+association O
+with O
+cell O
+cycle O
+arrest O
+at O
+the O
+G2 O
+- O
+M O
+restriction O
+point O
+. O
+
+RESULTS O
+: O
+After O
+lavage O
+, O
+a O
+rapid O
+decrease O
+in O
+arterial O
+pH O
+and O
+PaO2 O
+, O
+and O
+an O
+increase O
+in O
+PaCO2 O
+and O
+PIP O
+were O
+observed O
+in O
+all O
+animals O
+. O
+
+CONCLUSIONS O
+: O
+Elevation O
+of O
+TBARS O
+and O
+decrease O
+of O
+GSH O
+show O
+the O
+presence O
+of O
+oxidative O
+stress O
+during O
+the O
+PFD O
+treatment O
+with O
+hemodiafilter O
+SG3 O
+. O
+
+Ozone O
+uptake O
+was O
+assessed O
+in O
+awake O
+, O
+spontaneously O
+breathing O
+Fischer O
+- O
+344 O
+Sprague O
+- O
+Dawley O
+, O
+and O
+Long O
+- O
+Evans O
+rats O
+and O
+Hartley O
+guinea O
+pigs O
+to O
+provide O
+data O
+on O
+the O
+dosimetry O
+of O
+O3 O
+in O
+small O
+laboratory O
+animals O
+. O
+
+E O
+. O
+R O
+. O
+C O
+. O
+P O
+. O
+
+is O
+an O
+important O
+advance O
+in O
+diagnosis O
+. O
+
+Deletion O
+analysis O
+of O
+the O
+3 O
+. O
+5kb O
+DNA O
+fragment O
+revealed O
+that O
+the O
+region O
+between O
+- O
+125 O
+to O
++ O
+1 O
+, O
+containing O
+a O
+single O
+Sp1 B
+binding I
+site I
+, O
+is O
+essential O
+for O
+transcription O
+of O
+the O
+embigin B
+gene I
+. O
+
+Resistance O
+to O
+Mup O
+was O
+classified O
+as O
+low O
+( O
+minimal O
+inhibitory O
+concentration O
+[ O
+MIC O
+] O
+> O
+or O
+= O
+8 O
+microg O
+/ O
+mL O
+) O
+or O
+high O
+( O
+MIC O
+> O
+or O
+= O
+512 O
+microg O
+/ O
+mL O
+) O
+degree O
+. O
+
+Extragonadal O
+endodermal O
+sinus O
+tumors O
+in O
+the O
+head O
+and O
+neck O
+are O
+very O
+rare O
+. O
+
+Lesions O
+of O
+this O
+kind O
+resemble O
+those O
+in O
+vitamin O
+A O
+- O
+deficient O
+chickens O
+and O
+are O
+the O
+first O
+to O
+be O
+induced O
+by O
+excess O
+vitamin O
+E O
+. O
+
+Essential O
+fatty O
+acid O
+deficiency O
+in O
+childhood O
+
+The O
+protein B
+kinase I
+C I
+inhibitor O
+GF O
+- O
+109203X O
+abolished O
+the O
+activation O
+by O
+phorbol O
+ester O
+and O
+inhibited O
+the O
+effect O
+of O
+CCK B
+by O
+78 O
+% O
+but O
+had O
+no O
+effect O
+on O
+EGF B
+- O
+activated O
+MAPK B
+activity O
+. O
+
+Activated O
+FGFR3 B
+predominantly O
+interacts O
+with O
+GRB2 B
+. O
+Sos B
+in O
+complex O
+with O
+a O
+previously O
+identified O
+90 O
+- O
+kDa O
+protein O
+and O
+designated O
+protein B
+80K I
+- I
+H I
+. O
+
+The O
+rate O
+of O
+collagen B
+synthesis O
+in O
+normal O
+scar O
+was O
+approximately O
+constant O
+between O
+6 O
+months O
+and O
+20 O
+years O
+after O
+the O
+initial O
+wounding O
+, O
+but O
+in O
+both O
+hypertrophic O
+scar O
+and O
+keloid O
+the O
+rate O
+was O
+initially O
+approximately O
+twice O
+that O
+in O
+normal O
+scar O
+, O
+and O
+2 O
+- O
+3 O
+years O
+after O
+wounding O
+it O
+fell O
+to O
+approximately O
+the O
+same O
+level O
+as O
+in O
+normal O
+scar O
+. O
+
+Evidence O
+for O
+a O
+role O
+of O
+Smad6 B
+in O
+chick O
+cardiac O
+development O
+. O
+
+Excellent O
+results O
+were O
+recorded O
+in O
+390 O
+( O
+83 O
+. O
+69 O
+% O
+) O
+of O
+the O
+patients O
+, O
+improvement O
+in O
+46 O
+( O
+9 O
+. O
+87 O
+% O
+) O
+where O
+in O
+the O
+majority O
+a O
+varicose O
+complex O
+was O
+involved O
+. O
+
+Mutational O
+analysis O
+of O
+yeast B
+CEG1 I
+demonstrated O
+that O
+four O
+of O
+the O
+five O
+conserved O
+motifs O
+are O
+essential O
+for O
+capping B
+enzyme I
+function O
+in O
+vivo O
+. O
+
+We O
+report O
+on O
+a O
+case O
+discovered O
+in O
+a O
+13 O
+year O
+- O
+old O
+girl O
+presenting O
+with O
+anaemia O
+. O
+
+The O
+LIF B
+appeared O
+to O
+be O
+released O
+by O
+the O
+patient O
+' O
+s O
+peripheral O
+blood O
+lymphocytes O
+when O
+cultured O
+with O
+optimal O
+doses O
+of O
+propranolol O
+. O
+
+STUDY O
+SELECTION O
+: O
+Not O
+applicable O
+. O
+
+Co O
+- O
+expression O
+of O
+PLD1 B
+in O
+COS O
+- O
+7 O
+cells O
+with O
+the O
+two O
+recombinant B
+CK2 I
+subunits I
+, O
+alpha O
+or O
+beta O
+, O
+suggests O
+that O
+the O
+association O
+of O
+PLD1 B
+with O
+the O
+kinase O
+is O
+through O
+the O
+beta O
+subunit O
+. O
+
+For O
+capsules O
+containing O
+only O
+the O
+drug O
+, O
+the O
+value O
+of O
+T50 O
+increased O
+as O
+the O
+particle O
+size O
+of O
+the O
+drug O
+decreased O
+. O
+
+The O
+LAB O
+in O
+the O
+cecum O
+( O
+mean O
+9 O
+. O
+4 O
+log O
+CFU O
+/ O
+g O
+) O
+increased O
+slightly O
+with O
+increasing O
+abattoir O
+holding O
+time O
+. O
+
+Our O
+objective O
+was O
+to O
+find O
+possible O
+predictors O
+for O
+the O
+expression O
+and O
+progression O
+of O
+LJM O
+and O
+to O
+evaluate O
+the O
+relationship O
+between O
+LJM O
+and O
+other O
+long O
+- O
+term O
+complications O
+of O
+insulin B
+- O
+dependent O
+diabetes O
+mellitus O
+. O
+
+Human B
+recombinant I
+erythropoietin I
+( O
+r B
+- I
+HuEPO I
+, O
+EprexR O
+) O
+was O
+administered O
+to O
+8 O
+children O
+with O
+chronic O
+renal O
+failure O
+and O
+high O
+transfusion O
+requirement O
+. O
+
+CONCLUSIONS O
+: O
+LHB O
+is O
+simple O
+, O
+easy O
+and O
+safe O
+to O
+implement O
+, O
+and O
+is O
+the O
+only O
+technique O
+capable O
+of O
+maintaining O
+independent O
+upper O
+and O
+lower O
+body O
+perfusion O
+pressure O
+. O
+
+Northern O
+analyses O
+further O
+confirm O
+that O
+the O
+expression O
+of O
+endogenous B
+alpha B
+- I
+ENaC I
+gene I
+in O
+salivary O
+Pa O
+- O
+4 O
+cells O
+is O
+suppressed O
+by O
+an O
+ectopic O
+HMGI B
+- I
+C I
+overexpression O
+. O
+
+Removal O
+of O
+cyclin B
+- I
+dependant I
+kinases I
+( O
+cdks B
+) O
+or O
+cdk2 B
+from O
+these O
+extracts O
+using O
+affinity O
+matrices O
+severely O
+inhibits O
+initiation O
+of O
+S O
+phase O
+. O
+
+Gel O
+mobility O
+shift O
+analyses O
+reveal O
+that O
+FRTL O
+- O
+5 O
+thyroid O
+cell O
+nuclear O
+extracts O
+form O
+a O
+specific O
+protein O
+/ O
+DNA O
+complex O
+with O
+this O
+region O
+, O
+which O
+is O
+prevented O
+by O
+the O
+TTF B
+- I
+1 I
+binding I
+element I
+from O
+the O
+TG B
+promoter I
+; O
+FRT O
+and O
+BRL O
+cell O
+nuclear O
+extracts O
+do O
+not O
+have O
+TTF B
+- I
+1 I
+and O
+do O
+not O
+form O
+this O
+complex O
+. O
+
+The O
+Sty1 B
+kinase I
+is O
+stimulated O
+by O
+a O
+variety O
+of O
+different O
+stress O
+conditions O
+including O
+osmotic O
+and O
+oxidative O
+stress O
+and O
+heat O
+shock O
+. O
+
+No O
+viral O
+RNA O
+replication O
+could O
+be O
+detected O
+in O
+cells O
+transfected O
+with O
+mutant O
+RNAs O
+. O
+
+Acad O
+. O
+
+Comparison O
+of O
+the O
+genes O
+coding O
+for O
+mouse O
+and O
+human B
+p36 I
+( O
+annexin B
+II I
+) O
+and O
+mouse O
+, O
+rat O
+and O
+human B
+p35 I
+( O
+annexin B
+I I
+) O
+and O
+pigeon B
+cp35 I
+( O
+an O
+annexin B
+I I
+- I
+related I
+protein I
+) O
+shows O
+strong O
+genomic O
+structural O
+conservation O
+supporting O
+the O
+hypothesis O
+that O
+these O
+genes O
+had O
+a O
+common O
+ancestor O
+. O
+
+When O
+incubated O
+with O
+infective O
+larvae O
+which O
+had O
+penetrated O
+mouse O
+skin O
+, O
+both O
+normal O
+and O
+immune O
+cells O
+attached O
+to O
+larvae O
+in O
+the O
+absence O
+of O
+serum O
+. O
+
+A O
+31 O
+- O
+year O
+- O
+old O
+man O
+with O
+primary O
+myelofibrosis O
+initially O
+received O
+low O
+dose O
+Ara O
+C O
+. O
+
+Collectively O
+, O
+these O
+studies O
+suggest O
+that O
+the O
+major O
+EGF B
+- O
+stimulated O
+mitotic O
+growth O
+pathways O
+may O
+not O
+be O
+absolutely O
+linked O
+to O
+the O
+stat91 B
+signaling O
+pathways O
+and O
+that O
+such O
+transcription O
+complexes O
+are O
+more O
+complex O
+than O
+previously O
+reported O
+. O
+
+FEurea O
+was O
+also O
+measured O
+during O
+stable O
+graft O
+function O
+, O
+7 O
+- O
+14 O
+days O
+prior O
+to O
+allograft O
+dysfunction O
+. O
+
+Nonsuicidal O
+mortality O
+in O
+late O
+- O
+life O
+depression O
+. O
+
+Few O
+triers O
+or O
+users O
+had O
+received O
+SLT O
+counseling O
+from O
+their O
+dentist O
+despite O
+high O
+dental O
+utilization O
+rates O
+. O
+
+However O
+, O
+UV O
+resistance O
+is O
+only O
+minimally O
+restored O
+, O
+and O
+mutant O
+cells O
+remain O
+sensitive O
+to O
+gamma O
+radiation O
+. O
+
+The O
+oxalate B
+oxidase I
+method O
+results O
+in O
+a O
+mean O
+and O
+reference O
+interval O
+for O
+oxalate O
+excretion O
+that O
+are O
+comparable O
+with O
+those O
+by O
+isotope O
+dilution O
+, O
+gas O
+- O
+chromatographic O
+, O
+colorimetric O
+, O
+and O
+other O
+enzymic O
+procedures O
+. O
+
+In O
+addition O
+, O
+we O
+show O
+that O
+expression O
+of O
+antisense O
+mRNA O
+for O
+p130CAS B
+resulted O
+in O
+reversion O
+of O
+the O
+transformed O
+phenotype O
+of O
+all O
+these O
+cell O
+lines O
+. O
+
+Starches O
+had O
+no O
+effect O
+. O
+
+Maximal O
+Expiratory O
+Flow O
+Rates O
+such O
+as O
+Peak O
+Expiratory O
+Flow O
+Rate O
+( O
+PEFR O
+) O
+, O
+rates O
+at O
+25 O
+% O
+, O
+50 O
+% O
+and O
+75 O
+% O
+of O
+forced O
+vital O
+capacity O
+( O
+V O
+max O
+25 O
+% O
+, O
+V O
+max O
+50 O
+% O
+and O
+V O
+max O
+75 O
+% O
+) O
+and O
+forced O
+expiratory O
+flow O
+during O
+the O
+middle O
+half O
+of O
+forced O
+vital O
+capacity O
+( O
+FEF O
+25 O
+- O
+75 O
+% O
+) O
+were O
+measured O
+in O
+273 O
+healthy O
+non O
+- O
+smoking O
+adults O
+( O
+144 O
+males O
+, O
+129 O
+females O
+) O
+aged O
+15 O
+- O
+63 O
+years O
+living O
+in O
+Madras O
+. O
+
+The O
+amino O
+acid O
+sequence O
+of O
+the O
+protein O
+encoded O
+by O
+MSK1 B
+is O
+homologous O
+to O
+yeast B
+cytoplasmic I
+lysyl I
+- I
+tRNA I
+synthetase I
+and O
+to O
+the O
+product O
+of O
+the O
+herC B
+gene I
+, O
+which O
+has O
+recently O
+been O
+suggested O
+to O
+code O
+for O
+the O
+Escherichia O
+coli O
+enzyme O
+. O
+
+Similar O
+to O
+the O
+D B
+, I
+B I
+/ I
+B I
+' I
+and I
+E I
+proteins I
+, O
+the O
+F B
+and I
+G I
+proteins I
+do O
+not O
+possess O
+any O
+of O
+the O
+known O
+RNA O
+binding O
+motifs O
+, O
+suggesting O
+that O
+other O
+types O
+of O
+RNA O
+- O
+protein O
+interactions O
+occur O
+in O
+the O
+snRNP O
+core O
+. O
+
+These O
+observations O
+suggest O
+that O
+clr4 B
++ I
+and O
+rik1 B
++ I
+must O
+play O
+a O
+role O
+in O
+the O
+assembly O
+of O
+Swi6p B
+into O
+a O
+transcriptionally O
+silent O
+, O
+inaccessible O
+chromatin O
+structure O
+at O
+fission O
+yeast O
+centromeres O
+which O
+is O
+required O
+to O
+facilitate O
+interactions O
+with O
+spindle O
+microtubules O
+and O
+to O
+ensure O
+normal O
+chromosome O
+segregation O
+. O
+
+Characterization O
+of O
+a O
+DEAD B
+box I
+ATPase I
+/ O
+RNA B
+helicase I
+protein I
+of O
+Arabidopsis O
+thaliana O
+. O
+
+Amplitude O
+of O
+late O
+surface O
+( O
+P2 O
+and O
+N2 O
+) O
+and O
+depth O
+( O
+B O
+and O
+C O
+) O
+components O
+significantly O
+decreased O
+when O
+patients O
+shifted O
+from O
+SWS O
+IV O
+to O
+PS O
+and O
+increased O
+from O
+PS O
+to O
+W2 O
+. O
+
+Oligo O
+- O
+[ O
+alpha O
+] O
+- O
+deoxynucleotides O
+can O
+be O
+derived O
+by O
+stabilizing O
+( O
+intercalating O
+) O
+agents O
+or O
+reactive O
+groups O
+( O
+cleaving O
+reagents O
+, O
+cross O
+- O
+linkers O
+. O
+. O
+. O
+) O
+. O
+
+This O
+vector O
+should O
+be O
+applicable O
+for O
+high O
+- O
+throughput O
+characterization O
+of O
+new O
+open O
+reading O
+frames O
+found O
+in O
+genome O
+sequencing O
+. O
+
+The O
+subjects O
+were O
+17 O
+patients O
+with O
+android O
+obesity O
+( O
+four O
+men O
+and O
+13 O
+women O
+) O
+aged O
+21 O
+to O
+58 O
+years O
+with O
+a O
+body O
+mass O
+index O
+( O
+BMI O
+) O
+ranging O
+from O
+32 O
+. O
+0 O
+to O
+52 O
+. O
+2 O
+kg O
+/ O
+m2 O
+and O
+an O
+abdominal O
+- O
+gluteal O
+ratio O
+greater O
+than O
+1 O
+. O
+0 O
+. O
+
+No O
+universally O
+accepted O
+standardized O
+classification O
+system O
+for O
+acne O
+vulgaris O
+exists O
+, O
+although O
+there O
+is O
+a O
+strong O
+need O
+for O
+it O
+. O
+
+Blood O
+samples O
+for O
+determination O
+of O
+fibrinolytic O
+activity O
+and O
+factor B
+VIII I
+in O
+plasma O
+were O
+obtained O
+before O
+and O
+immediately O
+after O
+the O
+end O
+of O
+compression O
+and O
+application O
+of O
+a O
+stocking O
+, O
+respectively O
+. O
+
+Neither O
+symptoms O
+, O
+virions O
+, O
+nor O
+viral O
+RNA O
+was O
+detectable O
+in O
+plants O
+inoculated O
+with O
+this O
+mutant O
+or O
+a O
+mutant O
+with O
+a O
+frameshift O
+mutation O
+in O
+the O
+coat B
+gene I
+. O
+
+The O
+cumulative O
+length O
+of O
+the O
+RGSV O
+genome O
+, O
+including O
+RNAs O
+5 O
+and O
+6 O
+, O
+was O
+25142 O
+nt O
+. O
+
+Risk O
+ratios O
+decreased O
+with O
+increasing O
+age O
+and O
+increased O
+with O
+number O
+of O
+breast O
+biopsies O
+, O
+family O
+history O
+of O
+breast O
+cancer O
+, O
+estrogen O
+use O
+, O
+time O
+between O
+screenings O
+, O
+no O
+comparison O
+with O
+previous O
+mammograms O
+, O
+and O
+the O
+radiologist O
+' O
+s O
+tendency O
+to O
+call O
+mammograms O
+abnormal O
+. O
+
+The O
+AtNMT1 B
+expression O
+profile O
+indicated O
+ubiquity O
+in O
+roots O
+, O
+stem O
+, O
+leaves O
+, O
+flowers O
+, O
+and O
+siliques O
+( O
+approximately O
+1 O
+. O
+7 O
+kb O
+transcript O
+and O
+approximately O
+50 O
+kDa O
+immunoreactive O
+polypeptide O
+) O
+but O
+a O
+greater O
+level O
+in O
+the O
+younger O
+tissue O
+, O
+which O
+are O
+developmentally O
+very O
+active O
+. O
+
+The O
+ossification O
+was O
+located O
+on O
+the O
+left O
+side O
+of O
+C3 O
+- O
+4 O
+. O
+
+At O
+a O
+cutoff O
+point O
+for O
+KISA O
+% O
+of O
+100 O
+, O
+280 O
+of O
+281 O
+participants O
+( O
+99 O
+. O
+6 O
+% O
+) O
+were O
+correctly O
+classified O
+. O
+
+Following O
+replicate O
+control O
+measurements O
+, O
+test O
+ramps O
+were O
+repeated O
+in O
+the O
+presence O
+of O
+sodium O
+nitroprusside O
+( O
+1 O
+microM O
+) O
+and O
+phentolamine O
+( O
+1 O
+microM O
+) O
+to O
+eliminate O
+potential O
+smooth O
+muscle O
+and O
+alpha B
+1 I
+- I
+adrenoceptor I
+effects O
+, O
+respectively O
+. O
+
+Behavioral O
+effects O
+of O
+benzodiazepine O
+ligands O
+in O
+non O
+- O
+dependent O
+, O
+diazepam O
+- O
+dependent O
+and O
+diazepam O
+- O
+withdrawn O
+baboons O
+. O
+
+This O
+paper O
+reports O
+estimates O
+of O
+the O
+prevalence O
+of O
+mental O
+retardation O
+and O
+associated O
+factors O
+based O
+on O
+a O
+population O
+survey O
+of O
+2 O
+- O
+to O
+9 O
+- O
+year O
+- O
+old O
+children O
+in O
+Greater O
+Karachi O
+, O
+Pakistan O
+. O
+
+Thus O
+, O
+an O
+increase O
+in O
+lactate O
+concentration O
+of O
+the O
+magnitude O
+observed O
+during O
+alkali O
+therapy O
+need O
+not O
+indicate O
+a O
+worsening O
+of O
+the O
+metabolic O
+picture O
+in O
+lactic O
+acidosis O
+. O
+
+Adjusting O
+a O
+steady O
+- O
+state O
+warfarin O
+dose O
+depends O
+on O
+the O
+measured O
+INR O
+values O
+and O
+clinical O
+factors O
+: O
+the O
+dose O
+does O
+not O
+need O
+to O
+be O
+adjusted O
+for O
+a O
+single O
+INR O
+that O
+is O
+slightly O
+out O
+of O
+range O
+, O
+and O
+most O
+changes O
+should O
+alter O
+the O
+total O
+weekly O
+dose O
+by O
+5 O
+% O
+to O
+20 O
+% O
+. O
+
+All O
+of O
+this O
+region O
+is O
+part O
+of O
+a O
+prominent O
+CpG O
+island O
+that O
+may O
+be O
+acting O
+as O
+an O
+extended O
+, O
+enhancer O
+- O
+independent O
+promoter O
+. O
+
+Comparison O
+of O
+Healon O
+and O
+Amvisc O
+. O
+
+Large O
+volumes O
+of O
+bone O
+marrow O
+may O
+be O
+required O
+for O
+certain O
+types O
+of O
+autologous O
+bone O
+marrow O
+transplants O
+. O
+
+Further O
+analysis O
+of O
+the O
+CAP59 B
+locus I
+of O
+Cryptococcus O
+neoformans O
+: O
+structure O
+defined O
+by O
+forced O
+expression O
+and O
+description O
+of O
+a O
+new O
+ribosomal B
+protein I
+- I
+encoding I
+gene I
+. O
+
+We O
+speculate O
+that O
+the O
+enhancing O
+effect O
+of O
+glucose O
+and O
+galactose O
+on O
+fructose O
+absorption O
+may O
+be O
+due O
+to O
+activation O
+of O
+the O
+fructose B
+carrier I
+. O
+
+Virol O
+. O
+
+The O
+DFGF B
+- I
+R I
+protein I
+may O
+thus O
+participate O
+in O
+receiving O
+spatial O
+cues O
+that O
+guide O
+tracheal O
+cell O
+outgrowth O
+. O
+
+The O
+data O
+from O
+animal O
+experiments O
+indicate O
+that O
+the O
+incidence O
+of O
+solid O
+tumors O
+in O
+marrow O
+transplant O
+patients O
+may O
+still O
+rise O
+in O
+the O
+coming O
+decades O
+. O
+
+Patients O
+adopt O
+new O
+sets O
+based O
+partly O
+on O
+the O
+original O
+topic O
+and O
+partly O
+on O
+their O
+own O
+personal O
+idiosyncratic O
+concerns O
+. O
+
+The O
+NS B
+- I
+2 I
+isoforms I
+were O
+resolved O
+at O
+a O
+pI O
+value O
+close O
+to O
+5 O
+. O
+5 O
+as O
+three O
+groups O
+of O
+unevenly O
+phosphorylated O
+polypeptides O
+, O
+each O
+composed O
+of O
+at O
+least O
+two O
+protein O
+species O
+. O
+
+Prevalence O
+of O
+rheumatic O
+diseases O
+in O
+a O
+rural O
+population O
+in O
+western O
+India O
+: O
+a O
+WHO O
+- O
+ILAR O
+COPCORD O
+Study O
+. O
+
+A O
+. O
+nidulans O
+transformants O
+secreted O
+high O
+amounts O
+of O
+PGI B
+and O
+PGII B
+in O
+comparison O
+to O
+the O
+previously O
+characterized O
+A O
+. O
+niger O
+transformants O
+and O
+a O
+novel O
+polygalacturonase B
+( O
+PGC B
+) O
+was O
+produced O
+at O
+high O
+levels O
+by O
+A O
+. O
+nidulans O
+transformed O
+with O
+the O
+subcloned O
+pgaC B
+gene I
+. O
+
+This O
+interaction O
+is O
+functional O
+as O
+it O
+leads O
+to O
+retargeting O
+of O
+NF B
+- I
+kappa I
+B I
+p50 B
+from O
+the O
+nucleus O
+to O
+the O
+cytoplasm O
+. O
+
+The O
+orf2 B
+gene I
+product O
+is O
+a O
+protein O
+of O
+79 O
+amino O
+acids O
+with O
+characteristics O
+similar O
+to O
+those O
+of O
+the O
+Tat B
+( O
+transactivator B
+) O
+proteins O
+of O
+the O
+ungulate O
+lentiviruses O
+. O
+
+The O
+use O
+of O
+medication O
+is O
+of O
+minor O
+importance O
+in O
+the O
+treatment O
+of O
+flight O
+phobia O
+. O
+
+Elevated O
+total O
+serum O
+calcium O
+to O
+a O
+level O
+of O
+11 O
+. O
+9 O
++ O
+/ O
+- O
+0 O
+. O
+2 O
+mg O
+/ O
+dl O
+( O
+p O
+less O
+than O
+0 O
+. O
+001 O
+compared O
+to O
+control O
+group O
+) O
+developed O
+in O
+the O
+gentamicin O
+/ O
+1 O
+, O
+25 O
+( O
+OH O
+) O
+2 O
+vitamin O
+D3 O
+group O
+on O
+day O
+4 O
+, O
+2 O
+days O
+prior O
+to O
+pronounced O
+structural O
+damage O
+, O
+and O
+continued O
+to O
+be O
+elevated O
+through O
+day O
+7 O
+. O
+
+Rac2 B
+, O
+a O
+member O
+of O
+the O
+Rho B
+family I
+of O
+GTPases B
+, O
+is O
+highly O
+expressed O
+in O
+myeloid O
+cells O
+and O
+is O
+a O
+regulator O
+of O
+the O
+NADPH B
+- I
+oxidase I
+complex I
+. O
+
+In O
+vitro O
+kinase O
+assays O
+on O
+isolated O
+microvilli O
+and O
+microvillar O
+fractions O
+enriched O
+in O
+the O
+putative O
+signal O
+transduction O
+particle O
+showed O
+a O
+high O
+specific O
+activity O
+of O
+tyrosine B
+kinase I
+activity O
+compared O
+to O
+that O
+of O
+membranes O
+from O
+EGF B
+receptor I
+- O
+overexpressing O
+A431 O
+cells O
+maximally O
+activated O
+by O
+EGF B
+. O
+
+Effect O
+of O
+infantile O
+undernutrition O
+on O
+adult O
+sucrose O
+solution O
+consumption O
+in O
+the O
+rat O
+. O
+
+In O
+the O
+studies O
+described O
+in O
+this O
+report O
+, O
+we O
+have O
+identified O
+two O
+potential O
+Ets B
+binding I
+sites I
+, O
+EBS1 B
+and O
+EBS2 B
+, O
+which O
+are O
+conserved O
+in O
+both O
+the O
+human O
+and I
+murine B
+interleukin I
+- I
+2 I
+enhancers I
+. O
+
+KatA B
+, O
+AhpCF B
+, O
+heme O
+biosynthesis O
+enzymes O
+, O
+and O
+MrgA B
+are O
+also O
+induced O
+upon O
+entry O
+into O
+stationary O
+phase O
+under O
+conditions O
+of O
+iron O
+and O
+manganese O
+limitation O
+. O
+
+Although O
+the O
+Gly252Arg O
+substitution O
+observed O
+in O
+UM O
+: O
+JG5 O
+is O
+non O
+- O
+conservative O
+, O
+it O
+was O
+not O
+possible O
+to O
+distinguish O
+whether O
+it O
+is O
+a O
+mutation O
+or O
+a O
+polymorphism O
+. O
+
+This O
+region O
+shows O
+46 O
+% O
+identity O
+with O
+the O
+calmodulin B
+- I
+binding I
+region I
+of O
+rat B
+brain I
+Ca2 I
++ I
+/ I
+calmodulin I
+- I
+dependent I
+protein I
+kinase I
+II I
+and O
+32 O
+% O
+identity O
+with O
+the O
+equivalent O
+region O
+of O
+chicken B
+smooth I
+muscle I
+myosin I
+light I
+chain I
+kinase I
+. O
+
+The O
+perforated O
+splint O
+gives O
+superior O
+results O
+by O
+virtue O
+of O
+the O
+fact O
+that O
+it O
+does O
+not O
+require O
+to O
+be O
+removed O
+for O
+purposes O
+of O
+hygiene O
+and O
+can O
+thus O
+produce O
+a O
+satisfactory O
+result O
+even O
+in O
+those O
+patients O
+who O
+fail O
+to O
+grasp O
+the O
+technique O
+of O
+removal O
+and O
+replacement O
+of O
+the O
+splint O
+. O
+
+It O
+contains O
+31 O
+exons O
+and O
+a O
+high O
+proportion O
+of O
+class O
+0 O
+introns O
+, O
+alternative O
+splicing O
+of O
+which O
+results O
+in O
+significant O
+levels O
+of O
+variant O
+transcripts O
+that O
+maintain O
+the O
+original O
+open O
+reading O
+frame O
+of O
+MRP B
+mRNA I
+. O
+
+Issues O
+discussed O
+include O
+the O
+validity O
+of O
+the O
+MMPI O
+Mf O
+scale O
+, O
+questions O
+of O
+sample O
+representativeness O
+, O
+whether O
+" O
+straights O
+" O
+can O
+do O
+adequate O
+research O
+on O
+homosexuality O
+, O
+differences O
+in O
+heterosexual O
+and O
+homosexual O
+sexuality O
+, O
+the O
+role O
+of O
+subculture O
+acculturation O
+in O
+homosexual O
+psychological O
+adjustment O
+, O
+and O
+the O
+use O
+of O
+cluster O
+- O
+analysis O
+to O
+generate O
+typologies O
+of O
+homosexualities O
+. O
+
+A O
+brief O
+discussion O
+for O
+the O
+relationship O
+among O
+these O
+formulas O
+is O
+given O
+. O
+
+Lamivudine O
+therapy O
+for O
+acute O
+hepatitis O
+B O
+infection O
+following O
+peripheral O
+blood O
+stem O
+cell O
+transplantation O
+. O
+
+These O
+findings O
+suggest O
+that O
+NMDA B
+receptor I
+blockade O
+may O
+ameliorate O
+the O
+dyskinetic O
+complications O
+of O
+long O
+- O
+term O
+levodopa O
+therapy O
+, O
+without O
+diminishing O
+the O
+beneficial O
+effects O
+on O
+parkinsonian O
+signs O
+. O
+
+Furthermore O
+, O
+the O
+secondary O
+stress O
+responses O
+were O
+more O
+pronounced O
+and O
+the O
+ability O
+to O
+recover O
+from O
+them O
+seemed O
+to O
+be O
+impaired O
+in O
+exposed O
+fish O
+as O
+compared O
+to O
+unexposed O
+fish O
+. O
+
+The O
+distinct O
+spatial O
+pattern O
+of O
+expression O
+, O
+and O
+unusual O
+amino O
+acid O
+sequence O
+in O
+its O
+DNA O
+binding O
+domain O
+, O
+may O
+indicate O
+a O
+particular O
+role O
+for O
+DTEF B
+- I
+1 I
+in O
+cell O
+- O
+specific O
+gene O
+regulation O
+. O
+
+As O
+usual O
+tests O
+, O
+such O
+as O
+" O
+time O
+" O
+of O
+cephalin O
+are O
+slightly O
+sensible O
+to O
+LMW B
+- I
+Hep I
+, O
+only O
+anti B
+- I
+Xa I
+activity O
+can O
+be O
+used O
+. O
+
+Usher O
+syndrome O
+1C O
+( O
+USH1C O
+) O
+is O
+a O
+congenital O
+condition O
+manifesting O
+profound O
+hearing O
+loss O
+, O
+the O
+absence O
+of O
+vestibular O
+function O
+, O
+and O
+eventual O
+retinal O
+degeneration O
+. O
+
+Implantation O
+is O
+contraindicated O
+for O
+severe O
+dysplasia O
+of O
+the O
+cochlea O
+and O
+for O
+the O
+recently O
+described O
+variety O
+of O
+x O
+- O
+linked O
+deafness O
+with O
+deficient O
+bone O
+at O
+the O
+fundus O
+of O
+the O
+internal O
+auditory O
+meatus O
+. O
+
+Over O
+9 O
+kb O
+of O
+DNA O
+sequence O
+was O
+obtained O
+for O
+one O
+clone O
+( O
+A1 O
+) O
+with O
+a O
+total O
+IGS B
+length O
+of O
+approximately O
+12 O
+. O
+4 O
+kb O
+. O
+
+Scleraxis B
+overexpression O
+enhanced O
+expression O
+of O
+the O
+aggrecan B
+gene I
+, O
+which O
+is O
+not O
+normally O
+expressed O
+at O
+high O
+levels O
+in O
+these O
+osteoblastic O
+cells O
+. O
+
+This O
+study O
+demonstrates O
+that O
+the O
+exposure O
+to O
+sulphur O
+mustard O
+results O
+in O
+very O
+low O
+androgen O
+levels O
+and O
+hypo O
+- O
+responsiveness O
+to O
+GnRH B
+in O
+the O
+first O
+five O
+weeks O
+and O
+normalization O
+by O
+the O
+twelfth O
+week O
+after O
+injury O
+. O
+
+New O
+results O
+of O
+importance O
+for O
+optimization O
+of O
+the O
+postoperative O
+course O
+] O
+Complications O
+after O
+major O
+surgery O
+may O
+be O
+related O
+to O
+factors O
+in O
+the O
+surgical O
+stress O
+response O
+with O
+endocrine O
+- O
+metabolic O
+and O
+inflammatory O
+changes O
+. O
+
+Four O
+multicannulated O
+Holstein O
+steers O
+( O
+initial O
+BW O
+424 O
++ O
+/ O
+- O
+16 O
+kg O
+) O
+were O
+used O
+in O
+a O
+4 O
+x O
+4 O
+Latin O
+square O
+to O
+determine O
+the O
+influence O
+of O
+protein O
+supplementation O
+on O
+forage O
+intake O
+, O
+site O
+and O
+extent O
+of O
+digestion O
+, O
+and O
+nutrient O
+flow O
+in O
+steers O
+consuming O
+dormant O
+bluestem O
+- O
+range O
+forage O
+( O
+2 O
+. O
+3 O
+% O
+CP O
+) O
+. O
+
+Patients O
+with O
+risk O
+factors O
+were O
+compared O
+with O
+those O
+without O
+risk O
+factors O
+. O
+
+The O
+dermatoglyphic O
+pattern O
+demostrates O
+a O
+distal O
+triradius O
+and O
+small O
+whorl O
+abnormalities O
+. O
+
+The O
+term O
+Kartagener O
+syndrome O
+applies O
+to O
+this O
+syndrome O
+when O
+accompanied O
+by O
+infertility O
+and O
+dextrocardia O
+or O
+situs O
+inversus O
+. O
+
+Finally O
+, O
+we O
+tested O
+whether O
+activation O
+by O
+either O
+of O
+these O
+factors O
+is O
+dependent O
+on O
+components O
+of O
+the O
+SAGA B
+complex I
+. O
+
+Eight O
+of O
+the O
+17 O
+seropositive O
+patients O
+failed O
+to O
+develop O
+detectable O
+hepatitis B
+B I
+surface I
+antibody I
+within O
+three O
+months O
+of O
+the O
+third O
+injection O
+compared O
+with O
+only O
+one O
+of O
+the O
+18 O
+seronegative O
+patients O
+( O
+p O
+less O
+than O
+0 O
+. O
+01 O
+) O
+. O
+
+The O
+antimicrobial O
+of O
+choice O
+for O
+initial O
+prophylactic O
+therapy O
+among O
+asymptomatic O
+pregnant O
+women O
+exposed O
+to O
+Bacillus O
+anthracis O
+is O
+ciprofloxacin O
+, O
+500 O
+mg O
+twice O
+a O
+day O
+for O
+60 O
+days O
+. O
+
+Overexpression O
+of O
+eIF4E B
+transforms O
+cells O
+, O
+and O
+mutations O
+in O
+eIF4E B
+arrest O
+cells O
+in O
+G O
+, O
+in O
+cdc33 B
+mutants I
+. O
+
+Benzyl O
+alcohol O
+administration O
+in O
+neonates O
+. O
+
+Repression O
+of O
+the O
+herpes B
+simplex I
+virus I
+1 I
+alpha I
+4 I
+gene I
+by O
+its O
+gene O
+product O
+( O
+ICP4 B
+) O
+within O
+the O
+context O
+of O
+the O
+viral O
+genome O
+is O
+conditioned O
+by O
+the O
+distance O
+and O
+stereoaxial O
+alignment O
+of O
+the O
+ICP4 B
+DNA I
+binding I
+site I
+relative O
+to O
+the O
+TATA O
+box O
+. O
+
+As O
+anticipated O
+, O
+both O
+intracellular O
+p54 B
+- O
+SAPKbeta B
+activation O
+and O
+Bcl B
+- I
+2 I
+phosphorylation O
+are O
+blocked O
+by O
+co O
+- O
+transfection O
+with O
+the O
+MAP B
+kinase I
+specific O
+phosphatase O
+MKP3 B
+/ O
+PYST1 B
+. O
+
+Relation O
+between O
+circulating O
+immune O
+complexes O
+and O
+serum O
+ferritin B
+in O
+hemosiderosis O
+of O
+different O
+etiologies O
+
+PATIENT O
+( O
+S O
+) O
+: O
+Two O
+hundred O
+thirty O
+- O
+eight O
+patients O
+with O
+RPLs O
+, O
+48 O
+patients O
+with O
+recurrent O
+IVF O
+- O
+ET O
+failure O
+and O
+179 O
+nonpregnant O
+and O
+120 O
+pregnant O
+control O
+group O
+women O
+. O
+
+Many O
+of O
+the O
+metabolic O
+effects O
+induced O
+by O
+thiazide O
+diuretics O
+, O
+however O
+, O
+can O
+be O
+limited O
+by O
+the O
+use O
+of O
+low O
+doses O
+. O
+
+Teboroxime O
+is O
+a O
+new O
+boronic O
+acid O
+adduct O
+of O
+technetium O
+dioxime O
+( O
+BATO O
+) O
+compound O
+that O
+demonstrates O
+favorable O
+characteristics O
+in O
+preliminary O
+studies O
+. O
+
+The O
+total O
+area O
+under O
+the O
+blood O
+glucose O
+curve O
+over O
+the O
+initial O
+value O
+was O
+not O
+altered O
+2 O
+h O
+after O
+treatment O
+with O
+SH O
+B O
+209 O
+AB O
+or O
+Neogynon O
+. O
+
+Treatment O
+of O
+excessive O
+bleeding O
+after O
+cardiopulmonary O
+bypass O
+was O
+based O
+on O
+an O
+algorithm O
+using O
+point O
+- O
+of O
+- O
+care O
+testing O
+with O
+whole O
+blood O
+prothrombin B
+time O
+, O
+activated O
+partial O
+thromboplastin B
+time O
+, O
+heparinase B
+activated O
+clotting O
+time O
+, O
+and O
+platelet O
+count O
+. O
+
+In O
+all O
+cases O
+, O
+a O
+large O
+fraction O
+of O
+soluble O
+Al O
+became O
+insoluble O
+in O
+the O
+stomach O
+after O
+ingestion O
+. O
+
+To O
+assess O
+the O
+safety O
+of O
+the O
+angiotensin B
+converting I
+enzyme I
+inhibitor O
+enalapril O
+a O
+multicenter O
+, O
+open O
+, O
+randomized O
+, O
+prazosin O
+- O
+controlled O
+trial O
+was O
+designed O
+comparing O
+the O
+incidence O
+and O
+severity O
+of O
+symptomatic O
+hypotension O
+on O
+the O
+first O
+day O
+of O
+treatment O
+. O
+
+Glucose O
+may O
+reduce O
+slightly O
+the O
+pool O
+of O
+amino O
+nitrogen O
+available O
+for O
+albumin B
+and O
+urea O
+synthesis O
+by O
+diverting O
+some O
+of O
+the O
+infused O
+amino O
+acids O
+from O
+protein O
+synthesis O
+by O
+the O
+liver O
+to O
+muscle O
+. O
+
+BACKGROUND O
+. O
+
+We O
+have O
+previously O
+reported O
+the O
+first O
+isolation O
+of O
+a O
+c B
+- I
+myc I
+- O
+null O
+cell O
+line O
+. O
+
+Results O
+demonstrated O
+that O
+for O
+both O
+S O
+. O
+europaea O
+and O
+A O
+. O
+prostrata O
+, O
+the O
+total O
+number O
+of O
+seeds O
+that O
+germinated O
+decreased O
+throughout O
+the O
+growing O
+season O
+. O
+
+A O
+nationwide O
+record O
+linkage O
+of O
+the O
+Finnish O
+Twin O
+Cohort O
+Study O
+( O
+FTCS O
+) O
+with O
+the O
+Hospital O
+Discharge O
+Registry O
+and O
+the O
+Registry O
+of O
+Rights O
+for O
+Free O
+medication O
+is O
+presented O
+. O
+
+Considering O
+these O
+two O
+facts O
+together O
+, O
+we O
+propose O
+that O
+vasectomy O
+may O
+lead O
+to O
+decrease O
+in O
+the O
+incidence O
+of O
+prostatic O
+tumors O
+- O
+a O
+disease O
+that O
+claims O
+nearly O
+22 O
+, O
+000 O
+lives O
+each O
+year O
+in O
+the O
+United O
+States O
+alone O
+. O
+
+Antibodies O
+specific O
+to O
+the O
+different O
+members O
+of O
+the O
+Jun B
+and O
+Fos B
+family O
+of O
+transcription O
+factors O
+show O
+that O
+, O
+in O
+gel O
+retardation O
+assays O
+, O
+a O
+Jun B
+- I
+like I
+factor I
+is O
+a O
+component O
+of O
+the O
+H3 B
+. I
+2 I
+specific I
+complex I
+. O
+
+She O
+had O
+been O
+diagnosed O
+with O
+severe O
+aplastic O
+anemia O
+1 O
+year O
+previously O
+and O
+, O
+while O
+hospitalized O
+, O
+had O
+received O
+methyl O
+prednisolone O
+pulse O
+therapy O
+, O
+which O
+was O
+not O
+successful O
+. O
+
+The O
+recombinant B
+L I
+/ I
+F I
+- I
+transferase I
+is O
+as O
+active O
+as O
+the O
+previously O
+purified O
+wild O
+type O
+enzyme O
+and O
+contains O
+no O
+detectable O
+RNA O
+component O
+. O
+
+Cord O
+formation O
+in O
+BACTEC O
+7H12 O
+medium O
+for O
+rapid O
+, O
+presumptive O
+identification O
+of O
+Mycobacterium O
+tuberculosis O
+complex O
+. O
+
+Moreover O
+, O
+site O
+- O
+specific O
+integration O
+of O
+the O
+ITR O
+- O
+flanked O
+DNA O
+was O
+also O
+detected O
+by O
+PCR O
+amplification O
+of O
+the O
+ITR B
+- O
+aavs1 B
+junction O
+in O
+transduced O
+human O
+fibroblasts O
+. O
+
+Oct B
+- I
+1 I
+is O
+a O
+ubiquitously O
+expressed O
+regulatory O
+gene O
+of O
+the O
+POU B
+domain I
+family I
+. O
+
+In O
+both O
+study O
+stages O
+. O
+post O
+- O
+exposure O
+treatment O
+consisted O
+of O
+five O
+injections O
+of O
+vaccine O
+[ O
+( O
+D O
+) O
+ays O
+0 O
+, O
+3 O
+, O
+7 O
+, O
+14 O
+, O
+28 O
+] O
+, O
+together O
+with O
+a O
+dose O
+of O
+rabies B
+immunoglobulin I
+( O
+RIG B
+) O
+of O
+equine O
+or O
+human O
+origin O
+on O
+D0 O
+. O
+
+( O
+3 O
+) O
+With O
+the O
+exception O
+of O
+the O
+anteroposterior O
+direction O
+of O
+layers O
+II O
+- O
+- O
+III O
+and O
+the O
+mediolateral O
+direction O
+of O
+layer O
+IV O
+, O
+the O
+vertical O
+conductivity O
+of O
+the O
+cortex O
+was O
+always O
+greater O
+than O
+either O
+of O
+the O
+horizontal O
+conductivities O
+. O
+
+Our O
+study O
+investigated O
+the O
+hypothesis O
+that O
+the O
+combination O
+of O
+a O
+high O
+NaCl O
+diet O
+and O
+social O
+isolation O
+stress O
+would O
+increase O
+systolic O
+blood O
+pressure O
+( O
+SBP O
+) O
+and O
+endogenous O
+sodium B
+pump I
+ligands I
+( O
+SPL B
+) O
+, O
+ouabainlike B
+compound O
+( O
+OLC O
+) O
+, O
+and O
+marinobufagenin O
+( O
+MBG O
+) O
+. O
+
+The O
+relationship O
+between O
+polymorphonuclear O
+granulocytes O
+and O
+cartilage O
+destruction O
+in O
+rheumatoid O
+arthritis O
+. O
+
+It O
+is O
+suggested O
+that O
+the O
+loss O
+of O
+weight O
+, O
+the O
+decrease O
+in O
+food O
+intake O
+and O
+the O
+increase O
+in O
+brain O
+MOPEG O
+- O
+SO4 O
+induced O
+by O
+cyanamide O
+reflect O
+possible O
+anorectic O
+properties O
+of O
+the O
+drug O
+. O
+
+RESULTS O
+: O
+Twenty O
+- O
+two O
+patients O
+( O
+30 O
+% O
+) O
+showed O
+ST O
+- O
+segment O
+depression O
+during O
+AEM O
+and O
+34 O
+( O
+49 O
+% O
+) O
+on O
+ExT O
+. O
+
+The O
+virus O
+must O
+progress O
+past O
+the O
+immediate O
+- O
+early O
+phase O
+and O
+express O
+an O
+early B
+gene I
+product I
+( I
+s I
+) I
+for O
+activation O
+of O
+cyclin B
+E I
+expression O
+. O
+
+In O
+CYP7A1 B
+transgenic O
+mice O
+, O
+livers O
+contained O
+approximately O
+3 O
+- O
+fold O
+more O
+sterol B
+response I
+element I
+- I
+binding I
+protein I
+- I
+2 I
+mRNA I
+. O
+
+Adenocarcinoma O
+and O
+large O
+cell O
+carcinoma O
+have O
+a O
+worse O
+prognosis O
+than O
+squamous O
+cell O
+carcinoma O
+in O
+the O
+T1N1 O
+and O
+T2N1 O
+subsets O
+. O
+
+In O
+group O
+I O
+during O
+the O
+pain O
+free O
+period O
+26 O
+of O
+81 O
+patients O
+had O
+positive O
+thallium O
+- O
+201 O
+scans O
+, O
+whereas O
+20 O
+patients O
+had O
+an O
+abnormal O
+ECG O
+at O
+that O
+time O
+; O
+during O
+angina O
+18 O
+patients O
+had O
+transient O
+ECG O
+changes O
+. O
+
+The O
+prototype O
+now O
+structures O
+oncology O
+- O
+related O
+information O
+available O
+on O
+the O
+Internet O
+and O
+also O
+places O
+resources O
+maintained O
+locally O
+at O
+users O
+' O
+disposal O
+. O
+
+Binding O
+of O
+the O
+TorR B
+regulator I
+to O
+cis O
+- O
+acting O
+direct O
+repeats O
+activates O
+tor B
+operon I
+expression O
+. O
+
+For O
+the O
+most O
+part O
+, O
+only O
+aerobic O
+microbial O
+degradation O
+systems O
+have O
+been O
+reported O
+so O
+far O
+. O
+
+Asymptomatic O
+ischaemia O
+during O
+daily O
+life O
+in O
+stable O
+coronary O
+artery O
+disease O
+: O
+relevant O
+or O
+redundant O
+? O
+
+This O
+is O
+a O
+consensus O
+casein B
+kinase I
+II I
+( O
+CKII B
+) O
+site O
+and O
+, O
+using O
+purified O
+wild O
+- O
+type O
+and O
+mutant O
+proteins O
+, O
+we O
+show O
+that O
+it O
+is O
+the O
+main O
+CKII B
+site I
+in O
+the O
+body O
+of O
+the O
+N O
+- O
+terminal O
+complex O
+- O
+forming O
+region O
+. O
+
+In O
+contrast O
+to O
+Phase O
+III O
+, O
+which O
+has O
+a O
+single O
+study O
+design O
+- O
+- O
+the O
+controlled O
+, O
+randomized O
+, O
+double O
+- O
+blind O
+study O
+- O
+- O
+Phase O
+IV O
+requires O
+different O
+designs O
+for O
+each O
+of O
+the O
+many O
+different O
+questions O
+. O
+
+Treatment O
+with O
+polyinosinic O
+- O
+polycytidylic O
+acid O
+to O
+induce O
+expression O
+of O
+Cre B
+resulted O
+in O
+complete O
+disruption O
+of O
+the O
+Arnt B
+gene I
+and O
+loss O
+of O
+ARNT B
+messenger I
+RNA I
+( I
+mRNA I
+) I
+expression O
+in O
+liver O
+. O
+
+Physical O
+map O
+of O
+the O
+genome O
+of O
+sonchus O
+yellow O
+net O
+virus O
+, O
+a O
+plant O
+rhabdovirus O
+with O
+six O
+genes O
+and O
+conserved O
+gene O
+junction O
+sequences O
+. O
+
+Tubular O
+dysfunction O
+in O
+renal O
+lithiasis O
+: O
+cause O
+or O
+consequence O
+? O
+] O
+To O
+investigate O
+whether O
+overall O
+tubular O
+dysfunction O
+is O
+encountered O
+in O
+a O
+particular O
+subgroup O
+of O
+patients O
+with O
+urolithiasis O
+, O
+the O
+following O
+parameters O
+of O
+renal O
+tubular O
+function O
+have O
+been O
+measured O
+in O
+fasting O
+morning O
+urine O
+in O
+124 O
+male O
+stone O
+formers O
+: O
+excretion O
+of O
+lysozyme B
+and O
+gamma B
+- I
+glutamyl I
+transpeptidase I
+( O
+gamma B
+- I
+GT I
+) O
+, O
+fractional O
+excretion O
+( O
+FE O
+) O
+or O
+glucose O
+, O
+insulin B
+, O
+bicarbonate O
+after O
+an O
+alkali O
+load O
+, O
+and O
+theoretical O
+phosphate O
+threshold O
+( O
+TmP O
+/ O
+
+GFR O
+) O
+. O
+
+Interaction O
+between O
+the O
+tobacco O
+DNA O
+- O
+binding O
+activity O
+CBF B
+and O
+the O
+cyt B
+- I
+1 I
+promoter I
+element I
+of O
+the O
+Agrobacterium B
+tumefaciens I
+T I
+- I
+DNA I
+gene I
+T B
+- I
+CYT I
+correlates O
+with O
+cyt B
+- I
+1 I
+directed O
+gene O
+expression O
+in O
+multiple O
+tobacco O
+tissue O
+types O
+. O
+
+As O
+expected O
+, O
+the O
+QOLS O
+- O
+N O
+had O
+a O
+lower O
+correlation O
+with O
+physical O
+health O
+( O
+r O
+= O
+0 O
+. O
+24 O
+, O
+p O
+< O
+0 O
+. O
+000 O
+) O
+and O
+self O
+- O
+reported O
+symptoms O
+( O
+r O
+= O
+- O
+0 O
+. O
+20 O
+, O
+p O
+< O
+0 O
+. O
+001 O
+) O
+, O
+and O
+a O
+higher O
+correlation O
+with O
+mental O
+health O
+( O
+r O
+= O
+0 O
+. O
+52 O
+, O
+p O
+< O
+0 O
+. O
+000 O
+) O
+. O
+
+The O
+N1 O
+- O
+P2 O
+amplitudes O
+of O
+the O
+AEP O
+decreased O
+with O
+increasing O
+strength O
+of O
+muscular O
+innervation O
+. O
+
+SN O
+- O
+38 O
+rebound O
+concentrations O
+were O
+observed O
+in O
+many O
+courses O
+at O
+about O
+0 O
+. O
+5 O
+to O
+1 O
+hour O
+following O
+the O
+end O
+of O
+the O
+i O
+. O
+v O
+. O
+infusion O
+, O
+which O
+is O
+suggestive O
+of O
+enterohepatic O
+recycling O
+. O
+
+Sequence O
+analysis O
+of O
+AEBP2 B
+cDNA I
+revealed O
+that O
+it O
+encodes O
+a O
+protein O
+containing O
+three O
+Gli B
+- O
+Kruppel B
+( O
+Cys2 O
+- O
+His2 O
+) O
+- O
+type O
+zinc O
+fingers O
+. O
+
+In O
+the O
+case O
+of O
+the O
+pT181 O
+plasmid O
+, O
+inactivation O
+of O
+the O
+initiator O
+RepC B
+protein I
+occurs O
+by O
+the O
+attachment O
+of O
+an O
+oligonucleotide O
+to O
+its O
+active O
+tyrosine O
+residue O
+. O
+
+Xanthoepocin O
+, O
+a O
+new O
+antibiotic O
+from O
+Penicillium O
+simplicissimum O
+IFO5762 O
+. O
+
+Extracellular B
+regulated I
+kinases I
+( I
+ERK I
+) I
+1 I
+and O
+ERK2 B
+are O
+authentic O
+substrates O
+for O
+the O
+dual O
+- O
+specificity O
+protein B
+- I
+tyrosine I
+phosphatase I
+VHR I
+. O
+
+Leukocytoclasic O
+vasculitis O
+during O
+treatment O
+with O
+low O
+- O
+dose O
+captopril O
+
+H O
+. O
+
+Truncations O
+from O
+Hip B
+' I
+s I
+N I
+terminus I
+resulted O
+in O
+an O
+apparent O
+loss O
+of O
+Hip B
+homo O
+- O
+oligomerization O
+, O
+but O
+these O
+mutants O
+retained O
+association O
+with O
+hsp70 B
+and O
+were O
+recovered O
+in O
+receptor O
+complexes O
+. O
+
+The O
+biological O
+basis O
+for O
+the O
+changes O
+in O
+CNAPs O
+produced O
+by O
+CS2 O
+is O
+under O
+investigation O
+. O
+
+A O
+very O
+large O
+PC O
+LAN O
+as O
+the O
+basis O
+for O
+a O
+hospital O
+information O
+system O
+. O
+
+This O
+was O
+tragically O
+highlighted O
+by O
+the O
+death O
+of O
+a O
+17 O
+year O
+old O
+dental O
+nurse O
+after O
+taking O
+a O
+single O
+1 O
+g O
+tablet O
+of O
+sodium O
+nitrite O
+. O
+
+The O
+human O
+protein O
+is O
+encoded O
+by O
+a O
+900 O
+- O
+base O
+pair O
+- O
+long O
+mRNA O
+that O
+is O
+expressed O
+in O
+the O
+glandular O
+epithelial O
+cells O
+of O
+the O
+endometrium O
+in O
+a O
+cyclic O
+manner O
+; O
+in O
+addition O
+, O
+it O
+is O
+found O
+in O
+the O
+mucosal O
+epithelial O
+cells O
+of O
+the O
+fallopian O
+tubes O
+. O
+
+In O
+this O
+report O
+, O
+we O
+describe O
+a O
+patient O
+with O
+renal O
+cell O
+carcinoma O
+who O
+experienced O
+ventricular O
+tachycardia O
+while O
+undergoing O
+treatment O
+with O
+high O
+- O
+dose O
+bolus O
+IL B
+- I
+2 I
+. O
+
+Four O
+antifungal O
+agents O
+were O
+compared O
+: O
+amphotericin O
+B O
+, O
+flucytosine O
+, O
+miconazole O
+, O
+and O
+ketoconazole O
+. O
+
+The O
+regulatory O
+genes O
+cnrYXH B
+have O
+been O
+cloned O
+, O
+overexpressed O
+, O
+and O
+purified O
+in O
+Escherichia O
+coli O
+. O
+
+Examination O
+of O
+the O
+Coomassie O
+- O
+stained O
+gels O
+revealed O
+that O
+the O
+capsid O
+- O
+like O
+particles O
+composed O
+of O
+the O
+N11 B
+- O
+VP1 B
+protein O
+did O
+not O
+contain O
+any O
+host B
+- I
+derived I
+histones I
+. O
+
+Conversion O
+of O
+an O
+NF B
+- I
+kappaB I
+into O
+a O
+GABP B
+binding I
+site I
+is O
+likely O
+to O
+have O
+occurred O
+also O
+during O
+the O
+worldwide O
+spread O
+of O
+HIV O
+- O
+1 O
+, O
+as O
+we O
+noticed O
+the O
+same O
+LTR O
+modification O
+in O
+subtype O
+E O
+isolates O
+from O
+Thailand O
+. O
+
+Protein O
+binding O
+to O
+UAS1MLS1 B
+was O
+observed O
+with O
+extracts O
+from O
+derepressed O
+but O
+not O
+from O
+repressed O
+cells O
+, O
+and O
+could O
+be O
+competed O
+for O
+by O
+an O
+excess O
+of O
+the O
+unlabelled O
+CSRE B
+( O
+ICL1 B
+) O
+sequence O
+. O
+
+We O
+then O
+isolated O
+the O
+full O
+- O
+length O
+coding O
+region O
+of O
+the O
+human B
+BACH1 I
+gene I
+using O
+expressed O
+sequence O
+tags O
+, O
+reverse O
+transcription O
+- O
+polymerase O
+chain O
+reaction O
+and O
+rapid O
+amplification O
+of O
+cDNA O
+ends O
+. O
+
+Authors O
+present O
+the O
+anatomical O
+variations O
+of O
+the O
+course O
+of O
+the O
+inferior O
+mesenteric O
+artery O
+and O
+its O
+branches O
+in O
+62 O
+human O
+fetus O
+. O
+
+The O
+7 B
+. I
+2 I
+kb I
+EcoRI I
+fragment I
+of O
+AfMNPV O
+was O
+cloned O
+and O
+the O
+nucleotide O
+sequences O
+of O
+the O
+polyhedrin B
+coding I
+region I
+and O
+its O
+flanking O
+regions O
+were O
+determined O
+. O
+
+1 O
+. O
+
+The O
+increments O
+in O
+median O
+plasma B
+secretin I
+concentration O
+were O
+1 O
+. O
+6 O
+, O
+3 O
+. O
+0 O
+, O
+and O
+6 O
+. O
+4 O
+pmol O
+x O
+1 O
+( O
+- O
+1 O
+) O
+after O
+secretin B
+, O
+125 O
+, O
+250 O
+and O
+500 O
+fmol O
+x O
+kg O
+- O
+1 O
+, O
+and O
+the O
+corresponding O
+15 O
+- O
+min O
+bicarbonate O
+output O
+283 O
+, O
+442 O
+, O
+and O
+1435 O
+micromol O
+, O
+respectively O
+. O
+
+The O
+resulting O
+threshold O
+elevation O
+curves O
+fell O
+into O
+a O
+small O
+number O
+of O
+distinct O
+groups O
+, O
+suggesting O
+the O
+existence O
+of O
+discrete O
+spatial O
+frequency O
+mechanisms O
+in O
+human O
+central O
+vision O
+. O
+
+Because O
+c B
+- I
+myb I
+encodes O
+a O
+transcriptional O
+activator O
+that O
+functions O
+via O
+DNA O
+binding O
+, O
+it O
+is O
+likely O
+that O
+c B
+- I
+myb I
+exerts O
+its O
+biological O
+activity O
+by O
+regulating O
+the O
+transcription O
+of O
+genes O
+required O
+for O
+DNA O
+synthesis O
+and O
+cell O
+cycle O
+progression O
+. O
+
+The O
+rest O
+of O
+the O
+3 O
+' O
+untranslated O
+sequences O
+were O
+common O
+to O
+both O
+cDNA O
+clones O
+. O
+
+Coexpression O
+of O
+c B
+- I
+Rel I
+in O
+combination O
+with O
+ATF B
+- I
+1 I
+, O
+CREB2 B
+, O
+or O
+ATF B
+- I
+1 I
+/ O
+CREB2 B
+leads O
+to O
+synergistic O
+transactivation O
+of O
+a O
+CD28RE B
+- O
+TRE O
+reporter O
+plasmid O
+in O
+quiescent O
+Jurkat O
+T O
+- O
+cells O
+. O
+
+Conventional O
+toxicological O
+considerations O
+suggest O
+that O
+the O
+adverse O
+health O
+effects O
+of O
+any O
+necessary O
+increase O
+in O
+coal O
+combustion O
+effluents O
+would O
+be O
+greatest O
+per O
+unit O
+of O
+coal O
+in O
+those O
+areas O
+which O
+are O
+most O
+heavily O
+populated O
+and O
+have O
+the O
+highest O
+preexisting O
+levels O
+of O
+the O
+gas O
+- O
+aerosol O
+complex O
+. O
+
+The O
+genes O
+on O
+each O
+chromosome O
+involved O
+in O
+this O
+translocation O
+have O
+been O
+identified O
+as O
+the O
+transcription O
+factor O
+- O
+encoding O
+genes O
+PAX3 B
+and O
+FKHR B
+. O
+
+A O
+search O
+was O
+conducted O
+for O
+suppressors O
+of O
+the O
+inositol O
+auxotrophic O
+phenotype O
+of O
+the O
+ino4 B
+- I
+8 I
+mutant I
+of O
+yeast O
+. O
+
+Anesthesia O
+was O
+induced O
+by O
+droperidol O
+0 O
+. O
+2 O
+mg O
+. O
+kg O
+- O
+1 O
+, O
+fentanyl O
+50 O
+micrograms O
+, O
+thiamylal O
+150 O
+- O
+250 O
+mg O
+, O
+and O
+succinylcholine O
+1 O
+mg O
+. O
+kg O
+- O
+1 O
+, O
+and O
+maintained O
+with O
+nitrous O
+oxide O
+and O
+O2 O
+( O
+67 O
+: O
+33 O
+) O
+supplemented O
+with O
+repeated O
+i O
+. O
+v O
+. O
+doses O
+of O
+fentanyl O
+( O
+within O
+15 O
+micrograms O
+. O
+kg O
+- O
+1 O
+) O
+. O
+
+Complexities O
+in O
+the O
+host O
+- O
+pathogen O
+interactions O
+during O
+actual O
+infection O
+with O
+Gram O
+- O
+negative O
+bacteria O
+may O
+account O
+for O
+the O
+difficulties O
+in O
+demonstrating O
+this O
+phenomena O
+in O
+vivo O
+. O
+
+This O
+novel O
+TRPC7 B
+gene I
+could O
+be O
+a O
+candidate O
+gene O
+for O
+genetic O
+disorders O
+such O
+as O
+bipolar O
+affective O
+disorder O
+, O
+nonsyndromic O
+hereditary O
+deafness O
+, O
+Knobloch O
+syndrome O
+, O
+and O
+holoprosencephaly O
+, O
+which O
+were O
+mapped O
+to O
+this O
+region O
+. O
+
+Paradoxically O
+, O
+loop O
+3i O
+from O
+the O
+M1Ach B
+- I
+muscarinic I
+receptor I
+also O
+maximally O
+inhibited O
+GnRH B
+agonist O
+- O
+stimulated O
+cAMP O
+accumulation O
+and O
+PRL B
+release O
+by O
+40 O
+% O
+( O
+both O
+effects O
+mediated O
+through O
+activation O
+of O
+the O
+Gs B
+protein I
+) O
+. O
+
+We O
+present O
+the O
+case O
+of O
+a O
+patient O
+who O
+presented O
+an O
+unusually O
+large O
+mucoid O
+cyst O
+measuring O
+38 O
+x O
+25 O
+mm O
+in O
+an O
+uncommon O
+localization O
+, O
+the O
+right O
+maxillary O
+. O
+
+Acoustic O
+- O
+property O
+measurements O
+of O
+the O
+oxide O
+superconductor O
+BaPb1 O
+- O
+xBixO3 O
+by O
+the O
+sphere O
+- O
+resonance O
+method O
+. O
+
+In O
+7 O
+men O
+and O
+1 O
+woman O
+who O
+died O
+suddenly O
+the O
+functionally O
+important O
+areas O
+of O
+myocardium O
+in O
+the O
+sino O
+- O
+auricular O
+area O
+and O
+the O
+subendocardial O
+layers O
+of O
+left O
+ventricle O
+were O
+obtained O
+by O
+necropsy O
+no O
+more O
+than O
+3 O
+h O
+after O
+death O
+, O
+and O
+then O
+prepared O
+for O
+study O
+by O
+electron O
+microscopy O
+. O
+
+IGF B
+- I
+I I
+levels O
+were O
+measured O
+in O
+the O
+CSF O
+of O
+11 O
+children O
+with O
+autism O
+( O
+4 O
+females O
+, O
+7 O
+males O
+; O
+mean O
+age O
+3 O
+. O
+8 O
+years O
+, O
+SD O
+1 O
+. O
+1 O
+) O
+using O
+a O
+sensitive O
+radioimmunoassay O
+method O
+and O
+compared O
+with O
+levels O
+in O
+11 O
+control O
+participants O
+( O
+6 O
+females O
+, O
+5 O
+males O
+; O
+mean O
+age O
+3 O
+. O
+8 O
+years O
+) O
+. O
+
+In O
+a O
+subsequent O
+phase O
+- O
+II O
+clinical O
+trial O
+safety O
+and O
+efficacy O
+of O
+transrectal O
+HIFU O
+as O
+a O
+novel O
+minimally O
+invasive O
+treatment O
+modality O
+for O
+patients O
+with O
+symptomatic O
+benign O
+prostatic O
+hyperplasia O
+( O
+BPH O
+; O
+n O
+= O
+102 O
+) O
+was O
+determined O
+. O
+
+Three O
+high O
+- O
+amylose O
+rice O
+varieties O
+, O
+IR42 O
+, O
+IR36 O
+, O
+and O
+IR62 O
+, O
+with O
+similar O
+chemical O
+composition O
+including O
+amylose O
+content O
+( O
+26 O
+. O
+7 O
+- O
+27 O
+. O
+0 O
+% O
+) O
+, O
+were O
+cooked O
+under O
+the O
+same O
+conditions O
+and O
+tested O
+for O
+in O
+vitro O
+digestibility O
+as O
+well O
+as O
+blood O
+glucose O
+and O
+insulin B
+responses O
+in O
+healthy O
+human O
+volunteers O
+. O
+
+Slowly O
+adapting O
+type O
+I O
+mechanoreceptor O
+discharge O
+as O
+a O
+function O
+of O
+dynamic O
+force O
+versus O
+dynamic O
+displacement O
+of O
+glabrous O
+skin O
+of O
+raccoon O
+and O
+squirrel O
+monkey O
+hand O
+. O
+
+Using O
+beta B
+1 I
+- I
+AR I
+- O
+luciferase B
+reporter O
+recombinants O
+, O
+we O
+have O
+previously O
+determined O
+that O
+important O
+beta B
+1 I
+- I
+AR I
+genetic O
+elements O
+controlling O
+expression O
+within O
+the O
+C6 O
+glioma O
+cell O
+line O
+are O
+contained O
+within O
+the O
+region O
+- O
+396 O
+to O
+- O
+299 O
+, O
+relative O
+to O
+the O
+translational O
+start O
+site O
+. O
+
+FACS O
+analysis O
+demonstrated O
+that O
+MCs O
+had O
+reached O
+middle O
+to O
+late O
+G1 O
+phase O
+of O
+cell O
+cycle O
+progression O
+at O
+this O
+timepoint O
+. O
+
+Our O
+case O
+, O
+however O
+, O
+had O
+no O
+histologic O
+evidence O
+of O
+malignancy O
+, O
+no O
+serum O
+alpha B
+fetoprotein I
+at O
+7 O
+months O
+of O
+age O
+, O
+and O
+no O
+recurrence O
+at O
+1 O
+years O
+. O
+
+Analysis O
+of O
+tobacco O
+mRNA O
+using O
+the O
+ACBF B
+cDNA I
+as O
+probe O
+showed O
+that O
+while O
+ACBF B
+mRNA I
+was O
+present O
+in O
+all O
+tissues O
+examined O
+, O
+the O
+highest O
+transcript O
+accumulation O
+occurred O
+in O
+stem O
+tissues O
+. O
+
+Cotransfection O
+experiments O
+revealed O
+that O
+both O
+hGATA B
+- I
+4 I
+and O
+PMA O
+/ O
+A23187 O
+stimulation O
+are O
+necessary O
+for O
+the O
+IL B
+- I
+5 I
+promoter I
+activation O
+. O
+
+Here O
+we O
+show O
+that O
+expression O
+of O
+KRAB B
+domain I
+suppresses O
+in O
+vivo O
+the O
+activating O
+function O
+of O
+various O
+defined O
+activating O
+transcription O
+factors O
+, O
+and O
+we O
+demonstrate O
+that O
+the O
+KRAB B
+domain I
+specifically O
+silences O
+the O
+activity O
+of O
+promoters O
+whose O
+initiation O
+is O
+dependent O
+on O
+the O
+presence O
+of O
+a O
+TATA O
+box O
+. O
+
+Adult O
+- O
+onset O
+parkinsonism O
+has O
+appeared O
+in O
+several O
+previously O
+unaffected O
+members O
+in O
+families O
+with O
+DRD O
+suggesting O
+that O
+this O
+may O
+be O
+an O
+additional O
+phenotypical O
+expression O
+of O
+the O
+disease O
+. O
+
+We O
+tested O
+the O
+effects O
+of O
+antifungal O
+drugs O
+on O
+adherence O
+of O
+Candida O
+albicans O
+in O
+vitro O
+. O
+
+The O
+signs O
+of O
+enterocolitis O
+, O
+pathological O
+microbial O
+flora O
+in O
+the O
+stool O
+and O
+changes O
+in O
+the O
+colon O
+mucosa O
+were O
+absent O
+. O
+
+These O
+results O
+support O
+an O
+in O
+vivo O
+interaction O
+between O
+Nck B
+and O
+CKI B
+- I
+gamma2 I
+and O
+suggest O
+that O
+CKI B
+- I
+gamma2 I
+could O
+be O
+involved O
+in O
+signaling O
+pathways O
+downstream O
+of O
+RTKs B
+. O
+
+Correlation O
+of O
+nitrogen O
+, O
+carbohydrate O
+and O
+lipid O
+metabolic O
+indices O
+in O
+rats O
+cooled O
+under O
+conditions O
+of O
+an O
+altered O
+gaseous O
+environment O
+
+Reactivation O
+of O
+hepatitis O
+B O
+virus O
+replication O
+is O
+a O
+rare O
+event O
+during O
+the O
+natural O
+history O
+of O
+chronic O
+hepatitis O
+B O
+. O
+
+A O
+minimal O
+region O
+which O
+stimulates O
+origin O
+function O
+mapped O
+to O
+50 O
+amino O
+acids O
+within O
+the O
+C O
+- O
+terminus O
+of O
+Abf1p B
+. O
+
+Cutaneous O
+melanoma O
+and O
+bilateral O
+retinoblastoma O
+. O
+
+Treatment O
+of O
+JEA2 O
+cells O
+with O
+interleukin B
+( I
+IL I
+) I
+- I
+7 I
+induces O
+CBLB B
+phosphorylation O
+as O
+well O
+. O
+
+Phosphorylation O
+by O
+Cdc28 B
+activates O
+the O
+Cdc20 B
+- O
+dependent O
+activity O
+of O
+the O
+anaphase O
+- O
+promoting O
+complex O
+. O
+
+METHOD O
+: O
+After O
+eligibility O
+, O
+patients O
+were O
+randomly O
+allocated O
+in O
+one O
+of O
+the O
+following O
+groups O
+: O
+M O
+= O
+methylprednisolone O
+30 O
+mg O
+. O
+kg O
+- O
+1 O
+over O
+1 O
+hour O
+, O
+followed O
+by O
+5 O
+. O
+4 O
+mg O
+. O
+kg O
+- O
+1 O
+. O
+h O
+- O
+1 O
+for O
+23 O
+hours O
+, O
+N O
+= O
+nimodipine O
+0 O
+. O
+015 O
+mg O
+. O
+kg O
+- O
+1 O
+. O
+h O
+- O
+1 O
+over O
+2 O
+hours O
+followed O
+by O
+0 O
+. O
+03 O
+mg O
+. O
+kg O
+- O
+1 O
+. O
+h O
+- O
+1 O
+for O
+7 O
+days O
+, O
+MN O
+or O
+P O
+. O
+
+The O
+amount O
+of O
+overlap O
+in O
+VFI O
+, O
+EF O
+, O
+and O
+RVF O
+values O
+among O
+the O
+clinical O
+groups O
+was O
+considerable O
+. O
+
+After O
+5 O
+, O
+850 O
+C14 O
+BP O
+, O
+the O
+decrease O
+in O
+Acer O
+stands O
+could O
+be O
+attributed O
+to O
+fire O
+as O
+suggested O
+by O
+the O
+strong O
+increase O
+in O
+Betula O
+and O
+by O
+the O
+delayed O
+expansion O
+of O
+Pinus O
+cembra O
+. O
+
+Assays O
+of O
+APRE B
+- O
+luciferase B
+reporter O
+plasmids O
+transfected O
+into O
+HepG2 O
+cells O
+show O
+that O
+a O
+mutated O
+APRE B
+that O
+binds O
+only O
+BPi B
+functions O
+as O
+an O
+IL B
+- I
+1 I
+alpha I
+inducible I
+enhancer I
+, O
+whereas O
+a O
+mutated O
+APRE B
+that O
+binds O
+only O
+BPc B
+does O
+not O
+. O
+
+RNA O
+unwinding O
+in O
+U4 B
+/ O
+U6 B
+snRNPs O
+requires O
+ATP O
+hydrolysis O
+and O
+the O
+DEIH B
+- I
+box I
+splicing I
+factor I
+Brr2 B
+. O
+
+Several O
+sequences O
+resembling O
+binding O
+sites O
+for O
+liver O
+- O
+and O
+fat O
+body O
+- O
+specific O
+transcription O
+factors O
+were O
+identified O
+within O
+1 O
+kb O
+upstream O
+and O
+downstream O
+of O
+the O
+gene O
+. O
+
+Northern O
+blot O
+analysis O
+linked O
+Plk B
+expression O
+to O
+the O
+proliferative O
+activity O
+of O
+cells O
+and O
+tissues O
+. O
+
+It O
+also O
+showed O
+which O
+amino O
+acid O
+residues O
+would O
+contact O
+an O
+extended O
+TATA O
+box O
+with O
+a O
+B O
+recognition O
+element O
+, O
+and O
+evolutionary O
+conservation O
+of O
+the O
+TBP B
+- O
+TFB B
+- O
+DNA O
+complex O
+orientation O
+between O
+two O
+archaeal O
+organisms O
+with O
+widely O
+different O
+optimal O
+temperature O
+for O
+growth O
+( O
+37 O
+and O
+100 O
+degrees O
+C O
+) O
+. O
+
+Studies O
+with O
+and O
+without O
+attenuating O
+media O
+were O
+performed O
+, O
+and O
+myocardium O
+- O
+to O
+- O
+defect O
+count O
+ratios O
+and O
+defect O
+sizes O
+from O
+dual O
+- O
+isotope O
+SPECT O
+images O
+were O
+compared O
+to O
+myocardium O
+- O
+to O
+- O
+defect O
+count O
+ratios O
+and O
+defect O
+sizes O
+from O
+single O
+- O
+isotope O
+( O
+201Tl O
+and O
+99mTc O
+) O
+SPECT O
+images O
+. O
+
+Comparison O
+of O
+this O
+gene O
+with O
+the O
+available O
+databases O
+reveals O
+very O
+significant O
+homology O
+to O
+the O
+ETS B
+factor I
+PE B
+- I
+1 I
+and O
+probable O
+near O
+- O
+identity O
+with O
+the O
+recently O
+cloned O
+factor B
+ERF I
+. O
+
+Patients O
+with O
+Eales O
+' O
+disease O
+, O
+chorioretinitis O
+, O
+central O
+serous O
+retinopathy O
+, O
+or O
+malignant O
+choroidal O
+melanoma O
+were O
+tested O
+for O
+HLA B
+antigen I
+deviation O
+. O
+
+Copyright O
+1999 O
+Academic O
+Press O
+. O
+
+The O
+1 O
+. O
+5 O
+- O
+Mb O
+region O
+was O
+covered O
+by O
+137 O
+cosmids O
+with O
+a O
+minimum O
+overlap O
+set O
+of O
+52 O
+cosmids O
+assigned O
+to O
+17 O
+bins O
+and O
+9 O
+contigs O
+. O
+
+Similarly O
+, O
+beta B
+adrenoceptors I
+blockade O
+has O
+been O
+shown O
+to O
+be O
+of O
+value O
+in O
+achieving O
+continence O
+in O
+a O
+small O
+group O
+of O
+patients O
+. O
+
+Estrogen O
+has O
+positive O
+effects O
+on O
+mood O
+, O
+sexual O
+function O
+, O
+target O
+end O
+organs O
+and O
+cognitive O
+function O
+, O
+and O
+may O
+play O
+an O
+important O
+role O
+in O
+the O
+etiology O
+of O
+Alzheimer O
+' O
+s O
+Disease O
+by O
+acting O
+to O
+prevent O
+amyloid O
+plaque O
+formation O
+, O
+oxidative O
+stress O
+, O
+or O
+deterioration O
+of O
+the O
+cholinergic O
+neurotransmitter O
+system O
+. O
+
+These O
+data O
+also O
+demonstrate O
+that O
+insulin B
+and O
+TPA O
+activate O
+MBP B
+/ O
+MAP2 B
+kinase I
+activity O
+by O
+de O
+novo O
+phosphorylation O
+of O
+threonine O
+and O
+tyrosine O
+residues O
+via O
+a O
+very O
+similar O
+pathway O
+. O
+
+Effect O
+of O
+capsaicin O
+on O
+hexobarbital O
+- O
+anesthetized O
+rats O
+
+Triethylene O
+glycol O
+. O
+
+Such O
+tetranucleotides O
+are O
+common O
+in O
+promoter O
+regions O
+, O
+particularly O
+in O
+activating B
+transcription I
+factor I
+/ O
+cyclic B
+AMP I
+response I
+element I
+- I
+binding I
+protein I
+( O
+ATF B
+/ O
+CREB B
+) O
+and O
+E O
+- O
+box O
+motifs O
+, O
+suggesting O
+that O
+PIF B
+may O
+modulate O
+the O
+transcription O
+of O
+many O
+genes O
+. O
+
+Red O
+blood O
+cell O
+binding O
+of O
+99mTc O
+- O
+EC O
+and O
+131I O
+- O
+OIH O
+was O
+6 O
+. O
+1 O
+% O
+and O
+20 O
+% O
+, O
+respectively O
+. O
+
+The O
+dominant O
+inhibitory O
+biological O
+activity O
+of O
+the O
+N O
+terminus O
+correlated O
+with O
+its O
+ability O
+to O
+impair O
+EGF B
+- O
+dependent O
+activation O
+of O
+GTP B
+- I
+Ras I
+and O
+of O
+MAP B
+kinase I
+, O
+as O
+well O
+with O
+the O
+ability O
+of O
+endogenous B
+Sos I
+to O
+form O
+a O
+stable O
+complex O
+with O
+activated O
+EGF B
+receptors I
+. O
+
+Brainstem O
+auditory O
+evoked O
+potential O
+responses O
+( O
+BAEPs O
+) O
+were O
+recorded O
+from O
+CZ O
+- O
+A1 O
+and O
+CZ O
+- O
+A2 O
+scalp O
+regions O
+in O
+23 O
+hypertensive O
+and O
+14 O
+normotensive O
+subjects O
+. O
+
+SM B
+binds O
+RNA O
+in O
+vitro O
+, O
+suggesting O
+that O
+sequence O
+- O
+or O
+structure O
+- O
+specific O
+mRNA O
+interactions O
+might O
+mediate O
+SM B
+specificity O
+. O
+
+The O
+characterization O
+of O
+fly O
+receptors O
+with O
+features O
+similar O
+to O
+mammalian B
+glycoprotein I
+hormone I
+receptors I
+allows O
+a O
+better O
+understanding O
+of O
+the O
+evolution O
+of O
+this O
+unique O
+group O
+of O
+GPCRs B
+and O
+future O
+elucidation O
+of O
+their O
+ligand O
+signaling O
+mechanisms O
+. O
+
+Here O
+we O
+show O
+that O
+these O
+sequences O
+are O
+essential O
+for O
+processing O
+of O
+U18 B
+and O
+snR38 B
+snoRNAs I
+and O
+that O
+they O
+compensate O
+for O
+the O
+lack O
+of O
+a O
+canonical O
+terminal O
+stem O
+. O
+
+The O
+use O
+of O
+aluminum O
+hydroxide O
+was O
+associated O
+with O
+an O
+increase O
+in O
+fecal O
+fluoride O
+excretion O
+and O
+a O
+decrease O
+in O
+net O
+absorption O
+of O
+fluoride O
+regardless O
+of O
+the O
+intake O
+fluoride O
+, O
+calcium O
+, O
+phosphorus O
+, O
+or O
+magnesium O
+. O
+
+In O
+humans O
+, O
+there O
+was O
+a O
+statistically O
+significant O
+decrease O
+of O
+TEWL O
+on O
+both O
+forearm O
+and O
+thigh O
+in O
+CS O
+- O
+treated O
+patients O
+compared O
+to O
+non O
+- O
+CS O
+- O
+treated O
+patients O
+and O
+controls O
+( O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+. O
+
+Kramer O
+Hamburg O
+1988 O
+, O
+ISBN O
+: O
+3 O
+926952 O
+07 O
+5 O
+) O
+, O
+the O
+syndromatic O
+day O
+- O
+to O
+- O
+day O
+shifting O
+of O
+the O
+psychopathological O
+features O
+with O
+manic O
+, O
+depressive O
+and O
+several O
+mixed O
+states O
+has O
+a O
+well O
+- O
+defined O
+time O
+structure O
+, O
+as O
+in O
+25 O
+patients O
+studied O
+and O
+reported O
+on O
+in O
+this O
+paper O
+. O
+
+Ras B
+involvement O
+in O
+signal O
+transduction O
+by O
+the O
+serotonin B
+5 I
+- I
+HT2B I
+receptor I
+. O
+
+Analysis O
+of O
+exon O
+2 O
+of O
+the O
+factor B
+IX I
+gene I
+revealed O
+a O
+C O
+- O
+- O
+> O
+T O
+mutation O
+in O
+codon O
+10 O
+of O
+the O
+propeptide O
+region O
+, O
+resulting O
+in O
+the O
+substitution O
+of O
+alanine O
+by O
+valine O
+. O
+
+There O
+was O
+a O
+direct O
+proportional O
+relationship O
+between O
+the O
+spiral O
+artery O
+flow O
+and O
+the O
+pressure O
+difference O
+between O
+the O
+spiral O
+artery O
+and O
+the O
+amniotic O
+fluid O
+; O
+the O
+pressure O
+difference O
+per O
+flow O
+( O
+the O
+resistance O
+of O
+the O
+cotyledonary O
+unit O
+) O
+was O
+found O
+to O
+be O
+1 O
+- O
+- O
+3 O
+mm O
+Hg O
+. O
+
+ml O
+- O
+1 O
+. O
+min O
+( O
+8 O
+- O
+- O
+24kPa O
+. O
+ml O
+- O
+1 O
+. O
+s O
+) O
+. O
+
+Three O
+putative O
+ORFs O
+have O
+significant O
+homology O
+with O
+known O
+proteins O
+: O
+L0968 B
+is O
+a O
+new O
+member O
+of O
+the O
+very O
+large O
+' B
+seripauperins I
+' I
+family I
+, O
+comprising O
+at O
+least O
+20 O
+yeast O
+members O
+; O
+L1313 B
+is O
+a O
+new O
+ABC B
+transporter I
+highly O
+homologous O
+to O
+the O
+yeast B
+cadmium I
+resistance I
+protein I
+Ycf1p I
+and O
+to O
+the O
+human B
+multidrug I
+resistance I
+protein I
+hMRP1 I
+; O
+the O
+C O
+- O
+terminal O
+part O
+of O
+L1325 B
+present O
+in O
+our O
+sequence O
+is O
+very O
+homologous O
+to O
+the O
+fruit B
+fly I
+abdominal I
+segment I
+formation I
+protein I
+Pumilio I
+. O
+
+The O
+cells O
+were O
+densely O
+ciliated O
+, O
+each O
+cilium O
+showing O
+a O
+typical O
+9 O
++ O
+2 O
+fibrilar O
+pattern O
+. O
+
+Immunofluorescence O
+obtained O
+using O
+antibodies O
+against O
+alphaI B
+SigmaI I
+/ I
++ I
++ I
+betaI I
+SigmaI I
+spectrin I
+and O
+Abl B
+tyrosine I
+kinase I
+but O
+not O
+against O
+alphaII B
+/ I
+betaII I
+spectrin I
+colocalized O
+with O
+the O
+overexpressed O
+green B
+fluorescent I
+protein I
+- I
+SH3 I
+- I
+binding I
+protein I
+. O
+
+Extracellular B
+protein I
+kinase I
+A I
+as O
+a O
+cancer O
+biomarker O
+: O
+its O
+expression O
+by O
+tumor O
+cells O
+and O
+reversal O
+by O
+a O
+myristate O
+- O
+lacking O
+Calpha B
+and O
+RIIbeta B
+subunit I
+overexpression O
+. O
+
+Detection O
+of O
+sinusoidal O
+gratings O
+by O
+pattern O
+- O
+specific O
+detectors O
+: O
+further O
+evidence O
+for O
+the O
+correlation O
+principle O
+in O
+human O
+vision O
+. O
+
+This O
+B O
+- O
+box O
+is O
+not O
+present O
+in O
+ETS1 B
+, O
+ETS2 B
+, O
+PEA3 B
+or O
+PU B
+. I
+1 I
+and O
+these O
+proteins O
+were O
+unable O
+to O
+form O
+ternary O
+complexes O
+with O
+SRF B
+and O
+Egrl B
+- O
+SREs O
+or O
+c B
+- I
+fos I
+SRE O
+. O
+
+MADS B
+- I
+box I
+genes I
+in O
+plants O
+are O
+a O
+diverse O
+class O
+of O
+transcription O
+factors O
+that O
+are O
+involved O
+in O
+regulating O
+developmental O
+processes O
+, O
+particularly O
+meristem O
+and O
+organ O
+identity O
+during O
+floral O
+development O
+. O
+
+Elevated O
+systolic O
+blood O
+pressure O
+and O
+high O
+postglucose O
+serum B
+insulin I
+levels O
+showed O
+an O
+independent O
+, O
+significant O
+association O
+with O
+left O
+ventricular O
+mass O
+in O
+female O
+diabetic O
+subjects O
+. O
+
+This O
+study O
+investigated O
+if O
+signal O
+- O
+averaged O
+low O
+amplitude O
+atrial O
+potentials O
+predict O
+atrial O
+fibrillation O
+or O
+flutter O
+( O
+AFF O
+) O
+. O
+
+Thirty O
+- O
+five O
+pts O
+were O
+transplanted O
+for O
+constitutional O
+disease O
+: O
+Fanconi O
+anemia O
+( O
+FA O
+) O
+( O
+26 O
+pts O
+) O
+, O
+Dyskeratosis O
+congenita O
+( O
+2 O
+pts O
+) O
+, O
+Blackfan O
+- O
+Diamond O
+erythroblastopenia O
+( O
+2 O
+pts O
+) O
+, O
+Glanzmann O
+thrombasthenia O
+( O
+1 O
+pt O
+) O
+, O
+osteopetrosis O
+( O
+1 O
+pt O
+) O
+and O
+Gaucher O
+' O
+s O
+disease O
+( O
+1 O
+pt O
+) O
+. O
+
+Viral B
+protein I
+U I
+( O
+Vpu B
+) O
+is O
+a O
+protein O
+encoded O
+by O
+human O
+immunodeficiency O
+virus O
+type O
+1 O
+( O
+HIV O
+- O
+1 O
+) O
+that O
+promotes O
+the O
+degradation O
+of O
+the O
+virus O
+receptor O
+, O
+CD4 B
+, O
+and O
+enhances O
+the O
+release O
+of O
+virus O
+particles O
+from O
+cells O
+. O
+
+Because O
+the O
+variation O
+in O
+the O
+carbohydrate O
+content O
+of O
+human O
+milk O
+is O
+very O
+small O
+, O
+a O
+more O
+simple O
+alternative O
+approach O
+would O
+be O
+to O
+include O
+only O
+an O
+average O
+carbohydrate O
+value O
+for O
+an O
+estimate O
+of O
+energy O
+content O
+. O
+
+Level O
+II O
+mosaicism O
+occurred O
+in O
+0 O
+. O
+9 O
+per O
+cent O
+of O
+CVS O
+mesenchyme O
+and O
+1 O
+. O
+5 O
+per O
+cent O
+of O
+amniotic O
+fluid O
+cultures O
+and O
+in O
+general O
+was O
+not O
+perceived O
+to O
+be O
+of O
+sufficient O
+concern O
+to O
+warrant O
+cytogenetic O
+follow O
+- O
+up O
+studies O
+. O
+
+Biol O
+. O
+
+IV O
+. O
+
+Sleeping O
+position O
+and O
+sudden O
+infant O
+death O
+syndrome O
+( O
+SIDS O
+) O
+: O
+effect O
+of O
+an O
+intervention O
+programme O
+to O
+avoid O
+prone O
+sleeping O
+. O
+
+CSEn B
+stimulated O
+transcription O
+of O
+a O
+variety O
+of O
+promoters O
+, O
+including O
+the O
+hCS B
+, O
+human B
+growth I
+hormone I
+, O
+thymidine B
+kinase I
+, O
+and O
+Rous B
+sarcoma I
+virus I
+promoters I
+, O
+in O
+human O
+choriocarcinoma O
+cell O
+lines O
+( O
+BeWo O
+and O
+JEG O
+- O
+3 O
+) O
+but O
+not O
+HeLa O
+cells O
+or O
+rat O
+somatolactotrophes O
+( O
+GC O
+) O
+. O
+
+Pretreatment O
+of O
+human O
+skin O
+with O
+tRA O
+inhibited O
+UV O
+induction O
+of O
+c B
+- I
+Jun I
+protein I
+and O
+, O
+consequently O
+, O
+AP B
+- I
+1 I
+. O
+
+c B
+- I
+Jun I
+protein I
+inhibition O
+occurred O
+via O
+a O
+posttranscriptional O
+mechanism O
+, O
+since O
+tRA O
+did O
+not O
+inhibit O
+UV O
+induction O
+of O
+c B
+- I
+Jun I
+mRNA I
+. O
+
+Thus O
+, O
+apoptosis O
+in O
+hematopoietic O
+cells O
+is O
+the O
+end O
+result O
+of O
+a O
+conflict O
+between O
+death O
+and O
+survival O
+signals O
+, O
+rather O
+than O
+a O
+simple O
+death O
+by O
+default O
+. O
+
+Effect O
+of O
+age O
+on O
+glucose O
+, O
+reducing O
+sugars O
+and O
+plasma B
+insulin I
+in O
+blood O
+of O
+milk O
+- O
+fed O
+calves O
+. O
+
+CONCLUSIONS O
+: O
+Results O
+of O
+this O
+study O
+suggest O
+that O
+both O
+male O
+and O
+female O
+soldiers O
+who O
+are O
+diagnosed O
+with O
+chlamydia O
+infections O
+have O
+relatively O
+high O
+risks O
+of O
+reinfection O
+through O
+their O
+20s O
+. O
+
+During O
+seed O
+maturation O
+, O
+the O
+transcriptional O
+activity O
+of O
+napin B
+genes I
+is O
+regulated O
+by O
+developmental O
+signals O
+involving O
+the O
+transcriptional O
+activator O
+ABI3 B
+and O
+abscisic O
+acid O
+( O
+ABA O
+) O
+. O
+
+DESIGN O
+: O
+Intradermally O
+injected O
+human O
+squamous O
+cell O
+carcinoma O
+cells O
+were O
+grown O
+to O
+40 O
+to O
+80 O
+mm3 O
+in O
+athymic O
+nude O
+mice O
+and O
+irradiated O
+with O
+675 O
+- O
+nm O
+light O
+( O
+75 O
+J O
+/ O
+cm2 O
+, O
+75 O
+mW O
+/ O
+cm2 O
+) O
+24 O
+hours O
+after O
+the O
+intraperitoneal O
+injection O
+of O
+SiPc O
+IV O
+( O
+1 O
+. O
+0 O
+mg O
+/ O
+kg O
+) O
+. O
+
+This O
+results O
+in O
+a O
+decreased O
+secretion O
+of O
+immunoglobulin B
+A I
+, O
+and O
+, O
+consequently O
+, O
+a O
+decreased O
+resistance O
+against O
+infections O
+. O
+
+The O
+absolute O
+CD4 B
+count O
+of O
+patients O
+with O
+de O
+novo O
+IBD O
+was O
+210 O
+- O
+700 O
+cells O
+/ O
+ml O
+at O
+the O
+time O
+of O
+IBD O
+. O
+
+Categorisation O
+of O
+the O
+different O
+substructures O
+within O
+the O
+sections O
+allows O
+them O
+to O
+be O
+analysed O
+and O
+displayed O
+separately O
+. O
+
+To O
+study O
+the O
+mechanisms O
+and O
+the O
+signaling O
+pathways O
+involved O
+, O
+IGF B
+- I
+1R I
+promoter I
+reporter I
+constructs I
+were O
+transiently O
+transfected O
+in O
+CHO O
+- O
+AT1 O
+cells O
+that O
+overexpress O
+angiotensin B
+AT1 I
+receptors I
+. O
+
+With O
+this O
+study O
+, O
+a O
+total O
+of O
+13 O
+operators O
+for O
+the O
+glp B
+regulon I
+have O
+been O
+characterized O
+. O
+
+Natl O
+. O
+
+Coexpression O
+of O
+a O
+dominant B
+negative I
+c I
+- I
+jun I
+antagonized O
+the O
+ras B
+- O
+dependent O
+stimulation O
+of O
+the O
+92 B
+- I
+kDa I
+gelatinase I
+B I
+promoter I
+- O
+driven O
+CAT B
+reporter I
+. O
+
+In O
+two O
+patients O
+, O
+a O
+male O
+homosexual O
+and O
+an O
+hemophiliac O
+, O
+thrombocytopenia O
+was O
+associated O
+with O
+AIDS O
+- O
+related O
+complex O
+. O
+
+However O
+, O
+LXRalpha B
+inhibited O
+binding O
+of O
+PPARalpha B
+/ O
+RXRalpha B
+heterodimers O
+to O
+PPREs O
+, O
+and O
+coexpression O
+of O
+LXRalpha B
+in O
+mammalian O
+cells O
+antagonized O
+peroxisome O
+proliferator O
+signaling O
+mediated O
+by O
+PPARalpha B
+/ O
+RXRalpha B
+in O
+vivo O
+. O
+
+The O
+results O
+can O
+be O
+summarized O
+as O
+follows O
+. O
+
+A O
+case O
+of O
+heterotopic O
+gastric O
+mucosa O
+( O
+pyloric O
+gland O
+) O
+in O
+the O
+wall O
+of O
+the O
+gallbladder O
+was O
+reported O
+. O
+
+These O
+findings O
+suggest O
+that O
+the O
+mechanism O
+of O
+ribosomal O
+frameshifting O
+at O
+the O
+PVM O
+signal O
+is O
+different O
+from O
+the O
+one O
+described O
+by O
+the O
+' O
+simultaneous O
+slippage O
+' O
+model O
+in O
+that O
+only O
+the O
+string O
+of O
+four O
+adenosine O
+nucleotides O
+represents O
+the O
+slippery O
+sequence O
+involved O
+in O
+a O
+- O
+1 O
+P O
+- O
+site O
+slippage O
+. O
+
+CTDK1 B
+and O
+CTDK2 B
+also O
+differ O
+in O
+their O
+protein O
+substrate O
+specificity O
+. O
+
+This O
+communication O
+presents O
+two O
+patients O
+with O
+clinically O
+massive O
+PE O
+of O
+recent O
+onset O
+( O
+confirmed O
+by O
+lung O
+perfusion O
+scans O
+) O
+who O
+were O
+successfully O
+treated O
+with O
+a O
+single O
+i O
+. O
+v O
+. O
+dose O
+of O
+30 O
+mg O
+of O
+anisoylated O
+lys B
+- I
+plasminogen I
+streptokinase I
+activator I
+complex I
+( O
+APSAC O
+, O
+comparable O
+to O
+1 O
+, O
+500 O
+, O
+000 O
+U O
+of O
+streptokinase B
+) O
+followed O
+by O
+systemic O
+heparinization O
+for O
+7 O
+days O
+. O
+
+A O
+Laboratory O
+Manual O
+, O
+2nd O
+ed O
+. O
+
+Engineering O
+temperature O
+- O
+sensitive O
+SH3 B
+domains I
+. O
+
+A O
+mean O
+value O
+for O
+HbA1 B
+greater O
+than O
+10 O
+% O
+was O
+associated O
+with O
+an O
+increased O
+risk O
+of O
+progression O
+of O
+retinopathy O
+and O
+a O
+mean O
+value O
+less O
+than O
+8 O
+. O
+7 O
+% O
+was O
+associated O
+with O
+a O
+diminished O
+risk O
+. O
+
+Allergic O
+field O
+: O
+how O
+to O
+detect O
+it O
+? O
+
+At O
+1 O
+min O
+postalfentanil O
+, O
+N2O O
+caused O
+significantly O
+more O
+rigidity O
+than O
+100 O
+% O
+O2 O
+( O
+p O
+< O
+0 O
+. O
+001 O
+) O
+. O
+
+The O
+preparative O
+regimen O
+consisted O
+of O
+fractionated O
+total O
+body O
+irradiation O
+( O
+TBI O
+) O
+and O
+cyclophosphamide O
+( O
+CY O
+) O
+. O
+
+NGF B
+also O
+induced O
+a O
+synthetic O
+promoter O
+with O
+repeated O
+Sp1 B
+sites I
+linked O
+to O
+a O
+core O
+promoter O
+, O
+and O
+a O
+plasmid O
+regulated O
+by O
+a O
+chimeric O
+transactivator O
+in O
+which O
+the O
+Gal4 B
+DNA I
+binding I
+domain I
+is O
+fused O
+to O
+the O
+Sp1 B
+transactivation I
+domain I
+, O
+indicating O
+that O
+this O
+transactivation O
+domain O
+is O
+regulated O
+by O
+NGF B
+. O
+
+The O
+toxicity O
+of O
+copper O
+to O
+the O
+collembolan O
+Folsomia O
+fimetaria O
+L O
+. O
+was O
+studied O
+in O
+soil O
+incubated O
+with O
+copper O
+sulfate O
+for O
+different O
+periods O
+before O
+the O
+introduction O
+of O
+collembolans O
+, O
+to O
+assess O
+the O
+effect O
+of O
+aging O
+of O
+contamination O
+on O
+the O
+toxicity O
+of O
+copper O
+. O
+
+The O
+frequency O
+of O
+severe O
+congestive O
+heart O
+failure O
+( O
+Killip O
+class O
+III O
+or O
+IV O
+) O
+at O
+admission O
+was O
+significantly O
+higher O
+in O
+patients O
+with O
+early O
+presentation O
+, O
+than O
+with O
+late O
+presentation O
+( O
+30 O
+. O
+7 O
+% O
+vs O
+7 O
+. O
+6 O
+% O
+, O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+. O
+
+Comparative O
+ultrafiltration O
+( O
+UF O
+) O
+studies O
+with O
+BiGG O
+and O
+standard O
+lactate O
+( O
+La O
+) O
+solutions O
+in O
+rabbits O
+showed O
+that O
+net O
+UF O
+with O
+La O
+solution O
+peaked O
+at O
+2 O
+h O
+and O
+decreased O
+significantly O
+at O
+4 O
+h O
+and O
+6 O
+h O
+. O
+
+The O
+Giessener O
+Tumordokumentationssystem O
+( O
+GTDS O
+) O
+is O
+such O
+a O
+disease O
+specific O
+system O
+. O
+
+Measurement O
+of O
+protein O
+in O
+natural O
+rubber O
+latex O
+. O
+
+In O
+cotransfection O
+assays O
+, O
+a O
+small O
+fragment O
+of O
+Sin O
+retaining O
+the O
+Src B
+- O
+SH3 B
+- O
+binding O
+site O
+and O
+one O
+tyrosine O
+- O
+containing O
+motif O
+induced O
+c B
+- I
+Src I
+activation O
+as O
+measured O
+by O
+a O
+transcriptional O
+reporter O
+. O
+
+The O
+related O
+tumor O
+suppressor O
+, O
+p130 B
+, O
+also O
+effects O
+this O
+function O
+. O
+
+p107 B
+levels O
+increase O
+substantially O
+as O
+cells O
+progress O
+through O
+S O
+phase O
+. O
+
+p107 B
+induction O
+of O
+E2F B
+DNA O
+binding O
+was O
+observed O
+primarily O
+in O
+S O
+phase O
+cells O
+coincident O
+with O
+the O
+increase O
+in O
+p107 B
+protein I
+levels O
+. O
+
+Both O
+flavoproteins O
+are O
+active O
+as O
+AhpC B
+reductases I
+and O
+mediate O
+electron O
+transfer O
+, O
+resulting O
+in O
+the O
+NADH O
+- O
+dependent O
+reduction O
+of O
+hydrogen O
+peroxide O
+and O
+cumene O
+hydroperoxide O
+. O
+
+Transcriptional O
+regulation O
+of O
+the O
+murine B
+k I
+- I
+fgf I
+gene I
+. O
+
+Further O
+, O
+cells O
+cotransfected O
+with O
+a O
+UF B
+promoter I
+- O
+luciferase B
+( O
+- O
+1935UF I
+- O
+Luc I
+) O
+reporter O
+gene O
+and O
+the O
+BTEB B
+expression O
+vector O
+had O
+2 O
+- O
+fold O
+higher O
+Luc B
+activity O
+than O
+those O
+cotransfected O
+with O
+reporter O
+gene O
+and O
+pcDNA O
+- O
+3 O
+. O
+
+Evasion O
+of O
+host O
+immunity O
+by O
+Toxocara O
+canis O
+infective O
+larvae O
+is O
+mediated O
+by O
+the O
+nematode O
+surface O
+coat O
+, O
+which O
+is O
+shed O
+in O
+response O
+to O
+binding O
+by O
+host O
+antibody O
+molecules O
+or O
+effector O
+cells O
+. O
+
+A O
+Frank O
+vectorcardiogram O
+was O
+recorded O
+before O
+and O
+every O
+15 O
+- O
+30 O
+minutes O
+for O
+10 O
+hours O
+after O
+the O
+occlusion O
+. O
+
+In O
+agreement O
+with O
+this O
+, O
+archaea O
+appear O
+to O
+lack O
+eIF5 B
+, O
+eIF2B B
+and O
+the O
+lysine O
+- O
+rich O
+binding O
+domain O
+for O
+these O
+factors O
+in O
+their O
+eIF2beta B
+homolog I
+. O
+
+Derepression O
+of O
+RAR B
+signaling O
+by O
+expressing O
+a O
+dominant O
+- O
+negative O
+corepressor O
+resulted O
+in O
+embryos O
+that O
+exhibited O
+phenotypes O
+similar O
+to O
+those O
+treated O
+by O
+RA O
+. O
+
+Chemiluminescence O
+induced O
+by O
+opsonized O
+zymosan O
+increased O
+significantly O
+( O
+P O
+less O
+than O
+0 O
+. O
+05 O
+) O
+after O
+treatment O
+with O
+bacterial O
+extracts O
+, O
+whereas O
+no O
+significant O
+changes O
+were O
+observed O
+in O
+the O
+fMLP O
+- O
+stimulated O
+PMNs O
+. O
+
+Lastly O
+, O
+several O
+restriction O
+length O
+polymorphisms O
+were O
+identified O
+and O
+mapped O
+within O
+a O
+1 O
+kb O
+region O
+located O
+immediately O
+upstream O
+from O
+the O
+JH B
+cluster I
+. O
+
+Radiographic O
+spatial O
+frequencies O
+essential O
+to O
+the O
+diagnosis O
+of O
+incipient O
+interproximal O
+lesions O
+. O
+
+Promoter O
+region O
+of O
+the O
+human B
+alpha I
+2A I
+adrenergic I
+receptor I
+gene I
+. O
+
+( O
+1982 O
+) O
+. O
+
+( O
+99m O
+) O
+Tc O
+Ethyl O
+Cysteinate O
+Dimer O
+stable O
+during O
+6h O
+has O
+contributed O
+to O
+develop O
+ictal O
+studies O
+to O
+evaluate O
+the O
+location O
+of O
+partial O
+seizure O
+. O
+
+LiF O
+thermoluminescence O
+dosimeters O
+( O
+TLD O
+) O
+in O
+chip O
+form O
+were O
+placed O
+onto O
+1 O
+eyelid O
+, O
+the O
+skin O
+over O
+the O
+thyroid O
+, O
+and O
+the O
+patient O
+' O
+s O
+clothes O
+covering O
+the O
+region O
+of O
+breasts O
+and O
+ovaries O
+of O
+female O
+patients O
+and O
+the O
+testicles O
+of O
+male O
+patients O
+. O
+
+Thus O
+, O
+the O
+in O
+vivo O
+function O
+of O
+Gle2p B
+is O
+strictly O
+coupled O
+to O
+the O
+short O
+GLEBS B
+within O
+Nup116p B
+which O
+links O
+this O
+putative O
+mRNA O
+transport O
+factor O
+to O
+the O
+nuclear O
+pores O
+. O
+
+DNMT2 B
+binds O
+AdoHcy O
+in O
+the O
+same O
+conformation O
+as O
+confirmed O
+m B
+( I
+5 I
+) I
+C I
+MTases I
+and O
+, O
+while O
+DNMT2 B
+shares O
+all O
+sequence O
+and O
+structural O
+features O
+with O
+m B
+( I
+5 I
+) I
+C I
+MTases I
+, O
+it O
+has O
+failed O
+to O
+demonstrate O
+detectable O
+transmethylase B
+activity O
+. O
+
+The O
+structure O
+of O
+the O
+murine B
+Dtk I
+gene I
+has O
+been O
+determined O
+. O
+
+In O
+previous O
+studies O
+, O
+we O
+showed O
+that O
+the O
+nuclear O
+import O
+of O
+SREBP B
+- I
+2 I
+occurs O
+via O
+the O
+direct O
+interaction O
+of O
+importin B
+beta I
+with O
+the O
+HLH O
+- O
+Zip O
+domain O
+. O
+
+In O
+the O
+normal O
+controls O
+the O
+plasma O
+FPA O
+level O
+( O
+mean O
++ O
+/ O
+- O
+SD O
+) O
+was O
+1 O
+. O
+43 O
++ O
+/ O
+- O
+0 O
+. O
+46 O
+ng O
+/ O
+ml O
+. O
+
+In O
+this O
+study O
+we O
+cloned O
+the O
+cDNA O
+of O
+AD1 B
+Ag I
+from O
+a O
+rat O
+basophilic O
+leukemia O
+2H3 O
+cDNA O
+library O
+. O
+
+Ten O
+patients O
+( O
+aged O
+28 O
+- O
+76 O
+years O
+) O
+with O
+a O
+terminal O
+jejunostomy O
+located O
+within O
+the O
+first O
+meter O
+of O
+jejunum O
+were O
+treated O
+by O
+infusion O
+of O
+an O
+elemental O
+diet O
+into O
+the O
+distal O
+small O
+bowel O
+( O
+IEDDSB O
+) O
+. O
+
+The O
+procedure O
+was O
+technically O
+successful O
+in O
+12 O
+of O
+14 O
+( O
+86 O
+% O
+) O
+stenoses O
+in O
+the O
+fibromuscular O
+dysplasia O
+subgroup O
+but O
+in O
+only O
+one O
+of O
+five O
+( O
+20 O
+% O
+) O
+lesions O
+in O
+the O
+neurofibromatosis O
+subgroup O
+. O
+
+Conventional O
+and O
+digital O
+radiography O
+of O
+the O
+heart O
+, O
+aorta O
+, O
+and O
+pulmonary O
+vascularity O
+. O
+
+Regulation O
+of O
+the O
+p21 B
+- I
+activated I
+kinase I
+( O
+PAK B
+) O
+by O
+a O
+human B
+Gbeta I
+- I
+like I
+WD I
+- I
+repeat I
+protein I
+, O
+hPIP1 B
+. O
+
+Other O
+clinicopathological O
+features O
+have O
+no O
+definite O
+influence O
+in O
+survival O
+expectancy O
+. O
+
+These O
+studies O
+suggest O
+that O
+tandem O
+alpha O
+- O
+helices O
+located O
+near O
+the O
+C O
+- O
+terminus O
+of O
+PC B
+- I
+TP I
+facilitate O
+membrane O
+binding O
+and O
+extraction O
+of O
+phosphatidylcholines O
+. O
+
+The O
+striking O
+similarity O
+in O
+preference O
+for O
+mismatched O
+and O
+weakly O
+paired O
+nucleotides O
+for O
+binding O
+and O
+for O
+excision O
+suggests O
+a O
+functional O
+relationship O
+between O
+binding O
+and O
+cleavage O
+reactions O
+. O
+
+Interestingly O
+, O
+these O
+" O
+activation O
+- O
+defective O
+" O
+mutants O
+segregated O
+into O
+two O
+classes O
+: O
+1 O
+) O
+those O
+that O
+were O
+unable O
+to O
+form O
+dimers O
+but O
+that O
+could O
+still O
+form O
+higher O
+order O
+oligomers O
+and O
+transform O
+cells O
+, O
+and O
+2 O
+) O
+those O
+that O
+were O
+defective O
+for O
+PDGF B
+- I
+R I
+binding O
+and O
+were O
+transformation O
+- O
+incompetent O
+. O
+
+APL O
+patients O
+showed O
+a O
+low O
+, O
+yet O
+variable O
+, O
+level O
+of O
+JEM B
+- I
+1 I
+mRNA I
+in O
+bone O
+marrow O
+. O
+
+CONCLUSIONS O
+: O
+The O
+results O
+show O
+that O
+intranasal O
+challenge O
+with O
+FLU O
+induces O
+changes O
+in O
+leukocyte O
+histamine O
+release O
+, O
+but O
+not O
+other O
+systemic O
+immune O
+and O
+inflammatory O
+responses O
+. O
+
+We O
+have O
+shown O
+previously O
+that O
+EGF B
+receptor I
+activation O
+stimulates O
+gastrin B
+gene I
+expression O
+through O
+a O
+GC O
+- O
+rich O
+element O
+called O
+gERE O
+. O
+
+We O
+have O
+earlier O
+proposed O
+that O
+CG O
+rich O
+sequences O
+resembling O
+CpG O
+islands O
+, O
+which O
+are O
+associated O
+with O
+many O
+imprinted O
+genes O
+and O
+often O
+subject O
+to O
+parental O
+- O
+specific O
+methylation O
+, O
+could O
+act O
+as O
+a O
+common O
+imprinting O
+element O
+. O
+
+The O
+secondary O
+end O
+points O
+included O
+creatine B
+kinase I
+peak O
+, O
+ventricular O
+fibrillation O
+/ O
+tachycardia O
+within O
+the O
+first O
+24 O
+hours O
+, O
+death O
+and O
+congestive O
+heart O
+failure O
+within O
+the O
+30 O
+- O
+day O
+follow O
+- O
+up O
+, O
+and O
+30 O
+- O
+day O
+left O
+ventricular O
+ejection O
+fraction O
+. O
+
+Prevention O
+of O
+gravid O
+Rhesus O
+isoimmunization O
+
+All O
+relapses O
+occurred O
+within O
+the O
+first O
+year O
+and O
+were O
+confined O
+to O
+patients O
+with O
+PS O
+II O
+disease O
+and O
+four O
+or O
+more O
+sites O
+of O
+involvement O
+. O
+
+This O
+demonstrates O
+the O
+presence O
+of O
+a O
+PKC B
+- O
+dependent O
+pathway O
+which O
+functions O
+independently O
+from O
+Lck B
+in O
+MAP B
+kinase I
+activation O
+. O
+
+This O
+interesting O
+exon O
+junction O
+resulted O
+in O
+novel O
+deduced O
+amino O
+terminal O
+open O
+reading O
+frames O
+, O
+which O
+are O
+completely O
+in O
+- O
+frame O
+with O
+sequences O
+located O
+further O
+downstream O
+. O
+
+Cell O
+lines O
+expressing O
+single O
+amino O
+acid O
+substitutions O
+of O
+the O
+carboxyl O
+- O
+terminal O
+asparagine O
+of O
+CD2 B
+are O
+incapable O
+of O
+avidity O
+regulation O
+by O
+TCR B
+signaling O
+, O
+PMA O
+treatment O
+, O
+or O
+elevation O
+of O
+intracellular O
+cAMP O
+levels O
+, O
+demonstrating O
+that O
+each O
+of O
+these O
+stimuli O
+utilizes O
+a O
+common O
+structural O
+element O
+for O
+regulating O
+CD2 B
+avidity O
+. O
+
+12 O
+per O
+cent O
+was O
+observed O
+with O
+the O
+use O
+of O
+tetracycline O
+and O
+4 O
+- O
+epianhydrotetracycline O
+in O
+doses O
+of O
+1000 O
+and O
+100gamma O
+per O
+embryo O
+respectively O
+. O
+
+Present O
+investigation O
+was O
+undertaken O
+to O
+elucidate O
+what O
+pharmacokinetic O
+parameters O
+in O
+animal O
+experiment O
+could O
+be O
+of O
+more O
+predictable O
+for O
+human O
+clinical O
+trial O
+of O
+beta O
+- O
+blocking O
+agents O
+. O
+
+The O
+atpA B
+reading I
+frame I
+ends O
+with O
+four O
+tandem O
+UGA O
+codons O
+which O
+overlap O
+four O
+tandem O
+AUG O
+codons O
+initiating O
+an O
+unidentified O
+reading O
+frame O
+, O
+orf214 O
+. O
+
+When O
+transfected O
+into O
+HepG2 O
+cells O
+, O
+which O
+lack O
+C B
+/ I
+EBP I
+alpha I
+, O
+the O
+mouse B
+ob I
+promoter I
+was O
+only O
+weakly O
+active O
+. O
+
+Vasodilator O
+and O
+hypotensive O
+effects O
+of O
+the O
+optical O
+isomers O
+of O
+nicardipine O
+( O
+YC O
+- O
+93 O
+) O
+, O
+a O
+new O
+Ca2 O
++ O
+- O
+antagonist O
+. O
+
+Between O
+1988 O
+and O
+1995 O
+, O
+341 O
+children O
+with O
+acute O
+myeloid O
+leukaemia O
+( O
+AML O
+) O
+were O
+treated O
+on O
+the O
+Medical O
+Research O
+Council O
+Acute O
+Myeloid O
+Leukaemia O
+Trial O
+( O
+MRC O
+AML10 O
+) O
+. O
+
+A O
+heterologous O
+promoter O
+construct O
+containing O
+three O
+repeats O
+of O
+a O
+consensus O
+Sp1 B
+site I
+, O
+cloned O
+upstream O
+of O
+a O
+single O
+copy O
+of O
+the O
+ZII B
+( O
+CREB B
+/ I
+AP1 I
+) O
+element O
+from O
+the O
+BZLF1 B
+promoter I
+linked O
+to O
+the O
+beta B
+- I
+globin I
+TATA O
+box O
+, O
+exhibited O
+phorbol O
+ester O
+inducibility O
+. O
+
+Nicotinic B
+receptor I
+antagonists O
+mecamylamine O
+( O
+0 O
+. O
+5 O
+and O
+1 O
+mg O
+/ O
+kg O
+) O
+and O
+hexamethonium O
+( O
+5 O
+and O
+10 O
+mg O
+/ O
+kg O
+) O
+reduced O
+the O
+response O
+induced O
+by O
+nicotine O
+( O
+0 O
+. O
+25 O
+mg O
+/ O
+kg O
+) O
+. O
+
+Appl O
+. O
+
+Thus O
+, O
+the O
+predicted O
+M3 B
+ORF I
+is O
+a O
+functional O
+gene O
+that O
+encodes O
+an O
+abundant O
+secreted O
+protein O
+which O
+is O
+a O
+candidate O
+for O
+interacting O
+with O
+host O
+cellular O
+receptors O
+or O
+cytokines O
+. O
+
+Protein O
+metabolism O
+disorders O
+in O
+burns O
+
+The O
+cumulative O
+dose O
+to O
+nursing O
+staff O
+for O
+the O
+week O
+after O
+treatment O
+was O
+dependent O
+on O
+patient O
+mobility O
+and O
+was O
+estimated O
+at O
+0 O
+. O
+08 O
+mSv O
+for O
+a O
+self O
+- O
+caring O
+patient O
+to O
+6 O
+. O
+3 O
+mSv O
+for O
+a O
+totally O
+helpless O
+patient O
+( O
+1840 O
+MBq O
+/ O
+group O
+A O
+) O
+. O
+
+JCAHO O
+to O
+use O
+ORYX O
+data O
+to O
+detect O
+sentinel O
+events O
+. O
+
+We O
+also O
+show O
+that O
+psbH B
+and O
+psbT B
+are O
+transcribed O
+from O
+the O
+upstream O
+psbB B
+gene I
+promoter I
+, O
+and O
+that O
+the O
+psbH B
+mRNA I
+has O
+its O
+own O
+target O
+sequence O
+for O
+Mbb1 B
+function O
+. O
+
+To O
+test O
+whether O
+Cd O
+exposure O
+would O
+increase O
+Ca O
+release O
+from O
+bone O
+during O
+pregnancy O
+and O
+lactation O
+in O
+relation O
+to O
+the O
+etiological O
+mechanism O
+of O
+Itai O
+- O
+Itai O
+disease O
+, O
+virgin O
+female O
+mice O
+with O
+45Ca O
+prelabeled O
+skeletons O
+( O
+15 O
+microCi O
+/ O
+mouse O
+) O
+were O
+subjected O
+to O
+one O
+round O
+of O
+pregnancy O
+/ O
+lactation O
+and O
+were O
+exposed O
+to O
+a O
+Ca O
+- O
+deficient O
+diet O
+containing O
+0 O
+, O
+5 O
+, O
+or O
+25 O
+ppm O
+Cd O
+or O
+25 O
+ppm O
+Pb O
+for O
+32 O
+days O
+, O
+from O
+conception O
+until O
+Lactation O
+Day O
+14 O
+. O
+
+O5257 B
+shows O
+homology O
+with O
+the O
+SAS2 B
+protein I
+and O
+another O
+hypothetical O
+protein O
+from O
+yeast O
+. O
+
+Principles O
+of O
+thyroid O
+hormone O
+treatment O
+
+Significance O
+of O
+esophagocardiac O
+reflexes O
+for O
+inducing O
+thoracic O
+pain O
+
+The O
+fate O
+of O
+ochratoxin O
+A O
+during O
+malting O
+and O
+brewing O
+. O
+
+METHODS O
+: O
+Precision O
+and O
+accuracy O
+were O
+measured O
+using O
+controls O
+and O
+method O
+comparison O
+studies O
+. O
+
+Messenger O
+RNA O
+for O
+the O
+Ad2 B
+DNA I
+binding I
+protein I
+: O
+DNA O
+sequences O
+encoding O
+the O
+first O
+leader O
+and O
+heterogenity O
+at O
+the O
+mRNA O
+5 O
+' O
+end O
+. O
+
+Consistent O
+with O
+this O
+hypothesis O
+, O
+stimulation O
+of O
+A B
+( I
+2A I
+) I
+- I
+R I
+or O
+PKA B
+enhanced O
+nuclear B
+aPKC I
+activity O
+. O
+
+Atrial O
+dissociation O
+. O
+
+The O
+gene O
+sequence O
+predicts O
+a O
+150 O
+, O
+825 O
+mol O
+wt O
+apoprotein O
+of O
+1363 O
+amino O
+acids O
+having O
+an O
+N O
+- O
+terminal O
+hydrophobic O
+signal O
+sequence O
+of O
+17 O
+amino O
+acids O
+, O
+19 O
+potential O
+N O
+- O
+linked O
+glycosylation O
+sites O
+, O
+a O
+hydrophobic O
+anchor O
+sequence O
+of O
+approximately O
+17 O
+amino O
+acids O
+near O
+the O
+C O
+terminus O
+, O
+and O
+a O
+hydrophilic O
+cysteine O
+- O
+rich O
+C O
+terminus O
+of O
+35 O
+amino O
+acids O
+. O
+
+However O
+, O
+depending O
+upon O
+the O
+promoter O
+context O
+, O
+we O
+observed O
+cooperative O
+interactions O
+between O
+the O
+two O
+domains O
+to O
+confer O
+high O
+DNA O
+- O
+binding O
+affinity O
+and O
+specificity O
+. O
+
+As O
+a O
+result O
+, O
+relative O
+biological O
+effects O
+( O
+RBE O
+) O
+of O
+2 O
+. O
+3 O
+- O
+2 O
+. O
+7 O
+was O
+obtained O
+from O
+the O
+straight O
+line O
+that O
+was O
+given O
+by O
+modifying O
+by O
+the O
+method O
+of O
+least O
+squares O
+the O
+curves O
+of O
+the O
+frequency O
+of O
+anomalous O
+fetuses O
+in O
+total O
+implants O
+and O
+survived O
+embryos O
+irradiated O
+from O
+20 O
+to O
+120 O
+rad O
+by O
+Cf O
+- O
+252 O
+and O
+from O
+80 O
+to O
+220 O
+rad O
+by O
+Co O
+- O
+60 O
+on O
+day O
+8 O
+of O
+pregnancy O
+. O
+
+Samples O
+( O
+1 O
+g O
+) O
+were O
+extracted O
+with O
+0 O
+. O
+5 O
+% O
+potassium O
+chloride O
+( O
+KCl O
+) O
+in O
+70 O
+% O
+methanol O
+( O
+5 O
+ml O
+) O
+and O
+diluted O
+subsequently O
+to O
+give O
+two O
+- O
+fold O
+to O
+ten O
+- O
+fold O
+step O
+- O
+wise O
+dilutions O
+in O
+phosphate O
+- O
+buffered O
+saline O
+containing O
+0 O
+. O
+05 O
+% O
+Tween O
+20 O
+and O
+0 O
+. O
+2 O
+% O
+bovine B
+serum I
+albumin I
+( O
+PBS O
+- O
+T O
+BSA B
+) O
+. O
+
+To O
+our O
+knowledge O
+108 O
+cases O
+of O
+EAT O
+treated O
+by O
+catheter O
+ablation O
+of O
+the O
+ectopic O
+focus O
+are O
+reported O
+in O
+the O
+literature O
+with O
+a O
+success O
+rate O
+superior O
+to O
+90 O
+% O
+. O
+
+Following O
+immunization O
+of O
+transgenic O
+mice O
+, O
+hybrid O
+molecules O
+were O
+isolated O
+from O
+B O
+cell O
+DNA O
+which O
+contained O
+the O
+transgene O
+recombined O
+with O
+the O
+endogenous B
+IgH I
+locus I
+. O
+
+It O
+produced O
+extrapyramidal O
+disturbances O
+in O
+nearly O
+every O
+subject O
+, O
+the O
+most O
+common O
+being O
+akathisia O
+and O
+the O
+most O
+severe O
+, O
+in O
+the O
+case O
+of O
+one O
+individual O
+, O
+being O
+acute O
+dystonia O
+. O
+
+Northern O
+blot O
+analysis O
+indicated O
+that O
+both O
+human O
+and O
+murine O
+genes O
+encode O
+approximately O
+6 O
+- O
+kb O
+transcripts O
+. O
+
+Transforming B
+growth I
+factor I
+beta I
+activates O
+the O
+promoter O
+of O
+cyclin B
+- I
+dependent I
+kinase I
+inhibitor O
+p15INK4B B
+through O
+an O
+Sp1 B
+consensus I
+site I
+. O
+
+Cox O
+proportional O
+hazard O
+analysis O
+identified O
+dialysis O
+modality O
+and O
+pre O
+- O
+dialysis O
+UV O
+of O
+less O
+than O
+1 O
+, O
+000 O
+ml O
+/ O
+m2 O
+per O
+24 O
+h O
+as O
+the O
+only O
+significant O
+risk O
+factors O
+for O
+UV O
+survival O
+. O
+
+The O
+hyperpigmentation O
+is O
+linked O
+to O
+the O
+presence O
+of O
+numerous O
+single O
+melanosomes O
+and O
+polymelanosomes O
+in O
+keratinocytes O
+at O
+all O
+levels O
+of O
+the O
+epidermis O
+, O
+and O
+in O
+dermal O
+Factor B
+XIIIa I
+- O
+positive O
+dendrocytes O
+. O
+
+Possible O
+or O
+definite O
+neglect O
+or O
+abuse O
+before O
+36 O
+months O
+of O
+age O
+was O
+correlated O
+with O
+low O
+DBH B
+activity O
+. O
+
+Previously O
+, O
+we O
+identified O
+two O
+human B
+SMC I
+family I
+proteins I
+, O
+hCAP B
+- I
+C I
+and O
+hCAP B
+- I
+E I
+, O
+which O
+form O
+a O
+heterodimeric O
+complex O
+( O
+hCAP B
+- I
+C I
+- O
+hCAP B
+- I
+E I
+) O
+in O
+the O
+cell O
+. O
+
+The O
+mouse B
+alpha I
+A I
+- I
+CRYBP1 I
+gene I
+specifies O
+a O
+2 O
+, O
+688 O
+- O
+amino O
+acid O
+protein O
+with O
+72 O
+% O
+amino O
+acid O
+identity O
+to O
+its O
+human O
+homologue O
+, O
+PRDII B
+- I
+BF1 I
+. O
+
+Methylation O
+interference O
+analysis O
+established O
+at O
+single O
+nucleotide O
+resolution O
+that O
+purified O
+recombinant B
+Fos I
+and O
+Jun B
+proteins I
+bind O
+in O
+a O
+sequence O
+- O
+specific O
+manner O
+to O
+the O
+AP B
+- I
+1 I
+sites I
+within O
+the O
+VDRE O
+and O
+OC O
+box O
+. O
+
+These O
+include O
+urinalysis O
+, O
+chest O
+X O
+- O
+P O
+, O
+ECG O
+, O
+hematological O
+examinations O
+( O
+RBC O
+, O
+WBC O
+, O
+Ht O
+, O
+Hb B
+, O
+PLT O
+and O
+ESR O
+) O
+and O
+biochemical O
+tests O
+( O
+AST B
+, O
+ALT B
+, O
+ALP B
+, O
+gamma B
+GTP I
+, O
+LDH B
+, O
+CPK B
+, O
+Chol O
+, O
+T O
+- O
+Bil O
+, O
+TP O
+, O
+Alb B
+, O
+TG O
+, O
+BUN O
+, O
+Cr O
+, O
+Glu O
+, O
+Na O
+, O
+K O
+, O
+Ca O
+, O
+P O
+and O
+CRP B
+) O
+. O
+
+Both O
+the O
+inactive O
+domain B
+II I
+P68 I
+mutant I
+and O
+the O
+deletion O
+mutant O
+lacking O
+aa O
+91 O
+- O
+243 O
+were O
+less O
+inhibitory O
+to O
+growth O
+in O
+yeast O
+due O
+to O
+the O
+reduced O
+ability O
+to O
+phosphorylate O
+initiation B
+factor I
+2 I
+alpha I
+in O
+vivo O
+. O
+
+All O
+patients O
+studied O
+were O
+pregnant O
+women O
+and O
+their O
+delivered O
+children O
+. O
+
+Current O
+body O
+size O
+( O
+wt O
+/ O
+ht2 O
+) O
+was O
+significantly O
+associated O
+with O
+life O
+- O
+time O
+weight O
+dissatisfaction O
+in O
+both O
+sexes O
+( O
+P O
+less O
+than O
+0 O
+. O
+0005 O
+) O
+. O
+
+Mad3 B
+and O
+Mad4 B
+: O
+novel O
+Max B
+- O
+interacting O
+transcriptional O
+repressors O
+that O
+suppress O
+c B
+- I
+myc I
+dependent O
+transformation O
+and O
+are O
+expressed O
+during O
+neural O
+and O
+epidermal O
+differentiation O
+. O
+
+CONCLUSIONS O
+: O
+Patients O
+' O
+attainment O
+of O
+TGB O
+monotherapy O
+was O
+associated O
+with O
+their O
+achievement O
+of O
+positive O
+changes O
+of O
+varying O
+degree O
+on O
+psychological O
+tests O
+. O
+
+The O
+pcaR B
+regulatory I
+locus I
+has O
+been O
+found O
+to O
+be O
+required O
+for O
+both O
+induction O
+of O
+all O
+of O
+the O
+genes O
+within O
+the O
+pca B
+regulon I
+( O
+pcaBDC B
+, O
+pcaIJ B
+, O
+and O
+pcaF B
+) O
+and O
+the O
+chemotactic O
+response O
+of O
+the O
+bacteria O
+to O
+aromatic O
+compounds O
+. O
+
+Furthermore O
+, O
+we O
+have O
+identified O
+the O
+major O
+open O
+reading O
+frame O
+( O
+RF4 B
+; O
+2 O
+. O
+3 O
+kb O
+) O
+as O
+being O
+essential O
+for O
+activation O
+, O
+and O
+we O
+have O
+shown O
+that O
+the O
+NF B
+kappa I
+B I
+, O
+SP1 B
+, O
+and O
+TATA O
+box O
+motifs O
+in O
+the O
+human B
+immunodeficiency I
+virus I
+LTR I
+are O
+all O
+required O
+for O
+full O
+induction O
+of O
+the O
+promoter O
+by O
+the O
+HHV B
+- I
+6 I
+- I
+encoded I
+transactivator I
+. O
+
+However O
+, O
+mutations O
+of O
+the O
+C O
+- O
+rich O
+element O
+that O
+disrupted O
+a O
+GC O
+box O
+located O
+on O
+the O
+inverse O
+strand O
+eliminated O
+PMA O
+responsiveness O
+and O
+, O
+in O
+gel O
+mobility O
+shift O
+assays O
+, O
+eliminated O
+binding O
+of O
+Sp1 B
+. O
+
+TFIIB B
+and O
+VDR B
+can O
+also O
+interact O
+directly O
+, O
+and O
+these O
+factors O
+synergize O
+to O
+mediate O
+transactivation O
+. O
+
+Both O
+algorithms O
+have O
+been O
+implemented O
+and O
+applied O
+to O
+data O
+simulated O
+for O
+a O
+scanner O
+with O
+a O
+large O
+axial O
+aperture O
+( O
+30 O
+degrees O
+) O
+, O
+and O
+also O
+to O
+data O
+acquired O
+with O
+the O
+ECAT O
+HR O
+and O
+the O
+ECAT O
+HR O
++ O
+scanners O
+. O
+
+The O
+well O
+- O
+trained O
+group O
+was O
+measured O
+once O
+in O
+the O
+respiration O
+chamber O
+for O
+36 O
+h O
+according O
+to O
+the O
+same O
+protocol O
+. O
+
+Samarium O
+- O
+153 O
+for O
+intravascular O
+irradiation O
+therapy O
+with O
+liquid O
+- O
+filled O
+balloons O
+to O
+prevent O
+restenosis O
+: O
+acute O
+and O
+long O
+- O
+term O
+results O
+in O
+a O
+hypercholesterolemic O
+rabbit O
+restenosis O
+model O
+. O
+
+Only O
+viable O
+bacteria O
+at O
+a O
+high O
+concentration O
+induced O
+purulent O
+otitis O
+media O
+, O
+which O
+was O
+culture O
+positive O
+in O
+58 O
+% O
+of O
+the O
+cases O
+on O
+day O
+4 O
+. O
+
+Polyoma O
+virus O
+in O
+urine O
+during O
+pregnancy O
+. O
+
+Transfer O
+of O
+F O
+- O
+like O
+plasmids O
+is O
+regulated O
+by O
+the O
+FinOP B
+system O
+, O
+which O
+controls O
+the O
+expression O
+of O
+traJ B
+, O
+a O
+positive O
+regulator O
+of O
+the O
+transfer O
+operon O
+. O
+
+PKCI B
+- I
+1 I
+is O
+a O
+member O
+of O
+the O
+HIT B
+family I
+of O
+proteins O
+, O
+shown O
+by O
+sequence O
+identity O
+to O
+be O
+conserved O
+in O
+a O
+broad O
+range O
+of O
+organisms O
+including O
+mycoplasma O
+, O
+plants O
+, O
+and O
+humans O
+. O
+
+Conversion O
+of O
+glucose O
+phosphate O
+- O
+14C O
+to O
+glucose O
+- O
+14C O
+in O
+passage O
+through O
+human O
+brain O
+in O
+vivo O
+. O
+
+A O
+simple O
+technique O
+for O
+obtaining O
+ultra O
+- O
+thin O
+sections O
+of O
+coccidian O
+oocysts O
+is O
+reported O
+. O
+
+It O
+was O
+found O
+that O
+on O
+the O
+14th O
+and O
+21st O
+day O
+after O
+cimetidine O
+administration O
+serum O
+gastrin B
+levels O
+were O
+significantly O
+elevated O
+. O
+
+Dual O
+signal O
+peptides O
+mediate O
+the O
+signal B
+recognition I
+particle I
+/ O
+Sec B
+- O
+independent O
+insertion O
+of O
+a O
+thylakoid O
+membrane O
+polyprotein O
+, O
+PsbY B
+. O
+
+The O
+resulting O
+score O
+, O
+which O
+allowed O
+the O
+disease O
+to O
+be O
+expressed O
+as O
+a O
+continuous O
+variable O
+, O
+was O
+effectively O
+utilized O
+to O
+see O
+the O
+correlations O
+between O
+the O
+severity O
+of O
+coronary O
+arterial O
+disease O
+( O
+CAD O
+) O
+and O
+individual O
+risk O
+factors O
+/ O
+risk O
+markers O
+. O
+
+On O
+guanidine O
+and O
+the O
+treatment O
+of O
+botulism O
+. O
+
+Electronic O
+structure O
+of O
+Si O
+( O
+111 O
+) O
+- O
+NiSi2 O
+( O
+111 O
+) O
+A O
+- O
+type O
+and O
+B O
+- O
+type O
+interfaces O
+. O
+
+In O
+our O
+case O
+the O
+development O
+of O
+the O
+tumor O
+at O
+the O
+posterior O
+side O
+of O
+the O
+prostate O
+, O
+the O
+lack O
+of O
+PSA B
+immunoreactivity O
+and O
+the O
+presence O
+of O
+mucinous O
+glands O
+, O
+sometimes O
+" O
+endocervical O
+- O
+like O
+" O
+, O
+could O
+suggest O
+an O
+origin O
+from O
+embryonic O
+mullerian O
+remnants O
+in O
+the O
+prostatic O
+utricle O
+rather O
+than O
+urogenital O
+sinus O
+. O
+
+Upon O
+increasing O
+the O
+Marangoni O
+number O
+beyond O
+this O
+threshold O
+, O
+the O
+initially O
+stationary O
+flow O
+becomes O
+quickly O
+time O
+dependent O
+. O
+
+The O
+results O
+showed O
+differential O
+activation O
+of O
+each O
+parahippocampal O
+region O
+during O
+verbal O
+memory O
+tasks O
+in O
+which O
+the O
+side O
+activated O
+shifted O
+depending O
+on O
+the O
+nature O
+of O
+the O
+task O
+employed O
+; O
+an O
+increase O
+in O
+rCBF O
+in O
+the O
+left O
+parahippocampal O
+gyrus O
+was O
+associated O
+with O
+retrieval O
+strategy O
+of O
+non O
+- O
+matching O
+, O
+and O
+an O
+increase O
+in O
+rCBF O
+in O
+the O
+right O
+parahippocampal O
+gyrus O
+was O
+associated O
+with O
+retrieval O
+strategy O
+of O
+matching O
+. O
+
+Evolution O
+of O
+cytomegalovirus O
+antibodies O
+of O
+maternal O
+origin O
+and O
+acquired O
+, O
+throughout O
+the O
+first O
+year O
+of O
+life O
+
+Demonstration O
+of O
+changes O
+in O
+fetal O
+liver O
+erythropoiesis O
+using O
+echo O
+- O
+planar O
+magnetic O
+resonance O
+imaging O
+. O
+
+The O
+actual O
+placement O
+of O
+the O
+lesions O
+was O
+determined O
+after O
+mapping O
+of O
+the O
+GPi O
+by O
+microrecording O
+, O
+using O
+stimulation O
+to O
+identify O
+the O
+sensorimotor O
+region O
+and O
+its O
+somatotopic O
+organization O
+. O
+
+Effect O
+of O
+prostaglandin O
+E2 O
+on O
+experimental O
+atherosclerosis O
+. O
+
+Both O
+the O
+arterial O
+and O
+venous O
+thrombi O
+were O
+clearly O
+discernible O
+at O
+2 O
+to O
+8 O
+h O
+after O
+injection O
+of O
+99Tcm O
+- O
+SZ O
+- O
+51 O
+. O
+
+The O
+effect O
+of O
+lung O
+edema O
+on O
+pulmonary O
+vasoactivity O
+of O
+furosemide O
+. O
+
+However O
+, O
+the O
+malaria O
+vectors O
+Anopheles O
+funestus O
+and O
+An O
+. O
+gambiae O
+have O
+both O
+become O
+more O
+abundant O
+during O
+the O
+1970s O
+and O
+1980s O
+and O
+sporozoite O
+- O
+positive O
+specimens O
+of O
+both O
+have O
+been O
+found O
+. O
+
+Soluble O
+extracts O
+from O
+FGF B
+- O
+treated O
+as O
+compared O
+with O
+quiescent O
+fibroblasts O
+exhibited O
+up O
+to O
+3 O
+- O
+fold O
+higher O
+kinase O
+activity O
+towards O
+S6 B
+in O
+exogenously O
+added O
+rat B
+liver I
+40S I
+ribosomes I
+and O
+a O
+synthetic O
+peptide O
+, O
+RRLSSLRA O
+. O
+
+In O
+bell O
+pepper O
+, O
+a O
+gene O
+encoding O
+a O
+major O
+plastid O
+- O
+lipid O
+associated O
+protein O
+is O
+expressed O
+as O
+both O
+partially O
+and O
+totally O
+spliced O
+transcripts O
+( O
+respectively O
+PAP2 B
+and O
+PAP1 B
+) O
+. O
+
+Inhibitory O
+receptors O
+are O
+characterized O
+by O
+the O
+presence O
+of O
+a O
+characteristic O
+sequence O
+known O
+as O
+an O
+immunoreceptor O
+tyrosine O
+- O
+based O
+inhibitory O
+motif O
+( O
+ITIM O
+) O
+in O
+their O
+cytoplasmic O
+tail O
+. O
+
+We O
+conclude O
+that O
+LGCS O
+is O
+successful O
+in O
+treating O
+esophageal O
+varices O
+in O
+the O
+setting O
+of O
+hyperdynamic O
+portal O
+circulation O
+with O
+acceptable O
+liver O
+function O
+. O
+
+Candidate O
+factors O
+have O
+been O
+identified O
+by O
+the O
+observation O
+that O
+changes O
+in O
+glucocorticoid O
+induction O
+parameters O
+in O
+CV O
+- O
+1 O
+cells O
+could O
+be O
+reproduced O
+by O
+varying O
+the O
+cellular O
+levels O
+of O
+coactivators O
+[ O
+transcriptional B
+intermediary I
+factor I
+2 I
+( O
+TIF2 B
+) O
+, O
+steroid B
+receptor I
+coactivator I
+1 I
+( O
+SRC B
+- I
+1 I
+) O
+, O
+and O
+amplified B
+in I
+breast I
+cancer I
+1 I
+( O
+AIB1 B
+) O
+] O
+, O
+comodulator O
+[ O
+CREB B
+- I
+binding I
+protein I
+( O
+CBP B
+) O
+] O
+, O
+or O
+corepressor O
+[ O
+silencing B
+mediator I
+for I
+retinoid I
+and I
+thyroid I
+- I
+hormone I
+receptors I
+( O
+SMRT B
+) O
+] O
+without O
+
+concomitant O
+increases O
+in O
+GR B
+. O
+
+Immunoblot O
+analyses O
+revealed O
+that O
+the O
+loss O
+of O
+activator O
+function O
+coincides O
+with O
+selective O
+removal O
+of O
+the O
+C O
+- O
+terminal O
+domain O
+( O
+CTD O
+) O
+- O
+hyperphosphorylated O
+RNAP B
+IIO I
+along O
+with O
+NC2 B
+. O
+
+The O
+nucleotide O
+sequence O
+of O
+the O
+gene O
+encoding O
+this O
+product O
+was O
+determined O
+and O
+the O
+amino O
+acid O
+sequence O
+deduced O
+. O
+
+At O
+9 O
+months O
+postpartum O
+, O
+serum O
+fT4 O
+and O
+fT3 O
+levels O
+were O
+low O
+normal O
+( O
+8 O
+. O
+0 O
+and O
+1 O
+. O
+7 O
+pmol O
+/ O
+L O
+, O
+respectively O
+) O
+, O
+but O
+TSH B
+was O
+not O
+raised O
+( O
+0 O
+. O
+4 O
+mU O
+/ O
+L O
+) O
+. O
+
+RESULTS O
+: O
+Three O
+patients O
+did O
+not O
+tolerate O
+PPI O
+medication O
+and O
+were O
+managed O
+by O
+treatment O
+with O
+type O
+2 O
+histamine B
+( O
+H2 O
+) O
+blockers O
+. O
+
+It O
+is O
+considered O
+important O
+, O
+therefore O
+, O
+when O
+treating O
+diabetic O
+patients O
+with O
+peripheral O
+neuropathy O
+not O
+to O
+assume O
+that O
+the O
+diabetes O
+itself O
+is O
+the O
+cause O
+in O
+all O
+cases O
+. O
+
+TFIIIB B
+assembles O
+autonomously O
+on O
+the O
+upstream O
+promoter O
+of O
+the O
+yeast B
+U6 I
+snRNA I
+( O
+SNR6 B
+) O
+gene O
+in O
+vitro O
+, O
+through O
+the O
+interaction O
+of O
+its O
+TBP B
+subunit I
+with O
+a O
+consensus O
+TATA O
+box O
+located O
+at O
+base O
+pair O
+- O
+30 O
+. O
+
+Mutational O
+analysis O
+of O
+the O
+IME2 B
+UAS I
+reveals O
+two O
+critical O
+sequence O
+elements O
+: O
+a O
+G O
++ O
+C O
+- O
+rich O
+sequence O
+( O
+called O
+URS1 O
+) O
+, O
+previously O
+identified O
+at O
+many O
+meiotic O
+genes O
+, O
+and O
+a O
+newly O
+described O
+element O
+, O
+the O
+T4C B
+site O
+, O
+that O
+we O
+found O
+at O
+a O
+subset O
+of O
+meiotic O
+genes O
+. O
+
+Molecular O
+analysis O
+of O
+the O
+mannitol B
+operon I
+of I
+Clostridium O
+acetobutylicum O
+encoding O
+a O
+phosphotransferase O
+system O
+and O
+a O
+putative O
+PTS O
+- O
+modulated O
+regulator O
+. O
+
+Our O
+results O
+show O
+that O
+a O
+combination O
+of O
+Pfu B
+exo I
+( I
+- I
+) I
+at O
+the O
+primer O
+extension O
+step O
+and O
+Taq B
+at O
+the O
+PCR O
+amplification O
+step O
+is O
+ideal O
+for O
+in O
+vivo O
+DNA O
+analysis O
+and O
+DNA O
+damage O
+mapping O
+using O
+LMPCR O
+. O
+
+Effect O
+of O
+TNF B
+, O
+IL B
+- I
+1 I
+, O
+and O
+IL B
+- I
+6 I
+on O
+the O
+proliferation O
+of O
+human O
+Tenon O
+' O
+s O
+capsule O
+fibroblasts O
+in O
+tissue O
+culture O
+. O
+
+Estimating O
+the O
+health O
+care O
+costs O
+of O
+smokers O
+. O
+
+Using O
+lacZ B
+- O
+inducible O
+T O
+cells O
+as O
+a O
+probe O
+, O
+we O
+screened O
+a O
+splenic O
+cDNA O
+library O
+in O
+transiently O
+transfected O
+antigen O
+- O
+presenting O
+cells O
+( O
+APCs O
+) O
+and O
+isolated O
+a O
+cDNA O
+clone O
+that O
+allowed O
+expression O
+of O
+the O
+appropriate O
+peptide B
+/ I
+Kb I
+MHC I
+complex I
+in O
+APC O
+. O
+
+Endotoxemia O
+and O
+bacteremia O
+in O
+patients O
+with O
+sepsis O
+syndrome O
+in O
+the O
+intensive O
+care O
+unit O
+. O
+
+Early O
+attempts O
+for O
+modifying O
+growth O
+functions O
+to O
+annual O
+variations O
+dating O
+back O
+up O
+to O
+2 O
+decades O
+are O
+recalled O
+together O
+with O
+examples O
+for O
+their O
+application O
+showing O
+rather O
+different O
+degrees O
+of O
+approximation O
+. O
+
+A O
+significant O
+reduction O
+in O
+total O
+cellular O
+p27 B
+protein I
+levels O
+and O
+a O
+moderate O
+reduction O
+in O
+p27 B
+mRNA I
+are O
+observed O
+, O
+but O
+no O
+changes O
+in O
+Cdk B
+regulatory I
+kinases I
+and I
+phosphatases I
+occur O
+. O
+
+Genetic O
+linkage O
+mapping O
+of O
+the O
+CYP11A1 B
+gene I
+encoding O
+the O
+cholesterol B
+side I
+- I
+chain I
+cleavage I
+P450scc I
+close O
+to O
+the O
+CYP1A1 B
+gene I
+and O
+D15S204 B
+in O
+the O
+chromosome O
+15q22 O
+. O
+33 O
+- O
+q23 O
+region O
+. O
+
+Genetic O
+and O
+physiological O
+experiments O
+suggest O
+a O
+close O
+relationship O
+between O
+cdc27 B
++ I
+and O
+the O
+cdc2 B
++ I
+gene I
+, O
+a O
+key O
+regulator O
+of O
+mitosis O
+in O
+yeast O
+and O
+also O
+in O
+higher O
+eukaryotic O
+cells O
+. O
+
+The O
+study O
+was O
+performed O
+in O
+a O
+class O
+100 O
+laminar O
+flow O
+clean O
+bench O
+in O
+order O
+to O
+minimize O
+particulate O
+contamination O
+from O
+extraneous O
+sources O
+. O
+
+The O
+cloned O
+rRNA O
+operon O
+was O
+transcribed O
+in O
+vitro O
+by O
+using O
+purified O
+RNA B
+polymerase I
+of I
+Escherichia I
+coli I
+. O
+
+Of O
+the O
+CSF O
+tested O
+, O
+24 O
+stimulated O
+oxygen O
+consumption O
+above O
+our O
+cut O
+off O
+, O
+and O
+8 O
+did O
+not O
+( O
+0 O
+. O
+84 O
++ O
+/ O
+- O
+0 O
+. O
+34 O
+, O
+n O
+= O
+24 O
+compared O
+with O
+the O
+rate O
+of O
+0 O
+. O
+27 O
++ O
+/ O
+- O
+0 O
+. O
+1 O
+mumol O
+/ O
+min O
+/ O
+g O
+dry O
+wt O
+, O
+respectively O
+; O
+SD O
+n O
+= O
+8 O
+) O
+at O
+180 O
+minutes O
+. O
+
+The O
+sequence O
+of O
+the O
+gene O
+upstream O
+to O
+the O
+cap O
+site O
+contains O
+characteristic O
+RNA B
+polymerase I
+II I
+promoter I
+- I
+binding I
+sites I
+: O
+a O
+putative O
+TATA O
+box O
+at O
+position O
+- O
+29 O
+and O
+a O
+Sp B
+1 I
+binding I
+site I
+( O
+GGGGCGGAGA O
+) O
+at O
+position O
+- O
+48 O
+. O
+
+The O
+kinetics O
+of O
+[ O
+14C O
+] O
+NG O
+in O
+the O
+blood O
+of O
+the O
+dosed O
+animals O
+was O
+followed O
+. O
+
+These O
+clones O
+contain O
+most O
+of O
+the O
+exon O
+of O
+cyclin B
+D2 I
+except O
+exon O
+5 O
+. O
+
+One O
+had O
+a O
+48 O
+- O
+hour O
+cycle O
+and O
+the O
+other O
+a O
+24 O
+- O
+hour O
+cycle O
+. O
+
+This O
+action O
+could O
+be O
+antagonized O
+by O
+aminophylline O
+, O
+a O
+competitive O
+antagonist O
+on O
+P1 B
+purinoceptors I
+. O
+
+Evidence O
+for O
+Gcr1p B
+/ O
+Gcr2p B
+interaction O
+has O
+been O
+presented O
+earlier O
+and O
+is O
+now O
+supported O
+by O
+the O
+isolation O
+of O
+mutations O
+in O
+Gcr1p B
+suppressing O
+gcr2 B
+, O
+as O
+assessed O
+by O
+growth O
+and O
+enzyme O
+assay O
+. O
+
+Keys O
+can O
+be O
+used O
+for O
+identifying O
+species O
+from O
+the O
+European O
+part O
+of O
+the O
+USSR O
+and O
+north O
+- O
+eastern O
+Kazakhstan O
+. O
+
+Promoter O
+constructs O
+containing O
+mutations O
+in O
+the O
+PTRE B
+sequence I
+that O
+selectively O
+abolished O
+the O
+binding O
+of O
+either O
+one O
+or O
+both O
+complexes O
+exerted O
+opposite O
+effects O
+on O
+the O
+transcriptional O
+activity O
+of O
+trypsin B
+promoters I
+in O
+A O
+. O
+gambiae O
+and O
+Aedes O
+aegypti O
+cell O
+lines O
+. O
+
+The O
+Rep78 B
+protein I
+of O
+adeno O
+- O
+associated O
+virus O
+( O
+AAV O
+) O
+contains O
+amino O
+acid O
+sequence O
+motifs O
+common O
+to O
+rolling B
+- I
+circle I
+replication I
+( I
+RCR I
+) I
+initiator I
+proteins I
+. O
+
+Plasma B
+prolactin I
+in O
+patients O
+with O
+colorectal O
+cancer O
+. O
+
+Reality O
+and O
+clinical O
+application O
+of O
+immunoglobulin B
+preparations O
+
+The O
+extent O
+of O
+myocardial O
+ischemia O
+in O
+the O
+coronary O
+sinus O
+study O
+was O
+significantly O
+correlated O
+to O
+the O
+coronary O
+diameters O
+of O
+the O
+proximal O
+and O
+middle O
+segments O
+of O
+the O
+Ramus O
+interventricularis O
+anterior O
+and O
+the O
+middle O
+segment O
+of O
+the O
+Ramus O
+circumflexus O
+( O
+r O
+= O
+0 O
+. O
+87 O
+, O
+p O
+< O
+0 O
+. O
+02 O
+) O
+. O
+
+The O
+in O
+- O
+plane O
+orientational O
+anisotropy O
+of O
+the O
+8CB O
+films O
+grown O
+on O
+unidirectionally O
+photopolymerized O
+PVCN O
+substrates O
+is O
+considerably O
+lower O
+than O
+the O
+intrinsic O
+surface O
+orientational O
+anisotropy O
+of O
+these O
+substrates O
+, O
+which O
+can O
+explain O
+the O
+generally O
+found O
+weak O
+surface O
+anchoring O
+of O
+liquid O
+crystals O
+on O
+PVCN O
+alignment O
+layers O
+. O
+
+Nuclear O
+transcription O
+assays O
+confirmed O
+that O
+cys B
+- I
+3 I
++ I
+was O
+under O
+sulfur O
+- O
+regulated O
+transcriptional O
+control O
+and O
+that O
+cys B
+- I
+3 I
++ I
+transcription O
+was O
+constitutive O
+in O
+sulfur B
+controller I
+( O
+scon B
+) O
+- O
+negative O
+regulator O
+mutants O
+. O
+
+The O
+rifampicin O
+resistance O
+of O
+uvsW B
+- O
+repressed O
+replication O
+suggests O
+that O
+it O
+involves O
+either O
+tertiary O
+initiation O
+or O
+some O
+novel O
+mode O
+of O
+initiation O
+. O
+
+Pharmacokinetics O
+of O
+skin O
+penetration O
+. O
+
+Furthermore O
+, O
+the O
+regulation O
+conferred O
+on O
+a O
+reporter O
+gene O
+in O
+Drosophila O
+by O
+three O
+closely O
+related O
+sequences O
+demonstrates O
+that O
+even O
+subtle O
+sequence O
+changes O
+within O
+an O
+E O
+box O
+or O
+flanking O
+bases O
+have O
+dramatic O
+consequences O
+on O
+the O
+overall O
+repertoire O
+of O
+proteins O
+that O
+can O
+bind O
+in O
+vivo O
+. O
+
+Buspirone O
+therapy O
+for O
+Type O
+A O
+behavior O
+, O
+hostility O
+, O
+and O
+perceived O
+stress O
+in O
+cardiac O
+patients O
+. O
+
+Recently O
+we O
+have O
+performed O
+a O
+detailed O
+analysis O
+of O
+specific O
+neuronal O
+populations O
+affected O
+by O
+the O
+mutation O
+which O
+shed O
+new O
+light O
+on O
+the O
+role O
+of O
+Krox B
+- I
+20 I
+in O
+the O
+segmentation O
+and O
+on O
+the O
+physiological O
+consequences O
+of O
+its O
+inactivation O
+. O
+
+A O
+species O
+comparison O
+of O
+cDNA O
+sequences O
+and O
+isolation O
+of O
+a O
+genomic O
+clone O
+. O
+
+The O
+inhibition O
+of O
+monoamine B
+oxidase I
+( O
+MAO B
+) O
+by O
+tranylcypromine O
+was O
+studied O
+in O
+6 O
+healthy O
+volunteers O
+given O
+increasing O
+doses O
+of O
+10 O
+, O
+15 O
+, O
+20 O
+and O
+25 O
+mg O
+/ O
+day O
+over O
+a O
+4 O
+- O
+week O
+period O
+. O
+
+Deletion O
+mutagenesis O
+of O
+the O
+promoter O
+indicated O
+that O
+a O
+positive O
+regulatory O
+element O
+( O
+PRE O
+) O
+was O
+likely O
+to O
+exist O
+downstream O
+of O
+the O
+UL94 B
+mRNA I
+start I
+site I
+, O
+while O
+a O
+negative O
+regulatory O
+element O
+( O
+NRE O
+) O
+was O
+present O
+upstream O
+of O
+the O
+TATA O
+box O
+. O
+
+Expression O
+of O
+Helios B
+was O
+detected O
+in O
+the O
+earliest O
+hematopoietic O
+sites O
+of O
+the O
+embryo O
+, O
+in O
+hematopoietic O
+stem O
+cells O
+in O
+the O
+adult O
+and O
+was O
+subsequently O
+restricted O
+to O
+a O
+subset O
+of O
+cells O
+in O
+the O
+T O
+cell O
+lineage O
+. O
+
+Metapsychiatry O
+is O
+a O
+term O
+born O
+of O
+necessity O
+to O
+designate O
+the O
+important O
+but O
+hitherto O
+unclassified O
+interface O
+between O
+psychiatry O
+and O
+mysticism O
+. O
+
+Effects O
+of O
+negative O
+pi O
+mesons O
+on O
+mouse O
+bone O
+marrow O
+cells O
+. O
+
+Using O
+probes O
+containing O
+C B
+/ I
+EBP I
+- I
+binding I
+sites I
+from O
+the O
+iNOS B
+gene I
+revealed O
+further O
+binding O
+of O
+different O
+complexes O
+, O
+all O
+of O
+which O
+were O
+strongly O
+inducible O
+by O
+cAMP O
+and O
+to O
+a O
+lower O
+extent O
+also O
+by O
+IL B
+- I
+1beta I
+. O
+
+The O
+Pi O
+signals O
+are O
+conveyed O
+to O
+PHO8 B
+by O
+binding O
+of O
+PHO4 B
+protein I
+, O
+a O
+positive O
+regulatory O
+factor O
+, O
+to O
+a O
+promoter O
+region O
+of O
+PHO8 B
+( O
+PHO8p B
+) O
+under O
+the O
+influence O
+of O
+the O
+PHO O
+regulatory O
+circuit O
+. O
+
+Thus O
+, O
+the O
+end O
+of O
+a O
+linearized O
+DNA O
+fragment O
+can O
+initiate O
+new O
+DNA O
+synthesis O
+by O
+BIR B
+in O
+which O
+the O
+newly O
+synthesized O
+DNA O
+is O
+displaced O
+and O
+subsequently O
+forms O
+circles O
+by O
+NHEJ O
+. O
+
+It O
+would O
+seem O
+that O
+caution O
+should O
+be O
+exercised O
+in O
+using O
+HPL O
+values O
+as O
+an O
+index O
+of O
+placental O
+function O
+in O
+anaemic O
+women O
+. O
+
+A O
+case O
+of O
+acquired O
+immune O
+deficiency O
+syndrome O
+before O
+1980 O
+. O
+
+These O
+data O
+suggest O
+that O
+multiple O
+genetic O
+recombination O
+among O
+bacteriophages O
+with O
+different O
+immunities O
+took O
+place O
+to O
+generate O
+the O
+prophage O
+VT1 O
+- O
+Sakai O
+. O
+
+The O
+adenovirus B
+E1B I
+19 I
+, I
+000 I
+- I
+molecular I
+- I
+weight I
+( I
+19K I
+) I
+protein I
+is O
+a O
+potent O
+inhibitor O
+of O
+apoptosis O
+and O
+cooperates O
+with O
+E1A B
+to O
+transform O
+primary O
+rodent O
+cells O
+. O
+
+Desensitization O
+of O
+the O
+growth B
+hormone I
+- O
+induced O
+Janus B
+kinase I
+2 I
+( O
+Jak B
+2 I
+) O
+/ O
+signal B
+transducer I
+and I
+activator I
+of I
+transcription I
+5 I
+( O
+Stat5 B
+) O
+- O
+signaling O
+pathway O
+requires O
+protein O
+synthesis O
+and O
+phospholipase B
+C I
+. O
+
+In O
+two O
+separate O
+studies O
+, O
+specimens O
+of O
+saliva O
+from O
+57 O
+individuals O
+over O
+the O
+age O
+of O
+65 O
+years O
+( O
+mean O
+age O
+, O
+76 O
+. O
+7 O
+years O
+) O
+and O
+37 O
+persons O
+under O
+the O
+age O
+of O
+40 O
+years O
+( O
+mean O
+age O
+, O
+28 O
+. O
+8 O
+years O
+) O
+were O
+examined O
+for O
+concentrations O
+of O
+IgA B
+as O
+functions O
+of O
+volume O
+, O
+total O
+protein O
+, O
+and O
+electrolyte O
+conductivity O
+; O
+some O
+were O
+also O
+tested O
+for O
+IgG B
+and O
+IgM B
+content O
+. O
+
+E2A B
+- O
+HLF B
+- O
+mediated O
+cell O
+transformation O
+requires O
+both O
+the O
+trans O
+- O
+activation O
+domains O
+of O
+E2A B
+and O
+the O
+leucine O
+zipper O
+dimerization O
+domain O
+of O
+HLF B
+. O
+
+Two O
+adjacent O
+, O
+highly O
+homologous O
+endoglucanase B
+genes I
+, O
+celD B
+and O
+celE B
+from O
+Fibrobacter O
+succinogenes O
+S85 I
+, O
+which O
+were O
+separated O
+by O
+an O
+AT O
+- O
+rich O
+223 O
+- O
+nucleotide O
+intergenic O
+region O
+were O
+characterized O
+. O
+
+The O
+Seldinger O
+technique O
+for O
+difficult O
+transurethral O
+catheterization O
+: O
+a O
+gentle O
+alternative O
+to O
+suprapubic O
+puncture O
+( O
+Br O
+J O
+Surg O
+2000 O
+; O
+87 O
+: O
+1729 O
+- O
+30 O
+) O
+. O
+
+We O
+screened O
+an O
+A O
+. O
+thaliana O
+cDNA O
+library O
+, O
+whose O
+inserts O
+are O
+under O
+the O
+control O
+of O
+the O
+galactose O
+- O
+inducible O
+GAL10 B
+promoter I
+, O
+for O
+cDNAs O
+which O
+enabled O
+YDH8 O
+cells O
+to O
+grow O
+at O
+the O
+restrictive O
+temperature O
+. O
+
+We O
+generated O
+" O
+signature O
+" O
+oligonucleotides O
+from O
+these O
+CDR3s B
+and O
+probed O
+PCR O
+amplified O
+V B
+kappa I
+products O
+from O
+the O
+synovium O
+and O
+PBLs O
+of O
+the O
+same O
+patient O
+, O
+and O
+from O
+PBLs O
+and O
+spleen O
+of O
+individuals O
+without O
+rheumatic O
+disease O
+. O
+
+One O
+of O
+the O
+major O
+transcripts O
+encodes O
+MEQ B
+, O
+a O
+339 B
+- I
+amino I
+- I
+acid I
+bZIP I
+protein I
+which O
+is O
+homologous O
+to O
+the O
+Jun B
+/ O
+Fos B
+family O
+of O
+transcription O
+factors O
+. O
+
+It O
+is O
+concluded O
+that O
+the O
+new O
+class O
+of O
+competitive O
+NMDA B
+receptor I
+antagonists O
+, O
+exemplified O
+by O
+CGP O
+37849 O
+, O
+is O
+the O
+most O
+promising O
+candidate O
+for O
+clinical O
+trials O
+in O
+anxiety O
+disorders O
+. O
+
+An O
+emended O
+diagnosis O
+of O
+Tylocephalum O
+is O
+proposed O
+excluding O
+this O
+feature O
+, O
+along O
+with O
+distribution O
+of O
+the O
+testes O
+in O
+the O
+preovarian O
+field O
+and O
+circummedullary O
+distribution O
+of O
+vitelline O
+follicles O
+. O
+
+Induction O
+of O
+interferon B
+- I
+alpha I
+( O
+IFNalpha B
+) O
+gene O
+expression O
+in O
+virus O
+- O
+infected O
+cells O
+requires O
+phosphorylation O
+- O
+induced O
+activation O
+of O
+the O
+transcription O
+factors O
+IRF3 B
+and O
+IRF7 B
+. O
+
+METHODS O
+: O
+The O
+prevalence O
+of O
+haemagglutination B
+inhibiting I
+( I
+HI I
+) I
+antibodies I
+to O
+JE I
+virus I
+( O
+JEV O
+) O
+, O
+West O
+Nile O
+virus O
+( O
+WNV O
+) O
+and O
+dengue O
+- O
+2 O
+virus O
+( O
+DEN O
+- O
+2 O
+) O
+was O
+detected O
+by O
+HI O
+test O
+and O
+IgM B
+antibody I
+capture O
+ELISA O
+( O
+MAC O
+ELISA O
+) O
+was O
+performed O
+to O
+determine O
+recent O
+infections O
+with O
+JE O
+virus O
+. O
+
+Moreover O
+, O
+since O
+the O
+integrated O
+transforming O
+DNA O
+was O
+not O
+altered O
+or O
+lost O
+expression O
+of O
+the O
+RbcS2 B
+: O
+: O
+aadA B
+: O
+: O
+RbcS2 B
+gene I
+( I
+s I
+) I
+appears O
+to O
+be O
+repressed O
+. O
+
+Donehower O
+and O
+H O
+. O
+
+A O
+characteristic O
+feature O
+is O
+their O
+tendency O
+to O
+form O
+homo O
+- O
+and O
+/ O
+or O
+heterodimeric O
+complexes O
+. O
+
+Further O
+, O
+more O
+recent O
+communications O
+suggest O
+that O
+liver O
+disease O
+led O
+to O
+a O
+differential O
+alteration O
+of O
+the O
+cytochrome B
+P I
+- I
+450s I
+with O
+regard O
+to O
+protein O
+content O
+and O
+activity O
+. O
+
+Apparent O
+Buschke O
+- O
+Loewenstein O
+tumour O
+of O
+the O
+penis O
+. O
+
+This O
+effect O
+was O
+stronger O
+after O
+multiple O
+predoses O
+of O
+sertraline O
+, O
+when O
+imipramine O
+Cmax O
+and O
+AUC O
+( O
+0 O
+- O
+infinity O
+) O
+were O
+increased O
+by O
+39 O
+% O
+and O
+68 O
+% O
+, O
+respectively O
+. O
+
+Mutations O
+in O
+nifR1 B
+( O
+ntrC B
+) O
+and O
+nifR4 B
+( O
+rpoN B
+, O
+encoding O
+sigma54 B
+) O
+had O
+no O
+influence O
+on O
+xdh B
+gene I
+expression O
+. O
+
+We O
+therefore O
+propose O
+that O
+PRR2 B
+, O
+and O
+not O
+PVR B
+, O
+is O
+the O
+true O
+human B
+homolog I
+of I
+MPH I
+. O
+
+Swarming O
+of O
+Moraxella O
+
+Biochem O
+. O
+
+In O
+contrast O
+, O
+vRel B
+lacks O
+a O
+strong O
+C O
+- O
+terminal O
+gene O
+activation O
+function O
+, O
+since O
+a O
+LexA B
+fusion I
+protein I
+containing O
+C O
+- O
+terminal O
+vRel B
+sequences I
+alone O
+only O
+weakly O
+activated O
+transcription O
+. O
+
+The O
+crystal O
+structure O
+of O
+the O
+yeast B
+Phe I
+- I
+tRNAPhe I
+ternary I
+complex I
+with O
+Thermus B
+aquaticus I
+EF I
+- I
+Tu I
+- I
+GDPNP I
+( O
+Phe O
+- O
+TC O
+) O
+has O
+previously O
+been O
+determined O
+as O
+one O
+representative O
+of O
+this O
+general O
+yet O
+highly O
+discriminating O
+complex O
+formation O
+. O
+
+Bovine O
+anaplasmosis O
+: O
+susceptibility O
+of O
+seronegative O
+cows O
+from O
+an O
+infected O
+herd O
+to O
+experimental O
+infection O
+with O
+Anaplasma O
+marginale O
+. O
+
+Because O
+of O
+gut O
+fermentation O
+, O
+a O
+substantial O
+portion O
+( O
+16 O
+- O
+80 O
+% O
+) O
+of O
+N O
+is O
+absorbed O
+as O
+ammonia O
+N O
+( O
+NH3N O
+) O
+. O
+
+Quantitative O
+measurement O
+of O
+antigamma B
+globulin I
+factors I
+( O
+rheumatoid B
+factors I
+) O
+using O
+laser O
+- O
+nephelometry O
+in O
+comparison O
+with O
+the O
+latex O
+agglutination O
+test O
+and O
+the O
+Waaler O
+- O
+Rose O
+test O
+
+The O
+densities O
+ranged O
+between O
+2 O
+and O
+3976 O
+neurites O
+/ O
+mm2 O
+skin O
+surface O
+, O
+but O
+the O
+overlap O
+between O
+subjects O
+and O
+without O
+PHN O
+was O
+small O
+. O
+
+Zoonotic O
+areas O
+in O
+which O
+HIV O
+co O
+- O
+infection O
+is O
+common O
+could O
+also O
+be O
+at O
+risk O
+as O
+sandflies O
+can O
+become O
+infected O
+from O
+co O
+- O
+infected O
+individuals O
+. O
+
+The O
+determination O
+of O
+antithrombin B
+III I
+( O
+AT B
+III I
+) O
+and O
+its O
+clinical O
+significance O
+
+The O
+kinetics O
+of O
+erythromycin O
+( O
+E O
+. O
+) O
+was O
+studied O
+in O
+16 O
+patients O
+with O
+different O
+degrees O
+of O
+impairment O
+of O
+renal O
+function O
+after O
+a O
+single O
+intravenous O
+dose O
+. O
+
+Base O
+substitutions O
+within O
+this O
+NFIL B
+- I
+6 I
+site I
+resulted O
+in O
+virtual O
+elimination O
+of O
+LPS O
+- O
+induced O
+IL B
+- I
+1 I
+beta I
+gene I
+transcription O
+. O
+
+Mortality O
+rates O
+were O
+not O
+different O
+( O
+chi2 O
+: O
+0 O
+. O
+0298 O
+, O
+p O
+> O
+0 O
+. O
+5 O
+) O
+. O
+
+The O
+MALDI O
+- O
+TOF O
+experiment O
+, O
+however O
+, O
+proved O
+to O
+be O
+superior O
+to O
+the O
+GC O
+experiment O
+, O
+particularly O
+with O
+regard O
+to O
+baseline O
+resolution O
+of O
+unsaturated O
+acids O
+. O
+
+Modern O
+aspects O
+of O
+shock O
+- O
+treatment O
+in O
+extensive O
+burns O
+( O
+author O
+' O
+s O
+transl O
+) O
+
+Of O
+the O
+private O
+practices O
+accredited O
+in O
+August O
+1995 O
+, O
+40 O
+. O
+6 O
+per O
+cent O
+( O
+122 O
+) O
+participated O
+. O
+
+A O
+Drosophila O
+subobscura O
+genomic O
+fragment O
+containing O
+all O
+the O
+exons O
+and O
+the O
+late O
+and O
+early O
+promotors O
+in O
+the O
+Sxl B
+gene I
+of O
+D O
+. O
+melanogaster O
+was O
+isolated O
+. O
+
+Collectively O
+, O
+a O
+unique O
+mechanism O
+involving O
+NF B
+- I
+ATp I
+appears O
+to O
+regulate O
+the O
+cell O
+type O
+- O
+specific O
+and O
+activation O
+- O
+dependent O
+expression O
+of O
+the O
+SCM B
+- I
+1 I
+genes I
+. O
+
+The O
+sensitivity O
+of O
+central B
+dopamine I
+receptors I
+was O
+assessed O
+with O
+the O
+growth B
+hormone I
+response O
+to O
+apomorphine O
+application O
+. O
+
+Oral O
+basal O
+body O
+temperature O
+( O
+BBT O
+) O
+recordings O
+of O
+46 O
+women O
+that O
+conceived O
+by O
+donor O
+insemination O
+and O
+who O
+had O
+midcycle O
+monitoring O
+of O
+luteinising B
+hormone I
+( O
+LH B
+) O
+were O
+analysed O
+to O
+establish O
+features O
+associated O
+with O
+an O
+optimal O
+cycle O
+. O
+
+Our O
+results O
+admit O
+that O
+a O
+ribosome O
+scanning O
+mechanism O
+of O
+the O
+MP B
+gene I
+expression O
+from O
+I B
+( I
+2 I
+) I
+sgRNA I
+operates O
+concurrently O
+. O
+
+The O
+three O
+- O
+dimensional O
+structure O
+of O
+the O
+E B
+. I
+coli I
+CR I
+domain I
+indicates O
+that O
+this O
+sequence O
+conservation O
+is O
+likely O
+to O
+result O
+in O
+a O
+conserved O
+structural O
+motif O
+. O
+
+Otosclerosis O
+in O
+monozygotic O
+twins O
+: O
+clinical O
+and O
+genetical O
+analysis O
+
+A O
+DNA O
+fragment O
+that O
+complements O
+the O
+uvs B
+- I
+2 I
+mutation I
+was O
+subcloned O
+by O
+monitoring O
+its O
+ability O
+to O
+transform O
+the O
+uvs B
+- I
+2 I
+mutant I
+to O
+MMS O
+resistance O
+. O
+
+The O
+human B
+lbc I
+oncogene I
+product I
+is O
+a O
+guanine B
+nucleotide I
+exchange I
+factor I
+that O
+specifically O
+activates O
+the O
+Rho B
+small I
+GTP I
+binding I
+protein I
+, O
+thus O
+resulting O
+in O
+biologically O
+active O
+, O
+GTP O
+- O
+bound O
+Rho B
+, O
+which O
+in O
+turn O
+mediates O
+actin B
+cytoskeletal O
+reorganization O
+, O
+gene O
+transcription O
+, O
+and O
+entry O
+into O
+the O
+mitotic O
+S O
+phase O
+. O
+
+Insulin B
+- O
+stimulated O
+autophosphorylation O
+at O
+specific O
+sites O
+in O
+the O
+tyrosine B
+kinase I
+domain I
+of O
+the O
+receptor O
+' O
+s O
+beta O
+- O
+subunit O
+is O
+correlated O
+kinetically O
+with O
+activation O
+of O
+kinase O
+- O
+catalyzed O
+phosphorylation O
+of O
+a O
+model O
+substrate O
+( O
+reduced B
+and I
+carboxyamidomethylated I
+lysozyme I
+; O
+RCAM B
+- I
+lysozyme I
+) O
+. O
+
+The O
+critical O
+obstacle O
+in O
+modeling O
+psychiatric O
+disorders O
+has O
+been O
+limited O
+information O
+about O
+their O
+origin O
+and O
+underlying O
+neural O
+mechanisms O
+. O
+
+BACKGROUND O
+: O
+Allergic O
+rhinoconjunctivitis O
+is O
+a O
+common O
+disorder O
+, O
+affecting O
+> O
+20 O
+% O
+of O
+people O
+of O
+all O
+socioeconomic O
+strata O
+. O
+
+The O
+results O
+of O
+these O
+studies O
+indicate O
+that O
+EHV B
+- I
+1 I
+gp13 I
+is O
+the O
+structural O
+homolog O
+of I
+herpes I
+simplex I
+virus I
+glycoprotein I
+C I
+and O
+further O
+suggest O
+that O
+the O
+epitope O
+- O
+containing O
+N O
+- O
+terminal O
+amino O
+acid O
+sequences O
+of O
+the O
+herpesvirus B
+gC I
+- I
+like I
+glycoproteins I
+have O
+undergone O
+more O
+extensive O
+evolutionary O
+divergence O
+than O
+the O
+C O
+- O
+terminal O
+sequences O
+. O
+
+Within O
+the O
+final O
+11 O
+amino O
+acids O
+there O
+are O
+5 O
+aromatic O
+, O
+2 O
+basic O
+, O
+and O
+no O
+acidic O
+residues O
+and O
+it O
+has O
+been O
+proposed O
+that O
+these O
+residues O
+stack O
+with O
+and O
+electrostatically O
+interact O
+with O
+the O
+kinked O
+DNA O
+at O
+the O
+site O
+of O
+a O
+pyrimidine O
+dimer O
+. O
+
+By O
+contrast O
+, O
+footprint O
+II O
+at O
+position O
+- O
+125 O
+is O
+common O
+to O
+both O
+HeLa O
+and O
+GH3 O
+cell O
+extracts O
+and O
+overlies O
+a O
+15 O
+- O
+base O
+- O
+pair O
+sequence O
+found O
+in O
+all O
+members O
+of O
+the O
+growth B
+hormone I
+gene I
+family I
+. O
+
+Significance O
+of O
+the O
+determination O
+of O
+vascular O
+tonus O
+in O
+the O
+differential O
+diagnosis O
+of O
+rheumatic O
+and O
+arteriosclerotic O
+lesions O
+of O
+the O
+heart O
+and O
+vessels O
+in O
+middle O
+- O
+aged O
+and O
+elderly O
+persons O
+with O
+fibrillation O
+arrhythmia O
+
+The O
+gene O
+responsible O
+for O
+multiple O
+endocrine O
+neoplasia O
+type O
+1 O
+( O
+MEN1 O
+) O
+, O
+a O
+heritable O
+predisposition O
+to O
+endocrine O
+tumours O
+in O
+man O
+, O
+has O
+recently O
+been O
+identified O
+. O
+
+Toxicological O
+effects O
+of O
+dietary O
+Maillard O
+reaction O
+products O
+in O
+the O
+rat O
+. O
+
+AST B
+activity O
+in O
+PMNs O
+was O
+significantly O
+low O
+, O
+approximately O
+2 O
+% O
+of O
+that O
+observed O
+in O
+HPLFs O
+. O
+
+Specifically O
+, O
+we O
+engineered O
+two O
+chimeras O
+in O
+which O
+the O
+N O
+- O
+terminal O
+lobe O
+of O
+the O
+SH1 B
+domain I
+of O
+c B
+- I
+Abl I
+was O
+swapped O
+with O
+that O
+of O
+v B
+- I
+Src I
+. O
+
+Biochemical O
+analyses O
+revealed O
+that O
+the O
+concentration O
+of O
+norepinephrine O
+was O
+reduced O
+significantly O
+in O
+cortex O
+- O
+hippocampus O
+and O
+olfactory O
+bulb O
+but O
+not O
+in O
+other O
+regions O
+, O
+while O
+dopamine O
+and O
+serotonin O
+levels O
+were O
+not O
+altered O
+in O
+any O
+brain O
+region O
+examined O
+. O
+
+The O
+cDNA O
+contains O
+a O
+reading O
+frame O
+for O
+a O
+145 O
+- O
+amino O
+- O
+acid O
+protein O
+and O
+it O
+lacks O
+the O
+UGA O
+codons O
+, O
+which O
+have O
+been O
+found O
+in O
+the O
+reading O
+frame O
+of O
+the O
+mouse B
+MCS I
+cDNA I
+and O
+have O
+been O
+presumed O
+to O
+encode O
+the O
+selenocysteine O
+in O
+the O
+amino O
+terminal O
+of O
+the O
+deduced O
+mouse O
+amino O
+acid O
+sequence O
+. O
+
+These O
+results O
+suggest O
+that O
+repetitive O
+GAA O
+sequences O
+enhance O
+splicing O
+by O
+binding O
+a O
+protein O
+complex O
+containing O
+a O
+sequence O
+- O
+specific O
+RNA O
+binding O
+protein O
+and O
+a O
+general O
+splicing O
+activator O
+that O
+, O
+in O
+turn O
+, O
+recruit O
+additional O
+SR B
+proteins I
+. O
+
+Letter O
+: O
+Dehydrated O
+test O
+strip O
+for O
+the O
+detection O
+of O
+yeasts O
+. O
+
+Cell O
+sloughing O
+with O
+proparacaine O
+. O
+
+Cytomegalovirus O
+infection O
+- O
+- O
+modern O
+diagnosis O
+
+Highly O
+conserved O
+regions O
+called O
+src B
+homology I
+2 I
+and I
+3 I
+( O
+SH2 B
+and O
+SH3 B
+) O
+, O
+comprising O
+amino O
+acid O
+residues O
+88 O
+to O
+250 O
+, O
+are O
+believed O
+to O
+modulate O
+the O
+protein B
+- I
+tyrosine I
+kinase I
+activity O
+present O
+in O
+the O
+carboxy O
+- O
+terminal O
+halves O
+of O
+the O
+src B
+proteins I
+. O
+
+Interestingly O
+, O
+the O
+NES B
+mutant I
+proteins I
+appeared O
+to O
+have O
+altered O
+interactions O
+with O
+the O
+splicing O
+complex O
+, O
+binding O
+more O
+tightly O
+to O
+SC35 B
+in O
+co O
+- O
+immunoprecipitation O
+assays O
+. O
+
+We O
+propose O
+2 O
+separate O
+PAI B
+- I
+1 I
+inductory O
+pathways O
+for O
+PMA O
+and O
+IL B
+- I
+1alpha I
+in O
+HepG2 O
+, O
+both O
+involving O
+protein B
+tyrosine I
+kinase I
+activation O
+; O
+the O
+serum O
+- O
+induced O
+signaling O
+pathway O
+may O
+( O
+partially O
+) O
+overlap O
+with O
+the O
+PMA B
+- I
+activated I
+protein I
+kinase I
+C I
+/ O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+kinase I
+pathway O
+, O
+leading O
+to O
+c B
+- I
+Jun I
+homodimer I
+binding O
+to O
+the O
+PAI B
+- I
+1 I
+TRE O
+. O
+
+We O
+show O
+that O
+sae1 B
+- I
+1 I
+and O
+sae3 B
+- I
+1 I
+mutations I
+each O
+confer O
+a O
+distinct O
+defect O
+in O
+meiotic O
+recombination O
+. O
+
+sae1 B
+- I
+1 I
+produces O
+recombinants O
+but O
+very O
+slowly O
+and O
+ultimately O
+to O
+less O
+than O
+half O
+the O
+wild O
+- O
+type O
+level O
+; O
+sae3 B
+- I
+1 I
+makes O
+persistent O
+hyper O
+- O
+resected O
+meiotic O
+double O
+- O
+strand O
+breaks O
+and O
+has O
+a O
+severe O
+defect O
+in O
+formation O
+of O
+recombinants O
+. O
+
+G6620 O
+is O
+the O
+3 O
+' O
+end O
+of O
+the O
+MOL1 B
+gene I
+coding O
+for O
+a O
+polypeptide O
+similar O
+to O
+stress O
+- O
+inducible O
+proteins O
+from O
+Fusarium O
+; O
+G6630 O
+is O
+the O
+NAT2 B
+gene I
+which O
+encodes O
+a O
+methionine B
+N I
+- I
+acetyltransferase I
+; O
+G6635 O
+is O
+the O
+RPL30B B
+gene I
+coding O
+for O
+the O
+ribosomal B
+protein I
+L30 I
+; O
+G6658 O
+is O
+RSR1 B
+encoding O
+a O
+ras B
+- I
+related I
+protein I
+; O
+G6667 O
+is O
+CYS4 B
+, O
+the O
+gene O
+for O
+cystathionine B
+beta I
+- I
+synthase I
+
+; O
+G6670 O
+is O
+identical O
+to O
+ORF2 O
+located O
+close O
+to O
+CYS4 B
+; O
+G6673 O
+is O
+PEM1 B
+/ O
+CHO2 B
+encoding O
+a O
+phosphatidylethanolamine B
+methyltransferase I
+; O
+G7001 O
+is O
+the O
+NSR1 B
+gene I
+coding O
+for O
+a O
+nuclear O
+signal O
+recognition O
+protein O
+. O
+
+Transcriptional O
+analysis O
+of O
+this O
+gene O
+cluster O
+was O
+performed O
+by O
+detecting O
+the O
+presence O
+of O
+mRNAs O
+spanning O
+adjacent O
+genes O
+as O
+well O
+as O
+by O
+using O
+a O
+promoterless O
+lacZ B
+reporter I
+gene I
+fused O
+to O
+each O
+of O
+the O
+seven O
+genes O
+contained O
+in O
+the O
+tol B
+- O
+oprL B
+locus O
+. O
+
+Serum O
+IgG B
+and O
+IgA B
+level O
+were O
+decreased O
+. O
+
+Histopathologically O
+, O
+( O
+mice O
+killed O
+with O
+high O
+doses O
+of O
+GMC O
+- O
+II O
+, O
+given O
+orally O
+) O
+there O
+were O
+diffuse O
+hyperemia O
+of O
+the O
+liver O
+, O
+parenchymal O
+degeneration O
+of O
+the O
+kidney O
+tubuli O
+epithelium O
+, O
+and O
+edema O
+and O
+emphysema O
+of O
+the O
+lungs O
+. O
+
+The O
+contribution O
+of O
+reviewers O
+and O
+editors O
+to O
+the O
+scientific O
+work O
+of O
+the O
+authors O
+
+The O
+effects O
+of O
+space O
+radiation O
+are O
+partially O
+known O
+on O
+astronauts O
+, O
+but O
+much O
+remains O
+to O
+be O
+discovered O
+. O
+
+Therefore O
+the O
+effect O
+of O
+GAL11 B
+on O
+PGK B
+transcription O
+must O
+be O
+mediated O
+at O
+the O
+PGK B
+UAS I
+, O
+presumably O
+as O
+part O
+of O
+the O
+activation O
+complex O
+. O
+
+Wingless B
+/ O
+Wnt B
+signaling O
+directs O
+cell O
+- O
+fate O
+choices O
+during O
+embryonic O
+development O
+. O
+
+RNase B
+protection O
+analysis O
+reveals O
+a O
+10 O
+- O
+fold O
+increase O
+in O
+the O
+expression O
+of O
+SCD2 B
+mRNA I
+during O
+3T3 O
+- O
+L1 O
+preadipocyte O
+differentiation O
+. O
+
+To O
+determine O
+whether O
+transcription O
+of O
+orfX B
+and O
+vfr B
+are O
+controlled O
+by O
+the O
+same O
+mechanisms O
+that O
+control O
+transcription O
+of O
+the O
+region O
+of O
+the O
+divergent O
+ORF O
+( O
+dorf B
+) O
+and O
+of O
+crp B
+, O
+we O
+compared O
+the O
+vfr B
+- O
+orfX B
+and O
+crp B
+- O
+dorf B
+intergenic O
+regions O
+. O
+
+As O
+a O
+member O
+of O
+the O
+uncoupling B
+protein I
+family I
+, O
+UCP2 B
+is O
+ubiquitously O
+expressed O
+in O
+rodents O
+and O
+humans O
+, O
+implicating O
+a O
+major O
+role O
+in O
+thermogenesis O
+. O
+
+Copyright O
+1998 O
+Academic O
+Press O
+. O
+
+Parental O
+and O
+vector O
+- O
+transfected O
+MCF7 O
+cells O
+, O
+which O
+were O
+sensitive O
+to O
+the O
+growth O
+- O
+inhibitory O
+effects O
+of O
+atRA O
+, O
+exhibited O
+atRA O
+- O
+dependent O
+retinoic B
+acid I
+receptor I
+( O
+RAR B
+) O
+transactivation O
+and O
+transrepression O
+of O
+12 O
+- O
+O O
+- O
+tetradecanoylphorbol O
+- O
+13 O
+- O
+acetate O
+- O
+induced O
+AP B
+- I
+1 I
+activity O
+. O
+
+The O
+majority O
+of O
+the O
+respondents O
+( O
+83 O
+. O
+4 O
+% O
+) O
+considered O
+that O
+coitus O
+should O
+not O
+be O
+stopped O
+during O
+pregnancy O
+. O
+
+Based O
+on O
+the O
+ratios O
+of O
+the O
+areas O
+under O
+the O
+concentration O
+- O
+time O
+curves O
+in O
+CSF O
+and O
+serum O
+, O
+the O
+overall O
+penetration O
+of O
+rifampicin O
+into O
+CSF O
+was O
+0 O
+. O
+13 O
+- O
+0 O
+. O
+42 O
+( O
+median O
+= O
+0 O
+. O
+22 O
+) O
+. O
+
+The O
+differential O
+diagnosis O
+of O
+mineral O
+oil O
+lipidosis O
+in O
+lymph O
+nodes O
+with O
+reaction O
+to O
+radiopaque O
+oils O
+and O
+Whipple O
+' O
+s O
+disease O
+is O
+discussed O
+. O
+
+With O
+rats O
+fed O
+on O
+the O
+Zn O
+- O
+sufficient O
+diet O
+, O
+NaFe3 O
++ O
+EDTA O
+and O
+Na2EDTA O
+similarly O
+increased O
+the O
+absorption O
+, O
+urinary O
+excretion O
+and O
+retention O
+of O
+Zn O
+but O
+to O
+a O
+lesser O
+extent O
+. O
+
+99Tcm O
+- O
+labelled O
+albumin B
+colloid O
+, O
+albures O
+( O
+radius O
+250 O
+nm O
+) O
+or O
+nanocoll O
+( O
+radius O
+25 O
+nm O
+) O
+, O
+or O
+both O
+were O
+used O
+as O
+test O
+substances O
+to O
+study O
+the O
+kinetics O
+of O
+vascular O
+clearance O
+after O
+RES O
+stimulation O
+. O
+
+Meq B
+/ O
+c B
+- I
+Jun I
+heterodimers O
+bind O
+to O
+an O
+AP1 B
+- I
+like I
+sequence I
+in O
+the O
+meq B
+promoter I
+region I
+with O
+an O
+affinity O
+much O
+greater O
+than O
+that O
+of O
+Meq B
+/ O
+Meq B
+or O
+c B
+- I
+Jun I
+/ O
+c B
+- I
+Jun I
+homodimers O
+. O
+
+Moreover O
+, O
+the O
+noncoordinate O
+effects O
+of O
+FSK B
+on O
+PMA O
+- O
+stimulated O
+MKK B
+and O
+MAPK B
+activities O
+indicates O
+the O
+presence O
+of O
+a O
+additional O
+distal O
+cAMP O
+- O
+dependent O
+inhibitory O
+mechanisms O
+. O
+
+These O
+findings O
+indicated O
+that O
+p35 B
+is O
+a O
+trans O
+- O
+dominant O
+factor O
+that O
+facilitates O
+AcMNPV O
+growth O
+in O
+a O
+cell O
+line O
+- O
+specific O
+manner O
+. O
+
+Pseudotumor O
+form O
+of O
+pulmonary O
+nocardia O
+infection O
+( O
+Nocardia O
+nova O
+) O
+in O
+a O
+renal O
+transplant O
+patient O
+
+Hematological O
+parameters O
+( O
+leukocyte O
+, O
+neutrophil O
+and O
+platelet O
+counts O
+) O
+and O
+liver O
+function O
+tests O
+were O
+determined O
+by O
+standard O
+procedures O
+. O
+
+Karyo O
+- O
+and O
+cytometric O
+investigations O
+of O
+cortical O
+layer O
+V O
+pyramidal O
+neurons O
+of O
+albino O
+rat O
+after O
+three O
+various O
+fixations O
+
+Clinical O
+experience O
+gained O
+from O
+a O
+combined O
+study O
+of O
+252Cf O
+brachytherapy O
+by O
+the O
+staff O
+- O
+members O
+of O
+the O
+Research O
+Institute O
+of O
+Medical O
+Radiology O
+, O
+USSR O
+AMS O
+, O
+was O
+generalized O
+. O
+
+The O
+team O
+physician O
+and O
+conditioning O
+of O
+athletes O
+for O
+sports O
+: O
+a O
+consensus O
+statement O
+. O
+
+To O
+probe O
+the O
+inter O
+- O
+relationship O
+between O
+the O
+virion O
+- O
+anchoring O
+function O
+and O
+the O
+oligomerization O
+function O
+, O
+we O
+constructed O
+two O
+serotype O
+3 O
+( O
+T3 O
+) O
+sigma B
+1 I
+deletion O
+mutants O
+in O
+SV40 O
+expression O
+vectors O
+, O
+one O
+lacking O
+the O
+hydrophobic O
+tail O
+and O
+the O
+hinge O
+, O
+and O
+the O
+other O
+lacking O
+an O
+adjacent O
+region O
+which O
+constituted O
+part O
+of O
+the O
+coiled O
+- O
+coil O
+. O
+
+AIMS O
+: O
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+assess O
+static O
+and O
+dynamic O
+bone O
+changes O
+in O
+patients O
+suffering O
+from O
+rickets O
+. O
+
+The O
+law O
+and O
+the O
+chiropractor O
+. O
+
+In O
+contrast O
+, O
+overexpression O
+of O
+the O
+DREB2A B
+cDNA I
+induced O
+weak O
+expression O
+of O
+the O
+target O
+genes O
+under O
+unstressed O
+conditions O
+and O
+caused O
+growth O
+retardation O
+of O
+the O
+transgenic O
+plants O
+. O
+
+Our O
+findings O
+suggest O
+that O
+AIF O
+may O
+be O
+a O
+morphologic O
+correlate O
+of O
+tumor O
+regression O
+following O
+preoperative O
+cytotoxic O
+chemotherapy O
+. O
+
+Mean O
+total O
+homocysteine O
+( O
+tHcy O
+) O
+was O
+21 O
+. O
+1 O
++ O
+/ O
+- O
+9 O
+. O
+5 O
+micromol O
+/ O
+L O
+and O
+median O
+concentration O
+was O
+19 O
+micromol O
+/ O
+L O
+. O
+
+Efficacy O
+of O
+probiotic O
+feed O
+additives O
+: O
+guidelines O
+for O
+the O
+evaluation O
+of O
+the O
+efficiency O
+of O
+microorganisms O
+in O
+dogs O
+, O
+cats O
+, O
+and O
+horses O
+] O
+Probiotic O
+microorganisms O
+are O
+frequently O
+in O
+use O
+as O
+feed O
+additives O
+for O
+farm O
+and O
+pet O
+animals O
+. O
+
+Lung O
+transplantation O
+is O
+warranted O
+for O
+stable O
+, O
+ventilator O
+- O
+dependent O
+recipients O
+. O
+
+Site O
+- O
+directed O
+mutagenesis O
+shows O
+that O
+sites O
+throughout O
+the O
+IRE O
+alter O
+negative O
+control O
+and O
+IRE B
+- I
+BP I
+binding O
+reflecting O
+the O
+fact O
+that O
+the O
+footprint O
+of O
+the O
+IRE O
+- O
+BP O
+is O
+over O
+the O
+entire O
+IRE O
+. O
+
+An O
+alternative O
+approach O
+to O
+random O
+integration O
+of O
+large O
+DNA O
+fragments O
+into O
+plants O
+is O
+to O
+utilize O
+one O
+of O
+several O
+site O
+- O
+specific O
+recombination O
+( O
+SSR O
+) O
+systems O
+, O
+such O
+as O
+Cre B
+/ O
+lox B
+. O
+
+Neonatal O
+masculinization O
+affects O
+maternal O
+behavior O
+sensitivity O
+in O
+female O
+rats O
+. O
+
+Recombinant B
+mouse I
+GSTT1 I
+- I
+1 I
+was O
+catalytically O
+active O
+towards O
+1 O
+, O
+2 O
+- O
+epoxy O
+- O
+3 O
+- O
+( O
+p O
+- O
+nitrophenoxy O
+) O
+propane O
+, O
+4 O
+- O
+nitrobenzyl O
+chloride O
+and O
+dichloromethane O
+. O
+
+In O
+addition O
+, O
+six O
+other O
+landmarks O
+favored O
+the O
+xeroradiograph O
+but O
+not O
+to O
+the O
+degree O
+of O
+statistical O
+significance O
+. O
+
+Nonlethal O
+sec71 B
+- I
+1 I
+and O
+sec72 B
+- I
+1 I
+mutations I
+eliminate O
+proteins O
+associated O
+with O
+the O
+Sec63p B
+- O
+BiP B
+complex O
+from O
+S O
+. O
+cerevisiae O
+. O
+
+Sequence O
+and O
+deletion O
+analysis O
+of O
+the O
+recombination B
+enhancement I
+gene I
+( O
+ref B
+) O
+of O
+bacteriophage O
+P1 O
+: O
+evidence O
+for O
+promoter O
+- O
+operator O
+and O
+attenuator O
+- O
+antiterminator O
+control O
+. O
+
+A O
+high O
+titer O
+of O
+anti B
+- I
+HBc I
+, O
+thus O
+suggested O
+to O
+be O
+an O
+indicator O
+of O
+persistent O
+hepatitis O
+B O
+virus O
+infection O
+, O
+was O
+found O
+rarely O
+in O
+seronegative O
+patients O
+with O
+chronic O
+hepatitis O
+, O
+non O
+- O
+alcoholic O
+cirrhosis O
+, O
+or O
+alcoholic O
+liver O
+diseases O
+. O
+
+Adaptability O
+of O
+Nippostrongylus O
+brasiliensis O
+( O
+Travassos O
+, O
+1914 O
+) O
+to O
+lead O
+contamination O
+
+Eph B
+receptors I
+and O
+their O
+membrane O
+- O
+associated O
+ephrin B
+ligands I
+regulate O
+cell O
+- O
+cell O
+interactions O
+during O
+development O
+. O
+
+We O
+discuss O
+the O
+possibility O
+that O
+DNA O
+- O
+protein O
+interactions O
+at O
+homologous O
+nucleotide O
+sequences O
+like O
+those O
+identified O
+in O
+PII B
+are O
+part O
+of O
+a O
+regulatory O
+gene O
+cascade O
+that O
+participates O
+in O
+timing O
+fla B
+gene I
+expression O
+in O
+the O
+C O
+. O
+crescentus O
+cell O
+cycle O
+. O
+
+Postcontrast O
+images O
+were O
+also O
+acquired O
+in O
+the O
+sagittal O
+( O
+six O
+patients O
+) O
+and O
+coronal O
+( O
+three O
+patients O
+) O
+planes O
+. O
+
+Nature O
+of O
+the O
+thermopower O
+in O
+bipolar O
+semiconductors O
+. O
+
+To O
+increase O
+the O
+number O
+of O
+circulating O
+polymorphonuclear O
+neutrophils O
+, O
+the O
+patient O
+was O
+treated O
+with O
+recombinant B
+granulocyte I
+- I
+macrophage I
+colony I
+- I
+stimulating I
+factor I
+( O
+GM B
+- I
+CSF I
+) O
+at O
+a O
+dose O
+of O
+2 O
+micrograms O
+protein O
+/ O
+kg O
+bodyweight O
+s O
+. O
+c O
+. O
+/ O
+12 O
+h O
+. O
+
+By O
+using O
+methanol O
+- O
+0 O
+. O
+15 O
+M O
+borate O
+buffer O
+of O
+pH O
+8 O
+. O
+0 O
+, O
+cate B
+- I
+chol I
+- I
+O I
+- I
+methyltransferase I
+activity O
+might O
+be O
+assayed O
+. O
+
+All O
+patients O
+were O
+peritonitis O
+- O
+free O
+at O
+least O
+6 O
+weeks O
+before O
+each O
+PET O
+. O
+
+The O
+amino O
+acid O
+residues O
+and O
+subdomains O
+important O
+for O
+DNA O
+binding O
+, O
+hormone O
+binding O
+, O
+dimerization O
+, O
+and O
+transactivation O
+are O
+mostly O
+conserved O
+among O
+all O
+VDR B
+species O
+. O
+
+Transcripts O
+appear O
+to O
+be O
+initiated O
+from O
+an O
+upstream O
+promoter O
+, O
+P1 O
+, O
+located O
+in O
+front O
+of O
+the O
+tRNA B
+( I
+met1 I
+) I
+gene I
+and O
+from O
+three O
+internal O
+promoters O
+: O
+P2 O
+is O
+located O
+immediately O
+in O
+front O
+of O
+the O
+tRNA B
+( I
+met2 I
+) I
+gene I
+; O
+PL10 B
+is O
+near O
+the O
+beginning O
+of O
+the O
+L1 B
+- O
+L10 B
+intergenic O
+space O
+, O
+and O
+PL12 B
+is O
+at O
+the O
+end O
+of O
+the O
+L10 B
+gene I
+sequence I
+. O
+
+Based O
+on O
+the O
+deduced O
+amino O
+acid O
+sequence O
+identity O
+we O
+designated O
+GAPC1 B
+and O
+GAPC2 B
+as O
+group O
+I O
+( O
+97 O
+% O
+identical O
+) O
+and O
+GAPC3 B
+and O
+GAPC4 B
+as O
+group O
+II O
+( O
+99 O
+. O
+4 O
+% O
+identical O
+) O
+. O
+
+A O
+case O
+of O
+functioning O
+parathyroid O
+carcinoma O
+with O
+hypereninemic O
+hypertension O
+. O
+
+Finally O
+, O
+gel O
+shift O
+assays O
+showed O
+that O
+ORF2 O
+was O
+able O
+to O
+bind O
+to O
+promoter O
+fragment O
+566 O
+- O
+888 O
+. O
+
+Critical O
+review O
+of O
+general O
+results O
+
+Saturated O
+fatty O
+acids O
+induce O
+a O
+1 O
+. O
+6 O
+- O
+fold O
+increase O
+in O
+transcription O
+activity O
+, O
+whereas O
+a O
+large O
+family O
+of O
+unsaturated O
+fatty O
+acids O
+repress O
+OLE1 B
+transcription O
+as O
+much O
+as O
+60 O
+- O
+fold O
+. O
+
+This O
+polypeptide O
+includes O
+the O
+first O
+three O
+zinc O
+fingers O
+of O
+the O
+TFIIIA B
+DNA I
+binding I
+domain I
+. O
+
+An O
+exception O
+is O
+the O
+Bcl B
+- I
+6 I
+gene I
+, O
+encoding O
+a O
+transcription O
+factor O
+, O
+which O
+was O
+found O
+to O
+be O
+mutated O
+in O
+normal O
+human O
+memory O
+B O
+cells O
+. O
+
+3 O
+. O
+
+A O
+chest O
+- O
+X O
+ray O
+film O
+showed O
+infiltrative O
+shadows O
+in O
+the O
+right O
+middle O
+and O
+lower O
+lung O
+fields O
+, O
+but O
+a O
+chest O
+CT O
+scan O
+showed O
+an O
+abnormal O
+lung O
+density O
+in O
+the O
+right O
+lower O
+lobe O
+. O
+
+In O
+both O
+liver O
+and O
+pancreatic O
+islet O
+, O
+glucokinase B
+is O
+subject O
+to O
+inhibition O
+by O
+a O
+regulatory O
+protein O
+( O
+GCKR B
+) O
+. O
+
+MRI O
+measurements O
+of O
+the O
+brain O
+. O
+
+Similarly O
+, O
+TAM O
+- O
+67 O
+reverted O
+the O
+morphology O
+of O
+the O
+AdoMetDC B
+- O
+antisense O
+expressors O
+. O
+
+Of O
+concern O
+is O
+the O
+high O
+, O
+unexplained O
+prevalence O
+of O
+BV O
+among O
+African O
+- O
+American O
+women O
+, O
+who O
+are O
+also O
+at O
+extremely O
+high O
+risk O
+for O
+preterm O
+birth O
+. O
+
+The O
+use O
+of O
+bentonite O
+in O
+the O
+compounding O
+of O
+hydrogels O
+
+Cotransfection O
+of O
+expression O
+plasmids O
+encoding O
+the O
+protein B
+kinase I
+A I
+inhibitor O
+, O
+or O
+an O
+inactive O
+protein B
+kinase I
+A I
+( O
+PKA B
+) O
+catalytic O
+beta O
+subunit O
+, O
+inhibited O
+both O
+forskolin O
+and O
+PACAP B
+activation O
+of O
+chromogranin B
+A I
+transcription O
+, O
+revealing O
+that O
+PACAP B
+- O
+induced O
+trans O
+- O
+activation O
+is O
+highly O
+dependent O
+on O
+PKA B
+. O
+
+GH B
+induced O
+rapid O
+tyrosine O
+phosphorylation O
+of O
+a O
+protein O
+at O
+approximately O
+93 O
+kDa O
+in O
+normal O
+fibroblasts O
+, O
+and O
+Western O
+blotting O
+with O
+STAT B
+- I
+specific I
+antibodies I
+revealed O
+STAT5 B
+activation O
+( O
+phosphorylation O
+) O
+by O
+GH B
+. O
+
+The O
+most O
+valid O
+method O
+was O
+the O
+AXB O
+bearing O
+with O
+the O
+cephalometric O
+clinical O
+diagnosis O
+a O
+90 O
+. O
+91 O
+% O
+concordance O
+. O
+
+The O
+cdc42W97R B
+temperature I
+- I
+sensitive I
+allele I
+in O
+S O
+. O
+cerevisiae O
+displayed O
+the O
+same O
+cell O
+- O
+division O
+- O
+cycle O
+arrest O
+phenotype O
+( O
+large O
+, O
+round O
+unbudded O
+cells O
+) O
+as O
+the O
+cdc42 B
+- I
+1ts I
+mutant I
+. O
+
+The O
+cyanobacterial B
+phycobilisome I
+is O
+a O
+large O
+protein O
+complex O
+located O
+on O
+the O
+photosynthetic O
+membrane O
+. O
+
+One O
+day O
+after O
+injection O
+48 O
+% O
+of O
+the O
+injected O
+activity O
+was O
+in O
+the O
+skeleton O
+, O
+9 O
+. O
+3 O
+% O
+in O
+the O
+liver O
+, O
+3 O
+% O
+in O
+the O
+kidneys O
+and O
+4 O
+. O
+4 O
+% O
+in O
+the O
+rest O
+of O
+the O
+organs O
+. O
+
+OBJECTIVE O
+: O
+To O
+assess O
+laboratory O
+practice O
+in O
+the O
+examination O
+of O
+blood O
+films O
+for O
+malarial O
+parasites O
+. O
+
+BACKGROUND O
+: O
+A O
+thorough O
+understanding O
+of O
+malignant O
+fibrous O
+histiocytoma O
+( O
+MFH O
+) O
+, O
+the O
+most O
+common O
+subtype O
+of O
+soft O
+tissue O
+sarcoma O
+, O
+will O
+lead O
+to O
+improved O
+histologic O
+- O
+specific O
+protocols O
+. O
+
+Sequence O
+analyses O
+revealed O
+a O
+partial O
+941 O
+bp O
+cDNA O
+that O
+encoded O
+a O
+313 O
+- O
+amino O
+- O
+acid O
+polypeptide O
+. O
+
+Furthermore O
+, O
+CBP B
+/ O
+p300 B
+stimulated O
+both O
+TGF B
+- I
+beta I
+- O
+and O
+Smad B
+- O
+induced O
+transcription O
+in O
+a O
+Smad4 B
+/ O
+DPC4 B
+- O
+dependent O
+fashion O
+. O
+
+Sequences O
+within O
+and O
+flanking O
+hypersensitive O
+sites O
+3 O
+and O
+2 O
+of O
+the O
+beta B
+- I
+globin I
+locus I
+control I
+region I
+required O
+for O
+synergistic O
+versus O
+additive O
+interaction O
+with O
+the O
+epsilon B
+- I
+globin I
+gene I
+promoter I
+. O
+
+Sequence O
+analysis O
+revealed O
+100 O
+% O
+homology O
+of O
+all O
+RA O
+- O
+derived O
+PTEN B
+fragments I
+to O
+those O
+from O
+normal O
+SF O
+as O
+well O
+as O
+to O
+the O
+published O
+GenBank O
+sequence O
+( O
+accession O
+number O
+U93051 O
+) O
+. O
+
+174 O
+, O
+233 O
+- O
+247 O
+) O
+and O
+Serrate B
+( O
+Serrate1 B
+and I
+2 I
+; O
+Myat O
+, O
+A O
+. O
+, O
+Henrique O
+, O
+D O
+. O
+, O
+Ish O
+- O
+Horowicz O
+, O
+D O
+. O
+and O
+Lewis O
+, O
+J O
+. O
+, O
+1996 O
+. O
+
+Many O
+retroviruses O
+, O
+including O
+the O
+human O
+and O
+simian O
+immunodeficiency O
+viruses O
+, O
+contain O
+a O
+leucine O
+zipper O
+- O
+like O
+repeat O
+in O
+a O
+highly O
+conserved O
+region O
+of O
+the O
+external O
+domain O
+of O
+the O
+transmembrane B
+( I
+TM I
+) I
+glycoprotein I
+. O
+
+Functional O
+importance O
+of O
+a O
+properly O
+folded O
+surface O
+loop O
+covering O
+the O
+catalytic O
+center O
+. O
+
+The O
+most O
+frequent O
+abnormality O
+was O
+GH B
+deficiency O
+( O
+six O
+cases O
+) O
+, O
+followed O
+by O
+gonadotropin B
+( O
+four O
+cases O
+) O
+, O
+cortisol O
+( O
+four O
+cases O
+) O
+, O
+and O
+TSH B
+( O
+one O
+case O
+) O
+, O
+whereas O
+four O
+patients O
+showed O
+high O
+serum B
+PRL I
+values O
+. O
+
+Recombinant O
+vaccinia B
+viruses O
+that O
+express O
+the O
+bacteriophage B
+T3 I
+RNA I
+polymerase I
+( O
+VV B
+- I
+T3pol I
+) O
+or O
+the O
+Escherichia B
+coli I
+lac I
+repressor I
+( O
+VV B
+- I
+lacI I
+) O
+under O
+control O
+of O
+the O
+early B
+- O
+late I
+vaccinia O
+promoter O
+P7 B
+. I
+5 I
+were O
+constructed O
+. O
+
+Internal O
+controls O
+over O
+the O
+volume O
+of O
+milk O
+suckled O
+do O
+not O
+appear O
+until O
+infant O
+rats O
+are O
+about O
+2 O
+weeks O
+of O
+age O
+at O
+which O
+time O
+gastric O
+distension O
+, O
+milk O
+, O
+systemic O
+dehydration O
+, O
+and O
+intestinal O
+hormone O
+cholecystokinin B
+suppress O
+milk O
+intake O
+derived O
+through O
+suckling O
+. O
+
+Shields O
+needed O
+for O
+pacemakers O
+. O
+
+Concerning O
+the O
+practical O
+approach O
+in O
+a O
+clinical O
+setting O
+, O
+it O
+has O
+to O
+be O
+pointed O
+out O
+that O
+with O
+these O
+diseases O
+a O
+hepatitis O
+C O
+infection O
+has O
+to O
+be O
+considered O
+and O
+testing O
+for O
+hepatitis B
+C I
+antibodies I
+and O
+, O
+if O
+positive O
+, O
+hepatitis O
+C O
+- O
+RNA O
+is O
+indicated O
+. O
+
+Confocal O
+fluorescent O
+microscopy O
+analysis O
+demonstrated O
+that O
+WT O
+, O
+VaI O
+, O
+and O
+VaII B
+all O
+distribute O
+equally O
+to O
+the O
+cell O
+surface O
+while O
+, O
+as O
+expected O
+, O
+a O
+WT O
+mutant O
+lacking O
+the O
+two O
+C O
+- O
+terminal O
+valine O
+residues O
+does O
+not O
+. O
+
+However O
+, O
+it O
+is O
+not O
+easy O
+to O
+establish O
+the O
+diagnosis O
+of O
+thoracic O
+MFH O
+. O
+
+In O
+both O
+cell O
+types O
+, O
+insulin B
+led O
+to O
+a O
+dose O
+- O
+dependent O
+increase O
+in O
+the O
+association O
+of O
+tyrosine O
+phosphorylated O
+IRS B
+- I
+1 I
+with O
+the O
+SH2 B
+domain I
+of O
+the O
+p85 B
+regulatory I
+subunit I
+of O
+PI B
+- I
+3 I
+kinase I
+, O
+and O
+also O
+increased O
+the O
+amount O
+of O
+PI B
+kinase I
+activity O
+detected O
+in O
+anti B
+- I
+IRS I
+- I
+1 I
+immunoprecipitates O
+. O
+
+The O
+" O
+Ulm O
+Zucker O
+Uhr O
+System O
+" O
+comprises O
+a O
+microdialysis O
+probe O
+, O
+a O
+biosensor O
+( O
+Glucosensor O
+Unitec O
+Ulm O
+s O
+. O
+c O
+. O
+) O
+, O
+a O
+sender O
+transferring O
+telemetrically O
+the O
+glucose O
+concentrations O
+, O
+and O
+a O
+receiving O
+indicator O
+. O
+
+The O
+Xenopus B
+annexin I
+II I
+heavy I
+chain I
+lacks O
+the O
+highly O
+conserved O
+tyrosine O
+at O
+position O
+23 O
+which O
+is O
+the O
+site O
+of O
+src B
+oncogene I
+tyrosine B
+kinase I
+phosphorylation O
+in O
+the O
+murine O
+protein O
+. O
+
+No O
+bafilomycin O
+- O
+sensitive O
+ATPase B
+is O
+detected O
+in O
+a O
+vacuolar O
+fraction O
+. O
+
+Plasmids O
+bearing O
+the O
+P B
+. I
+stipitis I
+URA3 I
+gene I
+and O
+ARS2 O
+element O
+produced O
+more O
+than O
+30 O
+, O
+000 O
+transformants O
+per O
+micrograms O
+of O
+plasmid O
+DNA O
+. O
+
+Unfractionated O
+heparin O
+( O
+UFH O
+) O
+given O
+at O
+a O
+dose O
+of O
+0 O
+. O
+3 O
+mg O
+x O
+kg O
+- O
+1 O
+bolus O
++ O
+0 O
+. O
+3 O
+mg O
+x O
+kg O
+- O
+1 O
+x O
+h O
+- O
+1 O
+infusion O
+did O
+not O
+improve O
+the O
+incidence O
+of O
+reperfusion O
+or O
+lower O
+the O
+incidence O
+of O
+reocclusion O
+. O
+
+The O
+scores O
+for O
+these O
+three O
+factors O
+, O
+which O
+corresponded O
+to O
+recognizable O
+dimensions O
+of O
+depressive O
+illness O
+, O
+were O
+then O
+correlated O
+with O
+rCBF O
+. O
+
+Cloning O
+, O
+sequence O
+analysis O
+, O
+and O
+expression O
+of O
+the O
+gene B
+encoding I
+formaldehyde B
+dismutase I
+from I
+Pseudomonas I
+putida I
+F61 O
+. O
+
+However O
+, O
+at O
+the O
+time O
+of O
+salvage O
+treatment O
+, O
+the O
+mean O
+serum B
+PSA I
+levels O
+were O
+9 O
+. O
+1 O
+and O
+1 O
+. O
+1 O
+ng O
+/ O
+mL O
+for O
+the O
+salvage O
+RP O
+and O
+salvage O
+RT O
+groups O
+, O
+respectively O
+( O
+P O
+= O
+0 O
+. O
+0001 O
+) O
+. O
+
+Protease O
+digestion O
+and O
+alkaline O
+extraction O
+of O
+microsomes O
+containing O
+labeled O
+mutant O
+proteins O
+further O
+showed O
+that O
+segment O
+3 O
+was O
+sufficient O
+for O
+stable O
+membrane O
+anchoring O
+of O
+the O
+glycoproteins O
+, O
+indicating O
+that O
+this O
+segment O
+may O
+specify O
+the O
+transmembrane O
+domain O
+of O
+the O
+gB B
+glycoprotein I
+. O
+
+The O
+mean O
+times O
+to O
+LNR O
+in O
+these O
+groups O
+were O
+42 O
+. O
+0 O
+months O
+( O
+range O
+, O
+3 O
+. O
+0 O
+- O
+194 O
+. O
+5 O
+months O
+) O
+and O
+49 O
+. O
+0 O
+months O
+( O
+range O
+, O
+3 O
+. O
+6 O
+- O
+209 O
+. O
+0 O
+months O
+) O
+respectively O
+. O
+
+A O
+gene O
+( O
+FMR B
+- I
+1 I
+) O
+was O
+identified O
+within O
+a O
+four O
+cosmid O
+contig O
+of O
+YAC O
+DNA O
+that O
+expresses O
+a O
+4 O
+. O
+8 O
+kb O
+message O
+in O
+human O
+brain O
+. O
+
+Detailed O
+comparison O
+of O
+the O
+sequences O
+of O
+cp35 B
+and O
+human B
+calpactin I
+II I
+shows O
+that O
+the O
+only O
+substantial O
+sequence O
+dissimilarity O
+is O
+a O
+domain O
+encoding O
+amino O
+acids O
+between O
+residues O
+20 O
+and O
+40 O
+which O
+includes O
+a O
+tyrosine O
+phosphorylation O
+site O
+in O
+the O
+human O
+molecule O
+, O
+along O
+with O
+other O
+residues O
+of O
+possible O
+physiological O
+significance O
+. O
+
+Exogenous O
+heart O
+stress O
+raised O
+log O
+circulating O
+NE O
+concentration O
+in O
+proportion O
+to O
+the O
+rise O
+in O
+heart O
+rate O
+at O
+a O
+given O
+work O
+load O
+so O
+that O
+the O
+usual O
+relationship O
+between O
+these O
+variables O
+, O
+previously O
+observed O
+during O
+other O
+stresses O
+, O
+was O
+preserved O
+. O
+
+The O
+implication O
+of O
+Rac B
+and O
+Cdc42 B
+was O
+analyzed O
+in O
+transient O
+transfection O
+experiments O
+using O
+either O
+constitutively O
+active O
+( O
+V12 B
+) O
+or O
+dominant O
+- O
+interfering O
+( O
+N17 O
+) O
+mutants O
+. O
+
+Alternative O
+immune B
+globulin I
+preparation O
+when O
+standard O
+immune B
+serum I
+globulin I
+is O
+not O
+available O
+. O
+
+Plasma B
+insulin I
+responses O
+to O
+glucose O
+in O
+femoral O
+, O
+hepatic O
+, O
+and O
+pancreatic O
+veins O
+in O
+dogs O
+. O
+
+The O
+bioconversion O
+of O
+penicillin O
+G O
+, O
+an O
+inexpensive O
+substrate O
+, O
+to O
+the O
+valuable O
+intermediate O
+for O
+semisynthetic O
+cephalosporin O
+production O
+, O
+deacetoxycephalosporin O
+G O
+( O
+DAOG O
+) O
+, O
+had O
+been O
+recently O
+shown O
+to O
+be O
+increased O
+by O
+eliminating O
+agitation O
+and O
+adding O
+decane O
+. O
+
+Elevated O
+potassium O
+stimulation O
+of O
+GAL B
+mRNA I
+was O
+completely O
+blocked O
+, O
+but O
+pituitary B
+adenylyl I
+cyclase I
+- I
+activating I
+polypeptide I
+and O
+histamine O
+stimulations O
+were O
+only O
+partially O
+blocked O
+, O
+by O
+cycloheximide O
+. O
+
+In O
+lyzozyme B
+activity O
+there O
+was O
+periodicity O
+in O
+three O
+groups O
+but O
+not O
+in O
+the O
+youngest O
+foals O
+. O
+
+GBF1 B
+and O
+GBF2 B
+mRNA I
+is O
+present O
+in O
+light O
+and O
+dark O
+grown O
+leaves O
+as O
+well O
+as O
+in O
+roots O
+. O
+
+We O
+now O
+report O
+identification O
+and O
+analysis O
+of O
+transcriptional O
+activities O
+mediated O
+by O
+three O
+cis O
+- O
+acting O
+sites O
+within O
+a O
+90 O
+- O
+bp O
+portion O
+of O
+the O
+rDNA O
+enhancer O
+designated O
+the O
+modulator O
+region O
+. O
+
+A O
+porcine O
+model O
+of O
+diffuse O
+axonal O
+injury O
+, O
+developed O
+with O
+information O
+from O
+these O
+physical O
+models O
+and O
+earlier O
+in O
+vitro O
+tissue O
+modeling O
+studies O
+, O
+is O
+used O
+to O
+correlate O
+histologic O
+and O
+radiologic O
+evidence O
+of O
+axonal O
+injury O
+to O
+predicted O
+regions O
+of O
+injury O
+from O
+the O
+experimental O
+and O
+theoretical O
+analysis O
+. O
+
+Sample O
+size O
+requirement O
+for O
+repeated O
+measurements O
+in O
+continuous O
+data O
+. O
+
+A O
+transient O
+induction O
+of O
+both O
+c B
+- I
+fos I
+and O
+c B
+- I
+jun I
+mRNAs I
+by O
+TPA O
+was O
+observed O
+in O
+both O
+cell O
+populations O
+, O
+together O
+with O
+an O
+associated O
+suppression O
+of O
+BSP B
+mRNA I
+in O
+the O
+fetal O
+rat O
+calvarial O
+cells O
+. O
+
+Videoanalysis O
+confirms O
+the O
+ballistic O
+character O
+of O
+the O
+initial O
+phase O
+of O
+the O
+reaching O
+movement O
+. O
+
+The O
+isomerization O
+of O
+the O
+pre O
+- O
+existing O
+closed O
+complex O
+to O
+an O
+open O
+promoter O
+form O
+, O
+as O
+judged O
+by O
+the O
+local O
+denaturation O
+of O
+promoter O
+DNA O
+which O
+rendered O
+sequences O
+from O
++ O
+5 O
+to O
+- O
+10 O
+reactive O
+towards O
+KMnO4 O
+, O
+was O
+shown O
+to O
+be O
+fully O
+dependent O
+on O
+NifA B
+. O
+
+HPV B
+- O
+16 O
+MARs I
+are O
+context O
+dependent O
+transcriptional O
+enhancers O
+, O
+and O
+activated O
+expression O
+of O
+HPV B
+- I
+16 I
+oncogenes I
+dependent O
+on O
+chromosomal O
+integration O
+may O
+positively O
+select O
+tumorigenic O
+cells O
+during O
+the O
+multistep O
+etiology O
+of O
+cervical O
+cancer O
+. O
+
+Sociological O
+analysis O
+of O
+the O
+family O
+. O
+
+This O
+enhancer O
+element O
+functioned O
+in O
+a O
+position O
+- O
+and O
+orientation O
+- O
+independent O
+manner O
+both O
+on O
+the O
+Pax B
+- I
+QNR B
+P0 O
+promoter O
+and O
+the O
+heterologous O
+thymidine B
+kinase I
+promoter I
+. O
+
+These O
+data O
+suggest O
+that O
+overexpression O
+of O
+MT B
+potentiates O
+the O
+growth O
+of O
+MCF7 O
+cells O
+, O
+whereas O
+downregulation O
+of O
+MT B
+elicits O
+antiproliferative O
+effects O
+. O
+
+A O
+multivariant O
+study O
+of O
+pituitary O
+adenoma O
+, O
+obtainment O
+of O
+two O
+logistic O
+regression O
+equations O
+as O
+an O
+auxiliary O
+support O
+in O
+the O
+diagnosis O
+of O
+these O
+tumors O
+. O
+
+Bile O
+salts O
+, O
+hormonal O
+control O
+, O
+and O
+the O
+male O
+disadvantage O
+. O
+
+Number O
+of O
+warm O
+- O
+units O
+with O
+higher O
+rates O
+of O
+firing O
+and O
+greater O
+thermal O
+coefficients O
+, O
+comparable O
+to O
+those O
+of O
+warm O
+- O
+units O
+in O
+the O
+adult O
+, O
+gradually O
+increased O
+with O
+growth O
+. O
+
+Such O
+unique O
+recognition O
+capabilities O
+are O
+generated O
+with O
+minimal O
+alterations O
+in O
+the O
+CDR3 B
+loops I
+of O
+the O
+TCR B
+. O
+
+To O
+this O
+effect O
+, O
+the O
+present O
+survey O
+puts O
+in O
+evidence O
+that O
+the O
+maximum O
+delay O
+of O
+stream O
+that O
+guarantees O
+the O
+good O
+dimensional O
+stability O
+of O
+these O
+class O
+A O
+alginates O
+is O
+of O
+45 O
+minutes O
+in O
+the O
+hot O
+and O
+humid O
+climatic O
+tropical O
+country O
+conditions O
+. O
+
+Gene B
+1 I
+of O
+the O
+murine O
+coronavirus O
+, O
+MHV O
+- O
+A59 O
+, O
+encodes O
+approximately O
+800 O
+kDa O
+of O
+protein O
+products O
+within O
+two O
+overlapping O
+open O
+reading O
+frames O
+( O
+ORFs O
+1a O
+and O
+1b O
+) O
+. O
+
+For O
+this O
+interaction O
+, O
+the O
+C O
+- O
+terminal O
+part O
+of O
+Sp1 B
+and O
+the O
+N O
+terminus O
+of O
+E2F1 B
+, O
+a O
+domain O
+also O
+present O
+in O
+E2F2 B
+and O
+E2F3 B
+but O
+absent O
+in O
+E2F4 B
+and O
+E2F5 B
+, O
+were O
+essential O
+. O
+
+Our O
+results O
+suggest O
+a O
+biological O
+role O
+for O
+Elf B
+- I
+1 I
+in O
+the O
+regulation O
+of O
+IgH B
+gene I
+expression O
+, O
+attribute O
+a O
+functional O
+role O
+for O
+receptor O
+- O
+induced O
+AP B
+- I
+1 I
+proteins I
+in O
+B O
+lymphocytes O
+and O
+provide O
+evidence O
+for O
+a O
+direct O
+link O
+between O
+IgM B
+receptor O
+- O
+mediated O
+signalling O
+and O
+3 O
+' O
+enhancer O
+activation O
+. O
+
+Oncogenic O
+activation O
+of O
+RET B
+is O
+detected O
+in O
+human O
+papillary O
+thyroid O
+tumours O
+and O
+in O
+multiple O
+endocrine O
+neoplasia O
+type O
+2 O
+syndromes O
+. O
+
+CD4 B
+degradation O
+mediated O
+by O
+Vpu B
+does O
+not O
+require O
+the O
+ER O
+chaperone O
+calnexin B
+and O
+is O
+dependent O
+on O
+an O
+intact O
+ubiquitin B
+- O
+conjugating O
+system O
+. O
+
+The O
+maternal B
+par I
+genes I
+and O
+the O
+segregation O
+of O
+cell O
+fate O
+specification O
+activities O
+in O
+early O
+Caenorhabditis O
+elegans O
+embryos O
+. O
+
+These O
+effects O
+were O
+antagonized O
+by O
+prior O
+administration O
+of O
+1 O
+- O
+( O
+2 O
+- O
+methoxyphenyl O
+) O
+- O
+4 O
+- O
+[ O
+- O
+( O
+2 O
+- O
+phthalimido O
+) O
+butyl O
+] O
+piperazine O
+) O
+( O
+0 O
+. O
+5 O
+mg O
+/ O
+kg O
+, O
+i O
+. O
+p O
+. O
+) O
+. O
+
+PURPOSE O
+: O
+To O
+evaluate O
+the O
+effect O
+of O
+adding O
+a O
+pulsating O
+bristle O
+action O
+to O
+the O
+established O
+oscillating O
+/ O
+rotating O
+action O
+of O
+the O
+Braun O
+Oral O
+- O
+B O
+Ultra O
+Plaque O
+Remover O
+( O
+D9 O
+) O
+on O
+plaque O
+removal O
+. O
+
+Detailed O
+analysis O
+of O
+the O
+predicted O
+amino O
+acid O
+sequence O
+revealed O
+sequence O
+elements O
+which O
+are O
+conserved O
+in O
+many O
+DNA B
+and I
+RNA I
+polymerases I
+. O
+
+Sub O
+- O
+inhibitory O
+and O
+post O
+- O
+antibiotic O
+effects O
+of O
+spiramycin O
+and O
+erythromycin O
+on O
+Staphylococcus O
+aureus O
+. O
+
+The O
+CydDC B
+system O
+appears O
+to O
+be O
+the O
+first O
+prokaryotic O
+example O
+of O
+a O
+heterodimeric O
+ABC I
+transport O
+system O
+in O
+which O
+each O
+polypeptide O
+contains O
+both O
+hydrophobic O
+and O
+ATP O
+- O
+binding O
+domains O
+. O
+
+The O
+single O
+- O
+copy O
+U20 B
+sequence I
+is O
+located O
+on O
+the O
+same O
+DNA O
+strand O
+as O
+the O
+nucleolin B
+mRNA I
+. O
+
+Gel O
+shift O
+and O
+southwestern O
+experiments O
+revealed O
+nuclear O
+proteins O
+of O
+43 O
+kDa O
+and O
+30 O
+kDa O
+in O
+GC O
+and O
+fish O
+cells O
+, O
+respectively O
+, O
+that O
+bind O
+specifically O
+to O
+the O
+tGH B
+CRE O
+, O
+suggesting O
+the O
+involvement O
+of O
+CRE B
+- I
+binding I
+- I
+protein I
+/ O
+activating B
+- I
+transcription I
+- I
+factor I
+- I
+l I
+- I
+related I
+peptides I
+in O
+cAMP O
+response O
+. O
+
+The O
+coding O
+sequence O
+of O
+rat B
+MEK I
+kinase I
+1 I
+( O
+MEKK1 B
+) O
+has O
+been O
+determined O
+from O
+multiple O
+, O
+independent O
+cDNA O
+clones O
+. O
+
+In O
+response O
+to O
+the O
+need O
+for O
+better O
+quantitative O
+estimates O
+of O
+the O
+regional O
+distribution O
+of O
+the O
+active O
+bone O
+marrow O
+organ O
+in O
+infants O
+and O
+children O
+, O
+a O
+method O
+using O
+various O
+anatomical O
+data O
+has O
+been O
+developed O
+. O
+
+We O
+compared O
+these O
+responses O
+for O
+six O
+hatchling O
+and O
+eight O
+adult O
+Chrysemys O
+picta O
+from O
+an O
+Ohio O
+population O
+. O
+
+On O
+the O
+basis O
+of O
+experiments O
+with O
+mutant O
+virus O
+and O
+transfection O
+with O
+isolated O
+genes O
+, O
+the O
+herpes B
+simplex I
+virus I
+immediate I
+- I
+early I
+gene I
+product I
+ICP4 B
+is O
+known O
+to O
+positively O
+regulate O
+the O
+transcription O
+of O
+viral O
+early O
+and O
+late O
+genes O
+and O
+negatively O
+regulate O
+expression O
+from O
+its O
+own O
+promoter O
+. O
+
+A O
+female O
+infant O
+with O
+isolated O
+noncompaction O
+of O
+ventricular O
+myocardium O
+who O
+developed O
+ventricular O
+tachyarrhythmia O
+is O
+described O
+. O
+
+Recent O
+, O
+highly O
+visible O
+reviews O
+on O
+the O
+subject O
+have O
+clearly O
+pointed O
+out O
+that O
+little O
+is O
+known O
+about O
+the O
+cellular O
+mechanisms O
+through O
+which O
+inhaled O
+asbestos O
+fibers O
+cause O
+the O
+well O
+known O
+, O
+debilitating O
+lung O
+disease O
+- O
+asbestosis O
+( O
+i O
+. O
+e O
+. O
+interstitial O
+pulmonary O
+fibrosis O
+) O
+. O
+
+The O
+POU B
+- I
+specific I
+domain I
+of O
+Pit B
+- I
+1 I
+is O
+essential O
+for O
+sequence O
+- O
+specific O
+, O
+high O
+affinity O
+DNA O
+binding O
+and O
+DNA O
+- O
+dependent O
+Pit B
+- I
+1 I
+- O
+Pit B
+- I
+1 I
+interactions O
+. O
+
+Also O
+, O
+the O
+placebo O
+nondepressed O
+patients O
+had O
+significantly O
+better O
+treatment O
+outcome O
+compared O
+with O
+the O
+placebo O
+depressed O
+patients O
+. O
+
+Obtaining O
+kidney O
+cells O
+from O
+a O
+beagle O
+puppy O
+( O
+RPB O
+- O
+1 O
+) O
+and O
+the O
+establishment O
+of O
+a O
+cryopreservation O
+bank O
+
+These O
+results O
+suggest O
+an O
+essential O
+role O
+of O
+the O
+binding O
+of O
+HNF B
+- I
+4 I
+and O
+/ O
+or O
+HNF B
+- I
+4 I
+- I
+related I
+nuclear I
+factors I
+to O
+the O
+6 O
+beta O
+A O
+- O
+A O
+site O
+on O
+the O
+basal O
+transcriptional O
+activation O
+of O
+the O
+CYP3A2 B
+gene I
+in O
+liver O
+cells O
+. O
+
+It O
+is O
+envisaged O
+that O
+the O
+WHOQOL O
+- O
+BREF O
+will O
+be O
+most O
+useful O
+in O
+studies O
+that O
+require O
+a O
+brief O
+assessment O
+of O
+quality O
+of O
+life O
+, O
+for O
+example O
+, O
+in O
+large O
+epidemiological O
+studies O
+and O
+clinical O
+trials O
+where O
+quality O
+of O
+life O
+is O
+of O
+interest O
+. O
+
+Restriction O
+mapping O
+showed O
+that O
+the O
+two O
+recombinant O
+plasmids O
+shared O
+an O
+EcoRI B
+fragment I
+of O
+8 O
+. O
+9 O
+kb O
+. O
+
+Usefulness O
+of O
+glucocorticoids O
+in O
+the O
+treatment O
+of O
+congestive O
+heart O
+failure O
+
+The O
+chromosomal O
+location O
+of O
+these O
+YACs O
+was O
+verified O
+using O
+FISH O
+, O
+which O
+also O
+demonstrated O
+their O
+nonchimeric O
+nature O
+. O
+
+After O
+first O
+strand O
+cDNA O
+synthesis O
+from O
+fetal O
+brain O
+mRNAs O
+, O
+short O
+fragment O
+cDNAs O
+( O
+sf O
+- O
+cDNAs O
+) O
+were O
+synthesized O
+with O
+a O
+two O
+- O
+step O
+amplification O
+system O
+by O
+use O
+of O
+our O
+modified O
+Degenerate O
+Oligonucleotide O
+Primed O
+Shuttle O
+Polymerase O
+Chain O
+Reaction O
+( O
+DOP O
+- O
+Shuttle O
+- O
+PCR O
+) O
+method O
+. O
+
+For O
+evaluation O
+of O
+the O
+model O
+, O
+simulations O
+of O
+physiological O
+excitation O
+and O
+of O
+pathologies O
+( O
+Wolff O
+- O
+Parkinson O
+- O
+White O
+syndrome O
+, O
+complete O
+AV O
+- O
+block O
+, O
+inferior O
+wall O
+ischaemia O
+) O
+were O
+examined O
+. O
+
+Profilins B
+IIa I
+and I
+IIb I
+are O
+also O
+present O
+in O
+humans O
+, O
+suggesting O
+that O
+all O
+mammals O
+have O
+three O
+profilin B
+isoforms I
+. O
+
+Using O
+the O
+yeast O
+two O
+- O
+hybrid O
+system O
+, O
+we O
+have O
+isolated O
+an O
+835 B
+amino I
+acid I
+RING I
+finger I
+( I
+C3HC4 I
+zinc I
+finger I
+) I
+protein I
+, O
+TIF1 B
+beta I
+( O
+also O
+named O
+KAP B
+- I
+1 I
+) O
+, O
+that O
+specifically O
+interacts O
+with O
+the O
+KRAB B
+domain I
+of O
+the O
+human O
+zinc B
+finger I
+factor I
+KOX1 I
+/ O
+ZNF10 B
+. O
+
+The O
+authors O
+report O
+about O
+the O
+exeresis O
+of O
+a O
+pyelonephrictic O
+left O
+small O
+kidney O
+with O
+laparoscopic O
+surgery O
+. O
+
+New O
+protein O
+- O
+free O
+products O
+for O
+diet O
+therapy O
+in O
+chronic O
+renal O
+insufficiency O
+
+Unestablished O
+quail O
+myoblasts O
+were O
+infected O
+with O
+a O
+retroviral O
+vector O
+encoding O
+the O
+oncogenic O
+form O
+of O
+H B
+- I
+Ras I
+in O
+order O
+to O
+investigate O
+the O
+mechanism O
+by O
+which O
+this O
+oncoprotein O
+interferes O
+with O
+terminal O
+differentiation O
+. O
+
+Early O
+detection O
+and O
+signs O
+of O
+hepatoangiosarcoma O
+among O
+vinyl O
+chloride O
+workers O
+. O
+
+The O
+reduced O
+expression O
+caused O
+by O
+multimerization O
+of O
+UAS2 O
+in O
+the O
+native O
+promoter O
+was O
+observed O
+only O
+in O
+the O
+presence O
+of O
+ADR1 B
+. O
+
+VP4 B
+differentially O
+regulates O
+TRAF2 B
+signaling O
+, O
+disengaging O
+JNK B
+activation O
+while O
+directing O
+NF B
+- I
+kappa I
+B I
+to O
+effect O
+rotavirus O
+- O
+specific O
+cellular O
+responses O
+. O
+
+On O
+the O
+3rd O
+day O
+after O
+ischemia O
+of O
+the O
+remained O
+kidney O
+for O
+30 O
+min O
+, O
+structural O
+components O
+of O
+the O
+walls O
+of O
+the O
+glomerular O
+arterioles O
+and O
+those O
+of O
+the O
+filtration O
+- O
+reabsorption O
+barrier O
+undergo O
+certain O
+ultrastructural O
+changes O
+, O
+that O
+with O
+time O
+elapsed O
+( O
+7 O
+, O
+14 O
+days O
+) O
+gradually O
+pass O
+away O
+, O
+and O
+amount O
+of O
+cells O
+with O
+hypertrophic O
+processes O
+increases O
+. O
+
+The O
+purified O
+RAG1 B
+protein I
+overexpressed O
+in O
+E O
+. O
+coli O
+exhibited O
+the O
+expected O
+cleavage O
+activity O
+when O
+combined O
+with O
+RAG2 B
+purified O
+from O
+transfected O
+293T O
+cells O
+. O
+
+19 O
+, O
+4967 O
+- O
+4973 O
+) O
+. O
+
+Preventing O
+the O
+heterosexual O
+spread O
+of O
+HIV O
+into O
+this O
+vulnerable O
+population O
+is O
+a O
+formidable O
+public O
+health O
+challenge O
+. O
+
+Moreover O
+, O
+we O
+show O
+that O
+GATA B
+- I
+1 I
+and O
+Sp1 B
+synergize O
+from O
+a O
+distance O
+in O
+constructs O
+designed O
+to O
+mimic O
+the O
+architecture O
+of O
+globin B
+locus I
+control I
+regions I
+and O
+downstream O
+globin B
+promoters I
+. O
+
+Superovulation O
+with O
+intrauterine O
+insemination O
+( O
+SO O
+- O
+IUI O
+) O
+has O
+been O
+suggested O
+as O
+an O
+alternative O
+to O
+gamete O
+intrafallopian O
+transfer O
+( O
+GIFT O
+) O
+, O
+despite O
+the O
+absence O
+of O
+controlled O
+or O
+comparative O
+trials O
+. O
+
+Mammalian O
+chromosome O
+ends O
+contain O
+long O
+arrays O
+of O
+TTAGGG O
+repeats O
+that O
+are O
+complexed O
+to O
+a O
+telomere O
+specific O
+protein O
+, O
+the O
+TTAGGG B
+repeat I
+binding I
+factor I
+, O
+TRF1 B
+. O
+
+Genotype O
+- O
+phenotype O
+correlations O
+in O
+male O
+patients O
+with O
+a O
+partial O
+nullisomy O
+of O
+the O
+X O
+chromosome O
+have O
+suggested O
+that O
+at O
+least O
+one O
+locus O
+involved O
+in O
+MRX B
+is O
+on O
+Xp22 O
+. O
+3 O
+. O
+
+Mean O
+disposition O
+constants O
+( O
++ O
+/ O
+- O
+SD O
+) O
+were O
+obtained O
+from O
+individualized O
+fits O
+( O
+V1 O
+: O
+0 O
+. O
+398 O
++ O
+/ O
+- O
+0 O
+. O
+336 O
+LITER O
+/ O
+KG O
+, O
+Vdarea O
+: O
+2 O
+. O
+53 O
++ O
+/ O
+- O
+0 O
+. O
+72 O
+liter O
+/ O
+kg O
+, O
+alpha O
+: O
+0 O
+. O
+316 O
++ O
+/ O
+- O
+0 O
+. O
+294 O
+min O
+- O
+1 O
+, O
+beta O
+: O
+0 O
+. O
+00204 O
++ O
+/ O
+- O
+0 O
+. O
+00262 O
+min O
+- O
+1 O
+, O
+k2 O
+: O
+0 O
+. O
+0305 O
++ O
+/ O
+- O
+0 O
+. O
+0101 O
+min O
+- O
+1 O
+) O
+. O
+
+The O
+gene O
+, O
+from O
+the O
+initiator O
+methionine O
+to O
+the O
+polyadenylation O
+site O
+, O
+is O
+contained O
+within O
+13 O
+244 O
+basepairs O
+and O
+contains O
+19 O
+exons O
+. O
+
+In O
+the O
+unit O
+housing O
+of O
+a O
+compact O
+cyclotron O
+and O
+positron O
+emission O
+CT O
+( O
+PET O
+) O
+, O
+positron O
+emitting O
+gas O
+such O
+as O
+15O O
+, O
+11C O
+, O
+C15O2 O
+, O
+C15O O
+etc O
+. O
+
+is O
+supplied O
+from O
+a O
+cyclotron O
+to O
+a O
+PET O
+room O
+through O
+a O
+transportation O
+pipe O
+with O
+an O
+appropriate O
+shield O
+to O
+reduce O
+positron O
+annihilation O
+radiation O
+. O
+
+Adhesion O
+was O
+inhibited O
+by O
+mAbs O
+against O
+the O
+COOH O
+- O
+terminus O
+and O
+central O
+cell O
+binding O
+domains O
+of O
+fibronectin B
+, O
+as O
+well O
+as O
+by O
+the O
+corresponding O
+CS1 B
+and O
+RGD O
+peptides O
+. O
+
+These O
+results O
+were O
+not O
+obtained O
+using O
+either O
+preimmune O
+sera O
+or O
+antiserum O
+specific O
+for O
+the O
+luminal O
+portion O
+of O
+the O
+glycoprotein O
+precursor O
+. O
+
+Cerebral O
+blood O
+flow O
+was O
+measured O
+using O
+the O
+iv O
+method O
+of O
+133 O
+- O
+Xe O
+CBF O
+determination O
+and O
+AVDO2 O
+was O
+measured O
+using O
+systemic O
+arterial O
+- O
+jugular O
+venous O
+oxygen O
+content O
+differences O
+. O
+
+Activation O
+of O
+the O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+( O
+MAPK B
+) O
+pathway O
+enhances O
+long O
+- O
+range O
+transactivation O
+by O
+the O
+beta B
+- I
+globin I
+locus I
+control I
+region I
+( O
+LCR O
+) O
+( O
+W O
+. O
+
+In O
+situ O
+hybridization O
+of O
+whole O
+- O
+mount O
+mouse O
+embryos O
+with O
+Mex5 B
+antisense I
+RNA I
+provide O
+no O
+evidence O
+for O
+the O
+exclusion O
+of O
+Mex5 B
+during O
+embryonic O
+development O
+. O
+
+In O
+three O
+other O
+patients O
+the O
+electrophysiologic O
+characteristics O
+of O
+atrioventricular O
+conduction O
+prevented O
+a O
+demonstration O
+of O
+these O
+differences O
+. O
+
+Human O
+psychophysical O
+analysis O
+of O
+receptive O
+field O
+- O
+like O
+properties O
+- O
+- O
+II O
+. O
+
+3 O
+. O
+
+New O
+strategies O
+are O
+needed O
+to O
+prevent O
+coronary O
+rethrombosis O
+in O
+patients O
+with O
+minimal O
+atherosclerosis O
+after O
+thrombolytic O
+therapy O
+for O
+acute O
+myocardial O
+infarction O
+. O
+
+The O
+Ick B
+protein B
+tyrosine I
+kinase I
+is O
+not O
+involved O
+in O
+antibody O
+- O
+mediated O
+CD4 B
+( O
+CDR3 B
+- I
+loop I
+) O
+signal O
+transduction O
+that O
+inhibits O
+HIV O
+- O
+1 O
+transcription O
+. O
+
+Programmed O
+peritoneal O
+lavage O
+in O
+suppurative O
+complications O
+of O
+perforated O
+ulcer O
+of O
+the O
+stomach O
+
+Deletion O
+analysis O
+of O
+the O
+7 B
+. I
+3 I
+- I
+kb I
+GATA I
+- I
+2 I
+promoter I
+region I
+revealed O
+that O
+a O
+1 O
+. O
+1 O
+- O
+kb O
+DNA O
+sequence O
+is O
+critical O
+for O
+expression O
+of O
+GATA B
+- I
+2 I
+in O
+neurons O
+. O
+
+The O
+model O
+therefore O
+predicts O
+that O
+1 O
+) O
+on O
+- O
+line O
+calculation O
+of O
+airway O
+dead O
+space O
+and O
+end O
+- O
+expired O
+lung O
+volume O
+can O
+be O
+made O
+by O
+the O
+addition O
+of O
+an O
+oxygen O
+sine O
+- O
+wave O
+perturbation O
+component O
+to O
+the O
+mean O
+FIO2 O
+; O
+and O
+( O
+2 O
+) O
+QS O
+/ O
+QT O
+can O
+be O
+measured O
+from O
+the O
+resultant O
+oxygen O
+perturbation O
+sine O
+- O
+wave O
+amplitudes O
+in O
+the O
+expired O
+gas O
+and O
+in O
+arterial O
+and O
+mixed O
+- O
+venous O
+blood O
+and O
+is O
+independent O
+of O
+the O
+mean O
+blood O
+oxygen O
+partial O
+pressure O
+and O
+oxyhemoglobin B
+saturation O
+values O
+. O
+
+Consistent O
+with O
+this O
+, O
+rh5 B
+expression O
+in O
+R8 O
+disappears O
+when O
+R7 O
+cells O
+are O
+absent O
+( O
+in O
+sevenless B
+mutant I
+) O
+. O
+
+The O
+fusion O
+gene O
+cassette O
+was O
+placed O
+under O
+the O
+control O
+of O
+a O
+vaccinia B
+virus I
+early I
+promoter I
+and O
+cloned O
+in O
+a O
+host O
+- O
+restricted O
+fowlpox O
+viral O
+vector O
+. O
+
+Psoriasis O
+on O
+tumor O
+. O
+
+Fulminant O
+hepatic O
+failure O
+in O
+these O
+cases O
+could O
+be O
+characterized O
+by O
+: O
+( O
+1 O
+) O
+rapid O
+decrease O
+in O
+serum B
+alanine I
+transaminase I
+( O
+ALT B
+) O
+level O
+after O
+discontinuation O
+of O
+ecarazine O
+, O
+( O
+2 O
+) O
+prolonged O
+jaundice O
+despite O
+discontinuation O
+of O
+ecarazine O
+, O
+( O
+3 O
+) O
+high O
+incidence O
+of O
+anti B
+- I
+nuclear I
+antibody I
+( O
+ANA B
+) O
+( O
+57 O
+% O
+) O
+, O
+and O
+( O
+4 O
+) O
+histological O
+findings O
+of O
+extensive O
+hepatocellular O
+necrosis O
+ranging O
+from O
+bridging O
+necrosis O
+to O
+massive O
+necrosis O
+. O
+
+These O
+data O
+suggest O
+that O
+the O
+secreted O
+, O
+truncated O
+receptor O
+encoded O
+by O
+the O
+2 B
+. I
+6 I
+- I
+kb I
+c I
+- I
+erbB I
+transcript I
+can O
+bind O
+to O
+TGF B
+alpha I
+and O
+may O
+play O
+an O
+important O
+growth O
+- O
+regulatory O
+function O
+in O
+vitro O
+. O
+
+Localization O
+of O
+the O
+porcine O
+enzyme O
+in O
+the O
+endoplasmic O
+reticulum O
+is O
+consistent O
+with O
+immuno O
+- O
+electron O
+- O
+microscopic O
+studies O
+using O
+pig O
+hepatocytes O
+. O
+
+A O
+close O
+homologue O
+of O
+the O
+APK2a B
+gene I
+, O
+named O
+APK2b B
+, O
+was O
+also O
+isolated O
+from O
+the O
+Arabidopsis O
+cDNA O
+library O
+. O
+
+Thus O
+, O
+the O
+rates O
+of O
+a B
+- I
+factor I
+receptor I
+endocytosis O
+and O
+consequent O
+vacuolar O
+turnover O
+depend O
+on O
+the O
+available O
+level O
+of O
+ubiquitin B
+in O
+the O
+cell O
+. O
+
+Using O
+the O
+same O
+approach O
+we O
+have O
+shown O
+that O
+hFIRE B
+binds O
+the O
+stimulatory O
+proteins O
+Sp1 B
+and O
+Sp3 B
+in O
+addition O
+to O
+CBF B
+. O
+
+Non O
+- O
+specific O
+immunological O
+abnormalities O
+were O
+detected O
+in O
+8 O
+of O
+the O
+13 O
+patients O
+in O
+whom O
+they O
+were O
+looked O
+for O
+. O
+
+Using O
+a O
+combined O
+pharmacokinetic O
+- O
+pharmacodynamic O
+model O
+, O
+the O
+impact O
+of O
+various O
+factors O
+on O
+the O
+effective O
+bioavailability O
+and O
+on O
+its O
+estimation O
+, O
+using O
+the O
+intravenous O
+- O
+to O
+- O
+oral O
+dose O
+ratio O
+required O
+to O
+produce O
+the O
+same O
+area O
+under O
+the O
+response O
+time O
+curve O
+after O
+acute O
+administration O
+, O
+are O
+explored O
+. O
+
+CONCLUSIONS O
+: O
+The O
+RRM O
+is O
+one O
+of O
+the O
+most O
+common O
+and O
+best O
+characterized O
+RNA O
+- O
+binding O
+motifs O
+. O
+
+The O
+cyclin B
+- I
+dependent I
+kinase I
+Cdk2 B
+associates O
+with O
+cyclins B
+A I
+, I
+D I
+, I
+and I
+E I
+and O
+has O
+been O
+implicated O
+in O
+the O
+control O
+of O
+the O
+G1 O
+to O
+S O
+phase O
+transition O
+in O
+mammals O
+. O
+
+Mol O
+. O
+
+The O
+amino O
+- O
+terminal O
+gag B
+- I
+encoded I
+region O
+of O
+P140gag B
+- O
+fps B
+contains O
+a O
+phosphotyrosine O
+residue O
+in O
+addition O
+to O
+normal O
+gag B
+phosphorylation O
+sites O
+. O
+
+Rad18 B
+is O
+required O
+for O
+DNA O
+repair O
+and O
+checkpoint O
+responses O
+in O
+fission O
+yeast O
+. O
+
+A O
+less O
+common O
+and O
+much O
+more O
+perplexing O
+circumstance O
+occurs O
+when O
+evaluating O
+patients O
+with O
+sarcoidosis O
+established O
+for O
+several O
+years O
+present O
+with O
+evidence O
+of O
+progressive O
+or O
+chronic O
+pulmonary O
+involvement O
+and O
+dyspnea O
+. O
+
+2 O
+, O
+4 O
+- O
+and O
+2 O
+, O
+6 O
+- O
+toluenediamine O
+in O
+hydrolysed O
+plasma O
+and O
+urine O
+after O
+test O
+- O
+chamber O
+exposure O
+of O
+humans O
+to O
+2 O
+, O
+4 O
+- O
+and O
+2 O
+, O
+6 O
+- O
+toluene O
+diisocyanate O
+. O
+
+Further O
+studies O
+are O
+warranted O
+to O
+determine O
+whether O
+these O
+findings O
+are O
+idiosyncratic O
+, O
+coincidental O
+, O
+or O
+a O
+more O
+general O
+phenomenon O
+. O
+
+After O
+1 O
+day O
+, O
+none O
+of O
+the O
+labeled O
+erythrocytes O
+were O
+detected O
+. O
+
+This O
+substrate O
+was O
+cleaved O
+efficiently O
+in O
+trans O
+by O
+protease B
+3C I
+derived O
+from O
+another O
+recombinant O
+vaccinia O
+virus O
+expressing O
+a O
+3C B
+precursor I
+protein I
+. O
+
+The O
+activity O
+of O
+gamma B
+- I
+glutamyl I
+transpeptidase I
+in O
+the O
+serum O
+of O
+problem O
+drinkers O
+. O
+
+Patients O
+with O
+endocarditis O
+or O
+vascular O
+infection O
+were O
+more O
+frequently O
+immunocompromised O
+and O
+older O
+than O
+those O
+with O
+acute O
+Q O
+fever O
+. O
+
+The O
+effects O
+of O
+oxalate O
+- O
+containing O
+products O
+on O
+the O
+exposed O
+dentine O
+surface O
+: O
+an O
+SEM O
+investigation O
+. O
+
+The O
+technique O
+used O
+by O
+this O
+system O
+involves O
+a O
+transient O
+, O
+externally O
+applied O
+increase O
+in O
+resistance O
+to O
+breathing O
+. O
+
+We O
+evaluated O
+99mTc O
+- O
+ECD O
+SPECT O
+comparing O
+with O
+rCBF O
+images O
+obtained O
+by O
+PET O
+in O
+12 O
+patients O
+with O
+spinocerebellar O
+degeneration O
+( O
+SCD O
+) O
+. O
+
+Monoclonal O
+antibodies O
+to O
+the O
+hapten O
+phenyloxazolone O
+were O
+raised O
+7 O
+days O
+after O
+immunization O
+in O
+mice O
+of O
+six O
+strains O
+( O
+BALB O
+/ O
+c O
+, O
+C57BL O
+- O
+Igha O
+, O
+DBA2 O
+, O
+RF O
+, O
+A O
+/ O
+J O
+, O
+and O
+CE O
+) O
+. O
+
+In O
+particular O
+, O
+lacZ B
+transcripts I
+synthesised O
+this O
+way O
+are O
+highly O
+unstable O
+and O
+yield O
+little O
+beta B
+- I
+galactosidase I
+. O
+
+Six O
+cDNAs O
+represent O
+human O
+homologs O
+of O
+genes O
+known O
+in O
+other O
+species O
+, O
+namely O
+, O
+mouse B
+HSPE71 I
+, O
+Rat B
+RhoGAP I
+protein I
+, O
+S B
+cerevisiae I
+leucyl I
+tRNA I
+synthetase I
+and O
+S B
+cerevisiae I
+chromosome I
+II I
+ORF I
+YBLO44W I
+. O
+
+The O
+thalamic O
+SD O
+was O
+regularly O
+triggered O
+by O
+short O
+( O
+0 O
+. O
+02 O
+- O
+0 O
+. O
+05 O
+s O
+) O
+high O
+- O
+frequency O
+( O
+200 O
+- O
+500 O
+Hz O
+) O
+ES O
+of O
+the O
+parietal O
+cortical O
+surface O
+. O
+
+All O
+three O
+SSV O
+- O
+transformed O
+cells O
+secreted O
+v B
+- I
+sis I
+gene I
+product I
+( O
+p44 B
+) O
+. O
+
+p44 B
+was O
+secreted O
+but O
+remained O
+tightly O
+associated O
+with O
+the O
+cell O
+surface O
+. O
+
+It O
+is O
+suggested O
+that O
+the O
+mechanism O
+of O
+intestinal O
+absorption O
+of O
+vitamin O
+D O
+and O
+25 O
+- O
+hydroxy O
+- O
+vitamin O
+D O
+may O
+differ O
+in O
+man O
+, O
+the O
+absorption O
+of O
+25 O
+- O
+hydroxy O
+- O
+vitamin O
+D O
+possibly O
+being O
+less O
+dependent O
+on O
+bile O
+acids O
+. O
+
+To O
+determine O
+the O
+role O
+of O
+elevated O
+FAK B
+expression O
+in O
+facilitating O
+epidermal B
+growth I
+factor I
+( O
+EGF B
+) O
+- O
+stimulated O
+human O
+adenocarcinoma O
+( O
+A549 O
+) O
+cell O
+motility O
+, O
+antisense O
+oligonucleotides O
+were O
+used O
+to O
+reduce O
+FAK B
+protein I
+expression O
+> O
+75 O
+% O
+. O
+
+It O
+tends O
+to O
+be O
+higher O
+between O
+frazioni O
+of O
+the O
+same O
+community O
+than O
+between O
+communities O
+. O
+
+The O
+BRSV B
+L I
+gene I
+is O
+6573 O
+nt O
+in O
+length O
+and O
+the O
+derived O
+polypeptide O
+has O
+2162 O
+aa O
+. O
+
+To O
+further O
+study O
+the O
+role O
+of O
+tTG B
+in O
+liver O
+disease O
+, O
+we O
+initiated O
+investigations O
+into O
+the O
+effect O
+of O
+a O
+proinflammatory O
+mediator O
+, O
+tumor B
+necrosis I
+factor I
+( I
+TNF I
+) I
+- I
+alpha I
+, O
+on O
+tTG B
+activity O
+in O
+cultured O
+liver O
+cells O
+. O
+
+Availability O
+of O
+a O
+less O
+palatable O
+diet O
+( O
+chow O
+) O
+following O
+presentation O
+of O
+palatable O
+diets O
+will O
+not O
+result O
+in O
+diminished O
+caloric O
+intake O
+, O
+body O
+weight O
+, O
+obesity O
+and O
+hyperinsulinemia O
+. O
+
+By O
+contrast O
+, O
+CIS O
+failed O
+to O
+affect O
+the O
+IL B
+- I
+9 I
+response O
+. O
+
+METHODS O
+AND O
+RESULTS O
+: O
+With O
+an O
+array O
+of O
+112 O
+unipole O
+, O
+epicardial O
+maps O
+of O
+electrically O
+induced O
+AF O
+in O
+6 O
+dogs O
+( O
+acute O
+group O
+) O
+, O
+self O
+- O
+sustained O
+AF O
+in O
+6 O
+dogs O
+( O
+chronic O
+group O
+) O
+, O
+and O
+sinus O
+rhythm O
+and O
+atrial O
+pacing O
+in O
+3 O
+dogs O
+( O
+control O
+group O
+) O
+were O
+analyzed O
+before O
+and O
+after O
+creating O
+linear O
+radiofrequency O
+ablation O
+lesions O
+in O
+both O
+atria O
+that O
+eliminated O
+the O
+AF O
+. O
+
+In O
+response O
+to O
+phosphorus O
+limitation O
+, O
+the O
+fungus O
+Neurospora O
+crassa O
+synthesizes O
+a O
+number O
+of O
+enzymes O
+that O
+function O
+to O
+bring O
+more O
+phosphate O
+into O
+the O
+cell O
+. O
+
+The O
+effects O
+of O
+inoculum O
+size O
+, O
+medium O
+, O
+temperature O
+, O
+and O
+duration O
+of O
+growth O
+on O
+the O
+in O
+vitro O
+susceptibility O
+testing O
+of O
+Aspergillus O
+fumigatus O
+were O
+investigated O
+using O
+broth O
+micro O
+- O
+and O
+macro O
+- O
+dilution O
+techniques O
+. O
+
+We O
+have O
+analyzed O
+the O
+function O
+of O
+these O
+putative O
+SL O
+structures O
+in O
+RNA O
+translation O
+by O
+constructing O
+chimeric B
+chloramphenicol I
+acetyltransferase I
+( O
+CAT B
+) O
+RNAs O
+, O
+flanked O
+either O
+by O
+both O
+5 O
+' O
+- O
+and O
+3 O
+' O
+- O
+terminal O
+sequence O
+domains O
+from O
+the O
+RV O
+genome O
+or O
+several O
+deletion O
+derivatives O
+of O
+the O
+same O
+sequences O
+. O
+
+Periarteritis O
+nodosa O
+with O
+ruptures O
+of O
+the O
+renal O
+vessels O
+and O
+the O
+persistence O
+of O
+the O
+hepatitis O
+B O
+and O
+C O
+viruses O
+in O
+the O
+blood O
+
+Despite O
+the O
+fact O
+that O
+biochemical O
+estimates O
+of O
+bone O
+turnover O
+indicate O
+that O
+( O
+short O
+- O
+term O
+) O
+administration O
+of O
+rhGH B
+and O
+IGF B
+- I
+I I
+stimulates O
+bone O
+metabolism O
+in O
+non O
+- O
+osteoporotic O
+older O
+people O
+, O
+no O
+significant O
+changes O
+have O
+been O
+observed O
+in O
+bone O
+mineral O
+density O
+at O
+the O
+proximal O
+femur O
+. O
+
+Compression O
+of O
+pulmonary O
+artery O
+and O
+right O
+ventricular O
+outflow O
+tract O
+by O
+aneurysm O
+of O
+ascending O
+aorta O
+. O
+
+However O
+, O
+patients O
+with O
+DPX O
+should O
+be O
+observed O
+for O
+the O
+potential O
+occurrence O
+of O
+an O
+associated O
+condition O
+. O
+
+Blood O
+pressure O
+was O
+controlled O
+long O
+term O
+( O
+with O
+/ O
+without O
+diuretics O
+/ O
+beta B
+- I
+adrenoreceptor I
+blocking O
+drugs O
+) O
+in O
+sixteen O
+out O
+of O
+nineteen O
+patients O
+with O
+mild O
+- O
+moderate O
+hypertension O
+. O
+
+However O
+, O
+FosB B
+- I
+L I
+and O
+FosB B
+- I
+S I
+do O
+not O
+differ O
+in O
+all O
+trans O
+- O
+regulatory O
+properties O
+: O
+Trans O
+- O
+activation O
+of O
+a O
+5x O
+TRE B
+- O
+CAT B
+reporter O
+construct O
+in O
+HeLa O
+and O
+NIH O
+- O
+3T3 O
+cells O
+was O
+found O
+with O
+both O
+FosB B
+forms O
+. O
+
+Mutations O
+in O
+glnB B
+, O
+nifR1 B
+( O
+ntrC B
+) O
+, O
+and O
+NifR4 B
+( O
+ntrA B
+encoding O
+sigma B
+54 I
+) O
+had O
+no O
+influence O
+on O
+put B
+gene I
+expression O
+. O
+
+Disruption O
+of O
+INP53 B
+, O
+but O
+not O
+the O
+related O
+INP51 B
+and O
+INP52 B
+genes I
+, O
+resulted O
+in O
+alpha B
+- I
+factor I
+maturation O
+defects O
+and O
+exacerbated O
+alpha B
+- I
+factor I
+maturation O
+defects O
+when O
+combined O
+with O
+chc1 B
+- I
+521 I
+. O
+
+Impact O
+of O
+cytokine O
+gene O
+polymorphisms O
+on O
+outcomes O
+of O
+coronary O
+artery O
+bypass O
+graft O
+surgery O
+. O
+
+Regardless O
+of O
+muscle O
+tensioning O
+or O
+marination O
+treatments O
+, O
+aging O
+of O
+the O
+carcass O
+for O
+24 O
+h O
+( O
+T1 O
+, O
+T2 O
+, O
+and O
+T3 O
+) O
+produced O
+meats O
+with O
+lower O
+shear O
+values O
+than O
+those O
+from O
+hot O
+- O
+boned O
+carcasses O
+( O
+T4 O
+and O
+T5 O
+) O
+. O
+
+Blood O
+and O
+whole O
+- O
+brain O
+mercury O
+concentrations O
+were O
+determined O
+in O
+pups O
+on O
+PN O
+0 O
+( O
+birth O
+) O
+and O
+PN O
+21 O
+( O
+weaning O
+) O
+. O
+
+By O
+subtractive O
+and O
+differential O
+screening O
+, O
+we O
+have O
+cloned O
+12 O
+of O
+these O
+sequences O
+, O
+2 O
+of O
+which O
+were O
+c B
+- I
+fos I
+and O
+krox B
+- I
+24 I
+. O
+
+When O
+stratifying O
+FLM O
+values O
+< O
+34 O
+and O
+> O
+34 O
+wks O
+' O
+gestation O
+, O
+again O
+no O
+difference O
+was O
+found O
+in O
+mean O
+difference O
+of O
+L O
+/ O
+S O
+and O
+LB O
+before O
+and O
+after O
+34 O
+wks O
+. O
+
+Cotransfection O
+of O
+a O
+junB B
+stimulated O
+the O
+basal O
+activity O
+of O
+the O
+alpha B
+2 I
+( I
+I I
+) I
+collagen I
+promoter I
+93 O
+- O
+fold O
+, O
+respectively O
+. O
+
+Glutathione B
+reductase I
+( O
+GR B
+) O
+was O
+purified O
+from O
+the O
+cyanobacterium O
+Anabaena O
+PCC O
+7120 O
+. O
+
+Additional O
+simulations O
+account O
+for O
+interactions O
+of O
+spatial O
+frequency O
+with O
+stimulus O
+duration O
+, O
+effects O
+of O
+adaptation O
+, O
+and O
+properties O
+of O
+residual O
+traces O
+, O
+as O
+opposed O
+to O
+visual O
+persistence O
+. O
+
+Fractional O
+Ca O
+retention O
+was O
+measured O
+from O
+the O
+72 O
+- O
+h O
+postdose O
+WBR O
+divided O
+by O
+WBR O
+at O
+time O
+0 O
+. O
+
+METHODS O
+: O
+The O
+study O
+population O
+included O
+70 O
+patients O
+with O
+acute O
+coronary O
+syndromes O
+( O
+14 O
+with O
+recent O
+acute O
+myocardial O
+infarction O
+and O
+56 O
+with O
+unstable O
+angina O
+pectoris O
+) O
+, O
+105 O
+patients O
+with O
+stable O
+angina O
+pectoris O
+, O
+and O
+75 O
+control O
+subjects O
+. O
+
+Furthermore O
+, O
+rubella B
+IgM I
+antibody I
+was O
+never O
+detected O
+after O
+immunization O
+in O
+women O
+who O
+were O
+HAI B
+- O
+negative O
+and O
+LA B
+- O
+positive O
+during O
+pregnancy O
+. O
+
+Disease O
+- O
+free O
+interval O
+was O
+greater O
+in O
+node O
+- O
+negative O
+Lx O
+patients O
+for O
+both O
+T1 O
+( O
+P O
+less O
+than O
+0 O
+. O
+007 O
+) O
+and O
+T2 O
+( O
+P O
+less O
+than O
+0 O
+. O
+05 O
+) O
+presentations O
+. O
+
+5 O
+' O
+- O
+Deletion O
+of O
+the O
+Stat B
+- I
+binding I
+sites I
+abolished O
+all O
+promoter O
+- O
+reporter O
+activity O
+in O
+response O
+to O
+PRL B
+. O
+
+A O
+review O
+of O
+156 O
+patients O
+younger O
+than O
+40 O
+treated O
+at O
+our O
+Department O
+between O
+1960 O
+and O
+1991 O
+with O
+transitional O
+cell O
+carcinoma O
+of O
+the O
+bladder O
+revealed O
+that O
+89 O
+. O
+1 O
+% O
+had O
+superficial O
+( O
+Ta O
+/ O
+T1 O
+) O
+disease O
+and O
+the O
+remaining O
+10 O
+. O
+9 O
+% O
+presented O
+with O
+invasive O
+disease O
+. O
+
+Plasma O
+beta B
+- I
+thromboglobulin I
+( O
+beta B
+- I
+TG I
+) O
+, O
+a O
+platelet O
+- O
+specific O
+protein O
+, O
+is O
+a O
+marker O
+of O
+intravascular O
+platelet O
+degranulation O
+. O
+
+John O
+' O
+s O
+wort O
+
+DESIGN O
+, O
+SETTING O
+AND O
+SUBJECTS O
+: O
+The O
+analysis O
+is O
+based O
+on O
+data O
+collected O
+in O
+the O
+first O
+two O
+rounds O
+of O
+the O
+nationally O
+representative O
+Ghana O
+Living O
+Standards O
+Survey O
+, O
+held O
+in O
+1987 O
+/ O
+88 O
+( O
+GLSS O
+- O
+I O
+) O
+and O
+1988 O
+/ O
+89 O
+( O
+GLSS O
+- O
+II O
+) O
+, O
+with O
+both O
+surveys O
+covering O
+approximately O
+3000 O
+households O
+. O
+
+The O
+DNA O
+- O
+binding O
+proteins O
+are O
+without O
+effect O
+on O
+the O
+transcription O
+of O
+plasmids O
+lacking O
+binding O
+sites O
+or O
+when O
+the O
+binding O
+sites O
+are O
+located O
+further O
+upstream O
+. O
+
+The O
+Gastrointestinal O
+Tumor O
+Study O
+Group O
+( O
+GITSG O
+) O
+protocol O
+GI O
+- O
+7175 O
+randomized O
+227 O
+patients O
+between O
+1975 O
+and O
+1980 O
+following O
+complete O
+surgical O
+resection O
+of O
+stages O
+B2 O
+and O
+C O
+rectal O
+adenocarcinoma O
+to O
+four O
+treatment O
+arms O
+: O
+( O
+1 O
+) O
+no O
+adjuvant O
+therapy O
+, O
+( O
+2 O
+) O
+chemotherapy O
+only O
+, O
+( O
+3 O
+) O
+radiotherapy O
+only O
+, O
+and O
+( O
+4 O
+) O
+radiotherapy O
+and O
+chemotherapy O
+( O
+combined O
+modality O
+) O
+. O
+
+The O
+RTI40 B
+gene I
+spans O
+35 O
+kilobase O
+pairs O
+; O
+it O
+contains O
+6 O
+exons O
+and O
+at O
+least O
+6 O
+rat O
+Identifier O
+repetitive O
+elements O
+. O
+
+The O
+DNA O
+element O
+through O
+which O
+EBNA B
+- I
+3C I
+activates O
+the O
+LMP B
+- I
+1 I
+promoter I
+includes O
+a O
+Spi B
+- I
+1 I
+/ O
+Spi B
+- I
+B I
+binding O
+site O
+, O
+previously O
+characterized O
+as O
+an O
+important O
+EBNA B
+- I
+2 I
+response I
+element I
+. O
+
+DP B
+- I
+1 I
+and O
+DP B
+- I
+2 I
+encode O
+maternally O
+stored O
+transcripts O
+that O
+are O
+expressed O
+during O
+early O
+development O
+. O
+
+Furthermore O
+, O
+deletion O
+of O
+two O
+potential O
+Ste11 B
+recognition I
+sites I
+in O
+the O
+fus1 B
+promoter I
+region I
+abolished O
+transcription O
+, O
+and O
+expression O
+could O
+be O
+restored O
+when O
+we O
+inserted O
+a O
+different O
+Ste11 B
+site I
+from O
+the O
+mat1 B
+- I
+P I
+promoter I
+. O
+
+However O
+, O
+an O
+analogous O
+myristoylated O
+peptide O
+derived O
+from O
+c B
+- I
+Yes I
+also O
+has O
+no O
+inhibitory O
+activity O
+. O
+
+The O
+oral O
+movements O
+which O
+did O
+occur O
+in O
+the O
+HAL O
+- O
+treated O
+rats O
+were O
+slower O
+than O
+normal O
+. O
+
+Finally O
+, O
+we O
+demonstrate O
+that O
+animals O
+carrying O
+a O
+snf B
+mutation I
+that O
+converts O
+SNF B
+from O
+a O
+bifunctional O
+protein O
+to O
+a O
+U1 B
+snRNP I
+- O
+specific O
+protein O
+are O
+viable O
+. O
+
+These O
+sequence O
+differences O
+are O
+reflected O
+in O
+differences O
+in O
+gene O
+expression O
+in O
+three O
+cell O
+lines O
+. O
+
+This O
+pathway O
+has O
+been O
+reported O
+to O
+mediate O
+heterodimer O
+interactions O
+with O
+the O
+proapoptotic O
+regulator O
+, O
+Bad B
+. O
+
+Mutating O
+bases O
+- O
+142 O
+to O
+- O
+151 O
+abolishes O
+formation O
+of O
+complex O
+VII O
+and O
+partially O
+inhibits O
+complex O
+IV O
+, O
+suggesting O
+that O
+the O
+proteins O
+forming O
+these O
+complexes O
+bind O
+neighboring O
+segments O
+of O
+DNA O
+. O
+
+The O
+DFA O
+slide O
+prepared O
+from O
+the O
+ThinPrep O
+Test O
+and O
+the O
+conventional O
+DFA O
+sample O
+prepared O
+from O
+the O
+endocervical O
+swab O
+were O
+evaluated O
+independently O
+. O
+
+Moclobemide O
+is O
+a O
+well O
+- O
+tolerated O
+alternative O
+antidepressant O
+, O
+but O
+there O
+is O
+a O
+need O
+for O
+prospective O
+controlled O
+trials O
+to O
+evaluate O
+its O
+long O
+- O
+term O
+efficacy O
+. O
+
+METHODS O
+: O
+Autocapture O
+devices O
+( O
+Pacesetter O
+Microny O
+SR O
++ O
+/ O
+- O
+and O
+Regency O
+SR O
++ O
+/ O
+- O
+; O
+Pacesetter O
+, O
+Solna O
+, O
+Sweden O
+) O
+and O
+steroid O
+- O
+eluting O
+epicardial O
+pacing O
+leads O
+( O
+Medtronic O
+CapSure O
+Epi O
+10366 O
+; O
+Medtronic O
+, O
+Inc O
+, O
+Minneapolis O
+, O
+MN O
+) O
+were O
+implanted O
+in O
+14 O
+children O
+. O
+
+Hormonal O
+replacement O
+therapy O
+for O
+women O
+with O
+a O
+personal O
+history O
+of O
+breast O
+cancer O
+? O
+
+Recently O
+, O
+we O
+reported O
+that O
+SMRT B
+also O
+directly O
+associates O
+with O
+LAZ3 B
+( O
+BCL B
+- I
+6 I
+) O
+, O
+a O
+POZ B
+/ I
+Zn I
+finger I
+transcriptional I
+repressor I
+involvedin O
+the O
+pathogenesis O
+of O
+non O
+- O
+Hodgkin O
+lymphomas O
+. O
+
+Using O
+reporter O
+gene O
+constructs O
+driven O
+by O
+the O
+CD4 B
+promoter I
+, O
+we O
+report O
+that O
+HHV O
+- O
+6 O
+can O
+efficiently O
+transactivate O
+such O
+genetic O
+elements O
+. O
+
+Characterization O
+of O
+a O
+cDNA O
+encoding O
+CNN B
+predicts O
+a O
+novel O
+structural O
+protein O
+with O
+three O
+leucine O
+zipper O
+motifs O
+and O
+several O
+coiled O
+- O
+coil O
+domains O
+exhibiting O
+limited O
+homology O
+to O
+the O
+rod O
+portion O
+of O
+myosin B
+. O
+
+A O
+preformed O
+SREBP B
+- I
+1a I
+: O
+[ O
+32P O
+] O
+DNA O
+complex O
+bound O
+specifically O
+to O
+membrane O
+- O
+immobilized O
+GST B
+- O
+CBP B
+fusion O
+proteins O
+that O
+contained O
+amino O
+- O
+terminal O
+portions O
+of O
+CBP B
+. O
+
+Pyridostigmine O
+pretreatment O
+was O
+supplemented O
+by O
+therapy O
+with O
+two O
+doses O
+of O
+an O
+antidotal O
+combination O
+( O
+A O
+, O
+TM O
+, O
+B O
+) O
+consisting O
+of O
+0 O
+. O
+05 O
+mg O
+/ O
+kg O
+atropine O
+, O
+2 O
+. O
+24 O
+mg O
+/ O
+kg O
+TMB O
+- O
+4 O
+, O
+and O
+0 O
+. O
+4 O
+mg O
+/ O
+kg O
+benactyzine O
+which O
+assured O
+survival O
+in O
+five O
+of O
+six O
+animals O
+following O
+three O
+separate O
+exposures O
+to O
+10 O
+LD50 O
+soman O
+. O
+
+Previous O
+work O
+established O
+that O
+the O
+TAL1 B
+proteins I
+are O
+phosphorylated O
+exclusively O
+on O
+serine O
+and O
+identified O
+Ser122 O
+as O
+a O
+substrate O
+for O
+the O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+ERK I
+- I
+1 I
+. O
+
+Rapid O
+, O
+sensitive O
+gas O
+chromatographic O
+analysis O
+of O
+8 O
+- O
+methoxypsoralen O
+in O
+human O
+plasma O
+. O
+
+If O
+the O
+size O
+of O
+the O
+cystic O
+liver O
+- O
+lesions O
+excludes O
+a O
+curative O
+operative O
+treatment O
+or O
+if O
+the O
+patient O
+refuses O
+surgery O
+, O
+the O
+indication O
+for O
+chemotherapy O
+with O
+mebendazole O
+is O
+given O
+. O
+
+When O
+cotransfected O
+with O
+the O
+HIV B
+LTR I
+CAT I
+into O
+CV O
+- O
+1 O
+cells O
+, O
+both O
+the O
+pCD41 O
+and O
+pGD41 O
+clones O
+trans O
+- O
+activated O
+the O
+HIV B
+LTR I
+. O
+
+The O
+induction O
+of O
+the O
+composite O
+H B
+- I
+PK I
+/ O
+Tag B
+and O
+SV B
+- I
+PK I
+/ O
+Tag B
+transgenes O
+by O
+a O
+carbohydrate O
+- O
+rich O
+diet O
+in O
+the O
+liver O
+was O
+similar O
+to O
+that O
+of O
+the O
+endogenous B
+L I
+- I
+PK I
+gene I
+. O
+
+Patients O
+with O
+advanced O
+ovarian O
+carcinoma O
+, O
+Stage O
+III O
+or O
+IV O
+( O
+International O
+Federation O
+of O
+Gynaecology O
+and O
+Obstetrics O
+) O
+, O
+were O
+randomized O
+to O
+primary O
+chemotherapy O
+with O
+doxorubicin O
+( O
+Adriamycin O
+) O
+and O
+cisplatin O
+plus O
+or O
+minus O
+hexamethylmelamine O
+, O
+and O
+cyclophosphamide O
+( O
+CHAP O
+) O
+. O
+
+Exit O
+from O
+mitosis O
+in O
+Drosophila O
+syncytial O
+embryos O
+requires O
+proteolysis O
+and O
+cyclin B
+degradation O
+, O
+and O
+is O
+associated O
+with O
+localized O
+dephosphorylation O
+. O
+
+Cough O
+- O
+CPR O
+, O
+a O
+deep O
+rhythmic O
+forceful O
+cough O
+repeated O
+30 O
+- O
+60 O
+times O
+per O
+minute O
+, O
+can O
+be O
+an O
+effective O
+resuscitative O
+technique O
+during O
+emergencies O
+occurring O
+in O
+the O
+cardiac O
+catheterization O
+laboratory O
+. O
+
+To O
+understand O
+this O
+dramatic O
+effect O
+, O
+we O
+examined O
+the O
+localization O
+of O
+SR B
+proteins I
+and O
+found O
+that O
+SC35 B
+was O
+shifted O
+to O
+the O
+cytoplasm O
+in O
+sky1Delta B
+yeast O
+, O
+although O
+this O
+phenomenon O
+was O
+not O
+obvious O
+with O
+ASF B
+/ O
+SF2 B
+, O
+indicating O
+that O
+nuclear O
+import O
+of O
+SR B
+proteins I
+may O
+be O
+differentially O
+regulated O
+by O
+phosphorylation O
+. O
+
+Probiotics O
+, O
+prebiotics O
+, O
+vaccination O
+, O
+and O
+acidification O
+of O
+drinking O
+water O
+were O
+assessed O
+as O
+means O
+of O
+reducing O
+Salmonella O
+. O
+
+On O
+the O
+contrary O
+i O
+. O
+v O
+. O
+administration O
+of O
+calcitonin B
+increased O
+intrapyloric O
+pressure O
+via O
+vagal O
+nerves O
+in O
+atropinized O
+or O
+gallaminized O
+animals O
+. O
+
+We O
+conclude O
+that O
+in O
+the O
+presence O
+of O
+fatty O
+acids O
+in O
+the O
+medium O
+transcription O
+of O
+SPS19 B
+is O
+directly O
+regulated O
+by O
+both O
+Pip2p B
+- O
+Oaf1p B
+and O
+Adr1p B
+. O
+
+Gas O
+exchange O
+was O
+measured O
+breath O
+by O
+breath O
+. O
+
+We O
+found O
+that O
+in O
+premature O
+infants O
+plasminogen B
+levels O
+are O
+low O
+; O
+thus O
+, O
+defense O
+against O
+intra O
+- O
+alveolar O
+fibrin B
+deposition O
+during O
+birth O
+trauma O
+is O
+reduced O
+. O
+
+Analysis O
+of O
+nt O
+sequence O
+was O
+carried O
+out O
+on O
+three O
+out O
+of O
+the O
+more O
+than O
+15 O
+of O
+these O
+regions O
+present O
+in O
+the O
+mouse O
+genome O
+. O
+
+Studies O
+on O
+the O
+reaction O
+of O
+cytochrome B
+c I
+with O
+corticosteroids O
+. O
+
+However O
+, O
+both O
+RAR B
+- O
+and O
+RXR B
+- O
+specific O
+ligands O
+increase O
+CaSki B
+number O
+by O
+> O
+or O
+= O
+20 O
+% O
+. O
+
+Also O
+, O
+in O
+patients O
+with O
+MYD O
+, O
+there O
+was O
+a O
+significant O
+decrease O
+in O
+arterial O
+PO2 O
+from O
+the O
+seated O
+posture O
+to O
+the O
+supine O
+posture O
+, O
+without O
+a O
+significant O
+change O
+in O
+the O
+arterial O
+PCO2 O
+. O
+
+The O
+primary O
+structures O
+of O
+the O
+human B
+KB I
+cell I
+( I
+FR B
+- I
+KB1 I
+) O
+folate B
+receptor I
+( O
+FR B
+) O
+and O
+of O
+a O
+human O
+placental O
+( O
+FR B
+- I
+P2 I
+) O
+FR B
+, O
+proteins O
+important O
+in O
+cellular O
+accumulation O
+of O
+folates O
+, O
+have O
+been O
+deduced O
+from O
+cDNA O
+sequences O
+. O
+
+The O
+general O
+concept O
+of O
+RARE O
+- O
+cleavage O
+mapping O
+as O
+well O
+as O
+its O
+applications O
+and O
+limitations O
+are O
+discussed O
+. O
+
+To O
+further O
+investigate O
+the O
+role O
+of O
+PKR B
+in O
+transcriptional O
+signaling O
+, O
+we O
+expressed O
+the O
+wild B
+type I
+human I
+PKR I
+and O
+a O
+catalytically O
+inactive O
+dominant O
+negative O
+PKR B
+mutant I
+in O
+the O
+murine O
+pre O
+- O
+B O
+lymphoma O
+70Z O
+/ O
+3 O
+cells O
+. O
+
+Selective O
+upper O
+abdominal O
+sympathectomy O
+increased O
+basal O
+acid O
+output O
+in O
+rats O
+but O
+was O
+without O
+effect O
+on O
+stimulated O
+acid O
+output O
+, O
+serum B
+gastrin I
+concentration O
+, O
+and O
+gastric B
+mucosal I
+histidine I
+decarboxylase I
+activity O
+. O
+
+Reasons O
+are O
+presented O
+to O
+support O
+the O
+contention O
+that O
+this O
+increase O
+is O
+in O
+part O
+real O
+. O
+
+Patients O
+received O
+either O
+sodium O
+cephalothin O
+or O
+placebo O
+intravenously O
+before O
+the O
+procedure O
+and O
+for O
+up O
+to O
+8 O
+additional O
+doses O
+. O
+
+In O
+- O
+111 O
+- O
+BLMC O
+uptake O
+was O
+directly O
+proportional O
+to O
+Ki B
+- I
+67 I
+/ O
+MIB B
+- I
+1 I
+activity O
+and O
+number O
+of O
+mitoses O
+in O
+tumor O
+tissue O
+. O
+
+Heating O
+had O
+no O
+effect O
+upon O
+either O
+force O
+decline O
+or O
+slowing O
+of O
+relaxation O
+during O
+fatiguing O
+contractions O
+. O
+
+Binding O
+of O
+transformed O
+Ah B
+receptor I
+complex I
+to O
+a O
+dioxin O
+responsive O
+transcriptional O
+enhancer O
+: O
+evidence O
+for O
+two O
+distinct O
+heteromeric O
+DNA O
+- O
+binding O
+forms O
+. O
+
+Interestingly O
+, O
+VDR B
+was O
+able O
+to O
+bind O
+to O
+VDREs O
+with O
+high O
+affinity O
+and O
+to O
+fully O
+activate O
+transcription O
+in O
+intact O
+yeast O
+cells O
+in O
+the O
+presence O
+of O
+the O
+retinoid B
+X I
+receptor I
+( O
+RXR B
+) O
+. O
+
+Thus O
+, O
+it O
+appears O
+that O
+moxalactam O
+is O
+a O
+reliable O
+and O
+useful O
+antibiotic O
+for O
+the O
+treatment O
+of O
+complicated O
+urinary O
+tract O
+infections O
+. O
+
+A O
+fine O
+- O
+structure O
+radiation O
+hybrid O
+map O
+for O
+the O
+region O
+that O
+extends O
+from O
+D8S520 B
+( O
+distal O
+) O
+to O
+D8S1759 B
+( O
+proximal O
+) O
+was O
+prepared O
+, O
+followed O
+by O
+construction O
+of O
+a O
+single O
+, O
+integrated O
+YAC O
+/ O
+BAC O
+contig O
+for O
+the O
+interval O
+. O
+
+The O
+protein O
+contains O
+a O
+SHAQKYF O
+amino O
+acid O
+signature O
+motif O
+in O
+the O
+second O
+myb B
+- I
+like I
+repeat I
+, O
+which O
+is O
+highly O
+conserved O
+in O
+a O
+number O
+of O
+recently O
+identified O
+plant O
+myb B
+- I
+related I
+genes I
+, O
+thus O
+defining O
+a O
+new O
+class O
+of O
+plant O
+DNA O
+- O
+binding O
+proteins O
+. O
+
+IV O
+. O
+
+It O
+has O
+been O
+shown O
+that O
+renin B
+secretion O
+is O
+stimulated O
+by O
+endothelin B
+, O
+a O
+recently O
+discovered O
+peptide O
+with O
+strong O
+vasoconstrictive O
+properties O
+and O
+stimulating O
+effects O
+on O
+renin B
+secretion O
+. O
+
+Here O
+we O
+describe O
+the O
+cloning O
+and O
+initial O
+characterization O
+of O
+IPP B
+, O
+a O
+novel O
+human O
+gene O
+that O
+predicts O
+a O
+kelch B
+family I
+protein I
+homologous O
+to O
+the O
+mouse B
+Ipp I
+gene I
+, O
+a O
+previously O
+described O
+kelch B
+family I
+member I
+. O
+
+The O
+encoded O
+260 O
+- O
+amino O
+- O
+acid O
+( I
+aa O
+) I
+( I
+H1 I
+- I
+I I
+) I
+and O
+240 O
+- O
+aa O
+( I
+H1 I
+- I
+II I
+) I
+polypeptides O
+possess O
+the O
+typical O
+tripartite O
+organization O
+of O
+animal B
+H1 I
+histones I
+, O
+with O
+variable O
+N O
+- O
+and O
+C O
+- O
+terminal O
+domains O
+flanking O
+a O
+conserved O
+' O
+globular O
+' O
+DNA O
+- O
+binding O
+domain O
+. O
+
+Instead O
+, O
+the O
+large O
+difference O
+in O
+ssDNA O
+- O
+binding O
+affinities O
+reflects O
+the O
+loss O
+of O
+hexamerization O
+ability O
+by O
+uvsY B
+, O
+suggesting O
+that O
+a O
+form O
+of O
+intrahexamer O
+synergism O
+or O
+cooperativity O
+between O
+binding O
+sites O
+within O
+the O
+uvsY B
+hexamer I
+leads O
+to O
+its O
+high O
+observed O
+affinity O
+for O
+ssDNA O
+. O
+
+No O
+significant O
+difference O
+was O
+seen O
+found O
+between O
+the O
+two O
+groups O
+in O
+the O
+degree O
+of O
+postoperative O
+deterioration O
+in O
+cardiopulmonary O
+function O
+or O
+in O
+interleukin B
+- I
+6 I
+levels O
+. O
+
+The O
+PK B
+domain I
+showed O
+pairwise O
+in O
+vitro O
+binding O
+interactions O
+with O
+the O
+pseudokinase O
+, O
+HisRS B
+, O
+and O
+C O
+- O
+term O
+domains O
+; O
+additionally O
+, O
+the O
+HisRS B
+domain I
+interacted O
+with O
+the O
+C O
+- O
+term O
+region O
+. O
+
+The O
+effects O
+of O
+erythrosine O
+( O
+Red O
+3 O
+) O
+, O
+rose O
+bengal O
+B O
+( O
+Red O
+105 O
+) O
+and O
+thyroidectomy O
+on O
+the O
+development O
+of O
+thyroid O
+tumor O
+were O
+examined O
+in O
+male O
+Wistar O
+rats O
+treated O
+with O
+N O
+- O
+bis O
+( O
+2 O
+- O
+hydroxypropyl O
+) O
+nitrosamine O
+( O
+DHPN O
+) O
+. O
+
+The O
+AmyI B
+specific I
+3 I
+' I
+- I
+UTR I
+is O
+characterized O
+by O
+the O
+absence O
+of O
+IR O
+sequences O
+and O
+the O
+presence O
+of O
+a O
+putative O
+' O
+AATAAA O
+' O
+polyadenylation O
+signal O
+. O
+
+To O
+initiate O
+our O
+analysis O
+of O
+factors O
+required O
+for O
+eIF B
+- I
+2 I
+alpha I
+expression O
+, O
+selected O
+a O
+CAP O
+- O
+proximal O
+element O
+shown O
+by O
+in O
+vivo O
+methylation O
+protection O
+analysis O
+to O
+bind O
+a O
+potential O
+regulatory O
+factor O
+. O
+
+Furthermore O
+, O
+addition O
+of O
+the O
+recombinant B
+NF I
+- I
+YA I
+subunit I
+restores O
+NF B
+- I
+Y I
+binding O
+. O
+
+Reversible O
+pressure O
+- O
+induced O
+amorphization O
+in O
+solid O
+C70 O
+: O
+Raman O
+and O
+photoluminescence O
+study O
+. O
+
+Alternative O
+roles O
+of O
+these O
+DNA O
+motifs O
+as O
+activators O
+of O
+early O
+mRNA O
+transcription O
+and O
+as O
+an O
+initiator O
+element O
+for O
+late O
+mRNA O
+transcription O
+help O
+explain O
+how O
+polyomavirus O
+gene O
+expression O
+is O
+regulated O
+during O
+lytic O
+growth O
+and O
+provides O
+a O
+model O
+for O
+cellular O
+transcription O
+during O
+development O
+. O
+
+Our O
+results O
+suggest O
+that O
+Sp1 B
+binding I
+site I
+can O
+function O
+as O
+a O
+distinct O
+TGF B
+- I
+beta I
+responsive I
+element I
+for O
+TGF B
+- I
+beta I
+mediated O
+promoter O
+expression O
+and O
+Sp1 B
+per O
+se O
+can O
+mediate O
+this O
+response O
+. O
+
+Effect O
+of O
+bromocriptine O
+and O
+metoclopramide O
+on O
+serum B
+prolactin I
+levels O
+in O
+patients O
+with O
+amyotrophic O
+lateral O
+sclerosis O
+. O
+
+Phase O
+I O
+study O
+of O
+5 O
+- O
+fluorouracil O
+and O
+leucovorin O
+by O
+a O
+14 O
+- O
+day O
+circadian O
+infusion O
+in O
+metastatic O
+adenocarcinoma O
+patients O
+. O
+
+The O
+results O
+of O
+this O
+study O
+demonstrate O
+that O
+release O
+of O
+a O
+single O
+pulley O
+after O
+repair O
+of O
+the O
+tendons O
+in O
+this O
+area O
+improved O
+gliding O
+excursions O
+of O
+the O
+tendons O
+and O
+reduced O
+resistance O
+to O
+motion O
+of O
+the O
+repaired O
+tendons O
+, O
+and O
+provide O
+support O
+for O
+partial O
+A2 O
+pulley O
+incision O
+after O
+repair O
+of O
+the O
+tendons O
+in O
+the O
+area O
+of O
+the O
+pulley O
+. O
+
+Heart O
+rate O
+and O
+oxygen O
+consumption O
+increased O
+75 O
++ O
+/ O
+- O
+4 O
+bpm O
+and O
+26 O
+. O
+3 O
++ O
+/ O
+- O
+1 O
+. O
+4 O
+ml O
+O2 O
+/ O
+kg O
+x O
+min O
+( O
+- O
+1 O
+) O
+from O
+supine O
+resting O
+values O
+, O
+respectively O
+. O
+
+To O
+evaluate O
+the O
+effect O
+of O
+selective O
+thromboxane O
+A2 O
+blockade O
+on O
+clinical O
+findings O
+and O
+platelet O
+reactivity O
+in O
+refractory O
+unstable O
+angina O
+, O
+OKY O
+- O
+046 O
+( O
+600 O
+mg O
+/ O
+day O
+, O
+p O
+. O
+o O
+. O
+) O
+was O
+administered O
+to O
+another O
+14 O
+patients O
+with O
+refractory O
+unstable O
+angina O
+in O
+addition O
+to O
+the O
+conventional O
+therapy O
+. O
+
+Prolongation O
+of O
+prothrombin B
+time O
+was O
+not O
+due O
+to O
+depletion O
+of O
+vitamin O
+K O
+- O
+dependent O
+coagulation O
+factors O
+or O
+manifest O
+fibrinolysis O
+, O
+but O
+due O
+to O
+the O
+presence O
+of O
+circulating O
+fibrinogen B
+fibrinmonomer B
+- O
+FDP B
+complexes O
+. O
+
+Effect O
+of O
+tetracycline O
+on O
+the O
+glycogen O
+- O
+producing O
+function O
+of O
+the O
+liver O
+and O
+intestinal O
+microflora O
+in O
+white O
+mice O
+
+A O
+case O
+report O
+. O
+
+Mutation O
+of O
+K14 O
+in O
+H3 B
+, O
+which O
+serves O
+as O
+the O
+major O
+target O
+of O
+recombinant B
+Gcn5p I
+acetylation O
+in O
+vitro O
+, O
+confers O
+a O
+strong O
+, O
+synthetic O
+growth O
+defect O
+in O
+gcn5 B
+cells O
+. O
+
+On O
+the O
+other O
+hand O
+, O
+V3 O
+" O
+values O
+were O
+not O
+significantly O
+correlated O
+with O
+the O
+degree O
+of O
+tremor O
+, O
+seborrhea O
+, O
+and O
+duration O
+of O
+the O
+illness O
+. O
+
+All O
+patients O
+whose O
+PSA B
+levels O
+reached O
+0 O
+. O
+1 O
+ng O
+. O
+/ O
+ml O
+. O
+
+In O
+addition O
+, O
+we O
+found O
+that O
+the O
+transactivation O
+mediated O
+by O
+the O
+p68c B
+- I
+ets I
+- I
+1 I
+pr O
+p55erg B
+through O
+the O
+Polyomavirus B
+enhancer I
+sequence I
+is O
+specifically O
+inhibited O
+by O
+the O
+p46kDaPax B
+- I
+QNR I
+in O
+transient O
+transfection O
+assay O
+. O
+
+Treatment O
+with O
+ACE B
+inhibitors O
+after O
+acute O
+myocardial O
+infarction O
+
+Conversely O
+, O
+as O
+a O
+GAL B
+- I
+4 I
+chimera I
+, O
+the O
+isolated O
+LAZ3 B
+/ O
+BCL6 B
+BTB B
+/ O
+POZ O
+domain O
+appears O
+nearly O
+as O
+efficient O
+as O
+the O
+entire O
+protein O
+at O
+inducing O
+transcriptional O
+repression O
+. O
+
+A O
+new O
+myocyte B
+- I
+specific I
+enhancer I
+- I
+binding I
+factor I
+that O
+recognizes O
+a O
+conserved O
+element O
+associated O
+with O
+multiple O
+muscle O
+- O
+specific O
+genes O
+. O
+
+Diclofenac O
+sodium O
+: O
+blood O
+concentration O
+of O
+the O
+slow O
+- O
+release O
+form O
+and O
+influence O
+on O
+the O
+metabolism O
+of O
+kallikrein B
+. O
+
+The O
+LS B
+gene I
+promoter I
+sequence I
+has O
+homology O
+with O
+Escherichia O
+coli O
+promoter O
+sequences O
+; O
+its O
+terminator O
+sequence O
+is O
+capable O
+of O
+forming O
+a O
+stem O
+- O
+and O
+- O
+loop O
+structure O
+. O
+
+We O
+demonstrate O
+that O
+the O
+recently O
+proposed O
+synthetic O
+imaging O
+technique O
+[ O
+J O
+. O
+
+Overexpression O
+of O
+either O
+Sp1 B
+or O
+phosphorylated O
+CREB B
+transactivated O
+the O
+mCgA B
+promoter I
+dose O
+dependently O
+, O
+while O
+coexpression O
+of O
+both O
+transcription O
+factors O
+resulted O
+in O
+an O
+additive O
+mCgA B
+promoter I
+response O
+. O
+
+mCgA O
+- O
+92 O
+to O
+- O
+64 O
+bp O
+, O
+comprising O
+the O
+Sp1 B
+/ O
+Egr B
+- I
+1 I
+site I
+and O
+the O
+CRE O
+motif O
+, O
+conferred O
+gastrin B
+responsiveness O
+to O
+a O
+heterologous O
+thymidine B
+kinase I
+promoter I
+system O
+, O
+and O
+therefore O
+functions O
+as O
+a O
+" O
+true O
+" O
+enhancer O
+element O
+. O
+
+Together O
+with O
+the O
+up O
+- O
+regulation O
+of O
+the O
+cAMP B
+response I
+element I
+modulator I
+protein I
+( O
+CREM B
+) O
+mRNA O
+and O
+protein O
+levels O
+demonstrated O
+previously O
+in O
+CREB B
+mutant I
+mice O
+, O
+we O
+suggest O
+that O
+the O
+up O
+- O
+regulation O
+of O
+CREB B
+beta I
+may O
+also O
+contribute O
+to O
+compensation O
+within O
+the O
+CREB B
+/ O
+ATF B
+family O
+of O
+transcription O
+factors O
+, O
+when O
+CREB B
+delta I
+and O
+CREB B
+alpha I
+are O
+absent O
+. O
+
+The O
+data O
+obtained O
+with O
+cellular O
+RNA O
+from O
+HepG2 O
+cells O
+demonstrated O
+that O
+transcription O
+is O
+initiated O
+891 O
+bases O
+upstream O
+of O
+the O
+translation O
+- O
+start O
+site O
+and O
+that O
+the O
+polyadenylation O
+site O
+is O
+located O
+550 O
+bases O
+downstream O
+of O
+the O
+stop O
+codon O
+. O
+
+Finally O
+, O
+there O
+is O
+now O
+appropriate O
+recognition O
+of O
+the O
+pivotal O
+role O
+of O
+BP O
+reduction O
+in O
+forestalling O
+pressure O
+- O
+related O
+cardiovascular O
+complications O
+, O
+even O
+among O
+high O
+- O
+risk O
+persons O
+with O
+diabetes O
+mellitus O
+and O
+renal O
+insufficiency O
+. O
+
+Individual O
+and O
+combined O
+effects O
+of O
+fumonisin O
+B1 O
+present O
+in O
+Fusarium O
+moniliforme O
+culture O
+material O
+and O
+diacetoxyscirpenol O
+or O
+ochratoxin O
+A O
+in O
+turkey O
+poults O
+. O
+
+It O
+is O
+hypothesized O
+this O
+occurs O
+through O
+antagonism O
+of O
+PML B
+/ O
+RAR B
+alpha I
+actions O
+in O
+these O
+leukemic O
+cells O
+. O
+
+13 O
+: O
+961 O
+- O
+969 O
+, O
+1993 O
+) O
+suggested O
+that O
+T B
+antigen I
+could O
+mediate O
+transcriptional O
+activation O
+through O
+interaction O
+with O
+the O
+TATA B
+- I
+binding I
+protein I
+, O
+as O
+well O
+as O
+upstream O
+bound O
+transcription O
+factors O
+. O
+
+The O
+Grb2 B
+SH3 B
+( I
+C I
+) I
+binding O
+region O
+of O
+Gab1 B
+has O
+significant O
+homology O
+to O
+a O
+region O
+of O
+the O
+adapter B
+protein I
+SLP I
+- I
+76 I
+. O
+
+A O
+phase O
+II O
+study O
+of O
+interferon B
+- I
+alpha I
+, O
+interleukin B
+- I
+2 I
+and O
+5 O
+- O
+fluorouracil O
+in O
+advanced O
+renal O
+carcinoma O
+: O
+clinical O
+data O
+and O
+laboratory O
+evidence O
+of O
+protease O
+activation O
+. O
+
+Activation O
+of O
+the O
+cytotactin B
+promoter I
+by O
+the O
+homeobox B
+- O
+containing O
+gene I
+Evx I
+- I
+1 I
+. O
+
+CONCLUSION O
+/ O
+INTERPRETATION O
+: O
+We O
+found O
+an O
+increased O
+risk O
+of O
+hip O
+fracture O
+in O
+women O
+younger O
+than O
+75 O
+years O
+with O
+Type O
+I O
+diabetes O
+or O
+with O
+Type O
+II O
+diabetes O
+of O
+long O
+duration O
+. O
+
+Maternal O
+behavior O
+was O
+assessed O
+using O
+observational O
+techniques O
+. O
+
+Rat B
+p8 I
+mRNA I
+was O
+discovered O
+because O
+of O
+its O
+strong O
+activation O
+in O
+pancreas O
+during O
+the O
+acute O
+phase O
+of O
+pancreatitis O
+. O
+
+LV O
+compliance O
+was O
+determined O
+from O
+the O
+slope O
+of O
+the O
+LV O
+end O
+- O
+diastolic O
+pressure O
+( O
+LVEDP O
+) O
+vs O
+. O
+
+The O
+practice O
+of O
+measuring O
+of O
+AChE B
+levels O
+in O
+acute O
+poisoning O
+is O
+limited O
+. O
+
+Vasodilation O
+in O
+congestive O
+heart O
+failure O
+is O
+an O
+established O
+therapeutic O
+principal O
+. O
+
+The O
+collicular O
+labels O
+found O
+after O
+injections O
+within O
+the O
+MST O
+area O
+exhibited O
+their O
+distribution O
+over O
+the O
+deep O
+SC O
+subdivision O
+, O
+whereas O
+they O
+spared O
+all O
+the O
+superficial O
+layers O
+but O
+the O
+deep O
+part O
+of O
+the O
+SO O
+. O
+
+When O
+furA O
+alone O
+was O
+introduced O
+into O
+the O
+Delta O
+( O
+furA I
+- I
+katG I
+) I
+mutant O
+, O
+survival O
+in O
+mouse O
+lungs O
+was O
+moderately O
+increased O
+, O
+suggesting O
+that O
+FurA B
+could O
+regulate O
+genes O
+, O
+other O
+than O
+katG B
+, O
+that O
+are O
+involved O
+in O
+pathogenesis O
+. O
+
+The O
+effects O
+of O
+cefazolin O
+, O
+given O
+into O
+the O
+III O
+cerebral O
+ventricle O
+at O
+different O
+doses O
+were O
+studied O
+on O
+GABA O
+content O
+, O
+GAD B
+and O
+GABA B
+- I
+T I
+in O
+the O
+brain O
+- O
+stem O
+of O
+young O
+chickens O
+( O
+Gallus O
+domesticus O
+) O
+. O
+
+Subclones O
+of O
+R15 O
+which O
+reverted O
+to O
+kappa B
+light I
+chain I
+production O
+contained O
+genomic O
+deletions O
+of O
+R15ns O
+and O
+/ O
+or O
+the O
+surrounding O
+intron O
+. O
+
+The O
+disorders O
+are O
+accompanied O
+by O
+consistent O
+, O
+but O
+similarly O
+reversible O
+, O
+electroencephalographic O
+changes O
+. O
+
+The O
+delayed O
+activation O
+of O
+the O
+prostaglandin B
+G I
+/ I
+H I
+synthase I
+- I
+2 I
+promoter I
+in O
+bovine O
+granulosa O
+cells O
+is O
+associated O
+with O
+down O
+- O
+regulation O
+of O
+truncated B
+upstream I
+stimulatory I
+factor I
+- I
+2 I
+. O
+
+The O
+authors O
+recommend O
+in O
+cases O
+with O
+an O
+elevated O
+transaminase O
+serum O
+activity O
+more O
+frequent O
+check O
+- O
+up O
+examinations O
+to O
+avoid O
+missing O
+of O
+a O
+relapse O
+, O
+and O
+to O
+examine O
+repeatedly O
+IgM B
+anti I
+- I
+HAV I
+as O
+in O
+protracted O
+forms O
+of O
+hepatitis O
+IgM B
+anti I
+- I
+HAV I
+may O
+persist O
+even O
+when O
+the O
+transaminase O
+activity O
+is O
+normal O
+. O
+
+Mean O
+latency O
+periods O
+were O
+29 O
+. O
+6 O
+among O
+insulators O
+, O
+35 O
+. O
+4 O
+among O
+dock O
+workers O
+, O
+43 O
+. O
+7 O
+in O
+a O
+heterogeneous O
+group O
+defined O
+as O
+various O
+, O
+46 O
+. O
+4 O
+in O
+non O
+- O
+shipbuilding O
+industry O
+workers O
+, O
+49 O
+. O
+4 O
+in O
+shipyard O
+workers O
+, O
+51 O
+. O
+7 O
+among O
+women O
+with O
+a O
+history O
+of O
+domestic O
+exposure O
+to O
+asbestos O
+, O
+and O
+56 O
+. O
+2 O
+in O
+people O
+employed O
+in O
+maritime O
+trades O
+. O
+
+The O
+strategy O
+uses O
+RNA B
+ligase I
+to O
+add O
+DNA O
+oligonucleotide O
+priming O
+sites O
+to O
+the O
+RNA O
+for O
+subsequent O
+reverse O
+transcription O
+and O
+PCR O
+( O
+RNA B
+ligase I
+, O
+reverse O
+transcription O
+- O
+PCR O
+, O
+or O
+RL O
+/ O
+RT O
+/ O
+PCR O
+) O
+. O
+
+We O
+analyzed O
+the O
+effects O
+of O
+light O
+on O
+tubulin B
+mRNA I
+abundance O
+in O
+Arabidopsis O
+seedlings O
+using O
+RNA O
+gel O
+blot O
+hybridizations O
+and O
+gene O
+- O
+specific O
+probes O
+. O
+
+More O
+important O
+, O
+ligand O
+- O
+activated O
+insulin B
+and O
+IGF B
+- I
+I I
+receptors I
+phosphorylate O
+SHC B
+proteins I
+in O
+vitro O
+, O
+indicating O
+that O
+SHC B
+proteins I
+could O
+be O
+direct O
+substrates O
+for O
+insulin B
+and O
+IGF B
+- I
+I I
+receptors I
+. O
+
+This O
+chimera O
+transduced O
+IL B
+- I
+4 I
+- O
+specific O
+signals O
+in O
+response O
+to O
+IL B
+- I
+2 I
+binding O
+and O
+dramatically O
+enhanced O
+type O
+2 O
+responses O
+( O
+IL B
+- I
+4 I
+, O
+IL B
+- I
+5 I
+, O
+and O
+immunoglobulin B
+E I
+production O
+) O
+upon O
+in O
+vitro O
+TCR B
+stimulation O
+or O
+in O
+vivo O
+antigen O
+challenge O
+. O
+
+A O
+distinct O
+5 O
+' O
+- O
+sequence O
+in O
+clone O
+hMIWC2 B
+suggested O
+an O
+alternative O
+upstream O
+transcription O
+initiation O
+site O
+. O
+
+Two O
+human B
+beta I
+- I
+1 I
+, I
+6 I
+- I
+N I
+- I
+acetylglucosaminyltransferases I
+forming O
+the O
+core O
+2 O
+O O
+- O
+glycan O
+branch O
+, O
+C2GnT B
+and O
+the O
+I O
+antigen I
+, O
+IGnT B
+, O
+are O
+homologous O
+to O
+each O
+other O
+in O
+three O
+regions O
+of O
+the O
+catalytic O
+domain O
+( O
+A O
+, O
+B O
+, O
+C O
+) O
+and O
+their O
+genes O
+reside O
+at O
+the O
+same O
+locus O
+, O
+chromosome O
+9 O
+, O
+band O
+q21 O
+( O
+Bierhuizen O
+, O
+M O
+. O
+F O
+. O
+A O
+. O
+, O
+Mattei O
+, O
+M O
+. O
+- O
+G O
+. O
+and O
+Fukuda O
+, O
+M O
+. O
+, O
+Genes O
+Dev O
+. O
+, O
+7 O
+, O
+
+468 O
+- O
+478 O
+, O
+1993 O
+) O
+. O
+
+Significantly O
+higher O
+levels O
+of O
+vitamin O
+C O
+and O
+catalase B
+activity O
+were O
+found O
+in O
+vegetarians O
+( O
+C O
+- O
+63 O
+. O
+6 O
+and O
+86 O
+. O
+5 O
+mumol O
+/ O
+l O
+; O
+CAT B
+- O
+1497 O
+and O
+1313 O
+U O
+/ O
+ml O
+for O
+males O
+and O
+females O
+, O
+respectively O
+) O
+when O
+compared O
+to O
+nonvegetarians O
+( O
+C O
+- O
+41 O
+. O
+3 O
+and O
+54 O
+. O
+4 O
+mumol O
+/ O
+l O
+; O
+CAT B
+- O
+1192 O
+and O
+1086 O
+U O
+/ O
+ml O
+) O
+. O
+
+Cutting O
+the O
+intraorbital O
+nerves O
+produced O
+a O
+temporary O
+retrieval O
+impairment O
+that O
+was O
+indistinguishable O
+from O
+that O
+produced O
+by O
+intramystacial O
+lidocaine O
+injection O
+. O
+
+Developmental O
+regulation O
+of O
+expression O
+of O
+the O
+malate B
+synthase I
+gene I
+in O
+transgenic O
+plants O
+. O
+
+In O
+contrast O
+, O
+no O
+change O
+in O
+the O
+level O
+of O
+either O
+p53 B
+or O
+activation O
+of O
+mdm2 B
+protein I
+by O
+p53 B
+was O
+observed O
+in O
+hamster O
+UV61 O
+cells O
+after O
+UV O
+exposure O
+. O
+
+On O
+day O
+1 O
+at O
+3500 O
+m O
+, O
+RI O
+showed O
+a O
+significant O
+fall O
+in O
+body O
+weight O
+( O
+BW O
+) O
+with O
+respect O
+to O
+SL O
+but O
+AI O
+maintained O
+it O
+. O
+
+Transcriptional O
+activation O
+of O
+the O
+proopiomelanocortin B
+gene I
+by O
+cyclic B
+AMP I
+- I
+responsive I
+element I
+binding I
+protein I
+. O
+
+The O
+NF1 B
+family I
+members I
+and O
+HNF4 B
+interacted O
+with O
+overlapping O
+sequences O
+of O
+the O
+L O
+- O
+II O
+element O
+, O
+wherein O
+the O
+5 O
+' O
+half O
+- O
+site O
+was O
+more O
+critical O
+for O
+NF1 B
+binding O
+, O
+and O
+the O
+3 O
+' O
+site O
+was O
+more O
+important O
+for O
+HNF4 B
+binding O
+. O
+
+RAP B
+has O
+been O
+shown O
+to O
+be O
+a O
+useful O
+vaccine O
+target O
+site O
+, O
+and O
+RIP B
+and O
+inhibitory O
+AIPs B
+as O
+therapeutic O
+molecules O
+to O
+prevent O
+and O
+suppress O
+S O
+. O
+aureus O
+infections O
+. O
+
+After O
+institution O
+of O
+insulin B
+treatment O
+, O
+diabetic O
+control O
+was O
+improved O
+as O
+demonstrated O
+by O
+decreasing O
+levels O
+of O
+HbA1 B
+. O
+
+The O
+mouse B
+lactoferrin I
+gene I
+promoter I
+was O
+active O
+in O
+human O
+endometrium O
+carcinoma O
+RL O
+95 O
+- O
+2 O
+cells O
+and O
+in O
+rat O
+glioma O
+C6 O
+cells O
+. O
+
+The O
+1 O
+- O
+year O
+and O
+2 O
+- O
+year O
+survival O
+rates O
+for O
+the O
+patients O
+with O
+N0 O
+- O
+3 O
+significantly O
+exceeded O
+those O
+of O
+N4 O
+patients O
+. O
+
+Measurement O
+of O
+the O
+spectral O
+sensitivity O
+and O
+the O
+ERG O
+can O
+thus O
+help O
+in O
+the O
+diagnosis O
+of O
+these O
+three O
+hereditary O
+diseases O
+. O
+
+As O
+a O
+quantitative O
+index O
+of O
+cochlear O
+function O
+, O
+2f1 O
+- O
+f2 O
+distortion O
+- O
+product O
+otoacoustic O
+emissions O
+( O
+DPOAEs O
+) O
+were O
+monitored O
+systematically O
+over O
+time O
+in O
+three O
+groups O
+of O
+rabbits O
+, O
+with O
+each O
+group O
+experiencing O
+a O
+unique O
+paradigm O
+that O
+incorporated O
+repeated O
+exposure O
+to O
+the O
+low O
+- O
+frequency O
+tone O
+. O
+
+The O
+subjects O
+' O
+lungs O
+were O
+ventilated O
+with O
+N2O O
+in O
+O2 O
+( O
+FIO2 O
+0 O
+. O
+3 O
+) O
+to O
+the O
+end O
+- O
+tidal O
+CO2 O
+present O
+before O
+anesthesia O
+, O
+and O
+then O
+CBF O
+was O
+measured O
+using O
+intravenous O
+133Xe O
+and O
+ten O
+scintillation O
+counters O
+, O
+five O
+over O
+each O
+cerebral O
+hemisphere O
+. O
+
+This O
+indicates O
+changes O
+in O
+postvaccination O
+allergy O
+to O
+BCG O
+. O
+
+Analysis O
+of O
+1 O
+Mb O
+of O
+published O
+sequence O
+from O
+the O
+region O
+of O
+conserved O
+synteny O
+on O
+human O
+chromosome O
+5q31 O
+- O
+q33 O
+identified O
+45 O
+gene O
+candidates O
+, O
+including O
+35 O
+expressed O
+genes O
+in O
+the O
+human B
+IL I
+- I
+4 I
+cytokine I
+gene I
+cluster I
+. O
+
+There O
+is O
+no O
+indication O
+from O
+these O
+experiments O
+that O
+linker B
+histones I
+bind O
+fundamentally O
+differently O
+to O
+5 B
+S I
+and O
+bulk O
+nucleosomes O
+. O
+
+Km O
+values O
+of O
+the O
+uncoupled O
+enzymes B
+IIGlc I
+for O
+glucose O
+ranged O
+from O
+0 O
+. O
+5 O
+to O
+2 O
+. O
+5 O
+mM O
+, O
+2 O
+orders O
+of O
+magnitude O
+higher O
+than O
+the O
+value O
+of O
+normal O
+IIGlc B
+. O
+
+Cytochrome B
+bd I
+biosynthesis O
+in O
+Escherichia O
+coli O
+: O
+the O
+sequences O
+of O
+the O
+cydC B
+and O
+cydD B
+genes I
+suggest O
+that O
+they O
+encode O
+the O
+components O
+of O
+an O
+ABC B
+membrane I
+transporter I
+. O
+
+In O
+contrast O
+, O
+inhibition O
+of O
+MAPK B
+activity O
+by O
+MAPK B
+kinase I
+inhibitor O
+( O
+PD O
+98059 O
+) O
+or O
+by O
+overexpression O
+of O
+kinase O
+- O
+deficient O
+MAPKs B
+activated O
+basal O
+and O
+GnRH B
+- I
+A I
+- O
+stimulated O
+GnRHR B
+- O
+Luc B
+activity O
+. O
+
+The O
+influence O
+of O
+gas O
+composition O
+in O
+the O
+air O
+cell O
+on O
+pipping O
+and O
+liver O
+metabolism O
+in O
+embryonic O
+chicks O
+. O
+
+Historically O
+, O
+Cyps B
+were O
+first O
+identified O
+by O
+their O
+ability O
+to O
+bind O
+the O
+immunosuppressive O
+agent O
+cyclosporin O
+A O
+( O
+CsA O
+) O
+with O
+high O
+affinity O
+; O
+they O
+later O
+were O
+found O
+to O
+have O
+peptidyl B
+- I
+prolyl I
+cis I
+- I
+trans I
+isomerase I
+( O
+PPIase B
+) O
+activity O
+, O
+which O
+catalyzes O
+the O
+folding O
+of O
+oligopeptides O
+at O
+proline O
+- O
+peptide O
+bonds O
+in O
+vitro O
+and O
+may O
+be O
+important O
+for O
+protein O
+folding O
+in O
+vivo O
+. O
+
+Thus O
+, O
+oxyR B
+mutants I
+are O
+locked O
+on O
+for O
+Ag43 B
+expression O
+, O
+whereas O
+dam B
+mutants I
+are O
+locked O
+off O
+for O
+Ag43 B
+expression O
+. O
+
+A O
+rare O
+tRNA B
+- I
+Arg I
+( I
+CCU I
+) I
+that O
+regulates O
+Ty1 B
+element O
+ribosomal O
+frameshifting O
+is O
+essential O
+for O
+Ty1 B
+retrotransposition O
+in O
+Saccharomyces O
+cerevisiae O
+. O
+
+Several O
+35 O
+- O
+mm O
+slides O
+of O
+dystrophin B
+- O
+, O
+laminin B
+- O
+, O
+and O
+concanavalin B
+A I
+( O
+ConA B
+) O
+- O
+stained O
+muscle O
+sections O
+were O
+used O
+to O
+calculate O
+myofiber O
+cross O
+- O
+sectional O
+areas O
+and O
+to O
+compare O
+different O
+techniques O
+and O
+settings O
+of O
+an O
+image O
+capture O
+system O
+. O
+
+In O
+addition O
+, O
+both O
+inhibitors O
+blocked O
+phosphatidylcholine O
+hydrolysis O
+and O
+protein B
+kinase I
+C I
+translocation O
+. O
+
+New O
+, O
+selective O
+catechol B
+- I
+O I
+- I
+methyltransferase I
+inhibitors O
+as O
+therapeutic O
+agents O
+in O
+Parkinson O
+' O
+s O
+disease O
+. O
+
+Furthermore O
+, O
+the O
+social O
+learning O
+theory O
+of O
+depression O
+, O
+developed O
+by O
+Lewinsohn O
+, O
+is O
+described O
+. O
+
+Laser O
+soldering O
+with O
+exogenous O
+fibrinogen B
+is O
+feasible O
+without O
+topical O
+administration O
+of O
+additional O
+clotting O
+agents O
+, O
+significantly O
+improves O
+the O
+bursting O
+strength O
+of O
+primary O
+laser O
+welded O
+anastomoses O
+, O
+and O
+appears O
+to O
+result O
+from O
+urokinase B
+- O
+resistant O
+fibrinogen B
+cross O
+- O
+linking O
+. O
+
+Intensity O
+variations O
+from O
+the O
+variable O
+TR O
+were O
+removed O
+, O
+and O
+the O
+data O
+were O
+evaluated O
+for O
+correlation O
+with O
+the O
+lateralized O
+stimulus O
+. O
+
+Routine O
+imaging O
+modalities O
+revealed O
+a O
+total O
+of O
+79 O
+metastases O
+. O
+
+We O
+have O
+previously O
+reported O
+that O
+analgesic O
+doses O
+of O
+morphine O
+accelerate O
+mortality O
+of O
+rats O
+exposed O
+to O
+hemorrhage O
+( O
+Feuerstein O
+and O
+Siren O
+: O
+Circ O
+Shock O
+19 O
+: O
+293 O
+- O
+300 O
+, O
+1986 O
+) O
+. O
+
+We O
+describe O
+a O
+novel O
+stat B
+- I
+related I
+factor I
+, O
+p93 B
+, O
+that O
+is O
+found O
+in O
+EGF B
+- O
+treated O
+A431 O
+cell O
+extracts O
+but O
+appears O
+to O
+be O
+absent O
+in O
+bovine B
+fibroblast I
+growth I
+factor I
+( O
+bFGF B
+) O
+, O
+IFN B
+- I
+gamma I
+, O
+tumor B
+necrosis I
+factor I
+- I
+alpha I
+( O
+TNF B
+- I
+alpha I
+) O
+, O
+and O
+untreated O
+cells O
+. O
+
+p93 B
+appears O
+to O
+be O
+antigenically O
+related O
+to O
+stat91 B
+. O
+
+p185c B
+- I
+neu I
++ O
+, O
+EGFr B
++ O
+( O
+M1 O
+) O
+, O
+and O
+p185c B
+- I
+neu I
+- O
+kinase O
+inactive O
+, O
+EGFr B
++ O
+( O
+NEN757 B
+) O
+expressing O
+cells O
+undergo O
+different O
+mitotic O
+responses O
+to O
+EGF B
+. O
+
+In O
+addition O
+, O
+Fc B
+epsilon I
+R1 I
+cross O
+- O
+linking O
+activates O
+PI B
+3 I
+- I
+kinase I
+. O
+
+When O
+single O
+- O
+point O
+mutation O
+was O
+introduced O
+to O
+each O
+GC O
+box O
+, O
+EBS B
+, O
+and O
+GT O
+box O
+in O
+PFP9a20 B
+, O
+at O
+least O
+3 O
+- O
+fold O
+less O
+CAT B
+activity O
+was O
+observed O
+in O
+CTLL O
+- O
+R8 O
+cells O
+. O
+
+Ribosome O
+association O
+of O
+GCN2 B
+protein I
+kinase I
+, O
+a O
+translational O
+activator O
+of O
+the O
+GCN4 B
+gene I
+of I
+Saccharomyces I
+cerevisiae I
+. O
+
+Treatment O
+with O
+H7 O
+did O
+not O
+affect O
+IL B
+- I
+4R I
+- O
+mediated O
+immediate O
+signaling O
+events O
+such O
+as O
+tyrosine O
+phosphorylation O
+of O
+Jak1 B
+, O
+Jak3 B
+, O
+insulin B
+receptor I
+substrate I
+( I
+IRS I
+) I
+- I
+1 I
+and O
+IRS B
+- I
+2 I
+, O
+or O
+tyrosine O
+phosphorylation O
+and O
+DNA O
+binding O
+of O
+Stat6 B
+. O
+
+Thus O
+, O
+STK1 B
+is O
+most O
+likely O
+the O
+human B
+homologue I
+of I
+MO15 I
+. O
+
+BACKGROUND O
+: O
+Recent O
+iterative O
+methods O
+for O
+sequence O
+alignment O
+have O
+indicated O
+that O
+the O
+380 O
+kDa O
+motor O
+unit O
+of O
+dynein B
+belongs O
+to O
+the O
+AAA B
+class I
+of O
+chaperone B
+- I
+like I
+ATPases I
+. O
+
+When O
+the O
+VBP B
+- I
+1 I
+protein I
+was O
+solely O
+expressed O
+, O
+it O
+located O
+to O
+the O
+cytoplasm O
+and O
+did O
+not O
+localize O
+to O
+the O
+nucleus O
+. O
+
+Consistent O
+with O
+other O
+experiments O
+with O
+these O
+compounds O
+, O
+cocaine O
+was O
+the O
+most O
+potent O
+of O
+the O
+group O
+. O
+
+The O
+significance O
+of O
+these O
+changes O
+in O
+relation O
+to O
+the O
+control O
+of O
+phosphorus O
+balance O
+in O
+ruminants O
+is O
+discussed O
+. O
+
+Transfection O
+assays O
+using O
+the O
+first O
+600 O
+bp O
+of O
+the O
+upstream O
+nucleotide O
+sequences O
+indicated O
+that O
+a O
+region O
+from O
+- O
+75 O
+to O
+- O
+120 O
+was O
+necessary O
+for O
+the O
+ALDH2 B
+gene I
+expression O
+, O
+and O
+especially O
+NF B
+- I
+Y I
+/ O
+CP1 B
+binding O
+site O
+from O
+- O
+92 O
+to O
+- O
+96 O
+( O
+CCAAT O
+box O
+) O
+is O
+important O
+in O
+the O
+expression O
+of O
+the O
+gene O
+. O
+
+This O
+distinct O
+biochemical O
+difference O
+between O
+STAT5A B
+and O
+STAT5B B
+was O
+confirmed O
+with O
+purified O
+activated O
+STAT5 B
+recombinant I
+proteins I
+. O
+
+The O
+results O
+show O
+that O
+in O
+uninfected O
+NIH O
+- O
+3T3 O
+cells O
+Avarol O
+( O
+i O
+) O
+causes O
+a O
+50 O
+% O
+reduction O
+of O
+the O
+growth O
+rate O
+only O
+at O
+the O
+high O
+concentration O
+of O
+29 O
+. O
+6 O
+microM O
+and O
+( O
+ii O
+) O
+is O
+accumulated O
+in O
+the O
+cytoplasm O
+close O
+to O
+the O
+nucleus O
+. O
+
+Blood B
+coagulation I
+Factor I
+X I
+and O
+its O
+activated O
+form O
+Factor B
+Xa I
+play O
+an O
+essential O
+role O
+in O
+the O
+midphase O
+of O
+the O
+clotting O
+cascade O
+. O
+
+The O
+exon O
+sequences O
+determined O
+from O
+genomic O
+DNA O
+sequencing O
+showed O
+some O
+differences O
+when O
+compared O
+to O
+the O
+published O
+rat B
+GLUT2 I
+cDNA I
+. O
+
+Intramolecular O
+interaction O
+is O
+believed O
+to O
+result O
+in O
+the O
+formation O
+of O
+MxA B
+monomers I
+, O
+whereas O
+intermolecular O
+interaction O
+may O
+induce O
+the O
+formation O
+of O
+large O
+MxA B
+oligomers I
+. O
+
+The O
+psbA B
+gene I
+encodes O
+the O
+D1 B
+protein I
+of I
+photosystem I
+II I
+, O
+which O
+is O
+synthesized O
+at O
+very O
+high O
+rates O
+in O
+the O
+light O
+in O
+order O
+to O
+replace O
+photodamaged O
+protein O
+. O
+
+The O
+three O
+more O
+slower O
+migrating O
+Stat5B B
+bands I
+observed O
+in O
+response O
+to O
+GH B
+contain O
+phosphorylated O
+tyrosyl O
+residues O
+. O
+
+The O
+maximum O
+levels O
+of O
+reporter O
+proteins O
+attained O
+in O
+transformed O
+cells O
+after O
+prolonged O
+induction O
+represented O
+from O
+1 O
+% O
+to O
+7 O
+% O
+of O
+total O
+cellular O
+protein O
+. O
+
+Specifically O
+, O
+we O
+demonstrate O
+that O
+this O
+25 O
+- O
+base O
+pair O
+region O
+mediates O
+the O
+up O
+- O
+regulatory O
+effect O
+of O
+TGF B
+- I
+beta I
+on O
+COL1A2 B
+promoter I
+activity O
+and O
+allows O
+antagonistic O
+activity O
+of O
+TNF B
+- I
+alpha I
+on O
+the O
+TGF B
+- I
+beta I
+effect O
+. O
+
+Sin4 B
+and O
+Srb10 B
+, O
+components O
+of O
+specific O
+RNA B
+polymerase I
+II I
+sub O
+- O
+complexes O
+that O
+are O
+required O
+for O
+Ssn6 B
+- O
+Tup1 B
+repression O
+activity O
+, O
+are O
+found O
+to O
+be O
+required O
+for O
+Sfl1 B
+repression O
+function O
+. O
+
+Translation O
+of O
+mok B
+is O
+tightly O
+regulated O
+by O
+Sok B
+RNA I
+, O
+and O
+Sok B
+RNA I
+thus O
+regulates O
+hok B
+translation O
+indirectly O
+through O
+mok B
+. O
+
+Depending O
+on O
+the O
+patient O
+' O
+s O
+body O
+position O
+telemetrically O
+measured O
+CSF O
+- O
+pressures O
+varied O
+between O
+- O
+20 O
+cmH2O O
+in O
+erect O
+and O
+15 O
+cmH2O O
+in O
+supine O
+position O
+. O
+
+One O
+- O
+hour O
+O3 O
+, O
+NO2 O
+, O
+and O
+SO2 O
+personal O
+exposures O
+were O
+measured O
+using O
+samplers O
+developed O
+in O
+our O
+laboratory O
+, O
+while O
+short O
+- O
+term O
+PM2 O
+. O
+5 O
+, O
+CO O
+, O
+and O
+VOCs O
+exposures O
+were O
+measured O
+using O
+currently O
+available O
+monitors O
+. O
+
+These O
+Tlr B
+family I
+members I
+, O
+unlike O
+others O
+reported O
+to O
+date O
+, O
+were O
+identified O
+within O
+a O
+genomic O
+database O
+. O
+
+We O
+hypothesized O
+that O
+subjects O
+would O
+demonstrate O
+PKAR O
+during O
+both O
+hopping O
+and O
+stepping O
+, O
+adding O
+support O
+to O
+the O
+hypothesis O
+that O
+PKAR O
+is O
+a O
+centrally O
+mediated O
+adaptation O
+of O
+general O
+locomotor O
+trajectory O
+that O
+is O
+not O
+specific O
+to O
+the O
+form O
+of O
+locomotion O
+used O
+while O
+on O
+the O
+rotating O
+disk O
+. O
+
+In O
+this O
+study O
+, O
+transcriptional O
+fusions O
+were O
+constructed O
+between O
+the O
+xcpP B
+and O
+xcpR B
+genes I
+and O
+the O
+lacZ B
+reporter I
+. O
+
+To O
+explore O
+the O
+mechanism O
+of O
+insulin B
+receptor I
+phosphorylation O
+we O
+have O
+used O
+NIH3T3 O
+cells O
+transfected O
+with O
+two O
+receptor O
+constructs O
+: O
+one O
+encoding O
+a O
+chimeric O
+receptor O
+composed O
+of O
+the O
+extracellular O
+domain O
+of O
+the O
+human B
+EGF I
+receptor I
+and O
+the O
+cytosolic O
+domain O
+of O
+the O
+human B
+insulin I
+receptor I
+beta I
+- I
+subunit I
+, O
+and O
+a O
+second O
+construct O
+encoding O
+a O
+kinase O
+- O
+defiecient O
+human B
+insulin I
+receptor I
+. O
+
+It O
+is O
+pathogenetically O
+proved O
+to O
+use O
+antithrombin B
+III I
+concentrate O
+preparations O
+with O
+anti O
+- O
+and O
+dysaggregatory O
+properties O
+, O
+fibronectin B
+preparations O
+, O
+trasylol O
+or O
+its O
+analogs O
+during O
+complex O
+preoperative O
+preparation O
+of O
+patients O
+. O
+
+Stimulation O
+of O
+the O
+endosteal O
+bone O
+formation O
+rate O
+was O
+mainly O
+impaired O
+in O
+D O
+- O
+depleted O
+rats O
+, O
+resulting O
+in O
+trabecular O
+bone O
+loss O
+, O
+which O
+, O
+in O
+- O
+D O
+mother O
+rats O
+, O
+was O
+associated O
+with O
+decreased O
+bone O
+ash O
+and O
+total O
+bone O
+calcium O
+. O
+
+Hematopoietic B
+progenitor I
+kinase I
+1 I
+( O
+HPK1 B
+) O
+is O
+a O
+member O
+of O
+the O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+kinase I
+kinase I
+kinase I
+( O
+MAP4K B
+) O
+family O
+and O
+an O
+upstream O
+activator O
+of O
+the O
+c B
+- I
+Jun I
+N I
+- I
+terminal I
+kinase I
+( O
+JNK B
+) O
+signaling O
+cascade O
+. O
+
+We O
+have O
+used O
+the O
+chloramphenicol B
+acetyltransferase I
+( O
+CAT B
+) O
+reporter O
+gene O
+system O
+to O
+study O
+the O
+effect O
+of O
+T B
+on O
+the O
+long O
+terminal O
+repeats O
+( O
+LTRs O
+) O
+of O
+a O
+large O
+family O
+of O
+human O
+endogenous O
+retrovirus O
+- O
+like O
+sequences O
+, O
+RTVL O
+- O
+H O
+. O
+
+To O
+investigate O
+this O
+possibility O
+, O
+we O
+conducted O
+split O
+- O
+visual O
+- O
+field O
+studies O
+in O
+which O
+we O
+manipulated O
+stimulus O
+sets O
+, O
+recognition O
+task O
+, O
+and O
+exposure O
+duration O
+. O
+
+In O
+conclusion O
+, O
+ANH B
+had O
+no O
+negative O
+effects O
+on O
+the O
+endocrine O
+stress O
+response O
+during O
+orthopedic O
+surgery O
+under O
+epidural O
+anesthesia O
+. O
+
+Finally O
+, O
+the O
+conservation O
+of O
+the O
+two O
+residues O
+most O
+sensitive O
+to O
+mutations O
+( O
+Y949 O
+and O
+Y953 O
+) O
+in O
+TM11 O
+, O
+and O
+in O
+the O
+homologous O
+TM5 O
+, O
+of O
+all O
+mammalian B
+P I
+- I
+gps I
+and O
+also O
+in O
+other O
+ABC B
+transporters I
+, O
+suggests O
+that O
+these O
+residues O
+and O
+domains O
+may O
+play O
+an O
+important O
+role O
+in O
+structural O
+as O
+well O
+as O
+mechanistic O
+aspects O
+common O
+to O
+this O
+family O
+of O
+proteins O
+. O
+
+Based O
+on O
+the O
+requirement O
+for O
+CREM B
+/ O
+ICER B
+and O
+Rad6B B
+proteins I
+in O
+spermatogenesis O
+, O
+we O
+determined O
+expression O
+of O
+Cdc34 B
+, O
+Rad6B B
+, O
+CREM B
+/ O
+ICER B
+isoforms O
+, O
+and O
+the O
+Skp1 B
+- O
+Cullin B
+- O
+F O
+- O
+box I
+ubiquitin I
+protein O
+ligase O
+subunits O
+Cul B
+- I
+1 I
+and O
+Cul B
+- I
+2 I
+, O
+which O
+are O
+associated O
+with O
+Cdc34 B
+activity O
+during O
+murine O
+testicular O
+development O
+. O
+
+The O
+enigma O
+of O
+aging O
+bone O
+loss O
+. O
+
+Transcription B
+factor I
+IIIC I
+( O
+TFIIIC B
+) O
+is O
+required O
+for O
+the O
+assembly O
+of O
+a O
+preinitiation O
+complex O
+on O
+5S B
+RNA I
+, O
+tRNA O
+, O
+and O
+adenovirus B
+VA I
+RNA I
+genes I
+and O
+contains O
+two O
+separable O
+components O
+, O
+TFIIIC1 B
+and O
+TFIIIC2 B
+. O
+
+Furthermore O
+, O
+we O
+show O
+that O
+Nck B
+- I
+2 I
+is O
+capable O
+of O
+recognizing O
+several O
+key O
+components O
+of O
+growth B
+factor I
+receptor I
+kinase O
+- O
+signaling O
+pathways O
+including O
+EGF B
+receptors I
+, O
+PDGF B
+receptor I
+- I
+beta I
+, O
+and O
+IRS B
+- I
+1 I
+. O
+
+These O
+two O
+enhancer O
+elements O
+also O
+enhanced O
+transcription O
+when O
+fused O
+separately O
+to O
+the O
+basal O
+promoter O
+region O
+of O
+the O
+chicken B
+vimentin I
+gene I
+. O
+
+When O
+they O
+were O
+exposed O
+to O
+intermittent O
+schedules O
+of O
+punishment O
+( O
+fixed O
+- O
+interval O
+[ O
+FI O
+] O
+120 O
+s O
+or O
+FI O
+300 O
+s O
+) O
+, O
+SIB O
+for O
+all O
+but O
+1 O
+of O
+the O
+participants O
+increased O
+to O
+levels O
+similar O
+to O
+those O
+observed O
+during O
+baseline O
+. O
+
+Deep O
+bite O
+CL O
+II O
+Div O
+. O
+
+Patients O
+with O
+binocular O
+pregeniculate O
+visual O
+loss O
+, O
+patients O
+with O
+balanced O
+binocular O
+pregeniculate O
+loss O
+without O
+RAPD O
+, O
+and O
+patients O
+with O
+monocular O
+pregeniculate O
+visual O
+loss O
+had O
+significantly O
+larger O
+pupils O
+than O
+age O
+- O
+matched O
+controls O
+. O
+
+Protein O
+sequencing O
+, O
+electrophoretic O
+mobility O
+shift O
+assay O
+, O
+and O
+immunoblot O
+analyses O
+identify O
+p54 B
+and O
+p47 B
+/ I
+48 I
+as O
+members O
+of O
+the O
+hepatocyte B
+nuclear I
+factor I
+3 I
+( O
+HNF3 B
+[ O
+forkhead B
+] O
+) O
+family O
+of O
+transcription O
+factors O
+. O
+
+p54 B
+belongs O
+to O
+the O
+subfamily O
+of O
+HNF3 B
+beta I
+proteins I
+, O
+while O
+p47 B
+/ I
+48 I
+binding O
+activity O
+includes O
+HNF3 B
+gamma I
+. O
+
+In O
+this O
+cross O
+- O
+over O
+controlled O
+study O
+, O
+five O
+male O
+volunteers O
+donated O
+one O
+unit O
+of O
+red O
+cells O
+by O
+MCS O
+and O
+one O
+unit O
+of O
+whole O
+blood O
+by O
+the O
+conventional O
+manual O
+method O
+, O
+3 O
+months O
+apart O
+. O
+
+Promoter O
+activity O
+was O
+assayed O
+by O
+transient O
+transfection O
+of O
+luciferase B
+reporter I
+constructs I
+containing O
+nested O
+deletions O
+of O
+the O
+upstream O
+sequence O
+in O
+the O
+human O
+RPE O
+cell O
+lines O
+ARPE19 O
+and O
+D407 O
+, O
+as O
+well O
+as O
+in O
+the O
+SK O
+- O
+Mel O
+- O
+28 O
+and O
+HeLa O
+cell O
+lines O
+. O
+
+This O
+model O
+system O
+exploits O
+the O
+polyomavirus O
+late O
+transcription O
+termination O
+and O
+polyadenylation O
+signals O
+, O
+which O
+are O
+sufficiently O
+weak O
+to O
+allow O
+the O
+production O
+of O
+many O
+multigenome O
+- O
+length O
+primary O
+transcripts O
+with O
+repeating O
+introns O
+, O
+exons O
+, O
+and O
+poly O
+( O
+A O
+) O
+sites O
+. O
+
+Magnification O
+- O
+corrected O
+planimetry O
+of O
+the O
+parapapillary O
+region O
+was O
+performed O
+according O
+to O
+Littmann O
+' O
+s O
+method O
+in O
+312 O
+unselected O
+eyes O
+with O
+chronic O
+primary O
+open O
+- O
+angle O
+glaucoma O
+and O
+in O
+125 O
+normal O
+eyes O
+of O
+an O
+age O
+- O
+and O
+refraction O
+- O
+matched O
+control O
+group O
+using O
+optic O
+disk O
+photographs O
+. O
+
+Although O
+the O
+elevated O
+signalling O
+is O
+eliminated O
+by O
+deletion O
+of O
+Ste20p B
+( O
+or O
+components O
+downstream O
+of O
+Ste20p B
+) O
+, O
+the O
+growth O
+and O
+morphological O
+abnormalities O
+of O
+cells O
+lacking O
+Akr1p B
+are O
+not O
+rescued O
+by O
+deletion O
+of O
+any O
+of O
+the O
+known O
+pheromone O
+response O
+pathway O
+components O
+. O
+
+Southern O
+hybridization O
+of O
+genomic O
+DNA O
+from O
+WT O
+and O
+Lp O
+/ O
+Lp O
+embryos O
+failed O
+to O
+identify O
+specific O
+rearrangements O
+at O
+or O
+near O
+the O
+Nhlh1 B
+locus I
+, O
+and O
+Northern O
+RNA O
+blotting O
+and O
+RT O
+- O
+PCR O
+evaluation O
+of O
+Nhlh1 B
+mRNA I
+expression O
+indicated O
+that O
+both O
+the O
+levels O
+and O
+types O
+of O
+Nhlh1 B
+mRNAs I
+produced O
+in O
+WT O
+and O
+Lp O
+/ O
+Lp O
+embryos O
+were O
+indistinguishable O
+. O
+
+In O
+addition O
+, O
+mrp17 B
+- I
+1 I
+, O
+in O
+combination O
+with O
+some O
+mutations O
+affecting O
+another O
+mitochondrial O
+ribosomal O
+protein O
+, O
+caused O
+a O
+synthetic O
+defective O
+phenotype O
+. O
+
+Expression O
+, O
+characterization O
+, O
+and O
+genomic O
+structure O
+of O
+carp B
+JAK1 I
+kinase I
+gene I
+. O
+
+Significantly O
+, O
+the O
+murine B
+P I
+- I
+selectin I
+gene I
+had O
+several O
+features O
+not O
+found O
+in O
+the O
+human O
+gene O
+. O
+
+Fluorescent O
+in O
+situ O
+hybridization O
+( O
+FISH O
+) O
+analysis O
+showed O
+that O
+the O
+novel O
+regions O
+involved O
+in O
+the O
+NFKB2 B
+rearrangement O
+originated O
+from O
+chromosome O
+7q34 O
+, O
+thus O
+implying O
+the O
+occurrence O
+of O
+a O
+t O
+( O
+7 O
+; O
+10 O
+) O
+( O
+q34 O
+; O
+q24 O
+) O
+reciprocal O
+chromosomal O
+translocation O
+. O
+
+Transient O
+- O
+expression O
+assay O
+analysis O
+of O
+subclones O
+of O
+pPstI B
+- I
+G I
+localized O
+the O
+trans O
+- O
+active O
+factor O
+to O
+a O
+3 B
+. I
+0 I
+- I
+kilobase I
+XbaI I
+fragment I
+. O
+
+MGF B
+is O
+a O
+novel O
+member O
+of O
+the O
+cytokine O
+- O
+regulated O
+transcription O
+factor O
+gene O
+family O
+. O
+
+This O
+is O
+the O
+first O
+report O
+that O
+the O
+PH B
+domain I
+of O
+an O
+IRS B
+protein I
+can O
+function O
+in O
+a O
+dominant O
+negative O
+manner O
+to O
+inhibit O
+insulin B
+signaling O
+. O
+
+A O
+29 O
+. O
+425 O
+kb O
+segment O
+on O
+the O
+left O
+arm O
+of O
+yeast O
+chromosome O
+XV O
+contains O
+more O
+than O
+twice O
+as O
+many O
+unknown O
+as O
+known O
+open O
+reading O
+frames O
+. O
+
+This O
+result O
+, O
+together O
+with O
+the O
+fact O
+that O
+unrearranged O
+V B
+kappa I
+genes I
+are O
+transcriptionally O
+silent O
+, O
+suggests O
+that O
+structural O
+features O
+of O
+both O
+the O
+V B
+kappa I
+and O
+C B
+kappa I
+loci I
+contribute O
+to O
+the O
+overall O
+transcriptional O
+efficiency O
+of O
+a O
+rearranged O
+V B
+kappa I
+- I
+C I
+kappa I
+gene O
+. O
+
+The O
+first O
+270 O
+bp O
+of O
+the O
+promoter O
+region O
+were O
+sequenced O
+and O
+found O
+to O
+contain O
+a O
+CATAA O
+box O
+rather O
+than O
+a O
+TATAA O
+box O
+and O
+several O
+DNA O
+motifs O
+found O
+in O
+activation O
+genes O
+. O
+
+C O
+. O
+glabrata O
+cells O
+containing O
+the O
+CBF1 B
+gene I
+under O
+the O
+influence O
+of O
+a O
+shutdown O
+promoter O
+( O
+tetO B
+- O
+ScHOP O
+) O
+arrested O
+their O
+growth O
+after O
+5 O
+h O
+of O
+cultivation O
+in O
+the O
+presence O
+of O
+the O
+reactive O
+drug O
+doxycycline O
+. O
+
+SF1 B
+/ O
+mBBP B
+utilizes O
+a O
+" B
+maxi I
+- I
+K I
+homology I
+" I
+( O
+maxi B
+- I
+KH I
+) O
+domain O
+for O
+recognition O
+of O
+the O
+single O
+- O
+stranded O
+BPS O
+and O
+requires O
+a O
+cooperative O
+interaction O
+with O
+splicing O
+factor O
+U2AF65 B
+bound O
+to O
+an O
+adjacent O
+polypyrimidine O
+tract O
+( O
+PPT O
+) O
+for O
+high O
+- O
+affinity O
+binding O
+. O
+
+An O
+X B
+- I
+linked I
+zinc I
+finger I
+gene I
+mapping O
+to O
+Xq21 O
+. O
+1 O
+- O
+q21 O
+. O
+3 O
+closely O
+related O
+to O
+ZFX B
+and O
+ZFY B
+: O
+possible O
+origins O
+from O
+a O
+common O
+ancestral O
+gene O
+. O
+
+Validity O
+of O
+the O
+short O
+- O
+form O
+QIF O
+was O
+assessed O
+by O
+correlation O
+with O
+motor O
+scores O
+and O
+using O
+analysis O
+of O
+variance O
+by O
+motor O
+levels O
+and O
+motor O
+score O
+groupings O
+. O
+
+Juvenile O
+angiofibromas O
+. O
+
+Comment O
+on O
+" O
+Critical O
+behavior O
+of O
+a O
+binary O
+mixture O
+of O
+protein O
+and O
+salt O
+water O
+" O
+
+The O
+pineal O
+hormone O
+melatonin O
+( O
+MLT O
+) O
+is O
+able O
+to O
+exert O
+an O
+oncostatic O
+action O
+. O
+
+In O
+addition O
+, O
+there O
+was O
+an O
+increase O
+in O
+the O
+amount O
+of O
+p120 B
+Ras B
+- O
+specific O
+GTPase B
+- I
+activating I
+protein I
+( O
+GAP B
+) O
+and O
+GAP B
+- O
+associated O
+p190 B
+. O
+
+Additional O
+transection O
+of O
+both O
+ADN O
+eliminated O
+the O
+remaining O
+sigmoidal O
+correlation O
+between O
+MAP O
+and O
+RSNA O
+with O
+further O
+increases O
+in O
+resting O
+MAP O
+and O
+RSNA O
+. O
+
+Pregnancy O
+was O
+ensued O
+in O
+4 O
+cases O
+in O
+group O
+I O
+. O
+
+The O
+1 O
+. O
+3 O
+- O
+kb O
+DNA O
+, O
+when O
+placed O
+upstream O
+of O
+the O
+chloramphenicol B
+acetyltransferase I
+gene I
+, O
+was O
+shown O
+to O
+be O
+functionally O
+active O
+. O
+
+Controversy O
+exists O
+regarding O
+both O
+the O
+natural O
+life O
+cycle O
+for O
+this O
+parasite O
+as O
+well O
+as O
+the O
+species O
+identity O
+of O
+opossum O
+Sarcocystis O
+. O
+
+The O
+mean O
+was O
+66 O
+cells O
+/ O
+mm2 O
+in O
+the O
+laser O
+group O
+and O
+63 O
+. O
+7 O
+cells O
+/ O
+mm2 O
+in O
+the O
+control O
+group O
+. O
+
+Prazosin O
+in O
+the O
+treatment O
+of O
+high O
+blood O
+pressure O
+
+The O
+5 O
+- O
+HT3 O
+antagonist O
+ondansetron O
+reduced O
+alcohol O
+intake O
+in O
+both O
+the O
+medium O
+and O
+high O
+alcohol O
+preferring O
+rats O
+at O
+doses O
+between O
+0 O
+. O
+01 O
+and O
+0 O
+. O
+16 O
+mg O
+/ O
+kg O
+. O
+
+Oral O
+hypoglycemic O
+agents O
+
+1 O
+. O
+
+In O
+this O
+system O
+, O
+enhancers O
+act O
+primarily O
+to O
+increase O
+the O
+probability O
+of O
+rapid O
+and O
+efficient O
+transcription O
+complex O
+formation O
+and O
+initiation O
+. O
+
+The O
+relationship O
+between O
+donor O
+status O
+for O
+antibody O
+to O
+hepatitis B
+B I
+core I
+antigen I
+and O
+the O
+occurrence O
+of O
+non O
+- O
+A O
+, O
+non O
+- O
+B O
+posttransfusion O
+hepatitis O
+in O
+the O
+recipient O
+was O
+prospectively O
+studied O
+in O
+112 O
+patients O
+undergoing O
+open O
+- O
+heart O
+surgery O
+who O
+were O
+followed O
+for O
+6 O
+. O
+5 O
+months O
+after O
+surgery O
+. O
+
+By O
+sequencing O
+of O
+exonuclease B
+III I
+deletion O
+clones O
+an O
+open O
+reading O
+frame O
+of O
+405 O
+nucleotides O
+was O
+found O
+coding O
+for O
+a O
+protein O
+of O
+135 O
+amino O
+acids O
+with O
+a O
+molecular O
+mass O
+of O
+15 O
+kDa O
+. O
+
+The O
+pepI B
+gene I
+was O
+overexpressed O
+in O
+Escherichia O
+coli O
+. O
+
+Treatment O
+of O
+steroid O
+resistant O
+rejection O
+following O
+renal O
+transplantation O
+: O
+benefits O
+and O
+risks O
+of O
+OKT3 B
+therapy O
+. O
+
+The O
+level O
+of O
+transcription O
+generated O
+by O
+all O
+of O
+these O
+activators O
+is O
+greater O
+than O
+the O
+sum O
+of O
+the O
+levels O
+generated O
+by O
+individual O
+factors O
+, O
+a O
+phenomenon O
+designated O
+transcriptional O
+synergy O
+. O
+
+Conservation O
+of O
+this O
+zinc O
+finger O
+motif O
+from O
+yeast O
+to O
+mouse O
+and O
+human O
+implies O
+functional O
+importance O
+. O
+
+This O
+nuclear O
+/ O
+organellar O
+gene O
+transfer O
+event O
+is O
+strikingly O
+similar O
+to O
+the O
+experimentally O
+accessible O
+process O
+of O
+nuclear O
+integration O
+of O
+introduced O
+heterologous O
+DNA O
+. O
+
+RESULTS O
+: O
+In O
+the O
+test O
+data O
+set O
+, O
+the O
+single O
+- O
+sample O
+model O
+was O
+confirmed O
+to O
+give O
+excellent O
+estimation O
+of O
+the O
+AUC O
+: O
+AUC O
+( O
+mg O
+/ O
+ml O
+x O
+min O
+) O
+= O
+0 O
+. O
+93 O
+x O
+C3h O
++ O
+0 O
+. O
+47 O
+( O
+MPE O
+% O
+= O
+4 O
+. O
+4 O
+% O
+, O
+RMSE O
+% O
+= O
+8 O
+. O
+9 O
+% O
+) O
+. O
+
+SH3A B
+competes O
+with O
+the O
+SH3 B
+domains I
+of O
+Grb2 B
+in O
+binding O
+to O
+mSos1 B
+, O
+and O
+the O
+intersectin B
+- O
+mSos1 B
+complex O
+can O
+be O
+separated O
+from O
+Grb2 B
+by O
+sucrose O
+gradient O
+centrifugation O
+. O
+
+Comparison O
+between O
+the O
+Ricketts O
+and O
+Bimler O
+therapeutic O
+technics O
+in O
+the O
+treatment O
+of O
+cases O
+of O
+class O
+II O
+, O
+division O
+I O
+mmalocclusion O
+
+This O
+resulted O
+in O
+a O
+shift O
+of O
+C1 O
+/ O
+C2 O
+, O
+so O
+that O
+the O
+effect O
+of O
+collagen B
+was O
+more O
+pronounced O
+( O
+maximal O
+increase O
+of O
+C1 O
+/ O
+C2 B
+= O
+134 O
+% O
+) O
+than O
+ADP O
+( O
+maximal O
+increase O
+of O
+C1 O
+/ O
+C2 O
+= O
+79 O
+% O
+) O
+. O
+
+We O
+conclude O
+that O
+exercise O
+- O
+induced O
+ST O
+- O
+segment O
+elevation O
+in O
+patients O
+without O
+a O
+history O
+of O
+myocardial O
+infarction O
+or O
+left O
+ventricular O
+aneurysm O
+is O
+caused O
+by O
+coronary O
+spasm O
+of O
+a O
+major O
+coronary O
+vessel O
+. O
+
+Xnr3 B
+is O
+transcriptionally O
+activated O
+by O
+wnt B
+signaling O
+during O
+gastrulation O
+in O
+the O
+Xenopus O
+embryo O
+. O
+
+For O
+economical O
+reasons O
+, O
+we O
+could O
+not O
+send O
+a O
+questionnaire O
+to O
+all O
+the O
+35 O
+, O
+779 O
+individuals O
+, O
+but O
+based O
+the O
+investigation O
+on O
+a O
+SRS O
+of O
+4 O
+, O
+000 O
+men O
+, O
+post O
+- O
+stratified O
+in O
+a O
+high O
+- O
+risk O
+and O
+a O
+low O
+- O
+risk O
+group O
+. O
+
+Several O
+waveforms O
+of O
+both O
+the O
+somatosensory O
+( O
+N20 O
+, O
+P O
+/ O
+N O
+30 O
+, O
+and O
+P200 O
+) O
+and O
+the O
+brainstem O
+auditory O
+- O
+evoked O
+response O
+( O
+I O
+, O
+III O
+, O
+IV O
+, O
+and O
+V O
+) O
+demonstrated O
+shorter O
+( O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+latencies O
+in O
+growth O
+- O
+retarded O
+fetuses O
+relative O
+to O
+normal O
+- O
+sized O
+fetuses O
+. O
+
+Effect O
+of O
+choline O
+magnesium O
+trisalicylate O
+on O
+prostacyclin O
+production O
+by O
+isolated O
+vascular O
+tissue O
+of O
+the O
+rat O
+. O
+
+The O
+sequences O
+of O
+two O
+previously O
+known O
+tail B
+genes I
+, O
+R O
+and O
+S O
+, O
+of O
+the O
+temperate O
+bacteriophage O
+P2 O
+and O
+the O
+sequence O
+of O
+an O
+additional O
+open O
+reading O
+frame O
+( O
+orf O
+- O
+30 O
+) O
+located O
+between O
+S O
+and O
+V O
+, O
+were O
+determined O
+. O
+
+The O
+high O
+prevalence O
+of O
+atrial O
+septal O
+defect O
+in O
+tetralogy O
+of O
+Fallot O
+is O
+cited O
+as O
+a O
+possible O
+analogy O
+because O
+right O
+ventricular O
+pressure O
+is O
+high O
+and O
+right O
+ventricular O
+compliance O
+is O
+low O
+from O
+birth O
+. O
+
+The O
+stress O
+/ O
+BHV O
+- O
+1 O
+model O
+resulted O
+in O
+a O
+mild O
+respiratory O
+infection O
+in O
+all O
+calves O
+with O
+no O
+difference O
+observed O
+between O
+treatment O
+groups O
+. O
+
+Solution O
+of O
+the O
+Boltzmann O
+equation O
+in O
+a O
+random O
+magnetic O
+field O
+. O
+
+GH B
+signals O
+by O
+interacting O
+with O
+GH B
+receptor I
+( O
+GHR B
+) O
+. O
+
+Ultraviolet O
+crosslinking O
+experiments O
+using O
+element O
+B O
+revealed O
+the O
+specific O
+binding O
+of O
+two O
+proteins O
+of O
+approximately O
+43 O
+and O
+80 O
+kDa O
+. O
+
+RESULTS O
+: O
+At O
+short O
+dwell O
+times O
+, O
+uncorrected O
+( O
+whole O
+plasma O
+) O
+D O
+/ O
+P O
+and O
+Cp O
+of O
+urea O
+values O
+were O
+higher O
+than O
+the O
+corrected O
+( O
+plasma O
+water O
+) O
+values O
+by O
+5 O
+. O
+7 O
+% O
+- O
+5 O
+. O
+9 O
+% O
+. O
+
+The O
+recovery O
+of O
+xanthomegnin O
+added O
+to O
+corn O
+samples O
+at O
+levels O
+of O
+0 O
+. O
+75 O
+- O
+- O
+9 O
+. O
+6 O
+mg O
+/ O
+kg O
+averaged O
+41 O
+% O
+with O
+a O
+coefficient O
+of O
+variation O
+of O
+25 O
+% O
+. O
+
+The O
+extraordinary O
+high O
+substrate O
+specificity O
+of O
+rPulA B
+together O
+with O
+its O
+thermal O
+stability O
+makes O
+this O
+enzyme O
+a O
+good O
+candidate O
+for O
+biotechnological O
+applications O
+in O
+the O
+starch O
+- O
+processing O
+industry O
+. O
+
+A O
+relationship O
+between O
+the O
+immunological O
+changes O
+and O
+the O
+disease O
+stage O
+was O
+discovered O
+: O
+the O
+index O
+of O
+the O
+3H O
+- O
+thymidine O
+incorporation O
+was O
+found O
+to O
+be O
+67 O
+. O
+9 O
+at O
+the O
+stage O
+of O
+disease O
+exacerbation O
+, O
+and O
+208 O
+. O
+8 O
+at O
+the O
+stage O
+of O
+remission O
+; O
+the O
+complement O
+titre O
+reached O
+, O
+respectively O
+, O
+46 O
+. O
+64 O
++ O
+/ O
+- O
+5 O
+. O
+28 O
+and O
+112 O
+. O
+0 O
++ O
+/ O
+- O
+6 O
+. O
+0 O
+units O
+per O
+ml O
+. O
+
+Sodium O
+dodecylsulfate O
+polyacrylamide O
+gel O
+electrophoresis O
+( O
+SDS O
+- O
+PAGE O
+) O
+showed O
+two O
+bands O
+of O
+about O
+the O
+same O
+intensity O
+with O
+apparent O
+molecular O
+masses O
+of O
+24 O
+. O
+5 O
+and O
+22 O
+. O
+5 O
+kDa O
+. O
+
+Consistent O
+with O
+an O
+effect O
+on O
+transcription O
+, O
+p21 B
+was O
+localized O
+in O
+nuclei O
+of O
+transfected O
+cells O
+. O
+
+Analysis O
+of O
+pseudo B
+VH I
+gene I
+segment I
+recombination O
+products O
+reveals O
+no O
+bias O
+in O
+D B
+gene I
+segment O
+reading O
+frame O
+utilization O
+. O
+
+Plasma B
+prolactin B
+concentrations O
+during O
+incubation O
+, O
+25 O
+. O
+8 O
++ O
+/ O
+- O
+2 O
+. O
+3 O
+ng O
+/ O
+ml O
+, O
+decreased O
+to O
+baseline O
+levels O
+, O
+10 O
+. O
+8 O
++ O
+/ O
+- O
+1 O
+. O
+9 O
+ng O
+/ O
+ml O
+, O
+within O
+24 O
+hr O
+after O
+nestbox O
+removal O
+. O
+
+After O
+30 O
+weeks O
+of O
+amifostine O
+therapy O
+, O
+the O
+morphology O
+of O
+the O
+MDS O
+switched O
+to O
+a O
+chronic O
+myelomonocytic O
+leukemia O
+( O
+CMML O
+) O
+- O
+like O
+appearance O
+, O
+with O
+continuously O
+increasing O
+leukocytes O
+, O
+so O
+that O
+we O
+discontinued O
+amifostine O
+therapy O
+for O
+1 O
+month O
+to O
+exclude O
+a O
+possible O
+side O
+effect O
+of O
+amifostine O
+. O
+
+Heart O
+disease O
+. O
+
+A O
+new O
+B O
+- O
+cell O
+- O
+specific O
+enhancer O
+element O
+has O
+been O
+identified O
+3 O
+' O
+of O
+E4 B
+and O
+the O
+octamerlike O
+motifs O
+in O
+the O
+human B
+immunoglobulin I
+heavy I
+- I
+chain I
+gene I
+enhancer I
+. O
+
+CONCLUSIONS O
+: O
+This O
+initial O
+experience O
+indicates O
+that O
+there O
+is O
+short O
+- O
+to O
+middle O
+- O
+term O
+efficiency O
+and O
+safety O
+when O
+using O
+GKS O
+to O
+treat O
+MTLE O
+. O
+
+Two O
+cases O
+of O
+Paraquat O
+poisoning O
+of O
+anticonservative O
+origin O
+are O
+described O
+. O
+
+Genetic O
+mutation O
+or O
+loss O
+of O
+activin B
+/ O
+transforming B
+growth I
+factor I
+- I
+beta I
+( I
+TGFbeta I
+) I
+receptor I
+function O
+has O
+been O
+shown O
+in O
+human O
+lymphoid O
+, O
+breast O
+, O
+and O
+colorectal O
+tumors O
+as O
+well O
+as O
+Hep2B O
+and O
+Mv1Lu O
+cell O
+lines O
+. O
+
+A O
+poly O
+( O
+ortho O
+ester O
+) O
+designed O
+for O
+combined O
+ocular O
+delivery O
+of O
+dexamethasone O
+sodium O
+phosphate O
+and O
+5 O
+- O
+fluorouracil O
+: O
+subconjunctival O
+tolerance O
+and O
+in O
+vitro O
+release O
+. O
+
+We O
+now O
+describe O
+a O
+HepG2 B
+cell I
+casein I
+kinase I
+II I
+beta I
+subunit I
+cDNA I
+of I
+2 I
+. I
+57 I
+kb I
+containing O
+96 O
+bases O
+of O
+5 O
+' O
+untranslated O
+sequence O
+, O
+645 O
+bases O
+of O
+open O
+reading O
+frame O
+, O
+and O
+1832 O
+bases O
+of O
+3 O
+' O
+untranslated O
+sequence O
+with O
+two O
+polyadenylation O
+consensus O
+signal O
+sequences O
+and O
+two O
+poly O
+( O
+A O
+) O
+stretches O
+. O
+
+Brome B
+mosaic I
+virus I
+polymerase I
+- I
+like I
+protein I
+2a I
+is O
+directed O
+to O
+the O
+endoplasmic O
+reticulum O
+by O
+helicase B
+- I
+like I
+viral I
+protein I
+1a I
+. O
+
+Diagnostic O
+importance O
+of O
+determining O
+leucine B
+aminotransferase I
+activity O
+in O
+acute O
+pancreatitis O
+
+Therapeutic O
+iodine O
+125 O
+for O
+hyperthyroidism O
+: O
+evidence O
+for O
+a O
+special O
+radiobiological O
+effect O
+on O
+the O
+follicular O
+cell O
+. O
+
+Maintenance O
+metabolizable O
+- O
+energy O
+( O
+ME O
+) O
+requirement O
+averaged O
+31 O
+. O
+0 O
+kcal O
+/ O
+kg O
+body O
+wt O
+. O
+
+This O
+finding O
+is O
+of O
+importance O
+because O
+it O
+completes O
+an O
+explanation O
+for O
+central O
+near O
+- O
+location O
+errors O
+in O
+the O
+partial O
+- O
+report O
+bar O
+- O
+probe O
+task O
+. O
+
+A O
+DNA O
+binding O
+protein O
+was O
+identified O
+which O
+binds O
+to O
+two O
+novel O
+target O
+- O
+like O
+sequences O
+: O
+( O
+i O
+) O
+at O
+the O
+5 O
+' O
+flanking O
+site O
+of O
+the O
+breakpoint O
+junction O
+of O
+chromosome O
+8 O
+in O
+a O
+patient O
+with O
+T O
+- O
+acute O
+lymphoblastic O
+leukemia O
+( O
+ALL O
+) O
+carrying O
+the O
+t O
+( O
+8 O
+; O
+14 O
+) O
+( O
+q24 O
+; O
+q11 O
+) O
+rearrangement O
+and O
+( O
+ii O
+) O
+on O
+chromosome O
+1 O
+in O
+three O
+of O
+five O
+T O
+- O
+ALL O
+patients O
+with O
+the O
+t O
+( O
+1 O
+; O
+14 O
+) O
+( O
+p32 O
+; O
+q11 O
+) O
+rearrangement O
+. O
+
+Nedocromil O
+sodium O
+shifted O
+the O
+severity O
+of O
+the O
+early O
+allergic O
+reaction O
+( O
+EAR O
+) O
+from O
+mean O
+- O
+34 O
+. O
+8 O
+% O
+to O
+- O
+6 O
+. O
+9 O
+% O
+and O
+inhibited O
+the O
+later O
+allergic O
+reaction O
+( O
+LAR O
+) O
+from O
+- O
+30 O
+. O
+5 O
+% O
+to O
++ O
+0 O
+. O
+4 O
+% O
+( O
+p O
+less O
+than O
+0 O
+. O
+005 O
+) O
+. O
+
+The O
+Mer1 B
+protein I
+contains O
+the O
+KH B
+motif O
+found O
+in O
+some O
+RNA O
+- O
+binding O
+proteins O
+, O
+and O
+RNA O
+gel O
+mobility O
+shift O
+assays O
+demonstrate O
+that O
+Mer1 B
+binds O
+specifically O
+to O
+MER2 B
+RNA I
+. O
+
+Results O
+obtained O
+from O
+the O
+tritium O
+test O
+and O
+direct O
+chemical O
+analysis O
+were O
+compared O
+. O
+
+We O
+found O
+that O
+in O
+anesthetized O
+, O
+paralyzed O
+cats O
+, O
+the O
+visual O
+evoked O
+potential O
+( O
+VEP O
+) O
+was O
+dependent O
+only O
+on O
+magnitude O
+of O
+delta O
+C O
+at O
+each O
+pattern O
+transition O
+, O
+and O
+was O
+independent O
+of O
+the O
+starting O
+or O
+ending O
+contrast O
+level O
+. O
+
+Experiment O
+B O
+: O
+Clinical O
+, O
+biochemical O
+, O
+and O
+histological O
+variables O
+were O
+measured O
+over O
+a O
+12 O
+- O
+day O
+period O
+after O
+the O
+zymosan O
+had O
+been O
+given O
+. O
+
+Direct O
+saturation O
+analysis O
+
+From O
+this O
+asymmetry O
+, O
+we O
+suggested O
+previously O
+that O
+GCN4 B
+interacts O
+with O
+nonequivalent O
+and O
+possibly O
+overlapping O
+half O
+- O
+sites O
+( O
+ATGAC O
+and O
+ATGAG O
+) O
+that O
+have O
+different O
+affinities O
+. O
+
+Furthermore O
+the O
+aldosterone O
+stimulating O
+effect O
+of O
+low O
+sodium O
+diet O
+( O
+17 O
+children O
+) O
+, O
+severe O
+and O
+prolonged O
+vomiting O
+( O
+19 O
+children O
+) O
+and O
+synthetic B
+ACTH I
+( O
+10 O
+children O
+) O
+has O
+been O
+studied O
+by O
+our O
+modified O
+method O
+. O
+
+A O
+case O
+control O
+study O
+( O
+1 O
+: O
+2 O
+) O
+of O
+182 O
+pairs O
+of O
+Hepatitis O
+A O
+was O
+carried O
+out O
+in O
+Weng O
+- O
+ling O
+Zhe O
+- O
+jiang O
+during O
+April O
+1988 O
+. O
+
+The O
+mutant O
+strain O
+carries O
+three O
+tandem O
+copies O
+of O
+the O
+18 O
+bp O
+sequence O
+that O
+is O
+duplicated O
+in O
+the O
+amdI66 B
+mutation I
+. O
+
+Although O
+cDNA O
+encoding O
+a O
+human B
+phagocyte I
+formyl I
+peptide I
+- I
+binding I
+protein I
+has O
+been O
+reported O
+recently O
+( O
+Boulay O
+, O
+F O
+. O
+, O
+Tardif O
+, O
+M O
+. O
+, O
+Brouchon O
+, O
+L O
+. O
+, O
+and O
+Vignais O
+, O
+P O
+. O
+
+In O
+NIH O
+3T3 O
+fibroblasts O
+the O
+high O
+affinity O
+IL B
+- I
+2R I
+bearing O
+a O
+deletion O
+of O
+a O
+region O
+rich O
+in O
+acidic O
+amino O
+acids O
+( O
+the O
+" O
+acidic O
+" O
+region O
+) O
+in O
+the O
+IL B
+- I
+2R I
+beta I
+- I
+chain I
+failed O
+to O
+induce O
+the O
+tyrosine O
+phosphorylation O
+of O
+MAP B
+kinase I
+as O
+well O
+as O
+the O
+expression O
+of O
+the O
+all O
+three O
+nuclear O
+proto O
+- O
+oncogenes O
+. O
+
+A O
+small O
+molecule O
+ILK B
+inhibitor O
+suppresses O
+the O
+phosphorylation O
+of O
+PKB B
+at O
+the O
+Ser O
+- O
+473 O
+but O
+not O
+the O
+Thr O
+- O
+308 O
+site O
+in O
+the O
+PTEN B
+mutant I
+cells O
+. O
+
+The O
+avian O
+carcinoma O
+virus O
+MH2 O
+contains O
+a O
+hybrid O
+gene O
+delta B
+gag I
+- O
+mht B
+with O
+a O
+contiguous O
+open O
+reading O
+frame O
+of O
+2682 O
+base O
+pairs O
+as O
+well O
+as O
+v B
+- I
+myc I
+and O
+avian O
+helper O
+virus O
+- O
+related O
+sequences O
+. O
+delta B
+gag I
+is O
+a O
+partial O
+retroviral B
+core I
+protein I
+gene I
+while O
+v B
+- I
+mht I
+and O
+v B
+- I
+myc I
+are O
+cell O
+- O
+drived O
+sequences O
+. O
+
+The O
+results O
+in O
+the O
+untreated O
+patients O
+demonstrate O
+the O
+primary O
+importance O
+of O
+bulk O
+reduction O
+at O
+initial O
+laparotomy O
+. O
+
+Of O
+3841 O
+serum O
+samples O
+from O
+sows O
+received O
+from O
+the O
+Tennessee O
+State O
+Diagnostic O
+Laboratory O
+in O
+1991 O
+- O
+1992 O
+, O
+1130 O
+were O
+positive O
+for O
+Toxoplasma O
+gondii O
+antibody O
+. O
+
+These O
+findings O
+also O
+demonstrate O
+that O
+unless O
+excluded O
+by O
+other O
+factors O
+, O
+the O
+C B
+proteins I
+are O
+likely O
+to O
+be O
+located O
+along O
+the O
+length O
+of O
+nascent O
+transcripts O
+. O
+
+In O
+this O
+group O
+of O
+patients O
+, O
+the O
+mean O
+LH B
+( O
+9 O
+. O
+3 O
++ O
+/ O
+- O
+5 O
+. O
+9 O
+IU O
+/ O
+l O
+) O
+and O
+sex B
+- I
+hormone I
+binding I
+globulin I
+( O
+SHBG B
+) O
+( O
+54 O
+. O
+5 O
++ O
+/ O
+- O
+22 O
+. O
+9 O
+nmol O
+/ O
+l O
+) O
+concentrations O
+were O
+significantly O
+greater O
+than O
+those O
+of O
+five O
+normal O
+control O
+subjects O
+( O
+4 O
+. O
+7 O
++ O
+/ O
+- O
+1 O
+. O
+11 O
+IU O
+/ O
+l O
+and O
+26 O
+. O
+0 O
++ O
+/ O
+- O
+7 O
+. O
+0 O
+nmol O
+/ O
+l O
+respectively O
+) O
+. O
+
+We O
+have O
+now O
+completed O
+the O
+primary O
+structure O
+of O
+fibrillin B
+, O
+elucidated O
+the O
+exon O
+/ O
+intron O
+organization O
+of O
+the O
+gene O
+and O
+derived O
+a O
+physical O
+map O
+of O
+the O
+genetic O
+locus O
+. O
+
+The O
+BCL B
+- I
+6 I
+POZ O
+domain O
+and O
+other O
+POZ O
+domains O
+interact O
+with O
+the O
+co O
+- O
+repressors O
+N B
+- I
+CoR I
+and O
+SMRT B
+. O
+
+Cytokine O
+inducibility O
+of O
+VCAM1 B
+in O
+endothelial O
+cells O
+utilizes O
+the O
+interaction O
+of O
+heterodimeric O
+p50 B
+/ O
+p65 B
+proteins O
+with O
+IRF B
+- I
+1 I
+. O
+
+In O
+particular O
+, O
+MF O
+males O
+receiving O
+either O
+a O
+5 O
+. O
+0 O
+- O
+mg O
+/ O
+kg O
+CDP O
+dose O
+or O
+a O
+3 O
+. O
+0 O
+- O
+mg O
+/ O
+kg O
+RO O
+dose O
+explored O
+the O
+object O
+more O
+often O
+than O
+MM O
+males O
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+250 O
+WORDS O
+) O
+
+To O
+gain O
+additional O
+insights O
+into O
+this O
+novel O
+apoptotic O
+checkpoint O
+, O
+we O
+have O
+now O
+characterized O
+the O
+mouse B
+survivin I
+locus I
+. O
+
+Both O
+proteins O
+share O
+sequence O
+similarity O
+with O
+the O
+myelin B
+- I
+associated I
+glycoprotein I
+, O
+an O
+adhesion O
+molecule O
+of O
+oligodendrocytes O
+and O
+Schwann O
+cells O
+that O
+has O
+been O
+implicated O
+in O
+the O
+process O
+of O
+myelination O
+, O
+raising O
+the O
+important O
+question O
+of O
+whether O
+myelin B
+- I
+associated I
+glycoprotein I
+is O
+also O
+a O
+sialic B
+acid I
+- I
+binding I
+protein I
+. O
+
+Localized O
+Bicaudal B
+- I
+C I
+RNA I
+encodes O
+a O
+protein O
+containing O
+a O
+KH B
+domain O
+, O
+the O
+RNA O
+binding O
+motif O
+of O
+FMR1 B
+. O
+
+To O
+facilitate O
+the O
+characterization O
+of O
+NF B
+- I
+E2 I
+functions O
+in O
+human O
+cells O
+, O
+we O
+isolated O
+cDNAs O
+encoding O
+two O
+members O
+of O
+the O
+small B
+Maf I
+family I
+, O
+MafK B
+and O
+MafG B
+. O
+
+Indigenous O
+microbial O
+flora O
+and O
+the O
+large O
+intestine O
+in O
+tadpoles O
+. O
+
+Copyright O
+1998 O
+The O
+Association O
+for O
+the O
+Study O
+of O
+Animal O
+Behaviour O
+. O
+
+In O
+contrast O
+to O
+the O
+restricted O
+tissue O
+expression O
+of O
+gonadotropin B
+and O
+TSH B
+receptors I
+in O
+gonads O
+and O
+thyroid O
+, O
+respectively O
+, O
+LGR4 B
+is O
+expressed O
+in O
+diverse O
+tissues O
+including O
+ovary O
+, O
+testis O
+, O
+adrenal O
+, O
+placenta O
+, O
+thymus O
+, O
+spinal O
+cord O
+, O
+and O
+thyroid O
+, O
+whereas O
+LGR5 B
+is O
+found O
+in O
+muscle O
+, O
+placenta O
+, O
+spinal O
+cord O
+, O
+and O
+brain O
+. O
+
+Not O
+only O
+will O
+it O
+substantially O
+reduce O
+incident O
+cases O
+of O
+hepatitis O
+B O
+for O
+the O
+next O
+decade O
+, O
+it O
+will O
+also O
+provide O
+a O
+framework O
+for O
+the O
+successful O
+introduction O
+of O
+future O
+adolescent O
+vaccine O
+initiatives O
+in O
+Australia O
+. O
+
+A O
+new O
+technique O
+for O
+the O
+identification O
+of O
+phases O
+contained O
+within O
+a O
+polymer O
+blend O
+is O
+described O
+in O
+this O
+paper O
+. O
+
+Radioactively O
+labeled O
+microspheres O
+were O
+used O
+to O
+determine O
+and O
+compare O
+the O
+hemodynamic O
+effects O
+of O
+sodium O
+nitroprusside O
+( O
+SNP O
+) O
+, O
+nitroglycerin O
+( O
+NTG O
+) O
+, O
+and O
+deep O
+enflurane O
+anesthesia O
+on O
+oral O
+tissues O
+during O
+controlled O
+hypotension O
+when O
+compared O
+with O
+controls O
+. O
+
+Their O
+central O
+projections O
+were O
+indistinguishable O
+from O
+those O
+of O
+control O
+axons O
+in O
+all O
+four O
+trigeminal O
+subnuclei O
+. O
+
+The O
+JNK B
+/ O
+SAPK B
+activator O
+mixed B
+lineage I
+kinase I
+3 I
+( O
+MLK3 B
+) O
+transforms O
+NIH O
+3T3 O
+cells O
+in O
+a O
+MEK B
+- O
+dependent O
+fashion O
+. O
+
+The O
+decision O
+support O
+system O
+uses O
+the O
+network O
+at O
+its O
+core O
+and O
+helps O
+not O
+only O
+in O
+reaching O
+a O
+diagnosis O
+but O
+also O
+in O
+finding O
+the O
+optimal O
+way O
+to O
+reach O
+that O
+diagnosis O
+. O
+
+In O
+contrast O
+to O
+the O
+effect O
+on O
+DNA O
+replication O
+, O
+the O
+L13V O
+substitution O
+in O
+large B
+T I
+antigen I
+did O
+not O
+prevent O
+complex O
+formation O
+with O
+Hsc70 B
+and O
+the O
+Rb B
+protein I
+. O
+
+To O
+explore O
+the O
+effect O
+of O
+persistent O
+cardiomegaly O
+on O
+cardiovascular O
+function O
+, O
+groups O
+of O
+newborn O
+rats O
+inhaled O
+up O
+to O
+500 O
+ppm O
+CO O
+for O
+33 O
+days O
+, O
+after O
+which O
+development O
+continued O
+in O
+ambient O
+air O
+. O
+
+Bandwidth O
+of O
+auditory O
+units O
+in O
+the O
+chick O
+forebrain O
+( O
+field O
+L O
+/ O
+Hv O
+complex O
+) O
+was O
+measured O
+with O
+isointensity O
+tone O
+stimuli O
+. O
+
+Members O
+of O
+the O
+steroid B
+/ I
+hormone I
+nuclear I
+receptor I
+superfamily I
+regulate O
+target O
+gene O
+transcription O
+via O
+recognition O
+and O
+association O
+with O
+specific O
+cis O
+- O
+acting O
+sequences O
+of O
+DNA O
+, O
+called O
+hormone O
+response O
+elements O
+( O
+HREs O
+) O
+. O
+
+Indeed O
+, O
+DEX O
+also O
+enhanced O
+the O
+RA O
+- O
+dependent O
+increase O
+in O
+RARbeta B
+mRNA I
+in O
+a O
+cycloheximide O
+- O
+sensitive O
+manner O
+. O
+
+The O
+highest O
+concentration O
+of O
+respirable O
+mineral O
+fibres O
+was O
+found O
+during O
+the O
+overhaul O
+of O
+a O
+truck O
+with O
+asbestos O
+insulation O
+; O
+respirable O
+fibre O
+concentration O
+reached O
+the O
+value O
+of O
+5 O
+f O
+/ O
+cm3 O
+, O
+and O
+total O
+dust O
+concentration O
+- O
+the O
+value O
+of O
+about O
+80 O
+mg O
+/ O
+m3 O
+. O
+
+Avian B
+EMILIN I
+was O
+extracted O
+from O
+19 O
+- O
+day O
+- O
+old O
+embryonic O
+chick O
+aortas O
+and O
+associated O
+blood O
+vessels O
+and O
+purified O
+by O
+ion O
+- O
+exchange O
+chromatography O
+and O
+gel O
+filtration O
+. O
+
+CYP51P1 B
+is O
+96 O
+. O
+5 O
+% O
+identical O
+to O
+the O
+human B
+CYP51 I
+coding I
+sequence I
+and O
+is O
+not O
+interrupted O
+with O
+introns O
+but O
+has O
+six O
+in O
+- O
+frame O
+stop O
+codons O
+resulting O
+from O
+point O
+mutations O
+. O
+
+We O
+report O
+here O
+that O
+AChE B
+activity O
+tends O
+to O
+decrease O
+in O
+individuals O
+sampled O
+in O
+tanks O
+at O
+a O
+salinity O
+of O
+30 O
+per O
+thousand O
+as O
+temperature O
+increases O
+. O
+
+Three O
+RasV12 B
+mutants I
+( O
+S35 O
+, O
+G37 O
+, O
+and O
+C40 O
+) O
+which O
+differ O
+by O
+their O
+ability O
+to O
+bind O
+to O
+Ras B
+effectors I
+( O
+Raf B
+, O
+Ral B
+- I
+GEFs I
+, O
+and O
+the O
+p110 B
+subunit I
+of O
+PI B
+3 I
+- I
+kinase I
+, O
+respectively O
+) O
+were O
+able O
+to O
+induce O
+sustained O
+NR O
+cell O
+proliferation O
+, O
+although O
+none O
+of O
+these O
+mutants O
+was O
+reported O
+to O
+transform O
+NIH O
+3T3 O
+cells O
+. O
+
+Mating O
+response O
+, O
+ovulation O
+rate O
+, O
+follicle O
+and O
+corpus O
+luteum O
+size O
+, O
+gestation O
+length O
+, O
+pregnancy O
+rate O
+, O
+lambing O
+rate O
+, O
+and O
+lamb O
+birth O
+weight O
+were O
+recorded O
+. O
+
+Membrane O
+extraction O
+has O
+been O
+interfaced O
+with O
+gas O
+chromatography O
+and O
+mass O
+spectroscopy O
+for O
+the O
+analysis O
+of O
+volatile O
+organics O
+in O
+water O
+. O
+
+A O
+significant O
+difference O
+in O
+the O
+distribution O
+of O
+antibodies O
+to O
+thyroglobulin B
+and O
+thyroid B
+peroxidase I
+was O
+found O
+in O
+subgroup O
+2 O
+. O
+
+Here O
+, O
+we O
+characterize O
+TCR B
+/ O
+CD48 B
+and O
+TCR B
+/ O
+CD28 B
+costimulation O
+in O
+T O
+cells O
+expressing O
+Lck B
+Src B
+homology I
+3 I
+( O
+SH3 B
+) O
+mutants O
+. O
+
+High O
+expression O
+of O
+p51A B
+( O
+TAp63gamma B
+) O
+in O
+the O
+skeletal O
+muscle O
+tissue O
+drove O
+us O
+to O
+investigate O
+a O
+differentiation O
+- O
+inducible O
+myoblastic O
+cell O
+line O
+which O
+showed O
+increased O
+p51A B
+expression O
+after O
+differentiation O
+induction O
+. O
+
+The O
+rate O
+for O
+Arm O
+III O
+( O
+CAF O
+therapy O
+) O
+was O
+61 O
+. O
+5 O
+% O
+( O
+32 O
+/ O
+52 O
+) O
+, O
+a O
+little O
+higher O
+than O
+that O
+for O
+the O
+other O
+two O
+. O
+
+These O
+results O
+induce O
+that O
+the O
+putative O
+TATA O
+box O
+and O
+initiator O
+are O
+not O
+involved O
+in O
+the O
+promoter O
+activity O
+, O
+and O
+that O
+the O
+vitronectin B
+promoter I
+lacks O
+the O
+TATA O
+box O
+, O
+initiator O
+and O
+GC O
+box O
+. O
+
+Using O
+the O
+interaction O
+- O
+trap O
+assay O
+to O
+identify O
+candidate O
+proteins O
+that O
+bind O
+the O
+cytoplasmic O
+region O
+of O
+the O
+LAR B
+transmembrane B
+protein I
+tyrosine I
+phosphatase I
+( O
+PT B
+- I
+Pase I
+) O
+, O
+we O
+isolated O
+a O
+cDNA O
+encoding O
+a O
+2861 O
+- O
+amino O
+acid O
+protein O
+termed O
+Trio B
+that O
+contains O
+three O
+enzyme O
+domains O
+: O
+two O
+functional O
+GEF B
+domains O
+and O
+a O
+protein B
+serine I
+/ I
+threonine I
+kinase I
+( O
+PSK B
+) O
+domain O
+. O
+
+We O
+have O
+isolated O
+two O
+H19 B
+cDNAs I
+( O
+AP B
+and O
+ES B
+) O
+that O
+contain O
+this O
+ORF4 O
+and O
+correspond O
+to O
+incomplete O
+copies O
+of O
+the O
+unique O
+2 B
+. I
+3 I
+kb I
+H19 I
+RNA I
+. O
+
+The O
+combined O
+in O
+vitro O
+effects O
+of O
+ethanol O
+wih O
+methaqualone O
+, O
+phenobarbital O
+, O
+pyrazole O
+or O
+disulfiram O
+were O
+studied O
+using O
+rat B
+brain I
+microsomal I
+NA I
+- I
+K I
+- I
+ATPase I
+. O
+
+The O
+related O
+adhesion O
+focal B
+tyrosine I
+kinase I
+is O
+tyrosine O
+- O
+phosphorylated O
+after O
+beta1 B
+- I
+integrin I
+stimulation O
+in O
+B O
+cells O
+and O
+binds O
+to O
+p130cas B
+. O
+
+Earlier O
+reports O
+have O
+localized O
+mutations O
+which O
+affect O
+the O
+processing O
+and O
+transport O
+of O
+herpes B
+simplex I
+virus I
+1 I
+glycoproteins I
+to O
+a O
+region O
+located O
+between O
+the O
+genes O
+specifying O
+glycoprotein B
+B I
+and O
+the O
+major O
+viral O
+DNA O
+- O
+binding O
+protein O
+( O
+beta B
+8 I
+) O
+. O
+
+These O
+results O
+indicate O
+that O
+the O
+2127 O
+- O
+bp O
+cDNA O
+encodes O
+a O
+functional O
+feline B
+L I
+/ I
+B I
+/ I
+K I
+- I
+type I
+ALP I
+expressed O
+on O
+cell O
+surfaces O
+via O
+phosphatidylinositol O
+- O
+glycan O
+linkage O
+. O
+
+Our O
+experience O
+suggests O
+that O
+T2 O
+weighting O
+is O
+adequate O
+and O
+is O
+the O
+method O
+of O
+choice O
+for O
+the O
+early O
+recognition O
+of O
+necrosis O
+of O
+the O
+lunate O
+. O
+
+Analysis O
+of O
+a O
+Het B
+- I
+mutation I
+in O
+Anabaena O
+sp O
+. O
+strain O
+PCC O
+7120 O
+implicates O
+a O
+secondary O
+metabolite O
+in O
+the O
+regulation O
+of O
+heterocyst O
+spacing O
+. O
+
+Here O
+we O
+report O
+that O
+components O
+of O
+the O
+Ras B
+/ O
+Raf B
+/ O
+MAPK B
+pathway O
+are O
+constitutively O
+activated O
+in O
+these O
+lck B
+- O
+transformed O
+immature O
+thymoblasts O
+. O
+
+p56 B
+( O
+lck B
+) O
+utilizes O
+Shc B
+and O
+Grb2 B
+adaptors I
+to O
+mediate O
+activation O
+of O
+p21 B
+( O
+ras B
+) O
+in O
+the O
+thymoblast O
+lines O
+by O
+promoting O
+tyrosine O
+phosphorylation O
+of O
+the O
+Shc B
+protein I
+and O
+constitutive O
+interaction O
+between O
+Shc B
+and O
+Grb2 B
+. O
+
+The O
+rec8 B
+( I
++ I
+) I
+, O
+rec10 B
+( I
++ I
+) I
+, O
+and O
+rec11 B
+( I
++ I
+) I
+genes I
+of O
+the O
+fission O
+yeast O
+Schizosaccharomyces O
+pombe O
+exhibit O
+similar O
+specificities O
+for O
+meiotic O
+recombination O
+and O
+rec8 B
+( I
++ I
+) I
+is O
+required O
+for O
+sister O
+chromatid O
+cohesion O
+and O
+homolog O
+pairing O
+. O
+
+Based O
+on O
+the O
+results O
+of O
+this O
+analysis O
+, O
+we O
+also O
+predict O
+that O
+the O
+budding B
+yeast I
+arsenate I
+resistance I
+protein I
+Acr2 I
+and O
+the O
+ORF O
+Ygr203w B
+encode O
+protein O
+phosphatases O
+with O
+catalytic O
+properties O
+similar O
+to O
+that O
+of O
+the O
+Cdc25 B
+family I
+. O
+
+At O
+onset O
+of O
+first O
+post O
+- O
+weaning O
+estrus O
+, O
+sows O
+received O
+either O
+an O
+intravulval O
+injection O
+of O
+3 O
+. O
+75 O
+mg O
+of O
+prostaglandin O
+analogue O
+( O
+PGF O
+) O
+or O
+, O
+served O
+as O
+a O
+non O
+- O
+injected O
+control O
+( O
+CON O
+) O
+. O
+
+We O
+concluded O
+that O
+HFV O
+can O
+achieve O
+values O
+of O
+CO2 O
+elimination O
+close O
+to O
+the O
+estimated O
+metabolic O
+CO2 O
+production O
+in O
+normal O
+unintubated O
+subjects O
+over O
+short O
+periods O
+of O
+time O
+. O
+
+The O
+PHO5 B
+gene I
+is O
+activated O
+by O
+the O
+Pho4p B
+transcription I
+factor I
+, O
+which O
+itself O
+is O
+negatively O
+regulated O
+through O
+phosphorylation O
+by O
+the O
+products O
+of O
+PHO80 B
+and O
+PHO85 B
+. O
+
+Although O
+the O
+only O
+authoritative O
+way O
+to O
+determine O
+the O
+effect O
+of O
+diet O
+on O
+urinary O
+pH O
+is O
+a O
+feeding O
+trial O
+, O
+there O
+is O
+no O
+universally O
+accepted O
+protocol O
+for O
+measuring O
+urinary O
+pH O
+. O
+
+Analysis O
+of O
+the O
+DNA O
+sequence O
+upstream O
+of O
+the O
+narQ B
+gene I
+, O
+which O
+encodes O
+the O
+second O
+nitrate O
+- O
+responsive O
+sensor O
+- O
+transmitter O
+protein O
+in O
+Escherichia O
+coli O
+, O
+revealed O
+an O
+open O
+reading O
+frame O
+( O
+ORF O
+) O
+whose O
+product O
+shows O
+a O
+high O
+degree O
+of O
+similarity O
+to O
+a O
+number O
+of O
+iron B
+- I
+sulfur I
+proteins I
+as O
+well O
+as O
+to O
+the O
+beta O
+subunit O
+of O
+glutamate B
+synthase I
+( O
+gltD B
+) O
+of O
+E O
+. O
+coli O
+. O
+
+Endothelial O
+purine O
+content O
+. O
+
+We O
+suggest O
+that O
+the O
+responses O
+to O
+types B
+I I
+and I
+II I
+collagen I
+were O
+caused O
+by O
+a O
+cross O
+- O
+reaction O
+with O
+type B
+III I
+collagen I
+peptides I
+. O
+
+Possibilities O
+and O
+limints O
+of O
+immunofluorescence O
+in O
+the O
+laboratory O
+diagnosis O
+of O
+rabies O
+
+The O
+5 O
+' O
+half O
+of O
+the O
+EWS B
+gene I
+has O
+recently O
+been O
+described O
+to O
+be O
+fused O
+to O
+the O
+3 O
+' O
+regions O
+of O
+genes O
+encoding O
+the O
+DNA O
+- O
+binding O
+domain O
+of O
+several O
+transcriptional O
+regulators O
+, O
+including O
+ATF1 B
+, O
+FLI B
+- I
+1 I
+, O
+and O
+ERG B
+, O
+in O
+several O
+human O
+tumors O
+. O
+
+PDGF B
+stimulated O
+CDK2 B
+activity O
+in O
+mesangial O
+cells O
+and O
+decreased O
+the O
+level O
+of O
+p27 B
+( O
+kip1 B
+) O
+cyclin B
+kinase O
+inhibitor O
+protein O
+. O
+
+Recombinant B
+apoA I
+- I
+I I
+protein I
+recovered O
+from O
+the O
+soluble O
+fraction O
+of O
+the O
+bacterial O
+cell O
+pellet O
+was O
+purified O
+to O
+greater O
+than O
+95 O
+% O
+homogeneity O
+by O
+reversed O
+- O
+phase O
+high O
+- O
+performance O
+liquid O
+chromatography O
+. O
+
+The O
+influence O
+of O
+different O
+temperatures O
+between O
+13 O
+degrees O
+C O
+and O
+45 O
+degrees O
+C O
+on O
+coagulation O
+factors O
+in O
+vitro O
+was O
+studied O
+by O
+measuring O
+clotting O
+time O
+with O
+the O
+recalcification O
+time O
+, O
+partial O
+thromboplastin B
+time O
+( O
+PTT O
+) O
+, O
+and O
+thromboplastin B
+time O
+test O
+. O
+
+On O
+average O
+, O
+rCMRglc O
+values O
+were O
+23 O
+% O
+below O
+control O
+values O
+for O
+all O
+regions O
+studied O
+, O
+with O
+the O
+greatest O
+differences O
+in O
+posterior O
+brain O
+regions O
+( O
+visual O
+association O
+cortex O
+, O
+primary O
+visual O
+cortex O
+, O
+and O
+parietal O
+cortex O
+) O
+and O
+thalamus O
+. O
+
+Thus O
+, O
+transgene O
+expression O
+directed O
+by O
+both O
+the O
+human B
+and I
+mouse I
+Rb I
+promoters I
+is O
+restricted O
+to O
+a O
+subset O
+of O
+tissues O
+in O
+which O
+Rb B
+is O
+normally O
+expressed O
+during O
+embryogenesis O
+. O
+
+Thus O
+, O
+Tax1 B
+activates O
+CArG B
+- O
+mediated O
+transcription O
+without O
+mitogenic O
+signals O
+through O
+interaction O
+with O
+a O
+CArG B
+- I
+binding I
+factor I
+, O
+p67SRF B
+. O
+
+In O
+experiment O
+1 O
+, O
+subjects O
+were O
+required O
+to O
+discriminate O
+male O
+from O
+female O
+faces O
+and O
+no O
+hemispheric O
+asymmetries O
+were O
+found O
+. O
+
+Membrane O
+depolarization O
+is O
+a O
+critical O
+element O
+of O
+neuronal O
+signaling O
+. O
+
+The O
+transcription O
+start O
+site O
+was O
+localized O
+224 O
+bp O
+upstream O
+the O
+ATG O
+codon O
+by O
+RNase B
+protection O
+and O
+primer O
+extension O
+mapping O
+. O
+
+All O
+the O
+cognate O
+gene O
+clones O
+were O
+constructed O
+, O
+using O
+either O
+PCR O
+products O
+amplified O
+from O
+genomic O
+DNA O
+, O
+or O
+gap O
+- O
+repair O
+. O
+
+Rising O
+antibody O
+titres O
+to O
+the O
+astrovirus O
+particles O
+were O
+demonstrated O
+in O
+one O
+child O
+, O
+and O
+IgM B
+was O
+also O
+demonstrated O
+in O
+this O
+patient O
+' O
+s O
+serum O
+. O
+
+Effect O
+of O
+isobarin O
+on O
+electrocardiographic O
+indices O
+in O
+hypertensive O
+disease O
+
+Although O
+RAD17 B
+, O
+RAD24 B
+and O
+MEC3 B
+are O
+not O
+required O
+for O
+cell O
+cycle O
+arrest O
+when O
+S O
+phase O
+is O
+inhibited O
+by O
+hydroxyurea O
+( O
+HU O
+) O
+, O
+they O
+do O
+contribute O
+to O
+the O
+viability O
+of O
+yeast O
+cells O
+grown O
+in O
+the O
+presence O
+of O
+HU O
+, O
+possibly O
+because O
+they O
+are O
+required O
+for O
+the O
+repair O
+of O
+HU O
+- O
+induced O
+DNA O
+damage O
+. O
+
+Long O
+chain O
+acyl O
+- O
+CoA O
+esters O
+are O
+important O
+intermediates O
+in O
+degradation O
+and O
+synthesis O
+of O
+fatty O
+acids O
+, O
+as O
+well O
+as O
+having O
+important O
+functions O
+in O
+regulation O
+of O
+intermediary O
+metabolism O
+and O
+gene O
+expression O
+. O
+
+PTP1 B
+- O
+lacZ B
+studies O
+indicate O
+that O
+PTP1 B
+is O
+spatially O
+localized O
+to O
+prestalk O
+and O
+anterior O
+- O
+like O
+cell O
+types O
+. O
+
+When O
+translated O
+in O
+- O
+frame O
+with O
+PKC B
+zeta I
+, O
+a O
+stop O
+codon O
+is O
+located O
+28 O
+amino O
+acids O
+towards O
+the O
+N O
+- O
+terminus O
+of O
+the O
+divergence O
+point O
+and O
+the O
+intervening O
+sequence O
+lacks O
+an O
+expected O
+initiating O
+methionine O
+. O
+psi B
+PKC I
+zeta I
+is O
+non O
+- O
+functional O
+in O
+terms O
+of O
+protein O
+synthesis O
+since O
+Western O
+blotting O
+with O
+an O
+antibody O
+directed O
+against O
+the O
+C O
+- O
+terminus O
+of O
+PKC B
+zeta I
+failed O
+to O
+reveal O
+a O
+protein O
+smaller O
+than O
+PKC B
+zeta I
+, O
+and O
+synthetic B
+psi B
+PKC I
+zeta I
+RNA I
+failed O
+to O
+support O
+protein O
+synthesis O
+in O
+a O
+translation O
+system O
+in O
+vitro O
+. O
+
+W O
+. O
+, O
+and O
+Touster O
+, O
+O O
+. O
+
+Electrically O
+induced O
+undulations O
+and O
+their O
+competition O
+with O
+electrically O
+induced O
+convection O
+in O
+cholesteric O
+liquid O
+crystals O
+. O
+
+The O
+sequence O
+immediately O
+upstream O
+of O
+the O
+translation O
+start O
+site O
+was O
+G O
++ O
+C O
+rich O
+( O
+greater O
+than O
+75 O
+% O
+) O
+and O
+contained O
+a O
+consensus O
+CCAAT O
+sequence O
+despite O
+the O
+absence O
+of O
+a O
+TATA O
+box O
+. O
+
+These O
+conditions O
+may O
+determine O
+an O
+increase O
+in O
+the O
+level O
+of O
+indoor O
+pollutants O
+( O
+tobacco O
+smoke O
+, O
+gases O
+produced O
+by O
+cooling O
+processes O
+etc O
+. O
+) O
+and O
+of O
+allergens O
+derived O
+from O
+mites O
+, O
+domestic O
+animals O
+and O
+cockroaches O
+. O
+
+Nevertheless O
+, O
+lower O
+doses O
+which O
+alone O
+were O
+lacking O
+in O
+activity O
+( O
+100 O
+- O
+250 O
+mg O
+/ O
+kg O
+B1 O
+and O
+B6 O
+, O
+1 O
+- O
+2 O
+. O
+5 O
+mg O
+/ O
+kg O
+B12 O
+p O
+. O
+o O
+. O
+) O
+dose O
+- O
+dependently O
+potentiated O
+the O
+antinociceptive O
+of O
+diclofenac O
+. O
+
+For O
+O3 O
+, O
+the O
+correlation O
+between O
+personal O
+exposures O
+and O
+ambient O
+levels O
+was O
+weakest O
+in O
+the O
+winter O
+for O
+residential O
+microenvironments O
+( O
+rs O
+= O
+0 O
+. O
+05 O
+, O
+p O
+> O
+0 O
+. O
+05 O
+) O
+, O
+and O
+was O
+strongest O
+in O
+the O
+summer O
+for O
+outdoor O
+near O
+- O
+roadway O
+microenvironments O
+( O
+rs O
+= O
+0 O
+. O
+91 O
+, O
+p O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+Changes O
+in O
+water O
+and O
+electrolyte O
+content O
+of O
+the O
+brain O
+and O
+edema O
+formation O
+after O
+acute O
+, O
+drug O
+- O
+induced O
+hypertension O
+were O
+studied O
+in O
+albino O
+rabbits O
+. O
+
+Like O
+Rev B
+- O
+Erb B
+, O
+BD73 B
+binds O
+as O
+a O
+monomer O
+to O
+a O
+DNA O
+sequence O
+which O
+consists O
+of O
+a O
+specific O
+A O
+/ O
+T O
+- O
+rich O
+sequence O
+upstream O
+of O
+the O
+consensus O
+hexameric O
+half O
+- O
+site O
+specified O
+by O
+the O
+P O
+box O
+of O
+the O
+DNA O
+- O
+binding O
+domain O
+. O
+
+In O
+contrast O
+, O
+the O
+holo B
+- I
+dTFIIA I
+( I
+L I
+/ I
+S I
+) I
+binds O
+TBP B
+with O
+high O
+affinity O
+. O
+
+Overexpression O
+of O
+wild O
+type O
+and O
+SeCys O
+/ O
+Cys O
+mutant O
+of O
+human B
+thioredoxin I
+reductase I
+in O
+E O
+. O
+coli O
+: O
+the O
+role O
+of O
+selenocysteine O
+in O
+the O
+catalytic O
+activity O
+. O
+
+Biopsy O
+of O
+the O
+lesion O
+revealed O
+granulomatous O
+inflammation O
+and O
+numerous O
+septate O
+hyphae O
+. O
+
+Western O
+and O
+immunocytochemical O
+analysis O
+implied O
+that O
+PREB B
+accumulates O
+specifically O
+in O
+GH3 O
+cell O
+nuclei O
+. O
+
+Two O
+genes O
+from O
+the O
+family O
+encoding O
+mouse B
+ribosomal I
+protein I
+S16 I
+were O
+cloned O
+, O
+sequenced O
+, O
+and O
+analyzed O
+. O
+
+A O
+novel O
+serine B
+kinase I
+activated O
+by O
+rac1 B
+/ O
+CDC42Hs B
+- O
+dependent O
+autophosphorylation O
+is O
+related O
+to O
+PAK65 B
+and O
+STE20 B
+. O
+
+The O
+deduced O
+gene O
+product O
+was O
+found O
+to O
+have O
+significant O
+sequence O
+similarity O
+to O
+the O
+yeast B
+and I
+prokaryotic I
+RNA I
+polymerase I
+subunits I
+involved O
+with O
+subunit O
+assembly O
+. O
+
+Maximum O
+overexpression O
+of O
+holoenzyme O
+activity O
+was O
+achieved O
+by O
+the O
+inclusion O
+in O
+such O
+plasmids O
+of O
+Salmonella B
+typhimurium I
+cysG I
+, O
+which O
+encodes O
+a O
+uroporphyrinogen B
+III I
+methyltransferase I
+required O
+for O
+the O
+synthesis O
+of O
+siroheme O
+, O
+a O
+cofactor O
+for O
+the O
+hemoprotein O
+. O
+
+Overexpression O
+of O
+SNURF B
+in O
+cultured O
+mammalian O
+cells O
+enhanced O
+not O
+only O
+androgen O
+, O
+glucocorticoid O
+, O
+and O
+progesterone B
+receptor I
+- O
+dependent O
+transactivation O
+but O
+also O
+basal O
+transcription O
+from O
+steroid O
+- O
+regulated O
+promoters O
+. O
+
+The O
+human O
+protein O
+binds O
+most O
+strongly O
+to O
+the O
+SH3 B
+domain I
+from O
+the O
+abl B
+proto I
+- I
+oncogene I
+. O
+
+Suprapubic O
+and O
+intravesical O
+methods O
+
+These O
+data O
+show O
+that O
+tyrosine O
+phosphorylation O
+by O
+FES B
+affects O
+the O
+interaction O
+of O
+BCR B
+with O
+multiple O
+signaling O
+partners O
+and O
+suggest O
+a O
+general O
+role O
+for O
+BCR B
+in O
+non B
+- I
+receptor I
+protein I
+- I
+tyrosine I
+kinase I
+regulation O
+and O
+signal O
+transduction O
+. O
+
+We O
+have O
+shown O
+that O
+the O
+human O
+cell O
+MRC O
+closely O
+resembles O
+the O
+murine O
+cell O
+MRC O
+, O
+in O
+both O
+its O
+protein O
+composition O
+and O
+its O
+fractionation O
+and O
+chromatographic O
+profile O
+. O
+
+From O
+1977 O
+to O
+1985 O
+, O
+42 O
+patients O
+with O
+squamous O
+cell O
+carcinoma O
+of O
+the O
+anal O
+canal O
+were O
+treated O
+with O
+mitomycin O
+C O
+( O
+15 O
+mg O
+/ O
+m2 O
+) O
+and O
+5 O
+- O
+fluorouracil O
+( O
+750 O
+mg O
+/ O
+m2 O
+) O
+on O
+day O
+1 O
+, O
+5 O
+- O
+FU O
+( O
+750 O
+mg O
+/ O
+m2 O
+/ O
+d O
+) O
+alone O
+on O
+days O
+2 O
+to O
+5 O
+, O
+and O
+radiation O
+therapy O
+( O
+3000 O
+cGy O
+) O
+on O
+days O
+7 O
+to O
+28 O
+. O
+
+For O
+any O
+given O
+age O
+, O
+high O
+- O
+stressed O
+plantaris O
+tendons O
+were O
+of O
+a O
+higher O
+fatigue O
+quality O
+than O
+low O
+- O
+stressed O
+extensor O
+tendons O
+. O
+
+In O
+addition O
+to O
+TAK1 B
+, O
+TGF B
+- I
+beta I
+also O
+stimulated O
+JNK B
+activity O
+. O
+
+Foamy O
+viruses O
+( O
+FVs O
+) O
+express O
+the O
+Gag B
+protein I
+as O
+a O
+precursor O
+with O
+a O
+molecular O
+mass O
+of O
+74 O
+kDa O
+( O
+pr74 B
+) O
+from O
+which O
+a O
+70 O
+- O
+kDa O
+protein O
+( O
+p70 B
+) O
+is O
+cleaved O
+by O
+the O
+viral B
+protease O
+. O
+
+Our O
+results O
+suggest O
+that O
+at O
+least O
+some O
+chloroplast O
+- O
+like O
+tRNA O
+genes O
+in O
+wheat O
+mtDNA O
+are O
+transcribed O
+, O
+with O
+transcripts O
+undergoing O
+processing O
+, O
+post O
+- O
+transcriptional O
+modification O
+and O
+3 O
+' O
+- O
+CCA O
+addition O
+, O
+to O
+produce O
+mature O
+tRNAs O
+that O
+may O
+participate O
+in O
+mitochondrial O
+protein O
+synthesis O
+. O
+
+If O
+, O
+however O
+, O
+myocardial O
+stunning O
+is O
+severe O
+, O
+and O
+it O
+involves O
+large O
+parts O
+of O
+the O
+LV O
+and O
+thus O
+impairs O
+global O
+LV O
+function O
+, O
+it O
+can O
+be O
+reversed O
+with O
+inotropic O
+agents O
+and O
+procedures O
+. O
+
+268 O
+, O
+6858 O
+- O
+6861 O
+) O
+. O
+
+The O
+occurrence O
+of O
+the O
+different O
+types O
+of O
+TCRB B
+rearrangement I
+patterns O
+has O
+implications O
+for O
+PCR O
+- O
+based O
+clonality O
+assessment O
+and O
+for O
+PCR O
+- O
+based O
+detection O
+of O
+minimal O
+residual O
+disease O
+via O
+TCRB B
+gene I
+analysis O
+. O
+
+Under O
+control O
+conditions O
+, O
+pretreatment O
+with O
+lithium O
+during O
+7 O
+days O
+did O
+not O
+modify O
+the O
+hyperlocomotion O
+produced O
+by O
+d O
+- O
+amphetamine O
+. O
+
+Six O
+patients O
+underwent O
+an O
+electrophysiologic O
+study O
+. O
+
+Rats O
+on O
+the O
+multiple O
+oral O
+dosage O
+regimen O
+were O
+given O
+unlabelled O
+HMCF O
+in O
+their O
+drinking O
+water O
+for O
+13 O
+days O
+before O
+the O
+administration O
+of O
+a O
+bolus O
+dose O
+of O
+[ O
+14C O
+] O
+HMCF O
+on O
+day O
+14 O
+. O
+
+After O
+multivariate O
+analysis O
+, O
+TWA O
+correlated O
+with O
+age O
+( O
+P O
+= O
+0 O
+. O
+02 O
+) O
+and O
+LV O
+function O
+( O
+P O
+= O
+0 O
+. O
+002 O
+) O
+and O
+occurred O
+more O
+often O
+in O
+patients O
+after O
+nonanterior O
+MI O
+( O
+P O
+= O
+0 O
+. O
+03 O
+) O
+. O
+
+No O
+patient O
+demonstrated O
+a O
+decrease O
+in O
+bone O
+marrow O
+fibrosis O
+as O
+determined O
+by O
+serial O
+procollagen B
+( O
+PC B
+III I
+) O
+serum O
+level O
+analysis O
+. O
+
+Asthma O
+diagnoses O
+were O
+made O
+according O
+to O
+recommended O
+National O
+Asthma O
+Expert O
+Panel O
+Guidelines O
+. O
+
+Charcot O
+joints O
+. O
+
+Idealized O
+versus O
+realized O
+overall O
+treatment O
+times O
+. O
+
+Non O
+- O
+suppressed O
+thyroidal O
+radioactive O
+iodine O
+uptake O
+( O
+RAIU O
+) O
+in O
+thyrotoxic O
+phase O
+in O
+a O
+case O
+of O
+subacute O
+thyroiditis O
+with O
+thyroid B
+- I
+stimulating I
+antibodies I
+( O
+TSAb B
+) O
+. O
+
+Ultra O
+- O
+energy O
+( O
+UHE O
+) O
+imaging O
+is O
+usually O
+performed O
+in O
+simultaneous O
+F O
+- O
+18 O
+FDG O
+/ O
+Tc O
+- O
+99m O
+MIBI O
+studies O
+. O
+
+Bilateral O
+renal O
+oncocytoma O
+in O
+a O
+Greyhound O
+dog O
+. O
+
+Uncoupling O
+gene O
+activity O
+from O
+chromatin O
+structure O
+: O
+promoter O
+mutations O
+can O
+inactivate O
+transcription O
+of O
+the O
+yeast B
+HSP82 I
+gene I
+without O
+eliminating O
+nucleosome O
+- O
+free O
+regions O
+. O
+
+Ectopic O
+expression O
+of O
+cyclin B
+D1 I
+in O
+progestin O
+- O
+inhibited O
+cells O
+led O
+to O
+the O
+reappearance O
+of O
+the O
+120 O
+- O
+kDa O
+active O
+form O
+of O
+cyclin B
+E I
+- O
+Cdk2 B
+preceding O
+the O
+resumption O
+of O
+cell O
+cycle O
+progression O
+. O
+
+Unlike O
+these O
+contaminant O
+- O
+responsive O
+T O
+cells O
+, O
+those O
+that O
+are O
+truly O
+specific O
+for O
+natural O
+AChR B
+epitopes I
+appear O
+less O
+heterogeneous O
+and O
+therefore O
+more O
+suitable O
+targets O
+for O
+selective O
+immunotherapy O
+. O
+
+Because O
+the O
+wa B
+- I
+2 I
+mutation I
+was O
+mapped O
+previously O
+to O
+the O
+vicinity O
+of O
+the O
+EGF B
+/ O
+TGF B
+- I
+alpha I
+receptor I
+( O
+EGFR B
+) O
+gene O
+on O
+mouse O
+chromosome O
+11 O
+, O
+we O
+hypothesized O
+that O
+the O
+wa B
+- I
+2 I
+phenotype I
+might O
+result O
+from O
+a O
+defect O
+in O
+either O
+the O
+expression O
+or O
+activity O
+of O
+EGFR B
+, O
+or O
+both O
+. O
+
+Region O
+I O
+includes O
+the O
+two O
+cysteine O
+- O
+cysteine O
+zinc O
+fingers O
+that O
+comprise O
+a O
+DNA O
+- O
+binding O
+domain O
+which O
+typifies O
+all O
+members O
+of O
+the O
+superfamily O
+. O
+
+Southern O
+zoo O
+blot O
+analysis O
+indicated O
+that O
+ZNF236 B
+is O
+conserved O
+in O
+the O
+genomes O
+of O
+all O
+mammalian O
+species O
+tested O
+, O
+but O
+not O
+in O
+yeast O
+. O
+
+RNA O
+determinants O
+required O
+for O
+L4 O
+- O
+mediated O
+attenuation O
+control O
+of O
+the O
+S10 B
+r I
+- I
+protein I
+operon I
+of I
+Escherichia I
+coli I
+. O
+
+Spodoptera O
+frugiperda O
+( O
+Sf9 O
+) O
+cells O
+have O
+proved O
+a O
+suitable O
+cell O
+system O
+in O
+which O
+to O
+study O
+this O
+association O
+and O
+to O
+produce O
+recombinant B
+CR3 I
+, O
+and O
+we O
+show O
+here O
+that O
+another O
+lepidopteran O
+cell O
+line O
+, O
+Trichoplusia O
+niTN O
+- O
+5B1 O
+- O
+4 O
+( O
+High O
+- O
+Five O
+) O
+cells O
+, O
+allows O
+the O
+recovery O
+of O
+large O
+amounts O
+of O
+functional B
+recombinant I
+CR3 I
+. O
+
+INTERVENTIONS O
+: O
+Postoperative O
+follow O
+- O
+up O
+consisted O
+of O
+serial O
+determination O
+of O
+different O
+biochemical O
+markers O
+( O
+CK B
+, O
+CK B
+- I
+MB I
+, O
+cTnI B
+) O
+, O
+ECGs O
+, O
+and O
+echocardiography O
+. O
+
+At O
+the O
+first O
+phase O
+( O
+1 O
+- O
+43 O
+ms O
+for O
+the O
+VMN O
+and O
+1 O
+- O
+10 O
+ms O
+for O
+the O
+LN O
+) O
+the O
+hypothalamic O
+- O
+cortical O
+responses O
+completely O
+inhibited O
+the O
+formation O
+of O
+the O
+VC O
+response O
+to O
+the O
+light O
+stimulus O
+. O
+
+6 O
+, O
+320 O
+cells O
+/ O
+mm3 O
+, O
+respectively O
+; O
+P O
+less O
+than O
+. O
+005 O
+) O
+; O
+twelve O
+( O
+86 O
+% O
+) O
+of O
+the O
+14 O
+inmates O
+who O
+developed O
+AIDS O
+had O
+counts O
+of O
+less O
+than O
+5 O
+, O
+000 O
+cells O
+/ O
+mm3 O
+, O
+compared O
+with O
+only O
+six O
+( O
+14 O
+% O
+) O
+of O
+the O
+42 O
+controls O
+( O
+P O
+less O
+than O
+. O
+00001 O
+) O
+. O
+
+There O
+is O
+, O
+however O
+, O
+uncertainty O
+as O
+to O
+how O
+results O
+obtained O
+in O
+recent O
+experiments O
+scale O
+up O
+to O
+landscape O
+and O
+regional O
+levels O
+and O
+generalize O
+across O
+ecosystem O
+types O
+and O
+processes O
+. O
+
+The O
+facilitation O
+started O
+preceding O
+the O
+onset O
+of O
+electromyographic O
+activity O
+of O
+the O
+masseter O
+muscle O
+. O
+
+The O
+recruitment O
+of O
+constitutively O
+phosphorylated O
+p185 B
+( O
+neu B
+) O
+and O
+the O
+activated O
+mitogenic O
+pathway O
+proteins O
+to O
+this O
+membrane O
+- O
+microfilament O
+interaction O
+site O
+provides O
+a O
+physical O
+model O
+for O
+integrating O
+the O
+assembly O
+of O
+the O
+mitogenic O
+pathway O
+with O
+the O
+transmission O
+of O
+growth O
+factor O
+signal O
+to O
+the O
+cytoskeleton O
+. O
+
+Deletion O
+of O
+the O
+region O
+from O
+amino O
+acid O
+residues O
+2 O
+- O
+67 O
+in O
+E1A B
+, O
+which O
+has O
+been O
+postulated O
+to O
+interact O
+with O
+p300 B
+/ O
+CBP B
+, O
+also O
+abolished O
+the O
+inhibitory O
+effect O
+of O
+E1A B
+, O
+whereas O
+deletion O
+of O
+the O
+region O
+from O
+residues O
+120 O
+to O
+140 O
+had O
+no O
+effect O
+. O
+
+Quantitative O
+Tl O
+- O
+201 O
+analysis O
+after O
+stress O
+has O
+also O
+shown O
+viable O
+myocardium O
+in O
+most O
+mild O
+to O
+moderate O
+( O
+51 O
+% O
+to O
+85 O
+% O
+of O
+normal O
+uptake O
+) O
+irreversible O
+Tl O
+- O
+201 O
+defects O
+. O
+
+The O
+point O
+mutation O
+Asp O
+- O
+316 O
+- O
+- O
+> O
+Asn O
+in O
+the O
+C O
+- O
+terminus O
+of O
+p38 B
+, O
+analogous O
+to O
+the O
+ERK2 B
+( O
+extracellular B
+- I
+signal I
+- I
+regulated I
+kinase I
+2 I
+) O
+sevenmaker O
+mutation O
+, O
+dramatically O
+decreases O
+its O
+binding O
+to O
+MKP B
+- I
+1 I
+and O
+substantially O
+compromises O
+its O
+stimulatory O
+effect O
+on O
+the O
+catalytic O
+activity O
+of O
+this O
+phosphatase O
+. O
+
+J O
+. O
+
+Causal O
+modeling O
+combines O
+theory O
+and O
+research O
+, O
+and O
+because O
+the O
+interpretation O
+of O
+data O
+is O
+possible O
+only O
+within O
+the O
+context O
+of O
+the O
+proposed O
+theory O
+, O
+it O
+offers O
+an O
+important O
+method O
+for O
+advancing O
+the O
+science O
+while O
+maintaining O
+the O
+specificity O
+of O
+the O
+practice O
+. O
+
+In O
+one O
+trial O
+, O
+116 O
+subjects O
+with O
+transfusion O
+- O
+related O
+chronic O
+hepatitis O
+C O
+were O
+treated O
+with O
+lymphoblastoid B
+interferon I
+( O
+5 O
+MU O
+/ O
+m2 O
+three O
+times O
+a O
+week O
+for O
+2 O
+mo O
+, O
+then O
+3 O
+MU O
+/ O
+m2 O
+three O
+times O
+a O
+week O
+for O
+4 O
+or O
+10 O
+mo O
+) O
+. O
+
+A O
+derived O
+RA O
+- O
+resistant O
+line O
+, O
+NT2 O
+/ O
+D1 O
+- O
+R1 O
+, O
+is O
+deficient O
+in O
+this O
+activity O
+and O
+is O
+co O
+- O
+resistant O
+to O
+cisplatin O
+. O
+
+BCR B
+- O
+ABL B
+elicits O
+transformation O
+of O
+both O
+fibroblast O
+and O
+hematopoietic O
+cells O
+and O
+blocks O
+apoptosis O
+following O
+cytokine O
+deprivation O
+in O
+various O
+factor O
+- O
+dependent O
+cells O
+. O
+
+Aggregation O
+in O
+washed O
+platelets O
+from O
+rats O
+with O
+diabetes O
+was O
+enhanced O
+. O
+
+Sequence O
+analysis O
+of O
+this O
+region O
+showed O
+it O
+contained O
+five O
+potential O
+copies O
+of O
+the O
+sterol O
+regulatory O
+element O
+( O
+SRE O
+- O
+1 O
+) O
+( O
+Smith O
+, O
+J O
+. O
+R O
+. O
+, O
+Osborne O
+, O
+T O
+. O
+F O
+. O
+, O
+Brown O
+, O
+M O
+. O
+S O
+. O
+, O
+Goldstein O
+, O
+J O
+. O
+L O
+. O
+, O
+and O
+Gil O
+, O
+G O
+. O
+
+Mutations O
+in O
+Saccharomyces O
+cerevisiae O
+that O
+block O
+meiotic O
+prophase O
+chromosome O
+metabolism O
+and O
+confer O
+cell O
+cycle O
+arrest O
+at O
+pachytene O
+identify O
+two O
+new O
+meiosis O
+- O
+specific O
+genes O
+SAE1 B
+and O
+SAE3 B
+. O
+
+Isolation O
+and O
+characterization O
+of O
+human O
+orthologs O
+of O
+yeast O
+CCR4 B
+- O
+NOT B
+complex O
+subunits O
+. O
+
+Thus O
+, O
+the O
+i B
+- I
+leader I
+protein I
+is O
+a O
+viral O
+gene O
+product O
+of O
+unknown O
+function O
+and O
+high O
+stability O
+that O
+is O
+made O
+in O
+large O
+quantities O
+at O
+intermediate O
+times O
+of O
+productive O
+infection O
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+400 O
+WORDS O
+) O
+
+CONCLUSIONS O
+: O
+Latanoprost O
+administered O
+once O
+daily O
+was O
+significantly O
+more O
+effective O
+in O
+reducing O
+IOP O
+compared O
+with O
+unoprostone O
+administered O
+twice O
+daily O
+in O
+patients O
+with O
+POAG O
+and O
+OH O
+. O
+
+The O
+molecular O
+dynamics O
+simulations O
+provide O
+insight O
+into O
+the O
+conformational O
+flexibility O
+of O
+these O
+analogs O
+. O
+
+In O
+alfalfa O
+, O
+the O
+insecticides O
+caused O
+significant O
+mortality O
+to O
+most O
+of O
+the O
+insects O
+evaluated O
+. O
+
+Therefore O
+, O
+we O
+have O
+reevaluated O
+the O
+age O
+- O
+related O
+changes O
+in O
+serum B
+leptin I
+levels O
+and O
+their O
+relationship O
+with O
+adiposity O
+and O
+androgen O
+levels O
+in O
+a O
+large O
+group O
+of O
+community O
+dwelling O
+men O
+. O
+
+Injections O
+of O
+PD O
+solutions O
+with O
+13 O
+. O
+6 O
+, O
+22 O
+. O
+7 O
+, O
+and O
+38 O
+. O
+6 O
+g O
+/ O
+liter O
+of O
+glucose O
+reduced O
+the O
+ingestion O
+of O
+sucrose O
+by O
+12 O
+. O
+4 O
+% O
+, O
+23 O
+. O
+6 O
+% O
+and O
+36 O
+. O
+1 O
+% O
+, O
+respectively O
+, O
+but O
+did O
+not O
+affect O
+the O
+ingestion O
+of O
+protein O
+. O
+
+It O
+is O
+recommended O
+that O
+area O
+correction O
+be O
+attempted O
+in O
+bioequivalence O
+studies O
+of O
+drugs O
+where O
+high O
+intrasubject O
+variability O
+in O
+clearance O
+is O
+known O
+or O
+suspected O
+. O
+
+Expression O
+of O
+the O
+E2 B
+protein I
+resulted O
+in O
+rapid O
+repression O
+of O
+HPV B
+E6 I
+and O
+E7 B
+expression O
+, O
+followed O
+approximately O
+12 O
+h O
+later O
+by O
+profound O
+inhibition O
+of O
+cellular O
+DNA O
+synthesis O
+. O
+
+Plasma O
+renin B
+activity O
+in O
+end O
+- O
+stage O
+kidney O
+disease O
+. O
+
+Immunoblotting O
+with O
+antiphosphotyrosine B
+antibody I
+showed O
+that O
+many O
+yeast O
+proteins O
+, O
+including O
+the O
+p34CDC28 B
+kinase I
+, O
+became O
+phosphorylated O
+at O
+tyrosine O
+in O
+cells O
+expressing O
+v B
+- I
+src I
+. O
+
+Renal O
+cell O
+carcinoma O
+induced O
+Coombs O
+negative O
+autoimmune O
+hemolytic O
+anemia O
+and O
+severe O
+thrombocytopenia O
+responsive O
+to O
+nephrectomy O
+. O
+
+Pretreatment O
+of O
+rats O
+with O
+different O
+dose O
+levels O
+of O
+CCl4 O
+resulted O
+in O
+a O
+prolongation O
+of O
+TMO O
+half O
+- O
+life O
+, O
+and O
+increase O
+of O
+the O
+area O
+under O
+the O
+curve O
+( O
+AUC O
+) O
+, O
+and O
+a O
+decrease O
+of O
+clearance O
+, O
+but O
+the O
+apparent O
+volume O
+of O
+distribution O
+( O
+Vd O
+) O
+was O
+not O
+significantly O
+decreased O
+. O
+
+In O
+cells O
+co O
+- O
+expressing O
+high O
+levels O
+of O
+the O
+p38 B
+( I
+MAPK I
+) I
+kinase I
+( O
+MKK3 B
+) O
+together O
+with O
+the O
+p38 B
+( O
+MAPK B
+) O
+, O
+a O
+significant O
+inhibition O
+of O
+mitogen O
+- O
+induced O
+cyclin B
+D1 I
+expression O
+was O
+observed O
+. O
+
+In O
+patients O
+autografted O
+in O
+CR1 O
+, O
+the O
+transplant O
+- O
+related O
+mortality O
+( O
+TRM O
+) O
+was O
+15 O
++ O
+/ O
+- O
+4 O
+% O
+, O
+the O
+relapse O
+incidence O
+( O
+RI O
+) O
+was O
+58 O
++ O
+/ O
+- O
+5 O
+% O
+, O
+the O
+leukaemia O
+- O
+free O
+survival O
+( O
+LFS O
+) O
+was O
+36 O
++ O
+/ O
+- O
+5 O
+% O
+and O
+the O
+overall O
+survival O
+was O
+47 O
++ O
+/ O
+- O
+5 O
+% O
+at O
+3 O
+years O
+. O
+
+Administration O
+of O
+FR O
+34235 O
+reduced O
+aortic O
+blood O
+pressure O
+and O
+increased O
+cardiac O
+output O
+in O
+anesthetized O
+dogs O
+with O
+an O
+ameroid O
+- O
+induced O
+coronary O
+artery O
+occlusion O
+. O
+
+The O
+primary O
+conditions O
+for O
+acceptable O
+hospital O
+use O
+were O
+that O
+exhaled O
+- O
+volume O
+monitoring O
+be O
+performed O
+for O
+all O
+patients O
+and O
+that O
+O2 O
+monitoring O
+be O
+performed O
+both O
+when O
+setting O
+FIO2 O
+and O
+continuously O
+when O
+FIO2 O
+levels O
+are O
+critical O
+. O
+
+The O
+RHO1 B
+gene I
+encodes O
+a O
+homolog O
+of O
+the O
+mammalian B
+RhoA I
+small I
+GTP I
+- I
+binding I
+protein I
+in O
+the O
+yeast O
+Saccharomyces O
+cerevisiae O
+. O
+
+As O
+regards O
+the O
+short O
+stature O
+, O
+they O
+have O
+proved O
+that O
+the O
+syndrome O
+is O
+related O
+to O
+low O
+levels O
+of O
+somatomedin B
+C I
+( O
+SmC B
+) O
+. O
+
+2 O
+. O
+
+Menstrual O
+and O
+lunar O
+cycles O
+. O
+
+HBO O
+had O
+marked O
+effects O
+on O
+these O
+enzymes O
+: O
+lung B
+SOD I
+increased O
+( O
+guinea O
+pigs O
+47 O
+% O
+, O
+rats O
+88 O
+% O
+) O
+and O
+CAT B
+and O
+GSHPx B
+activities O
+decreased O
+( O
+33 O
+% O
+) O
+in O
+brain O
+and O
+lung O
+. O
+
+Smectic O
+- O
+A O
+ordering O
+at O
+a O
+liquid O
+- O
+vapor O
+interface O
+. O
+
+Phylogenetic O
+analysis O
+of O
+yeast O
+, O
+invertebrate O
+, O
+and O
+multiple O
+mammalian B
+isoforms I
+of O
+SNF4 B
+shows O
+that O
+the O
+gene O
+duplication O
+likely O
+occurred O
+early O
+in O
+the O
+metazoan O
+lineage O
+, O
+as O
+the O
+protein O
+products O
+of O
+the O
+different O
+loci O
+are O
+relatively O
+divergent O
+. O
+
+Hard O
+methacrylic O
+polymers O
+. O
+
+Thus O
+the O
+Hi O
+- O
+RARE O
+represents O
+a O
+new O
+type O
+of O
+RA O
+response O
+element O
+with O
+a O
+role O
+in O
+the O
+modulation O
+of O
+the O
+expression O
+of O
+MHC B
+class I
+1 I
+family I
+genes I
+. O
+
+We O
+found O
+multiple O
+transcription O
+start O
+sites O
+located O
+within O
+a O
+15 O
+- O
+base O
+pair O
+region O
+, O
+205 O
+base O
+pairs O
+upstream O
+of O
+the O
+translation O
+start O
+codon O
+. O
+
+During O
+the O
+last O
+three O
+days O
+of O
+the O
+study O
+, O
+mean O
+urine O
+osmolality O
+( O
+Uosm O
+) O
+and O
+free O
+water O
+reabsorption O
+( O
+TCH2O O
+) O
+increased O
+significantly O
+: O
+[ O
+formula O
+: O
+see O
+text O
+] O
+. O
+
+The O
+structural O
+intestinal O
+defects O
+are O
+presumed O
+to O
+be O
+the O
+result O
+of O
+defective O
+collagen B
+synthesis O
+in O
+these O
+hereditary O
+connective O
+tissue O
+disorders O
+. O
+
+Rev O
+. O
+
+Although O
+indomethacin O
+is O
+useful O
+for O
+examining O
+the O
+role O
+of O
+cyclooxygenase B
+products O
+in O
+asthmatic O
+responses O
+, O
+it O
+should O
+not O
+be O
+considered O
+in O
+the O
+treatment O
+of O
+asthma O
+. O
+
+Incidence O
+of O
+beta O
+- O
+thalassemia O
+carriers O
+and O
+those O
+deficient O
+in O
+erythrocyte O
+glucose B
+- I
+6 I
+- I
+phosphate I
+dehydrogenase I
+in O
+the O
+greater O
+Buenos O
+Aires O
+area O
+
+Both O
+v B
+- I
+Myb I
+and O
+c B
+- I
+Myb I
+bind O
+specifically O
+to O
+delta B
+E3 I
+. O
+
+Anatomical O
+considerations O
+in O
+transsphenoidal O
+hypophysectomy O
+. O
+
+The O
+salt O
+sensitivity O
+of O
+the O
+interaction O
+indicated O
+that O
+two O
+ion O
+pairs O
+are O
+involved O
+in O
+the O
+association O
+of O
+Zn2 O
++ O
+( O
+NC B
+- O
+F1 I
+) O
+with O
+polynucleotide O
+, O
+whereas O
+one O
+ion O
+pair O
+is O
+found O
+in O
+the O
+metal O
+- O
+free O
+peptide O
+- O
+nucleic O
+acid O
+complex O
+. O
+
+Investigation O
+on O
+the O
+asymmetrical O
+induced O
+yields O
+in O
+90Sr O
+- O
+90Y O
+- O
+beta O
+- O
+irradiated O
+D O
+- O
+and O
+L O
+- O
+alanines O
+. O
+
+An O
+hcr1 B
+null I
+mutant I
+was O
+viable O
+, O
+but O
+showed O
+slight O
+reduction O
+of O
+growth O
+when O
+compared O
+with O
+the O
+wild O
+- O
+type O
+strain O
+. O
+
+Serum O
+levels O
+of O
+total O
+and O
+specific O
+immunoglobulin B
+E I
+( O
+IgE B
+) O
+have O
+been O
+determined O
+by O
+radioimmunoassays O
+in O
+sixty O
+- O
+nine O
+allergic O
+subjects O
+. O
+
+IgE B
+- I
+binding I
+proteins I
+of O
+Psocoptera O
+were O
+determined O
+by O
+immunoblotting O
+experiments O
+. O
+
+We O
+also O
+show O
+that O
+the O
+products O
+of O
+both O
+the O
+GIY B
+- O
+YIG B
+ORF O
+and O
+the O
+non O
+- O
+canonical O
+LAGLI B
+- O
+DADG B
+- O
+GIY B
+- O
+YIG B
+ORF O
+, O
+which O
+is O
+generated O
+by O
+its O
+integration O
+, O
+have O
+endonuclease O
+activities O
+which O
+recognize O
+and O
+cut O
+the O
+insertion O
+site O
+of O
+the O
+optional O
+sequence O
+. O
+
+Further O
+, O
+we O
+find O
+that O
+the O
+BMI1 B
+protein I
+can O
+also O
+interact O
+with O
+itself O
+. O
+
+Indeed O
+, O
+ectopic O
+expression O
+of O
+MOX4 B
+in O
+aerobic O
+cells O
+resulted O
+in O
+partially O
+constitutive O
+expression O
+of O
+DAN1 B
+. O
+
+We O
+measured O
+electromyograms O
+( O
+EMG O
+) O
+of O
+the O
+alae O
+nasi O
+to O
+determine O
+the O
+relationship O
+between O
+their O
+activity O
+and O
+timing O
+to O
+contraction O
+of O
+the O
+rib O
+cage O
+muscles O
+and O
+diaphragm O
+during O
+obstructive O
+apnea O
+in O
+nine O
+patients O
+. O
+
+Hybridization O
+was O
+detected O
+between O
+polyadenylated O
+H B
+chain I
+mRNA I
+, O
+isolated O
+from O
+the O
+majority O
+of O
+the O
+hybridomas O
+, O
+and O
+the O
+VH B
+probe O
+. O
+
+Identification O
+of O
+a O
+putative O
+infC B
+- O
+rpmI B
+- O
+rplT B
+operon O
+flanked O
+by O
+long O
+inverted O
+repeats O
+in O
+Mycoplasma O
+fermentans O
+( O
+incognitus O
+strain O
+) O
+. O
+
+The O
+standardized O
+incidence O
+in O
+Europeans O
+has O
+risen O
+significantly O
+to O
+4 O
+. O
+7 O
+/ O
+10 O
+( O
+5 O
+) O
+/ O
+year O
+from O
+3 O
+. O
+4 O
+/ O
+10 O
+( O
+5 O
+) O
+/ O
+year O
+in O
+the O
+1970s O
+( O
+chi O
+2 O
+= O
+8 O
+. O
+1 O
+, O
+p O
+less O
+than O
+0 O
+. O
+005 O
+) O
+. O
+
+Neurological O
+toxicity O
+occurred O
+in O
+8 O
+/ O
+219 O
+patients O
+treated O
+with O
+fludarabine O
+( O
+FAMP O
+) O
+, O
+30 O
+mg O
+/ O
+m2 O
+per O
+day O
+and O
+cytosine O
+arabinoside O
+( O
+Ara O
+- O
+C O
+) O
+, O
+0 O
+. O
+5 O
+g O
+/ O
+m2 O
+per O
+hour O
+for O
+2 O
+- O
+6 O
+hours O
+for O
+5 O
+days O
+, O
+for O
+new O
+or O
+relapsed O
+acute O
+leukemia O
+or O
+myelodysplasia O
+. O
+
+Evaluation O
+of O
+gamma B
+- I
+glutamyl I
+transpeptidase I
+in O
+myocardial O
+infarction O
+. O
+
+Loss O
+of O
+pRb B
+or O
+p107 B
+binding O
+results O
+in O
+the O
+loss O
+of O
+transforming O
+activity O
+. O
+
+The O
+analysis O
+of O
+results O
+suggests O
+that O
+seroprevalence O
+of O
+Lyme O
+borreliosis O
+in O
+dogs O
+of O
+the O
+Kosice O
+region O
+is O
+not O
+negligible O
+. O
+
+Peak O
+insulin B
+response O
+to O
+glucose O
+infusion O
+declined O
+from O
+Groups O
+1 O
+to O
+3 O
+( O
+51 O
++ O
+/ O
+- O
+14 O
+, O
+42 O
+. O
+4 O
++ O
+/ O
+- O
+31 O
+, O
+20 O
+. O
+4 O
++ O
+/ O
+- O
+6 O
+. O
+8 O
+microU O
+/ O
+ml O
+, O
+respectively O
+) O
+with O
+Group O
+3 O
+exhibiting O
+a O
+significantly O
+decreased O
+mean O
+peak O
+level O
+compared O
+to O
+the O
+other O
+groups O
+. O
+
+Iris O
+binding O
+and O
+bioavailability O
+. O
+
+The O
+influence O
+of O
+a O
+high O
+n O
+- O
+3 O
+PUFA O
+intake O
+on O
+measures O
+of O
+lipid O
+peroxidation O
+has O
+been O
+equivocal O
+. O
+
+The O
+proliferative O
+potential O
+of O
+the O
+pilocytic O
+astrocytoma O
+: O
+the O
+relation O
+between O
+MIB B
+- I
+1 I
+labeling O
+and O
+clinical O
+and O
+neuro O
+- O
+radiological O
+follow O
+- O
+up O
+. O
+
+RESULTS O
+: O
+Here O
+, O
+we O
+report O
+the O
+identification O
+of O
+two O
+major O
+and O
+novel O
+Shc B
+tyrosine O
+phosphorylation O
+sites O
+, O
+Y239 O
+and O
+Y240 O
+. O
+
+Dominant B
+- I
+negative I
+upf1 I
+mutations I
+were O
+isolated O
+following O
+in O
+vitro O
+mutagenesis O
+of O
+a O
+plasmid O
+containing O
+the O
+UPF1 B
+gene I
+. O
+
+The O
+tensile O
+strengths O
+of O
+an O
+adhesive O
+luting O
+resin O
+' O
+Panavia O
+EX O
+' O
+to O
+the O
+bovine O
+dentin O
+decreased O
+significantly O
+by O
+the O
+zinc O
+iontophoresis O
+. O
+
+We O
+previously O
+identified O
+a O
+highly O
+conserved O
+L O
+- O
+X O
+- O
+X O
+- O
+L O
+- O
+F O
+sequence O
+near O
+the O
+C O
+terminus O
+of O
+the O
+p6 B
+domain I
+of O
+the O
+Gag B
+precursor I
+as O
+the O
+major O
+virion O
+association O
+motif O
+for O
+HIV B
+- I
+1 I
+Vpr I
+. O
+
+Papillomavirus B
+type I
+16 I
+oncogenes I
+downregulate O
+expression O
+of O
+interferon B
+- I
+responsive I
+genes I
+and O
+upregulate O
+proliferation O
+- O
+associated O
+and O
+NF B
+- I
+kappaB I
+- O
+responsive O
+genes O
+in O
+cervical O
+keratinocytes O
+. O
+
+The O
+A3B3 B
+domain I
+had O
+a O
+mass O
+of O
+34 O
+, O
+462 O
+, O
+with O
+a O
+glycosylation O
+mass O
+of O
+14 O
+, O
+900 O
+, O
+in O
+good O
+agreement O
+with O
+seven O
+N O
+- O
+linked O
+glycosylation O
+sites O
+of O
+average O
+mass O
+2100 O
+. O
+
+We O
+found O
+that O
+the O
+frequency O
+spectrum O
+of O
+physiologic O
+chest O
+sounds O
+is O
+contained O
+entirely O
+within O
+that O
+of O
+jet O
+rotocraft O
+noise O
+. O
+
+The O
+human B
+CA11 I
+gene I
+appears O
+to O
+be O
+located O
+between O
+the O
+secretor B
+type I
+alpha I
+( I
+1 I
+, I
+2 I
+) I
+- I
+fucosyltransferase I
+gene I
+cluster O
+( O
+FUT1 B
+- O
+FUT2 B
+- O
+FUT2P B
+) O
+and O
+the O
+D B
+- I
+site I
+binding I
+protein I
+gene I
+( O
+DBP B
+) O
+on O
+chromosome O
+19q13 O
+. O
+3 O
+. O
+
+An O
+anoerxiant O
+, O
+mazindol O
+suppresses O
+food O
+intake O
+by O
+1 O
+) O
+stimulating O
+beta B
+- I
+adrenergic I
+receptors I
+, O
+2 O
+) O
+inhibiting O
+the O
+feeding O
+center O
+and O
+, O
+3 O
+) O
+stimulating O
+the O
+satiety O
+center O
+in O
+the O
+hypothalamus O
+. O
+
+These O
+segments O
+may O
+represent O
+pseudogenes O
+. O
+
+The O
+fusion O
+of O
+AML1 B
+to O
+MDS1 B
+is O
+in O
+frame O
+, O
+and O
+adds O
+127 O
+codons O
+to O
+the O
+interrupted O
+AML1 B
+. O
+
+In O
+this O
+study O
+, O
+the O
+effect O
+of O
+the O
+antibiotic O
+lasalocid O
+on O
+the O
+rumen O
+anaerobic O
+fungus O
+Neocallimastix O
+frontalis O
+RK O
+21 O
+was O
+examined O
+. O
+
+WBC O
+differential O
+( O
+SEG O
+, O
+BAND O
+, O
+LYMPH O
+, O
+MONO O
+, O
+EOSINO O
+, O
+BASO O
+) O
+usually O
+showed O
+log O
+- O
+normal O
+distribution O
+. O
+
+A O
+model O
+for O
+oligomerization O
+- O
+dependent O
+subunit O
+folding O
+. O
+
+Chromosome O
+- O
+specific O
+STSs O
+for O
+27 O
+telomeres O
+were O
+identified O
+from O
+the O
+196 O
+TYACs O
+. O
+
+Second O
+, O
+overexpression O
+of O
+RIM11 B
+can O
+suppress O
+an O
+ime1 B
+missense I
+mutation I
+( O
+ime1 B
+- I
+L321F I
+) O
+but O
+not O
+an O
+ime1 B
+deletion I
+. O
+
+Calculation O
+of O
+energy O
+levels O
+, O
+E1 O
+transition O
+amplitudes O
+, O
+and O
+parity O
+violation O
+in O
+francium O
+. O
+
+All O
+except O
+the O
+last O
+two O
+interventions O
+are O
+physical O
+treatments O
+that O
+create O
+a O
+wound O
+- O
+tissue O
+environment O
+conducive O
+to O
+healing O
+. O
+
+This O
+50 O
+- O
+kDa O
+protein O
+contains O
+two O
+SH2 B
+domains I
+and O
+an O
+inter B
+- I
+SH2 I
+domain I
+of O
+p85alpha B
+, O
+but O
+the O
+SH3 B
+and O
+bcr B
+homology I
+domains I
+of O
+p85alpha B
+were O
+replaced O
+by O
+a O
+unique O
+6 O
+- O
+amino O
+acid O
+sequence O
+. O
+
+Hydropathy O
+analysis O
+of O
+deduced O
+A4 B
+amino I
+acid I
+sequence I
+revealed O
+four O
+putative O
+membrane O
+- O
+spanning O
+alpha O
+- O
+helices O
+. O
+
+A O
+clinical O
+double O
+- O
+blind O
+trial O
+of O
+topical O
+miconazole O
+and O
+clotrimazole O
+against O
+superficial O
+fungal O
+infections O
+and O
+erythrasma O
+. O
+
+Studies O
+on O
+low O
+- O
+dose O
+oral O
+contraceptives O
+: O
+cervical O
+mucus O
+and O
+plasma O
+hormone O
+changes O
+in O
+relation O
+to O
+circulating O
+D O
+- O
+norgestrel O
+and O
+17alpha O
+ethynyl O
+- O
+estradiol O
+concentrations O
+. O
+
+Herewith O
+C O
+. O
+psittaci O
+could O
+be O
+diagnosed O
+in O
+all O
+positive O
+samples O
+. O
+
+The O
+more O
+sustained O
+effect O
+of O
+cyclofenil O
+on O
+prolactin B
+secretion O
+with O
+a O
+reduced O
+frequency O
+of O
+relapse O
+, O
+and O
+the O
+lower O
+oestradiol O
+level O
+, O
+which O
+might O
+indicate O
+a O
+reduced O
+risk O
+of O
+thromboembolism O
+, O
+suggest O
+that O
+this O
+drug O
+has O
+some O
+advantage O
+over O
+bromocriptine O
+in O
+the O
+inhibition O
+of O
+postpartum O
+lactation O
+. O
+
+Response O
+surface O
+methodology O
+was O
+employed O
+to O
+describe O
+the O
+relationship O
+between O
+soman O
+- O
+induced O
+incapacitation O
+and O
+the O
+ATR O
+/ O
+DZ O
+or O
+ATR O
+/ O
+SCP O
+dosages O
+. O
+
+The O
+brains O
+were O
+bisected O
+and O
+T1 O
+and O
+T2 O
+relaxation O
+times O
+were O
+determined O
+for O
+the O
+right O
+and O
+left O
+hemispheres O
+by O
+MR O
+spectroscopy O
+immediately O
+after O
+dissection O
+. O
+
+Simulations O
+of O
+velocities O
+, O
+vorticity O
+, O
+pressure O
+and O
+certain O
+stress O
+values O
+were O
+developed O
+by O
+a O
+computer O
+and O
+displayed O
+for O
+man O
+- O
+machine O
+interaction O
+. O
+
+In O
+the O
+present O
+study O
+, O
+we O
+report O
+the O
+entire O
+genomic O
+structure O
+of O
+KCNQ1 B
+, O
+which O
+consists O
+of O
+19 O
+exons O
+spanning O
+400 O
+kb O
+on O
+chromosome O
+11p15 O
+. O
+5 O
+. O
+
+Northern O
+( O
+RNA O
+) O
+blot O
+hybridization O
+analysis O
+with O
+the O
+p68c B
+- I
+ets I
+- I
+1 I
+- I
+specific I
+sequence I
+and O
+RNase B
+protection O
+experiments O
+showed O
+that O
+the O
+corresponding O
+mRNA O
+was O
+expressed O
+in O
+normal O
+chicken O
+spleen O
+and O
+not O
+in O
+normal O
+chicken O
+thymus O
+or O
+in O
+various O
+T O
+lymphoid O
+cell O
+lines O
+. O
+
+To O
+investigate O
+this O
+issue O
+, O
+we O
+used O
+a O
+recognition O
+task O
+in O
+which O
+two O
+strings O
+of O
+letters O
+are O
+presented O
+sequentially O
+. O
+
+Kettin B
+is O
+a O
+large O
+modular O
+protein O
+associated O
+with O
+thin O
+filaments O
+in O
+the O
+Z O
+- O
+disc O
+region O
+of O
+insect O
+muscles O
+. O
+
+Enzymatic O
+and O
+chemical O
+structure O
+probing O
+revealed O
+mainly O
+the O
+conserved O
+terminal O
+part O
+( O
+termed O
+3 O
+' O
+C O
+) O
+of O
+the O
+DI9c B
+3 I
+' I
+UTR I
+containing O
+distinctive O
+RNA O
+motifs O
+, O
+i O
+. O
+e O
+. O
+, O
+a O
+stable O
+stem O
+- O
+loop O
+, O
+SL O
+I O
+, O
+near O
+the O
+RNA O
+3 O
+' O
+terminus O
+and O
+a O
+considerably O
+less O
+stable O
+stem O
+- O
+loop O
+, O
+SL O
+II O
+, O
+that O
+forms O
+the O
+5 O
+' O
+portion O
+of O
+3 O
+' O
+C O
+. O
+
+This O
+review O
+chronicles O
+the O
+characteristics O
+of O
+deliberate O
+and O
+accidental O
+mass O
+poisonings O
+that O
+occurred O
+in O
+World O
+Wars O
+I O
+and O
+II O
+, O
+in O
+Bhopal O
+, O
+and O
+in O
+other O
+historical O
+cases O
+up O
+to O
+and O
+including O
+modern O
+wars O
+. O
+
+The O
+effects O
+of O
+4 O
+weeks O
+of O
+cyclosporin O
+A O
+( O
+7 O
+mg O
+/ O
+kg O
+per O
+day O
+) O
+( O
+CyA O
+) O
+on O
+the O
+survival O
+of O
+vascularized O
+osteochondral O
+grafts O
+between O
+rat O
+strains O
+[ O
+DA O
+( O
+donor O
+) O
+and O
+Lewis O
+( O
+recipient O
+) O
+] O
+and O
+the O
+presence O
+and O
+significance O
+of O
+host O
+immune O
+tolerance O
+and O
+graft O
+antigen O
+modulation O
+after O
+cessation O
+of O
+immunosuppression O
+have O
+been O
+examined O
+. O
+
+By O
+incorporating O
+a O
+stent O
+with O
+posts O
+that O
+pivot O
+about O
+their O
+base O
+, O
+such O
+that O
+a O
+10 O
+% O
+expansion O
+at O
+the O
+commissures O
+is O
+realized O
+, O
+we O
+were O
+able O
+to O
+reduce O
+the O
+compressive O
+commissural O
+stressing O
+from O
+250 O
+to O
+150 O
+kPa O
+. O
+
+In O
+group O
+1 O
+, O
+mean O
+z O
+- O
+score O
+for O
+GFR O
+was O
+- O
+0 O
+. O
+27 O
+( O
+94 O
+. O
+6 O
+% O
+of O
+normal O
+) O
+and O
+in O
+group O
+2 O
+mean O
+z O
+- O
+score O
+was O
+- O
+1 O
+. O
+51 O
+( O
+72 O
+. O
+7 O
+% O
+of O
+normal O
+for O
+two O
+kidneys O
+) O
+( O
+P O
+= O
+0 O
+. O
+022 O
+, O
+Mann O
+- O
+Whitney O
+U O
+- O
+test O
+) O
+. O
+
+The O
+cooperation O
+between O
+health O
+and O
+hospital O
+services O
+
+The O
+free O
+fraction O
+of O
+amitriptyline O
+( O
+AT O
+) O
+, O
+measured O
+by O
+equilibrium O
+dialysis O
+in O
+plasma O
+from O
+29 O
+AT O
+- O
+treated O
+depressed O
+patients O
+, O
+was O
+5 O
+. O
+4 O
+- O
+9 O
+. O
+8 O
+% O
+( O
+mean O
+7 O
+. O
+7 O
+% O
+) O
+, O
+which O
+was O
+the O
+same O
+as O
+the O
+values O
+in O
+26 O
+healthy O
+controls O
+( O
+4 O
+. O
+9 O
+- O
+9 O
+. O
+6 O
+% O
+, O
+mean O
+7 O
+. O
+6 O
+% O
+) O
+. O
+
+Different O
+effects O
+of O
+reoxygenation O
+on O
+the O
+electrical O
+activity O
+of O
+ventricular O
+muscle O
+. O
+
+Metastatic O
+tumours O
+of O
+bone O
+in O
+Nigerians O
+. O
+
+However O
+, O
+microinjection O
+of O
+reconstituted O
+mRNPs O
+into O
+Xenopus O
+oocytes O
+demonstrates O
+that O
+although O
+translational O
+repression O
+occurs O
+in O
+the O
+absence O
+of O
+consensus O
+RNA O
+binding O
+sequences O
+for O
+FRGY2 B
+, O
+the O
+presence O
+of O
+FRGY2 B
+recognition I
+elements I
+within O
+mRNA O
+potentiates O
+translational O
+repression O
+. O
+
+Any O
+respectative O
+material O
+( O
+class O
+0 O
+) O
+was O
+not O
+obtained O
+from O
+334 O
+patients O
+( O
+4 O
+. O
+2 O
+% O
+) O
+, O
+class O
+I O
+- O
+II O
+findings O
+belonged O
+to O
+6m141 O
+patients O
+( O
+76 O
+. O
+7 O
+% O
+) O
+, O
+950 O
+patients O
+( O
+11 O
+. O
+9 O
+% O
+) O
+were O
+classified O
+as O
+class O
+HII O
+and O
+IV O
+, O
+578 O
+patients O
+( O
+7 O
+. O
+2 O
+% O
+) O
+as O
+class O
+V O
+. O
+
+However O
+, O
+whether O
+this O
+was O
+associated O
+with O
+spleen O
+removal O
+after O
+adjustment O
+for O
+risk O
+factors O
+was O
+not O
+determined O
+. O
+
+Virgin O
+, O
+P O
+. O
+
+IL B
+- I
+6 I
+was O
+detected O
+in O
+the O
+urine O
+of O
+52 O
+% O
+of O
+children O
+with O
+pyelonephritis O
+compared O
+with O
+15 O
+% O
+of O
+other O
+children O
+( O
+P O
+< O
+0 O
+. O
+001 O
+) O
+. O
+
+We O
+have O
+determined O
+the O
+complete O
+cDNA O
+sequence O
+of O
+rat B
+plectin I
+from O
+a O
+number O
+of O
+well O
+- O
+characterized O
+overlapping O
+lambda O
+gt11 O
+clones O
+. O
+
+SETTING O
+- O
+- O
+Hospital O
+laboratories O
+in O
+the O
+United O
+States O
+submitting O
+pneumococcal O
+isolates O
+to O
+the O
+CDC O
+between O
+October O
+1 O
+, O
+1991 O
+, O
+and O
+September O
+30 O
+, O
+1992 O
+. O
+
+The O
+terminal O
+a O
+sequence O
+of O
+the O
+herpes O
+simplex O
+virus O
+genome O
+contains O
+the O
+promoter O
+of O
+a O
+gene O
+located O
+in O
+the O
+repeat O
+sequences O
+of O
+the O
+L O
+component O
+. O
+
+In O
+contrast O
+to O
+p62 B
+( O
+dok B
+) O
+, O
+DOKL B
+lacks O
+YxxP O
+motifs O
+in O
+the O
+C O
+terminus O
+and O
+does O
+not O
+bind O
+to O
+Ras B
+GTPase I
+- I
+activating I
+protein I
+( O
+RasGAP B
+) O
+upon O
+phosphorylation O
+. O
+
+These O
+observations O
+demonstrate O
+that O
+KSR B
+is O
+capable O
+of O
+uncoupling O
+the O
+MAP B
+kinase I
+activation O
+from O
+its O
+target O
+phosphorylation O
+, O
+and O
+thus O
+provide O
+a O
+novel O
+mechanism O
+for O
+modulating O
+the O
+Ras B
+- O
+MAP B
+kinase I
+signaling O
+pathway O
+. O
+
+G B
+- I
+CSF I
+( O
+10 O
+microg O
+/ O
+kg O
+) O
+was O
+started O
+on O
+day O
++ O
+1 O
+and O
+all O
+patients O
+engrafted O
+within O
+a O
+median O
+day O
+number O
+of O
+12 O
+( O
+range O
+, O
+10 O
+- O
+22 O
+) O
+until O
+leukocytes O
+> O
+1 O
+. O
+0 O
+x O
+10 O
+( O
+9 O
+) O
+/ O
+l O
+and O
+a O
+median O
+day O
+number O
+of O
+56 O
+( O
+range O
+, O
+10 O
+- O
+180 O
+) O
+until O
+platelets O
+> O
+20 O
+. O
+0 O
+x O
+10 O
+( O
+9 O
+) O
+/ O
+l O
+( O
+ie O
+platelet O
+transfusion O
+independence O
+) O
+. O
+
+A O
+higher O
+percentage O
+of O
+children O
+with O
+cerebral O
+malaria O
+( O
+40 O
+per O
+cent O
+) O
+than O
+with O
+non O
+- O
+cerebral O
+malaria O
+( O
+29 O
+per O
+cent O
+) O
+or O
+controls O
+( O
+20 O
+per O
+cent O
+) O
+also O
+had O
+either O
+serum O
+ferritin B
+< O
+100 O
+micrograms O
+/ O
+l O
+and O
+inflammation O
+or O
+sTfR B
+> O
+7 O
+. O
+3 O
+mg O
+/ O
+l O
+or O
+both O
+. O
+
+During O
+the O
+burst O
+period O
+( O
+approximately O
+5 O
+- O
+10 O
+min O
+) O
+, O
+local O
+blood O
+H2O2 O
+concentrations O
+and O
+xanthine B
+oxidase I
+activities O
+were O
+highly O
+correlated O
+( O
+r O
+= O
+0 O
+. O
+999 O
+) O
+. O
+
+Previous O
+studies O
+have O
+demonstrated O
+that O
+the O
+21 O
+- O
+or O
+the O
+72 O
+- O
+bp O
+repeat O
+transcriptional O
+control O
+elements O
+enhance O
+the O
+efficiency O
+of O
+SV40 O
+DNA O
+replication O
+in O
+vivo O
+, O
+provided O
+either O
+of O
+these O
+repeats O
+is O
+located O
+near O
+the O
+end O
+of O
+the O
+core O
+replication O
+origin O
+containing O
+the O
+17 O
+- O
+bp O
+A O
++ O
+T O
+- O
+containing O
+sequence O
+. O
+
+UV O
+cross O
+- O
+linking O
+and O
+Southwestern O
+analysis O
+suggested O
+that O
+KTP1 B
+is O
+a O
+DNA O
+- O
+binding O
+protein O
+clearly O
+distinct O
+from O
+AP2 B
+, O
+and O
+this O
+protein O
+may O
+be O
+responsible O
+for O
+the O
+basal O
+keratinocyte O
+- O
+specific O
+expression O
+of O
+the O
+BPAG1 B
+gene I
+. O
+
+The O
+model O
+of O
+the O
+complex O
+provides O
+a O
+rationale O
+for O
+conserved O
+ITAM B
+residues I
+, O
+substrate O
+specificity O
+, O
+and O
+suggests O
+that O
+substrate O
+binds O
+only O
+the O
+active O
+conformation O
+of O
+the O
+Src B
+family I
+tyrosine B
+kinase I
+, O
+unlike O
+the O
+ATP O
+cofactor O
+, O
+which O
+can O
+bind O
+the O
+inactive O
+form O
+. O
+
+Here O
+we O
+demonstrate O
+that O
+a O
+region O
+of O
+high O
+homology O
+between O
+the O
+members O
+of O
+this O
+class O
+of O
+proteins O
+contains O
+a O
+type O
+A O
+nucleotide O
+binding O
+site O
+consensus O
+sequence O
+which O
+has O
+ATPase B
+activity O
+and O
+is O
+sufficient O
+to O
+bind O
+DNA O
+containing O
+specific O
+mismatched O
+residues O
+. O
+
+Copyright O
+1999 O
+Academic O
+Press O
+. O
+
+Nickel O
+release O
+from O
+tools O
+on O
+the O
+Swedish O
+market O
+. O
+
+S O
+- O
+phase O
+- O
+promoting O
+cyclin B
+- I
+dependent I
+kinases I
+( O
+Cdks B
+) O
+and O
+the O
+kinase O
+Dbf4 B
+- O
+Cdc7 B
+then O
+act O
+to O
+initiate O
+replication O
+. O
+
+NF B
+- I
+kappaB I
+only O
+partially O
+mediates O
+Epstein B
+- I
+Barr I
+virus I
+latent I
+membrane I
+protein I
+1 I
+activation O
+of O
+B O
+cells O
+. O
+
+Purified O
+fER B
+exhibited O
+a O
+distribution O
+constant O
+( O
+KD O
+) O
+for O
+17 O
+beta O
+- O
+estradiol O
+of O
+0 O
+. O
+45 O
+nM O
+. O
+
+The O
+long O
+terminal O
+repeat O
+is O
+590 O
+bp O
+in O
+length O
+, O
+with O
+the O
+U3 O
+region O
+containing O
+consensus O
+sequences O
+likely O
+to O
+be O
+involved O
+in O
+viral O
+gene O
+expression O
+. O
+
+An O
+incorrect O
+response O
+on O
+the O
+previous O
+trial O
+enhanced O
+the O
+accuracy O
+in O
+the O
+current O
+trial O
+only O
+in O
+the O
+left O
+visual O
+field O
+( O
+LVF O
+) O
+. O
+
+The O
+peptides O
+are O
+generated O
+in O
+the O
+cytosol O
+, O
+then O
+translocated O
+across O
+the O
+membrane O
+of O
+the O
+endoplasmic O
+reticulum O
+by O
+the O
+transporter B
+associated I
+with I
+antigen I
+processing I
+( O
+TAP B
+) O
+. O
+
+It O
+competes O
+with O
+the O
+calcium O
+ion O
+which O
+brings O
+about O
+inhibition O
+of O
+myosine B
+kinase I
+, O
+and O
+therefore O
+a O
+drop O
+in O
+phosphorylated O
+myosine B
+. O
+
+Comparison O
+with O
+the O
+data O
+of O
+clinical O
+development O
+and O
+hemodynamic O
+results O
+
+Sera O
+collected O
+in O
+1973 O
+- O
+1975 O
+from O
+3053 O
+residents O
+of O
+12 O
+selected O
+Alaskan O
+Eskimo O
+villages O
+were O
+tested O
+for O
+evidence O
+of O
+hepatitis O
+B O
+virus O
+infection O
+. O
+
+Injection O
+of O
+horseradish B
+peroxidase I
+( O
+HRP B
+) O
+into O
+the O
+cerebellar O
+flocculus O
+of O
+the O
+rat O
+was O
+employed O
+to O
+identify O
+neurons O
+in O
+the O
+abducens O
+nucleus O
+that O
+project O
+to O
+the O
+flocculus O
+. O
+
+To O
+assay O
+for O
+sequences O
+that O
+could O
+potentially O
+regulate O
+Xenopus B
+proenkephalin I
+expression O
+, O
+we O
+transfected O
+constructs O
+that O
+contained O
+upstream O
+genomic O
+sequences O
+linked O
+to O
+the O
+CAT B
+reporter I
+gene I
+into O
+various O
+eukaryotic O
+cell O
+lines O
+. O
+
+This O
+suggests O
+that O
+the O
+ratio O
+of O
+IL B
+- I
+6 I
+to O
+IL B
+- I
+10 I
+may O
+be O
+used O
+to O
+predict O
+the O
+injury O
+severity O
+after O
+trauma O
+. O
+
+UVB O
+- O
+induced O
+association O
+of O
+tumor B
+necrosis I
+factor I
+( I
+TNF I
+) I
+receptor I
+1 I
+/ O
+TNF B
+receptor I
+- I
+associated I
+factor I
+- I
+2 I
+mediates O
+activation O
+of O
+Rel B
+proteins I
+. O
+
+A O
+major O
+feature O
+of O
+this O
+genomic O
+sequence O
+is O
+the O
+presence O
+of O
+a O
+first O
+intron O
+( O
+Il O
+) O
+, O
+215 O
+bp O
+long O
+, O
+located O
+48 O
+bp O
+downstream O
+of O
+the O
+translation O
+start O
+ATG O
+codon O
+. O
+
+Experimental O
+studies O
+and O
+clinical O
+application O
+of O
+plasma O
+ACTH B
+radioimmunoassay O
+kit O
+without O
+extraction O
+process O
+
+In O
+the O
+cervical O
+enlargement O
+they O
+were O
+located O
+in O
+the O
+middle O
+part O
+of O
+lamina O
+VII O
+and O
+in O
+lamina O
+VIII O
+, O
+accounting O
+for O
+about O
+25 O
+% O
+of O
+the O
+total O
+labeled O
+neurons O
+. O
+
+Nature O
+and O
+incidence O
+of O
+conditioned O
+responses O
+in O
+a O
+methadone O
+population O
+: O
+a O
+comparison O
+of O
+laboratory O
+, O
+clinic O
+, O
+and O
+naturalistic O
+settings O
+. O
+
+While O
+some O
+still O
+automatically O
+refuse O
+all O
+patients O
+with O
+positive O
+mediastinoscopy O
+, O
+most O
+authors O
+still O
+remain O
+very O
+interventionistic O
+for O
+N2 O
+patients O
+selected O
+on O
+very O
+accurate O
+criteria O
+that O
+are O
+analyzed O
+above O
+. O
+
+Our O
+previous O
+studies O
+demonstrated O
+that O
+the O
+promyelocytic B
+leukemia I
+gene I
+, O
+PML B
+which O
+involved O
+in O
+the O
+15 O
+; O
+17 O
+translocation O
+in O
+acute O
+promyelocytic O
+leukemia O
+( O
+APL O
+) O
+is O
+a O
+growth O
+and O
+transformation O
+suppressor O
+. O
+
+A O
+sharp O
+transition O
+from O
+a O
+random O
+chaotic O
+state O
+to O
+a O
+correlated O
+turbulent O
+state O
+of O
+finite O
+coherence O
+time O
+is O
+found O
+when O
+the O
+Rayleigh O
+number O
+becomes O
+larger O
+than O
+a O
+critical O
+value O
+Ra O
+( O
+c O
+) O
+approximately O
+equal O
+to O
+5 O
+x O
+10 O
+( O
+7 O
+) O
+. O
+
+Our O
+data O
+define O
+Ile O
+( O
+16 O
+) O
+, O
+Val O
+( O
+18 O
+) O
+, O
+Val O
+( O
+31 O
+) O
+, O
+and O
+Ile O
+( O
+33 O
+) O
+as O
+crucial O
+for O
+protein B
+S I
+binding O
+, O
+with O
+secondary O
+effects O
+from O
+Leu O
+( O
+38 O
+) O
+and O
+Val O
+( O
+39 O
+) O
+. O
+
+In O
+the O
+yeast O
+two O
+- O
+hybrid O
+assays O
+, O
+PNRC B
+interacted O
+with O
+the O
+orphan O
+receptors O
+SF1 B
+and O
+ERRalpha1 B
+in O
+a O
+ligand O
+- O
+independent O
+manner O
+. O
+
+Nuclear O
+export O
+of O
+proteins O
+in O
+plants O
+: O
+AtXPO1 B
+is O
+the O
+export O
+receptor O
+for O
+leucine O
+- O
+rich O
+nuclear O
+export O
+signals O
+in O
+Arabidopsis O
+thaliana O
+. O
+
+Thus O
+, O
+CR2 B
+possesses O
+an O
+essential O
+function O
+besides O
+pRb B
+- O
+binding O
+. O
+
+From O
+the O
+autopsy O
+findings O
+, O
+in O
+5 O
+out O
+of O
+the O
+remaining O
+23 O
+expired O
+patients O
+, O
+Legionella O
+pneumonia O
+seemed O
+to O
+be O
+successfully O
+treated O
+, O
+but O
+other O
+disease O
+or O
+other O
+bacterial O
+pneumonia O
+put O
+an O
+end O
+to O
+the O
+patients O
+. O
+
+Nitroglycerin O
+( O
+glyceryl O
+trinitrate O
+) O
+as O
+a O
+monoamine B
+oxidase I
+inhibitor O
+. O
+
+This O
+high O
+dose O
+5 O
+- O
+FU O
++ O
+Act O
+- O
+D O
+protocol O
+was O
+effective O
+for O
+drug O
+resistant O
+cases O
+with O
+MEA O
+protocol O
+. O
+
+With O
+stimulation O
+beyond O
+the O
+theta O
+- O
+range O
+three O
+phenomena O
+occurred O
+: O
+shift O
+of O
+the O
+burst O
+frequencies O
+to O
+higher O
+or O
+lower O
+harmonics O
+of O
+stimulation O
+frequencies O
+; O
+complex O
+interactions O
+of O
+basic O
+background O
+frequency O
+with O
+rhythm O
+of O
+stimulation O
+( O
+" O
+beating O
+" O
+) O
+; O
+return O
+to O
+background O
+theta O
+- O
+burst O
+frequency O
+in O
+spite O
+of O
+continuing O
+stimulation O
+( O
+" O
+escape O
+" O
+) O
+. O
+
+CONCLUSIONS O
+: O
+Transpulmonary O
+stable O
+air O
+microbubbles O
+bound O
+to O
+a O
+galactose O
+carrier O
+represent O
+a O
+useful O
+and O
+safe O
+contrast O
+agent O
+in O
+case O
+of O
+an O
+insufficient O
+native O
+signal O
+in O
+transcranial O
+Doppler O
+investigation O
+. O
+
+K562 O
+erythroleukemia O
+cells O
+stably O
+transfected O
+with O
+constructs O
+containing O
+the O
+human B
+Agamma I
+- I
+globin I
+promoter O
+linked O
+to O
+an O
+enhanced B
+green I
+fluorescent I
+protein I
+( O
+EGFP B
+) O
+reporter O
+, O
+with O
+or O
+without O
+HS2 B
+, O
+were O
+analyzed O
+for O
+EGFP B
+expression O
+by O
+flow O
+cytometry O
+. O
+
+Gastrin B
+stimulates O
+transcription O
+of O
+the O
+human B
+histidine I
+decarboxylase I
+( O
+HDC B
+) O
+gene O
+through O
+binding O
+to O
+the O
+G B
+- I
+protein I
+- I
+coupled I
+cholecystokinin I
+- I
+B I
+/ O
+gastrin B
+receptor I
+. O
+
+Here O
+, O
+we O
+report O
+the O
+isolation O
+of O
+a O
+new O
+spindle O
+checkpoint O
+gene O
+, O
+mph1 B
+( O
+Mps1p B
+- I
+like I
+pombe I
+homolog I
+) O
+, O
+in O
+the O
+fission O
+yeast O
+Schizosaccharomyces O
+pombe O
+, O
+that O
+is O
+required O
+for O
+checkpoint O
+activation O
+in O
+response O
+to O
+spindle O
+defects O
+. O
+
+mph1 B
+functions O
+upstream O
+of O
+mad2 B
+, O
+a O
+previously O
+characterized O
+component O
+of O
+the O
+spindle O
+checkpoint O
+. O
+
+Hepatocyte B
+growth I
+factor I
+( O
+HGF B
+) O
+is O
+an O
+inducible O
+cytokine O
+that O
+is O
+essential O
+for O
+the O
+normal O
+growth O
+and O
+development O
+of O
+various O
+tissues O
+, O
+such O
+as O
+the O
+liver O
+. O
+
+However O
+, O
+all O
+pathophysiologic O
+assessments O
+reported O
+to O
+date O
+have O
+been O
+carried O
+out O
+during O
+or O
+immediately O
+after O
+IVOX O
+utilization O
+. O
+
+Reduced O
+concentrations O
+of O
+antithrombin B
+III I
+, O
+plasminogen B
+, O
+( B
+free I
+) I
+protein I
+S I
+, O
+and O
+protein B
+C I
+were O
+found O
+in O
+some O
+patients O
+but O
+were O
+not O
+associated O
+with O
+either O
+thrombosis O
+or O
+lupus O
+anticoagulant O
+. O
+
+The O
+first O
+decision O
+in O
+management O
+is O
+to O
+consider O
+cardioversion O
+which O
+can O
+be O
+achieved O
+in O
+suitable O
+cases O
+electrically O
+, O
+or O
+pharmacologically O
+with O
+a O
+class O
+Ic O
+antiarrhythmic O
+drug O
+like O
+flecainide O
+or O
+propafenone O
+. O
+
+Structure O
+and O
+chromosomal O
+localization O
+of O
+the O
+human O
+gene O
+of O
+the O
+phosphotyrosyl B
+phosphatase I
+activator I
+( O
+PTPA B
+) O
+of O
+protein B
+phosphatase I
+2A I
+. O
+
+R O
+of O
+the O
+chest O
+wall O
+was O
+maximum O
+( O
+35 O
+. O
+6 O
+cmH2O O
+. O
+L O
+- O
+1 O
+. O
+sec O
+- O
+1 O
++ O
+/ O
+- O
+2 O
+. O
+2 O
+SE O
+) O
+at O
+0 O
+. O
+2 O
+Hz O
+- O
+10 O
+ml O
+and O
+decreased O
+with O
+increasing O
+f O
+and O
+VT O
+, O
+although O
+the O
+VT O
+effect O
+diminished O
+at O
+the O
+higher O
+f O
+. O
+
+Since O
+1988 O
+Modulit O
+- O
+SZ O
+- O
+20 O
+has O
+been O
+tested O
+for O
+localization O
+of O
+nephroliths O
+and O
+ureteroliths O
+. O
+
+JCAHO O
+moves O
+to O
+rewrite O
+many O
+rules O
+to O
+lessen O
+hospitals O
+' O
+regulatory O
+burden O
+. O
+
+These O
+transcripts O
+directed O
+the O
+synthesis O
+of O
+three O
+proteins O
+: O
+the O
+virus B
+trans I
+- I
+activator I
+protein I
+( O
+EIAV B
+Tat I
+) O
+encoded O
+by O
+ORF B
+S1 B
+, O
+a O
+protein O
+of O
+unknown O
+function O
+encoded O
+by O
+ORF O
+S2 I
+, O
+and O
+the O
+virus B
+envelope I
+glycoprotein I
+. O
+
+However O
+, O
+no O
+significant O
+difference O
+in O
+either O
+the O
+Valsalva O
+ratio O
+or O
+delta O
+SBP O
+was O
+found O
+between O
+diabetic O
+patients O
+and O
+controls O
+. O
+
+Transmural O
+metabolic O
+heterogeneity O
+at O
+high O
+cardiac O
+work O
+states O
+. O
+
+We O
+therefore O
+investigated O
+whether O
+the O
+promoter O
+activity O
+of O
+the O
+mouse B
+TRH I
+gene I
+is O
+directly O
+regulated O
+by O
+RA O
+using O
+a O
+transient O
+transfection O
+assay O
+into O
+CV O
+- O
+1 O
+cells O
+. O
+
+Spinal O
+injuries O
+in O
+a O
+multiple O
+trauma O
+patient O
+. O
+
+The O
+unusual O
+properties O
+of O
+TRAC B
+activity O
+and O
+its O
+relationship O
+, O
+if O
+any O
+, O
+with O
+the O
+enigmatic O
+Ku B
+protein I
+, O
+are O
+discussed O
+. O
+
+Statistical O
+aspects O
+of O
+the O
+relation O
+of O
+the O
+radioprotective O
+action O
+of O
+mercaptoethylamine O
+derivatives O
+and O
+analogs O
+to O
+their O
+electron O
+parameters O
+
+Cerebellar O
+functional O
+compensation O
+after O
+its O
+complete O
+destruction O
+by O
+a O
+neoplasm O
+
+The O
+RNA O
+, O
+whether O
+antisense O
+, O
+ribozyme O
+, O
+or O
+RNA O
+aptamer O
+, O
+must O
+be O
+efficiently O
+transcribed O
+, O
+stabilized O
+against O
+rapid O
+degradation O
+, O
+folded O
+correctly O
+, O
+and O
+directed O
+to O
+the O
+part O
+of O
+the O
+cell O
+where O
+it O
+can O
+be O
+most O
+effective O
+. O
+
+We O
+have O
+isolated O
+and O
+determined O
+the O
+complete O
+nucleotide O
+sequence O
+of O
+another O
+operon O
+, O
+cpeCD B
+, O
+that O
+encodes O
+the O
+linker O
+proteins O
+associated O
+with O
+phycoerythrin B
+hexamers I
+in O
+the O
+phycobilisome O
+. O
+
+A B
+. I
+thaliana I
+cystathionine I
+beta I
+- I
+lyase I
+exhibits O
+22 O
+% O
+sequence O
+identity O
+with O
+the O
+E O
+. O
+coli O
+corresponding O
+enzyme O
+and O
+contains O
+a O
+70 O
+amino O
+acid O
+N O
+- O
+terminal O
+additional O
+sequence O
+compared O
+with O
+the O
+bacterial O
+protein O
+. O
+
+The O
+enzyme O
+ACC B
+oxidase I
+catalyses O
+the O
+last O
+step O
+of O
+ethylene O
+biosynthesis O
+in O
+plants O
+, O
+converting O
+1 O
+- O
+aminocyclopropane O
+- O
+1 O
+- O
+carboxylic O
+acid O
+( O
+ACC O
+) O
+to O
+ethylene O
+. O
+
+A O
+99m O
+Tc O
+bone O
+scan O
+showed O
+a O
+focal O
+area O
+of O
+an O
+increased O
+uptake O
+at O
+the O
+site O
+of O
+the O
+mass O
+below O
+the O
+calcaneus O
+. O
+
+Renal O
+function O
+was O
+evaluated O
+in O
+a O
+group O
+of O
+24 O
+patients O
+( O
+21 O
+men O
+and O
+3 O
+women O
+, O
+mean O
+age O
+47 O
+years O
+) O
+who O
+had O
+survived O
+the O
+malignant O
+phase O
+of O
+hypertension O
+during O
+the O
+period O
+of O
+1969 O
+- O
+1979 O
+. O
+
+The O
+need O
+for O
+such O
+guidelines O
+is O
+clear O
+on O
+both O
+clinical O
+and O
+scientific O
+grounds O
+. O
+
+When O
+expressed O
+in O
+thymidine B
+kinase I
+- O
+deficient O
+L O
+cells O
+or O
+3T3 O
+cells O
+, O
+C B
+/ I
+EBPalpha I
+is O
+detected O
+in O
+a O
+protein O
+complex O
+which O
+binds O
+to O
+the O
+E2F B
+binding I
+sites I
+found O
+in O
+the O
+promoters O
+of O
+the O
+genes O
+for O
+E2F B
+- I
+1 I
+and O
+dihydrofolate B
+reductase I
+( O
+DHFR B
+) O
+. O
+
+Members O
+of O
+the O
+CRE B
+- I
+binding I
+protein I
+( O
+CREB B
+) O
+/ O
+activating B
+transcription I
+factor I
+transcription O
+family O
+as O
+well O
+as O
+members O
+of O
+the O
+Jun B
+/ O
+Fos B
+family O
+have O
+been O
+shown O
+to O
+bind O
+to O
+this O
+sequence O
+. O
+
+Csk B
+( O
+C B
+- I
+terminal I
+Src I
+kinase I
+) O
+is O
+a O
+protein B
+tyrosine I
+kinase I
+that O
+phosphorylates O
+Src B
+family I
+member O
+C O
+- O
+terminal O
+tails O
+, O
+resulting O
+in O
+downregulation O
+of O
+Src B
+family I
+members I
+. O
+
+Role O
+of O
+double B
+- I
+stranded I
+RNA I
+- I
+dependent I
+protein I
+kinase I
+in O
+mediating O
+hypersensitivity O
+of O
+Fanconi O
+anemia I
+complementation O
+group O
+C O
+cells O
+to O
+interferon B
+gamma I
+, O
+tumor B
+necrosis I
+factor I
+- I
+alpha I
+, O
+and O
+double O
+- O
+stranded O
+RNA O
+. O
+
+In O
+clinical O
+stroke O
+cardiovascular O
+abnormalities O
+are O
+frequently O
+neglected O
+although O
+they O
+occur O
+more O
+often O
+than O
+it O
+is O
+generally O
+assumed O
+. O
+
+In O
+the O
+presence O
+of O
+high O
+concentrations O
+( O
+propofol O
+100 O
+microg O
+mL O
+- O
+1 O
+, O
+thiopental O
+50 O
+microg O
+mL O
+- O
+1 O
+) O
+marked O
+relaxation O
+was O
+observed O
+( O
+propofol O
+- O
+32 O
+% O
+up O
+to O
+- O
+49 O
+% O
+, O
+P O
+< O
+0 O
+, O
+05 O
+; O
+thiopental O
+- O
+23 O
+% O
+up O
+to O
+- O
+67 O
+% O
+, O
+P O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+Our O
+results O
+suggest O
+a O
+dose O
+- O
+dependent O
+activity O
+of O
+lysine B
+vasopressin I
+on O
+the O
+EEG O
+, O
+which O
+might O
+be O
+similar O
+to O
+that O
+observed O
+in O
+animal O
+and O
+man O
+after O
+administration O
+of O
+nicotine O
+. O
+
+Mutations O
+of O
+the O
+human B
+PTEN I
+gene I
+. O
+
+Guanylyl B
+cyclase I
+C I
+, O
+the O
+apparent O
+guanylin B
+receptor I
+, O
+was O
+found O
+in O
+abundant O
+amounts O
+in O
+the O
+intestine O
+by O
+Northern O
+analysis O
+, O
+and O
+by O
+the O
+polymerase O
+chain O
+reaction O
+or O
+cDNA O
+cloning O
+it O
+was O
+also O
+found O
+in O
+adrenal O
+gland O
+, O
+airway O
+epithelial O
+cells O
+, O
+brain O
+, O
+and O
+olfactory O
+and O
+tracheal O
+mucosa O
+. O
+
+In O
+the O
+present O
+study O
+we O
+have O
+used O
+Southern O
+blot O
+analysis O
+to O
+demonstrate O
+that O
+TSG6 B
+is O
+a O
+single O
+- O
+copy O
+gene O
+in O
+the O
+human O
+and O
+murine O
+species O
+. O
+
+Reaction O
+of O
+aromatic O
+/ O
+heterocyclic O
+sulfonamides O
+possessing O
+free O
+amino O
+, O
+imino O
+or O
+hydrazino O
+moieties O
+with O
+7 O
+- O
+chloro O
+- O
+4 O
+- O
+chloromethylcoumarin O
+afforded O
+a O
+series O
+of O
+N O
+- O
+[ O
+( O
+7 O
+- O
+chloro O
+- O
+4 O
+- O
+coumarinyl O
+) O
+- O
+methyl O
+] O
+- O
+derivatives O
+which O
+showed O
+effective O
+inhibition O
+of O
+three O
+carbonic B
+anhydrase I
+( O
+CA B
+) O
+isozymes O
+. O
+
+As O
+well O
+, O
+variation O
+in O
+capillary O
+size O
+and O
+density O
+was O
+apparent O
+between O
+ventricles O
+in O
+the O
+fetal O
+and O
+neonatal O
+periods O
+. O
+
+The O
+Polycomb B
+group I
+proteins I
+are O
+involved O
+in O
+maintenance O
+of O
+the O
+silenced O
+state O
+of O
+several O
+developmentally O
+regulated O
+genes O
+. O
+
+Uncertainty O
+exists O
+about O
+the O
+function O
+of O
+these O
+potential O
+isoforms O
+of O
+the O
+Cbfa1 B
+gene I
+. O
+
+When O
+using O
+the O
+high O
+- O
+impedance O
+testing O
+device O
+, O
+the O
+post O
+shock O
+rhythm O
+was O
+initially O
+displayed O
+as O
+' O
+no O
+signal O
+' O
+( O
+Hewlett O
+Packard O
+XL O
+) O
+or O
+' O
+asystole O
+' O
+( O
+Physio O
+- O
+Control O
+LIFEPAK O
+9 O
+) O
+. O
+
+Human B
+CD38 I
+, O
+a O
+leukocyte O
+receptor O
+and O
+ectoenzyme O
+, O
+is O
+a O
+member O
+of O
+a O
+novel O
+eukaryotic O
+gene O
+family O
+of O
+nicotinamide B
+adenine I
+dinucleotide I
++ I
+- I
+converting I
+enzymes I
+: O
+extensive O
+structural O
+homology O
+with O
+the O
+genes O
+for O
+murine B
+bone I
+marrow I
+stromal I
+cell I
+antigen I
+1 I
+and O
+aplysian B
+ADP I
+- I
+ribosyl I
+cyclase I
+. O
+
+It O
+is O
+noteworthy O
+that O
+under O
+more O
+physiological O
+conditions O
+mimicking O
+the O
+cellular O
+GDP O
+/ O
+GTP O
+ratio O
+, O
+Raf B
+enhances O
+the O
+GEF B
+- O
+stimulated O
+GDP O
+/ O
+GTP O
+exchange O
+on O
+Ha B
+- I
+Ras I
+, O
+in O
+agreement O
+with O
+the O
+sequestration O
+of O
+Ras B
+. I
+GTP I
+by O
+Raf B
+. O
+
+When O
+O O
+- O
+2A O
+/ O
+c B
+- I
+myc I
+cells O
+underwent O
+terminal O
+differentiation O
+APprog B
+complexes O
+were O
+lost O
+and O
+conventional O
+AP B
+- I
+1 I
+DNA O
+- O
+binding O
+activity O
+became O
+evident O
+, O
+particularly O
+in O
+astrocytes O
+. O
+
+From O
+the O
+deduced O
+amino O
+acid O
+sequence O
+, O
+a O
+molecular O
+weight O
+of O
+38 O
+, O
+549 O
+was O
+calculated O
+for O
+the O
+ADH B
+subunit I
+. O
+
+The O
+higher O
+level O
+of O
+calories O
+was O
+attained O
+by O
+an O
+increased O
+intake O
+of O
+carbohydrates O
+. O
+
+A O
+simple O
+algorithm O
+fitting O
+the O
+data O
+for O
+the O
+moving O
+192Ir O
+source O
+is O
+proposed O
+. O
+
+TAF B
+- I
+1 I
+activates O
+transcription O
+constitutively O
+and O
+was O
+mapped O
+to O
+the O
+first O
+32 O
+amino O
+acids O
+of O
+the O
+A O
+- O
+region O
+. O
+
+For O
+the O
+first O
+, O
+short O
+- O
+term O
+( O
+concurrent O
+) O
+TAL O
+, O
+two O
+different O
+- O
+flavored O
+stimuli O
+were O
+presented O
+at O
+the O
+same O
+time O
+, O
+one O
+associated O
+with O
+simultaneous O
+intragastric O
+administration O
+of O
+an O
+aversive O
+product O
+, O
+hypertonic O
+NaCl O
+, O
+and O
+the O
+other O
+with O
+saline O
+. O
+
+The O
+great O
+cardiac O
+vein O
+flow O
+became O
+zero O
+due O
+to O
+the O
+cardiac O
+arrest O
+and O
+remained O
+at O
+zero O
+for O
+a O
+moment O
+( O
+dead O
+time O
+) O
+after O
+the O
+initiation O
+of O
+reperfusion O
+. O
+
+INTERNET O
+is O
+literally O
+a O
+world O
+of O
+data O
+, O
+dialogue O
+, O
+and O
+discourse O
+on O
+any O
+topic O
+imaginable O
+, O
+right O
+at O
+your O
+fingertips O
+. O
+
+Attention O
+is O
+devoted O
+in O
+particular O
+to O
+the O
+action O
+of O
+thermoregulating O
+nervous O
+and O
+hormonal O
+mechanisms O
+. O
+
+The O
+mammalian O
+UPR O
+is O
+mediated O
+by O
+the O
+cis O
+- O
+acting O
+ER O
+stress O
+response O
+element O
+consisting O
+of O
+19 O
+nt O
+( O
+CCAATN O
+( O
+9 O
+) O
+CCACG O
+) O
+, O
+the O
+CCACG O
+part O
+of O
+which O
+is O
+considered O
+to O
+provide O
+specificity O
+. O
+
+The O
+formation O
+of O
+a O
+D O
+- O
+loop O
+is O
+an O
+essential O
+step O
+in O
+DNA O
+double O
+- O
+strand O
+break O
+repair O
+through O
+recombination O
+. O
+
+The O
+cDNA O
+is O
+predicted O
+to O
+encode O
+a O
+polypeptide O
+of O
+298 O
+amino O
+acids O
+that O
+is O
+homologous O
+to O
+the O
+Y B
+- I
+box I
+( I
+inverted I
+CCAAT I
+) I
+family I
+of I
+DNA I
+- I
+binding I
+transcription I
+factors I
+. O
+
+Toward O
+this O
+end O
+, O
+we O
+used O
+two O
+cultured O
+colon O
+cancer O
+cell O
+lines O
+; O
+one O
+( O
+RKO O
+) O
+has O
+a O
+transcriptionally O
+activated O
+u B
+- I
+PAR I
+gene I
+, O
+and O
+the O
+other O
+( O
+GEO O
+) O
+overexpresses O
+the O
+receptor O
+only O
+after O
+phorbol O
+ester O
+treatment O
+. O
+
+Site O
+- O
+directed O
+mutagenesis O
+of O
+the O
+conserved O
+cysteine O
+residue O
+( O
+tom1C3235A B
+) O
+in O
+the O
+hect B
+- I
+domain I
+, O
+supposed O
+to O
+be O
+necessary O
+for O
+thioester O
+- O
+bond O
+formation O
+with O
+ubiquitin B
+, O
+abolished O
+the O
+gene O
+function O
+. O
+
+The O
+two O
+yeast B
+pheromone I
+receptors I
+, O
+the O
+a B
+and I
+alpha I
+- I
+factor I
+receptors I
+, O
+share O
+many O
+functional O
+similarities O
+: O
+both O
+G B
+protein I
+- I
+coupled I
+receptors I
+couple O
+to O
+the O
+same O
+downstream O
+signal O
+transduction O
+pathway O
+, O
+and O
+both O
+receptors O
+undergo O
+feedback O
+regulation O
+involving O
+increased O
+phosphorylation O
+on O
+their O
+C O
+- O
+terminal O
+domains O
+in O
+response O
+to O
+ligand O
+challenge O
+. O
+
+Moreover O
+, O
+the O
+formation O
+of O
+the O
+complex O
+between O
+IclR B
+and O
+the O
+operator O
+/ O
+promoter O
+region O
+has O
+been O
+found O
+to O
+be O
+impaired O
+by O
+phosphoenol O
+pyruvate O
+but O
+insensitive O
+to O
+acetate O
+, O
+acetyl O
+- O
+CoA O
+, O
+pyruvate O
+, O
+and O
+oxaloacetate O
+. O
+
+After O
+enzymatic O
+hydrolysis O
+of O
+the O
+water O
+soluble O
+fraction O
+, O
+it O
+is O
+shown O
+that O
+28 O
+% O
+is O
+again O
+extractable O
+by O
+DCM O
+of O
+which O
+57 O
+% O
+consists O
+of O
+unchanged O
+SC4453 O
+which O
+is O
+therefore O
+the O
+main O
+partner O
+of O
+conjugated O
+products O
+. O
+
+The O
+expression O
+pattern O
+of O
+the O
+reporter O
+gene O
+was O
+compared O
+to O
+that O
+of O
+the O
+endogenous B
+PDGFbeta I
+r I
+gene I
+. O
+
+The O
+two O
+SH3 B
+domains I
+are O
+separated O
+by O
+a O
+54 O
+amino O
+acid O
+linker O
+region O
+, O
+whose O
+length O
+is O
+highly O
+conserved O
+in O
+xenopus O
+, O
+chicken O
+, O
+and O
+mamalian B
+Crk I
+II I
+proteins I
+. O
+
+This O
+complex O
+was O
+eliminated O
+by O
+mutation O
+of O
+either O
+half O
+- O
+site O
+, O
+and O
+it O
+was O
+supershifted O
+by O
+antibodies O
+against O
+chicken B
+ovalbumin I
+upstream I
+promoter I
+- I
+transcription I
+factor I
+( O
+COUP B
+- I
+TF I
+) O
+. O
+
+The O
+fz B
+- I
+1 I
+and O
+fz B
+- I
+2 I
+genes I
+are O
+widely O
+expressed O
+in O
+rat O
+tissues O
+with O
+the O
+highest O
+steady O
+- O
+state O
+levels O
+of O
+mRNA O
+in O
+kidney O
+, O
+liver O
+, O
+heart O
+, O
+uterus O
+, O
+and O
+ovary O
+. O
+
+fz B
+- I
+1 I
+and I
+- I
+2 I
+mRNA I
+levels O
+were O
+greater O
+in O
+neonatal O
+than O
+in O
+corresponding O
+adult O
+tissues O
+. O
+
+These O
+results O
+indicate O
+that O
+the O
+changes O
+in O
+the O
+patient O
+' O
+s O
+thyroid O
+scan O
+and O
+RAIU O
+were O
+attributable O
+to O
+the O
+presence O
+of O
+TSAb O
+. O
+
+The O
+methods O
+used O
+were O
+the O
+AOAC O
+method O
+of O
+dilution O
+and O
+heating O
+; O
+the O
+addition O
+of O
+mercuric O
+chloride O
+, O
+charcoal O
+, O
+and O
+Carrez O
+reagents O
+at O
+2 O
+different O
+pH O
+values O
+; O
+and O
+direct O
+analysis O
+of O
+sample O
+supernatants O
+with O
+no O
+treatment O
+( O
+control O
+) O
+. O
+
+Cytochemical O
+and O
+ultrastructural O
+observations O
+on O
+the O
+tegument O
+of O
+the O
+trematode O
+Megalodiscus O
+temperatus O
+. O
+
+In O
+this O
+report O
+, O
+we O
+establish O
+that O
+the O
+heteromeric B
+CCAAT I
+- I
+binding I
+factor I
+CBF I
+is O
+the O
+major O
+component O
+of O
+the O
+C1 B
+- I
+binding I
+factor I
+( O
+C1F B
+) O
+in O
+human O
+cells O
+. O
+
+A O
+40 O
+- O
+fold O
+stimulation O
+of O
+chloramphenicol B
+acetyltransferase I
+activity O
+mediated O
+by O
+four O
+tandem O
+repeats O
+of O
+the O
+SNE O
+could O
+be O
+induced O
+within O
+2 O
+h O
+( O
+and O
+up O
+to O
+250 O
+- O
+fold O
+within O
+6 O
+h O
+) O
+after O
+addition O
+of O
+TPA O
+in O
+DNA O
+- O
+transfected O
+U O
+- O
+937 O
+cells O
+, O
+indicating O
+that O
+the O
+stimulation O
+appeared O
+likely O
+to O
+be O
+a O
+true O
+protein B
+kinase I
+C I
+- O
+mediated O
+signal O
+transduction O
+event O
+rather O
+than O
+a O
+differentiation O
+response O
+. O
+
+This O
+increased O
+frequency O
+of O
+infection O
+has O
+been O
+accompanied O
+by O
+significant O
+excess O
+mortality O
+. O
+
+Deletion O
+mutants O
+of O
+the O
+human B
+CHOP I
+promoter I
+identify O
+a O
+region O
+comprising O
+nucleotides O
+- O
+75 O
+to O
+- O
+104 O
+required O
+for O
+both O
+constitutive O
+and O
+ER O
+- O
+stress O
+- O
+inducible O
+expression O
+. O
+
+The O
+duration O
+of O
+PGE2 O
+and O
+PGF2 O
+alpha O
+elevations O
+as O
+well O
+as O
+the O
+peak O
+values O
+were O
+influenced O
+by O
+day O
+of O
+the O
+cycle O
+. O
+
+We O
+propose O
+that O
+the O
+cDNA O
+encodes O
+an O
+apical O
+plasma O
+membrane O
+protein O
+that O
+plays O
+a O
+role O
+in O
+the O
+functional O
+expression O
+of O
+the O
+amiloride O
+- O
+sensitive O
+epithelial B
+sodium I
+channel I
+. O
+
+Electrophysiology O
+and O
+pharmacology O
+of O
+epicardial O
+, O
+endocardial O
+, O
+and O
+M O
+cells O
+. O
+
+In O
+contrast O
+, O
+an O
+N B
+- I
+terminal I
+RNAP I
+mutant I
+that O
+has O
+a O
+decreased O
+capacity O
+to O
+bind O
+single O
+- O
+stranded O
+RNA O
+forms O
+halted O
+complexes O
+with O
+much O
+lower O
+levels O
+of O
+stability O
+than O
+the O
+WT O
+enzyme O
+, O
+and O
+these O
+complexes O
+are O
+not O
+stabilized O
+by O
+the O
+presence O
+of O
+the O
+NT O
+strand O
+. O
+
+A O
+cephalothoracophagus O
+disymmetros O
+buffalo O
+calf O
+. O
+
+A O
+mouse O
+brain O
+cDNA O
+library O
+in O
+lambdagt11 O
+was O
+screened O
+for O
+this O
+association O
+, O
+and O
+two O
+positive O
+clones O
+encoding O
+tyrosine B
+phosphatase I
+SH B
+- I
+PTP2 I
+were O
+isolated O
+. O
+
+Disorganization O
+scores O
+of O
+the O
+hypertrophy O
+zone O
+and O
+trabecular O
+bone O
+were O
+low O
+, O
+approaching O
+normal O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+, O
+for O
+turkey O
+poults O
+fed O
+on O
+diets O
+with O
+phytase B
+supplementation O
+, O
+and O
+tibial O
+abnormality O
+scores O
+were O
+linearly O
+decreased O
+( O
+P O
+< O
+0 O
+. O
+001 O
+) O
+as O
+nP O
+levels O
+increased O
+( O
+zero O
+score O
+is O
+considered O
+normal O
+) O
+. O
+
+Repression O
+was O
+strictly O
+dependent O
+on O
+the O
+presence O
+of O
+upstream O
+Oshox1 B
+binding I
+sites I
+in O
+the O
+reporter O
+gene O
+constructs O
+and O
+a O
+function O
+of O
+the O
+N O
+- O
+terminal O
+region O
+of O
+Oshox1 B
+, O
+preceding O
+the O
+homeodomain B
+. O
+
+Ondansetron O
+is O
+thus O
+an O
+effective O
+first O
+- O
+line O
+antiemetic O
+in O
+children O
+undergoing O
+chemotherapy O
+, O
+radiotherapy O
+and O
+surgery O
+. O
+
+To O
+elucidate O
+the O
+molecular O
+mechanism O
+by O
+which O
+the O
+Ras B
+signaling O
+pathway O
+activates O
+a O
+cell O
+- O
+type O
+- O
+specific O
+gene O
+, O
+we O
+have O
+used O
+the O
+pituitary B
+- I
+specific I
+rat I
+prolactin I
+( O
+rPRL B
+) O
+promoter O
+as O
+a O
+target O
+of O
+oncogenic B
+Ras I
+and O
+Raf B
+in O
+GH4 O
+rat O
+pituitary O
+cells O
+. O
+
+The O
+human B
+RFC I
+- I
+1 I
+gene I
+differs O
+from O
+the O
+mouse O
+and O
+hamster O
+genes O
+both O
+in O
+terms O
+of O
+the O
+total O
+number O
+of O
+exons O
+and O
+in O
+regard O
+to O
+alternatives O
+of O
+exon O
+1 O
+which O
+encode O
+5 O
+' O
+end O
+heterogeneity O
+. O
+
+Type O
+C O
+units O
+summate O
+the O
+responses O
+to O
+the O
+two O
+- O
+tone O
+stimulus O
+, O
+and O
+show O
+little O
+or O
+no O
+inhibitory O
+influences O
+. O
+
+HGF B
+treatment O
+increased O
+cyclin B
+A I
+, O
+cyclin B
+G1 I
+and O
+nuclear B
+transcriptional I
+factor I
+( O
+NFkappaB I
+) O
+protein O
+expression O
+. O
+
+Since O
+blood O
+serotonin O
+is O
+primarily O
+produced O
+peripherally O
+, O
+these O
+results O
+suggest O
+that O
+some O
+aspect O
+of O
+peripheral O
+serotonin O
+metabolism O
+is O
+abnormal O
+in O
+major O
+depression O
+. O
+
+Although O
+several O
+large O
+waterborne O
+outbreaks O
+occurred O
+during O
+the O
+past O
+decade O
+, O
+most O
+were O
+in O
+small O
+communities O
+. O
+
+Cytogenetic O
+structures O
+showed O
+a O
+mixte O
+karyotype O
+: O
+mosaicim O
+46 O
+XX O
+/ O
+46 O
+XY O
+with O
+a O
+ratio O
+of O
+a O
+80 O
+/ O
+20 O
+. O
+
+The O
+1 O
+. O
+6 O
+- O
+kb O
+cDNA O
+( O
+CBF B
+- I
+A I
+) O
+encoding O
+285 O
+amino O
+acids O
+( O
+aa O
+) O
+was O
+obtained O
+, O
+and O
+a O
+beta B
+- I
+galactosidase I
+fusion I
+protein I
+, O
+bacterially O
+produced O
+from O
+the O
+cDNA O
+, O
+bound O
+to O
+DNA O
+fragments O
+containing O
+several O
+CArG O
+boxes O
+. O
+
+Mutant B
+M I
+proteins I
+were O
+tested O
+for O
+their O
+ability O
+to O
+complement O
+growth O
+of O
+the O
+temperature B
+- I
+sensitive I
+M I
+protein I
+mutant I
+virus I
+tsO23 O
+at O
+the O
+nonpermissive O
+temperature O
+. O
+
+In O
+this O
+paper O
+we O
+review O
+evidence O
+on O
+smoking O
+and O
+lung O
+cancer O
+among O
+Latinos O
+, O
+including O
+findings O
+from O
+several O
+unpublished O
+studies O
+and O
+technical O
+reports O
+. O
+
+The O
+yjr041c B
+delta O
+haploid O
+cells O
+gave O
+rise O
+to O
+microcolonies O
+comprising O
+about O
+20 O
+to O
+50 O
+cells O
+. O
+
+Despite O
+these O
+high O
+initial O
+rates O
+of O
+transcription O
+, O
+of O
+all O
+the O
+promoter O
+constructs O
+only O
+LAT B
+- I
+LTR I
+was O
+able O
+to O
+remain O
+transcriptionally O
+active O
+after O
+the O
+establishment O
+of O
+a O
+latent O
+state O
+. O
+
+Two O
+mutants O
+, O
+mapping O
+at O
+the O
+HindIII B
+site I
+( O
+between O
+the O
+consensus O
+sequences O
+) O
+of O
+the O
+pSC101 B
+tetA I
+promoter I
+, O
+were O
+studied O
+: O
+MA2 B
+corresponds O
+to O
+a O
+4 O
+bp O
+deletion O
+between O
+positions O
+- O
+12 O
+and O
+- O
+15 O
+; O
+B30 O
+bears O
+a O
+44 O
+bp O
+insertion O
+C O
+( O
+TA O
+) O
+21 O
+G O
+at O
+the O
+HindIII B
+site I
+. O
+
+We O
+concluded O
+that O
+these O
+results O
+support O
+the O
+feasibility O
+and O
+usefulness O
+of O
+N O
+- O
+of O
+- O
+1 O
+RCT O
+in O
+rheumatology O
+practice O
+. O
+
+Sci O
+. O
+
+Effects O
+of O
+timepidium O
+bromide O
+( O
+TB O
+; O
+anticholinergic O
+agent O
+) O
+, O
+acetylcholine O
+( O
+ACh O
+) O
+and O
+neostigmine O
+( O
+Neost O
+) O
+on O
+gastric O
+and O
+duodenal O
+blood O
+flow O
+distribution O
+were O
+studied O
+by O
+the O
+use O
+of O
+131I O
+- O
+labeled O
+macroaggregated B
+human I
+serum I
+albumin I
+( O
+MAA B
+) O
+in O
+rabbits O
+. O
+
+These O
+extrachromosomal O
+copies O
+can O
+be O
+isolated O
+as O
+covalently O
+closed O
+molecules O
+with O
+lengths O
+around O
+3mu O
+. O
+
+Comparison O
+of O
+the O
+footprint O
+patterns O
+of O
+the O
+mouse O
+and O
+human B
+HPRT I
+genes I
+demonstrated O
+that O
+the O
+in O
+vivo O
+binding O
+of O
+regulatory O
+proteins O
+between O
+these O
+species O
+is O
+generally O
+conserved O
+but O
+not O
+identical O
+. O
+
+Here O
+, O
+we O
+describe O
+the O
+three O
+- O
+dimensional O
+structure O
+of O
+the O
+enzyme O
+from O
+Escherichia O
+colidetermined O
+and O
+refined O
+to O
+2 O
+. O
+0 O
+A O
+resolution O
+. O
+
+Our O
+Northern O
+and O
+Southern O
+blot O
+analyses O
+of O
+meningiomas O
+clearly O
+suggest O
+the O
+CLH B
+- I
+22 I
+gene I
+may O
+be O
+involved O
+in O
+the O
+tumor O
+development O
+and O
+can O
+be O
+considered O
+as O
+a O
+candidate O
+for O
+a O
+tumor O
+suppressor O
+. O
+
+Plasmodium O
+vivax O
+malaria O
+. O
+
+This O
+set O
+of O
+genetic O
+and O
+physical O
+interactions O
+suggests O
+a O
+role O
+for O
+yeast O
+RNA O
+- O
+binding O
+proteins O
+in O
+transcriptional O
+regulation O
+. O
+
+POPULATION O
+AND O
+METHODS O
+: O
+105 O
+patients O
+were O
+followed O
+prospectively O
+( O
+male O
+: O
+87 O
+% O
+; O
+age O
+: O
+56 O
++ O
+/ O
+- O
+10 O
+) O
+; O
+clinical O
+evaluation O
+was O
+performed O
+in O
+the O
+1st O
+, O
+3rd O
+and O
+6th O
+month O
+, O
+SEKG O
+in O
+the O
+4th O
+month O
+and O
+recatheterization O
+for O
+angiographic O
+control O
+in O
+the O
+6th O
+month O
+. O
+
+All O
+other O
+cysts O
+showed O
+a O
+unilocular O
+, O
+purely O
+cystic O
+pattern O
+, O
+with O
+homogeneous O
+fluids O
+, O
+although O
+the O
+T2 O
+relaxation O
+times O
+of O
+four O
+lesions O
+overlapped O
+those O
+of O
+odontogenic O
+keratocysts O
+. O
+
+Genetic O
+diagnosis O
+of O
+respiratory O
+diseases O
+
+The O
+c B
+- I
+Jun I
+delta I
+- I
+domain I
+inhibits O
+neuroendocrine O
+promoter O
+activity O
+in O
+a O
+DNA O
+sequence O
+- O
+and O
+pituitary O
+- O
+specific O
+manner O
+. O
+
+Cross O
+- O
+sectional O
+studies O
+continue O
+to O
+dominate O
+. O
+
+The O
+role O
+of O
+the O
+medical O
+facilities O
+in O
+the O
+prognosis O
+of O
+the O
+patient O
+with O
+tetanus O
+specially O
+the O
+importance O
+of O
+considering O
+at O
+the O
+same O
+time O
+the O
+severity O
+of O
+the O
+disease O
+and O
+the O
+characteristics O
+of O
+the O
+therapy O
+deserve O
+further O
+study O
+in O
+order O
+to O
+contribute O
+to O
+the O
+development O
+of O
+the O
+medical O
+assistance O
+to O
+the O
+patients O
+with O
+tetanus O
+. O
+
+Differences O
+were O
+not O
+found O
+in O
+colons O
+by O
+SEM O
+. O
+
+Increasing O
+the O
+height O
+of O
+the O
+agar O
+column O
+overlying O
+the O
+SN O
+fabric O
+diminished O
+the O
+inhibitory O
+effect O
+of O
+SN O
+on O
+microbial O
+growth O
+. O
+
+Neither O
+raw O
+nor O
+retrograded O
+resistant O
+starch O
+lowers O
+fasting O
+serum O
+cholesterol O
+concentrations O
+in O
+healthy O
+normolipidemic O
+subjects O
+. O
+
+( O
+5 O
+) O
+. O
+
+Hepatitis O
+B O
+markers O
+in O
+Lancashire O
+police O
+officers O
+. O
+
+In O
+the O
+other O
+two O
+groups O
+( O
+NAAR O
+and O
+PLA O
+) O
+, O
+no O
+variation O
+in O
+this O
+serum O
+protease O
+was O
+observed O
+. O
+
+Maximum O
+likelihood O
+estimation O
+in O
+covariance O
+structure O
+analysis O
+with O
+truncated O
+data O
+. O
+
+A O
+single O
+dose O
+of O
+Cef O
+was O
+administered O
+intravenously O
+to O
+11 O
+patients O
+with O
+autoimmune O
+diseases O
+and O
+varying O
+degrees O
+of O
+renal O
+impairment O
+( O
+Group O
+I O
+CLCR O
+less O
+than O
+50 O
+ml O
+/ O
+min O
+, O
+Group O
+II O
+CLCR O
+greater O
+than O
+50 O
+ml O
+/ O
+min O
+) O
+. O
+
+The O
+liver O
+- O
+specific O
+sequence O
+contains O
+unique O
+consensus O
+sites O
+for O
+phosphorylation O
+by O
+cyclic B
+AMP I
+- I
+dependent I
+protein I
+kinase I
+and O
+by O
+protein B
+kinase I
+C I
+. O
+
+Effect O
+of O
+gentamycin O
+on O
+the O
+kidney O
+functional O
+state O
+in O
+experimental O
+pyelonephritis O
+
+They O
+represent O
+a O
+physiologically O
+more O
+meaningful O
+pattern O
+than O
+the O
+arithmetic O
+mean O
+with O
+standard O
+deviation O
+. O
+
+The O
+Valpha B
+and O
+Vbeta B
+domains O
+have O
+the O
+canonical O
+features O
+of O
+known O
+teleost O
+and O
+mammalian B
+TCR I
+V I
+domains I
+, O
+including O
+conserved O
+residues O
+in O
+the O
+beginning O
+of O
+FR2 B
+and O
+at O
+the O
+end O
+of O
+FR3 B
+. O
+
+Whether O
+this O
+lack O
+of O
+preferential O
+repair O
+has O
+to O
+be O
+explained O
+by O
+a O
+defect O
+in O
+repair O
+or O
+in O
+general O
+transcription O
+is O
+unclear O
+at O
+present O
+. O
+
+This O
+study O
+examines O
+LEIBNIZ O
+' O
+idea O
+of O
+Veterinary O
+medicine O
+in O
+a O
+biographical O
+context O
+. O
+
+Dipetalonema O
+( O
+Acanthocheilonema O
+) O
+didelphis O
+sp O
+. O
+
+n O
+. O
+
+However O
+, O
+the O
+MCMI O
+- O
+III O
+group O
+profile O
+was O
+significantly O
+lower O
+in O
+magnitude O
+compared O
+with O
+the O
+MCMI O
+- O
+II O
+. O
+
+While O
+there O
+is O
+growing O
+evidence O
+that O
+perception O
+and O
+imagery O
+share O
+common O
+neural O
+substrates O
+, O
+the O
+fact O
+that O
+D O
+. O
+F O
+. O
+shows O
+intact O
+visual O
+imagery O
+in O
+the O
+face O
+of O
+a O
+massive O
+perceptual O
+deficit O
+in O
+form O
+vision O
+challenges O
+recent O
+suggestions O
+that O
+these O
+two O
+psychological O
+processes O
+share O
+common O
+input O
+pathways O
+in O
+early O
+vision O
+. O
+
+An O
+ethnic O
+analysis O
+was O
+made O
+of O
+8947 O
+cases O
+of O
+primary O
+central O
+nervous O
+system O
+( O
+CNS O
+) O
+tumors O
+seen O
+at O
+the O
+Armed O
+Forces O
+Institute O
+of O
+Pathology O
+( O
+AFIP O
+) O
+, O
+Washington O
+, O
+DC O
+, O
+from O
+1971 O
+to O
+1985 O
+. O
+
+The O
+exact O
+function O
+of O
+IP B
+- I
+30 I
+is O
+not O
+yet O
+known O
+, O
+but O
+it O
+may O
+play O
+a O
+role O
+in O
+gamma B
+- I
+interferon I
+mediated O
+immune O
+reactions O
+. O
+
+The O
+levels O
+of O
+products O
+expressed O
+from O
+these O
+chimeric O
+cDNAs O
+in O
+COS O
+cells O
+were O
+assessed O
+by O
+activity O
+assay O
+and O
+by O
+metabolic O
+labeling O
+of O
+the O
+proteins O
+followed O
+by O
+immunoprecipitation O
+and O
+SDS O
+- O
+PAGE O
+. O
+
+In O
+this O
+report O
+, O
+we O
+demonstrate O
+that O
+FRS2 B
+forms O
+a O
+complex O
+with O
+the O
+N B
+- I
+terminal I
+SH2 I
+domain I
+of O
+the O
+protein B
+tyrosine I
+phosphatase I
+Shp2 B
+in O
+response O
+to O
+FGF B
+stimulation O
+. O
+
+It O
+is O
+concluded O
+that O
+the O
+drinking O
+ampules O
+of O
+VP O
+- O
+16 O
+- O
+213 O
+can O
+be O
+replaced O
+with O
+the O
+new O
+oral O
+capsules O
+with O
+a O
+recommended O
+initial O
+dose O
+of O
+100 O
+- O
+130 O
+mg O
+/ O
+m2 O
+given O
+in O
+5 O
+- O
+day O
+courses O
+every O
+21 O
+- O
+28 O
+days O
+. O
+
+The O
+H5 B
+mutants I
+were O
+: O
+DH5 O
+( O
+all O
+amino O
+acids O
+in O
+D O
+configuration O
+) O
+and O
+H5F B
+( O
+where O
+all O
+His O
+are O
+replaced O
+by O
+Phe O
+at O
+positions O
+3 O
+, O
+7 O
+, O
+8 O
+, O
+15 O
+, O
+18 O
+, O
+19 O
+, O
+21 O
+) O
+. O
+
+Although O
+the O
+number O
+of O
+kits O
+has O
+increased O
+, O
+the O
+precision O
+has O
+improved O
+, O
+showing O
+that O
+more O
+robust O
+methods O
+are O
+now O
+employed O
+. O
+
+These O
+results O
+establish O
+that O
+the O
+DNA O
+fragment O
+we O
+have O
+isolated O
+contains O
+the O
+human B
+gp130 I
+promoter I
+and O
+that O
+interleukin B
+- I
+6 I
+type I
+cytokines I
+may O
+influence O
+the O
+activity O
+of O
+this O
+promoter O
+via O
+activated O
+STATs B
+. O
+
+When O
+targeted O
+to O
+the O
+GAL1 B
+promoter I
+by O
+fusing O
+with O
+the O
+Gal4p B
+DNA I
+- I
+binding I
+domain I
+, O
+Sko1p B
+acts O
+as O
+an O
+Ssn6 B
+/ O
+Tup1p B
+- O
+dependent O
+repressor O
+regulated O
+by O
+osmotic O
+stress O
+. O
+
+The O
+unexpected O
+prevalence O
+of O
+c B
+- I
+myc I
+and O
+alpha B
+- I
+tubulin I
+in O
+the O
+S O
+- O
+phase O
+library O
+is O
+supported O
+by O
+Northern O
+analysis O
+of O
+RNA O
+from O
+phase O
+- O
+synchronous O
+cells O
+. O
+
+Growth O
+factors O
+promote O
+cell O
+survival O
+through O
+phosphorylation O
+of O
+Bad B
+, O
+resulting O
+in O
+its O
+dissociation O
+from O
+Bcl B
+- I
+2 I
+and O
+Bcl B
+- I
+x I
+( I
+L I
+) I
+and O
+its O
+association O
+with O
+14 B
+- I
+3 I
+- I
+3tau I
+. O
+
+A O
+representative O
+group O
+of O
+patients O
+undergoing O
+open O
+radical O
+nephrectomy O
+for O
+clinical O
+T1 O
+, O
+T2 O
+lesions O
+was O
+also O
+identified O
+. O
+
+By O
+applying O
+a O
+sufficiently O
+strong O
+crusher O
+gradient O
+in O
+the O
+EPI O
+pulse O
+sequence O
+, O
+the O
+temporal O
+variation O
+induced O
+by O
+SSFP O
+disturbance O
+can O
+be O
+suppressed O
+due O
+to O
+diffusion O
+. O
+
+However O
+, O
+in O
+each O
+case O
+in O
+which O
+either O
+the O
+DQ B
+alpha I
+- O
+or O
+DQ B
+beta I
+- I
+chain I
+was O
+exchanged O
+, O
+major O
+alterations O
+or O
+reversals O
+of O
+this O
+pattern O
+of O
+interaction O
+were O
+observed O
+. O
+
+Only O
+the O
+native O
+structure O
+of O
+phosphorylated O
+ERK B
+was O
+recognized O
+by O
+VHR B
+and O
+was O
+inactivated O
+with O
+a O
+second O
+- O
+order O
+rate O
+constant O
+of O
+40 O
+, O
+000 O
+M O
+- O
+1 O
+s O
+- O
+1 O
+. O
+
+From O
+1998 O
+to O
+1999 O
+, O
+a O
+large O
+number O
+of O
+community O
+- O
+acquired O
+respiratory O
+tract O
+isolates O
+of O
+Streptococcus O
+pneumoniae O
+( O
+n O
+= O
+566 O
+) O
+, O
+Haemophilus O
+influenzae O
+( O
+n O
+= O
+513 O
+) O
+and O
+Moraxella O
+catarrhalis O
+( O
+n O
+= O
+228 O
+) O
+were O
+collected O
+from O
+15 O
+centres O
+in O
+Australia O
+, O
+Hong O
+Kong O
+, O
+Japan O
+, O
+China O
+, O
+the O
+Philippines O
+, O
+Singapore O
+, O
+South O
+Africa O
+and O
+Taiwan O
+through O
+the O
+SENTRY O
+Antimicrobial O
+Surveillance O
+Program O
+. O
+
+Diethyldithiocarbamate O
+and O
+amphetamine O
+stereotype O
+behavior O
+. O
+
+We O
+used O
+an O
+immobilized O
+template O
+- O
+based O
+assay O
+to O
+examine O
+transcription O
+termination O
+by O
+VA1 B
+, O
+7SL B
+, O
+and O
+Alu B
+class O
+III O
+templates O
+and O
+the O
+role O
+of O
+transcript O
+release O
+in O
+the O
+pol B
+III I
+terminator O
+- O
+dependent O
+inhibition O
+of O
+processing O
+of O
+B1 B
+- I
+Alu I
+transcripts I
+. O
+
+A O
+novel O
+zinc O
+finger O
+- O
+containing O
+RNA O
+- O
+binding O
+protein O
+conserved O
+from O
+fruitflies O
+to O
+humans O
+. O
+
+Although O
+IL B
+- I
+6 I
+can O
+activate O
+ERK B
+- I
+1 I
+in O
+HepG2 O
+cells O
+, O
+STAT3 B
+transactivation O
+and O
+Ser O
+( O
+727 O
+) O
+phosphorylation O
+were O
+not O
+reduced O
+by O
+using O
+the O
+MAP B
+kinase I
+/ O
+ERK B
+kinase I
+( O
+MEK B
+) O
+inhibitor O
+PD98059 O
+or O
+by O
+overexpression O
+of O
+dominant B
+- I
+negative I
+Raf I
+. O
+
+6 O
+h O
+after O
+ingestion O
+of O
+aspirin O
+on O
+day O
+1 O
+to O
+day O
+14 O
+, O
+both O
+TX O
+and O
+PGI2 O
+levels O
+also O
+significantly O
+decreased O
+( O
+p O
+< O
+0 O
+. O
+0001 O
+) O
+. O
+
+Tritiated O
+1 O
+, O
+24 O
+, O
+25 O
+- O
+trihydroxyvitamin O
+D3 O
+was O
+synthesized O
+biologically O
+and O
+used O
+as O
+tracer O
+to O
+monitor O
+the O
+recovery O
+of O
+endogenous O
+metabolite O
+during O
+isolation O
+from O
+serum O
+. O
+
+Joint O
+ultrasonography O
+demonstrating O
+thickening O
+of O
+synoviae O
+and O
+tendons O
+has O
+become O
+a O
+useful O
+non O
+- O
+invasive O
+diagnostic O
+tool O
+, O
+although O
+it O
+is O
+not O
+specific O
+for O
+beta B
+2 I
+- I
+M I
+amyloidosis O
+, O
+and O
+results O
+depend O
+on O
+observer O
+experience O
+. O
+
+Immunofluorescence O
+tests O
+for O
+Borrelia O
+burgdorferi O
+serum O
+antibodies O
+had O
+positive O
+results O
+, O
+but O
+G O
+- O
+penicillin O
+treatment O
+was O
+ineffective O
+. O
+
+The O
+size O
+and O
+the O
+predicted O
+N O
+- O
+terminal O
+sequence O
+of O
+the O
+mouse O
+protein O
+were O
+confirmed O
+experimentally O
+. O
+
+Nuclear O
+runoff O
+assays O
+show O
+that O
+complementation O
+by O
+HPV16 B
+E7 I
+restores O
+the O
+ability O
+of O
+the O
+E1A B
+mutants I
+to O
+stimulate O
+early B
+gene I
+expression O
+at O
+the O
+level O
+of O
+transcription O
+. O
+
+Yet O
+IL B
+- I
+2 I
+and O
+IFN B
+- I
+gamma I
+production O
+are O
+independently O
+regulated O
+, O
+as O
+demonstrated O
+by O
+their O
+differential O
+expression O
+in O
+certain O
+T O
+cell O
+subsets O
+, O
+suggesting O
+that O
+the O
+regulatory O
+elements O
+in O
+these O
+two O
+genes O
+must O
+differ O
+. O
+
+We O
+conclude O
+that O
+a O
+0 O
+. O
+25 O
+mg O
+dose O
+of O
+triazolam O
+does O
+not O
+effectively O
+counteract O
+a O
+posture O
+- O
+induced O
+sleep O
+disturbance O
+, O
+but O
+induces O
+changes O
+in O
+the O
+EEG O
+spectra O
+which O
+are O
+typical O
+for O
+benzodiazepine B
+receptor I
+agonists O
+. O
+
+Anisotropy O
+of O
+Hc2 O
+and O
+the O
+breadth O
+of O
+the O
+resistive O
+transition O
+of O
+polycrystalline O
+YBa2Cu O
+
+Microscopic O
+examination O
+of O
+these O
+colonies O
+showed O
+a O
+high O
+percentage O
+of O
+histiocytes O
+identical O
+to O
+those O
+seen O
+in O
+the O
+patient O
+' O
+s O
+bone O
+marrow O
+. O
+
+Functional O
+uncoupling O
+of O
+the O
+Janus B
+kinase I
+3 I
+- O
+Stat5 B
+pathway O
+in O
+malignant O
+growth O
+of O
+human O
+T O
+cell O
+leukemia O
+virus O
+type O
+1 O
+- O
+transformed O
+human O
+T O
+cells O
+. O
+
+The O
+herpesvirus B
+entry I
+mediator I
+C I
+( O
+HveC B
+) O
+, O
+previously O
+known O
+as O
+poliovirus B
+receptor I
+- I
+related I
+protein I
+1 I
+( O
+PRR1 B
+) O
+, O
+and O
+the O
+herpesvirus B
+Ig I
+- I
+like I
+receptor I
+( O
+HIgR B
+) O
+are O
+the O
+bona O
+fide O
+receptors O
+employed O
+by O
+herpes O
+simplex O
+virus O
+- O
+1 O
+and O
+- O
+2 O
+( O
+HSV O
+- O
+1 O
+and O
+- O
+2 O
+) O
+for O
+entry O
+into O
+the O
+human O
+cell O
+lines O
+most O
+frequently O
+used O
+in O
+HSV O
+studies O
+. O
+
+4 O
+- O
+Hydroxyproline O
+assays O
+were O
+performed O
+to O
+determine O
+collagen B
+content O
+. O
+
+The O
+combination O
+of O
+ICP47 B
+and O
+US11 B
+rendered O
+fibroblasts O
+negative O
+for O
+surface O
+class B
+I I
+MHC I
+and O
+allowed O
+a O
+class B
+I I
+MHC I
+- O
+low O
+population O
+of O
+T O
+cells O
+to O
+be O
+sorted O
+by O
+flow O
+cytometry O
+. O
+
+Although O
+IRS B
+- I
+1 I
+, I
+- I
+2 I
+, I
+and I
+- I
+4 I
+are O
+similar O
+in O
+overall O
+structure O
+, O
+IRS B
+- I
+3 I
+is O
+approximately O
+50 O
+% O
+shorter O
+and O
+differs O
+with O
+respect O
+to O
+sites O
+of O
+tyrosine O
+phosphorylation O
+. O
+
+The O
+interaction O
+of O
+different O
+protein O
+systems O
+with O
+microtubules O
+is O
+a O
+critical O
+step O
+in O
+the O
+cellular O
+function O
+of O
+these O
+organelles O
+. O
+
+In O
+addition O
+, O
+we O
+mapped O
+a O
+putative O
+hnRNP B
+A1 I
+binding I
+site I
+in O
+U5 B
+RNA I
+and O
+demonstrated O
+that O
+p40CRS B
+( O
+hnRNP B
+A1 I
+) O
+binding O
+to O
+that O
+site O
+correlates O
+with O
+CRS B
+function O
+. O
+
+Sailer O
+, O
+K O
+. O
+
+Copyright O
+2000 O
+Academic O
+Press O
+. O
+
+This O
+element O
+was O
+required O
+for O
+both O
+basal O
+and O
+activated O
+expression O
+and O
+almost O
+certainly O
+functions O
+as O
+a O
+TATA B
+- I
+binding I
+protein I
+interaction I
+site I
+. O
+
+In O
+HepG2 O
+cells O
+, O
+SREBP B
+- I
+1c I
+mRNA I
+and O
+precursor O
+protein O
+levels O
+were O
+induced O
+by O
+treatment O
+with O
+22 O
+( O
+R O
+) O
+- O
+hydroxycholesterol O
+and O
+9 O
+- O
+cis O
+- O
+retinoic O
+acid O
+, O
+confirming O
+that O
+endogenous O
+LXR B
+- O
+RXR B
+activation O
+can O
+induce O
+endogenous O
+SREBP B
+- I
+1c I
+expression O
+. O
+
+Univariate O
+and O
+multivariate O
+analysis O
+was O
+used O
+to O
+calculate O
+the O
+5 O
+- O
+year O
+survival O
+probabilities O
+with O
+respect O
+to O
+the O
+following O
+variables O
+: O
+age O
+( O
+< O
+or O
+= O
+65 O
+, O
+> O
+65 O
+) O
+, O
+sex O
+, O
+depth O
+of O
+invasion O
+( O
+mucosal O
+, O
+submucosal O
+) O
+tumor O
+location O
+( O
+upper O
+, O
+middle O
+and O
+lower O
+third O
+) O
+, O
+gross O
+appearance O
+( O
+type O
+I O
+, O
+type O
+II O
+and O
+type O
+III O
+) O
+, O
+size O
+( O
+< O
+or O
+= O
+1 O
+. O
+5 O
+cm O
+, O
+> O
+1 O
+. O
+5 O
+cm O
+) O
+, O
+presence O
+or O
+absence O
+of O
+lymph O
+node O
+metastasis O
+, O
+histological O
+type O
+( O
+intestinal O
+, O
+diffuse O
+) O
+, O
+extent O
+of O
+
+lymphadenectomy O
+( O
+limited O
+or O
+extended O
+) O
+, O
+and O
+type O
+of O
+gastrectomy O
+( O
+total O
+or O
+distal O
+subtotal O
+) O
+. O
+
+This O
+integration O
+results O
+in O
+the O
+production O
+of O
+MMTV O
+/ O
+mdr3 I
+fusion O
+transcripts O
+that O
+originate O
+from O
+the O
+antisense O
+5 O
+' O
+LTR O
+of O
+the O
+provirus O
+. O
+
+In O
+32 O
+of O
+them O
+the O
+results O
+of O
+an O
+exercise O
+performance O
+test O
+based O
+on O
+heart O
+rate O
+response O
+to O
+submaximal O
+exercise O
+( O
+VO2 O
+, O
+170 O
+[ O
+bpm O
+] O
+) O
+was O
+compared O
+with O
+another O
+index O
+of O
+physical O
+performance O
+capacity O
+, O
+which O
+is O
+independent O
+from O
+heart O
+rate O
+: O
+the O
+ventilatory O
+threshold O
+. O
+
+Sequence O
+comparisons O
+reveal O
+that O
+the O
+P B
+. I
+woesei I
+GTP I
+- I
+binding I
+protein I
+is O
+strikingly O
+related O
+in O
+sequence O
+to O
+eubacterial B
+FtsZ I
+and O
+is O
+marginally O
+more O
+similar O
+to O
+eukaryotic B
+tubulins I
+than O
+are O
+bacterial B
+FtsZ I
+proteins I
+. O
+
+Four O
+of O
+15 O
+patients O
+with O
+R2 O
+had O
+rheumatoid O
+arthritis O
+and O
+in O
+two O
+of O
+these O
+four O
+cases O
+the O
+antibody O
+was O
+of O
+the O
+IgA B
+class O
+. O
+
+Phosphate O
+compounds O
+in O
+isolated O
+, O
+perfused O
+hearts O
+during O
+pH O
+variation O
+due O
+to O
+changes O
+in O
+extracellular O
+PCO2 O
+and O
+bicarbonate O
+
+Vav B
+and O
+Dbl B
+are O
+members O
+of O
+a O
+novel O
+class O
+of O
+oncogene O
+proteins O
+that O
+share O
+significant O
+sequence O
+identity O
+in O
+a O
+approximately O
+250 O
+- O
+amino O
+- O
+acid O
+domain O
+, O
+designated O
+the O
+Dbl B
+homology I
+domain I
+. O
+
+Serum O
+AFP B
+is O
+a O
+useful O
+tumor O
+marker O
+for O
+monitoring O
+the O
+results O
+of O
+therapy O
+. O
+
+The O
+possible O
+equivalency O
+of O
+a O
+short O
+form O
+and O
+the O
+long O
+form O
+of O
+the O
+Multiple O
+Affect O
+Adjective O
+Check O
+List O
+- O
+Revised O
+( O
+MAACL O
+- O
+R O
+; O
+Zuckerman O
+& O
+Lubin O
+, O
+1985 O
+) O
+was O
+studied O
+by O
+correlating O
+both O
+forms O
+of O
+the O
+MAACL O
+- O
+R O
+with O
+the O
+State O
+Trait O
+Personality O
+Inventory O
+( O
+Spielberger O
+, O
+1995 O
+) O
+; O
+the O
+Affect O
+Balance O
+Scale O
+( O
+Bradburn O
+, O
+1969 O
+) O
+; O
+and O
+the O
+Sensation O
+Seeking O
+Scale O
+( O
+Zuckerman O
+, O
+1978 O
+) O
+. O
+
+The O
+data O
+show O
+that O
+processing O
+time O
+as O
+a O
+function O
+of O
+intensity O
+is O
+modified O
+not O
+only O
+at O
+the O
+retina O
+but O
+also O
+at O
+later O
+processing O
+sites O
+. O
+
+Identification O
+of O
+masked O
+toxins O
+in O
+the O
+exotoxin B
+complex I
+of I
+Staphylococcus I
+pyogenes I
+und O
+Cl O
+. O
+perfringens O
+; O
+significance O
+of O
+their O
+existence O
+for O
+clarifying O
+of O
+the O
+masking O
+mechanism O
+
+Unlike O
+LANA1 B
+, O
+LANA2 B
+does O
+not O
+elicit O
+a O
+serologic O
+response O
+from O
+patients O
+with O
+KS O
+, O
+PEL O
+, O
+or O
+CD O
+as O
+measured O
+by O
+Western O
+blot O
+hybridization O
+. O
+
+However O
+, O
+this O
+posttranslational O
+modification O
+of O
+the O
+gar2 B
+protein I
+does O
+not O
+appear O
+to O
+be O
+essential O
+for O
+normal O
+production O
+of O
+18S B
+rRNA I
+. O
+
+Here O
+, O
+we O
+analyzed O
+the O
+interaction O
+of O
+CYT B
+- I
+18 I
+with O
+a O
+small O
+RNA O
+( O
+P4 B
+- O
+P6 B
+RNA O
+) O
+corresponding O
+to O
+the O
+isolated O
+P4 B
+- O
+P6 B
+domain O
+of O
+the O
+N B
+. O
+crassa O
+mitochondrial I
+large I
+subunit I
+ribosomal I
+RNA I
+intron O
+. O
+
+The O
+deduced O
+amino O
+acid O
+sequence O
+of O
+PutR B
+( I
+154 I
+amino I
+acid I
+residues I
+) I
+showed O
+homology O
+to O
+the O
+small B
+regulatory I
+proteins I
+Lrp I
+, O
+BkdR B
+, O
+and O
+AsnC B
+. O
+
+When O
+yeast O
+cells O
+reach O
+a O
+critical O
+size O
+in O
+late O
+G1 O
+they O
+simultaneously O
+start O
+budding O
+, O
+initiate O
+DNA O
+synthesis O
+, O
+and O
+activate O
+transcription O
+of O
+a O
+set O
+of O
+genes O
+that O
+includes O
+G1 B
+cyclins I
+CLN1 B
+, O
+CLN2 B
+, O
+and O
+many O
+DNA O
+synthesis O
+genes O
+. O
+
+Functional O
+PET O
+scanning O
+in O
+the O
+preoperative O
+assessment O
+of O
+cerebral O
+arteriovenous O
+malformations O
+. O
+
+In O
+addition O
+, O
+269 O
+mice O
+from O
+a O
+( O
+Mus O
+spretus O
+x O
+C57BL O
+/ O
+6J O
+) O
+F1 O
+x O
+C57BL O
+/ O
+6J O
+interspecific O
+backcross O
+were O
+also O
+used O
+to O
+order O
+marker O
+loci O
+and O
+calculate O
+intergene O
+distances O
+for O
+this O
+region O
+. O
+
+Accordingly O
+, O
+superpeptide O
+antigenic O
+material O
+was O
+readily O
+detected O
+by O
+immunoblotting O
+cell O
+extracts O
+and O
+enriched O
+in O
+vacuolar O
+preparations O
+of O
+PrA B
+deficient O
+mutant O
+cells O
+. O
+
+Blockade O
+of O
+T O
+cell O
+activation O
+using O
+a O
+surface O
+- O
+linked O
+single O
+- O
+chain O
+antibody O
+to O
+CTLA B
+- I
+4 I
+( O
+CD152 B
+) O
+. O
+
+Water O
+pair O
+and O
+three O
+- O
+body O
+potential O
+of O
+spectroscopic O
+quality O
+from O
+Ab O
+initio O
+calculations O
+
+4 O
+) O
+Mutation O
+of O
+the O
+three O
+extracellular O
+cysteine O
+residues O
+of O
+GFKAR B
+beta I
+indicated O
+that O
+the O
+two O
+conserved O
+cysteine O
+residues O
+( O
+C305 O
+and O
+C385 O
+) O
+, O
+located O
+between O
+two O
+transmembrane O
+segments O
+, O
+form O
+a O
+solvent O
+- O
+accessible O
+disulfide O
+bond O
+. O
+
+In O
+this O
+work O
+, O
+we O
+have O
+used O
+Xenopus O
+oocyte O
+maturation O
+as O
+a O
+read O
+- O
+out O
+for O
+examining O
+the O
+ability O
+of O
+the O
+neu B
+tyrosine I
+kinase I
+( O
+p185neu B
+) O
+to O
+participate O
+with O
+the O
+epidermal B
+growth I
+factor I
+( I
+EGF I
+) I
+receptor I
+in O
+a O
+common O
+signal O
+transduction O
+pathway O
+. O
+
+The O
+best O
+- O
+studied O
+neurotrophin O
+, O
+nerve B
+growth I
+factor I
+( O
+NGF B
+) O
+, O
+is O
+a O
+major O
+survival O
+factor O
+in O
+sympathetic O
+and O
+sensory O
+neurons O
+and O
+promotes O
+differentiation O
+in O
+a O
+well O
+- O
+studied O
+model O
+system O
+, O
+PC12 O
+cells O
+. O
+
+In O
+contrast O
+, O
+MAPK B
+activation O
+stimulated O
+by O
+the O
+Gq B
+- I
+coupled I
+alpha I
+1B I
+AR I
+or O
+M1 B
+muscarinic I
+cholinergic I
+receptor I
+is O
+unaffected O
+by O
+expression O
+of O
+beta B
+ARKct I
+or O
+RasN17 B
+expression O
+or O
+by O
+PTK B
+inhibitors O
+, O
+but O
+is O
+blocked O
+by O
+expression O
+of O
+N B
+delta I
+Raf I
+or O
+by O
+PKC B
+depletion O
+. O
+
+Transcriptional O
+analysis O
+indicates O
+that O
+human B
+TBP I
+functions O
+poorly O
+at O
+promoters O
+recognized O
+by O
+RNA B
+polymerases I
+I I
+and I
+III I
+and O
+at O
+RNA B
+Pol I
+II I
+promoters I
+lacking O
+a O
+conventional O
+TATA O
+element O
+. O
+
+The O
+steady O
+- O
+state O
+levels O
+of O
+Cdk2 B
+, O
+Cdk4 B
+and O
+Cyclin B
+A I
+proteins I
+were O
+unaffected O
+by O
+HPR B
+, O
+while O
+those O
+of O
+Cyclin B
+D1 I
+were O
+significantly O
+reduced O
+in O
+all O
+three O
+cell O
+lines O
+. O
+
+Mapping O
+the O
+5 O
+' O
+and O
+3 O
+' O
+termini O
+of O
+TED B
+RNAs I
+indicated O
+that O
+the O
+LTRs O
+have O
+a O
+retroviral O
+U3 B
+- O
+R O
+- O
+U5 B
+structural O
+organization O
+that O
+is O
+capable O
+of O
+directing O
+the O
+synthesis O
+of O
+transcripts O
+that O
+represent O
+potential O
+substrates O
+for O
+reverse O
+transcription O
+and O
+intermediates O
+in O
+transposition O
+. O
+
+Human O
+forearm O
+was O
+used O
+as O
+a O
+dummy O
+ear O
+and O
+the O
+electrode O
+HN O
+- O
+5 O
+was O
+fixed O
+thereon O
+, O
+and O
+a O
+sound O
+stimulus O
+of O
+90dBnHL O
+was O
+delivered O
+by O
+the O
+earphone O
+( O
+NC O
+- O
+3 O
+) O
+. O
+
+These O
+proteins O
+were O
+detected O
+by O
+an O
+antibody O
+which O
+recognizes O
+the O
+N O
+- O
+terminus O
+of O
+SRK3 B
+and O
+, O
+in O
+an O
+F2 O
+progeny O
+segregating O
+for O
+the O
+S3 O
+haplotype O
+, O
+were O
+only O
+expressed O
+in O
+plants O
+possessing O
+the O
+S3 O
+haplotype O
+. O
+
+The O
+blood O
+pressures O
+in O
+43 O
+subjects O
+were O
+compared O
+during O
+rapid O
+weight O
+loss O
+and O
+at O
+identical O
+weights O
+during O
+post O
+- O
+fast O
+weight O
+gain O
+( O
+Study O
+A O
+) O
+. O
+
+The O
+animals O
+were O
+followed O
+over O
+a O
+1 O
+- O
+to O
+6 O
+- O
+h O
+posttraumatic O
+course O
+, O
+and O
+processed O
+for O
+the O
+LM O
+and O
+TEM O
+visualization O
+of O
+HRP B
+. O
+
+Total O
+body O
+water O
+and O
+distribution O
+space O
+of O
+Na24 O
+in O
+women O
+with O
+various O
+body O
+weight O
+
+Three O
+experiments O
+using O
+20 O
+microM O
+2 O
+- O
+( O
+hydroxyamino O
+) O
+- O
+1 O
+- O
+methyl O
+- O
+6 O
+- O
+phenylimidazo O
+[ O
+4 O
+, O
+5 O
+- O
+b O
+] O
+pyridine O
+( O
+N O
+- O
+OH O
+- O
+PhIP O
+) O
+were O
+performed O
+to O
+induce O
+mutations O
+in O
+the O
+dihydrofolate B
+reductase I
+( O
+DHFR B
+) O
+gene O
+of O
+a O
+hemizygous O
+Chinese O
+hamster O
+ovary O
+( O
+CHO O
+) O
+cell O
+line O
+( O
+UA21 O
+) O
+. O
+
+This O
+is O
+mediated O
+by O
+vascular O
+remodeling O
+, O
+an O
+active O
+process O
+that O
+results O
+in O
+a O
+change O
+in O
+the O
+geometry O
+of O
+the O
+blood O
+vessel O
+. O
+
+Our O
+results O
+separate O
+these O
+factors O
+into O
+four O
+regulatory O
+classes O
+: O
+( O
+i O
+) O
+constitutive O
+factors O
+, O
+such O
+as O
+Oct B
+- I
+1 I
+and O
+probably O
+Sp1 B
+, O
+that O
+are O
+expressed O
+in O
+thymocytes O
+at O
+all O
+stages O
+; O
+( O
+ii O
+) O
+inducible O
+factors O
+, O
+such O
+as O
+NF B
+- I
+kappa I
+B I
+and O
+complexes O
+binding O
+to O
+the O
+region O
+of O
+a O
+CD28 B
+response I
+element I
+, O
+that O
+can O
+be O
+activated O
+in O
+all O
+thymocytes O
+, O
+including O
+those O
+cells O
+( O
+CD4 B
++ O
+CD8 B
++ O
+TcRlow B
+) O
+that O
+can O
+undergo O
+selection O
+; O
+( O
+iii O
+) O
+inducible O
+factors O
+, O
+such O
+as O
+NF B
+- I
+AT I
+and O
+AP B
+- I
+1 I
+, O
+that O
+can O
+be O
+activated O
+
+in O
+mature O
+( O
+CD4 B
++ O
+CD8 B
+- O
+TcRhigh B
+) O
+and O
+immature O
+( O
+CD4 B
+- O
+CD8 B
+- O
+TcR B
+- O
+) O
+thymocytes O
+alike O
+but O
+not O
+in O
+the O
+transitional O
+stages O
+when O
+the O
+cells O
+( O
+CD4 B
++ O
+CD8 B
++ O
+TcRlow B
+) O
+are O
+subject O
+to O
+selection O
+; O
+and O
+( O
+iv O
+) O
+a O
+factor O
+containing O
+CREB B
+, O
+which O
+can O
+be O
+activated O
+in O
+thymocytes O
+of O
+all O
+developmental O
+stages O
+by O
+culture O
+but O
+does O
+not O
+require O
+specific O
+induction O
+. O
+
+Thus O
+, O
+22 O
+% O
+of O
+MDS O
+responded O
+to O
+oral O
+PLAC O
+. O
+
+Posterior O
+osteophytes O
+around O
+the O
+posterior O
+edges O
+of O
+vertebral O
+body O
+resulted O
+in O
+intervertebral O
+insufficiency O
+, O
+and O
+corresponded O
+to O
+hypertrophic O
+spur O
+in O
+osteochondrosis O
+. O
+
+They O
+showed O
+moderate O
+in O
+vitro O
+antifungal O
+activity O
+against O
+a O
+wide O
+variety O
+of O
+fungi O
+and O
+yeasts O
+including O
+clinically O
+important O
+pathogens O
+, O
+and O
+were O
+highly O
+effective O
+in O
+systemic O
+infection O
+with O
+Candida O
+albicans O
+in O
+mice O
+after O
+iv O
+and O
+im O
+administrations O
+. O
+
+Of O
+these O
+four O
+PP2C B
+genes I
+, O
+the O
+expression O
+of O
+the O
+PP2Cbeta B
+gene I
+has O
+been O
+reported O
+to O
+be O
+tissue O
+- O
+specific O
+and O
+development O
+- O
+dependent O
+. O
+
+We O
+also O
+show O
+that O
+in O
+fusions O
+with O
+the O
+DNA O
+binding O
+domain O
+of O
+GAL4 B
+, O
+full O
+activity O
+requires O
+the O
+entire O
+BHV B
+- I
+alpha I
+TIF I
+, O
+although O
+both O
+amino O
+and O
+carboxyl O
+termini O
+display O
+some O
+activity O
+on O
+their O
+own O
+. O
+
+The O
+induction O
+by O
+dexamethasone O
+of O
+rat B
+liver I
+CYP3A1 I
+differs O
+from O
+classical O
+glucocorticoid O
+gene O
+regulation O
+in O
+part O
+because O
+both O
+glucocorticoids O
+and O
+antiglucocorticoids O
+such O
+as O
+pregnenolone O
+16 O
+alpha O
+- O
+carbonitrile O
+( O
+PCN O
+) O
+induce O
+CYP3A1 B
+through O
+transcriptional O
+gene O
+activation O
+. O
+
+Moreover O
+, O
+antibody O
+binding O
+to O
+the O
+same O
+two O
+determinants O
+was O
+also O
+inhibited O
+when O
+ZAP B
+- I
+70 I
+or O
+the O
+SH2 B
+domains I
+bound O
+to O
+the O
+zeta O
+chain O
+or O
+to O
+a O
+2pY B
+- I
+ITAM I
+. O
+
+This O
+surface O
+in O
+specimens O
+from O
+unfertilized O
+eggs O
+is O
+almost O
+flat O
+. O
+
+Fetal O
+transplants O
+rescue O
+axial O
+muscle O
+representations O
+in O
+M1 O
+cortex O
+of O
+neonatally O
+transected O
+rats O
+that O
+develop O
+weight O
+support O
+. O
+
+We O
+examined O
+the O
+contribution O
+of O
+the O
+M O
+- O
+MuLV O
+enhancers O
+to O
+the O
+transcriptional O
+activity O
+and O
+pathogenesis O
+of O
+M O
+- O
+MuLV O
+by O
+constructing O
+LTRs O
+containing O
+heterologous O
+enhancer O
+elements O
+. O
+
+There O
+were O
+no O
+major O
+postoperative O
+complications O
+and O
+at O
+follow O
+- O
+up O
+of O
+the O
+13 O
+patients O
+at O
+10 O
+to O
+26 O
+months O
+after O
+operation O
+the O
+results O
+were O
+satisfactory O
+. O
+
+The O
+immunoreactive B
+antithrombin I
+III I
+increased O
+significantly O
+while O
+the O
+increase O
+in O
+antithrombin B
+III I
+activity O
+was O
+insignificant O
+in O
+20 O
+male O
+Caucasian O
+Danes O
+upon O
+3 O
+weeks O
+supplementation O
+of O
+the O
+diet O
+with O
+10 O
+ml O
+daily O
+of O
+a O
+cod O
+liver O
+oil O
+concentrate O
+. O
+
+Northern O
+blot O
+analysis O
+confirmed O
+that O
+ADAMTS B
+- I
+1 I
+was O
+up O
+- O
+regulated O
+in O
+both O
+metaphyseal O
+( O
+14 O
+- O
+to O
+35 O
+- O
+fold O
+) O
+and O
+diaphyseal O
+( O
+4 O
+. O
+2 O
+- O
+fold O
+) O
+bone O
+1 O
+h O
+after O
+PTH B
+- I
+( I
+1 I
+- I
+38 I
+) I
+injection O
+and O
+returned O
+to O
+control O
+levels O
+by O
+24 O
+h O
+. O
+
+The O
+transcriptional O
+transactivator O
+( O
+Tas B
+) O
+of O
+simian O
+foamy O
+virus O
+type O
+1 O
+strongly O
+augments O
+gene O
+expression O
+directed O
+by O
+both O
+the O
+promoter O
+in O
+the O
+viral O
+long O
+terminal O
+repeat O
+and O
+the O
+newly O
+discovered O
+internal O
+promoter O
+located O
+within O
+the O
+env B
+gene I
+. O
+
+In O
+the O
+other O
+two O
+cases O
+, O
+fluoxetine O
+adjunct O
+produced O
+benefits O
+with O
+no O
+additional O
+side O
+effects O
+. O
+
+Deletion O
+of O
+this O
+consensus O
+element O
+from O
+the O
+spo6 B
+promoter I
+abolished O
+the O
+transcription O
+of O
+spo6 B
++ I
+and O
+resulted O
+in O
+a O
+sporulation O
+deficiency O
+. O
+
+Chem O
+. O
+
+Mutations O
+in O
+the O
+beta B
+- I
+galactosidase I
+gene I
+result O
+in O
+the O
+lysosomal O
+storage O
+disorders O
+GM1 O
+- O
+gangliosidosis O
+and O
+Morquio O
+B O
+syndrome O
+. O
+
+Results O
+indicated O
+that O
+hobbies O
+/ O
+leisure O
+activities O
+, O
+mobility O
+, O
+transport O
+, O
+social O
+relationships O
+, O
+working O
+capacity O
+, O
+energy O
+and O
+doing O
+things O
+slower O
+were O
+aspects O
+relevant O
+to O
+IPF O
+patients O
+' O
+QOL O
+. O
+
+We O
+have O
+generated O
+transgenic O
+fly O
+strains O
+with O
+mutations O
+affecting O
+specific O
+TRA B
+- I
+2 I
+isoforms I
+to O
+investigate O
+their O
+individual O
+roles O
+in O
+regulating O
+the O
+alternative O
+processing O
+of O
+doublesex B
+, O
+exuperantia B
+and O
+tra B
+- I
+2 I
+pre I
+- I
+mRNA I
+. O
+
+The O
+IR4 B
+ORF I
+exhibits O
+significant O
+homology O
+to O
+the O
+immediate B
+- I
+early I
+gene I
+US1 I
+( O
+ICP22 B
+) O
+of O
+herpes O
+simplex O
+virus O
+type O
+1 O
+and O
+to O
+the O
+ICP22 B
+homologs I
+of I
+varicella I
+- I
+zoster I
+virus I
+( O
+ORF63 B
+) O
+, O
+pseudorabies O
+virus O
+( O
+RSp40 O
+) O
+, O
+and O
+equine O
+herpesvirus I
+4 I
+( O
+ORF4 B
+) I
+. O
+
+These O
+studies O
+define O
+a O
+class O
+of O
+DNA O
+elements O
+with O
+a O
+mode O
+of O
+action O
+that O
+has O
+not O
+been O
+heretofore O
+described O
+. O
+
+We O
+were O
+able O
+to O
+demonstrate O
+a O
+significant O
+statistical O
+interaction O
+effect O
+between O
+gender O
+and O
+globulin B
+protein O
+concentration O
+on O
+Vu O
+( O
+p O
+= O
+0 O
+. O
+022 O
+) O
+. O
+
+Chest O
+X O
+- O
+P O
+revealed O
+an O
+abnormal O
+shadow O
+in O
+the O
+left O
+upper O
+lobe O
+. O
+
+From O
+the O
+frozen O
+specimen O
+, O
+a O
+large O
+number O
+of O
+sections O
+with O
+good O
+morphologic O
+characteristics O
+may O
+be O
+produced O
+. O
+
+These O
+include O
+not O
+only O
+antioxidants O
+, O
+N B
+- I
+methyl I
+- I
+D I
+- I
+aspartate I
+receptor I
+antagonists O
+, O
+inhibitors O
+of O
+glutamate O
+release O
+, O
+calcium O
+channel O
+blockers O
+, O
+polyamine O
+antagonists O
+, O
+and O
+nitric B
+oxide I
+synthase I
+inhibitors O
+, O
+but O
+cannabinoids O
+, O
+aspirin O
+, O
+melatonin O
+, O
+and O
+vitamin O
+B O
+- O
+12 O
+. O
+
+A O
+series O
+of O
+mutations O
+were O
+constructed O
+within O
+the O
+E2 B
+open O
+reading O
+frame O
+which O
+delete O
+various O
+regions O
+of O
+the O
+conserved O
+DNA O
+binding O
+and O
+transactivation O
+domains O
+as O
+well O
+as O
+the O
+internal O
+hinge O
+region O
+. O
+
+CrkII B
+and O
+CrkL B
+constitutively O
+formed O
+complex O
+with O
+the O
+guanine B
+nucleotide I
+exchange I
+factor I
+C3G B
+, O
+in O
+unstimulated O
+as O
+well O
+as O
+PDGF B
+- O
+stimulated O
+cells O
+. O
+
+In O
+further O
+support O
+of O
+the O
+biological O
+significance O
+of O
+these O
+DNA O
+- O
+protein O
+interactions O
+, O
+the O
+IL2RA B
+oligonucleotide I
+from O
+- O
+291 O
+to O
+- O
+245 O
+proved O
+to O
+be O
+sufficient O
+in O
+either O
+orientation O
+to O
+confer O
+PMA O
+inducibility O
+to O
+the O
+mitogen O
+- O
+insensitive O
+thymidine B
+kinase I
+gene I
+promoter I
+in O
+Jurkat O
+cells O
+. O
+
+The O
+plasma O
+steroid O
+levels O
+in O
+the O
+CAPD O
+patients O
+after O
+each O
+infusion O
+rate O
+were O
+equal O
+to O
+or O
+greater O
+than O
+the O
+levels O
+in O
+normal O
+subjects O
+. O
+
+With O
+BCPP O
+protocol O
+, O
+12 O
+achieved O
+a O
+complete O
+response O
+, O
+11 O
+evidenced O
+a O
+75 O
+% O
+response O
+, O
+and O
+7 O
+displayed O
+a O
+50 O
+% O
+response O
+. O
+
+The O
+RPC31 B
+gene I
+encoding O
+the O
+C31 B
+subunit I
+of O
+Saccharomyces B
+cerevisiae I
+RNA I
+polymerase I
+C I
+( I
+III I
+) I
+has O
+been O
+isolated O
+, O
+starting O
+from O
+a O
+C O
+- O
+terminal O
+fragment O
+cloned O
+on O
+a O
+lambda O
+gt11 O
+library O
+. O
+
+Electrophoretic O
+mobility O
+shift O
+assays O
+demonstrated O
+that O
+sequences O
+within O
+this O
+region O
+bind O
+members O
+of O
+the O
+Sp1 B
+family I
+of I
+transcription I
+factors I
+. O
+
+The O
+phosphatase O
+active O
+site O
+is O
+located O
+within O
+residues O
+367 O
+- O
+374 O
+. O
+
+After O
+at O
+least O
+one O
+year O
+follow O
+- O
+up O
+, O
+argon O
+laser O
+showed O
+a O
+statistically O
+significant O
+effect O
+( O
+p O
+less O
+of O
+0 O
+, O
+01 O
+; O
+Kolmogorow O
+- O
+Smirnov O
+test O
+) O
+on O
+the O
+stabilization O
+or O
+the O
+amelioration O
+of O
+visual O
+acuity O
+compared O
+with O
+the O
+non O
+treated O
+group O
+. O
+
+Further O
+studies O
+aim O
+at O
+characterizing O
+the O
+trans O
+- O
+acting O
+factors O
+that O
+mediate O
+the O
+spatial O
+and O
+temporal O
+expression O
+of O
+Hox B
+genes I
+in O
+the O
+developing O
+embryo O
+. O
+
+Contraindications O
+to O
+adenosine O
+and O
+drug O
+interactions O
+are O
+noted O
+in O
+this O
+article O
+. O
+
+As O
+to O
+the O
+side O
+effects O
+of O
+SISO O
+, O
+cylindruria O
+with O
+aggravation O
+of O
+microscopic O
+hematuria O
+and O
+elevations O
+of O
+GOT B
+, O
+GPT B
+and O
+A1 B
+- I
+P I
+were O
+observed O
+each O
+one O
+of O
+them O
+, O
+respectively O
+. O
+
+Serum O
+C3 B
+was O
+measured O
+in O
+1 O
+, O
+282 O
+school O
+children O
+with O
+abnormal O
+urinary O
+findings O
+between O
+1980 O
+and O
+1997 O
+. O
+
+Two O
+measures O
+of O
+sensory O
+inhibition O
+were O
+employed O
+, O
+S2 O
+/ O
+S1 O
+x O
+100 O
+amplitude O
+ratio O
+and O
+S1 O
+- O
+S2 O
+amplitude O
+difference O
+. O
+
+Computer O
+analysis O
+revealed O
+that O
+the O
+human B
+protein I
+P1 I
+sequence I
+corresponding O
+to O
+amino O
+acid O
+residues O
+within O
+the O
+N O
+- O
+terminal O
+RNA O
+binding O
+domain O
+displays O
+high O
+homology O
+( O
+greater O
+than O
+54 O
+% O
+identity O
+; O
+61 O
+to O
+94 O
+% O
+similarity O
+) O
+with O
+two O
+animal O
+virus O
+proteins O
+which O
+possess O
+RNA O
+binding O
+activity O
+( O
+vaccinia B
+virus I
+E3L I
+; O
+rotavirus B
+VP2 I
+) O
+and O
+two O
+proteins O
+of O
+unknown O
+function O
+( O
+murine B
+TIK I
+; O
+rotavirus B
+NS34 I
+) O
+, O
+but O
+which O
+are O
+likely O
+RNA O
+binding O
+proteins O
+. O
+
+Determinants O
+of O
+recurrent O
+ischaemia O
+and O
+revascularisation O
+procedures O
+after O
+thrombolysis O
+with O
+recombinant O
+tissue B
+plasminogen I
+activator I
+in O
+primary O
+coronary O
+occlusion O
+. O
+
+For O
+large O
+breasts O
+( O
+> O
+70 O
+mm O
+) O
+the O
+use O
+of O
+X O
+- O
+ray O
+sets O
+such O
+as O
+the O
+IGE O
+DMR O
+, O
+which O
+automatically O
+select O
+the O
+beam O
+quality O
+for O
+each O
+breast O
+, O
+resulted O
+in O
+lower O
+doses O
+compared O
+with O
+sets O
+using O
+manual O
+tube O
+potential O
+selection O
+. O
+
+Experimental O
+exposure O
+of O
+poults O
+with O
+each O
+of O
+two O
+strains O
+representing O
+the O
+rarely O
+reported O
+capsular O
+group O
+B O
+indicated O
+that O
+both O
+were O
+virulent O
+. O
+
+Computer O
+system O
+trains O
+employees O
+to O
+meet O
+JCAHO O
+safety O
+ED O
+requirements O
+. O
+
+Finally O
+, O
+transfection O
+of O
+Grb10 B
+genes I
+with O
+specific O
+mutations O
+in O
+their O
+SH2 B
+domains O
+induces O
+apoptosis O
+in O
+HTC B
+- I
+IR I
+and O
+COS O
+- O
+7 O
+cells O
+. O
+
+Comparison O
+of O
+dose O
+volume O
+histograms O
+revealed O
+that O
+the O
+6 O
+- O
+field O
+plan O
+spared O
+relatively O
+more O
+heart O
+whereas O
+the O
+8 O
+- O
+field O
+plan O
+spared O
+relatively O
+more O
+lung O
+. O
+
+We O
+have O
+demonstrated O
+that O
+a O
+putative O
+HOX B
+cofactor I
+, O
+PBX1A B
+, O
+participates O
+in O
+cooperative O
+DNA O
+binding O
+with O
+HOXA B
+- I
+1 I
+and O
+the O
+Deformed B
+group I
+protein I
+HOXD B
+- I
+4 I
+. O
+
+The O
+CHL B
+1 I
+( O
+CTF B
+1 I
+) O
+gene O
+product O
+of O
+Saccharomyces O
+cerevisiae O
+is O
+important O
+for O
+chromosome O
+transmission O
+and O
+normal O
+cell O
+cycle O
+progression O
+in O
+G2 O
+/ O
+M O
+. O
+
+Heterotrimeric B
+guanine I
+nucleotide I
+- I
+binding I
+proteins I
+( O
+G B
+- I
+proteins I
+) O
+function O
+as O
+signal O
+transducers O
+for O
+a O
+variety O
+of O
+hormone O
+- O
+coupled O
+enzyme O
+and O
+ion O
+transport O
+systems O
+in O
+eukaryotic O
+cells O
+. O
+
+In O
+contrast O
+, O
+polypropylene O
+glycol O
+, O
+PG O
+- O
+C O
+, O
+and O
+corn O
+oil O
+all O
+removed O
+68 O
+- O
+86 O
+% O
+of O
+the O
+MDI O
+in O
+the O
+first O
+h O
+, O
+74 O
+- O
+79 O
+% O
+at O
+4 O
+h O
+, O
+and O
+72 O
+- O
+86 O
+% O
+at O
+8 O
+h O
+. O
+
+DDD O
+( O
+R O
+) O
+pacing O
+with O
+automatic O
+mode O
+switch O
+in O
+patients O
+with O
+paroxysmal O
+atrial O
+fibrillation O
+following O
+AV O
+nodal O
+ablation O
+. O
+
+There O
+was O
+a O
+highly O
+significant O
+decrease O
+in O
+serum B
+eosinophil I
+cationic I
+protein I
+in O
+patients O
+with O
+elevated O
+AGA O
+. O
+
+Sequence O
+analysis O
+revealed O
+that O
+Hv B
+- I
+p68 I
+belongs O
+to O
+the O
+large O
+family O
+of O
+FAD B
+- I
+dependent I
+glucose I
+methanol I
+choline I
+oxidoreductases I
+and O
+that O
+it O
+shares O
+significant O
+sequence O
+identity O
+( O
+> O
+67 O
+% O
+) O
+with O
+the O
+alcohol B
+oxidases I
+of O
+the O
+methylotrophic O
+yeasts O
+. O
+
+It O
+is O
+required O
+for O
+correct O
+expression O
+of O
+both O
+genes O
+. O
+
+In O
+the O
+HIV B
+LTR I
+, O
+this O
+region O
+has O
+been O
+demonstrated O
+to O
+have O
+both O
+positive O
+and O
+negative O
+regulatory O
+effects O
+on O
+HIV O
+gene O
+expression O
+. O
+
+A O
+comparison O
+between O
+attenuation O
+- O
+corrected O
+and O
+- O
+uncorrected O
+transmission O
+- O
+emission O
+SPECT O
+images O
+obtained O
+with O
+Tl O
+- O
+201 O
+in O
+CAD O
+patients O
+
+Accumulation O
+of O
+amines O
+in O
+the O
+isolated O
+perfused O
+rabbit O
+lung O
+. O
+
+Since O
+it O
+is O
+often O
+necessary O
+to O
+resort O
+to O
+thoracotomy O
+as O
+a O
+final O
+step O
+in O
+making O
+such O
+a O
+diagnosis O
+, O
+we O
+have O
+sought O
+a O
+procedure O
+that O
+is O
+simpler O
+while O
+capable O
+of O
+providing O
+the O
+same O
+information O
+. O
+
+Both O
+control O
+and O
+Mn O
+- O
+exposed O
+quail O
+accumulated O
+5 O
+to O
+10 O
+times O
+more O
+Mn O
+in O
+their O
+livers O
+than O
+similarly O
+treated O
+rodents O
+. O
+
+Small O
+t O
+also O
+inhibited O
+the O
+dephosphorylation O
+of O
+cAMP B
+- I
+dependent I
+protein I
+kinase I
+( O
+PKA B
+) O
+- O
+phosphorylated O
+CREB B
+in O
+rat O
+liver O
+nuclear O
+extracts O
+. O
+
+A O
+retrospective O
+analysis O
+of O
+data O
+accumulated O
+over O
+a O
+21 O
+- O
+month O
+period O
+, O
+from O
+December O
+1989 O
+to O
+September O
+1991 O
+, O
+regarding O
+investigational O
+use O
+of O
+a O
+308 O
+nanometer O
+Xenon O
+Chloride O
+Excimer O
+Laser O
+Coronary O
+Angioplasty O
+( O
+ELCA O
+) O
+system O
+( O
+Advanced O
+Interventional O
+Systems O
+, O
+Inc O
+. O
+, O
+Irvine O
+, O
+CA O
+) O
+was O
+performed O
+. O
+
+Presently O
+, O
+we O
+made O
+chain O
+pair O
+switch O
+, O
+chimeric O
+, O
+and O
+site B
+mutant I
+gamma I
+delta I
+TCRs I
+and O
+transfected O
+them O
+into O
+TCR B
+- O
+mutant O
+Jurkat O
+T O
+cells O
+to O
+examine O
+the O
+effects O
+of O
+changing O
+the O
+TCR B
+gamma I
+junctional I
+region I
+sequences I
+on O
+reactivity O
+to O
+prenyl O
+pyrophosphate O
+Ags O
+. O
+
+Fos B
+/ O
+Jun B
+bound O
+to O
+an O
+unacetylated O
+nucleosome O
+with O
+only O
+a O
+4 O
+- O
+to O
+5 O
+- O
+fold O
+reduction O
+in O
+DNA O
+binding O
+affinity O
+compared O
+with O
+naked O
+DNA O
+. O
+
+Activated O
+Ki B
+- I
+Ras I
+suppresses O
+12 O
+- O
+O O
+- O
+tetradecanoylphorbol O
+- O
+13 O
+- O
+acetate O
+- O
+induced O
+activation O
+of O
+the O
+c B
+- I
+Jun I
+NH2 I
+- I
+terminal I
+kinase I
+pathway O
+in O
+human O
+colon O
+cancer O
+cells O
+. O
+
+Electromobility O
+shift O
+analysis O
+using O
+oligonucleotides O
+encompassing O
+the O
+proximal O
+, O
+distal O
+, O
+and O
+BED B
+/ O
+AP B
+- I
+1 I
+- O
+binding O
+regions O
+failed O
+to O
+demonstrate O
+selective O
+transactivation O
+after O
+CD2 B
+signaling O
+of O
+LPMC O
+. O
+
+The O
+present O
+report O
+shows O
+that O
+a O
+cis O
+- O
+acting O
+element O
+between O
+- O
+189 O
+and O
+- O
+175 O
+bp O
+, O
+which O
+binds O
+thyroid B
+transcription I
+factor I
+- I
+1 I
+( O
+TTF B
+- I
+1 I
+) O
+, O
+is O
+involved O
+in O
+both O
+activities O
+. O
+
+Increased O
+platelet B
+- I
+derived I
+growth I
+factor I
+production O
+and O
+intimal O
+thickening O
+during O
+healing O
+of O
+Dacron O
+grafts O
+in O
+a O
+canine O
+model O
+. O
+
+Despite O
+their O
+high O
+degree O
+of O
+sequence O
+similarity O
+, O
+all O
+five O
+RFC B
+genes I
+are O
+essential O
+for O
+cell O
+proliferation O
+in O
+S O
+. O
+cerevisiae O
+. O
+
+Moreover O
+, O
+we O
+show O
+that O
+ectopic O
+expression O
+of O
+the O
+E2A B
+protein I
+E12 B
+in O
+this O
+macrophage O
+line O
+results O
+in O
+the O
+induction O
+of O
+many O
+B O
+lineage O
+genes O
+, O
+including O
+EBF B
+, O
+IL7Ralpha B
+, O
+lambda5 B
+, O
+and O
+Rag B
+- I
+1 I
+, O
+and O
+the O
+ability O
+to O
+induce O
+kappa B
+light I
+chain I
+in O
+response O
+to O
+mitogen O
+. O
+
+Also O
+, O
+anti B
+- I
+HIV I
+gp120 I
+and O
+anti B
+- I
+CD4 I
+crosslinking O
+induced O
+a O
+10 O
+- O
+15 O
+- O
+fold O
+increase O
+in O
+levels O
+of O
+both O
+PI B
+3 I
+- I
+and I
+PI I
+4 I
+- I
+kinase I
+activity O
+in O
+anti B
+- I
+CD4 I
+precipitates O
+. O
+
+The O
+differences O
+of O
+percentages O
+for O
+HIV O
+- O
+1 O
+infection O
+in O
+intravenous O
+drug O
+users O
+( O
+IVDU O
+) O
+were O
+67 O
+. O
+7 O
+% O
+and O
+in O
+non O
+IVDU O
+were O
+3 O
+. O
+8 O
+% O
+with O
+a O
+significant O
+statistical O
+difference O
+( O
+chi O
+2 O
+= O
+557 O
+. O
+5 O
+; O
+p O
+< O
+0 O
+. O
+0001 O
+) O
+. O
+
+One O
+of O
+the O
+ORFs O
+in O
+the O
+Methanococcus O
+jannaschii O
+genome O
+possesses O
+high O
+similarity O
+to O
+the O
+M O
+. O
+aeolicus O
+ilvB O
+, O
+indicating O
+that O
+it O
+is O
+an O
+authentic O
+AHAS B
+. O
+
+More O
+than O
+80 O
+% O
+appropriate O
+lever O
+responding O
+was O
+established O
+after O
+27 O
+, O
+38 O
+and O
+44 O
+daily O
+training O
+sessions O
+with O
+DN O
+- O
+2327 O
+, O
+diazepam O
+and O
+PTZ O
+, O
+respectively O
+, O
+as O
+the O
+training O
+drug O
+. O
+
+We O
+have O
+used O
+nuclear O
+magnetic O
+resonance O
+( O
+NMR O
+) O
+to O
+obtain O
+the O
+structure O
+of O
+an O
+RNA O
+" O
+kissing O
+" O
+hairpin O
+complex O
+formed O
+between O
+the O
+HIV O
+- O
+2 O
+TAR I
+hairpin O
+loop O
+and O
+a O
+hairpin O
+with O
+a O
+complementary O
+loop O
+sequence O
+. O
+
+RESULTS O
+: O
+In O
+men O
+, O
+weight O
+/ O
+height2 O
+met O
+the O
+criteria O
+for O
+a O
+satisfactory O
+index O
+in O
+that O
+there O
+was O
+a O
+very O
+strong O
+correlation O
+with O
+triceps O
+skinfold O
+, O
+and O
+a O
+negligible O
+correlation O
+with O
+height O
+. O
+
+PRP20 B
+is O
+related O
+, O
+both O
+in O
+structure O
+and O
+function O
+, O
+to O
+the O
+RCC1 B
+gene I
+of O
+mammals O
+and O
+the O
+PIM1 B
+gene I
+of O
+Schizosaccharomyces O
+pombe O
+, O
+both O
+of O
+which O
+appear O
+to O
+regulate O
+entry O
+into O
+mitosis O
+and O
+chromosome O
+condensation O
+. O
+
+No O
+consensus O
+binding O
+sequence O
+could O
+be O
+discerned O
+in O
+these O
+fragments O
+and O
+bound O
+factor O
+is O
+in O
+rapid O
+equilibrium O
+with O
+unbound O
+. O
+
+A O
+selective O
+transcriptional O
+induction O
+system O
+for O
+mammalian O
+cells O
+based O
+on O
+Gal4 B
+- O
+estrogen B
+receptor I
+fusion O
+proteins O
+. O
+
+Kinase O
+renaturation O
+tests O
+designed O
+to O
+detect O
+reactivated O
+protein O
+kinases O
+after O
+electrophoresis O
+in O
+sodium O
+dodecyl O
+sulfate O
+- O
+polyacrylamide O
+gels O
+revealed O
+the O
+presence O
+of O
+a O
+60 O
+- O
+kDa O
+kinase O
+in O
+the O
+washed O
+immunoprecipitate O
+obtained O
+from O
+liver O
+cytosol O
+using O
+anti B
+- I
+AHR I
+antibody I
+( O
+IgG B
+) O
+and O
+protein B
+A I
+/ I
+G I
+/ O
+agarose O
+beads O
+but O
+not O
+when O
+a O
+nonspecific O
+IgG B
+was O
+used O
+instead O
+of O
+anti B
+- I
+AHR I
+antibody I
+. O
+
+Immunoblotting O
+using O
+a O
+phosphospecific O
+anti B
+- I
+Src I
+( I
+416Y I
+) I
+antibody I
+showed O
+a O
+ceramide O
+- O
+induced O
+increase O
+in O
+pp60 B
+( O
+src B
+) O
+tyrosine O
+phosphorylation O
+. O
+
+In O
+contrast O
+, O
+dominant B
+negative I
+Rac I
+( O
+N17Rac1 B
+) O
+inhibited O
+JNK B
+activation O
+by O
+Galpha12 B
+in O
+HEK293 O
+cells O
+as O
+well O
+as O
+three O
+other O
+cell O
+lines O
+. O
+
+Metabolic O
+studies O
+of O
+tetrabenazine O
+, O
+a O
+psychotropic O
+drug O
+in O
+animals O
+and O
+man O
+. O
+
+Reading O
+disability O
+in O
+twins O
+. O
+
+These O
+results O
+suggest O
+that O
+1a B
+, O
+which O
+also O
+interacts O
+independently O
+with O
+the O
+ER O
+and O
+viral O
+RNA O
+, O
+is O
+a O
+key O
+organizer O
+of O
+RNA O
+replication O
+complex O
+assembly O
+. O
+
+HrpE B
+is O
+similar O
+to O
+YscL B
+of O
+Yersinia O
+spp O
+. O
+
+Effect O
+of O
+a O
+high O
+sugar O
+intake O
+on O
+some O
+metabolic O
+and O
+regulatory O
+indicators O
+in O
+young O
+men O
+. O
+
+Production O
+of O
+a O
+chicken O
+meat O
+infusion O
+broth O
+suitable O
+for O
+the O
+mass O
+production O
+of O
+a O
+Haemophilus O
+gallinarum O
+bacterin O
+. O
+
+The O
+results O
+indicate O
+that O
+expression O
+of O
+proU B
+in O
+E O
+. O
+coli O
+is O
+directed O
+from O
+two O
+promoters O
+, O
+one O
+( O
+P2 O
+) O
+characterized O
+earlier O
+by O
+other O
+workers O
+with O
+the O
+start O
+site O
+of O
+transcription O
+60 O
+nucleotides O
+upstream O
+of O
+the O
+initiation O
+codon O
+of O
+the O
+first O
+structural O
+gene O
+( O
+proV B
+) O
+, O
+and O
+the O
+other O
+( O
+P1 O
+) O
+situated O
+250 O
+nucleotides O
+upstream O
+of O
+proV B
+. O
+
+The O
+maximal O
+rise O
+in O
+plasma O
+adrenaline O
+was O
+of O
+similar O
+magnitude O
+in O
+all O
+three O
+groups O
+but O
+a O
+lower O
+plasma O
+glucose O
+was O
+required O
+to O
+stimulate O
+this O
+hormonal O
+response O
+in O
+the O
+' O
+unaware O
+' O
+patients O
+, O
+in O
+whom O
+the O
+plasma O
+adrenaline O
+concentration O
+was O
+lower O
+at O
+the O
+time O
+of O
+the O
+reaction O
+. O
+
+Through O
+interactions O
+with O
+the O
+pre O
+- O
+mRNA O
+and O
+the O
+CTD O
+domain O
+of O
+the O
+Polymerase B
+II I
+, O
+SR B
+proteins I
+have O
+been O
+shown O
+to O
+regulate O
+alternative O
+splicing O
+. O
+
+One O
+child O
+, O
+recently O
+fed O
+, O
+vomited O
+a O
+small O
+amount O
+of O
+breast O
+milk O
+after O
+a O
+short O
+period O
+of O
+crying O
+and O
+apparently O
+had O
+a O
+laryngospasm O
+, O
+shown O
+by O
+a O
+sudden O
+drop O
+in O
+the O
+PtcO2 O
+level O
+without O
+any O
+other O
+signs O
+of O
+discomfort O
+. O
+
+Changes O
+in O
+the O
+size O
+and O
+organisation O
+of O
+the O
+brain O
+in O
+man O
+and O
+his O
+ancestors O
+. O
+
+Only O
+Staphylococcus O
+xylosus O
+SX63 O
+was O
+detected O
+as O
+a O
+strain O
+with O
+high O
+adherence O
+activity O
+. O
+
+It O
+also O
+produces O
+an O
+NH2 O
+terminus O
+that O
+corresponds O
+to O
+an O
+equivalent O
+NH2 O
+terminus O
+on O
+the O
+processed O
+matrix O
+form O
+of O
+the O
+similar O
+alpha1 B
+( I
+XI I
+) I
+chain I
+, O
+thus O
+suggesting O
+physiological O
+significance O
+. O
+
+Transmission O
+of O
+mutans O
+streptococci O
+to O
+infants O
+following O
+short O
+term O
+application O
+of O
+an O
+iodine O
+- O
+NaF O
+solution O
+to O
+mothers O
+' O
+dentition O
+. O
+
+Expression O
+of O
+Msx B
+- I
+1 I
+and O
+Msx B
+- I
+2 I
+has O
+been O
+studied O
+during O
+development O
+of O
+the O
+osteoblast O
+phenotype O
+, O
+but O
+the O
+role O
+of O
+Dlx B
+in O
+this O
+context O
+and O
+in O
+the O
+regulation O
+of O
+bone O
+- O
+expressed O
+genes O
+is O
+unknown O
+. O
+
+Scalp O
+blood O
+flow O
+was O
+recorded O
+by O
+a O
+laser O
+Doppler O
+flow O
+sensor O
+that O
+was O
+incorporated O
+in O
+the O
+transcutaneous O
+PO2 O
+electrode O
+. O
+
+DESIGN O
+: O
+Activating B
+protein I
+- I
+1 I
+( O
+AP B
+- I
+1 I
+) O
+and O
+Tat B
+- O
+induced O
+transcription O
+were O
+assessed O
+using O
+Jun B
+and O
+hybrid O
+Tat B
+/ O
+Jun B
+- O
+expression O
+plasmids O
+and O
+reporter O
+gene O
+constructs O
+which O
+contained O
+AP B
+- I
+1 I
+binding I
+sites I
+upstream O
+of O
+the O
+rat B
+prolactin I
+TATAA I
+element I
+or O
+an O
+HIV B
+- I
+1 I
+LTR I
+construct I
+in O
+which O
+AP B
+- I
+1 I
+binding I
+sites I
+replaced O
+the O
+TAR B
+element O
+. O
+
+Mycobacterium O
+tuberculosis O
+inhibits O
+IFN B
+- I
+gamma I
+transcriptional O
+responses O
+without O
+inhibiting O
+activation O
+of O
+STAT1 B
+. O
+
+Rabbit B
+KCC1 I
+( O
+rbKCC1 B
+) O
+and O
+rat B
+KCC1 I
+( O
+rtKCC1 B
+) O
+were O
+cloned O
+by O
+screening O
+rabbit O
+kidney O
+and O
+rat O
+brain O
+cDNA O
+libraries O
+using O
+homologous O
+cDNA O
+probes O
+. O
+
+However O
+, O
+using O
+wet O
+weight O
+/ O
+dry O
+weight O
+methodology O
+, O
+we O
+found O
+that O
+administration O
+of O
+U74006F O
+significantly O
+reduced O
+water O
+content O
+in O
+the O
+right O
+hippocampus O
+( O
+contralateral O
+to O
+the O
+site O
+of O
+injury O
+) O
+compared O
+to O
+saline O
+- O
+treated O
+animals O
+( O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+. O
+
+GH B
+stimulated O
+the O
+activity O
+of O
+promoter O
+fragments O
+with O
+5 O
+' O
+- O
+ends O
+between O
+nucleotide O
+( O
+nt O
+) O
+- O
+2001 O
+and O
+nt O
+- O
+653 O
+by O
+1 O
+. O
+9 O
+- O
+to O
+2 O
+. O
+7 O
+- O
+fold O
+. O
+
+We O
+have O
+recently O
+shown O
+that O
+induced O
+expression O
+of O
+a O
+CDK B
+target O
+site O
+- O
+deficient O
+mutant O
+, O
+Op18 B
+- I
+S25A O
+, O
+S38A O
+, O
+blocks O
+human O
+cell O
+lines O
+during O
+G2 O
+/ O
+M O
+transition O
+. O
+
+A O
+protein O
+which O
+promotes O
+DNA O
+strand O
+transfer O
+between O
+linear O
+double O
+- O
+stranded O
+M13mp19 B
+DNA O
+and O
+single O
+- O
+stranded O
+viral B
+M13mp19 I
+DNA I
+has O
+been O
+isolated O
+from O
+recA B
+- I
+E I
+. I
+coli I
+. O
+
+The O
+brains O
+were O
+processed O
+according O
+to O
+the O
+tetramethylbenzidine O
+( O
+TMB O
+) O
+protocol O
+of O
+Mesulam O
+( O
+' O
+78 O
+) O
+and O
+studied O
+with O
+darkfield O
+microscopy O
+. O
+
+Seizure O
+recurrence O
+( O
+HR O
+1 O
+. O
+30 O
+; O
+95 O
+% O
+CI O
+= O
+0 O
+. O
+84 O
+, O
+2 O
+. O
+01 O
+) O
+and O
+antiepileptic O
+drug O
+treatment O
+( O
+HR O
+0 O
+. O
+97 O
+; O
+95 O
+% O
+CI O
+= O
+0 O
+. O
+67 O
+, O
+1 O
+. O
+38 O
+) O
+did O
+not O
+influence O
+mortality O
+rate O
+. O
+
+One O
+day O
+postoperatively O
+, O
+the O
+mononuclear B
+leukocyte I
+beta I
+2 I
+- I
+receptor I
+density O
+decreased O
+maximally O
+by O
+45 O
++ O
+/ O
+- O
+11 O
+% O
+in O
+the O
+enflurane O
+patients O
+, O
+and O
+by O
+53 O
++ O
+/ O
+- O
+6 O
+% O
+in O
+the O
+neurolept O
+patients O
+. O
+
+The O
+serum O
+levels O
+of O
+cortisol O
+and O
+prolactin B
+after O
+nasal O
+instillation O
+of O
+a O
+suspension O
+of O
+vaginal O
+exudate O
+showed O
+lower O
+values O
+than O
+in O
+control O
+conditions O
+( O
+nasal O
+instillation O
+of O
+saline O
+) O
+. O
+
+IgE B
+antibody I
+to O
+twelve O
+common O
+food O
+and O
+inhalant O
+allergens O
+was O
+measured O
+by O
+enzyme O
+- O
+linked O
+immunosorbent O
+assay O
+( O
+ELISA O
+) O
+in O
+the O
+sera O
+of O
+thirteen O
+atopic O
+patients O
+with O
+one O
+or O
+more O
+allergic O
+disorders O
+( O
+asthma O
+occurring O
+in O
+eleven O
+; O
+rhinitis O
+in O
+ten O
+; O
+eczema O
+in O
+six O
+; O
+urticaria O
+in O
+four O
+; O
+mouth O
+and O
+gastro O
+- O
+intestinal O
+symptoms O
+in O
+six O
+) O
+, O
+of O
+twelve O
+non O
+- O
+atopic O
+patients O
+with O
+various O
+clinical O
+symptoms O
+( O
+asthma O
+in O
+four O
+; O
+rhinitis O
+in O
+four O
+; O
+eczema O
+in O
+one O
+; O
+urticaria O
+in O
+
+two O
+; O
+mouth O
+and O
+gastro O
+- O
+intestinal O
+symptoms O
+in O
+four O
+) O
+and O
+sixteen O
+cord O
+blood O
+sera O
+. O
+
+Innervation O
+of O
+reticular O
+papillae O
+in O
+sheep O
+and O
+goats O
+. O
+
+Biochemical O
+status O
+was O
+examined O
+using O
+erythrocyte O
+enzyme O
+function O
+and O
+blood O
+vitamin O
+levels O
+. O
+
+Sexual O
+adventurism O
+, O
+high O
+- O
+risk O
+behavior O
+, O
+and O
+human O
+immunodeficiency O
+virus O
+- O
+1 O
+seroconversion O
+among O
+the O
+Chicago O
+MACS O
+- O
+CCS O
+cohort O
+, O
+1984 O
+to O
+1992 O
+. O
+
+Pendulin B
+, O
+a O
+Drosophila O
+protein O
+with O
+cell O
+cycle O
+- O
+dependent O
+nuclear O
+localization O
+, O
+is O
+required O
+for O
+normal O
+cell O
+proliferation O
+. O
+
+Paradoxically O
+there O
+is O
+a O
+decrease O
+in O
+the O
+level O
+of O
+soluble O
+A B
+beta I
+secreted O
+from O
+the O
+cells O
+. O
+
+Signaling O
+through O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+and O
+Rac B
+/ O
+Rho B
+does O
+not O
+duplicate O
+the O
+effects O
+of O
+activated O
+Ras B
+on O
+skeletal O
+myogenesis O
+. O
+
+Internalization O
+of O
+prolactin B
+receptor I
+and O
+prolactin B
+in O
+transfected O
+cells O
+does O
+not O
+involve O
+nuclear O
+translocation O
+. O
+
+Using O
+mammalian O
+expression O
+vectors O
+( O
+pRSV O
+- O
+neo B
+and O
+pSV2 O
+- O
+neo O
+) O
+, O
+antisense O
+constructs O
+for O
+perforin B
+and O
+granzyme B
+B I
+were O
+independently O
+electroporated O
+into O
+YT O
+- O
+INDY O
+, O
+a O
+human O
+non O
+- O
+MHC B
+- O
+restricted O
+, O
+IL B
+- I
+2 I
+- O
+independent O
+, O
+cytotoxic O
+lymphocyte O
+. O
+
+When O
+expressed O
+in O
+Escherichia O
+coli O
+, O
+SH B
+- I
+PTP2 I
+displays O
+tyrosine B
+- I
+specific I
+phosphatase I
+activity O
+. O
+
+The O
+structure O
+elucidation O
+of O
+the O
+iridoid O
+compounds O
+2 O
+and O
+3 O
+are O
+discussed O
+in O
+detail O
+. O
+
+The O
+results O
+of O
+a O
+study O
+to O
+investigate O
+the O
+effectiveness O
+of O
+a O
+propolis O
+- O
+containing O
+mouthrinse O
+in O
+the O
+inhibition O
+of O
+de O
+novo O
+plaque O
+formation O
+are O
+presented O
+. O
+
+Effects O
+of O
+shosaikoto O
+, O
+an O
+oriental O
+herbal O
+medicinal O
+mixture O
+, O
+on O
+restraint O
+- O
+stressed O
+mice O
+. O
+
+The O
+region O
+surrounding O
+the O
+ZNF35 B
+zinc I
+finger I
+protein I
+gene I
+on O
+3p21 O
+is O
+of O
+particular O
+interest O
+, O
+as O
+this O
+region O
+of O
+chromosome O
+3 O
+is O
+frequently O
+involved O
+in O
+rearrangements O
+and O
+/ O
+or O
+deletions O
+associated O
+with O
+various O
+human O
+tumors O
+including O
+lung O
+and O
+renal O
+carcinoma O
+. O
+
+In O
+the O
+promoters O
+of O
+many O
+immediate B
+early I
+genes I
+, O
+including O
+c B
+- I
+fos I
+, O
+CArG B
+DNA I
+regulatory I
+elements I
+mediate O
+basal O
+constituitive O
+expression O
+and O
+rapid O
+and O
+transient O
+serum O
+induction O
+. O
+
+The O
+biological O
+activity O
+of O
+these O
+mutants O
+was O
+tested O
+by O
+determining O
+their O
+capacity O
+to O
+( O
+i O
+) O
+reconstitute O
+RNA B
+polymerase I
+activity O
+in O
+vivo O
+by O
+cotransfection O
+with O
+proteins B
+NP B
+, O
+PB1 B
+, O
+and O
+PA B
+and O
+a O
+virion O
+- O
+like O
+RNA O
+encoding O
+the O
+cat B
+gene I
+into O
+vaccinia O
+virus O
+T7 O
+- O
+infected O
+COS O
+- O
+1 O
+cells O
+and O
+( O
+ii O
+) O
+complete O
+with O
+the O
+wild B
+- I
+type I
+PB2 I
+activity O
+. O
+
+Transient O
+thyrotoxicosis O
+in O
+primary O
+anti O
+- O
+phospholipid O
+syndrome O
+. O
+
+We O
+were O
+unable O
+to O
+construct O
+chvI B
+or O
+chvG B
+insertion I
+mutants I
+of O
+R O
+. O
+meliloti O
+, O
+whereas O
+mutants O
+carrying O
+insertions O
+outside O
+of O
+these O
+genes O
+were O
+readily O
+obtained O
+. O
+
+Western O
+blot O
+analyses O
+reveals O
+that O
+cJun B
+and O
+the O
+C B
+/ I
+EBP I
+family I
+member O
+C B
+/ I
+EBP I
+- I
+beta I
+are O
+physiologically O
+relevant O
+transcription O
+factors O
+whose O
+expression O
+corresponds O
+with O
+mda B
+- I
+7 I
+mRNA I
+expression O
+. O
+
+In O
+isolated O
+olfactory O
+cilia O
+certain O
+odorants O
+elicit O
+a O
+rapid O
+and O
+transient O
+cAMP O
+response O
+, O
+terminated O
+by O
+a O
+concerted O
+process O
+which O
+requires O
+the O
+action O
+of O
+two O
+protein O
+kinases O
+, O
+protein B
+kinase I
+A I
+( O
+PKA B
+) O
+and O
+a O
+receptor B
+- I
+specific I
+kinase I
+( O
+GRK3 B
+) O
+( O
+Schleicher O
+, O
+S O
+. O
+, O
+Boekhoff O
+, O
+I O
+. O
+
+Acetyl B
+- I
+CoA I
+carboxylase I
+from I
+yeast I
+is O
+an O
+essential O
+enzyme O
+and O
+is O
+regulated O
+by O
+factors O
+that O
+control O
+phospholipid O
+metabolism O
+. O
+
+To O
+investigate O
+the O
+role O
+of O
+this O
+domain O
+in O
+the O
+incorporation O
+of O
+the O
+SIV B
+Env I
+into O
+virions O
+, O
+we O
+generated O
+a O
+series O
+of O
+SIV B
+Env I
+mutants I
+carrying O
+small O
+in O
+- O
+frame O
+deletions O
+within O
+the O
+cytoplasmic O
+domain O
+. O
+
+Computer O
+analysis O
+, O
+simple O
+correlation O
+hypothesis O
+, O
+and O
+distribution O
+method O
+with O
+1 O
+degree O
+of O
+freedom O
+revealed O
+significant O
+correlation O
+between O
+vertical O
+root O
+fracture O
+and O
+the O
+technique O
+of O
+instrumentation O
+and O
+obturation O
+of O
+the O
+canal O
+( O
+p O
+= O
+0 O
+. O
+025 O
+) O
+, O
+the O
+length O
+of O
+the O
+post O
+( O
+p O
+= O
+0 O
+. O
+05 O
+) O
+, O
+and O
+the O
+existence O
+of O
+the O
+post O
+( O
+p O
+= O
+0 O
+. O
+05 O
+) O
+. O
+
+Minute B
+virus I
+of I
+mice I
+NS1 I
+, O
+an O
+83 O
+- O
+kDa O
+mainly O
+nuclear O
+phosphoprotein O
+, O
+is O
+the O
+only O
+viral O
+nonstructural O
+protein O
+required O
+in O
+all O
+cell O
+types O
+and O
+it O
+is O
+involved O
+in O
+multiple O
+processes O
+necessary O
+for O
+virus O
+propagation O
+. O
+
+The O
+TDx O
+assay O
+for O
+cyclosporine O
+and O
+its O
+metabolites O
+in O
+blood O
+samples O
+compared O
+with O
+HPLC O
+and O
+RIA O
+methods O
+. O
+
+However O
+, O
+the O
+sequence O
+of O
+mRAR B
+- I
+beta I
+3 I
+region I
+A I
+differs O
+from O
+that O
+of O
+mRAR B
+- I
+beta I
+1 I
+by O
+an O
+additional O
+27 O
+C O
+- O
+terminal O
+amino O
+acids O
+encoded O
+in O
+an O
+81 O
+nucleotide O
+- O
+long O
+putative O
+exon O
+which O
+is O
+spliced O
+in O
+between O
+the O
+exons O
+encoding O
+the O
+A O
+and O
+B O
+regions O
+of O
+mRAR B
+- I
+beta I
+1 I
+. O
+
+We O
+propose O
+that O
+GCD7 B
+and O
+GCD2 B
+play O
+important O
+roles O
+in O
+the O
+regulatory O
+interaction O
+between O
+eIF B
+- I
+2 I
+and O
+eIF B
+- I
+2B I
+and O
+that O
+the O
+suppressor O
+mutations O
+we O
+isolated O
+in O
+these O
+genes O
+decrease O
+the O
+susceptibility O
+of O
+eIF B
+- I
+2B I
+to O
+the O
+inhibitory O
+effects O
+of O
+phosphorylated O
+eIF B
+- I
+2 I
+without O
+impairing O
+the O
+essential O
+catalytic O
+function O
+of O
+eIF B
+- I
+2B I
+in O
+translation O
+initiation O
+. O
+
+The O
+3 O
+' O
+region O
+of O
+the O
+transcript O
+contained O
+a O
+fully O
+conserved O
+, O
+correctly O
+spliced O
+TCR B
+alpha I
+C I
+region I
+which O
+was O
+polyadenylated O
+at O
+the O
+3 O
+' O
+end O
+. O
+
+These O
+data O
+demonstrate O
+that O
+CCTalpha B
+can O
+be O
+regulated O
+by O
+lipids O
+by O
+two O
+independent O
+domains O
+: O
+( O
+i O
+) O
+the O
+three O
+amphipathic O
+alpha O
+- O
+helical O
+repeats O
+that O
+interact O
+with O
+both O
+neutral O
+and O
+anionic O
+lipid O
+mixtures O
+and O
+( O
+ii O
+) O
+the O
+last O
+57 O
+residues O
+that O
+interact O
+with O
+anionic O
+lipids O
+. O
+
+Sorting O
+information O
+to O
+the O
+chloroplastic O
+inner O
+envelope O
+is O
+contained O
+in O
+an O
+NH2 O
+- O
+proximal O
+part O
+of O
+mature B
+IEP110 I
+( I
+110N I
+) I
+. O
+
+Most O
+of O
+these O
+elements O
+are O
+adjacent O
+to O
+type O
+X O
+telomeric O
+repeats O
+, O
+and O
+regions O
+flanking O
+four O
+of O
+five O
+characterized O
+S O
+. O
+paradoxus O
+insertions O
+carry O
+autonomously O
+replicating O
+sequences O
+. O
+
+From O
+1981 O
+to O
+1989 O
+, O
+a O
+total O
+of O
+26 O
+women O
+with O
+locally O
+or O
+regionally O
+advanced O
+carcinoma O
+of O
+the O
+uterine O
+cervix O
+were O
+treated O
+with O
+radiotherapy O
+( O
+RT O
+) O
+and O
+pelvic O
+regional O
+hyperthermia O
+( O
+HT O
+) O
+, O
+in O
+the O
+Divisions O
+of O
+Radiation O
+Oncology O
+at O
+the O
+University O
+of O
+Utah O
+Medical O
+Center O
+( O
+UU O
+) O
+and O
+the O
+Kenneth O
+Norris O
+Jr O
+Cancer O
+Hospital O
+of O
+the O
+University O
+of O
+Southern O
+California O
+( O
+USC O
+) O
+. O
+
+The O
+ARE O
+is O
+loosely O
+defined O
+as O
+the O
+five O
+- O
+nucleotide O
+sequence O
+AUUUA O
+embedded O
+in O
+a O
+uracil O
+- O
+rich O
+region O
+. O
+
+Lack O
+of O
+changes O
+in O
+milk O
+production O
+and O
+milk O
+composition O
+suggest O
+that O
+acute O
+increases O
+in O
+somatotropin B
+with O
+concomitant O
+increases O
+in O
+insulin B
+are O
+not O
+sufficient O
+to O
+stimulate O
+synthesis O
+of O
+milk O
+and O
+milk O
+components O
+by O
+cows O
+during O
+established O
+lactation O
+. O
+
+The O
+material O
+then O
+was O
+cut O
+with O
+a O
+diamond O
+saw O
+into O
+sheets O
+of O
+8 O
+x O
+10 O
+x O
+3 O
+mm O
+, O
+and O
+the O
+upper O
+surface O
+was O
+polished O
+by O
+colloidal O
+SiO2 O
+and O
+/ O
+or O
+covered O
+with O
+a O
+carbon O
+- O
+titanium O
+( O
+C O
+: O
+Ti O
+) O
+layer O
+( O
+3 O
+. O
+3 O
+microm O
+) O
+using O
+the O
+plasma O
+- O
+enhanced O
+physical O
+vapor O
+deposition O
+method O
+. O
+
+Iomazenil O
+- O
+SPECT O
+revealed O
+a O
+highly O
+significant O
+increase O
+in O
+the O
+benzodiazepine B
+receptor I
+uptake O
+in O
+all O
+studied O
+cortical O
+regions O
+except O
+temporal O
+cortices O
+. O
+
+Both O
+in O
+the O
+Federal O
+Republic O
+of O
+Germany O
+and O
+in O
+some O
+neighbouring O
+countries O
+the O
+epizootic O
+situation O
+of O
+Aujeszky O
+' O
+s O
+disease O
+has O
+been O
+unsatisfactory O
+for O
+a O
+long O
+time O
+, O
+especially O
+in O
+areas O
+with O
+a O
+high O
+pig O
+density O
+. O
+
+Since O
+RIP140 B
+generally O
+down O
+- O
+regulates O
+receptor O
+activity O
+in O
+mammalian O
+cells O
+and O
+specifically O
+down O
+- O
+regulates O
+coactivation O
+mediated O
+by O
+SRC B
+- I
+1 I
+, O
+we O
+propose O
+a O
+model O
+in O
+which O
+RIP140 B
+indirectly O
+regulates O
+nuclear O
+receptor O
+AF O
+- O
+2 O
+activity O
+by O
+competition O
+for O
+coactivators O
+such O
+as O
+SRC B
+- I
+1 I
+. O
+
+DIC O
+and O
+low O
+grade O
+fibrinolysis O
+may O
+account O
+for O
+the O
+coagulation O
+abnormalities O
+of O
+the O
+syndrome O
+. O
+
+As O
+in O
+the O
+case O
+of O
+the O
+chicken O
+homologue O
+, O
+there O
+are O
+two O
+hPR B
+forms O
+, O
+A O
+and O
+B O
+, O
+which O
+originate O
+from O
+translational O
+initiation O
+at O
+AUG2 O
+( O
+codon O
+165 O
+) O
+and O
+AUG1 O
+, O
+respectively O
+. O
+
+Fluctuations O
+of O
+the O
+measured O
+ECF O
+energy O
+- O
+related O
+substances O
+corresponded O
+to O
+various O
+clinical O
+events O
+presumably O
+involving O
+hypoxia O
+/ O
+ischemia O
+. O
+
+Using O
+lasers O
+in O
+diabetic O
+wound O
+healing O
+. O
+
+Furthermore O
+, O
+the O
+zincon O
+- O
+loaded O
+resin O
+was O
+applied O
+to O
+the O
+selective O
+concentration O
+of O
+trace O
+amounts O
+of O
+chalcophile O
+elements O
+in O
+natural O
+water O
+samples O
+prior O
+to O
+neutron O
+activation O
+analysis O
+. O
+
+In O
+cells O
+stably O
+transfected O
+with O
+G B
+alpha I
+i I
+- I
+2 I
+or O
+G B
+alpha I
+i I
+- I
+3 I
+gene I
+5 O
+' O
+- O
+flanking O
+sequences O
+fused O
+to O
+firefly B
+luciferase I
+cDNA I
+reporter I
+, O
+temporal O
+10 O
+- O
+15 O
+- O
+fold O
+transcriptional O
+activation O
+of O
+both O
+genes O
+occurred O
+before O
+cellular O
+polarization O
+. O
+
+CONCLUSIONS O
+: O
+These O
+results O
+suggest O
+that O
+histamine B
+- I
+2 I
+receptor I
+activation O
+mechanisms O
+may O
+not O
+be O
+involved O
+in O
+postoperative O
+IL B
+- I
+6 I
+synthesis O
+. O
+
+In O
+resume O
+response O
+to O
+treatment O
+with O
+usual O
+regimens O
+, O
+doxycycline O
+plus O
+streptomycin O
+of O
+doxycycline O
+rifampicin O
+is O
+good O
+, O
+being O
+however O
+time O
+elapsed O
+until O
+pain O
+ceases O
+of O
+mean O
+length O
+in O
+hospital O
+stay O
+shorter O
+in O
+the O
+group O
+receiving O
+doxycycline O
+plus O
+streptomycin O
+. O
+
+Fibrosis O
+of O
+the O
+adjacent O
+myocardium O
+was O
+seen O
+in O
+five O
+cases O
+. O
+
+Purified O
+preparations O
+of O
+all O
+four O
+AGT B
+mutants I
+showed O
+an O
+approximately O
+similar O
+degree O
+( O
+74 O
+- O
+120 O
+- O
+fold O
+) O
+of O
+reduction O
+in O
+the O
+rate O
+of O
+reaction O
+with O
+O6 O
+- O
+benzylguanine O
+. O
+
+Significant O
+reductions O
+were O
+noted O
+in O
+vertical O
+GRFs O
+per O
+newton O
+of O
+body O
+weight O
+exerted O
+at O
+10 O
+% O
+( O
+P O
+= O
+0 O
+. O
+0009 O
+) O
+and O
+20 O
+% O
+( O
+P O
+= O
+0 O
+. O
+0383 O
+) O
+of O
+stance O
+phase O
+and O
+in O
+anteroposterior O
+GRFs O
+exerted O
+at O
+10 O
+% O
+( O
+P O
+= O
+0 O
+. O
+0009 O
+) O
+and O
+50 O
+% O
+( O
+P O
+= O
+0 O
+. O
+0033 O
+) O
+of O
+stance O
+phase O
+when O
+ambulation O
+was O
+compared O
+with O
+and O
+without O
+the O
+orthotic O
+device O
+. O
+
+Identification O
+of O
+a O
+68 B
+- I
+kilodalton I
+nuclear I
+ATP I
+- I
+binding I
+phosphoprotein I
+encoded O
+by O
+bovine O
+papillomavirus O
+type O
+1 O
+. O
+
+It O
+is O
+suggested O
+that O
+biliary O
+secretion O
+of O
+both O
+TBZ O
+and O
+FBZ O
+and O
+their O
+metabolites O
+may O
+contribute O
+to O
+this O
+recycling O
+. O
+
+During O
+chordotonal O
+organ O
+development O
+, O
+the O
+3 O
+' O
+enhancer O
+directs O
+expression O
+in O
+proneural O
+clusters O
+; O
+whereas O
+successive O
+modular O
+enhancers O
+located O
+in O
+the O
+5 O
+' O
+region O
+drive O
+tissue O
+- O
+specific O
+expression O
+in O
+chordotonal O
+organ O
+precursors O
+in O
+the O
+embryo O
+and O
+larval O
+leg O
+, O
+wing O
+and O
+antennal O
+imaginal O
+discs O
+. O
+
+The O
+use O
+of O
+self O
+- O
+measured O
+blood O
+pressure O
+determinations O
+in O
+assessing O
+dynamics O
+of O
+drug O
+compliance O
+in O
+a O
+study O
+with O
+amlodipine O
+once O
+a O
+day O
+, O
+morning O
+versus O
+evening O
+. O
+
+Nucleocapsid O
+structure O
+and O
+thermostability O
+of O
+the O
+virion O
+, O
+nucleocapsid O
+and O
+polymerase O
+complex O
+. O
+
+A O
+vascular O
+component O
+to O
+impotence O
+was O
+shown O
+to O
+be O
+common O
+in O
+those O
+with O
+neurological O
+impairment O
+, O
+and O
+may O
+alter O
+management O
+. O
+
+RESULTS O
+- O
+- O
+The O
+maximal O
+early O
+asthmatic O
+response O
+after O
+allergen O
+with O
+placebo O
+treatment O
+was O
+18 O
+. O
+4 O
+% O
+( O
+SE O
+4 O
+. O
+4 O
+% O
+) O
+and O
+with O
+WEB O
+2086 O
+18 O
+. O
+9 O
+% O
+( O
+4 O
+. O
+4 O
+% O
+) O
+. O
+
+Column O
+chromatographic O
+determination O
+of O
+polymyxin O
+B O
+sulfate O
+. O
+
+Usefulness O
+of O
+computerized O
+tomography O
+in O
+hemodialysis O
+patients O
+. O
+
+The O
+aim O
+of O
+our O
+study O
+was O
+to O
+determine O
+whether O
+exercise O
+training O
+can O
+augment O
+left O
+ventricular O
+diastolic O
+filling O
+at O
+rest O
+and O
+during O
+exercise O
+in O
+patients O
+with O
+ischemic O
+cardiomyopathy O
+and O
+whether O
+any O
+correlation O
+exists O
+between O
+changes O
+in O
+diastolic O
+filling O
+and O
+changes O
+in O
+exercise O
+tolerance O
+. O
+
+On O
+the O
+pharmacology O
+of O
+9 O
+, O
+10 O
+- O
+dihydro O
+- O
+10 O
+- O
+( O
+1 O
+- O
+methyl O
+- O
+4 O
+- O
+piperidylidene O
+) O
+- O
+9 O
+- O
+anthrol O
+( O
+WA O
+335 O
+) O
+, O
+a O
+histamine O
+and O
+serotonin O
+antagonist O
+
+METHODOLOGY O
+: O
+A O
+case O
+control O
+study O
+of O
+survivors O
+with O
+gestational O
+age O
+( O
+GA O
+) O
+< O
+28 O
+weeks O
+or O
+birthweight O
+( O
+BW O
+) O
+< O
+1000 O
+g O
+using O
+data O
+collected O
+prospectively O
+in O
+our O
+Neonatal O
+Intensive O
+Care O
+Unit O
+database O
+. O
+
+There O
+are O
+two O
+regulatory O
+regions O
+between O
+the O
+US3 B
+and O
+the O
+US6 B
+transcription I
+units I
+. O
+
+Database O
+searches O
+revealed O
+a O
+50 O
+- O
+63 O
+% O
+similarity O
+and O
+34 O
+- O
+42 O
+% O
+identity O
+with O
+several O
+families O
+of O
+serine B
+proteases I
+, O
+in O
+particular O
+the O
+trypsin B
+- I
+like I
+proteases I
+, O
+members O
+of O
+the O
+glandular B
+kallikrein I
+family I
+( O
+including O
+prostate B
+- I
+specific I
+antigen I
+, O
+nerve B
+growth I
+factor I
+gamma I
+, O
+and O
+epidermal B
+growth I
+factor I
+- I
+binding I
+protein I
+) O
+and O
+the O
+activators O
+for O
+the O
+kringle B
+family I
+proteins I
+( O
+including O
+the O
+human B
+tissue I
+plasminogen I
+activator I
+and O
+human B
+hepatocyte I
+growth I
+factor I
+activator I
+) O
+. O
+
+Manifestation O
+of O
+superfluidity O
+in O
+an O
+evolving O
+bose O
+- O
+einstein O
+condensed O
+Gas O
+We O
+study O
+the O
+generation O
+of O
+excitations O
+due O
+to O
+an O
+" O
+impurity O
+" O
+( O
+static O
+perturbation O
+) O
+placed O
+into O
+an O
+oscillating O
+Bose O
+- O
+Einstein O
+condensed O
+gas O
+in O
+the O
+time O
+- O
+dependent O
+trapping O
+field O
+. O
+
+4 O
+. O
+7 O
++ O
+/ O
+- O
+0 O
+. O
+6 O
+micromol O
+. O
+
+kg O
+- O
+1 O
+. O
+
+min O
+- O
+1 O
+) O
+but O
+was O
+not O
+changed O
+by O
+training O
+. O
+
+We O
+established O
+that O
+, O
+in O
+unstimulated O
+lymphocytes O
+, O
+the O
+Src B
+homology I
+2 I
+( O
+SH2 B
+) O
+and O
+SH3 B
+domain O
+- O
+containing O
+protein O
+Grb2 B
+and O
+the O
+p85 B
+subunit I
+of O
+phosphatidylinositol B
+3 I
+- I
+kinase I
+, O
+associate O
+constitutively O
+with O
+Cbl B
+via O
+their O
+SH3 B
+domains O
+. O
+
+Zta B
+stimulated O
+the O
+HAT B
+activity O
+of O
+CBP B
+that O
+had O
+been O
+partially O
+purified O
+or O
+immunoprecipitated O
+from O
+mammalian O
+cells O
+as O
+well O
+as O
+from O
+affinity O
+- O
+purified O
+, O
+baculovirus O
+expressed O
+CBP B
+. O
+
+Increased O
+gliadin B
+antibody I
+levels O
+were O
+found O
+more O
+frequently O
+in O
+patients O
+with O
+subtotal O
+villous O
+atrophy O
+( O
+9 O
+out O
+of O
+17 O
+patients O
+, O
+or O
+53 O
+% O
+; O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+than O
+in O
+patients O
+with O
+partial O
+villous O
+atrophy O
+( O
+2 O
+out O
+of O
+13 O
+patients O
+, O
+or O
+15 O
+% O
+) O
+or O
+normal O
+villous O
+appearance O
+( O
+2 O
+out O
+of O
+10 O
+patients O
+, O
+or O
+20 O
+% O
+) O
+. O
+
+However O
+, O
+the O
+optimum O
+compressive O
+strength O
+reached O
+values O
+up O
+to O
+40 O
+% O
+higher O
+than O
+CC O
+- O
+free O
+samples O
+. O
+
+Expression O
+of O
+the O
+Hox B
+genes I
+egl B
+- I
+5 I
+and O
+mab B
+- I
+5 I
+is O
+reduced O
+in O
+lin B
+- I
+49 I
+and O
+lin B
+- I
+59 I
+mutants I
+, O
+suggesting O
+lin B
+- I
+49 I
+and O
+lin B
+- I
+59 I
+regulate O
+HOM B
+- I
+C I
+gene I
+expression O
+in O
+C O
+. O
+elegans O
+as O
+the O
+trx B
+- I
+G I
+genes I
+do O
+in O
+Drosophila O
+. O
+
+lin B
+- I
+49 I
+and O
+lin B
+- I
+59 I
+transgenes I
+are O
+expressed O
+widely O
+throughout O
+C O
+. O
+elegans O
+animals O
+. O
+
+Interleukin B
+- I
+1 I
+increased O
+the O
+noradrenaline O
+release O
+. O
+
+Magnetic O
+field O
+influence O
+on O
+central O
+nervous O
+system O
+function O
+. O
+
+3 O
+patients O
+with O
+acute O
+leukaemia O
+, O
+HLA B
+antibodies I
+and O
+thrombocytopenia O
+refractory O
+to O
+random O
+donor O
+platelet O
+transfusions O
+were O
+treated O
+with O
+high O
+- O
+dose O
+i O
+. O
+v O
+. O
+immunoglobulin B
+. O
+
+Two O
+genes O
+( O
+ptsI B
+and O
+ptsA B
+) O
+that O
+encode O
+homologues O
+of O
+the O
+energy B
+coupling I
+Enzyme I
+I I
+of O
+the O
+phosphoenolpyruvate B
+- I
+dependent I
+sugar I
+- I
+transporting I
+phosphotransferase I
+system O
+( O
+PTS O
+) O
+have O
+previously O
+been O
+identified O
+on O
+the O
+Escherichia O
+coli O
+chromosome O
+. O
+
+Eight O
+of O
+these O
+suppressors O
+for O
+into O
+two O
+complementation O
+groups O
+, O
+designated O
+KCS1 B
+and O
+KCS2 B
+. O
+
+These O
+results O
+point O
+towards O
+post O
+- O
+translational O
+steric O
+and O
+/ O
+or O
+allosteric O
+control O
+of O
+EKLF B
+function O
+that O
+may O
+be O
+important O
+not O
+just O
+for O
+its O
+DNA O
+binding O
+ability O
+, O
+but O
+also O
+for O
+its O
+potential O
+to O
+interact O
+with O
+other O
+proteins O
+that O
+fully O
+establish O
+the O
+correct O
+stereospecific O
+array O
+leading O
+to O
+efficient O
+switching O
+of O
+beta B
+- I
+globin I
+transcription O
+during O
+development O
+. O
+
+Oxalates O
+and O
+the O
+digestive O
+tract O
+
+However O
+, O
+the O
+addition O
+of O
+intravenous O
+injection O
+of O
+FPFD O
+101 O
+resulted O
+in O
+a O
+marked O
+improvement O
+in O
+their O
+symptoms O
+. O
+
+Western O
+blot O
+experiments O
+detected O
+SMBP B
+as O
+a O
+70 O
+kDa O
+protein O
+that O
+may O
+be O
+further O
+cleaved O
+into O
+an O
+active O
+34 O
+kDa O
+N O
+- O
+terminal O
+polypeptide O
+. O
+
+The O
+aetiology O
+and O
+management O
+of O
+diabetic O
+impotence O
+is O
+well O
+- O
+documented O
+; O
+the O
+effects O
+of O
+diabetes O
+on O
+female O
+sexuality O
+are O
+not O
+so O
+clear O
+. O
+
+Treatment O
+of O
+diabetes O
+and O
+retinal O
+complications O
+
+The O
+activated O
+glucocorticoid B
+receptor I
+forms O
+a O
+complex O
+with O
+Stat5 B
+and O
+enhances O
+Stat5 B
+- O
+mediated O
+transcriptional O
+induction O
+. O
+
+Taken O
+together O
+, O
+these O
+findings O
+demonstrate O
+that O
+ZNF76 B
+and O
+ZNF143 B
+are O
+two O
+members O
+of O
+a O
+same O
+family O
+of O
+transactivator O
+proteins O
+. O
+
+For O
+example O
+, O
+the O
+presence O
+of O
+two O
+related O
+genes O
+, O
+b B
+and O
+b B
+' I
+, O
+in O
+the O
+cyanobacterium O
+suggests O
+that O
+its O
+ATP B
+synthase I
+is O
+a O
+complex O
+of O
+nine O
+polypeptides O
+, O
+and O
+that O
+it O
+may O
+have O
+single O
+copies O
+of O
+related O
+b B
+and O
+b B
+' I
+proteins I
+rather O
+than O
+two O
+copies O
+of O
+identical O
+b O
+subunits O
+as O
+found O
+in O
+the O
+E O
+. O
+coli O
+enzyme O
+. I
+4 I
++ I
+off I
+
+Antiserum O
+raised O
+against O
+rat B
+liver I
+S6 I
+kinase I
+specifically O
+immunoprecipitates O
+the O
+purified O
+32P O
+- O
+labeled O
+H4 O
+hepatoma O
+insulin B
+- O
+stimulated O
+S6 B
+kinase I
+. O
+
+CRKL B
+, O
+an O
+SH2 B
+- O
+SH3 B
+- O
+SH3 B
+adapter O
+protein O
+, O
+is O
+one O
+of O
+the O
+major O
+tyrosine O
+phosphoproteins O
+detected O
+in O
+primary O
+leukemic O
+neutrophils O
+from O
+patients O
+with O
+CML O
+. O
+
+KU O
+- O
+1257 O
+also O
+significantly O
+accelerated O
+the O
+healing O
+of O
+acetic O
+acid O
+- O
+induced O
+duodenal O
+ulcers O
+as O
+well O
+as O
+famotidine O
+and O
+roxatidine O
+acetate O
+. O
+
+To O
+further O
+identify O
+the O
+residues O
+responsible O
+for O
+the O
+activity O
+, O
+we O
+isolated O
+the O
+mutant O
+viruses O
+that O
+were O
+not O
+neutralized O
+with O
+the O
+soluble O
+form O
+of O
+MHV B
+receptor I
+proteins I
+, O
+since O
+such O
+mutants O
+were O
+expected O
+to O
+have O
+mutations O
+in O
+amino O
+acids O
+responsible O
+for O
+receptor O
+- O
+binding O
+activity O
+. O
+
+It O
+is O
+suggested O
+that O
+death O
+of O
+S O
+. O
+mansoni O
+cercariae O
+during O
+penetration O
+of O
+mammalian O
+host O
+skin O
+is O
+probably O
+due O
+to O
+exhaustion O
+of O
+their O
+energy O
+reserves O
+. O
+
+Especially O
+if O
+the O
+number O
+of O
+dimensions O
+of O
+the O
+samples O
+is O
+large O
+, O
+it O
+can O
+be O
+said O
+that O
+BPN O
+is O
+better O
+than O
+k O
+- O
+NN O
+in O
+classification O
+ability O
+. O
+
+In O
+contrast O
+, O
+inactivation O
+of O
+the O
+Sir4p B
+- I
+interacting I
+protein I
+Rap1p B
+reduces O
+partitioning O
+by O
+a O
+LexA B
+- O
+Sir4p B
+fusion O
+. O
+
+Nine O
+individuals O
+who O
+were O
+stable O
+after O
+1 O
+month O
+of O
+therapy O
+at O
+low O
+dosage O
+were O
+randomized O
+to O
+a O
+further O
+month O
+of O
+therapy O
+at O
+low O
+or O
+high O
+dosage O
+, O
+during O
+which O
+one O
+of O
+four O
+at O
+high O
+dosage O
+had O
+a O
+partial O
+response O
+, O
+and O
+none O
+of O
+five O
+at O
+low O
+dosage O
+manifested O
+response O
+. O
+
+BACKGROUND O
+: O
+Murine B
+Nramp I
+is O
+a O
+candidate O
+for O
+the O
+macrophage O
+resistance O
+gene O
+Ity B
+/ O
+Lsh B
+/ O
+Bcg B
+. O
+
+In O
+cases O
+in O
+which O
+it O
+was O
+identified O
+, O
+insulitis O
+affected O
+23 O
+% O
+of O
+islets O
+containing O
+insulin B
+, O
+but O
+affected O
+only O
+1 O
+% O
+of O
+islets O
+which O
+were O
+insulin B
+deficient O
+, O
+thus O
+supporting O
+the O
+concept O
+that O
+insulitis O
+represents O
+an O
+immunologically O
+mediated O
+destruction O
+of O
+insulin B
+secreting O
+B O
+cells O
+. O
+
+( O
+4 O
+) O
+Expression O
+in O
+different O
+sites O
+in O
+the O
+central O
+nervous O
+system O
+is O
+driven O
+by O
+separable O
+elements O
+widely O
+dispersed O
+throughout O
+8 O
+kb O
+3 O
+' O
+of O
+the O
+gene O
+. O
+
+To O
+investigate O
+possible O
+roles O
+for O
+HCP B
+during O
+late O
+erythroid O
+differentiation O
+, O
+effects O
+of O
+manipulating O
+HCP B
+expression O
+or O
+recruitment O
+on O
+EPO B
+- O
+induced O
+hemoglobinization O
+in O
+erythroleukemic O
+SKT6 O
+cells O
+have O
+been O
+investigated O
+. O
+
+The O
+other O
+end O
+of O
+this O
+cluster O
+contained O
+the O
+human B
+type I
+I I
+cytokeratin I
+K20 I
+and O
+K12 B
+gene I
+loci I
+. O
+
+An O
+11 O
+. O
+5 O
+- O
+kb O
+intron O
+is O
+found O
+at O
+the O
+end O
+of O
+transmembrane O
+6 O
+, O
+and O
+the O
+rest O
+of O
+the O
+ORF O
+is O
+in O
+exon O
+3 O
+. O
+
+Are O
+there O
+any O
+lessons O
+to O
+be O
+learnt O
+? O
+
+Eighteen O
+patients O
+with O
+advanced O
+epidermoid O
+carcinoma O
+of O
+the O
+head O
+and O
+neck O
+were O
+entered O
+into O
+a O
+phase O
+II O
+trial O
+of O
+N O
+- O
+Methylformamide O
+( O
+NMF O
+) O
+, O
+800 O
+mg O
+/ O
+M2 O
+IV O
+daily O
+for O
+5 O
+days O
+every O
+4 O
+weeks O
+. O
+
+We O
+provided O
+evidence O
+that O
+CaM B
+kinase I
+II I
+played O
+a O
+role O
+in O
+regulating O
+neurite O
+outgrowth O
+and O
+growth O
+cone O
+motility O
+in O
+these O
+cells O
+, O
+and O
+that O
+the O
+autophosphorylation O
+is O
+essential O
+for O
+the O
+kinase O
+to O
+sufficiently O
+exert O
+its O
+cellular O
+function O
+in O
+vivo O
+[ O
+Y O
+. O
+
+However O
+, O
+in O
+transient O
+transfection O
+assays O
+, O
+a O
+truncation O
+of O
+as O
+little O
+as O
+15 O
+Nurr1 B
+COOH O
+- O
+terminal O
+amino O
+acids O
+diminished O
+transcriptional O
+activation O
+of O
+B1A B
+- O
+thymidine B
+kinase I
+- O
+chloramphenicol B
+acetyltransferase I
+reporter O
+. O
+
+All O
+sows O
+nursed O
+nine O
+pigs O
+. O
+
+In O
+the O
+second O
+group O
+the O
+untreated O
+fellow O
+eye O
+was O
+microscopically O
+intact O
+, O
+but O
+was O
+shown O
+( O
+as O
+the O
+treated O
+eye O
+) O
+to O
+alter O
+the O
+concentration O
+of O
+uronic O
+acid O
+in O
+different O
+parts O
+of O
+the O
+sclera O
+. O
+
+Effects O
+were O
+studied O
+of O
+extremely O
+high O
+- O
+frequency O
+electromagnetic O
+radiation O
+( O
+EHF O
+EMR O
+) O
+on O
+indices O
+for O
+the O
+immune O
+and O
+endocrine O
+systems O
+in O
+a O
+series O
+of O
+48 O
+patients O
+presenting O
+with O
+hyperplastic O
+processes O
+in O
+endometrium O
+. O
+
+Characterization O
+of O
+human B
+activating I
+transcription I
+factor I
+4 I
+, O
+a O
+transcriptional O
+activator O
+that O
+interacts O
+with O
+multiple O
+domains O
+of O
+cAMP B
+- I
+responsive I
+element I
+- I
+binding I
+protein I
+( I
+CREB I
+) I
+- I
+binding I
+protein I
+. O
+
+Effect O
+of O
+a O
+constant O
+magnetic O
+field O
+on O
+different O
+models O
+of O
+carcinogenesis O
+
+In O
+contrast O
+to O
+the O
+reciprocal O
+effects O
+of O
+Gab1 B
+and O
+Gab2 B
+in O
+mediating O
+Elk B
+- I
+1 I
+induction O
+, O
+these O
+two O
+molecules O
+have O
+a O
+similar O
+function O
+in O
+extracellular B
+signal I
+- I
+regulated I
+kinase I
+activation O
+induced O
+by O
+either O
+oncogenic B
+Ras I
+or O
+growth O
+factor O
+stimulation O
+. O
+
+This O
+result O
+is O
+consistent O
+with O
+the O
+previous O
+observation O
+that O
+expression O
+of O
+the O
+hsp70 B
+genes I
+in O
+T O
+. O
+brucei O
+is O
+mainly O
+controlled O
+at O
+the O
+posttranscriptional O
+level O
+. O
+
+A O
+definition O
+of O
+bias O
+founded O
+on O
+the O
+concept O
+of O
+the O
+study O
+base O
+. O
+
+Chromaffin O
+cells O
+transfected O
+with O
+a O
+plasmid O
+with O
+the O
+entire O
+coding O
+sequence O
+of O
+c B
+- I
+Rabphilin3a I
+inserted O
+in O
+the O
+antisense O
+orientation O
+inhibited O
+secretion O
+of O
+co O
+- O
+expressed O
+GH B
+by O
+approximately O
+30 O
+% O
+. O
+
+Using O
+a O
+set O
+of O
+sera O
+for O
+which O
+full O
+chlamydial O
+micro O
+- O
+immunofluorescence O
+results O
+suggested O
+a O
+clear O
+diagnosis O
+, O
+we O
+have O
+evaluated O
+the O
+Chlamydia O
+Spot O
+- O
+IF O
+test O
+( O
+bioMerieux O
+) O
+, O
+which O
+allows O
+a O
+comparison O
+of O
+titres O
+to O
+Chlamydia O
+trachomatis O
+and O
+C O
+. O
+psittaci O
+antigens O
+. O
+
+An O
+environmental O
+investigation O
+found O
+evidence O
+of O
+suboptimal O
+food O
+storage O
+and O
+cooking O
+temperatures O
+at O
+Restaurant O
+A O
+; O
+cross O
+contamination O
+of O
+foods O
+may O
+have O
+contributed O
+to O
+the O
+low O
+attributable O
+risk O
+identified O
+for O
+chile O
+rellenos O
+. O
+
+Evidence O
+from O
+four O
+areas O
+- O
+- O
+sensory O
+deprivation O
+, O
+enriched O
+environments O
+, O
+nervous O
+system O
+plasticity O
+, O
+and O
+sensitive O
+periods O
+of O
+neurodevelopment O
+- O
+- O
+suggests O
+that O
+sensory O
+stimulation O
+programs O
+are O
+potentially O
+beneficial O
+for O
+STR O
+patients O
+. O
+
+In O
+each O
+study O
+group O
+, O
+elevated O
+levels O
+of O
+serum O
+I O
+were O
+observed O
+. O
+
+With O
+repetitive O
+intermittent O
+exercise O
+, O
+gradual O
+increases O
+in O
+blood O
+lactate O
+concentration O
+[ O
+( O
+LA O
+] O
+b O
+) O
+occurred O
+, O
+whereas O
+its O
+rate O
+of O
+accumulation O
+( O
+delta O
+[ O
+LA O
+] O
+b O
+) O
+decreased O
+. O
+
+A O
+physical O
+and O
+genetic O
+map O
+covering O
+the O
+entire O
+RP12 B
+candidate I
+gene I
+region I
+was O
+constructed O
+. O
+
+The O
+single O
+copy O
+flotillin B
+- I
+1 I
+gene I
+is O
+located O
+at O
+6p21 O
+. O
+3 O
+in O
+the O
+MHC B
+class I
+I I
+region I
+and O
+consists O
+of O
+13 O
+exons O
+over O
+15 O
+kb O
+. O
+
+An O
+atypical O
+form O
+of O
+juvenile O
+myasthenia O
+gravis O
+associated O
+with O
+severe O
+emaciation O
+, O
+muscle O
+atrophy O
+, O
+ophthalmoplegia O
+, O
+bulbar O
+signs O
+and O
+joint O
+contracture O
+
+The O
+in O
+vivo O
+response O
+of O
+the O
+PacC B
+- I
+like I
+decamers I
+to O
+external O
+pH O
+was O
+dependent O
+on O
+the O
+status O
+of O
+the O
+pH O
+- O
+regulated O
+activator O
+YlRim101p B
+, O
+which O
+is O
+homologous O
+to O
+the O
+A B
+. I
+nidulans I
+PacC I
+regulator I
+. O
+
+Electron O
+microscopic O
+visualization O
+of O
+the O
+general O
+population O
+of O
+active O
+genes O
+in O
+flies O
+overexpressing O
+hnRNP O
+proteins O
+also O
+indicated O
+that O
+the O
+great O
+majority O
+of O
+genes O
+seemed O
+normal O
+in O
+terms O
+of O
+cotranscriptional O
+RNA O
+processing O
+events O
+, O
+although O
+there O
+were O
+a O
+few O
+abnormalities O
+consistent O
+with O
+rare O
+exon O
+- O
+skipping O
+events O
+. O
+
+Having O
+demonstrated O
+proper O
+localization O
+of O
+GFP B
+- O
+calmodulin B
+in O
+budding O
+yeast O
+, O
+we O
+examined O
+the O
+localization O
+of O
+a O
+fusion O
+between O
+GFP B
+and O
+calmodulin B
+( O
+GFP B
+- O
+Camlp B
+) O
+in O
+fission O
+yeast O
+, O
+where O
+calmodulin B
+had O
+not O
+been O
+localized O
+by O
+any O
+method O
+. O
+
+Sera O
+from O
+33 O
+newborn O
+infants O
+with O
+gestational O
+ages O
+ranging O
+from O
+27 O
+to O
+41 O
+weeks O
+were O
+tested O
+by O
+radioimmunoassay O
+for O
+IgG B
+antibodies I
+to O
+surface O
+antigens O
+of O
+group O
+B O
+streptococci O
+( O
+GBS O
+) O
+types O
+Ia O
+, O
+Ib O
+, O
+II O
+and O
+III O
+. O
+
+In O
+frozen O
+sections O
+the O
+spots O
+appear O
+as O
+blue O
+labelled O
+neurones O
+with O
+a O
+light O
+microscope O
+, O
+or O
+as O
+a O
+brilliant O
+red O
+neurones O
+surrounded O
+by O
+reddish O
+tissue O
+with O
+a O
+fluorescence O
+microscope O
+. O
+
+The O
+percentage O
+distribution O
+of O
+types O
+of O
+fixation O
+disparity O
+curves O
+was O
+found O
+to O
+be O
+similar O
+to O
+some O
+previous O
+studies O
+, O
+with O
+a O
+higher O
+prevalence O
+of O
+Type O
+I O
+curve O
+( O
+64 O
+. O
+3 O
+% O
+) O
+, O
+followed O
+by O
+Type O
+II O
+( O
+28 O
+. O
+6 O
+% O
+) O
+and O
+Type O
+III O
+( O
+7 O
+. O
+1 O
+% O
+) O
+curves O
+. O
+
+The O
+BUR O
+was O
+set O
+at O
+20 O
+/ O
+min O
+and O
+the O
+IT O
+at O
+. O
+5 O
+seconds O
+. O
+
+These O
+data O
+are O
+discussed O
+in O
+the O
+context O
+of O
+the O
+pathogenesis O
+and O
+differential O
+diagnosis O
+of O
+EEC O
+. O
+
+Seminal B
+prolactin I
+levels O
+were O
+significantly O
+elevated O
+in O
+all O
+infertile O
+males O
+. O
+
+Northern O
+blot O
+analysis O
+identified O
+retina O
+- O
+specific O
+transcripts O
+of O
+3 O
+. O
+0 O
+kb O
+for O
+rod B
+G I
+alpha I
+t I
+and O
+2 O
+. O
+6 O
+kb O
+for O
+cone B
+G I
+alpha I
+t I
+. O
+
+In O
+the O
+univariate O
+models O
+of O
+either O
+fixed O
+or O
+time O
+dependent O
+covariates O
+, O
+many O
+variables O
+were O
+significantly O
+associated O
+with O
+risk O
+of O
+progression O
+to O
+AIDS O
+( O
+T4 O
+cell O
+count O
+, O
+T4 O
+/ O
+T8 O
+ratio O
+, O
+blastogenic O
+responses O
+to O
+phytohemagglutinin B
+, O
+concanavalin B
+A I
+, O
+and O
+pokeweed B
+mitogen I
+, O
+serum B
+IgA I
+, O
+appearance O
+of O
+p24 B
+antigen I
+, O
+and O
+the O
+development O
+of O
+oral O
+hairy O
+leukoplakia O
+, O
+thrush O
+, O
+or O
+herpes O
+zoster O
+) O
+. O
+
+Adenovirus O
+- O
+mediated O
+gene O
+transfer O
+of O
+MMAC1 B
+/ O
+PTEN B
+to O
+glioblastoma O
+cells O
+inhibits O
+S O
+phase O
+entry O
+by O
+the O
+recruitment O
+of O
+p27Kip1 B
+into O
+cyclin B
+E I
+/ O
+CDK2 B
+complexes O
+. O
+
+Cost O
+analysis O
+and O
+the O
+HSA O
+: O
+a O
+framework O
+. O
+
+These O
+cells O
+also O
+showed O
+an O
+increase O
+in O
+cyclin B
+A I
+and O
+cyclin B
+A I
+- I
+and I
+E I
+- I
+associated I
+kinase I
+activities O
+characteristic O
+of O
+S O
+phase O
+induction O
+. O
+
+Characterization O
+of O
+a O
+tonB B
+- O
+phoA B
+gene O
+fusion O
+suggests O
+that O
+the O
+amino O
+- O
+terminal O
+41 O
+amino O
+acids O
+of O
+TonB B
+are O
+sufficient O
+to O
+promote O
+export O
+of O
+the O
+fusion O
+protein O
+and O
+presumably O
+TonB B
+as O
+well O
+. O
+
+Calcium O
+bilirubinate O
+crystals O
+were O
+seen O
+in O
+gallbladder O
+bile O
+or O
+wall O
+scrapings O
+of O
+7 O
+of O
+8 O
+TPN O
+animals O
+but O
+in O
+none O
+of O
+the O
+controls O
+( O
+P O
+less O
+than O
+0 O
+. O
+001 O
+) O
+. O
+
+This O
+domain O
+encompasses O
+the O
+region O
+of O
+ARP B
+- I
+1 I
+/ O
+COUP B
+- I
+TFII I
+corresponding O
+to O
+helices O
+3 O
+to O
+12 O
+in O
+the O
+recently O
+published O
+crystal O
+structure O
+of O
+other O
+members O
+of O
+the O
+nuclear B
+receptor I
+superfamily I
+. O
+
+Different O
+clinical O
+variants O
+of O
+the O
+empty O
+sella O
+turcica O
+syndrome O
+are O
+demonstrated O
+, O
+including O
+variants O
+resultant O
+from O
+substitution O
+therapy O
+of O
+thyroid O
+hypofunction O
+, O
+from O
+dopamine O
+agonist O
+therapy O
+for O
+hyperprolactinemic O
+hypogonadism O
+, O
+from O
+radiotherapy O
+of O
+hypophyseal O
+adenoma O
+. O
+
+Both O
+genes O
+ARO3 B
+and O
+ARO4 B
+are O
+strongly O
+regulated O
+under O
+the O
+general O
+control O
+regulatory O
+system O
+. O
+
+Polar O
+effects O
+of O
+transposon O
+insertions O
+demonstrated O
+that O
+all O
+of O
+these O
+mRNAs O
+arose O
+from O
+a O
+single O
+promoter O
+region O
+, O
+where O
+transcription O
+initiated O
+80 O
+bp O
+5 O
+' O
+to O
+nifH B
+. O
+
+J O
+. O
+, O
+& O
+Olefsky O
+, O
+J O
+. O
+
+Importantly O
+, O
+a O
+single O
+base O
+change O
+in O
+the O
+fifth O
+position O
+of O
+the O
+c B
+- I
+fos I
+sequence I
+( O
+GGTCTnnnAGACC O
+to O
+GGTCA O
+/ O
+GnnnAGACC O
+) O
+produced O
+an O
+element O
+that O
+bound O
+the O
+estrogen B
+receptor I
+and O
+conferred O
+estrogen O
+- O
+dependent O
+transcriptional O
+activation O
+of O
+a O
+reporter O
+gene O
+. O
+
+Measuring O
+the O
+dim O
+light O
+melatonin O
+onset O
+( O
+DLMO O
+) O
+is O
+a O
+useful O
+and O
+practical O
+way O
+to O
+assess O
+circadian O
+phase O
+position O
+in O
+humans O
+. O
+
+Co O
+- O
+expression O
+of O
+a O
+gag B
+- O
+TRalpha B
+fusion O
+protein O
+in O
+AEV O
+- O
+transformed O
+cells O
+and O
+addition O
+of O
+ligand O
+derepresses O
+CAII B
+transcription O
+. O
+
+The O
+IB2 B
+gene I
+( O
+HGMW B
+- O
+approved I
+symbol I
+MAPK8IP2 B
+) O
+maps O
+to O
+human O
+chromosome O
+22q13 O
+and O
+contains O
+10 O
+coding O
+exons O
+. O
+
+Transcription O
+start O
+sites O
+of O
+sal B
+and O
+salR B
+genes I
+were O
+determined O
+to O
+lie O
+30 O
+- O
+and O
+24 O
+- O
+bp O
+upstream O
+of O
+the O
+respective O
+initiation O
+codons O
+and O
+separated O
+from O
+each O
+other O
+by O
+78 O
+nucleotides O
+. O
+
+1 O
+. O
+23 O
+) O
+as O
+a O
+PPARalpha B
+- I
+interacting I
+protein I
+. O
+
+Here O
+we O
+demonstrate O
+that O
+the O
+T B
+cell I
+antigen I
+receptor I
+zeta I
+- I
+chain I
+- I
+associated I
+ZAP I
+- I
+70 I
+kinase I
+and O
+T B
+cell I
+antigen I
+receptor I
+zeta I
+- I
+chain I
+immunoreceptor O
+tyrosine O
+- O
+based O
+activation O
+motifs O
+are O
+essential O
+for O
+the O
+membrane O
+recruitment O
+of O
+SOS B
+and O
+Vav B
+. O
+
+We O
+carried O
+out O
+two O
+experiments O
+to O
+investigate O
+this O
+problem O
+. O
+
+When O
+linked O
+to O
+the O
+herpes B
+simplex I
+thymidine I
+kinase I
+minimal I
+promoter I
+, O
+this O
+fragment O
+acts O
+as O
+an O
+enhancing O
+element O
+in O
+Rcho O
+but O
+not O
+GC O
+cells O
+. O
+
+A O
+mammalian O
+protein O
+called O
+RFX B
+or O
+NF B
+- I
+X I
+binds O
+to O
+the O
+X O
+box O
+( O
+or O
+X1 O
+box O
+) O
+in O
+the O
+promoters O
+of O
+a O
+number O
+of O
+major B
+histocompatibility I
+( I
+MHC I
+) I
+class I
+II I
+genes I
+. O
+
+Site O
+- O
+directed O
+mutagenesis O
+was O
+conducted O
+to O
+investigate O
+the O
+functional O
+significance O
+of O
+this O
+element O
+and O
+the O
+3 O
+' O
+minus O
+- O
+strand O
+terminal O
+sequence O
+" O
+3 O
+' O
+- O
+OH O
+- O
+CCCUAU O
+, O
+" O
+which O
+contains O
+the O
+minus O
+- O
+strand O
+3 O
+' O
+- O
+end O
+sequence O
+" O
+3 O
+' O
+- O
+OH O
+- O
+CC O
+( O
+1 O
+- O
+2 O
+) O
+( O
+A O
+/ O
+U O
+) O
+( O
+A O
+/ O
+U O
+) O
+( O
+A O
+/ O
+U O
+) O
+" O
+found O
+in O
+all O
+carmovirus O
+RNAs O
+. O
+
+The O
+incidence O
+of O
+the O
+variability O
+of O
+the O
+free O
+PSA B
+/ O
+total O
+PSA B
+ratio O
+on O
+the O
+early O
+diagnosis O
+of O
+prostate O
+cancer O
+
+VBP B
+and O
+a1 B
+/ I
+EBP I
+could O
+mediate O
+the O
+high O
+rates O
+of O
+ALV O
+and O
+RSV B
+LTR I
+- O
+enhanced O
+transcription O
+in O
+bursal O
+lymphoma O
+cells O
+and O
+many O
+other O
+cell O
+types O
+. O
+
+In O
+the O
+second O
+, O
+37 O
+students O
+were O
+given O
+trimethoprim O
+/ O
+sulphamethoxazole O
+( O
+160 O
+mg O
+TMP O
+- O
+SMX O
+800 O
+mg O
+) O
+, O
+38 O
+TMP O
+( O
+200 O
+mg O
+) O
+, O
+and O
+in O
+35 O
+a O
+placebo O
+was O
+given O
+b O
+. O
+i O
+. O
+d O
+. O
+for O
+five O
+days O
+. O
+
+Developmental O
+slot O
+blots O
+demonstrate O
+that O
+mRNAs O
+corresponding O
+to O
+the O
+three O
+LHM B
+cDNAs I
+are O
+transcribed O
+from O
+prophase O
+of O
+meiosis O
+I O
+to O
+the O
+uninucleate O
+microspore O
+stage O
+, O
+while O
+Northern O
+analysis O
+reveals O
+these O
+tapetally O
+expressed O
+cDNAs O
+to O
+correspond O
+with O
+transcripts O
+of O
+some O
+500 O
+bp O
+. O
+
+One O
+hundred O
+men O
+who O
+received O
+alpha O
+- O
+tocopherol O
+were O
+matched O
+on O
+age O
+, O
+study O
+center O
+, O
+and O
+length O
+of O
+time O
+between O
+blood O
+draws O
+to O
+100 O
+men O
+who O
+received O
+a O
+placebo O
+. O
+
+The O
+contribution O
+of O
+residues O
+outside O
+the O
+Ras B
+binding I
+domain I
+of O
+Raf B
+( O
+RafRBD B
+) O
+to O
+Ras B
+- O
+Raf B
+interaction O
+and O
+Ras B
+- O
+dependent O
+Raf B
+activation O
+has O
+remained O
+unresolved O
+. O
+
+Other O
+recommendations O
+for O
+enhancing O
+the O
+safety O
+of O
+potent O
+antiplatelet O
+agents O
+in O
+a O
+variety O
+of O
+clinical O
+situations O
+are O
+provided O
+. O
+
+RESULTS O
+- O
+- O
+261 O
+patients O
+were O
+enrolled O
+into O
+this O
+study O
+; O
+of O
+these O
+, O
+138 O
+( O
+53 O
+% O
+) O
+patients O
+attended O
+for O
+repeat O
+colposcopy O
+and O
+cytology O
+at O
+one O
+year O
+. O
+
+Changes O
+in O
+the O
+greater O
+omentum O
+of O
+mice O
+of O
+different O
+strains O
+after O
+intraperitoneal O
+immunization O
+with O
+sheep O
+erythrocytes O
+. O
+
+In O
+this O
+study O
+, O
+we O
+sought O
+to O
+determine O
+the O
+specific O
+effect O
+of O
+HIV B
+protease I
+inhibitors O
+on O
+patient O
+weight O
+. O
+
+However O
+massive O
+necrosis O
+of O
+the O
+renal O
+tubules O
+had O
+been O
+found O
+with O
+more O
+than O
+15mg O
+of O
+DSM O
+administration O
+. O
+
+The O
+characteristics O
+of O
+a O
+simple O
+apparatus O
+for O
+clinical O
+use O
+to O
+measure O
+DEOAEs O
+are O
+described O
+together O
+with O
+typical O
+examples O
+of O
+emissions O
+. O
+
+To O
+obtain O
+information O
+on O
+the O
+functional O
+role O
+of O
+the O
+Rac1 B
+/ O
+p38 B
+/ O
+MAPKAPK B
+- I
+2 I
+pathway O
+in O
+RA O
+signaling O
+, O
+the O
+effects O
+of O
+pharmacological O
+inhibition O
+of O
+p38 B
+on O
+RA O
+- O
+induced O
+gene O
+transcription O
+and O
+cell O
+differentiation O
+were O
+determined O
+. O
+
+The O
+cost O
+and O
+effectiveness O
+of O
+nurse O
+education O
+- O
+- O
+1 O
+. O
+
+The O
+ATF B
+/ I
+CRE I
+site O
+is O
+also O
+essential O
+for O
+CD4 B
+promoter I
+activation O
+by O
+forskolin O
+, O
+an O
+activator O
+of O
+adenylate B
+cyclase I
+. O
+
+YLL031c B
+is O
+an O
+essential O
+gene O
+. O
+
+Restricted O
+expression O
+of O
+a O
+novel O
+murine B
+atonal I
+- I
+related I
+bHLH I
+protein I
+in O
+undifferentiated O
+neural O
+precursors O
+. O
+
+Since O
+the O
+early O
+1900s O
+, O
+a O
+genetic O
+hypothesis O
+has O
+been O
+suggested O
+. O
+
+We O
+report O
+the O
+genomic O
+organization O
+of O
+the O
+mouse B
+orphan I
+receptor I
+related I
+to I
+tyrosine I
+kinases I
+( O
+Ryk B
+) O
+, O
+a O
+structurally O
+unclassified O
+member O
+of O
+the O
+growth B
+factor I
+receptor I
+family I
+. O
+
+In O
+contrast O
+, O
+T229E B
+- I
+p70s6k I
+migrated O
+more O
+slowly O
+in O
+SDS O
+- O
+polyacrylamide O
+gels O
+, O
+but O
+demonstrated O
+partial O
+kinase O
+activity O
+( O
+approximately O
+20 O
+% O
+compared O
+with O
+the O
+wild O
+type O
+) O
+. O
+
+The O
+structure O
+and O
+expression O
+of O
+the O
+murine B
+gene I
+encoding I
+granulocyte I
+- I
+macrophage I
+colony I
+stimulating I
+factor I
+: O
+evidence O
+for O
+utilisation O
+of O
+alternative O
+promoters O
+. O
+
+Thus O
+, O
+the O
+search O
+for O
+genetic O
+and O
+acquired O
+susceptibility O
+to O
+nontuberculous O
+mycobacteria O
+is O
+also O
+a O
+search O
+for O
+susceptibility O
+factors O
+for O
+MTB O
+as O
+well O
+as O
+an O
+opportunity O
+to O
+recognize O
+endogenous O
+pathways O
+that O
+can O
+be O
+exploited O
+therapeutically O
+. O
+
+Liver O
+disease O
+and O
+HCV O
+infection O
+after O
+transplantation O
+of O
+organs O
+from O
+hepatitis B
+C I
+antibody I
+positive O
+donors O
+. O
+
+After O
+dialysis O
+online O
+, O
+lactate O
+was O
+converted O
+by O
+means O
+of O
+lactate B
+oxidase I
+immobilized O
+to O
+porous O
+glass O
+, O
+and O
+the O
+depletion O
+of O
+oxygen O
+was O
+registered O
+by O
+means O
+of O
+a O
+Clark O
+electrode O
+. O
+
+The O
+deduced O
+amino O
+- O
+acid O
+sequence O
+of O
+the O
+mature O
+enzyme O
+showed O
+very O
+low O
+homology O
+( O
+< O
+20 O
+. O
+4 O
+% O
+identity O
+) O
+to O
+those O
+of O
+known O
+pectinolytic O
+enzymes O
+in O
+the O
+large O
+pectate B
+lyase I
+superfamily I
+( O
+the O
+polysaccharide B
+lyase I
+family I
+1 I
+) O
+. O
+
+Incubation O
+of O
+HeLa O
+cell O
+cytoplasmic O
+extracts O
+with O
+a O
+purified O
+recombinant O
+glutathione B
+S I
+- I
+transferase I
+- O
+raf B
+fusion O
+protein O
+in O
+the O
+presence O
+of O
+ATP O
+released O
+active O
+NF B
+- I
+kappa I
+B I
+that O
+could O
+be O
+detected O
+by O
+electrophoretic O
+gel O
+mobility O
+shift O
+assay O
+. O
+
+Despite O
+this O
+loss O
+, O
+YEpFAS1 B
+is O
+still O
+able O
+to O
+complement O
+a O
+fas1 B
+mutation I
+at O
+the O
+enoyl B
+reductase I
+domain I
+. O
+
+Cross O
+- O
+species O
+characterization O
+of O
+the O
+promoter O
+region O
+of O
+the O
+cystic B
+fibrosis I
+transmembrane I
+conductance I
+regulator I
+gene I
+reveals O
+multiple O
+levels O
+of O
+regulation O
+. O
+
+Pretreatment O
+with O
+lipid O
+X O
+was O
+not O
+necessary O
+to O
+improve O
+survival O
+: O
+16 O
+of O
+17 O
+( O
+94 O
+% O
+) O
+infected O
+and O
+visibly O
+ill O
+animals O
+that O
+received O
+lipid O
+X O
+and O
+ticarcillin O
+6 O
+h O
+after O
+thigh O
+inoculation O
+survived O
+versus O
+30 O
+of O
+44 O
+( O
+68 O
+% O
+) O
+control O
+animals O
+treated O
+with O
+ticarcillin O
+alone O
+( O
+P O
+less O
+than O
+0 O
+. O
+0001 O
+) O
+. O
+
+The O
+predicted O
+vav B
+oncogene I
+protein I
+sequence I
+exhibits O
+several O
+motifs O
+reminiscent O
+of O
+transcriptional O
+factors O
+. O
+
+The O
+pharmacokinetics O
+were O
+best O
+described O
+by O
+a O
+two O
+- O
+compartment O
+open O
+model O
+giving O
+distribution O
+half O
+- O
+lives O
+of O
+0 O
+. O
+31 O
+h O
+and O
+1 O
+. O
+53 O
+h O
+, O
+and O
+elimination O
+half O
+- O
+lives O
+of O
+69 O
+. O
+7 O
+h O
+and O
+60 O
+. O
+3 O
+h O
+for O
+oxolinic O
+acid O
+and O
+oxytetracycline O
+, O
+respectively O
+. O
+
+The O
+predictive O
+value O
+of O
+the O
+remotely O
+sensed O
+map O
+based O
+on O
+NDVI O
+data O
+appears O
+to O
+be O
+better O
+than O
+that O
+from O
+forecast O
+indices O
+based O
+only O
+on O
+climatic O
+data O
+. O
+
+It O
+has O
+been O
+confirmed O
+in O
+animal O
+experiments O
+that O
+the O
+number O
+of O
+microspheres O
+in O
+a O
+myocardial O
+sample O
+approximately O
+follows O
+a O
+Poisson O
+distribution O
+, O
+under O
+adequate O
+experimental O
+conditions O
+. O
+
+Hepatitis B
+B I
+immune I
+globulins I
+and O
+HIV B
+antibodies I
+. O
+
+This O
+gene O
+is O
+divided O
+into O
+six O
+exons O
+spanning O
+about O
+3kb O
+, O
+and O
+encodes O
+a O
+175 O
+amino O
+acid O
+protein O
+with O
+40 O
+- O
+52 O
+% O
+identity O
+with O
+the O
+other O
+five O
+mouse B
+Reg I
+( O
+regenerating B
+gene I
+product I
+) O
+proteins O
+. O
+
+The O
+p63 B
+sequence I
+also O
+features O
+an O
+acidic O
+domain O
+characteristic O
+of O
+transcriptional O
+activation O
+factors O
+, O
+as O
+well O
+as O
+sequence O
+blocks O
+displaying O
+limited O
+similarity O
+to O
+positionally O
+equivalent O
+regions O
+in O
+sigma B
+factors I
+from O
+eubacteria O
+related O
+to O
+mitochondria O
+. O
+
+In O
+contrast O
+, O
+a O
+similar O
+fusion O
+protein O
+( O
+hGH B
+- O
+LDLR B
+- O
+DAF17 B
+, O
+abbreviated O
+HLD B
+) O
+containing O
+a O
+fragment O
+of O
+the O
+serine O
+/ O
+threonine O
+- O
+rich O
+domain O
+of O
+the O
+LDL B
+receptor I
+( O
+LDLR B
+) O
+in O
+place O
+of O
+the O
+DAF B
+- I
+derived I
+serine O
+/ O
+threonine O
+- O
+rich O
+sequences O
+, O
+does O
+not O
+become O
+GPI O
+anchored O
+. O
+
+Thus O
+, O
+the O
+pathway O
+to O
+Fc B
+epsilonRI I
+- O
+mediated O
+MEK B
+/ O
+ERK B
+and O
+ERK B
+activation O
+can O
+apparently O
+bypass O
+Ras B
+and O
+Raf B
+- I
+1 I
+. O
+
+To O
+assess O
+whether O
+thallium O
+- O
+201 O
+thallous O
+chloride O
+( O
+Tl O
+) O
+can O
+detect O
+childhood O
+tumors O
+and O
+whether O
+diagnostic O
+effectiveness O
+improves O
+with O
+combined O
+blood O
+flow O
+imaging O
+, O
+28 O
+children O
+( O
+1 O
+. O
+0 O
+- O
+18 O
+. O
+6 O
+years O
+) O
+were O
+studied O
+using O
+single O
+photon O
+emission O
+computed O
+tomography O
+( O
+SPECT O
+) O
+: O
+Tl O
+( O
+1 O
+. O
+3 O
+- O
+1 O
+. O
+8 O
+mCi O
+intravenously O
+) O
+, O
+followed O
+in O
+13 O
+of O
+the O
+patients O
+by O
+technetium O
+- O
+99m O
+- O
+hexamethylpropyleneamine O
+oxime O
+( O
+99mTc O
+- O
+HMPAO O
+; O
+8 O
+- O
+18 O
+mCi O
+
+intravenously O
+) O
+. O
+
+Ftz B
+, O
+on O
+the O
+other O
+hand O
+, O
+influences O
+Ftz B
+- I
+F1 I
+activity O
+by O
+interacting O
+with O
+its O
+AF O
+- O
+2 O
+domain O
+in O
+a O
+manner O
+that O
+mimics O
+a O
+nuclear O
+receptor O
+coactivator O
+. O
+
+Successive O
+5 O
+' O
+deletions O
+of O
+the O
+[ O
+- O
+326 O
+; O
++ O
+20 O
+] I
+type I
+II I
+sPLA2 I
+promoter I
+indicated O
+that O
+the O
+region O
+upstream O
+of O
+position O
+- O
+195 O
+inhibits O
+the O
+transcription O
+activity O
+sixfold O
+in O
+HepG2 O
+cells O
+but O
+not O
+in O
+HeLa O
+cells O
+. O
+
+Forty O
+- O
+five O
+patients O
+with O
+recent O
+- O
+onset O
+hyperthyroidism O
+( O
+< O
+12 O
+weeks O
+) O
+were O
+sex O
+and O
+menopause O
+stratified O
+and O
+randomly O
+allocated O
+to O
+treatment O
+with O
+carbimazole O
+( O
+Neotomizol O
+) O
+, O
+carbimazole O
+plus O
+low O
+dose O
+CT O
+( O
+Calsynar O
+; O
+100 O
+IU O
+/ O
+day O
+, O
+2 O
+days O
+/ O
+week O
+) O
+, O
+or O
+carbimazole O
+plus O
+high O
+dose O
+CT O
+( O
+Calsynar O
+; O
+100 O
+IU O
+/ O
+day O
+, O
+14 O
+days O
+/ O
+month O
+) O
+. O
+
+The O
+cloning O
+of O
+CWH43 B
+showed O
+that O
+it O
+corresponds O
+to O
+YCR017c B
+and O
+encodes O
+a O
+protein O
+with O
+14 O
+- O
+16 O
+transmembrane O
+segments O
+containing O
+several O
+putative O
+phosphorylation O
+and O
+glycosylation O
+sites O
+. O
+
+However O
+, O
+strains O
+in O
+which O
+both O
+of O
+the O
+two O
+most O
+highly O
+related O
+genes O
+, O
+DdPIK1 B
+and O
+DdPIK2 B
+, O
+were O
+disrupted O
+showed O
+both O
+growth O
+and O
+developmental O
+defects O
+, O
+while O
+double O
+knockouts O
+of O
+DdPIK1 B
+and O
+DdPIK3 B
+and O
+DdPIK2 B
+and O
+DdPIK3 B
+appear O
+to O
+be O
+lethal O
+. O
+
+This O
+mechanism O
+seems O
+to O
+be O
+involved O
+in O
+VIP B
+- O
+induced O
+PRL B
+gene I
+regulation O
+. O
+
+Competition O
+and O
+methylation O
+interference O
+assays O
+showed O
+that O
+the O
+binding O
+site O
+for O
+the O
+novel O
+factor O
+was O
+limited O
+to O
+nucleotides O
+in O
+the O
+3 O
+' O
+half O
+of O
+the O
+kappa B
+B I
+site I
+. O
+
+These O
+properties O
+prompted O
+us O
+to O
+investigate O
+Ets B
+- I
+1 I
+expression O
+in O
+32 O
+human O
+astroglial O
+tumors O
+of O
+WHO O
+grades O
+I O
+- O
+IV O
+and O
+to O
+correlate O
+the O
+data O
+with O
+the O
+expression O
+pattern O
+of O
+VEGF B
+, O
+Flt B
+- I
+1 I
+, O
+and O
+KDR B
+. O
+
+Mean O
+concentration O
+of O
+insulin B
+in O
+maternal O
+plasma O
+across O
+all O
+sampling O
+times O
+was O
+higher O
+in O
+ethanol O
+treated O
+animals O
+. O
+
+The O
+strongly O
+DNA O
+binding O
+p50 B
+subunit I
+showed O
+only O
+very O
+weak O
+, O
+if O
+any O
+, O
+induction O
+of O
+gene O
+expression O
+. O
+
+The O
+results O
+obtained O
+demonstrate O
+the O
+applicability O
+of O
+countercurrent O
+chromatography O
+to O
+the O
+determination O
+of O
+ultratrace O
+elements O
+. O
+
+E1A B
++ O
+cHa B
+- I
+ras I
+transformed O
+rat O
+embryo O
+fibroblast O
+cells O
+are O
+characterized O
+by O
+high O
+and O
+constitutive O
+DNA O
+binding O
+activities O
+of O
+AP B
+- I
+1 I
+dimers I
+with O
+significantly O
+altered O
+composition O
+. O
+
+Minor O
+changes O
+within O
+the O
+transmembrane O
+domains O
+( O
+TMs O
+) O
+sometimes O
+produced O
+major O
+effects O
+and O
+more O
+drastic O
+changes O
+in O
+the O
+TMs O
+ablated O
+surface O
+expression O
+entirely O
+. O
+
+Nuclear O
+localization O
+of O
+this O
+SNF2 B
+- I
+like I
+putative I
+helicase B
+is O
+dependent O
+on O
+a O
+nuclear O
+localization O
+sequence O
+located O
+in O
+the O
+NH2 O
+- O
+terminal O
+region O
+. O
+
+The O
+feasibility O
+of O
+creating O
+CR1 B
+/ O
+Ig B
+chimeras O
+makes O
+possible O
+a O
+new O
+strategy O
+of O
+targeting O
+complement O
+inhibition O
+by O
+the O
+use O
+of O
+Ig B
+fusion I
+partners O
+having O
+particular O
+antigenic O
+specificities O
+. O
+
+Morphological O
+- O
+functional O
+status O
+of O
+the O
+edentulous O
+mandible O
+and O
+selection O
+of O
+the O
+most O
+effective O
+method O
+for O
+functional O
+impression O
+- O
+taking O
+
+They O
+are O
+both O
+insensitive O
+to O
+inhibitors O
+of O
+serine B
+and O
+aspartyl B
+proteinases I
+but O
+are O
+sensitive O
+to O
+sulfhydryl O
+reagents O
+and O
+0 O
+. O
+5 O
+mM O
+ZnCl2 O
+. O
+
+The O
+tau O
+v O
+at O
+rest O
+was O
+4 O
+. O
+06 O
++ O
+/ O
+- O
+2 O
+. O
+16 O
+s O
+and O
+decreased O
+to O
+2 O
+. O
+44 O
++ O
+/ O
+- O
+1 O
+. O
+07 O
+s O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+at O
+1 O
+Hz O
+and O
+to O
+1 O
+. O
+81 O
++ O
+/ O
+- O
+0 O
+. O
+4 O
+s O
+at O
+5 O
+Hz O
+. O
+
+The O
+authors O
+investigate O
+in O
+a O
+group O
+of O
+211 O
+children O
+aged O
+2 O
+- O
+6 O
+years O
+, O
+incl O
+. O
+in O
+particular O
+a O
+group O
+of O
+33 O
+2 O
+- O
+year O
+- O
+old O
+ones O
+, O
+in O
+1990 O
+and O
+checked O
+in O
+1991 O
+at O
+two O
+sites O
+in O
+Bratislava O
+- O
+- O
+a O
+town O
+with O
+a O
+varying O
+concentration O
+of O
+NOX O
+, O
+SO2 O
+, O
+dustiness O
+and O
+dust O
+fallout O
+- O
+- O
+their O
+influence O
+on O
+the O
+incidence O
+, O
+type O
+and O
+course O
+of O
+relapsing O
+respiratory O
+disease O
+. O
+
+However O
+, O
+no O
+statistical O
+difference O
+in O
+the O
+Ca O
+/ O
+P O
+ratio O
+, O
+carbon O
+concentration O
+and O
+surface O
+energy O
+were O
+observed O
+with O
+different O
+heat O
+treatments O
+. O
+
+Using O
+in O
+vivo O
+genomic O
+dimethyl O
+sulfate O
+and O
+KMnO4 O
+footprinting O
+, O
+we O
+showed O
+that O
+the O
+promoter O
+region O
+is O
+differentially O
+protected O
+, O
+depending O
+upon O
+which O
+holoenzyme O
+is O
+bound O
+. O
+
+Here O
+we O
+show O
+that O
+inhibition O
+occurs O
+with O
+a O
+NS1 B
+- O
+Rev B
+chimera O
+in O
+which O
+the O
+78 O
+amino O
+- O
+terminal O
+amino O
+acids O
+of O
+the O
+NS1A B
+protein I
+comprising O
+its O
+entire O
+RNA O
+- O
+binding O
+domain O
+is O
+deleted O
+, O
+thereby O
+establishing O
+that O
+this O
+carboxyl O
+portion O
+of O
+the O
+NS1A B
+protein I
+can O
+function O
+as O
+an O
+independent O
+effector O
+domain O
+. O
+
+Overall O
+, O
+it O
+appears O
+that O
+prenatal O
+exposure O
+to O
+androgen O
+- O
+based O
+synthetic O
+progestin O
+exerted O
+a O
+masculinizing O
+and O
+/ O
+or O
+defeminizing O
+influence O
+on O
+human O
+behavioral O
+development O
+, O
+whereas O
+prenatal O
+exposure O
+to O
+natural O
+progesterone O
+and O
+progesterone O
+- O
+based O
+synthetic O
+progestin O
+had O
+a O
+feminizing O
+and O
+/ O
+or O
+demasculinizing O
+influence O
+, O
+particularly O
+among O
+female O
+subjects O
+. O
+
+The O
+testes O
+of O
+8 O
+specimens O
+of O
+Triturus O
+marmoratus O
+were O
+collected O
+during O
+each O
+month O
+of O
+1987 O
+and O
+processed O
+for O
+electron O
+microscopy O
+and O
+light O
+microscopy O
+demonstration O
+of O
+testosterone O
+( O
+T O
+) O
+following O
+the O
+ABC B
+( O
+avidin B
+- I
+biotin I
+peroxidase I
+complex I
+) O
+method O
+. O
+
+MTX O
+therapy O
+decreased O
+Ga O
+- O
+67 O
+uptake O
+in O
+liver O
+, O
+tumor O
+, O
+and O
+muscle O
+. O
+
+In O
+stage O
+I O
+, O
+histochemistry O
+for O
+copper O
+was O
+positive O
+in O
+11 O
+out O
+of O
+21 O
+cases O
+: O
+6 O
+cases O
+were O
+T O
++ O
+; O
+1 O
+case O
+R O
++ O
+and O
+2 O
+cases O
+O O
++ O
+; O
+2 O
+cases O
+were O
+T O
++ O
+, O
+R O
++ O
+, O
+O O
++ O
+. O
+
+Encapsulation O
+of O
+sodium O
+fluorescein O
+for O
+dye O
+release O
+studies O
+. O
+
+Primer O
+extension O
+analysis O
+and O
+subcloning O
+of O
+the O
+virJ B
+- O
+phoA B
+fusion O
+indicate O
+that O
+the O
+acetosyringone O
+- O
+inducible O
+promoter O
+lies O
+directly O
+upstream O
+of O
+the O
+virJ B
+structural I
+gene I
+. O
+
+To O
+isolate O
+genes O
+that O
+contain O
+zinc O
+finger O
+motifs O
+, O
+a O
+human O
+brain O
+cDNA O
+library O
+was O
+screened O
+with O
+an O
+oligonucleotide O
+complementary O
+to O
+the O
+conserved O
+" O
+linker O
+" O
+sequence O
+between O
+adjacent O
+zinc O
+fingers O
+. O
+
+Percentage O
+incremental O
+18 O
+- O
+OHB O
+responses O
+to O
+metoclopramide O
+were O
+greater O
+( O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+in O
+the O
+subjects O
+after O
+5 O
+days O
+on O
+a O
+200 O
+- O
+meq O
+sodium O
+intake O
+than O
+after O
+5 O
+days O
+on O
+a O
+10 O
+- O
+meq O
+sodium O
+intake O
+. O
+
+Using O
+in O
+vivo O
+screening O
+, O
+we O
+first O
+identified O
+a O
+gene O
+that O
+appeared O
+to O
+interfere O
+with O
+the O
+His O
+- O
+Asp O
+phosphorelay O
+between O
+the O
+HPt B
+domain I
+and O
+the O
+receiver O
+domain O
+of O
+OmpR B
+, O
+provided O
+that O
+the O
+gene O
+product O
+was O
+expressed O
+through O
+a O
+multicopy O
+plasmid O
+. O
+
+The O
+non O
+- O
+major B
+histocompatibility I
+complex I
+( O
+MHC B
+) O
+- O
+encoded O
+CD1 B
+family O
+has O
+recently O
+emerged O
+as O
+a O
+new O
+antigen O
+- O
+presenting O
+system O
+that O
+is O
+distinct O
+from O
+either O
+MHC B
+class I
+I I
+or O
+class B
+II I
+molecules I
+. O
+
+The O
+predicted O
+amino O
+acid O
+sequence O
+of O
+Pst1p B
+possessed O
+high O
+sequence O
+homology O
+with O
+the O
+Sin3 B
+family I
+of O
+proteins O
+, O
+known O
+for O
+their O
+interaction O
+with O
+histone B
+deacetylases I
+. O
+
+Quinethazone O
+
+Studies O
+on O
+nitrogen O
+- O
+containing O
+heterocyclic O
+compounds O
+. O
+
+Removal O
+of O
+ink4a B
+dramatically O
+reduces O
+the O
+lymphoid O
+and O
+neurological O
+defects O
+seen O
+in O
+bmi B
+- I
+1 I
+- O
+deficient O
+mice O
+, O
+indicating O
+that O
+ink4a B
+is O
+a O
+critical O
+in O
+vivo O
+target O
+for O
+Bmi B
+- I
+1 I
+. O
+
+We O
+found O
+that O
+RXR B
+and O
+VDR B
+transactivated O
+selectively O
+from O
+VDRE O
+- O
+linked O
+templates O
+exclusively O
+as O
+a O
+heterodimeric O
+complex O
+, O
+since O
+neither O
+receptor O
+alone O
+enhanced O
+transcription O
+in O
+vitro O
+. O
+
+METHODS O
+: O
+We O
+performed O
+nasal O
+mupirocin O
+treatment O
+on O
+10 O
+infants O
+who O
+were O
+MRSA O
+- O
+positive O
+either O
+in O
+the O
+nose O
+or O
+the O
+pharynx O
+and O
+evaluated O
+the O
+effect O
+of O
+mupirocin O
+on O
+the O
+eradication O
+of O
+MRSA O
+. O
+
+RESULTS O
+: O
+Of O
+10 O
+, O
+709 O
+, O
+701 O
+chemistry O
+specimens O
+submitted O
+to O
+the O
+participating O
+laboratories O
+during O
+the O
+data O
+collection O
+period O
+, O
+37 O
+, O
+208 O
+( O
+0 O
+. O
+35 O
+% O
+) O
+were O
+rejected O
+prior O
+to O
+testing O
+. O
+
+Early O
+complement O
+components O
+, O
+C1q B
+and O
+C4 B
+, O
+and O
+IgA B
+secretory I
+piece I
+were O
+absent O
+. O
+
+Administration O
+of O
+SnCl2 O
+and O
+ZnSO4 O
+( O
+group O
+V O
+) O
+resulted O
+in O
+a O
+decrease O
+of O
+ALA B
+- I
+D I
+activity O
+and O
+in O
+an O
+increase O
+in O
+CP B
+- I
+U I
+. O
+
+Using O
+a O
+dominant O
+negative O
+form O
+of O
+Sp3 B
+and O
+transcriptional O
+activation O
+assays O
+in O
+Schneider O
+SL O
+- O
+2 O
+insect O
+cells O
+, O
+it O
+was O
+confirmed O
+that O
+ERalpha B
+- O
+Sp3 B
+interactions O
+define O
+a O
+pathway O
+for O
+E2 O
+- O
+mediated O
+inhibition O
+of O
+gene O
+expression O
+, O
+and O
+this O
+represents O
+a O
+new O
+mechanism O
+for O
+decreased O
+gene O
+expression O
+by O
+E2 O
+. O
+
+From O
+the O
+supposition O
+that O
+there O
+exists O
+a O
+possible O
+connection O
+between O
+certain O
+psychopathological O
+symptoms O
+, O
+and O
+/ O
+or O
+syndromes O
+( O
+e O
+. O
+g O
+. O
+, O
+hallucinations O
+) O
+and O
+regional O
+cerebral O
+dysfunction O
+, O
+patients O
+suffering O
+from O
+auditory O
+and O
+tactile O
+hallucinations O
+were O
+investigated O
+, O
+in O
+a O
+symptom O
+- O
+oriented O
+study O
+, O
+using O
+the O
+method O
+of O
+technetium O
+- O
+99m O
+- O
+Hexamethyl O
+- O
+propylenamine O
+Oxime O
+( O
+99m O
+- O
+Tc O
+- O
+HMPAO O
+) O
+- O
+Single O
+Photon O
+Emission O
+Computed O
+Tomography O
+( O
+SPECT O
+) O
+and O
+compared O
+with O
+normal O
+controls O
+
+. O
+
+The O
+lack O
+of O
+chronically O
+depressed O
+LCBF O
+( O
+after O
+1 O
+day O
+) O
+may O
+be O
+related O
+to O
+the O
+quick O
+structural O
+repair O
+of O
+endothelium O
+. O
+
+In O
+this O
+study O
+, O
+to O
+elucidate O
+the O
+possible O
+mechanism O
+of O
+action O
+of O
+EM O
+, O
+we O
+examined O
+the O
+effect O
+of O
+the O
+drug O
+on O
+the O
+expression O
+of O
+neutrophil O
+adhesion O
+molecules O
+such O
+as O
+L B
+- I
+selectin I
+and O
+Mac B
+- I
+1 I
+. O
+
+Tissue O
+expansion O
+was O
+used O
+successfully O
+to O
+prepare O
+adequate O
+soft O
+tissue O
+for O
+closure O
+following O
+a O
+difficult O
+clubfoot O
+correction O
+. O
+
+The O
+transcription O
+start O
+site O
+was O
+identified O
+by O
+primer O
+extension O
+analysis O
+and O
+over O
+800 O
+bp O
+of O
+5 O
+' O
+flanking O
+DNA O
+was O
+sequenced O
+. O
+
+The O
+reporter O
+gene O
+with O
+two O
+copies O
+of O
+the O
+wild O
+- O
+type O
+Repeat O
+2 O
++ O
+3 O
+sequence O
+was O
+transcribed O
+actively O
+in O
+sterol O
+- O
+deprived O
+cells O
+and O
+was O
+repressed O
+by O
+more O
+than O
+80 O
+% O
+when O
+sterols O
+were O
+present O
+. O
+
+Changes O
+in O
+tension O
+were O
+monitored O
+isometrically O
+on O
+spiral O
+strips O
+of O
+freshly O
+obtained O
+bovine O
+basilar O
+arteries O
+. O
+
+A O
+1 O
+. O
+5 O
+- O
+month O
+- O
+old O
+boy O
+with O
+Sandifer O
+' O
+s O
+syndrome O
+is O
+described O
+. O
+
+However O
+, O
+PC12 O
+cell O
+clones O
+which O
+expressed O
+p33rsu B
+- I
+1 I
+at O
+an O
+increased O
+level O
+in O
+a O
+regulatable O
+fashion O
+in O
+response O
+to O
+dexamethasone O
+were O
+isolated O
+. O
+
+In O
+this O
+study O
+, O
+we O
+verified O
+that O
+PI B
+3 I
+- I
+kinase I
+associates O
+with O
+the O
+CD4 B
+: O
+p56lck B
+complex O
+as O
+judged O
+by O
+the O
+presence O
+of O
+PI O
+3 O
+- O
+phosphate O
+generated O
+from O
+anti B
+- I
+CD4 I
+immunoprecipitates O
+and O
+detected O
+by O
+high O
+- O
+pressure O
+liquid O
+chromatographic O
+analysis O
+. O
+
+The O
+clinical O
+picture O
+, O
+the O
+light O
+and O
+electron O
+microscopic O
+appearance O
+, O
+and O
+the O
+histochemical O
+findings O
+are O
+described O
+in O
+six O
+cases O
+of O
+fibroma O
+of O
+tendon O
+sheath O
+. O
+
+However O
+, O
+their O
+stability O
+was O
+low O
+as O
+already O
+reported O
+for O
+the O
+ARS O
+in O
+S O
+. O
+occidentalis O
+. O
+
+In O
+this O
+study O
+, O
+a O
+site O
+of O
+PDGF B
+- O
+induced O
+tyrosine O
+phosphorylation O
+was O
+mapped O
+to O
+Tyr O
+138 O
+in O
+the O
+SH3 B
+domain I
+; O
+Tyr O
+138 O
+is O
+exposed O
+on O
+the O
+SH3 B
+peptide I
+binding O
+surface O
+. O
+
+The O
+results O
+of O
+this O
+study O
+suggest O
+that O
+in O
+patients O
+with O
+syndrome O
+X O
+, O
+myocardial O
+ischemia O
+frequently O
+develops O
+during O
+daily O
+life O
+; O
+silent O
+ischemia O
+is O
+an O
+important O
+component O
+of O
+this O
+syndrome O
+; O
+and O
+increased O
+oxygen O
+demand O
+in O
+the O
+presence O
+of O
+impaired O
+coronary O
+vasodilatory O
+capacity O
+is O
+not O
+the O
+only O
+cause O
+of O
+myocardial O
+ischemia O
+. O
+
+We O
+also O
+identified O
+a O
+DNA O
+fragment O
+, O
+10 O
+. O
+7 O
+kbp O
+upstream O
+from O
+the O
+first O
+coding O
+exon O
+of O
+human B
+aFGF I
+, O
+whose O
+sequence O
+is O
+conserved O
+in O
+both O
+the O
+primate O
+and O
+rodent O
+genomes O
+. O
+
+The O
+false O
+positive O
+fraction O
+( O
+FPF O
+) O
+decreased O
+significantly O
+if O
+the O
+count O
+density O
+increased O
+; O
+no O
+difference O
+in O
+FPF O
+was O
+found O
+for O
+a O
+change O
+in O
+lesion O
+tracer O
+concentration O
+. O
+
+These O
+events O
+were O
+only O
+weakly O
+stimulated O
+by O
+the O
+activated O
+PDGF B
+alpha I
+- I
+receptor I
+. O
+
+Human B
+plastin I
+genes I
+. O
+
+Buserelin O
+offers O
+an O
+effective O
+alternative O
+medical O
+treatment O
+of O
+carcinoma O
+of O
+the O
+prostate O
+and O
+, O
+apart O
+from O
+impotence O
+, O
+does O
+not O
+have O
+the O
+side O
+effects O
+of O
+oestrogens O
+. O
+
+C B
+/ I
+EBP I
+delta I
+( O
+NFIL B
+- I
+6 I
+beta I
+) O
+was O
+not O
+detected O
+in O
+complexes O
+utilizing O
+extracts O
+from O
+the O
+IL B
+- I
+1 I
+nonproducing O
+T O
+cell O
+line O
+. O
+
+Reduced O
+risk O
+of O
+upper O
+gastrointestinal O
+ulcer O
+complications O
+with O
+celecoxib O
+, O
+a O
+novel O
+COX B
+- I
+2 I
+inhibitor O
+. O
+
+Moreover O
+, O
+our O
+recent O
+findings O
+on O
+the O
+Tc52 B
+encoding I
+gene I
+underline O
+the O
+interest O
+of O
+genetic O
+manipulation O
+of O
+T O
+. O
+cruzi O
+, O
+not O
+only O
+making O
+it O
+possible O
+to O
+use O
+more O
+closely O
+an O
+in O
+vitro O
+approach O
+to O
+find O
+out O
+how O
+genes O
+function O
+, O
+but O
+also O
+to O
+obtain O
+' O
+attenuated O
+' O
+strains O
+that O
+could O
+be O
+used O
+in O
+the O
+development O
+of O
+vaccinal O
+strategies O
+. O
+
+Infra O
+- O
+red O
+spectroscopy O
+of O
+tissues O
+in O
+the O
+700 O
+- O
+400 O
+cm O
+- O
+1 O
+region O
+. O
+
+YDL003w B
+( O
+also O
+termed O
+MCD1 B
+) O
+is O
+a O
+homologue B
+of I
+Schizosaccharomyces I
+pombe I
+rad21 I
+, O
+an O
+essential O
+gene O
+implicated O
+in O
+DNA O
+double O
+- O
+strand O
+break O
+repair O
+and O
+nuclear O
+organization O
+in O
+fission O
+yeast O
+. O
+
+The O
+recent O
+concept O
+of O
+a O
+bioartificial O
+organ O
+is O
+an O
+attempt O
+to O
+avoid O
+such O
+disadvantages O
+. O
+
+The O
+objectives O
+of O
+this O
+study O
+were O
+1 O
+) O
+to O
+quantify O
+the O
+comparative O
+structural O
+static O
+and O
+fatigue O
+properties O
+of O
+the O
+pointe O
+shoe O
+toe O
+box O
+, O
+and O
+2 O
+) O
+to O
+evaluate O
+the O
+preferred O
+shoe O
+characteristics O
+as O
+determined O
+by O
+a O
+survey O
+of O
+local O
+dancers O
+. O
+
+In O
+the O
+postoperative O
+patient O
+with O
+tetralogy O
+of O
+Fallot O
+with O
+symptomatic O
+ventricular O
+arrhythmias O
+, O
+it O
+is O
+concluded O
+that O
+electrophysiologic O
+study O
+is O
+useful O
+in O
+reproducing O
+clinical O
+episodes O
+of O
+VT O
+and O
+in O
+selecting O
+effective O
+antiarrhythmic O
+medication O
+; O
+a O
+small O
+number O
+of O
+patients O
+with O
+ventricular O
+premature O
+complexes O
+alone O
+will O
+have O
+inducible O
+sustained O
+VT O
+during O
+electrophysiologic O
+study O
+; O
+prognosis O
+of O
+these O
+patients O
+may O
+be O
+improved O
+by O
+treatment O
+that O
+results O
+in O
+prevention O
+of O
+VT O
+induction O
+; O
+and O
+in O
+patients O
+with O
+right O
+ventricular O
+hypertension O
+, O
+
+VT O
+is O
+likely O
+to O
+be O
+refractory O
+to O
+drug O
+treatment O
+. O
+
+Indications O
+for O
+therapy O
+using O
+MAO B
+inhibitors O
+
+The O
+absorbance O
+of O
+the O
+eluent O
+was O
+monitored O
+at O
+254 O
+nm O
+. O
+
+Here O
+, O
+we O
+describe O
+the O
+results O
+of O
+a O
+detailed O
+study O
+aimed O
+at O
+identifying O
+the O
+gene O
+or O
+genes O
+responsible O
+for O
+the O
+rapid O
+growth O
+- O
+arrest O
+response O
+obtained O
+with O
+human O
+chromosome O
+- O
+9 O
+. O
+
+Footprints O
+on O
+the O
+HPV O
+18 O
+enhancer O
+show O
+five O
+protected O
+regions O
+with O
+homologies O
+to O
+NF1 B
+, O
+AP1 B
+and O
+EFII B
+transcription I
+factor I
+binding I
+motifs I
+. O
+
+Insulin B
+binding O
+to O
+the O
+alpha O
+- O
+subunit O
+of O
+its O
+receptor O
+stimulates O
+the O
+receptor B
+tyrosine I
+kinase I
+to O
+phosphorylate O
+the O
+beta O
+- O
+subunit O
+and O
+several O
+endogenous O
+protein O
+substrates O
+, O
+including O
+pp120 B
+/ O
+HA4 B
+, O
+a O
+liver B
+- I
+specific I
+plasma I
+membrane I
+glycoprotein I
+of O
+M O
+( O
+r O
+) O
+20 O
+, O
+000 O
+. O
+
+Motilin B
+serum O
+levels O
+were O
+measured O
+for O
+one O
+hour O
+. O
+
+The O
+role O
+of O
+phosphorylation O
+on O
+receptor O
+desensitization O
+was O
+assessed O
+using O
+receptor O
+mutants O
+expressed O
+in O
+COS O
+cells O
+or O
+Chinese O
+hamster O
+lung O
+fibroblasts O
+. O
+
+First O
+aid O
+. O
+
+Improvement O
+of O
+some O
+pharmaceutical O
+properties O
+of O
+clofibrate O
+by O
+cyclodextrin O
+complexation O
+. O
+
+The O
+detection O
+limits O
+obtained O
+by O
+using O
+the O
+mixed O
+eluent O
+were O
+0 O
+. O
+05 O
+- O
+0 O
+. O
+13 O
+mg O
+/ O
+L O
+, O
+several O
+times O
+lower O
+than O
+those O
+obtained O
+by O
+using O
+single O
+KHPh O
+eluent O
+. O
+
+Early O
+diagnosis O
+and O
+early O
+surgical O
+division O
+of O
+the O
+biliary O
+tract O
+and O
+pancreatic O
+duct O
+is O
+recommended O
+for O
+children O
+with O
+AAPBD O
+. O
+
+We O
+have O
+analyzed O
+herein O
+the O
+roles O
+that O
+four O
+different O
+PIAS B
+proteins I
+( O
+ARIP3 B
+/ O
+PIASx B
+alpha I
+, O
+Miz1 B
+/ O
+PIASx B
+beta I
+, O
+GBP B
+/ O
+PIAS1 B
+, O
+and O
+PIAS3 B
+) O
+play O
+in O
+the O
+regulation O
+of O
+steroid B
+receptor I
+- O
+or O
+STAT B
+- O
+mediated O
+transcriptional O
+activation O
+. O
+
+Comparison O
+of O
+the O
+predicted O
+amino O
+acid O
+sequence O
+with O
+that O
+of O
+the O
+Drosophila O
+virilis O
+gene O
+shows O
+that O
+several O
+blocks O
+of O
+amino O
+acid O
+sequence O
+have O
+been O
+very O
+highly O
+conserved O
+. O
+
+Analyses O
+focused O
+on O
+two O
+platyrrhine O
+( O
+New O
+World O
+monkey O
+) O
+species O
+: O
+the O
+common O
+marmoset O
+( O
+Callithrix O
+jacchus O
+) O
+and O
+the O
+brown O
+capuchin O
+monkey O
+( O
+Cebus O
+apella O
+) O
+, O
+each O
+of O
+which O
+has O
+paired O
+, O
+non O
+- O
+allelic O
+gamma O
+loci O
+( O
+5 O
+' O
+- O
+gamma O
+1 O
+- O
+gamma I
+2 O
+- O
+3 O
+' O
+) O
+. O
+
+A O
+phase O
+II O
+clinical O
+trial O
+on O
+MDS O
+was O
+conducted O
+in O
+a O
+cooperative O
+study O
+with O
+orally O
+administrable O
+ara O
+- O
+C O
+analogue O
+, O
+PLAC O
+, O
+which O
+is O
+resistant O
+to O
+cytidine B
+deaminase I
+and O
+had O
+shown O
+an O
+anti O
+- O
+tumor O
+activity O
+on O
+various O
+experimental O
+tumors O
+by O
+oral O
+route O
+. O
+
+A O
+decrease O
+was O
+also O
+found O
+of O
+the O
+levels O
+of O
+total O
+cholesterol O
+and O
+LDL B
+- I
+cholesterol I
+. O
+
+Previously O
+, O
+we O
+had O
+shown O
+that O
+interleukin B
+8 I
+( O
+IL B
+- I
+8 I
+) O
+is O
+constitutively O
+expressed O
+in O
+HTLV O
+- O
+I O
+- O
+infected O
+cells O
+and O
+in O
+cells O
+transiently O
+expressing O
+Tax B
+. O
+
+Unlike O
+JNK B
+activation O
+, O
+ERK B
+activation O
+could O
+not O
+be O
+mapped O
+to O
+specific O
+reovirus O
+gene O
+segments O
+, O
+suggesting O
+that O
+ERK B
+activation O
+and O
+JNK B
+activation O
+are O
+triggered O
+by O
+different O
+events O
+during O
+virus O
+- O
+host O
+cell O
+interaction O
+. O
+
+Despite O
+the O
+same O
+decreases O
+or O
+increases O
+in O
+MAP O
+, O
+RSNA O
+was O
+attenuated O
+after O
+15 O
+and O
+30 O
+min O
+of O
+propofol O
+infusion O
+in O
+both O
+groups O
+compared O
+with O
+control O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+To O
+address O
+this O
+question O
+with O
+respect O
+to O
+skeletal O
+muscle O
+, O
+we O
+have O
+examined O
+the O
+effects O
+of O
+the O
+Providence B
+mutation I
+in O
+cultured O
+muscle O
+cells O
+, O
+after O
+adoptive O
+gene O
+transfer O
+to O
+adult O
+mice O
+, O
+and O
+in O
+two O
+infants O
+homozygous O
+for O
+spectrin B
+Providence B
+. O
+
+It O
+appears O
+to O
+be O
+useful O
+in O
+untreated O
+patients O
+with O
+stage O
+I O
+or O
+II O
+NHL O
+but O
+no O
+definite O
+radiographic O
+abnormalities O
+, O
+or O
+with O
+abnormal O
+radiographs O
+but O
+no O
+extrathoracic O
+spread O
+, O
+and O
+in O
+treated O
+patients O
+with O
+questionable O
+radiographs O
+. O
+
+B B
+and O
+C1 B
+fusions I
+with O
+yeast O
+GAL4 B
+DNA O
+- O
+binding O
+and O
+transcriptional O
+activation O
+domains O
+were O
+also O
+found O
+to O
+interact O
+when O
+synthesized O
+and O
+assayed O
+in O
+yeast O
+. O
+
+Because O
+of O
+the O
+data O
+, O
+we O
+suggest O
+that O
+LAC9 B
+contacts O
+positions O
+6 O
+, O
+7 O
+, O
+and O
+8 O
+, O
+both O
+plus O
+and O
+minus O
+, O
+of O
+the O
+UAS O
+, O
+which O
+are O
+separated O
+by O
+more O
+than O
+one O
+turn O
+of O
+the O
+DNA O
+helix O
+, O
+and O
+twists O
+part O
+way O
+around O
+the O
+DNA O
+, O
+thus O
+protecting O
+the O
+broad O
+region O
+of O
+the O
+minor O
+groove O
+between O
+the O
+major O
+- O
+groove O
+contacts O
+. O
+
+On O
+the O
+optic O
+tentacle O
+- O
+gonadal O
+axis O
+in O
+the O
+control O
+of O
+the O
+male O
+- O
+phase O
+ovotestis O
+in O
+the O
+slug O
+( O
+Ariolimax O
+californicus O
+) O
+. O
+
+Substitution O
+of O
+cholinergic O
+drugs O
+in O
+the O
+treatment O
+of O
+Alzheimer O
+type O
+dementia O
+( O
+AD O
+/ O
+SDAT O
+) O
+has O
+hitherto O
+not O
+been O
+very O
+successful O
+. O
+
+Here O
+we O
+show O
+that O
+the O
+nucleotide O
+in O
+the O
+middle O
+of O
+the O
+anticodon O
+( O
+i O
+. O
+e O
+. O
+, O
+psi B
+35 I
+) O
+also O
+contributes O
+to O
+the O
+suppressor O
+efficiency O
+displayed O
+by O
+cytoplasmic B
+tRNA I
+( I
+Tyr I
+) I
+. O
+
+The O
+root O
+- O
+mean O
+- O
+square O
+deviation O
+of O
+bond O
+lengths O
+from O
+the O
+ideal O
+values O
+is O
+0 O
+. O
+02 O
+A O
+. O
+
+Jet O
+lag O
+and O
+melatonin O
+. O
+
+In O
+addition O
+, O
+these O
+results O
+suggest O
+that O
+the O
+interactions O
+, O
+and O
+consequently O
+the O
+mechanisms O
+, O
+governing O
+transcriptional O
+activation O
+by O
+CTF B
+are O
+distinct O
+from O
+those O
+mediating O
+DNA O
+replication O
+. O
+
+A O
+TAAATA O
+sequence O
+is O
+present O
+26 O
+nt O
+upstream O
+from O
+the O
+major O
+CAP O
+site O
+, O
+and O
+within O
+the O
+5 O
+' O
+- O
+flanking O
+region O
+there O
+are O
+several O
+putative O
+transcription O
+factor O
+binding O
+sites O
+. O
+
+It O
+was O
+found O
+that O
+both O
+versions O
+of O
+the O
+brief O
+SL O
+& O
+amp O
+; O
+shy O
+; O
+ASIA O
+had O
+similar O
+correlations O
+to O
+the O
+target O
+variables O
+as O
+the O
+full O
+scale O
+SL O
+& O
+amp O
+; O
+shy O
+; O
+ASIA O
+. O
+
+The O
+reconstituted O
+enzyme O
+binds O
+DNA O
+with O
+an O
+affinity O
+that O
+is O
+approximately O
+20 O
+- O
+fold O
+lower O
+than O
+that O
+of O
+the O
+intact O
+topo70 B
+. O
+
+Treatment O
+with O
+KP O
+- O
+45 O
+preparation O
+usually O
+resulted O
+in O
+partial O
+regression O
+of O
+tumor O
+growth O
+, O
+accompanied O
+by O
+improvement O
+of O
+the O
+clinical O
+state O
+of O
+these O
+patients O
+, O
+as O
+well O
+as O
+reappearance O
+of O
+normal O
+values O
+of O
+blood O
+picture O
+and O
+biochemical O
+parameters O
+. O
+
+Istanbul O
+, O
+Turkey O
+. O
+
+We O
+propose O
+that O
+optimal O
+transcription O
+of O
+the O
+gD B
+gene I
+depends O
+on O
+the O
+interaction O
+of O
+ICP4 B
+with O
+multiple O
+binding O
+sites O
+across O
+the O
+gene O
+and O
+cellular O
+factors O
+that O
+recognize O
+specific O
+sequence O
+elements O
+in O
+the O
+promoter O
+. O
+
+Recently O
+, O
+we O
+and O
+other O
+laboratories O
+have O
+identified O
+a O
+family O
+of O
+caveolin B
+- I
+related I
+proteins I
+; O
+caveolin B
+has O
+been O
+re O
+- O
+termed O
+caveolin B
+- I
+1 I
+. O
+
+Role O
+of O
+zinc B
+- I
+finger I
+proteins I
+Sp1 I
+and O
+zif268 B
+/ O
+egr B
+- I
+1 I
+in O
+transcriptional O
+regulation O
+of O
+the O
+human B
+synaptobrevin I
+II I
+gene I
+. O
+
+The O
+human B
+Fc I
+gamma I
+receptor I
+gene I
+Fc B
+gamma I
+RIIA I
+is O
+expressed O
+in O
+platelets O
+, O
+neutrophils O
+, O
+monocytes O
+and O
+macrophages O
+. O
+
+This O
+dip O
+also O
+occurred O
+during O
+prednisone O
+and O
+vitamin O
+D O
+treatment O
+, O
+but O
+did O
+not O
+occur O
+when O
+calcium O
+was O
+added O
+to O
+prednisone O
+, O
+although O
+the O
+baseline O
+value O
+was O
+lower O
+at O
+the O
+start O
+of O
+combined O
+treatment O
+with O
+prednisone O
+and O
+calcium O
+. O
+
+E O
+. O
+granulosus O
+infection O
+has O
+been O
+confirmed O
+in O
+25 O
+patients O
+( O
+20 O
+. O
+6 O
+% O
+) O
+, O
+in O
+16 O
+cases O
+by O
+finding O
+parasite O
+protoscoleces O
+or O
+hooks O
+and O
+in O
+nine O
+cases O
+by O
+detection O
+of O
+an O
+antigen O
+specific O
+for O
+E O
+. O
+granulosus O
+, O
+antigen B
+5 I
+( O
+Ag5 B
+) O
+. O
+
+The O
+effect O
+of O
+stimulation O
+of O
+the O
+entopeduncular O
+nucleus O
+( O
+EP O
+) O
+on O
+the O
+jaw O
+- O
+opening O
+reflex O
+( O
+JOR O
+) O
+was O
+studied O
+in O
+the O
+cat O
+anesthetized O
+with O
+sodium O
+pentobarbital O
+. O
+
+A O
+Premenstrual O
+Syndrome O
+, O
+the O
+late O
+luteal O
+phase O
+disorder O
+of O
+DSM O
+- O
+IIIR O
+criteria O
+, O
+was O
+identified O
+in O
+6 O
+% O
+of O
+the O
+women O
+. O
+
+First O
+, O
+mutations O
+in O
+the O
+IFNgamma B
+- I
+activated I
+sequence I
+( O
+GAS B
+) O
+, O
+either O
+multimerized O
+or O
+in O
+the O
+context O
+of O
+the O
+1 B
+. I
+7 I
+- I
+kb I
+IRF I
+- I
+1 I
+promoter I
+, O
+failed O
+to O
+mediate O
+a O
+PRL B
+response O
+, O
+showing O
+that O
+the O
+IRF B
+- I
+1 I
+GAS I
+is O
+a O
+target O
+of O
+PRL B
+signaling O
+. O
+
+025 O
+) O
+. O
+
+RESULTS O
+: O
+PET O
+revealed O
+wide O
+variations O
+in O
+CBF O
+between O
+regions O
+during O
+isoflurane O
+anaesthesia O
+, O
+particularly O
+in O
+comparison O
+with O
+propofol O
+anaesthesia O
+, O
+while O
+rCMRO2 O
+decreased O
+globally O
+in O
+a O
+dose O
+- O
+dependent O
+manner O
+during O
+both O
+isoflurane O
+and O
+propofol O
+anaesthesia O
+. O
+
+This O
+selective O
+squelching O
+activity O
+suggests O
+that O
+GRIM B
+can O
+interact O
+with O
+an O
+essential O
+component O
+of O
+the O
+RNA B
+polymerase I
+II I
+transcription O
+machinery O
+. O
+
+This O
+is O
+the O
+first O
+description O
+of O
+an O
+integron B
+located O
+on O
+a O
+composite O
+transposon O
+. O
+
+The O
+nine O
+subjects O
+were O
+treated O
+in O
+random O
+sequence O
+with O
+cimetidine O
+0 O
+- O
+8 O
+- O
+1 O
+- O
+0 O
+g O
+on O
+one O
+day O
+and O
+placebo O
+capsules O
+on O
+the O
+other O
+. O
+
+The O
+protein O
+was O
+overexpressed O
+in O
+Escherichia O
+coli O
+and O
+purified O
+to O
+homogeneity O
+. O
+
+Identification O
+and O
+characterization O
+of O
+a O
+yeast O
+gene O
+encoding O
+the O
+U2 B
+small I
+nuclear I
+ribonucleoprotein I
+particle I
+B I
+" I
+protein I
+. O
+
+A O
+360 O
+- O
+bp O
+DNA O
+fragment O
+located O
+over O
+500 O
+bp O
+upstream O
+from O
+the O
+cfl B
+transcriptional I
+start I
+site I
+was O
+used O
+in O
+DNase B
+I I
+protection O
+assays O
+to O
+define O
+the O
+specific O
+bases O
+bound O
+by O
+CorR B
+. O
+
+Taking O
+into O
+account O
+certain O
+well O
+defined O
+conditions O
+( O
+frequent O
+feedings O
+, O
+no O
+supplementary O
+feeding O
+before O
+4 O
+- O
+6 O
+months O
+, O
+method O
+only O
+to O
+be O
+used O
+in O
+the O
+absence O
+of O
+menstruation O
+) O
+, O
+LAM O
+can O
+be O
+relied O
+on O
+for O
+contraceptive O
+protection O
+for O
+up O
+to O
+1 O
+year O
+post O
+partum O
+. O
+
+Nramp2 B
+contains O
+a O
+classical O
+iron O
+responsive O
+element O
+in O
+the O
+3 O
+' O
+untranslated O
+region O
+that O
+confers O
+iron O
+dependent O
+mRNA O
+stabilization O
+. O
+
+Likewise O
+, O
+epidural O
+morphine O
+does O
+not O
+modify O
+the O
+intraoperative O
+metabolic O
+and O
+hormonal O
+responses O
+. O
+
+CONCLUSIONS O
+- O
+- O
+Postlumbar O
+puncture O
+headache O
+may O
+be O
+mediated O
+by O
+the O
+release O
+of O
+substance B
+P I
+triggered O
+by O
+lumbar O
+puncture O
+, O
+in O
+patients O
+predisposed O
+to O
+headache O
+by O
+a O
+hypersensitivity O
+to O
+substance B
+P I
+. O
+
+Continuous O
+arterial O
+blood O
+sampling O
+method O
+based O
+on O
+the O
+microsphere O
+model O
+was O
+used O
+as O
+a O
+quantitative O
+rCBF O
+measurement O
+. O
+
+A O
+mutated B
+ABF1 I
+site I
+that O
+displays O
+a O
+very O
+low O
+affinity O
+for O
+ABF1 B
+does O
+not O
+functionally O
+replace O
+the O
+ILV1 B
+REB1 B
+site I
+. O
+
+Given O
+a O
+rapid O
+induction O
+of O
+Egr B
+- I
+1 I
+on O
+stimulation O
+with O
+growth O
+factors O
+or O
+injury O
+, O
+these O
+findings O
+may O
+represent O
+at O
+least O
+one O
+of O
+the O
+molecular O
+mechanisms O
+underlying O
+phenotypic O
+modulation O
+of O
+smooth O
+muscles O
+after O
+vascular O
+injury O
+. O
+
+A O
+nationwide O
+survey O
+uncovered O
+a O
+tenfold O
+variation O
+between O
+counties O
+in O
+the O
+prescribing O
+of O
+IFNB B
+. O
+
+In O
+this O
+first O
+- O
+person O
+account O
+, O
+the O
+author O
+chronicles O
+her O
+experience O
+of O
+being O
+mentally O
+ill O
+and O
+homeless O
+in O
+New O
+York O
+and O
+New O
+Jersey O
+in O
+the O
+early O
+1980s O
+. O
+
+Rectal O
+temperatures O
+after O
+the O
+walk O
+were O
+greater O
+( O
+P O
+< O
+. O
+001 O
+) O
+in O
+native O
+Simmental O
+( O
+39 O
+. O
+87 O
++ O
+/ O
+- O
+. O
+05 O
+degrees O
+C O
+) O
+than O
+in O
+Bos O
+indicus O
+( O
+39 O
+. O
+46 O
++ O
+/ O
+- O
+. O
+05 O
+degrees O
+C O
+) O
+. O
+
+Dominant O
+- O
+negative O
+mutations O
+in O
+the O
+G B
+- I
+protein I
+- I
+coupled I
+alpha I
+- I
+factor I
+receptor I
+map O
+to O
+the O
+extracellular O
+ends O
+of O
+the O
+transmembrane O
+segments O
+. O
+
+Such O
+simple O
+injuries O
+may O
+however O
+be O
+accompanied O
+by O
+far O
+reaching O
+consequences O
+. O
+
+This O
+is O
+the O
+first O
+report O
+which O
+clearly O
+proved O
+CEA B
+synthesis O
+in O
+the O
+cells O
+of O
+HCC O
+. O
+
+By O
+screening O
+a O
+human O
+testis O
+cDNA O
+library O
+with O
+a O
+probe O
+containing O
+the O
+mouse O
+PEA3 B
+ETS B
+domain O
+, O
+we O
+isolated O
+a O
+2 O
+. O
+2 O
+kb O
+clone O
+containing O
+a O
+510 O
+AA O
+open O
+reading O
+frame O
+. O
+
+AU O
+- O
+rich O
+elements O
+in O
+the O
+3 O
+' O
+- O
+untranslated O
+region O
+of O
+a O
+new O
+mucin B
+- I
+type I
+gene I
+family I
+of O
+Trypanosoma O
+cruzi O
+confers O
+mRNA O
+instability O
+and O
+modulates O
+translation O
+efficiency O
+. O
+
+These O
+findings O
+suggest O
+that O
+IL B
+- I
+1 I
+- O
+stimulated O
+, O
+Rho B
+- O
+dependent O
+cytoskeletal O
+reorganization O
+may O
+cluster O
+signaling O
+molecules O
+in O
+specific O
+architectures O
+that O
+are O
+necessary O
+for O
+persistent O
+cell O
+activation O
+in O
+chronic O
+inflammatory O
+disease O
+. O
+
+Changes O
+in O
+testicular O
+testosterone O
+and O
+acid B
+and I
+alkaline I
+phosphatase I
+activity O
+in O
+testis O
+and O
+accessory O
+sex O
+organs O
+after O
+induction O
+of O
+varicocele O
+in O
+Noble O
+rats O
+. O
+
+M O
+. O
+, O
+Apps O
+, O
+D O
+. O
+
+These O
+data O
+suggest O
+that O
+weight O
+gain O
+or O
+increased O
+caloric O
+intake O
+, O
+in O
+contrast O
+to O
+its O
+large O
+effect O
+on O
+peripheral O
+thyroid O
+function O
+, O
+has O
+relatively O
+little O
+effect O
+on O
+CNS B
+TRH I
+activity O
+. O
+
+Alfalfa O
+phosphorus O
+release O
+kinetics O
+showed O
+high O
+bacterial O
+phosphorus O
+contamination O
+. O
+
+The O
+quantitative O
+analysis O
+of O
+1 O
+- O
+alpha O
+- O
+acetylmethadol O
+and O
+its O
+principal O
+metabolites O
+in O
+biological O
+specimens O
+by O
+gas O
+chromatography O
+- O
+chemical O
+ionization O
+- O
+multiple O
+ion O
+monitoring O
+mass O
+spectrometry O
+. O
+
+Clinical O
+evidence O
+provides O
+tentative O
+suggestions O
+on O
+( O
+a O
+) O
+possible O
+additional O
+risk O
+of O
+cigarette O
+smoking O
+( O
+b O
+) O
+avoidance O
+of O
+venography O
+( O
+c O
+) O
+avoidance O
+of O
+varicose O
+vein O
+surgery O
+. O
+
+Effects O
+of O
+prolonged O
+inhibition O
+of O
+labour O
+pains O
+with O
+Th O
+1165a O
+and O
+Isoptin O
+on O
+the O
+heart O
+, O
+circulation O
+, O
+organ O
+- O
+and O
+metabolic O
+parameters O
+of O
+the O
+mother O
+
+Skytthe O
+, O
+and O
+K O
+. O
+
+In O
+the O
+Saccharomyces B
+cerevisiae I
+actin I
+intron I
+a O
+silent O
+branch O
+point O
+- O
+like O
+sequence O
+( O
+UACUAAG O
+) O
+is O
+located O
+7 O
+nt O
+upstream O
+of O
+the O
+canonical O
+sequence O
+. O
+
+The O
+requirement O
+for O
+an O
+essential O
+interaction O
+between O
+NPH B
+I I
+and O
+H4L B
+provides O
+an O
+explanation O
+for O
+the O
+observed O
+restriction O
+of O
+transcription O
+termination O
+to O
+early O
+viral O
+genes O
+. O
+
+After O
+birth O
+, O
+there O
+was O
+a O
+significantly O
+higher O
+increase O
+of O
+IgA B
+and O
+IgM B
+anti I
+- I
+M I
+. I
+leprae I
+antibody I
+activity O
+in O
+sera O
+taken O
+3 O
+- O
+6 O
+months O
+after O
+birth O
+from O
+babies O
+of O
+Group O
+1 O
+compared O
+to O
+Group O
+2 O
+, O
+but O
+the O
+IgA B
+and O
+IgM B
+activity O
+in O
+sera O
+taken O
+after O
+6 O
+months O
+of O
+age O
+showed O
+the O
+same O
+increase O
+in O
+the O
+two O
+groups O
+. O
+
+The O
+relation O
+between O
+the O
+changes O
+of O
+bone O
+density O
+and O
+the O
+level O
+of O
+blood O
+calcium O
+, O
+blood O
+phosphorus O
+and O
+alkaline B
+phosphatase I
+( O
+AKP B
+) O
+as O
+well O
+as O
+the O
+metabolism O
+of O
+vitamin O
+D O
+was O
+studied O
+. O
+
+These O
+results O
+demonstrate O
+the O
+extensive O
+homology O
+in O
+sequence O
+among O
+light O
+chains O
+of O
+IgM B
+kappa I
+autoantibodies I
+and O
+indicate O
+that O
+a O
+particular O
+V B
+kappa I
+germ I
+line I
+gene I
+, O
+kappa B
+IIIb I
+, O
+is O
+expressed O
+as O
+a O
+phylogenetic O
+response O
+to O
+certain O
+self O
+antigens O
+or O
+as O
+part O
+of O
+a O
+selection O
+process O
+by O
+which O
+these O
+autoimmune O
+responses O
+are O
+regulated O
+. O
+
+In O
+addition O
+, O
+the O
+findings O
+confirmed O
+previous O
+studies O
+which O
+showed O
+that O
+monkeys O
+with O
+total O
+bilateral O
+striatectomies O
+could O
+require O
+the O
+ability O
+to O
+execute O
+accurate O
+visually O
+guided O
+reaches O
+. O
+
+Comparison O
+of O
+the O
+sequences O
+of O
+the O
+alpha B
+- I
+like I
+DNA I
+polymerases I
+including O
+E B
+. I
+coli I
+DNA I
+polymerase I
+II I
+showed O
+that O
+there O
+were O
+nine O
+highly O
+conserved O
+regions O
+, O
+and O
+we O
+constructed O
+an O
+unrooted O
+phylogenetic O
+tree O
+of O
+the O
+DNA B
+polymerases O
+based O
+on O
+the O
+differences O
+in O
+these O
+conserved O
+regions O
+. O
+
+Before O
+and O
+6 O
+and O
+12 O
+months O
+after O
+H O
+. O
+pylori O
+eradication O
+the O
+patients O
+were O
+evaluated O
+for O
+fasting O
+gastrinemia B
+and O
+pepsinogen B
+I I
+, O
+basal O
+and O
+peak O
+acid O
+output O
+, O
+and O
+detailed O
+histological O
+assessment O
+including O
+the O
+ECL O
+cell O
+proliferative O
+patterns O
+. O
+
+Four O
+experiments O
+examined O
+the O
+role O
+of O
+the O
+cholinergic O
+projections O
+from O
+the O
+septum O
+and O
+vertical O
+limb O
+nucleus O
+of O
+the O
+diagonal O
+band O
+of O
+Broca O
+( O
+VDB O
+) O
+in O
+acquisition O
+and O
+performance O
+of O
+a O
+conditional O
+visual O
+discrimination O
+. O
+
+trans O
+- O
+activation O
+of O
+the O
+HIV B
+- I
+1 I
+LTR I
+by O
+the O
+HIV B
+- I
+1 I
+Tat I
+and O
+HTLV B
+- I
+I I
+Tax I
+proteins I
+is O
+mediated O
+by O
+different O
+cis O
+- O
+acting O
+sequences O
+. O
+
+Defective O
+concanavalin B
+A I
+- O
+induced O
+suppression O
+in O
+bancroftian O
+filariasis O
+. O
+
+For O
+more O
+detailed O
+mapping O
+, O
+we O
+constructed O
+mouse O
+A9 O
+cells O
+containing O
+STFs O
+derived O
+from O
+human O
+chromosome O
+2 O
+tagged O
+with O
+pSTneo B
+at O
+different O
+regions O
+in O
+2q31 O
+- O
+qter O
+. O
+
+Left O
+ventricular O
+insufficiency O
+requires O
+two O
+SP O
+/ O
+patient O
+, O
+with O
+good O
+results O
+in O
+approximately O
+81 O
+p O
+. O
+cent O
+. O
+
+However O
+, O
+there O
+are O
+some O
+cows O
+that O
+fail O
+to O
+produce O
+adequate O
+1 O
+, O
+25 O
+- O
+dihydroxyvitamin O
+D O
+at O
+the O
+onset O
+of O
+lactation O
+. O
+
+Acidic O
+carboxyl O
+- O
+terminal O
+domain O
+of O
+gene B
+2 I
+. I
+5 I
+protein I
+of I
+bacteriophage I
+T7 I
+is O
+essential O
+for O
+protein O
+- O
+protein O
+interactions O
+. O
+
+This O
+result O
+, O
+together O
+with O
+the O
+fact O
+that O
+unrearranged O
+V B
+kappa I
+genes I
+are O
+transcriptionally O
+silent O
+, O
+suggests O
+that O
+structural O
+features O
+of O
+both O
+the O
+V B
+kappa I
+and O
+C B
+kappa I
+loci I
+contribute O
+to O
+the O
+overall O
+transcriptional O
+efficiency O
+of O
+a O
+rearranged O
+V B
+kappa I
+- I
+C I
+kappa I
+gene O
+. O
+
+A O
+total O
+of O
+10 O
+, O
+763 O
+men O
+and O
+3 O
+, O
+118 O
+women O
+has O
+been O
+studied O
+, O
+of O
+whom O
+97 O
+% O
+and O
+89 O
+% O
+, O
+respectively O
+, O
+have O
+been O
+traced O
+and O
+36 O
+% O
+and O
+16 O
+% O
+have O
+died O
+. O
+
+NSD1 B
+contains O
+a O
+SET O
+domain O
+and O
+multiple O
+PHD B
+fingers I
+. O
+
+EMG O
+- O
+based O
+measures O
+of O
+fatigue O
+during O
+a O
+repetitive O
+squat O
+exercise O
+. O
+
+We O
+have O
+introduced O
+the O
+same O
+change O
+in O
+a O
+yeast B
+tRNA I
+( I
+Trp I
+) I
+gene I
+and O
+demonstrated O
+that O
+the O
+tRNA O
+acts O
+as O
+an O
+efficient O
+amber O
+suppressor O
+in O
+vivo O
+. O
+
+This O
+evaluation O
+examines O
+several O
+analytical O
+and O
+cost O
+parameters O
+for O
+five O
+representative O
+assays O
+: O
+IgG B
+, O
+IgA B
+, O
+IgM B
+, O
+phenytoin O
+, O
+and O
+phenobarbital O
+. O
+
+These O
+results O
+suggest O
+that O
+UvrA B
+is O
+involved O
+in O
+triplet O
+repeat O
+instability O
+in O
+cells O
+. O
+
+Among O
+women O
+, O
+plasma B
+factor I
+VII I
+: O
+Ag B
+was O
+inversely O
+associated O
+with O
+income O
+. O
+
+A O
+novel O
+protein B
+kinase I
+C I
+( O
+PKC B
+) O
+- O
+interacting O
+protein O
+was O
+identified O
+by O
+the O
+yeast O
+two O
+- O
+hybrid O
+screening O
+using O
+the O
+regulatory O
+domain O
+of O
+PKC B
+beta I
+I I
+as O
+a O
+bait O
+. O
+
+CONCLUSIONS O
+: O
+The O
+number O
+of O
+Spanish O
+articles O
+published O
+in O
+Anesthesiology O
+, O
+BJA O
+, O
+and O
+Anesth O
+Analg O
+is O
+low O
+, O
+although O
+the O
+comparison O
+of O
+our O
+productivity O
+with O
+that O
+of O
+other O
+EU O
+countries O
+in O
+function O
+of O
+GNPpc O
+places O
+us O
+in O
+an O
+intermediate O
+position O
+. O
+
+One O
+of O
+the O
+repeating O
+domains O
+( O
+Yheb1 B
+) O
+, O
+consisting O
+of O
+67 O
+amino O
+acids O
+, O
+was O
+cloned O
+from O
+the O
+E O
+. O
+coli O
+chromosome O
+and O
+purified O
+by O
+metal O
+chelating O
+chromatography O
+. O
+
+Phosphorylation O
+at O
+Ser O
+( O
+670 O
+) O
+impairs O
+the O
+ability O
+of O
+GRK2 B
+to O
+phosphorylate O
+both O
+soluble O
+and O
+membrane O
+- O
+incorporated O
+receptor O
+substrates O
+and O
+dramatically O
+attenuates O
+Gbetagamma B
+- O
+mediated O
+activation O
+of O
+this O
+enzyme O
+. O
+
+METHODS O
+: O
+CD4 B
+cell O
+counts O
+and O
+interview O
+data O
+were O
+recorded O
+in O
+a O
+survey O
+of O
+136 O
+adult O
+patients O
+attending O
+a O
+community O
+hospital O
+- O
+based O
+HIV O
+outpatient O
+clinic O
+. O
+
+Biol O
+. O
+
+Inhibition O
+of O
+endogenous B
+Cdk2 I
+by O
+dominant B
+negative I
+Cdk2 I
+attenuated O
+phosphorylation O
+of O
+Thr447 O
+, O
+Thr490 O
+and O
+Thr497 O
+, O
+but O
+had O
+no O
+effect O
+upon O
+Ser581 O
+modification O
+. O
+
+A O
+rabbit O
+antiserum O
+raised O
+against O
+a O
+unique O
+( O
+V3 O
+domain O
+) O
+bacterially O
+expressed O
+PKC B
+theta I
+fragment I
+immunoprecipitated O
+specifically O
+an O
+82 O
+- O
+kDa O
+protein O
+from O
+Jurkat O
+cell O
+lysates O
+. O
+
+Histological O
+examination O
+revealed O
+variable O
+loss O
+of O
+motor O
+neurons O
+limited O
+to O
+the O
+injection O
+site O
+. O
+
+This O
+is O
+the O
+most O
+northern O
+and O
+, O
+at O
+the O
+same O
+time O
+largest O
+, O
+Q O
+fever O
+epidemic O
+recorded O
+in O
+Germany O
+over O
+the O
+last O
+28 O
+years O
+. O
+
+Symptoms O
+, O
+skin O
+- O
+prick O
+tests O
+( O
+SPT O
+) O
+with O
+environmental O
+allergens O
+and O
+Pt O
+salt O
+, O
+total O
+serum B
+IgE I
+, O
+lung O
+function O
+, O
+and O
+bronchial O
+hyperresponsiveness O
+were O
+assessed O
+by O
+standard O
+procedures O
+. O
+
+Binding O
+sites O
+were O
+mapped O
+for O
+each O
+factor O
+. O
+
+Complementary O
+DNA O
+libraries O
+from O
+liver O
+and O
+ovary O
+of O
+an O
+immature O
+female O
+channel O
+catfish O
+were O
+screened O
+with O
+a O
+homologous B
+ERalpha I
+cDNA I
+probe O
+. O
+
+The O
+binding O
+of O
+PTB B
+was O
+antagonistic O
+to O
+the O
+binding O
+of O
+U2AF B
+to O
+the O
+enhancer O
+- O
+located O
+pyrimidine O
+tract O
+. O
+
+VLA B
+- I
+4 I
+integrin I
+cross O
+- O
+linking O
+on O
+human O
+monocytic O
+THP O
+- O
+1 O
+cells O
+induces O
+tissue O
+factor O
+expression O
+by O
+a O
+mechanism O
+involving O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+. O
+
+However O
+, O
+studies O
+using O
+the O
+A20 B
+promoter I
+demonstrated O
+that O
+LMP1 B
+transcriptionally O
+activates O
+the O
+A20 B
+gene I
+through O
+cis O
+- O
+acting O
+kappa B
+B I
+sites I
+. O
+
+Southern O
+blot O
+analysis O
+revealed O
+that O
+CCaMK B
+is O
+encoded O
+by O
+a O
+single O
+gene O
+. O
+
+Surgical O
+methods O
+in O
+the O
+treatment O
+of O
+rhinophyma O
+. O
+
+Phenazopyridine O
+- O
+induced O
+hemolytic O
+anemia O
+in O
+a O
+patient O
+with O
+G6PD B
+deficiency O
+. O
+
+Finally O
+, O
+we O
+demonstrated O
+that O
+although O
+the O
+DNA O
+- O
+binding O
+domain O
+of O
+c B
+- I
+myb I
+is O
+required O
+for O
+both O
+the O
+differentiation O
+block O
+and O
+the O
+shift O
+in O
+cell O
+cycle O
+after O
+PMA O
+treatment O
+, O
+phosphorylation O
+by O
+casein B
+kinase I
+II I
+and O
+mitogen B
+- I
+activated I
+protein I
+kinase I
+at O
+positions O
+11 O
+and O
+12 O
+or O
+532 O
+of O
+c B
+- I
+myb I
+, O
+respectively O
+, O
+are O
+not O
+. O
+
+The O
+activation O
+of O
+NF B
+- I
+kappaB I
+- O
+dependent O
+reporter O
+gene O
+transcription O
+by O
+E1A B
+was O
+potently O
+suppressed O
+upon O
+coexpression O
+of O
+the O
+E1B B
+19 I
+- I
+kDa I
+protein I
+( O
+19K O
+) O
+. O
+
+Our O
+results O
+showed O
+that O
+direct O
+enantiomeric O
+separation O
+of O
+mephenytoin O
+was O
+obtained O
+by O
+using O
+a O
+chiral O
+capillary O
+column O
+, O
+the O
+retention O
+times O
+for O
+S O
+- O
+and O
+R O
+- O
+mephenytoin O
+were O
+25 O
+. O
+5 O
+and O
+26 O
+. O
+2 O
+min O
+respectively O
+, O
+with O
+a O
+detection O
+limit O
+less O
+than O
+50 O
+ng O
+/ O
+ml O
+of O
+mephenytoin O
+. O
+
+The O
+myeloid B
+zinc I
+finger I
+gene I
+1 I
+( O
+MZF1 B
+) O
+encodes O
+a O
+C B
+( I
+2 I
+) I
+H I
+( I
+2 I
+) I
+zinc I
+finger I
+transcription I
+factor I
+that O
+regulates O
+granulopoiesis O
+and O
+may O
+have O
+a O
+regulatory O
+role O
+in O
+cellular O
+proliferation O
+and O
+oncogenesis O
+. O
+
+Snails O
+infected O
+with O
+three O
+or O
+five O
+miracidia O
+produced O
+more O
+metacercariae O
+than O
+those O
+infected O
+with O
+a O
+single O
+miracidium O
+. O
+
+We O
+conclude O
+that O
+GRF1 B
+and O
+GRF2 B
+can O
+form O
+homo O
+- O
+and O
+hetero O
+- O
+oligomers O
+via O
+their O
+DH O
+domains O
+, O
+that O
+mutational O
+inactivation O
+of O
+oligomer O
+formation O
+by O
+GRF1 B
+is O
+associated O
+with O
+impaired O
+biological O
+and O
+signaling O
+activities O
+, O
+and O
+that O
+in O
+293T O
+cells O
+GRF1 B
+mediates O
+at O
+least O
+two O
+pathways O
+for O
+Raf B
+activation O
+: O
+one O
+a O
+constitutive O
+signal O
+that O
+is O
+mainly O
+Ras B
+- O
+dependent O
+, O
+and O
+one O
+an O
+ionomycin O
+- O
+induced O
+signal O
+that O
+cooperates O
+with O
+the O
+constitutive O
+signal O
+without O
+further O
+augmenting O
+the O
+level O
+of O
+GTP B
+- I
+Ras I
+
+. O
+
+For O
+the O
+target O
+stimuli O
+, O
+P3 O
+amplitude O
+and O
+latency O
+were O
+negatively O
+correlated O
+and O
+most O
+tightly O
+coupled O
+over O
+the O
+frontal O
+- O
+central O
+and O
+right O
+medial O
+/ O
+lateral O
+recording O
+sites O
+. O
+
+Mitoxantrone O
+plus O
+ara O
+- O
+C O
+is O
+an O
+active O
+combination O
+with O
+great O
+promise O
+for O
+the O
+therapy O
+of O
+previously O
+untreated O
+patients O
+with O
+AML O
+. O
+
+In O
+the O
+renal O
+cortex O
+, O
+spleen O
+, O
+distal O
+colon O
+, O
+ileum O
+, O
+gallbladder O
+, O
+and O
+stomach O
+body O
+, O
+regional O
+O2 O
+delivery O
+was O
+significantly O
+decreased O
+with O
+hemodilution O
+to O
+20 O
+% O
+in O
+both O
+groups O
+. O
+
+( O
+A O
+short O
+account O
+of O
+Karl O
+Touton O
+' O
+s O
+life O
+is O
+also O
+included O
+. O
+) O
+After O
+reviewing O
+the O
+historical O
+development O
+of O
+the O
+concept O
+of O
+giant O
+cells O
+and O
+current O
+interpretations O
+of O
+their O
+nature O
+, O
+the O
+unitarian O
+view O
+of O
+polykaryons O
+now O
+favored O
+by O
+workers O
+in O
+the O
+field O
+is O
+extended O
+to O
+include O
+also O
+the O
+" O
+xanthelasmatic O
+giant O
+cell O
+" O
+of O
+Touton O
+, O
+whose O
+characteristic O
+appearance O
+is O
+determined O
+merely O
+by O
+the O
+presence O
+of O
+demonstrable O
+lipid O
+in O
+the O
+cytoplasm O
+. O
+
+Chronic O
+active O
+hepatitis O
+and O
+pregnancy O
+. O
+
+Influenza O
+virus O
+- O
+induced O
+NF B
+- I
+kappaB I
+- O
+dependent O
+gene O
+expression O
+is O
+mediated O
+by O
+overexpression O
+of O
+viral O
+proteins O
+and O
+involves O
+oxidative O
+radicals O
+and O
+activation O
+of O
+IkappaB B
+kinase I
+. O
+
+These O
+observed O
+changes O
+were O
+not O
+found O
+when O
+assessing O
+NPY B
+level O
+in O
+plasma O
+fluid O
+. O
+
+Reversible O
+topology O
+of O
+a O
+bifunctional O
+transmembrane O
+protein O
+depends O
+upon O
+the O
+charge O
+balance O
+around O
+its O
+transmembrane O
+domain O
+. O
+
+Protein B
+kinase I
+C I
+( O
+PKC B
+) O
+activation O
+after O
+treatment O
+of O
+human O
+neuroblastoma O
+SK O
+- O
+N O
+- O
+BE O
+( O
+2 O
+) O
+C O
+cells O
+with O
+phorbol O
+12 O
+- O
+myristate O
+13 O
+- O
+acetate O
+( O
+PMA O
+) O
+was O
+found O
+to O
+enhance O
+transcription O
+of O
+the O
+human B
+dopamine I
+beta I
+- I
+hydroxylase I
+( O
+DBH B
+) O
+in O
+those O
+cells O
+. O
+
+The O
+second O
+( O
+control O
+) O
+group O
+was O
+represented O
+by O
+cases O
+diagnosed O
+as O
+HSIL O
+by O
+cytology O
+. O
+
+The O
+illuminator O
+uses O
+a O
+grain O
+- O
+of O
+- O
+wheat O
+light O
+bulb O
+and O
+an O
+adjustable O
+bulb O
+holder O
+fashioned O
+from O
+bent O
+paper O
+clips O
+. O
+
+Bedbug O
+( O
+Cimex O
+lectularius O
+) O
+samples O
+adult O
+and O
+nymphs O
+either O
+engorged O
+or O
+starved O
+from O
+Central O
+Security O
+Forces O
+sleeping O
+wards O
+, O
+laboratory O
+animal O
+house O
+and O
+control O
+samples O
+from O
+laboratory O
+reared O
+colonies O
+were O
+ground O
+and O
+subjected O
+to O
+ELISA O
+test O
+of O
+hepatitis B
+B I
+surface I
+antigen I
+together O
+with O
+276 O
+serum O
+samples O
+from O
+the O
+recruits O
+slept O
+in O
+those O
+wards O
+. O
+
+The O
+genomic O
+organization O
+in O
+this O
+region O
+is O
+similar O
+to O
+the O
+neural O
+- O
+restricted O
+family O
+members O
+, O
+Hel B
+- I
+N1 I
+( O
+ELAVL2 B
+) O
+and O
+mHuD B
+( O
+Elavl4 B
+) O
+. O
+
+Synergistic O
+induction O
+of O
+apoptosis O
+in O
+human O
+leukemia O
+cells O
+( O
+U937 O
+) O
+exposed O
+to O
+bryostatin O
+1 O
+and O
+the O
+proteasome O
+inhibitor O
+lactacystin O
+involves O
+dysregulation O
+of O
+the O
+PKC B
+/ O
+MAPK B
+cascade O
+. O
+
+With O
+the O
+help O
+of O
+partially O
+overlapping O
+parenchymatous O
+sutures O
+, O
+different O
+renal O
+segments O
+were O
+devitalized O
+. O
+
+Promoter O
+elements O
+and O
+transcriptional O
+control O
+of O
+the O
+mouse B
+acetylcholinesterase I
+gene I
+. O
+
+The O
+average O
+cumulative O
+UVA O
+dose O
+was O
+65 O
+J O
+/ O
+cm2 O
+; O
+40 O
+patients O
+had O
+received O
+more O
+than O
+200 O
+J O
+/ O
+cm2 O
+. O
+
+Malformations O
+of O
+the O
+regenerating O
+optic O
+tectum O
+of O
+larvae O
+of O
+the O
+Egyptian O
+toad O
+, O
+Bufo O
+regularis O
+Reuss O
+. O
+
+These O
+morphological O
+changes O
+are O
+associated O
+with O
+a O
+marked O
+induction O
+of O
+P450arom B
+gene I
+expression O
+. O
+
+The O
+immunoprofile O
+of O
+60 O
+adult O
+patients O
+of O
+pulmonary O
+tuberculosis O
+was O
+studied O
+and O
+compared O
+with O
+22 O
+normal O
+controls O
+. O
+
+Central O
+- O
+venous O
+- O
+catheter O
+- O
+related O
+infection O
+is O
+readily O
+diagnosed O
+by O
+comparing O
+simultaneous O
+quantitative O
+cultures O
+of O
+blood O
+samples O
+obtained O
+via O
+the O
+catheter O
+and O
+a O
+peripheral O
+vein O
+. O
+
+The O
+role O
+of O
+haptoglobin B
+in O
+asphyxia O
+mechanism O
+( O
+II O
+) O
+- O
+- O
+Acute O
+drowning O
+and O
+hanging O
+
+Processing O
+MES O
+data O
+requires O
+large O
+bit O
+manipulations O
+and O
+heavy O
+memory O
+storage O
+requirements O
+. O
+
+Thus O
+, O
+BCR B
+ligation O
+initiates O
+a O
+PI B
+3 I
+- I
+kinase I
+/ O
+Akt B
+/ O
+GSK B
+- I
+3 I
+signaling O
+pathway O
+. O
+
+cDNA O
+cloning O
+and O
+transcriptional O
+properties O
+of O
+a O
+novel O
+GC B
+box I
+- I
+binding I
+protein I
+, O
+BTEB2 B
+. O
+
+This O
+activity O
+creates O
+a O
+4 O
+- O
+bp O
+staggered O
+cut O
+with O
+3 O
+' O
+OH O
+overhangs O
+within O
+a O
+specific O
+sequence O
+of O
+the O
+21S B
+rRNA I
+gene I
+of O
+omega O
+- O
+strains O
+. O
+
+The O
+two O
+ORFs O
+had O
+significant O
+similarity O
+with O
+the O
+putative O
+replication O
+protein O
+from O
+plasmid O
+pTiK12 O
+of O
+Thiobacillus O
+intermedius O
+and O
+other O
+CoIE2 O
+- O
+related O
+plasmids O
+. O
+
+In O
+contrast O
+SF B
+, O
+but O
+not O
+GM B
+- I
+CSF I
+or O
+IL B
+- I
+3 I
+, O
+induced O
+tyrosine O
+phosphorylation O
+of O
+phospholipase B
+C I
+- I
+gamma I
+( O
+PLC B
+- I
+gamma I
+) O
+. O
+
+Phase O
+I O
+clinical O
+trial O
+with O
+a O
+combination O
+of O
+methotrexate O
+and O
+mitomycin O
+C O
+. O
+
+Replacement O
+of O
+Val20 O
+- O
+Leu21 O
+with O
+Ala O
+- O
+Ala O
+produced O
+a O
+dimeric O
+RII B
+beta I
+protein I
+that O
+binds O
+AKAP75 B
+approximately O
+4 O
+% O
+as O
+avidly O
+as O
+wild B
+- I
+type I
+RII I
+beta I
+. O
+
+The O
+temporal O
+expression O
+of O
+CRAlBP B
+is O
+similar O
+to O
+IRBP B
+while O
+bFGF B
+is O
+not O
+expressed O
+until O
+after O
+photoreceptor O
+differentiation O
+is O
+complete O
+. O
+
+I O
+. O
+
+In O
+T O
+cells O
+these O
+two O
+signal O
+pathways O
+are O
+critical O
+for O
+interleukin B
+- I
+2 I
+production O
+. O
+
+Replacement O
+of O
+a O
+valine O
+( O
+V68 O
+) O
+in O
+the O
+ETS B
+domain I
+of O
+SAP1a B
+by O
+aspartic O
+acid O
+( O
+as O
+found O
+in O
+c B
+- I
+Ets I
+- I
+1 I
+, O
+Elk B
+- I
+1 I
+, O
+and O
+Net B
+) O
+enhanced O
+ternary O
+complex O
+formation O
+by O
+more O
+than O
+60 O
+- O
+fold O
+. O
+
+In O
+order O
+to O
+investigate O
+the O
+effect O
+of O
+the O
+local O
+direct O
+action O
+of O
+danazol O
+upon O
+endometriosis O
+, O
+intravaginal O
+and O
+intrauterine O
+application O
+were O
+tried O
+. O
+
+The O
+NF B
+- I
+kappaB I
+/ O
+Rel B
+transcription O
+factors O
+participate O
+in O
+the O
+activation O
+of O
+immune O
+system O
+regulatory O
+genes O
+and O
+viral B
+early I
+genes I
+including O
+the O
+human B
+immunodeficiency I
+virus I
+type I
+1 I
+long I
+terminal I
+repeat I
+. O
+
+A O
+total O
+of O
+4 O
+, O
+916 O
+children O
+were O
+examined O
+and O
+the O
+questionnaire O
+satisfactorily O
+completed O
+by O
+a O
+relative O
+or O
+guardian O
+( O
+usually O
+the O
+mother O
+) O
+of O
+4 O
+, O
+651 O
+. O
+
+cDNA O
+cloning O
+reveals O
+two O
+mouse B
+beta5 I
+integrin I
+transcripts I
+distinct O
+in O
+cytoplasmic O
+domains O
+as O
+a O
+result O
+of O
+alternative O
+splicing O
+. O
+
+Earlier O
+nonoptical O
+methods O
+probably O
+did O
+not O
+include O
+the O
+portion O
+of O
+the O
+film O
+that O
+contained O
+mucus O
+. O
+
+OBJECTIVE O
+: O
+To O
+summarise O
+quantitatively O
+the O
+association O
+between O
+moderate O
+alcohol O
+intake O
+and O
+biological O
+markers O
+of O
+risk O
+of O
+coronary O
+heart O
+disease O
+and O
+to O
+predict O
+how O
+these O
+changes O
+would O
+lower O
+the O
+risk O
+. O
+
+Like O
+other O
+known O
+GCD B
+genes I
+, O
+GCD14 B
+and O
+GCD15 B
+are O
+therefore O
+probably O
+required O
+for O
+general O
+translation O
+initiation O
+in O
+addition O
+to O
+their O
+roles O
+in O
+GCN4 B
+- O
+specific O
+translational O
+control O
+. O
+
+The O
+presence O
+of O
+highly O
+correlated O
+frequencies O
+provided O
+strong O
+evidence O
+of O
+a O
+medium O
+- O
+frequency O
+pattern O
+generator O
+which O
+may O
+remain O
+operative O
+beyond O
+the O
+neonatal O
+period O
+. O
+
+This O
+gene O
+is O
+named O
+PKNOX1 B
+by O
+the O
+Human O
+Nomenclature O
+Committee O
+. O
+
+Differentiation O
+of O
+porcine O
+mycoplasma O
+strains O
+by O
+means O
+of O
+a O
+simple O
+paper O
+chromatography O
+test O
+. O
+
+HIV O
+- O
+2 O
+in O
+Spain O
+. O
+
+No O
+effect O
+of O
+4 O
+beta O
+- O
+phorbol O
+12 O
+- O
+myristate O
+13 O
+- O
+acetate O
+was O
+observed O
+on O
+the O
+expression O
+of O
+hnRNP B
+H I
+. O
+
+Patients O
+commonly O
+considered O
+the O
+external O
+frame O
+cumbersome O
+. O
+
+D O
+. O
+
+The O
+atf1 B
++ I
+gene I
+of O
+Schizosaccharomyces O
+pombe O
+encodes O
+a O
+bZIP B
+transcription I
+factor I
+with O
+strong O
+homology O
+to O
+the O
+mammalian B
+factor I
+ATF I
+- I
+2 I
+. O
+
+The O
+effects O
+of O
+different O
+sources O
+of O
+commercial O
+rations O
+on O
+the O
+humoral O
+immune O
+response O
+of O
+broilers O
+to O
+Newcastle O
+disease O
+vaccination O
+. O
+
+Multiple O
+attempts O
+aimed O
+at O
+disruption O
+of O
+the O
+chromosomal B
+fabG I
+gene I
+were O
+unsuccessful O
+. O
+
+Primary O
+TJRs O
+were O
+clinically O
+evaluated O
+for O
+degree O
+of O
+osteoarthrosis O
+. O
+
+Radiation O
+sensitivity O
+of O
+rats O
+irradiated O
+in O
+a O
+condition O
+of O
+hypoxia O
+
+The O
+activity O
+of O
+plasminogen B
+activator I
+has O
+been O
+measured O
+in O
+tissue O
+sections O
+with O
+the O
+aid O
+of O
+a O
+modified O
+Todd O
+technique O
+. O
+
+The O
+complexity O
+of O
+some O
+of O
+the O
+reports O
+of O
+VACURG O
+studies O
+has O
+led O
+some O
+to O
+believe O
+that O
+this O
+group O
+was O
+opposed O
+to O
+estrogens O
+, O
+but O
+that O
+is O
+not O
+true O
+. O
+
+Thus O
+, O
+the O
+mutants O
+are O
+deficient O
+in O
+production O
+of O
+the O
+O B
+- I
+antigen I
+polymerase I
+and O
+were O
+termed O
+rfc B
+mutants I
+. O
+
+Up O
+to O
+1988 O
+, O
+145 O
+cases O
+had O
+been O
+reported O
+in O
+literature O
+and O
+32 O
+cases O
+in O
+our O
+country O
+. O
+
+Focal O
+glomerulosclerosis O
+- O
+like O
+disease O
+with O
+nephrotic O
+syndrome O
+in O
+a O
+horse O
+. O
+
+The O
+antihypertensive O
+action O
+corresponds O
+to O
+those O
+of O
+established O
+diuretics O
+. O
+
+Interconversions O
+between O
+haloperidol O
+and O
+reduced O
+haloperidol O
+in O
+schizophrenic O
+patients O
+and O
+guinea O
+pigs O
+: O
+a O
+steady O
+- O
+state O
+study O
+. O
+
+The O
+frequency O
+of O
+eating O
+dark O
+- O
+meat O
+fish O
+was O
+positively O
+associated O
+with O
+serum O
+eicosapentaenoic O
+acid O
+and O
+docosahexaenoic O
+acid O
+, O
+omega3 O
+fatty O
+acids O
+, O
+and O
+inversely O
+associated O
+with O
+serum O
+stearic O
+acid O
+and O
+linoleic O
+acid O
+. O
+
+Effect O
+of O
+food O
+on O
+hemodynamics O
+. O
+
+The O
+D443N O
+substitution O
+is O
+an O
+activating O
+mutation O
+that O
+increases O
+the O
+activity O
+of O
+SCAP O
+and O
+renders O
+it O
+resistant O
+to O
+inhibition O
+by O
+25 O
+- O
+hydroxycholesterol O
+. O
+
+Central O
+( O
+heart O
+rate O
+, O
+VE O
+, O
+VO2 O
+) O
+or O
+local O
+( O
+muscle O
+and O
+blood O
+lactate O
+, O
+adenosine O
+triphosphate O
+, O
+creatine B
+phosphokinase I
+, O
+glycogen O
+) O
+cues O
+highlighted O
+in O
+these O
+studies O
+demonstrate O
+both O
+the O
+complexity O
+of O
+effort O
+perception O
+, O
+and O
+the O
+need O
+for O
+better O
+understanding O
+of O
+the O
+physiological O
+components O
+upon O
+which O
+it O
+is O
+based O
+. O
+
+The O
+gene O
+is O
+predicted O
+to O
+encode O
+an O
+880 O
+- O
+amino O
+- O
+acid O
+protein O
+which O
+contains O
+two O
+C2H2 O
+zinc O
+fingers O
+, O
+a O
+nuclear O
+localization O
+sequence O
+and O
+two O
+transcriptional O
+activation O
+domains O
+. O
+
+This O
+approach O
+allowed O
+examination O
+of O
+baseline O
+factors O
+as O
+well O
+as O
+the O
+effect O
+of O
+change O
+in O
+mileage O
+, O
+the O
+occurrence O
+of O
+a O
+musculoskeletal O
+problem O
+, O
+or O
+the O
+occurrence O
+of O
+another O
+health O
+problem O
+on O
+the O
+rate O
+of O
+dropout O
+. O
+
+Microalbuminuria O
+: O
+a O
+marker O
+of O
+systemic O
+disease O
+. O
+
+Regulation O
+of O
+activating B
+transcription I
+factor I
+- I
+1 I
+and O
+the O
+cAMP B
+response I
+element I
+- I
+binding I
+protein I
+by O
+Ca2 B
++ I
+/ I
+calmodulin I
+- I
+dependent I
+protein I
+kinases I
+type I
+I I
+, I
+II I
+, I
+and I
+IV I
+. O
+
+Coronary O
+arteries O
+were O
+found O
+in O
+the O
+biopsy O
+tissue O
+of O
+30 O
+( O
+76 O
+% O
+) O
+of O
+the O
+39 O
+patients O
+who O
+formed O
+the O
+study O
+group O
+. O
+
+Serum B
+amyloid I
+A I
+( O
+SAA B
+) O
+is O
+a O
+plasma O
+protein O
+which O
+has O
+been O
+associated O
+with O
+several O
+diseases O
+, O
+including O
+amyloidosis O
+, O
+arthritis O
+, O
+and O
+atherosclerosis O
+, O
+and O
+its O
+abnormal O
+expression O
+, O
+particularly O
+in O
+nonhepatic O
+cells O
+, O
+is O
+implicated O
+in O
+the O
+pathogenesis O
+of O
+these O
+diseases O
+. O
+
+Phenacetin O
+nephritis O
+
+We O
+have O
+been O
+developing O
+a O
+digital O
+fluoroscopic O
+imaging O
+system O
+to O
+replace O
+the O
+portal O
+films O
+that O
+are O
+currently O
+used O
+to O
+verify O
+patient O
+positioning O
+during O
+radiotherapy O
+treatments O
+. O
+
+The O
+human B
+p18 I
+gene I
+spans O
+at O
+least O
+7 O
+. O
+5 O
+kb O
+and O
+is O
+composed O
+of O
+three O
+exons O
+, O
+two O
+of O
+which O
+encode O
+the O
+p18 B
+protein I
+. O
+
+Serum B
+creatinine I
+kinase I
+activity O
+was O
+7 O
+, O
+800 O
+- O
+17 O
+, O
+500 O
+U O
+/ O
+l O
+, O
+making O
+acute O
+muscle O
+damage O
+likely O
+, O
+probably O
+rhabdomyolysis O
+. O
+
+These O
+results O
+suggest O
+that O
+termination O
+is O
+a O
+highly O
+specific O
+event O
+, O
+and O
+not O
+merely O
+a O
+consequence O
+of O
+decreased O
+stability O
+of O
+the O
+EC O
+. O
+
+Like O
+Mdm2 B
+, O
+MdmX B
+is O
+able O
+to O
+bind O
+p53 B
+and O
+inhibit O
+p53 B
+transactivation O
+; O
+however O
+, O
+the O
+ability O
+of O
+MdmX B
+to O
+degrade O
+p53 B
+has O
+yet O
+to O
+be O
+examined O
+. O
+
+PURPOSE O
+: O
+Second O
+malignant O
+neoplasms O
+( O
+SMNs O
+) O
+are O
+a O
+rare O
+occurrence O
+after O
+the O
+successful O
+treatment O
+of O
+childhood O
+cancer O
+. O
+
+Recent O
+geological O
+studies O
+focusing O
+on O
+the O
+Davie O
+Fracture O
+Zone O
+of O
+the O
+Mozambique O
+Channel O
+offer O
+a O
+resolution O
+to O
+this O
+situation O
+, O
+by O
+suggesting O
+the O
+presence O
+of O
+a O
+land O
+- O
+bridge O
+from O
+the O
+mid O
+- O
+Eocene O
+to O
+the O
+early O
+Miocene O
+, O
+an O
+interval O
+that O
+matches O
+the O
+ages O
+of O
+Madagascar O
+' O
+s O
+mammalian O
+groups O
+. O
+
+The O
+nucleotide O
+sequence O
+of O
+a O
+PCR O
+- O
+amplified O
+SMT3A B
+genomic I
+DNA I
+fragment I
+was O
+found O
+to O
+be O
+identical O
+to O
+that O
+of O
+SMT3A B
+cDNA I
+, O
+indicating O
+the O
+absence O
+of O
+intron O
+( O
+s O
+) O
+in O
+its O
+protein O
+coding O
+region O
+. O
+
+Mutant B
+p53 I
+DNA O
+clones O
+from O
+human O
+colon O
+carcinomas O
+cooperate O
+with O
+ras B
+in O
+transforming O
+primary O
+rat O
+cells O
+: O
+a O
+comparison O
+of O
+the O
+" O
+hot O
+spot O
+" O
+mutant O
+phenotypes O
+. O
+
+Gas O
+chromatographic O
+analysis O
+of O
+headspace O
+samples O
+of O
+alkalinized O
+vaginal O
+discharges O
+indicated O
+the O
+presence O
+of O
+trimethylamine O
+in O
+all O
+11 O
+samples O
+with O
+the O
+fishy O
+odor O
+but O
+not O
+in O
+the O
+other O
+samples O
+. O
+
+Standing O
+values O
+: O
+placebo O
+114 O
+/ O
+79 O
+; O
+BHT O
+- O
+933 O
+92 O
+/ O
+67 O
+. O
+
+The O
+Ixodes O
+fauna O
+in O
+the O
+Michourin O
+region O
+, O
+where O
+the O
+pastures O
+in O
+1971 O
+were O
+grazed O
+only O
+by O
+sheep O
+, O
+shows O
+the O
+following O
+trends O
+: O
+H O
+. O
+punctata O
+and O
+R O
+. O
+turanicus O
+ticks O
+, O
+which O
+are O
+preferably O
+parasitising O
+in O
+sheep O
+, O
+increase O
+their O
+relative O
+share O
+. O
+
+The O
+SEC27 B
+gene I
+was O
+cloned O
+, O
+and O
+the O
+sequence O
+predicts O
+a O
+99 O
+. O
+4 O
+- O
+kDa O
+protein O
+with O
+45 O
+% O
+sequence O
+identity O
+to O
+mammalian B
+beta I
+' I
+- I
+COP I
+. O
+
+Studies O
+of O
+fetal O
+maturity O
+
+Fetal O
+arterial O
+and O
+sagittal O
+sinus O
+pH O
+, O
+base O
+excess O
+, O
+po2 O
+, O
+and O
+oxygen O
+saturation O
+decreased O
+, O
+and O
+hydrogen O
+ion O
+concentrations O
+and O
+pco2 O
+increased O
+during O
+asphyxia O
+alone O
+and O
+asphyxia O
+plus O
+isoflurane O
+- O
+oxygen O
+. O
+
+Therefore O
+, O
+it O
+appears O
+that O
+GCN2 B
+protein I
+kinase I
+function O
+is O
+stimulated O
+posttranslationally O
+in O
+amino O
+acid O
+- O
+starved O
+cells O
+. O
+
+Although O
+paclitaxel O
+alone O
+failed O
+to O
+induce O
+p38 B
+MAPK I
+activation O
+, O
+subsequent O
+( O
+but O
+not O
+prior O
+) O
+exposure O
+to O
+PD98059 O
+induced O
+a O
+dramatic O
+increase O
+in O
+p38 B
+MAPK I
+phosphorylation O
+. O
+
+In O
+3 O
+of O
+the O
+5 O
+patients O
+with O
+AVNRT O
+and O
+AJR O
+, O
+junctional O
+beats O
+served O
+as O
+a O
+trigger O
+for O
+reentry O
+. O
+
+The O
+three O
+respective O
+time O
+control O
+groups O
+( O
+C5 O
+, O
+C10 O
+, O
+and O
+C15 O
+) O
+were O
+injected O
+with O
+saline O
+solution O
+. O
+
+Sequence O
+analysis O
+of O
+cDNA O
+clones O
+encoding O
+human O
+gamma O
+revealed O
+an O
+open O
+reading O
+frame O
+predicting O
+a O
+protein O
+of O
+299 O
+amino O
+acids O
+( O
+approximately O
+32 O
+kDa O
+) O
+, O
+half O
+the O
+size O
+of O
+the O
+bovine O
+gamma O
+subunit O
+. O
+
+A O
+positive O
+FTA B
+- I
+ABS I
+- O
+19S B
+- I
+IgM I
+test O
+indicates O
+the O
+necessity O
+of O
+treatment O
+. O
+
+Our O
+data O
+suggest O
+that O
+some O
+defects O
+observed O
+in O
+BS O
+, O
+WS O
+or O
+RTS O
+are O
+the O
+consequence O
+of O
+unrestrained O
+recombination O
+. O
+
+The O
+promoter O
+for O
+HMG B
+- I
+CoA I
+synthase I
+contains O
+two O
+binding O
+sites O
+for O
+the O
+sterol B
+regulatory I
+element I
+- I
+binding I
+proteins I
+( O
+SREBPs B
+) O
+. O
+
+These O
+data O
+indicate O
+that O
+chromatic O
+processing O
+in O
+areas O
+V1 O
+and O
+V2 O
+is O
+normal O
+after O
+V4 O
+lesions O
+and O
+, O
+together O
+with O
+the O
+behavioural O
+evidence O
+, O
+that O
+these O
+areas O
+are O
+sufficient O
+for O
+some O
+basic O
+aspects O
+of O
+colour O
+perception O
+. O
+
+The O
+curse O
+of O
+the O
+Pharaohs O
+. O
+
+Covariates O
+were O
+lower O
+extremity O
+range O
+of O
+motion O
+and O
+sensory O
+status O
+. O
+
+Characterization O
+and O
+targeted O
+disruption O
+of O
+murine B
+Nup50 I
+, O
+a O
+p27 B
+( O
+Kip1 B
+) O
+- O
+interacting O
+component O
+of O
+the O
+nuclear O
+pore O
+complex O
+. O
+
+p27 B
+( O
+Kip1 B
+) O
+is O
+a O
+member O
+of O
+the O
+Cip B
+- O
+Kip B
+family O
+of O
+cyclin B
+- I
+dependent I
+kinase I
+( O
+Cdk B
+) O
+inhibitors O
+that O
+binds O
+to O
+cyclin B
+- O
+Cdk B
+complexes O
+and O
+inhibits O
+their O
+catalytic O
+activity O
+in O
+response O
+to O
+antiproliferative O
+stimuli O
+. O
+
+p27 B
+( O
+Kip1 B
+) O
+is O
+regulated O
+by O
+several O
+posttranscriptional O
+mechanisms O
+, O
+including O
+subcellular O
+localization O
+. O
+
+Therefore O
+, O
+the O
+Ogg1 B
+protein I
+is O
+a O
+eukaryotic O
+DNA B
+glycosylase I
+/ O
+AP B
+lyase I
+. O
+
+One O
+patient O
+had O
+chronic O
+dysphoria O
+and O
+one O
+encephalopatia O
+toxica O
+. O
+
+Alveoli O
+- O
+capillary O
+diffusion O
+. O
+
+Mutations O
+of O
+SIN4 B
+, O
+ROX3 B
+, O
+SRB8 B
+, O
+SRB9 B
+, O
+SRB10 B
+, O
+SRB11 B
+, O
+and O
+two O
+novel O
+genes O
+, O
+NUT1 B
+and O
+NUT2 B
+, O
+relieve O
+the O
+requirement O
+of O
+Swi4p B
+for O
+expression O
+of O
+this O
+reporter O
+. O
+
+The O
+software O
+is O
+in O
+BASIC O
+adapted O
+for O
+the O
+Hewlett O
+- O
+Packard O
+calculators O
+HP O
+- O
+9845B O
+and O
+HP O
+- O
+85A O
+. O
+
+For O
+Thermus O
+strain I
+ZO5 I
+dihydroorotase B
+( O
+DHOase B
+; O
+encoded O
+by O
+pyrC B
+) O
+, O
+the O
+highest O
+similarity O
+scores O
+( O
+about O
+40 O
+% O
+identity O
+) O
+were O
+obtained O
+with O
+DHOases B
+from O
+B O
+. O
+caldolyticus O
+and O
+Bacillus O
+subtilis O
+. O
+
+Precision O
+of O
+data O
+from O
+models O
+of O
+sodium O
+kinetics O
+in O
+hemodialysis O
+
+These O
+data O
+suggest O
+that O
+the O
+fibrinogen B
+gamma I
+chain I
+region I
+Gly190 O
+- O
+Val202 O
+functions O
+as O
+a O
+minimal O
+recognition O
+sequence O
+for O
+the O
+leukocyte O
+integrin B
+CD11b B
+/ O
+CD18 B
+. O
+
+Attenuated O
+serum O
+cortisol O
+responses O
+were O
+found O
+in O
+six O
+of O
+the O
+patients O
+despite O
+a O
+normal O
+ACTH B
+test O
+. O
+
+We O
+recently O
+described O
+the O
+isolation O
+and O
+characterization O
+of O
+nontoxic O
+PAP B
+mutants I
+, O
+NT123 O
+- O
+2 O
+, O
+which O
+has O
+a O
+point O
+mutation O
+( O
+E176V O
+) O
+in O
+the O
+active O
+site O
+that O
+abolishes O
+enzymatic O
+activity O
+, O
+and O
+NT124 O
+- O
+3 O
+, O
+which O
+has O
+a O
+nonsense O
+mutation O
+that O
+results O
+in O
+deletion O
+of O
+the O
+C O
+- O
+terminal O
+25 O
+aa O
+( O
+W237Stop O
+) O
+. O
+
+Toxicity O
+of O
+benzoyl O
+chloride O
+( O
+2 O
+, O
+4 O
+, O
+6 O
+- O
+trichlorophenyl O
+) O
+hydrazone O
+( O
+Banamite O
+) O
+and O
+potential O
+metabolites O
+to O
+twospotted O
+spider O
+mites O
+and O
+potency O
+as O
+inhibitors O
+of O
+rat B
+liver I
+monoamine I
+oxidase I
+. O
+
+The O
+screen O
+identifies O
+mutants O
+whose O
+growth O
+depends O
+on O
+high O
+levels O
+of O
+expression O
+of O
+that O
+gene O
+. O
+
+The O
+genes O
+expressed O
+during O
+the O
+embryonic O
+( O
+zeta O
+) O
+or O
+fetal O
+and O
+adult O
+stage O
+( O
+alpha B
+2 I
+and O
+alpha B
+1 I
+) O
+can O
+be O
+modified O
+by O
+point O
+mutations O
+which O
+affect O
+either O
+the O
+processing O
+- O
+translation O
+of O
+mRNA O
+or O
+make O
+the O
+polypeptide O
+chains O
+extremely O
+unstable O
+. O
+
+In O
+a O
+study O
+in O
+Singapore O
+, O
+Chinese O
+, O
+Malay O
+and O
+Indian O
+patients O
+with O
+pulmonary O
+tuberculosis O
+received O
+2 O
+months O
+of O
+daily O
+treatment O
+with O
+streptomycin O
+, O
+isoniazid O
+, O
+rifampicin O
+, O
+and O
+pyrazinamide O
+followed O
+by O
+daily O
+isoniazid O
+, O
+and O
+rifampicin O
+either O
+with O
+pyrazinamide O
+( O
+SHRZ O
+/ O
+HRZ O
+) O
+or O
+without O
+it O
+( O
+SHRZ O
+/ O
+HR O
+) O
+, O
+allocated O
+at O
+random O
+. O
+
+Kaposi B
+' I
+s I
+sarcoma I
+- I
+associated I
+herpesvirus B
+/ I
+human I
+herpesvirus I
+- I
+8 I
+ORF50 I
+gene I
+product I
+contains O
+a O
+potent O
+C O
+- O
+terminal O
+activation O
+domain O
+which O
+activates O
+gene O
+expression O
+via O
+a O
+specific O
+target O
+sequence O
+. O
+
+NSAIDS O
+and O
+the O
+microcirculation O
+of O
+the O
+stomach O
+. O
+
+The O
+efficiency O
+of O
+transfections O
+was O
+normalized O
+relative O
+to O
+the O
+net O
+amount O
+of O
+CAT B
+plasmid O
+actually O
+transfected O
+into O
+recipient O
+cells O
+, O
+determined O
+by O
+a O
+modified O
+Southern O
+hybridization O
+procedure O
+. O
+
+Genomic O
+Southern O
+blot O
+analysis O
+suggests O
+that O
+the O
+human O
+haploid O
+genome O
+contains O
+a O
+single O
+Gs B
+alpha I
+gene I
+. O
+
+Evaluation O
+of O
+the O
+effects O
+of O
+chelation O
+therapy O
+with O
+time O
+following O
+strontium O
+exposure O
+to O
+mice O
+. O
+
+In O
+the O
+present O
+study O
+we O
+found O
+that O
+CD34 B
+downregulation O
+during O
+hematopoiesis O
+occured O
+at O
+the O
+level O
+of O
+transcriptional O
+initiation O
+. O
+
+Allergen O
+- O
+stimulated O
+levels O
+of O
+PGD2 O
+were O
+1274 O
++ O
+/ O
+- O
+565 O
+versus O
+1468 O
++ O
+/ O
+- O
+679 O
+after O
+prednisone O
+; O
+likewise O
+, O
+allergen O
+- O
+stimulated O
+5 O
+- O
+HETE O
+levels O
+were O
+95 O
++ O
+/ O
+- O
+21 O
+versus O
+82 O
++ O
+/ O
+- O
+21 O
+; O
+those O
+of O
+LTE4 O
+were O
+54 O
++ O
+/ O
+- O
+20 O
+versus O
+91 O
++ O
+/ O
+- O
+51 O
+; O
+and O
+those O
+of O
+15 O
+- O
+HETE O
+were O
+63 O
++ O
+/ O
+- O
+19 O
+versus O
+60 O
++ O
+/ O
+- O
+25 O
+. O
+
+Foreign O
+DNA O
+inserts O
+contained O
+within O
+the O
+fowlpox O
+virus O
+sequence O
+were O
+transferred O
+to O
+the O
+viral O
+genome O
+by O
+homologous O
+recombination O
+occurring O
+in O
+cells O
+infected O
+with O
+a O
+fowlpox O
+virus O
+temperature O
+- O
+sensitive O
+mutant O
+and O
+transfected O
+with O
+both O
+wild O
+- O
+type O
+viral O
+DNA O
+and O
+plasmid O
+DNA O
+. O
+
+Although O
+there O
+is O
+evidence O
+that O
+cone O
+ratios O
+do O
+determine O
+colour O
+appearance O
+under O
+many O
+conditions O
+, O
+the O
+site O
+or O
+sites O
+of O
+their O
+computation O
+is O
+unknown O
+. O
+
+Furthermore O
+, O
+we O
+demonstrate O
+that O
+in O
+myeloid O
+and O
+B O
+cell O
+extracts O
+, O
+PU B
+. I
+1 I
+forms O
+a O
+novel O
+, O
+specific O
+, O
+more O
+slowly O
+migrating O
+complex O
+( O
+PU B
+- I
+SF I
+) O
+when O
+binding O
+the O
+GM B
+- I
+CSF I
+receptor I
+alpha I
+promoter I
+PU B
+. I
+1 I
+site I
+. O
+
+Several O
+components O
+in O
+cytokine O
+signaling O
+remain O
+unidentified O
+. O
+
+This O
+is O
+the O
+first O
+report O
+demonstrating O
+specificity O
+at O
+the O
+level O
+of O
+the O
+energy O
+coupling O
+proteins O
+of O
+the O
+PTS O
+. O
+
+In O
+contrast O
+, O
+stem O
+- O
+loop O
+structures O
+2 O
+, O
+3 O
+, O
+and O
+4 O
+of O
+the O
+3 O
+' O
+domain O
+showed O
+great O
+variations O
+in O
+size O
+, O
+sequence O
+, O
+and O
+structure O
+. O
+
+A O
+spectrophotometric O
+method O
+for O
+the O
+microdetermination O
+of O
+periodate O
+. O
+
+Result O
+were O
+as O
+followed O
+: O
+1 O
+) O
+Early O
+cancer O
+- O
+like O
+advanced O
+cancers O
+were O
+consisted O
+of O
+133 O
+lesions O
+, O
+of O
+which O
+128 O
+lesions O
+( O
+96 O
+. O
+2 O
+% O
+) O
+had O
+peptic O
+ulcer O
+in O
+cancerous O
+lesion O
+( O
+73 O
+lesions O
+were O
+active O
+stage O
+and O
+55 O
+lesions O
+were O
+scarring O
+stage O
+) O
+. O
+
+Effect O
+of O
+hyperaemia O
+on O
+thallium O
+- O
+201 O
+redistribution O
+in O
+normal O
+canine O
+myocardium O
+. O
+
+Immunoblotting O
+showed O
+that O
+both O
+the O
+( O
+1 O
+- O
+404 O
+) O
+- O
+peptide O
+and O
+( O
+1 O
+- O
+506 O
+) O
+- O
+peptide O
+are O
+recognized O
+by O
+95J10 B
+, O
+a O
+monoclonal O
+antibody O
+that O
+was O
+previously O
+raised O
+against O
+perlecan B
+- I
+( I
+24 I
+- I
+404 I
+) I
+- I
+peptide I
+expressed O
+in O
+Escherichia O
+coli O
+. O
+
+The O
+anesthesiologist O
+and O
+the O
+cardiac O
+surgeon O
+. O
+
+To O
+gain O
+further O
+insights O
+into O
+these O
+events O
+, O
+the O
+porcine B
+G I
+alpha I
+i I
+- I
+3 I
+gene I
+minimal I
+promoter I
+was O
+characterized O
+and O
+found O
+67 O
+base O
+pairs O
+upstream O
+from O
+the O
+major O
+transcription O
+start O
+site O
+. O
+
+FDP O
+- O
+1 O
+( O
+200 O
+micrograms O
+. O
+kg O
+- O
+1 O
+) O
+of O
+intracoronary O
+injection O
+increased O
+collateral O
+flow O
+, O
+reduced O
+systemic O
+artery O
+resistance O
+, O
+and O
+coronary O
+systolic O
+pressure O
+in O
+infarcted O
+region O
+and O
+the O
+area O
+of O
+infarction O
+decreased O
+from O
+28 O
+. O
+9 O
++ O
+/ O
+- O
+1 O
+. O
+3 O
+% O
+to O
+15 O
+. O
+3 O
++ O
+/ O
+- O
+1 O
+. O
+2 O
+% O
+( O
+P O
+< O
+0 O
+. O
+01 O
+, O
+n O
+= O
+6 O
+) O
+. O
+
+Pathophysiologic O
+mechanisms O
+underlying O
+spatial O
+disorientation O
+in O
+patients O
+with O
+Alzheimer O
+' O
+s O
+disease O
+. O
+
+Many O
+human O
+malignant O
+cells O
+lack O
+methylthioadenosine B
+phosphorylase I
+( O
+MTAP B
+) O
+enzyme O
+activity O
+. O
+
+Following O
+40 O
+min O
+" O
+ischemia O
+" O
+, O
+preparations O
+treated O
+with O
+PC O
+recovered O
+from O
+transmural O
+conduction O
+block O
+more O
+rapidly O
+( O
+PC1 O
+group O
+, O
+4 O
+min O
+, O
+P O
+less O
+than O
+0 O
+. O
+05 O
+; O
+PC2 O
+group O
+, O
+23 O
+min O
+, O
+ns O
+) O
+, O
+compared O
+to O
+control O
+. O
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+250 O
+WORDS O
+) O
+
+The O
+novel O
+gene O
+spans O
+16 O
+. O
+7 O
+kb O
+of O
+genomic O
+sequence O
+and O
+it O
+is O
+formed O
+of O
+11 O
+exons O
+and O
+10 O
+intervening O
+introns O
+. O
+
+G B
+- I
+box I
+binding I
+factors I
+( O
+GBFs B
+) O
+constitute O
+a O
+family O
+of O
+plant O
+DNA O
+- O
+binding O
+proteins O
+that O
+bind O
+to O
+the O
+G O
+- O
+box O
+motif O
+, O
+a O
+regulatory O
+cis O
+element O
+present O
+in O
+many O
+plant O
+genes O
+with O
+a O
+palindromic O
+DNA O
+motif O
+of O
+CACGTG O
+. O
+
+CONCLUSION O
+: O
+In O
+an O
+acute O
+canine O
+model O
+of O
+progressive O
+LCX O
+coronary O
+stenosis O
+, O
+CFR O
+was O
+impaired O
+in O
+both O
+ischemic O
+and O
+remote O
+nonischemic O
+regions O
+in O
+association O
+with O
+mild O
+to O
+moderate O
+ischemic O
+- O
+induced O
+regional O
+myocardial O
+dysfunction O
+. O
+
+A O
+third O
+- O
+order O
+polynominal O
+fit O
+showed O
+a O
+good O
+correlation O
+for O
+the O
+parameter O
+Q O
+* O
+and O
+MTT O
+, O
+whereas O
+T O
+and O
+SImax O
+were O
+found O
+to O
+have O
+a O
+poor O
+correlation O
+. O
+
+Late O
+results O
+in O
+the O
+treatment O
+of O
+urotuberculosis O
+
+Changes O
+in O
+the O
+frequency O
+of O
+X O
+- O
+chromatin O
+in O
+women O
+under O
+Prednisone O
+therapy O
+
+Other O
+toxicities O
+attributed O
+to O
+CPT O
+- O
+11 O
+included O
+dehydration O
+, O
+nausea O
+, O
+vomiting O
+, O
+and O
+asthenia O
+. O
+
+Proceedings O
+: O
+Influence O
+of O
+halothane O
+on O
+mortality O
+from O
+murine O
+hepatitis O
+virus O
+( O
+MHV3 O
+) O
+. O
+
+These O
+results O
+extend O
+our O
+knowledge O
+of O
+this O
+SNF2 B
+- I
+like I
+family I
+member I
+and O
+suggest O
+a O
+role O
+for O
+PASG B
+in O
+leukemogenesis O
+. O
+
+The O
+difference O
+between O
+the O
+results O
+in O
+the O
+high O
+dose O
+AHLG O
+and O
+in O
+the O
+control O
+group O
+was O
+significant O
+( O
+p O
+less O
+than O
+0 O
+. O
+05 O
+) O
+. O
+
+Results O
+of O
+this O
+study O
+indicate O
+that O
+when O
+amniotic O
+fluid O
+samples O
+are O
+stored O
+frozen O
+and O
+strict O
+quality O
+control O
+is O
+maintained O
+in O
+analytic O
+procedures O
+, O
+only O
+minimal O
+changes O
+occur O
+in O
+phospholipid O
+concentrations O
+over O
+12 O
+months O
+. O
+
+Retinoic O
+acid O
+, O
+which O
+inhibits O
+the O
+progression O
+of O
+certain O
+cancers O
+, O
+repressed O
+v B
+- I
+src I
+- O
+induced O
+MMP B
+- I
+1 I
+transcription O
+. O
+
+The O
+pattern O
+of O
+net O
+RNA O
+expression O
+in O
+adult O
+mouse O
+tissues O
+is O
+different O
+. O
+
+Immunoprecipitation O
+of O
+spinophilin B
+or O
+neurabin B
+from O
+crude O
+brain O
+extracts O
+selectively O
+coprecipitated O
+PP1gamma B
+( I
+1 I
+) I
+over O
+PP1beta B
+. O
+
+The O
+authors O
+discussed O
+their O
+experience O
+in O
+investigating O
+20 O
+patients O
+with O
+maxillary O
+malignant O
+tumors O
+using O
+routine O
+x O
+- O
+ray O
+studies O
+and O
+MR O
+- O
+tomography O
+, O
+and O
+13 O
+patients O
+, O
+investigated O
+in O
+the O
+same O
+way O
+plus O
+CT O
+. O
+
+Reduction O
+of O
+p53 B
+protein I
+was O
+detected O
+after O
+1 O
+day O
+of O
+OM O
+treatment O
+and O
+reached O
+maximal O
+suppression O
+of O
+10 O
+- O
+20 O
+% O
+of O
+control O
+after O
+3 O
+days O
+in O
+H3922 O
+and O
+40 O
+% O
+of O
+control O
+after O
+4 O
+days O
+in O
+MCF O
+- O
+7 O
+cells O
+. O
+
+Association O
+of O
+Syk B
+protein B
+tyrosine I
+kinase I
+( O
+PTK B
+) O
+with O
+LMP2A B
+occurs O
+at O
+the O
+two O
+tyrosines O
+of O
+the O
+LMP2A B
+immunoreceptor I
+tyrosine I
+- I
+based I
+activation I
+motif I
+, O
+and O
+it O
+is O
+hypothesized O
+that O
+Lyn B
+PTK B
+associates O
+with O
+the O
+YEEA O
+amino O
+acid O
+motif O
+at O
+LMP2A B
+tyrosine O
+112 O
+( O
+Y112 O
+) O
+. O
+
+The O
+treatment O
+with O
+glucocorticoids O
+and O
+immunosuppressants O
+resulted O
+in O
+a O
+more O
+noticeable O
+decrease O
+in O
+the O
+levels O
+of O
+T3 O
+and O
+E B
+- I
+RCF O
+. O
+
+Four O
+of O
+these O
+fibroblast O
+clones O
+were O
+infected O
+with O
+a O
+retrovirus O
+containing O
+the O
+cDNA O
+encoding O
+myoD B
+and O
+a O
+puromycin O
+selection O
+marker O
+. O
+
+Serum O
+estriol O
+levels O
+during O
+beta B
+- I
+receptor I
+agonist O
+infusion O
+in O
+the O
+third O
+trimester O
+of O
+pregnancy O
+. O
+
+In O
+this O
+study O
+, O
+we O
+investigated O
+the O
+mechanism O
+by O
+which O
+Tax B
+activates O
+gene O
+expression O
+in O
+conjunction O
+with O
+members O
+of O
+the O
+ATF B
+/ O
+CREB B
+family O
+. O
+
+Four O
+of O
+12 O
+patients O
+( O
+33 O
+% O
+) O
+were O
+initially O
+diagnosed O
+as O
+having O
+a O
+benign O
+disease O
+( O
+false O
+- O
+negatives O
+) O
+. O
+
+However O
+, O
+it O
+was O
+observed O
+that O
+storage O
+time O
+affected O
+significantly O
+the O
+biochemical O
+changes O
+occurring O
+in O
+the O
+constituents O
+of O
+carrots O
+exposed O
+to O
+gamma O
+- O
+irradiation O
+. O
+
+Suppression O
+of O
+the O
+cka1 B
+delta I
+cka2 B
+- I
+8 I
+mutant O
+phenotype O
+occurs O
+by O
+interaction O
+of O
+CKB1 B
+with O
+the O
+defective O
+, O
+cka2 B
+- I
+8 I
+- O
+encoded O
+, O
+catalytic O
+subunit O
+. O
+
+The O
+median O
+cumulative O
+incidence O
+rates O
+were O
+found O
+to O
+be O
+341 O
+per O
+million O
+for O
+males O
+and O
+296 O
+per O
+million O
+for O
+females O
+. O
+
+Thomas O
+, O
+S O
+. O
+S O
+. O
+
+Similarly O
+, O
+antisense O
+TGF B
+- I
+beta I
+type I
+II I
+receptor I
+oligodeoxynucleotides O
+( O
+40 O
+microM O
+) O
+resulted O
+in O
+a O
+58 O
+% O
+increase O
+in O
+branching O
+, O
+compared O
+to O
+scrambled O
+and O
+mismatched O
+sequence O
+controls O
+, O
+while O
+TGF B
+- I
+beta I
+, I
+type I
+II I
+receptor I
+mRNA I
+and O
+its O
+protein O
+expression O
+levels O
+were O
+suppressed O
+by O
+95 O
+and O
+84 O
+% O
+, O
+respectively O
+. O
+
+Secretion O
+of O
+cuticle O
+over O
+and O
+between O
+the O
+domed O
+apical O
+surfaces O
+of O
+these O
+cells O
+leads O
+to O
+a O
+honeycomb O
+- O
+like O
+structure O
+and O
+gives O
+the O
+superficial O
+wart O
+- O
+like O
+phenotype O
+of O
+mitotic O
+clones O
+on O
+the O
+adult O
+. O
+
+Taken O
+together O
+, O
+these O
+results O
+indicate O
+that O
+ICSBP B
+and O
+PU B
+. I
+1 I
+are O
+critical O
+elements O
+for O
+IL B
+- I
+18 I
+gene I
+expression O
+. O
+
+Based O
+on O
+these O
+results O
+, O
+it O
+has O
+been O
+concluded O
+that O
+an O
+IPFSA O
+can O
+promote O
+the O
+healing O
+process O
+in O
+the O
+avascular O
+zone O
+of O
+a O
+torn O
+meniscus O
+in O
+rabbits O
+and O
+that O
+systemic O
+vascularity O
+to O
+the O
+synovium O
+or O
+the O
+meniscus O
+is O
+not O
+essential O
+for O
+healing O
+to O
+occur O
+. O
+
+NASA O
+CR O
+- O
+1223 O
+. O
+
+The O
+magnitude O
+of O
+all O
+four O
+parameters O
+increased O
+in O
+an O
+exponential O
+fashion O
+with O
+increasing O
+sperm O
+number O
+up O
+to O
+400 O
+x O
+10 O
+( O
+6 O
+) O
+per O
+ejaculate O
+. O
+
+We O
+studied O
+about O
+the O
+histological O
+findings O
+of O
+the O
+kidneys O
+including O
+of O
+the O
+infiltrated O
+macrophages O
+in O
+one O
+hour O
+post O
+- O
+transplantation O
+kidney O
+biopsies O
+( O
+one O
+hour O
+biopsies O
+) O
+and O
+re O
+- O
+biopsies O
+on O
+11 O
+patients O
+. O
+
+An O
+additional O
+stimulation O
+of O
+D1 B
+receptors I
+by O
+giving O
+SKF38393 O
+30 O
+min O
+later O
+produced O
+an O
+almost O
+continuous O
+pattern O
+of O
+jaw O
+openings O
+but O
+less O
+closure O
+movements O
+from O
+the O
+rest O
+position O
+, O
+and O
+the O
+openings O
+were O
+accompanied O
+by O
+frequent O
+tongue O
+protrusions O
+. O
+
+( O
+control O
+hearts O
+) O
+. O
+
+The O
+( O
+0 O
+0 O
+2 O
+) O
+diffraction O
+of O
+the O
+synthesized O
+HAp B
+crystals O
+on O
+a O
+Col O
+fiber O
+showed O
+an O
+around O
+60 O
+arching O
+angle O
+, O
+while O
+that O
+on O
+a O
+ChS O
+fiber O
+showed O
+just O
+around O
+10 O
+degrees O
+. O
+
+During O
+4 O
+% O
+O2 O
+ventilation O
+, O
+baseline O
+pulmonary O
+vascular O
+resistance O
+( O
+PVR O
+) O
+and O
+the O
+dilator O
+response O
+to O
+both O
+ACh O
+and O
+SNP O
+were O
+greater O
+in O
+2D O
+lungs O
+. O
+
+To O
+determine O
+the O
+role O
+of O
+the O
+transmembrane O
+region O
+of O
+HN B
+on O
+fusion O
+- O
+promoting O
+activity O
+, O
+mutant B
+HN I
+proteins I
+were O
+expressed O
+and O
+their O
+biological O
+activities O
+examined O
+. O
+
+To O
+be O
+a O
+nurse O
+. O
+
+Transient O
+transfection O
+assays O
+indicated O
+that O
+the O
+( O
+- O
+4551 O
+) O
+UCP1 B
+- O
+CAT B
+construct O
+, O
+containing O
+the O
+5 O
+' O
+- O
+regulatory O
+region O
+of O
+the O
+rat B
+ucp I
+- I
+1 I
+gene I
+, O
+was O
+activated O
+by O
+PPARalpha B
+co O
+- O
+transfection O
+in O
+a O
+dose O
+- O
+dependent O
+manner O
+and O
+this O
+activation O
+was O
+potentiated O
+by O
+Wy O
+14 O
+, O
+643 O
+and O
+retinoid B
+X I
+receptor I
+alpha I
+. O
+
+Synthesis O
+of O
+2 O
+- O
+( O
+2 O
+' O
+- O
+thiazolyl O
+) O
+alkanebenzimidazoles O
+- O
+- O
+potential O
+anthelmintics O
+
+Human B
+CR2 I
+has O
+a O
+restricted O
+cellular O
+distribution O
+, O
+being O
+expressed O
+on O
+B O
+lymphocytes O
+, O
+dendritic O
+cells O
+of O
+the O
+spleen O
+, O
+pharyngeal O
+epithelial O
+cells O
+, O
+and O
+at O
+low O
+levels O
+on O
+some O
+T O
+lymphocytes O
+. O
+
+ADR1 B
+in O
+extracts O
+made O
+from O
+glucose O
+- O
+repressed O
+and O
+- O
+derepressed O
+cells O
+bound O
+UAS1 O
+DNA O
+with O
+similar O
+affinities O
+despite O
+having O
+greatly O
+different O
+abilities O
+to O
+activate O
+ADH2 B
+gene I
+expression O
+in O
+vivo O
+. O
+
+Furthermore O
+, O
+agonist O
+action O
+at O
+a O
+5 B
+- I
+HT1 I
+receptor I
+and O
+antagonist O
+action O
+at O
+5 B
+- I
+HT2 I
+receptors I
+both O
+appear O
+to O
+contribute O
+to O
+antidepressant O
+- O
+like O
+activity O
+on O
+the O
+DRL O
+72 O
+- O
+s O
+schedule O
+. O
+
+MsEPV B
+genes O
+with O
+putative O
+functions O
+in O
+prevention O
+and O
+repair O
+of O
+DNA O
+damage O
+include O
+a O
+complete O
+base O
+excision O
+repair O
+pathway O
+( O
+uracil B
+DNA I
+glycosylase I
+, O
+AP B
+endonuclease I
+, O
+DNA B
+polymerase I
+beta I
+, O
+and O
+an O
+NAD B
++ I
+- I
+dependent I
+DNA I
+ligase I
+) O
+, O
+a O
+photoreactivation O
+repair O
+pathway O
+( O
+cyclobutane B
+pyrimidine I
+dimer I
+photolyase I
+) O
+, O
+a O
+LINE B
+- I
+type I
+reverse I
+transcriptase I
+, O
+and O
+a O
+mutT B
+homologue I
+. O
+
+These O
+three O
+groups O
+were O
+further O
+examined O
+with O
+regard O
+to O
+the O
+modulation O
+of O
+discharge O
+rate O
+i O
+) O
+during O
+motor O
+activity O
+in O
+W O
+, O
+ii O
+) O
+at O
+the O
+transitional O
+phase O
+from O
+SS O
+to O
+paradoxical O
+sleep O
+( O
+PS O
+) O
+, O
+iii O
+) O
+during O
+rapid O
+eye O
+movements O
+( O
+REMs O
+) O
+in O
+PS O
+, O
+and O
+iv O
+) O
+following O
+electrical O
+stimulation O
+of O
+the O
+midbrain O
+reticular O
+formation O
+( O
+MRF O
+) O
+. O
+
+Likewise O
+, O
+the O
+consensus O
+signal O
+believed O
+to O
+be O
+involved O
+in O
+terminating O
+VV B
+early I
+gene I
+transcription O
+, O
+TTTTTNT O
+, O
+was O
+evident O
+at O
+the O
+3 O
+' O
+- O
+boundary O
+of O
+both O
+the O
+N2 B
+and O
+M1 B
+ORFs I
+suggesting O
+that O
+these O
+genes O
+may O
+be O
+VV B
+early I
+genes I
+. O
+
+This O
+radiolabeled O
+, O
+900 O
+- O
+bp O
+amplicon O
+was O
+used O
+as O
+a O
+hybridization O
+probe O
+to O
+screen O
+a O
+cDNA O
+library O
+constructed O
+from O
+poly O
+( O
+A O
+) O
+( O
++ O
+) O
+RNA O
+isolated O
+from O
+induced O
+Taxus O
+cells O
+, O
+from O
+which O
+a O
+full B
+- I
+length I
+transacetylase I
+sequence I
+was O
+obtained O
+. O
+
+Low O
+temperature O
+( O
+8 O
+degrees O
+C O
+) O
+impairs O
+secretory O
+activity O
+, O
+again O
+independently O
+of O
+the O
+photoperiod O
+selected O
+. O
+
+Left O
+ventricle O
+to O
+coronary O
+sinus O
+fistula O
+. O
+
+In O
+this O
+report O
+we O
+describe O
+the O
+structure O
+and O
+DNA O
+sequence O
+of O
+transcriptional O
+control O
+regions O
+from O
+both O
+human O
+and O
+Wistar O
+- O
+rat I
+single I
+copy I
+EGF I
+genes I
+and O
+their O
+functional O
+analysis O
+in O
+epithelial O
+cell O
+cultures O
+. O
+
+The O
+magnesium O
+content O
+in O
+leukocytes O
+could O
+not O
+be O
+estimated O
+because O
+of O
+interaction O
+between O
+the O
+ion O
+and O
+the O
+Percoll O
+( O
+R O
+) O
+media O
+. O
+
+The O
+sequence O
+of O
+three O
+of O
+them O
+revealed O
+pure O
+CAG O
+stretches O
+. O
+
+Furthermore O
+, O
+mutations O
+in O
+element O
+II O
+result O
+in O
+changes O
+in O
+the O
+RNA O
+structure O
+near O
+element O
+III O
+, O
+consistent O
+with O
+a O
+long O
+- O
+range O
+interaction O
+that O
+may O
+promote O
+translation O
+. O
+
+Although O
+the O
+QT O
+duration O
+was O
+higher O
+( O
+p O
+= O
+0 O
+. O
+0001 O
+) O
+at O
+night O
+, O
+the O
+beat O
+- O
+to O
+- O
+beat O
+variability O
+of O
+this O
+interval O
+was O
+lower O
+: O
+in O
+the O
+time O
+domain O
+( O
+decreased O
+standard O
+deviation O
+, O
+p O
+= O
+0 O
+. O
+0005 O
+) O
+, O
+in O
+the O
+frequency O
+domain O
+( O
+decreased O
+low O
+- O
+frequency O
+power O
+of O
+the O
+spectra O
+, O
+p O
+= O
+0 O
+. O
+004 O
+) O
+, O
+and O
+the O
+chaotic O
+domain O
+( O
+tighter O
+clustering O
+of O
+the O
+points O
+in O
+the O
+Poincare O
+plots O
+) O
+. O
+
+The O
+biological O
+functions O
+of O
+rat B
+surfactant I
+protein I
+A I
+( O
+SP B
+- I
+A I
+) O
+, O
+an O
+oligomer O
+composed O
+of O
+18 O
+polypeptide O
+subunits O
+derived O
+from O
+a O
+single O
+gene O
+, O
+are O
+dependent O
+on O
+intact O
+disulfide O
+bonds O
+. O
+
+A O
+V1 B
+mutant I
+generated O
+in O
+vivo O
+with O
+11 O
+of O
+the O
+14 O
+N O
+- O
+terminal O
+amino O
+acids O
+altered O
+, O
+was O
+viable O
+and O
+produced O
+symptoms O
+typical O
+of O
+a O
+wild O
+- O
+type O
+infection O
+. O
+
+This O
+seems O
+to O
+take O
+place O
+in O
+the O
+same O
+nuclear O
+compartment O
+as O
+normal O
+cis O
+splicing O
+and O
+proceeds O
+through O
+Y O
+- O
+branched O
+intermediates O
+analogous O
+to O
+the O
+lariats O
+formed O
+in O
+cis O
+splicing O
+. O
+
+We O
+have O
+demonstrated O
+that O
+the O
+specific O
+determination O
+and O
+identification O
+of O
+plasma O
+FbDP O
+alone O
+is O
+not O
+sufficient O
+to O
+follow O
+the O
+effectiveness O
+of O
+thrombolytic O
+therapy O
+. O
+
+Chronic O
+, O
+recurrent O
+multifocal O
+osteomyelitis O
+. O
+
+Maximum O
+baroreceptor O
+activity O
+measured O
+at O
+140 O
+mm O
+Hg O
+and O
+the O
+slope O
+of O
+the O
+pressure O
+- O
+activity O
+curve O
+were O
+reduced O
+in O
+atherosclerotic O
+( O
+n O
+= O
+15 O
+) O
+compared O
+with O
+normal O
+( O
+n O
+= O
+13 O
+) O
+rabbits O
+( O
+425 O
++ O
+/ O
+- O
+34 O
+versus O
+721 O
++ O
+/ O
+- O
+30 O
+spikes O
+per O
+second O
+and O
+6 O
+. O
+2 O
++ O
+/ O
+- O
+0 O
+. O
+6 O
+versus O
+10 O
+. O
+8 O
++ O
+/ O
+- O
+0 O
+. O
+8 O
+spikes O
+per O
+second O
+per O
+mm O
+Hg O
+, O
+respectively O
+, O
+P O
+< O
+. O
+05 O
+) O
+. O
+
+A O
+pathogenetic O
+relation O
+with O
+the O
+Eisenmenger O
+' O
+s O
+syndrome O
+is O
+discussed O
+. O
+
+Coronary O
+vasoconstriction O
+caused O
+by O
+endothelin B
+- I
+1 I
+is O
+enhanced O
+by O
+ischemia O
+- O
+reperfusion O
+and O
+by O
+norepinephrine O
+present O
+in O
+concentrations O
+typically O
+observed O
+after O
+neonatal O
+cardiopulmonary O
+bypass O
+. O
+
+Located O
+between O
+the O
+3 O
+' O
+trans O
+- O
+spliced O
+leader O
+acceptor O
+site O
+and O
+the O
+translational O
+initiation O
+codon O
+of O
+the O
+GP63 B
+gene I
+is O
+an O
+area O
+of O
+conserved O
+hexanucleotide O
+direct O
+repeats O
+( O
+CTCGCC O
+) O
+which O
+vary O
+in O
+number O
+according O
+to O
+species O
+. O
+
+An O
+association O
+was O
+found O
+between O
+zafirlukast O
+plasma O
+concentrations O
+and O
+increases O
+in O
+PC8SRaw O
+10 O
+h O
+after O
+treatment O
+( O
+p O
+= O
+0 O
+. O
+001 O
+) O
+. O
+
+Insulin B
+- O
+secreting O
+islet O
+- O
+cell O
+tumours O
+of O
+the O
+pancreas O
+. O
+
+Disruption O
+and O
+reconstruction O
+: O
+narrative O
+insights O
+into O
+the O
+experience O
+of O
+family O
+members O
+caring O
+for O
+a O
+relative O
+diagnosed O
+with O
+serious O
+mental O
+illness O
+. O
+
+The O
+results O
+suggest O
+that O
+the O
+posterior O
+wall O
+is O
+more O
+compliant O
+than O
+the O
+anterior O
+wall O
+( O
+that O
+is O
+, O
+for O
+a O
+given O
+difference O
+in O
+transmural O
+pressure O
+, O
+the O
+local O
+segment O
+length O
+change O
+of O
+the O
+posterior O
+wall O
+was O
+greater O
+) O
+. O
+
+We O
+have O
+previously O
+demonstrated O
+that O
+pyrene O
+in O
+diesel O
+- O
+exhaust O
+particles O
+( O
+DEP O
+) O
+has O
+an O
+adjuvant O
+activity O
+on O
+immunoglobulin B
+E I
+( O
+IgE B
+) O
+antibody O
+production O
+in O
+mice O
+immunized O
+with O
+Japanese B
+cedar I
+pollen I
+allergen I
+( O
+JCPA B
+) O
+or O
+ovalbumin B
+( O
+OA B
+) O
+intraperitoneally O
+. O
+
+Partial O
+characterization O
+of O
+the O
+CCAAT O
+box O
+in O
+the O
+promoter O
+of O
+the O
+hLGFBP B
+- I
+1 I
+gene I
+: O
+interaction O
+with O
+negatively O
+acting O
+transcription O
+factors O
+in O
+decidualized O
+human O
+endometrial O
+stromal O
+cells O
+. O
+
+We O
+conclude O
+that O
+transcription O
+of O
+both O
+SCD1 B
+and O
+SCD2 B
+genes I
+is O
+responsive O
+to O
+cellular O
+sterol O
+levels O
+and O
+to O
+the O
+levels O
+of O
+nuclear O
+SREBP B
+/ O
+ADD1 B
+and O
+that O
+transcriptional O
+induction O
+requires O
+three O
+spatially O
+conserved O
+cis O
+elements O
+, O
+that O
+bind O
+SREBP B
+and O
+NF B
+- I
+Y I
+. O
+
+Three O
+transcriptional O
+control O
+elements O
+within O
+300 O
+base O
+pairs O
+of O
+the O
+5 O
+' O
+- O
+flanking O
+region O
+of O
+the O
+rat B
+glucagon I
+gene I
+interact O
+with O
+regulatory O
+cellular O
+proteins O
+and O
+direct O
+transcription O
+only O
+in O
+glucagon B
+- O
+producing O
+islet O
+cells O
+. O
+
+A O
+role O
+for O
+phosphatidylinositol B
+3 I
+- I
+kinase I
+in O
+the O
+regulation O
+of O
+beta B
+1 I
+integrin I
+activity O
+by O
+the O
+CD2 B
+antigen I
+. O
+
+Relationship O
+between O
+age O
+- O
+associated O
+endocrine O
+deficiencies O
+and O
+muscle O
+function O
+in O
+elderly O
+women O
+: O
+a O
+cross O
+- O
+sectional O
+study O
+. O
+
+In O
+contrast O
+, O
+the O
+sequences O
+essential O
+for O
+the O
+transcription O
+of O
+EFT1 B
+were O
+localized O
+to O
+the O
+region O
+between O
+the O
+start O
+ATG O
+and O
+the O
+stop O
+codon O
+of O
+the O
+VPS17 B
+gene I
+that O
+terminates O
+267 O
+nt O
+upstream O
+on O
+the O
+same O
+strand O
+. O
+
+Exposure O
+of O
+raft O
+cultures O
+to O
+activators O
+of O
+protein B
+kinase I
+C I
+, O
+such O
+as O
+phorbol O
+esters O
+, O
+results O
+in O
+the O
+further O
+induction O
+of O
+late O
+gene O
+expression O
+as O
+well O
+as O
+virion O
+assembly O
+. O
+
+A O
+case O
+of O
+2 O
+cancers O
+of O
+the O
+colon O
+
+The O
+" O
+Gregg O
+phenomenon O
+" O
+implies O
+that O
+myocardial O
+function O
+and O
+oxygen O
+consumption O
+( O
+MVO2 O
+) O
+increase O
+when O
+coronary O
+perfusion O
+is O
+enhanced O
+within O
+or O
+above O
+the O
+autoregulatory O
+range O
+. O
+
+We O
+have O
+mapped O
+the O
+specific O
+domains O
+within O
+each O
+of O
+the O
+proteins O
+responsible O
+for O
+this O
+interaction O
+. O
+
+In O
+each O
+of O
+the O
+studied O
+HPV O
+types O
+, O
+the O
+two O
+CDP B
+/ O
+Cut B
+binding O
+sites O
+of O
+PSM O
+overlap O
+with O
+the O
+known O
+or O
+presumed O
+binding O
+sites O
+of O
+the O
+replication B
+initiator I
+protein I
+E1 I
+. O
+
+Reduced O
+cell O
+numbers O
+72 O
+h O
+after O
+insonation O
+were O
+recorded O
+when O
+the O
+cells O
+were O
+insonated O
+at O
+an O
+antinode O
+but O
+not O
+when O
+they O
+were O
+at O
+a O
+node O
+. O
+
+Hydroxyl O
+radical O
+footprinting O
+of O
+DNA O
+complexes O
+of O
+the O
+ets B
+domain I
+of O
+PU B
+. I
+1 I
+and O
+its O
+comparison O
+to O
+the O
+crystal O
+structure O
+. O
+
+ATF B
+is O
+formulated O
+from O
+the O
+prothrombin B
+time O
+( O
+PT O
+) O
+, O
+fibrinogen B
+transformation O
+rate O
+( O
+FTR O
+) O
+( O
+a O
+representation O
+of O
+thrombin B
+activity O
+) O
+, O
+and O
+a O
+consideration O
+of O
+the O
+fibrinogen B
+( O
+FBG B
+) O
+content O
+of O
+blood O
+plasma O
+. O
+
+( O
+LH B
+P O
+< O
+0 O
+. O
+05 O
+, O
+LH B
+/ O
+FSH B
+P O
+< O
+0 O
+. O
+01 O
+) O
+. O
+
+Inhibition O
+of O
+Raf B
+- I
+1 I
+signaling O
+by O
+a O
+monoclonal O
+antibody O
+, O
+which O
+interferes O
+with O
+Raf B
+- I
+1 I
+activation O
+and O
+with O
+Mek B
+substrate O
+binding O
+. O
+
+Phenotypic O
+and O
+molecular O
+analyses O
+of O
+patients O
+with O
+partial O
+chromosome O
+21 O
+monosomy O
+enabled O
+us O
+to O
+define O
+a O
+region O
+, O
+spanning O
+2 O
+. O
+4 O
+Mb O
+between O
+D21S190 B
+and O
+D21S226 B
+, O
+associated O
+with O
+arthrogryposis O
+, O
+mental O
+retardation O
+, O
+hypertonia O
+, O
+and O
+several O
+facial O
+anomalies O
+. O
+
+The O
+classic O
+sterol O
+regulatory O
+cis O
+element O
+( O
+sre O
+- O
+1 O
+) O
+in O
+the O
+LDL B
+receptor I
+promoter I
+mediates O
+sterol B
+regulatory I
+element I
+binding I
+protein I
+( O
+SREBP B
+) O
+- O
+binding O
+and O
+the O
+effects O
+of O
+insulin B
+and O
+platelet B
+derived I
+growth I
+factor I
+( O
+PDGF B
+) O
+. O
+
+The O
+Ca2 O
++ O
+concentration O
+in O
+rats O
+serum O
+after O
+intragastrically O
+fenarimol O
+administration O
+( O
+doses O
+1 O
+/ O
+40 O
+, O
+1 O
+/ O
+20 O
+and O
+1 O
+/ O
+10 O
+LD50 O
+) O
+during O
+5 O
+days O
+was O
+investigated O
+. O
+
+In O
+Cos O
+7 O
+cells O
+transfected O
+with O
+oCRF1var B
+, O
+cAMP O
+accumulation O
+was O
+only O
+observed O
+at O
+the O
+highest O
+concentration O
+of O
+oCRF B
+utilized O
+( O
+100 O
+nM O
+) O
+. O
+
+Pyknotic O
+osteocytes O
+increased O
+at O
+12 O
+h O
+( O
+p O
+less O
+than O
+0 O
+. O
+01 O
+) O
+and O
+2 O
+days O
+( O
+p O
+less O
+than O
+0 O
+. O
+001 O
+) O
+of O
+ischemia O
+. O
+
+The O
+right O
+cornea O
+of O
+rats O
+was O
+cauterized O
+by O
+drops O
+of O
+1 O
+. O
+5 O
+N O
+HC1 O
+over O
+30 O
+s O
+; O
+the O
+left O
+one O
+served O
+as O
+a O
+control O
+. O
+
+The O
+isoproterenol O
+infusion O
+was O
+adjusted O
+so O
+that O
+heart O
+rate O
+( O
+HR O
+) O
+was O
+at O
+least O
+30 O
+beats O
+/ O
+min O
+greater O
+than O
+baseline O
+. O
+
+This O
+is O
+probably O
+because O
+, O
+in O
+vivo O
+, O
+some O
+bacteria O
+( O
+perhaps O
+dormant O
+forms O
+) O
+are O
+not O
+entirely O
+dependent O
+upon O
+urease B
+for O
+survival O
+. O
+
+The O
+system O
+consists O
+of O
+a O
+microcomputer O
+and O
+six O
+laboratory O
+analyzers O
+: O
+a O
+blood O
+gas O
+analyzer O
+, O
+a O
+flame O
+photometer O
+, O
+a O
+plasma O
+osmotic O
+pressure O
+meter O
+, O
+a O
+chloride O
+ion O
+titrator O
+, O
+a O
+blood O
+sugar O
+analyzer O
+, O
+and O
+a O
+hemoglobin B
+concentration O
+and O
+saturation O
+meter O
+. O
+
+Comparing O
+the O
+outcome O
+of O
+the O
+group O
+having O
+histologically O
+normal O
+biopsies O
+with O
+the O
+group O
+having O
+nonspecifically O
+abnormal O
+ones O
+it O
+is O
+concluded O
+that O
+frontal O
+biopsy O
+is O
+not O
+of O
+such O
+high O
+prognostic O
+value O
+as O
+has O
+been O
+claimed O
+in O
+previous O
+reports O
+. O
+
+He O
+presented O
+with O
+left O
+lower O
+abdominal O
+pain O
+and O
+hematoma O
+after O
+a O
+fall O
+. O
+
+Fusion O
+of O
+mouse O
+CD8 B
++ O
+class B
+I I
+MHC I
+- O
+restricted O
+T O
+cells O
+with O
+the O
+BW5147 O
+thymoma O
+invariably O
+yields O
+CD8 B
+- I
+hybridomas O
+in O
+which O
+RNA O
+transcribed O
+from O
+the O
+CD8 B
+alpha I
+( O
+Lyt B
+- I
+2 I
+) O
+gene O
+is O
+undetectable O
+. O
+
+Peak O
+plasma O
+ACTH B
+responses O
+were O
+not O
+significantly O
+different O
+between O
+control O
+and O
+patient O
+groups O
+. O
+
+For O
+the O
+P B
+transcript I
+from O
+phage O
+with O
+the O
+G O
+( O
+- O
+) O
+orientation O
+, O
+full O
+termination O
+activity O
+required O
+both O
+the O
+region O
+containing O
+the O
+stem O
+- O
+loop O
+structure O
+and O
+upstream O
+sequences O
+. O
+
+Development O
+of O
+neural O
+control O
+of O
+alimentary O
+motor O
+function O
+in O
+the O
+vertebrates O
+. O
+
+Nb2 O
+- O
+11C O
+cells O
+expressed O
+three O
+PNR B
+- I
+related I
+mRNA I
+transcripts I
+of O
+2 O
+. O
+5 O
+, O
+3 O
+. O
+0 O
+and O
+> O
+10 O
+kb O
+. O
+
+These O
+results O
+suggest O
+that O
+the O
+Reg1 B
+- O
+Glc7 B
+phosphatase O
+is O
+a O
+cytoplasmic O
+component O
+of O
+the O
+machinery O
+responsible O
+for O
+returning O
+Snf1 B
+kinase I
+activity O
+to O
+its O
+basal O
+level O
+and O
+reestablishing O
+glucose O
+repression O
+. O
+
+However O
+, O
+the O
+blend O
+of O
+Metanil O
+yellow O
+and O
+Orange O
+II O
+( O
+1 O
+: O
+1 O
+) O
+resulted O
+in O
+the O
+D1 O
+50 O
+. O
+value O
+of O
+288 O
+min O
+. O
+
+The O
+majority O
+of O
+these O
+cells O
+were O
+also O
+OKT4 B
+positive O
+( O
+helper O
+/ O
+inducer O
+T O
+lymphocytes O
+) O
+, O
+while O
+the O
+minority O
+were O
+OKT8 B
+positive O
+( O
+suppressor O
+/ O
+cytotoxic O
+T O
+lymphocytes O
+) O
+. O
+
+AIMS O
+: O
+We O
+postulated O
+that O
+perhexiline O
+, O
+a O
+novel O
+anti O
+- O
+ischaemic O
+agent O
+with O
+an O
+oxygen O
+- O
+sparing O
+metabolic O
+effect O
+in O
+the O
+myocardium O
+( O
+via O
+inhibition O
+of O
+carnitine B
+palmitoyltransferase I
+- I
+1 I
+) O
+and O
+no O
+adverse O
+haemodynamic O
+effects O
+, O
+may O
+improve O
+symptomatic O
+status O
+in O
+elderly O
+patients O
+with O
+severe O
+aortic O
+stenosis O
+. O
+
+The O
+IFNAR B
+chain I
+interacts O
+with O
+both O
+IFN B
+- I
+alpha I
+2 I
+and O
+IFN B
+- I
+beta I
+, O
+as O
+demonstrated O
+by O
+cross O
+- O
+linking O
+. O
+
+To O
+clone O
+cDNAs O
+for O
+the O
+beta O
+subunit O
+of O
+rabbit B
+eIF I
+- I
+2B I
+, O
+amino O
+acid O
+sequence O
+data O
+was O
+first O
+obtained O
+and O
+used O
+to O
+design O
+redundant O
+oligonucleotide O
+primers O
+for O
+use O
+in O
+PCR O
+. O
+
+We O
+report O
+the O
+cloning O
+of O
+the O
+ade1 B
+gene I
+on O
+a O
+4 O
+. O
+4 O
+kb O
+Sau3A O
+insert O
+in O
+the O
+yeast O
+shuttle O
+vector O
+pWH5 O
+. O
+
+Nimodipine O
+( O
+5 O
+micrograms O
+/ O
+kg O
+) O
+followed O
+by O
+infusion O
+of O
+0 O
+. O
+75 O
+microgram O
+/ O
+kg O
+/ O
+min O
+lowered O
+the O
+blood O
+pressure O
+by O
+10 O
+% O
+in O
+both O
+normotensive O
+and O
+hypertensive O
+rats O
+; O
+the O
+same O
+dose O
+schedule O
+of O
+nifedipine O
+did O
+not O
+lower O
+MAP O
+. O
+
+Results O
+of O
+these O
+in O
+vitro O
+studies O
+may O
+be O
+relevant O
+to O
+the O
+pathogenesis O
+of O
+alveolitis O
+in O
+organic O
+dust O
+- O
+induced O
+lung O
+diseases O
+. O
+
+The O
+odds O
+of O
+atopy O
+( O
+defined O
+as O
+a O
+positive O
+test O
+for O
+at O
+least O
+one O
+of O
+the O
+antigens O
+) O
+were O
+5 O
+times O
+higher O
+( O
+odds O
+ratio O
+= O
+7 O
+. O
+0 O
+; O
+95 O
+% O
+confidence O
+interval O
+= O
+1 O
+. O
+6 O
+- O
+31 O
+. O
+1 O
+% O
+; O
+p O
+= O
+0 O
+. O
+01 O
+) O
+in O
+the O
+uninfected O
+group O
+, O
+after O
+taking O
+into O
+account O
+the O
+potential O
+influence O
+of O
+gender O
+and O
+age O
+. O
+
+A O
+selectable O
+marker O
+for O
+transformation O
+was O
+constructed O
+by O
+transcriptional O
+fusion O
+of O
+a O
+Ustilago O
+maydis O
+heat B
+shock I
+gene I
+promoter I
+with O
+the O
+hygromycin B
+B I
+phosphotransferase I
+gene I
+of O
+Escherichia O
+coli O
+. O
+
+The O
+structure O
+of O
+the O
+mAR B
+ORF I
+was O
+confirmed O
+by O
+sequence O
+analysis O
+of O
+mAR B
+cDNA I
+fragments I
+, O
+which O
+were O
+obtained O
+by O
+PCR O
+amplification O
+of O
+mouse O
+testis O
+cDNA O
+, O
+using O
+mAR B
+specific O
+primers O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+determine O
+the O
+response O
+properties O
+of O
+the O
+human O
+visual O
+cortex O
+to O
+chromatic O
+stimuli O
+using O
+magnetoencephalography O
+( O
+MEG O
+) O
+. O
+
+The O
+role O
+of O
+NUT1 B
+and O
+regulation O
+of O
+nitrogen O
+metabolism O
+in O
+the O
+disease O
+process O
+was O
+evaluated O
+by O
+pathogenicity O
+assays O
+. O
+
+These O
+three O
+phases O
+of O
+cyclin B
+E I
+association O
+with O
+chromatin O
+may O
+facilitate O
+the O
+diverse O
+activities O
+of O
+cyclin B
+E I
+- O
+- O
+Cdk2 B
+in O
+initiating O
+replication O
+, O
+blocking O
+rereplication O
+, O
+and O
+allowing O
+resetting O
+of O
+origins O
+after O
+mitosis O
+. O
+
+No O
+IORT O
+related O
+mortality O
+has O
+been O
+observed O
+. O
+
+Dermatophagoides O
+farinae O
+- O
+sensitized O
+lymphocytes O
+in O
+asthmatic O
+children O
+as O
+evaluated O
+by O
+interleukin B
+- I
+2 I
+( O
+IL B
+- I
+2 I
+) O
+production O
+and O
+acquisition O
+of O
+IL B
+- I
+2 I
+responsiveness O
+
+Enterotoxin O
+production O
+by O
+staphylococci O
+isolated O
+from O
+foods O
+in O
+France O
+. O
+
+Measurements O
+in O
+rats O
+given O
+a O
+dose O
+of O
+propranolol O
+that O
+partially O
+inhibited O
+the O
+NA O
+- O
+induced O
+increase O
+in O
+Q O
+to O
+IBAT O
+indicated O
+that O
+the O
+decline O
+in O
+ENAIBAT O
+was O
+attributable O
+primarily O
+to O
+the O
+increase O
+in O
+Q O
+rather O
+than O
+to O
+increasing O
+saturation O
+of O
+uptake O
+mechanisms O
+. O
+
+Plasma B
+LH I
+and O
+progesterone O
+levels O
+after O
+single O
+or O
+multiple O
+injections O
+of O
+synthetic B
+LH I
+- I
+RH I
+in O
+anoestrous O
+ewes O
+and O
+comparison O
+with O
+levels O
+during O
+the O
+oestrous O
+cycle O
+. O
+
+MATERIAL O
+AND O
+METHODS O
+: O
+
+But O
+, O
+when O
+mated O
+males O
+built O
+nests O
+in O
+the O
+absence O
+of O
+young O
+, O
+T O
+levels O
+were O
+higher O
+than O
+in O
+all O
+other O
+conditions O
+, O
+though O
+only O
+for O
+early O
+broods O
+. O
+
+Primers O
+were O
+developed O
+for O
+specific O
+amplification O
+of O
+9804 O
+gene O
+fragments O
+. O
+
+The O
+promyelocytic B
+leukemia I
+protein I
+interacts O
+with O
+Sp1 B
+and O
+inhibits O
+its O
+transactivation O
+of O
+the O
+epidermal B
+growth I
+factor I
+receptor I
+promoter I
+. O
+
+The O
+mutants O
+retained O
+the O
+parental O
+ability O
+to O
+participate O
+in O
+intergeneric O
+coaggregation O
+with O
+human O
+oral O
+actinomyces O
+, O
+indicating O
+the O
+specificity O
+of O
+the O
+mutation O
+in O
+altering O
+intrageneric O
+coaggregations O
+. O
+
+The O
+Saccharomyces O
+cerevisiae O
+targets O
+of O
+rapamycin O
+, O
+TOR1 B
+and O
+TOR2 B
+, O
+signal O
+activation O
+of O
+cell O
+growth O
+in O
+response O
+to O
+nutrient O
+availability O
+. O
+
+Biology O
+of O
+Anopheles O
+quadrimaculatus O
+under O
+field O
+conditions O
+in O
+central O
+Florida O
+. O
+
+Immunogenicity O
+tested O
+in O
+experiments O
+on O
+guinea O
+pigs O
+and O
+rabbits O
+was O
+not O
+reduced O
+and O
+corresponded O
+to O
+that O
+of O
+the O
+reference O
+STI O
+- O
+1 O
+vaccine O
+. O
+
+The O
+Thrombolysis O
+in O
+Myocardial O
+Infarction O
+( O
+TIMI O
+) O
+Phase O
+II O
+Trial O
+randomized O
+3 O
+, O
+339 O
+patients O
+to O
+either O
+an O
+invasive O
+( O
+INV O
+, O
+n O
+= O
+1 O
+, O
+681 O
+) O
+or O
+a O
+conservative O
+( O
+CON O
+, O
+n O
+= O
+1 O
+, O
+658 O
+) O
+strategy O
+after O
+intravenous O
+recombinant B
+tissue I
+- I
+type I
+plasminogen I
+activator I
+( O
+rt B
+- I
+PA I
+) O
+for O
+acute O
+myocardial O
+infarction O
+. O
+
+In O
+addition O
+, O
+mutations O
+within O
+the O
+Ubx B
+unit I
+exons I
+are O
+known O
+and O
+most O
+of O
+these O
+behave O
+as O
+null O
+alleles O
+. O
+
+Taken O
+together O
+, O
+these O
+data O
+suggest O
+that O
+the O
+Smad3 B
+/ O
+Smad4 B
+complex O
+has O
+at O
+least O
+two O
+separable O
+nuclear O
+functions O
+: O
+it O
+forms O
+a O
+rapid O
+, O
+yet O
+transient O
+sequence O
+- O
+specific O
+DNA O
+binding O
+complex O
+, O
+and O
+it O
+potentiates O
+AP1 B
+- O
+dependent O
+transcriptional O
+activation O
+. O
+
+When O
+phentermine O
+was O
+mixed O
+with O
+other O
+unlabeled O
+reversible O
+MAO B
+inhibitors O
+( O
+e O
+. O
+g O
+. O
+pseudoephedrine O
+, O
+ephedrine O
+, O
+norephedrine O
+; O
+estradiol O
+benzoate O
+) O
+, O
+the O
+degree O
+of O
+MAO B
+inhibition O
+was O
+additive O
+. O
+
+Here O
+we O
+report O
+that O
+point O
+mutations O
+of O
+the O
+Abd B
+- I
+B I
+gene I
+in O
+trans O
+suppress O
+the O
+Fab B
+- I
+7 I
+phenotype O
+in O
+a O
+pairing O
+- O
+dependent O
+manner O
+and O
+thus O
+represent O
+a O
+type O
+of O
+transvection O
+. O
+
+4 O
+382 O
+new O
+mothers O
+were O
+examined O
+retrospectively O
+with O
+the O
+enzyme O
+- O
+linked O
+immunosorbent O
+assay O
+( O
+ELISA O
+) O
+for O
+IgG B
+activity O
+to O
+cytomegalovirus O
+( O
+CMV O
+) O
+during O
+pregnancy O
+. O
+
+Also O
+, O
+residues O
+273 O
+to O
+287 O
+, O
+which O
+are O
+identical O
+in O
+sequence O
+to O
+a O
+15 O
+- O
+amino O
+- O
+acid O
+segment O
+near O
+the O
+carboxy O
+terminus O
+of O
+the O
+simian B
+foamy I
+virus I
+transcriptional I
+activator I
+Taf I
+, O
+can O
+independently O
+enhance O
+the O
+activity O
+of O
+the O
+minimal O
+activator O
+region O
+. O
+
+An O
+analogue O
+of O
+calcium O
+, O
+strontium O
+chloride O
+Sr O
+89 O
+is O
+rapidly O
+cleared O
+from O
+the O
+blood O
+after O
+i O
+. O
+v O
+. O
+injection O
+. O
+
+The O
+effect O
+of O
+pneumoperitoneum O
+on O
+dissemination O
+and O
+scar O
+implantation O
+of O
+intra O
+- O
+abdominal O
+tumor O
+cells O
+. O
+
+In O
+two O
+of O
+these O
+nine O
+patients O
+, O
+a O
+decrease O
+in O
+dyskinesia O
+score O
+was O
+observed O
+without O
+a O
+concomitant O
+worsening O
+of O
+parkinsonian O
+symptoms O
+, O
+whereas O
+in O
+the O
+remaining O
+seven O
+, O
+full O
+parkinsonian O
+akinesia O
+followed O
+THDL O
+administration O
+. O
+
+Alterations O
+in O
+TCR B
+- O
+MHC B
+contacts O
+subsequent O
+to O
+cross O
+- O
+recognition O
+of O
+class B
+I I
+MHC I
+and O
+singly O
+substituted O
+peptide O
+variants O
+. O
+
+Two O
+patients O
+with O
+Ewing O
+' O
+s O
+sarcoma O
+relapsed O
+( O
+1 O
+patient O
+with O
+both O
+local O
+and O
+distant O
+failure O
+) O
+at O
+26 O
+and O
+58 O
+months O
+and O
+were O
+again O
+rendered O
+disease O
+- O
+free O
+with O
+surgery O
+, O
+total O
+body O
+irradiation O
+and O
+further O
+chemotherapy O
+. O
+
+The O
+cloning O
+of O
+human B
+apo I
+B I
+- I
+100 I
+has O
+provided O
+new O
+insights O
+into O
+the O
+structure O
+and O
+physicochemical O
+properties O
+of O
+apo B
+B I
+- I
+100 I
+and O
+will O
+facilitate O
+studies O
+on O
+the O
+factors O
+modulating O
+apo B
+B I
+- I
+100 I
+biosynthesis O
+and O
+the O
+expression O
+of O
+the O
+apo B
+B I
+- I
+100 I
+gene I
+in O
+patients O
+with O
+dyslipoproteinemias O
+. O
+
+Angiographic O
+follow O
+- O
+up O
+was O
+obtained O
+in O
+92 O
+% O
+of O
+patients O
+with O
+a O
+primary O
+success O
+of O
+angioplasty O
+. O
+
+Acceptability O
+of O
+home O
+monitoring O
+as O
+an O
+aid O
+to O
+conception O
+. O
+
+Repeated O
+interferon B
+- I
+beta I
+( O
+IFN B
+- I
+beta I
+) O
+silencer B
+B I
+motifs O
+and O
+a O
+lysozyme B
+silencer I
+1 I
+motif I
+have O
+been O
+found O
+in O
+the O
+CD95 B
+gene I
+at O
+approximately O
+- O
+1 O
+, O
+600 O
+and O
+- O
+1 O
+, O
+100 O
+, O
+respectively O
+. O
+
+Action O
+against O
+Vibrio O
+cholerae O
+O1 O
+Tox B
++ I
+of O
+chemical O
+products O
+used O
+in O
+the O
+lemon O
+production O
+. O
+
+Patients O
+with O
+the O
+chronic O
+photosensitivity O
+dermatitis O
+with O
+actinic O
+reticuloid O
+syndrome O
+have O
+high O
+total O
+serum O
+IgE B
+concentrations O
+. O
+
+The O
+sequence O
+of O
+the O
+25 O
+- O
+kDa O
+chain O
+of O
+the O
+alpha O
+subunit O
+was O
+found O
+in O
+a O
+cDNA O
+clone O
+, O
+and O
+the O
+amino O
+acid O
+sequence O
+deduced O
+from O
+the O
+cDNA O
+establishes O
+the O
+complete O
+amino O
+acid O
+sequence O
+of O
+the O
+25 O
+- O
+kDa O
+chain O
+. O
+
+Characterization O
+of O
+the O
+chromosome O
+19 O
+breakpoint O
+region O
+revealed O
+that O
+the O
+transcription O
+factor O
+- O
+encoding O
+USF2 B
+gene I
+is O
+affected O
+. O
+
+Tax B
+and O
+the O
+active O
+Tax B
+mutants I
+were O
+able O
+to O
+abrogate O
+the O
+G1 O
+arrest O
+and O
+apoptosis O
+induced O
+by O
+p53 B
+, O
+and O
+this O
+effect O
+does O
+not O
+correlate O
+with O
+an O
+altered O
+localization O
+of O
+nuclear B
+p53 I
+or O
+with O
+the O
+disruption O
+of O
+p53 B
+- I
+DNA I
+complexes I
+. O
+
+When O
+patients O
+were O
+admitted O
+within O
+one O
+week O
+of O
+the O
+onset O
+of O
+dark O
+urine O
+, O
+45 O
+% O
+were O
+found O
+to O
+be O
+shedding O
+HAV O
+, O
+whereas O
+only O
+11 O
+% O
+of O
+specimens O
+obtained O
+from O
+patients O
+admitted O
+during O
+the O
+second O
+week O
+contained O
+virus O
+. O
+
+Biochemical O
+studies O
+have O
+identified O
+a O
+cellular O
+non O
+- O
+P B
+element O
+- O
+encoded O
+DNA O
+binding O
+protein O
+, O
+termed O
+the O
+inverted B
+repeat I
+binding I
+protein I
+( O
+IRBP B
+) O
+, O
+that O
+specifically O
+interacts O
+with O
+the O
+outer O
+half O
+of O
+the O
+31 O
+- O
+bp O
+terminal O
+inverted O
+repeats O
+. O
+
+Threefold O
+risks O
+were O
+observed O
+for O
+men O
+with O
+the O
+highest O
+level O
+of O
+intensity O
+and O
+for O
+those O
+with O
+the O
+highest O
+probability O
+of O
+EMF O
+exposure O
+, O
+although O
+women O
+with O
+heavy O
+EMF O
+exposure O
+did O
+not O
+experience O
+increased O
+risk O
+. O
+
+In O
+the O
+spontaneous O
+abortion O
+group O
+, O
+the O
+levels O
+of O
+PAPP B
+- I
+A I
+were O
+significantly O
+lower O
+than O
+in O
+normal O
+pregnancy O
+but O
+higher O
+than O
+in O
+non O
+- O
+pregnant O
+controls O
+. O
+
+We O
+report O
+the O
+sequence O
+of O
+a O
+7941 O
+bp O
+DNA O
+fragment O
+from O
+the O
+left O
+arm O
+of O
+chromosome O
+VII O
+of O
+Saccharomyces O
+cerevisiae O
+which O
+contains O
+four O
+open O
+reading O
+frames O
+( O
+ORFs O
+) O
+of O
+greater O
+than O
+100 O
+amino O
+acid O
+residues O
+. O
+
+A O
+4 B
+. I
+0 I
+- I
+kb I
+Nlk I
+message I
+is O
+also O
+present O
+during O
+embryogenesis O
+, O
+detectable O
+at O
+day O
+E10 O
+. O
+
+Promoting O
+fat O
+utilisation O
+by O
+reducing O
+the O
+carbohydrate O
+- O
+fat O
+ratio O
+of O
+the O
+TPN O
+reduces O
+free O
+radical O
+activity O
+to O
+a O
+similar O
+extent O
+as O
+fat O
+exclusion O
+. O
+
+In O
+cells O
+infected O
+with O
+a O
+recombinant O
+vaccinia O
+virus O
+expressing O
+HCV O
+structural O
+proteins O
+( O
+core B
+, O
+E1 B
+, O
+and O
+E2 B
+) O
+, O
+DDX3 B
+and O
+core B
+colocalized O
+in O
+distinct O
+spots O
+in O
+the O
+perinuclear O
+region O
+of O
+the O
+cytoplasm O
+. O
+
+Mutating O
+this O
+sequence O
+eliminated O
+complex O
+formation O
+and O
+markedly O
+reduced O
+basal O
+and O
+cAMP O
+- O
+dependent O
+promoter O
+activity O
+of O
+transfected O
+reporter O
+genes O
+. O
+
+The O
+lowest O
+PaCO2 O
+values O
+were O
+significantly O
+lower O
+in O
+MCE O
+than O
+in O
+the O
+F O
+, O
+W O
+, O
+and O
+D O
+( O
+F O
++ O
+W O
++ O
+D O
+) O
+group O
+or O
+controls O
+. O
+
+The O
+translational O
+product O
+of O
+UL26 B
+. I
+5 I
+is O
+infected B
+- I
+cell I
+protein I
+35c I
+, I
+d I
+( O
+ICP35c B
+, I
+d I
+) O
+( O
+F O
+. O
+
+The O
+mouse B
+tapasin I
+gene I
+was O
+mapped O
+about O
+70 O
+kilobases O
+from O
+H2 B
+- I
+K I
+at O
+the O
+centromeric O
+end O
+of O
+the O
+mouse B
+MHC I
+. O
+
+Due O
+to O
+significant O
+homology O
+to O
+the O
+C O
+- O
+terminus O
+of O
+the O
+Mutator B
+transposase I
+this O
+alternative O
+gene O
+product O
+was O
+named O
+Trap B
+( O
+transposon B
+- I
+associated I
+protein I
+) O
+. O
+
+Nonetheless O
+, O
+the O
+majority O
+were O
+located O
+within O
+three O
+short O
+sequences O
+at O
+the O
+N O
+terminus O
+, O
+middle O
+, O
+and O
+C O
+terminus O
+that O
+are O
+phylogenetically O
+conserved O
+among O
+all O
+known O
+eubacterial O
+and O
+chloroplast O
+versions O
+of O
+this O
+protein O
+. O
+
+The O
+c B
+- I
+raf I
+- I
+1 I
+proto I
+- I
+oncogene I
+is O
+the O
+cellular B
+homologue I
+of I
+v I
+- I
+raf I
+, O
+the O
+oncogene O
+of O
+the O
+acutely O
+transforming O
+retrovirus O
+3611 O
+- O
+MSV O
+. O
+
+Using O
+gel O
+retardation O
+analysis O
+, O
+four O
+binding O
+sites O
+for O
+Rap1p B
+have O
+been O
+identified O
+within O
+the O
+promoter O
+of O
+the O
+RAP1 B
+gene I
+. O
+
+In O
+general O
+, O
+the O
+scallop O
+extract O
+potentiated O
+phototactic O
+suppression O
+. O
+
+Alcohol O
+abuse O
+and O
+treatment O
+resistance O
+in O
+skin O
+disease O
+. O
+
+The O
+mean O
+serum B
+CDT I
+increased O
+from O
+8 O
+. O
+5 O
+( O
+SD O
+2 O
+. O
+2 O
+) O
+U O
+/ O
+l O
+to O
+16 O
+. O
+6 O
+( O
+SD O
+7 O
+. O
+2 O
+) O
+U O
+/ O
+l O
+( O
+P O
+< O
+0 O
+. O
+001 O
+) O
+. O
+
+Subsequent O
+analysis O
+revealed O
+that O
+MyD88 B
+possesses O
+a O
+unique O
+modular O
+structure O
+, O
+which O
+consists O
+of O
+an O
+N O
+- O
+terminal O
+" O
+death O
+domain O
+, O
+" O
+similar O
+to O
+the O
+intracellular O
+segments O
+of O
+TNF B
+receptor I
+1 I
+and O
+Fas B
+, O
+and O
+a O
+C O
+- O
+terminal O
+region O
+related O
+to O
+the O
+cytoplasmic O
+domains O
+of O
+the O
+Drosophila B
+morphogen I
+Toll I
+and O
+vertebrate B
+interleukin I
+- I
+1 I
+receptors I
+. O
+
+RT O
+- O
+PCR O
+analysis O
+of O
+FGFR B
+- I
+3 I
+mRNA I
+showed O
+the O
+presence O
+of O
+a O
+splice O
+variant O
+in O
+which O
+exons O
+7 O
+and O
+8 O
+are O
+deleted O
+. O
+
+In O
+human O
+myxoid O
+liposarcoma O
+, O
+a O
+chromosomal O
+rearrangement O
+leads O
+to O
+fusion O
+of O
+the O
+growth O
+- O
+arresting O
+and O
+DNA O
+- O
+damage O
+- O
+inducible O
+transcription O
+factor O
+CHOP B
+( O
+GADD153 B
+) O
+to O
+a O
+peptide O
+fragment O
+encoded O
+by O
+the O
+TLS B
+gene I
+. O
+
+They O
+also O
+show O
+that O
+M O
+. O
+malmoense O
+can O
+be O
+isolated O
+from O
+the O
+environment O
+which O
+may O
+be O
+the O
+source O
+of O
+the O
+infection O
+. O
+
+The O
+monkeys O
+had O
+been O
+administered O
+a O
+common O
+lead O
+isotope O
+" O
+mix O
+" O
+at O
+the O
+rate O
+of O
+about O
+1300 O
+micrograms O
+Pb O
+/ O
+kg O
+body O
+wt O
+/ O
+day O
+from O
+age O
+10 O
+months O
+until O
+the O
+start O
+of O
+the O
+study O
+. O
+
+We O
+previously O
+described O
+the O
+upregulation O
+of O
+the O
+MT2 B
+antigen I
+during O
+urodele O
+limb O
+regeneration O
+and O
+characterized O
+the O
+MT2 B
+antigen I
+as O
+a O
+310 O
+- O
+to O
+325 O
+- O
+kDa O
+chondroitin O
+- O
+sulfated O
+glycoprotein O
+with O
+a O
+core O
+protein O
+of O
+285 O
+- O
+300 O
+kDa O
+. O
+
+Analysis O
+of O
+the O
+MCV B
+- I
+1 I
+RPO1 I
+revealed O
+high O
+amino O
+acid O
+homologies O
+to O
+the O
+corresponding O
+polypeptides O
+of O
+vaccinia O
+and O
+variola O
+virus O
+. O
+
+The O
+effects O
+of O
+dopamine O
+and O
+of O
+dopamine B
+D2 I
+receptor I
+blocker O
+haloperidol O
+on O
+the O
+activity O
+of O
+carotid O
+chemoreceptors O
+were O
+studied O
+in O
+24 O
+anesthetized O
+, O
+paralyzed O
+and O
+artificially O
+ventilated O
+newborn O
+kittens O
+aged O
+0 O
+- O
+17 O
+days O
+. O
+
+Fifty O
+- O
+seven O
+per O
+cent O
+of O
+the O
+primary O
+patients O
+reporting O
+mild O
+symptoms O
+had O
+abnormal O
+levels O
+of O
+leucocytes O
+in O
+their O
+CSF O
+. O
+
+When O
+proper O
+controls O
+were O
+used O
+, O
+the O
+psychophysical O
+data O
+and O
+computer O
+simulation O
+gave O
+remarkably O
+comparable O
+results O
+. O
+
+Patients O
+were O
+treated O
+with O
+either O
+4 O
+. O
+8 O
+million O
+units O
+of O
+procaine O
+penicillin O
+with O
+1 O
+g O
+probenecid O
+, O
+3 O
+. O
+5 O
+or O
+4 O
+. O
+5 O
+g O
+of O
+ampicillin O
+with O
+1 O
+g O
+probenecid O
+, O
+or O
+9 O
+. O
+5 O
+g O
+of O
+tetracycline O
+given O
+over O
+4 O
+days O
+. O
+
+The O
+results O
+of O
+this O
+study O
+indicate O
+that O
+the O
+Improved O
+Crest O
+Complete O
+with O
+longer O
+rippled O
+outer O
+bristles O
+provided O
+significantly O
+superior O
+( O
+p O
+< O
+0 O
+. O
+05 O
+) O
+interproximal O
+penetration O
+overall O
+and O
+at O
+the O
+gumline O
+than O
+the O
+Colgate O
+Total O
+and O
+Oral O
+- O
+B O
+Advantage O
+brushes O
+. O
+
+Cardiac O
+NE O
+spillover O
+was O
+higher O
+( O
+P O
+< O
+. O
+05 O
+) O
+at O
+baseline O
+in O
+the O
+patient O
+group O
+than O
+in O
+healthy O
+subjects O
+, O
+whereas O
+renal O
+and O
+whole O
+- O
+body O
+NE O
+spillovers O
+were O
+similar O
+between O
+the O
+study O
+groups O
+. O
+
+The O
+activity O
+of O
+platelet B
+factor I
+4 I
+in O
+plasma O
+of O
+healthy O
+and O
+high O
+risk O
+newborns O
+. O
+
+Plasma O
+renin B
+activity O
+in O
+essential O
+arterial O
+hypertension O
+. O
+
+A O
+trend O
+was O
+observed O
+toward O
+increased O
+graft O
+half O
+- O
+life O
+in O
+era O
+2 O
+( O
+p O
+= O
+NS O
+) O
+. O
+
+The O
+proteins O
+encoded O
+by O
+these O
+genes O
+, O
+called O
+GF14 B
+proteins I
+, O
+participate O
+in O
+protein O
+/ O
+DNA O
+complexes O
+and O
+show O
+more O
+than O
+60 O
+% O
+identity O
+with O
+a O
+highly O
+conserved O
+, O
+widely O
+distributed O
+protein O
+family O
+, O
+collectively O
+referred O
+to O
+as O
+14 B
+- I
+3 I
+- I
+3 I
+proteins I
+. O
+
+The O
+p58 B
+( I
+PITSLRE I
+beta I
+1 I
+) I
+protein I
+kinase I
+( O
+PK B
+) O
+is O
+a O
+member O
+of O
+a O
+large O
+supergene O
+family O
+related O
+to O
+the O
+master O
+mitotic O
+protein O
+kinase O
+, O
+p34cdc2 B
+. O
+
+Maximal O
+exercise O
+duration O
+and O
+peak O
+oxygen O
+consumption O
+were O
+not O
+changed O
+. O
+
+In O
+contrast O
+, O
+NF B
+- I
+kappa I
+B I
+activation O
+was O
+observed O
+in O
+these O
+cells O
+after O
+PMA O
+stimulation O
+. O
+
+PtdIns O
+( O
+4 O
+, O
+5 O
+) O
+P2 O
+synthesis O
+, O
+on O
+the O
+other O
+hand O
+, O
+is O
+only O
+moderately O
+affected O
+even O
+in O
+fab1Delta B
+mutants I
+. O
+
+A O
+simple O
+procedure O
+for O
+accurate O
+quantitation O
+of O
+factor B
+VIII I
+inhibitors O
+. O
+
+We O
+found O
+that O
+48 O
+% O
+of O
+the O
+patients O
+had O
+their O
+thoracolumbar O
+blood O
+supply O
+based O
+on O
+two O
+anterior O
+radiculospinal O
+arteries O
+the O
+lowest O
+of O
+which O
+was O
+located O
+at O
+, O
+or O
+lower O
+than O
+, O
+T12 O
+, O
+and O
+the O
+second O
+and O
+higher O
+one O
+between O
+T6 O
+and O
+T10 O
+. O
+
+Low O
+serum B
+C3 I
+values O
+were O
+observed O
+in O
+all O
+11 O
+children O
+at O
+some O
+stage O
+of O
+their O
+illness O
+. O
+
+The O
+plants O
+were O
+then O
+brought O
+to O
+our O
+Houston O
+laboratory O
+where O
+they O
+were O
+measured O
+and O
+analyzed O
+for O
+lignin O
+and O
+protein O
+content O
+and O
+for O
+phenylalanine B
+ammonia I
+- I
+lyase I
+( O
+PAL B
+) O
+and O
+peroxidase B
+activities O
+. O
+
+Pax B
+- I
+6 I
+constructs I
+lacking O
+the O
+C O
+- O
+terminal O
+activation O
+domain O
+repressed O
+betaB1 B
+- I
+crystallin I
+promoter I
+activity O
+as O
+effectively O
+as O
+the O
+full O
+- O
+length O
+protein O
+, O
+but O
+the O
+PD O
+alone O
+or O
+Pax B
+- I
+6 I
+( I
+5a I
+) I
+, O
+a O
+splice O
+variant O
+with O
+an O
+altered O
+PD O
+affecting O
+its O
+DNA O
+binding O
+specificity O
+, O
+did O
+not O
+. O
+
+A O
+regression O
+analysis O
+showed O
+that O
+86 O
+% O
+of O
+the O
+variance O
+in O
+weight O
+gain O
+was O
+predicted O
+by O
+two O
+leading O
+indicators O
+in O
+the O
+middle O
+phase O
+of O
+treatment O
+. O
+
+OBJECTIVE O
+: O
+Respiratory O
+- O
+related O
+electromyographic O
+( O
+EMG O
+) O
+activity O
+of O
+the O
+superior O
+pharyngeal I
+constrictor I
+( O
+SPC O
+) O
+muscle O
+was O
+analyzed O
+during O
+the O
+early O
+stage O
+of O
+forced O
+breathing O
+. O
+
+The O
+predicted O
+amino O
+acid O
+sequence O
+contained O
+all O
+consensus O
+regions O
+for O
+S B
+- I
+adenosyl I
+methionine I
+methyltransferases I
+and O
+presented O
+26 O
+% O
+identity O
+with O
+Saccharomyces B
+cerevisiae I
+DHHB I
+- I
+methyltransferase I
+and O
+38 O
+% O
+identity O
+with O
+the O
+rat O
+protein O
+, O
+as O
+well O
+as O
+with O
+a O
+bacterial O
+( O
+Escherichia O
+coli O
+and O
+Salmonella O
+typhimurium O
+) O
+methyltransferase O
+encoded O
+by O
+the O
+UBIG B
+gene I
+. O
+
+Letter O
+: O
+Ballistocardiography O
+. O
+
+The O
+introduction O
+of O
+FWD1 B
+into O
+cells O
+significantly O
+promotes O
+ubiquitination O
+and O
+degradation O
+of O
+IkappaBalpha B
+in O
+concert O
+with O
+IkappaB B
+kinases I
+, O
+resulting O
+in O
+nuclear O
+translocation O
+of O
+NF B
+- I
+kappaB I
+. O
+
+Fosinopril O
+decreased O
+blood O
+pressure O
+from O
+174 O
+/ O
+101 O
+mm O
+Hg O
+to O
+149 O
+/ O
+88 O
+mm O
+Hg O
+in O
+patients O
+with O
+diastolic O
+hypertension O
+and O
+from O
+182 O
+/ O
+86 O
+mm O
+Hg O
+to O
+151 O
+/ O
+80 O
+mm O
+Hg O
+in O
+patients O
+with O
+ISH O
+. O
+
+Although O
+CB O
+- O
+4 O
+isolates O
+were O
+less O
+resistant O
+to O
+chlorine O
+than O
+CB O
+- O
+5 O
+isolates O
+, O
+after O
+1 O
+, O
+000 O
+min O
+of O
+contact O
+0 O
+. O
+01 O
+% O
+of O
+the O
+input O
+virus O
+was O
+still O
+infectious O
+. O
+
+The O
+treatment O
+of O
+Sudeck O
+' O
+s O
+atrophy O
+in O
+the O
+upper O
+limb O
+by O
+sympathetic O
+blockade O
+. O
+
+To O
+assess O
+the O
+effect O
+on O
+thrombus O
+growth O
+, O
+we O
+determined O
+the O
+accretion O
+of O
+125I O
+- O
+labeled O
+fibrinogen B
+onto O
+autologous O
+non O
+- O
+radioactive O
+thrombi O
+preformed O
+in O
+the O
+jugular O
+veins O
+of O
+rabbits O
+. O
+
+Thallium O
+- O
+201 O
+scintigraphy O
+after O
+dipyridamole O
+infusion O
+with O
+low O
+level O
+exercise O
+. O
+
+A O
+kinetic O
+model O
+for O
+99mTc O
+- O
+DMSA O
+in O
+the O
+rat O
+. O
+
+Crude O
+drugs O
+from O
+aquatic O
+plants O
+. O
+
+Yet O
+testosterone O
+was O
+predominant O
+in O
+the O
+plasma O
+of O
+the O
+Type O
+II O
+male O
+morph O
+which O
+neither O
+courts O
+females O
+nor O
+nests O
+, O
+but O
+instead O
+parasitizes O
+Type O
+I O
+males O
+with O
+sneak O
+or O
+satellite O
+spawning O
+tactics O
+. O
+
+Comparison O
+of O
+the O
+therapeutic O
+effectiveness O
+of O
+membrane O
+and O
+centrifugation O
+plasmapheresis O
+
+Amino O
+- O
+terminal O
+polymorphisms O
+of O
+the O
+human B
+beta I
+2 I
+- I
+adrenergic I
+receptor I
+impart O
+distinct O
+agonist O
+- O
+promoted O
+regulatory O
+properties O
+. O
+
+Hence O
+, O
+it O
+is O
+perhaps O
+not O
+necessary O
+to O
+perform O
+spinal O
+puncture O
+if O
+the O
+only O
+purpose O
+is O
+to O
+determine O
+the O
+CSF O
+/ O
+serum O
+ratio O
+. O
+
+Two O
+plasmids O
+, O
+one O
+containing O
+the O
+amino O
+terminus O
+of O
+P B
+fused O
+to O
+the O
+DNA O
+- O
+binding O
+domain O
+of O
+the O
+yeast O
+transactivator O
+, O
+GAL4 B
+, O
+and O
+the O
+other O
+containing O
+the O
+amino O
+terminus O
+of O
+NP B
+fused O
+to O
+the O
+herpesvirus O
+transactivator O
+, O
+VP16 B
+, O
+were O
+transfected O
+in O
+COS O
+- O
+1 O
+cells O
+along O
+with O
+a O
+chloramphenicol B
+acetyltransferase I
+( O
+CAT B
+) O
+reporter O
+plasmid O
+containing O
+GAL4 B
+DNA I
+- I
+binding I
+sites I
+. O
+
+Biochemical O
+experiments O
+and O
+genome O
+sequencing O
+have O
+shown O
+that O
+, O
+despite O
+the O
+prokaryotic O
+cell O
+and O
+genome O
+organization O
+, O
+basal O
+transcriptional O
+elements O
+of O
+members O
+of O
+the O
+domain O
+Archaea O
+( O
+i O
+. O
+e O
+. O
+, O
+TATA O
+box O
+- O
+like O
+sequences O
+, O
+RNA B
+polymerase I
+, O
+and O
+transcription O
+factors O
+TBP B
+, O
+TFIIB B
+, O
+and O
+TFIIS B
+) O
+are O
+of O
+the O
+eukaryotic O
+type O
+. O
+
+Humoral O
+immunity O
+is O
+altered O
+with O
+the O
+drop O
+in O
+IgG B
+levels O
+. O
+
+For O
+the O
+second O
+phase O
+, O
+it O
+was O
+12 O
+. O
+5 O
+wk O
+for O
+RIR O
+and O
+10 O
+for O
+WL O
+males O
+, O
+whereas O
+it O
+was O
+5 O
+wk O
+for O
+RIR O
+and O
+6 O
+for O
+WL O
+females O
+. O
+
+Modified O
+Grocott O
+' O
+s O
+methenamine O
+silver O
+nitrate O
+method O
+for O
+quick O
+staining O
+of O
+Pneumocystis O
+carinii O
+. O
+
+Additionally O
+, O
+VAHS O
+is O
+often O
+associated O
+with O
+fatal O
+infectious O
+mononucleosis O
+( O
+IM O
+) O
+. O
+
+RESULTS O
+: O
+In O
+patients O
+with O
+necrotising O
+fasciitis O
+the O
+arterial O
+PO2 O
+rose O
+about O
+7 O
+- O
+fold O
+whereas O
+the O
+arterial O
+PCO2 O
+increased O
+only O
+slightly O
+during O
+exposure O
+to O
+2 O
+. O
+5 O
+absolute O
+atmospheres O
+( O
+ATA O
+) O
+of O
+oxygen O
+. O
+
+We O
+report O
+on O
+a O
+case O
+of O
+a O
+43 O
+- O
+old O
+- O
+male O
+with O
+a O
+bronchogenic O
+cyst O
+in O
+the O
+distal O
+esophagus O
+, O
+which O
+was O
+misdiagnosed O
+as O
+a O
+malignant O
+esophageal O
+tumor O
+based O
+on O
+preoperative O
+imaging O
+and O
+high O
+levels O
+of O
+the O
+tumor O
+markers O
+CA B
+19 I
+- I
+9 I
+and O
+CA B
+125 I
+. O
+
+100 O
+and O
+51 O
+p O
+. O
+
+A O
+plasma O
+cell O
+- O
+rich O
+infiltrate O
+was O
+present O
+in O
+the O
+connective O
+tissue O
+cores O
+of O
+the O
+papillae O
+. O
+
+During O
+normoxic O
+exercise O
+, O
+at O
+a O
+mean O
+O2 O
+uptake O
+( O
+VO2 O
+) O
+of O
+4 O
+. O
+0 O
+l O
+/ O
+min O
+, O
+almitrine O
+increased O
+arterial O
+PO2 O
+( O
+PaO2 O
+) O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+, O
+SaO2 O
+( O
+P O
+< O
+0 O
+. O
+01 O
+) O
+, O
+and O
+VE O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+and O
+decreased O
+arterial O
+PCO2 O
+( O
+P O
+< O
+0 O
+. O
+01 O
+) O
+, O
+without O
+affecting O
+pulmonary O
+hemodynamics O
+or O
+ventilation O
+- O
+perfusion O
+distributions O
+. O
+
+Gene B
+GPR I
+51 I
+was O
+localized O
+by O
+radiation O
+hybrid O
+mapping O
+to O
+chromosome O
+9 O
+, O
+4 O
+. O
+81 O
+cR O
+from O
+the O
+WI B
+- I
+8684 I
+marker O
+, O
+and O
+proximal O
+to O
+the O
+hereditary B
+sensory I
+neuropathy I
+type I
+1 I
+locus I
+. O
+
+We O
+conclude O
+that O
+the O
+outcome O
+of O
+patients O
+with O
+uterine O
+MMMT O
+is O
+mainly O
+influenced O
+by O
+the O
+initial O
+stage O
+and O
+the O
+type O
+of O
+epithelial O
+component O
+. O
+
+The O
+expression O
+of O
+the O
+leukocyte B
+EL I
+- I
+246 I
+antigen I
+was O
+regulated O
+in O
+the O
+same O
+manner O
+as O
+L B
+- I
+selectin I
+and O
+EL B
+- I
+246 I
+recognized O
+anti B
+- I
+L I
+- I
+selectin I
+mAb I
+affinity O
+- O
+purified O
+antigen O
+in O
+SDS O
+/ O
+PAGE O
+Western O
+blot O
+analysis O
+. O
+
+Other O
+Fischer O
+- O
+344 O
+rats O
+were O
+also O
+exposed O
+for O
+1 O
+hr O
+to O
+0 O
+. O
+0 O
+or O
+to O
+0 O
+. O
+6 O
+ppm O
+O3 O
+. O
+
+A O
+computerized O
+database O
+of O
+veterans O
+discharged O
+from O
+the O
+military O
+after O
+1967 O
+was O
+selected O
+as O
+the O
+source O
+because O
+it O
+contains O
+about O
+50 O
+% O
+of O
+the O
+total O
+Vietnam O
+era O
+veteran O
+population O
+, O
+is O
+reasonably O
+unbiased O
+, O
+and O
+provides O
+a O
+feasible O
+method O
+for O
+identifying O
+twins O
+. O
+
+To O
+examine O
+the O
+functional O
+relationship O
+between O
+distinct O
+cis O
+- O
+active O
+elements O
+within O
+the O
+distal O
+enhancer O
+region O
+of O
+the O
+rat B
+PRL I
+gene I
+, O
+we O
+have O
+used O
+deletional O
+and O
+mutational O
+analysis O
+of O
+that O
+region O
+in O
+transient O
+transfection O
+studies O
+in O
+GH3 O
+pituitary O
+tumor O
+cells O
+. O
+
+The O
+entire O
+coding O
+region O
+of O
+an O
+ovine B
+endometrial I
+oxytocin I
+receptor I
+( O
+OTR B
+) O
+cDNA O
+was O
+generated O
+by O
+PCR O
+, O
+subcloned O
+into O
+the O
+SV40 B
+major I
+late I
+promoter I
+expression O
+vector O
+pSVLJ O
+and O
+transiently O
+expressed O
+in O
+Cos O
+- O
+7 O
+cells O
+. O
+
+Alcohol O
+and O
+stomach O
+diseases O
+
+These O
+operons O
+encode O
+subunits O
+of O
+photosystems B
+I I
+( O
+psa B
+) O
+and O
+II I
+( O
+psb B
+) O
+, O
+the O
+cytochrome B
+bGf I
+complex I
+( O
+pet B
+) O
+, O
+the O
+plastid B
+NAD I
+( I
+P I
+) I
+H I
+dehydrogenase I
+( O
+ndh B
+) O
+, O
+and O
+the O
+unidentified O
+open O
+reading O
+frame O
+ycf9 B
+. O
+
+The O
+phosphatidylglycerol B
+/ I
+phosphatidylinositol I
+transfer I
+protein I
+( O
+PG B
+/ I
+PI I
+- I
+TP I
+) O
+is O
+a O
+new O
+and O
+original O
+phospholipid B
+transfer I
+protein I
+( O
+PLTP B
+) O
+isolated O
+from O
+the O
+Deuteromycete O
+, O
+Aspergillus O
+oryzae O
+. O
+
+Transcriptional O
+modulation O
+of O
+the O
+anti B
+- I
+apoptotic I
+protein I
+BCL I
+- I
+XL I
+by O
+the O
+paired B
+box I
+transcription I
+factors I
+PAX3 B
+and O
+PAX3 B
+/ O
+FKHR B
+. O
+
+The O
+level O
+of O
+expression O
+of O
+the O
+PDE B
+protein O
+was O
+monitored O
+by O
+immunoblot O
+analysis O
+using O
+two O
+specific O
+cAMP B
+- I
+PDE I
+polyclonal I
+antibodies I
+and O
+by O
+measuring O
+the O
+PDE B
+activity O
+. O
+
+Blotting O
+analysis O
+of O
+intestinal O
+RNA O
+and O
+hybridization O
+of O
+the O
+blots O
+with O
+carboxy B
+apoB I
+cDNA I
+probes O
+produced O
+a O
+single O
+15 O
+- O
+kb O
+hybridization O
+band O
+whereas O
+hybridization O
+with O
+amino O
+terminal O
+probes O
+produced O
+two O
+hybridization O
+bands O
+of O
+15 O
+and O
+8 O
+kb O
+. O
+
+Since O
+UmuD B
+protein I
+is O
+proteolytically O
+processed O
+to O
+an O
+active O
+form O
+( O
+UmuD B
+* I
+) O
+in O
+a O
+RecA B
+* I
+- O
+dependent O
+fashion O
+, O
+and O
+MucA B
+shares O
+extensive O
+amino O
+acid O
+homology O
+with O
+UmuD B
+, O
+we O
+examined O
+whether O
+MucA B
+is O
+similarly O
+processed O
+in O
+the O
+cell O
+, O
+using O
+antiserum O
+against O
+a O
+LacZ B
+' I
+- O
+' B
+MucA I
+fusion O
+protein O
+. O
+
+Influence O
+of O
+long O
+- O
+term O
+zimelidine O
+treatment O
+on O
+LSD O
+- O
+induced O
+behavioural O
+effects O
+. O
+
+We O
+have O
+determined O
+the O
+molecular O
+organization O
+and O
+transcription O
+start O
+points O
+( O
+tsp O
+) O
+for O
+the O
+murine O
+gene O
+( O
+TK B
+) O
+encoding O
+thymidine B
+kinase I
+. O
+
+Together O
+with O
+a O
+number O
+of O
+phase O
+II O
+trials O
+, O
+phase O
+I O
+trials O
+utilizing O
+escalating O
+doses O
+of O
+carboplatin O
+and O
+paclitaxel O
+with O
+growth O
+factor O
+or O
+growth O
+factor O
+and O
+blood O
+stem O
+- O
+cell O
+support O
+have O
+shown O
+that O
+substantial O
+increases O
+in O
+dose O
+intensity O
+can O
+be O
+achieved O
+. O
+
+It O
+is O
+an O
+untested O
+argument O
+that O
+conventional O
+beta B
+- I
+adrenoceptor I
+antagonists O
+possess O
+unwanted O
+metabolic O
+effects O
+that O
+may O
+counter O
+some O
+of O
+their O
+potential O
+cardiac O
+benefits O
+. O
+
+Genetic O
+polymorphisms O
+in O
+the O
+5 O
+' O
+- O
+flanking O
+region O
+change O
+transcriptional O
+regulation O
+of O
+the O
+human B
+cytochrome I
+P450IIE1 I
+gene I
+. O
+
+Although O
+the O
+occurrence O
+of O
+any O
+ventricular O
+ectopic O
+activity O
+, O
+as O
+detected O
+by O
+either O
+or O
+both O
+methods O
+, O
+was O
+common O
+, O
+the O
+incidence O
+was O
+significantly O
+higher O
+( O
+P O
+less O
+than O
+0 O
+. O
+001 O
+) O
+in O
+patients O
+with O
+coronary O
+heart O
+disease O
+( O
+86 O
+percent O
+; O
+77 O
+/ O
+90 O
+) O
+, O
+as O
+compared O
+to O
+that O
+in O
+normal O
+subjects O
+( O
+40 O
+percent O
+; O
+12 O
+/ O
+30 O
+) O
+. O
+
+Increased O
+trabecular O
+spacing O
+, O
+such O
+as O
+it O
+occurs O
+in O
+osteoporosis O
+, O
+reduces O
+the O
+spatial O
+field O
+inhomogeneity O
+and O
+thus O
+prolongs O
+T2 O
+* O
+, O
+which O
+has O
+been O
+shown O
+both O
+in O
+vitro O
+and O
+in O
+vivo O
+. O
+
+Healthy O
+preterm O
+infants O
+of O
+gestational O
+age O
+26 O
+- O
+29 O
+weeks O
+showed O
+a O
+' O
+mature O
+' O
+pattern O
+of O
+permeability O
+at O
+birth O
+, O
+followed O
+by O
+a O
+temporary O
+period O
+of O
+enhanced O
+permeability O
+after O
+3 O
+- O
+4 O
+weeks O
+of O
+life O
+. O
+
+These O
+studies O
+reveal O
+that O
+CREM B
+, O
+a O
+tissue O
+- O
+specific O
+factor O
+, O
+is O
+expressed O
+and O
+regulated O
+by O
+gonadotropins B
+in O
+the O
+ovary O
+, O
+that O
+the O
+predominant O
+CREM B
+transcripts I
+encode O
+the O
+repressor B
+protein I
+ICER I
+, O
+and O
+that O
+ICER B
+is O
+capable O
+of O
+inhibiting O
+cAMP O
+- O
+induced O
+expression O
+of O
+the O
+inhibin B
+alpha I
+- I
+subunit I
+gene I
+. O
+
+The O
+Brassica B
+BTH1 I
+gene I
+may O
+correspond O
+to O
+the O
+Arabidopsis B
+TH I
+- I
+1 I
+gene I
+. O
+
+The O
+same O
+pattern O
+of O
+firing O
+was O
+seen O
+with O
+saccades O
+in O
+light O
+and O
+in O
+complete O
+darkness O
+. O
+
+While O
+these O
+could O
+be O
+unusual O
+cases O
+of O
+chronic O
+non O
+- O
+A O
+, O
+non O
+- O
+B O
+hepatitis O
+, O
+this O
+can O
+be O
+only O
+speculation O
+until O
+a O
+serologic O
+test O
+for O
+non O
+- O
+A O
+, O
+non O
+- O
+B O
+hepatitis O
+becomes O
+available O
+. O
+
+Acanthamoeba B
+myosin I
+I I
+heavy I
+chain I
+kinase I
+( O
+MIHCK B
+) O
+phosphorylates O
+the O
+heavy O
+chains O
+of O
+amoeba B
+myosins I
+I I
+, O
+increasing O
+their O
+actin B
+- O
+activated O
+ATPase I
+activities O
+. O
+
+Mutation O
+of O
+the O
+HNF3 B
+element I
+significantly O
+reduced O
+promoter O
+activity O
+in O
+HepG2 O
+cells O
+, O
+whereas O
+this O
+element O
+in O
+isolation O
+conferred O
+HNF3beta B
+responsiveness O
+to O
+a O
+heterologous O
+promoter O
+. O
+
+The O
+mitochondrial B
+tyrosyl I
+- I
+tRNA I
+synthetase I
+of I
+Podospora I
+anserina I
+is O
+a O
+bifunctional O
+enzyme O
+active O
+in O
+protein O
+synthesis O
+and O
+RNA O
+splicing O
+. O
+
+The O
+findings O
+in O
+the O
+human O
+multiple O
+myeloma O
+cell O
+lines O
+represent O
+the O
+first O
+examples O
+of O
+B O
+cells O
+with O
+downregulated O
+PU B
+. I
+1 I
+expression O
+and O
+apparently O
+contradict O
+observations O
+in O
+the O
+murine O
+system O
+in O
+which O
+PU B
+. I
+1 I
+is O
+expressed O
+and O
+active O
+in O
+plasmacytoma O
+cell O
+lines O
+. O
+
+The O
+traW B
+gene I
+of O
+the I
+Escherichia I
+coli I
+K I
+- I
+12 I
+sex I
+factor I
+, I
+F I
+, O
+encodes O
+one O
+of O
+the O
+numerous O
+proteins O
+required O
+for O
+conjugative O
+transfer O
+of O
+this O
+plasmid O
+. O
+
+Mibefradil O
+( O
+Ro O
+40 O
+- O
+5967 O
+) O
+is O
+a O
+novel O
+nondihydropyridine O
+calcium O
+antagonist O
+. O
+
+However O
+, O
+technical O
+advances O
+have O
+shown O
+the O
+limitations O
+of O
+these O
+tests O
+as O
+tests O
+for O
+IgM B
+can O
+be O
+positive O
+because O
+of O
+residual O
+specific O
+IgM B
+or O
+even O
+in O
+subjects O
+free O
+of O
+acute O
+infection O
+due O
+to O
+the O
+existence O
+of O
+natural O
+interfering O
+IgM B
+. O
+
+Carcinogenic O
+action O
+of O
+groundnut O
+meal O
+containing O
+aflatoxin O
+in O
+rats O
+. O
+
+( O
+1991 O
+) O
+EMBO O
+J O
+. O
+
+We O
+have O
+utilized O
+transient O
+transfections O
+, O
+mutation O
+analysis O
+, O
+electromobility O
+gel O
+- O
+shifts O
+, O
+and O
+immunoblot O
+analysis O
+to O
+test O
+the O
+hypothesis O
+that O
+expression O
+of O
+the O
+CTalpha B
+gene I
+is O
+controlled O
+in O
+part O
+by O
+the O
+binding O
+of O
+three O
+trans O
+- O
+acting O
+nuclear O
+factors O
+, O
+Sp1 B
+, O
+Sp2 B
+, O
+and O
+Sp3 B
+. O
+
+AMPK B
+is O
+a O
+heterotrimer O
+composed O
+of O
+a O
+catalytic O
+subunit O
+( O
+alpha O
+) O
+and O
+two O
+regulatory O
+subunits O
+( O
+beta O
+and O
+gamma O
+) O
+. O
+
+The O
+evolutionary O
+significance O
+of O
+the O
+similarities O
+of O
+intron O
+secondary O
+structures O
+and O
+open O
+reading O
+frames O
+of O
+the O
+ND3 B
+, I
+4 I
+and O
+ATPase B
+6 I
+genes I
+is O
+discussed O
+, O
+including O
+the O
+possible O
+separate O
+evolution O
+of O
+structural O
+and O
+coding O
+sequences O
+. O
+
+Antinuclear O
+antibodies O
+, O
+rheumatoid B
+factor I
+and O
+C B
+- I
+reactive I
+protein I
+in O
+serum O
+of O
+normal O
+women O
+using O
+oral O
+contraceptives O
+. O
+
+The O
+destruction O
+of O
+the O
+mesometrium O
+did O
+not O
+lengthen O
+the O
+oestrous O
+cycle O
+. O
+
+Concentrations O
+of O
+platelet O
+nitrite O
+and O
+total O
+nitrate O
+/ O
+nitrite O
+were O
+determined O
+using O
+simple O
+and O
+sensitive O
+nitrate O
+/ O
+nitrite O
+fluorometric O
+assay O
+techniques O
+. O
+
+Power O
+deposition O
+by O
+inverse O
+- O
+bremsstrahlung O
+is O
+modeled O
+with O
+a O
+scheme O
+based O
+on O
+Gaussian O
+quadrature O
+to O
+accommodate O
+a O
+deposition O
+rate O
+whose O
+spatial O
+variation O
+is O
+highly O
+nonuniform O
+. O
+
+The O
+sulfur O
+species O
+could O
+be O
+separated O
+within O
+less O
+than O
+4 O
+min O
+by O
+CZE O
+with O
+a O
+pyromellitic O
+acid O
+electrolyte O
+at O
+pH O
+3 O
+. O
+5 O
+to O
+5 O
+. O
+0 O
+. O
+
+We O
+propose O
+that O
+unc B
+- I
+37 I
+may O
+be O
+regulated O
+by O
+unc B
+- I
+4 I
+. O
+
+Adenovirus O
+infection O
+of O
+hepatoma O
+cells O
+inhibited O
+transcription O
+of O
+the O
+phosphoenolpyruvate B
+carboxykinase I
+( I
+GTP I
+) I
+( O
+EC B
+4 I
+. I
+1 I
+. I
+1 I
+. I
+32 I
+) O
+( O
+PEPCK B
+) O
+gene O
+and O
+virtually O
+eliminated O
+transcription O
+of O
+a O
+chimeric O
+gene O
+which O
+contained O
+the O
+PEPCK B
+promoter I
+linked O
+to O
+the O
+structural O
+gene O
+for O
+chloramphenicol B
+acetyltransferase I
+( O
+CAT B
+) O
+. O
+
+After O
+discharge O
+, O
+he O
+was O
+finally O
+given O
+a O
+diagnosis O
+of O
+PCH O
+because O
+a O
+Donath O
+- O
+Landsteiner O
+test O
+was O
+positive O
+. O
+
+The O
+second O
+intron O
+is O
+the O
+smallest O
+of O
+all O
+the O
+introns O
+( O
+116 O
+bp O
+) O
+. O
+
+Expression O
+of O
+the O
+gene O
+encoding O
+transcription O
+factor O
+cyclic B
+adenosine I
+3 I
+' I
+, I
+5 I
+' I
+- I
+monophosphate I
+( I
+cAMP I
+) I
+response I
+element I
+- I
+binding I
+protein I
+( O
+CREB B
+) O
+: O
+regulation O
+by O
+follicle B
+- I
+stimulating I
+hormone I
+- O
+induced O
+cAMP O
+signaling O
+in O
+primary O
+rat O
+Sertoli O
+cells O
+. O
+
+Efficacy O
+was O
+evaluated O
+in O
+24 O
+patients O
+, O
+of O
+whom O
+eight O
+received O
+RD O
+and O
+16 O
+SD O
+. O
+
+A O
+silica O
+- O
+based O
+, O
+fluoride O
+- O
+free O
+placebo O
+containing O
+NaTPP O
+, O
+and O
+a O
+NaF O
+- O
+containing O
+silica O
+- O
+based O
+USP O
+reference O
+standard O
+toothpaste O
+were O
+used O
+as O
+negative O
+and O
+positive O
+control O
+toothpastes O
+, O
+respectively O
+. O
+
+The O
+overall O
+response O
+rate O
+including O
+CR O
+and O
+PR O
+was O
+23 O
+. O
+5 O
+% O
+( O
+4 O
+/ O
+17 O
+) O
+. O
+
+High O
+and O
+pathological O
+PAI B
+- I
+1 I
+levels O
+before O
+and O
+after O
+the O
+VO O
+test O
+were O
+consistent O
+with O
+a O
+defective O
+fibrinolytic O
+potential O
+due O
+to O
+the O
+inhibitory O
+effect O
+of O
+PAI B
+- I
+1 I
+on O
+plasminogen B
+activation O
+. O
+
+During O
+hexamethylene O
+bisactamide O
+( O
+HMBA O
+) O
+- O
+induced O
+differentiation O
+of O
+murine O
+erythroleukemia O
+( O
+MEL O
+) O
+cells O
+erythroid O
+genes O
+are O
+transcriptionally O
+activated O
+while O
+c B
+- I
+myb I
+and O
+several O
+other O
+nuclear O
+proto O
+- O
+oncogenes O
+are O
+down O
+- O
+regulated O
+. O
+
+The O
+recovery O
+of O
+adults O
+schistosomes O
+by O
+extracorporeal O
+filtration O
+. O
+
+Torsion O
+of O
+the O
+contralateral O
+testis O
+5 O
+years O
+after O
+orchiopexy O
+. O
+
+Frequency O
+of O
+recurrence O
+of O
+fibroids O
+after O
+myomectomy O
+has O
+been O
+evaluated O
+in O
+145 O
+women O
+( O
+median O
+age O
+38 O
+years O
+, O
+range O
+21 O
+- O
+52 O
+) O
+who O
+underwent O
+myomectomy O
+. O
+
+Choline B
+acetyltransferase I
+immunohistochemistry O
+combined O
+with O
+the O
+retrograde O
+transport O
+of O
+horseradish B
+peroxidase I
+showed O
+that O
+the O
+reticular O
+and O
+mediodorsal O
+thalamic O
+nuclei O
+of O
+the O
+cat O
+receive O
+an O
+important O
+input O
+from O
+cholinergic O
+and O
+non O
+- O
+cholinergic O
+neurons O
+of O
+substantia O
+innominata O
+and O
+adjacent O
+structures O
+in O
+the O
+basal O
+forebrain O
+. O
+
+( O
+i O
+) O
+The O
+chimeric O
+gene O
+consisting O
+of O
+the O
+coding O
+and O
+5 O
+' O
+nontranslated O
+leader O
+regions O
+of O
+the O
+TK B
+gene I
+fused O
+to O
+portions O
+of O
+the O
+domain O
+of O
+alpha B
+gene I
+0 I
+extending O
+largely O
+upstream O
+from O
+the O
+site O
+of O
+initiation O
+of O
+transcription O
+of O
+alpha B
+gene I
+0 I
+was O
+regulated O
+in O
+the O
+same O
+fashion O
+as O
+the O
+alpha B
+4 I
+- I
+and I
+alpha I
+27 I
+- I
+TK I
+chimeras I
+. O
+
+Ethanol O
+preference O
+in O
+strains O
+of O
+rats O
+selectively O
+bred O
+for O
+behavioral O
+characteristics O
+. O
+
+For O
+the O
+albino O
+, O
+both O
+the O
+ST1 O
+and O
+ST2 O
+spatial O
+responses O
+peak O
+at O
+around O
+0 O
+. O
+3 O
+cycles O
+deg O
+- O
+1 O
+, O
+and O
+both O
+curves O
+are O
+displaced O
+considerably O
+to O
+the O
+low O
+spatial O
+frequency O
+side O
+of O
+the O
+normal O
+ST2 O
+spatial O
+response O
+. O
+
+Nuclear O
+proteins O
+bound O
+the O
+cad B
++ O
+55 O
+/ O
++ O
+75 O
+element O
+in O
+a O
+cell O
+cycle O
+- O
+dependent O
+manner O
+in O
+electromobility O
+shift O
+assays O
+; O
+antibodies O
+specific O
+to O
+USF B
+and O
+Max B
+blocked O
+the O
+DNA O
+- O
+binding O
+activity O
+of O
+different O
+growth O
+- O
+regulated O
+protein O
+- O
+DNA O
+complexes O
+. O
+
+Thus O
+, O
+an O
+unmodified O
+threonine O
+at O
+position O
+169 O
+in O
+Cdc28 B
+is O
+important O
+for O
+interaction O
+with O
+G1 B
+cyclins I
+. O
+
+Additional O
+genetic O
+analyses O
+described O
+herein O
+suggest O
+that O
+Skb1 B
+is O
+a O
+component O
+of O
+the O
+morphology O
+control O
+branch O
+of O
+the O
+Ras B
+signaling I
+cascade I
+in O
+S O
+. O
+pombe O
+and O
+that O
+it O
+positively O
+modulates O
+Shk1 B
+function O
+. O
+
+Recent O
+studies O
+have O
+concentrated O
+on O
+the O
+methods O
+of O
+preparation O
+of O
+coffee O
+, O
+which O
+vary O
+from O
+country O
+to O
+country O
+. O
+
+From O
+a O
+chromosomal O
+cosmid O
+library O
+of O
+Streptomyces O
+argillaceus O
+, O
+a O
+Mtm O
+producer O
+, O
+a O
+clone O
+( O
+cosAR7 O
+) O
+was O
+isolated O
+by O
+homology O
+to O
+the O
+actI B
+/ I
+III I
+region I
+of O
+S O
+. O
+coelicolor O
+and O
+the O
+strDEM B
+genes I
+of O
+S O
+. O
+griseus O
+. O
+
+In O
+this O
+report O
+, O
+we O
+investigated O
+whether O
+the O
+cleavage O
+of O
+the O
+RRKR O
+motif O
+of O
+MT B
+- I
+MMP1 I
+by O
+Golgi B
+- I
+associated I
+furin I
+is O
+analogous O
+to O
+a O
+similar O
+enzyme O
+activation O
+mechanism O
+observed O
+with O
+stromelysin B
+- I
+3 I
+. O
+
+Coexpression O
+of O
+C B
+/ I
+EBP I
+alpha I
+altered O
+the O
+cell O
+specificity O
+. O
+
+A O
+preterm O
+formula O
+with O
+a O
+traditional O
+corn O
+oil O
+/ O
+MCT O
+blend O
+containing O
+38 O
+% O
+MCTs O
+( O
+MCT O
+group O
+) O
+was O
+compared O
+to O
+a O
+new O
+fat O
+blend O
+, O
+designed O
+to O
+resemble O
+human O
+milk O
+more O
+, O
+containing O
+6 O
+% O
+MCTs O
+( O
+LCT O
+group O
+) O
+. O
+
+Thirty O
+- O
+three O
+small O
+glottic O
+carcinomas O
+( O
+T1 O
+and O
+small O
+T2 O
+; O
+UICC O
+, O
+1978 O
+) O
+were O
+examined O
+by O
+malignancy O
+grading O
+using O
+the O
+8 O
+- O
+factor O
+system O
+proposed O
+by O
+Jakobsson O
+et O
+al O
+. O
+
+Phenylalanine O
+and O
+tyrosine O
+levels O
+were O
+higher O
+in O
+those O
+who O
+received O
+Vamin O
+9 O
+glucose O
+but O
+55 O
+% O
+of O
+infants O
+given O
+Vamin O
+Infant O
+had O
+tyrosine O
+levels O
+below O
+the O
+lower O
+limit O
+of O
+the O
+target O
+range O
+. O
+
+We O
+sought O
+to O
+test O
+whether O
+a O
+prolonged O
+infusion O
+of O
+magnesium O
+sulfate O
+( O
+MgSO O
+( O
+4 O
+) O
+; O
+40 O
+mmol O
+/ O
+24 O
+hours O
+) O
+would O
+normalize O
+QT O
+interval O
+variability O
+in O
+patients O
+with O
+compensated O
+heart O
+failure O
+. O
+
+Escherichia O
+coli O
+strains O
+carrying O
+recA730 B
+( O
+or O
+other O
+recA B
+* I
+alleles I
+) O
+exhibit O
+dramatic O
+increases O
+in O
+SOS O
+- O
+dependent O
+spontaneous O
+mutator O
+activity O
+. O
+
+Outlook O
+in O
+oral O
+and O
+cutaneous O
+Kaposi O
+' O
+s O
+sarcoma O
+. O
+
+We O
+report O
+the O
+complete O
+nucleotide O
+sequence O
+of O
+the O
+camC B
+gene I
+along O
+with O
+155 O
+base O
+pairs O
+of O
+5 O
+' O
+and O
+175 O
+base O
+pairs O
+of O
+3 O
+' O
+flanking O
+sequence O
+. O
+
+However O
+, O
+it O
+is O
+only O
+loosely O
+associated O
+, O
+or O
+not O
+associated O
+, O
+with O
+viral O
+particles O
+. O
+
+gp170 B
+is O
+generated O
+by O
+an O
+alternatively O
+spliced O
+Env B
+mRNA I
+using O
+a O
+splice O
+donor O
+and O
+splice O
+acceptor O
+pair O
+localized O
+within O
+the O
+env B
+open I
+reading I
+frame I
+( O
+ORF O
+) O
+, O
+which O
+is O
+normally O
+used O
+to O
+generate O
+Bell B
+and O
+Bet B
+transcripts I
+derived O
+from O
+the O
+internal O
+promoter O
+within O
+the O
+env B
+ORF I
+. O
+
+gp170 B
+is O
+expressed O
+at O
+a O
+level O
+30 O
+to O
+50 O
+% O
+of O
+the O
+Env B
+precursor I
+gp130 B
+. O
+
+In O
+marked O
+contrast O
+to O
+the O
+previously O
+published O
+human B
+CD6 I
+sequence I
+, O
+the O
+mouse O
+sequence O
+predicts O
+a O
+long O
+cytoplasmic O
+tail O
+that O
+is O
+not O
+closely O
+related O
+to O
+other O
+proteins O
+and O
+possesses O
+two O
+proline O
+- O
+rich O
+motifs O
+containing O
+the O
+SH3 B
+- I
+domain I
+binding I
+consensus I
+sequence I
+, O
+three O
+protein B
+kinase I
+C I
+phosphorylation I
+site I
+motifs O
+, O
+nine O
+casein B
+kinase I
+- I
+2 I
+phosphorylation I
+site I
+motifs I
+, O
+and O
+a O
+serine O
+- O
+threonine O
+- O
+rich O
+motif O
+repeated O
+three O
+times O
+. O
+
+ET B
+- I
+1 I
+limited O
+the O
+electrocardiographic O
+evidence O
+of O
+subendocardial O
+ischemia O
+and O
+attenuated O
+contractile O
+dysfunction O
+compared O
+with O
+mechanical O
+stenosis O
+at O
+the O
+same O
+coronary O
+flows O
+, O
+even O
+though O
+lactate O
+flux O
+was O
+similar O
+. O
+
+Our O
+results O
+are O
+consistent O
+with O
+TCOF1 B
+mutations O
+leading O
+to O
+the O
+Treacher B
+Collins I
+syndrome I
+phenotype I
+. O
+
+Experimental O
+production O
+of O
+a O
+syndrome O
+analogous O
+to O
+hydramnios O
+in O
+the O
+rat O
+fetus O
+
+Total O
+cross O
+sections O
+for O
+electron O
+scattering O
+by O
+CO2 O
+molecules O
+in O
+the O
+energy O
+range O
+400 O
+- O
+5000 O
+eV O
+. O
+
+Thus O
+, O
+the O
+cognitive O
+performance O
+of O
+elderly O
+subjects O
+could O
+be O
+trained O
+to O
+a O
+large O
+extent O
+. O
+
+Partial O
+albinism O
+and O
+immunodeficiency O
+: O
+ultrastructural O
+study O
+of O
+haemophagocytosis O
+and O
+bone O
+marrow O
+erythroblasts O
+in O
+one O
+case O
+. O
+
+Residues O
+that O
+affect O
+PLCbeta B
+and O
+adenylyl B
+cyclase I
+II I
+activity O
+are O
+found O
+on O
+opposite O
+sides O
+of O
+the O
+central O
+tunnel O
+, O
+suggesting O
+that O
+PLC B
+and O
+adenylyl B
+cyclase I
+, O
+like O
+the O
+alpha O
+subunit O
+, O
+make O
+many O
+contacts O
+on O
+the O
+top O
+surface O
+. O
+
+The O
+dynamics O
+of O
+protozoa O
+were O
+studied O
+in O
+two O
+groups O
+of O
+rumen O
+- O
+fistulated O
+cattle O
+fed O
+on O
+a O
+basal O
+diet O
+of O
+molasses O
+ad O
+lib O
+. O
+, O
+with O
+oaten O
+chaff O
+given O
+at O
+6 O
+or O
+18 O
+g O
+/ O
+kg O
+live O
+weight O
+. O
+
+The O
+CBS B
+- I
+1 I
+gene I
+was O
+mapped O
+to O
+human O
+chromosome O
+10p12 O
+between O
+markers O
+WI O
+- O
+8535 O
+and O
+WI O
+- O
+4724 O
+, O
+and O
+is O
+tightly O
+linked O
+to O
+the O
+two O
+STRP O
+markers O
+of O
+D10S1789 B
+and O
+D10S550 B
+. O
+
+Blood O
+ammonia O
+concentration O
+was O
+significantly O
+higher O
+in O
+males O
+at O
+70 O
+, O
+80 O
+and O
+90 O
+% O
+of O
+VO2 O
+peak O
+. O
+
+Value O
+of O
+bone O
+scintigraphy O
+with O
+Tc99MDP O
+in O
+the O
+early O
+diagnosis O
+of O
+mobilization O
+of O
+the O
+total O
+hip O
+prosthesis O
+
+Youssoufian O
+, O
+A O
+. O
+
+The O
+dipper O
+( O
+RONF O
+of O
+BP O
+( O
+or O
+HR O
+) O
+> O
+or O
+= O
+10 O
+% O
+2 O
+. O
+
+In O
+the O
+present O
+study O
+, O
+we O
+have O
+investigated O
+the O
+effects O
+of O
+SDZ O
+ENA O
+713 O
+on O
+spatial O
+learning O
+deficits O
+in O
+aged O
+rats O
+. O
+
+MATERIALS O
+AND O
+METHODS O
+: O
+A O
+seven O
+- O
+wavelength O
+frequency O
+- O
+domain O
+photon O
+migration O
+probe O
+was O
+used O
+to O
+perform O
+noninvasive O
+NIR O
+measurements O
+in O
+the O
+breasts O
+of O
+28 O
+healthy O
+women O
+, O
+both O
+pre O
+- O
+and O
+postmenopausal O
+, O
+aged O
+18 O
+- O
+64 O
+years O
+. O
+
+YACs O
+, O
+BACs O
+, O
+cosmids O
+, O
+and O
+STSs O
+are O
+defined O
+to O
+aid O
+in O
+further O
+study O
+of O
+this O
+gene O
+. O
+
+HCVR O
+- O
+L O
+significantly O
+increased O
+dVAS O
+/ O
+dPCO2 O
+to O
+4 O
+. O
+9 O
++ O
+/ O
+- O
+0 O
+. O
+7 O
+mm O
+/ O
+Torr O
+compared O
+to O
+HCVR O
+- O
+S O
+( O
+p O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+The O
+MEF B
+- I
+2 I
+proteins I
+are O
+a O
+family O
+of O
+transcriptional O
+activators O
+that O
+have O
+been O
+detected O
+in O
+a O
+wide O
+variety O
+of O
+cell O
+types O
+. O
+
+The O
+ferric B
+uptake I
+regulation I
+( O
+fur B
+) O
+gene O
+product O
+participates O
+in O
+regulating O
+expression O
+of O
+the O
+manganese B
+- I
+and I
+iron I
+- I
+containing I
+superoxide I
+dismutase I
+genes I
+of O
+Escherichia O
+coli O
+. O
+
+To O
+date O
+, O
+6 O
+mammalian B
+GRKs I
+have O
+been O
+identified O
+by O
+molecular O
+cloning O
+. O
+
+[ O
+( O
+OP O
+) O
+2Cu O
+] O
++ O
+also O
+detected O
+protections O
+in O
+the O
+C O
+alpha O
+- O
+helix O
+, O
+the O
+interdomain O
+hinge O
+, O
+and O
+beta O
+- O
+strands O
+2 O
+- O
+7 O
+. O
+
+The O
+aim O
+of O
+the O
+present O
+study O
+was O
+to O
+investigate O
+the O
+influence O
+of O
+long O
+term O
+intravenous O
+administration O
+of O
+naftidrofuryl O
+( O
+Dusodril O
+- O
+Lipha O
+Arzn O
+) O
+twice O
+daily O
+in O
+a O
+dose O
+of O
+200 O
+mg O
+in O
+continuous O
+, O
+4 O
+- O
+hour O
+infusion O
+in O
+500 O
+ml O
+0 O
+. O
+9 O
+% O
+NaCl O
+to O
+the O
+patients O
+suffering O
+from O
+a O
+peripheral O
+arterial O
+occlusive O
+disease O
+( O
+PAOD O
+) O
+in O
+a O
+clinical O
+condition O
+with O
+special O
+attention O
+paid O
+to O
+transcutaneous O
+partial O
+oxygen O
+pressure O
+measurements O
+( O
+tcPO2 O
+) O
+and O
+rheographic O
+parameters O
+. O
+
+Vertebrate B
+U6 I
+small I
+nuclear I
+RNA I
+( I
+snRNA I
+) I
+loci I
+exemplify O
+a O
+novel O
+class O
+of O
+polymerase B
+III I
+- I
+transcribed I
+genes I
+that O
+lack O
+an O
+intragenic O
+control O
+region O
+( O
+ICR O
+) O
+. O
+
+Elements O
+of O
+the O
+hAT B
+transposon I
+family I
+, O
+such O
+as O
+the O
+maize B
+activator I
+( O
+Ac B
+) O
+, O
+have O
+been O
+discovered O
+in O
+a O
+large O
+number O
+of O
+eukaryotic O
+species O
+. O
+
+Judge O
+Christian O
+Byk O
+renders O
+service O
+to O
+the O
+Steering O
+Committee O
+on O
+Bioethics O
+of O
+the O
+Council O
+of O
+Europe O
+( O
+CDBI O
+) O
+by O
+proposing O
+a O
+draft O
+of O
+the O
+protocol O
+destined O
+to O
+fill O
+in O
+a O
+gap O
+in O
+international O
+law O
+on O
+the O
+status O
+of O
+the O
+human O
+embryo O
+. O
+
+Correlation O
+coefficients O
+between O
+SF O
+thickness O
+and O
+NIR O
+optical O
+density O
+readings O
+at O
+940 O
+nm O
+( O
+OD1 O
+) O
+and O
+950 O
+nm O
+( O
+OD2 O
+) O
+wavelengths O
+ranged O
+from O
+r O
+= O
+- O
+0 O
+. O
+30 O
+( O
+subscapula O
+) O
+to O
+r O
+= O
+- O
+0 O
+. O
+67 O
+( O
+biceps O
+) O
+for O
+OD1 O
+and O
+r O
+= O
+- O
+0 O
+. O
+39 O
+( O
+axilla O
+) O
+to O
+r O
+= O
+- O
+0 O
+. O
+68 O
+( O
+biceps O
+) O
+for O
+OD2 O
+. O
+
+We O
+found O
+both O
+the O
+v B
+- I
+Ras I
+- O
+and O
+PC B
+- I
+PLC I
+- O
+transformed O
+cells O
+to O
+be O
+insensitive O
+to O
+stimulation O
+with O
+platelet B
+- I
+derived I
+growth I
+factor I
+( O
+PDGF B
+) O
+. O
+
+Analysis O
+of O
+domain O
+deletion O
+mutants O
+demonstrated O
+strong O
+synergy O
+between O
+the O
+RRM O
+and O
+a O
+central O
+degenerate O
+RRM B
+repeat I
+in O
+binding O
+to O
+RNA O
+. O
+
+Sequence O
+analysis O
+of O
+the O
+catfish O
+JH B
+- O
+CH I
+intron O
+suggests O
+that O
+several O
+sequences O
+are O
+present O
+which O
+appear O
+similar O
+to O
+important O
+transcriptional O
+regulatory O
+elements O
+found O
+within O
+JH B
+- O
+CH B
+introns O
+of O
+higher O
+vertebrates O
+. O
+
+The O
+patient O
+groups O
+consisted O
+of O
+31 O
+with O
+dilated O
+cardiomyopathy O
+, O
+22 O
+with O
+hypertrophic O
+cardiomyopathy O
+, O
+38 O
+with O
+myocardial O
+infarction O
+, O
+15 O
+with O
+angina O
+pectoris O
+and O
+26 O
+with O
+rheumatic O
+valvular O
+disease O
+. O
+
+100 O
+. O
+
+However O
+, O
+the O
+pre3 B
+- I
+2 I
+mutation I
+strengthened O
+phenotypes O
+induced O
+by O
+other O
+20 B
+S I
+proteasomal I
+mutations O
+, O
+indicating O
+that O
+the O
+peptidylglutamyl O
+peptide O
+- O
+hydrolyzing O
+activity O
+has O
+to O
+fulfill O
+some O
+rescue O
+functions O
+. O
+
+Whereas O
+Sprague O
+- O
+Dawleys O
+displayed O
+lights O
+- O
+off O
+and O
+lights O
+- O
+on O
+peaks O
+of O
+ingestive O
+activity O
+, O
+only O
+a O
+minority O
+of O
+Fisher O
+- O
+344s O
+displayed O
+a O
+consistent O
+lights O
+- O
+on O
+peak O
+of O
+ingestive O
+activity O
+. O
+
+RESULTS O
+: O
+In O
+76 O
+trials O
+, O
+5 O
+, O
+351 O
+patients O
+received O
+24 O
+different O
+regimens O
+of O
+droperidol O
+. O
+
+The O
+tro B
+operon I
+is O
+flanked O
+by O
+a O
+Holliday B
+structure I
+DNA I
+helicase I
+homolog I
+( O
+upstream O
+) O
+and O
+two O
+ORFs O
+representing O
+a O
+purine B
+nucleoside I
+phosphorylase I
+homolog I
+and O
+tpp15 B
+, O
+a O
+previously O
+characterized O
+gene O
+encoding O
+a O
+membrane O
+lipoprotein O
+( O
+downstream O
+) O
+. O
+
+We O
+report O
+nine O
+consecutive O
+cases O
+of O
+ACB O
+, O
+which O
+occurred O
+in O
+five O
+males O
+and O
+four O
+females O
+and O
+were O
+detected O
+in O
+11 O
+, O
+159 O
+routine O
+spiral O
+CT O
+examinations O
+of O
+the O
+chest O
+, O
+performed O
+between O
+1994 O
+and O
+1998 O
+. O
+
+In O
+order O
+to O
+search O
+for O
+mutations O
+in O
+the O
+multicopy O
+RBM B
+genes I
+that O
+might O
+be O
+associated O
+with O
+male O
+infertility O
+, O
+we O
+have O
+used O
+sequence O
+data O
+from O
+the O
+reported O
+cDNA O
+clone O
+to O
+determine O
+the O
+intron O
+exon O
+boundaries O
+of O
+the O
+YRRM B
+1 I
+gene I
+. O
+
+98 O
+, O
+93 O
+- O
+98 O
+) O
+. O
+
+Studies O
+on O
+the O
+excretion O
+of O
+selenium O
+in O
+urine O
+and O
+feces O
+and O
+distribution O
+in O
+the O
+organs O
+of O
+rats O
+by O
+a O
+method O
+of O
+radioactivity O
+measurement O
+
+The O
+use O
+of O
+the O
+two O
+pharmacokinetic O
+parameters O
+, O
+t1 O
+/ O
+2 O
+and O
+Cltp O
+, O
+as O
+indices O
+of O
+drug O
+elimination O
+ability O
+are O
+discussed O
+. O
+
+Gastric O
+secretory O
+inhibition O
+induced O
+by O
+three O
+methyl O
+analogs O
+of O
+prostaglandin O
+E2 O
+administered O
+intragastrically O
+to O
+man O
+. O
+
+By O
+RT O
+- O
+PCR O
+, O
+different O
+levels O
+of O
+E75 B
+expression O
+can O
+be O
+detected O
+in O
+the O
+epidermis O
+, O
+nerve O
+cord O
+and O
+the O
+eyestalk O
+of O
+early O
+pre O
+- O
+molt O
+shrimp O
+. O
+
+The O
+vicinity O
+of O
+large O
+industrial O
+emissions O
+of O
+lead O
+, O
+where O
+mean O
+Pb O
+- O
+B O
+concentrations O
+were O
+usually O
+twice O
+as O
+high O
+as O
+in O
+rural O
+areas O
+of O
+the O
+Katowice O
+voivodship O
+. O
+
+Forty O
+- O
+five O
+per O
+cent O
+of O
+the O
+dose O
+was O
+excreted O
+as O
+methyldopa O
+as O
+opposed O
+to O
+18 O
+% O
+normally O
+seen O
+after O
+oral O
+methyldopa O
+dosages O
+. O
+
+No O
+cleavage O
+of O
+gp B
+130 I
+was O
+observed O
+in O
+analogous O
+pulse O
+- O
+chase O
+radiolabelling O
+of O
+Ad O
+- O
+gB B
+- O
+infected O
+human O
+fibroblasts O
+, O
+even O
+though O
+these O
+cells O
+are O
+permissive O
+for O
+HCMV O
+replication O
+and O
+can O
+process O
+the O
+native O
+gB B
+molecule I
+. O
+
+A O
+phylogenetic O
+comparison O
+of O
+32 O
+species O
+showed O
+minor O
+differences O
+in O
+the O
+apoB B
+mRNA I
+sequence I
+, O
+and O
+the O
+apoB B
+mRNA I
+from O
+31 O
+species O
+was O
+robustly O
+edited O
+in O
+vitro O
+. O
+
+The O
+other O
+five O
+from O
+within O
+the O
+SRO O
+may O
+provide O
+an O
+entrance O
+point O
+for O
+the O
+cloning O
+of O
+candidate O
+genes O
+for O
+neuroblastoma O
+. O
+
+Sugar O
+analysis O
+was O
+performed O
+on O
+alpha O
+- O
+TM O
+to O
+investigate O
+a O
+possible O
+biosynthetic O
+mechanism O
+for O
+part O
+- O
+time O
+PGs O
+. O
+
+Pediatric O
+patients O
+- O
+- O
+handle O
+with O
+care O
+. O
+
+These O
+include O
+the O
+genes O
+, O
+undefined B
+1 I
+( O
+UD1 B
+) O
+, O
+UD2 B
+, O
+and O
+UD3 B
+, O
+each O
+coding O
+for O
+proteins O
+of O
+unknown O
+function O
+, O
+the O
+ken B
+gene I
+encoding O
+a O
+new O
+Kruppel B
+- I
+like I
+putative I
+transcription I
+factor I
+, O
+the O
+fly O
+homologues O
+of O
+the O
+mammalian B
+mitochondrial I
+trifunctional I
+enzyme I
+( O
+thiolase B
+) O
+, O
+and O
+the O
+TAR B
+DNA I
+- I
+binding I
+protein I
+- I
+43 I
+( O
+TBPH B
+) O
+, O
+the O
+first O
+nonvertebrate O
+member O
+of O
+the O
+transmembrane B
+4 I
+superfamily I
+( O
+TM4SF B
+) O
+gene O
+, O
+a O
+new O
+homeodomain B
+gene I
+, O
+and O
+a O
+gene O
+coding O
+for O
+
+a O
+putative O
+nuclear B
+binding I
+protein I
+( O
+PNBP B
+) O
+that O
+is O
+homologous O
+to O
+maleless B
+, O
+and O
+a O
+Copia B
+- I
+like I
+element I
+. O
+
+TRAF2 B
+has O
+previously O
+been O
+demonstrated O
+to O
+activate O
+both O
+transcription B
+factor I
+nuclear I
+factor I
+kappaB I
+( O
+NFkappaB B
+) O
+and O
+the O
+c B
+- I
+Jun I
+N I
+- I
+terminal I
+kinase I
+/ O
+stress B
+- I
+activated I
+protein I
+kinase I
+( O
+JNK B
+/ O
+SAPK B
+) O
+pathway O
+, O
+which O
+in O
+turn O
+stimulates O
+transcription B
+factor I
+activating I
+protein I
+1 I
+( O
+AP1 B
+) O
+mainly O
+via O
+phosphorylation O
+of O
+the O
+c B
+- I
+Jun I
+component O
+. O
+
+A O
+procaryotic O
+regulatory O
+factor O
+with O
+a O
+histone B
+H1 I
+- I
+like I
+carboxy I
+- I
+terminal I
+domain I
+: O
+clonal O
+variation O
+of O
+repeats O
+within O
+algP B
+, O
+a O
+gene O
+involved O
+in O
+regulation O
+of O
+mucoidy O
+in O
+Pseudomonas O
+aeruginosa O
+. O
+
+The O
+host O
+range O
+( O
+HR O
+) O
+of O
+poliovirus O
+is O
+thought O
+to O
+be O
+primarily O
+determined O
+by O
+a O
+cell O
+surface O
+molecule O
+that O
+functions O
+as O
+poliovirus B
+receptor I
+( O
+PVR B
+) O
+, O
+since O
+it O
+has O
+been O
+shown O
+that O
+transgenic O
+mice O
+are O
+made O
+poliovirus O
+sensitive O
+by O
+introducing O
+the O
+human B
+PVR I
+gene I
+into O
+the O
+genome O
+. O
+
+Human B
+alcohol I
+dehydrogenase I
+( O
+ADH B
+) O
+exists O
+as O
+a O
+heterogeneous O
+group O
+of O
+isozymes O
+capable O
+of O
+oxidizing O
+a O
+wide O
+variety O
+of O
+aliphatic O
+and O
+aromatic O
+alcohols O
+. O
+
+The O
+control O
+of O
+human B
+aromatase I
+expression O
+is O
+complex O
+in O
+that O
+several O
+promoters O
+drive O
+aromatase B
+expression O
+in O
+a O
+tissue O
+- O
+specific O
+manner O
+. O
+
+In O
+addition O
+, O
+renal O
+sympathetic O
+activity O
+was O
+measured O
+in O
+a O
+separate O
+group O
+of O
+rats O
+. O
+
+This O
+incompatibility O
+phenotype O
+requires O
+the O
+global O
+transcriptional O
+repressor O
+, O
+KorB B
+, O
+and O
+the O
+target O
+for O
+incC O
+- O
+mediated O
+incompatibility O
+is O
+a O
+KorB B
+- I
+binding I
+site I
+( O
+O B
+( I
+B I
+) I
+) O
+. O
+
+Bodily O
+referents O
+and O
+the O
+experience O
+of O
+affect O
+. O
+
+The O
+effect O
+of O
+the O
+negative O
+regulatory O
+element O
+is O
+negated O
+by O
+the O
+viral B
+IE2 I
+protein I
+( O
+L O
+. O
+
+RXRalpha B
+/ O
+RARalpha B
+heterodimers O
+and O
+HNF B
+- I
+4 I
+homodimers I
+bind O
+to O
+DR B
+- I
+1 I
+motifs O
+on O
+elements O
+B O
+and O
+I4 O
+, O
+respectively O
+. O
+
+Evidence O
+for O
+involvement O
+of O
+proteins O
+HU B
+and O
+RpoS B
+in O
+transcription O
+of O
+the O
+osmoresponsive O
+proU B
+operon I
+in O
+Escherichia O
+coli O
+. O
+
+However O
+, O
+a O
+lesser O
+extent O
+effect O
+was O
+noticed O
+in O
+nonpregnant O
+than O
+seen O
+in O
+pregnant O
+rats O
+. O
+
+Morphine O
+administration O
+acutely O
+reduced O
+plasma O
+clearance O
+of O
+sulfobromophthalein O
+( O
+BSP O
+) O
+in O
+mice O
+and O
+increased O
+hepatic O
+retention O
+of O
+this O
+dye O
+. O
+
+Buchstein O
+, O
+L O
+. O
+- O
+L O
+. O
+
+Intraspinal O
+and O
+mediastinal O
+foregut O
+cyst O
+compressing O
+the O
+spinal O
+cord O
+. O
+
+The O
+nutraceuticals O
+of O
+specific O
+vitamins O
+, O
+minerals O
+, O
+phytoestrogens O
+, O
+and O
+essential O
+fatty O
+acid O
+supplementations O
+are O
+a O
+vital O
+component O
+of O
+the O
+risk O
+reduction O
+health O
+program O
+. O
+
+Characterization O
+of O
+a O
+unique O
+protein O
+component O
+of O
+yeast B
+RNase I
+MRP I
+: O
+an O
+RNA O
+- O
+binding O
+protein O
+with O
+a O
+zinc O
+- O
+cluster O
+domain O
+. O
+
+The O
+present O
+study O
+indicates O
+that O
+the O
+high O
+- O
+dose O
+5 O
+- O
+fluorouracil O
+regimen O
+shows O
+weak O
+activity O
+in O
+advanced O
+pancreatic O
+cancer O
+which O
+seems O
+comparable O
+to O
+gemcitabine O
+. O
+
+Like O
+the O
+nuclear O
+envelope O
+, O
+the O
+intranuclear O
+double O
+membrane O
+lamellae O
+enclosed O
+a O
+defined O
+cisterna O
+that O
+was O
+interrupted O
+by O
+pores O
+but O
+, O
+unlike O
+the O
+nuclear O
+envelope O
+pores O
+, O
+they O
+lacked O
+NPCs O
+. O
+
+The O
+22 O
+- O
+d O
+orbital O
+flight O
+of O
+rats O
+onboard O
+the O
+Cosmos O
+- O
+605 O
+biosatellite O
+was O
+followed O
+by O
+inhibition O
+of O
+erythroblastosis O
+, O
+alteration O
+in O
+the O
+morphology O
+of O
+megakaryocytes O
+, O
+and O
+stimulation O
+of O
+myelopoiesis O
+. O
+
+An O
+OD O
+650 O
+greater O
+than O
+0 O
+. O
+15 O
+appears O
+to O
+be O
+a O
+rapid O
+, O
+reliable O
+indicator O
+of O
+fetal O
+lung O
+maturity O
+. O
+
+The O
+role O
+of O
+PORT O
+in O
+the O
+treatment O
+of O
+N2 O
+tumours O
+is O
+not O
+clear O
+and O
+may O
+justify O
+further O
+research O
+. O
+
+We O
+concluded O
+that O
+RXR B
+- I
+gamma I
+induced O
+terminal O
+differentiation O
+in O
+SCC O
+lines O
+, O
+suggesting O
+a O
+potential O
+tumor O
+suppressor O
+function O
+for O
+this O
+transcription O
+factor O
+. O
+
+Phosphorylated O
+tyrosine O
+residues O
+were O
+subsequently O
+identified O
+by O
+sequencing O
+the O
+separated O
+phosphopeptides O
+by O
+matrix O
+assisted O
+laser O
+desorption O
+ionization O
+mass O
+spectrometry O
+( O
+MALDI O
+- O
+MS O
+) O
+and O
+Edman O
+degradation O
+. O
+
+The O
+infection O
+of O
+cells O
+with O
+Moloney O
+murine O
+leukemia O
+virus O
+( O
+M O
+- O
+MuLV O
+) O
+causes O
+an O
+increase O
+in O
+specific O
+cellular O
+gene O
+products O
+, O
+including O
+the O
+major B
+histocompatibility I
+complex I
+( I
+MHC I
+) I
+class I
+I I
+antigens I
+. O
+
+These O
+data O
+demonstrate O
+that O
+oleosin B
+gene I
+transcription O
+is O
+regulated O
+in O
+a O
+tissue O
+- O
+specific O
+and O
+temporally O
+regulated O
+manner O
+and O
+clearly O
+indicate O
+that O
+oleosin B
+protein I
+expression O
+is O
+co O
+- O
+ordinated O
+primarily O
+at O
+the O
+transcriptional O
+level O
+. O
+
+Myocardial O
+technetium O
+- O
+99m O
+- O
+teboroxime O
+uptake O
+during O
+adenosine O
+- O
+induced O
+hyperemia O
+in O
+dogs O
+with O
+either O
+a O
+critical O
+or O
+mild O
+coronary O
+stenosis O
+: O
+comparison O
+to O
+thallium O
+- O
+201 O
+and O
+regional O
+blood O
+flow O
+. O
+
+UICC O
+criteria O
+) O
+for O
+VM O
+and O
+35 O
+% O
+for O
+VE O
+( O
+not O
+significant O
+) O
+. O
+
+Although O
+immunoglobulin B
+and O
+CRP B
+concentration O
+increased O
+, O
+anemia O
+obviously O
+improved O
+with O
+hemoglobin B
+levels O
+increasing O
+from O
+4 O
+. O
+8 O
+g O
+/ O
+dl O
+to O
+8 O
+. O
+5 O
+g O
+/ O
+dl O
+without O
+any O
+side O
+effects O
+. O
+
+Diff O
+- O
+Quik O
+stain O
+for O
+Tzanck O
+smears O
+. O
+
+Experience O
+in O
+using O
+the O
+Romashka O
+- O
+1 O
+laser O
+surgical O
+unit O
+in O
+treating O
+suppurative O
+wounds O
+
+At O
+D28 O
+, O
+149 O
+of O
+386 O
+patients O
+( O
+49 O
+% O
+) O
+had O
+had O
+episodes O
+of O
+automatic O
+mode O
+switch O
+prompted O
+by O
+atrial O
+arrhythmias O
+. O
+
+Together O
+, O
+these O
+results O
+implicate O
+Fal1p B
+in O
+the O
+18S B
+rRNA I
+maturation O
+pathway O
+rather O
+than O
+in O
+translation O
+initiation O
+. O
+
+Most O
+other O
+differences O
+between O
+these O
+two O
+Leporipoxviruses O
+are O
+located O
+in O
+the O
+telomeres O
+. O
+
+We O
+challenge O
+each O
+of O
+55 O
+consecutive O
+ragweed O
+( O
+RW O
+) O
+- O
+allergic O
+patients O
+with O
+hay O
+fever O
+and O
+with O
+graded O
+increasing O
+doses O
+of O
+ragweed O
+extract O
+to O
+investigate O
+the O
+frequency O
+and O
+relationship O
+between O
+the O
+early O
+( O
+ER O
+) O
+, O
+late O
+( O
+LPR O
+) O
+, O
+and O
+rechallenge O
+reactions O
+( O
+RCRs O
+) O
+to O
+nasal O
+challenge O
+. O
+
+The O
+expression O
+of O
+CAPL B
+, O
+a O
+second O
+protein O
+involved O
+in O
+calcium O
+metabolism O
+, O
+was O
+only O
+moderately O
+elevated O
+in O
+the O
+doxorubicin O
+- O
+resistant O
+cells O
+. O
+
+The O
+central O
+region O
+of O
+the O
+sarcomere O
+, O
+coincident O
+with O
+the O
+M O
+line O
+, O
+was O
+selectively O
+labeled O
+with O
+antibodies O
+to O
+the O
+short O
+C O
+- O
+terminal O
+form O
+. O
+
+Despite O
+this O
+dependency O
+, O
+however O
+, O
+a O
+B B
+. I
+japonicum I
+fixK I
+mutant I
+did O
+not O
+have O
+the O
+phenotypic O
+characteristics O
+of O
+B B
+. I
+japonicum I
+fixL I
+and O
+fixJ B
+mutants I
+: O
+the O
+fixK B
+mutant I
+was O
+neither O
+Fix B
+- O
+in O
+symbiosis O
+with O
+soybean O
+plants O
+nor O
+defective O
+in O
+anaerobic O
+respiration O
+with O
+nitrate O
+as O
+the O
+terminal O
+electron O
+acceptor O
+. O
+
+ANL O
+- O
+7535 O
+. O
+
+The O
+QCS O
+appears O
+comparable O
+with O
+the O
+MMSE O
+and O
+is O
+quicker O
+to O
+administer O
+. O
+
+We O
+used O
+high O
+- O
+resolution O
+ultrasound O
+to O
+characterize O
+postprandial O
+antral O
+excursion O
+characteristics O
+in O
+15 O
+healthy O
+volunteers O
+. O
+
+Copyright O
+1998 O
+Academic O
+Press O
+. O
+
+Human B
+PDNP3 I
+is O
+expressed O
+in O
+glioma O
+cells O
+, O
+prostate O
+, O
+and O
+uterus O
+, O
+but O
+not O
+in O
+the O
+alimentary O
+tract O
+. O
+
+Epithelial O
+cells O
+had O
+abnormal O
+and O
+accelerated O
+exfoliation O
+which O
+resulted O
+in O
+multifocal O
+epithelial O
+defects O
+. O
+
+Tight O
+- O
+binding O
+band O
+structure O
+calculations O
+for O
+beta O
+- O
+MNX O
+( O
+M O
+= O
+Zr O
+, O
+X O
+= O
+Cl O
+, O
+Br O
+; O
+M O
+= O
+Hf O
+, O
+X O
+= O
+Cl O
+) O
+, O
+ZrCl O
+, O
+and O
+Y O
+( O
+2 O
+) O
+C O
+( O
+2 O
+) O
+Br O
+( O
+2 O
+) O
+are O
+reported O
+. O
+
+Screening O
+of O
+a O
+human O
+foetal O
+brain O
+genomic O
+DNA O
+library O
+allowed O
+us O
+to O
+isolate O
+an O
+EcoRI B
+- O
+EcoRI B
+fragment O
+containing O
+6 O
+kb O
+of O
+the O
+5 O
+' O
+- O
+flanking O
+region O
+, O
+the O
+open O
+reading O
+frame O
+and O
+4 O
+kb O
+of O
+the O
+3 O
+' O
+- O
+flanking O
+region O
+of O
+the O
+alpha2C4 B
+gene I
+. O
+
+The O
+psychosomatic O
+approach O
+to O
+temporomandibular O
+arthrosis O
+
+The O
+rate O
+of O
+decrease O
+of O
+PRA O
+after O
+REM O
+onset O
+closely O
+approximates O
+the O
+most O
+recent O
+estimations O
+of O
+PRA O
+half O
+- O
+life O
+, O
+which O
+suggests O
+that O
+REM O
+onset O
+is O
+associated O
+with O
+a O
+virtual O
+cessation O
+in O
+renin B
+production O
+. O
+
+Similarly O
+, O
+interfering O
+with O
+MEKK B
+, O
+which O
+lies O
+upstream O
+of O
+JNK1 B
+, O
+using O
+a O
+dominant O
+negative O
+expression O
+vector O
+reduced O
+MMP B
+- I
+9 I
+promoter I
+activity O
+over O
+the O
+same O
+concentration O
+range O
+which O
+repressed O
+the O
+AP B
+- I
+1 I
+- O
+thymidine B
+kinase I
+CAT B
+reporter O
+construct O
+. O
+
+There O
+was O
+no O
+difference O
+in O
+serum O
+albumin B
+and O
+transferrin B
+levels O
+, O
+but O
+serum B
+prealbumin I
+levels O
+in O
+the O
+group O
+fed O
+early O
+were O
+more O
+desirable O
+than O
+those O
+of O
+the O
+control O
+group O
+( O
+from O
+15 O
+. O
+8 O
++ O
+/ O
+- O
+2 O
+. O
+5 O
+mg O
+/ O
+dl O
+to O
+28 O
+. O
+9 O
++ O
+/ O
+- O
+3 O
+. O
+8 O
+mg O
+/ O
+dl O
+vs O
+from O
+18 O
+. O
+0 O
++ O
+/ O
+- O
+2 O
+. O
+0 O
+mg O
+/ O
+dl O
+to O
+25 O
+. O
+9 O
++ O
+/ O
+- O
+3 O
+. O
+9 O
+mg O
+/ O
+dl O
+) O
+. O
+
+The O
+repeats O
+are O
+highly O
+conserved O
+both O
+within O
+a O
+given O
+element O
+as O
+well O
+as O
+between O
+different O
+members O
+of O
+the O
+family O
+( O
+less O
+than O
+10 O
+% O
+divergence O
+) O
+. O
+
+Utility O
+of O
+thallium O
+- O
+201 O
+scintigraphy O
+in O
+detecting O
+right O
+ventricular O
+dysfunction O
+in O
+pulmonary O
+embolism O
+. O
+
+CONCLUSIONS O
+: O
+The O
+system O
+developed O
+in O
+this O
+study O
+can O
+be O
+used O
+as O
+a O
+method O
+to O
+detect O
+air O
+- O
+trapping O
+during O
+TGI O
+. O
+
+The O
+carboxyl O
+- O
+terminal O
+75 O
+amino O
+acids O
+of O
+the O
+two O
+proteins O
+contain O
+the O
+bHLH O
+motif O
+and O
+differ O
+from O
+each O
+other O
+by O
+only O
+three O
+conservative O
+amino O
+acid O
+changes O
+, O
+while O
+the O
+amino O
+- O
+terminal O
+portions O
+are O
+markedly O
+divergent O
+from O
+each O
+other O
+. O
+
+In O
+a O
+rat O
+model O
+of O
+SAH O
+, O
+we O
+assessed O
+BBB O
+changes O
+by O
+means O
+of O
+the O
+quantitative O
+[ O
+14C O
+] O
+- O
+alpha O
+- O
+aminoisobutyric O
+acid O
+technique O
+. O
+
+Pollinosis O
+in O
+the O
+U O
+. O
+A O
+. O
+R O
+. O
+
+Northern O
+blot O
+analysis O
+of O
+enoyl B
+- I
+ACP I
+reductase I
+mRNA I
+steady O
+- O
+state O
+levels O
+during O
+seed O
+development O
+suggests O
+that O
+the O
+increase O
+in O
+enzyme O
+activity O
+during O
+the O
+phase O
+of O
+storage O
+lipid O
+accumulation O
+is O
+regulated O
+at O
+the O
+level O
+of O
+gene O
+expression O
+. O
+
+Time O
+between O
+tests O
+( O
+usually O
+less O
+than O
+one O
+year O
+) O
+did O
+not O
+affect O
+the O
+correlations O
+, O
+but O
+MMPI O
+response O
+- O
+set O
+variables O
+( O
+L O
+, O
+F O
+, O
+K O
+, O
+F O
+- O
+K O
+) O
+did O
+. O
+
+The O
+differences O
+in O
+binding O
+( O
+Kdapp O
+) O
+, O
+incorporation O
+, O
+and O
+extension O
+kinetics O
+of O
+8 O
+- O
+oxo O
+- O
+dGTP O
+compared O
+to O
+normal O
+dNTP O
+incorporation O
+at O
+template O
+8 O
+- O
+oxo O
+- O
+G O
+adducts O
+indicate O
+that O
+polymerase O
+fidelity O
+does O
+not O
+depend O
+solely O
+upon O
+the O
+overall O
+geometry O
+of O
+Watson O
+- O
+Crick O
+base O
+pairs O
+and O
+reflects O
+the O
+asymmetry O
+of O
+the O
+enzyme O
+active O
+site O
+. O
+
+This O
+constant O
+expression O
+profile O
+, O
+coupled O
+with O
+the O
+observation O
+that O
+over O
+- O
+expression O
+of O
+mSin3A B
+does O
+not O
+augment O
+the O
+anti B
+- I
+Myc I
+activity O
+of O
+Mxi1 B
+- O
+SR B
+in O
+the O
+rat O
+embryo O
+fibroblast O
+( O
+REF O
+) O
+transformation O
+assay O
+, O
+suggests O
+that O
+mSin3A B
+is O
+not O
+a O
+limiting O
+factor O
+in O
+the O
+regulation O
+of O
+Myc B
+superfamily I
+function O
+. O
+
+The O
+sequences O
+at O
+- O
+10 O
+and O
+- O
+35 O
+relative O
+to O
+the O
+transcriptional O
+starting O
+site O
+showed O
+55 O
+% O
+homology O
+with O
+the O
+consensus O
+sequences O
+of O
+the O
+Escherichia B
+coli I
+sigma I
+70 I
+- I
+type I
+promoter I
+. O
+
+The O
+results O
+were O
+subjected O
+to O
+analysis O
+of O
+23 O
+autopsies O
+carried O
+out O
+in O
+children O
+dying O
+of O
+intoxication O
+with O
+Amanita O
+phalloides O
+. O
+
+METHODS O
+: O
+The O
+Die O
+Deutsche O
+Diabetes O
+Dialyse O
+Studie O
+is O
+a O
+prospective O
+randomized O
+placebo O
+- O
+controlled O
+trial O
+that O
+tests O
+the O
+hypothesis O
+that O
+atorvastatin O
+, O
+a O
+hydroxymethyl B
+- I
+glutaryl I
+coenzyme I
+A I
+reductase I
+inhibitor O
+, O
+decreases O
+the O
+rate O
+of O
+cardiovascular O
+mortality O
+and O
+of O
+nonfatal O
+myocardial O
+infarction O
+in O
+patients O
+with O
+type O
+2 O
+diabetes O
+who O
+have O
+been O
+on O
+hemodialysis O
+treatment O
+for O
+no O
+more O
+than O
+two O
+years O
+. O
+
+There O
+was O
+no O
+significant O
+correlation O
+between O
+serum O
+amiodarone O
+or O
+desethylamiodarone O
+levels O
+and O
+dosage O
+of O
+amiodarone O
+. O
+
+The O
+effect O
+of O
+monaural O
+middle O
+ear O
+destruction O
+on O
+postnatal O
+development O
+of O
+mouse O
+inferior O
+colliculus O
+. O
+
+This O
+unusual O
+behaviour O
+may O
+be O
+explained O
+by O
+the O
+18 B
+amino I
+acid I
+- I
+long I
+CDR I
+- I
+H3 I
+and O
+could O
+be O
+of O
+value O
+in O
+the O
+design O
+of O
+' O
+single O
+domain O
+' O
+antibodies O
+. O
+
+A O
+definitive O
+answer O
+to O
+the O
+question O
+must O
+come O
+from O
+large O
+scale O
+mortality O
+studies O
+of O
+patients O
+in O
+whom O
+the O
+risk O
+/ O
+benefit O
+ratio O
+of O
+thrombolysis O
+is O
+not O
+unacceptably O
+high O
+, O
+in O
+whom O
+electrocardiographic O
+criteria O
+of O
+infarction O
+are O
+unequivocal O
+, O
+and O
+in O
+whom O
+treatment O
+can O
+be O
+initiated O
+early O
+after O
+the O
+onset O
+of O
+symptoms O
+with O
+regimens O
+that O
+will O
+induce O
+not O
+only O
+early O
+recanalization O
+, O
+but O
+also O
+sustained O
+patency O
+in O
+infarct O
+- O
+related O
+arteries O
+. O
+
+Parameters O
+of O
+sperm O
+quality O
+were O
+evaluated O
+before O
+and O
+after O
+freezing O
+/ O
+thawing O
+. O
+
+It O
+has O
+also O
+been O
+previously O
+demonstrated O
+that O
+LPS O
+treatment O
+of O
+splenic O
+B O
+cells O
+from O
+athymic O
+mice O
+results O
+in O
+a O
+decrease O
+in O
+steady O
+state O
+mRNA O
+encoding O
+the O
+A B
+alpha I
+class I
+II I
+protein I
+. O
+
+Amongst O
+53 O
+" O
+inoperable O
+" O
+( O
+T4 O
+, O
+N0 O
+, O
+N1 O
+, O
+T O
+. O
+, O
+N2 O
+, O
+N3 O
+) O
+cases O
+, O
+5 O
+( O
+10 O
+% O
+) O
+had O
+a O
+positive O
+scan O
+and O
+5 O
+a O
+doubtful O
+scan O
+. O
+
+Chemical O
+structure O
+of O
+antibiotic O
+SF O
+- O
+837 O
+. O
+
+Aspirin O
+therapy O
+in O
+the O
+rheumatic O
+diseases O
+. O
+
+Is O
+conventional O
+sperm O
+analysis O
+of O
+any O
+use O
+? O
+
+The O
+computerised O
+records O
+of O
+867 O
+couples O
+were O
+used O
+to O
+investigate O
+the O
+prognostic O
+significance O
+of O
+semen O
+volume O
+, O
+motility O
+, O
+density O
+and O
+morphology O
+. O
+
+It O
+was O
+observed O
+that O
+muscle O
+infarction O
+in O
+the O
+IPC O
+( O
+24 O
++ O
+/ O
+- O
+2 O
+% O
+) O
+and O
+preischemic O
+LMK O
+( O
+21 O
++ O
+/ O
+- O
+2 O
+% O
+) O
+groups O
+were O
+smaller O
+( O
+P O
+< O
+0 O
+. O
+05 O
+) O
+than O
+that O
+in O
+the O
+control O
+( O
+42 O
++ O
+/ O
+- O
+2 O
+% O
+) O
+. O
+
+High O
+- O
+affinity O
+binding O
+was O
+also O
+observed O
+with O
+recombinant B
+SH2 I
+domains I
+from O
+v B
+- I
+src I
+and O
+v B
+- I
+fps I
+, O
+raising O
+the O
+possibility O
+of O
+protein O
+- O
+protein O
+interactions O
+between O
+various O
+members O
+of O
+the O
+cytoplasmic B
+PTK I
+family I
+. O
+
+Mutational O
+analysis O
+of O
+the O
+putative O
+effector O
+domain O
+of O
+the O
+GTP B
+- I
+binding I
+Ypt1 I
+protein I
+in I
+yeast I
+suggests O
+specific O
+regulation O
+by O
+a O
+novel O
+GAP B
+activity O
+. O
+
+The O
+interaction O
+obtained O
+with O
+DBM O
+scores O
+was O
+further O
+qualified O
+by O
+a O
+three O
+- O
+way O
+interaction O
+that O
+limited O
+this O
+pattern O
+to O
+participants O
+scoring O
+higher O
+on O
+self O
+- O
+deception O
+. O
+
+The O
+broad O
+range O
+protein B
+tyrosine I
+kinase I
+inhibitor O
+genistein O
+and O
+the O
+phosphatidylinositol B
+3 I
+- I
+kinase I
+inhibitors O
+wortmannin O
+and O
+LY O
+294002 O
+( O
+2 O
+- O
+( O
+4 O
+- O
+morpholinyl O
+) O
+- O
+8 O
+- O
+phenyl O
+- O
+4H O
+- O
+1 O
+- O
+benzopyran O
+- O
+4 O
+- O
+one O
+) O
+also O
+blocked O
+adenosine B
+A3 I
+receptor I
+stimulation O
+of O
+p42 B
+/ O
+p44 B
+MAPK O
+. O
+
+Surprisingly O
+, O
+although O
+Mist1 B
+binds O
+to O
+E O
+- O
+boxes O
+in O
+vivo O
+, O
+the O
+Mist1 B
+protein I
+lacks O
+a O
+functional O
+transcription O
+activation O
+domain O
+. O
+
+As O
+exogenously O
+expressed O
+PKR B
+can O
+form O
+heterodimers O
+with O
+endogenous O
+PKR B
+, O
+the O
+results O
+obtained O
+on O
+the O
+functional O
+characterization O
+of O
+mutant O
+forms O
+of O
+PKR B
+have O
+been O
+taken O
+with O
+caution O
+. O
+
+Orlistat O
+is O
+a O
+specific O
+lipase B
+inhibitor O
+that O
+impairs O
+fat O
+absorption O
+, O
+thereby O
+reducing O
+fat O
+uptake O
+. O
+
+The O
+metalloproteinase O
+mediating O
+Met O
+cleavage O
+was O
+specifically O
+inhibited O
+by O
+the O
+tissue B
+inhibitor I
+of I
+metalloproteinases I
+( I
+TIMP I
+) I
+- I
+3 I
+, O
+but O
+not O
+by O
+TIMP B
+- I
+1 I
+or O
+TIMP B
+- I
+2 I
+. O
+
+This O
+demonstrates O
+a O
+relative O
+independence O
+of O
+the O
+given O
+synchronizer O
+of O
+rhythmicity O
+at O
+a O
+tissue O
+level O
+from O
+any O
+influence O
+of O
+the O
+higher O
+regulatory O
+center O
+. O
+
+It O
+is O
+also O
+conceivable O
+that O
+elevated O
+insulin B
+levels O
+may O
+cause O
+hypertriglyceridaemia O
+and O
+possibly O
+other O
+abnormalities O
+of O
+lipid O
+metabolism O
+. O
+
+Flicker O
+thresholds O
+were O
+measured O
+from O
+1 O
+to O
+40 O
+Hz O
+with O
+a O
+vertical O
+- O
+line O
+target O
+used O
+for O
+the O
+asynchrony O
+thresholds O
+. O
+
+The O
+clr1 B
+locus I
+regulates O
+the O
+expression O
+of O
+the O
+cryptic B
+mating I
+- I
+type I
+loci I
+of O
+fission O
+yeast O
+. O
+
+Use O
+of O
+ELISAs O
+for O
+the O
+diagnosis O
+of O
+canine O
+atopy O
+. O
+
+A O
+clinical O
+study O
+. O
+
+METHODS O
+. O
+
+Instead O
+, O
+HBx B
+is O
+shown O
+to O
+activate O
+the O
+cyclin B
+A I
+promoter I
+, O
+induce O
+cyclin B
+A I
+- O
+cyclin B
+- I
+dependent I
+kinase I
+2 I
+complexes O
+, O
+and O
+promote O
+cycling O
+of O
+growth O
+- O
+arrested O
+cells O
+into O
+G1 O
+through O
+a O
+pathway O
+involving O
+activation O
+of O
+Src B
+tyrosine I
+kinases I
+. O
+
+Growth B
+hormone I
+exerts O
+its O
+effects O
+on O
+the O
+ovarian O
+follicular O
+cycle O
+directly O
+or O
+by O
+local O
+production O
+of O
+insulin B
+- I
+like I
+growth I
+factor I
+1 I
+( O
+IGF B
+- I
+1 I
+) O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+evaluate O
+the O
+impact O
+of O
+the O
+ESRD O
+treatment O
+modality O
+on O
+the O
+quality O
+of O
+life O
+in O
+patients O
+with O
+Type O
+I O
+( O
+insulin B
+- O
+dependent O
+) O
+diabetes O
+mellitus O
+. O
+
+The O
+subjects O
+were O
+started O
+on O
+indomethacin O
+25 O
+mg O
+thrice O
+daily O
+. O
+
+A O
+Buddhist O
+view O
+of O
+abortion O
+. O
+
+The O
+arterial O
+blood O
+pressure O
+was O
+measured O
+by O
+using O
+bloody O
+method O
+in O
+anesthizied O
+animals O
+. O
+
+After O
+15 O
+min O
+of O
+hemorrhage O
+the O
+cardiovascular O
+parameters O
+were O
+the O
+same O
+in O
+fed O
+and O
+starved O
+animals O
+, O
+but O
+at O
+45 O
+min O
+striking O
+differences O
+were O
+observed O
+. O
+
+Decidual B
+/ I
+trophoblast I
+prolactin I
+- I
+related I
+protein I
+: O
+characterization O
+of O
+gene O
+structure O
+and O
+cell O
+- O
+specific O
+expression O
+. O
+
+Fluorescence O
+in O
+situ O
+hybridization O
+was O
+used O
+to O
+investigate O
+the O
+physical O
+distribution O
+and O
+revealed O
+that O
+both O
+retrotransposon O
+families O
+are O
+present O
+on O
+all O
+sugar O
+beet O
+chromosomes O
+and O
+largely O
+excluded O
+from O
+chromosomal O
+regions O
+harbouring O
+the O
+18S B
+- O
+5 B
+. I
+8S I
+- O
+25S B
+rRNA O
+genes O
+. O
+
+Plasma O
+NE O
+and O
+E O
+increased O
+to O
+significantly O
+higher O
+values O
+after O
+15 O
+min O
+in O
+the O
+young O
+subjects O
+: O
+1 O
+. O
+68 O
++ O
+/ O
+- O
+0 O
+. O
+18 O
+vs O
+. O
+
+An O
+insertion O
+sequence O
+element O
+( O
+IS1170 B
+) O
+was O
+identified O
+upstream O
+of O
+the O
+nimC B
+gene I
+. O
+
+The O
+organelles O
+synthesize O
+their O
+own O
+set O
+of O
+Fe B
+/ I
+S I
+proteins I
+, O
+and O
+they O
+initiate O
+the O
+generation O
+of O
+extramitochondrial O
+Fe B
+/ I
+S I
+proteins I
+. O
+
+Most O
+significantly O
+, O
+the O
+cyclin B
+E I
+- O
+Cdk2 B
+complex O
+is O
+maximally O
+active O
+at O
+the O
+G1 O
+/ O
+S O
+transition O
+, O
+and O
+overexpression O
+of O
+cyclin B
+E I
+decreases O
+the O
+time O
+it O
+takes O
+the O
+cell O
+to O
+complete O
+G1 O
+and O
+enter O
+S O
+phase O
+. O
+
+A O
+genomic O
+clone O
+of O
+the O
+chicken B
+osteopontin I
+- I
+encoding I
+gene I
+( O
+opn B
+) O
+was O
+isolated O
+and O
+found O
+to O
+be O
+organized O
+as O
+follows O
+: O
+an O
+untranslated O
+5 O
+' O
+exon O
+; O
+a O
+signal O
+peptide O
+; O
+a O
+recognition O
+sequence O
+for O
+phosphorylation O
+by O
+casein B
+kinase I
+II I
+; O
+a O
+domain O
+containing O
+a O
+possible O
+O O
+- O
+linkage O
+site O
+for O
+glycosylation O
+; O
+a O
+second O
+casein B
+kinase I
+II I
+phosphorylation I
+site O
+; O
+an O
+exon O
+containing O
+three O
+functional O
+regions O
+, O
+the O
+poly O
+- O
+Asp O
+sequence O
+of O
+seven O
+consecutive O
+Asp O
+residues O
+, O
+the O
+RGD B
+integrin I
+recognition I
+site I
+and O
+a O
+potential O
+N O
+
+- O
+linkage O
+site O
+for O
+glycosylation O
+; O
+and O
+a O
+large O
+C O
+- O
+terminal O
+exon O
+which O
+also O
+contains O
+a O
+potential O
+N O
+- O
+linkage O
+site O
+for O
+glycosylation O
+. O
+
+However O
+, O
+neither O
+SF B
+- I
+1 I
+nor O
+NGF B
+- I
+IB I
+alone O
+, O
+binding O
+as O
+monomers O
+, O
+increases O
+transcription O
+. O
+
+Satisfactory O
+correlation O
+was O
+also O
+obtained O
+between O
+the O
+in O
+vivo O
+and O
+the O
+in O
+vitro O
+results O
+. O
+
+Structural O
+organization O
+of O
+the O
+human B
+Elk1 I
+gene I
+and O
+its O
+processed O
+pseudogene O
+Elk2 B
+. O
+
+After O
+cumulative O
+occlusions O
+of O
+15 O
+, O
+30 O
+, O
+45 O
+, O
+and O
+90 O
+min O
+, O
+transmural O
+needle O
+biopsies O
+were O
+taken O
+from O
+the O
+ischemic O
+area O
+to O
+be O
+analyzed O
+for O
+adenine O
+nucleotides O
+, O
+nucleosides O
+, O
+creatine O
+phosphate O
+, O
+and O
+ultrastructural O
+changes O
+. O
+
+The O
+prevalence O
+of O
+ocular O
+/ O
+adnexal O
+SCC O
+was O
+significantly O
+greater O
+for O
+all O
+hair O
+colors O
+when O
+compared O
+with O
+bay O
+, O
+brown O
+, O
+or O
+black O
+( O
+P O
+less O
+than O
+0 O
+. O
+01 O
+) O
+. O
+
+Seven O
+patients O
+were O
+without O
+a O
+syndromic O
+diagnosis O
+. O
+
+In O
+treatments O
+R1 O
+and O
+R2 O
+, O
+feed O
+quality O
+was O
+restricted O
+by O
+withholding O
+concentrates O
+for O
+3 O
+and O
+4 O
+. O
+5 O
+mo O
+, O
+respectively O
+. O
+
+In O
+addition O
+, O
+while O
+GCN1 B
+is O
+required O
+in O
+vivo O
+for O
+phosphorylation O
+of O
+eIF B
+- I
+2 I
+alpha I
+by O
+GCN2 B
+, O
+cell O
+extracts O
+from O
+gcn1 B
+delta I
+strains O
+contained O
+wild O
+- O
+type O
+levels O
+of O
+GCN2 B
+eIF B
+- I
+2 I
+alpha I
+- I
+kinase I
+activity O
+. O
+
+SCOF B
+- I
+1 I
+localized O
+to O
+the O
+nucleus O
+but O
+did O
+not O
+bind O
+directly O
+to O
+either O
+C O
+- O
+repeat O
+/ O
+dehydration O
+( O
+CRT O
+/ O
+DRE O
+) O
+or O
+ABA O
+responsive O
+element O
+( O
+ABRE O
+) O
+, O
+cis O
+- O
+acting O
+DNA O
+regulatory O
+elements O
+present O
+in O
+COR B
+gene I
+promoters I
+. O
+
+On O
+the O
+basis O
+of O
+these O
+findings O
+we O
+suggest O
+that O
+the O
+acceptor O
+peptide O
+binds O
+the O
+transferase O
+in O
+a O
+beta O
+- O
+like O
+conformation O
+and O
+that O
+penultimate O
+residue O
+side O
+chain O
+steric O
+interactions O
+may O
+play O
+a O
+role O
+in O
+determining O
+extent O
+that O
+a O
+given O
+Ser O
+or O
+Thr O
+is O
+glycosylated O
+. O
+
+The O
+concentration O
+of O
+vitamin O
+B1 O
+, O
+B2 O
+and O
+B6 O
+are O
+found O
+to O
+be O
+9 O
+. O
+96 O
+, O
+9 O
+. O
+92 O
+and O
+3 O
+. O
+01 O
+mg O
+, O
+respectively O
+in O
+240 O
+mg O
+of O
+capsule O
+powder O
+of O
+a O
+standard O
+company O
+( O
+name O
+has O
+not O
+been O
+disclosed O
+due O
+to O
+secrecy O
+purpose O
+) O
+. O
+
+Polymorphisms O
+in O
+the O
+CCR5 B
+genes I
+of O
+African O
+green O
+monkeys O
+and O
+mice O
+implicate O
+specific O
+amino O
+acids O
+in O
+infections O
+by O
+simian O
+and O
+human O
+immunodeficiency O
+viruses O
+. O
+
+Furthermore O
+, O
+we O
+detect O
+hCoch B
+- I
+5B2 I
+on O
+three O
+overlapping O
+YACs O
+, O
+two O
+of O
+which O
+also O
+contain O
+one O
+of O
+the O
+markers O
+linked O
+to O
+DFNA9 B
+. O
+
+mCoch B
+- I
+5B2 I
+was O
+genetically O
+mapped O
+in O
+the O
+mouse O
+to O
+chromosome O
+12 O
+, O
+in O
+a O
+region O
+of O
+homologous O
+synteny O
+with O
+human O
+14q11 O
+. O
+2 O
+- O
+q13 O
+, O
+which O
+contains O
+the O
+asp1 B
+( O
+audiogenic B
+seizure I
+prone I
+) I
+locus I
+in O
+the O
+mouse O
+. O
+
+Absence O
+of O
+nitroso O
+formation O
+from O
+( O
+14C O
+) O
+methomyl O
+and O
+sodium O
+nitrite O
+under O
+simulated O
+stomach O
+conditions O
+. O
+
+Although O
+no O
+detectable O
+phenotypes O
+are O
+associated O
+with O
+a O
+disruption O
+allele O
+of O
+ABP1 B
+, O
+mutations O
+that O
+create O
+a O
+requirement O
+for O
+this O
+protein O
+have O
+now O
+been O
+isolated O
+in O
+the O
+previously O
+identified O
+gene B
+SAC6 I
+and O
+in O
+two O
+new O
+genes O
+, O
+SLA1 B
+and O
+SLA2 B
+. O
+
+The O
+local O
+median O
+scores O
+( O
+ranges O
+) O
+of O
+the O
+above O
+tests O
+were O
+as O
+follows O
+- O
+AMT O
+: O
+9 O
+( O
+6 O
+- O
+10 O
+) O
+; O
+CMMS O
+: O
+25 O
+( O
+16 O
+- O
+28 O
+) O
+; O
+SBT O
+: O
+2 O
+( O
+0 O
+- O
+10 O
+) O
+; O
+WL O
+- O
+i O
+: O
+17 O
+( O
+8 O
+- O
+27 O
+) O
+; O
+WL O
+- O
+d O
+: O
+5 O
+( O
+0 O
+- O
+10 O
+) O
+; O
+WL O
+- O
+r O
+: O
+9 O
+( O
+1 O
+- O
+10 O
+) O
+; O
+ST O
+: O
+13 O
+( O
+6 O
+- O
+25 O
+) O
+; O
+BNT O
+: O
+14 O
+( O
+10 O
+- O
+15 O
+) O
+; O
+CPT O
+: O
+1 O
+( O
+0 O
+- O
+3 O
+) O
+; O
+BDT O
+: O
+19 O
+( O
+0 O
+- O
+42 O
+) O
+; O
+OAT O
+: O
+
+20 O
+( O
+3 O
+- O
+33 O
+) O
+. O
+
+Antigen O
+dose O
+- O
+response O
+curves O
+were O
+drawn O
+, O
+and O
+the O
+cumulative O
+dose O
+required O
+for O
+a O
+35 O
+% O
+reduction O
+in O
+specific O
+airway O
+conductance O
+was O
+calculated O
+and O
+designated O
+Provocation O
+Dose O
+( O
+PD35 O
+) O
+. O
+
+Cross O
+- O
+talk O
+between O
+transcription B
+factors I
+NF I
+- I
+kappa I
+B I
+and O
+C B
+/ I
+EBP I
+in O
+the O
+transcriptional O
+regulation O
+of O
+genes O
+. O
+
+Elective O
+replacement O
+of O
+the O
+aortic O
+root O
+in O
+Marfan O
+' O
+s O
+syndrome O
+. O
+
+The O
+detergent O
+- O
+solubilized O
+complex O
+oxidizes O
+caldariella O
+quinol O
+at O
+high O
+rates O
+and O
+is O
+completely O
+inhibited O
+by O
+cyanide O
+and O
+by O
+quinolone O
+analogs O
+, O
+potent O
+inhibitors O
+of O
+quinol B
+oxidases I
+. O
+
+We O
+have O
+characterized O
+a O
+new O
+cDNA O
+, O
+33k B
+- I
+6 I
+, O
+potentially O
+encoding O
+a O
+tobacco B
+33 I
+kDa I
+chloroplast I
+RNP I
+( O
+cp33 B
+) O
+homologue O
+. O
+
+The O
+regions O
+encoding O
+the O
+mature O
+proteinases O
+were O
+cloned O
+into O
+an O
+expression O
+vector O
+and O
+recombinant O
+protein O
+produced O
+in O
+Escherichia O
+coli O
+. O
+
+Furthermore O
+, O
+CL100 O
+suppresses O
+the O
+[ B
+val12 I
+] I
+ras I
+- O
+induced O
+activation O
+of O
+MAP B
+kinase I
+in O
+a O
+cell O
+- O
+free O
+system O
+from O
+Xenopus O
+oocytes O
+. O
+
+The O
+Xenopus B
+homeobox I
+gene I
+twin B
+mediates O
+Wnt B
+induction O
+of O
+goosecoid B
+in O
+establishment O
+of O
+Spemann O
+' O
+s O
+organizer O
+. O
+
+Between O
+1988 O
+and O
+1994 O
+, O
+data O
+from O
+3 O
+large O
+sites O
+revealed O
+a O
+3 O
+- O
+5 O
+fold O
+increase O
+in O
+the O
+prevalence O
+of O
+antidepressant O
+( O
+ATD O
+) O
+treatment O
+for O
+U O
+. O
+S O
+. O
+youths O
+aged O
+2 O
+- O
+19 O
+years O
+. O
+
+The O
+vaccinia O
+virus O
+D6R B
+open O
+reading O
+frame O
+encodes O
+the O
+small O
+subunit O
+of O
+the O
+heterodimeric B
+vaccinia I
+virus I
+early I
+transcription I
+factor I
+( O
+VETF B
+) O
+that O
+activates O
+transcription O
+of O
+early B
+genes I
+in O
+vitro O
+. O
+
+The O
+Sensititre O
+MIC O
+panels O
+containing O
+meropenem O
+offer O
+a O
+convenient O
+and O
+valid O
+alternative O
+to O
+the O
+NCCLS O
+reference O
+method O
+for O
+the O
+susceptibility O
+testing O
+of O
+potential O
+pathogens O
+likely O
+to O
+be O
+recovered O
+from O
+mixed O
+infections O
+. O
+
+Recognition O
+of O
+DNA O
+by O
+single O
+- O
+chain O
+derivatives O
+of O
+the O
+phage B
+434 I
+repressor I
+: O
+high O
+affinity O
+binding O
+depends O
+on O
+both O
+the O
+contacted O
+and O
+non O
+- O
+contacted O
+base O
+pairs O
+. O
+
+The O
+paper O
+calls O
+for O
+standardized O
+question O
+formats O
+and O
+a O
+centralized O
+body O
+to O
+monitor O
+changes O
+in O
+these O
+parameters O
+of O
+sexual O
+behaviour O
+. O
+
+We O
+show O
+that O
+GCNF B
+binds O
+to O
+one O
+of O
+the O
+two O
+DRO O
+sequences O
+in O
+the O
+Prm1 B
+promoter I
+, O
+and O
+to O
+the O
+DRO O
+sequence O
+in O
+the O
+Prm2 B
+promoter I
+in O
+a O
+specific O
+manner O
+. O
+
+139La O
+NQR O
+relaxation O
+and O
+microSR O
+study O
+of O
+Zn O
+- O
+doping O
+effects O
+in O
+La2CuO4 O
+. O
+
+The O
+data O
+also O
+suggest O
+that O
+gamma B
+CACCC I
+box I
+binding I
+factors I
+mediate O
+LCR B
+- I
+gamma I
+interactions O
+which O
+normally O
+enhance O
+gamma B
+- I
+globin I
+and O
+suppress O
+beta B
+- I
+globin I
+gene I
+expression O
+in O
+fetal O
+erythroid O
+cells O
+. O
+
+However O
+, O
+the O
+in O
+vivo O
+attachment O
+strength O
+of O
+the O
+CSTi O
+- O
+2 O
+coating O
+was O
+comparable O
+both O
+to O
+CSTi O
+- O
+1 O
+and O
+to O
+an O
+HA B
+- O
+coated O
+control O
+after O
+8 O
+weeks O
+. O
+
+Octamer O
+recognition O
+is O
+mediated O
+by O
+the O
+POU B
+domain I
+, O
+a O
+conserved O
+structural O
+motif O
+which O
+- O
+- O
+like O
+the O
+zinc O
+finger O
+and O
+leucine O
+zipper O
+- O
+- O
+defines O
+a O
+family O
+of O
+related O
+transcription O
+factors O
+. O
+
+All O
+testosterone O
+treatments O
+raised O
+plasma O
+testosterone O
+concentrations O
+above O
+control O
+and O
+pretreatment O
+levels O
+( O
+testosterone O
+and O
+synovex O
++ O
+testosterone O
+> O
+synovex O
+> O
+control O
+; O
+all O
+P O
+< O
+0 O
+. O
+05 O
+) O
+. O
+
+Lifestyle O
+characteristics O
+were O
+ascertained O
+by O
+a O
+self O
+- O
+administered O
+questionnaire O
+. O
+
+The O
+major O
+promoter O
+element O
+of O
+the O
+Xenopus B
+laevis I
+5S I
+RNA I
+gene I
+is O
+located O
+within O
+the O
+transcribed O
+region O
+of O
+the O
+gene O
+and O
+forms O
+the O
+binding O
+site O
+for O
+the O
+transcription B
+initiation I
+factor I
+TFIIIA I
+. O
+
+During O
+each O
+step O
+of O
+the O
+pulse O
+infusion O
+the O
+osteocalcin B
+responses O
+to O
+changes O
+in O
+CaI O
+in O
+general O
+were O
+parallel O
+to O
+the O
+changes O
+in O
+PTH B
+( O
+r O
+= O
+0 O
+. O
+462 O
+; O
+P O
+= O
+0 O
+. O
+02 O
+) O
+and O
+were O
+inversely O
+correlated O
+to O
+CaI O
+( O
+r O
+= O
+- O
+0 O
+. O
+562 O
+; O
+P O
+= O
+0 O
+. O
+003 O
+) O
+. O
+
+The O
+gamma B
+- I
+GCS I
+gene I
+is O
+expressed O
+ubiquitously O
+and O
+induced O
+coordinately O
+with O
+NAD B
+( I
+P I
+) I
+H I
+: I
+quinone I
+oxidoreductase I
+( I
+1 I
+) I
+( O
+NQO1 B
+) O
+and O
+glutathione B
+S I
+- I
+transferase I
+Ya I
+( O
+GST B
+Ya I
+) O
+in O
+response O
+to O
+xenobiotics O
+and O
+antioxidants O
+. O
+
+Interestingly O
+, O
+the O
+expression O
+of O
+Id4 B
+in O
+Sertoli O
+cells O
+is O
+only O
+detectable O
+after O
+stimulation O
+with O
+FSH B
+or O
+cAMP O
+. O
+
+We O
+determined O
+their O
+N O
+- O
+terminal O
+amino O
+acid O
+sequence O
+and O
+found O
+that O
+these O
+polypeptides O
+were O
+CotT B
+, O
+YeeK O
+, O
+YxeE O
+, O
+CotF B
+, O
+YrbA O
+( O
+31 O
+and O
+45 O
+kDa O
+) O
+, O
+and O
+SpoIVA B
+, O
+respectively O
+. O
+
+The O
+effect O
+of O
+betamethasone O
+on O
+duodenal O
+calcium O
+absorption O
+and O
+1 O
+, O
+25 O
+- O
+dihydroxy O
+vitamin O
+D3 O
+production O
+in O
+the O
+chick O
+. O
+
+Furthermore O
+, O
+it O
+is O
+also O
+established O
+that O
+serine O
+phosphorylation O
+of O
+STAT5a B
+transactivation I
+domain I
+, O
+via O
+the O
+MAPK B
+pathway O
+, O
+is O
+a O
+means O
+of O
+modifying O
+GH B
+- O
+induced O
+transcriptional O
+activation O
+. O
+
+ES O
+cells O
+in O
+which O
+the O
+gene O
+for O
+the O
+erythroid B
+transcription I
+factor I
+GATA I
+- I
+1 I
+has O
+been O
+disrupted O
+fail O
+to O
+produce O
+mature O
+erythroid O
+cells O
+either O
+in O
+vivo O
+or O
+in O
+vitro O
+. O
+
+Two O
+conserved O
+motifs O
+, O
+W89RKRRY94 O
+and O
+P156KKIKP161 O
+, O
+seemed O
+to O
+act O
+as O
+nuclear O
+addressing O
+signals O
+. O
+
+It O
+is O
+concluded O
+that O
+the O
+predominant O
+action O
+of O
+LSD O
+on O
+the O
+female O
+copulatory O
+response O
+is O
+not O
+mediated O
+by O
+increased O
+dopamine B
+receptor I
+activity O
+but O
+that O
+the O
+LSD O
+effect O
+might O
+be O
+modulated O
+by O
+decreased O
+dopaminergic O
+activity O
+. O
+
+Therefore O
+, O
+in O
+VDR B
+- O
+mediated O
+transcriptional O
+activation O
+, O
+1 O
+, O
+25 O
+( O
+OH O
+) O
+2D3 O
+binding O
+to O
+VDR B
+alters O
+the O
+conformation O
+of O
+the O
+ligand O
+binding O
+domain O
+such O
+that O
+it O
+: O
+( O
+i O
+) O
+engages O
+in O
+strong O
+heterodimerization O
+with O
+RXR B
+to O
+facilitate O
+VDRE O
+binding O
+, O
+( O
+ii O
+) O
+influences O
+the O
+RXR B
+ligand O
+binding O
+domain O
+such O
+that O
+it O
+is O
+resistant O
+to O
+the O
+binding O
+of O
+9 O
+- O
+cis O
+RA O
+but O
+active O
+in O
+recruiting O
+coactivator O
+to O
+its O
+AF O
+- O
+2 O
+and O
+( O
+iii O
+) O
+presents O
+the O
+AF O
+- O
+2 O
+region O
+in O
+VDR B
+for O
+coactivator O
+association O
+. O
+
+In O
+patients O
+, O
+750 O
+mL O
+of O
+saline O
+lowered O
+DL O
+( O
+CO O
+) O
+( O
+- O
+8 O
+% O
+, O
+P O
+< O
+0 O
+. O
+01 O
+versus O
+baseline O
+) O
+, O
+D O
+( O
+M O
+) O
+( O
+- O
+10 O
+% O
+, O
+P O
+< O
+0 O
+. O
+01 O
+versus O
+baseline O
+) O
+, O
+aldosterone O
+( O
+- O
+29 O
+% O
+, O
+P O
+< O
+0 O
+. O
+01 O
+versus O
+baseline O
+) O
+, O
+renin B
+( O
+- O
+52 O
+% O
+, O
+P O
+< O
+0 O
+. O
+01 O
+versus O
+baseline O
+) O
+, O
+and O
+hematocrit O
+( O
+- O
+6 O
+% O
+, O
+P O
+< O
+0 O
+. O
+05 O
+versus O
+baseline O
+) O
+and O
+increased O
+V O
+( O
+C O
+) O
+( O
+20 O
+% O
+, O
+P O
+< O
+0 O
+. O
+01 O
+versus O
+baseline O
+) O
+, O
+without O
+changing O
+rap O
+
+and O
+wpp O
+. O
+
+We O
+have O
+previously O
+identified O
+LIT1 B
+, O
+a O
+paternally O
+expressed O
+antisense O
+RNA O
+within O
+the O
+KvLQT1 B
+locus I
+through O
+a O
+positional O
+screening O
+approach O
+using O
+human O
+monochromosomal O
+hybrids O
+. O
+
+A O
+series O
+of O
+deletion O
+mutants O
+was O
+expressed O
+transiently O
+in O
+two O
+human O
+hepatocytes O
+, O
+HepG2 O
+and O
+PLC O
+. O
+
+The O
+predicted O
+amino O
+acid O
+sequence O
+of O
+the O
+FlaB2 B
+polypeptide I
+was O
+92 O
+% O
+identical O
+to O
+that O
+of O
+T B
+. I
+pallidum I
+FlaB2 I
+, O
+with O
+a O
+76 O
+% O
+identity O
+at O
+the O
+nucleotide O
+level O
+. O
+
+Comparative O
+analyses O
+indicate O
+that O
+the O
+5 O
+' O
+- O
+peripheral O
+domain O
+exhibits O
+a O
+75 O
+- O
+bp O
+length O
+polymorphism O
+near O
+sequences O
+associated O
+with O
+the O
+termination O
+of O
+the O
+H O
+- O
+strand O
+replication O
+. O
+
+The O
+survival O
+of O
+patients O
+with O
+a O
+short O
+bowel O
+, O
+even O
+if O
+they O
+need O
+long O
+- O
+term O
+parenteral O
+nutrition O
+, O
+is O
+good O
+. O
+
+Thus O
+, O
+cross O
+- O
+resistance O
+between O
+fluoroquinolones O
+was O
+shown O
+for O
+both O
+enterococci O
+and O
+MRSA O
+. O
+
+The O
+5 O
+' O
+ends O
+of O
+the O
+P B
+and O
+O B
+gene I
+mRNAs O
+are O
+separated O
+by O
+109 O
+nucleotide O
+pairs O
+in O
+the O
+DNA O
+template O
+. O
+
+Using O
+community O
+development O
+approaches O
+. O
+
+Biol O
+. O
+
+We O
+have O
+cloned O
+the O
+cDNA O
+for O
+the O
+SLBP B
+from O
+humans I
+, O
+mice I
+, O
+and O
+frogs O
+, O
+using O
+the O
+recently O
+developed O
+yeast O
+three O
+- O
+hybrid O
+system O
+. O
+
+Along O
+with O
+these O
+species O
+, O
+F O
+. O
+graminearum O
+group O
+2 O
+( O
+ZON O
+, O
+DON O
+and O
+/ O
+or O
+3AcDON O
+or O
+15AcDON O
+) O
+; O
+F O
+. O
+chlamydosporum O
+; O
+F O
+. O
+acuminatum O
+( O
+type O
+- O
+A O
+trichothecene O
+derivatives O
+) O
+; O
+and O
+F O
+. O
+semitectum O
+were O
+often O
+found O
+to O
+be O
+associated O
+. O
+
+TGF B
+- I
+beta1 I
+induced O
+phosphorylation O
+of O
+Smad2 B
+and O
+Smad3 B
+in O
+Mv1Lu O
+mink O
+lung O
+epithelial O
+cells O
+. O
+
+There O
+is O
+little O
+supportive O
+evidence O
+that O
+ACE B
+inhibitors O
+( O
+captopril O
+or O
+enalapril O
+) O
+are O
+teratogenic O
+. O
+
+Thus O
+, O
+the O
+potential O
+induction O
+of O
+this O
+gene O
+rearrangement O
+by O
+E1A B
+gene O
+therapy O
+is O
+unlikely O
+to O
+be O
+clinically O
+significant O
+in O
+the O
+treatment O
+of O
+advanced O
+malignant O
+disease O
+. O
+
+Although O
+the O
+cDNAs O
+of O
+HMG B
+- I
+14 I
+and O
+HMG B
+- I
+17 I
+do O
+not O
+cross O
+- O
+hybridize O
+, O
+they O
+have O
+several O
+similar O
+structural O
+features O
+: O
+the O
+open O
+reading O
+frame O
+comprises O
+only O
+23 O
+% O
+of O
+the O
+transcripts O
+, O
+the O
+5 O
+' O
+- O
+untranslated O
+region O
+is O
+extremely O
+GC O
+rich O
+whereas O
+the O
+3 O
+' O
+- O
+untranslated O
+region O
+is O
+unusually O
+long O
+and O
+AT O
+rich O
+. O
+
+Previously O
+, O
+we O
+reported O
+the O
+identification O
+of O
+a O
+23 O
+- O
+kD O
+protein O
+that O
+interacts O
+with O
+zyxin B
+in O
+vitro O
+( O
+Sadler O
+et O
+al O
+. O
+, O
+1992 O
+) O
+. O
+
+If O
+vascular O
+induction O
+between O
+a O
+vascular O
+carrier O
+and O
+the O
+selected O
+jejunal O
+segment O
+is O
+done O
+as O
+a O
+kind O
+of O
+flap O
+prefabrication O
+, O
+the O
+jejunal O
+interposition O
+flap O
+can O
+be O
+used O
+without O
+the O
+need O
+for O
+complex O
+microsurgery O
+. O
+
+In O
+gel O
+mobility O
+shift O
+assays O
+, O
+high O
+binding O
+activities O
+of O
+ATPC B
+- I
+2 I
+and O
+low O
+binding O
+activities O
+of O
+CBF B
+were O
+observed O
+with O
+nuclear O
+extracts O
+from O
+tissue O
+with O
+low O
+AtpC B
+expression O
+levels O
+, O
+and O
+the O
+opposite O
+was O
+observed O
+with O
+extracts O
+from O
+tissues O
+with O
+high O
+AtpC B
+expression O
+levels O
+. O
+
+Activation O
+of O
+tyrosine B
+kinase I
+- I
+containing I
+receptors I
+, O
+heterotrimeric B
+G I
+proteins I
+, O
+and O
+protein B
+kinase I
+C I
+enhanced O
+the O
+activities O
+of O
+both O
+MEK B
+isoforms I
+in O
+293 O
+and O
+PC12 O
+cells O
+. O
+
+The O
+Fugu B
+rubripes I
+( O
+Fugu B
+) O
+gene O
+fragment O
+was O
+used O
+to O
+isolate O
+the O
+GH B
+gene I
+from O
+a O
+Fugu O
+genomic O
+library O
+. O
+
+An O
+in O
+vitro O
+' O
+glass O
+stomach O
+' O
+( O
+containing O
+various O
+volumes O
+of O
+hydrochloric O
+acid O
+[ O
+HCl O
+] O
+and O
+ammonium O
+chloride O
+[ O
+NH4Cl O
+] O
+) O
+was O
+used O
+to O
+evaluate O
+the O
+means O
+of O
+increasing O
+' O
+gastric O
+' O
+pH O
+to O
+that O
+of O
+the O
+NH4 O
++ O
+- O
+- O
+> O
+NH3 O
+transition O
+that O
+occurs O
+significantly O
+at O
+pH O
+9 O
+. O
+24 O
+. O
+
+Acyclovir O
+( O
+3 O
+% O
+ointment O
+) O
+used O
+topically O
+one O
+to O
+five O
+times O
+a O
+day O
+on O
+acute O
+ocular O
+HSV O
+infection O
+gave O
+beneficial O
+results O
+as O
+measured O
+by O
+a O
+reduction O
+in O
+corneal O
+involvement O
+, O
+conjunctivitis O
+, O
+iritis O
+, O
+and O
+corneal O
+clouding O
+. O
+
+We O
+have O
+documented O
+previously O
+that O
+glucocorticoid O
+hormones O
+modulate O
+the O
+posttranslational O
+localization O
+of O
+cell O
+surface O
+mouse B
+mammary I
+tumor I
+virus I
+( I
+MMTV I
+) I
+glycoproteins I
+in O
+the O
+viral O
+- O
+infected O
+M1 O
+. O
+54 O
+rat O
+HTC O
+hepatoma O
+cell O
+line O
+. O
+
+Partial O
+proteolysis O
+of O
+cell O
+surface O
+- O
+iodinated O
+B B
+- I
+G I
+molecules I
+generates O
+extremely O
+similar O
+patterns O
+of O
+spots O
+, O
+both O
+within O
+and O
+between O
+haplotypes O
+. O
+
+SETTING O
+: O
+University O
+research O
+laboratory O
+. O
+
+There O
+was O
+a O
+57 O
+% O
+reduction O
+in O
+IGF B
+IR I
+mRNA I
+levels O
+in O
+clone O
+CA9 O
+after O
+confluence O
+compared O
+with O
+clone O
+ME10 O
+. O
+
+Oligomers O
+corresponding O
+to O
+the O
+region O
+of O
+the O
+mlc B
+- I
+1 I
+/ I
+3 I
+enhancer I
+, O
+which O
+encompasses O
+this O
+conserved O
+sequence O
+, O
+bound O
+MEF B
+- I
+2 I
+and O
+competed O
+for O
+its O
+binding O
+to O
+the O
+mck B
+enhancer I
+. O
+
+Similar O
+tissue O
+- O
+specific O
+patterns O
+are O
+observed O
+with O
+a O
+fusion O
+between O
+the O
+caufliflower B
+mosaic I
+virus I
+35S I
+RNA I
+promotor I
+and O
+the O
+GUS B
+gene I
+. O
+
+This O
+difference O
+between O
+SP B
+- I
+1 I
+and O
+SP B
+- I
+2 I
+peptides I
+was O
+not O
+due O
+to O
+their O
+differential O
+uptake O
+by O
+cell O
+, O
+since O
+approximately O
+100 O
+times O
+more O
+SP B
+- I
+2 I
+peptide I
+could O
+be O
+found O
+in O
+cytoplasmic O
+extracts O
+than O
+SP B
+- I
+1 I
+peptide I
+in O
+experiments O
+using O
+radiolabeled O
+peptides O
+. O
+
+One O
+function O
+of O
+p53 B
+is O
+in O
+regulating O
+cell O
+cycle O
+check O
+- O
+point O
+control O
+after O
+DNA O
+damage O
+. O
+
+We O
+used O
+event O
+- O
+related O
+functional O
+magnetic O
+resonance O
+imaging O
+( O
+fMRI O
+) O
+during O
+a O
+cued O
+spatial O
+- O
+attention O
+task O
+to O
+dissociate O
+brain O
+activity O
+related O
+to O
+attentional O
+control O
+from O
+that O
+related O
+to O
+selective O
+processing O
+of O
+target O
+stimuli O
+. O
+
+BACKGROUND O
+: O
+The O
+extract O
+of O
+medicinal O
+plants O
+containing O
+curcumin O
+is O
+traditionally O
+believed O
+to O
+have O
+a O
+positive O
+contraction O
+effect O
+on O
+the O
+human O
+gall O
+- O
+bladder O
+. O
+
+Apoptosis O
+triggered O
+through O
+Fas B
+and O
+F B
+/ I
+F I
+was O
+inhibited O
+by O
+coexpression O
+of O
+CrmA B
+and O
+p35 B
+, O
+but O
+not O
+Bcl B
+- I
+xL I
+. O
+
+The O
+product O
+of O
+one O
+gene O
+, O
+Bv80 B
+, O
+has O
+a O
+single O
+divergent O
+copy O
+of O
+a O
+sequence O
+of O
+149 O
+amino O
+acids O
+( O
+approx O
+. O
+
+The O
+1031 O
+- O
+bp O
+wild I
+- I
+type I
+HIT1 I
+DNA I
+which O
+contained O
+an O
+open O
+reading O
+frame O
+encoding O
+a O
+protein O
+of O
+164 O
+amino O
+acids O
+and O
+the O
+AGG B
+arginine I
+tRNA I
+gene I
+complemented O
+all O
+hit1 B
+- I
+1 I
+mutant I
+phenotypes O
+, O
+indicating O
+that O
+the O
+mutant O
+phenotypes O
+were O
+caused O
+by O
+the O
+deletion O
+of O
+these O
+genes O
+. O
+
+We O
+found O
+a O
+prevalence O
+of O
+eating O
+disorders O
+of O
+5 O
+. O
+9 O
+% O
+( O
+lifetime O
+prevalence O
+of O
+10 O
+% O
+) O
+, O
+irrespective O
+of O
+gender O
+and O
+type O
+of O
+diabetes O
+; O
+4 O
+. O
+1 O
+% O
+of O
+the O
+whole O
+sample O
+reported O
+intentional O
+insulin B
+undertreatment O
+or O
+omission O
+. O
+
+Tilisolol O
+and O
+carboxymethylcellulose O
+sodium O
+salt O
+( O
+CMC O
+) O
+were O
+used O
+as O
+the O
+model O
+ophthalmic O
+drug O
+and O
+viscous O
+polymer O
+, O
+respectively O
+. O
+
+These O
+results O
+are O
+discussed O
+in O
+the O
+context O
+of O
+a O
+model O
+of O
+the O
+myogenic O
+lineage O
+that O
+is O
+based O
+on O
+the O
+expression O
+of O
+desmin B
+. O
+
+We O
+identified O
+two O
+potential O
+phosphorylation O
+sites O
+at O
+serine49 O
+and O
+serine133 O
+, O
+both O
+of O
+which O
+seem O
+to O
+be O
+necessary O
+for O
+Myf B
+- I
+5 I
+activity O
+. O
+
+We O
+constructed O
+a O
+series O
+of O
+chimeric O
+genes O
+containing O
+part O
+of O
+the O
+first O
+exon O
+and O
+increasingly O
+longer O
+5 O
+' O
+flanking O
+sequences O
+of O
+the O
+ODC B
+gene I
+fused O
+to O
+either O
+bacterial B
+chloramphenicol I
+acetyltransferase I
+( O
+CAT B
+) O
+or O
+luciferase B
+reporter I
+genes I
+. O
+
+CVO2 O
+saturation O
+is O
+a O
+reliable O
+and O
+sensitive O
+method O
+for O
+detecting O
+blood O
+loss O
+. O
+
+The O
+gene O
+encoding O
+the O
+Neisseria B
+lactamica I
+III I
+DNA I
+methyltransferase I
+( O
+M B
+. I
+NlaIII I
+) O
+which O
+recognizes O
+the O
+sequence O
+CATG O
+has O
+been O
+cloned O
+and O
+expressed O
+in O
+Escherichia O
+coli O
+. O
+
+This O
+latter O
+complex O
+reacts O
+with O
+an O
+antibody O
+to O
+serum B
+response I
+factor I
+( O
+SRF B
+) O
+and O
+exhibits O
+the O
+same O
+binding O
+characteristics O
+as O
+purified B
+SRF I
+. O
+
+The O
+second O
+patient O
+was O
+successfully O
+treated O
+with O
+intravenous O
+prostaglandin O
+F2 O
+alpha O
+( O
+PGF2 O
+alpha O
+) O
+. O
+
+Alignment O
+of O
+the O
+rat B
+and I
+human I
+WIN I
+cDNAs I
+and O
+their O
+comparison O
+with O
+mouse O
+genomic O
+sequence O
+revealed O
+that O
+the O
+WIN B
+DNA I
+binding I
+domain I
+is O
+encoded O
+by O
+four O
+exons O
+, O
+two O
+of O
+which O
+( O
+exons O
+4 O
+and O
+6 O
+) O
+are O
+alternatively O
+spliced O
+to O
+generate O
+at O
+least O
+three O
+classes O
+of O
+mRNA O
+transcripts O
+. O
+
+In O
+a O
+pilot O
+study O
+in O
+which O
+two O
+dogs O
+were O
+given O
+parenteral O
+rifampin O
+before O
+and O
+after O
+operation O
+and O
+grafts O
+were O
+preclotted O
+with O
+blood O
+that O
+contained O
+rifampin O
+, O
+it O
+was O
+suggested O
+that O
+there O
+was O
+a O
+slight O
+increase O
+in O
+inhibition O
+at O
+24 O
+hours O
+( O
+93 O
+% O
+) O
+. O
+
+A O
+flow O
+probe O
+for O
+direct O
+measurement O
+of O
+blood O
+flow O
+of O
+the O
+mitral O
+valve O
+was O
+devised O
+. O
+
+Here O
+, O
+we O
+analyzed O
+the O
+interaction O
+of O
+the O
+Lactococcus B
+lactis I
+Ll I
+. I
+LtrB I
+group I
+II I
+intron I
+endonuclease I
+with O
+its O
+DNA O
+target O
+site O
+by O
+DNA O
+footprinting O
+and O
+modification O
+- O
+interference O
+approaches O
+. O
+
+Clinical O
+trials O
+bring O
+informations O
+for O
+pharmacology O
+and O
+epidemiology O
+. O
+
+In O
+several O
+steps O
+we O
+converted O
+the O
+retinoid O
+specific O
+response O
+element O
+of O
+the O
+human B
+retinoic I
+acid I
+receptor I
+beta I
+promoter I
+into O
+the O
+vitamin O
+D O
+/ O
+retinoic O
+acid O
+response O
+element O
+of O
+the O
+human B
+osteocalcin I
+promoter I
+. O
+
+The O
+immediate O
+5 O
+' O
+- O
+flanking O
+region O
+was O
+GC O
+- O
+rich O
+with O
+3 O
+SP B
+- I
+1 I
+- I
+like I
+and O
+2 O
+AP B
+- I
+2 I
+sites I
+identified O
+in O
+close O
+proximity O
+to O
+the O
+transcription O
+start O
+site O
+. O
+
+Akt B
+- O
+dependent O
+antiapoptotic O
+action O
+of O
+insulin B
+is O
+sensitive O
+to O
+farnesyltransferase B
+inhibitor O
+. O
+
+For O
+all O
+samples O
+, O
+the O
+sensitivity O
+of O
+the O
+blast O
+flag O
+on O
+the O
+CD3500 O
+was O
+85 O
+% O
+with O
+a O
+specificity O
+of O
+91 O
+% O
+( O
+STKS O
+: O
+sensitivity O
+, O
+75 O
+% O
+; O
+specificity O
+, O
+85 O
+% O
+) O
+; O
+the O
+sensitivity O
+of O
+the O
+CD3500 B
+IG O
+flag O
+was O
+72 O
+% O
+with O
+a O
+specificity O
+of O
+76 O
+% O
+( O
+STKS O
+: O
+sensitivity O
+, O
+75 O
+% O
+: O
+specificity O
+, O
+73 O
+% O
+) O
+; O
+and O
+the O
+sensitivity O
+of O
+the O
+NRBC O
+flag O
+was O
+43 O
+% O
+with O
+a O
+specificity O
+of O
+94 O
+% O
+( O
+STKS O
+sensitivity O
+, O
+37 O
+% O
+; O
+specificity O
+, O
+88 O
+% O
+) O
+. O
+
+Control O
+of O
+ovulation O
+in O
+mares O
+in O
+the O
+early O
+breeding O
+season O
+with O
+ovarian O
+steroids O
+and O
+prostaglandin O
+. O
+
+Reasons O
+are O
+given O
+for O
+suggesting O
+that O
+tiapamil O
+warrants O
+further O
+clinical O
+evaluation O
+, O
+after O
+which O
+it O
+may O
+join O
+the O
+more O
+established O
+calcium O
+antagonists O
+as O
+a O
+valuable O
+therapeutic O
+agent O
+. O
+
+The O
+central O
+venous O
+O2 O
+saturation O
+test O
+in O
+acute O
+pulmonary O
+fat O
+embolism O
+. O
+
+Two O
+of O
+the O
+proteins O
+UPRF B
+- I
+1 I
+and O
+UPRF B
+- I
+2 I
+( O
+which O
+is O
+apparently O
+a O
+proteolytic O
+degradation O
+product O
+of O
+UPRF B
+- I
+1 I
+) O
+bind O
+inefficiently O
+to O
+mutant O
+versions O
+of O
+the O
+UPR O
+that O
+are O
+unable O
+to O
+confer O
+responsiveness O
+to O
+unfolded O
+proteins O
+to O
+the O
+( B
+CYC1 I
+) I
+promoter I
+. O
+
+Identification O
+of O
+domains O
+mediating O
+transcription O
+activation O
+, O
+repression O
+, O
+and O
+inhibition O
+in O
+the O
+paired B
+- I
+related I
+homeobox I
+protein I
+, O
+Prx2 B
+( O
+S8 I
+) O
+. O
+
+METHODS O
+: O
+A O
+spatial O
+counting O
+approach O
+in O
+which O
+the O
+location O
+of O
+each O
+and O
+every O
+PN O
+and O
+NP O
+in O
+the O
+stratum O
+pyramidale O
+of O
+sectors O
+CA1 O
+- O
+4 O
+was O
+applied O
+to O
+11 O
+normal O
+control O
+( O
+CONs O
+) O
+and O
+10 O
+SZs O
+matched O
+for O
+age O
+and O
+postmortem O
+interval O
+, O
+as O
+well O
+as O
+4 O
+manic O
+depressive O
+( O
+MD O
+) O
+subjects O
+matched O
+for O
+age O
+. O
+
+Analytical O
+scanning O
+isoelectrofocusing O
+. O
+
+Upstream B
+stimulatory I
+factor I
+USF B
+is O
+a O
+human O
+transcriptional O
+activation O
+factor O
+, O
+which O
+uses O
+a O
+basic O
+/ O
+helix O
+- O
+loop O
+- O
+helix O
+/ O
+leucin O
+zipper O
+( O
+b O
+/ O
+HLH O
+/ O
+Z O
+) O
+motif O
+to O
+homodimerize O
+and O
+recognize O
+specific O
+sequences O
+in O
+the O
+promoter O
+region O
+of O
+both O
+nuclear O
+and O
+viral O
+genes O
+transcribed O
+by O
+RNA B
+polymerase I
+II I
+. O
+
+43 O
+% O
+, O
+6 O
+/ O
+14 O
+; O
+P O
+= O
+0 O
+. O
+013 O
+) O
+, O
+whereas O
+, O
+in O
+RCC O
+samples O
+with O
+VHL B
+methylation O
+or O
+mutation O
+, O
+the O
+frequency O
+of O
+3p14 O
+- O
+p21 O
+LOH O
+did O
+not O
+differ O
+from O
+that O
+of O
+sp25 O
+- O
+p26 O
+( O
+72 O
+% O
+, O
+18 O
+/ O
+25 O
+vs O
+. O
+
+Sequences O
+homologous O
+to O
+the O
+consensus B
+TUF B
+- I
+binding I
+UAS I
+boxes I
+are O
+present O
+in O
+the O
+5 O
+' O
+flanking O
+regions O
+of O
+both O
+genes O
+. O
+
+The O
+analysis O
+predicted O
+that O
+progressive O
+increases O
+in O
+serum O
+creatinine O
+or O
+aspartate B
+transaminase I
+activity O
+will O
+result O
+in O
+only O
+a O
+50 O
+% O
+reduction O
+of O
+clearance O
+. O
+
+RESULTS O
+: O
+Although O
+low O
+levels O
+of O
+vIRF B
+- I
+2 I
+mRNAs I
+can O
+be O
+detected O
+in O
+the O
+HHV O
+- O
+8 O
+- O
+positive O
+BCBL O
+- O
+1 O
+tumor O
+cell O
+line O
+, O
+12 O
+- O
+0 O
+- O
+tetradecanoylphorbol O
+- O
+13 O
+- O
+acetate O
+( O
+TPA O
+) O
+treatment O
+does O
+not O
+stimulate O
+expression O
+of O
+vIRF B
+- I
+2 I
+gene I
+together O
+with O
+primary O
+lytic O
+cycle O
+genes O
+. O
+
+Central O
+projections O
+of O
+gastric O
+afferent O
+vagal O
+inputs O
+. O
+
+DNA O
+sequence O
+of O
+the O
+UL6 B
+to O
+UL20 B
+genes I
+of O
+infectious O
+laryngotracheitis O
+virus O
+and O
+characterization O
+of O
+the O
+UL10 B
+gene I
+product I
+as O
+a O
+nonglycosylated O
+and O
+nonessential O
+virion O
+protein O
+. O
+
+Coimmunoprecipitation O
+analysis O
+suggests O
+that O
+these O
+residues O
+likely O
+contribute O
+to O
+the O
+multimerization O
+function O
+required O
+for O
+homomeric O
+complex O
+formation O
+or O
+heteromeric O
+complex O
+formation O
+with O
+p50 B
+in O
+that O
+no O
+association O
+of O
+p65 B
+delta I
+with O
+itself O
+or O
+with O
+p50 B
+was O
+evident O
+. O
+
+Cytostatic O
+activity O
+of O
+some O
+essential O
+oils O
+against O
+HEp O
+- O
+2 O
+cells O
+. O
+
+A O
+yeast O
+mitochondrial O
+translation O
+initiation O
+codon O
+mutation O
+affecting O
+the O
+gene O
+for O
+cytochrome B
+oxidase I
+subunit I
+III I
+( O
+COX3 B
+) O
+was O
+partially O
+suppressed O
+by O
+a O
+spontaneous O
+nuclear O
+mutation O
+. O
+
+Only O
+the O
+27 O
+- O
+kDa O
+protein O
+was O
+detected O
+after O
+N B
+- I
+glycosidase I
+treatment O
+, O
+indicating O
+that O
+PLP B
+- I
+H I
+is O
+a O
+glycoprotein O
+. O
+
+Moreover O
+, O
+we O
+studied O
+the O
+relationship O
+between O
+initial O
+percentage O
+of O
+bone O
+marrow O
+plasma O
+cells O
+and O
+prognosis O
+. O
+
+These O
+results O
+demonstrate O
+that O
+GGTase B
+- I
+I I
+inhibitors O
+arrest O
+cells O
+in O
+G0 O
+/ O
+G1 O
+and O
+induce O
+accumulation O
+of O
+p21WAF B
+in O
+a O
+p53 B
+- O
+independent O
+manner O
+and O
+that O
+FTase B
+inhibitors O
+can O
+interfere O
+with O
+cell O
+cycle O
+events O
+by O
+a O
+mechanism O
+that O
+involves O
+neither O
+p21WAF B
+nor O
+p27KIP B
+. O
+
+We O
+report O
+here O
+on O
+an O
+eight O
+- O
+year O
+- O
+old O
+boy O
+who O
+first O
+developed O
+acute O
+intravascular O
+hemolysis O
+following O
+therapy O
+with O
+amphotericin O
+B O
+( O
+AmB O
+) O
+and O
+subsequently O
+a O
+delayed O
+hemolytic O
+transfusion O
+reaction O
+due O
+to O
+alloantibodies O
+. O
+
+The O
+temporal O
+sequence O
+of O
+organ O
+failure O
+was O
+lung O
+, O
+clotting O
+system O
+, O
+kidney O
+, O
+and O
+liver O
+. O
+
+The O
+potential O
+biological O
+significance O
+of O
+the O
+identified O
+structural O
+motif O
+shared O
+by O
+the O
+human B
+CCR5 I
+, O
+CCR3 B
+, O
+CCR2B B
+and O
+other O
+GPCRs B
+is O
+discussed O
+. O
+
+Analysis O
+of O
+rat O
+brain O
+, O
+heart O
+, O
+lung O
+, O
+liver O
+, O
+kidney O
+and O
+skeletal O
+muscle O
+revealed O
+psi B
+PKC I
+zeta I
+mRNA I
+only O
+in O
+brain O
+. O
+
+The O
+papers O
+provide O
+a O
+broad O
+perspective O
+of O
+MPAs O
+and O
+include O
+social O
+, O
+economic O
+, O
+cultural O
+, O
+biological O
+and O
+statistical O
+components O
+. O
+
+Management O
+of O
+patients O
+with O
+Ewing O
+' O
+s O
+sarcoma O
+has O
+been O
+discussed O
+with O
+reference O
+to O
+the O
+need O
+to O
+achieve O
+an O
+excellent O
+local O
+result O
+from O
+radiation O
+therapy O
+now O
+that O
+patients O
+are O
+experiencing O
+long O
+- O
+term O
+survival O
+. O
+
+Furthermore O
+, O
+the O
+rapid O
+light O
+- O
+mediated O
+increase O
+of O
+CPRF B
+proteins I
+was O
+insensitive O
+to O
+transcriptional O
+inhibitors O
+, O
+suggesting O
+that O
+a O
+post O
+- O
+transcriptional O
+mechanism O
+controls O
+CPRF B
+accumulation O
+. O
+
+In O
+those O
+patients O
+who O
+before O
+transplantation O
+were O
+serological O
+negative O
+for O
+CMV O
+but O
+had O
+received O
+organs O
+from O
+CMV B
+- I
+IgG I
+positive O
+donors O
+, O
+the O
+incidence O
+of O
+the O
+disease O
+was O
+highest O
+. O
+
+Since O
+1985 O
+the O
+combination O
+of O
+chlorambucil O
+( O
+10 O
+mg O
+daily O
+, O
+initially O
+for O
+six O
+weeks O
+, O
+then O
+alternating O
+fortnights O
+for O
+12 O
+weeks O
+) O
+and O
+interferon B
+- I
+alpha I
+2b I
+( O
+Schering O
+- O
+Plough O
+; O
+2 O
+x O
+10 O
+( O
+6 O
+) O
+U O
+/ O
+m2 O
+three O
+times O
+weekly O
+by O
+subcutaneous O
+injection O
+for O
+18 O
+weeks O
+) O
+has O
+been O
+compared O
+in O
+a O
+randomised O
+trial O
+with O
+chlorambucil O
+alone O
+in O
+previously O
+untreated O
+patients O
+with O
+stage O
+III O
+or O
+IV O
+follicular O
+lymphoma O
+. O
+
+The O
+BDU O
+neurons O
+and O
+the O
+ALM O
+touch O
+neurons O
+are O
+lineal O
+sister O
+cells O
+in O
+the O
+AB O
+. O
+a O
+lineage O
+and O
+the O
+VA O
+and O
+VB O
+motor O
+neurons O
+are O
+lineal O
+sister O
+cells O
+in O
+the O
+AB O
+. O
+p O
+lineage O
+. O
+
+We O
+compared O
+retrospectively O
+the O
+efficacy O
+of O
+granulocyte B
+colony I
+stimulating I
+factor I
+( O
+G B
+- I
+CSF I
+) O
+alone O
+with O
+chemotherapy O
+plus O
+G B
+- I
+CSF I
+in O
+mobilizing O
+CD34 B
+- I
+positive I
+cells O
+in O
+patients O
+with O
+malignant O
+lymphoma O
+. O
+
+Serum O
+concentrations O
+of O
+hormones O
+in O
+patients O
+classified O
+as O
+C O
+were O
+characteristically O
+and O
+inclined O
+to O
+be O
+hypergonadotropic O
+and O
+hypoestrogenic O
+. O
+
+Cervical O
+CT O
+revealed O
+an O
+irregular O
+low O
+density O
+at O
+the O
+periphery O
+of O
+the O
+cervical O
+vertebra O
+from O
+the O
+C2 O
+to O
+C4 O
+level O
+. O
+
+Incorporation O
+of O
+this O
+information O
+in O
+the O
+data O
+brought O
+about O
+a O
+revised O
+five O
+- O
+year O
+survival O
+estimate O
+of O
+55 O
+percent O
+. O
+
+These O
+motifs O
+, O
+and O
+their O
+cognate O
+transcription O
+factors O
+, O
+appear O
+to O
+act O
+in O
+concert O
+, O
+with O
+partial O
+redundancy O
+, O
+so O
+that O
+discrete O
+mutations O
+were O
+only O
+partially O
+effective O
+in O
+reducing O
+transcriptional O
+activity O
+. O
+
+We O
+now O
+show O
+that O
+purified O
+recombinant O
+c B
+- I
+sis I
+/ O
+PDGF B
+can O
+induce O
+this O
+binding O
+activity O
+which O
+we O
+have O
+termed O
+SIF B
+, O
+for O
+sis B
+- I
+inducible I
+factor I
+. O
+
+Statistical O
+conservation O
+laws O
+in O
+turbulent O
+transport O
+. O
+
+Expression O
+of O
+the O
+bacteriophage B
+T4 I
+DNA I
+terminase I
+genes I
+16 I
+and I
+17 I
+yields O
+multiple O
+proteins O
+. O
+
+Erdheim O
+- O
+Chester O
+disease O
+: O
+a O
+distinct O
+lipoidosis O
+or O
+part O
+of O
+the O
+spectrum O
+of O
+histiocytosis O
+? O
+
+Erdheim O
+- O
+Chester O
+disease O
+has O
+always O
+been O
+considered O
+a O
+distinct O
+lipoidosis O
+based O
+on O
+clinical O
+and O
+radiographic O
+criteria O
+. O
+
+Self O
+- O
+consistent O
+calculation O
+of O
+the O
+surface O
+electronic O
+structure O
+of O
+the O
+( O
+1 O
+x O
+2 O
+) O
+reconstructed O
+Au O
+( O
+110 O
+) O
+surface O
+. O
+
+The O
+plasmid O
+was O
+found O
+to O
+confer O
+drug O
+resistance O
+specifically O
+to O
+LMB O
+. O
+
+Two O
+pharmacokinetic O
+models O
+were O
+compared O
+. O
+
+A O
+higher O
+median O
+proportion O
+of O
+spirochaetes O
+was O
+observed O
+in O
+sites O
+after O
+diagnosis O
+of O
+loss O
+of O
+attachment O
+. O
+
+Ocular O
+injuries O
+during O
+general O
+anesthesia O
+. O
+
+Of O
+81 O
+girls O
+cured O
+from O
+the O
+bacteriuria O
+24 O
+recurred O
+, O
+5 O
+with O
+a O
+symptomatic O
+pyelonephritis O
+and O
+3 O
+with O
+cystitis O
+. O
+
+The O
+performances O
+of O
+two O
+tests O
+, O
+the O
+ProstAsure O
+index O
+and O
+the O
+percent O
+free O
+PSA B
+test O
+, O
+were O
+evaluated O
+in O
+detecting O
+cancer O
+. O
+
+The O
+protein O
+encoded O
+by O
+the O
+NF2 B
+gene I
+has O
+a O
+similarity O
+to O
+ezrin B
+, O
+radixin B
+and O
+moesin B
+( O
+ERM B
+) O
+proteins O
+that O
+link O
+membrane O
+proteins O
+to O
+the O
+cytoskeleton O
+. O
+
+PATIENTS O
+- O
+- O
+125 O
+women O
+consulting O
+the O
+general O
+practitioner O
+for O
+symptomatic O
+bacterial O
+vaginosis O
+. O
+
+In O
+the O
+healing O
+tendons O
+, O
+the O
+rate O
+of O
+collagen B
+synthesis O
+decreased O
+and O
+the O
+rate O
+of O
+noncollagen O
+protein O
+synthesis O
+remained O
+unchanged O
+. O
+
+From O
+our O
+own O
+investigations O
+on O
+phantoms O
+, O
+the O
+smallest O
+signal O
+- O
+to O
+- O
+noise O
+ratio O
+( O
+delta O
+S O
+min O
+/ O
+delta O
+R O
+) O
+was O
+obtained O
+which O
+determines O
+the O
+minimal O
+contrast O
+, O
+given O
+the O
+film O
+properties O
+( O
+film O
+response O
+S O
+, O
+film O
+gradient O
+gamma O
+) O
+and O
+the O
+amount O
+of O
+scatter O
+. O
+
+However O
+, O
+one O
+activity O
+binds O
+preferentially O
+to O
+G O
++ O
+C O
+- O
+rich O
+promoters O
+, O
+and O
+another O
+activity O
+appears O
+to O
+bind O
+preferentially O
+to O
+only O
+two O
+of O
+the O
+promoters O
+tested O
+. O
+
+Cardiovascular O
+effects O
+in O
+man O
+of O
+intravenous O
+prizidilol O
+hydrochloride O
+( O
+SK O
+& O
+F O
+92657 O
+) O
+; O
+a O
+new O
+antihypertensive O
+agent O
+. O
+
+From O
+the O
+Centers O
+for O
+Disease O
+Control O
+and O
+Prevention O
+. O
+
+Expression O
+of O
+a O
+cDNA O
+clone O
+in O
+yeast O
+containing O
+a O
+large O
+portion O
+of O
+the O
+open O
+reading O
+frame O
+produced O
+cAMP B
+PDEase I
+activity O
+identical O
+in O
+properties O
+to O
+the O
+Drosophila O
+enzyme O
+affected O
+by O
+the O
+dnc B
+mutation I
+. O
+
+FdsR B
+purified O
+to O
+homogeneity O
+after O
+overexpression O
+of O
+fdsR B
+in O
+E O
+. O
+coli O
+is O
+a O
+130 O
+kDa O
+homotetramer O
+binding O
+to O
+the O
+fds B
+control I
+region I
+located O
+between O
+the O
+fdsR B
+and O
+fdsG B
+genes I
+. O
+
+ZNS O
+, O
+in O
+the O
+mmolar O
+range O
+, O
+scavenged O
+hydroxyl O
+and O
+nitric O
+oxide O
+radicals O
+in O
+a O
+dose O
+- O
+dependent O
+manner O
+. O
+
+The O
+orthologs O
+of O
+the O
+Y O
+( O
+1 O
+) O
+and O
+Y O
+( O
+2 O
+) O
+subtypes O
+display O
+high O
+amino O
+acid O
+sequence O
+identities O
+between O
+pig O
+, O
+human O
+, O
+and O
+mouse O
+( O
+92 O
+% O
+- O
+94 O
+% O
+) O
+, O
+whereas O
+the O
+Y O
+( O
+4 O
+) O
+, O
+Y O
+( O
+5 O
+) O
+, O
+and O
+y O
+( O
+6 O
+) O
+subtypes O
+display O
+lower O
+identities O
+( O
+76 O
+% O
+- O
+87 O
+% O
+) O
+. O
+
+Binding O
+of O
+ZAP B
+- I
+70 I
+to O
+phospho O
+- O
+TAMs O
+is O
+notable O
+for O
+the O
+high O
+level O
+of O
+cooperativity O
+between O
+the O
+two O
+SH2 B
+domains I
+, O
+which O
+individually O
+demonstrate O
+low O
+affinity O
+interaction O
+with O
+the O
+ligand O
+. O
+
+The O
+benzo O
+- O
+pyrone O
+drug O
+Venalot O
+had O
+a O
+considerable O
+effect O
+in O
+reducing O
+the O
+protein O
+concentration O
+in O
+the O
+air O
+spaces O
+and O
+the O
+interstitial O
+tissue O
+, O
+and O
+of O
+the O
+oedema O
+in O
+the O
+latter O
+. O
+
+Radiation O
+was O
+delivered O
+in O
+a O
+single O
+4 O
+- O
+mJ O
+pulse O
+of O
+200 O
+microseconds O
+duration O
+by O
+means O
+of O
+an O
+articulated O
+zirconium O
+fluoride O
+optical O
+fibre O
+and O
+a O
+320 O
+- O
+microns O
+quartz O
+- O
+fibre O
+tip O
+. O
+
+Perception O
+of O
+sweetness O
+cannot O
+be O
+used O
+to O
+accurately O
+meter O
+the O
+metabolizable O
+energy O
+or O
+nutritive O
+value O
+of O
+a O
+food O
+. O
+
+The O
+leader O
+peptide O
+was O
+hypothesized O
+to O
+inhibit O
+ribosome O
+release O
+at O
+the O
+tnaC B
+stop O
+codon O
+, O
+thereby O
+blocking O
+Rho B
+' O
+s O
+access O
+to O
+the O
+transcript O
+. O
+
+Response O
+properties O
+of O
+single O
+units O
+in O
+the O
+accessory O
+optic O
+system O
+of O
+the O
+dark O
+- O
+reared O
+cat O
+. O
+
+Excretion O
+of O
+radiopharmaceuticals O
+into O
+breast O
+milk O
+. O
+
+Influence O
+of O
+huanglian O
+used O
+in O
+combination O
+with O
+huangqin O
+and O
+gancao O
+on O
+the O
+erythrocytic O
+osmotic O
+fragilitas O
+of O
+experimental O
+glucose B
+- I
+6 I
+- I
+phosphate I
+dehydrogenase I
+deficiency O
+in O
+rats O
+] O
+OBJECTIVE O
+: O
+To O
+study O
+the O
+influence O
+of O
+common O
+combination O
+of O
+Huanglian O
+( O
+Coptis O
+chinensis O
+) O
+on O
+the O
+erythrocytic O
+osmotic O
+fragilitas O
+of O
+glucose B
+- I
+6 I
+- I
+phosphate I
+dehydrogenase I
+( O
+G6PD B
+) O
+deficiency O
+in O
+rats O
+. O
+
+The O
+leukotriene B
+receptor I
+antagonist O
+zafirlukast O
+inhibits O
+sulfur O
+dioxide O
+- O
+induced O
+bronchoconstriction O
+in O
+patients O
+with O
+asthma O
+. O
+
+This O
+sequence O
+was O
+sufficient O
+to O
+confer O
+p53 B
+- O
+dependent O
+activation O
+to O
+a O
+heterologous O
+promoter O
+and O
+p53 B
+was O
+capable O
+of O
+binding O
+to O
+this O
+sequence O
+as O
+assessed O
+by O
+gel O
+shift O
+analysis O
+. O
+
+The O
+embryology O
+of O
+the O
+vertebral O
+column O
+is O
+reviewed O
+briefly O
+, O
+and O
+the O
+origin O
+of O
+each O
+anomaly O
+of O
+the O
+C2 O
+vertebra O
+is O
+traced O
+to O
+one O
+of O
+the O
+two O
+early O
+stages O
+in O
+development O
+as O
+follows O
+: O
+1 O
+) O
+the O
+formation O
+of O
+the O
+mesenchymal O
+vertebra O
+or O
+2 O
+) O
+its O
+induction O
+to O
+cartilage O
+. O
+
+Two O
+of O
+the O
+three O
+groups O
+were O
+submitted O
+to O
+two O
+different O
+levels O
+of O
+hypoxia O
+( O
+FiO2 O
+= O
+0 O
+. O
+05 O
+, O
+group O
+F5 O
+and O
+FiO2 O
+= O
+0 O
+. O
+1 O
+, O
+group O
+F10 O
+) O
+and O
+the O
+third O
+to O
+normoxia O
+( O
+FiO2 O
+= O
+0 O
+. O
+21 O
+, O
+group O
+F21 O
+) O
+in O
+a O
+thermoneutral O
+and O
+controlled O
+environment O
+. O
+
+Parathyroid B
+hormone I
+responses O
+of O
+cyclic O
+AMP O
+- O
+, O
+serum O
+- O
+and O
+phorbol O
+ester O
+- O
+responsive O
+reporter O
+genes O
+in O
+osteoblast O
+- O
+like O
+UMR O
+- O
+106 O
+cells O
+. O
+
+Our O
+results O
+strongly O
+suggest O
+that O
+activation O
+of O
+the O
+beta O
+origin O
+by O
+a O
+distant O
+replication O
+enhancer O
+element O
+requires O
+a O
+small O
+target O
+sequence O
+essential O
+for O
+initiator O
+protein O
+- O
+mediated O
+DNA O
+looping O
+. O
+
+HNF4alpha7 B
+mRNA I
+is O
+also O
+found O
+in O
+totipotent O
+embryonic O
+stem O
+cells O
+. O
+
+Penicillamine O
+- O
+induced O
+myasthenia O
+gravis O
+associated O
+with O
+antibodies O
+to O
+acetylcholine B
+receptor I
+. O
+
+Magnetic O
+force O
+and O
+torque O
+at O
+1 O
+. O
+5 O
+T O
+did O
+not O
+dislodge O
+the O
+GF O
+or O
+result O
+in O
+perforation O
+of O
+canine O
+IVC O
+by O
+the O
+GF O
+. O
+
+A O
+. O
+
+LCCH1 B
+was O
+identical O
+to O
+the O
+Rdl B
+gene I
+, O
+a O
+known O
+GABA B
+receptor I
+subunit I
+gene I
+from O
+D O
+. O
+melanogaster O
+, O
+whereas O
+LCCH2 B
+and O
+LCCH3 B
+were O
+novel O
+D O
+. O
+melanogaster O
+sequences O
+that O
+exhibited O
+structural O
+similarity O
+to O
+other O
+members O
+of O
+the O
+ligand B
+- I
+gated I
+chloride I
+channel I
+gene I
+family I
+. O
+
+A O
+significant O
+increase O
+of O
+gastric O
+mucosal O
+permeability O
+was O
+observed O
+in O
+six O
+normal O
+human O
+subjects O
+after O
+instillation O
+of O
+ethanol O
+( O
+20 O
+percent O
+v O
+/ O
+v O
+) O
+. O
+
+Using O
+a O
+simulated O
+cough O
+machine O
+, O
+we O
+analyzed O
+the O
+effect O
+of O
+adding O
+tensio O
+- O
+active O
+liquids O
+as O
+sol O
+phase O
+simulant O
+on O
+the O
+clearance O
+of O
+gel O
+mucus O
+simulant O
+by O
+cough O
+. O
+
+First O
+, O
+the O
+amino O
+- O
+terminal O
+regulatory O
+arm O
+of O
+the O
+GDI B
+binds O
+to O
+the O
+switch O
+I O
+and O
+II O
+domains O
+of O
+Cdc42 B
+leading O
+to O
+the O
+inhibition O
+of O
+both O
+GDP O
+dissociation O
+and O
+GTP O
+hydrolysis O
+. O
+
+By O
+a O
+combination O
+of O
+alternative O
+promoter O
+usage O
+and O
+exon O
+splicing O
+, O
+each O
+ROR B
+gene I
+generates O
+several O
+isoforms O
+that O
+differ O
+only O
+in O
+their O
+amino O
+terminus O
+. O
+
+Electrophoretic O
+mobility O
+- O
+shift O
+assays O
+showed O
+a O
+rapid O
+induction O
+of O
+nuclear O
+proteins O
+that O
+bound O
+to O
+the O
+consensus B
+kappa B
+B I
+motif I
+. O
+
+Analysis O
+of O
+larger O
+cDNA O
+clones O
+demonstrates O
+that O
+there O
+are O
+at O
+least O
+two O
+isoforms O
+of O
+RIP14 B
+that O
+differ O
+in O
+the O
+N O
+- O
+terminal O
+( O
+A O
+and O
+B O
+) O
+and O
+hinge O
+( O
+D O
+) O
+domains O
+. O
+
+Multiple O
+copies O
+of O
+this O
+binding O
+site O
+are O
+found O
+in O
+the O
+viral O
+genomes O
+. O
+
+During O
+subsequent O
+CS O
+- O
+alone O
+trials O
+, O
+the O
+responses O
+of O
+( O
++ O
+) O
+MK O
+- O
+801 O
+- O
+injected O
+mice O
+were O
+extinguished O
+as O
+easily O
+as O
+those O
+of O
+saline O
+- O
+injected O
+mice O
+. O
+
+In O
+contrast O
+, O
+the O
+tail O
+deviated O
+ipsilaterally O
+in O
+cats O
+with O
+a O
+hemisection O
+, O
+and O
+the O
+tail O
+was O
+ventroflexed O
+in O
+cats O
+with O
+a O
+transection O
+. O
+
+The O
+major O
+open O
+reading O
+frame O
+of O
+the O
+cDNA O
+predicts O
+a O
+protein O
+of O
+59 O
+kD O
+, O
+with O
+a O
+leucine O
+zipper O
+situated O
+adjacent O
+to O
+an O
+myc B
+- I
+related I
+motif I
+that O
+has O
+been O
+proposed O
+to O
+assume O
+a O
+helix O
+- O
+loop O
+- O
+helix O
+structure O
+. O
+
+This O
+residue O
+, O
+although O
+located O
+55 O
+rather O
+than O
+35 O
+residues O
+NH2 O
+- O
+terminal O
+of O
+the O
+essential O
+glutamate O
+, O
+is O
+undoubtedly O
+the O
+analog O
+of O
+the O
+second O
+aspartate O
+of O
+the O
+Asp O
+- O
+Asp O
+- O
+35 O
+- O
+Glu O
+motif O
+found O
+in O
+other O
+family O
+members O
+. O
+
+In O
+addition O
+to O
+loss O
+of O
+digit O
+identity O
+and O
+varying O
+degrees O
+of O
+polydactyly O
+, O
+proximal O
+skeletal O
+elements O
+are O
+severely O
+shortened O
+in O
+Xt O
+; O
+ld O
+double O
+homozygous O
+limbs O
+. O
+
+The O
+PEP4 B
+gene I
+was O
+isolated O
+from O
+a O
+genomic O
+DNA O
+library O
+by O
+complementation O
+of O
+the O
+pep4 B
+- I
+3 I
+mutation I
+. O
+
+A O
+gene O
+with O
+a O
+high O
+degree O
+of O
+sequence O
+identity O
+with O
+mammalian B
+ADP I
+- I
+ribosylation I
+factors I
+( O
+ARFs B
+) O
+, O
+believed O
+to O
+be O
+important O
+in O
+vesicular O
+transport O
+, O
+was O
+identified O
+. O
+
+Off O
+- O
+shell O
+effect O
+in O
+Rydberg O
+- O
+atom O
+- O
+alkali O
+- O
+metal O
+- O
+atom O
+scattering O
+. O
+
+Short O
+- O
+term O
+growth O
+: O
+rhythms O
+, O
+chaos O
+, O
+or O
+noise O
+? O
+
+Association O
+between O
+diaphragm O
+use O
+and O
+asymptomatic O
+bacteriuria O
+. O
+
+The O
+effect O
+of O
+iron O
+on O
+the O
+toxigenicity O
+of O
+Vibrio O
+cholerae O
+. O
+
+The O
+Tat B
+protein I
+coded O
+by O
+human O
+immunodeficiency O
+virus O
+( O
+HIV O
+) O
+is O
+a O
+strong O
+activator O
+of O
+viral O
+gene O
+expression O
+from O
+the O
+long O
+terminal O
+repeat O
+( O
+LTR O
+) O
+. O
+
+Is O
+it O
+time O
+for O
+a O
+wine O
+trial O
+? O
+
+The O
+average O
+coefficient O
+of O
+variation O
+between O
+assays O
+for O
+gas O
+chromatography O
+mass O
+spectrometry O
+was O
+5 O
+. O
+8 O
+% O
+and O
+for O
+radioimmunoassay O
+was O
+12 O
+. O
+3 O
+% O
+, O
+while O
+the O
+average O
+coefficient O
+of O
+variation O
+within O
+assays O
+for O
+gas O
+chromatography O
+mass O
+spectrometry O
+was O
+4 O
+. O
+9 O
+% O
+and O
+for O
+radioimmunoassay O
+6 O
+. O
+9 O
+% O
+. O
+
+Macrophages O
+: O
+modulators O
+of O
+immunity O
+. O
+
+The O
+NH2 O
+- O
+terminal O
+fragments O
+were O
+tested O
+for O
+susceptibility O
+to O
+modification O
+with O
+Nalpha O
+- O
+( O
+3 O
+- O
+maleimidylpropionyl O
+) O
+biocytin O
+, O
+which O
+attaches O
+a O
+biotin O
+group O
+to O
+cysteine O
+sulfhydryls O
+. O
+
+Production O
+of O
+VT O
+was O
+also O
+examined O
+retrospectively O
+in O
+32 O
+E O
+. O
+coli O
+strains O
+of O
+serotype O
+O26 O
+: O
+H11 O
+isolated O
+from O
+children O
+with O
+diarrhoea O
+; O
+eight O
+( O
+25 O
+% O
+) O
+of O
+them O
+produced O
+moderate O
+to O
+high O
+levels O
+of O
+verotoxin B
+1 I
+despite O
+several O
+years O
+storage O
+in O
+vitro O
+. O
+
+Serum O
+pituitary O
+and O
+steroid O
+hormone O
+levels O
+in O
+the O
+adult O
+male O
+: O
+one O
+value O
+is O
+as O
+good O
+as O
+the O
+mean O
+of O
+three O
+. O
+
+The O
+sections O
+were O
+stained O
+with O
+anti B
+- I
+polymorphonuclear I
+leukocyte I
+antibody I
+, O
+the O
+endothelial O
+marker O
+factor B
+VIII I
+- I
+related I
+antigen I
+, O
+and O
+with O
+hematoxylin O
+and O
+eosin O
+. O
+
+Mapping O
+of O
+the O
+region O
+in O
+KAP B
+- I
+1 I
+required O
+for O
+HP1 B
+interaction O
+showed O
+that O
+amino O
+acid O
+substitutions O
+which O
+abolish O
+HP1 B
+binding O
+in O
+vitro O
+reduce O
+KAP B
+- I
+1 I
+mediated O
+repression O
+in O
+vivo O
+. O
+
+The O
+flanking O
+open O
+reading O
+frames O
+in O
+pARGC2 B
+showed O
+no O
+homologies O
+to O
+arginine O
+biosynthetic O
+genes O
+. O
+
+Promoter O
+activity O
+of O
+the O
+proliferating B
+- I
+cell I
+nuclear I
+antigen I
+gene I
+is O
+associated O
+with O
+inducible O
+CRE B
+- I
+binding I
+proteins I
+in O
+interleukin B
+2 I
+- O
+stimulated O
+T O
+lymphocytes O
+. O
+
+METHODS O
+: O
+Levels O
+of O
+sIL B
+- I
+2R I
+were O
+measured O
+simultaneously O
+in O
+plasma O
+and O
+pleural O
+fluid O
+in O
+111 O
+patients O
+with O
+pleural O
+effusions O
+of O
+unknown O
+causes O
+. O
+
+The O
+GIS O
+software O
+program O
+, O
+ArcView O
+, O
+was O
+used O
+for O
+spatial O
+analysis O
+and O
+distance O
+calculations O
+. O
+
+chi2 O
+Tests O
+were O
+used O
+to O
+compare O
+the O
+distribution O
+of O
+the O
+characteristics O
+between O
+intersection O
+and O
+midblock O
+collisions O
+. O
+
+A O
+phase O
+II O
+study O
+was O
+initiated O
+to O
+evaluate O
+the O
+effect O
+of O
+a O
+combination O
+of O
+the O
+pure O
+L O
+- O
+isomer O
+of O
+LV O
+and O
+5 O
+- O
+FU O
+along O
+with O
+epirubicin O
+in O
+patients O
+with O
+advanced O
+pancreatic O
+cancer O
+. O
+
+RESULTS O
+: O
+After O
+3 O
+weeks O
+of O
+therapy O
+, O
+the O
+patient O
+had O
+an O
+increase O
+in O
+platelet O
+count O
+from O
+a O
+baseline O
+of O
+5 O
+, O
+000 O
+to O
+8 O
+, O
+000 O
+/ O
+microliter O
+to O
+a O
+maximal O
+level O
+of O
+33 O
+, O
+000 O
+/ O
+microliter O
+. O
+
+The O
+specificity O
+of O
+the O
+transcriptional O
+activation O
+by O
+ISGF3 B
+is O
+mediated O
+by O
+specific O
+elements O
+termed O
+IFN B
+- I
+stimulatory I
+response I
+element I
+( O
+ISRE B
+) O
+located O
+in O
+the O
+promoter O
+region O
+of O
+IFN B
+- O
+inducible O
+genes O
+. O
+
+It O
+appears O
+that O
+the O
+K O
+- O
+ABC O
+is O
+a O
+relatively O
+nonbiased O
+test O
+suitable O
+for O
+the O
+evaluation O
+of O
+both O
+gifted O
+and O
+nongifted O
+children O
+regardless O
+of O
+race O
+or O
+gender O
+. O
+
+In O
+another O
+patient O
+, O
+IRPF O
+recurred O
+in O
+the O
+ureter O
+of O
+a O
+living O
+related O
+renal O
+graft O
+6 O
+months O
+after O
+transplantation O
+. O
+
+These O
+mutants O
+, O
+assayed O
+by O
+injection O
+into O
+Xenopus O
+oocyte O
+nuclei O
+, O
+delimit O
+the O
+promoter O
+to O
+36 O
+bp O
+of O
+DNA O
+upstream O
+of O
+the O
+cap O
+site O
+and O
+73 O
+bp O
+of O
+the O
+untranslated O
+mRNA O
+leader O
+. O
+
+Upstream O
+tissue B
+inhibitor I
+of I
+metalloproteinases I
+- I
+1 I
+( O
+TIMP B
+- I
+1 I
+) I
+element O
+- I
+1 I
+, O
+a O
+novel O
+and O
+essential O
+regulatory O
+DNA O
+motif O
+in O
+the O
+human B
+TIMP I
+- I
+1 I
+gene I
+promoter I
+, O
+directly O
+interacts O
+with O
+a O
+30 O
+- O
+kDa O
+nuclear O
+protein O
+. O
+
+The O
+results O
+of O
+these O
+experiments O
+indicated O
+that O
+charcoal O
+, O
+imbiber O
+beads O
+, O
+and O
+the O
+anion O
+exchanges O
+resins O
+, O
+Dowex O
+XFS O
+- O
+4022 O
+and O
+Dowex O
+SBR O
+- O
+C1 O
+, O
+would O
+not O
+be O
+useful O
+agents O
+for O
+increasing O
+the O
+amount O
+of O
+dieldrin O
+eliminated O
+via O
+feces O
+( O
+droppings O
+) O
+of O
+chickens O
+. O
+
+The O
+receptor O
+for O
+CSF B
+- I
+1 I
+, O
+c B
+- I
+Fms I
+, O
+is O
+expressed O
+in O
+osteoclasts O
+, O
+possesses O
+intrinsic O
+tyrosine B
+- I
+kinase I
+activity O
+, O
+and O
+signals O
+via O
+rapid O
+phosphorylation O
+of O
+selected O
+proteins O
+. O
+
+Adaptive O
+effects O
+of O
+repeated O
+immersion O
+exposure O
+on O
+the O
+human O
+body O
+
+To O
+this O
+end O
+we O
+generated O
+a O
+detailed O
+physical O
+map O
+of O
+the O
+genomic O
+region O
+spanning O
+between O
+sequence O
+- O
+tagged O
+site O
+markers O
+D16S518 B
+and O
+D16S516 B
+. O
+
+Spinophilin B
+, O
+a O
+novel O
+protein B
+phosphatase I
+1 I
+binding I
+protein I
+localized O
+to O
+dendritic O
+spines O
+. O
+
+We O
+have O
+found O
+that O
+pro B
+- I
+IGF I
+- I
+2 I
+can O
+initially O
+form O
+two O
+disulfide O
+isomers O
+that O
+undergo O
+rearrangement O
+to O
+a O
+single O
+conformation O
+in O
+vivo O
+. O
+
+While O
+working O
+on O
+the O
+toxicity O
+of O
+war O
+gases O
+. O
+
+he O
+formulated O
+' O
+Haber O
+' O
+s O
+rule O
+' O
+, O
+also O
+known O
+as O
+C O
+x O
+T O
+= O
+constant O
+in O
+order O
+to O
+characterize O
+the O
+toxicity O
+of O
+an O
+inhalant O
+. O
+
+The O
+existence O
+of O
+a O
+TFIIIB B
+assembly O
+pathway O
+leading O
+to O
+the O
+faithful O
+transcription O
+of O
+natural O
+eukaryotic O
+tRNA O
+genes O
+in O
+the O
+absence O
+of O
+TFIIIC B
+provides O
+novel O
+insights O
+into O
+the O
+functional O
+flexibility O
+of O
+the O
+eukaryotic O
+tRNA O
+gene O
+transcription O
+machinery O
+and O
+on O
+its O
+evolution O
+from O
+an O
+ancestral O
+RNA B
+polymerase I
+III I
+system O
+relying O
+on O
+upstream O
+, O
+TATA O
+- O
+centered O
+control O
+elements O
+. O
+
+Ectopic O
+Xbra B
+can O
+induce O
+Xegr B
+- I
+1 I
+transcription O
+by O
+an O
+indirect O
+mechanism O
+that O
+appears O
+to O
+operate O
+via O
+primary O
+activation O
+of O
+fibroblast B
+growth I
+factor I
+secretion O
+. O
+
+A O
+rapid O
+mixing O
+device O
+for O
+quasielastic O
+light O
+scattering O
+studies O
+of O
+reacting O
+systems O
+. O
+
+The O
+major O
+transcription O
+start O
+site O
+, O
+designated O
+as O
++ O
+1 O
+, O
+was O
+determined O
+by O
+RACE O
+( O
+rapid O
+amplification O
+of O
+cDNA O
+ends O
+) O
+analysis O
+of O
+human O
+liver O
+cDNA O
+and O
+was O
+found O
+to O
+be O
+located O
+50 O
+bp O
+upstream O
+from O
+the O
+translation O
+start O
+site O
+. O
+
+These O
+aa O
+residues O
+correspond O
+to O
+codons O
+59 O
+and O
+108 O
+in O
+the O
+P B
+. I
+falciparum I
+DHFR I
+active I
+site I
+in O
+which O
+similar O
+aa O
+substitutions O
+( O
+Cys O
+Arg O
+- O
+59 O
+and O
+Ser O
+Asn O
+- O
+108 O
+) O
+are O
+associated O
+with O
+pyrimethamine O
+resistance O
+. O
+
+Of O
+all O
+YASR O
+syndromes O
+, O
+the O
+highest O
+stability O
+was O
+for O
+the O
+Anxious O
+/ O
+Depressed O
+scale O
+. O
+
+Here O
+we O
+investigate O
+the O
+mechanism O
+of O
+TPA O
+induction O
+of O
+FGF B
+- I
+BP I
+gene I
+expression O
+in O
+the O
+human O
+ME O
+- O
+180 O
+SCC O
+cell O
+line O
+. O
+
+Between O
+the O
+RNA O
+initiation O
+site O
+and O
+the O
+coding O
+region O
+is O
+a O
+GC O
+- O
+rich O
+hairpin O
+structure O
+followed O
+by O
+8 O
+T O
+residues O
+that O
+looks O
+like O
+a O
+rho B
+- O
+independent O
+transcription O
+terminator O
+. O
+
+Conversely O
+the O
+rate O
+of O
+bioavailability O
+was O
+significantly O
+different O
+, O
+because O
+from O
+the O
+Reference O
+patch O
+the O
+release O
+rate O
+is O
+fast O
+in O
+the O
+first O
+24 O
+h O
+, O
+leading O
+to O
+an O
+E2 O
+peak O
+at O
+8 O
+h O
+and O
+to O
+a O
+Cmax O
+in O
+average O
+at O
+23 O
+h O
+. O
+
+3 O
+) O
+The O
+progress O
+of O
+fibrinolysis O
+was O
+observed O
+by O
+serial O
+collection O
+of O
+middle O
+ear O
+fluid O
+in O
+the O
+same O
+side O
+ear O
+of O
+5 O
+cases O
+out O
+of O
+17 O
+cases O
+having O
+much O
+activity O
+for O
+fibrin B
+degradation O
+, O
+and O
+lowering O
+of O
+fibrinolytic O
+activity O
+was O
+revealed O
+in O
+4 O
+out O
+of O
+these O
+5 O
+cases O
+as O
+the O
+result O
+. O
+
+Thus O
+G17 B
+targets O
+the O
+c B
+- I
+fos I
+promoter I
+CArG O
+sequence O
+via O
+Rho B
+A I
+- O
+dependent O
+pathways O
+, O
+and O
+Rho B
+A I
+appears O
+to O
+play O
+an O
+important O
+role O
+in O
+the O
+regulation O
+of O
+the O
+trophic O
+action O
+of O
+G17 B
+. O
+
+The O
+MIC90 O
+of O
+ABK O
+against O
+coagulase B
+type O
+IV O
+strains O
+was O
+rather O
+high O
+, O
+12 O
+. O
+5 O
+micrograms O
+/ O
+ml O
+. O
+
+In O
+each O
+patient O
+, O
+MBF O
+was O
+quantified O
+in O
+the O
+three O
+major O
+vascular O
+territories O
+: O
+the O
+left O
+anterior O
+descending O
+and O
+left O
+circumflex O
+coronary O
+artery O
+territories O
+and O
+the O
+right O
+coronary O
+artery O
+( O
+control O
+region O
+) O
+territory O
+. O
+
+These O
+results O
+demonstrate O
+that O
+m2 B
+receptors I
+couple O
+to O
+both O
+G B
+alpha I
+i2 I
+and O
+G B
+alpha I
+i3 I
+in O
+vivo O
+and O
+that O
+this O
+interaction O
+is O
+integral O
+to O
+both O
+positive O
+and O
+negative O
+regulatory O
+pathways O
+leading O
+to O
+activation O
+of O
+PLC B
+and O
+desensitization O
+of O
+receptor O
+signaling O
+. O
+
+Platelet O
+count O
+and O
+plasma O
+volume O
+were O
+significantly O
+higher O
+in O
+group O
+A O
+than O
+in O
+group O
+B O
+throughout O
+pregnancy O
+. O
+
+The O
+fru B
+gene I
+has O
+seven O
+exons O
+spanning O
+15 O
+- O
+kb O
+encoding O
+two O
+transcripts O
+with O
+ORFs O
+of O
+841 O
+and O
+695 O
+amino O
+acids O
+. O
+
+HC B
+- I
+toxin I
+exerts O
+a O
+potent O
+cytostatic O
+effect O
+on O
+plant O
+and O
+animal O
+cells O
+by O
+inhibiting O
+histone B
+deacetylase I
+. O
+
+The O
+human B
+RIL I
+gene I
+: O
+mapping O
+to O
+human O
+chromosome O
+5q31 O
+. O
+1 O
+, O
+genomic O
+organization O
+and O
+alternative O
+transcripts O
+. O
+
+The O
+delta O
+mean O
+VAF O
+and O
+delta O
+mean O
+SABP O
+indicated O
+varied O
+mean O
+values O
+of O
+VAF O
+and O
+SABP O
+, O
+respectively O
+. O
+
+Azoospermia O
+was O
+graded O
+in O
+the O
+following O
+way O
+: O
+adequate O
+spermatozoa O
+( O
+A1 O
+) O
+, O
+low O
+, O
+scanty O
+or O
+rare O
+spermatozoa O
+( O
+A2 O
+) O
+, O
+spermatid O
+arrest O
+( O
+B1 O
+) O
+, O
+spermatocyte O
+arrest O
+( O
+B2 O
+) O
+, O
+Sertoli O
+cell O
+- O
+only O
+pattern O
+( O
+C O
+) O
+and O
+sclerosis O
+( O
+D O
+) O
+. O
+